PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Le, TN; Du, GY; Fonseca, M; Zhou, QP; Wigle, JT; Eisenstat, DD				Le, Trung N.; Du, Guoyan; Fonseca, Mario; Zhou, Qing-Ping; Wigle, Jeffrey T.; Eisenstat, David D.			Dlx homeobox genes promote cortical interneuron migration from the basal forebrain by direct repression of the semaphorin receptor Neuropilin-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-MIGRATION; GANGLIONIC EMINENCE; TRANSCRIPTIONAL REGULATION; NEOCORTICAL PROJECTION; TANGENTIAL MIGRATION; GABAERGIC NEURONS; RETINAL GANGLION; AXON GUIDANCE; HOMEODOMAIN; PROTEIN	Dlx homeobox genes play an important role in vertebrate forebrain development. Dlx1/Dlx2 null mice die at birth with an abnormal cortical phenotype, including impaired differentiation and migration of GABAergic interneurons to the neocortex. However, the molecular basis for these defects downstream of loss of Dlx1/Dlx2 function is unknown. Neuropilin-2 (NRP-2) is a receptor for Class III semaphorins, which inhibit neuronal migration. Herein, we show that Neuropilin-2 is a specific DLX1 and DLX2 transcriptional target by applying chromatin immunoprecipitation to embryonic forebrain tissues. Both homeobox proteins repress Nrp-2 expression in vitro, confirming the functional significance of DLX binding. Furthermore, the homeodomain of DLX1 and DLX2 is necessary for DNA binding and this binding is essential for Dlx repression of Nrp-2 expression. Of importance, there is up-regulated and aberrant expression of NRP-2 in the forebrains of Dlx1/Dlx2 null mice. This is the first report that DLX1 or DLX2 can function as transcriptional repressors. Our data show that DLX proteins specifically mediate the repression of Neuropilin-2 in the developing forebrain. As well, our results support the hypothesis that down-regulation of Neuropilin-2 expression may facilitate tangential interneuron migration from the basal forebrain.	Univ Manitoba, St Boniface Gen Hosp, Res Ctr, Dept Biochem & Med Genet, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, St Boniface Gen Hosp, Res Ctr, Dept Pediat & Child Hlth, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, St Boniface Gen Hosp, Res Ctr, Dept Human Anat & Cell Sci, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, St Boniface Gen Hosp, Res Ctr, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba	Eisenstat, DD (corresponding author), Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	eisensta@cc.umanitoba.ca	Wigle, J.t./G-2005-2014; Eisenstat, David/AAA-4653-2020	Wigle, J.t./0000-0002-4985-7684; 				Anderson S, 1999, CEREB CORTEX, V9, P646, DOI 10.1093/cercor/9.6.646; Anderson SA, 1997, SCIENCE, V278, P474, DOI 10.1126/science.278.5337.474; Anderson SA, 2002, CEREB CORTEX, V12, P702, DOI 10.1093/cercor/12.7.702; Anderson SA, 2001, DEVELOPMENT, V128, P353; Anderson SA, 1997, NEURON, V19, P27, DOI 10.1016/S0896-6273(00)80345-1; Bulfone A, 1998, NEURON, V21, P1273, DOI 10.1016/S0896-6273(00)80647-9; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Chase MB, 2002, MOL CELL BIOL, V22, P2505, DOI 10.1128/MCB.22.8.2505-2514.2002; Chen H, 2000, NEURON, V25, P43, DOI 10.1016/S0896-6273(00)80870-3; Chiba S, 2003, P NATL ACAD SCI USA, V100, P15577, DOI 10.1073/pnas.2536757100; Cloutier JF, 2002, NEURON, V33, P877, DOI 10.1016/S0896-6273(02)00635-9; Cobos I, 2005, NAT NEUROSCI, V8, P1059, DOI 10.1038/nn1499; de Melo J, 2005, DEVELOPMENT, V132, P311, DOI 10.1242/dev.01560; de Melo J, 2003, J COMP NEUROL, V461, P187, DOI 10.1002/cne.10674; Eisenstat DD, 1999, J COMP NEUROL, V414, P217, DOI 10.1002/(SICI)1096-9861(19991115)414:2<217::AID-CNE6>3.0.CO;2-I; Falk J, 2005, NEURON, V48, P63, DOI 10.1016/j.neuron.2005.08.033; Feledy JA, 1999, NUCLEIC ACIDS RES, V27, P764, DOI 10.1093/nar/27.3.764; Feng JC, 2006, GENE DEV, V20, P1470, DOI 10.1101/gad.1416106; Flames N, 2004, NEURON, V44, P251, DOI 10.1016/j.neuron.2004.09.028; Garrity PA, 2005, NAT NEUROSCI, V8, P1635, DOI 10.1038/nn1205-1635; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Giger RJ, 2000, NEURON, V25, P29, DOI 10.1016/S0896-6273(00)80869-7; Givens ML, 2005, J BIOL CHEM, V280, P19156, DOI 10.1074/jbc.M502004200; Guan KL, 2003, NAT REV NEUROSCI, V4, P941, DOI 10.1038/nrn1254; Hanashima C, 2006, CELL, V125, P24, DOI 10.1016/j.cell.2006.03.021; Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248-9261.2004; ILER N, 1995, MECH DEVELOP, V53, P87, DOI 10.1016/0925-4773(95)00427-0; Kessler DS, 1997, P NATL ACAD SCI USA, V94, P13017, DOI 10.1073/pnas.94.24.13017; Lee H, 2006, GENE DEV, V20, P784, DOI 10.1101/gad.1392006; Letinic K, 2002, NATURE, V417, P645, DOI 10.1038/nature00779; Liu JK, 1997, DEV DYNAM, V210, P498, DOI 10.1002/(SICI)1097-0177(199712)210:4<498::AID-AJA12>3.0.CO;2-3; Long JE, 2003, J NEUROSCI, V23, P568, DOI 10.1523/JNEUROSCI.23-02-00568.2003; Lopez-Bendito G, 2006, CELL, V125, P127, DOI 10.1016/j.cell.2006.01.042; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Marin O, 2003, DEVELOPMENT, V130, P1889, DOI 10.1242/dev.00417; Marin O, 2000, J NEUROSCI, V20, P6063; Marin O, 2001, SCIENCE, V293, P872, DOI 10.1126/science.1061891; Marin O, 2001, NAT REV NEUROSCI, V2, P780, DOI 10.1038/35097509; Masuda Y, 2001, J BIOL CHEM, V276, P5331, DOI 10.1074/jbc.M008590200; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; Panganiban G, 2002, DEVELOPMENT, V129, P4371; Park GT, 2001, FEBS LETT, V496, P60, DOI 10.1016/S0014-5793(01)02398-5; Pasterkamp RJ, 2003, CURR OPIN NEUROBIOL, V13, P79, DOI 10.1016/S0959-4388(03)00003-5; PELLERIN I, 1994, MOL CELL BIOL, V14, P4532, DOI 10.1128/MCB.14.7.4532; Pleasure SJ, 2000, NEURON, V28, P727, DOI 10.1016/S0896-6273(00)00149-5; PORTELLA G, 1994, INVAS METAST, V14, P7; Pozas E, 2005, NEURON, V45, P701, DOI 10.1016/j.neuron.2005.01.043; Qiu MS, 1997, DEV BIOL, V185, P165, DOI 10.1006/dbio.1997.8556; Robledo RF, 2002, GENE DEV, V16, P1089, DOI 10.1101/gad.988402; Shinozaki K, 2002, DEVELOPMENT, V129, P3479; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; Stenman J, 2003, DEVELOPMENT, V130, P1113, DOI 10.1242/dev.00328; Stoykova A, 2000, J NEUROSCI, V20, P8042; Stuhmer T, 2002, CEREB CORTEX, V12, P75, DOI 10.1093/cercor/12.1.75; Tamamaki N, 2003, J COMP NEUROL, V455, P238, DOI 10.1002/cne.10476; Wichterle H, 2003, P NATL ACAD SCI USA, V100, P727, DOI 10.1073/pnas.242721899; Wichterle H, 2001, DEVELOPMENT, V128, P3759; Wichterle H, 1999, NAT NEUROSCI, V2, P461, DOI 10.1038/8131; Wonders C, 2005, NAT NEUROSCI, V8, P979, DOI 10.1038/nn0805-979; Yu GY, 2001, DEV BRAIN RES, V130, P217, DOI 10.1016/S0165-3806(01)00239-5; Yun K, 2001, DEVELOPMENT, V128, P193; Zerucha T, 2000, J NEUROSCI, V20, P709, DOI 10.1523/JNEUROSCI.20-02-00709.2000; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920; Zhou QP, 2004, NUCLEIC ACIDS RES, V32, P884, DOI 10.1093/nar/gkh233	65	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2007	282	26					19071	19081		10.1074/jbc.M607486200	http://dx.doi.org/10.1074/jbc.M607486200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	181ZQ	17259176	hybrid			2022-12-25	WOS:000247475300049
J	Chiang, YR; Ismail, W; Muller, M; Fuchs, G				Chiang, Yin-Ru; Ismail, Wael; Mueller, Michael; Fuchs, Georg			Initial steps in the anoxic metabolism of cholesterol by the denitrifying Sterolibacterium denitrificans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ETHYLBENZENE DEHYDROGENASE; STREPTOMYCES-HYGROSCOPICUS; SP-NOV; OXIDASE; DEGRADATION; BIOHYDROGENATION; REDUCTION; MECHANISM; MEMBER; GENE	The anoxic metabolism of the ubiquitous triterpene cholesterol is challenging because of its complex chemical structure, low solubility in water, low number of active functional groups, and the presence of four alicyclic rings and two quaternary carbon atoms. Consequently, the aerobic metabolism depends on oxygenase catalyzed reactions requiring molecular oxygen as co-substrate. Sterolibacterium denitrificans is shown to metabolize cholesterol anoxically via the oxidation of ring A, followed by an oxygen-independent hydroxylation of the terminal C-25 of the side chain. The anaerobic hydroxylation of a tertiary carbon using water as oxygen donor is unprecedented and may be catalyzed by a novel molybdenum containing enzyme.	Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany; Univ Freiburg, Inst Pharmazeut Wissensch, D-79104 Freiburg, Germany	University of Freiburg; University of Freiburg	Fuchs, G (corresponding author), Univ Freiburg, Fak Biol, Schanzlestr 1, D-79104 Freiburg, Germany.	georg.fuchs@biologie.uni-freiburg.de	Chiang, Yin-Ru/L-7727-2019; Ismail, Wael/X-5336-2019	Ahmed Ismail El Moslimany, Wael/0000-0002-3027-928X; Chiang, Yin-Ru/0000-0001-6899-3166				BJORKHEM I, 1971, EUR J BIOCHEM, V21, P428, DOI 10.1111/j.1432-1033.1971.tb01488.x; BRINKLEY AW, 1982, APPL ENVIRON MICROB, V43, P86, DOI 10.1128/AEM.43.1.86-89.1982; CHEETHAM PSJ, 1982, BIOCHEM J, V201, P515, DOI 10.1042/bj2010515; EYSSEN HJ, 1973, EUR J BIOCHEM, V36, P411, DOI 10.1111/j.1432-1033.1973.tb02926.x; Foss S, 1998, SYST APPL MICROBIOL, V21, P365, DOI 10.1016/S0723-2020(98)80046-5; FREIER TA, 1994, INT J SYST BACTERIOL, V44, P137, DOI 10.1099/00207713-44-1-137; Gadda G, 1997, EUR J BIOCHEM, V250, P369, DOI 10.1111/j.1432-1033.1997.0369a.x; Harder J, 1997, ARCH MICROBIOL, V167, P269, DOI 10.1007/s002030050442; Hayakawa S, 1973, Adv Lipid Res, V11, P143; Heyen U, 2000, APPL ENVIRON MICROB, V66, P3004, DOI 10.1128/AEM.66.7.3004-3009.2000; Hille R, 2005, ARCH BIOCHEM BIOPHYS, V433, P107, DOI 10.1016/j.abb.2004.08.012; Horinouchi M, 2003, APPL ENVIRON MICROB, V69, P4421, DOI 10.1128/AEM.69.8.4421-4430.2003; HORINOUCHI S, 1991, APPL ENVIRON MICROB, V57, P1386, DOI 10.1128/AEM.57.5.1386-1393.1991; Hylemon PB, 1998, FEMS MICROBIOL REV, V22, P475, DOI 10.1111/j.1574-6976.1998.tb00382.x; Jin CJ, 1997, ARCH BIOCHEM BIOPHYS, V341, P207, DOI 10.1006/abbi.1997.9949; Johnson HA, 2001, J BACTERIOL, V183, P4536, DOI 10.1128/JB.183.15.4536-4542.2001; KIESLICH K, 1985, J BASIC MICROB, V25, P461, DOI 10.1002/jobm.3620250713; Kniemeyer O, 2001, J BIOL CHEM, V276, P21381, DOI 10.1074/jbc.M101679200; LI JY, 1993, BIOCHEMISTRY-US, V32, P11507, DOI 10.1021/bi00094a006; LI L, 1995, APPL MICROBIOL BIOT, V43, P887, DOI 10.1007/s002530050501; MACKENZIE AS, 1982, SCIENCE, V217, P491, DOI 10.1126/science.217.4559.491; MacLachlan J, 2000, J STEROID BIOCHEM, V72, P169, DOI 10.1016/S0960-0760(00)00044-3; MATHEWS CK, 1996, BIOCHEMISTRY-US, P678; OWEN RW, 1983, J LIPID RES, V24, P1500; PARMENTIER G, 1974, BIOCHIM BIOPHYS ACTA, V348, P279, DOI 10.1016/0005-2760(74)90239-2; PFENNIG N, 1978, INT J SYST BACTERIOL, V28, P283, DOI 10.1099/00207713-28-2-283; Pollegioni L, 1999, EUR J BIOCHEM, V264, P140, DOI 10.1046/j.1432-1327.1999.00586.x; RABUS R, 1995, ARCH MICROBIOL, V163, P96, DOI 10.1007/BF00381782; Ramon DJ, 2004, CURR ORG CHEM, V8, P149, DOI 10.2174/1385272043486025; RUDEL LL, 1973, J LIPID RES, V14, P364; SADZIKOWSKI MR, 1977, APPL ENVIRON MICROB, V34, P355, DOI 10.1128/AEM.34.4.355-362.1977; Tarlera S, 2003, INT J SYST EVOL MICR, V53, P1085, DOI 10.1099/ijs.0.02039-0; TSCHECH A, 1984, ARCH MICROBIOL, V137, P163, DOI 10.1007/BF00414460; WAKEHAM SG, 1989, NATURE, V342, P787, DOI 10.1038/342787a0	34	47	47	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13240	13249		10.1074/jbc.M610963200	http://dx.doi.org/10.1074/jbc.M610963200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17307741	hybrid			2022-12-25	WOS:000246060300012
J	Siner, JM; Jiang, G; Cohen, ZI; Shan, PY; Zhang, XC; Lee, CG; Elias, JA; Lee, PJ				Siner, Jonathan M.; Jiang, Ge; Cohen, Zaza I.; Shan, Peiying; Zhang, Xuchen; Lee, Chun Geun; Elias, Jack A.; Lee, Patty J.			VEGF-induced heme oxygenase-1 confers cytoprotection from lethal hyperoxia in vivo	FASEB JOURNAL			English	Article						oxidant injury; angiogenesis; endothelial; acute lung injury	ENDOTHELIAL GROWTH-FACTOR; GENE-TRANSFER; VASCULAR-PERMEABILITY; CELL-DEATH; LUNG; EXPRESSION; PROTECTS; OVEREXPRESSION; INJURY; INTERLEUKIN-11	Prolonged exposure to hyperoxia results in hyperoxic acute lung injury (HALI). Vascular endothelial growth factor ( VEGF) has been shown to have cytoprotective effects and prolong survival in an in vivo model of HALI. Heme oxygenase- 1 ( HO-1) has protective effects in hyperoxia; therefore, we hypothesized that induction of HO- 1 would be an important contributor to VEGF- induced cytoprotection. Using inducible, lung- specific VEGF overexpressing transgenic mice, we demonstrated that VEGF is a potent inducer of HO-1 mRNA and protein in mouse lung. To evaluate the effect of inhibition of HO-1 on injury, VEGF transgenic mice were treated with HO-1 short interfering RNA ( HO-1 siRNA) and exposed to hyperoxia. Total lung lavage protein concentration, TUNEL staining, lipid peroxidation, and wet- to- dry ratio were all increased, consistent with increased injury. These findings were corroborated by survival studies in which inhibition of HO-1 function using tin-protoporphryin or silencing of HO-1 with lentiviral HO-1 short hairpin RNA ( ShRNA) significantly decreased survival in hyperoxia. We conclude from these data that VEGF- induced HO-1 is an important contributor to cytoprotection in this in vivo model of acute lung injury and that alterations in VEGF function in the lung are likely to be important determinants of the outcome of acute lung injury.	Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Div Pulm & Crit Care, Newark, NJ 07103 USA	Yale University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Lee, PJ (corresponding author), Yale Univ, Sch Med, Pulm & Crit Care Med Sect, POB 208057, New Haven, CT 06520 USA.	patty.lee@yale.edu	zhang, xu/GYE-3558-2022; Lee, Chun Geun/AAC-2838-2021	Zhang, Xuchen/0000-0002-1484-4672; Lee, Chun Geun/0000-0002-9514-3658	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071595, F32HL078127] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL071595, 5 F32 HL078127] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abadie Y, 2005, EUR RESPIR J, V25, P139, DOI 10.1183/09031936.04.00065504; ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BUSSOLATI B, 2003, BLOOD; Christofidou-Solomidou M, 2003, AM J PHYSIOL-LUNG C, V285, pL283, DOI 10.1152/ajplung.00021.2003; Corne J, 2000, J CLIN INVEST, V106, P783, DOI 10.1172/JCI9674; Deramaudt BMJM, 1998, J CELL BIOCHEM, V68, P121, DOI 10.1002/(SICI)1097-4644(19980101)68:1<121::AID-JCB12>3.0.CO;2-K; Fernandez M, 2003, BRIT J PHARMACOL, V139, P634, DOI 10.1038/sj.bjp.0705272; FISHER AB, 1980, AM REV RESPIR DIS, V122, P61, DOI 10.1164/arrd.1980.122.5P2.61; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; He CH, 2005, J CLIN INVEST, V115, P1039, DOI 10.1172/JCI200523004; Jozkowicz A, 2003, ANTIOXID REDOX SIGN, V5, P155, DOI 10.1089/152308603764816514; Kaner RJ, 2000, AM J RESP CELL MOL, V22, P657, DOI 10.1165/ajrcmb.22.6.3779; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kasahara Y, 2001, AM J RESP CRIT CARE, V163, P737, DOI 10.1164/ajrccm.163.3.2002117; Klekamp JG, 1999, AM J PATHOL, V154, P823, DOI 10.1016/S0002-9440(10)65329-1; Langouche L, 2005, J CLIN INVEST, V115, P2277, DOI 10.1172/JCI25385; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Maitre B, 2001, EUR RESPIR J, V18, P100, DOI 10.1183/09031936.01.00074701; Maniscalco WM, 1997, AM J RESP CELL MOL, V16, P557, DOI 10.1165/ajrcmb.16.5.9160838; MARCZIN N, 2003, DIS MARKERS EXHALED; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Perkowski S, 2003, AM J RESP CELL MOL, V28, P682, DOI 10.1165/rcmb.4692; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Stapleton RD, 2005, CHEST, V128, P525, DOI 10.1378/chest.128.2.525; Taylor JL, 1998, AM J PHYSIOL-LUNG C, V274, pL582, DOI 10.1152/ajplung.1998.274.4.L582; Thickett DR, 2002, AM J RESP CRIT CARE, V166, P1332, DOI 10.1164/rccm.2105057; Thickett DR, 2001, AM J RESP CRIT CARE, V164, P1601, DOI 10.1164/ajrccm.164.9.2011071; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Ward NS, 1999, CHEST, V116, p26S, DOI 10.1016/S0012-3692(15)30647-4; Waxman AB, 1998, J CLIN INVEST, V101, P1970, DOI 10.1172/JCI1337; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729; Yang LM, 1999, AM J PHYSIOL-LUNG C, V277, pL127, DOI 10.1152/ajplung.1999.277.1.L127; Zhang XC, 2005, J IMMUNOL, V175, P4834, DOI 10.4049/jimmunol.175.8.4834; Zhang XC, 2004, J BIOL CHEM, V279, P10677, DOI 10.1074/jbc.M312941200; Zhang XC, 2003, AM J RESP CELL MOL, V28, P305, DOI 10.1165/rcmb.2002-0156OC; Zhang XC, 2006, FASEB J, V20, P2156, DOI 10.1096/fj.06-5668fje	40	58	58	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1422	1432		10.1096/fj.06-6661com	http://dx.doi.org/10.1096/fj.06-6661com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264168				2022-12-25	WOS:000246117000018
J	Pratt, JT; Tamayo, R; Tischler, AD; Camilli, A				Pratt, Jason T.; Tamayo, Rita; Tischler, Anna D.; Camilli, Andrew			PilZ domain proteins bind cyclic diguanylate and regulate diverse processes in Vibrio cholerae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-DI-GMP; CELLULOSE SYNTHESIS; BIOFILM FORMATION; ACETOBACTER-XYLINUM; EAL DOMAIN; ALLOSTERIC CONTROL; ESCHERICHIA-COLI; GENE FUSIONS; EXPRESSION; PHOSPHODIESTERASE	Cyclic diguanylate (c-di-GMP) is an allosteric activator and second messenger implicated in the regulation of a variety of biological processes in diverse bacteria. In Vibrio cholerae, c-diGMP has been shown to inversely regulate biofilm-specific and virulence gene expression, suggesting that c-di-GMP signaling is important for the transition of V. cholerae from the environment to the host. However, the mechanism behind this regulation remains unknown. Recently, it was proposed that the PilZ protein domain represents a c-di-GMP-binding domain. Here we show that V. cholerae PilZ proteins bind c-di-GMP specifically and are involved in the regulation of biofilm formation, motility, and virulence. These findings confirm a role for PilZ proteins as c-di-GMP-sensing proteins within the c-di-GMP signaling network.	Tufts Univ, Howard Hughes Med Inst, Sch Med, Boston, MA 02111 USA; Tufts Univ, Dept Mol Biol & Microbiol, Sch Med, Boston, MA 02111 USA	Howard Hughes Medical Institute; Tufts University; Tufts University	Camilli, A (corresponding author), Tufts Univ, Howard Hughes Med Inst, Sch Med, 136 Harrison Ave, Boston, MA 02111 USA.	andrew.camilli@tufts.edu		Tischler, Anna/0000-0001-8404-0250	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034928] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI045746, R01 AI045746-06A1, AI45746] Funding Source: Medline; NIDDK NIH HHS [P30 DK34928, P30 DK034928] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aldridge P, 2003, MOL MICROBIOL, V47, P1695, DOI 10.1046/j.1365-2958.2003.03401.x; Amikam D, 2006, BIOINFORMATICS, V22, P3, DOI 10.1093/bioinformatics/bti739; AMIKAM D, 1989, J BACTERIOL, V171, P6649, DOI 10.1128/jb.171.12.6649-6655.1989; Ausmees N, 2001, FEMS MICROBIOL LETT, V204, P163, DOI 10.1111/j.1574-6968.2001.tb10880.x; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Beyhan S, 2006, J BACTERIOL, V188, P3600, DOI 10.1128/JB.188.10.3600-3613.2006; Bobrov AG, 2005, FEMS MICROBIOL LETT, V247, P123, DOI 10.1016/j.femsle.2005.04.036; CALLAHAN LT, 1971, INFECT IMMUN, V4, P611, DOI 10.1128/IAI.4.5.611-618.1971; Camilli A, 1995, MOL MICROBIOL, V18, P671, DOI 10.1111/j.1365-2958.1995.mmi_18040671.x; Chan C, 2004, P NATL ACAD SCI USA, V101, P17084, DOI 10.1073/pnas.0406134101; Christen M, 2005, J BIOL CHEM, V280, P30829, DOI 10.1074/jbc.M504429200; Correa NE, 2005, J BACTERIOL, V187, P6324, DOI 10.1128/JB.187.18.6324-6332.2005; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a; Garcia B, 2004, MOL MICROBIOL, V54, P264, DOI 10.1111/j.1365-2958.2004.04269.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERRINGTON DA, 1988, J EXP MED, V168, P1487, DOI 10.1084/jem.168.4.1487; Hickman JW, 2005, P NATL ACAD SCI USA, V102, P14422, DOI 10.1073/pnas.0507170102; Hisert KB, 2005, MOL MICROBIOL, V56, P1234, DOI 10.1111/j.1365-2958.2005.04632.x; HOLMGREN J, 1973, INFECT IMMUN, V7, P759, DOI 10.1128/IAI.7.5.759-763.1973; Huang BX, 2003, J BACTERIOL, V185, P7068, DOI 10.1128/JB.185.24.7068-7076.2003; HUQ A, 1983, APPL ENVIRON MICROB, V45, P275, DOI 10.1128/AEM.45.1.275-283.1983; Kaper James B., 1994, P145; Kaysner Charles A., 1994, P27; Kirillina O, 2004, MOL MICROBIOL, V54, P75, DOI 10.1111/j.1365-2958.2004.04253.x; Klose KE, 1998, MOL MICROBIOL, V28, P501, DOI 10.1046/j.1365-2958.1998.00809.x; Klose KE, 1998, J BACTERIOL, V180, P303, DOI 10.1128/JB.180.2.303-316.1998; Ko M, 2000, J MOL BIOL, V303, P371, DOI 10.1006/jmbi.2000.4147; KOLTER R, 1978, CELL, V15, P1199, DOI 10.1016/0092-8674(78)90046-6; Lee SH, 1998, J BACTERIOL, V180, P2298, DOI 10.1128/JB.180.9.2298-2305.1998; Lee SH, 1999, CELL, V99, P625, DOI 10.1016/S0092-8674(00)81551-2; Lee SH, 2001, P NATL ACAD SCI USA, V98, P6889, DOI 10.1073/pnas.111581598; MAYER R, 1991, P NATL ACAD SCI USA, V88, P5472, DOI 10.1073/pnas.88.12.5472; MILLER VL, 1985, J BACTERIOL, V163, P580, DOI 10.1128/JB.163.2.580-585.1985; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; Paul R, 2004, GENE DEV, V18, P715, DOI 10.1101/gad.289504; Prouty MG, 2001, MOL MICROBIOL, V39, P1595, DOI 10.1046/j.1365-2958.2001.02348.x; Ramelot TA, 2007, PROTEINS, V66, P266, DOI 10.1002/prot.21199; ROSS P, 1986, CARBOHYD RES, V149, P101, DOI 10.1016/S0008-6215(00)90372-0; ROSS P, 1987, NATURE, V325, P279, DOI 10.1038/325279a0; Ryan RP, 2006, P NATL ACAD SCI USA, V103, P6712, DOI 10.1073/pnas.0600345103; Ryjenkov DA, 2005, J BACTERIOL, V187, P1792, DOI 10.1128/JB.187.5.1792-1798.2005; Ryjenkov DA, 2006, J BIOL CHEM, V281, P30310, DOI 10.1074/jbc.C600179200; Schmidt AJ, 2005, J BACTERIOL, V187, P4774, DOI 10.1128/JB.187.14.4774-4781.2005; Schoolnik GK, 2001, METHOD ENZYMOL, V336, P3, DOI 10.1016/S0076-6879(01)36573-4; SENANAYAKE SD, 1995, MOL BIOTECHNOL, V4, P13, DOI 10.1007/BF02907467; Simm R, 2004, MOL MICROBIOL, V53, P1123, DOI 10.1111/j.1365-2958.2004.04206.x; Tal R, 1998, J BACTERIOL, V180, P4416, DOI 10.1128/JB.180.17.4416-4425.1998; Tamayo R, 2005, J BIOL CHEM, V280, P33324, DOI 10.1074/jbc.M506500200; TAMPLIN ML, 1990, APPL ENVIRON MICROB, V56, P1977, DOI 10.1128/AEM.56.6.1977-1980.1990; TAYLOR RK, 1987, P NATL ACAD SCI USA, V84, P2833, DOI 10.1073/pnas.84.9.2833; Tischler AD, 2004, MOL MICROBIOL, V53, P857, DOI 10.1111/j.1365-2958.2004.04155.x; Tischler AD, 2005, INFECT IMMUN, V73, P5873, DOI 10.1128/IAI.73.9.5873-5882.2005; Watnick PI, 1999, MOL MICROBIOL, V34, P586, DOI 10.1046/j.1365-2958.1999.01624.x; Weinhouse H, 1997, FEBS LETT, V416, P207, DOI 10.1016/S0014-5793(97)01202-7; Yildiz FH, 2001, J BACTERIOL, V183, P1716, DOI 10.1128/JB.183.5.1716-1726.2001	58	141	150	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12860	12870		10.1074/jbc.M611593200	http://dx.doi.org/10.1074/jbc.M611593200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17307739	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000245942800058
J	Bright, DP; Adham, SD; Lemaire, LCJM; Benavides, R; Gruss, M; Taylor, GW; Smith, EH; Franks, NP				Bright, Damian P.; Adham, Sara D.; Lemaire, Lucienne C. J. M.; Benavides, Rodrigo; Gruss, Marco; Taylor, Graham W.; Smith, Edward H.; Franks, Nicholas P.			Identification of anesthetic binding sites on human serum albumin using a novel etomidate photolabel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GENERAL-ANESTHETICS; HALOTHANE BINDING; STRUCTURAL BASIS; AMINO-ACID; RAT; DIAZIRINES; RESOLUTION; ISOMERS; KINASE	We have synthesized a novel analog of the general anesthetic etomidate in which the ethoxy group has been replaced by an azide group, and which can be used as a photolabel to identify etomidate binding sites. This acyl azide analog is a potent general anesthetic in both rats and tadpoles and, as with etomidate, is stereoselective in its actions, with the R( +) enantiomer being significantly more potent than the S( -) enantiomer. Its effects on alpha 1 beta 2 gamma 2s GABA(A) receptors expressed in HEK-293 cells are virtually indistinguishable from the parent compound etomidate, showing stereoselective potentiation of GABA-induced currents, as well as direct mimetic effects at higher concentrations. In addition, a point mutation ( beta 2 N265M), which is known to attenuate the potentiating actions of etomidate, also blocks the effects of the acyl azide analog. We have investigated the utility of the analog to identify etomidate binding sites by using it to photolabel human serum albumin, a protein that binds similar to 75% of etomidate in human plasma and which is thought to play a major role in its pharmacokinetics. Using HPLC/mass spectrometry we have identified two anesthetic binding sites on HSA. One site is the well-characterized drug binding site I, located in HSA subdomain IIA, and the second site is also an established drug binding site located in subdomain IIIB, which also binds propofol. The acyl azide etomidate may prove to be a useful new photolabel to identify anesthetic binding sites on the GABAA receptor or other putative targets.	Univ London Imperial Coll Sci Technol & Med, Biophys Sect, Blackett Lab, London SW7 2AZ, England; Univ London Imperial Coll Sci Technol & Med, Dept Chem, London SW7 2AZ, England	Imperial College London; Imperial College London	Franks, NP (corresponding author), Univ London Imperial Coll Sci Technol & Med, Biophys Sect, Blackett Lab, London SW7 2AZ, England.	n.franks@imperial.ac.uk	Taylor, Graham Walter/R-4811-2019	Taylor, Graham Walter/0000-0002-9672-8463; Franks, Nicholas/0000-0003-4874-4212; Bright, Damian/0000-0001-9130-2677				Addona GH, 2002, J BIOL CHEM, V277, P25685, DOI 10.1074/jbc.M201303200; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; Blencowe A, 2005, SOFT MATTER, V1, P178, DOI 10.1039/b501989c; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Curry S, 1999, BBA-MOL CELL BIOL L, V1441, P131, DOI 10.1016/S1388-1981(99)00148-1; Darbandi-Tonkabon R, 2003, J BIOL CHEM, V278, P13196, DOI 10.1074/jbc.M213168200; Das J, 2004, J BIOL CHEM, V279, P37964, DOI 10.1074/jbc.M405137200; Downie DL, 1996, BRIT J PHARMACOL, V118, P493, DOI 10.1111/j.1476-5381.1996.tb15430.x; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; Eckenhoff RG, 1996, J BIOL CHEM, V271, P15521, DOI 10.1074/jbc.271.26.15521; Eckenhoff RG, 2002, J MED CHEM, V45, P1879, DOI 10.1021/jm0104926; FLEMING SA, 1995, TETRAHEDRON, V51, P12479; Franks NP, 2006, BRIT J PHARMACOL, V147, pS72, DOI 10.1038/sj.bjp.0706441; Ghuman J, 2005, J MOL BIOL, V353, P38, DOI 10.1016/j.jmb.2005.07.075; GODEFROI EF, 1965, J MED CHEM, V8, P220, DOI 10.1021/jm00326a017; Husain SS, 1999, J MED CHEM, V42, P3300, DOI 10.1021/jm9806300; Husain SS, 2003, J MED CHEM, V46, P1257, DOI 10.1021/jm020465v; Jurd R, 2002, FASEB J, V16, P250, DOI 10.1096/fj.02-0611fje; Li GD, 2006, J NEUROSCI, V26, P11599, DOI 10.1523/JNEUROSCI.3467-06.2006; McGurk KA, 1998, BRIT J PHARMACOL, V124, P13, DOI 10.1038/sj.bjp.0701787; MEULDERMANS WEG, 1976, ARCH INT PHARMACOD T, V221, P150; Petitpas I, 2003, P NATL ACAD SCI USA, V100, P6440, DOI 10.1073/pnas.1137188100; Pratt MB, 2000, J BIOL CHEM, V275, P29441, DOI 10.1074/jbc.M004710200; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Tomlin SL, 1998, ANESTHESIOLOGY, V88, P708, DOI 10.1097/00000542-199803000-00022; WAUD DR, 1972, J PHARMACOL EXP THER, V183, P577; Ziebell MR, 2004, J BIOL CHEM, V279, P17640, DOI 10.1074/jbc.M313886200	28	8	8	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12038	12047		10.1074/jbc.M700479200	http://dx.doi.org/10.1074/jbc.M700479200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17311911	hybrid			2022-12-25	WOS:000245941900046
J	Antignani, A; Youle, RJ				Antignani, Antonella; Youle, Richard J.			The cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), can deliver Bcl-XL as an extracellular fusion protein to protect cells from apoptosis and retain differentiation induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL APOPTOSIS; STEM-CELLS; IN-VITRO; RECEPTOR; INHIBITION; LEUKEMIA; FAMILY; DEATH; TRANSDUCTION; ACTIVATION	Bcl-XL, a member of the Bcl-2 protein family, is able to suppress cell death induced by diverse stimuli in many cell types, including hematopoietic cells. Human granulocyte-macrophage colony-stimulating factor ( GM-CSF) is a cytokine that promotes the proliferation and maturation of neutrophils, eosinophils, and macrophages from bone marrow progenitors. We fused GM-CSF to Bcl-XL and examined the capacity of this chimera to bind human cells through the GM-CSF receptor and prevent apoptosis. We found that the chimeric protein increased the proliferation of human monocytes in culture from 24 h until at least 72 h. In the presence of different apoptotic agents, GM-CSF-Bcl-XL protected cells from induced cell death and promoted proliferation, whereas GM-CSF alone was completely inhibited. In the presence of cytarabine, GM-CSF-Bcl-XL was able also to promote the differentiation of the CD34(+) myeloid precursor whereas Lfn-Bcl-XL, lacking the GM-CSF domain-stimulated cell proliferation and not differentiation. We conclude that recombinant GM-CSF-Bcl-XL binds the GM-CSF receptor on human monocyte/macrophage cells and bone marrow progenitors inducing differentiation and allowing Bcl-XL entry into cells where it blocks cell death and allows amplified cell proliferation. This fully human fusion protein has potential to prevent monocytopenia and represents a new strategy for engineering anti-apoptotic therapeutics.	NINDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Youle, RJ (corresponding author), NINDS, Biochem Sect, Surg Neurol Branch, NIH, 35 Convent Dr MSC 3704, Bethesda, MD 20892 USA.	youler@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002674, Z01NS002674] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Antignani A, 2005, BIOCHEMISTRY-US, V44, P4074, DOI 10.1021/bi0477687; Basak SK, 2002, BLOOD, V99, P2869, DOI 10.1182/blood.V99.8.2869; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bruserud O, 2000, STEM CELLS, V18, P343; BURGESS AW, 1980, BLOOD, V56, P947; Cao GD, 2002, J NEUROSCI, V22, P5423; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dietz GPH, 2002, MOL CELL NEUROSCI, V21, P29, DOI 10.1006/mcne.2002.1165; Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2; Eager R, 2005, MOL THER, V12, P18, DOI 10.1016/j.ymthe.2005.02.012; GRABSTEIN KH, 1986, SCIENCE, V232, P506, DOI 10.1126/science.3083507; Guchelaar HJ, 1998, CANCER CHEMOTH PHARM, V42, P77, DOI 10.1007/s002800050788; Guthridge MA, 1998, STEM CELLS, V16, P301, DOI 10.1002/stem.160301; Haman A, 1999, J BIOL CHEM, V274, P34155, DOI 10.1074/jbc.274.48.34155; Hillion JA, 2005, J CEREBR BLOOD F MET, V25, P154, DOI 10.1038/sj.jcbfm.9600003; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hubel K, 2002, J INFECT DIS, V185, P1490, DOI 10.1086/340221; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; KAUSHANSKY K, 1989, P NATL ACAD SCI USA, V86, P1213, DOI 10.1073/pnas.86.4.1213; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Kreitman RJ, 1997, BLOOD, V90, P252; Liu XH, 1999, P NATL ACAD SCI USA, V96, P9563, DOI 10.1073/pnas.96.17.9563; Liu XH, 2001, J BIOL CHEM, V276, P46326, DOI 10.1074/jbc.M108930200; Masquelier M, 2004, BIOCHEM PHARMACOL, V67, P1047, DOI 10.1016/j.bcp.2003.10.025; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAWADA M, 1993, NEUROSCI LETT, V160, P131, DOI 10.1016/0304-3940(93)90396-3; Slukvin II, 2006, J IMMUNOL, V176, P2924, DOI 10.4049/jimmunol.176.5.2924; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; Theilgaard-Monch K, 2003, BONE MARROW TRANSPL, V32, P1125, DOI 10.1038/sj.bmt.1704297; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464	37	7	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11246	11254		10.1074/jbc.M609824200	http://dx.doi.org/10.1074/jbc.M609824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311927	hybrid			2022-12-25	WOS:000245941500047
J	Sjoberg, AP; Trouw, LA; Clark, SJ; Sjolander, J; Heinegard, D; Sim, RB; Day, AJ; Blom, AM				Sjoberg, Andreas P.; Trouw, Leendert A.; Clark, Simon J.; Sjolander, Jonatan; Heinegard, Dick; Sim, Robert B.; Day, Anthony J.; Blom, Anna M.			The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT ACTIVATION; ALTERNATIVE PATHWAY; C4B-BINDING PROTEIN; INHIBITORY-ACTIVITY; SITE; PROTEOGLYCANS; INFLAMMATION; PATHOGENESIS; POLYMORPHISM; HEPARIN	Recently, a polymorphism in the complement regulator factor H (FH) gene has been associated with age-related macular degeneration. When histidine instead of tyrosine is present at position 384 in the seventh complement control protein (CCP) domain of FH, the risk for age-related macular degeneration is increased. It was recently shown that these allotypic variants of FH, in the context of a recombinant construct corresponding to CCPs 6 - 8, recognize polyanionic structures differently, which may lead to altered regulation of the alternative pathway of complement. We show now that His-384, corresponding to the risk allele, binds C-reactive protein (CRP) poorly compared with the Tyr-384 form. We also found that C1q and phosphorylcholine do not compete with FH for binding to C-reactive protein. The interaction with extracellular matrix protein fibromodulin, which we now show to be mediated, at least in part, by CCP6 - 8 of FH, occurs via the polypeptide of fibromodulin and not through its glycosaminoglycan modifications. The Tyr-384 variant of FH bound fibromodulin better than the His-384 form. Furthermore, we find that CCP6 - 8 is able to interact with DNA and necrotic cells, but in contrast the His-384 allotype binds these ligands more strongly than the Tyr-384 variant. The variations in binding affinity of the two alleles indicate that complement activation and local inflammation in response to different targets will differ between His/His and Tyr/Tyr homozygotes.	Lund Univ, Dept Lab Med, Sect Med Prot Chem, Malmo Univ Hosp, S-20502 Malmo, Sweden; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England; Lund Univ, Dept Expt Med Sci, S-22184 Lund, Sweden; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	Lund University; Skane University Hospital; University of Oxford; Lund University; University of Manchester	Blom, AM (corresponding author), Lund Univ, Dept Lab Med, Sect Med Prot Chem, Malmo Univ Hosp, S-20502 Malmo, Sweden.	anna.blom@med.lu.se	Day, Anthony/O-1658-2015; Blom, Anna/AFS-7369-2022; Blom, Anna/B-9607-2009; Sim, Bob/A-1354-2008; Trouw, Leendert/AGK-5202-2022	Day, Anthony/0000-0002-1415-3134; Blom, Anna/0000-0002-1348-1734; Sim, Bob/0000-0002-2855-7455; Trouw, Leendert/0000-0001-5186-2290; Clark, Simon/0000-0001-8394-8355	Medical Research Council [MC_U138274352] Funding Source: Medline; NIAMS NIH HHS [5U01 AR050926] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U01AR050926] Funding Source: NIH RePORTER; MRC [MC_U138274352] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; ANTONSSON P, 1991, J BIOL CHEM, V266, P16859; ARONOV RA, 1992, PRIRODA, V3, P87; Bang R, 2005, J BIOL CHEM, V280, P25095, DOI 10.1074/jbc.M504782200; BIRO A, 2007, IMMUNOLOGY      0117; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102; BUCKWALTER JA, 1994, MICROSC RES TECHNIQ, V28, P398, DOI 10.1002/jemt.1070280506; Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DAY AJ, 1988, IMMUNOGENETICS, V27, P211, DOI 10.1007/BF00346588; Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Elward K, 2005, J BIOL CHEM, V280, P36342, DOI 10.1074/jbc.M506579200; Fishelson Z, 2001, MOL IMMUNOL, V38, P207, DOI 10.1016/S0161-5890(01)00055-4; GARDNER WD, 1980, BIOCHEM BIOPH RES CO, V94, P61, DOI 10.1016/S0006-291X(80)80187-2; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541; Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750; Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; Jarva H, 1999, J IMMUNOL, V163, P3957; JIANG HX, 1992, J BIOL CHEM, V267, P25597; Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6; Lutz HU, 2006, MOL IMMUNOL, V43, P2, DOI 10.1016/j.molimm.2005.06.020; MERI S, 1990, P NATL ACAD SCI USA, V87, P3982, DOI 10.1073/pnas.87.10.3982; MERI S, 1994, BIOCHEM BIOPH RES CO, V198, P52, DOI 10.1006/bbrc.1994.1008; Muller M, 2001, SCHMERZ, V15, P3, DOI 10.1007/s004820170042; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; Onnerfjord P, 2004, J BIOL CHEM, V279, P26, DOI 10.1074/jbc.M308689200; Padilla ND, 2004, J IMMUNOL METHODS, V293, P1, DOI 10.1016/j.jim.2004.06.011; Saunders RE, 2006, HUM MUTAT, V27, P21, DOI 10.1002/humu.20268; Schonherr E, 2004, J VASC RES, V41, P499, DOI 10.1159/000081806; Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704; Sjoberg A, 2005, J BIOL CHEM, V280, P32301, DOI 10.1074/jbc.M504828200; Sjoberg AP, 2006, J IMMUNOL, V176, P7612, DOI 10.4049/jimmunol.176.12.7612; STANESCU V, 1990, SEMIN ARTHRITIS RHEU, V20, P51, DOI 10.1016/0049-0172(90)90047-J; Sztrolovics R, 1999, SPINE, V24, P1765, DOI 10.1097/00007632-199909010-00003; Taylor KE, 2005, ARTERIOSCL THROM VAS, V25, P1225, DOI 10.1161/01.ATV.0000164623.41250.28; TENNER AJ, 1981, J IMMUNOL, V127, P648; Trouw LA, 2005, J EXP MED, V201, P1937, DOI 10.1084/jem.20050189	45	105	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10894	10900		10.1074/jbc.M610256200	http://dx.doi.org/10.1074/jbc.M610256200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17293598	hybrid			2022-12-25	WOS:000245941500008
J	Zhang, X; Zhou, K; Wang, RS; Cui, JK; Lipton, SA; Liao, FF; Xu, HX; Zhang, YW				Zhang, Xian; Zhou, Kun; Wang, Ruishan; Cui, Jiankun; Lipton, Stuart A.; Liao, Francesca-Fang; Xu, Huaxi; Zhang, Yun-wu			Hypoxia-inducible factor 1 alpha (HIF-1 alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA SH-SY5Y; ALPHA-SECRETASE CLEAVAGE; PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; TRANSCRIPTIONAL REGULATION; CEREBRAL-ISCHEMIA; INDUCIBLE FACTOR-1-ALPHA; GENE-EXPRESSION; MESSENGER-RNA; APP	The incidence of Alzheimer disease (AD) and vascular dementia is greatly increased following cerebral ischemia and stroke in which hypoxic conditions occur in affected brain areas. beta-Amyloid peptide (A beta), which is derived from the beta-amyloid precursor protein (APP) by sequential proteolytic cleavages from beta-secretase (BACE1) and presenilin-1 (PS1)/gamma-secretase, is widely believed to trigger a cascade of pathological events culminating in AD and vascular dementia. However, a direct molecular link between hypoxic insults and APP processing has yet to be established. Here, we demonstrate that acute hypoxia increases the expression and the enzymatic activity of BACE1 by up-regulating the level of BACE1 mRNA, resulting in increases in the APP C-terminal fragment-beta (beta CTF) and A beta. Hypoxia has no effect on the level of PS1, APP, and tumor necrosis factor-alpha-converting enzyme (TACE, an enzyme known to cleave APP at the alpha-secretase cleavage site). Sequence analysis, mutagenesis, and gel shift studies revealed binding of HIF-1 to the BACE1 promoter. Overexpression of HIF-1 alpha increases BACE1 mRNA and protein level, whereas down-regulation of HIF-1 alpha reduced the level of BACE1. Hypoxic treatment fails to further potentiate the stimulatory effect of HIF-1 alpha overexpression on BACE1 expression, suggesting that hypoxic induction of BACE1 expression is primarily mediated by HIF-1 alpha. Finally, we observed significant reduction in BACE1 protein levels in the hippocampus and the cortex of HIF-1 alpha conditional knock-out mice. Our results demonstrate an important role for hypoxia/ HIF-1 alpha in modulating the amyloidogenic processing of APP and provide a molecular mechanism for increased incidence of AD following cerebral ischemic and stroke injuries.	Burnham Inst Med Res, La Jolla, CA 92037 USA; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai 200025, Peoples R China; Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China; Xiamen Univ, Inst Biomed Res, Xiamen 361005, Peoples R China; Xiamen Univ, Sch Life Sci, Xiamen 361005, Peoples R China	Sanford Burnham Prebys Medical Discovery Institute; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Xiamen University; Xiamen University	Zhang, X (corresponding author), Burnham Inst Med Res, La Jolla, CA 92037 USA.	xuh@burnham.org; yunzhang@burnham.org	Zhang, Xian/AAV-7491-2021; Zhang, YW/G-3999-2010; Xu, Huaxi/AAV-7177-2021	Zhang, Yun-wu/0000-0002-7152-7630; Lipton, Stuart/0000-0002-3490-1259	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054880, R01NS046673] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG030197, R01AG021173] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG030197, R01 AG021173] Funding Source: Medline; NINDS NIH HHS [R01 NS046673, R01 NS054880] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badan I, 2004, EUR J NEUROSCI, V19, P2270, DOI 10.1111/j.0953-816X.2004.03323.x; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Christensen MA, 2004, MOL CELL BIOL, V24, P865, DOI 10.1128/MCB.24.2.865-874.2004; Chun YS, 2001, J CELL SCI, V114, P4051; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Greenfield JP, 2000, FRONT BIOSCI, V5, pD72, DOI 10.2741/Greenfield; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Helton R, 2005, J NEUROSCI, V25, P4099, DOI 10.1523/JNEUROSCI.4555-04.2005; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Johnston JA, 2005, BIOCHEM SOC T, V33, P1096, DOI 10.1042/BST0331096; Kalaria RN, 2000, NEUROBIOL AGING, V21, P321, DOI 10.1016/S0197-4580(00)00125-1; Koistinaho M, 2005, BRAIN RES REV, V48, P240, DOI 10.1016/j.brainresrev.2004.12.014; Kokmen E, 1996, NEUROLOGY, V46, P154, DOI 10.1212/WNL.46.1.154; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee EB, 2005, J CELL BIOL, V168, P291, DOI 10.1083/jcb.200407070; Lee PH, 2006, NEUROCHEM RES, V31, P821, DOI 10.1007/s11064-006-9086-y; Li R, 2004, P NATL ACAD SCI USA, V101, P3632, DOI 10.1073/pnas.0205689101; Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9; Marshall AJ, 2006, BRAIN RES, V1099, P18, DOI 10.1016/j.brainres.2006.05.008; Maxwell P, 2004, CANCER BIOL THER, V3, P29, DOI 10.4161/cbt.3.1.547; Nihashi T, 2001, ACTA NEUROCHIR, V143, P287, DOI 10.1007/s007010170109; Nowak K, 2006, J NEUROCHEM, V96, P1696, DOI 10.1111/j.1471-4159.2006.03692.x; Ohno M, 2004, NEURON, V41, P27, DOI 10.1016/S0896-6273(03)00810-9; Ono Y, 2006, J CELL BIOCHEM, V98, P642, DOI 10.1002/jcb.20804; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sastre M, 2006, P NATL ACAD SCI USA, V103, P443, DOI 10.1073/pnas.0503839103; Shi J, 2000, BRAIN RES, V853, P1, DOI 10.1016/S0006-8993(99)02113-7; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sun X, 2006, P NATL ACAD SCI USA, V103, P18727, DOI 10.1073/pnas.0606298103; Sun XL, 2006, FASEB J, V20, P1361, DOI 10.1096/fj.05-5628com; TATEMICHI TK, 1994, NEUROLOGY, V44, P1885, DOI 10.1212/WNL.44.10.1885; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vetrivel KS, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-4; Wang RS, 2006, MOL CELL BIOL, V26, P1347, DOI 10.1128/MCB.26.4.1347-1354.2006; Wang RS, 2006, FASEB J, V20, P1275, DOI 10.1096/fj.06-5839fje; Webster NJ, 2004, MOL BRAIN RES, V130, P161, DOI 10.1016/j.molbrainres.2004.06.042; Webster NJ, 2002, J NEUROCHEM, V83, P1262, DOI 10.1046/j.1471-4159.2002.01236.x; Wen Y, 2004, BRAIN RES, V1009, P1, DOI 10.1016/j.brainres.2003.09.086; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zheng H, 2006, MOL NEURODEGENER, V1, DOI 10.1186/1750-1326-1-5	47	306	319	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10873	10880		10.1074/jbc.M608856200	http://dx.doi.org/10.1074/jbc.M608856200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303576	hybrid			2022-12-25	WOS:000245941500006
J	Hashikawa, N; Yamamoto, N; Sakurai, H				Hashikawa, Naoya; Yamamoto, Noritaka; Sakurai, Hiroshi			Different mechanisms are involved in the transcriptional activation by yeast heat shock transcription factor through two different types of heat shock elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GCN4 LEUCINE-ZIPPER; METALLOTHIONEIN GENE-EXPRESSION; GENOME-WIDE ANALYSIS; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; FACTOR CONTAINS; COILED-COIL; FACTOR HSF1; TRIMERIZATION DOMAIN; NUCLEAR-LOCALIZATION	The hydrophobic repeat is a conserved structural motif of eukaryotic heat shock transcription factor ( HSF) that enables HSF to form a homotrimer. Homotrimeric HSF binds to heat shock elements ( HSEs) consisting of three inverted repeats of the sequence nGAAn. Sequences consisting of four or more nGAAn units are bound cooperatively by two HSF trimers. We show that in Saccharomyces cerevisiae cells oligomerization-defective Hsf1 is not able to bind HSEs with three units and is not extensively phosphorylated in response to stress; it is therefore unable to activate genes containing this type of HSE. Several lines of evidence indicate that oligomerization is a prerequisite for stress-induced hyperphosphorylation of Hsf1. In contrast, oligomerization and hyperphosphorylation are not necessary for gene activation via HSEs with four units. Intragenic suppressor screening of oligomerization- defective hsf1 showed that an interface between adjacent DNA- binding domains is important for the binding of Hsf1 to the HSE. We suggest that Saccharomyces cerevisiae HSEs with different structures are regulated differently; HSEs with three units require Hsf1 to be both oligomerized and hyperphosphorylated, whereas HSEs with four or more units do not require either.	Kanazawa Univ, Div Hlth Sci, Grad Sch Med Sci, Kanazawa, Ishikawa 9200942, Japan	Kanazawa University	Sakurai, H (corresponding author), Kanazawa Univ, Div Hlth Sci, Grad Sch Med Sci, 5-11-80 Kodatsuno, Kanazawa, Ishikawa 9200942, Japan.	sakurai@kenroku.kanazawa-u.ac.jp	SAKURAI, Hiroshi/L-3693-2015	Hashikawa, Naoya/0000-0001-8192-6881; Sakurai, Hiroshi/0000-0002-0336-2301				Ahn SG, 2001, GENE DEV, V15, P2134, DOI 10.1101/gad.894801; Ahn SG, 2003, GENE DEV, V17, P516, DOI 10.1101/gad.1044503; Alexandre H, 2001, FEBS LETT, V498, P98, DOI 10.1016/S0014-5793(01)02503-0; BONNER JJ, 1994, MOL CELL BIOL, V14, P501, DOI 10.1128/MCB.14.1.501; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Drees BL, 1997, J MOL BIOL, V273, P61, DOI 10.1006/jmbi.1997.1283; Eastmond DL, 2006, J BIOL CHEM, V281, P32909, DOI 10.1074/jbc.M602454200; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; FLICK KE, 1994, J BIOL CHEM, V269, P12475; GROSS DS, 1990, J MOL BIOL, V216, P611, DOI 10.1016/0022-2836(90)90387-2; Hahn JS, 2004, MOL CELL BIOL, V24, P5249, DOI 10.1128/MCB.24.12.5249-5256.2004; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hashikawa N, 2006, J BIOL CHEM, V281, P3936, DOI 10.1074/jbc.M510827200; Hashikawa N, 2004, MOL CELL BIOL, V24, P3648, DOI 10.1128/MCB.24.9.3648-3659.2004; Imazu H, 2005, EUKARYOT CELL, V4, P1050, DOI 10.1128/EC.4.6.1050-1056.2005; JAKOBSEN BK, 1988, MOL CELL BIOL, V8, P5040, DOI 10.1128/MCB.8.11.5040; Kadonaga JT, 2004, CELL, V116, P247, DOI 10.1016/S0092-8674(03)01078-X; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; Littlefield O, 1999, NAT STRUCT BIOL, V6, P464; Liu PCC, 1999, J BIOL CHEM, V274, P17219, DOI 10.1074/jbc.274.24.17219; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marchler G, 2001, EMBO J, V20, P499, DOI 10.1093/emboj/20.3.499; Morano KA, 1999, MOL CELL BIOL, V19, P402; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; NIETOSOTELO J, 1990, CELL, V62, P807, DOI 10.1016/0092-8674(90)90124-W; Orosz A, 1996, MOL CELL BIOL, V16, P7018; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; Peteranderl R, 1999, BIOCHEMISTRY-US, V38, P3559, DOI 10.1021/bi981774j; PETERANDERL R, 1992, BIOCHEMISTRY-US, V31, P12272, DOI 10.1021/bi00163a042; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Sakurai H, 2003, GENES CELLS, V8, P951, DOI 10.1046/j.1356-9597.2003.00689.x; Sakurai H, 2001, BIOCHEM BIOPH RES CO, V285, P696, DOI 10.1006/bbrc.2001.5234; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SEWELL AK, 1995, J BIOL CHEM, V270, P25079, DOI 10.1074/jbc.270.42.25079; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; SILAR P, 1991, MOL CELL BIOL, V11, P1232, DOI 10.1128/MCB.11.3.1232; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; SORGER PK, 1990, CELL, V62, P793, DOI 10.1016/0092-8674(90)90123-V; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Takemori Y, 2006, MOL GENET GENOMICS, V275, P89, DOI 10.1007/s00438-005-0065-9; TAMAI KT, 1994, MOL CELL BIOL, V14, P8155, DOI 10.1128/MCB.14.12.8155; Trott A, 2003, TOP CURR GENET, V1, P71; Vinson C, 2006, BBA-GENE STRUCT EXPR, V1759, P4, DOI 10.1016/j.bbaexp.2005.12.005; Voellmy R, 2004, CELL STRESS CHAPERON, V9, P122, DOI 10.1379/CSC-14R.1; Westerheide SD, 2005, J BIOL CHEM, V280, P33097, DOI 10.1074/jbc.R500010200; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094; Yamamoto A, 2005, J BIOL CHEM, V280, P11911, DOI 10.1074/jbc.M411256200; Yamamoto A, 2006, BIOCHEM BIOPH RES CO, V346, P1324, DOI 10.1016/j.bbrc.2006.06.057; YANG WM, 1991, MOL CELL BIOL, V11, P3676, DOI 10.1128/MCB.11.7.3676; YASHAR B, 1995, MOL CELL BIOL, V15, P6545; Zarzov P, 1997, J CELL SCI, V110, P1879; Zhao J, 2005, MOL CELL BIOL, V25, P8985, DOI 10.1128/MCB.25.20.8985-8999.2005; Zhong M, 1998, MOL CELL, V2, P101, DOI 10.1016/S1097-2765(00)80118-5; Zou JY, 1998, CELL STRESS CHAPERON, V3, P130, DOI 10.1379/1466-1268(1998)003<0130:CBGOAT>2.3.CO;2; Zou JY, 1998, CELL, V94, P471, DOI 10.1016/S0092-8674(00)81588-3; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	60	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10333	10340		10.1074/jbc.M609708200	http://dx.doi.org/10.1074/jbc.M609708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289668	hybrid			2022-12-25	WOS:000245941000023
J	Wilhelm, D; Hiramatsu, R; Mizusaki, H; Widjaja, L; Combes, AN; Kanai, Y; Koopman, P				Wilhelm, Dagmar; Hiramatsu, Ryuji; Mizusaki, Hirofumi; Widjaja, Laura; Combes, Alexander N.; Kanai, Yoshiakira; Koopman, Peter			SOX9 regulates prostaglandin D synthase gene transcription in vivo to ensure testis development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRY-RELATED GENE; SEX DETERMINATION REVEALS; CAMPOMELIC DYSPLASIA; ENHANCER ELEMENTS; GONAD DEVELOPMENT; COLLAGEN GENE; GENITAL RIDGE; MOUSE; EXPRESSION; DIFFERENTIATION	In mammals, male sex is determined by the Y-chromosomal gene Sry ( sex-determining region of Y chromosome). The expression of Sry and subsequently Sox9 ( SRY box containing gene 9) in precursors of the supporting cell lineage results in the differentiation of these cells into Sertoli cells. Sertoli cells in turn orchestrate the development of all other male-specific cell types. To ensure that Sertoli cells differentiate in sufficient numbers to induce normal testis development, the early testis produces prostaglandin D-2 ( PGD(2)), which recruits cells of the supporting cell lineage to a Sertoli cell fate. Here we show that the gene encoding prostaglandin D synthase ( Pgds), the enzyme that produces PGD2, is expressed in Sertoli cells immediately after the onset of Sox9 expression. Promoter analysis in silico and in vitro identified a paired SOX/SRY binding site. Interestingly, only SOX9, and not SRY, was able to bind as a dimer to this site and transactivate the Pgds promoter. In line with this, a transgenic mouse model showed that Pgds expression is not affected by ectopic Sry expression. Finally, chromatin immuno-precipitation proved that SOX9 but not SRY binds to the Pgds promoter in vivo.	Univ Queensland, Div Mol Genet & Dev, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Tokyo, Dept Vet Anat, Bunkyo Ku, Tokyo 1138657, Japan; Univ Queensland, ARC Ctr Excellence Biotechnol & Dev, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland; University of Tokyo; University of Queensland	Koopman, P (corresponding author), Univ Queensland, Div Mol Genet & Dev, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	p.koopman@imb.uq.edu.Au	Wilhelm, Dagmar/B-6915-2009; Combes, Alexander N/B-7228-2011; Koopman, Peter A/C-9416-2009	Wilhelm, Dagmar/0000-0002-7757-4075; Combes, Alexander N/0000-0001-6008-8786; Koopman, Peter A/0000-0001-6939-0914; Kanai, Yoshiakira/0000-0003-2116-7806				Adams IR, 2002, DEVELOPMENT, V129, P1155; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bernard P, 2003, HUM MOL GENET, V12, P1755, DOI 10.1093/hmg/ddg182; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Beverdam A, 2003, CYTOGENET GENOME RES, V101, P242, DOI 10.1159/000074344; Beverdam A, 2006, HUM MOL GENET, V15, P417, DOI 10.1093/hmg/ddi463; Bishop CE, 2000, NAT GENET, V26, P490, DOI 10.1038/82652; Bridgewater LC, 2003, NUCLEIC ACIDS RES, V31, P1541, DOI 10.1093/nar/gkg230; Bullejos M, 2001, DEV DYNAM, V221, P201, DOI 10.1002/dvdy.1134; BURGOYNE PS, 1988, DEVELOPMENT, V104, P683; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Fujimori K, 2005, J BIOL CHEM, V280, P18452, DOI 10.1074/jbc.M411755200; Fujimori K, 2003, J BIOL CHEM, V278, P6018, DOI 10.1074/jbc.M208288200; Gao F, 2006, P NATL ACAD SCI USA, V103, P11987, DOI 10.1073/pnas.0600994103; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HACKER A, 1995, DEVELOPMENT, V121, P1603; Hiramatsu R, 2003, DEV DYNAM, V228, P247, DOI 10.1002/dvdy.10379; Huang B, 1999, AM J MED GENET, V87, P349, DOI 10.1002/(SICI)1096-8628(19991203)87:4<349::AID-AJMG13>3.0.CO;2-N; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; Jenkins E, 2005, MATRIX BIOL, V24, P177, DOI 10.1016/j.matbio.2005.02.004; JESKE YWA, 1995, NAT GENET, V10, P480, DOI 10.1038/ng0895-480; Kent J, 1996, DEVELOPMENT, V122, P2813; Kidokoro T, 2005, DEV BIOL, V278, P511, DOI 10.1016/j.ydbio.2004.11.006; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KOOPMAN P, 1990, NATURE, V348, P450, DOI 10.1038/348450a0; Malki S, 2005, EMBO J, V24, P1798, DOI 10.1038/sj.emboj.7600660; McDowall S, 1999, J BIOL CHEM, V274, P24023, DOI 10.1074/jbc.274.34.24023; Nef S, 2005, DEV BIOL, V287, P361, DOI 10.1016/j.ydbio.2005.09.008; PALMER SJ, 1991, DEVELOPMENT, V112, P265; PATEK CE, 1991, DEVELOPMENT, V113, P311; Peirano RI, 2000, NUCLEIC ACIDS RES, V28, P3047, DOI 10.1093/nar/28.16.3047; Rentsendorj O, 2005, BIOCHEM J, V389, P705, DOI 10.1042/BJ20050214; Schepers G, 2003, J BIOL CHEM, V278, P28101, DOI 10.1074/jbc.M304067200; Small CL, 2005, BIOL REPROD, V72, P492, DOI 10.1095/biolreprod.104.033696; Sock E, 2003, HUM MOL GENET, V12, P1439, DOI 10.1093/hmg/ddg158; Urade Y, 2000, BBA-PROTEIN STRUCT M, V1482, P259, DOI 10.1016/S0167-4838(00)00161-8; Vidal VPI, 2001, NAT GENET, V28, P216, DOI 10.1038/90046; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; White DM, 1997, J BIOL CHEM, V272, P14387, DOI 10.1074/jbc.272.22.14387; Wilhelm D, 2005, DEV BIOL, V287, P111, DOI 10.1016/j.ydbio.2005.08.039; Wilhelm D, 2002, GENE DEV, V16, P1839, DOI 10.1101/gad.220102; Wilhelm D, 2006, NAT REV GENET, V7, P620, DOI 10.1038/nrg1903; Wilhelm D, 2006, GENESIS, V44, P168, DOI 10.1002/dvg.20200; Wilson MJ, 2005, J BIOL CHEM, V280, P5917, DOI 10.1074/jbc.M412806200; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15	49	172	175	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10553	10560		10.1074/jbc.M609578200	http://dx.doi.org/10.1074/jbc.M609578200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17277314	hybrid			2022-12-25	WOS:000245941000048
J	Park, JE; Park, JY; Kim, YS; Staswick, PE; Jeon, J; Yun, J; Kim, SY; Kim, J; Lee, YH; Park, CM				Park, Jung-Eun; Park, Ju-Young; Kim, Youn-Sung; Staswick, Paul E.; Jeon, Jin; Yun, Ju; Kim, Sun-Young; Kim, Jungmook; Lee, Yong-Hwan; Park, Chung-Mo			GH3-mediated auxin homeostasis links growth regulation with stress adaptation response in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFENSE GENE-EXPRESSION; SIGNALING PATHWAYS; TRANSCRIPTION FACTOR; DISEASE RESISTANCE; FITNESS COSTS; CROSS-TALK; ACID; HYPOCOTYL; THALIANA; PLANTS	Plants constantly monitor environmental fluctuations to optimize their growth and metabolism. One example is adaptive growth occurring in response to biotic and abiotic stresses. Here, we demonstrate that GH3-mediated auxin homeostasis is an essential constituent of the complex network of auxin actions that regulates stress adaptation responses in Arabidopsis. Endogenous auxin pool is regulated, at least in part, through negative feedback by a group of auxin-inducible GH3 genes encoding auxin-conjugating enzymes. An Arabidopsis mutant, wes1-D, in which a GH3 gene WES1 is activated by nearby insertion of the S-35 enhancer, exhibited auxin-deficient traits, including reduced growth and altered leaf shape. Interestingly, WES1 is also induced by various stress conditions as well as by salicylic acid and abscisic acid. Accordingly, wes1-D was resistant to both biotic and abiotic stresses, and stress-responsive genes, such as pathogenesis-related genes and CBF genes, were upregulated in this mutant. In contrast, a T-DNA insertional mutant showed reduced stress resistance. We therefore propose that GH3-mediated growth suppression directs reallocation of metabolic resources to resistance establishment and represents the fitness costs of induced resistance.	Seoul Natl Univ, Dept Chem, Mol Signalling Lab, Seoul 151742, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Seoul 151742, South Korea; Seoul Natl Univ, Ctr Agr Biomat, Seoul 151742, South Korea; Univ Nebraska, Dept Agron & Hort, Lincoln, NE 68583 USA; Chonnam Natl Univ, Dept Plant Biotechnol, Agr Plant Stress Res Ctr, Kwangju 500757, South Korea; Chonnam Natl Univ, Biotechnol Res Inst, Kwangju 500757, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); University of Nebraska System; University of Nebraska Lincoln; Chonnam National University; Chonnam National University	Park, CM (corresponding author), Seoul Natl Univ, Dept Chem, Mol Signalling Lab, Seoul 151742, South Korea.	cmpark@snu.ac.kr	Kim, Youn/AAT-3380-2021; Park, Chung-Mo/B-6175-2012; Kim, Sun/GSN-4867-2022	Kim, Jungmook/0000-0003-1735-5564				Berleth T, 2004, CURR OPIN PLANT BIOL, V7, P553, DOI 10.1016/j.pbi.2004.07.016; BOHNERT HJ, 1995, PLANT CELL, V7, P1099, DOI 10.1105/tpc.7.7.1099; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; Burdon JJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-227; COHEN JD, 1981, J LABELLED COMPD RAD, V18, P1393, DOI 10.1002/jlcr.2580180916; COHEN JD, 1986, PLANT PHYSIOL, V80, P14, DOI 10.1104/pp.80.1.14; Desveaux D, 2004, DEV CELL, V6, P229, DOI 10.1016/S1534-5807(04)00028-0; Dong XN, 2004, CURR OPIN PLANT BIOL, V7, P547, DOI 10.1016/j.pbi.2004.07.005; EPSTEIN E, 1981, J CHROMATOGR, V209, P413, DOI 10.1016/S0021-9673(00)80609-3; Feys BJ, 2000, TRENDS GENET, V16, P449, DOI 10.1016/S0168-9525(00)02107-7; Gazzarrini S, 2003, ANN BOT-LONDON, V91, P605, DOI 10.1093/aob/mcg064; GEE MA, 1991, PLANT CELL, V3, P419, DOI 10.1105/tpc.3.4.419; Genoud T, 1998, PLANT CELL, V10, P889, DOI 10.1105/tpc.10.6.889; Genoud T, 2002, PLANT J, V31, P87, DOI 10.1046/j.1365-313X.2002.01338.x; Glickmann E, 1998, MOL PLANT MICROBE IN, V11, P156, DOI 10.1094/MPMI.1998.11.2.156; Hagen G, 2002, PLANT MOL BIOL, V49, P373, DOI 10.1023/A:1015207114117; Hammond-Kosack KE, 2003, CURR OPIN BIOTECH, V14, P177, DOI 10.1016/S0958-1669(03)00035-1; Heil M, 2002, TRENDS PLANT SCI, V7, P61, DOI 10.1016/S1360-1385(01)02186-0; Jackson MW, 2004, MOL ECOL, V13, P3609, DOI 10.1111/j.1365-294X.2004.02343.x; Kachroo P, 2001, P NATL ACAD SCI USA, V98, P9448, DOI 10.1073/pnas.151258398; Katagiri F, 2004, CURR OPIN PLANT BIOL, V7, P506, DOI 10.1016/j.pbi.2004.07.013; Kim HJ, 2002, PLANT J, V29, P693, DOI 10.1046/j.1365-313X.2002.01249.x; KOCH E, 1990, PLANT CELL, V2, P437, DOI 10.1105/tpc.2.5.437; Kunkel BN, 2002, CURR OPIN PLANT BIOL, V5, P325, DOI 10.1016/S1369-5266(02)00275-3; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; Mengiste T, 2003, PLANT CELL, V15, P2551, DOI 10.1105/tpc.014167; Nakazawa M, 2001, PLANT J, V25, P213, DOI 10.1046/j.1365-313x.2001.00957.x; Navarro L, 2006, SCIENCE, V312, P436, DOI 10.1126/science.1126088; O'Donnell PJ, 2003, PLANT J, V33, P245, DOI 10.1046/j.1365-313X.2003.01619.x; Oetiker JH, 1997, PLANT PHYSIOL, V114, P1385, DOI 10.1104/pp.114.4.1385; Pieterse CM, 2004, CURR OPIN PLANT BIOL, V7, P456, DOI 10.1016/j.pbi.2004.05.006; Rampey RA, 2004, PLANT PHYSIOL, V135, P978, DOI 10.1104/pp.104.039677; Reymond P, 1998, CURR OPIN PLANT BIOL, V1, P404, DOI 10.1016/S1369-5266(98)80264-1; RISTIC Z, 1993, PROTOPLASMA, V172, P111, DOI 10.1007/BF01379368; Sakamoto H, 2004, PLANT PHYSIOL, V136, P2734, DOI 10.1104/pp.104.046599; Staswick PE, 2005, PLANT CELL, V17, P616, DOI 10.1105/tpc.104.026690; Staswick PE, 2004, PLANT CELL, V16, P2117, DOI 10.1105/tpc.104.023549; Staswick PE, 2002, PLANT CELL, V14, P1405, DOI 10.1105/tpc.000885; Steindler C, 1999, DEVELOPMENT, V126, P4235; Takase T, 2004, PLANT J, V37, P471, DOI 10.1046/j.1365-313X.2003.01973.x; Takase T, 2003, PLANT CELL PHYSIOL, V44, P1071, DOI 10.1093/pcp/pcg130; TANAKA S, 2002, PLANT PHYSIOL, V130, P887; Uppalapati SR, 2005, PLANT J, V42, P201, DOI 10.1111/j.1365-313X.2005.02366.x; Weigel D, 2000, PLANT PHYSIOL, V122, P1003, DOI 10.1104/pp.122.4.1003; WOODWARD AW, 2005, PLANT CELL S, pS165; Yang TB, 2000, J BIOL CHEM, V275, P3137, DOI 10.1074/jbc.275.5.3137	47	333	367	7	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10036	10046		10.1074/jbc.M610524200	http://dx.doi.org/10.1074/jbc.M610524200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276977	hybrid			2022-12-25	WOS:000245421700078
J	Roukos, V; Iliou, MS; Nishitani, H; Gentzel, M; Wilm, M; Taraviras, S; Lygerou, Z				Roukos, Vassilis; Iliou, Maria S.; Nishitani, Hideo; Gentzel, Marc; Wilm, Matthias; Taraviras, Stavros; Lygerou, Zoi			Geminin cleavage during apoptosis by caspase-3 alters its binding ability to the SWI/SNF subunit brahma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN CDC6; CASEIN KINASE-II; DNA-REPLICATION; CELL-CYCLE; LICENSING FACTOR; PHOSPHORYLATION; INHIBITION; DEATH; CDT1; DIFFERENTIATION	Geminin has been proposed to coordinate cell cycle and differentiation events through balanced interactions with the cell cycle regulator Cdt1 and with homeobox transcription factors and chromatin remodeling activities implicated in cell fate decisions. Here we show that Geminin is cleaved in primary cells and cancer cell lines induced to undergo apoptosis by a variety of stimuli. Geminin targeting is mediated by caspase-3 both in vivo and in vitro. Two sites at the carboxyl terminus of Geminin (named C1 and C2) are cleaved by the caspase, producing truncated forms of Geminin. We provide evidence that Geminin cleavage is regulated by phosphorylation. Casein kinase II alters Geminin cleavage at site C1 in vitro, whereas mutating phosphorylation competent Ser/Thr residues proximal to site C1 affects Geminin cleavage in vivo. We show that truncated Geminin produced by cleavage at Cl can promote apoptosis. In contrast, Geminin cleaved at site C2 has lost the ability to interact with Brahma (Brm), a catalytic subunit of the SWI/SNF chromatin remodeling complex, while binding efficiently to Cdt1, indicating that targeting of Geminin during apoptosis differentially affects interactions with its binding partners.	Univ Patras, Lab Gen Biol, Sch Med, Patras 26500, Greece; Kyushu Univ, Grad Sch Med Sci, Dept Biol Mol, Fukuoka 8128582, Japan; European Mol Biol Lab, Gene Express Unit, D-69117 Heidelberg, Germany; Univ Patras, Pharmacol Lab, Sch Med, Patras 26500, Greece	University of Patras; Kyushu University; European Molecular Biology Laboratory (EMBL); University of Patras	Lygerou, Z (corresponding author), Univ Patras, Lab Gen Biol, Sch Med, Patras 26500, Greece.	lygerou@med.upatras.gr	Roukos, Vassilis/K-6248-2012; Roukos, Vassilis/AAC-4827-2020; Taraviras, Stavros/AAJ-4690-2020	Taraviras, Stavros/0000-0002-7455-647X; Roukos, Vassilis/0000-0002-5065-3937; Wilm, Matthias/0000-0002-5461-6834; Nishitani, Hideo/0000-0001-5907-9380; Gentzel, Marc/0000-0002-4482-6010				BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Blanchard F, 2002, MOL BIOL CELL, V13, P1536, DOI 10.1091/mbc.02-02-0010; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Chan SL, 2000, J BIOL CHEM, V275, P17925, DOI 10.1074/jbc.C000146200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Del Bene F, 2004, NATURE, V427, P745, DOI 10.1038/nature02292; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; Hu YX, 2005, EMBO J, V24, P3543, DOI 10.1038/sj.emboj.7600823; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JARVIS WD, 1994, CANCER RES, V54, P1707; Kroll KL, 1998, DEVELOPMENT, V125, P3247; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; Kulartz M, 2004, BIOCHEM BIOPH RES CO, V315, P1011, DOI 10.1016/j.bbrc.2004.01.164; Lee C, 2004, NATURE, V430, P913, DOI 10.1038/nature02813; Li A, 2004, NAT CELL BIOL, V6, P260, DOI 10.1038/ncb1100; Luo LF, 2004, CELL CYCLE, V3, P711; Luo LF, 2004, NATURE, V427, P749, DOI 10.1038/nature02305; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; MIYASHITA T, 1993, BLOOD, V81, P151; Nishitani H, 2002, GENES CELLS, V7, P523, DOI 10.1046/j.1365-2443.2002.00544.x; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Okorokov AL, 2004, NAT STRUCT MOL BIOL, V11, P1021, DOI 10.1038/nsmb835; Pelizon C, 2002, EMBO REP, V3, P780, DOI 10.1093/embo-reports/kvf161; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Saxena S, 2004, MOL CELL, V15, P245, DOI 10.1016/j.molcel.2004.06.045; Seo S, 2005, GENE DEV, V19, P1723, DOI 10.1101/gad.1319105; Seo S, 2006, CELL CYCLE, V5, P374, DOI 10.4161/cc.5.4.2438; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tang DM, 1998, J BIOL CHEM, V273, P16601, DOI 10.1074/jbc.273.26.16601; Torres J, 2003, J BIOL CHEM, V278, P30652, DOI 10.1074/jbc.M212610200; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Xouri G, 2004, EUR J BIOCHEM, V271, P3368, DOI 10.1111/j.1432-1033.2004.04271.x; Yim H, 2003, MOL BIOL CELL, V14, P4250, DOI 10.1091/mbc.E03-01-0029; Yin XY, 2001, J BIOL CHEM, V276, P34567, DOI 10.1074/jbc.M106073200; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	46	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9346	9357		10.1074/jbc.M611643200	http://dx.doi.org/10.1074/jbc.M611643200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17261582	hybrid			2022-12-25	WOS:000245421700006
J	Barfod, ET; Moore, AL; Roe, MW; Lidofsky, SD				Barfod, Elisabeth T.; Moore, Ann L.; Roe, Michael W.; Lidofsky, Steven D.			Ca2+-activated IK1 channels associate with lipid rafts upon cell swelling and mediate volume recovery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEDIATE-CONDUCTANCE; K+ CHANNEL; PHOSPHATIDYLINOSITOL 3-KINASE; FUNCTIONAL EXPRESSION; INDUCED TRANSLOCATION; DEPENDENT REGULATION; ACTIN CYTOSKELETON; CA2+ CHANNELS; CALCIUM; MEMBRANE	Restoration of cell volume in the continued presence of osmotic stimuli is essential, particularly in hepatocytes, which swell upon nutrient uptake. Responses to swelling involve the Ca2+-dependent activation of K+ channels, which promote fluid efflux to drive volume recovery; however, the channels involved in hepatocellular volume regulation have not been identified. We found that hypotonic exposure of HTC hepatoma cells evoked the opening of 50 pS K+-permeable channels, consistent with intermediate conductance (IK) channels. We isolated from rat liver and HTC cells a cDNA with sequence identity to the coding region of IK1. Swelling-activated currents were inhibited by transfection with a dominant interfering IK1 mutant. The IK channel blockers clotrimazole and TRAM-34 inhibited whole cell swelling-activated K+ currents and volume recovery. To determine whether IK1 underwent volume-sensitive localization, we expressed a green fluorescent protein fusion of IK1 in HTC cells. The localization of IK1 was suggestive of distribution in lipid rafts. Consistent with this, there was a time-dependent increase in colocalization between IK1 and the lipid raft ganglioside GM1 on the plasma membrane, which subsequently decreased with volume recovery. Pharmacological disruption of lipid rafts altered the plasma membrane distribution of IK1 and inhibited volume recovery after hypotonic exposure. Collectively, these findings support the hypothesis that IK1 regulates compensatory responses to hepatocellular swelling and suggest that regulation of cell volume involves coordination of signaling from lipid rafts with IK1 function.	Univ Vermont, Dept Med, Burlington, VT 05405 USA; Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Lidofsky, SD (corresponding author), Univ Vermont, Dept Med, Given C-327, Burlington, VT 05405 USA.	steven.lidofsky@uvm.edu			NATIONAL CANCER INSTITUTE [P30CA022435] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056644, R56DK056644] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA22435] Funding Source: Medline; NCRR NIH HHS [P20 RR16435] Funding Source: Medline; NIDDK NIH HHS [DK56644] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barfod ET, 2005, J BIOL CHEM, V280, P25548, DOI 10.1074/jbc.M411717200; Barfod ET, 2001, AM J PHYSIOL-CELL PH, V280, pC836, DOI 10.1152/ajpcell.2001.280.4.C836; BEAR CE, 1987, PFLUG ARCH EUR J PHY, V410, P342, DOI 10.1007/BF00580288; Begenisich T, 2004, J BIOL CHEM, V279, P47681, DOI 10.1074/jbc.M409627200; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Bodily K, 1997, HEPATOLOGY, V25, P403; Caprini M, 2003, EMBO J, V22, P3004, DOI 10.1093/emboj/cdg294; Carini R, 2000, BBA-MOL BASIS DIS, V1500, P297, DOI 10.1016/S0925-4439(99)00114-3; Carton I, 2003, AM J PHYSIOL-CELL PH, V285, pC935, DOI 10.1152/ajpcell.00069.2003; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Dunkelberg JC, 2001, HEPATOLOGY, V33, P1349, DOI 10.1053/jhep.2001.24750; Dykstra M, 2003, ANNU REV IMMUNOL, V21, P457, DOI 10.1146/annurev.immunol.21.120601.141021; Feranchak AP, 2000, J HEPATOL, V33, P174, DOI 10.1016/S0168-8278(00)80357-8; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; FITZ JG, 1994, AM J PHYSIOL, V266, pG677, DOI 10.1152/ajpgi.1994.266.4.G677; Golub T, 2005, J CELL BIOL, V169, P151, DOI 10.1083/jcb.200407058; Haussinger D, 2003, GASTROENTEROLOGY, V124, P1476, DOI 10.1016/S0016-5085(03)00274-9; Haussinger D, 1996, Prog Liver Dis, V14, P29; Hayashi M, 2004, AM J PHYSIOL-CELL PH, V286, pC635, DOI 10.1152/ajpcell.00283.2003; Herrera GM, 2002, J PHYSIOL-LONDON, V541, P483, DOI 10.1113/jphysiol.2002.017707; Ishii TM, 1997, P NATL ACAD SCI USA, V94, P11651, DOI 10.1073/pnas.94.21.11651; Junankar PR, 2004, CELL PHYSIOL BIOCHEM, V14, P143, DOI 10.1159/000078106; Junankar PR, 2002, J BIOL CHEM, V277, P40324, DOI 10.1074/jbc.M204712200; KHALBUSS WE, 1991, HEPATOLOGY, V13, P962, DOI 10.1016/0270-9139(91)90271-V; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kindzelskii AL, 2004, J IMMUNOL, V172, P4681, DOI 10.4049/jimmunol.172.8.4681; Kuzhikandathil EV, 2000, J GEN PHYSIOL, V115, P697, DOI 10.1085/jgp.115.6.697; Lan WZ, 2006, AM J PHYSIOL-CELL PH, V291, pC93, DOI 10.1152/ajpcell.00602.2005; Leitinger B, 2002, J CELL SCI, V115, P963; Li X, 2004, GASTROENTEROLOGY, V126, P122, DOI 10.1053/j.gastro.2003.10.061; LIDOFSKY SD, 1995, P NATL ACAD SCI USA, V92, P7115, DOI 10.1073/pnas.92.15.7115; Lidofsky SD, 1997, AM J PHYSIOL-GASTR L, V273, pG849, DOI 10.1152/ajpgi.1997.273.4.G849; Magee AI, 2005, J CELL SCI, V118, P3141, DOI 10.1242/jcs.02442; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Mazzone A, 2006, HEPATOLOGY, V43, P287, DOI 10.1002/hep.21039; Meder D, 2006, P NATL ACAD SCI USA, V103, P329, DOI 10.1073/pnas.0509885103; Moore AL, 2002, J BIOL CHEM, V277, P34030, DOI 10.1074/jbc.M205945200; Morita T, 1997, AM J PHYSIOL-RENAL, V273, pF615, DOI 10.1152/ajprenal.1997.273.4.F615; Musch MW, 2004, J BIOL CHEM, V279, P39447, DOI 10.1074/jbc.M405363200; Neylon CB, 1999, CIRC RES, V85, pE33, DOI 10.1161/01.RES.85.9.e33; NICOLAOU SA, 2007, IN PRESS AM J PHYSL; Nyasae LK, 2003, MOL BIOL CELL, V14, P2689, DOI 10.1091/mbc.E02-12-0816; Pon DC, 1997, J CELL PHYSIOL, V171, P87; Roe MW, 2001, J BIOL CHEM, V276, P30871, DOI 10.1074/jbc.M102362200; Roman R, 2002, AM J PHYSIOL-GASTR L, V282, pG116, DOI 10.1152/ajpgi.2002.282.1.G116; Roman RM, 1998, HEPATOLOGY, V28, P1073, DOI 10.1002/hep.510280423; Sand P, 2004, ACTA PHYSIOL SCAND, V182, P361, DOI 10.1111/j.1365-201X.2004.01366.x; Sharma DK, 2005, CANCER RES, V65, P8233, DOI 10.1158/0008-5472.CAN-05-0803; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; Srivastava S, 2005, MOL CELL BIOL, V25, P3630, DOI 10.1128/MCB.25.9.3630-3638.2005; Thompson-Vest N, 2006, J ANAT, V208, P219, DOI 10.1111/j.1469-7580.2006.00515.x; Vazquez E, 2001, P NATL ACAD SCI USA, V98, P5329, DOI 10.1073/pnas.091096498; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; vom Dahl S, 2003, J BIOL CHEM, V278, P27088, DOI 10.1074/jbc.M210699200; vom Dahl S, 1998, GASTROENTEROLOGY, V114, P1046, DOI 10.1016/S0016-5085(98)70325-7; Wang J, 2003, AM J PHYSIOL-CELL PH, V284, pC77, DOI 10.1152/ajpcell.00132.2002; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Wang YJ, 2002, BIOCHEM J, V363, P117, DOI 10.1042/0264-6021:3630117; Webster CRL, 2000, J BIOL CHEM, V275, P29754, DOI 10.1074/jbc.M002831200; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151	61	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8984	8993		10.1074/jbc.M607730200	http://dx.doi.org/10.1074/jbc.M607730200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264085	hybrid			2022-12-25	WOS:000245780300045
J	Baratin, M; Roetynck, S; Pouvelle, B; Lemmers, C; Viebig, NK; Johansson, S; Bierling, P; Scherf, A; Gysin, J; Vivier, E; Ugolini, S				Baratin, Myriam; Roetynck, Sophie; Pouvelle, Bruno; Lemmers, Celine; Viebig, Nicola K.; Johansson, Sofia; Bierling, Philippe; Scherf, Artur; Gysin, Juerg; Vivier, Eric; Ugolini, Sophie			Dissection of the Role of PfEMP1 and ICAM-1 in the Sensing of Plasmodium falciparum-Infected Erythrocytes by Natural Killer Cells	PLOS ONE			English	Article								Background. Host innate immunity contributes to malaria clinical outcome by providing protective inflammatory cytokines such as interferon-gamma, and by shaping the adaptive immune response. Plasmodium falciparum (Pf) is the etiologic agent of the most severe forms of human malaria. Natural Killer (NK) cells are lymphocytes of the innate immune system that are the first effectors to produce interferon-gamma in response to Pf. However, the molecular bases of Pf-NK cell recognition events are unknown. Our study focuses on the role of Pf erythrocyte membrane protein 1 (PfEMP1), a major Pf virulence factor. PfEMP1 is expressed on parasitized-erythrocytes and participates to vascular obstruction through the binding to several host receptors. PfEMP1 is also a pivotal target for host antibody response to Pf infection. Methodology/Principal Findings. Using genetically-engineered parasite mutant strains, a human genetic deficiency, and blocking antibodies, we identified two receptor-ligand pairs involved in two uncoupled events occurring during the sensing of Pf infection by NK cells. First, PfEMP1 interaction with one of its host receptor, chondroitin sulfate A, mediates the cytoadhesion of Pf-infected erythrocytes to human NK cell lines, but is not required for primary NK cell activation. Second, intercellular adhesion molecule-1 (ICAM-1), another host receptor for PfEMP1, is mandatory for NK cell interferon-gamma response. In this case, ICAM-1 acts via its engagement with its host ligand, LFA-1, and not with PfEMP1, consistent with the obligatory cross-talk of NK cells with macrophages for their production of interferon-gamma. Conclusion/Significance. PfEMP1-independent but ICAM-1/LFA-1-dependent events occurring during NK cell activation by Pf highlight the fundamental role of cellular cooperation during innate immune response to malaria.	[Baratin, Myriam; Roetynck, Sophie; Lemmers, Celine; Johansson, Sofia; Vivier, Eric; Ugolini, Sophie] Aix Marseille Univ, Fac Sci Luminy, CIML, Marseille, France; [Baratin, Myriam; Roetynck, Sophie; Lemmers, Celine; Johansson, Sofia; Vivier, Eric; Ugolini, Sophie] INSERM, U631, F-13258 Marseille, France; [Baratin, Myriam; Roetynck, Sophie; Lemmers, Celine; Johansson, Sofia; Vivier, Eric; Ugolini, Sophie] CNRS, UMR6102, Marseille, France; [Pouvelle, Bruno; Gysin, Juerg] Univ Aix Marseille 2, Unite Parasitol Expt, Marseille, France; [Viebig, Nicola K.; Scherf, Artur] Inst Pasteur, Paris, France; [Viebig, Nicola K.; Scherf, Artur] CNRS, Paris, France; [Bierling, Philippe] Etab Francais Sang, Creteil, France; [Vivier, Eric] Hop Conception, AP HM, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Vivier, E (corresponding author), Aix Marseille Univ, Fac Sci Luminy, CIML, Marseille, France.	vivier@ciml.univ-mrs.fr; ugolini@ciml.univ-mrs.fr	Vivier, Eric/F-8939-2010; Pouvelle, Bruno/AAA-3968-2022; Scherf, Artur/A-9674-2014; Johansson, Sofia/B-9043-2011	Vivier, Eric/0000-0001-7022-8287; Johansson, Sofia/0000-0002-9295-6266; Ugolini, Sophie/0000-0003-4041-0103; Scherf, Artur/0000-0003-2411-3328	European Union [FP6, LSHB-CT-2004-503319-Allostem]; Ligue Nationale contre le Cancer ("Equipe labellisee La Ligue''); Agence Nationale de la Recherche ("Reseau Innovation Biotechnologies'' and "Microbiologie Immunologie-Maladies Emergentes''); INSERM; CNRS; Ministere de l'Enseignement Superieur et de la Recherche; BioMalPar program [LSHP-CT-2004-503578]; Fond Dedier, Institut Pasteur; Malaria in Pregnancy Initiative of the Melinda and Bill Gates Foundation [2902]	European Union(European Commission); Ligue Nationale contre le Cancer ("Equipe labellisee La Ligue'')(Institut National du Cancer (INCA) France); Agence Nationale de la Recherche ("Reseau Innovation Biotechnologies'' and "Microbiologie Immunologie-Maladies Emergentes'')(French National Research Agency (ANR)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); Ministere de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission); BioMalPar program; Fond Dedier, Institut Pasteur; Malaria in Pregnancy Initiative of the Melinda and Bill Gates Foundation(Bill & Melinda Gates Foundation)	E. V. lab is supported by European Union FP6, LSHB-CT-2004-503319-Allostem, Ligue Nationale contre le Cancer ("Equipe labellisee La Ligue''), Agence Nationale de la Recherche ("Reseau Innovation Biotechnologies'' and "Microbiologie Immunologie-Maladies Emergentes''), INSERM, CNRS and Ministere de l'Enseignement Superieur et de la Recherche. AS and JG labs are supported by the BioMalPar program (LSHP-CT-2004-503578), a FP6 funded network of excellence and the Fond Dedier, Institut Pasteur. JG lab is also supported by the Malaria Antigen Discovery Program (MADP) Malaria in Pregnancy Initiative of the Melinda and Bill Gates Foundation (grant no. 2902).	Artavanis-Tsakonas K, 2003, J IMMUNOL, V171, P5396, DOI 10.4049/jimmunol.171.10.5396; Artavanis-Tsakonas K, 2002, J IMMUNOL, V169, P2956, DOI 10.4049/jimmunol.169.6.2956; Baratin M, 2005, P NATL ACAD SCI USA, V102, P14747, DOI 10.1073/pnas.0507355102; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Chai WG, 2002, J BIOL CHEM, V277, P22438, DOI 10.1074/jbc.M111401200; Chakravorty SJ, 2005, EUR J CELL BIOL, V84, P15, DOI 10.1016/j.ejcb.2004.09.002; Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660; Craig A, 2000, HUM MOL GENET, V9, P525, DOI 10.1093/hmg/9.4.525; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; Dzikowski R, 2006, PLOS PATHOG, V2, P184, DOI 10.1371/journal.ppat.0020022; Flick K, 2004, MOL BIOCHEM PARASIT, V134, P3, DOI 10.1016/j.molbiopara.2003.09.010; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; Frick C, 2005, EUR J IMMUNOL, V35, P3610, DOI 10.1002/eji.200425914; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Hanna J, 2006, NAT MED, V12, P1065, DOI 10.1038/nm1452; Hargreaves DC, 2005, J CLIN IMMUNOL, V25, P503, DOI 10.1007/s10875-005-8065-4; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Hogg N, 2002, IMMUNOL REV, V186, P164, DOI 10.1034/j.1600-065X.2002.18614.x; Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9; Koopman LA, 2003, J EXP MED, V198, P1201, DOI 10.1084/jem.20030305; Korbel DS, 2005, J IMMUNOL, V175, P7466, DOI 10.4049/jimmunol.175.11.7466; Kraemer SM, 2006, CURR OPIN MICROBIOL, V9, P374, DOI 10.1016/j.mib.2006.06.006; Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200; Lee K, 1999, TRANSFUSION, V39, P873, DOI 10.1046/j.1537-2995.1999.39080873.x; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; McGilvray ID, 2000, BLOOD, V96, P3231, DOI 10.1182/blood.V96.9.3231; Moffett-King A, 2002, NAT REV IMMUNOL, V2, P656, DOI 10.1038/nri886; Moretta L, 2004, EMBO J, V23, P255, DOI 10.1038/sj.emboj.7600019; Newman KC, 2006, PLOS PATHOG, V2, P1120, DOI 10.1371/journal.ppat.0020118; OCKENHOUSE CF, 1991, J INFECT DIS, V164, P163, DOI 10.1093/infdis/164.1.163; Pouvelle B, 1998, INFECT IMMUN, V66, P4950, DOI 10.1128/IAI.66.10.4950-4956.1998; Ricke CH, 2000, J IMMUNOL, V165, P3309, DOI 10.4049/jimmunol.165.6.3309; Rug M, 2006, BLOOD, V108, P370, DOI 10.1182/blood-2005-11-4624; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Urban BC, 2005, CURR TOP MICROBIOL, V297, P25; Urban BC, 2001, P NATL ACAD SCI USA, V98, P8750, DOI 10.1073/pnas.151028698; Viebig NK, 2005, EMBO REP, V6, P775, DOI 10.1038/sj.embor.7400466; Walther M, 2006, J IMMUNOL, V177, P5736, DOI 10.4049/jimmunol.177.8.5736	41	37	37	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e228	10.1371/journal.pone.0000228	http://dx.doi.org/10.1371/journal.pone.0000228			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311092	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444500009
J	Perez, JM; Calderon, IL; Arenas, FA; Fuentes, DE; Pradenas, GA; Fuentes, EL; Sandoval, JM; Castro, ME; Elias, AO; Vasquez, CC				Perez, Jose M.; Calderon, Ivan L.; Arenas, Felipe A.; Fuentes, Derie E.; Pradenas, Gonzalo A.; Fuentes, Eugenia L.; Sandoval, Juan M.; Castro, Miguel E.; Elias, Alex O.; Vasquez, Claudio C.			Bacterial Toxicity of Potassium Tellurite: Unveiling an Ancient Enigma	PLOS ONE			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; GENE-EXPRESSION; RESISTANCE; INACTIVATION; IDENTIFICATION; SENSITIVITY; RESPONSES; ENZYMES; IBPB	Biochemical, genetic, enzymatic and molecular approaches were used to demonstrate, for the first time, that tellurite (TeO32-) toxicity in E. coli involves superoxide formation. This radical is derived, at least in part, from enzymatic TeO32- reduction. This conclusion is supported by the following observations made in K2TeO3-treated E. coli BW25113: i) induction of the ibpA gene encoding for the small heat shock protein IbpA, which has been associated with resistance to superoxide, ii) increase of cytoplasmic reactive oxygen species (ROS) as determined with ROS-specific probe 2'7'-dichlorodihydrofluorescein diacetate (H(2)DCFDA), iii) increase of carbonyl content in cellular proteins, iv) increase in the generation of thiobarbituric acid-reactive substances (TBARs), v) inactivation of oxidative stress-sensitive [Fe-S] enzymes such as aconitase, vi) increase of superoxide dismutase (SOD) activity, vii) increase of sodA, sodB and soxS mRNA transcription, and viii) generation of superoxide radical during in vitro enzymatic reduction of potassium tellurite.	[Perez, Jose M.; Calderon, Ivan L.; Arenas, Felipe A.; Fuentes, Derie E.; Pradenas, Gonzalo A.; Fuentes, Eugenia L.; Sandoval, Juan M.; Castro, Miguel E.; Elias, Alex O.; Vasquez, Claudio C.] Univ Santiago Chile, Mol Microbiol Lab, Fac Quim & Biol, Santiago, Chile	Universidad de Santiago de Chile	Vasquez, CC (corresponding author), Univ Santiago Chile, Mol Microbiol Lab, Fac Quim & Biol, Santiago, Chile.	cvasquez@usach.cl	Pérez-Donoso, José M./G-3668-2013; Fuentes, Derie/GLS-8773-2022	Pérez-Donoso, José M./0000-0002-9506-1716; Fuentes, Derie/0000-0002-8189-8515	MECESUP; CONICYT; FONDECYT [1060022]; Dicyt, Universidad de Santiago de Chile	MECESUP; CONICYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)); FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); Dicyt, Universidad de Santiago de Chile	JMP, DEF and JMS received fellowships from MECESUP and ILC, FAA, MEC received fellowships from CONICYT. This work was supported in part by FONDECYT grant 1060022 to CCV and by Dicyt, Universidad de Santiago de Chile.	Araya MA, 2004, J BIOL INORG CHEM, V9, P609, DOI 10.1007/s00775-004-0554-z; Avazeri C, 1997, MICROBIOL-SGM, V143, P1181, DOI 10.1099/00221287-143-4-1181; Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050; BERGMEYER HU, 1974, METHOD ENZYMAT AN, V1, P485; Bianchi AA, 1999, APPL ENVIRON MICROB, V65, P5023; Borsetti F, 2005, RES MICROBIOL, V156, P807, DOI 10.1016/j.resmic.2005.03.011; Calderon IL, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000070; Chen GZ, 2003, ANTIMICROB AGENTS CH, V47, P3485, DOI 10.1128/AAC.47.11.3485-3493.2003; CHIONG M, 1988, J BACTERIOL, V170, P3269, DOI 10.1128/jb.170.7.3269-3273.1988; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; Echave P, 2003, J BIOL CHEM, V278, P30193, DOI 10.1074/jbc.M304351200; FRIDOVICH I, 1995, ANNU REV BIOCHEM, V64, P97, DOI 10.1146/annurev.bi.64.070195.000525; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Goldenberg D, 1996, MOL MICROBIOL, V19, P241, DOI 10.1046/j.1365-2958.1996.363898.x; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; ITOH M, 1995, J BIOCHEM-TOKYO, V4, P780; Jakubowski W, 2000, FREE RADICAL BIO MED, V28, P659, DOI 10.1016/S0891-5849(99)00266-X; Kitagawa M, 2000, FEMS MICROBIOL LETT, V184, P165, DOI 10.1111/j.1574-6968.2000.tb09009.x; Kitagawa M, 2002, EUR J BIOCHEM, V269, P2907, DOI 10.1046/j.1432-1033.2002.02958.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lohmeier-Vogel EM, 2004, APPL ENVIRON MICROB, V70, P7342, DOI 10.1128/AEM.70.12.7342-7347.2004; Missiakas D, 1998, MOL MICROBIOL, V28, P1059, DOI 10.1046/j.1365-2958.1998.00865.x; Moscoso H, 1998, RES MICROBIOL, V149, P389, DOI 10.1016/S0923-2508(98)80321-5; OGara JP, 1997, APPL ENVIRON MICROB, V63, P4713, DOI 10.1128/AEM.63.12.4713-4720.1997; Refsgaard HHF, 2000, P NATL ACAD SCI USA, V97, P611, DOI 10.1073/pnas.97.2.611; Rice-Evans C, 1991, LAB TECHNIQUES BIOCH, V22, P147; Rojas DM, 2005, RES MICROBIOL, V156, P465, DOI 10.1016/j.resmic.2004.12.010; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNARR M, 1991, BIOCHIMIE, V73, P423, DOI 10.1016/0300-9084(91)90109-E; SEKO Y, SELENIUM BIOL MED, P70; Semchyshyn H, 2005, CELL BIOL INT, V29, P898, DOI 10.1016/j.cellbi.2005.08.002; Shapiro E, 2002, ANTIMICROB AGENTS CH, V46, P2490, DOI 10.1128/AAC.46.8.2490-2497.2002; Silver S, 1998, J IND MICROBIOL BIOT, V20, P1, DOI 10.1038/sj.jim.2900483; SPALLHOLZ JE, 1994, FREE RADICAL BIO MED, V17, P45, DOI 10.1016/0891-5849(94)90007-8; SUMMERS AO, 1977, J BACTERIOL, V129, P276, DOI 10.1128/JB.129.1.276-281.1977; Tantalean JC, 2003, J BACTERIOL, V185, P5831, DOI 10.1128/JB.185.19.5831-5837.2003; Taylor DE, 1999, TRENDS MICROBIOL, V7, P111, DOI 10.1016/S0966-842X(99)01454-7; Tremaroli V, 2007, ARCH MICROBIOL, V187, P127, DOI 10.1007/s00203-006-0179-4; Turner RJ, 1999, MICROBIOL-UK, V145, P2549, DOI 10.1099/00221287-145-9-2549; Vasquez CC, 2001, CURR MICROBIOL, V43, P418, DOI 10.1007/s002840010331; Wang AY, 2005, J BACTERIOL, V187, P3259, DOI 10.1128/JB.187.9.3259-3266.2005; Westenberg DJ, 1997, ADV GENET, V36, P187, DOI 10.1016/S0065-2660(08)60310-7	45	126	130	1	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e211	10.1371/journal.pone.0000211	http://dx.doi.org/10.1371/journal.pone.0000211			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299591	Green Published, gold			2022-12-25	WOS:000207444400012
J	Chen, D; Zhang, Z; Li, M; Wang, W; Li, Y; Rayburn, ER; Hill, DL; Wang, H; Zhang, R				Chen, D.; Zhang, Z.; Li, M.; Wang, W.; Li, Y.; Rayburn, E. R.; Hill, D. L.; Wang, H.; Zhang, R.			Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function	ONCOGENE			English	Article						p53; MDM2; RPS7; protein degradation; proteasome; ubiquitination; tumor suppressor	IN-VIVO ACTIVITIES; RIBOSOME BIOGENESIS; NEGATIVE REGULATOR; TUMOR SUPPRESSION; ONCOPROTEIN MDM2; PROSTATE-CANCER; PATHWAY; INHIBITION; UBIQUITINATION; DEGRADATION	As a major negative regulator of p53, the MDM2 oncogene plays an important role in carcinogenesis and tumor progression. MDM2 promotes p53 proteasomal degradation and negatively regulates p53 function. The mechanisms by which the MDM2-p53 interaction is regulated are not fully understood, although several MDM2interacting molecules have recently been identified. To search for novel MDM2-binding partners, we screened a human prostate cDNA library by the yeast two-hybrid assay using full-length MDM2 protein as the bait. Among the candidate proteins, ribosomal protein S7 was identified and confirmed as a novel MDM2-interacting protein. Herein, we demonstrate that S7 binds to MDM2, in vitro and in vivo, and that the interaction between MDM2 and S7 leads to modulation of MDM2-p53 binding by forming a ternary complex among MDM2, p53 and S7. This results in the stabilization of p53 protein through abrogation of MDM2-mediated p53 ubiquitination. Consequently, S7 overexpression increases p53 transactivational activities, induces apoptosis, and inhibits cell proliferation. The identification of S7 as a novel MDM2-interacting partner contributes to elucidation of the complex regulation of the MDM2-p53 interaction and has implications in cancer prevention and therapy.	Univ Alabama, Dept Pharmacol & Toxicol, Div Clin Pharmacol, Birmingham, AL 35294 USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Wang, H (corresponding author), Univ Alabama, Dept Pharmacol & Toxicol, Div Clin Pharmacol, VH 113,1670 Univ Blvd, Birmingham, AL 35294 USA.	hui.wang@ccc.uab.edu; ruiwen.zhang@ccc.uab.edu	高, 雨莉/HGU-8187-2022		NATIONAL CANCER INSTITUTE [R01CA112029] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112029] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1992, NATURE, V358, P16; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li M, 2005, CANCER RES, V65, P8200, DOI 10.1158/0008-5472.CAN-05-1302; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Poyurovsky MV, 2006, GENE DEV, V20, P125, DOI 10.1101/gad.1397506; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang H, 2003, PROSTATE, V54, P194, DOI 10.1002/pros.10187; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Zhang RW, 2005, CURR CANCER DRUG TAR, V5, P43, DOI 10.2174/1568009053332663; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhang Z, 2005, ONCOGENE, V24, P7238, DOI 10.1038/sj.onc.1208814; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zhang Z, 2005, CURR CANCER DRUG TAR, V5, P9, DOI 10.2174/1568009053332618; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	37	190	198	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5029	5037		10.1038/sj.onc.1210327	http://dx.doi.org/10.1038/sj.onc.1210327			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310983				2022-12-25	WOS:000248487400001
J	Chun, SY; Chen, F; Washburn, JG; MacDonald, JW; Innes, KL; Zhao, R; Cruz-Correa, MR; Dang, LH; Dang, DT				Chun, S. Y.; Chen, F.; Washburn, J. G.; MacDonald, J. W.; Innes, K. L.; Zhao, R.; Cruz-Correa, M. R.; Dang, L. H.; Dang, D. T.			CDX2 promotes anchorage-independent growth bytranscriptional repression of IGFBP-3	ONCOGENE			English	Article						CDX2; IGFBP-3; colorectal cancer; anchorageindependent growth	FACTOR BINDING PROTEIN-3; GENE-EXPRESSION; FACTOR (IGF)-I; MUTANT MICE; CANCER; TRANSCRIPTION; CELLS	CDX2 is a Drosophila caudal-related homeobox transcription factor that is important for the establishment and maintenance of intestinal epithelial cells. We have reported that CDX2 promotes tumorigenicity in a subset of human colorectal cancer cell lines. Here, we present evidence that CDX2 negatively regulates the well-documented growth inhibitor insulin-like growth factor binding protein-3 IGFBP-3). Specifically, CDX2 binds to the IGFBP-3 gene promoter and can repress IGFBP-3 transcription, protein expression and secretion. Furthermore, inhibition of IGFBP-3 partially rescues the decreased anchorage-independent growth phenotype observed in CDX2 knockout cells. These data demonstrate for the first time that (1) CDX2 can function as a transcriptional repressor, and ( 2) one mechanism by which CDX2 promotes anchorage-independent growth is by transcriptional repression of IGFBP-3.	Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Affymetrix & cDNA Microarray Core Facil, Ann Arbor, MI 48109 USA; Univ Puerto Rico, Ctr Comprehens Canc, Dept Internal Med, Div Gastroenterol, San Juan, PR 00936 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Puerto Rico; University of Puerto Rico Medical Sciences Campus	Dang, DT (corresponding author), Univ Michigan, Dept Internal Med, Div Gastroenterol, 1150 W Med Ctr Dr,MSRB I,Room 6514, Ann Arbor, MI 48109 USA.	dangd@umich.edu			NATIONAL CANCER INSTITUTE [P30CA046592, K22CA111897] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059970] Funding Source: NIH RePORTER; NCI NIH HHS [K22CA111897, 5 P30 CA46592] Funding Source: Medline; NIDDK NIH HHS [K08DK59970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Baxter RC, 2001, J CLIN PATHOL-MOL PA, V54, P145, DOI 10.1136/mp.54.3.145; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; Dang LH, 2006, ONCOGENE, V25, P2264, DOI 10.1038/sj.onc.1209247; Escaffit F, 2006, BIOCHEM BIOPH RES CO, V342, P66, DOI 10.1016/j.bbrc.2006.01.128; FRANCIS GL, 1992, J MOL ENDOCRINOL, V8, P213, DOI 10.1677/jme.0.0080213; GERMAN MS, 1994, GENOMICS, V24, P403, DOI 10.1006/geno.1994.1639; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; JAMES R, 1994, J BIOL CHEM, V269, P15229; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; Lee HY, 2002, CANCER RES, V62, P3530; Pollak MN, 2004, NAT REV CANCER, V4, P505, DOI 10.1038/nrc1387; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Sims RJ, 2004, CURR OPIN CELL BIOL, V16, P263, DOI 10.1016/j.ceb.2004.04.004; Yamamoto H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2	19	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4725	4729		10.1038/sj.onc.1210258	http://dx.doi.org/10.1038/sj.onc.1210258			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297462				2022-12-25	WOS:000248037900013
J	Leupold, JH; Yang, HS; Colburn, NH; Asangani, I; Post, S; Allgayer, H				Leupold, J. H.; Yang, H-S; Colburn, N. H.; Asangani, I.; Post, S.; Allgayer, H.			Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors	ONCOGENE			English	Article						Pdcd4; Sp1; Sp3; invasion; intravasation; u-PAR	PLASMINOGEN-ACTIVATOR SYSTEM; TRANSFORMATION SUPPRESSOR; EUKARYOTIC TRANSLATION; PROGNOSTIC IMPACT; BINDING-PROTEIN; GROWTH-FACTOR; CELL-LINE; REQUIREMENT; PROMOTER; INVASION	Tumor suppressor Pdcd4 has recently been shown to inhibit invasion by activating activator protein-1 (AP-1); however, little is known of the functionally significant Pdcd4-target genes. The urokinase receptor (u-PAR) promotes invasion/metastasis, and is associated with poor cancer-patient survival. The present study was conducted (1) to investigate a role for Pdcd4 in intravasation, invasion and u-PAR regulation, and (2) to describe mechanisms by which this is achieved. Fourteen cell lines showed reciprocal expression of u-PAR/Pdcd4. Resected tumor/normal tissues of 29 colorectal cancer patients demonstrated a significant inverse correlation between Pdcd4/u-PAR. siRNA-Pdcd4-transfected GEO cells significantly increased endogenous u-PAR mRNA/protein. A u-PAR-promoter-chloramphenicol acetyl transferase (CAT)-reporter was reduced in activity with increasing Pdcd4 expression in RKO. Deletion of a putative Sp-1-binding site (-402/-350) inhibited u-PAR promoter regulation by Pdcd4, this being paralleled by a reduction of Sp1 binding to this region in pdcd4-transfected cells. Pdcd4-transfected cells showed an increase in Sp3 binding to u-PAR promoter region -152/-135, the deletion of which reduces the ability of Pdcd4 to suppress u- PAR promoter activity. Surprisingly, the u-PAR-AP-1 site was not targeted by Pdcd4. Finally, RKO cells overexpressing Pdcd4 showed an inhibition of invasion/intravasation (chicken embryo metastasis assay). These data suggest Pdcd4 as a new negative regulator of intravasation, and qas the invasion-related gene u-PAR. It is the first study to implicate Pdcd4 regulation of gene expression via Sp1/Sp3.	Heidelberg Univ, DKFZ Heidelberg, Med Fac Mannheim, Dept Expt Surg & Mol Oncol Solid Tumors, D-6900 Heidelberg, Germany; NCI, Basic Res Lab, Gene Regulat Sect, Frederick, MD USA; Heidelberg Univ, Med Fac Mannheim, Dept Surg, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ruprecht Karls University Heidelberg	Allgayer, H (corresponding author), Heidelberg Univ, Med Fac Mannheim, Dept Expt Surg Mol Oncol Solid Tumors, Collaborat Unit German Canc Res Ctr DKFZ Heidelbe, D-68167 Mannheim, Germany.	heike.allgayer@chir.ma.uni-heidelberg.de	Yang, Hsin-Sheng/A-6419-2008; Yang, Hsin-Sheng/AAF-6793-2020	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036; asangani, irfan/0000-0001-5381-1702	NATIONAL CANCER INSTITUTE [ZIABC010026, Z01BC010026] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Ahmed N, 2003, BRIT J CANCER, V89, P374, DOI 10.1038/sj.bjc.6601098; ALBINI A, 1987, CANCER RES, V47, P3239; Allgayer H, 1999, J BIOL CHEM, V274, P4702, DOI 10.1074/jbc.274.8.4702; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; Azzoni L, 1998, J IMMUNOL, V161, P3493; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BOYD D, 1988, CANCER RES, V48, P3112; BOYD D, 1989, CANCER RES, V49, P1948; CHEN S, 2003, P ICASSP HONG KONG C, V4, P640; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DUFFY MJ, 1987, EUR J CANCER CLIN ON, V23, P583, DOI 10.1016/0277-5379(87)90326-9; Fuchs T, 2003, BIOL CHEM, V384, P755, DOI 10.1515/BC.2003.084; GALLI G, 1992, COMPUTER SIMULATION, P261; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Goke R, 2004, ANN NY ACAD SCI, V1014, P220, DOI 10.1196/annals.1294.024; Hapke S, 2001, MOL CELL BIOL, V21, P2118, DOI 10.1128/MCB.21.6.2118-2132.2001; Heiss MM, 1996, EUR J SURG ONCOL, V22, P74, DOI 10.1016/S0748-7983(96)91649-2; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; JANICKE F, 1993, BREAST CANCER RES TR, V24, P195, DOI 10.1007/BF01833260; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; Kang MJ, 2002, BIOCHEM BIOPH RES CO, V293, P617, DOI 10.1016/S0006-291X(02)00264-4; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Lankat-Buttgereit B, 2004, MOL CELL ENDOCRINOL, V214, P149, DOI 10.1016/j.mce.2003.10.058; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; MONTE S, 2002, BIOTECHNIQUES, V33, P98; Muehlenweg B, 2001, EXPERT OPIN BIOL TH, V1, P683; NEKARDA H, 1994, CANCER RES, V54, P2900; Onishi Y, 1996, BIOCHEM BIOPH RES CO, V228, P7, DOI 10.1006/bbrc.1996.1609; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; Ritchie S, 2000, J BIOL CHEM, V275, P847, DOI 10.1074/jbc.275.2.847; Schewe DM, 2005, CLIN CANCER RES, V11, P8538, DOI 10.1158/1078-0432.CCR-05-0786; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Shetty S, 2004, AM J RESP CELL MOL, V31, P100, DOI 10.1165/rcmb.2003-0104OC; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Soejima H, 1999, CYTOGENET CELL GENET, V87, P113, DOI 10.1159/000015408; Stalberg P, 2001, BIOCHEM BIOPH RES CO, V281, P227, DOI 10.1006/bbrc.2001.4329; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; WAGNER SN, 1995, AM J PATHOL, V147, P183; Wang AY, 2000, EUR J BIOCHEM, V267, P3248, DOI 10.1046/j.1432-1327.2000.01350.x; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Zakowicz H, 2005, RNA, V11, P261, DOI 10.1261/rna.7191905; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588; Zijlstra A, 2002, CANCER RES, V62, P7083	61	139	143	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4550	4562		10.1038/sj.onc.1210234	http://dx.doi.org/10.1038/sj.onc.1210234			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297470				2022-12-25	WOS:000247836100009
J	Boelaert, K; Smith, VE; Stratford, AL; Kogai, T; Tannahill, LA; Watkinson, JC; Eggo, MC; Franklyn, JA; McCabe, CJ				Boelaert, K.; Smith, V. E.; Stratford, A. L.; Kogai, T.; Tannahill, L. A.; Watkinson, J. C.; Eggo, M. C.; Franklyn, J. A.; McCabe, C. J.			PTTG and PBF repress the human sodium iodide symporter	ONCOGENE			English	Article						PTTG; PBF; NIS; thyroid cancer	TUMOR-TRANSFORMING GENE; PAPILLARY THYROID CARCINOMAS; TRANSCRIPTIONAL ACTIVATION FUNCTION; SODIUM/IODIDE-SYMPORTER; NA+/I-SYMPORTER; GROWTH-FACTOR; CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; CHROMATID SEPARATION; PITUITARY-ADENOMAS; FOLLICULAR CELLS	The ability of the thyroid to accumulate iodide provides the basis for radioiodine ablation of differentiated thyroid cancers and their metastases. Most thyroid tumours exhibit reduced iodide uptake, although the mechanisms accounting for this remain poorly understood. Pituitary tumour transforming gene (PTTG) is a proto-oncogene implicated in the pathogenesis of thyroid tumours. We now show that PTTG and its binding factor PBF repress expression of sodium iodide symporter (NIS) messenger RNA (mRNA), and inhibit iodide uptake. This process is mediated at least in part through. fibroblast growth factor-2. In detailed studies of the NIS promoter in rat FRTL-5 cells, PTTG and PBF demonstrated specific inhibition of promoter activity via the human upstream enhancer element (hNUE). Within this similar to 1 kb element, a complex PAX8-upstream stimulating factor 1 (USF1) response element proved critical both to basal promoter activity and to PTTG and PBF repression of NIS. In particular, repression by PTTG was contingent upon the USF1, but not the PAX8, site. Finally, in human primary thyroid cells, PTTG and PBF similarly repressed the NIS promoter via hNUE. Taken together, our data suggest that the reported overexpression of PTTG and PBF in differentiated thyroid cancer has profound implications for activity of the NIS gene, and hence significantly impacts upon the ef. ficacy of radioiodine treatment.	Univ Birmingham, Dept Med, Inst Biomed Res, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Univ Coll Los Angeles, V A Greater Los Angeles Healthcare Syst, Dept Med Endocrinol & Diabet Div, Los Angeles, CA USA	University of Birmingham	McCabe, CJ (corresponding author), Univ Birmingham, Dept Med, Inst Biomed Res, Div Med Sci, Birmingham B15 2TH, W Midlands, England.	mccabcjz@bham.ac.uk	Smith, Vicki E/F-6972-2010	Smith, Vicki E/0000-0003-0757-7198	MRC [G0601811] Funding Source: UKRI; Medical Research Council [G0601811] Funding Source: Medline; Wellcome Trust Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Arturi F, 2000, EUR J ENDOCRINOL, V143, P623, DOI 10.1530/eje.0.1430623; Arturi F, 2001, EUR J ENDOCRINOL, V145, P129, DOI 10.1530/eje.0.1450129; Behr M, 1998, BIOCHEM J, V331, P359, DOI 10.1042/bj3310359; Boelaert K, 2004, J MOL ENDOCRINOL, V33, P663, DOI 10.1677/jme.1.01606; Boelaert K, 2003, FASEB J, V17, P1631, DOI 10.1096/fj.02-0948com; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Boelaert K, 2003, LANCET, V361, P796, DOI 10.1016/S0140-6736(03)12720-1; Caillou B, 1998, J CLIN ENDOCR METAB, V83, P4102, DOI 10.1210/jc.83.11.4102; Castro MR, 1999, J ENDOCRINOL, V163, P495, DOI 10.1677/joe.0.1630495; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Chun JT, 2004, MOL ENDOCRINOL, V18, P2817, DOI 10.1210/me.2004-0020; Cocks HC, 2003, AM J PHYSIOL-ENDOC M, V285, pE460, DOI 10.1152/ajpendo.00519.2002; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; Dohan O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Eggo MC, 1996, J CLIN ENDOCR METAB, V81, P3056, DOI 10.1210/jc.81.8.3056; EGGO MC, 1995, J CLIN ENDOCR METAB, V80, P1006, DOI 10.1210/jc.80.3.1006; Heaney AP, 2001, J CLIN ENDOCR METAB, V86, P5025, DOI 10.1210/jc.86.10.5025; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Ishikawa H, 2001, J CLIN ENDOCR METAB, V86, P867, DOI 10.1210/jc.86.2.867; Jhiang SM, 1998, ENDOCRINOLOGY, V139, P4416, DOI 10.1210/en.139.10.4416; Kim D, 2005, ONCOGENE, V24, P4861, DOI 10.1038/sj.onc.1208659; Kim DS, 2006, J CLIN ENDOCR METAB, V91, P4603, DOI 10.1210/jc.2006-1291; Kogai T, 2000, P NATL ACAD SCI USA, V97, P8519, DOI 10.1073/pnas.140217197; Kogai T, 1997, ENDOCRINOLOGY, V138, P2227, DOI 10.1210/en.138.6.2227; Lazar V, 1999, J CLIN ENDOCR METAB, V84, P3228, DOI 10.1210/jc.84.9.3228; Lin XQ, 2004, THYROID, V14, P19, DOI 10.1089/105072504322783803; Liou MJ, 2000, CANCER LETT, V160, P75, DOI 10.1016/S0304-3835(00)00565-6; McCabe Chris, 2001, Current Opinion in Pharmacology, V1, P620, DOI 10.1016/S1471-4892(01)00106-0; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; McCabe CJ, 2002, J CLIN ENDOCR METAB, V87, P4238, DOI 10.1210/jc.2002-020309; Park HJ, 2000, THYROID, V10, P211, DOI 10.1089/thy.2000.10.211; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Pei L, 2000, J BIOL CHEM, V275, P31191, DOI 10.1074/jbc.M002451200; Puri R, 2001, CANCER LETT, V163, P131, DOI 10.1016/S0304-3835(00)00688-1; Ramsden JD, 2001, J CLIN ENDOCR METAB, V86, P2709, DOI 10.1210/jc.86.6.2709; Ringel MD, 2001, MODERN PATHOL, V14, P289, DOI 10.1038/modpathol.3880305; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Ryu KY, 1999, THYROID, V9, P405, DOI 10.1089/thy.1999.9.405; Ryu KY, 1998, J CLIN ENDOCR METAB, V83, P3247, DOI 10.1210/jc.83.9.3247; Saez C, 2006, J CLIN ENDOCR METAB, V91, P1404, DOI 10.1210/jc.2005-2532; Saito T, 1998, J CLIN INVEST, V101, P1296, DOI 10.1172/JCI1259; Schmidt D, 2001, CURR OPIN HEMATOL, V8, P1, DOI 10.1097/00062752-200101000-00001; Shibata Y, 2002, JPN J CLIN ONCOL, V32, P233, DOI 10.1093/jjco/hyf058; Smanik PA, 1996, BIOCHEM BIOPH RES CO, V226, P339, DOI 10.1006/bbrc.1996.1358; Smanik PA, 1997, ENDOCRINOLOGY, V138, P3555, DOI 10.1210/en.138.8.3555; Spitzweg C, 1999, THYROID, V9, P821, DOI 10.1089/thy.1999.9.821; Stratford AL, 2005, J CLIN ENDOCR METAB, V90, P4341, DOI 10.1210/jc.2005-0523; Taki K, 2002, MOL ENDOCRINOL, V16, P2266, DOI 10.1210/me.2002-0109; Tanaka K, 2000, EUR J ENDOCRINOL, V142, P340, DOI 10.1530/eje.0.1420340; Yaspo ML, 1998, GENOMICS, V49, P133, DOI 10.1006/geno.1998.5217; Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137; Yu R, 2001, BRAIN PATHOL, V11, P328; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	59	40	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4344	4356		10.1038/sj.onc.1210221	http://dx.doi.org/10.1038/sj.onc.1210221			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297475				2022-12-25	WOS:000247620000003
J	Hattermann, K; Picard, S; Borgeat, M; Leclerc, P; Pouliot, M; Borgeat, P				Hattermann, Kim; Picard, Serge; Borgeat, Mathieu; Leclerc, Patrick; Pouliot, Marc; Borgeat, Pierre			The toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B-4, prostaglandin E-2 and platelet-activating factor biosynthesis	FASEB JOURNAL			English	Article						PMN; lipid mediators	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; 5-LIPOXYGENASE ENZYME-ACTIVITY; ARACHIDONIC-ACID AVAILABILITY; CYTOSOLIC PHOSPHOLIPASE A(2); COACTOSIN-LIKE PROTEIN; CYCLOOXYGENASE-2 EXPRESSION; CPG DNA; MACROPHAGES; RELEASE; CELLS	Toll-like receptors (TLR) recognize pathogen-associated molecular patterns and play important roles in the innate immune system. While single-stranded viral RNA is the natural ligand of TLR7/TLR8, the imidazoquinoline resiquimod (R-848) is recognized as a potent synthetic agonist of TLR7/ TLR8. We investigated the effects of TLR7/ 8 activation on lipid mediator production in polymorphonuclear leukocytes exposed to R-848. Although R-848 had minimal effects by itself, it strongly enhanced leukotriene B-4 formation on subsequent stimulation by fMLP, platelet-activating factor, and the ionophore A23187. R-848 acted via TLR8 but not TLR7 as shown by the lack of effect of the TLR7-specific ligand imiquimod. Priming with R-848 also resulted in enhanced arachidonic acid release and platelet-activating factor formation following fMLP stimulation, as well as enhanced prostaglandin E-2 synthesis following the addition of arachidonic acid. Western blot analysis demonstrated that R-848 induced the phosphorylation of the cytosolic phospholipase A(2)alpha, promoted 5-lipoxygenase translocation and potently stimulated the expression of the type 2 cyclooxygenase. Bafilomycin A1, an inhibitor of endosomal acidification, efficiently inhibited all R-848-induced effects. These studies demonstrate that TLR8 signaling strongly promotes inflammatory lipid mediator biosynthesis and provide novel insights on innate immune response to viral infections.	CHU Laval, CHUQ Res Ctr, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada	Laval University; Laval University	Borgeat, P (corresponding author), CHU Laval, CHUQ Res Ctr, Ctr Rech Rhumatol & Immunol, 2705 Blvd Laurier,Local T1-49, Quebec City, PQ G1V 4G2, Canada.	pierre.borgeat@crchul.ulaval.ca	Pouliot, Marc/G-4103-2016	Pouliot, Marc/0000-0002-2466-5424				Behera AK, 1998, BIOCHEM BIOPH RES CO, V251, P704, DOI 10.1006/bbrc.1998.9537; BENGTSSON T, 1991, J LEUKOCYTE BIOL, V49, P236, DOI 10.1002/jlb.49.3.236; BORGEAT P, 1990, METHOD ENZYMOL, V187, P98; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Cadieux JS, 2005, J CELL SCI, V118, P1437, DOI 10.1242/jcs.01737; Chang YJ, 2005, J IMMUNOL, V175, P8242, DOI 10.4049/jimmunol.175.12.8242; Chen YJ, 2001, INT IMMUNOL, V13, P1013, DOI 10.1093/intimm/13.8.1013; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CHRISTMAN BW, 1993, J IMMUNOL, V151, P2096; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; Dockrell DH, 2001, J ANTIMICROB CHEMOTH, V48, P751, DOI 10.1093/jac/48.6.751; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; Fenteany G, 2004, CURR OPIN HEMATOL, V11, P15, DOI 10.1097/00062752-200401000-00004; Fischer L, 2005, BBA-MOL CELL BIOL L, V1736, P109, DOI 10.1016/j.bbalip.2005.07.006; Flamand L, 2004, J INFECT DIS, V189, P2001, DOI 10.1086/386374; Flamand N, 2006, J BIOL CHEM, V281, P129, DOI 10.1074/jbc.M506513200; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; Ghosh DK, 2001, INFECT IMMUN, V69, P7703, DOI 10.1128/IAI.69.12.7703-7710.2001; Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259; Gosselin J, 2005, J IMMUNOL, V174, P1587, DOI 10.4049/jimmunol.174.3.1587; Gosselin J, 1997, BLOOD, V89, P2122, DOI 10.1182/blood.V89.6.2122; Harrison KA, 1999, J MASS SPECTROM, V34, P330, DOI 10.1002/(SICI)1096-9888(199904)34:4<330::AID-JMS798>3.0.CO;2-#; Hayashi F, 2003, BLOOD, V102, P2660, DOI 10.1182/blood-2003-04-1078; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Krump E, 1997, J EXP MED, V186, P1401, DOI 10.1084/jem.186.8.1401; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; Nagase H, 2003, J IMMUNOL, V171, P3977, DOI 10.4049/jimmunol.171.8.3977; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nataraj C, 2001, J CLIN INVEST, V108, P1229, DOI 10.1172/JCI13640; NOKTA MA, 1995, VIROLOGY, V208, P590, DOI 10.1006/viro.1995.1190; PALMBLAD J, 1981, BLOOD, V58, P658; Pouliot M, 1998, FASEB J, V12, P1109, DOI 10.1096/fasebj.12.12.1109; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Provost P, 2001, J BIOL CHEM, V276, P16520, DOI 10.1074/jbc.M011205200; Qi HY, 2005, J BIOL CHEM, V280, P38969, DOI 10.1074/jbc.M509352200; Radmark O, 2005, BIOCHEM BIOPH RES CO, V338, P102, DOI 10.1016/j.bbrc.2005.08.013; Radsak MP, 2004, J IMMUNOL, V172, P4956, DOI 10.4049/jimmunol.172.8.4956; Rakonjac M, 2006, P NATL ACAD SCI USA, V103, P13150, DOI 10.1073/pnas.0605150103; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Rubin BB, 2005, J BIOL CHEM, V280, P7519, DOI 10.1074/jbc.M407438200; SALARI H, 1985, INFLAMMATION, V9, P127, DOI 10.1007/BF00917585; Schlaepfer E, 2006, J IMMUNOL, V176, P2888, DOI 10.4049/jimmunol.176.5.2888; Serhan CN, 2003, CHEM IMMUNOL, V83, P115; Suram S, 2006, J BIOL CHEM, V281, P5506, DOI 10.1074/jbc.M509824200; SURETTE ME, 1993, J EXP MED, V178, P1347, DOI 10.1084/jem.178.4.1347; Surette ME, 1998, FASEB J, V12, P1521, DOI 10.1096/fasebj.12.14.1521; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186	54	51	54	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1575	1585		10.1096/fj.06-7457com	http://dx.doi.org/10.1096/fj.06-7457com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264163				2022-12-25	WOS:000246117000032
J	Rodamilans, B; Munoz, IG; Bragado-Nilsson, E; Sarrias, MR; Padilla, O; Blanco, FJ; Lozano, F; Montoya, G				Rodamilans, Bernardo; Munoz, Ines G.; Bragado-Nilsson, Elisabeth; Sarrias, Maria Rosa; Padilla, Olga; Blanco, Francisco J.; Lozano, Francisco; Montoya, Guillermo			Crystal structure of the third extracellular domain of CD5 reveals the fold of a group B scavenger cysteine-rich receptor domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL SURFACE-IMMUNOGLOBULIN; POTENTIAL SELECTING LIGAND; SRCR DOMAIN; IDENTIFICATION; MEMBRANE; GLYCOPROTEIN; SUPERFAMILY; ANCIENT; DESIGN; MODULE	Scavenger receptor cysteine-rich ( SRCR) domains are ancient protein modules widely found among cell surface and secreted proteins of the innate and adaptive immune system, where they mediate ligand binding. We have solved the crystal structure at 2.2 angstrom of resolution of the SRCR CD5 domain III, a human lymphocyte receptor involved in the modulation of antigen specific receptor-mediated T cell activation and differentiation signals. The first structure of a member of a group B SRCR domain reveals the fold of this ancient protein module into a central core formed by two antiparallel beta-sheets and one alpha-helix, illustrating the conserved core at the protein level of genes coding for group A and B members of the SRCR superfamily. The novel SRCR group B structure permits the interpretation of site-directed mutagenesis data on the binding of activated leukocyte cell adhesion molecule ( ALCAM/CD166) binding to CD6, a closely related lymphocyte receptor homologue to CD5.	Macromol Crystallog Ctr, Madrid 28029, Spain; NMR Grp, Madrid 28029, Spain; Spanish Natl Canc Ctr, CNIO, Struct Biol & Biocomp Program, Madrid 28029, Spain; Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Dept Immunol, E-08036 Barcelona, Spain; Univ Barcelona, Fac Med, Dept Cell Biol & Pathol, E-08036 Barcelona, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona	Montoya, G (corresponding author), Macromol Crystallog Ctr, Madrid 28029, Spain.	gmontoya@cnio.es	sarrias, maria rosa/D-6205-2014; Blanco, Francisco J/D-4401-2009; LOZANO, FRANCISCO/AAB-7888-2019; Rodamilans, Bernardo/ABA-9093-2021; Munoz, Ines G/M-3285-2014; Abrams, William R/A-5782-2008; Lozano-Soto, Francisco/AAB-7930-2019	sarrias, maria rosa/0000-0001-6929-8069; Blanco, Francisco J/0000-0003-2545-4319; LOZANO, FRANCISCO/0000-0003-1119-4368; Rodamilans, Bernardo/0000-0002-6541-2589; Munoz, Ines G/0000-0001-6732-4059; Lozano-Soto, Francisco/0000-0003-3714-2304				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Aruffo A, 1997, IMMUNOL TODAY, V18, P498, DOI 10.1016/S0167-5699(97)01130-4; Biancone L, 1996, J EXP MED, V184, P811, DOI 10.1084/jem.184.3.811; Bikah G, 1998, INT IMMUNOL, V10, P1185, DOI 10.1093/intimm/10.8.1185; Bodian DL, 1997, BIOCHEMISTRY-US, V36, P2637, DOI 10.1021/bi962560+; Bowen MA, 1996, J BIOL CHEM, V271, P17390, DOI 10.1074/jbc.271.29.17390; Bowen MA, 2000, PROTEINS, V40, P420; Calvo J, 1999, TISSUE ANTIGENS, V54, P128, DOI 10.1034/j.1399-0039.1999.540203.x; Calvo J, 1999, EUR J IMMUNOL, V29, P2119, DOI 10.1002/(SICI)1521-4141(199907)29:07<2119::AID-IMMU2119>3.3.CO;2-6; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Dustin ML, 2002, ARTHRITIS RES THER, V4, pS119, DOI 10.1186/ar559; Gimferrer I, 2003, J BIOL CHEM, V278, P8564, DOI 10.1074/jbc.M209591200; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HARDY RR, 1994, IMMUNOL REV, V137, P91, DOI 10.1111/j.1600-065X.1994.tb00660.x; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Levitt DG, 2001, ACTA CRYSTALLOGR D, V57, P1013, DOI 10.1107/S0907444901006394; LUO W, 1992, J IMMUNOL, V148, P1630; McAlister MSB, 1998, PROTEIN ENG, V11, P847, DOI 10.1093/protein/11.10.847; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pospisil R, 2000, LEUKEMIA LYMPHOMA, V36, P353, DOI 10.3109/10428190009148857; Pospisil R, 1996, J EXP MED, V184, P1279, DOI 10.1084/jem.184.4.1279; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; Rodamilans B, 2007, J STRUCT BIOL, V159, P144, DOI 10.1016/j.jsb.2007.01.003; Sarrias MR, 2004, CRIT REV IMMUNOL, V24, P1; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Skonier JE, 1997, PROTEIN ENG, V10, P943, DOI 10.1093/protein/10.8.943; Somoza JR, 2003, STRUCTURE, V11, P1123, DOI 10.1016/S0969-2126(03)00148-5; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Van de Velde H, 1996, CELL IMMUNOL, V172, P84, DOI 10.1006/cimm.1996.0218; VAN DE VELDE H, 1991, NATURE, V351, P662; vanderMerwe PA, 1996, CURR OPIN IMMUNOL, V8, P257, DOI 10.1016/S0952-7915(96)80065-3; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121	41	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12669	12677		10.1074/jbc.M611699200	http://dx.doi.org/10.1074/jbc.M611699200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17322294	Green Published, hybrid			2022-12-25	WOS:000245942800036
J	Baron, S; Escande, A; Alberola, G; Bystricky, K; Balaguer, P; Richard-Foy, H				Baron, Sylvain; Escande, Aurelie; Alberola, Geraldine; Bystricky, Kerstin; Balaguer, Patrick; Richard-Foy, Helene			Estrogen receptor alpha and the activating protein-1 complex cooperate during insulin-like growth factor-I-induced transcriptional activation of the pS2/TFF1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; C-JUN; CATHEPSIN-D; PS2 GENE; RESPONSIVE ELEMENT; LEUCINE ZIPPER; MCF7 CELLS; CROSS-TALK; HA-RAS; PHOSPHORYLATION	Insulin like growth factor I ( IGF-I) displays estrogenic activity in breast cancer cells. This activity is strictly dependent on the presence of estrogen receptor alpha ( ER alpha). However the precise molecular mechanisms involved in this process are still unclear. IGF-I treatment induces phosphorylation of the AF1 domain of ER alpha and activation of estrogen regulated genes. These genes are characterized by important differences in promoter architecture and response element composition. We show that promoter structure is crucial for IGF-I-induced transcription activation. We demonstrate that on a complex promoter such as the pS2/TFF1 promoter, which contains binding sites for ER alpha and for the activating protein-1 ( AP1) complex, transcriptional activation by IGF-I requires both ER alpha and the AP1 complex. IGF-I is unable to stimulate transcription of an estrogen-regulated gene under the control of a minimal promoter containing only a binding site for ER alpha. We propose a molecular mechanism with stepwise assembly of the AP1 complex and ER alpha during transcription activation of pS2/TFF1 by IGF-I. IGF-I stimulation induces rapid phosphorylation and an increase in protein levels of the AP1 complex. Binding of the phosphorylated AP1 complex to the pS2/TFF1 promoter allows recruitment of the chromatin remodeling factor Brg1 followed by binding of ER alpha via its interaction with c-Jun.	Univ Toulouse 3, UMR 5099, CNRS, Lab Biol Mol Eucaryote,IFR109, F-31062 Toulouse, France; INSERM U540, F-34090 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm)	Richard-Foy, H (corresponding author), Univ Toulouse 3, UMR 5099, CNRS, Lab Biol Mol Eucaryote,IFR109, 118 Route Narbonne, F-31062 Toulouse, France.	hrfoy@ibcg.biotoul.fr	Bystricky, Kerstin/AAA-3003-2020; BYSTRICKY, Kerstin/B-8670-2009; Balaguer, Patrick/I-2973-2016	Bystricky, Kerstin/0000-0001-6717-3721; BYSTRICKY, Kerstin/0000-0001-6717-3721; 				ALEXANDER MC, 1988, P NATL ACAD SCI USA, V85, P5092, DOI 10.1073/pnas.85.14.5092; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ASTRUC ME, 1995, ENDOCRINOLOGY, V136, P824, DOI 10.1210/en.136.3.824; Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.1205506; Balaguer P, 2001, LUMINESCENCE, V16, P153, DOI 10.1002/bio.630; Barkhem T, 2002, MOL PHARMACOL, V61, P1273, DOI 10.1124/mol.61.6.1273; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Callige M, 2005, MOL CELL BIOL, V25, P4349, DOI 10.1128/MCB.25.11.4349-4358.2005; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CHALBOS D, 1993, ENDOCRINOLOGY, V133, P571, DOI 10.1210/en.133.2.571; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Cowley SM, 1997, J BIOL CHEM, V272, P19858, DOI 10.1074/jbc.272.32.19858; DATTA R, 1991, CELL GROWTH DIFFER, V2, P43; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; Giamarchi C, 1999, ONCOGENE, V18, P533, DOI 10.1038/sj.onc.1202317; Giamarchi C, 2002, BBA-GENE STRUCT EXPR, V1578, P12, DOI 10.1016/S0167-4781(02)00480-3; Jakacka M, 2001, J BIOL CHEM, V276, P13615, DOI 10.1074/jbc.M008384200; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LE GP, 1994, J BIOL CHEM, V269, P4458; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; MINER JN, 1991, CELL GROWTH DIFFER, V2, P525; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Pace P, 1997, J BIOL CHEM, V272, P25832, DOI 10.1074/jbc.272.41.25832; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Pillon A, 2005, ENVIRON HEALTH PERSP, V113, P278, DOI 10.1289/ehp.7522; PONTA H, 1992, BIOCHIM BIOPHYS ACTA, V1129, P255, DOI 10.1016/0167-4781(92)90501-P; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHULE R, 1991, TRENDS GENET, V7, P377, DOI 10.1016/0168-9525(91)90259-S; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Takahashi T, 2005, ENDOCRINOLOGY, V146, P4082, DOI 10.1210/en.2005-0302; Teyssier C, 2001, J BIOL CHEM, V276, P36361, DOI 10.1074/jbc.M101806200; Tremblay GB, 1999, MOL CELL BIOL, V19, P1919; Varma H, 2002, CANCER RES, V62, P3985; Vogt PK, 2002, NAT REV CANCER, V2, P465, DOI 10.1038/nrc818; WILLIAM F, 1990, J BIOL CHEM, V265, P18166	47	31	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11732	11741		10.1074/jbc.M610079200	http://dx.doi.org/10.1074/jbc.M610079200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17317669	hybrid			2022-12-25	WOS:000245941900015
J	Binet, V; Duthey, B; Lecaillon, J; Vol, C; Quoyer, J; Labesse, G; Pin, JP; Prezeau, L				Binet, Virginie; Duthey, Beatrice; Lecaillon, Jennifer; Vol, Claire; Quoyer, Julie; Labesse, Gilles; Pin, Jean-Philippe; Prezeau, Laurent			Common structural requirements for heptahelical domain function in class A and class C G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; POSITIVE ALLOSTERIC MODULATOR; HIGHLY-CONSERVED ARGININE; 3RD INTRACELLULAR LOOPS; GABA(B) RECEPTOR; MUTATIONAL ANALYSIS; ALPHA(1B)-ADRENERGIC RECEPTOR; DRY MOTIF; CONSTITUTIVE ACTIVATION; CRYSTAL-STRUCTURE	Gprotein-coupled receptors (GPCRs) are key players in cell communication. Several classes of such receptors have been identified. Although all GPCRs possess a heptahelical domain directly activating G proteins, important structural and sequence differences within receptors from different classes suggested distinct activation mechanisms. Here we show that highly conserved charged residues likely involved in an interaction network between transmembrane domains (TM) 3 and 6 at the cytoplasmic side of class C GPCRs are critical for activation of the gamma-aminobutyric acid type B receptor. Indeed, the loss of function resulting from the mutation of the conserved lysine residue into aspartate or glutamate in the TM3 of gamma-aminobutyric acid type B-2 can be partly rescued by mutating the conserved acidic residue of TM6 into either lysine or arginine. In addition, mutation of the conserved lysine into an acidic residue leads to a nonfunctional receptor that displays a high agonist affinity. This is reminiscent of a similar ionic network that constitutes a lock stabilizing the inactive state of many class A rhodopsin-like GPCRs. These data reveal that despite their original structure, class C GPCRs share with class A receptors at least some common structural feature controlling G protein activation.	Univ Montpellier I, Dept Mol Pharmacol, Inst Genom Fonctionnelle, CNRS,UMR 5203,INSERM U661, F-34094 Montpellier 5, France; Univ Montpellier 2, Dept Mol Pharmacol, Inst Genom Fonctionnelle, CNRS,UMR 5203,INSERM U661, F-34094 Montpellier 5, France; Ctr Hosp Univ Montpellier, F-34000 Montpellier, France; Univ Montpellier I, INSERM, U554, CNRS,UMR 5048,Ctr Biochim Struct, F-34000 Montpellier, France; Univ Montpellier 2, INSERM, U554, CNRS,UMR 5048,Ctr Biochim Struct, F-34000 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Prezeau, L (corresponding author), Univ Montpellier I, Dept Mol Pharmacol, Inst Genom Fonctionnelle, CNRS,UMR 5203,INSERM U661, 141 Rue Cardonille, F-34094 Montpellier 5, France.	laurent.prezeau@igf.cnrs.fr	Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X; Labesse, Gilles/0000-0002-6861-3300				Acharya S, 1996, J BIOL CHEM, V271, P25406, DOI 10.1074/jbc.271.41.25406; Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Binet V, 2004, J BIOL CHEM, V279, P29085, DOI 10.1074/jbc.M400930200; Bockaert J, 2002, INT REV CYTOL, V212, P63; Brock C, 2005, MOL BIOL CELL, V16, P5572, DOI 10.1091/mbc.E05-05-0400; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Capra V, 2004, MOL PHARMACOL, V66, P880, DOI 10.1124/mol.104.001487; Catherinot V, 2004, BIOINFORMATICS, V20, P3694, DOI 10.1093/bioinformatics/bth429; Chang WH, 2000, J BIOL CHEM, V275, P19955, DOI 10.1074/jbc.M909613199; Chen A, 2001, BIOCHEM BIOPH RES CO, V284, P596, DOI 10.1006/bbrc.2001.5027; Couve A, 2004, J BIOL CHEM, V279, P13934, DOI 10.1074/jbc.M311737200; Couve A, 1998, J BIOL CHEM, V273, P26361, DOI 10.1074/jbc.273.41.26361; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; Duthey B, 2002, J BIOL CHEM, V277, P3236, DOI 10.1074/jbc.M108900200; Fanelli F, 1999, PROTEINS, V37, P145, DOI 10.1002/(SICI)1097-0134(19991101)37:2<145::AID-PROT1>3.0.CO;2-R; Filipek S, 2004, PHOTOCH PHOTOBIO SCI, V3, P628, DOI 10.1039/b315661c; Flanagan CA, 2005, MOL PHARMACOL, V68, P1, DOI 10.1124/mol.105.014183; Foord SM, 2005, PHARMACOL REV, V57, P279, DOI 10.1124/pr.57.2.5; Francesconi A, 1998, J BIOL CHEM, V273, P5615, DOI 10.1074/jbc.273.10.5615; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Gaillard I, 2004, HUM MOL GENET, V13, P771, DOI 10.1093/hmg/ddh086; Galvez T, 2001, EMBO J, V20, P2152, DOI 10.1093/emboj/20.9.2152; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gomeza J, 1996, MOL PHARMACOL, V50, P923; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Goudet C, 2004, P NATL ACAD SCI USA, V101, P378, DOI 10.1073/pnas.0304699101; Goudet C., 2004, DRUG DISCOV TODAY TH, V1, P125, DOI DOI 10.1016/J.DDSTR.2004.08.017; Greasley PJ, 2002, MOL PHARMACOL, V61, P1025, DOI 10.1124/mol.61.5.1025; Gruijthuijsen YK, 2004, J GEN VIROL, V85, P897, DOI 10.1099/vir.0.19709-0; Havlickova M, 2003, J BIOL CHEM, V278, P35063, DOI 10.1074/jbc.M306555200; HIGGINS D, 1994, NUCLEIC ACIDS RES, P4673; Jiang PH, 2005, J BIOL CHEM, V280, P15238, DOI 10.1074/jbc.M414287200; JONES PG, 1995, EUR J PHARM-MOLEC PH, V288, P251, DOI 10.1016/0922-4106(95)90036-5; Karnik SS, 2003, TRENDS ENDOCRIN MET, V14, P431, DOI 10.1016/j.tem.2003.09.007; Kniazeff J, 2004, J NEUROSCI, V24, P370, DOI 10.1523/JNEUROSCI.3141-03.2004; Kniazeff J, 2002, J NEUROSCI, V22, P7352; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Liu JF, 2004, J BIOL CHEM, V279, P15824, DOI 10.1074/jbc.M313639200; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Lu ZL, 1997, MOL PHARMACOL, V51, P234, DOI 10.1124/mol.51.2.234; Malherbe P, 2003, MOL PHARMACOL, V64, P823, DOI 10.1124/mol.64.4.823; Malherbe P, 2003, J BIOL CHEM, V278, P8340, DOI 10.1074/jbc.M211759200; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14649, DOI 10.1073/pnas.251554498; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Mezler M, 2001, EUR J NEUROSCI, V13, P477, DOI 10.1046/j.1460-9568.2001.01410.x; Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okinaga S, 2003, BIOCHEMISTRY-US, V42, P9406, DOI 10.1021/bi034489v; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; Pagano A, 2001, J NEUROSCI, V21, P1189; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Perez DM, 2005, PHARMACOL REV, V57, P147, DOI 10.1124/pr.57.2.2; Perroy J, 2003, EMBO J, V22, P3816, DOI 10.1093/emboj/cdg383; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; Pin JP, 2005, FEBS J, V272, P2947, DOI 10.1111/j.1742-4658.2005.04728.x; Pin JP, 2003, PHARMACOL THERAPEUT, V98, P325, DOI 10.1016/S0163-7258(03)00038-X; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; Pin JP, 2004, BIOL CELL, V96, P335, DOI 10.1016/j.biolcel.2004.03.005; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; Ray K, 2005, J BIOL CHEM, V280, P37013, DOI 10.1074/jbc.M506681200; Robbins MJ, 2001, J NEUROSCI, V21, P8043, DOI 10.1523/JNEUROSCI.21-20-08043.2001; Rosenkilde MM, 2005, MOL PHARMACOL, V68, P11, DOI 10.1124/mol.105.011239; ROSENTHAL W, 1993, J BIOL CHEM, V268, P13030; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Scheer A, 2000, MOL PHARMACOL, V57, P219; Scheer A, 1997, J RECEPT SIGNAL TR R, V17, P57, DOI 10.3109/10799899709036594; Seibold A, 1998, RECEPTOR CHANNEL, V5, P375; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Tateyama M, 2004, NAT STRUCT MOL BIOL, V11, P637, DOI 10.1038/nsmb770; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wilbanks AM, 2002, BIOCHEMISTRY-US, V41, P11981, DOI 10.1021/bi020275m; YANO K, 1995, J CLIN ENDOCR METAB, V80, P1162, DOI 10.1210/jc.80.4.1162	78	58	60	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12154	12163		10.1074/jbc.M611071200	http://dx.doi.org/10.1074/jbc.M611071200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17310064	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000245941900058
J	Ong, HL; Liu, XB; Tsaneva-Atanasova, K; Singh, BB; Bandyopadhyay, BC; Swaim, WD; Russell, JT; Hegde, RS; Sherman, A; Ambudkar, IS				Ong, Hwei Ling; Liu, Xibao; Tsaneva-Atanasova, Krasimira; Singh, Brij B.; Bandyopadhyay, Bidhan C.; Swaim, William D.; Russell, James T.; Hegde, Ramanujan S.; Sherman, Arthur; Ambudkar, Indu S.			Relocalization of STIM1 for activation of store-operated Ca2+ entry is determined by the depletion of subplasma membrane endoplasmic reticulum Ca2+ store	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CHANNEL FUNCTION; CRAC CHANNELS; CALCIUM-ENTRY; GLAND CELLS; INFLUX; SENSOR; DYNAMICS; RELEASE; ORAI1	STIM1 (stromal interacting molecule 1), an endoplasmic reticulum (ER) protein that controls store-operated Ca2+ entry (SOCE), redistributes into punctae at the cell periphery after store depletion. This redistribution is suggested to have a causal role in activation of SOCE. However, whether peripheral STIM1 punctae that are involved in regulation of SOCE are determined by depletion of peripheral or more internal ER has not yet been demonstrated. Here we show that Ca2+ depletion in subplasma membrane ER is sufficient for peripheral redistribution of STIM1 and activation of SOCE. 1 mu M thapsigargin (Tg) induced substantial depletion of intracellular Ca2+ stores and rapidly activated SOCE. In comparison, 1 nM Tg induced slower, about 60 - 70% less Ca2+ depletion but similar SOCE. SOCE was confirmed by measuring I-SOC in addition to Ca2+, Mn2+, and Ba2+ entry. Importantly, 1 nM Tg caused redistribution of STIM1 only in the ER-plasma membrane junction, whereas 1 mu M Tg caused a relatively global relocalization of STIM1 in the cell. During the time taken for STIM1 relocalization and SOCE activation, 1 nM Bodipy-fluorescein Tg primarily labeled the subplasma membrane region, whereas 1 mu M Tg labeled the entire cell. The localization of Tg in the subplasma membrane region was associated with depletion of ER in this region and activation of SOCE. Together, these data suggest that peripheral STIM1 relocalization that is causal in regulation of SOCE is determined by the status of [Ca2+] in the ER in close proximity to the plasma membrane. Thus, the mechanism involved in regulation of SOCE is contained within the ER-plasma membrane junctional region.	NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA; Univ N Dakota, Sch Med & Hlth Sci, Dept Biochem & Mol Biol, Grand Forks, ND 58203 USA; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; NIDDK, Lab Biol Modeling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of North Dakota Grand Forks; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ambudkar, IS (corresponding author), NIDCR, Secretory Physiol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10,Rm 1N-113,10 Ctr Dr, Bethesda, MD 20892 USA.	indu.ambudkar@nih.gov	Tsaneva-Atanasova, Krasimira T/AAG-6766-2019; Bandyopadhyay, Bidhan/AAC-6828-2022	Tsaneva-Atanasova, Krasimira T/0000-0002-6294-7051; Bandyopadhyay, Bidhan/0000-0003-2364-8945; Hegde, Ramanujan/0000-0001-8338-852X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008752, Z01HD001206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK013028] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR017699, P20 RR017699-077011] Funding Source: Medline; NIDCR NIH HHS [R01 DE017102, R01 DE017102-03, R01 DE017102-01A1, R01 DE017102-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMBUDKAR IS, 2004, SCI STKE, pPE32; Bandyopadhyay BC, 2005, J BIOL CHEM, V280, P12908, DOI 10.1074/jbc.M410013200; Berridge Michael, 2004, Sci STKE, V2004, ppe33; Bollimuntha S, 2005, J BIOL CHEM, V280, P2132, DOI 10.1074/jbc.M407384200; Brostrom MA, 2003, CELL CALCIUM, V34, P345, DOI 10.1016/S0143-4160(03)00127-1; Burdakov D, 2005, CELL CALCIUM, V38, P303, DOI 10.1016/j.ceca.2005.06.010; Glitsch MD, 2000, J PHYSIOL-LONDON, V523, P283, DOI 10.1111/j.1469-7793.2000.t01-2-00283.x; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Huang Y, 1998, J BIOL CHEM, V273, P19554, DOI 10.1074/jbc.273.31.19554; Landolfi B, 1998, J CELL BIOL, V142, P1235, DOI 10.1083/jcb.142.5.1235; Lee MY, 2006, P NATL ACAD SCI USA, V103, P13232, DOI 10.1073/pnas.0605757103; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liu X, 2004, J MEMBRANE BIOL, V200, P93, DOI 10.1007/s00232-004-0698-3; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 2005, J BIOL CHEM, V280, P21600, DOI 10.1074/jbc.c400492200; Liu XB, 2003, J BIOL CHEM, V278, P11337, DOI 10.1074/jbc.M213271200; Liu XB, 2001, J BIOL CHEM, V276, P29891, DOI 10.1074/jbc.M103283200; Liu XB, 1999, J BIOL CHEM, V274, P25121, DOI 10.1074/jbc.274.35.25121; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; MERTZ LM, 1990, J BIOL CHEM, V265, P15010; Ong HL, 2007, PFLUG ARCH EUR J PHY, V453, P797, DOI 10.1007/s00424-006-0163-5; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parekh AB, 2003, J PHYSIOL-LONDON, V547, P333, DOI 10.1113/jphysiol.2002.034140; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Petersen OH, 2002, BIOL RES, V35, P177, DOI 10.4067/S0716-97602002000200008; Putney J W Jr, 2001, Mol Interv, V1, P84; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Singh BB, 2002, MOL CELL, V9, P739, DOI 10.1016/S1097-2765(02)00506-3; Smyth JT, 2006, BBA-MOL CELL RES, V1763, P1147, DOI 10.1016/j.bbamcr.2006.08.050; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P4040, DOI 10.1073/pnas.0510050103; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Won JH, 2006, AM J PHYSIOL-GASTR L, V291, pG146, DOI 10.1152/ajpgi.00003.2006; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Yao J, 2004, J BIOL CHEM, V279, P21511, DOI 10.1074/jbc.M314028200; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	42	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12176	12185		10.1074/jbc.M609435200	http://dx.doi.org/10.1074/jbc.M609435200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17298947	Green Accepted, hybrid			2022-12-25	WOS:000245941900060
J	Zhao, TJ; Yan, YB; Liu, Y; Zhou, HM				Zhao, Tong-Jin; Yan, Yong-Bin; Liu, Yang; Zhou, Hai-Meng			The generation of the oxidized form of creatine kinase is a negative regulation on muscle creatine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; M-LINE; MYOFIBRILLAR PROTEINS; M-BAND; COMPARTMENTATION; UBIQUITINATION; INACTIVATION; FLUORESCENCE; DEGRADATION; EXPRESSION	Muscle creatine kinase ( CK) is a crucial enzyme in energy metabolism, and it exists in two forms, the reduced form ( R-CK) and the oxidized form ( O-CK). In contrast with R-CK, O-CK contained an intrachain disulfide bond in each subunit. Here we explored the properties of O-CK and its regulatory role on muscle CK. The intrachain disulfide bond in O-CK was demonstrated to be formed between Cys(74) and Cys(146) by site-directed mutagenesis. Biophysical analysis indicated that O-CK showed decreased catalytic activity and that it might be structurally unstable. Further assays through guanidine hydrochloride denaturation and proteolysis by trypsin and protease K revealed that the tertiary structure of O-CK was more easily disturbed than that of R-CK. Surprisingly, O-CK, unlike R-CK, cannot interact with the M-line protein myomesin through biosensor assay, indicating that O-CK might have no role in muscle contraction. Through in vitro ubiquitination assay, CK was demonstrated to be a specific substrate of muscle ring finger protein 1 ( MURF-1). O-CK can be rapidly ubiquitinated by MURF-1, while R-CK can hardly be ubiquitinated, implying that CK might be degraded by the ATP-ubiquitin-proteasome pathway through the generation of O-CK. The results above were further confirmed by molecular modeling of the structure of O-CK. Therefore, it can be concluded that the generation of O-CK was a negative regulation of R-CK and that O-CK might play essential roles in the molecular turnover of MM-CK.	Tsinghua Univ, Dept Biol Sci & Technol, Beijing 100084, Peoples R China; Tsinghua Univ, Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Tsinghua Univ, Sch Life Sci & Engn, Prot Sci Lab, Minist Educ, Beijing 100084, Peoples R China; Tsing Hua Univ, Yangtze Delta Reg Inst, Jiaxing 314050, Zhejiang, Peoples R China	Tsinghua University; Tsinghua University; Tsinghua University; Tsinghua University	Zhou, HM (corresponding author), Tsinghua Univ, Dept Biol Sci & Technol, Beijing 100084, Peoples R China.	zhm-dbs@mail.tsinghua.edu.cn	Yan, Yong-Bin/A-4282-2008; Zhao, Tong-Jin/AFH-2915-2022	Yan, Yong-Bin/0000-0002-8565-3558; 				Borders CL, 2003, PROTEIN SCI, V12, P532, DOI 10.1110/ps.0230403; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; Burtis C.A., 1999, TIETZ TXB CLIN CHEM, P1654; Cox JM, 2003, BIOCHEMISTRY-US, V42, P1863, DOI 10.1021/bi027083b; Ellington WR, 2001, ANNU REV PHYSIOL, V63, P289, DOI 10.1146/annurev.physiol.63.1.289; GROSS M, 1995, BIOCHEMISTRY-US, V34, P10350, DOI 10.1021/bi00033a005; Guo SY, 2003, BIOCHIMIE, V85, P999, DOI 10.1016/j.biochi.2003.08.002; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hornemann T, 2000, J CELL BIOL, V149, P1225, DOI 10.1083/jcb.149.6.1225; Hornemann T, 2003, J MOL BIOL, V332, P877, DOI 10.1016/S0022-2836(03)00921-5; Hurne AM, 2000, J BIOL CHEM, V275, P25202, DOI 10.1074/jbc.M002278200; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Kedar V, 2004, P NATL ACAD SCI USA, V101, P18135, DOI 10.1073/pnas.0404341102; Kraft T, 2000, J MUSCLE RES CELL M, V21, P691, DOI 10.1023/A:1005623002979; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P13861, DOI 10.1021/bi026655p; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Liu Y, 2005, PROTEIN EXPRES PURIF, V44, P155, DOI 10.1016/j.pep.2005.03.030; MCCLURE WO, 1966, BIOCHEMISTRY-US, V5, P1908, DOI 10.1021/bi00870a018; MILLWARD DJ, 1981, ACTA BIOL MED GER, V40, P1309; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Rao JK, 1998, FEBS LETT, V439, P133; Solomon V, 1996, J BIOL CHEM, V271, P26690, DOI 10.1074/jbc.271.43.26690; VENTURACLAPIER R, 1994, MOL CELL BIOCHEM, V133, P125, DOI 10.1007/BF01267952; VINKEMEIER U, 1993, J CELL SCI, V106, P319; WALLIMANN T, 1978, P NATL ACAD SCI USA, V75, P4296, DOI 10.1073/pnas.75.9.4296; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1977, J CELL BIOL, V75, P297, DOI 10.1083/jcb.75.2.297; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; WANG XC, 1994, SCI CHINA SER B, V37, P964; Webb TI, 2001, PROTEINS, V42, P269, DOI 10.1002/1097-0134(20010201)42:2<269::AID-PROT140>3.0.CO;2-Y; WEGMANN G, 1992, J MUSCLE RES CELL M, V13, P420, DOI 10.1007/BF01738037; Witt SH, 2005, J MOL BIOL, V350, P713, DOI 10.1016/j.jmb.2005.05.021; WYSS M, 1993, BIOCHEMISTRY-US, V32, P10727, DOI 10.1021/bi00091a025; YAO QZ, 1982, SCI SIN B-CHEM B A M, V25, P1296; Zhao TJ, 2006, FEBS LETT, V580, P3835, DOI 10.1016/j.febslet.2006.05.076; Zhao TJ, 2006, INT J BIOCHEM CELL B, V38, P1614, DOI 10.1016/j.biocel.2006.04.002	38	44	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12022	12029		10.1074/jbc.M610363200	http://dx.doi.org/10.1074/jbc.M610363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17303563	hybrid			2022-12-25	WOS:000245941900044
J	Lo, KWH; Kogoy, JM; Pfister, KK				Lo, Kevin W. -H.; Kogoy, John M.; Pfister, K. Kevin			The DYNLT3 light chain directly links cytoplasmic dynein to a spindle checkpoint protein, Bub3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATION; DROSOPHILA EMBRYOS; INTERMEDIATE CHAIN; KINETOCHORE FIBERS; BETA-TUBULIN; LIVING CELLS; IN-VIVO; MITOSIS; TRANSPORT; TCTEX-1	Cytoplasmic dynein is the motor protein responsible for the intracellular transport of various organelles and other cargoes toward microtubule minus ends. However, it remains to be determined how dynein is regulated to accomplish its varied roles. The dynein complex contains six subunits, including three classes of light chains. The two isoforms of the DYNLT ( Tctex1) family of light chains, DYNLT1 and DYNLT3, have been proposed to link dynein to specific cargoes. However, no specific binding partner had been found for the DYNLT3 light chain. We find that DYNLT3 binds to Bub3, a spindle checkpoint protein. Bub3 binds exclusively to DYNLT3 and not to the other dynein light chains. Glutathione S-transferase pull-down and co-immunoprecipitation assays demonstrate that Bub3 interacts with the cytoplasmic dynein complex. DYNLT3 is present on kinetochores at prometaphase, but not later mitotic stages, demonstrating that this dynein light chain, like Bub3 and other checkpoint proteins, is depleted from the kinetochore during chromosome alignment. Knockdown of DYNLT3 with small interference RNA increases the mitotic index, in particular, the number of cells in prophase/prometaphase. These results demonstrate that dynein binds directly to a component of the spindle checkpoint complex through the DYNLT3 light chain. Thus, DYNLT3 contributes to dynein cargo binding specificity. These data also suggest that the subpopulation of dynein, containing the DYNLT3 light chain, may be important for chromosome congression, in addition to having a role in the transport of checkpoint proteins from the kinetochore to the spindle pole.	Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia	Pfister, KK (corresponding author), Univ Virginia, Sch Med, Dept Cell Biol, POB 800732, Charlottesville, VA 22908 USA.	kkp9w@virginia.edu						Aguilar RC, 1997, J BIOL CHEM, V272, P27160, DOI 10.1074/jbc.272.43.27160; ALEXANDER SP, 1991, J CELL BIOL, V113, P805, DOI 10.1083/jcb.113.4.805; Basto R, 2004, CURR BIOL, V14, P56, DOI 10.1016/j.cub.2003.12.025; Chan Gordon K, 2003, Prog Cell Cycle Res, V5, P431; Chuang JZ, 2001, J NEUROSCI, V21, P5501, DOI 10.1523/JNEUROSCI.21-15-05501.2001; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; Douglas MW, 2004, J BIOL CHEM, V279, P28522, DOI 10.1074/jbc.M311671200; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Fraschini R, 2001, EMBO J, V20, P6648, DOI 10.1093/emboj/20.23.6648; Gee M, 1998, EUR BIOPHYS J BIOPHY, V27, P466, DOI 10.1007/s002490050157; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Howell BJ, 2004, CURR BIOL, V14, P953, DOI 10.1016/j.cub.2004.05.053; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; Koonce MP, 2004, TRENDS CELL BIOL, V14, P612, DOI 10.1016/j.tcb.2004.09.013; Lai MZ, 2005, NAT NEUROSCI, V8, P435, DOI 10.1038/nn1418; LEE MK, 1990, CELL MOTIL CYTOSKEL, V17, P118, DOI 10.1002/cm.970170207; LEE MK, 1990, P NATL ACAD SCI USA, V87, P7195, DOI 10.1073/pnas.87.18.7195; Lo Kevin W-H, 2007, Methods Mol Biol, V392, P85, DOI 10.1007/978-1-59745-490-2_6; Lo KWH, 2006, J BIOL CHEM, V281, P9552, DOI 10.1074/jbc.M511721200; Lopes CS, 2005, J CELL SCI, V118, P187, DOI 10.1242/jcs.01602; Maiato H, 2004, J CELL BIOL, V167, P831, DOI 10.1083/jcb.200407090; Mallik R, 2004, CURR BIOL, V14, pR971, DOI 10.1016/j.cub.2004.10.046; Meraldi P, 2005, EMBO J, V24, P1621, DOI 10.1038/sj.emboj.7600641; Mok YK, 2001, J BIOL CHEM, V276, P14067, DOI 10.1074/jbc.M011358200; MYERS KR, 2007, J NEUROSCI RES; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; NAKAGAWA J, 1989, J CELL SCI, V94, P449; O'Connell CB, 2000, MOL BIOL CELL, V11, P1765, DOI 10.1091/mbc.11.5.1765; Ohka S, 2004, J VIROL, V78, P7186, DOI 10.1128/JVI.78.13.7186-7198.2004; Oiwa K, 2005, CURR OPIN CELL BIOL, V17, P98, DOI 10.1016/j.ceb.2004.12.006; Pfister KK, 2006, PLOS GENET, V2, P11, DOI 10.1371/journal.pgen.0020001; Pfister KK, 2005, J CELL BIOL, V171, P411, DOI 10.1083/jcb.200508078; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Schmidt DJ, 2005, MOL BIOL CELL, V16, P1200, DOI 10.1091/mbc.E04-06-0523; Schwarzer C, 2002, INT J BIOCHEM CELL B, V34, P1059, DOI 10.1016/S1357-2725(02)00026-2; Shah JV, 2004, CURR BIOL, V14, P942, DOI 10.1016/j.cub.2004.05.046; Sharp DJ, 2000, NAT CELL BIOL, V2, P922, DOI 10.1038/35046574; Sharp DJ, 2000, MOL BIOL CELL, V11, P241, DOI 10.1091/mbc.11.1.241; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tai AW, 1998, J BIOL CHEM, V273, P19639, DOI 10.1074/jbc.273.31.19639; Tang ZY, 2004, P NATL ACAD SCI USA, V101, P18012, DOI 10.1073/pnas.0408600102; Topper LM, 2001, J CELL BIOL, V154, P707, DOI 10.1083/jcb.200104130; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Waters JC, 1998, J CELL BIOL, V141, P1181, DOI 10.1083/jcb.141.5.1181; Wilson DK, 2005, J BIOL CHEM, V280, P13944, DOI 10.1074/jbc.M412919200; Wilson MJ, 2001, CELL MOTIL CYTOSKEL, V49, P229, DOI 10.1002/cm.1036; Wojcik E, 2001, NAT CELL BIOL, V3, P1001, DOI 10.1038/ncb1101-1001; Wu HW, 2005, STRUCTURE, V13, P213, DOI 10.1016/j.str.2004.11.013	58	39	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11205	11212		10.1074/jbc.M611279200	http://dx.doi.org/10.1074/jbc.M611279200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17289665	hybrid			2022-12-25	WOS:000245941500042
J	Rigoni, M; Pizzo, P; Schiavo, G; Weston, AE; Zatti, G; Caccin, P; Rossetto, O; Pozzan, T; Montecucco, C				Rigoni, Michela; Pizzo, Paola; Schiavo, Giampietro; Weston, Anne E.; Zatti, Giancarlo; Caccin, Paola; Rossetto, Ornella; Pozzan, Tullio; Montecucco, Cesare			Calcium influx and mitochondrial alterations at synapses exposed to snake neurotoxins or their phospholipid hydrolysis products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-BUNGAROTOXIN; NEUROMUSCULAR-JUNCTION; NERVE-TERMINALS; MEMBRANE-FUSION; SMOOTH-MUSCLE; CELLS; LYSOPHOSPHATIDYLCHOLINE; HEMIFUSION; EXOCYTOSIS; VESICLES	Snake presynaptic phospholipase A2 neurotoxins ( SPANs) bind to the presynaptic membrane and hydrolyze phosphatidylcholine with generation of lysophosphatidylcholine ( LysoPC) and fatty acid ( FA). The LysoPC + FA mixture promotes membrane fusion, inducing the exocytosis of the ready-to-release synaptic vesicles. However, also the reserve pool of synaptic vesicles disappears from nerve terminals intoxicated with SPAN or LysoPC + FA. Here, we show that LysoPC + FA and SPANs cause a large influx of extracellular calcium into swollen nerve terminals, which accounts for the extensive synaptic vesicle release. This is paralleled by the change of morphology and the collapse of membrane potential of mitochondria within nerve bulges. These results complete the picture of events occurring at nerve terminals intoxicated by SPANs and define the LysoPC + FA lipid mixture as a novel and effective agonist of synaptic vesicle release.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Inst Neurosci, I-35121 Padua, Italy; Lincolns Inn Field Labs, Canc Res UK London Res Inst, London WC2A 3PX, England; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Cancer Research UK; Veneto Institute Molecular Medicine	Montecucco, C (corresponding author), Univ Padua, Dept Biomed Sci, Viale G Colombo 3, I-35121 Padua, Italy.	cesare.montecucco@unipd.it	Pizzo, Paola/T-4874-2018; rossetto, ornella/AAC-3866-2022	Pizzo, Paola/0000-0001-6077-3265; rossetto, ornella/0000-0002-6113-3857; Schiavo, Giampietro/0000-0002-4319-8745; Weston, Anne/0000-0001-6701-224X; Zatti, Giancarlo/0000-0002-1434-8783				Arce V, 1999, J NEUROSCI RES, V55, P119, DOI 10.1002/(SICI)1097-4547(19990101)55:1<119::AID-JNR13>3.3.CO;2-Y; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bohnert S, 2005, J BIOL CHEM, V280, P42336, DOI 10.1074/jbc.M506750200; Bonanomi D, 2005, MOL PHARMACOL, V67, P1901, DOI 10.1124/mol.104.005678; Campanella M, 2004, BIOL RES, V37, P653; CECCARELLI B, 1972, J CELL BIOL, V54, P30, DOI 10.1083/jcb.54.1.30; CHEN I, 1970, VIRCHOWS ARCH B, V6, P318; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Chernomordik LV, 2005, CELL, V123, P375, DOI 10.1016/j.cell.2005.10.015; Corda D, 2006, TRENDS CELL BIOL, V16, P167, DOI 10.1016/j.tcb.2006.01.007; CULLCANDY SG, 1976, NEUROSCIENCE, V1, P175, DOI 10.1016/0306-4522(76)90074-9; Dixon RW, 1999, AM J PATHOL, V154, P447, DOI 10.1016/S0002-9440(10)65291-1; FASOLATO C, 1989, J BIOL CHEM, V264, P19630; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; Giacomello M, 2005, NEUROBIOL DIS, V18, P638, DOI 10.1016/j.nbd.2004.10.016; Giraudo CG, 2005, J CELL BIOL, V170, P249, DOI 10.1083/jcb.200501093; GOPALAKRISHNAKONE P, 1984, TOXICON, V22, P791, DOI 10.1016/0041-0101(84)90162-4; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; Kini R.M., 1997, VENOM PHOSPHOLIPASE; Leung YM, 1998, LIFE SCI, V63, P965, DOI 10.1016/S0024-3205(98)00354-3; LEVI G, 1984, BRAIN RES, V290, P77, DOI 10.1016/0006-8993(84)90737-6; Montecucco C, 2000, TRENDS BIOCHEM SCI, V25, P266, DOI 10.1016/S0968-0004(00)01556-5; Murthy VN, 2003, ANNU REV NEUROSCI, V26, P701, DOI 10.1146/annurev.neuro.26.041002.131445; NG RH, 1978, BIOCHEMISTRY-US, V17, P4978, DOI 10.1021/bi00616a019; NICHOLLS D, 1985, BIOCHEM J, V229, P653, DOI 10.1042/bj2290653; Reese C, 2005, J CELL BIOL, V171, P981, DOI 10.1083/jcb.200510018; Rigoni M, 2005, SCIENCE, V310, P1678, DOI 10.1126/science.1120640; Rigoni M, 2004, J CELL SCI, V117, P3561, DOI 10.1242/jcs.01218; Rizzoli SO, 2005, NAT REV NEUROSCI, V6, P57, DOI 10.1038/nrn1583; Rossetto O, 2006, J NEUROCHEM, V97, P1534, DOI 10.1111/j.1471-4159.2006.03965.x; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; RUGOLO M, 1986, BIOCHEM J, V233, P519, DOI 10.1042/bj2330519; Ryan TA, 2006, CURR OPIN CELL BIOL, V18, P416, DOI 10.1016/j.ceb.2006.06.013; So I, 2005, INT J IMPOT RES, V17, P475, DOI 10.1038/sj.ijir.3901356; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Ushkaryov YA, 2004, TOXICON, V43, P527, DOI 10.1016/j.toxicon.2004.02.008; Wilson-Ashworth HA, 2004, J MEMBRANE BIOL, V200, P25, DOI 10.1007/s00232-004-0691-x; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; WOODLEY SL, 1991, J MOL CELL CARDIOL, V23, P671, DOI 10.1016/0022-2828(91)90977-T; Wright CE, 1996, BRIT J PHARMACOL, V119, P49, DOI 10.1111/j.1476-5381.1996.tb15676.x; Xu YB, 2005, NAT STRUCT MOL BIOL, V12, P417, DOI 10.1038/nsmb921; Zheng MQ, 2006, PHARMACOLOGY, V76, P192, DOI 10.1159/000092041; Zimmerberg J, 2005, SCIENCE, V310, P1626, DOI 10.1126/science.1122439	44	53	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11238	11245		10.1074/jbc.M610176200	http://dx.doi.org/10.1074/jbc.M610176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311918	hybrid			2022-12-25	WOS:000245941500046
J	Valencia, JC; Rouzaud, F; Julien, S; Chen, KG; Passeron, T; Yamaguchi, Y; Abu-Asab, M; Tsokos, M; Costin, GE; Yamaguchi, H; Jenkins, LMM; Nagashima, K; Appella, E; Hearing, VJ				Valencia, Julio C.; Rouzaud, Francois; Julien, Sylvain; Chen, Kevin G.; Passeron, Thierry; Yamaguchi, Yuji; Abu-Asab, Mones; Tsokos, Maria; Costin, Gertrude E.; Yamaguchi, Hiroshi; Jenkins, Lisa M. Miller; Nagashima, Kunio; Appella, Ettore; Hearing, Vincent J.			Sialylated core 1 O-glycans influence the sorting of Pmel17/gp100 and determine its capacity to form fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX PROTEIN PMEL17/GP100; SURFACE SIALIC-ACID; LINKED GLYCOSYLATION; MELANOMA-CELLS; MESSENGER-RNA; GENOMIC ORGANIZATION; MUTANT DEFICIENT; PLASMA-MEMBRANE; UDP-GALACTOSE; DNA-DAMAGE	Pmel17 is a melanocyte/melanoma-specific protein that is essential for the maturation of melanosomes to form mature, fibrillar, and pigmented organelles. Recently, we reported that the less glycosylated form of Pmel17 ( termed iPmel17) is sorted via the plasma membrane in a manner distinct from mature Pmel17 ( termed mPmel17), which is sorted directly to melanosomes. To clarify the mechanism( s) underlying the distinct processing and sorting of Pmel17, we generated a highly specific antibody ( termed alpha PEP25h) against an epitope within the repeat domain of Pmel17 that is sensitive to changes in O-glycosylation. alpha PEP25h recognizes only iPmel17 and allows analysis of the processing and sorting of iPmel17 when compared with alpha PEP13h, an antibody that recognizes both iPmel17 and mPmel17. Our novel findings using alpha PEP25h demonstrate that iPmel17 differs from mPmel17 not only in its sensitivity to endoglycosidase H, but also in the content of core 1 O-glycans modified with sialic acid. This evidence reveals that iPmel17 is glycosylated differently in the Golgi and that it is sorted through the secretory pathway. Analysis of Pmel17 processing in glycosylation-deficient mutant cells reveals that Pmel17 lacking the correct addition of sialic acid and galactose loses the ability to form fibrils. Furthermore, we show that addition of sialic acid affects the stability and sorting of Pmel17 and reduces pigmentation. Alterations in sialyltransferase activity and substrates differ between normal and transformed melanocytes and may represent a critical change during malignant transformation.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Guys Hosp, Canc Res UK, Breast Canc Biol Grp, London SE1 9RT, England; NCI, Image Anal Lab, NIH, Ft Detrick, MD 21702 USA; NCI, Lab Pathol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Valencia, JC (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 2132, Bethesda, MD 20892 USA.	valencij@mail.nih.gov; hearingv@nih.gov	Chen, Kevin/GYU-8963-2022; Chen, Kevin G/D-6769-2011; Yamaguchi, Yuji/X-6681-2019; Jenkins, Lisa/AAI-2490-2021; Yamaguchi, Yuji/B-9312-2008	Chen, Kevin G/0000-0003-2983-6330; Abu-Asab, Mones/0000-0002-4047-1232; Passeron, Thierry/0000-0002-0797-6570; Yamaguchi, Yuji/0000-0003-4338-2662	Intramural NIH HHS [Z99 NS999999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010786, Z01SC009394] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEMA GJ, 1993, AM J PATHOL, V143, P1579; ADEMA GJ, 1994, J BIOL CHEM, V269, P20126; Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Angata K, 2003, BIOCHIMIE, V85, P195, DOI 10.1016/S0300-9084(03)00051-8; Azuma Y, 2000, GLYCOCONJUGATE J, V17, P301, DOI 10.1023/A:1007165403771; Bailin T, 1996, J INVEST DERMATOL, V106, P24, DOI 10.1111/1523-1747.ep12326976; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; BOSMANN HB, 1973, NATURE, V246, P487, DOI 10.1038/246487a0; Burchell J, 1999, GLYCOBIOLOGY, V9, P1307, DOI 10.1093/glycob/9.12.1307; CHANDRASEKARAN S, 1994, J BIOL CHEM, V269, P3356; Chen KG, 2005, PIGM CELL RES, V18, P102, DOI 10.1111/j.1600-0749.2005.00214.x; Chiamenti AM, 1996, MELANOMA RES, V6, P291, DOI 10.1097/00008390-199608000-00003; Costin GE, 2005, BIOCHEM J, V391, P249, DOI 10.1042/BJ20042070; Dalziel M, 2001, J BIOL CHEM, V276, P11007, DOI 10.1074/jbc.M006523200; Dell'Angelica EC, 2003, TRENDS CELL BIOL, V13, P503, DOI 10.1016/j.tcb.2003.08.001; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DOBROSSY L, 1981, CANCER RES, V41, P2262; DUSTIN ML, 1995, J BIOL CHEM, V270, P170, DOI 10.1074/jbc.270.1.170; Fowler DM, 2006, PLOS BIOL, V4, P100, DOI 10.1371/journal.pbio.0040006; Gasbarri A, 2003, MELANOMA RES, V13, P325, DOI 10.1097/00008390-200308000-00001; Giordanengo V, 1997, EUR J BIOCHEM, V247, P558, DOI 10.1111/j.1432-1033.1997.00558.x; GOLDBERG DE, 1983, J BIOL CHEM, V258, P3159; GOTTESMAN MM, 1980, SOMAT CELL GENET, V6, P45, DOI 10.1007/BF01538695; GOWN AM, 1986, AM J PATHOL, V123, P195; Hayes GR, 1997, BIOCHEMISTRY-US, V36, P5276, DOI 10.1021/bi962884y; Hoashi T, 2005, J BIOL CHEM, V280, P14006, DOI 10.1074/jbc.M413692200; Hoashi T, 2006, J BIOL CHEM, V281, P21198, DOI 10.1074/jbc.M601643200; Ikonen E, 1998, SEMIN CELL DEV BIOL, V9, P503, DOI 10.1006/scdb.1998.0258; Kim KK, 1996, PIGM CELL RES, V9, P42, DOI 10.1111/j.1600-0749.1996.tb00085.x; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; Kushimoto T, 2001, P NATL ACAD SCI USA, V98, P10698, DOI 10.1073/pnas.191184798; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; Land EJ, 2003, PIGM CELL RES, V16, P397, DOI 10.1034/j.1600-0749.2003.00063.x; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; Mendoza L, 1998, J CELL PHYSIOL, V174, P322; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; Nakagawa K, 2006, J NEUROCHEM, V96, P924, DOI 10.1111/j.1471-4159.2005.03595.x; Negroiu G, 2003, J BIOL CHEM, V278, P27035, DOI 10.1074/jbc.M303167200; Nichols SE, 2003, J INVEST DERMATOL, V121, P821, DOI 10.1046/j.1523-1747.2003.12474.x; Ochwat D, 2004, MELANOMA RES, V14, P479, DOI 10.1097/00008390-200412000-00007; Oelmann S, 2001, J BIOL CHEM, V276, P26291, DOI 10.1074/jbc.M011124200; Otto VI, 2004, J BIOL CHEM, V279, P35201, DOI 10.1074/jbc.M404947200; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; Rossi P, 2002, BIOCHEM CELL BIOL, V80, P41, DOI 10.1139/o01-209; Rottger S, 1998, J CELL SCI, V111, P45; Rouzaud F, 2003, FASEB J, V17, P2154, DOI 10.1096/fj.03-0206fje; Sewell R, 2006, J BIOL CHEM, V281, P3586, DOI 10.1074/jbc.M511826200; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; Sugrue RJ, 2001, J GEN VIROL, V82, P1375, DOI 10.1099/0022-1317-82-6-1375; Tadokoro T, 2003, FASEB J, V17, P1177, DOI 10.1096/fj.02-0865fje; Theos AC, 2006, DEV CELL, V10, P343, DOI 10.1016/j.devcel.2006.01.012; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Valencia JC, 2006, J CELL SCI, V119, P1080, DOI 10.1242/jcs.02804; Valencia JC, 2001, J INVEST MED, V49, P421, DOI 10.2310/6650.2001.33787; Valencia JC, 2006, PIGM CELL RES, V19, P250, DOI 10.1111/j.1600-0749.2006.00308.x; Van den Nieuwenhof IM, 2000, EUR J BIOCHEM, V267, P4753, DOI 10.1046/j.1432-1327.2000.01528.x; Varki A., 1999, ESSENTIALS GLYCOBIOL; Virador VM, 1999, ANAL BIOCHEM, V270, P207, DOI 10.1006/abio.1999.4090; Wang X, 2001, J BIOL CHEM, V276, P35953, DOI 10.1074/jbc.M103680200; Watabe H, 2004, J BIOL CHEM, V279, P7971, DOI 10.1074/jbc.M309714200; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; WILLIAMS AM, 1993, J BIOL CHEM, V268, P12780; Yamaguchi Y, 2006, FASEB J, V20, P1486, DOI 10.1096/fj.06-5725fje; Yasumoto K, 2004, J BIOL CHEM, V279, P28330, DOI 10.1074/jbc.M401269200; YOGEESWARAN G, 1980, BIOCHEM BIOPH RES CO, V95, P1452, DOI 10.1016/S0006-291X(80)80060-X	68	39	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11266	11280		10.1074/jbc.M608449200	http://dx.doi.org/10.1074/jbc.M608449200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303571	hybrid			2022-12-25	WOS:000245941500049
J	Roberts, SA; Ramsden, DA				Roberts, Steven A.; Ramsden, Dale A.			Loading of the nonhomologous end joining factor, Ku, on protein-occluded DNA ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV-DEPENDENT LIGATION; STRAND BREAK REPAIR; V(D)J RECOMBINATION; LIGASE-IV; EQUILIBRIUM ACCESSIBILITY; COMPLEX; BINDING; SINGLE; MECHANISM; AFFINITY	The nonhomologous end joining pathway for DNA double strand break repair requires Ku to bind DNA ends and subsequently recruit other nonhomologous end joining factors, including the DNA-dependent protein kinase catalytic subunit and the XRCC4-Ligase IV complex, to the break site. Ku loads at a break by threading the DNA ends through a circular channel in its structure. This binding mechanism explains both the high specificity of Ku for ends and its ability to translocate along DNA once loaded. However, DNA in cells is typically coated with other proteins ( e. g. histones), which might be expected to block the ability of Ku to load in this manner. Here we address how the nature of a protein obstruction dictates how Ku interacts with a DNA end. Ku is unable to access the ends within an important intermediate in V(D)J recombination ( a complex of RAG proteins bound to cleaved recombination targeting signals), but Ku readily displaces the linker histone, H1, from DNA. Ku also retains physiological affinity for nucleosome-associated ends. Loading onto nucleosome-associated ends still occurs by threading the end through its channel, but rather than displacing the nucleosome, Ku peels as much as 50 bp of DNA away from the histone octamer surface. We suggest a model where Ku utilizes an unusual characteristic of its three-dimensional structure to recognize certain protein-occluded ends without the extensive remodeling of chromatin structure required by other DNA repair pathways.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ramsden, DA (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB-7295, Chapel Hill, NC 27599 USA.	dale_ramsden@med.unc.edu		Ramsden, Dale/0000-0003-1575-4748	NATIONAL CANCER INSTITUTE [R01CA084442] Funding Source: NIH RePORTER; NCI NIH HHS [CA-84442, R01 CA084442] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Anderson JD, 2000, J MOL BIOL, V296, P979, DOI 10.1006/jmbi.2000.3531; Anderson JD, 2001, J MOL BIOL, V307, P977, DOI 10.1006/jmbi.2001.4528; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; CHRISTOPHER JA, 2004, SPOCK STRUCTURAL PRO; Clejan I, 2006, GENETICS, V173, P1301, DOI 10.1534/genetics.106.058628; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Dyer PN, 2004, METHOD ENZYMOL, V375, P23; FALZON M, 1993, J BIOL CHEM, V268, P10546; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hayes JJ, 1997, METHODS, V12, P2, DOI 10.1006/meth.1997.0441; Jones JM, 2003, P NATL ACAD SCI USA, V100, P15446, DOI 10.1073/pnas.2637012100; Jones JM, 2001, P NATL ACAD SCI USA, V98, P12926, DOI 10.1073/pnas.221471198; Kysela B, 2005, P NATL ACAD SCI USA, V102, P1877, DOI 10.1073/pnas.0401179102; Kysela B, 2003, J BIOL CHEM, V278, P22466, DOI 10.1074/jbc.M303273200; Lee J, 1999, IMMUNITY, V11, P771, DOI 10.1016/S1074-7613(00)80151-X; Li G, 2005, NAT STRUCT MOL BIOL, V12, P46, DOI 10.1038/nsmb869; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; Ma YM, 2001, BIOCHEMISTRY-US, V40, P9638, DOI 10.1021/bi010932v; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; MIMORI T, 1986, J BIOL CHEM, V261, P375; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Park EJ, 2003, NUCLEIC ACIDS RES, V31, P6819, DOI 10.1093/nar/gkg921; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; Reddy YVR, 2006, GENE DEV, V20, P1575, DOI 10.1101/gad.1432706; SCHNITZLER G, 2000, CURRENT PROTOCOLS MO, P21; Schwanbeck R, 2004, J BIOL CHEM, V279, P39933, DOI 10.1074/jbc.M406060200; Shim EY, 2007, MOL CELL BIOL, V27, P1602, DOI 10.1128/MCB.01956-06; Shim EY, 2005, MOL CELL BIOL, V25, P3934, DOI 10.1128/MCB.25.10.3934-3944.2005; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; WAGNER JP, 1995, J BIOL CHEM, V270, P7394, DOI 10.1074/jbc.270.13.7394; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; WeisGarcia F, 1997, MOL CELL BIOL, V17, P6379, DOI 10.1128/MCB.17.11.6379; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Yoo S, 1999, J BIOL CHEM, V274, P20034, DOI 10.1074/jbc.274.28.20034; Yurchenko V, 2003, GENE DEV, V17, P581, DOI 10.1101/gad.1058103; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	49	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10605	10613		10.1074/jbc.M611125200	http://dx.doi.org/10.1074/jbc.M611125200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289670	Green Published, hybrid			2022-12-25	WOS:000245941000054
J	vanVickle-Chavez, SJ; van Gelder, RN				vanVickle-Chavez, Sarah J.; van Gelder, Russell N.			Action spectrum of Drosophila cryptochrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-LIGHT PHOTORECEPTORS; CIRCADIAN PHOTORECEPTION; FISH CYPRINIDAE; S-POTENTIALS; ARABIDOPSIS; CLOCK; MELANOGASTER; PROTEIN; RETINA; UNITS	Cryptochromes are a highly conserved class of UV-A/blue light photoreceptors. In Drosophila, cryptochrome is required for the normal entrainment of circadian rhythms to light dark cycles. The photocycle and molecular mechanism of animal cryptochrome photoreception are presently unknown. Drosophila cryptochrome undergoes light-dependent degradation when heterologously expressed in Schneider-2 cells. We have generated Drosophila luciferase-cryptochrome fusion proteins to more precisely monitor light-dependent cryptochrome degradation. We found that the luciferase-cryptochrome fusion protein undergoes light-dependent degradation with luciferase activity declining similar to 50% within 5 min of light exposure and similar to 85% within 1 h of light exposure. Degradation is inhibited by MG-132, consistent with a proteasomal degradation mechanism. Irradiance-response curves yield an action spectrum similar to absorption spectra for prokaryotic and eukaryotic cryptochromes with highest sensitivity in the UV-A. A luciferase-cryptochrome fusion protein lacking the terminal 15 amino acids is stably expressed in the dark but demonstrates increased sensitivity to light-induced degradation. The conferral of light-dependent degradation on a heterologous protein by fusion to cryptochrome may be a useful tool for probing protein function in cell expression systems.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	van Gelder, RN (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, 660 S Euclid Ave, St Louis, MO 63110 USA.	vangelder@vision.wustl.edu	Van Gelder, Russell/ABB-4225-2021	Van Gelder, Russell/0000-0001-5368-3659				Ahmad M, 2002, PLANT PHYSIOL, V129, P774, DOI 10.1104/pp.010969; Bogyo M, 1997, BIOPOLYMERS, V43, P269, DOI 10.1002/(SICI)1097-0282(1997)43:4<269::AID-BIP2>3.0.CO;2-T; Bouly JP, 2007, J BIOL CHEM, V282, P9383, DOI 10.1074/jbc.M609842200; Busza A, 2004, SCIENCE, V304, P1503, DOI 10.1126/science.1096973; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Cermakian N, 2002, CURR BIOL, V12, P844, DOI 10.1016/S0960-9822(02)00835-7; Dissel S, 2004, NAT NEUROSCI, V7, P834, DOI 10.1038/nn1285; Emery P, 2000, NATURE, V404, P456, DOI 10.1038/35006558; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Helfrich-Forster C, 2002, J NEUROSCI, V22, P9255; Hendil KB, 2002, J MOL BIOL, V315, P627, DOI 10.1006/jmbi.2001.5285; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; Kleine T, 2003, PLANT J, V35, P93, DOI 10.1046/j.1365-313X.2003.01787.x; Lin CT, 2003, ANNU REV PLANT BIOL, V54, P469, DOI 10.1146/annurev.arplant.54.110901.160901; Lin FJ, 2001, MOL CELL BIOL, V21, P7287, DOI 10.1128/MCB.21.21.7287-7294.2001; NAKA KI, 1966, J PHYSIOL-LONDON, V185, P587, DOI 10.1113/jphysiol.1966.sp008003; NAKA KI, 1966, J PHYSIOL-LONDON, V185, P536, DOI 10.1113/jphysiol.1966.sp008001; Rosato E, 2001, CURR BIOL, V11, P909, DOI 10.1016/S0960-9822(01)00259-7; Sancar A, 2000, ANNU REV BIOCHEM, V69, P31, DOI 10.1146/annurev.biochem.69.1.31; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; Tu DC, 2004, SCIENCE, V306, P129, DOI 10.1126/science.1101484; Worthington EN, 2003, J BIOL CHEM, V278, P39143, DOI 10.1074/jbc.M305792200; Yang HQ, 2000, CELL, V103, P815, DOI 10.1016/S0092-8674(00)00184-7; ZETTLER F, 1969, Z VERGL PHYSIOL, V64, P432, DOI 10.1007/BF00340437	26	51	52	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10561	10566		10.1074/jbc.M609314200	http://dx.doi.org/10.1074/jbc.M609314200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284451	hybrid			2022-12-25	WOS:000245941000049
J	Heffernan, TP; Unsal-Kacmaz, K; Heinloth, AN; Simpson, DA; Paules, RS; Sancar, A; Cordeiro-Stone, M; Kaufmann, WK				Heffernan, Timothy P.; Unsal-Kacmaz, Keziban; Heinloth, Alexandra N.; Simpson, Dennis A.; Paules, Richard S.; Sancar, Aziz; Cordeiro-Stone, Marila; Kaufmann, William K.			Cdc7-dbf4 and the human S checkpoint response to UVC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; DIPLOID HUMAN FIBROBLASTS; CELL-CYCLE REGULATION; PHASE CHECKPOINT; PROTEIN-KINASE; DOWNSTREAM EFFECTOR; IONIZING-RADIATION; CDC7P-DBF4P KINASE; ULTRAVIOLET-LIGHT; POLYMERASE ALPHA	The S checkpoint response to ultraviolet radiation (UVC) that inhibits replicon initiation is dependent on the ATR and Chk1 kinases. Downstream effectors of this response, however, are not well characterized. Data reported here eliminated Cdc25A degradation and inhibition of Cdk2-cyclin E as intrinsic components of the UVC-induced pathway of inhibition of replicon initiation in human cells. A sublethal dose of UVC (1 j/m(2)), which selectively inhibits replicon initiation by 50%, failed to reduce the amount of Cdc25A protein or decrease Cdk2-cyclin E kinase activity. Cdc25A degradation was observed after irradiation with cytotoxic fluences of UVC, suggesting that severe inhibition of DNA chain elongation and activation of the replication checkpoint might be responsible for the UVC-induced degradation of Cdc25A. Another proposed effector of the S checkpoint is the Cdc7-Dbf4 complex. Dbf4 interacted weakly with Chk1 in vivo but was recognized as a substrate for Chk1-dependent phosphorylation in vitro. FLAG-Dbf4 formed complexes with endogenous Cdc7, and this interaction was stable in UVC-irradiated HeLa cells. Overexpression of FLAG- or Myc-tagged Dbf4 abrogated the S checkpoint response to UVC but not ionizing radiation. These findings implicate a Dbf4-dependent kinase as a possible target of the ATR- and Chk1-dependent S checkpoint response to UVC.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Environm Hlth & Susceptibil, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; NIEHS, Growth Control & Canc Grp, NIH, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Kaufmann, WK (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.	wkarlk@med.unc.edu		Paules, Richard S/0000-0001-9106-7486	NATIONAL CANCER INSTITUTE [P30CA016086, R55CA055065, R01CA055065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011012, P30ES010126, Z01ES021157, ZIAES021157] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA055065, CA055065, P30-CA 16086, P30 CA016086] Funding Source: Medline; NIEHS NIH HHS [P30 ES010126, ES07017, T32 ES007017, R01 ES011012, ES11012, P30-ES10126] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Agner J, 2005, EXP CELL RES, V302, P162, DOI 10.1016/j.yexcr.2004.08.035; Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chou DM, 2006, P NATL ACAD SCI USA, V103, P18143, DOI 10.1073/pnas.0609251103; Christiano C, 2003, J BIOL CHEM, V278, P30057, DOI 10.1074/jbc.M301136200; Cistulli CA, 1998, CANCER RES, V58, P1993; Cordeiro-Stone M, 1999, J MOL BIOL, V289, P1207, DOI 10.1006/jmbi.1999.2847; Cordeiro-Stone M, 2002, CARCINOGENESIS, V23, P959, DOI 10.1093/carcin/23.6.959; CORDEIROSTONE M, 1986, CARCINOGENESIS, V7, P1775, DOI 10.1093/carcin/7.10.1775; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; D Bomgarden R, 2006, EMBO J, V25, P2605, DOI 10.1038/sj.emboj.7601123; Dierov J, 2004, CANCER CELL, V5, P275, DOI 10.1016/S1535-6108(04)00056-X; Duncker BP, 2002, P NATL ACAD SCI USA, V99, P16087, DOI 10.1073/pnas.252093999; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2003, J BIOL CHEM, V278, P14806, DOI 10.1074/jbc.M210862200; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Goloudina A, 2003, CELL CYCLE, V2, P473, DOI 10.4161/cc.2.5.482; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; Hassepass I, 2003, J BIOL CHEM, V278, P29824, DOI 10.1074/jbc.M302704200; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Ishimi Y, 2003, J BIOL CHEM, V278, P24644, DOI 10.1074/jbc.M213252200; Jallepalli PV, 1998, P NATL ACAD SCI USA, V95, P8159, DOI 10.1073/pnas.95.14.8159; Jares P, 2000, EMBO REP, V1, P319, DOI 10.1093/embo-reports/kvd076; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Jin JP, 2003, GENE DEV, V17, P3062, DOI 10.1101/gad.1157503; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KAUFMANN WK, 1981, J MOL BIOL, V149, P171, DOI 10.1016/0022-2836(81)90297-7; KAUFMANN WK, 1990, MUTAT RES, V236, P107, DOI 10.1016/0921-8777(90)90038-7; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; Kim JM, 2003, MUTAT RES-FUND MOL M, V532, P29, DOI 10.1016/j.mrfmmm.2003.08.008; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Lei M, 1997, GENE DEV, V11, P3365, DOI 10.1101/gad.11.24.3365; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu PJ, 2006, J BIOL CHEM, V281, P30631, DOI 10.1074/jbc.M602982200; Lopes M, 2006, MOL CELL, V21, P15, DOI 10.1016/j.molcel.2005.11.015; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masai H, 2006, J BIOL CHEM, V281, P39249, DOI 10.1074/jbc.M608935200; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MENEGHINI R, 1981, BIOPHYS J, V33, P81, DOI 10.1016/S0006-3495(81)84873-4; Mimura S, 1998, EMBO J, V17, P5699, DOI 10.1093/emboj/17.19.5699; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Perkins G, 2001, EMBO J, V20, P4836, DOI 10.1093/emboj/20.17.4836; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shackelford RE, 2001, J BIOL CHEM, V276, P21951, DOI 10.1074/jbc.M011303200; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tenca P, 2007, J BIOL CHEM, V282, P208, DOI 10.1074/jbc.M604457200; Tsao CC, 2004, EMBO J, V23, P4660, DOI 10.1038/sj.emboj.7600463; Unsal-Kacmaz K, 2005, MOL CELL BIOL, V25, P3109, DOI 10.1128/MCB.25.8.3109-3116.2005; Walter J, 2000, MOL CELL, V5, P617, DOI 10.1016/S1097-2765(00)80241-5; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Weinreich M, 1999, EMBO J, V18, P5334, DOI 10.1093/emboj/18.19.5334; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Xiao Z, 2005, ONCOGENE, V24, P1403, DOI 10.1038/sj.onc.1208309; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yanow SK, 2003, J BIOL CHEM, V278, P41083, DOI 10.1074/jbc.M307144200; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	81	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9458	9468		10.1074/jbc.M611292200	http://dx.doi.org/10.1074/jbc.M611292200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276990	hybrid, Green Accepted, Green Submitted			2022-12-25	WOS:000245421700018
J	Miller, SLH; Scappini, EL; O'Bryan, J				Miller, Stephanie L. H.; Scappini, Erica L.; O'Bryan, John			Ubiquitin-interacting motifs inhibit aggregation of PolyQ-expanded huntingtin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; DISEASE; IDENTIFICATION; UBIQUITYLATION; PATHOGENESIS; AGGRESOMES; COMPONENTS; ATAXIN-3; EPS15; EPSIN	Expansion of polyglutamine (polyQ) tracts within proteins underlies a number of neurodegenerative diseases, such as Huntington disease, Kennedy disease, and spinocerebellar ataxias. The resulting mutant proteins are unstable, forming insoluble aggregates that are associated with components of the ubiquitin system, including ubiquitin, ubiquitin-like proteins, and proteins that bind to ubiquitin. Given the presence of these ubiquitin-binding proteins in the insoluble aggregates, we examined whether heterologous expression of short motifs that bind ubiquitin, termed ubiquitin-interacting motifs (UIMs), altered the aggregation of polyQ-expanded huntingtin (Htt), the protein product of the Huntington disease gene. We found that a subset of UIMs associated with mutant Htt. The ability to interact with ubiquitin was necessary, but not sufficient, for interaction with mutant Htt. Furthermore, we found that expression of single, isolated UIMs inhibited aggregation of mutant Htt. These data suggest that isolated UIMs might serve as potential inhibitors of polyQ-aggregation in vivo.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	O'Bryan, J (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott,Rm E403,M-C 868, Chicago, IL 60612 USA.	obryanj@uic.edu	Scappini, Erica/C-7684-2019	Scappini, Erica/0000-0002-9100-0027; O'Bryan, John/0000-0001-5386-1080	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Davidson JD, 2000, HUM MOL GENET, V9, P2305, DOI 10.1093/oxfordjournals.hmg.a018922; Doi H, 2004, FEBS LETT, V571, P171, DOI 10.1016/j.febslet.2004.06.077; Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Hecker CM, 2006, J BIOL CHEM, V281, P16117, DOI 10.1074/jbc.M512757200; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Johnston JA, 2002, CELL MOTIL CYTOSKEL, V53, P26, DOI 10.1002/cm.10057; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Lim KL, 2006, NEUROBIOL AGING, V27, P524, DOI 10.1016/j.neurobiolaging.2005.07.023; Matsumoto G, 2006, J BIOL CHEM, V281, P4477, DOI 10.1074/jbc.M509201200; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; MYERS RH, 1993, NAT GENET, V5, P168, DOI 10.1038/ng1093-168; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Oved S, 2006, J BIOL CHEM, V281, P21640, DOI 10.1074/jbc.M513034200; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Qin ZH, 2004, ACTA PHARMACOL SIN, V25, P1243; Regan-Klapisz E, 2005, J CELL SCI, V118, P4437, DOI 10.1242/jcs.02571; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Timsit YE, 2005, BIOCHEM BIOPH RES CO, V328, P550, DOI 10.1016/j.bbrc.2005.01.022; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Wang GH, 2000, HUM MOL GENET, V9, P1795, DOI 10.1093/hmg/9.12.1795; Wanker EE, 2000, BIOL CHEM, V381, P937, DOI 10.1515/BC.2000.114; Warrick JM, 2005, MOL CELL, V18, P37, DOI 10.1016/j.molcel.2005.02.030	29	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10096	10103		10.1074/jbc.M611151200	http://dx.doi.org/10.1074/jbc.M611151200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276991	hybrid			2022-12-25	WOS:000245421700083
J	Voutilainen, S; Tuomainen, TP; Korhonen, M; Mursu, J; Virtanen, JK; Happonen, P; Alfthan, G; Erlund, I; North, KE; Mosher, MJ; Kauhanen, J; Tiihonen, J; Kaplan, GA; Salonen, JT				Voutilainen, Sari; Tuomainen, Tomi-Pekka; Korhonen, Maarit; Mursu, Jaakko; Virtanen, Jyrki K.; Happonen, Pertti; Alfthan, Georg; Erlund, Iris; North, Kari E.; Mosher, M. J.; Kauhanen, Jussi; Tiihonen, Jari; Kaplan, George A.; Salonen, Jukka T.			Functional COMT Val158Met Polymorphism, Risk of Acute Coronary Events and Serum Homocysteine: The Kuopio Ischaemic Heart Disease Risk Factor Study	PLOS ONE			English	Article							CATECHOL-O-METHYLTRANSFERASE; MYOCARDIAL-INFARCTION; ASSOCIATION; PATHOPHYSIOLOGY; GENOTYPE; VARIANT; GENE	Background. The role of circulating levels of total homocysteine tHcy in the development of coronary heart disease (CHD) is still under debate. One reason for conflicting results between previous studies on homocysteine and heart diseases could be consequence of different interactions between homocysteine and genes in different study populations. Many genetic factors play a role in folate-homocysteine metabolism, like functional polymorphism (Val108Met) in the Catechol-O-methyltransferase (COMT) gene. Methodology and Findings. Our aim was to examine the role of COMT Val158Met polymorphism and interaction of this polymorphism with serum tHcy and folate concentration on the risk of acute coronary and events in middle-aged men from eastern Finland. A population-based prospective cohort of 792 men aged 46-64 years was examined as part of the Kuopio Ischaemic Heart Disease Risk Factor Study. During an average follow-up of 9.3 years, there were 69 acute coronary events in men with no previous history of CHD. When comparing the COMT low activity genotype with the others, we found an age and examination year adjusted hazard rate ratio (HRR) of 1.73 (95% confidence interval (CI), 1.07-2.79), and an age, examination year, serum LDL and HDL cholesterol, and triglyceride concentration, systolic blood pressure and smoking adjusted HRR of 1.77 (95% CI, 1.05-2.77). Although serum tHcy concentration was not statistically significantly associated with acute coronary events (HRR for the highest third versus others 1.52, 95% CI, 0.93-2.49), subjects with both high serum tHcy and the COMT low activity genotype had an additionally increased adjusted risk of HRR 2.94 (95% CI 1.50-5.76) as compared with other men. Conclusions. This prospective cohort study suggests that the functional COMT Val158Met polymorphism is associated with increased risk of acute coronary events and it may interact with high serum tHcy levels.	[Voutilainen, Sari; Tuomainen, Tomi-Pekka; Mursu, Jaakko; Virtanen, Jyrki K.; Salonen, Jukka T.] Univ Kuopio, Publ Hlth Res Inst, FIN-70211 Kuopio, Finland; [Tuomainen, Tomi-Pekka] Univ Kuopio, Atherosclerosis Res Unit, FIN-70211 Kuopio, Finland; [Korhonen, Maarit; Happonen, Pertti; Kauhanen, Jussi; Salonen, Jukka T.] Univ Kuopio, Dept Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland; [Alfthan, Georg; Erlund, Iris] Natl Publ Hlth Inst, Biomarker Lab, Helsinki, Finland; [North, Kari E.; Mosher, M. J.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; [Tiihonen, Jari] Univ Kuopio, Dept Forens Psychiat, FIN-70211 Kuopio, Finland; [Kaplan, George A.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA; [Salonen, Jukka T.] Oy Jurilab Ltd, Kuopio, Finland	University of Eastern Finland; University of Eastern Finland; University of Eastern Finland; Finland National Institute for Health & Welfare; University of North Carolina; University of North Carolina Chapel Hill; University of Eastern Finland; University of Michigan System; University of Michigan	Voutilainen, S (corresponding author), Univ Kuopio, Publ Hlth Res Inst, FIN-70211 Kuopio, Finland.	sari.voutilainen@uku.fi	Kauhanen, Jussi/ABC-4064-2021; Kaplan, George/AAJ-2398-2020; Erlund, Iris/AAA-4108-2019; Virtanen, Jyrki/G-5149-2013; Tiihonen, Jari/G-3078-2012; Virtanen, Jyrki/AAC-8945-2020	Virtanen, Jyrki/0000-0002-0648-999X; Tiihonen, Jari/0000-0002-0400-6798; Virtanen, Jyrki/0000-0002-0648-999X; Korhonen, Maarit/0000-0002-2953-4757	Academy of Finland [201688, 80185, 200942, 41471, 1041086, 2041022]; National Heart, Lung and Blood Institute of the USA Juho Vainio Foundation [HL44199]; Yrjo Jahnsson Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R24HD047861] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044199] Funding Source: NIH RePORTER	Academy of Finland(Academy of Finland); National Heart, Lung and Blood Institute of the USA Juho Vainio Foundation(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Yrjo Jahnsson Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported by Academy of Finland (grants 201688 and 80185 to SV, 200942 to JK), Juho Vainio Foundation and Yrjo Jahnsson Foundation. The KIHD study was supported by grants from the Academy of Finland (grants 41471, 1041086 and 2041022 to JTS) and the National Heart, Lung and Blood Institute of the USA (grant HL44199 to GAK).	ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015; Eriksson AL, 2004, EUR HEART J, V25, P386, DOI 10.1016/j.ehj.2003.12.026; Hallikainen T, 2000, AM J MED GENET, V96, P348, DOI 10.1002/1096-8628(20000612)96:3<348::AID-AJMG22>3.0.CO;2-Z; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; Knekt P, 2001, ARCH INTERN MED, V161, P1589, DOI 10.1001/archinte.161.13.1589; Lachman HM, 1998, AM J PSYCHIAT, V155, P835; Lievers KJA, 2003, ANN CLIN BIOCHEM, V40, P46, DOI 10.1258/000456303321016169; Norio R., 1981, BIOCULTURAL ASPECTS, P359; Nygard O, 1999, J INTERN MED, V246, P425, DOI 10.1046/j.1365-2796.1999.00512.x; SALONEN JT, 1995, BRIT MED J, V311, P1124, DOI 10.1136/bmj.311.7013.1124; SALONEN JT, 1988, ANN CLIN RES, V20, P46; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; Schwab U, 2002, AM J CLIN NUTR, V76, P961, DOI 10.1093/ajcn/76.5.961; Tiihonen J, 1999, MOL PSYCHIATR, V4, P286, DOI 10.1038/sj.mp.4000509; TUOMILEHTO J, 1992, EUR HEART J, V13, P577, DOI 10.1093/oxfordjournals.eurheartj.a060219; Voutilainen S, 2000, J INTERN MED, V248, P217, DOI 10.1046/j.1365-2796.2000.00741.x; Voutilainen S, 2004, AM J CLIN NUTR, V80, P317, DOI 10.1093/ajcn/80.2.317; Voutilainen S, 2001, CIRCULATION, V103, P2674, DOI 10.1161/01.CIR.103.22.2674; Voutilainen S, 2000, EUR J CLIN NUTR, V54, P424, DOI 10.1038/sj.ejcn.1600991; Zhu BT, 2002, HISTOL HISTOPATHOL, V17, P1283, DOI 10.14670/HH-17.1283; Zhu BT, 2002, CURR DRUG METAB, V3, P321, DOI 10.2174/1389200023337586	23	34	35	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2007	2	1							e181	10.1371/journal.pone.0000181	http://dx.doi.org/10.1371/journal.pone.0000181			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DH	17264883	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444200005
J	Wang, ZH; Shen, B; Yao, HL; Jia, Y; Ren, J; Feng, Y; Wang, YZ				Wang, Z. H.; Shen, B.; Yao, H. L.; Jia, Y. C.; Ren, J.; Feng, Y. J.; Wang, Y. Z.			Blockage of intermediate-conductance-Ca2(+)-activated K+ channels inhibits progression of human endometrial cancer	ONCOGENE			English	Article						endometrial cancer; proliferation; intermediate-conductance Ca2+-activated K+ (IKCa1) channel; electrophysiology	INTERMEDIATE-CONDUCTANCE; CELL-PROLIFERATION; UP-REGULATION; POTASSIUM CHANNELS; GROWTH-FACTOR; INVOLVEMENT; CYCLE; MECHANISM; LINE; IDENTIFICATION	Potassium ( K+) channels have been implicated in proliferation of some tumor cells. However, whether K+ channels are important to the pathogenesis of endometrial cancer ( EC) remains unknown. In the present study, we report that intermediate-conductance Ca2+ activated K+ ( IKCa1) channels play a critical role in the development of EC. The expression of IKCa1 at both mRNA and protein levels in EC tissues was greatly increased than that in atypical hyperplasia and normal tissues. Treatment of EC cells with clotrimazole and TRAM-34, two agents kn own to inhibit IKCa1 channels, suppressed the proliferation of EC cells a nd blocked EC cell cycle at G(0)/G(1) phase. Similarly, downregulation of IKCa1 by siRNA against IKCa1 inhibited EC cell proliferation and arrested its cell cycle at G0/G1 phase. A clotrimazole-sensitive K+ current was induced in EC cells in response to the increased Ca2+. The current density induced by Ca2+ was great ly reduced by clotrimazole, TRAM-34, charybdotoxin or downregulation of IKCa1 by the siRNA against IKCa1. Furthermore, TRAM-34 and clotrimazole slowed the formation in nude mice of tumor generated by injection of EC cells. Our results suggest that increased activity of IKCa1 channel is necessary for the development of EC.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, Shanghai 200031, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Mat Med, Shanghai 200031, Peoples R China; Fudan Univ, Med Ctr, Obstet & Gynecol Hosp, Shanghai 200433, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Shanghai Institutes for Biological Sciences, CAS; Fudan University	Wang, YZ (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Neurosci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	fengyj4806@sohu.com; yzwang@ion.ac.cn						Ahn SC, 2004, PFLUG ARCH EUR J PHY, V447, P426, DOI 10.1007/s00424-003-1201-1; Begenisich T, 2004, J BIOL CHEM, V279, P47681, DOI 10.1074/jbc.M409627200; Chittajallu R, 2002, P NATL ACAD SCI USA, V99, P2350, DOI 10.1073/pnas.042698399; Dunn PM, 1998, J MEMBRANE BIOL, V165, P133, DOI 10.1007/s002329900427; Farias LMB, 2004, CANCER RES, V64, P6996, DOI 10.1158/0008-5472.CAN-04-1204; Fraser SP, 2003, PFLUG ARCH EUR J PHY, V446, P559, DOI 10.1007/s00424-003-1077-0; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Jager H, 2004, MOL PHARMACOL, V65, P630, DOI 10.1124/mol.65.3.630; Lang F, 2003, CELL PHYSIOL BIOCHEM, V13, P41, DOI 10.1159/000070248; Legrand G, 2001, J BIOL CHEM, V276, P47608, DOI 10.1074/jbc.M107011200; Levine DA, 2002, CANCER J, V8, pS31; Lu XH, 1999, J GEN PHYSIOL, V113, P81, DOI 10.1085/jgp.113.1.81; Mork HK, 2005, ACTA PHYSIOL SCAND, V184, P141, DOI 10.1111/j.1365-201X.2005.01441.x; Nehrke K, 2003, AM J PHYSIOL-CELL PH, V284, pC535, DOI 10.1152/ajpcell.00044.2002; NILIUS B, 1992, J PHYSIOL-LONDON, V445, P537, DOI 10.1113/jphysiol.1992.sp018938; Ouadid-Ahidouch H, 2001, RECEPTOR CHANNEL, V7, P345; Ouadid-Ahidouch H, 2000, BIOCHEM BIOPH RES CO, V278, P272, DOI 10.1006/bbrc.2000.3790; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Parihar AS, 2003, EUR J PHARMACOL, V471, P157, DOI 10.1016/S0014-2999(03)01825-9; Pena TL, 2000, J BIOL CHEM, V275, P13677, DOI 10.1074/jbc.275.18.13677; Rane SG, 1999, ADV SEC MESS PHOSPH, V33, P107; Rane SG, 2000, BIOCHEM BIOPH RES CO, V269, P457, DOI 10.1006/bbrc.2000.2309; Rouzaire-Dubois B, 1998, J PHYSIOL-LONDON, V510, P93, DOI 10.1111/j.1469-7793.1998.093bz.x; Ryan AJ, 2005, CELL TISSUE RES, V322, P53, DOI 10.1007/s00441-005-1109-5; Schneider JJ, 2005, GYNECOL ONCOL, V97, P246, DOI 10.1016/j.ygyno.2004.12.016; Skryma RN, 1997, PROSTATE, V33, P112, DOI 10.1002/(SICI)1097-0045(19971001)33:2<112::AID-PROS5>3.0.CO;2-M; Smith GAM, 2002, J BIOL CHEM, V277, P18528, DOI 10.1074/jbc.M200592200; Wang J, 2003, AM J PHYSIOL-CELL PH, V284, pC77, DOI 10.1152/ajpcell.00132.2002; Wang SY, 1998, J CELL PHYSIOL, V176, P456, DOI 10.1002/(SICI)1097-4652(199809)176:3<456::AID-JCP2>3.0.CO;2-N; WONDERLIN WF, 1995, J CELL PHYSIOL, V165, P177, DOI 10.1002/jcp.1041650121	30	85	98	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5107	5114		10.1038/sj.onc.1210308	http://dx.doi.org/10.1038/sj.onc.1210308			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310992				2022-12-25	WOS:000248487400009
J	Fan, S; Meng, Q; Laterra, JJ; Rosen, EM				Fan, S.; Meng, Q.; Laterra, J. J.; Rosen, E. M.			Ras effector pathways modulate scatter factor-stimulated NF-kappa B signaling and protection against DNA damage	ONCOGENE			English	Article						scatter factor; ras; Ra1A; raf1; protection; adriamycin	ACTIVATED PROTEIN-KINASE; NUCLEOTIDE DISSOCIATION STIMULATOR; CELL-TRANSFORMATION; EPITHELIAL-CELLS; GENE-EXPRESSION; MET RECEPTOR; CANCER-CELLS; GROWTH; IDENTIFICATION; APOPTOSIS	Scatter factor (SF) (hepatocyte growth factor) is a pleiotrophic cytokine that accumulates within tumors in vivo and protects tumor cells against cytotoxicity and apoptosis due to DNA damaging agents in vitro. Previous studies have established that SF- mediated cell protection involves antiapoptotic signaling from its receptor (c-Met) to PI3 kinase -> c-Akt -> Pak1 (p21-activated kinase -1)-> NF- kappa B (nuclear factor-kappa B). Here, we found that Ras proteins (H-Ras and R-Ras) enhance SF-mediated activation of NF-kappa B and protection of DU-145 and MDCK (Madin-Darby canine kidney) cells against the topoisomerase II alpha inhibitor adriamycin. Studies of Ras effector loop mutants and their downstream effectors suggest that Ras/PI3 kinase and Ras/Raf1 pathways contribute to SF stimulation of NF-kappa B signaling and cell protection. Further studies revealed that Raf1 positively regulates the ability of SF to stimulate NF-kappa B activity and cell protection. The ability of Raf1 to stimulate NF-kappa B activity was not due to the classical Raf1 -> MEK1/2 -> ERK1/ 2 pathway. However, we found that a MEK3/6p -> 38 pathway contributes to SF-mediated activation of NF-kappa B. In contrast, RalA, a target of the Ras/RalGDS pathway negatively regulated the ability of SF to stimulate NF-kappa B activity and cell protection. Ras, Raf1 and RalA modulate SF stimulation of NF-kappa B activity, in part, by regulating I kappa B kinase (IKK)-kappa kinase activity. These findings suggest that Ras/ Raf1/ RalA pathways may converge to modulate NF-kappa B activation and SF-mediated survival signaling at the IKK complex and/or a kinase upstream of this complex.	Georgetown Univ, Dept Oncol, Lombard Comprehens Canc Ctr, Washington, DC 20057 USA; Kennedy Krieger Inst, Dept Neurol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Georgetown University; Kennedy Krieger Institute; Johns Hopkins University	Rosen, EM (corresponding author), Georgetown Univ, Dept Oncol, Lombard Comprehens Canc Ctr, 3970 Reservoir Rd NW,Box 571469, Washington, DC 20057 USA.	emr36@georgetown.edu			NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NINDS NIH HHS [R01-NS43987] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043987] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ALLEY MC, 1988, CANCER RES, V48, P589; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowers DC, 2000, CANCER RES, V60, P4277; Camonis JH, 2005, TRENDS CELL BIOL, V15, P327, DOI 10.1016/j.tcb.2005.04.002; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Costantini C, 2005, J MOL NEUROSCI, V25, P141, DOI 10.1385/JMN:25:2:141; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Fitzgerald EM, 2000, J PHYSIOL-LONDON, V527, P433, DOI 10.1111/j.1469-7793.2000.00433.x; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Herrmann C, 2003, CURR OPIN STRUC BIOL, V13, P122, DOI 10.1016/S0959-440X(02)00007-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hu MCT, 1998, GENE, V222, P31, DOI 10.1016/S0378-1119(98)00462-4; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; KRAUS MH, 1984, P NATL ACAD SCI-BIOL, V81, P5384, DOI 10.1073/pnas.81.17.5384; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Matteucci E, 2003, ONCOGENE, V22, P4062, DOI 10.1038/sj.onc.1206519; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McFarlin DR, 2003, CARCINOGENESIS, V24, P99, DOI 10.1093/carcin/24.1.99; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mochizuki N, 2000, J BIOL CHEM, V275, P12667, DOI 10.1074/jbc.275.17.12667; Mody N, 2003, BIOCHEM J, V372, P567, DOI 10.1042/BJ20030193; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Murai H, 1997, J BIOL CHEM, V272, P10483; Nick JA, 1999, J CLIN INVEST, V103, P851, DOI 10.1172/JCI5257; Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Rahman A, 2004, AM J PHYSIOL-LUNG C, V287, pL1017, DOI 10.1152/ajplung.00072.2004; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rosen EM, 1997, CIBA F SYMP, V212, P215; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Song KS, 2003, J BIOL CHEM, V278, P34890, DOI 10.1074/jbc.M303911200; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Stuckler D, 2005, CANCER RES, V65, P991; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Vitale N, 2005, J BIOL CHEM, V280, P29921, DOI 10.1074/jbc.M413748200; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wohlgemuth S, 2005, J MOL BIOL, V348, P741, DOI 10.1016/j.jmb.2005.02.048; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YAN MH, 1994, J BIOL CHEM, V269, P19067; Yang JJ, 1998, MOL CELL BIOL, V18, P2586, DOI 10.1128/MCB.18.5.2586; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; Zhong H, 2000, CANCER RES, V60, P1541	60	22	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4774	4796		10.1038/sj.onc.1210271	http://dx.doi.org/10.1038/sj.onc.1210271			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297451				2022-12-25	WOS:000248170400003
J	Vendrell, JA; Ghayad, S; Ben-Larbi, S; Dumontet, C; Mechti, N; Cohen, PA				Vendrell, J. A.; Ghayad, S.; Ben-Larbi, S.; Dumontet, C.; Mechti, N.; Cohen, P. A.			A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells	ONCOGENE			English	Article						A20/TNFAIP3; breast cancer; tamoxifen; resistance; estrogen receptor status; endocrine treatment	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; ZINC-FINGER PROTEIN; INDUCED APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; ENDOTHELIAL-CELLS; UP-REGULATION; A20; EXPRESSION; RECEPTOR	The zinc-finger protein A20/TNFAIP3, an inhibitor of nuclear factor-kappa B (NF-kappa B) activation, has been shown to protect MCF-7 breast carcinoma cells from TNF alpha-induced apoptosis. As estrogen receptor (ER) status is an important parameter in the development and progression of breast cancer, we analysed the effect of 17 beta-estradiol (E-2) treatment on the expression of A20. We found that A20 is a new E-2-regulated gene, whose expression correlates with ER expression in both cell lines and tumor samples. With the aim of investigating the impact of A20 expression on MCF-7 cells in response to ER ligands, we established stably transfected-MCF-7 cells overexpressing A20 (MCF-7-A20). These cells exhibited a phenotype of resistance to the 4-hydroxytamoxifen cytostatic and pro-apoptotic actions and of hyper-response to E-2. Dysregulations in bax, bcl2, bak, phospho-bad, cyclin D1, cyclin E2, cyclin D2 and cyclin A2 proteins expression were shown to be related to the resistant phenotype developed by the MCF-7-A20 cells. Interestingly, we found that A20 was also overexpressed in MVLN and VP tamoxifen-resistant cell lines. Furthermore, high A20 expression levels were observed in more aggressive breast tumors (ER-negative, progesterone receptor-negative and high histological grade). These overall findings strongly suggest that A20 is a key protein involved in tamoxifen resistance, and thus represents both a new breast cancer marker and a promising target for developing new strategies to prevent the emergence of acquired mechanisms of drug resistance in breast cancer.	Univ Lyon 1, Fac Pharm Lyon, ISPB, F-69008 Lyon, France; Fac Pharm Montpellier, CNRS, UMR 5160, Ctr Pharmacol & Biotechnol Sante Fac Pharm, Montpellier, France; INSERM, UMR 590, F-69008 Lyon, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cohen, PA (corresponding author), Univ Lyon 1, Fac Pharm Lyon, ISPB, 8 Av Rockefeller, F-69008 Lyon, France.	pascale.cohen@recherche.univ-lyon1.fr	Vendrell, Julie A/I-5867-2012; Cohen, Pascale/I-5875-2012	Cohen, Pascale/0000-0001-7016-9598; Dumontet, Charles/0000-0003-1875-134X				Ainbinder E, 2002, MOL CELL BIOL, V22, P6354, DOI 10.1128/MCB.22.18.6354-6362.2002; Badia E, 2000, CANCER RES, V60, P4130; Berstein LM, 2004, CLIN CANCER RES, V10, P1530, DOI 10.1158/1078-0432.CCR-0433-03; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Bredel M, 2006, J CLIN ONCOL, V24, P274, DOI 10.1200/JCO.2005.02.9405; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Clarke M, 1998, LANCET, V351, P1451; Codd JD, 1999, J PATHOL, V187, P549; DEGOEIJ AFPM, 1988, J STEROID BIOCHEM, V29, P465, DOI 10.1016/0022-4731(88)90180-X; DEMIRPENCE E, 1993, J STEROID BIOCHEM, V46, P355, DOI 10.1016/0960-0760(93)90225-L; DIXIT VM, 1990, J BIOL CHEM, V265, P2973; Faridi J, 2003, CLIN CANCER RES, V9, P2933; Ferran C, 1998, BLOOD, V91, P2249, DOI 10.1182/blood.V91.7.2249.2249_2249_2258; GOTTARDIS MM, 1988, CANCER RES, V48, P5183; Grey ST, 1999, J EXP MED, V190, P1135, DOI 10.1084/jem.190.8.1135; Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403; Heyninck K, 1999, ANTICANCER RES, V19, P2863; HONIG SF, 1996, DIS BREAST, P669; Jaattela M, 1996, J IMMUNOL, V156, P1166; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Kim R, 2005, CANCER-AM CANCER SOC, V103, P2199, DOI 10.1002/cncr.21029; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kurokawa H, 2000, CANCER RES, V60, P5887; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li HL, 2006, J CELL PHYSIOL, V208, P307, DOI 10.1002/jcp.20665; Longo CR, 2005, HEPATOLOGY, V42, P156, DOI 10.1002/hep.20741; Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004; Lu M, 2003, CANCER RES, V63, P3425; Martin LA, 2003, J BIOL CHEM, V278, P30458, DOI 10.1074/jbc.M305226200; Mauro C, 2006, J BIOL CHEM, V281, P18482, DOI 10.1074/jbc.M601502200; McCallum HM, 1996, BREAST CANCER RES TR, V39, P247, DOI 10.1007/BF01806153; Murphy LC, 2005, J MOL ENDOCRINOL, V34, P553, DOI 10.1677/jme.1.01688; Nabha SM, 2005, ONCOGENE, V24, P3166, DOI 10.1038/sj.onc.1208502; Nguyen H, 2006, VIROLOGY, V354, P58, DOI 10.1016/j.virol.2006.04.028; Onose A, 2006, EUR J PHARMACOL, V541, P198, DOI 10.1016/j.ejphar.2006.03.073; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Patel VI, 2006, FASEB J, V20, P1418, DOI 10.1096/fj.05-4981com; Pichon MF, 1996, BRIT J CANCER, V73, P1545, DOI 10.1038/bjc.1996.291; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Santen RJ, 2004, CLIN CANCER RES, V10, p337S, DOI 10.1158/1078-0432.CCR-031207; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Storz P, 2005, BIOCHEM J, V387, P47, DOI 10.1042/BJ20041443; TEWARI M, 1995, J IMMUNOL, V154, P1699; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tonetti DA, 2000, BRIT J CANCER, V83, P782, DOI 10.1054/bjoc.2000.1326; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Vendrell JA, 2005, ENDOCR-RELAT CANCER, V12, P75, DOI 10.1677/erc.1.00899; Vendrell JA, 2004, J MOL ENDOCRINOL, V32, P397, DOI 10.1677/jme.0.0320397; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Yue W, 2002, ENDOCRINOLOGY, V143, P3221, DOI 10.1210/en.2002-220186; Zetoune FS, 2001, CYTOKINE, V15, P282, DOI 10.1006/cyto.2001.0921; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971	58	74	81	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4656	4667		10.1038/sj.onc.1210269	http://dx.doi.org/10.1038/sj.onc.1210269			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297453				2022-12-25	WOS:000248037900006
J	Carie, AE; Sebti, SM				Carie, A. E.; Sebti, S. M.			A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway	ONCOGENE			English	Article						cAMP; Raf-1; Erk1/2; beta 2 adrenergic receptor; Pirbuterol; cancer therapy	ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; EPIDERMAL-GROWTH-FACTOR; GERANYLGERANYLTRANSFERASE-I INHIBITOR; MAP KINASE; SIGNAL-TRANSDUCTION; CYCLIC-AMP; H-RAS; K-RAS; B-RAF	A chemical biology approach identifies a beta 2 adrenergic receptor (beta 2AR) agonist ARA-211 (Pirbuterol), which causes apoptosis and human tumor regression in animal models. b2AR stimulation of cAMP formation and protein kinase A (PKA) activation leads to Raf-1 (but not B-Raf) kinase inactivation, inhibition of Mek-1 kinase and decreased phospho-extracellular signal-regulated kinase (Erk)1/2 levels. ARA-211 inhibition of the Raf/Mek/Erk1/2 pathway is mediated by PKA and not exchange protein activated by cAMP (EPAC). ARA-211 is selective and suppresses P-Erk1/2 but not P-JNK, P-p38, P-Akt or P-STAT3 levels. b2AR stimulation results in inhibition of anchorage-dependent and -independent growth, induction of apoptosis in vitro and tumor regression in vivo. b2AR antagonists and constitutively active Mek-1 rescue from the effects of ARA-211, demonstrating that b2AR stimulation and Mek kinase inhibition are required for ARA-211 antitumor activity. Furthermore, suppression of growth occurs only in human tumors where ARA-211 induces cAMP formation and decreases P-Erk1/2 levels. Thus, b2AR stimulation results in significant suppression of malignant transformation in cancers where it blocks the Raf-1/Mek-1/Erk1/2 pathway by a cAMP-dependent activation of PKA but not EPAC.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sebti, SM (corresponding author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	sebti@moffitt.usf.edu		Carie, Adam/0000-0001-7804-0465				Alvarez JV, 2004, CANCER BIOL THER, V3, P1045, DOI 10.4161/cbt.3.11.1172; Blaskovich MA, 2003, CANCER RES, V63, P1270; BOS JL, 1989, CANCER RES, V49, P4682; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; DIMARCO E, 1989, ONCOGENE, V4, P831; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FLEMING TP, 1992, EXP GERONTOL, V27, P523, DOI 10.1016/0531-5565(92)90007-M; Graells J, 2004, J INVEST DERMATOL, V123, P1151, DOI 10.1111/j.0022-202X.2004.23460.x; GRASSI V, 1986, INT J CLIN PHARM RES, V6, P93; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao D, 2002, CANCER INVEST, V20, P387, DOI 10.1081/CNV-120001184; Jiang Z, 2004, HISTOPATHOLOGY, V45, P218, DOI 10.1111/j.1365-2559.2004.01930.x; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Johnson JR, 2005, CLIN CANCER RES, V11, P6414, DOI 10.1158/1078-0432.CCR-05-0790; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; MOORE PF, 1978, J PHARMACOL EXP THER, V207, P410; Redell MS, 2005, CURR PHARM DESIGN, V11, P2873, DOI 10.2174/1381612054546699; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Slotkin TA, 2000, BREAST CANCER RES TR, V60, P153, DOI 10.1023/A:1006338232150; Slotkin TA, 2000, BREAST CANCER RES TR, V64, P259, DOI 10.1023/A:1026508605951; STEEN SN, 1974, CURR THER RES CLIN E, V16, P1077; Steinberg SF, 2000, CIRC RES, V87, P1079, DOI 10.1161/01.RES.87.12.1079; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3; Sun JZ, 2005, ONCOGENE, V24, P4701, DOI 10.1038/sj.onc.1208391; Sun JZ, 2003, CANCER RES, V63, P8922; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; Troadec JD, 2002, MOL PHARMACOL, V62, P1043, DOI 10.1124/mol.62.5.1043; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; VEBER N, 1994, EUR J CANCER, V30A, P1352, DOI 10.1016/0959-8049(94)90186-4; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Watanabe M, 1996, INT J CANCER, V67, P264, DOI 10.1002/(SICI)1097-0215(19960717)67:2<264::AID-IJC18>3.0.CO;2-B; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Weldon CB, 2002, SURGERY, V132, P293, DOI 10.1067/msy.2002.125389; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yu M, 1998, CLIN EXP METASTAS, V16, P185	52	59	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3777	3788		10.1038/sj.onc.1210172	http://dx.doi.org/10.1038/sj.onc.1210172			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17260025				2022-12-25	WOS:000247026400002
J	Elson-Schwab, L; Garner, OB; Schuksz, M; Crawford, BE; Esko, JD; Tor, Y				Elson-Schwab, Lev; Garner, Omai B.; Schuksz, Manuela; Crawford, Brett E.; Esko, Jeffrey D.; Tor, Yitzhak			Guanidinylated neomycin delivers large, bioactive cargo into cells through a heparan sulfate-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; CELLULAR-UPTAKE; FIBROBLAST-GROWTH; RICH PEPTIDES; TAT PEPTIDE; TRANSLOCATION; MOLECULES; PROTEIN; MEMBRANES; ARGININE	Facilitating the uptake of molecules into living cells is of substantial interest for basic research and drug delivery applications. Arginine-rich peptides have been shown to facilitate uptake of high molecular mass cargos into cells, but the mechanism of uptake is complex and may involve multiple receptors. In this report, we show that a derivative of the aminoglycoside antibiotic neomycin, in which all of the ammonium groups have been converted into guanidinium groups, can carry large (> 300 kDa) bioactive molecules across cell membranes. Delivery occurs at nanomolar transporter concentrations and under these conditions depends entirely on cell surface heparan sulfate proteoglycans. Conjugation of guanidinoneomycin to the plant toxin saporin, a ribosome-inactivating agent, results in proteoglycan-dependent cell toxicity. In contrast, an arginine-rich peptide shows both heparan sulfate-dependent and -independent cellular uptake. The high selectivity of guanidi-noneomycin for heparan sulfate suggests the possibility of exploiting differences in proteoglycan compositions to target delivery to different cell types.	Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Zacharon Pharmaceut Inc, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; BioMarin Pharmaceutical Inc.; Zacharon Pharmaceuticals Inc.	Esko, JD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA.	jesko@ucsd.edu; ytor@ucsd.edu			NCI NIH HHS [CA11227, CA67754] Funding Source: Medline; NIAID NIH HHS [5F31AI05891602, AI47673] Funding Source: Medline; NIGMS NIH HHS [GM77471, GM33063] Funding Source: Medline; NINDS NIH HHS [NS047101] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA067754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R01GM077471, R01GM033063] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P30NS047101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai XM, 1999, J BIOL CHEM, V274, P13017, DOI 10.1074/jbc.274.19.13017; Caesar CEB, 2006, BIOCHEMISTRY-US, V45, P7682, DOI 10.1021/bi052095t; Chung HH, 2004, BIOPOLYMERS, V76, P83, DOI 10.1002/bip.10597; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fernandex-Carneado J, 2005, J AM CHEM SOC, V127, P869, DOI 10.1021/ja044006q; Fillon YA, 2005, J AM CHEM SOC, V127, P11798, DOI 10.1021/ja052377g; Flavell DJ, 1998, CURR TOP MICROBIOL, V234, P57; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Fuchs SM, 2004, BIOCHEMISTRY-US, V43, P2438, DOI 10.1021/bi035933x; Futaki S, 2005, ADV DRUG DELIVER REV, V57, P547, DOI 10.1016/j.addr.2004.10.009; Futaki S, 2006, BIOPOLYMERS, V84, P241, DOI 10.1002/bip.20421; Futaki S, 2002, BIOCHEMISTRY-US, V41, P7925, DOI 10.1021/bi0256173; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Hardman J, 2006, AMINOGLYCOSIDES GOOD, V11; Hitz T, 2006, BIOCHEMISTRY-US, V45, P5817, DOI 10.1021/bi060285d; Kaplan IM, 2005, J CONTROL RELEASE, V102, P247, DOI 10.1016/j.jconrel.2004.10.018; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; Luedtke NW, 2003, J AM CHEM SOC, V125, P12374, DOI 10.1021/ja0360135; Luedtke NW, 2000, J AM CHEM SOC, V122, P12035, DOI 10.1021/ja002421m; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Richard JP, 2005, J BIOL CHEM, V280, P15300, DOI 10.1074/jbc.M401604200; Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003; Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536; RYSER HJP, 1968, SCIENCE, V159, P390, DOI 10.1126/science.159.3813.390; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Umezawa N, 2002, J AM CHEM SOC, V124, P368, DOI 10.1021/ja017283v; Wadia JS, 2005, ADV DRUG DELIVER REV, V57, P579, DOI 10.1016/j.addr.2004.10.005; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	35	61	71	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13585	13591		10.1074/jbc.M700463200	http://dx.doi.org/10.1074/jbc.M700463200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17311923	hybrid			2022-12-25	WOS:000246060300047
J	Madan, P; Rose, K; Watson, AJ				Madan, Pavneesh; Rose, Keeley; Watson, Andrew J.			Na/K-ATPase beta 1 subunit expression is required for blastocyst formation and normal assembly of trophectoderm tight junction-associated proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PREIMPLANTATION DEVELOPMENT; NA,K-ATPASE ALPHA-SUBUNIT; EMBRYO DEVELOPMENT; NA+/K+-ATPASE; IN-VITRO; DIFFERENTIATION; BETA(1)-SUBUNIT; SUPPRESSION; BIOGENESIS; CAVITATION	Na/K-ATPase plays an important role in mediating blastocyst formation. Despite the expression of multiple Na/K-ATPase alpha and beta isoforms during mouse preimplantation development, only the alpha 1 and beta 1 isoforms have been localized to the basolateral membrane regions of the trophectoderm. The aim of the present study was to selectively down-regulate the Na/KATPase beta 1 subunit employing microinjection of mouse 1 cell zygotes with small interfering RNA (siRNA) oligos. Experiments comprised of non- injected controls and two groups microinjected with either Stealth (TM) Na/K- ATPase beta 1 subunit oligos or nonspecific Stealth (TM) siRNA as control. Development to the 2-, 4-, 8-, and 16-cell and morula stages did not vary between the three groups. However, only 2.3% of the embryos microinjected with Na/K-ATPase beta 1 subunit siRNA oligos developed to the blastocyst stage as compared with 73% for control-injected and 91% for non-injected controls. Na/K-ATPase beta 1 subunit down-regulation was validated by employing reverse transcription-PCR and whole-mount immunofluorescence methods to demonstrate that Na/K-ATPase beta 1 subunit mRNAs and protein were not detectable in beta 1 subunit siRNA-microinjected embryos. Aggregation chimera experiments between beta 1 subunit siRNA-microinjected embryos and controls demonstrated that blockade of blastocyst formation was reversible. The distribution of Na/K-ATPase beta 1 and tight junction-associated proteins occludin and ZO-1 were compared among the three treatment groups. No differences in protein distribution were observed between control groups; however, all three polypeptides displayed an aberrant distribution in Na/K-ATPase beta 1 subunit siRNA-microinjected embryos. Our results demonstrate that the beta 1 subunit of the Na/K-ATPase is required for blastocyst formation and that this subunit is also required to maintain a normal Na/K-ATPase distribution and localization of tight junction-associated polypeptides during preimplantation development.	Univ Western Ontario, VRL, CHRI, Dept Obstet & Gynaecol, London, ON N6A 4G5, Canada; Univ Western Ontario, VRL, CHRI, Dept Physiol, London, ON N6A 4G5, Canada; Univ Western Ontario, VRL, CHRI, Dept Pharmacol, London, ON N6A 4G5, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Watson, AJ (corresponding author), Univ Western Ontario, VRL, CHRI, Dept Obstet & Gynaecol, 5th Floor,800 Commissioners Rd E, London, ON N6A 4G5, Canada.	awatson@uwo.ca	Watson, Andrew J/A-5636-2015	Watson, Andrew J/0000-0002-2344-3061				Barcroft LC, 1998, J REPROD FERTIL, V114, P327, DOI 10.1530/jrf.0.1140327; Barcroft LC, 2004, MECH DEVELOP, V121, P417, DOI 10.1016/j.mod.2004.04.005; Barwe SP, 2005, MOL BIOL CELL, V16, P1082, DOI 10.1091/mbc.E04-05-0427; Beguin P, 2000, MOL BIOL CELL, V11, P1657, DOI 10.1091/mbc.11.5.1657; Beguin P, 1998, J BIOL CHEM, V273, P24921, DOI 10.1074/jbc.273.38.24921; BENOS DJ, 1981, DEV BIOL, V83, P69, DOI 10.1016/S0012-1606(81)80009-7; Betts DH, 1998, DEV BIOL, V197, P77, DOI 10.1006/dbio.1998.8874; Betts DH, 1997, MOL REPROD DEV, V46, P114, DOI 10.1002/(SICI)1098-2795(199702)46:2&lt;114::AID-MRD2&gt;3.0.CO;2-T; BIGGERS JD, 1978, J PHYSIOL-LONDON, V280, P319, DOI 10.1113/jphysiol.1978.sp012386; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIZIO SM, 1977, DEV BIOL, V59, P198, DOI 10.1016/0012-1606(77)90254-8; DUMOULIN JCM, 1993, MOL REPROD DEV, V36, P320, DOI 10.1002/mrd.1080360306; Espineda CE, 2004, MOL BIOL CELL, V15, P1364, DOI 10.1091/mbc.E03-09-0646; FLEMING TP, 1989, J CELL BIOL, V108, P1407, DOI 10.1083/jcb.108.4.1407; FLEMING TP, 1993, J CELL SCI, P119; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; GARDINER CS, 1990, BIOL REPROD, V43, P788, DOI 10.1095/biolreprod43.5.788; Gardner RL, 2000, METH MOL B, V135, P397; Geering K, 2001, J BIOENERG BIOMEMBR, V33, P425, DOI 10.1023/A:1010623724749; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; Geering K, 1996, J CELL BIOL, V133, P1193, DOI 10.1083/jcb.133.6.1193; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Hasler U, 1998, J BIOL CHEM, V273, P30826, DOI 10.1074/jbc.273.46.30826; Houghton FD, 2003, DEV BIOL, V263, P360, DOI 10.1016/j.ydbio.2003.07.014; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; KAPLAN JH, 2005, SCI STKE, pPE31; MacPhee DJ, 2000, DEV BIOL, V222, P486, DOI 10.1006/dbio.2000.9708; Madan P, 2005, REPRODUCTION, V130, P41, DOI 10.1530/rep.1.00554; Natale DR, 2004, DEV BIOL, V268, P76, DOI 10.1016/j.ydbio.2003.12.011; OVERSTROM EW, 1989, J REPROD FERTIL, V85, P283, DOI 10.1530/jrf.0.0850283; Rajasekaran AK, 2003, ANN NY ACAD SCI, V986, P649, DOI 10.1111/j.1749-6632.2003.tb07276.x; Rajasekaran AK, 2003, AM J PHYSIOL-RENAL, V285, pF388, DOI 10.1152/ajprenal.00439.2002; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P279, DOI 10.1091/mbc.12.2.279; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P3717, DOI 10.1091/mbc.12.12.3717; Rajasekaran SA, 2004, MOL BIOL CELL, V15, P3224, DOI 10.1091/mbc.e04-03-0222; Sheth B, 2000, MECH DEVELOP, V97, P93, DOI 10.1016/S0925-4773(00)00416-0; Sheth B, 2000, DEVELOPMENT, V127, P831; SPINDLE A, 1980, IN VITRO CELL DEV B, V16, P669, DOI 10.1007/BF02619196; SUMMERS MC, 1995, BIOL REPROD, V53, P431, DOI 10.1095/biolreprod53.2.431; Tsukita S, 2000, ANN NY ACAD SCI, V915, P129, DOI 10.1111/j.1749-6632.2000.tb05235.x; VANWINKLE LJ, 1991, DEV BIOL, V146, P158, DOI 10.1016/0012-1606(91)90456-D; Violette MI, 2006, DEV BIOL, V289, P406, DOI 10.1016/j.ydbio.2005.11.004; Waelchli RO, 1997, BIOL REPROD, V57, P630, DOI 10.1095/biolreprod57.3.630; WATSON AJ, 1990, DEV GENET, V11, P41, DOI 10.1002/dvg.1020110106; WATSON AJ, 1988, DEV BIOL, V126, P80, DOI 10.1016/0012-1606(88)90241-2; WILEY LM, 1984, DEV BIOL, V105, P330, DOI 10.1016/0012-1606(84)90290-2	46	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12127	12134		10.1074/jbc.M700696200	http://dx.doi.org/10.1074/jbc.M700696200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17317668	hybrid			2022-12-25	WOS:000245941900055
J	Sharma, A; Awasthi, S; Harrod, CK; Matlock, EF; Khan, S; Xu, L; Chan, S; Yang, H; Thammavaram, CK; Rasor, RA; Burns, DK; Skiest, DJ; Van Lint, C; Girard, AM; McGee, M; Monnat, RJ; Harrod, R				Sharma, Anima; Awasthi, Soumya; Harrod, Carolyn K.; Matlock, Elizabeth F.; Khan, Saiqa; Xu, Louisa; Chan, Stephanie; Yang, Helen; Thammavaram, Charu K.; Rasor, Randall A.; Burns, Dennis K.; Skiest, Daniel J.; Van Lint, Carine; Girard, Anne-Marie; McGee, Monnie; Monnat, Raymond J., Jr.; Harrod, Robert			The Werner syndrome helicase is a cofactor for HIV-1 long terminal repeat transactivation and retroviral replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CREB-BINDING-PROTEIN; P-TEFB KINASE; NF-KAPPA-B; IN-VITRO; TRANSCRIPTIONAL REGULATION; HISTONE ACETYLTRANSFERASE; PCAF BROMODOMAIN; MESSENGER-RNA; T-LYMPHOCYTES	The Werner syndrome helicase ( WRN) participates in DNA replication, double strand break repair, telomere maintenance, and p53 activation. Mutations of wrn cause Werner syndrome ( WS), an autosomal recessive premature aging disorder associated with cancer predisposition, atherosclerosis, and other aging related symptoms. Here, we report that WRN is a novel cofactor for HIV-1 replication. Immortalized human WRN-/- WS fibroblasts, lacking a functional wrn gene, are impaired for basal and Tat-activated HIV-1 transcription. Overexpression of wild-type WRN transactivates the HIV-1 long terminal repeat ( LTR) in the absence of Tat, and WRN cooperates with Tat to promote high-level LTR transactivation. Ectopic WRN induces HIV-1 p24(Gag) production and retroviral replication in HIV-1-infected H9(HIV-1IIIB) lymphocytes. A dominant-negative helicase-minus mutant, WRNK577M, inhibits LTR transactivation and HIV-1 replication. Inhibition of endogenous WRN, through co-expression of WRNK577M, diminishes recruitment of p300/CREB-binding protein-associated factor ( PCAF) and positive transcription elongation factor b ( P-TEFb) to Tat/transactivation response-RNA complexes, and immortalized WRN-/- WS fibroblasts exhibit comparable defects in recruitment of PCAF and P-TEFb to the HIV-1 LTR. Our results demonstrate that WRN is a novel cellular cofactor for HIV-1 replication and suggest that the WRN helicase participates in the recruitment of PCAF/P-TEFb-containing transcription complexes. WRN may be a plausible target for antiretroviral therapy.	So Methodist Univ, Dept Biol Sci, Mol Virol Lab, Dallas, TX 75275 USA; Univ Texas, SW Med Ctr, Dept Pathol, Div Neuropathol, Dallas, TX 75235 USA; Baystate Med Ctr, Div Infect Dis, HIV Sect, Springfield, MA 01109 USA; Univ Libre Bruxelles, Inst Biol & Med Mol, Mol Virol Lab, Serv Chim Biol, B-6041 Brussels, Belgium; Oregon State Univ, Ctr Gene Res & Biotechnol, Corvallis, OR 97331 USA; So Methodist Univ, Dept Stat Sci, Dallas, TX 75275 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Southern Methodist University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baystate Medical Center; Universite Libre de Bruxelles; Oregon State University; Southern Methodist University; University of Washington; University of Washington Seattle	Harrod, R (corresponding author), 6501 Airline Dr,334-DLS, Dallas, TX 75275 USA.	rharrod@mail.smu.edu	xu, louisa/HGT-8566-2022	Girard, Anne-Marie/0000-0002-5346-981X				ALCAMI J, 1995, EMBO J, V14, P1552, DOI 10.1002/j.1460-2075.1995.tb07141.x; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bai YL, 2003, HUM GENET, V113, P337, DOI 10.1007/s00439-003-0972-y; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; Bordi L, 2004, CLIN EXP IMMUNOL, V138, P251, DOI 10.1111/j.1365-2249.2004.02622.x; Bres V, 2005, GENE DEV, V19, P1211, DOI 10.1101/gad.1291705; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Bres V, 2002, J BIOL CHEM, V277, P22215, DOI 10.1074/jbc.M201895200; CHANG SYP, 1993, NATURE, V363, P466, DOI 10.1038/363466a0; Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200; Crabbe L, 2004, SCIENCE, V306, P1951, DOI 10.1126/science.1103619; Deng LW, 2001, VIROLOGY, V289, P312, DOI 10.1006/viro.2001.1129; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; Harrod R, 2003, J BIOL CHEM, V278, P12310, DOI 10.1074/jbc.M211167200; Hotttiger MO, 1998, J VIROL, V72, P8252, DOI 10.1128/JVI.72.10.8252-8256.1998; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819; Kaehlcke K, 2003, MOL CELL, V12, P167, DOI 10.1016/S1097-2765(03)00245-4; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Laine JP, 2003, CANCER RES, V63, P7136; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Lusic M, 2003, EMBO J, V22, P6550, DOI 10.1093/emboj/cdg631; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Moser MJ, 2000, NUCLEIC ACIDS RES, V28, P648, DOI 10.1093/nar/28.2.648; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Pagans S, 2005, PLOS BIOL, V3, P210, DOI 10.1371/journal.pbio.0030041; PARROTT C, 1991, J VIROL, V65, P1414, DOI 10.1128/JVI.65.3.1414-1419.1991; PERKINS ND, 1993, EMBO J, V12, P3551, DOI 10.1002/j.1460-2075.1993.tb06029.x; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; Shiratori M, 2002, ONCOGENE, V21, P2447, DOI 10.1038/sj.onc.1205334; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; Steger DJ, 1997, EMBO J, V16, P2463, DOI 10.1093/emboj/16.9.2463; TONGSTARKSEN SE, 1990, J IMMUNOL, V145, P4348; Treand C, 2006, EMBO J, V25, P1690, DOI 10.1038/sj.emboj.7601074; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wong KS, 2005, J BIOL CHEM, V280, P9390, DOI 10.1074/jbc.M408643200; Zhou MS, 2004, J VIROL, V78, P13522, DOI 10.1128/JVI.78.24.13522-13533.2004; Zhou MS, 2003, P NATL ACAD SCI USA, V100, P12666, DOI 10.1073/pnas.1835726100; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	50	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12048	12057		10.1074/jbc.M608104200	http://dx.doi.org/10.1074/jbc.M608104200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17317667	hybrid			2022-12-25	WOS:000245941900047
J	Carrigan, A; Walther, RF; Salem, HA; Wu, DM; Atlas, E; Lefebvre, YA; Hache, RJG				Carrigan, Amanda; Walther, Rhian F.; Salem, Houssein Abdou; Wu, Dongmei; Atlas, Ella; Lefebvre, Yvonne A.; Hache, Robert J. G.			An active nuclear retention signal in the glucocorticoid receptor functions as a strong inducer of transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; NUCLEOCYTOPLASMIC TRANSPORT; SUBNUCLEAR TRAFFICKING; EXPORT; LOCALIZATION; PATHWAY; CHAPERONES; EXPRESSION; DOMAINS	The glucocorticoid receptor (GR) cycles between a naive chaperone-complexed form in the cytoplasm and a transcriptionally active steroid-bound nuclear form. Nuclear import of GR occurs rapidly and is mediated through the importin alpha/beta karyopherin import pathway. By contrast, nuclear export of GR occurs only slowly under most conditions, despite a dependence on active signaling. In this study we have defined a nuclear retention signal (NRS) in the hinge region of GR that actively opposes the nuclear export of GR as well as the nuclear export mediated through an ectopic CRM1-dependent nuclear export signal (NES). The GR NRS overlaps closely with the basic NL1 nuclear localization signal (NLS) but can be distinguished from NL1 by targeted mutagenesis. Substitution of the classical NLS from SV40 T antigen for the GR NL1 results in a receptor in which nuclear export is accelerated. Remarkably, although the SV40-modified GR remains predominantly nuclear in the presence of steroid and is recruited to transcriptional regulatory regions indistinguishably from wild-type GR, the substitution dramatically weakens the ability of GR to activate transcription of a mouse mammary tumor virus reporter gene. These results suggest that active nuclear retention of GR plays an integral role in glucocorticoid signaling.	Ottawa Hlth Res Inst, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Dept Med & Biochem, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Dept Microbiol, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Dept Immunol, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Grad Program Biochem, Ottawa, ON K1Y 4K9, Canada; Univ British Columbia, Providence Hlth Care, Vancouver, BC V6Z 1Y6, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; University of British Columbia	Hache, RJG (corresponding author), Ottawa Hosp, Ottawa Hlth Res Inst, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	rhache@ohri.ca						ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; Askjaer P, 1998, J BIOL CHEM, V273, P33414, DOI 10.1074/jbc.273.50.33414; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Charmandari E, 2004, ANN NY ACAD SCI, V1024, P1, DOI 10.1196/annals.1321.001; Chrousos GP, 2004, J CLIN ENDOCR METAB, V89, P563, DOI 10.1210/jc.2003-032026; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman ND, 2004, MOL BIOL CELL, V15, P2276, DOI 10.1091/mbc.E03-11-0839; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Ghisletti S, 2005, MOL CELL BIOL, V25, P2957, DOI 10.1128/MCB.25.8.2957-2968.2005; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GUSTAFSSON JA, 1986, J STEROID BIOCHEM, V24, P63, DOI 10.1016/0022-4731(86)90033-6; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; JEWELL CM, 1995, J STEROID BIOCHEM, V55, P135, DOI 10.1016/0960-0760(95)00174-X; Kino T, 2003, J BIOL CHEM, V278, P25651, DOI 10.1074/jbc.M302818200; Kumar R, 2005, J STEROID BIOCHEM, V94, P383, DOI 10.1016/j.jsbmb.2004.12.046; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Nagaich AK, 2004, ANN NY ACAD SCI, V1024, P213, DOI 10.1196/annals.1321.002; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; QI M, 1989, MOL ENDOCRINOL, V3, P1279, DOI 10.1210/mend-3-8-1279; Qiu Y, 2006, MOL CELL, V22, P669, DOI 10.1016/j.molcel.2006.04.019; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Stavreva DA, 2004, MOL CELL BIOL, V24, P2682, DOI 10.1128/MCB.24.7.2682-2697.2004; Tago K, 2004, MOL CELL ENDOCRINOL, V213, P131, DOI 10.1016/j.mce.2003.10.057; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; Walther RF, 2003, J BIOL CHEM, V278, P37858, DOI 10.1074/jbc.M306356200; Weis K, 2003, CELL, V112, P441, DOI 10.1016/S0092-8674(03)00082-5; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Yang J, 1997, J CELL BIOL, V137, P523, DOI 10.1083/jcb.137.3.523	37	43	45	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10963	10971		10.1074/jbc.M602931200	http://dx.doi.org/10.1074/jbc.M602931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17314103	hybrid			2022-12-25	WOS:000245941500016
J	Hardwick, SW; Pane-Farre, J; Delumeau, O; Marles-Wright, J; Murray, JW; Hecker, M; Lewis, RJ				Hardwick, Steven W.; Pane-Farre, Jan; Delumeau, Olivier; Marles-Wright, Jon; Murray, James W.; Hecker, Michael; Lewis, Richard J.			Structural and functional characterization of partner switching regulating the environmental stress response in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGMA(B) TRANSCRIPTION FACTOR; SIGNALING PATHWAY; FACTOR SPOIIAB; ENERGY STRESS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PROTEIN; ACTIVATION; PHOSPHATASE; COMPLEX	The general stress response of Bacillus subtilis and close relatives provides the cell with protection from a variety of stresses. The upstream component of the environmental stress signal transduction cascade is activated by the RsbT kinase that switches binding partners from a 25 S macromolecular complex, the stressosome, to the RsbU phosphatase. Once the RsbU phosphatase is activated by interacting with RsbT, the alternative sigma factor, sigma(B), directs transcription of the general stress regulon. Previously, we demonstrated that the N-terminal domain of RsbU mediates the binding of RsbT. We now describe residues in N-RsbU that are crucial to this interaction by experimentation both in vitro and in vivo. Furthermore, crystal structures of the N-RsbU mutants provide a molecular explanation for the loss of interaction. Finally, we also characterize mutants in RsbT that affect binding to both RsbU and a simplified, binary model of the stressosome and thus identify overlapping binding surfaces on the RsbT "switch.".	Newcastle Univ, Fac Med Sci, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Ernst Moritz Arndt Univ Greifswald, Inst Microbiol, D-17487 Greifswald, Germany	Newcastle University - UK; Ernst Moritz Arndt Universitat Greifswald	Lewis, RJ (corresponding author), Newcastle Univ, Fac Med Sci, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	R.Lewis@ncl.ac.uk		Murray, James/0000-0002-8897-0161; Hardwick, Steven/0000-0001-9246-1864; Marles-Wright, Jon/0000-0002-9156-3284; lewis, richard/0000-0003-2641-8643	Biotechnology and Biological Sciences Research Council [BB/D000521/1] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENSON AK, 1993, P NATL ACAD SCI USA, V90, P2330, DOI 10.1073/pnas.90.6.2330; BENSON AK, 1993, J BACTERIOL, V175, P2347, DOI 10.1128/JB.175.8.2347-2356.1993; BENSON AK, 1992, J BACTERIOL, V174, P749, DOI 10.1128/jb.174.3.749-757.1992; BOYLAN SA, 1992, J BACTERIOL, V174, P3695, DOI 10.1128/JB.174.11.3695-3706.1992; BOYLAN SA, 1993, J BACTERIOL, V175, P7931, DOI 10.1128/JB.175.24.7931-7937.1993; Brigulla M, 2003, J BACTERIOL, V185, P4305, DOI 10.1128/JB.185.15.4305-4314.2003; Brody MS, 2001, J BACTERIOL, V183, P6422, DOI 10.1128/JB.183.21.6422-6428.2001; Campbell EA, 2003, MOL CELL, V11, P1067, DOI 10.1016/S1097-2765(03)00148-5; Campbell EA, 2002, CELL, V108, P795, DOI 10.1016/S0092-8674(02)00662-1; Chen CC, 2003, MOL MICROBIOL, V49, P1657, DOI 10.1046/j.1365-2958.2003.03663.x; Delumeau O, 2004, J BIOL CHEM, V279, P40927, DOI 10.1074/jbc.M405464200; Delumeau O, 2002, J BACTERIOL, V184, P5583, DOI 10.1128/JB.184.20.5583-5589.2002; Delumeau O, 2006, J BACTERIOL, V188, P7885, DOI 10.1128/JB.00892-06; Dufour A, 1996, J BACTERIOL, V178, P3701, DOI 10.1128/jb.178.13.3701-9sigma.1996; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Dutta S, 2003, ACTA CRYSTALLOGR D, V59, P191, DOI 10.1107/SO907444902020723; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; Hecker M, 2001, ADV MICROB PHYSIOL, V44, P35, DOI 10.1016/S0065-2911(01)44011-2; Ho MS, 2003, J BIOL CHEM, V278, P20898, DOI 10.1074/jbc.M302305200; Iber D, 2006, NATURE, V441, P371, DOI 10.1038/nature04666; Kang CM, 1996, J BACTERIOL, V178, P3846, DOI 10.1128/jb.178.13.3846-3853.1996; Kang CM, 1998, MOL MICROBIOL, V30, P189, DOI 10.1046/j.1365-2958.1998.01052.x; Kim TJ, 2004, J BACTERIOL, V186, P6124, DOI 10.1128/jb.186.18.6124-6132.2004; Kim TJ, 2004, J MOL BIOL, V341, P135, DOI 10.1016/j.jmb.2004.05.043; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Kuo S, 2004, MICROBIOL-SGM, V150, P4125, DOI 10.1099/mic.0.27421-0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Magnin T, 1997, J BACTERIOL, V179, P3922, DOI 10.1128/jb.179.12.3922-3927.1997; Masuda S, 2004, J MOL BIOL, V340, P941, DOI 10.1016/j.jmb.2004.05.040; Murray JW, 2005, P NATL ACAD SCI USA, V102, P17320, DOI 10.1073/pnas.0506599102; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OShannessy DJ, 1996, ANAL BIOCHEM, V236, P275, DOI 10.1006/abio.1996.0167; Pane-Farre J, 2005, J MOL MICROB BIOTECH, V9, P65, DOI 10.1159/000088837; Pane-Farre J, 2006, INT J MED MICROBIOL, V296, P237, DOI 10.1016/j.ijmm.2005.11.011; Petersohn A, 2001, J BACTERIOL, V183, P5617, DOI 10.1128/JB.183.19.5617-5631.2001; Price CW, 2001, MOL MICROBIOL, V41, P757, DOI 10.1046/j.1365-2958.2001.02534.x; Rollenhagen C, 2003, J BACTERIOL, V185, P35, DOI 10.1128/JB.185.1.35-40.2003; Sonenshein AL., 2002, BACILLUS SUBTILIS IT, P369; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; STULKE J, 1993, J GEN MICROBIOL, V139, P2041, DOI 10.1099/00221287-139-9-2041; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Vijay K, 2000, MOL MICROBIOL, V35, P180, DOI 10.1046/j.1365-2958.2000.01697.x; VOELKER U, 1995, J BACTERIOL, V177, P114, DOI 10.1128/jb.177.1.114-122.1995; Woodbury RL, 2004, J BACTERIOL, V186, P2789, DOI 10.1128/JB.186.9.2789-2797.2004; Yang XF, 1996, GENE DEV, V10, P2265, DOI 10.1101/gad.10.18.2265	50	23	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11562	11572		10.1074/jbc.M609733200	http://dx.doi.org/10.1074/jbc.M609733200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303566	hybrid			2022-12-25	WOS:000245941500077
J	Kalie, E; Jaitin, DA; Abramovich, R; Schreiber, G				Kalie, Eyal; Jaitin, Diego A.; Abramovich, Renne; Schreiber, Gideon			An interferon alpha 2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING; I INTERFERONS; MUTATIONAL ANALYSIS; SIGNALING PATHWAYS; INDUCED APOPTOSIS; ALPHA-INTERFERON; CELLS; BETA; IFN-ALPHA-2; ANGIOGENESIS	All alpha-interferons ( IFN alpha) bind the IFNAR1 receptor subunit with low affinity. Increasing the binding affinity was shown to specifically increase the antiproliferative potency of IFN alpha 2. Here, we constructed a phage display library by randomizing three positions on IFN alpha 2 previously shown to confer weak binding to IFNAR1. The tightest binding variant selected, comprised of mutations H57Y, E58N, and Q61S ( YNS), was shown to bind IFNAR1 60-fold tighter compared with wild-type IFN alpha 2, and 3-fold tighter compared with IFN beta. Binding of YNS to IFNAR2 was comparable with wild-type IFN alpha 2. The YNS mutant conferred a 150-fold higher antiproliferative potency in WISH cells compared with wild-type IFN alpha 2, whereas its antiviral activity was increased by only 3.5-fold. The high antiproliferative activity was related to an induction of apoptosis, as demonstrated by annexin V binding assays, and to specific gene induction, particularly TRAIL. To determine the potency of the YNS mutant in a xenograft cancer model, we injected it twice a week to nude mice carrying transplanted MDA231 human breast cancer cells. After 5 weeks, no tumors remained in mice treated with YNS, whereas most mice treated with wild-type IFN alpha 2 showed visible tumors. Histological analysis of these tumors showed a significant anti-angiogenic effect of YNS, compared with wild-type IFN alpha 2. This work demonstrates the application of detailed biophysical understanding in the process of protein engineering, yielding an interferon variant with highly increased biological potency.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Schreiber, G (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	gideon.schreiber@weizmann.ac.il	Schreiber, Gideon/C-7332-2008					Brierley MM, 2002, J INTERF CYTOK RES, V22, P835, DOI 10.1089/107999002760274845; Caraglia M, 2004, CURR PROTEIN PEPT SC, V5, P475, DOI 10.2174/1389203043379378; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chen JB, 2004, J INTERF CYTOK RES, V24, P687, DOI 10.1089/jir.2004.24.687; COHEN B, 1995, MOL CELL BIOL, V15, P4208; Cooksley WGE, 2003, J VIRAL HEPATITIS, V10, P298, DOI 10.1046/j.1365-2893.2003.00450.x; Domanski Paul, 1996, Cytokine and Growth Factor Reviews, V7, P143, DOI 10.1016/1359-6101(96)00017-2; DVORAK HF, 1989, J NATL CANCER I, V81, P497, DOI 10.1093/jnci/81.7.497; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; Fidler I J, 2001, J Natl Cancer Inst Monogr, P10; Goldman LA, 1999, J INTERF CYTOK RES, V19, P15, DOI 10.1089/107999099314379; Goodin DS, 2002, NEUROLOGY, V58, P169, DOI 10.1212/WNL.58.2.169; Grumbach IM, 1999, J INTERF CYTOK RES, V19, P797, DOI 10.1089/107999099313659; Haller O, 2006, VIROLOGY, V344, P119, DOI 10.1016/j.virol.2005.09.024; JACOBS S, 1979, P NATL ACAD SCI USA, V76, P4918, DOI 10.1073/pnas.76.10.4918; Jaitin DA, 2006, MOL CELL BIOL, V26, P1888, DOI 10.1128/MCB.26.5.1888-1897.2006; Jaks E, 2007, J MOL BIOL, V366, P525, DOI 10.1016/j.jmb.2006.11.053; Klaus W, 1997, J MOL BIOL, V274, P661, DOI 10.1006/jmbi.1997.1396; Lamken P, 2004, J MOL BIOL, V341, P303, DOI 10.1016/j.jmb.2004.05.059; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Piehler J, 1999, J MOL BIOL, V289, P57, DOI 10.1006/jmbi.1999.2726; Piehler J, 2001, ANAL BIOCHEM, V289, P173, DOI 10.1006/abio.2000.4920; Piehler J, 2000, J BIOL CHEM, V275, P40425, DOI 10.1074/jbc.M006854200; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Pokrovskaja K, 2005, J INTERF CYTOK RES, V25, P799, DOI 10.1089/jir.2005.25.799; Rani MRS, 1999, J BIOL CHEM, V274, P32507, DOI 10.1074/jbc.274.45.32507; Riss TL, 2004, ASSAY DRUG DEV TECHN, V2, P51, DOI 10.1089/154065804322966315; Roisman LC, 2005, J MOL BIOL, V353, P271, DOI 10.1016/j.jmb.2005.08.042; ROSENBLUM MG, 1990, J INTERFERON RES, V10, P141, DOI 10.1089/jir.1990.10.141; Rubinstein M, 1981, Methods Enzymol, V78, P464; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; SIDKY YA, 1987, CANCER RES, V47, P5155; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; Slaton JW, 2001, CLIN CANCER RES, V7, P2840; Slutzki M, 2006, J MOL BIOL, V360, P1019, DOI 10.1016/j.jmb.2006.05.069; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Streck CJ, 2005, CANCER LETT, V228, P163, DOI 10.1016/j.canlet.2004.11.063; Subramaniam PS, 1998, ONCOGENE, V16, P1885, DOI 10.1038/sj.onc.1201712; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Thyrell L, 2004, J BIOL CHEM, V279, P24152, DOI 10.1074/jbc.M312219200; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; Vannucchi S, 2005, ONCOGENE, V24, P2536, DOI 10.1038/sj.onc.1208403; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; Wagner TC, 2004, INT J CANCER, V111, P32, DOI 10.1002/ijc.20236	45	78	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11602	11611		10.1074/jbc.M610115200	http://dx.doi.org/10.1074/jbc.M610115200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17310065	hybrid			2022-12-25	WOS:000245941500081
J	Park, PSH; Sapra, KT; Kolinski, M; Filipek, S; Palczewski, K; Muller, DJ				Park, Paul S. -H.; Sapra, K. Tanuj; Kolinski, Michal; Filipek, Slawomir; Palczewski, Krzysztof; Muller, Daniel J.			Stabilizing effect of Zn2+ in native bovine rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; DETECTING MOLECULAR-INTERACTIONS; ATOMIC-FORCE MICROSCOPY; PARTICLE MESH EWALD; SINGLE-MOLECULE; ZINC-BINDING; UNFOLDING PATHWAYS; DOPAMINE-RECEPTORS; MEMBRANE-PROTEINS; DISULFIDE BOND	Single-molecule force spectroscopy ( SMFS) is a powerful tool to dissect molecular interactions that govern the stability and function of proteins. We applied SMFS to understand the effect of Zn2+ on the molecular interactions underlying the structure of rhodopsin. Force-distance curves obtained from SMFS assays revealed the strength and location of molecular interactions that stabilize structural segments within this receptor. The inclusion of ZnCl2 inSMFSassay buffer increased the stability of most structural segments. This effect was not mimicked by CaCl2, CdCl2, or CoCl2. Thus, Zn2+ stabilizes the structure of rhodopsin in a specific manner.	Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Technol, Ctr Biotechnol, D-01307 Dresden, Germany; Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland	Case Western Reserve University; Technische Universitat Dresden; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej	Muller, DJ (corresponding author), Tatzberg 47, D-01307 Dresden, Germany.	mueller@biotec.tu-dresden.de	Kolinski, Michal/AAO-2946-2020; Müller, Daniel J./A-5967-2010; Filipek, Slawomir/A-2985-2008	Kolinski, Michal/0000-0003-1047-2186; Müller, Daniel J./0000-0003-3075-0665; Sapra, Tanuj/0000-0001-6945-0876; Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [K99EY018085, R00EY018085, R29EY008061, R01EY008061] Funding Source: NIH RePORTER; NEI NIH HHS [K99 EY018085-01, R01 EY008061, R01 EY008061-21, R00 EY018085-03, K99 EY018085-02, R00 EY018085, R00 EY018085-04, EY08061, K99 EY018085, R00 EY018085-05] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Berger O, 1997, BIOPHYS J, V72, P2002, DOI 10.1016/S0006-3495(97)78845-3; BUTT HJ, 1995, NANOTECHNOLOGY, V6, P1, DOI 10.1088/0957-4484/6/1/001; Cisneros DA, 2005, STRUCTURE, V13, P235, DOI 10.1016/j.str.2004.12.005; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; del Valle LJ, 2003, J BIOL CHEM, V278, P4719, DOI 10.1074/jbc.M210760200; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Fotiadis D, 2004, FEBS LETT, V564, P281, DOI 10.1016/S0014-5793(04)00194-2; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Fowler CB, 2004, BIOCHEMISTRY-US, V43, P8700, DOI 10.1021/bi036067r; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022; HIRAYAMA Y, 1990, ACTA HISTOCHEM, V89, P107, DOI 10.1016/S0065-1281(11)80328-4; Holst B, 2002, J BIOL CHEM, V277, P47662, DOI 10.1074/jbc.M202103200; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; Janovjak H, 2006, NEUROBIOL AGING, V27, P546, DOI 10.1016/j.neurobiolaging.2005.03.031; Janovjak H, 2003, EMBO J, V22, P5220, DOI 10.1093/emboj/cdg509; KARCIOGLU ZA, 1982, SURV OPHTHALMOL, V27, P114, DOI 10.1016/0039-6257(82)90195-3; Kedrov A, 2005, EMBO REP, V6, P668, DOI 10.1038/sj.embor.7400455; Kedrov A, 2006, J MOL BIOL, V362, P925, DOI 10.1016/j.jmb.2006.07.049; Klein-Seetharaman J, 2005, TRENDS PHARMACOL SCI, V26, P183, DOI 10.1016/j.tips.2005.02.009; Kono M, 1998, BIOCHEMISTRY-US, V37, P1302, DOI 10.1021/bi9721445; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Li J, 2004, J MOL BIOL, V343, P1409, DOI 10.1016/j.jmb.2004.08.090; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Liu Y, 2006, BIOCHEM BIOPH RES CO, V339, P873, DOI 10.1016/j.bbrc.2005.11.110; Moller C, 2003, J STRUCT BIOL, V142, P369, DOI 10.1016/S1047-8477(03)00066-2; Muller DJ, 2006, CURR OPIN STRUC BIOL, V16, P489, DOI 10.1016/j.sbi.2006.06.001; Muller DJ, 2002, BIOPHYS J, V83, P3578, DOI 10.1016/S0006-3495(02)75358-7; Oesterhelt F, 2000, SCIENCE, V288, P143, DOI 10.1126/science.288.5463.143; Okada T, 2004, J MOL BIOL, V342, P571, DOI 10.1016/j.jmb.2004.07.044; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Park PSH, 2004, BIOCHEMISTRY-US, V43, P15643, DOI 10.1021/bi047907k; Rader AJ, 2004, P NATL ACAD SCI USA, V101, P7246, DOI 10.1073/pnas.0401429101; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rosenkilde MM, 1998, FEBS LETT, V439, P35, DOI 10.1016/S0014-5793(98)01331-3; Sapra KT, 2006, J MOL BIOL, V358, P255, DOI 10.1016/j.jmb.2006.02.008; Sapra KT, 2006, J MOL BIOL, V355, P640, DOI 10.1016/j.jmb.2005.10.080; Schetz JA, 1999, J PHARMACOL EXP THER, V289, P956; Schetz JA, 1997, J NEUROCHEM, V68, P1990; Shuster TA, 1996, CURR EYE RES, V15, P1019, DOI 10.3109/02713689609017650; SHUSTER TA, 1992, BIOCHEM J, V282, P123, DOI 10.1042/bj2820123; Stojanovic A, 2004, J BIOL CHEM, V279, P35932, DOI 10.1074/jbc.M403821200; Swaminath G, 2003, J BIOL CHEM, V278, P352, DOI 10.1074/jbc.M206424200; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5; Ugarte M, 1999, EXP EYE RES, V69, P459, DOI 10.1006/exer.1999.0727; Ugarte M, 1998, GEN PHARMACOL-VASC S, V30, P297, DOI 10.1016/S0306-3623(97)00358-3; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; van der Spoel D, 1998, J CHEM PHYS, V108, P10220, DOI 10.1063/1.476482; Weiss JH, 2000, TRENDS PHARMACOL SCI, V21, P395, DOI 10.1016/S0165-6147(00)01541-8	57	52	54	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11377	11385		10.1074/jbc.M610341200	http://dx.doi.org/10.1074/jbc.M610341200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303564	hybrid, Green Accepted			2022-12-25	WOS:000245941500060
J	Ban, N; Matsumura, Y; Sakai, H; Takanezawa, Y; Sasaki, M; Arai, H; Inagaki, N				Ban, Nobuhiro; Matsumura, Yoshihiro; Sakai, Hiromichi; Takanezawa, Yasukazu; Sasaki, Mayumi; Arai, Hiroyuki; Inagaki, Nobuya			ABCA3 as a lipid transporter in pulmonary surfactant biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-DISTRESS-SYNDROME; INTERSTITIAL LUNG-DISEASE; CELLULAR CHOLESTEROL; PROTEIN-B; RAT LUNG; II CELLS; GENE; DEFICIENCY; MUTATIONS; PHOSPHOLIPIDS	ABCA3 protein is expressed predominantly at the limiting membrane of the lamellar bodies in alveolar type 11 cells, and mutations in the ABCA3 gene cause lethal respiratory distress in newborn infants. To investigate the function of ABCA3 protein, we generated Abca3-deficient mice by targeting Abca3. Fullterm Abca3(-/-) newborn pups died within an hour after birth because of acute respiratory failure. Ultrastructural analysis revealed abnormally dense lamellar body-like organelles and no normal lamellar bodies in Abca3(-/-) alveolar type II cells. TLC and electrospray ionization mass spectrometry analyses of lipids in the pulmonary interstitium showed that phosphatidylcholine and phosphatidylglycerol, which contain palmitic acid and are abundant in normal surfactant lipids, were dramatically decreased in Abca3(-/-) lung. These findings indicate that ABCA3 plays an essential role in pulmonary surfactant lipid metabolism and lamellar body biogenesis, probably by transporting these lipids as substrates.	Kyoto Univ, Dept Diabet & Clin Nutr, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan; JST, CREST, Kyoto 6068507, Japan; JST, CREST, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Physiol, Akita 0108543, Japan; Univ Tokyo, Dept Hlth Chem, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Kyoto University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Akita University; University of Tokyo	Inagaki, N (corresponding author), Kyoto Univ, Dept Diabet & Clin Nutr, Grad Sch Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	inagaki@metab.kuhp.kyoto-u.ac.jp	Sakai, Hiromichi/K-8457-2019	Matsumura, Yoshihiro/0000-0002-3108-0440; Takanezawa, Yasukazu/0000-0002-9220-5825; Inagaki, Nobuya/0000-0001-8261-2593				Abe-Dohmae S, 2004, J BIOL CHEM, V279, P604, DOI 10.1074/jbc.M309888200; Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100; BATENBURG JJ, 1989, BIOCHIM BIOPHYS ACTA, V1006, P329, DOI 10.1016/0005-2760(89)90020-9; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURBON JR, 1982, BIOCHIM BIOPHYS ACTA, V712, P382, DOI 10.1016/0005-2760(82)90356-3; Bullard JE, 2005, AM J RESP CRIT CARE, V172, P1026, DOI 10.1164/rccm.200503-504OC; BURRI PH, 1984, ANNU REV PHYSIOL, V46, P617, DOI 10.1146/annurev.ph.46.030184.003153; CHANDER A, 1990, AM J PHYSIOL, V258, P241; Cheong N, 2006, J BIOL CHEM, V281, P9791, DOI 10.1074/jbc.M507515200; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; DOBBS LG, 1989, ANNU REV MED, V40, P431; FARRELL PM, 1975, AM REV RESPIR DIS, V111, P657; FITZGERALD ML, 2007, IN PRESS J LIPID RES; Garmany TH, 2006, PEDIATR RES, V59, P801, DOI 10.1203/01.pdr.0000219311.14291.df; HALLMAN M, 1975, BIOCHIM BIOPHYS ACTA, V409, P172, DOI 10.1016/0005-2760(75)90152-6; Hiramatsu T, 2003, J BIOL CHEM, V278, P49438, DOI 10.1074/jbc.M213018200; HOLM BA, 1989, ANESTH ANALG, V69, P805; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Johansson J, 1997, EUR J BIOCHEM, V244, P675, DOI 10.1111/j.1432-1033.1997.00675.x; LANG MJ, 1990, J PEDIATR-US, V116, P295, DOI 10.1016/S0022-3476(05)82897-5; MAGOON MW, 1983, BIOCHIM BIOPHYS ACTA, V750, P18, DOI 10.1016/0005-2760(83)90200-X; Nogee LM, 2001, NEW ENGL J MED, V344, P573, DOI 10.1056/NEJM200102223440805; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; Oram JF, 2003, ARTERIOSCL THROM VAS, V23, P720, DOI 10.1161/01.ATV.0000054662.44688.9A; Ridsdale R, 2004, AM J PHYSIOL-LUNG C, V287, pL743, DOI 10.1152/ajplung.00146.2004; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; ROONEY SA, 1985, AM REV RESPIR DIS, V131, P439; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178; Taguchi R, 2000, J MASS SPECTROM, V35, P953, DOI 10.1002/1096-9888(200008)35:8<953::AID-JMS23>3.0.CO;2-4; VORBROKER DK, 1995, AM J PHYSIOL, V268, P647; Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; Yamano G, 2001, FEBS LETT, V508, P221, DOI 10.1016/S0014-5793(01)03056-3; Yoshida I, 2004, BIOCHEM BIOPH RES CO, V323, P547, DOI 10.1016/j.bbrc.2004.08.133	36	161	166	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9628	9634		10.1074/jbc.M611767200	http://dx.doi.org/10.1074/jbc.M611767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17267394	hybrid			2022-12-25	WOS:000245421700036
J	Su, HW; Yeh, HH; Wang, SW; Shen, MR; Chen, TL; Kiela, PR; Ghishan, FK; Tang, MJ				Su, Hsiao-Wen; Yeh, Hsuan-Heng; Wang, Shainn-Wei; Shen, Meng-Ru; Chen, Tsu-Ling; Kiela, Pawel R.; Ghishan, Fayez K.; Tang, Ming-Jer			Cell confluence-induced activation of signal transducer and activator of transcription-3 (Stat3) triggers epithelial dome formation via augmentation of sodium hydrogen exchanger-3 (NHE3) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; IN-VITRO; NA+/H+ EXCHANGER; CYCLIC-AMP; MDCK CELLS; DIFFERENTIATION; MEMBRANE; GENE; TRANSPORT; CHANNEL	Cell confluence induces the activation of signal transducer and activator of transcription-3 (Stat3) in various cancer and epithelial cells, yet the biological implications and the associated regulatory mechanisms remain unclear. Because confluent polarized epithelia demonstrate dome formation and sodium influx that mimic the onset of differentiation, we sought to elucidate the role of Stat3 in association with the regulation of selective epithelial transporters in this biological phenomenon. This study established the correlation between Stat3 activation and cell confluence-induced dome formation in Madin-Darby canine kidney cells (MDCK) by following Stat3 activation events in dome-forming cells. Epifluorescent and confocal microscopy provided evidence showing specific localization of phosphorylated Stat3 Tyr(705) in the nuclei of dome-forming cells at initial stages. The relationship was further elucidated by the establishment of tetracycline-inducible expression of constitutive Stat3 mutant (Stat3-C) in MDCK cells or expression of dominant negative Stat3 (Stat3-D) stable cell lines (MDCK and NMuMG). Dome formation was promoted by the expression of Stat3-C but inhibited by Stat3-D. Two trans-epithelial transporters, NHE3 and ENaC alpha-subunit, were found to be increased during cell confluence. Interestingly, NHE3 expression could be specifically up-regulated by Stat3-C but inhibited by Stat3-13 through promoter regulation, whereas NHE1 and ENaC alpha-subunit were not affected by Stat3 expression. Application of NHE3 shRNA, NHE3 inhibitors (EIPA and S3226) suppressed confluence-induced dome formation in MDCK or NMuMG cells. These results demonstrate a cell confluence-induced Stat3 signaling pathway in epithelial cells in triggering dome formation through NHE3 augmentation.	Natl Cheng Kung Univ, Dept Physiol, Coll Med, Tainan 701, Taiwan; Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan 701, Taiwan; Natl Cheng Kung Univ, Inst Mol Med, Coll Med, Tainan 701, Taiwan; Natl Cheng Kung Univ, Dept Pharmacol, Coll Med, Tainan 701, Taiwan; Natl Cheng Kung Univ, Ctr Gene Regulat & Signal Transduct Res, Coll Med, Tainan 701, Taiwan; Univ Arizona, Hlth Sci Ctr, Dept Pediat, Steele Childrens Res Ctr, Tucson, AZ 85724 USA; Univ Arizona, Hlth Sci Ctr, Dept Physiol, Steele Childrens Res Ctr, Tucson, AZ 85724 USA	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; University of Arizona; University of Arizona Health Sciences; University of Arizona; University of Arizona Health Sciences	Tang, MJ (corresponding author), Natl Cheng Kung Univ, Dept Physiol, Coll Med, 1 Da Hsueh Rd, Tainan 701, Taiwan.	mjtang1@mail.ncku.edu.tw	Wang, Shainn-Wei/B-9644-2009; Kiela, Pawel/AAF-5320-2020	Tang, Ming-Jer/0000-0002-0883-4363; Kiela, Pawel/0000-0002-0014-3517	NIDDK NIH HHS [5R01-DK41274] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041274] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1983, AM J PHYSIOL, V245, P647; BECK JC, 1991, J CLIN INVEST, V87, P2067, DOI 10.1172/JCI115237; Besser D, 1999, MOL CELL BIOL, V19, P1401; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brouard M, 1999, J CELL SCI, V112, P3343; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DREHER D, 1992, AM J PHYSIOL, V262, pC358, DOI 10.1152/ajpcell.1992.262.2.C358; Galey F R, 1980, Am J Otol, V1, P218; GAUSH CR, 1966, P SOC EXP BIOL MED, V122, P931; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Horster M, 2000, AM J PHYSIOL-RENAL, V279, pF982, DOI 10.1152/ajprenal.2000.279.6.F982; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Kandasamy RA, 1996, J BIOL CHEM, V271, P10551, DOI 10.1074/jbc.271.18.10551; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KENNEDY BG, 1984, J CELL PHYSIOL, V121, P51, DOI 10.1002/jcp.1041210108; Kiela PR, 2001, AM J PHYSIOL-GASTR L, V281, pG947, DOI 10.1152/ajpgi.2001.281.4.G947; LEVER JE, 1979, J SUPRAMOL STR CELL, V12, P259, DOI 10.1002/jss.400120210; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lubarsky B, 2003, CELL, V112, P19, DOI 10.1016/S0092-8674(02)01283-7; MCROBERTS JA, 1982, J BIOL CHEM, V257, P2260; MISFELDT DS, 1976, P NATL ACAD SCI USA, V73, P1212, DOI 10.1073/pnas.73.4.1212; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OBERLEITHNER H, 1990, PFLUG ARCH EUR J PHY, V416, P526, DOI 10.1007/BF00382685; Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3; RABITO CA, 1980, IN VITRO CELL DEV B, V16, P461, DOI 10.1007/BF02626458; RINDLER MJ, 1981, J BIOL CHEM, V256, P820; SAHAI A, 1992, KIDNEY INT, V42, P1145, DOI 10.1038/ki.1992.398; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; SEIFTER JL, 1986, J CLIN INVEST, V78, P859, DOI 10.1172/JCI112671; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Shlyonsky V, 2005, J BIOL CHEM, V280, P24181, DOI 10.1074/jbc.M413823200; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Steinman RA, 2003, ONCOGENE, V22, P3608, DOI 10.1038/sj.onc.1206523; Tattersall AL, 2003, CELL PHYSIOL BIOCHEM, V13, P215, DOI 10.1159/000072424; VALENTICH JD, 1979, J CELL PHYSIOL, V100, P291, DOI 10.1002/jcp.1041000210; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Wang YN, 2006, MOL PHARMACOL, V69, P85, DOI 10.1124/mol.105.016220; Warth R, 2003, PFLUG ARCH EUR J PHY, V446, P505, DOI 10.1007/s00424-003-1075-2; WEINMAN SA, 1984, J GEN PHYSIOL, V83, P57, DOI 10.1085/jgp.83.1.57; Xu H, 2005, AM J PHYSIOL-GASTR L, V289, pG36, DOI 10.1152/ajpgi.00552.2004; Yanagisawa M, 1999, NEUROSCI LETT, V269, P169, DOI 10.1016/S0304-3940(99)00447-4; Zegers MMP, 2003, TRENDS CELL BIOL, V13, P169, DOI 10.1016/S0962-8924(03)00036-9; Zucchi I, 1999, P NATL ACAD SCI USA, V96, P13766, DOI 10.1073/pnas.96.24.13766	49	37	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9883	9894		10.1074/jbc.M606754200	http://dx.doi.org/10.1074/jbc.M606754200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276988	hybrid			2022-12-25	WOS:000245421700063
J	Jonsson, G; Dahl, C; Staaf, J; Sandberg, T; Bendahl, PO; Ringner, M; Guldberg, P; Borg, A				Joensson, G.; Dahl, C.; Staaf, J.; Sandberg, T.; Bendahl, P-O; Ringner, M.; Guldberg, P.; Borg, A.			Genomic profiling of malignant melanoma using tiling-resolution arrayCGH	ONCOGENE			English	Article						melanoma; arrayCGH; mutation	BRAF MUTATIONS; SUSCEPTIBILITY LOCUS; CUTANEOUS MELANOMA; GENE; DELETION; PATHWAY; TBX2; INACTIVATION; DISRUPTION; SENESCENCE	Malignant melanoma is an aggressive, heterogeneous disease where new biomarkers for diagnosis and clinical outcome are needed. We searched for chromosomal aberrations that characterize its pathogenesis using 47 different melanoma cell lines and tiling-resolution bacterial artificial chromosome-arrays for comparative genomic hybridization. Major melanoma genes, including BRAF, NRAS, CDKN2A, TP53, CTNNB1, CDK4 and PTEN, were examined for mutations. Distinct copy number alterations were detected, including loss or gain of whole chromosomes but also minute amplifications and homozygous deletions. Most common overlapping regions with losses were mapped to 9p24.3-q13, 10 and 11q14.1-qter, whereas copy number gains were most frequent on chromosomes 1q, 7, 17q and 20q. Amplifications were delineated to oncogenes such as MITF (3p14), CCND1 (11q13), MDM2 (12q15), CCNE1 (19q12) and NOTCH2 (1p12). Frequent findings of homozygous deletions on 9p21 and 10q23 confirmed the importance of CDKN2A and PTEN. Pair-wise comparisons revealed distinct sets of alterations, for example, mutually exclusive mutations in BRAF and NRAS, mutual mutations in BRAF and PTEN, concomitant chromosome 7 gain and 10 loss and concomitant chromosome 15q22.2-q26.3 gain and 20 gain. Moreover, alterations of the various melanoma genes were associated with distinct chromosomal imbalances suggestive of specific genomic programs in melanoma development.	Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden; Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; Lund Univ, Dept Theoret Phys, S-22362 Lund, Sweden	Lund University; Skane University Hospital; Danish Cancer Society; Lund University	Borg, A (corresponding author), Lund Univ, Dept Oncol, SE-22185 Lund, Sweden.	ake.borg@med.lu.se	Jönsson, Göran/D-1212-2014; Ringnér, Markus/G-3641-2011	Ringnér, Markus/0000-0001-5469-8940				Autio R, 2003, BIOINFORMATICS, V19, P1714, DOI 10.1093/bioinformatics/btg230; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Cachia AR, 2000, CLIN CANCER RES, V6, P3511; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; Christensen C, 2005, ONCOGENE, V24, P6292, DOI 10.1038/sj.onc.1208758; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Gillanders E, 2003, AM J HUM GENET, V73, P301, DOI 10.1086/377140; Grafstrom E, 2005, CLIN CANCER RES, V11, P2991, DOI 10.1158/1078-0432.CCR-04-1731; Gronbaek K, 2000, LEUKEMIA, V14, P1727, DOI 10.1038/sj.leu.2401901; Guldberg P, 1997, HUM MUTAT, V9, P348, DOI 10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7; Guldberg P, 1997, CANCER RES, V57, P3660; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hayward NK, 2003, ONCOGENE, V22, P3053, DOI 10.1038/sj.onc.1206445; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jonsson G, 2005, JNCI-J NATL CANCER I, V97, P1377, DOI 10.1093/jnci/dji280; Jonsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Macara IG, 2004, NAT REV MOL CELL BIO, V5, P220, DOI 10.1038/nrm1332; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Massi D, 2006, MODERN PATHOL, V19, P616, DOI 10.1038/modpathol.3800585; McLean WHI, 2003, HUM MOL GENET, V12, P2395, DOI 10.1093/hmg/ddg234; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, MELANOMA RES, V12, P565, DOI 10.1097/00008390-200212000-00006; Ren SJ, 2004, CELL, V117, P239, DOI 10.1016/S0092-8674(04)00300-9; Saal LH, 2002, GENOME BIOL, V3; Sauter ER, 2002, CANCER RES, V62, P3200; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Takata M, 2005, J INVEST DERMATOL, V125, P318, DOI 10.1111/j.0022-202X.2005.23812.x; Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tucker MA, 2003, ONCOGENE, V22, P3042, DOI 10.1038/sj.onc.1206444; Vance KW, 2005, CANCER RES, V65, P2260, DOI 10.1158/0008-5472.CAN-04-3045; Walker GJ, 2004, GENE CHROMOSOME CANC, V41, P56, DOI 10.1002/gcc.20056; ZIPPELIUS A, 2006, CANC IMMUNOL IMMUNOT	38	89	94	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4738	4748		10.1038/sj.onc.1210252	http://dx.doi.org/10.1038/sj.onc.1210252			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17260012				2022-12-25	WOS:000248037900015
J	Waters, LC; Veverka, V; Bohm, M; Schmedt, T; Choong, PT; Muskett, FW; Klempnauer, KH; Carr, MD				Waters, L. C.; Veverka, V.; Boehm, M.; Schmedt, T.; Choong, P. T.; Muskett, F. W.; Klempnauer, K-H; Carr, M. D.			Structure of the C-terminal MA-3 domain of the tumour suppressor protein Pdcd4 and characterization of its interaction with eIF4A	ONCOGENE			English	Article						Pdcd4; MA-3; eIF4A; HEAT; NMR; translation	BOX RNA HELICASE; TRANSLATION INITIATION FACTOR-4A; TORSION ANGLE DYNAMICS; TRANSFORMATION SUPPRESSOR; EUKARYOTIC TRANSLATION; MUTATIONAL ANALYSIS; TISSUE INHIBITOR; CHEMICAL-SHIFT; BINDING; METALLOPROTEINASES-2	Programmed cell death protein 4(Pdcd4) is a novel tumour suppressor protein, which is involved in the control of eukaryotic transcription and translation. The regulation of translation involves specific interactions with eukaryotic initiation factor (eIF) 4A and eIF4G, which are mediated via the two tandem MA-3 domains. We have determined the structure of the C-terminal MA-3 domain of Pdcd4(Pdc d4MA-3 C), characterized its interaction with eIF4A and compared the features of nuclear magnetic resonance (NMR) spectra obtained from the single domain and tandem MA-3 region. Pdcd4M A-3(C) is composed of three layers of helix-turn-helix hairpins capped by a single helix and shows close structural homology to the atypical HEAT repeats found in many eIFs. The sequence conservation and NMR data strongly suggest that the tandem MA-3 region is composed of two equivalent domains connected by a somewhat. exible linker. Pdcd4 MA-3 C was found to interact with the Nterminal domain of eIF4A through a conserved surface region encompassing the loop connecting alpha 5 and alpha 6 and the turn linking alpha 3 and alpha 4. This site is strongly conserved in other MA-3 domains known to interact with eIF4A, including the preceding domain of Pdcd4, suggesting a common mode of binding.	Univ Leicester, Dept Biochem, Henry Wellcome Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England; Univ Munster, Inst Biochem, D-4400 Munster, Germany	University of Leicester; University of Munster	Carr, MD (corresponding author), Univ Leicester, Dept Biochem, Henry Wellcome Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	mdc12@le.ac.uk	Veverka, Vaclav/P-5251-2019; Veverka, Vaclav/G-9174-2014	Veverka, Vaclav/0000-0003-3782-5279; Veverka, Vaclav/0000-0003-3782-5279; Choong, Peter/0000-0001-7333-7665; Carr, Mark/0000-0002-3939-0996	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Bellsolell L, 2006, STRUCTURE, V14, P913, DOI 10.1016/j.str.2006.03.012; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; CHEN S, 2003, P ICASSP HONG KONG C, V4, P640; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jansen AP, 2004, MOL CANCER THER, V3, P103; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; Marintchev A, 2004, Q REV BIOPHYS, V37, P197, DOI 10.1017/S0033583505004026; Mazza C, 2001, MOL CELL, V8, P383, DOI 10.1016/S1097-2765(01)00299-4; Muskett FW, 1998, J BIOL CHEM, V273, P21736, DOI 10.1074/jbc.273.34.21736; Oberer M, 2005, GENE DEV, V19, P2212, DOI 10.1101/gad.1335305; Palamarchuk A, 2005, CANCER RES, V65, P11282, DOI 10.1158/0008-5472.CAN-05-3469; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Ponting CP, 2000, TRENDS BIOCHEM SCI, V25, P423, DOI 10.1016/S0968-0004(00)01628-5; Renshaw PS, 2002, J BIOL CHEM, V277, P21598, DOI 10.1074/jbc.M201625200; Renshaw PS, 2005, EMBO J, V24, P2491, DOI 10.1038/sj.emboj.7600732; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Svitkin YV, 2001, RNA, V7, P1743; Tanner NK, 2003, MOL CELL, V11, P127, DOI 10.1016/S1097-2765(03)00006-6; Waters L, 2006, J BIOL CHEM, V281, P14787, DOI 10.1074/jbc.M600237200; Waters LC, 2006, J BIOMOL NMR, V36, P18, DOI 10.1007/s10858-005-5887-6; Williamson RA, 1997, BIOCHEMISTRY-US, V36, P13882, DOI 10.1021/bi9712091; Yamamoto Y, 2005, P NATL ACAD SCI USA, V102, P16164, DOI 10.1073/pnas.0507960102; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Zakowicz H, 2005, RNA, V11, P261, DOI 10.1261/rna.7191905	43	46	51	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4941	4950		10.1038/sj.onc.1210305	http://dx.doi.org/10.1038/sj.onc.1210305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310995				2022-12-25	WOS:000248322500006
J	Ge, RB; Heinonen, JE; Svahn, MG; Mohamed, AJ; Lundin, KE; Smith, CIE				Ge, Rongbin; Heinonen, Juhana E.; Svahn, Mathias G.; Mohamed, Abdalla J.; Lundin, Karin E.; Smith, C. I. Edvard			Zorro locked nucleic acid induces sequence-specific gene silencing	FASEB JOURNAL			English	Article						peptide nucleic acid; gene transcription; PNA/LNA; DNA binding; oligonucleotide	TRIPLEX-FORMING OLIGONUCLEOTIDES; GREEN FLUORESCENT PROTEIN; STRAND-DISPLACEMENT; ANTISENSE OLIGONUCLEOTIDES; DUPLEX DNA; IN-VITRO; TRANSCRIPTION; PNA; INHIBITION; BINDING	Locked nucleic acids (LNAs) are synthetic analogs of nucleic acids that contain a bridging methylene carbon between the 2' and 4' positions of the ribose ring. In this study, we generated a novel sequence-specific antigene molecule "Zorro LNA", which simultaneously binds to both strands, and that induced effective and specific strand invasion into DNA duplexes and potent inhibition of gene transcription, also in a cellular context. By comparing the Zorro LNA with linear LNA as well as an optimized bisPNA ( peptide nucleic acid) oligonucleotide directed against the same target sites, respectively, we found that the Zorro LNA construct was unique in its ability to arrest gene transcription in mammalian cells. To our knowledge, this is the first time that in mammalian cells, gene transcription was blocked by a nucleic acid analog in a sequence-specific way using low but saturated binding of a blocking agent. This offers a novel type of antigene drug that is easy to synthesize.-Ge, R., Heinonen, J. E., Svahn, M. G., Mohamed, A. J., Lundin, K. E., Smith, C. I. E. Zorro locked nucleic acid induces sequence-specific gene silencing.	Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Clin Res Ctr, SE-14186 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Ge, RB (corresponding author), Karolinska Univ Hosp, Karolinska Inst, Dept Lab Med, Clin Res Ctr, SE-14186 Stockholm, Sweden.	ge.rongbin@ki.se; edvard.smith@ki.se	Svahn, Mathias/AAQ-1784-2020	SMITH, C. I. Edvard/0000-0003-1907-3392				Andreatta C, 2001, BIOTECHNIQUES, V30, P656, DOI 10.2144/01303dd03; Bentin T, 2003, BIOCHEMISTRY-US, V42, P13987, DOI 10.1021/bi0351918; Besch R, 2004, CURR DRUG TARGETS, V5, P691, DOI 10.2174/1389450043345100; Boffa LC, 1996, J BIOL CHEM, V271, P13228, DOI 10.1074/jbc.271.22.13228; Boffa LC, 2000, CANCER RES, V60, P2258; Braasch DA, 2002, NUCLEIC ACIDS RES, V30, P5160, DOI 10.1093/nar/gkf651; Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2; Brunet E, 2005, NUCLEIC ACIDS RES, V33, P4223, DOI 10.1093/nar/gki726; Brunet E, 2005, J BIOL CHEM, V280, P20076, DOI 10.1074/jbc.M500021200; Catapano CV, 2000, BIOCHEMISTRY-US, V39, P5126, DOI 10.1021/bi992185w; CHERNY DY, 1993, P NATL ACAD SCI USA, V90, P1667, DOI 10.1073/pnas.90.5.1667; Christensen L, 1995, J Pept Sci, V1, P175; Crinelli R, 2004, NUCLEIC ACIDS RES, V32, P1874, DOI 10.1093/nar/gkh503; Cutrona G, 2000, NAT BIOTECHNOL, V18, P300, DOI 10.1038/73745; DEMIDOV VV, 1995, P NATL ACAD SCI USA, V92, P2637, DOI 10.1073/pnas.92.7.2637; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; Dervan PB, 2003, CURR OPIN STRUC BIOL, V13, P284, DOI 10.1016/S0959-440X(03)00081-2; Diviacco S, 2001, FASEB J, V15, P2660, DOI 10.1096/fj.01-0440com; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Faria M, 2000, P NATL ACAD SCI USA, V97, P3862, DOI 10.1073/pnas.97.8.3862; Faria M, 2001, J MOL BIOL, V306, P15, DOI 10.1006/jmbi.2000.4386; Frieden M, 2003, NUCLEIC ACIDS RES, V31, P6365, DOI 10.1093/nar/gkg820; Grunweller A, 2003, NUCLEIC ACIDS RES, V31, P3185, DOI 10.1093/nar/gkg409; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; Hertoghs KML, 2003, NUCLEIC ACIDS RES, V31, P5817, DOI 10.1093/nar/gkg801; Janowski BA, 2005, NAT CHEM BIOL, V1, P216, DOI 10.1038/nchembio725; Kaihatsu K, 2003, BIOCHEMISTRY-US, V42, P13996, DOI 10.1021/bi035194k; Koshkin AA, 1998, J ORG CHEM, V63, P2778, DOI 10.1021/jo972239c; Li XQ, 1998, J BIOL CHEM, V273, P34970, DOI 10.1074/jbc.273.52.34970; Lundin KE, 2006, ADV GENET, V56, P1, DOI 10.1016/S0065-2660(06)56001-8; Lundin KE, 2005, BIOMOL ENG, V22, P185, DOI 10.1016/j.bioeng.2005.07.003; Lundin KE, 2004, BIOMOL ENG, V21, P51, DOI 10.1016/j.bioeng.2003.10.003; MOLLEGAARD NE, 1994, P NATL ACAD SCI USA, V91, P3892, DOI 10.1073/pnas.91.9.3892; Mologni L, 1999, BIOCHEM BIOPH RES CO, V264, P537, DOI 10.1006/bbrc.1999.1548; Ng PS, 2005, NANO LETT, V5, P107, DOI [10.1021/nl048246f, 10.1012/nl048246f]; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Nielsen PE, 2004, MOL BIOTECHNOL, V26, P233, DOI 10.1385/MB:26:3:233; NIELSEN PE, 1994, GENE, V149, P139, DOI 10.1016/0378-1119(94)90422-7; Obika S, 1998, TETRAHEDRON LETT, V39, P5401, DOI 10.1016/S0040-4039(98)01084-3; Parekh-Olmedo H, 2002, CHEM BIOL, V9, P1073, DOI 10.1016/S1074-5521(02)00236-3; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; Petersson B, 2005, J AM CHEM SOC, V127, P1424, DOI 10.1021/ja0458726; Schmidt KS, 2004, NUCLEIC ACIDS RES, V32, P5757, DOI 10.1093/nar/gkh862; Singh SK, 1998, J ORG CHEM, V63, P6078, DOI 10.1021/jo9806658; Svahn MG, 2007, OLIGONUCLEOTIDES, V17, P80, DOI 10.1089/oli.2006.0045; Svahn MG, 2004, J GENE MED, V6, pS36, DOI 10.1002/jgm.510; Vasquez KM, 2002, P NATL ACAD SCI USA, V99, P5848, DOI 10.1073/pnas.082193799; Vester B, 2002, J AM CHEM SOC, V124, P13682, DOI 10.1021/ja0276220; Vester B, 2004, BIOCHEMISTRY-US, V43, P13233, DOI 10.1021/bi0485732; Wahlestedt C, 2000, P NATL ACAD SCI USA, V97, P5633, DOI 10.1073/pnas.97.10.5633; Wang G, 1999, NUCLEIC ACIDS RES, V27, P2806, DOI 10.1093/nar/27.13.2806	51	21	23	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1902	1914		10.1096/fj.06-7225com	http://dx.doi.org/10.1096/fj.06-7225com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314142				2022-12-25	WOS:000246866500031
J	Tu, YG; Wu, WP; Wu, TQ; Cao, ZM; Wilkins, R; Toh, BH; Cooper, ME; Chai, ZL				Tu, Yugang; Wu, Weiping; Wu, Tieqiao; Cao, Zemin; Wilkins, Richard; Toh, Ban-Hock; Cooper, Mark E.; Chai, Zhonglin			Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA-1 TARGET DENTT; CELL-CYCLE ARREST; GROWTH-FACTOR; DNA-DAMAGE; DEPENDENT KINASES; CDK INHIBITORS; ERK ACTIVATION; PROTEIN SET; GENE; P21	We previously reported that overexpression of cell division autoantigen 1 ( CDA1) in HeLa cells arrests cell growth and inhibits DNA synthesis at S-phase ( 1). Here we show that CDA1-induced arrest of cell growth is accompanied by increases in protein and mRNA levels of the cyclin-dependent kinase ( Cdk) inhibitor protein, p21(Waf1/Cip1) ( p21). Both p21 induction and cell growth arrest are reversed when CDA1 expression is inhibited. CDA1 also increases p53 protein, but not its mRNA, in a time- and dose-dependent manner. MDM2, a ubiquitin ligase regulating p53 degradation, is inactivated by CDA1, suggesting that p53 protein accumulation is due to decreased protein degradation. Knockdown of p53, using siRNA targeting two sites of p53 mRNA, abrogates transcriptional induction of p21 by CDA1. Deletion of the p53 responsive element in the distal region of p21 promoter attenuates promoter activity in response to CDA1. DNA damage caused by camptothecin treatment increases mRNA and protein levels of CDA1, accompanied by induction of p53. The DNA damage-induced p53 induction is markedly attenuated by CDA1 knockdown. CDA1 induces phosphorylation of ERK1/2( p44/42), an activity blocked by PD98059 and U0126, inhibitors of the upstream kinase MEK1/2. The MEK inhibitors also block induction of p21 mRNA and abrogate p21 promoter activity stimulated by CDA1. Cell cycle kinases, Cdk1, -2, -4, and -6 are inhibited by CDA1 overexpression. We conclude that CDA1 induces p53- and MEK/ERK1/2 MAPK-dependent expression of p21 by acting through the p53 responsive element in the p21 promoter and that this contributes to its antiproliferative activity.	Baker Heart Res Inst, Cell Proliferat & Fibrosis Diabet Complicat Lab, Diabet & Metab Div, Melbourne, Vic 3004, Australia; Monash Univ, Autoimmun Lab, Ctr Inflammatory Dis, Dept Med, Clayton, Vic 3168, Australia; Monash Univ, Monash Inst Med Res, Clayton, Vic 3168, Australia	Baker Heart and Diabetes Institute; Monash University; Monash University	Chai, ZL (corresponding author), Baker Heart Res Inst, Cell Proliferat & Fibrosis Diabet Complicat Lab, Diabet & Metab Div, 75 Commercial Rd, Melbourne, Vic 3004, Australia.	zhonglin.chai@baker.edu.au	Cooper, Mark E/E-8680-2010; CHAI, ZHONGLIN/X-1342-2019; Cooper, Mark/AAC-5326-2020; Chai, Zhonglin/E-7482-2010	Cooper, Mark E/0000-0002-5953-642X; CHAI, ZHONGLIN/0000-0001-8182-8579; 				ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Adler HT, 1997, J BIOL CHEM, V272, P28407, DOI 10.1074/jbc.272.45.28407; Altman R, 1997, J CELL BIOL, V138, P119, DOI 10.1083/jcb.138.1.119; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chai ZL, 2001, J BIOL CHEM, V276, P33665, DOI 10.1074/jbc.M007681200; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Delbridge ML, 2004, CHROMOSOME RES, V12, P345, DOI 10.1023/B:CHRO.0000034134.91243.1c; Dickinson RJ, 2006, J CELL SCI, V119, P4607, DOI 10.1242/jcs.03266; Dotti G, 2005, BLOOD, V105, P4677, DOI 10.1182/blood-2004-08-3337; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Eichmuller S, 2001, P NATL ACAD SCI USA, V98, P629, DOI 10.1073/pnas.021386498; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; Facchinetti MM, 2004, CANCER RES, V64, P3629, DOI 10.1158/0008-5472.CAN-03-3741; GUPTA RS, 1988, CANCER RES, V48, P6404; HARPER JW, 1993, CELL, V75, P805; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Ito T, 2004, J BIOL CHEM, V279, P25204, DOI 10.1074/jbc.M402143200; Ito T, 1996, MOL CELL BIOL, V16, P3112; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Kim YK, 2006, CELL SIGNAL, V18, P236, DOI 10.1016/j.cellsig.2005.04.008; Kivinen L, 1999, CELL GROWTH DIFFER, V10, P621; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee BY, 2005, ARCH BIOCHEM BIOPHYS, V443, P113, DOI 10.1016/j.abb.2005.09.005; Lee YH, 2001, BIOCHEM BIOPH RES CO, V280, P675, DOI 10.1006/bbrc.2000.4215; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Liu Y, 1996, CANCER RES, V56, P31; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; Martinez A, 2002, DEV DYNAM, V224, P186, DOI 10.1002/dvdy.10096; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Okuwaki M, 2005, MOL CELL BIOL, V25, P10639, DOI 10.1128/MCB.25.23.10639-10651.2005; Ozbun LL, 2005, BBA-GENE STRUCT EXPR, V1728, P163, DOI 10.1016/j.bbaexp.2005.02.010; Ozbun LL, 2001, GENOMICS, V73, P179, DOI 10.1006/geno.2001.6505; Park YJ, 2005, J BIOL CHEM, V280, P1817, DOI 10.1074/jbc.M411347200; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Seomun Y, 2005, MOL VIS, V11, P764; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sun GF, 2002, BBA-MOL BASIS DIS, V1588, P241, DOI 10.1016/S0925-4439(02)00171-0; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; VON LM, 1992, MOL CELL BIOL, V12, P3346; VONLINDERN M, 1992, BAILLIERE CLIN HAEM, V5, P857, DOI 10.1016/S0950-3536(11)80049-1; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wang GS, 2004, NEURON, V42, P113, DOI 10.1016/S0896-6273(04)00139-4; WANG GS, 2004, NEURON, V43, P437; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Wu JX, 1997, NUCLEIC ACIDS RES, V25, P4181, DOI 10.1093/nar/25.21.4181; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	70	54	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11722	11731		10.1074/jbc.M609623200	http://dx.doi.org/10.1074/jbc.M609623200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17317670	hybrid			2022-12-25	WOS:000245941900014
J	Moretto, N; Bolchi, A; Rivetti, C; Imbimbo, BP; Villetti, G; Pietrini, V; Polonelli, L; Del Signore, S; Smith, KM; Ferrante, RJ; Ottonello, S				Moretto, Nadia; Bolchi, Angelo; Rivetti, Claudio; Imbimbo, Bruno P.; Villetti, Gino; Pietrini, Vladimiro; Polonelli, Luciano; Del Signore, Steven; Smith, Karen M.; Ferrante, Robert J.; Ottonello, Simone			Conformation-sensitive antibodies against Alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; IMMUNE-RESPONSE; MOUSE MODEL; MEMORY LOSS; IN-VIVO; DISEASE; OLIGOMERS; IMMUNOTHERAPY; VACCINATION; PLAQUES	Immunotherapy against the amyloid-beta(A beta) peptide is a valuable potential treatment for Alzheimer disease ( AD). An ideal antigen should be soluble and nontoxic, avoid the C-terminally located T-cell epitope of A beta, and yet be capable of eliciting antibodies that recognize A beta fibrils and neurotoxic A beta oligomers but not the physiological monomeric species of A beta. We have described here the construction and immunological characterization of a recombinant antigen with these features obtained by tandem multimerization of the immunodominant B-cell epitope peptide A beta 1-15 (A beta 15) within the active site loop of bacterial thioredoxin (Trx). Chimeric Trx(A beta 15)(n) polypeptides bearing one, four, or eight copies of A beta 15 were constructed and injected into mice in combination with alum, an adjuvant approved for human use. All three polypeptides were found to be immunogenic, yet eliciting antibodies with distinct recognition specificities. The anti-Trx(A beta 15)(4) antibody, in particular, recognized A beta 42 fibrils and oligomers but not monomers and exhibited the same kind of conformational selectivity against transthyretin, an amyloidogenic protein unrelated in sequence to A beta. We have also demonstrated that anti-Trx(A beta 15)(4), which binds to human AD plaques, markedly reduces A beta pathology in transgenic AD mice. The data indicate that a conformational epitope shared by oligomers and fibrils can be mimicked by a thioredoxin- constrained A beta fragment repeat and identify Trx(A beta 15)(4) as a promising new tool for AD immunotherapy.	Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Univ Parma, Chisi Farmaceut, R&D Dept, I-43100 Parma, Italy; Univ Parma, Dept Neurosci, Neurol Sect, I-43100 Parma, Italy; Univ Parma, Dept Pathol & Lab Med, I-43100 Parma, Italy; Bedford Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Dept Vet Affairs, Bedford, MA 01730 USA; Boston Univ, Med Ctr, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Psychiat, Boston, MA 02118 USA	University of Parma; University of Parma; University of Parma; University of Parma; University Hospital of Parma; Geriatric Research Education & Clinical Center; Boston University; Boston University; Boston University	Ottonello, S (corresponding author), Univ Parma, Dept Biochem & Mol Biol, Parco Area Sci 23-A, I-43100 Parma, Italy.	s.ottonello@unipr.it	Imbimbo, Bruno/E-2471-2013; Bolchi, Angelo/GOJ-9730-2022	Imbimbo, Bruno/0000-0002-0327-7262; Rivetti, Claudio/0000-0003-3775-6779; Pietrini, Vladimiro/0000-0002-7521-8093	NIA NIH HHS [AG13846] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG013846] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agadjanyan MG, 2005, J IMMUNOL, V174, P1580, DOI 10.4049/jimmunol.174.3.1580; Bard F, 2003, P NATL ACAD SCI USA, V100, P2023, DOI 10.1073/pnas.0436286100; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Blum H, 1996, CYTOKINE, V8, P6, DOI 10.1006/cyto.1996.0002; Blum JH, 2000, P NATL ACAD SCI USA, V97, P2241, DOI 10.1073/pnas.040573397; Boche D, 2005, CURR OPIN NEUROL, V18, P720, DOI 10.1097/01.wco.0000191513.60368.a7; Bonifacio MJ, 1996, BBA-MOL BASIS DIS, V1316, P35, DOI 10.1016/0925-4439(96)00014-2; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Chubb C, 2006, NEUROBIOL AGING, V27, P1462, DOI 10.1016/j.neurobiolaging.2005.08.023; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Cribbs DH, 2003, INT IMMUNOL, V15, P505, DOI 10.1093/intimm/dxg049; DWULET FE, 1986, J CLIN INVEST, V78, P880, DOI 10.1172/JCI112675; Franklin KBJ, 2008, MOUSE BRAIN STEREOTA, V3rd; Gelinas DS, 2004, P NATL ACAD SCI USA, V101, P14657, DOI 10.1073/pnas.0404866101; Ghochikyan A, 2006, VACCINE, V24, P2275, DOI 10.1016/j.vaccine.2005.11.039; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Imbimbo BP, 2002, ANN NEUROL, V51, P794, DOI 10.1002/ana.10218; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim HD, 2005, BIOCHEM BIOPH RES CO, V336, P84, DOI 10.1016/j.bbrc.2005.08.044; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lee EB, 2006, J BIOL CHEM, V281, P4292, DOI 10.1074/jbc.M511018200; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Leverone JF, 2003, VACCINE, V21, P2197, DOI 10.1016/S0264-410X(02)00754-5; Lindgren M, 2005, BIOPHYS J, V88, P4200, DOI 10.1529/biophysj.104.049700; Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499; Maier M, 2006, J NEUROSCI, V26, P4717, DOI 10.1523/JNEUROSCI.0381-06.2006; McLaurin J, 2002, NAT MED, V8, P1263, DOI 10.1038/nm790; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Robinson SR, 2003, BIOESSAYS, V25, P283, DOI 10.1002/bies.10236; Schenk D, 2004, CURR OPIN IMMUNOL, V16, P599, DOI 10.1016/j.coi.2004.07.012; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Solomon Beka, 2004, Current Alzheimer Research, V1, P149, DOI 10.2174/1567205043332126; Spooner ET, 2002, VACCINE, V21, P290, DOI 10.1016/S0264-410X(02)00464-4; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; Thai R, 2004, J BIOL CHEM, V279, P50257, DOI 10.1074/jbc.M405738200; Town T, 2001, NEUROSCI LETT, V307, P101, DOI 10.1016/S0304-3940(01)01951-6; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Zagorski MG, 1999, METHOD ENZYMOL, V309, P189; Zamora E, 2006, J IMMUNOL, V177, P2662, DOI 10.4049/jimmunol.177.4.2662; Zurbriggen R, 2005, J MOL NEUROSCI, V27, P157, DOI 10.1385/JMN:27:2:157	55	58	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11436	11445		10.1074/jbc.M609690200	http://dx.doi.org/10.1074/jbc.M609690200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17267402	hybrid			2022-12-25	WOS:000245941500065
J	Saavalainen, K; Tammi, MI; Bowen, T; Schmitz, ML; Carlberg, C				Saavalainen, Katri; Tammi, Markku I.; Bowen, Timothy; Schmitz, M. Lienhard; Carlberg, Carsten			Integration of the activation of the human hyaluronan synthase 2 gene promoter by common cofactors of the transcription factors retinoic acid receptor and nuclear factor kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALURONAN SYNTHASE-2 GENE; INTRACELLULAR HYALURONAN; COMPLEX; EPIDERMIS; BINDING; ACCUMULATION; ACETYLATION; TARGETS; CANCER; MOTIF	Hyaluronan ( HA) is a polysaccharide of the vertebrate extracellular matrix, produced by three related HA synthases ( HASs) that influence numerous physiological processes. We screened the first 2250 bp of the HAS2 promoter for transcription factor response elements ( REs) in silico and found 1 cluster of 2 retinoic acid ( RA) REs, 3 discrete NF-kappa B factors, and 12 Sp1 REs. In parallel, we scanned nine overlapping promoter regions in HaCaT human immortalized keratinocytes using chromatin immunoprecipitation assays to identify binding of mediator, coactivator, and corepressor proteins and Sp1 transcription factor in response to all-trans-RA and tumor necrosis factor-alpha (TNF-alpha). We found that all-trans-RA modulated the binding of the RA receptor and several coregulators to the region containing the RARE cluster at position - 1230. The importance of this region is supported in reporter gene assays by the all-trans-RA induction of the respective promoter region. Similarly, we showed by chromatin immunoprecipitation assays as well as by gel-shift assays with nuclear extracts that TNF-alpha induced NF-kappa B binding to regions at positions -380, -1420, and -1890, demonstrated its association with RNA polymerase II and cofactor proteins, and confirmed the functionality of the respective promoter regions in vivo. These findings partially explain the induction of HAS2 mRNA by all-trans-RA and TNF-alpha and provide an example how the action of different transcription factor families can use the same cofactors.	Univ Luxembourg, Life Sci Res Unit, L-1511 Luxembourg, Luxembourg; Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Anat, FIN-70211 Kuopio, Finland; Cardiff Univ, Inst Nephrol, Cardiff CF14 4XN, Wales; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany	University of Luxembourg; Finland National Institute for Health & Welfare; University of Eastern Finland; University of Eastern Finland; Cardiff University; Justus Liebig University Giessen	Carlberg, C (corresponding author), Univ Luxembourg, Life Sci Res Unit, 162A Ave Faiencerie, L-1511 Luxembourg, Luxembourg.	carsten.carlberg@uni.lu	Schmitz, M. Lienhard/D-9328-2017; Tammi, Markku/AAQ-7878-2021; Carlberg, Carsten/C-9075-2011	Schmitz, M. Lienhard/0000-0002-6984-7192; Carlberg, Carsten/0000-0003-2633-0684				BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Dunlop TW, 2004, J STEROID BIOCHEM, V89-90, P257, DOI 10.1016/j.jsbmb.2004.03.079; Glass CK, 2000, GENE DEV, V14, P121; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Karin M, 2006, MOL CARCINOGEN, V45, P355, DOI 10.1002/mc.20217; Karvinen S, 2003, J BIOL CHEM, V278, P49495, DOI 10.1074/jbc.M310445200; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Monslow J, 2004, J BIOL CHEM, V279, P20576, DOI 10.1074/jbc.M312666200; Monslow J, 2003, INT J BIOCHEM CELL B, V35, P1272, DOI 10.1016/S1357-2725(03)00048-7; Monslow J, 2006, J BIOL CHEM, V281, P18043, DOI 10.1074/jbc.M510467200; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nishida Y, 1999, J BIOL CHEM, V274, P21893, DOI 10.1074/jbc.274.31.21893; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Saavalainen K, 2005, J BIOL CHEM, V280, P14636, DOI 10.1074/jbc.M500206200; SCHMITZ ML, 1995, IMMUNOBIOLOGY, V193, P116, DOI 10.1016/S0171-2985(11)80534-6; SCHRADER M, 1993, NUCLEIC ACIDS RES, V21, P1231, DOI 10.1093/nar/21.5.1231; Shaffer PL, 2002, EMBO J, V21, P2242, DOI 10.1093/emboj/21.9.2242; Song CZ, 2002, J BIOL CHEM, V277, P7029, DOI 10.1074/jbc.M108826200; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; TAMMI R, 1989, J INVEST DERMATOL, V92, P326, DOI 10.1111/1523-1747.ep12277125; Tammi R, 2005, J INVEST DERMATOL, V124, P898, DOI 10.1111/j.0022-202X.2005.23697.x; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhang WJ, 2001, MOL CELL BIOL, V21, P2413, DOI 10.1128/MCB.21.7.2413-2422.2001	37	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11530	11539		10.1074/jbc.M607871200	http://dx.doi.org/10.1074/jbc.M607871200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307735	hybrid			2022-12-25	WOS:000245941500074
J	Lloyd-Smith, JO				Lloyd-Smith, James O.			Maximum Likelihood Estimation of the Negative Binomial Dispersion Parameter for Highly Overdispersed Data, with Applications to Infectious Diseases	PLOS ONE			English	Article							AGGREGATION; CURVES	Background. The negative binomial distribution is used commonly throughout biology as a model for overdispersed count data, with attention focused on the negative binomial dispersion parameter, k. A substantial literature exists on the estimation of k, but most attention has focused on datasets that are not highly overdispersed (i.e., those with k >= 1), and the accuracy of confidence intervals estimated for k is typically not explored. Methodology. This article presents a simulation study exploring the bias, precision, and confidence interval coverage of maximum-likelihood estimates of k from highly overdispersed distributions. In addition to exploring small-sample bias on negative binomial estimates, the study addresses estimation from datasets influenced by two types of event under-counting, and from disease transmission data subject to selection bias for successful outbreaks. Conclusions. Results show that maximum likelihood estimates of k can be biased upward by small sample size or under-reporting of zero-class events, but are not biased downward by any of the factors considered. Confidence intervals estimated from the asymptotic sampling variance tend to exhibit coverage below the nominal level, with overestimates of k comprising the great majority of coverage errors. Estimation from outbreak datasets does not increase the bias of k estimates, but can add significant upward bias to estimates of the mean. Because k varies inversely with the degree of overdispersion, these findings show that overestimation of the degree of overdispersion is very rare for these datasets.	Penn State Univ, Mueller Lab, Ctr Infect Dis Dynam, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Lloyd-Smith, JO (corresponding author), Penn State Univ, Mueller Lab, Ctr Infect Dis Dynam, University Pk, PA 16802 USA.	jlloydsmith@psu.edu	/K-4080-2012; Lloyd-Smith, James/AAG-4463-2021	/0000-0001-7941-502X; 	NIH-NIDA [R01-DA10135]; Center for Infectious Disease Dynamics	NIH-NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Center for Infectious Disease Dynamics	This research was performed as a postdoctoral researcher supported by NIH-NIDA (R01-DA10135) and a Center for Infectious Disease Dynamics Postdoctoral Fellowship. None of the sponsors played any role in the research.	Alexander N, 2000, Biostatistics, V1, P453, DOI 10.1093/biostatistics/1.4.453; ANDERSON R M, 1991; ANSCOMBE FJ, 1950, BIOMETRIKA, V37, P358, DOI 10.1093/biomet/37.3-4.358; Blaker H, 2000, CAN J STAT, V28, P783, DOI 10.2307/3315916; BLISS CI, 1953, BIOMETRICS, V9, P176, DOI 10.2307/3001850; Boswell M., 1970, RANDOM COUNTS SCI WO, V1, P3; CLARK SJ, 1989, BIOMETRICS, V45, P309, DOI 10.2307/2532055; Diekmann O., 2000, MATH EPIDEMIOLOGY IN; Donnelly CA, 2004, LANCET INFECT DIS, V4, P672, DOI 10.1016/S1473-3099(04)01173-9; Ferrari MJ, 2005, MATH BIOSCI, V198, P14, DOI 10.1016/j.mbs.2005.08.002; Gray BR, 2005, ECOL MODEL, V185, P1, DOI 10.1016/j.ecolmodel.2004.11.006; GREGORY RD, 1993, ACTA TROP, V54, P131, DOI 10.1016/0001-706X(93)90059-K; Harris TE, 1989, THEORY BRANCHING PRO; Lloyd-Smith JO, 2005, NATURE, V438, P355, DOI 10.1038/nature04153; PIEGORSCH WW, 1990, BIOMETRICS, V46, P863, DOI 10.2307/2532104; PIELOU E C, 1969, P286; PIETERS EP, 1977, BIOMETRICS, V33, P718, DOI 10.2307/2529470; Power JH, 1999, CAN J FISH AQUAT SCI, V56, P191, DOI 10.1139/cjfas-56-2-191; Rice J., 1995, MATH STAT DATA ANAL; Ridout M, 1998, INT BIOM C, V19, P179; Saha K, 2005, BIOMETRICS, V61, P179, DOI 10.1111/j.0006-341X.2005.030833.x; Shaw DJ, 1998, PARASITOLOGY, V117, P597, DOI 10.1017/S0031182098003448; Thompson WL, 2002, AUK, V119, P18, DOI 10.1642/0004-8038(2002)119[0018:TRBSAF]2.0.CO;2; Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255; Walther BA, 1998, PARASITOLOGY, V116, P395, DOI 10.1017/S0031182097002230; White GC, 1996, ECOLOGY, V77, P2549, DOI 10.2307/2265753; WILLSON LJ, 1984, BIOMETRICS, V40, P109, DOI 10.2307/2530749; Wilson K., 2001, ECOLOGY WILDLIFE DIS, P6; [No title captured]	29	110	112	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e180	10.1371/journal.pone.0000180	http://dx.doi.org/10.1371/journal.pone.0000180			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299582	Green Published, gold			2022-12-25	WOS:000207444400001
J	Ma, J; Arnold, HK; Lilly, MB; Sears, RC; Kraft, AS				Ma, J.; Arnold, H. K.; Lilly, M. B.; Sears, R. C.; Kraft, A. S.			Negative regulation of Pim-1 protein kinase levels by the B56 beta subunit of PP2A	ONCOGENE			English	Article						Pim-1; PP2A; B56 beta; protein kinase; Pin1	CONSTITUTIVELY ACTIVATED FLT3; PHOSPHATASE 2A; C-MYC; ALPHA-SUBUNIT; TRANSFORMATION; GROWTH; PIN1; DEGRADATION; STABILITY; SURVIVAL	The Pim protein kinases are serine threonine protein kinases that regulate important cellular signaling pathway molecules, and enhance the ability of c-Myc to induce lymphomas. We demonstrate that a cascade of events controls the cellular levels of Pim. We find that overexpression of the protein phosphatase ( PP) 2A catalytic subunit decreases the activity and protein levels of Pim-1. This effect is reversed by the application of okadaic acid, an inhibitor of PP2A, and is blocked by SV40 small T antigen that is known to disrupt B subunit binding to PP2A A and C subunits. Pim-1 can coimmunoprecipitate with th e PP2A regulatory B subunit, B56 beta, but not B56 alpha, c, delta, e or B55 alpha. Using short hairpin RNA targeted at B56b, we demonstrate that decreasing the level of B56b increases the half-life of Pim-1 from 0.7 to 2.8 h, and decreases the ubiquitinylation level of Pim-1. We also find that Pin1, a prolyl-isomerase, is capable of binding Pim-1 and leads to a decrease in the protein level of Pim-1. On the basis of these observations, we hypothesize that phosphorylated Pim-1 binds Pin1 allowing the interaction of PP2A through B56b. Dephosphorylation of Pim-1 then allows for ubiquitinylation and protein degradation of Pim-1.	Med Univ S Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA	Medical University of South Carolina; Oregon Health & Science University; University of California System; University of California Irvine	Kraft, AS (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, 86 Jonathan Lucas St, Charleston, SC 29425 USA.	kraft@musc.edu			NATIONAL CANCER INSTITUTE [R01CA100855, K01CA086957] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008617] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA086957, R01 CA100855] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM08617] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam M, 2006, CANCER RES, V66, P3828, DOI 10.1158/0008-5472.CAN-05-2309; Aho TLT, 2004, FEBS LETT, V571, P43, DOI 10.1016/j.febslet.2004.06.050; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arroyo JD, 2005, ONCOGENE, V24, P7746, DOI 10.1038/sj.onc.1209038; Bachmann M, 2005, INT J BIOCHEM CELL B, V37, P726, DOI 10.1016/j.biocel.2004.11.005; Boudreau RTM, 2005, INT IMMUNOPHARMACOL, V5, P1507, DOI 10.1016/j.intimp.2005.05.007; Campaner S, 2005, MOL CELL BIOL, V25, P6660, DOI 10.1128/MCB.25.15.6660-6672.2005; Chen W, 2004, CANCER CELL, V5, P127, DOI 10.1016/S1535-6108(04)00026-1; Chen WW, 2005, MOL CANCER RES, V3, P443, DOI 10.1158/1541-7786.MCR-05-0007; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; Cibull TL, 2006, J CLIN PATHOL, V59, P285, DOI 10.1136/jcp.2005.027672; CUYPERS HT, 1984, CELL, V37, P141; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Hammerman PS, 2004, CANCER RES, V64, P8341, DOI 10.1158/0008-5472.CAN-04-2284; Ionov Y, 2003, ANTICANCER RES, V23, P167; Janssens IA, 2005, BIOGEOSCIENCES, V2, P15, DOI 10.5194/bg-2-15-2005; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kim KT, 2005, BLOOD, V105, P1759, DOI 10.1182/blood-2004-05-2006; Kim KT, 2006, BRIT J HAEMATOL, V134, P500, DOI 10.1111/j.1365-2141.2006.06225.x; Lechward K, 2001, ACTA BIOCHIM POL, V48, P921; Losman JA, 2003, J BIOL CHEM, V278, P4800, DOI 10.1074/jbc.M208246200; Macdonald A, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-1; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Mikkers H, 2004, MOL CELL BIOL, V24, P6104, DOI 10.1128/MCB.24.13.6104-6115.2004; Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200; Qian KC, 2005, ACTA CRYSTALLOGR F, V61, P96, DOI 10.1107/S1744309104029963; Qian KC, 2005, J BIOL CHEM, V280, P6130, DOI 10.1074/jbc.M409123200; Richardson Paul G, 2005, Future Oncol, V1, P161, DOI 10.1517/14796694.1.2.161; Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279; Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; Shay KP, 2005, MOL CANCER RES, V3, P170; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Stukenberg PT, 2001, MOL CELL, V7, P1071, DOI 10.1016/S1097-2765(01)00245-3; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004; Van Hoof C, 2004, CANCER CELL, V5, P105, DOI 10.1016/S1535-6108(04)00027-3; Van Kanegan MJ, 2005, J BIOL CHEM, V280, P36029, DOI 10.1074/jbc.M506986200; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Wang Z, 2001, J Vet Sci, V2, P167; Xu Y, 2005, J SURG ONCOL, V92, P326, DOI 10.1002/jso.20325; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	49	58	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5145	5153		10.1038/sj.onc.1210323	http://dx.doi.org/10.1038/sj.onc.1210323			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17297438				2022-12-25	WOS:000248487400013
J	Min, JN; Huang, L; Zimonjic, DB; Moskophidis, D; Mivechi, NF				Min, J-N; Huang, L.; Zimonjic, D. B.; Moskophidis, D.; Mivechi, N. F.			Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors	ONCOGENE			English	Article						Hsf1; p53; tumorigenesis; molecular chaperone	HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; MICE; TUMORIGENESIS; CANCER; APOPTOSIS; INFLAMMATION; PATHWAYS; CELLS	A hallmark in the pathogenesis of cancer is the increased expression of heat shock proteins (Hsps) and other molecular chaperones observed in many tumor types, which is considered to be an adaptive response to enhance tumor cell survival. Heat shock transcription factor 1 (Hsf1) is a major transactivator of Hsp induction and has been proposed to affect tumor initiation and progression, regulating expression of Hsps and other molecular targets. In this report, we provide direct in vivo evidence that Hsf1 plays a critical role in the evolution of spontaneous tumors arising in p53 -/- mice. Thus, loss of Hsf1 function did not prolong tumor- free survival, but surprisingly altered the spectrum of tumors that arose in p53(-/-) mice. Tumor development is rapid in p53(-/-) mice, which predominantly (about 70%) succumb to lymphomas. In contrast, hsf1(-/-) p53(-/-) mice rarely develop lymphomas (<8%), but succumb to other tumor types including testicular carcinomas and soft tissue sarcomas. Our findings suggest that an increase in p53- independent apoptotic cell death in association with altered cytokine signaling and suppressed production of in. flammatory factors in hsf1(-/-) mice may contribute to selective lymphoma suppression. In conclusion, the data presented here link the loss of Hsf1- dependent function to decreased susceptibility to spontaneous lymphomagenesis, which may have implications for cancer prevention and therapy.	Med Coll Georgia, Ctr Mol Chaperone Radiobiol & Canc Virol, Augusta, GA 30912 USA; NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	University System of Georgia; Augusta University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mivechi, NF (corresponding author), Med Coll Georgia, Ctr Mol Chaperone Radiobiol & Canc Virol, 1410 Laney Walker Blvd, CN 3153, Augusta, GA 30912 USA.	dmoskophidis@mcg.edu; nmivechi@mcg.edu	Zimonjic, Drazen/AAX-7513-2020		NATIONAL CANCER INSTITUTE [R01CA062130, R01CA121951, Z01BC010038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070451] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [CA121951, CA62130] Funding Source: Medline; NIGMS NIH HHS [GM070451] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Donehower LA, 1997, CANCER SURV, V29, P329; Flohe SB, 2003, J IMMUNOL, V170, P2340, DOI 10.4049/jimmunol.170.5.2340; Fukatsu K, 1997, SEN-I GAKKAISHI, V53, P15, DOI 10.2115/fiber.53.15; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Inouye S, 2004, J BIOL CHEM, V279, P38701, DOI 10.1074/jbc.M405986200; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jiang LI, 2001, MAMM GENOME, V12, P89, DOI 10.1007/s003350010257; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Knowlton AA, 2006, CARDIOVASC RES, V69, P7, DOI 10.1016/j.cardiores.2005.10.009; Leonard WJ, 2005, NAT REV IMMUNOL, V5, P688, DOI 10.1038/nri1688; Li ZW, 2006, BLOOD REV, V20, P333, DOI 10.1016/j.blre.2005.08.003; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; Takaki E, 2006, J BIOL CHEM, V281, P4931, DOI 10.1074/jbc.M506911200; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Zhang Y, 2002, J CELL BIOCHEM, V86, P376, DOI 10.1002/jcb.10232; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306	30	123	130	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5086	5097		10.1038/sj.onc.1210317	http://dx.doi.org/10.1038/sj.onc.1210317			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310987				2022-12-25	WOS:000248487400007
J	Matskova, LV; Helmstetter, C; Ingham, RJ; Gish, G; Lindholm, CK; Ernberg, I; Pawson, T; Winberg, G				Matskova, L. V.; Helmstetter, C.; Ingham, R. J.; Gish, G.; Lindholm, C. K.; Ernberg, I.; Pawson, T.; Winberg, G.			The Shb signalling scaffold binds to and regulates constitutive signals from the Epstein-Barr virus LMP2A membrane protein	ONCOGENE			English	Article						Epstein-Barr virus; latency-associated membrane protein 2A (LMP2A); Syk; Shb; AIP4; Akt	SYK TYROSINE KINASE; T-CELL-RECEPTOR; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; NEGATIVE REGULATION; DOMAIN-PROTEIN; IN-VIVO; CBL; 2A; LYMPHOCYTES	The Epstein-Barr virus latency-associated membrane protein LMP2A has been shown to activate the survival kinase Akt in epithelial and B cells in a phosphoinositide 3-kinase-dependent fashion. In this study, we demonstrate that the signalling scaffold Shb associates through SH2 and PTB domain interactions with phosphorylated tyrosine motifs in the LMP2A N-terminal tail. Additionally, we show that mutation of tyrosines in these motifs as well as shRNA-mediated downregulation of Shb leads to a loss of constitutive Akt-activation in LMP2A-expressing cells. Furthermore, utilization by Shb of the LMP2A ITAM motif regulates stability of the Syk tyrosine kinase in LMP2A-expressing cells. Our data set the precedent for viral utilization of the Shb signalling scaffold and implicate Shb as a regulator of LMP2A-dependent Akt activation.	Karolinska Inst, MTC, SE-17177 Stockholm, Sweden; Univ Victoria, Dept Biol, Victoria, BC V8W 2Y2, Canada; Mt Sinai Hosp, Samuel Res Inst, Toronto, ON M5G 1X5, Canada; Univ Lausanne, Lausanne Branch, Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland	Karolinska Institutet; University of Victoria; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Ludwig Institute for Cancer Research; University of Lausanne	Matskova, LV (corresponding author), Karolinska Inst, MTC, Nobels Vag 16,Box 280, SE-17177 Stockholm, Sweden.	ludmat@ki.se	Pawson, Tony J/E-4578-2013; Matskova, Liudmila/AAF-4201-2020; Winberg, Gosta/I-5686-2013; Gish, Gerald D/C-7228-2017; Matskova, Liudmila/J-3843-2017	Matskova, Liudmila/0000-0002-3174-1560; Matskova, Liudmila/0000-0002-3174-1560; Peine, Caroline/0000-0001-6267-3452; Winberg, Gosta/0000-0002-3371-4056				Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; BEAUFILS P, 1993, EMBO J, V12, P5105, DOI 10.1002/j.1460-2075.1993.tb06205.x; Caldwell RG, 1998, IMMUNITY, V9, P405, DOI 10.1016/S1074-7613(00)80623-8; Casola S, 2004, NAT IMMUNOL, V5, P317, DOI 10.1038/ni1036; Coligan JE, 2001, CURRENT PROTOCOLS PR; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; DIANZANI U, 1994, J IMMUNOL, V153, P952; Engels N, 2001, J EXP MED, V194, P255, DOI 10.1084/jem.194.3.255; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Fodor S, 2006, IMMUNOL LETT, V104, P29, DOI 10.1016/j.imlet.2005.11.001; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fruehling S, 1996, J VIROL, V70, P6216, DOI 10.1128/JVI.70.9.6216-6226.1996; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grande Shannon M, 2006, Future Oncol, V2, P301, DOI 10.2217/14796694.2.2.301; HARLOWE E, 1988, ANTIBODIES LAB MANUA; Holmqvist K, 2004, J BIOL CHEM, V279, P22267, DOI 10.1074/jbc.M312729200; Ikeda M, 2000, VIROLOGY, V268, P178, DOI 10.1006/viro.1999.0166; Ikeda M, 2002, VIROLOGY, V300, P153, DOI 10.1006/viro.2002.1562; Ingham RJ, 2005, J BIOL CHEM, V280, P34133, DOI 10.1074/jbc.M507831200; KARLSSON T, 1995, ONCOGENE, V10, P1475; Katz E, 2005, J EXP MED, V201, P431, DOI 10.1084/jem.20041471; Koretzky GA, 2006, NAT REV IMMUNOL, V6, P67, DOI 10.1038/nri1750; Kunath T, 2003, NAT BIOTECHNOL, V21, P559, DOI 10.1038/nbt813; LAUX G, 1988, EMBO J, V7, P769, DOI 10.1002/j.1460-2075.1988.tb02874.x; Lindholm CK, 2002, EUR J BIOCHEM, V269, P3279, DOI 10.1046/j.1432-1033.2002.03008.x; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; Lu J, 2006, J BIOL CHEM, V281, P8806, DOI 10.1074/jbc.M507305200; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Matskova L, 2001, J VIROL, V75, P10941, DOI 10.1128/JVI.75.22.10941-10949.2001; Merchant M, 2000, J VIROL, V74, P9115, DOI 10.1128/JVI.74.19.9115-9124.2000; Morrison JA, 2005, J VIROL, V79, P2375, DOI 10.1128/JVI.79.4.2375-2382.2005; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Scholle F, 2001, VIROLOGY, V291, P208, DOI 10.1006/viro.2001.1197; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Silvennoinen O, 1996, J IMMUNOL, V156, P100; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Swart R, 1999, VIROLOGY, V263, P485, DOI 10.1006/viro.1999.9964; Tomlinson CC, 2004, J VIROL, V78, P1918, DOI 10.1128/JVI.78.4.1918-1927.2004; WELSH M, 1994, ONCOGENE, V9, P19; Welsh M, 1998, ONCOGENE, V16, P891, DOI 10.1038/sj.onc.1201607; Welsh N, 2002, MOL MED, V8, P695, DOI 10.1007/BF03402033; Winberg G, 2000, MOL CELL BIOL, V20, P8526, DOI 10.1128/MCB.20.22.8526-8535.2000; Zubiaur M, 1997, J IMMUNOL, V159, P193	47	16	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4908	4917		10.1038/sj.onc.1210298	http://dx.doi.org/10.1038/sj.onc.1210298			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17311000				2022-12-25	WOS:000248322500003
J	Loukin, SH; Kung, C; Saimi, Y				Loukin, Stephen H.; Kung, Ching; Saimi, Yoshiro			Lipid perturbations sensitize osmotic down-shock activated Ca2+ influx, a yeast "deletome" analysis	FASEB JOURNAL			English	Article						calcium flux; lipids; membrane mechanics; osmotic force; mechanosensitive channels; yeast deletants	CROSS-PATHWAY REGULATION; P-TYPE ATPASE; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID METHYLATION; PROTEIN-KINASE; GENE; CHANNEL; COMPLEX; GROWTH; BIOSYNTHESIS	Osmotic down shock causes an immediate influx of Ca2+ in yeast, likely through a membrane stretch-sensitive channel. To see how this channel is constituted and regulated, we screened the collection of 4,906 yeast gene deletants for major changes in this response by luminomtery. We discovered deletants that responded very strongly to much milder down shocks than wild-type required, but show little changes in up-shock response. Of all the possibilities (general metabolism, ion distribution, cytoskeleton, cell wall, membrane receptors, etc.), most of the over-responders turned out to be deleted of proteins functioning in the biogenesis of phospholipids, sphingolipids, or ergosterol. Other over-responders are annotated to have vesicular transport defects, traceable to lipid defects in some cases. The deletant lacking the de novo synthesis of phosphatidylcholine, opi3 Delta, is by far the strongest over-responder. opi3 deletion does not cause nonspecific leakage but greatly sensitizes the force-sensing Ca2+- influx mechanism. Choline supplementation normalizes the opi3 Delta response. Thus, the osmotic-pressure induced stretch force apparently controls channel activities through lipids. This unbiased examination of the yeast genome supports the view that forces intrinsic to the bilayer are determined by the geometry of the lipids and these forces, in turn, govern the activities of proteins embedded therein.-Loukin, S. H, Kung, C., Saimi, Y. Lipid perturbations sensitize osmotic downshock activated Ca2+ influx, a yeast " deletome" analysis.	Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Loukin, SH (corresponding author), Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA.	shloukin@wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047856] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54867, GM 47856] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Boumann HA, 2006, MOL BIOL CELL, V17, P1006, DOI 10.1091/mbc.E05-04-0344; Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010; Chen CY, 1999, J CELL BIOL, V147, P1223, DOI 10.1083/jcb.147.6.1223; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; Deutschbauer AM, 2002, P NATL ACAD SCI USA, V99, P15530, DOI 10.1073/pnas.202604399; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Guo WJ, 1999, AAPS PHARMSCI, V1; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; KEMPLE MD, 1990, EUR J BIOCHEM, V187, P131, DOI 10.1111/j.1432-1033.1990.tb15286.x; Kung C, 2005, NATURE, V436, P647, DOI 10.1038/nature03896; LOUBBARDI A, 1995, J BACTERIOL, V177, P1817, DOI 10.1128/jb.177.7.1817-1823.1995; MCGRAW P, 1989, GENETICS, V122, P317; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Palmer CP, 2001, P NATL ACAD SCI USA, V98, P7801, DOI 10.1073/pnas.141036198; Patel AJ, 2001, CURR OPIN CELL BIOL, V13, P422, DOI 10.1016/S0955-0674(00)00231-3; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; Peterson MR, 2001, TRAFFIC, V2, P476, DOI 10.1034/j.1600-0854.2001.20705.x; Ramu Y, 2006, NATURE, V442, P696, DOI 10.1038/nature04880; Saito K, 2004, MOL BIOL CELL, V15, P3418, DOI 10.1091/mbc.E03-11-0829; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Slessareva JE, 2006, CELL, V126, P191, DOI 10.1016/j.cell.2006.04.045; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stolz J, 1999, J BIOL CHEM, V274, P18747, DOI 10.1074/jbc.274.26.18747; SUKHAREV S, 2004, SCI STKE, pRE4; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; SUMMERS EF, 1988, GENETICS, V120, P909; Tamas MJ, 1999, MOL MICROBIOL, V31, P1087, DOI 10.1046/j.1365-2958.1999.01248.x; Tricoire L, 2006, P NATL ACAD SCI USA, V103, P9500, DOI 10.1073/pnas.0603176103; White WH, 2001, J BIOL CHEM, V276, P10794, DOI 10.1074/jbc.M009804200; Yamaji-Hasegawa A, 2006, BIOL PHARM BULL, V29, P1547, DOI 10.1248/bpb.29.1547; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zhou XL, 2005, EUR BIOPHYS J BIOPHY, V34, P413, DOI 10.1007/s00249-005-0465-0	41	10	10	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1813	1820		10.1096/fj.06-7898com	http://dx.doi.org/10.1096/fj.06-7898com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314135				2022-12-25	WOS:000246866500023
J	Ohba, S; Ikeda, T; Kugimiya, F; Yano, F; Lichtler, AC; Nakamura, K; Takato, T; Kawaguchi, H; Chung, UI				Ohba, Shinsuke; Ikeda, Toshiyuki; Kugimiya, Fumitaka; Yano, Fumiko; Lichtler, Alexander C.; Nakamura, Kozo; Takato, Tsuyoshi; Kawaguchi, Hiroshi; Chung, Ung-il			Identification of a potent combination of osteogenic genes for bone regeneration using embryonic stem (ES) cell-based sensor	FASEB JOURNAL			English	Article						osteogenesis; screening; biosensor; cell sheet	IN-VITRO; OSTEOBLAST DIFFERENTIATION; TRANSCRIPTION FACTOR; BETA INTERACTS; RUNX2; OVEREXPRESSION; MARROW; GROWTH; REPAIR; MECHANISMS	To identify potent bioactive factors for in vivo tissue regeneration by comprehensive screening remains a challenge for regenerative medicine. Here we report the development of an ES cell-based monitoring system for osteogenic differentiation, the identification of a potent combination of osteogenic genes using such a system, and an evaluation of its therapeutic potentials. ES cells were isolated from mice carrying a transgene expressing GFP driven by the 2.3 kb fragment of rat type I collagen alpha( 1) promoter. Using these cells engineered to fluoresce on osteogenic differentiation, we screened cDNA libraries and combinations of major osteogenesis-related genes. Among them, the combination of constitutively active activin receptorlike kinase 6 (caALK6) and runt-related transcription factor 2 ( Runx2) was the minimal unit that induced fluorescence. The combination efficiently induced osteogenic differentiation in various cell types, including terminally differentiated nonosteogenic cells. The cooperative action of the combination occurred through protein stabilization of core binding factor beta (Cbfb), induction of Runx2-Cbfb complex formation, and its DNA binding. Furthermore, transplantation of a monolayer sheet of fibroblasts transduced with the combination achieved bone regeneration within 4 wk in mouse calvarial bone defects. Thus, we successfully identified the potent combination of genes for bone regeneration, which helped broaden cell sources.-Ohba, S., Ikeda, T., Kugimiya, F., Yano, F., Lichtler, A. C., Nakamura, K., Takato, T., Kawaguchi, H., Chung, U. I. Identification of a potent combination of osteogenic genes for bone regeneration using embryonic stem ( ES) cell-based sensor.	Univ Tokyo, Fac Med, Ctr Dis Biol & Integrat Med, Bunkyo Ku, Tokyo 1130033, Japan; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06032 USA; Univ Tokyo, Fac Med, Div Sensory & Motor Syst Med, Bunkyo Ku, Tokyo 1130033, Japan; Japan Soc Promot Sci, Chiyoda Ku, Tokyo, Japan	University of Tokyo; University of Connecticut; University of Tokyo; Japan Society for the Promotion of Science	Chung, UI (corresponding author), Univ Tokyo, Fac Med, Ctr Dis Biol & Integrat Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	uichung-tky@umin.ac.jp	Ikeda, Toshiyuki/GVS-5588-2022	Ohba, Shinsuke/0000-0002-6874-8539				Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Balint E, 2003, J CELL BIOCHEM, V89, P401, DOI 10.1002/jcb.10515; Bauer TW, 2002, CLIN ORTHOP RELAT R, P11; BEE JS, 2006, IN PRESS J CELL BIOC; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Bridwell KH, 2004, J BONE JOINT SURG AM, V86A, P1587, DOI 10.2106/00004623-200407000-00033; Bruder S. P., 2000, PRINCIPLES TISSUE EN, P683; Buttery LDK, 2001, TISSUE ENG, V7, P89, DOI 10.1089/107632700300003323; Byers BA, 2004, TISSUE ENG, V10, P1757, DOI 10.1089/ten.2004.10.1757; Byers BA, 2002, J BONE MINER RES, V17, P1931, DOI 10.1359/jbmr.2002.17.11.1931; Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958; Franceschi RT, 2000, J CELL BIOCHEM, V78, P476, DOI 10.1002/1097-4644(20000901)78:3<476::AID-JCB12>3.0.CO;2-5; Geesink RGT, 1999, J BONE JOINT SURG BR, V81B, P710, DOI 10.1302/0301-620X.81B4.9311; GEY GO, 1952, CANCER RES, V12, P264; Hirata K, 2003, BONE, V32, P502, DOI 10.1016/S8756-3282(03)00054-1; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Jayme D W, 1985, Adv Biotechnol Processes, V5, P1; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Kalajzic I, 2002, J BONE MINER RES, V17, P15, DOI 10.1359/jbmr.2002.17.1.15; Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601-0825.2002.01829.x; KAUFMAN M, 1994, ATLAS MOUSE DEV, P495; Kojima H, 2005, J BIOL CHEM, V280, P2944, DOI 10.1074/jbc.M311598200; Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774-002-0408-0; Krebsbach PH, 2000, HUM GENE THER, V11, P1201, DOI 10.1089/10430340050015248; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Kugimiya F, 2005, J BIOL CHEM, V280, P35704, DOI 10.1074/jbc.M505166200; Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050; LANGER R, 1993, SCIENCE, V260, P920, DOI 10.1126/science.8493529; Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623-200206000-00022; Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006; Long FX, 2001, DEVELOPMENT, V128, P5099; Nakashima K, 2003, TRENDS GENET, V19, P458, DOI 10.1016/S0168-9525(03)00176-8; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Ogasawara T, 2004, MOL CELL BIOL, V24, P6560, DOI 10.1128/mcb.24.15.6560-6568.2004; Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Otto WR, 2004, CELL PROLIFERAT, V37, P97, DOI 10.1111/j.1365-2184.2004.00303.x; Patel MS, 2002, NEW ENGL J MED, V346, P1572, DOI 10.1056/NEJM200205163462011; Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109; Salgado AJ, 2005, BIODEGRADABLE SYSTEMS IN TISSUE ENGINEERING AND REGENERATIVE MEDICINE, P457; Sekiya I, 2002, P NATL ACAD SCI USA, V99, P4397, DOI 10.1073/pnas.052716199; Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602-587; VERBRUGGEN LA, 1980, ARCH DERMATOL RES, V269, P111, DOI 10.1007/BF00406531; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Yamato M, 2002, BIOMATERIALS, V23, P561, DOI 10.1016/S0142-9612(01)00138-7; Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705; Yano F, 2005, BIOCHEM BIOPH RES CO, V333, P1300, DOI 10.1016/j.bbrc.2005.06.041; Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015; zur Nieden NI, 2003, DIFFERENTIATION, V71, P18, DOI 10.1046/j.1432-0436.2003.700602.x	50	24	24	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1777	1787		10.1096/fj.06-7571com	http://dx.doi.org/10.1096/fj.06-7571com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317722				2022-12-25	WOS:000246866500020
J	Jeon, Y; Lee, KY; Ko, MJ; Lee, YS; Kang, S; Hwang, DS				Jeon, Yesu; Lee, Kyung Yong; Ko, Min Ji; Lee, Yong Sun; Kang, Sukhyun; Hwang, Deog Su			Human TopBP1 participates in cyclin E/CDK2 activation and preinitiation complex assembly during G(1)/S transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-BINDING-PROTEIN; CELL-CYCLE; S-PHASE; DNA-REPLICATION; KINASE COMPLEX; CDK INHIBITOR; XENOPUS CUT5; CDC7; ATR; PHOSPHORYLATION	Human TopBP1 with eight BRCA1 C terminus domains has been mainly reported to be involved in DNA damage response pathways. Here we show that TopBP1 is also required for G(1) to S progression in a normal cell cycle. TopBP1 deficiency inhibited cells from entering S phase by up-regulating p21 and p27, resulting in down-regulation of cyclin E/CDK2. Although co-depletion of p21 and p27 with TopBP1 restored the cyclin E/CDK2 kinase activity, however, cells remained arrested at the G(1)/S boundary, showing defective chromatin-loading of replication components. Based on these results, we suggest a dual role of TopBP1 necessary for the G(1)/S transition: one for activating cyclin E/CDK2 kinase and the other for loading replication components onto chromatin to initiate DNA synthesis.	Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea; Seoul Natl Univ, Dept Biol Sci, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Hwang, DS (corresponding author), Seoul Natl Univ, Inst Mol Biol & Genet, Seoul 151742, South Korea.	dshwang@snu.ac.kr		Kang, Sukhyun/0000-0002-7567-0231				ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; Dimitrova DS, 2000, EXP CELL RES, V254, P321, DOI 10.1006/excr.1999.4770; Dolan WP, 2004, CHROMOSOMA, V113, P145, DOI 10.1007/s00412-004-0302-8; Donaldson AD, 1998, GENE DEV, V12, P491, DOI 10.1101/gad.12.4.491; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Greer DA, 2003, CANCER RES, V63, P4829; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harris S, 2003, J CELL SCI, V116, P3519, DOI 10.1242/jcs.00677; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hashimoto Y, 2003, EMBO J, V22, P2526, DOI 10.1093/emboj/cdg238; Hashimoto Y, 2006, GENES CELLS, V11, P993, DOI 10.1111/j.1365-2443.2006.00998.x; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Hwang HC, 2005, ONCOGENE, V24, P2776, DOI 10.1038/sj.onc.1208613; Jares P, 2000, GENE DEV, V14, P1528; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kim JE, 2005, MOL CELL BIOL, V25, P10907, DOI 10.1128/MCB.25.24.10907-10915.2005; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Liu K, 2004, GENE DEV, V18, P673, DOI 10.1101/gad.1180204; Liu K, 2006, EMBO J, V25, P4795, DOI 10.1038/sj.emboj.7601355; Liu S, 2006, MOL CELL BIOL, V26, P6056, DOI 10.1128/MCB.00492-06; Machida YJ, 2005, J BIOL CHEM, V280, P27624, DOI 10.1074/jbc.M502615200; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; Masai H, 2002, J CELL PHYSIOL, V190, P287, DOI 10.1002/jcp.10070; Masai H, 2000, J BIOL CHEM, V275, P29042, DOI 10.1074/jbc.M002713200; Masumoto H, 2000, MOL CELL BIOL, V20, P2809, DOI 10.1128/MCB.20.8.2809-2817.2000; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Moroy T, 2004, INT J BIOCHEM CELL B, V36, P1424, DOI 10.1016/S1357-2725(03)00432-1; Nougarede R, 2000, MOL CELL BIOL, V20, P3795, DOI 10.1128/MCB.20.11.3795-3806.2000; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Parrilla-Castellar E, 2003, J BIOL CHEM, V278, P45507, DOI 10.1074/jbc.C300418200; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Radhakrishnan SK, 2004, ONCOGENE, V23, P4173, DOI 10.1038/sj.onc.1207571; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sato N, 2003, GENES CELLS, V8, P451, DOI 10.1046/j.1365-2443.2003.00647.x; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Ukomadu C, 2003, J BIOL CHEM, V278, P43586, DOI 10.1074/jbc.M307194200; Uto K, 2004, EMBO J, V23, P3386, DOI 10.1038/sj.emboj.7600328; Van Hatten RA, 2002, J CELL BIOL, V159, P541, DOI 10.1083/jcb.200207090; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Yamamoto RR, 2000, GENETICS, V156, P711; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 2003, CANCER RES, V63, P3049; Yamane K, 2002, MOL CELL BIOL, V22, P555, DOI 10.1128/MCB.22.2.555-566.2002; Yan S, 2006, J CELL BIOL, V173, P181, DOI 10.1083/jcb.200601076; You ZS, 2002, GENE DEV, V16, P1182, DOI 10.1101/gad.985302; Zeng L, 2005, J BIOL CHEM, V280, P29374, DOI 10.1074/jbc.M503016200; Zhong WW, 2003, NATURE, V423, P885, DOI 10.1038/nature01747	55	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14882	14890		10.1074/jbc.M609116200	http://dx.doi.org/10.1074/jbc.M609116200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17293600	hybrid			2022-12-25	WOS:000246589000025
J	Patel, HH; Tsutsumi, YM; Head, BP; Niesman, IR; Jennings, M; Horikawa, Y; Huang, D; Moreno, AL; Patel, PM; Insel, PA; Roth, DM				Patel, Hemal H.; Tsutsumi, Yasuo M.; Head, Brian P.; Niesman, Ingrid R.; Jennings, Michelle; Horikawa, Yousuke; Huang, Diane; Moreno, Ana L.; Patel, Piyush M.; Insel, Paul A.; Roth, David M.			Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1	FASEB JOURNAL			English	Article						protein tyrosine kinase; Src; phosphorylation heart	NITRIC-OXIDE SYNTHASE; PROTEIN-COUPLED RECEPTOR; ADENYLYL-CYCLASE; IN-VIVO; ISOFLURANE; PHOSPHORYLATION; ACTIVATION; EXPRESSION; MICRODOMAINS; ISCHEMIA	Caveolae, small invaginations in the plasma membrane, contain caveolins (Cav) that scaffold signaling molecules including the tyrosine kinase Src. We tested the hypothesis that cardiac protection involves a caveolin-dependent mechanism. We used in vitro and in vivo models of ischemia-reperfusion injury, electron microscopy ( EM), transgenic mice, and biochemical assays to address this hypothesis. We found that Cav-1 mRNA and protein were expressed in mouse adult cardiac myocytes (ACM). The volatile anesthetic, isoflurane, protected ACM from hypoxia-induced cell death and increased sarcolemmal caveolae. Hearts of wild-type (WT) mice showed rapid phosphorylation of Src and Cav-1 after isoflurane and ischemic preconditioning. The Src inhibitor PP2 reduced phosphorylation of Src (Y416) and Cav-1 in the heart and abolished isoflurane-induced cardiac protection in WT mice. Infarct size ( percent area at risk) was reduced by isoflurane in WT (30.5 +/- 4 vs. 44.2 +/- 3, n = 7, P < 0.05) but not Cav-1(-/-) mice (46.6 +/- 5 vs. 41.7 +/- 3, n = 7). Cav-1(-/-) mice exposed to isoflurane showed significant alterations in Src phosphorylation and recruitment of C-terminal Src kinase, a negative regulator of Src, when compared to WT mice. The results indicate that isoflurane modifies cardiac myocyte sarcolemmal membrane structure and composition and that activation of Src and phosphorylation of Cav-1 contribute to cardiac protection. Accordingly, therapies targeted to posttranslational modification of Src and Cav-1 may provide a novel approach for such protection.	Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Cellular & Mol Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pharmacol, San Diego, CA 92103 USA; Vet Affairs San Diego Healthcare Syst, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Roth, DM (corresponding author), VASDHS 125, 3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	droth@ucsd.edu	Tsutsumi, Yasuo M/G-1972-2012; Patel, Hemal/C-7325-2019	Niesman, Ingrid/0000-0001-9767-6629; Patel, Hemal/0000-0001-6722-9625; Tsutsumi, Yasuo/0000-0002-1997-082X	NHLBI NIH HHS [1P01 HL66941-01] Funding Source: Medline; NINDS NIH HHS [R01 NS 047570] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL066941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047570] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ander AN, 2004, DNA CELL BIOL, V23, P586, DOI 10.1089/1044549041939241; Ballard-Croft C, 2006, AM J PHYSIOL-HEART C, V291, pH658, DOI 10.1152/ajpheart.01354.2005; Belhomme D, 1999, CIRCULATION, V100, P340; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Cohen AW, 2004, PHYSIOL REV, V84, P1341, DOI 10.1152/physrev.00046.2003; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DEADY JE, 1981, ANESTH ANALG, V60, P380; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Feron O, 1998, J BIOL CHEM, V273, P3125, DOI 10.1074/jbc.273.6.3125; Feron O, 2006, CARDIOVASC RES, V69, P788, DOI 10.1016/j.cardiores.2005.12.014; Feron O, 2001, CIRC RES, V88, P129; Feron O, 1998, J BIOL CHEM, V273, P30249, DOI 10.1074/jbc.273.46.30249; Fryer RM, 2001, J PHARMACOL EXP THER, V299, P477; Fryer RM, 1999, AM J PHYSIOL-HEART C, V276, pH1229, DOI 10.1152/ajpheart.1999.276.4.H1229; Hausenloy DJ, 2006, CARDIOVASC RES, V70, P240, DOI 10.1016/j.cardiores.2006.01.017; Head BP, 2005, J BIOL CHEM, V280, P31036, DOI 10.1074/jbc.M502540200; Head BP, 2006, J BIOL CHEM, V281, P26391, DOI 10.1074/jbc.M602577200; Hu GC, 2006, ANESTHESIOLOGY, V104, P777, DOI 10.1097/00000542-200604000-00023; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Kamoun WS, 2006, HEPATOLOGY, V43, P182, DOI 10.1002/hep.20940; Kersten JR, 1997, ANESTHESIOLOGY, V87, P361, DOI 10.1097/00000542-199708000-00024; Krajewska WM, 2004, CELL MOL BIOL LETT, V9, P195; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Lu TL, 2006, CELL SIGNAL, V18, P1977, DOI 10.1016/j.cellsig.2006.03.002; Ludwig LM, 2004, ANESTHESIOLOGY, V100, P532, DOI 10.1097/00000542-200403000-00011; Ludwig LM, 2003, ANESTHESIOLOGY, V98, P705, DOI 10.1097/00000542-200303000-00019; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostrom RS, 1999, CIRC RES, V84, P1110, DOI 10.1161/01.RES.84.9.1110; PALADE GE, 1953, J APPL PHYS, V24, P1424; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Patel HH, 2006, AM J PHYSIOL-HEART C, V291, pH344, DOI 10.1152/ajpheart.01100.2005; Raikar LS, 2006, J CELL BIOCHEM, V98, P861, DOI 10.1002/jcb.20732; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sanguinetti AR, 2003, BIOCHEM J, V376, P159, DOI 10.1042/BJ20030336; Sanguinetti AR, 2003, CELL SIGNAL, V15, P289, DOI 10.1016/S0898-6568(02)00090-6; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Swaney JS, 2006, J BIOL CHEM, V281, P17173, DOI 10.1074/jbc.M513097200; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Tsutsumi YM, 2006, ANESTHESIOLOGY, V104, P495, DOI 10.1097/00000542-200603000-00017; Williams TM, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-3-214; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	50	119	129	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1565	1574		10.1096/fj.06-7719com	http://dx.doi.org/10.1096/fj.06-7719com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17272740				2022-12-25	WOS:000246117000031
J	Pavlovic, D; Fuller, W; Shattock, MJ				Pavlovic, Davor; Fuller, William; Shattock, Michael J.			The intracellular region of FXYD1 is sufficient to regulate cardiac Na/K ATPase	FASEB JOURNAL			English	Article						ion pumps; Na/K pump; protein kinase A; protein phosphorylation; phospholemman; FXYD	PHOSPHOLEMMAN CHANNEL MOLECULES; GAMMA-SUBUNIT; ION CURRENTS; XENOPUS OOCYTES; SODIUM-PUMP; NA,K-ATPASE; PROTEIN; PHOSPHORYLATION; EXPRESSION; NA+,K+-ATPASE	FXYD1 is a transmembrane protein predominantly expressed in excitable tissues that associates with and regulates Na/K ATPase. PKA phosphorylates FXYD1 at serine 68 ( S68), however, the effects of phosphorylation on Na/K ATPase activity are not fully characterized. The objectives of this study were to characterize Na/K ATPase currents in FXYD1 wild-type (WT) and knockout ( KO) adult mouse ventricular myocytes, and investigate the effects of FXYD1 on Na/ K ATPase currents using the whole-cell patch-clamp technique. A peptide representing the 19 C-terminal residues of FXYD1 ( FXYD1(54-72)) was introduced into the interior of FXYD1 KO and WT myocytes through the patch pipette. K-sensitive Na/K ATPase currents were higher in KO myocytes ( 2.9 +/- 0.1 pA/pF; n = 4) compared with WT ( 1.9 +/- 0.1 pA/pF; n = 4). Unphosphorylated FXYD1(54-72), at a concentration of 4 mu M, reduced the currents in WT ( from 2.1 +/- 0.1 to 1.3 +/- 0.1 pA/pF; P < 0.05, n = 7) and KO ( from 2.9 +/- 0.1 to 1.7 + 0.1 pA/ pF; P < 0.05, n = 5), whereas, 1 mu M of FXYD1(54-72) phosphorylated at S68 increased currents in WT ( from 1.91 +/- 0.09 to 3.1 +/- 0.5 pA/ pF; P < 0.05, n = 6) and KO ( from 2.7 +/- 0.11 to 3.8 +/- 0.2 pA/ pF; P < 0.05, n = 6) myocytes. Coimmunoprecipitation studies demonstrated that S68 phosphorylated and unphosphorylated FXYD1(54-72) associates with Na/ K ATPase alpha 1 subunit. We conclude that unphosphorylated FXYD1 inhibits Na/ K ATPase, whereas S68 phosphorylated FXYD1 stimulates Na/ K ATPase to a level above that seen in the absence of FXYD1.	Kings Coll London, St Thomas Hosp, Rayne Inst, Div Cardiovasc, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Shattock, MJ (corresponding author), Kings Coll London, St Thomas Hosp, Rayne Inst, Div Cardiovasc, London SE1 7EH, England.	michael.shattock@kcl.ac.uk		Fuller, William/0000-0002-5883-4433; Shattock, Michael/0000-0001-6242-7585; Pavlovic, Davor/0000-0002-3171-3551	British Heart Foundation [RG/07/001/22628] Funding Source: Medline	British Heart Foundation(British Heart Foundation)		BERRY RG, 2006, J MOL CELL CARDIOL, V40, P997; Bossuyt J, 2006, J BIOL CHEM, V281, P32765, DOI 10.1074/jbc.M606254200; Chen ZH, 1999, RECEPTOR CHANNEL, V6, P435; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Davis CE, 2004, NEUROCHEM RES, V29, P177, DOI 10.1023/B:NERE.0000010447.24128.ac; Despa S, 2005, CIRC RES, V97, P252, DOI 10.1161/01.RES.0000176532.97731.e5; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; Fuller W, 2004, FASEB J, V18, P197, DOI 10.1096/fj.03-0213fje; Gao J, 1999, J PHYSIOL-LONDON, V516, P377, DOI 10.1111/j.1469-7793.1999.0377v.x; Geering K, 2005, J BIOENERG BIOMEMBR, V37, P387, DOI 10.1007/s10863-005-9476-x; Jia LG, 2005, AM J PHYSIOL-HEART C, V288, pH1982, DOI 10.1152/ajpheart.00142.2004; Kowdley GC, 1997, BIOPHYS J, V72, P141, DOI 10.1016/S0006-3495(97)78653-3; Li CM, 2004, J BIOL CHEM, V279, P38895, DOI 10.1074/jbc.M406697200; Lifshitz Y, 2006, J BIOL CHEM, V281, P15790, DOI 10.1074/jbc.M601993200; Lindzen M, 2006, J BIOL CHEM, V281, P5947, DOI 10.1074/jbc.M512063200; Mahmmoud YA, 2003, J BIOL CHEM, V278, P37427, DOI 10.1074/jbc.M305126200; MOORMAN JR, 1995, NATURE, V377, P737, DOI 10.1038/377737a0; MOORMAN JR, 1992, J BIOL CHEM, V267, P14551; Mounsey JP, 1999, BBA-MOL CELL RES, V1451, P305, DOI 10.1016/S0167-4889(99)00102-0; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; Sha Q, 2001, J PHYSIOL-LONDON, V535, P407, DOI 10.1111/j.1469-7793.2001.t01-1-00407.x; Silverman BD, 2005, CARDIOVASC RES, V65, P93, DOI 10.1016/j.cardiores.2004.09.005; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Zhang XQ, 2006, J APPL PHYSIOL, V100, P212, DOI 10.1152/japplphysiol.00757.2005; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429; Zouzoulas A, 2003, J BIOL CHEM, V278, P40437, DOI 10.1074/jbc.M308610200	28	39	43	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1539	1546		10.1096/fj.06-7269com	http://dx.doi.org/10.1096/fj.06-7269com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17283221				2022-12-25	WOS:000246117000028
J	Velasco, LFR; Togashi, M; Walfish, PG; Pessanha, RP; Moura, FN; Barra, GB; Nguyen, P; Rebong, R; Yuan, C; Simeoni, LA; Ribeiro, RCJ; Baxter, JD; Webb, P; Neves, FAR				Velasco, Lara F. R.; Togashi, Marie; Walfish, Paul G.; Pessanha, Rutineia P.; Moura, Fanny N.; Barra, Gustavo B.; Nguyen, Phuong; Rebong, Rachelle; Yuan, Chaoshen; Simeoni, Luiz A.; Ribeiro, Ralff C. J.; Baxter, John D.; Webb, Paul; Neves, Francisco A. R.			Thyroid hormone response element organization dictates the composition of active receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; DNA-BINDING DOMAINS; HISTONE ACETYLATION; AUXILIARY PROTEIN; NUCLEAR RECEPTORS; ENHANCES BINDING; GENE ACTIVATION; DIRECT REPEATS; RXR-BETA; ACID	Thyroid hormone ( triiodothyronine, T-3) is known to activate transcription by binding heterodimers of thyroid hormone receptors ( TRs) and retinoid X receptors ( RXRs). RXR-TRs bind to T3 response elements ( TREs) composed of direct repeats of the sequence AGGTCA spaced by four nucleotides ( DR-4). In other TREs, however, the half-sites can be arranged as inverted palindromes and palindromes ( Pal). Here we show that TR homodimers and monomers activate transcription from representative TREs with alternate half-site placements. TR beta activates transcription more efficiently than TR alpha at an inverted palindrome ( F2), and this correlates with preferential TR beta homodimer formation at F2 in vitro. Furthermore, reconstruction of TR transcription complexes in yeast indicates that TR beta homodimers are active at F2, whereas RXR-TRs are active at DR-4 and Pal. Finally, analysis of TR beta mutations that block homodimer and/or heterodimer formation reveal TRE-selective requirements for these surfaces in mammalian cells, which suggest that TR beta homodimers are active at F2, RXR-TRs at DR-4, and TR monomers at Pal. TR beta requires higher levels of hormone for activation at F2 than other TREs, and this differential effect is abolished by a dimer surface mutation suggesting that it is related to composition of the TR center dot TRE complex. We propose that interactions of particular TR oligomers with different elements play unappreciated roles in TRE-selective actions of liganded TRs in vivo.	Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Brasilia, Mol Pharmacol Lab, Dept Pharmaceut Sci, Sch Hlth Sci, Brasilia, DF, Brazil; Univ Toronto, Mt Sinai Hosp, Sch Med, Dept Med,Endocrine Div, Toronto, ON M5G 1X5, Canada	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidade de Brasilia; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Webb, P (corresponding author), Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA.	pwebb@diabetes.ucsf.edu	Simeoni, Luiz Alberto/A-9088-2008; Togashi, Marie/L-3092-2018; Barra, Gustavo/G-6137-2012	Simeoni, Luiz Alberto/0000-0003-3401-290X; Barra, Gustavo/0000-0002-2136-3471; Togashi, Marie/0000-0002-0886-8766	NIDDK NIH HHS [DK41482, DK51281, DK61468] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051281] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anafi M, 2000, MOL ENDOCRINOL, V14, P718, DOI 10.1210/me.14.5.718; ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; Barros AC, 1998, NEUROREPORT, V9, P2933, DOI 10.1097/00001756-199809140-00003; Borngraeber S, 2003, P NATL ACAD SCI USA, V100, P15358, DOI 10.1073/pnas.2136689100; BURNSIDE J, 1990, J BIOL CHEM, V265, P2500; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DESVERGNE B, 1994, MOL CELL ENDOCRINOL, V100, P125, DOI 10.1016/0303-7207(94)90291-7; Diallo EM, 2005, PROTEIN EXPRES PURIF, V40, P292, DOI 10.1016/j.pep.2005.01.007; Diallo EM, 2007, MOL CELL ENDOCRINOL, V264, P149, DOI 10.1016/j.mce.2006.11.004; Glass CK, 2000, GENE DEV, V14, P121; Gloss B, 2005, ENDOCRINOLOGY, V146, P4926, DOI 10.1210/en.2005-0631; Hollenberg AN, 1996, J BIOL CHEM, V271, P28516, DOI 10.1074/jbc.271.45.28516; Hsia SCV, 2002, MOL CELL BIOL, V22, P4043, DOI 10.1128/MCB.22.12.4043-4052.2002; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; KATZ RW, 1994, J BIOL CHEM, V269, P18915; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAUDET V, 2002, NUCL RECEPTOR FACTS, P87; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Leitman DC, 1996, J BIOL CHEM, V271, P21950, DOI 10.1074/jbc.271.36.21950; LENG XH, 1994, J BIOL CHEM, V269, P31436; Liang FQ, 2003, J BIOL CHEM, V278, P15073, DOI 10.1074/jbc.M207593200; Liu Y, 1998, ENDOCRINOLOGY, V139, P4197, DOI 10.1210/en.139.10.4197; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEIER CA, 1993, J CLIN INVEST, V92, P1986, DOI 10.1172/JCI116793; Meng XW, 2005, P NATL ACAD SCI USA, V102, P6267, DOI 10.1073/pnas.0501491102; Meng XW, 2003, MOL ENDOCRINOL, V17, P1095, DOI 10.1210/me.2002-0294; MIYAMOTO T, 1993, MOL ENDOCRINOL, V7, P224, DOI 10.1210/me.7.2.224; MURRAY MB, 1989, MOL ENDOCRINOL, V3, P1434, DOI 10.1210/mend-3-9-1434; O'Shea PJ, 2002, J ENDOCRINOL, V175, P553, DOI 10.1677/joe.0.1750553; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; Ribeiro RCJ, 1998, J STEROID BIOCHEM, V65, P133, DOI 10.1016/S0960-0760(98)00029-6; RIBEIRO RCJ, 1994, ENDOCRINOLOGY, V135, P2076, DOI 10.1210/en.135.5.2076; Ribeiro RCJ, 2001, J BIOL CHEM, V276, P14987, DOI 10.1074/jbc.M010195200; Sachs LM, 2000, P NATL ACAD SCI USA, V97, P13138, DOI 10.1073/pnas.260141297; Santos GM, 2006, MOL PHARMACOL, V70, P793, DOI 10.1124/mol.106.025627; Shibusawa N, 2003, J BIOL CHEM, V278, P732, DOI 10.1074/jbc.M207264200; Shin DJ, 2006, NUCLEIC ACIDS RES, V34, P3853, DOI 10.1093/nar/gkl506; Togashi M, 2005, J BIOL CHEM, V280, P25665, DOI 10.1074/jbc.M501615200; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; Wu YF, 2001, J BIOL CHEM, V276, P3929, DOI 10.1074/jbc.M006743200; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; YEN PM, 1992, J BIOL CHEM, V267, P3565; YEN PM, 1992, J BIOL CHEM, V267, P23248; Yoh SM, 2001, J BIOL CHEM, V276, P16857, DOI 10.1074/jbc.M010022200; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	58	51	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12458	12466		10.1074/jbc.M610700200	http://dx.doi.org/10.1074/jbc.M610700200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17311926	Green Published, hybrid			2022-12-25	WOS:000245942800014
J	Heinemeyer, J; Braun, HP; Boekema, EJ; Kouril, R				Heinemeyer, Jesco; Braun, Hans-Peter; Boekema, Egbert J.; Kouril, Roman			A structural model of the cytochrome c reductase/oxidase supercomplex from yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY-CHAIN SUPERCOMPLEXES; DIMERIC ATP SYNTHASE; OXIDATIVE-PHOSPHORYLATION; INNER MEMBRANE; COMPLEX-I; OXIDASE; ARCHITECTURE; CARDIOLIPIN; RESOLUTION; BC(1)	Mitochondrial respiratory chain complexes are arranged in supercomplexes within the inner membrane. Interaction of cytochrome c reductase ( complex III) and cytochrome c oxidase ( complex IV) was investigated in Saccharomyces cerevisiae. Projection maps at 15 angstrom resolution of supercomplexes III2 + IV1 and III2 + IV2 were obtained by electron microscopy. Based on a comparison of our maps with atomic x-ray structures for complexes III and IV we present a pseudo-atomic model of their precise interaction. Two complex IV monomers are specifically attached to dimeric complex III with their convex sides. The opposite sides, which represent the complex IV dimer interface in the x-ray structure, are open for complex IV-complex IV interactions. This could lead to oligomerization of III2 + IV2 supercomplexes, but this was not detected. Instead, binding of cytochrome c to the supercomplexes was revealed. It was calculated that cytochrome c has to move less than 40 angstrom at the surface of the supercomplex for electron transport between complex III2 and complex IV. Hence, the prime function of the supercomplex III2 + IV2 is proposed to be a scaffold for effective electron transport between complexes III and IV.	Univ Groningen, GBB, Dept Biophys Chem, NL-9747 AG Groningen, Netherlands; Leibniz Univ Hannover, Fac Nat Sci, Inst Plant Genet, D-30419 Hannover, Germany	University of Groningen; Leibniz University Hannover	Boekema, EJ (corresponding author), Univ Groningen, GBB, Dept Biophys Chem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	e.j.boekema@rug.nl; r.kouril@rug.nl	Braun, Hans-Peter/E-7149-2011; KOUŘIL, Roman/A-9587-2018	Braun, Hans-Peter/0000-0002-4459-9727; KOUŘIL, Roman/0000-0001-8211-3348				ALLEN RD, 1989, J CELL BIOL, V108, P2233, DOI 10.1083/jcb.108.6.2233; BERRY EA, 1985, J BIOL CHEM, V260, P2458; Boumans H, 1998, J BIOL CHEM, V273, P4872, DOI 10.1074/jbc.273.9.4872; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Dudkina NV, 2006, FEBS LETT, V580, P3427, DOI 10.1016/j.febslet.2006.04.097; Dudkina NV, 2006, TRENDS PLANT SCI, V11, P232, DOI 10.1016/j.tplants.2006.03.007; Dudkina NV, 2005, FEBS LETT, V579, P5769, DOI 10.1016/j.febslet.2005.09.065; Dudkina NV, 2005, P NATL ACAD SCI USA, V102, P3225, DOI 10.1073/pnas.0408870102; Giraud MF, 2002, BBA-BIOENERGETICS, V1555, P174, DOI 10.1016/S0005-2728(02)00274-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARRIS JR, 1994, MICRON, V25, P5; HEINEMEYER J, 2007, PLANT MITOCHONDRIA A; Khalimonchuk E, 2005, MITOCHONDRION, V5, P363, DOI 10.1016/j.mito.2005.08.002; KIM CH, 1983, J BIOL CHEM, V258, P3543; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; Lee SJ, 2001, ACTA CRYSTALLOGR D, V57, P941, DOI 10.1107/S0907444901005625; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Mannella CA, 2006, BBA-MOL CELL RES, V1763, P542, DOI 10.1016/j.bbamcr.2006.04.006; Meisinger Chris, 2006, Methods Mol Biol, V313, P33; Minauro-Sanmiguel F, 2005, P NATL ACAD SCI USA, V102, P12356, DOI 10.1073/pnas.0503893102; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; PEARCE DA, 1995, P NATL ACAD SCI USA, V92, P3735, DOI 10.1073/pnas.92.9.3735; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200; Roberts VA, 1999, J BIOL CHEM, V274, P38051, DOI 10.1074/jbc.274.53.38051; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Schafer E, 2006, J BIOL CHEM, V281, P15370, DOI 10.1074/jbc.M513525200; Schagger H, 2002, BBA-BIOENERGETICS, V1555, P154, DOI 10.1016/S0005-2728(02)00271-2; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, IUBMB LIFE, V52, P119, DOI 10.1080/15216540152845911; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHWERZMANN K, 1986, J CELL BIOL, V102, P97, DOI 10.1083/jcb.102.1.97; Stroh A, 2004, J BIOL CHEM, V279, P5000, DOI 10.1074/jbc.M309505200; SUNDERHAU S, 2006, IN PRESS MITOCHONDRI; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; van Heel M, 2000, Q REV BIOPHYS, V33, P307, DOI 10.1017/S0033583500003644; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P95, DOI 10.1016/0304-3991(87)90010-6; Wittig I, 2006, BBA-BIOENERGETICS, V1757, P1066, DOI 10.1016/j.bbabio.2006.05.006; Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131; Zhang M, 2002, J BIOL CHEM, V277, P43553, DOI 10.1074/jbc.C200551200; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	44	133	138	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12240	12248		10.1074/jbc.M610545200	http://dx.doi.org/10.1074/jbc.M610545200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322303	Green Published, hybrid			2022-12-25	WOS:000245941900067
J	Mulherkar, N; Prasad, KV; Prabhakar, BS				Mulherkar, Nirupama; Prasad, Kanteti V.; Prabhakar, Bellur S.			MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation - Knockdown enhances trail-induced apoptosis of cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP/GTP EXCHANGE PROTEIN; DEATH DOMAIN PROTEIN; NECROSIS-FACTOR RECEPTOR; NEOPLASTIC-CELLS; DENN-SV; MADD; EXPRESSION; KINASE; SUSCEPTIBILITY; INHIBITION	The MADD variant of the IG20 gene is necessary and sufficient for cancer cell survival. Abrogation of MADD, but not the other IG20 splice variants, can render cancer cells more susceptible to spontaneous as well as TRAIL ( tumor necrosis factor alpha-related apoptosis-inducing ligand)-induced apoptosis. Both types of apoptosis in cells devoid of MADD can be inhibited by expression of CrmA or dominant-negative FADD, thereby suggesting that endogenous MADD may be targeting caspase-8 activation. Immunoprecipitation studies showed that MADD down-modulation could lead to caspase-8 activation at the death receptors without an apparent increase in the recruitment of death-inducing signaling complex components such as FADD. Further, we found that MADD can directly interact with death receptors, but not with either caspase-8 or FADD, and can inhibit caspase-8 activation. These results clearly demonstrate the importance of MADD in the control of cancer cell survival/death and in conferring significant resistance to TRAIL-induced apoptosis. In addition, our results indicate the therapeutic potential of MADD abrogation in enhancing TRAIL-induced selective apoptosis of cancer cells.	Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Prabhakar, BS (corresponding author), Rm E-705,835 S Wollcott Ave M-C 790, Chicago, IL 60610 USA.	bprabhak@uic.edu			NCI NIH HHS [5R01CA107506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; Boatright KM, 2003, CURR OPIN CELL BIOL, V15, P725, DOI 10.1016/j.ceb.2003.10.009; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; Brown TL, 1998, CURR BIOL, V8, pR191; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chow VTK, 1998, GENOME, V41, P543, DOI 10.1139/gen-41-4-543; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Del Villar K, 2004, P NATL ACAD SCI USA, V101, P4210, DOI 10.1073/pnas.0307349101; Donepudi M, 2003, MOL CELL, V11, P543, DOI 10.1016/S1097-2765(03)00059-5; Efimova E, 2003, CANCER RES, V63, P8768; Efimova EV, 2004, ONCOGENE, V23, P1076, DOI 10.1038/sj.onc.1207210; Iwasaki K, 2000, EMBO J, V19, P4806, DOI 10.1093/emboj/19.17.4806; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Lee MTM, 2003, J VIROL, V77, P11964, DOI 10.1128/JVI.77.22.11964-11972.2003; Levivier E, 2001, BIOCHEM BIOPH RES CO, V287, P688, DOI 10.1006/bbrc.2001.5652; Lim KM, 2004, INT J CANCER, V109, P24, DOI 10.1002/ijc.11660; Lim KM, 2002, MOL CARCINOGEN, V35, P110, DOI 10.1002/mc.10082; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mulherkar N, 2006, ONCOGENE, V25, P6252, DOI 10.1038/sj.onc.1209650; Murakami-Mori K, 1999, J IMMUNOL, V162, P3672; Ramaswamy M, 2004, ONCOGENE, V23, P6083, DOI 10.1038/sj.onc.1207804; RAMASWAMY M, 2004, THESIS U ILLINOIS CH; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; Sharp DA, 2005, J BIOL CHEM, V280, P19401, DOI 10.1074/jbc.M413962200; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Tanaka M, 2001, MOL BIOL CELL, V12, P1421, DOI 10.1091/mbc.12.5.1421; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; Yamaguchi K, 2002, P NATL ACAD SCI USA, V99, P14536, DOI 10.1073/pnas.212511399; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586	31	26	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11715	11721		10.1074/jbc.M701085200	http://dx.doi.org/10.1074/jbc.M701085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314102	hybrid			2022-12-25	WOS:000245941900013
J	Urbanowicz, BR; Catala, C; Irwin, D; Wilson, DB; Ripoll, DR; Rose, JKC				Urbanowicz, Breeanna R.; Catala, Carmen; Irwin, Diana; Wilson, David B.; Ripoll, Daniel R.; Rose, Jocelyn K. C.			A tomato endo-beta-1,4-glucanase, SlCel9C1, represents a distinct subclass with a new family of carbohydrate binding modules (CBM49)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALLS; CELLULOMONAS-FIMI; ACTIVE ENZYMES; PROTEIN; DOMAIN; GENE; EXPRESSION; FRUIT; PURIFICATION; ENDO-1,4-BETA-GLUCANASE	A critical structural feature of many microbial endo-beta-1,4-glucanases( EGases, or cellulases) is a carbohydrate binding module ( CBM), which is required for effective crystalline cellulose degradation. However, CBMs are absent from plant EGases that have been biochemically characterized to date, and accordingly, plant EGases are not generally thought to have the capacity to degrade crystalline cellulose. We report the biochemical characterization of a tomato EGase, Solanum lycopersicum Cel8 ( SlCel9C1), with a distinct C-terminal noncatalytic module that represents a previously uncharacterized family of CBMs. In vitro binding studies demonstrated that this module indeed binds to crystalline cellulose and can similarly bind as part of a recombinant chimeric fusion protein containing an EGase catalytic domain from the bacterium Thermobifida fusca. Site-directed mutagenesis studies show that tryptophans 559 and 573 play a role in crystalline cellulose binding. The SlCel9C1 CBM, which represents a new CBM family ( CBM49), is a defining feature of a new structural subclass ( Class C) of plant EGases, with members present throughout the plant kingdom. In addition, the SlCel9C1 catalytic domain was shown to hydrolyze artificial cellulosic polymers, cellulose oligosaccharides, and a variety of plant cell wall polysaccharides.	Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA; Cornell Univ, Computat Biol Serv Unit, Cornell Theory Ctr, Ithaca, NY 14853 USA	Cornell University; Cornell University; Cornell University	Rose, JKC (corresponding author), Cornell Univ, Dept Plant Biol, 228 Plant Sci Bldg, Ithaca, NY 14853 USA.	jr286@cornell.edu	Urbanowicz, Breeanna/C-6488-2012; Catala, Carmen/E-7059-2012	, Breeanna/0000-0001-5247-4513				Arpat AB, 2004, PLANT MOL BIOL, V54, P911, DOI 10.1007/s11103-004-0392-y; Bayer EA, 2004, ANNU REV MICROBIOL, V58, P521, DOI 10.1146/annurev.micro.57.030502.091022; Boraston AB, 2003, J BIOL CHEM, V278, P6120, DOI 10.1074/jbc.M209554200; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Brummell DA, 2001, PLANT MOL BIOL, V47, P311, DOI 10.1023/A:1010656104304; BRUMMELL DA, 1994, ACS SYM SER, V566, P100; Bujnicki JM, 2001, BIOINFORMATICS, V17, P750, DOI 10.1093/bioinformatics/17.8.750; Carrard G, 2000, P NATL ACAD SCI USA, V97, P10342, DOI 10.1073/pnas.160216697; Catala C., 1998, PLANT PHYSIOL, V118, P1535; Chen NJ, 2003, FUNCT PLANT BIOL, V30, P433, DOI 10.1071/FP02208; Coutinho PM, 1999, ROY SOC CH, P3; Davison A, 2005, MOL BIOL EVOL, V22, P1273, DOI 10.1093/molbev/msi107; Downes BP, 2001, PLANT PHYSIOL, V126, P244, DOI 10.1104/pp.126.1.244; Eckert K, 2002, APPL MICROBIOL BIOT, V60, P428, DOI 10.1007/s00253-002-1131-4; GHOSE TK, 1987, PURE APPL CHEM, V59, P257, DOI 10.1351/pac198759020257; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Harpster MH, 2002, PLANT MOL BIOL, V50, P345, DOI 10.1023/A:1019856929126; Henrissat B, 1998, FEBS LETT, V425, P352, DOI 10.1016/S0014-5793(98)00265-8; Henrissat B, 2001, PLANT MOL BIOL, V47, P55, DOI 10.1023/A:1010667012056; Hilden L, 2004, BIOTECHNOL LETT, V26, P1683, DOI 10.1007/s10529-004-4579-8; Irwin D, 1998, J BACTERIOL, V180, P1709, DOI 10.1128/JB.180.7.1709-1714.1998; IRWIN DC, 1993, BIOTECHNOL BIOENG, V42, P1002, DOI 10.1002/bit.260420811; Jahic M, 2003, J BIOTECHNOL, V102, P45, DOI 10.1016/S0168-1656(03)00003-8; JUNG ED, 1993, APPL ENVIRON MICROB, V59, P3032, DOI 10.1128/AEM.59.9.3032-3043.1993; Jung H, 2003, BIOTECHNOL BIOENG, V84, P151, DOI 10.1002/bit.10743; Kim JH, 2004, CAN J MICROBIOL, V50, P835, DOI 10.1139/W04-077; LEVER M, 1972, ANAL BIOCHEM, V47, P273, DOI 10.1016/0003-2697(72)90301-6; Libertini E, 2004, J MOL EVOL, V58, P506, DOI 10.1007/s00239-003-2571-x; Linder M, 1997, J BIOTECHNOL, V57, P15, DOI 10.1016/S0168-1656(97)00087-4; Lynd LR, 2005, CURR OPIN BIOTECH, V16, P577, DOI 10.1016/j.copbio.2005.08.009; Lynd LR, 2002, MICROBIOL MOL BIOL R, V66, P506, DOI 10.1128/MMBR.66.3.506-577.2002; MACLACHLAN G, 1988, METHOD ENZYMOL, V160, P382; Master ER, 2004, BIOCHEMISTRY-US, V43, P10080, DOI 10.1021/bi049453x; McLean BW, 2000, PROTEIN ENG, V13, P801, DOI 10.1093/protein/13.11.801; Molhoj M, 2002, PLANT CELL PHYSIOL, V43, P1399, DOI 10.1093/pcp/pcf163; Molhoj M, 2001, PLANT PHYSIOL, V127, P674, DOI 10.1104/pp.010269; Pauly M, 1999, PLANT J, V20, P629, DOI 10.1046/j.1365-313X.1999.00630.x; Rabinovich ML, 2002, BIOCHEMISTRY-MOSCOW+, V67, P850, DOI 10.1023/A:1019958419032; Robert S, 2005, PLANT CELL, V17, P3378, DOI 10.1105/tpc.105.036228; Rose JK, 2003, PLANT CELL WALL, V8, P264, DOI DOI 10.1002/9781119312994.APR0075; Rose JKC, 1999, TRENDS PLANT SCI, V4, P176, DOI 10.1016/S1360-1385(99)01405-3; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; SALMINEN O, 2002, THESIS CORNELL U ITH; Sanchez R, 1998, P NATL ACAD SCI USA, V95, P13597, DOI 10.1073/pnas.95.23.13597; SHOSEYOV O, 2001, Patent No. 6184440; Shpigel E, 1998, PLANT PHYSIOL, V117, P1185, DOI 10.1104/pp.117.4.1185; Trainotti L, 2006, J EXP BOT, V57, P589, DOI 10.1093/jxb/erj043; Trainotti L, 1999, PLANT MOL BIOL, V40, P323, DOI 10.1023/A:1006299821980; Wilson D. B., 1999, Advances in Biochemical Engineering/Biotechnology, V65, P1; Wolfgang DE, 1999, BIOCHEMISTRY-US, V38, P9746, DOI 10.1021/bi990401v; Woolley LC, 2001, PLANTA, V214, P11, DOI 10.1007/s004250100577; XU GY, 1995, BIOCHEMISTRY-US, V34, P6993, DOI 10.1021/bi00021a011; York WS, 1996, CARBOHYD RES, V285, P99, DOI 10.1016/0008-6215(96)00029-8	54	56	60	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12066	12074		10.1074/jbc.M607925200	http://dx.doi.org/10.1074/jbc.M607925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322304	hybrid			2022-12-25	WOS:000245941900049
J	Zhu, JQ; Boylan, B; Luo, BH; Newman, PJ; Springer, TA				Zhu, Jieqing; Boylan, Brian; Luo, Bing-Hao; Newman, Peter J.; Springer, Timothy A.			Tests of the extension and deadbolt models of integrin activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-LIKE DOMAIN; ALPHA(L)BETA(2) HYBRID DOMAIN; PLATELET GLYCOPROTEIN-IIIA; INSIDE-OUT ACTIVATION; LOW-AFFINITY STATE; MONOCLONAL-ANTIBODY; STRUCTURAL BASIS; LIGAND-BINDING; SUBUNIT; COMPLEX	Despite extensive evidence that integrin conformational changes between bent and extended conformations regulate affinity for ligands, an alternative hypothesis has been proposed in which a "deadbolt" can regulate affinity for ligand in the absence of extension. Here, we tested both the deadbolt and the extension models. According to the deadbolt model, a hairpin loop in the beta 3 tail domain could act as a deadbolt to restrain the displacement of the beta 3 I domain beta 6-alpha 7 loop and maintain integrin in the low affinity state. We found that mutating or deleting the beta 3 tail domain loop has no effect on ligand binding by either alpha IIb beta 3 or alpha V beta 3 integrins. In contrast, we found that mutations that lock integrins in the bent conformation with disulfide bonds resist inside-out activation induced by cytoplasmic domain mutation. Furthermore, we demonstrated that extension is required for accessibility to fibronectin but not smaller fragments. The data demonstrate that integrin extension is required for ligand binding during integrin inside-out signaling and that the deadbolt does not regulate integrin activation.	Harvard Univ, Sch Med, CBR, Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Blood Ctr Wisconsin, Blood Res Inst, Milwaukee, WI 53201 USA; Med Coll Wisconsin, Dept Pharmacol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Cellular Biol, Milwaukee, WI 53226 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Versiti Blood Center of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Springer, TA (corresponding author), Harvard Univ, Sch Med, CBR, Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	springeroffice@cbr.med.harvard.edu		Boylan, Brian/0000-0003-3930-4565	NHLBI NIH HHS [P01 HL048675, HL44612, P01 HL044612, HL48675] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048675, P01HL044612] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adair BD, 2005, J CELL BIOL, V168, P1109, DOI 10.1083/jcb.200410068; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Barton SJ, 2004, BIOCHEM J, V380, P401, DOI 10.1042/BJ20031973; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; Dechantsreiter MA, 1999, J MED CHEM, V42, P3033, DOI 10.1021/jm970832g; Ehirchiou D, 2005, J BIOL CHEM, V280, P8324, DOI 10.1074/jbc.M413525200; FARADAY N, 1994, J LAB CLIN MED, V123, P728; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GUPTA V, 2006, IN PRESS BLOOD; Hato T, 2006, J THROMB HAEMOST, V4, P2278, DOI 10.1111/j.1538-7836.2006.02137.x; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Iwasaki K, 2005, J STRUCT BIOL, V150, P259, DOI 10.1016/j.jsb.2005.03.005; Kamata T, 2001, J BIOL CHEM, V276, P44275, DOI 10.1074/jbc.M107021200; Kim M, 2003, SCIENCE, V301, P1720, DOI 10.1126/science.1084174; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; KOUNS WC, 1991, BLOOD, V78, P3215; Luo BH, 2005, P NATL ACAD SCI USA, V102, P3679, DOI 10.1073/pnas.0409440102; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; Luo BH, 2004, J BIOL CHEM, V279, P27466, DOI 10.1074/jbc.M404354200; Luo BH, 2004, J BIOL CHEM, V279, P10215, DOI 10.1074/jbc.M312732200; Luo BH, 2003, P NATL ACAD SCI USA, V100, P2403, DOI 10.1073/pnas.0438060100; Luo BH, 2006, CURR OPIN CELL BIOL, V18, P579, DOI 10.1016/j.ceb.2006.08.005; Mould AP, 2005, J BIOL CHEM, V280, P4238, DOI 10.1074/jbc.M412240200; Mould AP, 2003, J BIOL CHEM, V278, P39993, DOI 10.1074/jbc.M304627200; NEWMAN PJ, 1985, BLOOD, V65, P227; Nishida N, 2006, IMMUNITY, V25, P583, DOI 10.1016/j.immuni.2006.07.016; Partridge AW, 2005, J BIOL CHEM, V280, P7294, DOI 10.1074/jbc.M412701200; Peterson JA, 2003, BLOOD, V101, P937, DOI 10.1182/blood-2002-07-2336; Shattil SJ, 2004, BLOOD, V104, P1606, DOI 10.1182/blood-2004-04-1257; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2003, EMBO J, V22, P4607, DOI 10.1093/emboj/cdg445; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Tang RH, 2005, J BIOL CHEM, V280, P29208, DOI 10.1074/jbc.M503239200; Tng E, 2004, J BIOL CHEM, V279, P54334, DOI 10.1074/jbc.M407818200; Tokuhira M, 1996, THROMB HAEMOSTASIS, V76, P1038; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Xiao T, 2004, NATURE, V432, P59, DOI 10.1038/nature02976; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2003, BLOOD, V102, P1155, DOI 10.1182/blood-2003-01-0334; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200	44	47	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11914	11920		10.1074/jbc.M700249200	http://dx.doi.org/10.1074/jbc.M700249200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17301049	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000245941900034
J	During, U; Ossenbuhl, F; Wilde, A				Duehring, Ulf; Ossenbuehl, Friedrich; Wilde, Annegret			Late assembly steps and dynamics of the cyanobacterial photosystem I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNECHOCYSTIS SP; CHLAMYDOMONAS-REINHARDTII; TARGETED INACTIVATION; STRUCTURAL ORGANIZATION; PROTEIN COMPLEXES; DEFICIENT MUTANT; MEMBRANE-PROTEIN; SUBUNIT; PLASTOCYANIN; ARABIDOPSIS	The dynamics of photosystem I assembly in cyanobacteria have been addressed using in vivo pulse-chase labeling of Synechocystis sp. PCC 6803 proteins in combination with blue native polyacrylamide gel electrophoresis. The analyses indicate the existence of three different monomeric photosystem I complexes and also the high stability of photosystem I trimers. We show that in addition to a complete photosystem I monomer, containing all 11 subunits, we detected a PsaK-less monomer and a short-lived PsaL/PsaK-less complex. The latter two monomers were missing in the ycf37 mutant of Synechocystis sp. PCC 6803 that accumulates also less trimers. Pulse-chase experiments suggest that the three monomeric complexes have different functions in the biogenesis of the trimer. Based on these findings we propose a model where PsaK is incorporated in the latest step of photosystem I assembly. The PsaK-less photosystem I monomer may represent an intermediate complex that is important for the exchange of the two PsaK variants during high light acclimation. Implications of the presented data with respect to Ycf37 function are discussed.	Humboldt Univ, Inst Biol, D-10115 Berlin, Germany; Univ Ulm, Dept Mol Bot, D-89069 Ulm, Germany	Humboldt University of Berlin; Ulm University	Wilde, A (corresponding author), Humboldt Univ, Inst Biol Biochem Pflanzen, Chausseestr 117, D-10115 Berlin, Germany.	Annegret.Wilde@rz.hu-berlin.de						Ben-Shem A, 2003, NATURE, V426, P630, DOI 10.1038/nature02200; Boudreau E, 1997, EMBO J, V16, P6095, DOI 10.1093/emboj/16.20.6095; Chitnis PR, 2001, ANNU REV PLANT PHYS, V52, P593, DOI 10.1146/annurev.arplant.52.1.593; CHITNIS VP, 1993, FEBS LETT, V336, P330, DOI 10.1016/0014-5793(93)80831-E; CHITNIS VP, 1993, J BIOL CHEM, V268, P11678; CLARKE AK, 1993, P NATL ACAD SCI USA, V90, P9973, DOI 10.1073/pnas.90.21.9973; DUEHRING U, 2005, P 13 INT C PHOT, P802; DUEHRING U, 2006, BIOCHIM BIOPHYS ACTA, V1757, P3; FARAH J, 1995, EMBO J, V14, P4976, DOI 10.1002/j.1460-2075.1995.tb00180.x; Fromme P, 2004, PHOTOSYNTH RES, V80, P109, DOI 10.1023/B:PRES.0000030657.88242.e1; Fujimori T, 2005, J BIOL CHEM, V280, P22191, DOI 10.1074/jbc.M500369200; Giacomelli L, 2006, PLANT PHYSIOL, V141, P685, DOI 10.1104/pp.106.080150; Grotjohann I, 2005, PHOTOSYNTH RES, V85, P51, DOI 10.1007/s11120-005-1440-4; Hihara Y, 2001, PLANT CELL, V13, P793, DOI 10.1105/tpc.13.4.793; Hippler M, 1997, BIOCHEMISTRY-US, V36, P6343, DOI 10.1021/bi970082c; Hippler M, 2002, PROTIST, V153, P197, DOI 10.1078/1434-4610-00098; Jansch L, 1996, PLANT J, V9, P357, DOI 10.1046/j.1365-313X.1996.09030357.x; Jensen PE, 2000, J BIOL CHEM, V275, P24701, DOI 10.1074/jbc.M000550200; Jensen PE, 2003, PHYSIOL PLANTARUM, V119, P313, DOI 10.1034/j.1399-3054.2003.00157.x; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Karapetyan NV, 1999, FEBS LETT, V460, P395, DOI 10.1016/S0014-5793(99)01352-6; Khrouchtchova A, 2005, FEBS LETT, V579, P4808, DOI 10.1016/j.febslet.2005.07.061; Klinkert B, 2004, J BIOL CHEM, V279, P44639, DOI 10.1074/jbc.M405393200; Komenda J, 2004, J BIOL CHEM, V279, P48620, DOI 10.1074/jbc.M405725200; Kruip J, 1997, J BIOL CHEM, V272, P17061, DOI 10.1074/jbc.272.27.17061; Naithani S, 2000, PHOTOSYNTH RES, V63, P225, DOI 10.1023/A:1006463932538; Naver H, 2001, PLANT CELL, V13, P2731, DOI 10.1105/tpc.010253; Nishiyama Y, 2006, BBA-BIOENERGETICS, V1757, P742, DOI 10.1016/j.bbabio.2006.05.013; Ossenbuhl F, 2006, PLANT CELL, V18, P2236, DOI 10.1105/tpc.106.043646; Ossenbuhl F, 2004, PLANT CELL, V16, P1790, DOI 10.1105/tpc.023226; RIPPKA R, 1979, J GEN MICROBIOL, V11, P419; Rochaix JD, 2004, BIOCHEM SOC T, V32, P567, DOI 10.1042/BST0320567; Rochaix JD, 2002, FEBS LETT, V529, P34, DOI 10.1016/S0014-5793(02)03181-2; Rokka A, 2005, BIOCHEM J, V388, P159, DOI 10.1042/BJ20042098; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Scheller HV, 2001, BBA-BIOENERGETICS, V1507, P41, DOI 10.1016/S0005-2728(01)00196-7; Setif P, 2002, BBA-BIOENERGETICS, V1555, P204, DOI 10.1016/S0005-2728(02)00279-7; Stockel J, 2006, PLANT PHYSIOL, V141, P870, DOI 10.1104/pp.106.078147; Varotto C, 2002, PLANT PHYSIOL, V129, P616, DOI 10.1104/pp.002089; Wilde A, 2001, BIOCHEM J, V357, P211, DOI 10.1042/0264-6021:3570211; WILDE A, 1995, PLANT CELL, V7, P649, DOI 10.1105/tpc.7.5.649; XU Q, 1995, J BIOL CHEM, V270, P16243, DOI 10.1074/jbc.270.27.16243; XU Q, 1995, PLANT PHYSIOL, V108, P1067, DOI 10.1104/pp.108.3.1067; Xu W, 2001, BBA-BIOENERGETICS, V1507, P32, DOI 10.1016/S0005-2728(01)00208-0; Zak E, 2001, P NATL ACAD SCI USA, V98, P13443, DOI 10.1073/pnas.241503898; Zygadlo A, 2005, BBA-BIOENERGETICS, V1708, P154, DOI 10.1016/j.bbabio.2005.02.003	46	37	38	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10915	10921		10.1074/jbc.M609206200	http://dx.doi.org/10.1074/jbc.M609206200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303568	hybrid			2022-12-25	WOS:000245941500011
J	Fang, DX; Hawke, D; Zheng, YH; Xia, Y; Meisenhelder, J; Nika, H; Mills, GB; Kobayashi, R; Hunter, T; Lu, ZM				Fang, Dexing; Hawke, David; Zheng, Yanhua; Xia, Yan; Meisenhelder, Jill; Nika, Heinz; Mills, Gordon B.; Kobayashi, Ryuji; Hunter, Tony; Lu, Zhimin			Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN-KINASE; WNT SIGNALING PATHWAY; CELL-MIGRATION; HEPATOCELLULAR CARCINOMAS; TUMOR-FORMATION; E-CADHERIN; CYCLIN D1; EXON 3; CANCER	Increased transcriptional activity of beta-catenin resulting from Wnt/Wingless-dependent or -independent signaling has been detected in many types of human cancer, but the underlying mechanism of Wnt-independent regulation is poorly understood. We have demonstrated that AKT, which is activated downstream from epidermal growth factor receptor signaling, phosphorylates beta-catenin at Ser(552) in vitro and in vivo. AKT-mediated phosphorylation of beta-catenin causes its disassociation from cell-cell contacts and accumulation in both the cytosol and the nucleus and enhances its interaction with 14-3-3 zeta via a binding motif containing Ser(552). Phosphorylation of beta-catenin by AKT increases its transcriptional activity and promotes tumor cell invasion, indicating that AKT-dependent regulation of beta-catenin plays a critical role in tumor invasion and development.	Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Unit 1002, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Brain Tumor Ctr, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX 77030 USA; Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Salk Institute	Lu, ZM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Unit 1002, 1515 Holcombe Blvd, Houston, TX 77030 USA.	zhiminlu@mdanderson.org	yang, zheng/HGC-7753-2022		NCI NIH HHS [CA82683, P30 CA016672, R01 CA082683, R01 CA109035, CA55418, 1R01CA109035-01A1, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R44CA055418, R01CA082683, R43CA055418, R01CA109035, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Ashihara Koji, 2002, Medical Electron Microscopy, V35, P9, DOI 10.1007/s007950200001; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015; Heron-Milhavet L, 2006, MOL CELL BIOL, V26, P8267, DOI 10.1128/MCB.00201-06; Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005; Howe LR, 2003, CANCER RES, V63, P1906; Hoyal CR, 2003, P NATL ACAD SCI USA, V100, P5130, DOI 10.1073/pnas.1031526100; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Ihara A, 1996, HEPATOLOGY, V23, P1441, DOI 10.1053/jhep.1996.v23.pm0008675162; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Johnson JL, 2005, TRAFFIC, V6, P667, DOI 10.1111/j.1600-0854.2005.00308.x; Kau TR, 2003, CANCER CELL, V4, P463, DOI 10.1016/S1535-6108(03)00303-9; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kuo MT, 2002, ONCOGENE, V21, P1945, DOI 10.1038/sj.onc.1205117; LeBron C, 2006, EMBO J, V25, P1196, DOI 10.1038/sj.emboj.7601032; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lu ZM, 2004, CELL CYCLE, V3, P571; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Meng Q, 2006, CELL SIGNAL, V18, P2262, DOI 10.1016/j.cellsig.2006.05.019; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Polakis P, 2000, GENE DEV, V14, P1837; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Semplici F, 2002, ONCOGENE, V21, P3978, DOI 10.1038/sj.onc.1205574; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Song DH, 2003, J BIOL CHEM, V278, P24018, DOI 10.1074/jbc.M212260200; Stambolic V, 2006, TRENDS CELL BIOL, V16, P461, DOI 10.1016/j.tcb.2006.07.001; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tian Q, 2004, P NATL ACAD SCI USA, V101, P15370, DOI 10.1073/pnas.0406499101; Vasioukhin V, 2001, CURR OPIN CELL BIOL, V13, P76, DOI 10.1016/S0955-0674(00)00177-0; Weston CR, 2001, SCIENCE, V292, P2439, DOI 10.1126/science.1063279; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zhou GL, 2006, J BIOL CHEM, V281, P36443, DOI 10.1074/jbc.M600788200	72	656	678	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11221	11229		10.1074/jbc.M611871200	http://dx.doi.org/10.1074/jbc.M611871200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17287208	hybrid, Green Accepted			2022-12-25	WOS:000245941500044
J	Jang, SW; Kim, YS; Kim, YR; Sung, HJ; Ko, J				Jang, Sung-Wuk; Kim, Yoon Suk; Kim, Yoon Rim; Sung, Ho Joong; Ko, Jesang			Regulation of human LZIP expression by NF-kappa B and its involvement in monocyte cell migration induced by Lkn-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY RESPONSE GENES; NECROSIS-FACTOR-ALPHA; CC-CHEMOKINE; TRANSCRIPTION FACTORS; ADHESION MOLECULE-1; GROWTH-FACTORS; DNA-BINDING; HOS CELLS; IN-VITRO; CANCER	Human LZIP is a transcription factor that is involved in leukocyte cell mobility. Expression of LZIP is known to differentially regulate monocyte cell migration induced by CCR1-dependent chemokines. However, its transcriptional regulation has not been characterized. Our results indicate that Lkn-1 induces LZIP expression in a time- and dose-dependent manner, and the induction of LZIP shows an immediate early response to Lkn-1. We identified and cloned similar to 1.4 kb of the LZIP promoter from a human genomic DNA. To identify regulatory elements controlling restricted expression of LZIP, deletion mutants were constructed from the 1469-bp LZIP promoter region ( - 1219/ + 251) linked to the luciferase reporter gene. Maximal promoter activity was contained within 613 bp from the tentative transcription initiation site and was sharply reduced in a truncated construct ( - 338/ + 251). This promoter sequence contained consensus NF-kappa B- and Sp-1-binding sites. Results from an inhibitor assay showed that NF-kappa B is involved in Lkn-1-induced LZIP expression, but Sp-1 is not. We also demonstrated that NF-kappa B binds to the LZIP promoter and that the binding is specific, as revealed by an electrophoretic mobility shift assay and a mutation analysis. Chemotaxis analysis showed that LZIP expression because of the NF-kappa B subfamily is specifically involved in Lkn-1-induced chemotaxis. Our findings suggest that transcription factor NF-kappa B plays an important role in regulation of LZIP expression, and LZIP expression regulates the monocyte cell migration induced by Lkn-1.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea	Korea University	Ko, J (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, 5-1 Anam Dong, Seoul 136701, South Korea.	jesangko@korea.ac.kr						Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bontemps Y, 2003, J BIOL CHEM, V278, P21566, DOI 10.1074/jbc.M209366200; BURBELO PD, 1994, GENE, V139, P241, DOI 10.1016/0378-1119(94)90763-3; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; FURIE MB, 1995, AM J PATHOL, V146, P1287; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grossmann M, 1999, INT J BIOCHEM CELL B, V31, P1209, DOI 10.1016/S1357-2725(99)00068-0; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Huang S, 2000, CANCER RES, V60, P5334; Hwang JS, 2004, FEBS LETT, V570, P47, DOI 10.1016/j.febslet.2004.06.023; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Karashima T, 2003, CLIN CANCER RES, V9, P2786; Karl E, 2005, CANCER RES, V65, P5063, DOI 10.1158/0008-5472.CAN-05-0140; Kim CH, 1999, FEBS LETT, V449, P28, DOI 10.1016/S0014-5793(99)00390-7; Kim IS, 2003, LIFE SCI, V73, P447, DOI 10.1016/S0024-3205(03)00312-6; Ko J, 2004, FASEB J, V18, P890, DOI 10.1096/fj.03-0867fje; Ko JS, 2002, FEBS LETT, V515, P159, DOI 10.1016/S0014-5793(02)02465-1; Lee BH, 2000, J CELL BIOCHEM, V76, P437, DOI 10.1002/(SICI)1097-4644(20000301)76:3<437::AID-JCB11>3.0.CO;2-2; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Lu RQ, 2002, J BIOL CHEM, V277, P16592, DOI 10.1074/jbc.M111440200; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Martin B, 1999, NUCLEIC ACIDS RES, V27, P3402, DOI 10.1093/nar/27.17.3402; MATHEW S, 1993, ONCOGENE, V8, P191; MCMAHON SB, 1992, FASEB J, V6, P2707, DOI 10.1096/fasebj.6.9.1612295; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Minami T, 2001, J BIOL CHEM, V276, P47632, DOI 10.1074/jbc.M108363200; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Oyama N, 1999, J INVEST DERMATOL, V113, P600, DOI 10.1046/j.1523-1747.1999.00734.x; Phelps CB, 2000, J BIOL CHEM, V275, P24392, DOI 10.1074/jbc.M003784200; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; TAKEUCHI M, 1995, P NATL ACAD SCI USA, V92, P3561, DOI 10.1073/pnas.92.8.3561; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tolnay M, 2002, J IMMUNOL, V169, P6236, DOI 10.4049/jimmunol.169.11.6236; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; Wu DQ, 2005, CELL RES, V15, P52, DOI 10.1038/sj.cr.7290265; Youn BS, 1997, J IMMUNOL, V159, P5201; Yu R, 2004, ATHEROSCLEROSIS, V174, P35, DOI 10.1016/j.atherosclerosis.2003.11.024	49	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11092	11100		10.1074/jbc.M607962200	http://dx.doi.org/10.1074/jbc.M607962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17296613	hybrid			2022-12-25	WOS:000245941500030
J	Jousset, H; Frieden, M; Demaurex, N				Jousset, Helene; Frieden, Maud; Demaurex, Nicolas			STIM1 knockdown reveals that store-operated Ca2+ channels located close to sarco/endoplasmic Ca2+ ATPases (SERCA) pumps silently refill the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; CRAC CHANNELS; CALCIUM ENTRY; ACINAR-CELLS; MITOCHONDRIA; DEPLETION; ORAI1; SENSOR; HOMEOSTASIS; REGIONS	Stromal interaction molecule ( STIM) proteins are putative ER Ca2+ sensors that recruit and activate store-operated Ca2+ ( SOC) channels at the plasma membrane, a process triggered by the Ca2+ depletion of the endoplasmic reticulum ( ER). To test whether STIM1 is required for ER refilling, we used RNA interference and measured Ca2+ signals in the cytosol, the ER, and the mitochondria of HeLa cells. Knockdown of STIM1 ( mRNA levels, 73%) reducedSOCentry by 73% when sarco/ endoplasmic Ca2+ ATPases ( SERCA) were inhibited by thapsigargin but did not prevent Ca2+ stores refilling when cells were stimulated by physiological agonists. Stores could be fully refilled by increasing the external Ca2+ concentration above physiological values, but no cytosolic Ca2+ signals were detected during store refilling even at very high Ca2+ concentrations. [Ca2+](ER) measurements revealed that the basal activity of SERCA was not affected in STIM1 knockdown cells and that [ Ca2+](ER) levels were restored within 2 min in physiological saline following store depletion. Mitochondrial inhibitors reduced ER refilling in wild- type but not in STIM1 knockdown cells, indicating that ER refilling does not require functional mitochondria at low STIM1 levels. Our data show that ER refilling is largely preserved at reduced STIM1 levels, despite a drastic reduction of store- operated Ca2+ entry, because Ca2+ ions are directly transferred from SOC channels to SERCA. These findings are consistent with the formation of microdomains containing not only SOC channels on the plasma membrane and STIM proteins on the ER but also SERCA pumps and mitochondria to refill the ER without perturbing the cytosol.	Univ Geneva, Sch Med, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland	University of Geneva	Demaurex, N (corresponding author), Univ Geneva, Sch Med, Dept Cell Physiol & Metab, 1 Michel Servet, CH-1211 Geneva 4, Switzerland.	Nicolas.Demaurex@medecine.unige.ch		Frieden, Maud/0000-0001-7135-0874; Demaurex, Nicolas/0000-0002-9933-6772				Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; BYRON KL, 1992, J BIOL CHEM, V267, P108; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Frieden M, 2005, J BIOL CHEM, V280, P43198, DOI 10.1074/jbc.M510279200; Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Lemonnier L, 2006, FASEB J, V20, P503, DOI 10.1096/fj.05-4714fje; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liu XB, 2001, J BIOL CHEM, V276, P29891, DOI 10.1074/jbc.M103283200; Lomax RB, 2002, J BIOL CHEM, V277, P26479, DOI 10.1074/jbc.M201845200; Lopez JJ, 2006, J BIOL CHEM, V281, P28254, DOI 10.1074/jbc.M604272200; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Malli R, 2007, CELL CALCIUM, V41, P63, DOI 10.1016/j.ceca.2006.05.001; Malli R, 2003, J BIOL CHEM, V278, P44769, DOI 10.1074/jbc.M302511200; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; Montalvo GB, 2006, J BIOL CHEM, V281, P35616, DOI 10.1074/jbc.M603518200; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Yan XH, 2006, J GEN PHYSIOL, V128, P443, DOI 10.1085/jgp.200609611; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; ZHANG SL, 2006, P NATL ACAD SCI US; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147	33	115	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11456	11464		10.1074/jbc.M609551200	http://dx.doi.org/10.1074/jbc.M609551200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17283081	hybrid			2022-12-25	WOS:000245941500067
J	McGinness, KE; Bolon, DN; Kaganovich, M; Baker, TA; Sauer, RT				McGinness, Kathleen E.; Bolon, Daniel N.; Kaganovich, Mark; Baker, Tania A.; Sauer, Robert T.			Altered tethering of the SspB adaptor to the ClpXP protease causes changes in substrate delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECIFICITY-ENHANCING FACTOR; ZINC-BINDING DOMAIN; AAA PLUS PROTEASE; DEGRADATION MACHINE; STRUCTURAL BASIS; RECOGNITION; DESIGN; CHAPERONE; PROTEINS; ATP	SspB is a dimeric adaptor protein that increases the rate at which ssrA-tagged substrates are degraded by tethering them to the ClpXP protease. Each SspB subunit consists of a folded domain that forms the dimer interface and a flexible C-terminal tail. Ternary delivery complexes are stabilized by three sets of tethering interactions. The C-terminal XB peptide of each SspB subunit binds ClpX, the body of SspB binds one part of the ssrA-tag sequence, and ClpX binds another part of the tag. To test the functional importance of these tethering interactions, we engineered monomeric SspB variants and dimeric variants with different length linkers between the SspB body and the XB peptide and employed substrates with degradation tags that bind ClpX weakly and/or contain extensions between the binding sites for SspB and ClpX. We find that monomeric SspB variants can enhance ClpXP degradation of a subset of substrates, that doubling the number of tethering interactions stimulates degradation via changes in K-m and V-max, and that major alterations in the length of the 48-residue SspB linker cause only small changes in the efficiency of substrate delivery. These results indicate that the properties of the degradation tag and the number of SspB . ClpX tethering interactions are the major factors that determine the extent to which the substrate and ClpX are engaged in ternary delivery complexes.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Sauer, RT (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	bobsauer@mit.edu		Bolon, Daniel/0000-0001-5857-6676; Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-16892] Funding Source: Medline; NIGMS NIH HHS [R01 GM049224-16, R01 GM049224, R01 GM049224-15, GM-48224] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049224, R01GM048224] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 2006, TRENDS BIOCHEM SCI, V31, P647, DOI 10.1016/j.tibs.2006.10.006; Bolon DN, 2004, MOL CELL, V16, P343, DOI 10.1016/j.molcel.2004.10.001; Bolon DN, 2004, MOL CELL, V13, P443, DOI 10.1016/S1097-2765(04)00027-9; Burton RE, 2003, PROTEIN SCI, V12, P893, DOI 10.1110/ps.0237603; Chivers PT, 1999, PROTEIN SCI, V8, P2494, DOI 10.1110/ps.8.11.2494; Dahiyat BI, 1997, P NATL ACAD SCI USA, V94, P10172, DOI 10.1073/pnas.94.19.10172; Dahiyat BI, 1997, PROTEIN SCI, V6, P1333, DOI 10.1002/pro.5560060622; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; Donaldson LW, 2003, J BIOL CHEM, V278, P48991, DOI 10.1074/jbc.M307826200; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Flynn JM, 2004, GENE DEV, V18, P2292, DOI 10.1101/gad.1240104; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Flynn JM, 2001, P NATL ACAD SCI USA, V98, P10584, DOI 10.1073/pnas.191375298; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Hanson PI, 2005, NAT REV MOL CELL BIO, V6, P519, DOI 10.1038/nrm1684; Hersch GL, 2004, P NATL ACAD SCI USA, V101, P12136, DOI 10.1073/pnas.0404733101; Kenniston JA, 2005, P NATL ACAD SCI USA, V102, P1390, DOI 10.1073/pnas.0409634102; Kim DY, 2003, J BIOL CHEM, V278, P50664, DOI 10.1074/jbc.M305882200; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 2003, MOL CELL, V12, P365, DOI 10.1016/j.molcel.2003.08.014; Marshall SA, 2002, J MOL BIOL, V316, P189, DOI 10.1006/jmbi.2001.5326; MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010; McGinness KE, 2006, MOL CELL, V22, P701, DOI 10.1016/j.molcel.2006.04.027; Ortega J, 2000, MOL CELL, V6, P1515, DOI 10.1016/S1097-2765(00)00148-9; Park EY, 2007, J MOL BIOL, V367, P514, DOI 10.1016/j.jmb.2007.01.003; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Siddiqui SM, 2004, GENE DEV, V18, P369, DOI 10.1101/gad.1170304; Song HK, 2003, MOL CELL, V12, P75, DOI 10.1016/S1097-2765(03)00271-5; Thibault G, 2006, EMBO J, V25, P3367, DOI 10.1038/sj.emboj.7601223; Wah DA, 2003, MOL CELL, V12, P355, DOI 10.1016/S1097-2765(03)00272-7	34	24	24	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11465	11473		10.1074/jbc.M610671200	http://dx.doi.org/10.1074/jbc.M610671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17317664	hybrid			2022-12-25	WOS:000245941500068
J	Miyashita, Y; Ozawa, M				Miyashita, Yayoi; Ozawa, Masayuki			Increased internalization of p120-uncoupled E-cadherin and a requirement for a dileucine motif in the cytoplasmic domain for endocytosis of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL-ADHESION; MEMBRANE-PROXIMAL REGION; MOLECULE UVOMORULIN; MDCK CELLS; RAC; RHO; CATENIN; MORPHOGENESIS; P120-CATENIN; MODULATION	E-cadherin is a member of the cadherin family of Ca2+-dependent cell-cell adhesion molecules. E- cadherin associates with beta-catenin at the membrane-distal region of its cytosolic domain and with p120 at the membrane-proximal region of its cytoplasmic domain. It has been shown that a pool of cell surface E- cadherin is constitutively internalized and recycled back to the surface. Further, p120 knockdown by small interference RNA resulted in dose-dependent elimination of cell surface E- cadherin. Consistent with these observations, we found that selective uncoupling of p120 from E- cadherin by introduction of amino acid substitutions in the p120-binding site increased the level of E- cadherin endocytosis. The increased endocytosis was clathrin-dependent, because it was blocked by expression of a dominant-negative form of dynamin or by hypertonic shock. A dileucine motif in the juxtamembrane cytoplasmic domain is required for E-cadherin endocytosis, because substitution of these residues to alanine resulted in impaired internalization of the protein. The alanine substitutions in the p120- uncoupled construct reduced endocytosis of the protein, indicating that this motif was dominant to p120 binding in the control of E-cadherin endocytosis. Therefore, these results are consistent with the idea that p120 regulates E- cadherin endocytosis by masking the dileucine motif and preventing interactions with adaptor proteins required for internalization.	Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Biol, Kagoshima 890, Japan	Kagoshima University	Ozawa, M (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Biol, Kagoshima 890, Japan.	mozawa@m.kufm.kagoshima-u.ac.jp						Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Goodwin M, 2003, J BIOL CHEM, V278, P20533, DOI 10.1074/jbc.M213171200; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Izumi G, 2004, J CELL BIOL, V166, P237, DOI 10.1083/jcb.200401078; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kasai K, 1999, J BIOCHEM, V125, P780, DOI 10.1093/oxfordjournals.jbchem.a022349; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; LEVINE E, 1994, DEVELOPMENT, V120, P901; Miranda KC, 2003, J BIOL CHEM, V278, P43480, DOI 10.1074/jbc.M305525200; Miranda KC, 2001, J BIOL CHEM, V276, P22565, DOI 10.1074/jbc.M101907200; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Ozawa M, 2003, J BIOL CHEM, V278, P46014, DOI 10.1074/jbc.M307778200; Ozawa M, 2002, J BIOL CHEM, V277, P19600, DOI 10.1074/jbc.M202029200; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SHAPIRO L, 1995, NATURE, V374, P306; STEINBERG MS, 1994, P NATL ACAD SCI USA, V91, P206, DOI 10.1073/pnas.91.1.206; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Troyanovsky RB, 2006, MOL BIOL CELL, V17, P3484, DOI 10.1091/mbc.E06-03-0190; WHEELOCK MJ, 1992, J CELL BIOL, V117, P415, DOI 10.1083/jcb.117.2.415; Wildenberg GA, 2006, CELL, V127, P1027, DOI 10.1016/j.cell.2006.09.046; Xiao KY, 2005, MOL BIOL CELL, V16, P5141, DOI 10.1091/mbc.E05-05-0440; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; Young P, 2003, EMBO J, V22, P5723, DOI 10.1093/emboj/cdg560	41	95	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11540	11548		10.1074/jbc.M608351200	http://dx.doi.org/10.1074/jbc.M608351200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17298950	hybrid			2022-12-25	WOS:000245941500075
J	Siehl, DL; Castle, LA; Gorton, R; Keenan, RJ				Siehl, Daniel L.; Castle, Linda A.; Gorton, Rebecca; Keenan, Robert J.			The molecular basis of glyphosate resistance by an optimized microbial acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEROTONIN N-ACETYLTRANSFERASE; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; SUPERFAMILY; EVOLUTION; ENZYME; ACID; RESIDUES	GAT is an N- acetyltransferase from Bacillus licheniformis that was optimized by gene shuffling for acetylation of the broad spectrum herbicide, glyphosate, forming the basis of a novel mechanism of glyphosate tolerance in transgenic plants ( Castle, L. A., Siehl, D. L., Gorton, R., Patten, P. A., Chen, Y. H., Bertain, S., Cho, H. J., Duck, N., Wong, J., Liu, D., and Lassner, M. W. ( 2004) Science 304, 1151 - 1154). The 1.6-angstrom resolution crystal structure of an optimized GAT variant in ternary complex with acetyl coenzyme A and a competitive inhibitor, 3-phosphoglyerate, defines GAT as a member of the GCN5- related family of N-acetyltransferases. Four active site residues ( Arg-21, Arg-73, Arg-111, and His-138) contribute to a positively charged substrate-binding site that is conserved throughout the GAT subfamily. Structural and kinetic data suggest that His-138 functions as a catalytic base via substrate-assisted deprotonation of the glyphosate secondary amine, whereas another active site residue, Tyr-118, functions as a general acid. Although the physiological substrate is unknown, native GAT acetylates D-2-amino-3- phosphonopropionic acid with a k(cat)/K-m of 1500 min(-1) mM(-1). Kinetic data show preferential binding of short analogs to native GAT and progressively better binding of longer analogs to optimized variants. Despite a 200-fold increase in k(cat) and a 5.4-fold decrease in K-m for glyphosate, only 4 of the 21 substitutions present in R7 GAT lie in the active site. Single-site revertants constructed at these positions suggest that glyphosate binding is optimized through substitutions that increase the size of the substrate- binding site. The large improvement in kcat is likely because of the cooperative effects of additional substitutions located distal to the active site.	Pioneer HiBred Int Inc, Redwood City, CA 94063 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	DuPont; University of Chicago	Keenan, RJ (corresponding author), Pioneer HiBred Int Inc, Redwood City, CA 94063 USA.	dan.siehl@pioneer.com; bkeenan@uchicago.edu		Keenan, Robert/0000-0003-1466-0889				Aharoni A, 2005, NAT GENET, V37, P73, DOI 10.1038/ng1482; Angus-Hill ML, 1999, J MOL BIOL, V294, P1311, DOI 10.1006/jmbi.1999.3338; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Castle LA, 2004, SCIENCE, V304, P1151, DOI 10.1126/science.1096770; Cleland WW, 2000, ARCH BIOCHEM BIOPHYS, V382, P1, DOI 10.1006/abbi.2000.2011; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Draker KA, 2004, BIOCHEMISTRY-US, V43, P446, DOI 10.1021/bi035667n; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Eschenburg S, 2002, PLANTA, V216, P129, DOI 10.1007/s00425-002-0908-0; Franz J. E., 1997, GLYPHOSATE UNIQUE GL; Hegde SS, 2001, J BIOL CHEM, V276, P45876, DOI 10.1074/jbc.M108810200; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Keenan RJ, 2005, P NATL ACAD SCI USA, V102, P8887, DOI 10.1073/pnas.0502497102; Kim KS, 2000, P NATL ACAD SCI USA, V97, P6373, DOI 10.1073/pnas.97.12.6373; KITTREDGE JS, 1964, BIOCHEMISTRY-US, V3, P991, DOI 10.1021/bi00895a026; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Nishina Y, 2003, J BIOCHEM, V134, P835, DOI 10.1093/jb/mvg209; Oue S, 1999, J BIOL CHEM, V274, P2344, DOI 10.1074/jbc.274.4.2344; Padgette SR, 1995, HERBICIDE RESISTANT, P53; Piana S, 2002, PROTEIN SCI, V11, P2393, DOI 10.1110/ps.0206702; Scheibner KA, 2002, J BIOL CHEM, V277, P18118, DOI 10.1074/jbc.M200595200; SCOPES RK, 1994, PROTEIN PURIFICATION, P46; Siehl DL, 2005, PEST MANAG SCI, V61, P235, DOI 10.1002/ps.1014; SMITH JD, 1970, BIOCHEMISTRY-US, V9, P2152, DOI 10.1021/bi00812a018; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Tomatis PE, 2005, P NATL ACAD SCI USA, V102, P13761, DOI 10.1073/pnas.0503495102; Vetting MW, 2005, ARCH BIOCHEM BIOPHYS, V433, P212, DOI 10.1016/j.abb.2004.09.003; WALSH C, 1979, ENZYMATIC REACTION M, P34; WARREN WA, 1968, BIOCHIM BIOPHYS ACTA, V156, P340, DOI 10.1016/0304-4165(68)90263-8; Wybenga-Groot LE, 1999, STRUCTURE, V7, P497, DOI 10.1016/S0969-2126(99)80066-5	35	54	63	3	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11446	11455		10.1074/jbc.M610267200	http://dx.doi.org/10.1074/jbc.M610267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17272278	hybrid			2022-12-25	WOS:000245941500066
J	Tailford, LE; Money, VA; Smith, NL; Dumon, C; Davies, GJ; Gilbert, HJ				Tailford, Louise E.; Money, Victoria A.; Smith, Nicola L.; Dumon, Claire; Davies, Gideon J.; Gilbert, Harry J.			Mannose foraging by Bacteroides thetaiotaomicron - Structure and specificity of the beta-mannosidase, BtMan2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENT CONFORMATIONAL ITINERARIES; CARBOHYDRATE-BINDING MODULES; GLYCOSIDE HYDROLASE FAMILY-5; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; SUBSTRATE-SPECIFICITY; MANNANASE; XYLANASES; CLASSIFICATION; GALACTOSIDASE	The human colonic bacterium Bacteroides thetaiotaomicron, which plays an important role in maintaining human health, produces an extensive array of exo-acting glycoside hydrolases ( GH), including 32 family GH2 glycoside hydrolases. Although it is likely that these enzymes enable the organism to utilize dietary and host glycans as major nutrient sources, the biochemical properties of these GH2 glycoside hydrolases are currently unclear. Here we report the biochemical properties and crystal structure of the GH2 B. thetaiotaomicron enzyme BtMan2A. Kinetic analysis demonstrates that BtMan2A is a beta-mannosidase in which substrate binding energy is provided principally by the glycone binding site, whereas aglycone recognition is highly plastic. The three-dimensional structure, determined to a resolution of 1.7 angstrom, reveals a five-domain structure that is globally similar to the Escherichia coli LacZ beta-galactosidase. The catalytic center is housed mainly within a ( beta/alpha)(8) barrel although the N-terminal domain also contributes to the active site topology. The nature of the substrate-binding residues is quite distinct from other GH2 enzymes of known structure, instead they are similar to other clan GH-A enzymes specific for manno-configured substrates. Mutagenesis studies, informed by the crystal structure, identified a WDW motif in the N-terminal domain that makes a significant contribution to catalytic activity. The observation that this motif is invariant in GH2 mannosidases points to a generic role for these residues in this enzyme class. The identification of GH-A clan and GH2 specific residues in the active site of BtMan2A explains why this enzyme is able to harness substrate binding at the proximal glycone binding site more efficiently than mannan-hydrolyzing glycoside hydrolases in related enzyme families. The catalytic properties of BtMan2A are consistent with the flexible nutrient acquisition displayed by the colonic bacterium.	Newcastle Univ, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ York, Dept Chem, Struct Biol Lab, York YO10 5YW, N Yorkshire, England	Newcastle University - UK; University of York - UK	Gilbert, HJ (corresponding author), Newcastle Univ, Sch Med, Inst Cell & Mol Biosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	h.j.gilbert@ncl.ac.uk	Money, Victoria/E-8851-2013; Claire, Dumon/AAI-2553-2021; Davies, Gideon J/A-9042-2011	Claire, Dumon/0000-0003-4925-7336; Davies, Gideon J/0000-0002-7343-776X	Biotechnology and Biological Sciences Research Council [BBS/B/05974] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Andrews SR, 2004, J BIOL CHEM, V279, P54369, DOI 10.1074/jbc.M409044200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boraston AB, 2004, BIOCHEM J, V382, P769, DOI 10.1042/BJ20040892; Bourgault R, 2005, PROTEIN SCI, V14, P1233, DOI 10.1110/ps.041260905; Brett CT, 1996, PHYSL BIOCH PLANT CE; Brzozowski AM, 2000, BIOCHEMISTRY-US, V39, P9099, DOI 10.1021/bi0000317; Charnock SJ, 2000, BIOCHEMISTRY-US, V39, P5013, DOI 10.1021/bi992821q; COUGLAN MP, 1985, BIOTECHNOL GENET ENG, P1; COWTANKD, 1996, ACTA CRYSTALLOGR D, V49, P148; Davies GJ, 2003, BIOCHEM SOC T, V31, P523, DOI 10.1042/BST0310523; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; Dias FMV, 2004, J BIOL CHEM, V279, P25517, DOI 10.1074/jbc.M401647200; Ducros VMA, 2002, ANGEW CHEM INT EDIT, V41, P2824, DOI 10.1002/1521-3773(20020802)41:15<2824::AID-ANIE2824>3.0.CO;2-G; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FONTES CMGA, 1995, APPL MICROBIOL BIOT, V43, P52, DOI 10.1007/BF00170622; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hilge M, 1998, STRUCTURE, V6, P1433, DOI 10.1016/S0969-2126(98)00142-7; Hill J, 2006, P NATL ACAD SCI USA, V103, P11206, DOI 10.1073/pnas.0604600103; Hogg D, 2003, BIOCHEM J, V371, P1027, DOI 10.1042/BJ20021860; Hogg D, 2001, J BIOL CHEM, V276, P31186, DOI 10.1074/jbc.M010290200; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; Jain S, 1996, NAT STRUCT BIOL, V3, P375, DOI 10.1038/nsb0496-375; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsson AM, 2006, J MOL BIOL, V357, P1500, DOI 10.1016/j.jmb.2006.01.044; Le Nours K, 2005, BIOCHEMISTRY-US, V44, P12700, DOI 10.1021/bi050779v; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, P1; Lillelund VH, 2003, ORG BIOMOL CHEM, V1, P282, DOI 10.1039/b208784g; Money VA, 2006, ANGEW CHEM INT EDIT, V45, P5136, DOI 10.1002/anie.200600802; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sabini E, 2000, ACTA CRYSTALLOGR D, V56, P3, DOI 10.1107/S0907444999013943; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Skalova T, 2005, J MOL BIOL, V353, P282, DOI 10.1016/j.jmb.2005.08.028; Sonnenburg JL, 2005, SCIENCE, V307, P1955, DOI 10.1126/science.1109051; Stoll D, 2000, BIOCHEM J, V351, P833, DOI 10.1042/0264-6021:3510833; Vincent F, 2004, CHEMBIOCHEM, V5, P1596, DOI 10.1002/cbic.200400169; VOCADLO DJ, 2000, GLYCOSIDASE CATALYZE; Wen X, 2005, BIOCHEMISTRY-US, V44, P6729, DOI 10.1021/bi0500426; Williams SJ, 2000, J AM CHEM SOC, V122, P4229, DOI 10.1021/ja0002870; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029; Zechel DL, 2003, BIOCHEMISTRY-US, V42, P7195, DOI 10.1021/bi034329j	46	57	57	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11291	11299		10.1074/jbc.M610964200	http://dx.doi.org/10.1074/jbc.M610964200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17287210	hybrid			2022-12-25	WOS:000245941500051
J	Heldring, N; Pawson, T; McDonnell, D; Treuter, E; Gustafsson, JA; Pike, ACW				Heldring, Nina; Pawson, Tanya; McDonnell, Donald; Treuter, Eckardt; Gustafsson, Jan-Ake; Pike, Ashley C. W.			Structural insights into corepressor recognition by antagonist-bound estrogen receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; NUCLEAR RECEPTOR; N-COR; ER-ALPHA; BINDING; COMPLEX; RECRUITMENT; SURFACE; DOMAIN; IDENTIFICATION	Direct recruitment of transcriptional corepressors to estrogen receptors ( ER) is thought to contribute to the tissue-specific effects of clinically important ER antagonists. Here, we present the crystal structures of two affinity-selected peptides in complex with antagonist- bound ER alpha ligand-binding domain. Both peptides adopt helical conformations, bind along the activation function 2 coregulator interaction surface, and mimic corepressor ( CoRNR) sequence motif binding. Peptide binding is weak in a wild-type context but significantly enhanced by removal of ER helix 12. This region contains a previously unrecognized CoRNR motif that is able to compete with corepressors for binding to activation function 2, thereby providing a structural explanation for the poor ability of ER to directly interact with classical corepressors. Furthermore, the ability of other sequence motifs to mimic corepressor binding raises the possibility that coregulators do not necessarily require CoRNR motifs for direct recruitment to antagonist- bound ER.	Karolinska Inst, Dept Biosci & Nutr, S-14157 Huddinge, Sweden; Univ York, Struct Biol Lab, York YO10 5YW, N Yorkshire, England; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Karolinska Institutet; University of York - UK; Duke University	Heldring, N (corresponding author), Univ Oxford, Botnar Res Ctr, Struct Genom Consortium, Oxford OX3 7LD, England.	nina.heldring@biosci.ki.se; ashley.pike@sgc.ox.ac.uk		Treuter, Eckardt/0000-0002-4147-8989	Wellcome Trust [064803] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bavner A, 2005, TRENDS ENDOCRIN MET, V16, P478, DOI 10.1016/j.tem.2005.10.005; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Dobrzycka KM, 2003, ENDOCR-RELAT CANCER, V10, P517, DOI 10.1677/erc.0.0100517; Dotzlaw H, 2003, MOL CELL ENDOCRINOL, V213, P79, DOI 10.1016/j.mce.2003.10.036; Heldring N, 2004, MOL CELL BIOL, V24, P3445, DOI 10.1128/MCB.24.8.3445-3459.2004; Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang EY, 2000, GENE DEV, V14, P45; Huang HJ, 2002, MOL ENDOCRINOL, V16, P1778, DOI 10.1210/me.2002-0089; Iannone MA, 2004, MOL ENDOCRINOL, V18, P1064, DOI 10.1210/me.2003-0432; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Kong EH, 2005, P NATL ACAD SCI USA, V102, P3593, DOI 10.1073/pnas.0407189102; Lalli E, 2003, MOL ENDOCRINOL, V17, P1445, DOI 10.1210/me.2003-0159; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Levenson AS, 1997, J STEROID BIOCHEM, V60, P261, DOI 10.1016/S0960-0760(96)00184-7; Levenson AS, 2001, J STEROID BIOCHEM, V76, P61, DOI 10.1016/S0960-0760(00)00143-6; Marimuthu A, 2002, MOL ENDOCRINOL, V16, P271, DOI 10.1210/me.16.2.271; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Pike ACW, 2006, BEST PRACT RES CL EN, V20, P1, DOI 10.1016/j.beem.2005.09.002; Pike ACW, 2001, STRUCTURE, V9, P145, DOI 10.1016/S0969-2126(01)00568-8; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Wagner BL, 2003, MOL CELL BIOL, V23, P5780, DOI 10.1128/MCB.23.16.5780-5789.2003; Wang DQ, 2005, MOL ENDOCRINOL, V19, P1483, DOI 10.1210/me.2005-0012; Webb P, 2003, J BIOL CHEM, V278, P6912, DOI 10.1074/jbc.M208501200; Wu Y, 2006, MOL CELL BIOL, V26, P6633, DOI 10.1128/MCB.01534-05; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Yamamoto Y, 2001, J BIOL CHEM, V276, P42684, DOI 10.1074/jbc.M107844200; Yoon HG, 2006, MOL ENDOCRINOL, V20, P1048, DOI 10.1210/me.2005-0324; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zhang JS, 2002, MOL CELL, V9, P611, DOI 10.1016/S1097-2765(02)00468-9	41	63	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10449	10455		10.1074/jbc.M611424200	http://dx.doi.org/10.1074/jbc.M611424200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283072	hybrid			2022-12-25	WOS:000245941000036
J	Tapley, TL; Eichner, T; Gleiter, S; Ballou, DP; Bardwell, JCA				Tapley, Timothy L.; Eichner, Timo; Gleiter, Stefan; Ballou, David P.; Bardwell, James C. A.			Kinetic characterization of the disulfide bond-forming enzyme DsbB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARGE-TRANSFER COMPLEX; ESCHERICHIA-COLI; RESPIRATORY-CHAIN; FORMATION PATHWAY; REDOX POTENTIALS; DE-NOVO; PROTEIN; UBIQUINONE; CYSTEINES; MECHANISM	DsbB is an integral membrane protein responsible for the de novo synthesis of disulfide bonds in Escherichia coli and many other prokaryotes. In the process of transferring electrons from DsbA to a tightly bound ubiquinone cofactor, DsbB undergoes an unusual spectral transition at similar to 510 nm. We have utilized this spectral transition to study the kinetic cycle of DsbB in detail using stopped flow methods. We show that upon mixing of Dsb-B-ox and DsbA(red), there is a rapid increase in absorbance at 510 nm ( giving rise to a purple solution), followed by two slower decay phases. The rate of the initial phase is highly dependent upon DsbA concentration (k(1) similar to 5 similar to 10(5) M-1 s(-1)), suggesting this phase reflects the rate of DsbA binding. The rates of the subsequent decay phases are independent of DsbA concentration (k(2) similar to 2 s(-1); k(3) similar to 0.3 s(-1)), indicative of intramolecular reaction steps. Absorbance measurements at 275 nm suggest that k2 and k3 are associated with steps of quinone reduction. The rate of DsbA oxidation was found to be the same as the rate of quinone reduction, suggestive of a highly concerted reaction. The concerted nature of the reaction may explain why previous efforts to dissect the reaction mechanism of DsbB by examining individual pairs of cysteines yielded seemingly paradoxical results. Order of mixing experiments showed that the quinone must be pre-bound to DsbB to observe the purple intermediate as well as for efficient quinone reduction. These results are consistent with a kinetic model for DsbB action in which DsbA binding is followed by a rapid disulfide exchange event. This is followed by quinone reduction, which is rate-limiting in the overall reaction cycle.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Bardwell, JCA (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu	dballou@umich.edu, David P/A-1298-2007					Bader M, 1998, J BIOL CHEM, V273, P10302, DOI 10.1074/jbc.273.17.10302; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2000, J BIOL CHEM, V275, P26082, DOI 10.1074/jbc.M003850200; Frech C, 1996, EMBO J, V15, P392, DOI 10.1002/j.1460-2075.1996.tb00369.x; GENNIS RB, 1996, ESCHERICHIA COLI SAL, P222; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; Graige MS, 1998, P NATL ACAD SCI USA, V95, P11679, DOI 10.1073/pnas.95.20.11679; Grauschopf U, 2003, EMBO J, V22, P3503, DOI 10.1093/emboj/cdg356; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; Hennecke J, 1997, BIOCHEMISTRY-US, V36, P6391, DOI 10.1021/bi963017w; Inaba K, 2006, P NATL ACAD SCI USA, V103, P287, DOI 10.1073/pnas.0507570103; Inaba K, 2005, J BIOL CHEM, V280, P33035, DOI 10.1074/jbc.M506189200; Inaba K, 2004, J BIOL CHEM, V279, P6761, DOI 10.1074/jbc.M310765200; Inaba K, 2002, EMBO J, V21, P2646, DOI 10.1093/emboj/21.11.2646; Inaba K, 2006, CELL, V127, P789, DOI 10.1016/j.cell.2006.10.034; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kadokura H, 2002, EMBO J, V21, P2354, DOI 10.1093/emboj/21.10.2354; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; Kishigami S, 1996, GENES CELLS, V1, P201, DOI 10.1046/j.1365-2443.1996.d01-233.x; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; Nakamoto H, 2004, BBA-MOL CELL RES, V1694, P111, DOI 10.1016/j.bbamcr.2004.02.012; Regeimbal J, 2003, P NATL ACAD SCI USA, V100, P13779, DOI 10.1073/pnas.1935988100; Regeimbal J, 2002, J BIOL CHEM, V277, P32706, DOI 10.1074/jbc.M205433200; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Takahashi YH, 2004, J BIOL CHEM, V279, P47057, DOI 10.1074/jbc.M407153200; URBAN PF, 1969, EUR J BIOCHEM, V9, P519, DOI 10.1111/j.1432-1033.1969.tb00640.x; WAGNER GC, 1974, P NATL ACAD SCI USA, V71, P253, DOI 10.1073/pnas.71.2.253; Xie T, 2002, J BIOL CHEM, V277, P1649, DOI 10.1074/jbc.M108697200; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	31	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10263	10271		10.1074/jbc.M611541200	http://dx.doi.org/10.1074/jbc.M611541200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17267399	hybrid			2022-12-25	WOS:000245941000016
J	Connelly, L; Robinson-Benion, C; Chont, M; Saint-Jean, L; Li, HJ; Polosukhin, VV; Blackwell, TS; Yull, FE				Connelly, Linda; Robinson-Benion, Cheryl; Chont, Melissa; Saint-Jean, Leshana; Li, Haijing; Polosukhin, Vasiliy V.; Blackwell, Timothy S.; Yull, Fiona E.			A transgenic model reveals important roles for the NF-kappa B alternative pathway (p100/p52) in mammary development and links to tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; CYCLIN D1 EXPRESSION; TRANSCRIPTION FACTOR; GLAND DEVELOPMENT; MATRIX METALLOPROTEINASES; GENE-EXPRESSION; GROWTH-FACTORS; IKK-ALPHA; ACTIVATION; PROTEINS	A regulated pattern of nuclear factor kappa B (NF-kappa B) activation is essential for normal development of the mammary gland. An increase in NF-kappa B activity has been implicated in breast cancer. We have generated a novel transgenic mouse model to investigate the role of the alternative NF-kappa B pathway in ductal development and identify possible mediators of tumorigenesis downstream of p100/p52. By overexpressing the NF-kappa B p100/p52 subunit in mammary epithelium using the beta-lactoglobulin milk protein promoter, we found that transgene expression resulted in increased overall NF-kappa B activity during late pregnancy. During pregnancy, p100/p52 expression resulted in delayed ductal development with impaired secondary branching and increased levels of Cyclin D1, matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and cyclo-oxygenase-2 (COX-2) in the mammary gland. After multiple pregnancies the p100 transgenics exhibited a ductal thickening accompanied by small hyperplastic foci. In tumors from mice expressing the polyoma middle T oncoprotein (PyVT) in the mammary gland, increased levels of p100/p52 were present at the time of tumor development. These results show that increased p100/p52 disrupts normal ductal development and provides insight into the mechanism by which this may contribute to human breast cancer.	Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Yull, FE (corresponding author), Vanderbilt Univ, Dept Canc Biol, 771 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	Fiona.yull@vanderbilt.edu	Connelly, Linda/GVS-4612-2022					BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Brantley DM, 2000, MECH DEVELOP, V97, P149, DOI 10.1016/S0925-4773(00)00405-6; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Demicco EG, 2005, MOL CELL BIOL, V25, P10136, DOI 10.1128/MCB.25.22.10136-10147.2005; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Everhart MB, 2006, J IMMUNOL, V176, P4995, DOI 10.4049/jimmunol.176.8.4995; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Furth PA, 1999, J MAMMARY GLAND BIOL, V4, P123, DOI 10.1023/A:1018764922082; Geymayer S, 2000, FASEB J, V14, P1159, DOI 10.1096/fasebj.14.9.1159; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Han YP, 2001, J CELL SCI, V114, P131; Hennighausen L, 2005, NAT REV MOL CELL BIO, V6, P715, DOI 10.1038/nrm1714; Heppner KJ, 1996, AM J PATHOL, V149, P273; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Medina D, 1996, J MAMMARY GLAND BIOL, V1, P5, DOI 10.1007/BF02096299; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Newton R, 1997, BIOCHEM BIOPH RES CO, V237, P28, DOI 10.1006/bbrc.1997.7064; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Simian M, 2001, DEVELOPMENT, V128, P3117; Singh B, 2005, INT J ONCOL, V26, P1393; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Takahashi Y, 1999, FEBS LETT, V460, P145, DOI 10.1016/S0014-5793(99)01328-9; Wang DZ, 2004, SEMIN ONCOL, V31, P64, DOI 10.1053/j.seminoncol.2004.01.008; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wiseman BS, 2003, J CELL BIOL, V162, P1123, DOI 10.1083/jcb.200302090; Witty Jean P., 1995, Molecular Biology of the Cell, V6, P1287	45	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10028	10035		10.1074/jbc.M611300200	http://dx.doi.org/10.1074/jbc.M611300200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17261585	hybrid			2022-12-25	WOS:000245421700077
J	Aoki, K; Perlman, M; Lim, JM; Cantu, R; Wells, L; Tiemeyer, M				Aoki, Kazuhiro; Perlman, Mindy; Lim, Jae-Min; Cantu, Rebecca; Wells, Lance; Tiemeyer, Michael			Dynamic developmental elaboration of N-linked glycan complexity in the Drosophila melanogaster embryo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSECT CELLS; FUNCTIONAL-CHARACTERIZATION; HORSERADISH-PEROXIDASE; CAENORHABDITIS-ELEGANS; ACETYLNEURAMINIC ACID; SUBSTRATE-SPECIFICITY; PROTEIN GLYCOSYLATION; GRASSHOPPER EMBRYOS; MOLECULAR-CLONING; HEPARAN-SULFATE	The structural diversity of glycoprotein N-linked oligosaccharides is determined by the expression and regulation of glycosyltransferase activities and by the availability of the appropriate acceptor/donor substrates. Cells in different tissues and in different developmental stages utilize these control points to manifest unique glycan expression patterns in response to their surroundings. The activity of a Toll-like receptor, called Tollo/ Toll-8, induces a pattern of incompletely defined, but neural specific, glycan expression in the Drosophila embryo. Understanding the full extent of the changes in glycan expression that result from altered Tollo/Toll-8 signaling requires characterization of the complete N-linked glycan profile of both wild-type and mutant embryos. N-Linked glycans harvested from wildtype or mutant embryos were subjected to direct structural analysis by analytic and preparative high pressure liquid chromatography, by multidimensional mass spectrometry, and by exoglycosidase digestion, revealing a predominance of high mannose and paucimannose glycans. Di-, mono-, and nonfucosylated forms of hybrid, complex biantennary, and triantennary glycans account for 12% of the total wild-type glycan profile. Two sialylated glycans bearing N-acetylneuraminic acid were detected, the first direct demonstration of this modification in Drosophila. Glycan profiles change during normal development consistent with increasing a-mannosidase II and core fucosyltransferase enzyme activities, and with decreasing activity of the Fused lobes processing hexosaminidase. In tollo/toll-8 mutants, a dramatic, expected loss of difucosylated glycans is accompanied by unexpected decreases in monofucosylated and nonfucosylated hybrid glycans and increases in some nonfucosylated paucimannose and biantennary glycans. Therefore, tollo/toll-8 signaling influences flux through several processing steps that affect the maturation of N-linked glycans.	Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Chem, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Tiemeyer, M (corresponding author), Complex Carbohydrate Res Ctr, 315 Riverband Rd, Athens, GA 30602 USA.	mtiemeyer@ccrc.uga.edu	Aoki, Kazuhiro/H-8283-2014; Wells, Lance/H-3118-2013	Aoki, Kazuhiro/0000-0003-0029-4291; Wells, Lance/0000-0003-4956-5363	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072839] Funding Source: NIH RePORTER; NIGMS NIH HHS [1-R01-GM072839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN F, 1995, J BIOL CHEM, V270, P17344, DOI 10.1074/jbc.270.29.17344; Ashline D, 2005, ANAL CHEM, V77, P6250, DOI 10.1021/ac050724z; Aumiller JJ, 2006, PROTEIN EXPRES PURIF, V47, P571, DOI 10.1016/j.pep.2005.11.026; BALLOU L, 1990, P NATL ACAD SCI USA, V87, P3368, DOI 10.1073/pnas.87.9.3368; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; BUTTERS TD, 1981, BIOCHIM BIOPHYS ACTA, V640, P672, DOI 10.1016/0005-2736(81)90097-3; CALLAERTS P, 1995, ROUX ARCH DEV BIOL, V204, P229, DOI 10.1007/BF00208490; Cipollo JF, 2005, J BIOL CHEM, V280, P26063, DOI 10.1074/jbc.M503828200; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; DAMICO P, 1995, TISSUE CELL, V27, P23, DOI 10.1016/S0040-8166(95)80005-0; DELL A, 1993, GLYCOBIOLOGY PRACTIC, P187; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; Fabini G, 2001, J BIOL CHEM, V276, P28058, DOI 10.1074/jbc.M100573200; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; Foe Victoria E., 1993, P149; FOSTER JM, 1995, GENE, V154, P183, DOI 10.1016/0378-1119(94)00867-R; FREDIEU JR, 1994, ACTA ANAT, V149, P89; Freeze HH, 2002, BBA-GEN SUBJECTS, V1573, P388, DOI 10.1016/S0304-4165(02)00408-7; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; Haines N, 2005, GLYCOBIOLOGY, V15, P335, DOI 10.1093/glycob/cwi017; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Hanneman AJ, 2006, GLYCOBIOLOGY, V16, P874, DOI 10.1093/glycob/cwl011; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HASE S, 1981, J BIOCHEM-TOKYO, V90, P407, DOI 10.1093/oxfordjournals.jbchem.a133487; He JL, 2004, J BIOL CHEM, V279, P4705, DOI 10.1074/jbc.M311183200; Hollister J, 2002, BIOCHEMISTRY-US, V41, P15093, DOI 10.1021/bi026455d; Hu HY, 2001, NAT NEUROSCI, V4, P695, DOI 10.1038/89482; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JOHNSON SW, 1991, COMP BIOCHEM PHYS B, V99, P479, DOI 10.1016/0305-0491(91)90327-A; Kantor DB, 2004, NEURON, V44, P961, DOI 10.1016/j.neuron.2004.12.002; KERSCHER S, 1995, DEV BIOL, V168, P613, DOI 10.1006/dbio.1995.1106; Kim K, 2002, GLYCOBIOLOGY, V12, P73, DOI 10.1093/glycob/12.2.73; KOJIMA K, 1987, ANAL BIOCHEM, V165, P465, DOI 10.1016/0003-2697(87)90297-1; Koles K, 2004, J BIOL CHEM, V279, P4346, DOI 10.1074/jbc.M309912200; Landis G, 2001, GENETICS, V158, P1167; Leonard R, 2006, J BIOL CHEM, V281, P4867, DOI 10.1074/jbc.M511023200; Malykh YN, 1999, GLYCOCONJUGATE J, V16, P731, DOI 10.1023/A:1007115627708; Marchal I, 1999, GLYCOBIOLOGY, V9, P645, DOI 10.1093/glycob/9.7.645; Marchal I, 2001, BIOL CHEM, V382, P151, DOI 10.1515/BC.2001.023; Mechref Y, 2006, RAPID COMMUN MASS SP, V20, P1381, DOI 10.1002/rcm.2445; Michele DE, 2003, J BIOL CHEM, V278, P15457, DOI 10.1074/jbc.R200031200; Muller R, 2005, FEBS J, V272, P4295, DOI 10.1111/j.1742-4658.2005.04838.x; Muller R, 2002, J BIOL CHEM, V277, P32417, DOI 10.1074/jbc.C200381200; North SJ, 2006, GLYCOCONJUGATE J, V23, P345, DOI 10.1007/s10719-006-6693-4; OKU H, 1990, ANAL BIOCHEM, V185, P331, DOI 10.1016/0003-2697(90)90303-Q; PARKER GF, 1991, FEBS LETT, V290, P58, DOI 10.1016/0014-5793(91)81225-W; Paschinger K, 2005, GLYCOBIOLOGY, V15, P463, DOI 10.1093/glycob/cwi028; PATEL NH, 1994, DROSOPHILA MELANOGAS, P445; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; Rendic D, 2006, J BIOL CHEM, V281, P3343, DOI 10.1074/jbc.M508334200; Roberts DB, 1998, EUR J BIOCHEM, V253, P494, DOI 10.1046/j.1432-1327.1998.2530494.x; ROTH J, 1992, SCIENCE, V256, P673, DOI 10.1126/science.1585182; SAITO M, 1979, J BIOL CHEM, V254, P7845; Sarkar M, 2006, J BIOL CHEM, V281, P12776, DOI 10.1074/jbc.M512769200; Sarkar M, 2001, BIOL CHEM, V382, P209, DOI 10.1515/BC.2001.028; Seppo A, 2000, EUR J BIOCHEM, V267, P3549, DOI 10.1046/j.1432-1327.2000.01383.x; Seppo A, 2003, DEVELOPMENT, V130, P1439, DOI 10.1242/dev.00347; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; SNOW PM, 1987, J NEUROSCI, V7, P4137; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; TAKAHASHI N, 1995, ANAL BIOCHEM, V226, P139, DOI 10.1006/abio.1995.1201; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; Tian E, 2006, GLYCOBIOLOGY, V16, P83, DOI 10.1093/glycob/cwj051; Tomiya N, 2004, GLYCOCONJUGATE J, V21, P343, DOI 10.1023/B:GLYC.0000046275.28315.87; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; Tomiya N, 2006, J BIOL CHEM, V281, P19545, DOI 10.1074/jbc.M603312200; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; Vadaie N, 2004, J BIOL CHEM, V279, P33501, DOI 10.1074/jbc.M404925200; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Viswanathan K, 2006, J BIOL CHEM, V281, P15929, DOI 10.1074/jbc.M512186200; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Weinhold B, 2005, J BIOL CHEM, V280, P42971, DOI 10.1074/jbc.M511097200; WILLIAMS PJ, 1991, BIOCHIM BIOPHYS ACTA, V1075, P146, DOI 10.1016/0304-4165(91)90245-C; Yano H, 2005, P NATL ACAD SCI USA, V102, P13467, DOI 10.1073/pnas.0506681102; Zak BM, 2002, BBA-GEN SUBJECTS, V1573, P346, DOI 10.1016/S0304-4165(02)00402-6	78	210	216	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9127	9142		10.1074/jbc.M606711200	http://dx.doi.org/10.1074/jbc.M606711200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264077	hybrid			2022-12-25	WOS:000245780300060
J	Elter, A; Hartel, A; Sieben, C; Hertel, B; Fischer-Schliebs, E; Luttge, U; Moroni, A; Thiel, G				Elter, Astrid; Hartel, Andreas; Sieben, Christian; Hertel, Brigitte; Fischer-Schliebs, Elke; Luttge, Ulrich; Moroni, Anna; Thiel, Gerhard			A plant homolog of animal chloride intracellular channels (CLICs) generates an ion conductance in heterologous systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE TRANSFERASE; FUNCTIONAL-CHARACTERIZATION; FAMILY; PROTEIN; NCC27; CELLS; IDENTIFICATION; ARABIDOPSIS; EXPRESSION; ACTIN	The genome of Arabidopsis thaliana contains unusual members of the glutathione S-transferase (GST) superfamily with a cysteine in place of a serine at the active site. Four of these genes (at-dhar 1-4) have an appreciable homology to intracellular Cl- channels (CLICs) from vertebrates and invertebrates. Transient expression of AtDHAR1 as wild type protein or as a chimera with GFP in mammalian HEK293 or Chinese hamster ovary cells generated a distinct inward rectifying conductance with a characteristic biphasic kinetics but no apparent ion selectivity. Analysis of the subcellular localization of AtDHRA1::GFP showed that the bulk of the protein was located as soluble form in the cytoplasm; however, an appreciable fraction of it could also be found in association with the non-soluble microsomal fraction. These data suggest that plant members of the GST superfamily have similar to those from animals multiple functions. The increase of ion conductance by AtDHAR1 is better explained by a CLIC-like channel activity than by a modification of endogenous channel proteins.	Tech Univ Darmstadt, Inst Bot, D-64287 Darmstadt, Germany; Univ Milan, Dipartimento Biol, I-20133 Milan, Italy; Univ Milan, CNR, IBF, I-20133 Milan, Italy; Univ Milan, INFM Unita, I-20133 Milan, Italy	Technical University of Darmstadt; University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biofisica (IBF-CNR); University of Milan; University of Milan	Thiel, G (corresponding author), Tech Univ Darmstadt, Inst Bot, D-64287 Darmstadt, Germany.	thiel@bio.tu-darmstadt.de	Sieben, Christian/Z-6050-2019; moroni, anna/H-2097-2014	Sieben, Christian/0000-0002-2836-2623; moroni, anna/0000-0002-1860-406X; Thiel, Gerhard/0000-0002-2335-1351; Hartel, Andreas/0000-0002-2693-4472				Ashley RH, 2003, MOL MEMBR BIOL, V20, P1, DOI 10.1080/09687680210042746; Barbier-Brygoo H, 2000, BBA-BIOMEMBRANES, V1465, P199, DOI 10.1016/S0005-2736(00)00139-5; Berry KL, 2006, J MOL BIOL, V359, P1316, DOI 10.1016/j.jmb.2006.04.046; Berry KL, 2003, SCIENCE, V302, P2134, DOI 10.1126/science.1087667; Berryman M, 2004, J BIOL CHEM, V279, P34794, DOI 10.1074/jbc.M402835200; Berryman M, 2000, MOL BIOL CELL, V11, P1509, DOI 10.1091/mbc.11.5.1509; Cromer BA, 2002, EUR BIOPHYS J BIOPHY, V31, P356, DOI 10.1007/s00249-002-0219-1; Dixon DP, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews3004; Dixon DP, 2002, J BIOL CHEM, V277, P30859, DOI 10.1074/jbc.M202919200; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Edwards R, 2000, TRENDS PLANT SCI, V5, P193, DOI 10.1016/S1360-1385(00)01601-0; Gouaux E, 1997, CURR OPIN STRUC BIOL, V7, P566, DOI 10.1016/S0959-440X(97)80123-6; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; Hechenberger M, 1996, J BIOL CHEM, V271, P33632, DOI 10.1074/jbc.271.52.33632; Littler DR, 2004, J BIOL CHEM, V279, P9298, DOI 10.1074/jbc.M308444200; Moroni A, 2002, FEBS LETT, V530, P65, DOI 10.1016/S0014-5793(02)03397-5; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; Sakmann B., 1985, SINGLE CHANNEL RECOR, P37; Singh H, 2006, BIOPHYS J, V90, P1628, DOI 10.1529/biophysj.105.072678; Suginta W, 2001, BIOCHEM J, V359, P55, DOI 10.1042/0264-6021:3590055; Tonini R, 2000, FASEB J, V14, P1171, DOI 10.1096/fasebj.14.9.1171; Tulk BM, 2002, AM J PHYSIOL-CELL PH, V282, pC1103, DOI 10.1152/ajpcell.00402.2001; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Warton K, 2002, J BIOL CHEM, V277, P26003, DOI 10.1074/jbc.M203666200	25	27	28	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8786	8792		10.1074/jbc.M607241200	http://dx.doi.org/10.1074/jbc.M607241200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17267397	hybrid			2022-12-25	WOS:000245780300025
J	Touchman, JW; Wagner, DM; Hao, JC; Mastrian, SD; Shah, MK; Vogler, AJ; Allender, CJ; Clark, EA; Benitez, DS; Youngkin, DJ; Girard, JM; Auerbach, RK; Beckstrom-Sternberg, SM; Keim, P				Touchman, Jeffrey W.; Wagner, David M.; Hao, Jicheng; Mastrian, Stephen D.; Shah, Maulik K.; Vogler, Amy J.; Allender, Christopher J.; Clark, Erin A.; Benitez, Debbie S.; Youngkin, David J.; Girard, Jessica M.; Auerbach, Raymond K.; Beckstrom-Sternberg, Stephen M.; Keim, Paul			A North American Yersinia pestis Draft Genome Sequence: SNPs and Phylogenetic Analysis	PLOS ONE			English	Article								Background. Yersinia pestis, the causative agent of plague, is responsible for some of the greatest epidemic scourges of mankind. It is widespread in the western United States, although it has only been present there for just over 100 years. As a result, there has been very little time for diversity to accumulate in this region. Much of the diversity that has been detected among North American isolates is at loci that mutate too quickly to accurately reconstruct large-scale phylogenetic patterns. Slowly-evolving but stable markers such as SNPs could be useful for this purpose, but are difficult to identify due to the monomorphic nature of North American isolates. Methodology/Principal Findings. To identify SNPs that are polymorphic among North American populations of Y. pestis, a gapped genome sequence of Y. pestis strain FV-1 was generated. Sequence comparison of FV-1 with another North American strain, CO92, identified 19 new SNP loci that differ among North American isolates. Conclusions/Significance. The 19 SNP loci identified in this study should facilitate additional studies of the genetic population structure of Y. pestis across North America.	[Touchman, Jeffrey W.; Hao, Jicheng; Mastrian, Stephen D.; Shah, Maulik K.; Clark, Erin A.; Benitez, Debbie S.; Youngkin, David J.; Beckstrom-Sternberg, Stephen M.; Keim, Paul] Translat Genom Res Inst, Phoenix, AZ USA; [Touchman, Jeffrey W.] Arizona State Univ, Biodesign Inst, Tempe, AZ USA; [Wagner, David M.; Vogler, Amy J.; Allender, Christopher J.; Girard, Jessica M.; Auerbach, Raymond K.; Beckstrom-Sternberg, Stephen M.; Keim, Paul] No Arizona Univ, Ctr Microbial Genet & Genom, Flagstaff, AZ 86011 USA	Translational Genomics Research Institute; Arizona State University; Arizona State University-Tempe; Northern Arizona University	Touchman, JW (corresponding author), Translat Genom Res Inst, Phoenix, AZ USA.	jtouchman@tgen.org	Wagner, David M/A-5125-2010; Keim, Paul S/A-2269-2010	Wagner, David/0000-0003-2684-6007				Achtman M, 1999, P NATL ACAD SCI USA, V96, P14043, DOI 10.1073/pnas.96.24.14043; Achtman M, 2004, P NATL ACAD SCI USA, V101, P17837, DOI 10.1073/pnas.0408026101; ACHTMAN M, 2004, YERSINIA MOL CELLULA, P432; Chain PSG, 2006, J BACTERIOL, V188, P4453, DOI 10.1128/JB.00124-06; Chain PSG, 2004, P NATL ACAD SCI USA, V101, P13826, DOI 10.1073/pnas.0404012101; Cully JF, 2001, J MAMMAL, V82, P894, DOI 10.1644/1545-1542(2001)082&lt;0894:ICOSPI&gt;2.0.CO;2; Delcher AL, 2002, NUCLEIC ACIDS RES, V30, P2478, DOI 10.1093/nar/30.11.2478; Enscore RE, 2002, AM J TROP MED HYG, V66, P186, DOI 10.4269/ajtmh.2002.66.186; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Girard JM, 2004, P NATL ACAD SCI USA, V101, P8408, DOI 10.1073/pnas.0401561101; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Jaffe DB, 2003, GENOME RES, V13, P91, DOI 10.1101/gr.828403; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Kurtz S, 1999, BIOINFORMATICS, V15, P426, DOI 10.1093/bioinformatics/15.5.426; LINK V B, 1955, Public Health Monogr, V26, P1; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Parmenter RR, 1999, AM J TROP MED HYG, V61, P814, DOI 10.4269/ajtmh.1999.61.814; Pearson T, 2004, P NATL ACAD SCI USA, V101, P13536, DOI 10.1073/pnas.0403844101; PERROW C, 1997, ORG ENV, V10, P66, DOI DOI 10.1177/0921810697101009; Rotz LD, 2002, EMERG INFECT DIS, V8, P225, DOI 10.3201/eid0802.010164; SCHWARTZ S, 2003, NUCLEIC ACIDS RES, V31, P1; Thorstenson YR, 1998, GENOME RES, V8, P848, DOI 10.1101/gr.8.8.848	23	26	29	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e220	10.1371/journal.pone.0000220	http://dx.doi.org/10.1371/journal.pone.0000220			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311096	gold, Green Published			2022-12-25	WOS:000207444500001
J	Franco, MD; Bohbot, J; Fernandez, K; Hanna, J; Poppy, J; Vogt, R				Franco, Marie-dominique; Bohbot, Jonathan; Fernandez, Kenny; Hanna, Jayd; Poppy, James; Vogt, Richard			Sensory Cell Proliferation within the Olfactory Epithelium of Developing Adult Manduca sexta (Lepidoptera)	PLOS ONE			English	Article								Background. Insects detect a multitude of odors using a broad array of phenotypically distinct olfactory organs referred to as olfactory sensilla. Each sensillum contains one to several sensory neurons and at least three support cells; these cells arise from mitotic activities from one or a small group of defined precursor cells. Sensilla phenotypes are defined by distinct morphologies, and specificities to specific odors; these are the consequence of developmental programs expressed by associated neurons and support cells, and by selection and expression of subpopulations of olfactory genes encoding such proteins as odor receptors, odorant binding proteins, and odor degrading enzymes. Methodology/Principal Findings. We are investigating development of the olfactory epithelium of adult M. sexta, identifying events which might establish sensilla phenotypes. In the present study, antennal tissue was examined during the first three days of an 18 day development, a period when sensory mitotic activity was previously reported to occur. Each antenna develops as a cylinder with an outward facing sensory epithelium divided into approximately 80 repeat units or annuli. Mitotic proliferation of sensory cells initiated about 20-24 hrs after pupation (a. p.), in pre-existing zones of high density cells lining the proximal and distal borders of each annulus. These high density zones were observed as early as two hr. a. p., and expanded with mitotic activity to fill the mid-annular regions by about 72 hrs a. p. Mitotic activity initiated at a low rate, increasing dramatically after 40-48 hrs a. p.; this activity was enhanced by ecdysteroids, but did not occur in animals entering pupal diapause (which is also ecdysteroid sensitive). Conclusions/Significance. Sensory proliferation initiates in narrow zones along the proximal and distal borders of each annulus; these zones rapidly expand to fill the mid-annular regions. These zones exist prior to any mitotic activity as regions of high density cells which form either at or prior to pupation. Mitotic sensitivity to ecdysteroids may be a regulatory mechanism coordinating olfactory development with the developmental choice of diapause entry.	[Franco, Marie-dominique; Bohbot, Jonathan; Fernandez, Kenny; Hanna, Jayd; Poppy, James; Vogt, Richard] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Vogt, R (corresponding author), Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.	vogt@biol.sc.edu			National Science Foundation [IBN9731005, IBN0212510]; National Institutes of Health [NICDC DC-00588]; Department of Agriculture [CRGP 94-37302-0615]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000588] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Agriculture; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	We thank the National Science Foundation (IBN9731005, IBN0212510) the National Institutes of Health (NICDC DC-00588) and the Department of Agriculture (CRGP 94-37302-0615) for various support throughout this study.	BELL RA, 1975, J INSECT PHYSIOL, V21, P1471, DOI 10.1016/0022-1910(75)90210-3; BOWEN MF, 1985, J INSECT PHYSIOL, V31, P83, DOI 10.1016/0022-1910(85)90012-5; BOWEN MF, 1984, J EXP BIOL, V108, P9; BRADFIELD JY, 1980, GEN COMP ENDOCR, V41, P101, DOI 10.1016/0016-6480(80)90038-6; Byrd CA, 1996, J NEUROBIOL, V29, P445, DOI 10.1002/(SICI)1097-4695(199604)29:4<445::AID-NEU3>3.0.CO;2-8; Champlin DT, 1998, DEVELOPMENT, V125, P269; Champlin DT, 1998, DEVELOPMENT, V125, P2009; de Bruyne M, 2001, NEURON, V30, P537, DOI 10.1016/S0896-6273(01)00289-6; Denlinger D.L., 1985, P353; EASSA Y. E. E., 1953, TRANS ROY ENT SOC LONDON, V104, P39; GILBERT LI, 1996, METAMORPHOSIS POSTEM, V2, P59; Goulding SE, 2000, NEURON, V25, P69, DOI 10.1016/S0896-6273(00)80872-7; Gupta BP, 1997, GENES CELLS, V2, P225, DOI 10.1046/j.1365-2443.1997.d01-312.x; HANSON FE, 1973, J INSECT PHYSIOL, V19, P1019, DOI 10.1016/0022-1910(73)90028-0; Hansson BS, 2003, J COMP PHYSIOL A, V189, P301, DOI 10.1007/s00359-003-0403-5; Hiruma K, 1997, GEN COMP ENDOCR, V107, P84, DOI 10.1006/gcen.1997.6901; Kalinova B, 2001, CHEM SENSES, V26, P1175, DOI 10.1093/chemse/26.9.1175; KEIL TA, 1990, TISSUE CELL, V22, P319, DOI 10.1016/0040-8166(90)90007-V; KEIL TA, 1992, MICROSC RES TECHNIQ, V22, P351, DOI 10.1002/jemt.1070220405; KEIL TA, 1990, TISSUE CELL, V22, P705, DOI 10.1016/0040-8166(90)90066-I; KEIL TA, 1989, TISSUE CELL, V21, P139, DOI 10.1016/0040-8166(89)90028-1; KEIL TA, 1990, TISSUE CELL, V22, P821; KENT KS, 1987, PHILOS T ROY SOC B, V315, P3; KIRSCHENBAUM SR, 1995, J NEUROBIOL, V28, P234, DOI 10.1002/neu.480280209; LAFONT R, 1992, ECDYSONE HDB; Lage PIZ, 2003, DEVELOPMENT, V130, P4683, DOI 10.1242/dev.00680; Laue M, 2000, ARTHROPOD STRUCT DEV, V29, P57, DOI 10.1016/S1467-8039(00)00013-X; LEE JK, 1990, J NEUROCYTOL, V19, P519, DOI 10.1007/BF01257241; Levine Richard B., 1995, Current Opinion in Neurobiology, V5, P28, DOI 10.1016/0959-4388(95)80083-2; MacWhinnie SGB, 2005, DEV BIOL, V285, P285, DOI 10.1016/j.ydbio.2005.06.021; Monsma SA, 1996, J COMP NEUROL, V367, P10, DOI 10.1002/(SICI)1096-9861(19960325)367:1<10::AID-CNE2>3.0.CO;2-M; OLAND LA, 1988, J NEUROSCI, V8, P353; OLAND LA, 1993, J NEUROBIOL, V24, P1170, DOI 10.1002/neu.480240905; RAY K, 1995, DEV BIOL, V167, P426, DOI 10.1006/dbio.1995.1039; Reddy GV, 1997, DEVELOPMENT, V124, P703; Riddiford L.M., 1979, TCA (TISSUE CULTURE ASSOCIATION) MANUAL, V5, P975, DOI 10.1007/BF00919715; RIDDIFORD LM, 1993, AM ZOOL, V33, P340; RIDDIFORD LM, 1993, DEV DROSOPHILA MELAN, V2, P889; Riddiford Lynn M., 1995, P293, DOI 10.1017/CBO9780511529931.012; Rogers ME, 2001, J NEUROBIOL, V49, P47, DOI 10.1002/neu.1065; Rossler W, 1999, J NEUROSCI, V19, P9865; SANES JR, 1976, DEV BIOL, V51, P282, DOI 10.1016/0012-1606(76)90144-5; SANES JR, 1976, DEV BIOL, V51, P300, DOI 10.1016/0012-1606(76)90145-7; SCHWARTZ LM, 1983, DEV BIOL, V99, P103, DOI 10.1016/0012-1606(83)90257-9; Sen A, 2004, MECH DEVELOP, V121, P65, DOI 10.1016/j.mod.2003.10.002; Shanbhag SR, 1999, INT J INSECT MORPHOL, V28, P377, DOI 10.1016/S0020-7322(99)00039-2; Shields VDC, 1999, CAN J ZOOL, V77, P302, DOI 10.1139/cjz-77-2-302; Shields VDC, 1999, CAN J ZOOL, V77, P290, DOI 10.1139/cjz-77-2-290; Shields VDC, 2001, J COMP PHYSIOL A, V186, P1135, DOI 10.1007/s003590000165; STEINBRECHT RA, 1980, TISSUE CELL, V12, P73, DOI 10.1016/0040-8166(80)90053-1; Steinbrecht Rudolf Alexander, 1999, P155; SVACHA P, 1992, DEV BIOL, V154, P101, DOI 10.1016/0012-1606(92)90052-I; TAUBER MJ, 1978, ANNU REV ENTOMOL, V21, P81; Tissot M, 2000, PROG NEUROBIOL, V62, P89, DOI 10.1016/S0301-0082(99)00069-6; TOMIOKA K, 1995, ZOOL SCI, V12, P165, DOI 10.2108/zsj.12.165; Truman JW, 2006, SCIENCE, V312, P1385, DOI 10.1126/science.1123652; VOGT RG, 1993, J NEUROBIOL, V24, P581, DOI 10.1002/neu.480240505; Vogt RG, 2002, J EXP BIOL, V205, P719; VOGT RG, 2005, COMPREHENSIVE INSECT, V3, P753, DOI DOI 10.1016/B0-44-451924-6/00047-8; Vogt Richard G., 2003, P391, DOI 10.1016/B978-012107151-6/50016-5; WAKU Y, 1991, J MORPHOL, V207, P253, DOI 10.1002/jmor.1052070304; WARREN JT, 1986, INSECT BIOCHEM, V16, P65, DOI 10.1016/0020-1790(86)90080-6; Weeks JC, 1995, CURR OPIN NEUROBIOL, V5, P809, DOI 10.1016/0959-4388(95)80110-3; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Yao CA, 2005, J NEUROSCI, V25, P8359, DOI 10.1523/JNEUROSCI.2432-05.2005	65	10	12	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e215	10.1371/journal.pone.0000215	http://dx.doi.org/10.1371/journal.pone.0000215			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299595	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444400016
J	Horii, A; Wang, XM; Gelain, F; Zhang, SG				Horii, Akihiro; Wang, Xiumei; Gelain, Fabrizio; Zhang, Shuguang			Biological Designer Self-Assembling Peptide Nanofiber Scaffolds Significantly Enhance Osteoblast Proliferation, Differentiation and 3-D Migration	PLOS ONE			English	Article							STEM-CELLS; COMPLEMENTARY OLIGOPEPTIDE; TERMINAL PENTAPEPTIDE; PROGENITOR CELLS; IN-VITRO; BONE; GROWTH; HYDROGELS; ATTACHMENT; ADHESION	A class of self-assembling peptide nanofiber scaffolds has been shown to be an excellent biological material for 3-dimension cell culture and stimulating cell migration into the scaffold, as well as for repairing tissue defects in animals. We report here the development of several peptide nanofiber scaffolds designed specifically for osteoblasts. We designed one of the pure self-assembling peptide scaffolds RADA16-I through direct coupling to short biologically active motifs. The motifs included osteogenic growth peptide ALK (ALKRQGRTLYGF) bone-cell secreted-signal peptide, osteopontin cell adhesion motif DGR (DGRGDSVAYG) and 2-unit RGD binding sequence PGR (PRGDSGYRGDS). We made the new peptide scaffolds by mixing the pure RAD16 and designer-peptide solutions, and we examined the molecular integration of the mixed nanofiber scaffolds using AFM. Compared to pure RAD16 scaffold, we found that these designer peptide scaffolds significantly promoted mouse pre-osteoblast MC3T3-E1 cell proliferation. Moreover, alkaline phosphatase (ALP) activity and osteocalcin secretion, which are early and late markers for osteoblastic differentiation, were also significantly increased. We demonstrated that the designer, self-assembling peptide scaffolds promoted the proliferation and osteogenic differentiation of MC3T3-E1. Under the identical culture medium condition, confocal images unequivocally demonstrated that the designer PRG peptide scaffold stimulated cell migration into the 3-D scaffold. Our results suggest that these designer peptide scaffolds may be very useful for promoting bone tissue regeneration.	[Horii, Akihiro; Wang, Xiumei; Gelain, Fabrizio; Zhang, Shuguang] MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA; [Horii, Akihiro] Olympus Amer Inc, Center Valley, PA USA; [Gelain, Fabrizio] Univ Milano Bicocca, Dept Biosci & Biotechnol, Milan, Italy	Massachusetts Institute of Technology (MIT); Olympus Corporation; University of Milano-Bicocca	Zhang, SG (corresponding author), MIT, Ctr Biomed Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	Shuguang@mit.edu	Gelain, Fabrizio G/K-5069-2012	Gelain, Fabrizio G/0000-0002-2624-5853; Zhang, Shuguang/0000-0002-3856-3752	Olympus Corp	Olympus Corp	Akihiro Horii is from Olympus Corp. Dr. Xiumei Wang is supported by Olympus Corp. Fabrizio Gelain was from CARIPLO and Hospital S. Raffaele, Milano, Italy but supported by Olympus Corp.	Alsberg E, 2001, J DENT RES, V80, P2025, DOI 10.1177/00220345010800111501; BAB I, 1992, EMBO J, V11, P1867, DOI 10.1002/j.1460-2075.1992.tb05238.x; Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x; Bokhari MA, 2005, BIOMATERIALS, V26, P5198, DOI 10.1016/j.biomaterials.2005.01.040; Chen YC, 2002, J MED CHEM, V45, P1624, DOI 10.1021/jm010479l; Cornish J, 1998, AM J PHYSIOL-ENDOC M, V275, pE694, DOI 10.1152/ajpendo.1998.275.4.E694; Davis ME, 2005, CIRCULATION, V111, P442, DOI 10.1161/01.CIR.0000153847.47301.80; Endres M, 2003, TISSUE ENG, V9, P689, DOI 10.1089/107632703768247386; Fazzi R, 2002, LEUKEMIA RES, V26, P19, DOI 10.1016/S0145-2126(01)00091-1; Gelain F, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000119; Haubner R, 1997, ANGEW CHEM INT EDIT, V36, P1375; Haubner R, 1996, J AM CHEM SOC, V118, P7461, DOI 10.1021/ja9603721; Hayashibara T, 2004, J BONE MINER RES, V19, P455, DOI 10.1359/JBMR.0301263; Hong YS, 2003, BIOMACROMOLECULES, V4, P1433, DOI 10.1021/bm0341374; Hosseinkhani H, 2006, BIOMATERIALS, V27, P4079, DOI 10.1016/j.biomaterials.2006.03.030; Kantlehner M, 2000, CHEMBIOCHEM, V1, P107, DOI 10.1002/1439-7633(20000818)1:2<107::AID-CBIC107>3.0.CO;2-4; Kasten P, 2003, BIOMATERIALS, V24, P2593, DOI 10.1016/S0142-9612(03)00062-0; Kisiday J, 2002, P NATL ACAD SCI USA, V99, P9996, DOI 10.1073/pnas.142309999; KREIS TVR, 1999, GUIDE BOOK EXTRACELL, P457; Nguyen H, 2003, BIOCHEM BIOPH RES CO, V311, P179, DOI 10.1016/j.bbrc.2003.09.192; Rezania A, 1999, BIOTECHNOL PROGR, V15, P19, DOI 10.1021/bp980083b; Roberts C, 1998, J AM CHEM SOC, V120, P6548, DOI 10.1021/ja972467o; Shin H, 2004, J BIOMED MATER RES A, V69A, P535, DOI 10.1002/jbm.a.30027; Shin H, 2004, BIOMATERIALS, V25, P895, DOI 10.1016/S0142-9612(03)00602-1; Shin H, 2003, BIOMATERIALS, V24, P4353, DOI 10.1016/S0142-9612(03)00339-9; Shin H, 2002, J BIOMED MATER RES, V61, P169, DOI 10.1002/jbm.10193; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Weinand C, 2006, BONE, V38, P555, DOI 10.1016/j.bone.2005.10.016; ZHANG S, 2005, PURAMATRIX SELF ASSE, P218; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334; ZHANG SG, 1995, BIOMATERIALS, V16, P1385, DOI 10.1016/0142-9612(95)96874-Y; Zhang YZ, 2005, J BIOMED MATER RES B, V72B, P156, DOI 10.1002/jbm.b.30128	32	361	397	3	137	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2007	2	2							e190	10.1371/journal.pone.0000190	http://dx.doi.org/10.1371/journal.pone.0000190			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DI	17285144	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444300003
J	Levine, RS; Peterson, AT; Yorita, KL; Carroll, D; Damon, IK; Reynolds, MG				Levine, Rebecca S.; Peterson, A. Townsend; Yorita, Krista L.; Carroll, Darin; Damon, Inger K.; Reynolds, Mary G.			Ecological Niche and Geographic Distribution of Human Monkeypox in Africa	PLOS ONE			English	Article							DISEASE; VIRUS; CONGO	Monkeypox virus, a zoonotic member of the genus Orthopoxviridae, can cause a severe, smallpox-like illness in humans. Monkeypox virus is thought to be endemic to forested areas of western and Central Africa. Considerably more is known about human monkeypox disease occurrence than about natural sylvatic cycles of this virus in non-human animal hosts. We use human monkeypox case data from Africa for 1970-2003 in an ecological niche modeling framework to construct predictive models of the ecological requirements and geographic distribution of monkeypox virus across West and Central Africa. Tests of internal predictive ability using different subsets of input data show the model to be highly robust and suggest that the distinct phylogenetic lineages of monkeypox in West Africa and Central Africa occupy similar ecological niches. High mean annual precipitation and low elevations were shown to be highly correlated with human monkeypox disease occurrence. The synthetic picture of the potential geographic distribution of human monkeypox in Africa resulting from this study should support ongoing epidemiologic and ecological studies, as well as help to guide public health intervention strategies to areas at highest risk for human monkeypox.	[Levine, Rebecca S.; Carroll, Darin; Damon, Inger K.; Reynolds, Mary G.] Ctr Dis Control & Prevent, Poxvirus Program, Atlanta, GA 30333 USA; [Peterson, A. Townsend] Univ Kansas, Nat Hist Museum, Lawrence, KS 66045 USA; [Peterson, A. Townsend] Univ Kansas, Biodivers Res Ctr, Lawrence, KS 66045 USA; [Yorita, Krista L.] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; University of Kansas; University of Kansas; Centers for Disease Control & Prevention - USA	Reynolds, MG (corresponding author), Ctr Dis Control & Prevent, Poxvirus Program, Atlanta, GA 30333 USA.	nzr6@cdc.gov	Levine, Rebecca/ABB-9551-2020; Peterson, A. Townsend/I-5697-2013	Levine, Rebecca/0000-0001-6525-1132; Peterson, A. Townsend/0000-0003-0243-2379; Christensen, Krista/0000-0003-4431-336X; Reynolds, Mary/0000-0001-7882-4614	US Centers for Disease Control and Prevention	US Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This work was funded entirely by the US Centers for Disease Control and Prevention.	ARITA I, 1985, AM J TROP MED HYG, V34, P781, DOI 10.4269/ajtmh.1985.34.781; BREMAN JG, 1980, B WORLD HEALTH ORGAN, V58, P165; Breman JG, 2000, EMERGING INFECTIONS 4, P45; BREMAN JG, 1977, AM J TROP MED HYG, V26, P273, DOI 10.4269/ajtmh.1977.26.273; Chen NH, 2005, VIROLOGY, V340, P46, DOI 10.1016/j.virol.2005.05.030; FOSTER SO, 1972, B WORLD HEALTH ORGAN, V46, P569; Grinnell J, 1917, AM NAT, V51, P115, DOI 10.1086/279591; HOLT RD, 1992, EVOL ECOL, V6, P433, DOI 10.1007/BF02270702; Hutin YJF, 2001, EMERG INFECT DIS, V7, P434; JANSEGHERS L, 1984, ANN SOC BELG MED TR, V64, P295; JEZEK Z, 1986, J INFECT DIS, V154, P551, DOI 10.1093/infdis/154.4.551; Jezek Z, 1983, J Hyg Epidemiol Microbiol Immunol, V27, P13; KHODAKEVICH L, 1986, LANCET, V1, P98; LADNYJ ID, 1972, B WORLD HEALTH ORGAN, V46, P593; Learned LA, 2005, AM J TROP MED HYG, V73, P428, DOI 10.4269/ajtmh.2005.73.428; Likos AM, 2005, J GEN VIROL, V86, P2661, DOI 10.1099/vir.0.81215-0; Meyer A, 1991, Med Trop (Mars), V51, P53; Peterson AT, 2006, EMERG INFECT DIS, V12, P1822; Peterson AT, 1999, ECOL MODEL, V117, P159, DOI 10.1016/S0304-3800(99)00023-X; Peterson AT, 2003, INT J PARASITOL, V33, P919, DOI 10.1016/S0020-7519(03)00094-8; Peterson AT, 2004, EMERG INFECT DIS, V10, P2073, DOI 10.3201/eid1012.040346; Peterson AT, 2004, EMERG INFECT DIS, V10, P40, DOI 10.3201/eid1001.030125; Peterson AT, 2002, EMERG INFECT DIS, V8, P662, DOI 10.3201/eid0807.010454; Soberon Jorge, 2005, Biodiversity Informatics, V2, P1; Stockwell D, 1999, INT J GEOGR INF SCI, V13, P143, DOI 10.1080/136588199241391; Stockwell DRB, 2002, ECOL MODEL, V148, P1, DOI 10.1016/S0304-3800(01)00388-X; STOCKWELL DRB, 1992, MATH COMPUT SIMULAT, V33, P385, DOI 10.1016/0378-4754(92)90126-2; 1991, WKLY EPIDEMIOL REC, V67, P101	28	68	72	8	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2007	2	1							e176	10.1371/journal.pone.0000176	http://dx.doi.org/10.1371/journal.pone.0000176			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DH	17268575	Green Submitted, gold, Green Published			2022-12-25	WOS:000207444200001
J	Angeloni, D; Danilkovitch-Miagkova, A; Ivanova, T; Braga, E; Zabarovsky, E; Lerman, MI				Angeloni, D.; Danilkovitch-Miagkova, A.; Ivanova, T.; Braga, E.; Zabarovsky, E.; Lerman, M. I.			Hypermethylation of Ron proximal promoter associates with lack of full-length Ron and transcription of oncogenic short-Ron from an internal promoter	ONCOGENE			English	Article						3p21.3; differentiation; erythroleukemia; lung cancer; promoter methylation; Ron (MST1R)	RECEPTOR TYROSINE KINASE; ACTIVATION; FAMILY; CANCER; GENE; MET; PROGRESSION; DOMAIN; MOUSE; CELLS	The gene for tyrosine-kinase receptor Ron (MST1R) resides in the chromosome 3p21.3 region, frequently affected in common human malignancies. The gene generates two transcripts, 5 and 2 kb-long, full-length Ron (flRon) and short-form Ron (sfRon), respectively. Here, we show for the first time that the variegated Ron expression is associated with variations in the methylation patterns of two distinct CpG islands in Ron proximal promoter. Widespread hypermethylation associates with lack of flRon whereas hypermethylation of the distal island associates with transcription of sfRon, a constitutively active tyrosine-kinase that drives cell proliferation. sfRon inhibition with kinase-dead transgenes decreases cancer cell growth and induces cellular differentiation. sfRon could be a new drug target in cancer types in which it contributes to tumor progression.	NCI, Ctr Canc Res, Immunol Lab, Frederick, MD USA; Karolinska Inst, MTC, Stockholm, Sweden; Russian Acad Med Sci, Blokhin Canc Res Ctr, Inst Carcinogenesis, Moscow, Russia; CNR, Scuola Super St Anna, Inst Clin Physiol, Pisa, Italy; Russian State Genet Ctr, Lab Mol Diagnost, Moscow, Russia; Osiris Therapeut Inc, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Karolinska Institutet; N.N. Blokhin Russian Cancer Research Center; Russian Academy of Medical Sciences; Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR); Scuola Superiore Sant'Anna; Osiris Therapeutics	Angeloni, D (corresponding author), Scuola Super Sant Anna, Inst Clin Physiol, Via Mourzzi,1, I-56124 Pisa, Italy.	angeloni@ifc.cnr.it	Zabarovsky, Eugene R/A-6645-2010; Braga, Eleonora A./P-5574-2016	Braga, Eleonora/0000-0001-5188-4094; Angeloni, Debora/0000-0002-3850-5392	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC008579] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Angeloni D, 2004, J BIOL CHEM, V279, P3726, DOI 10.1074/jbc.M309342200; Angeloni D, 2000, GENE CHROMOSOME CANC, V29, P147, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1015>3.3.CO;2-E; Bardella C, 2004, CANCER RES, V64, P5154, DOI 10.1158/0008-5472.CAN-04-0600; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Camp ER, 2005, ANN SURG ONCOL, V12, P273, DOI 10.1245/ASO.2005.08.013; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Correll Pamela H., 1997, Genes and Function, V1, P69; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; DELGATTO F, 1995, BBA-GENE STRUCT EXPR, V1263, P93, DOI 10.1016/0167-4781(95)00082-R; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Ghigna C, 2005, MOL CELL, V20, P881, DOI 10.1016/j.molcel.2005.10.026; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; JOHNSON BE, 1988, CANCER RES, V48, P5163; Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; Persons DA, 1999, NAT GENET, V23, P159, DOI 10.1038/13787; Phelps RM, 1996, J CELL BIOCHEM, P32; RONSIN C, 1993, ONCOGENE, V8, P1195; Saleh A, 2004, IMMUNITY, V21, P55, DOI 10.1016/j.immuni.2004.06.005; Sambrook J, 2001, MOL CLONING LAB MANU; SUDA T, 1997, LEUKEMIA, V3, P451; Talley CJ, 1997, AM J HEMATOL, V54, P301, DOI 10.1002/(SICI)1096-8652(199704)54:4<301::AID-AJH7>3.0.CO;2-Z; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Villa-Moruzzi E, 1998, BIOCHEM J, V336, P235, DOI 10.1042/bj3360235; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI11881; Wang MH, 1996, EXP CELL RES, V226, P39, DOI 10.1006/excr.1996.0200; Wei X, 2005, J BIOL CHEM, V280, P40241, DOI 10.1074/jbc.M506806200	29	37	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4499	4512		10.1038/sj.onc.1210238	http://dx.doi.org/10.1038/sj.onc.1210238			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297469				2022-12-25	WOS:000247836100004
J	Liu, X; Hu, Y; Hao, C; Rempel, SA; Ye, K				Liu, X.; Hu, Y.; Hao, C.; Rempel, S. A.; Ye, K.			PIKE-A is a proto-oncogene promoting cell growth, transformation and invasion	ONCOGENE			English	Article						PIKE-A; Akt; proto-oncogene; transformation; cell invasion	HUMAN-MALIGNANT GLIOMAS; PROTEIN-KINASE B/AKT; NUCLEAR GTPASE; AKT; AMPLIFICATION; PHOSPHORYLATION; ONCOGENE; CANCER; HETEROZYGOSITY; IDENTIFICATION	PIKE-A (phosphoinositide 3-kinases (PI 3)-kinase enhancer) is a ubiquitously expressed GTPase, which binds to and enhances protein kinase B (Akt) kinase activity in a guanine nucleotide-dependent manner. PIKE-A is one of the components of the CDK4 amplicon that is ampli. ed in numerous human cancers. However, whether PIKE-A itself can mediate cell transformation, proliferation and migration remains unknown. Here, we show that PIKE-A is overexpressed in various human cancer samples, escalates U87MG glioblastoma invasion and provokes NIH3T3 cell transformation. Overexpression of wild-type (WT) PIKE-A enhances NIH3T3 and U87MG cell growth, which is further increased by cancer cell-derived PIKE-A active mutants. In contrast, both the dominant-negative mutant and the phosphoinositide lipids interaction-defective mutant antagonize cell proliferation. Moreover, PIKE-A and its active and inactive mutants similarly enhance or antagonize U87MG cell survival and invasion, and their ability to do so is coupled with the catalytic effect they have on Akt activation. Furthermore, PIKE-A WT and its active mutants signifi. cantly elicit NIH3T3 cell transformation. Thus, our. ndings support the concept that PIKE-A acts as a proto-oncogene, promoting cell transformation through Akt activation.	Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Henry Ford Hosp, Hermelin Brain Tumor Ctr, Dept Neurosurg, Barbara Jane Levy Lab Mol Neurooncol, Detroit, MI 48202 USA	Emory University; Henry Ford Health System; Henry Ford Hospital	Ye, K (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Room 145,Whitehead Bldg,615 Michael St, Atlanta, GA 30322 USA.	kye@emory.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045627] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS045627] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn JY, 2004, EMBO J, V23, P3995, DOI 10.1038/sj.emboj.7600392; Ahn JY, 2004, P NATL ACAD SCI USA, V101, P6993, DOI 10.1073/pnas.0400921101; Ahn JY, 2004, J BIOL CHEM, V279, P16441, DOI 10.1074/jbc.M312175200; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Coffer PJ, 1998, BIOCHEM J, V335, P1; COLLINS VP, 1995, GLIA, V15, P289, DOI 10.1002/glia.440150309; COX AD, 1994, METHOD ENZYMOL, V238, P277; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Hu YX, 2005, P NATL ACAD SCI USA, V102, P16853, DOI 10.1073/pnas.0507365102; Huang ZY, 2002, ONCOGENE, V21, P1325, DOI 10.1038/sj.onc.1205206; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Park BK, 2001, CANCER RES, V61, P7647; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Rempel SA, 2001, J NEURO-ONCOL, V53, P149, DOI 10.1023/A:1012201300188; Rong R, 2003, NAT NEUROSCI, V6, P1153, DOI 10.1038/nn1134; SMITH SH, 1992, CANCER RES, V52, P3746; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Ye KQ, 2000, CELL, V103, P919, DOI 10.1016/S0092-8674(00)00195-1; Ye KQ, 2005, J CELL BIOCHEM, V96, P463, DOI 10.1002/jcb.20549; Ye KQ, 2002, NATURE, V415, P541, DOI 10.1038/415541a	28	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4918	4927		10.1038/sj.onc.1210290	http://dx.doi.org/10.1038/sj.onc.1210290			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17297440				2022-12-25	WOS:000248322500004
J	Welch, C; Chen, Y; Stallings, RL				Welch, C.; Chen, Y.; Stallings, R. L.			MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells	ONCOGENE			English	Article						apoptosis; CGH; E2F3; microRNA; neuroblastoma; tumour suppressors	CHRONIC LYMPHOCYTIC-LEUKEMIA; N-MYC; HEPATOCELLULAR-CARCINOMA; COPY NUMBER; SHORT ARM; GENES; DIFFERENTIATION; EXPRESSION; DELETIONS; HETEROZYGOSITY	Neuroblastoma (NB) is one of the most common forms of cancer in children, accounting for 15% of pediatric cancer deaths. The clinical course of these tumors is highly variable and is dependent on such factors as age at presentation, stage, ploidy and genomic abnormalities. Hemizygous deletion of chromosome 1p occurs in approximately 30% of advanced stage tumors, is associated with a poor prognosis, and likely leads to the loss of one or more tumor suppressor genes. We show here that microRNA (miRNA)-34a (1p36.23) is generally expressed at lower levels in unfavorable primary NB tumors and cell lines relative to normal adrenal tissue and that reintroduction of this miRNA into three different NB cell lines causes a dramatic reduction in cell proliferation through the induction of a caspase-dependent apoptotic pathway. As a potential mechanistic explanation for this observation, we demonstrate that miR-34a directly targets the messenger ribonucleic acid (mRNA) encoding E2F3 and signi. cantly reduces the levels of E2F3 protein, a potent transcriptional inducer of cell-cycle progression. Furthermore, miR-34a expression increases during retinoic acid-induced differentiation of the SK-N-BE cell line, whereas E2F3 protein levels decrease. Thus, addingto the increasing role of miRNAs in cancer, miR-34a may act as a suppressor of NB tumorgenesis.	Univ Texas, Hlth Sci Ctr, Childrens Canc Res Inst, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Stallings, RL (corresponding author), Univ Texas, Hlth Sci Ctr, Childrens Canc Res Inst, 8403 Floyd Curl Dr,MC 7784, San Antonio, TX 78284 USA.	STALLINGS@uthscsa.edu	Stallings, Raymond/A-7213-2008					Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Ejeskar K, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-161; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Janoueix-Lerosey I, 2004, ONCOGENE, V23, P5912, DOI 10.1038/sj.onc.1207784; Johnson DG, 2006, CURR MOL MED, V6, P731; Lin YW, 1999, EUR J CANCER, V35, P1730, DOI 10.1016/S0959-8049(99)00205-1; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; Mosse YP, 2005, GENE CHROMOSOME CANC, V43, P390, DOI 10.1002/gcc.20198; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Spitz R, 2003, CLIN CANCER RES, V9, P52; Stallings RL, 2006, CANCER RES, V66, P3673, DOI 10.1158/0008-5472.CAN-05-4154; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Valentijn LJ, 2005, CANCER RES, V65, P3136, DOI 10.1158/0008-5472.CAN-04-2469; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618	27	639	695	0	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					5017	5022		10.1038/sj.onc.1210293	http://dx.doi.org/10.1038/sj.onc.1210293			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17297439				2022-12-25	WOS:000248322500014
J	Goubern, M; Andriamihaja, M; Nubel, T; Blachier, F; Bouillaud, F				Goubern, Marc; Andriamihaja, Mireille; Nubel, Tobias; Blachier, Francois; Bouillaud, Frederic			Sulfide, the first inorganic substrate for human cells	FASEB JOURNAL			English	Article						mitochondria; oxidation; cytochrome oxidase; gut epithelium; colon	SULFATE-REDUCING BACTERIA; HYDROGEN-SULFIDE; ULCERATIVE-COLITIS; CHROMATIUM-VINOSUM; HUMAN-COLON; OXIDATIVE-PHOSPHORYLATION; QUINONE REDUCTASE; ARENICOLA-MARINA; LARGE-INTESTINE; MITOCHONDRIA	Hydrogen sulfide ( H2S) is produced inside the intestine and is known as a poison that inhibits cellular respiration at the level of cytochrome oxidase. However, sulfide is used as an energetic substrate by many photo- and chemoautotrophic bacteria and by animals such as the lugworm Arenicola marina. The concentrations of sulfide present in their habitats are comparable with those present in the human colon. Using permeabilized colonic cells to which sulfide was added by an infusion pump we show that the maximal respiratory rate of colonocyte mitochondria in presence of sulfide compares with that obtained with succinate or L- alpha-glycerophosphate. This oxidation is accompanied by mitochondrial energization. In contrast, other cell types not naturally exposed to high concentration of sulfide showed much lower oxidation rates. Mitochondria showed a very high affinity for sulfide that permits its use as an energetic substrate at low micromolar concentrations, hence, below the toxic level. However, if the supply of sulfide exceeds the oxidation rate, poisoning renders mitochondria inefficient and our data suggest that an anaerobic mechanism involving partial reversion of Krebs cycle already known in invertebrates takes place. In conclusion, this work provides additional and compelling evidence that sulfide is not only a toxic compound. According to our study, sulfide appears to be the first inorganic substrate for mammalian cells characterized thus far.-Goubern, M., Andriamihaja, M., Nubel, T., Blachier, F., Bouillaud, F. Sulfide, the first inorganic substrate for human cells.	Univ Paris 05, CNRS, UPR9078, F-75730 Paris 15, France; INRA, Ecole Prat Hautes Etud, UR909, F-78352 Jouy En Josas, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Bouillaud, F (corresponding author), Univ Paris 05, CNRS, UPR9078, Site Necker 156 Rue Vaugirard, F-75730 Paris 15, France.	bouillaud@necker.fr	Bouillaud, Frédéric R/L-3238-2017	Bouillaud, Frédéric R/0000-0002-7518-9237				Attene-Ramos MS, 2006, MOL CANCER RES, V4, P9, DOI 10.1158/1541-7786.MCR-05-0126; Bronstein M, 2000, J BACTERIOL, V182, P3336, DOI 10.1128/JB.182.12.3336-3344.2000; Cortes P, 2000, BBA-BIOENERGETICS, V1456, P67, DOI 10.1016/S0005-2728(99)00109-7; Doeller JE, 2001, J EXP BIOL, V204, P3755; Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060; Fiorucci S, 2006, GASTROENTEROLOGY, V131, P259, DOI 10.1053/j.gastro.2006.02.033; FLORIN T, 1991, GUT, V32, P766, DOI 10.1136/gut.32.7.766; Furne J, 2001, BIOCHEM PHARMACOL, V62, P255, DOI 10.1016/S0006-2952(01)00657-8; Gaudio E, 1999, DIGEST DIS SCI, V44, P1458, DOI 10.1023/A:1026620322859; GIBSON GR, 1988, J APPL BACTERIOL, V65, P241, DOI 10.1111/j.1365-2672.1988.tb01891.x; Griesbeck C, 2002, BIOCHEMISTRY-US, V41, P11552, DOI 10.1021/bi026032b; Grieshaber MK, 1998, ANNU REV PHYSIOL, V60, P33, DOI 10.1146/annurev.physiol.60.1.33; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Leschelle X, 2005, BBA-GEN SUBJECTS, V1725, P201, DOI 10.1016/j.bbagen.2005.06.002; Leung FW, 2000, DIGEST DIS SCI, V45, P1472, DOI 10.1023/A:1005545128954; Levine J, 1998, AM J GASTROENTEROL, V93, P83, DOI 10.1111/j.1572-0241.1998.083_c.x; Levitt MD, 2002, J APPL PHYSIOL, V92, P1655, DOI 10.1152/japplphysiol.00907.2001; MACFARLANE GT, 1992, J APPL BACTERIOL, V72, P57, DOI 10.1111/j.1365-2672.1992.tb05187.x; Magee EA, 2000, AM J CLIN NUTR, V72, P1488; NICHOLLS P, 1975, BIOCHIM BIOPHYS ACTA, V396, P24, DOI 10.1016/0005-2728(75)90186-3; Pattaragulwanit K, 1998, ARCH MICROBIOL, V169, P434, DOI 10.1007/s002030050594; PETERSEN LC, 1977, BIOCHIM BIOPHYS ACTA, V460, P299, DOI 10.1016/0005-2728(77)90216-X; Pitcher MCL, 2000, GUT, V46, P64, DOI 10.1136/gut.46.1.64; Pitcher MCL, 1996, GUT, V39, P1, DOI 10.1136/gut.39.1.1; Pott AS, 1998, MICROBIOL-SGM, V144, P1881, DOI 10.1099/00221287-144-7-1881; POWELL MA, 1986, SCIENCE, V233, P563, DOI 10.1126/science.233.4763.563; Ramasamy S, 2006, AM J PHYSIOL-GASTR L, V291, pG288, DOI 10.1152/ajpgi.00324.2005; Reinartz M, 1998, ARCH MICROBIOL, V170, P59, DOI 10.1007/s002030050615; Roediger WEW, 1997, DIGEST DIS SCI, V42, P1571, DOI 10.1023/A:1018851723920; SVENSON A, 1980, ANAL BIOCHEM, V107, P51, DOI 10.1016/0003-2697(80)90490-X; Theissen U, 2003, MOL BIOL EVOL, V20, P1564, DOI 10.1093/molbev/msg174; Vande Weghe JG, 1999, J BIOL CHEM, V274, P13250, DOI 10.1074/jbc.274.19.13250; VIDAL H, 1988, J BIOL CHEM, V263, P9206; Volkel S, 1996, EUR J BIOCHEM, V235, P231, DOI 10.1111/j.1432-1033.1996.00231.x; Wang R, 2002, FASEB J, V16, P1792, DOI 10.1096/fj.02-0211hyp; WATT J, 1973, GUT, V14, P506, DOI 10.1136/gut.14.6.506; Yong R, 2001, COMP BIOCHEM PHYS B, V129, P129, DOI 10.1016/S1096-4959(01)00309-8; ZWEIBAUM A, 1985, J CELL PHYSIOL, V122, P21, DOI 10.1002/jcp.1041220105	40	296	309	1	47	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1699	1706		10.1096/fj.06-7407com	http://dx.doi.org/10.1096/fj.06-7407com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314140				2022-12-25	WOS:000246866500011
J	Ma, BY; Nakamura, N; Dlabac, V; Naito, H; Yamaguchi, S; Ishikawa, M; Nonaka, M; Ishiguro, M; Kawasaki, N; Oka, S; Kawasaki, T				Ma, Bruce Yong; Nakamura, Natsuko; Dlabac, Vladimir; Naito, Haruna; Yamaguchi, Shinsuke; Ishikawa, Makiko; Nonaka, Motohiro; Ishiguro, Masaji; Kawasaki, Nobuko; Oka, Shogo; Kawasaki, Toshisuke			Isolation, cloning, and characterization of a novel phosphomannan-binding lectin from porcine serum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE DEFENSE; 2 PARTS; PROTEIN; COMPLEMENT; PATHWAY; VIRUS; COLLECTINS; PROTECTION; INFECTION; SUSCEPTIBILITY	Mannan-binding protein (MBP) is a C-type serum lectin that is an important constituent of the innate immune defense because it activates the complement system via the lectin pathway. While the pig has been proposed to be an attractive source of xenotransplantable tissues and organs, little is known about porcine MBP. In our previous studies, phosphomannan, but not mannan, was found to be an effective inhibitor of the C1q-independent bactericidal activity of newborn piglet serum against some rough strains of Gram-negative bacteria. In contrast, the inhibitory activities of phosphomannan and mannan were very similar in the case of MBP-dependent bactericidal activity against rough strains of Escherichia coli K-12 and S-16. Based on these findings, we inferred that an MBP-like lectin with slightly or completely different carbohydrate binding specificity might exist in newborn piglet serum and be responsible for the C1-qindependent bactericidal activity. Herein we report that a novel phosphomannan-binding lectin (PMBL) of 33 kDa under reducing conditions was isolated from both newborn and adult porcine serum and characterized. Porcine PMBL functionally activated the complement system via the lectin pathway triggered by binding with both phosphomannan (P-mannan) and mannan, which, unlike MBP, was effectively inhibited by mannose 6-phosphate- or galatose-containing oligosaccharides. Our observations suggest that porcine PMBL plays a critical role in the innate immune defense from the newborn stage to adulthood, and the establishment of a newborn piglet experimental model for the innate immune system studies is a valuable step toward elucidation of the physiological function and molecular mechanism of lectin pathway.	Ritsumeikan Univ, Res Ctr Glycobiotechnol, Shiga 5258577, Japan; Kyoto Univ, Dept Biol Chem, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan; Kyoto Univ, Sch Hlth Sci, Fac Med, Kyoto 6068501, Japan; Acad Sci Czech Republ, Inst Microbiol, CR-14220 Prague, Czech Republic; Suntory Inst Bioorgan Res, Shimamoto, Osaka 6188503, Japan	Ritsumeikan University; Kyoto University; Kyoto University; Czech Academy of Sciences; Institute of Microbiology of the Czech Academy of Sciences; Suntory Holdings Ltd	Kawasaki, T (corresponding author), Ritsumeikan Univ, Res Ctr Glycobiotechnol, Nojishigashi 1-1-1, Shiga 5258577, Japan.	tkawasak@fc.ritsumei.ac.jp						Agah A, 2001, IMMUNOLOGY, V102, P338, DOI 10.1046/j.1365-2567.2001.01191.x; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; DLABAC V, 1994, IMMUNOBIOLOGY, V190, P399, DOI 10.1016/S0171-2985(11)80611-X; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; Eisen DP, 2003, CLIN INFECT DIS, V37, P1496, DOI 10.1086/379324; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; Fujita T, 2002, NAT REV IMMUNOL, V2, P346, DOI 10.1038/nri800; GADJEVA M, 2003, CURR PROT IMMUNOL, P1; Hansen S, 1998, IMMUNOBIOLOGY, V199, P165, DOI 10.1016/S0171-2985(98)80025-9; HARTLEY CA, 1992, J VIROL, V66, P4358, DOI 10.1128/JVI.66.7.4358-4363.1992; Hegele RA, 2000, J INVEST MED, V48, P198; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immunol.21.120601.140954; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; Jack DL, 2003, BIOCHEM SOC T, V31, P753, DOI 10.1042/BST0310753; Janeway Jr CA, 2001, IMMUNOBIOLOGY IMMUNE; JIN HK, 1995, J CLIN INVEST, V95, P1947, DOI 10.1172/JCI117877; Kawai T, 1998, GLYCOBIOLOGY, V8, P237, DOI 10.1093/glycob/8.3.237; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; KAWASAKI N, 1983, J BIOCHEM, V94, P937, DOI 10.1093/oxfordjournals.jbchem.a134437; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LU J, 1990, J IMMUNOL, V144, P2287; Ma Y, 1997, J BIOCHEM-TOKYO, V122, P810; Ma Y, 1999, P NATL ACAD SCI USA, V96, P371, DOI 10.1073/pnas.96.2.371; Miyatake T, 1998, J IMMUNOL, V160, P4114; Mogues T, 1996, GLYCOBIOLOGY, V6, P543, DOI 10.1093/glycob/6.5.543; Nagy A, 2003, J ALLERGY CLIN IMMUN, V112, P729, DOI 10.1016/S0091-6749(03)02010-4; Nauta AJ, 2004, J IMMUNOL, V173, P3044, DOI 10.4049/jimmunol.173.5.3044; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Sachs DH, 2001, ADV IMMUNOL, V79, P129, DOI 10.1016/S0065-2776(01)79004-9; SASTRY K, 1989, J EXP MED, V170, P1175, DOI 10.1084/jem.170.4.1175; SASTRY K, 1991, J IMMUNOL, V147, P692; Schwaeble W, 2002, IMMUNOBIOLOGY, V205, P455, DOI 10.1078/0171-2985-00146; SIMMS HH, 1990, J TRAUMA, V3, P1027; Suankratay C, 1998, J IMMUNOL, V160, P3006; Thomas CA, 2000, J EXP MED, V191, P147, DOI 10.1084/jem.191.1.147; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506	37	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12963	12975		10.1074/jbc.M611820200	http://dx.doi.org/10.1074/jbc.M611820200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17324926	hybrid			2022-12-25	WOS:000245942800067
J	Schmid, GM; Meda, P; Caille, D; Wargent, E; O'Dowd, J; Hochstrasser, DF; Cawthorne, MA; Sanchez, JC				Schmid, Gerhard M.; Meda, Paolo; Caille, Dorothee; Wargent, Ed; O'Dowd, Jacqueline; Hochstrasser, Denis F.; Cawthorne, Michael A.; Sanchez, Jean-Charles			Inhibition of insulin secretion by betagranin, an N-terminal chromogranin A fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOINHIBITORY ACTIVITY; PANCREATIC-ISLETS; MESSENGER-RNA; CELL-LINE; LEPTIN; PEPTIDES; RAT; EXPRESSION; VASOSTATINS; ACTIVATION	Betagranin, an N-terminal fragment of chromogranin A, results from a proteolytic processing, and is co-secreted with insulin. While other chromogranin A-derived peptides negatively modulate hormone secretion, the role of betagranin in pancreatic beta-cells is so far unknown. We have recently shown that pancreatic islet betagranin levels are down-regulated in obese, leptin-deficient mice. In the present study, we have investigated the distribution of betagranin in primary mouse islets and cells of the MIN6 line and have evaluated its effects on insulin secretion. We showed that betagranin co-localizes with insulin within secretory granules and strongly inhibited insulin secretion in response to both glucose and potassium, by blocking the influx of calcium. The data demonstrated a hitherto unknown inhibitory effect of betagranin on insulin secretion.	Univ Geneva, Dept Struct Biol & Bioinformat, BPRG, CH-1211 Geneva 4, Switzerland; Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Sanchez, JC (corresponding author), Univ Geneva, Dept Struct Biol & Bioinformat, BPRG, CH-1211 Geneva 4, Switzerland.	Jean-Charles.Sanchez@medecine.unige.ch		Wargent, Edward/0000-0002-8545-2430				AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Ahren B, 1999, AM J PHYSIOL-REG I, V277, pR959, DOI 10.1152/ajpregu.1999.277.4.R959; Andrades JA, 2001, GROWTH FACTORS, V18, P261, DOI 10.3109/08977190109029115; ANGELETTI RH, 1994, ACTA PHYSIOL SCAND, V152, P11, DOI 10.1111/j.1748-1716.1994.tb09780.x; ARDEN SD, 1994, BIOCHEM J, V298, P521, DOI 10.1042/bj2980521; Blois A, 2006, REGUL PEPTIDES, V134, P30, DOI 10.1016/j.regpep.2005.11.003; Bosco D, 2005, DIABETOLOGIA, V48, P1523, DOI 10.1007/s00125-005-1816-1; Calabrese A, 2003, DIABETES, V52, P417, DOI 10.2337/diabetes.52.2.417; Cerra MC, 2006, BASIC RES CARDIOL, V101, P43, DOI 10.1007/s00395-005-0547-2; DREES BM, 1991, ENDOCRINOLOGY, V129, P3381, DOI 10.1210/endo-129-6-3381; Emilsson V, 1997, DIABETES, V46, P313, DOI 10.2337/diabetes.46.2.313; FASCIOTTO BH, 1993, ENDOCRINOLOGY, V133, P461, DOI 10.1210/en.133.2.461; Fehmann HC, 1997, ACTA DIABETOL, V34, P249, DOI 10.1007/s005920050083; Feldman SA, 2003, ENDOCR PATHOL, V14, P3, DOI 10.1385/EP:14:1:3; Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200; Ghia JE, 2004, REGUL PEPTIDES, V121, P31, DOI 10.1016/j.regpep.2004.04.003; Grodsky G M, 1975, Methods Enzymol, V39, P364; Harvey J, 1997, J PHYSIOL-LONDON, V504, P527, DOI 10.1111/j.1469-7793.1997.527bd.x; HENDY GN, 1995, CLIN INVEST MED, V18, P47; Houseknecht KL, 1998, J ANIM SCI, V76, P1405; HUTTON JC, 1987, BIOCHEM J, V244, P449, DOI 10.1042/bj2440449; HUTTON JC, 1985, FEBS LETT, V188, P336, DOI 10.1016/0014-5793(85)80398-7; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; Kulkarni RN, 1997, J CLIN INVEST, V100, P2729, DOI 10.1172/JCI119818; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lam NT, 2004, J MOL ENDOCRINOL, V32, P415, DOI 10.1677/jme.0.0320415; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Maget-Dana R, 2002, ANN NY ACAD SCI, V971, P352, DOI 10.1111/j.1749-6632.2002.tb04494.x; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; McVicar CM, 2001, J NEUROENDOCRINOL, V13, P588, DOI 10.1046/j.1365-2826.2001.00671.x; MEDA P, 1990, J CLIN INVEST, V86, P759, DOI 10.1172/JCI114772; Pallett AL, 1997, BIOCHEM BIOPH RES CO, V238, P267, DOI 10.1006/bbrc.1997.7274; RUSSELL J, 1994, ENDOCRINOLOGY, V135, P337, DOI 10.1210/en.135.1.337; Sanchez JC, 2002, MOL CELL PROTEOMICS, V1, P509, DOI 10.1074/mcp.M200033-MCP200; Scherl A, 2005, J MICROBIOL METH, V60, P247, DOI 10.1016/j.mimet.2004.09.017; Seufert J, 2004, DIABETES, V53, pS152, DOI 10.2337/diabetes.53.2007.S152; Sharp GWG, 1996, AM J PHYSIOL-CELL PH, V271, pC1781, DOI 10.1152/ajpcell.1996.271.6.C1781; Stridsberg M, 2000, ADV EXP MED BIOL, V482, P319; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Tota B, 2003, REGUL PEPTIDES, V114, P123, DOI 10.1016/S0167-0115(03)00112-5; Tsiotra PC, 2001, INT J OBESITY, V25, P1018, DOI 10.1038/sj.ijo.0801657; Vives-Pi M, 2003, CLIN EXP IMMUNOL, V133, P208, DOI 10.1046/j.1365-2249.2003.02211.x; Wang H, 2001, BIOCHEM BIOPH RES CO, V289, P161, DOI 10.1006/bbrc.2001.5915; WATKINSON A, 1991, BIOCHEM J, V276, P471, DOI 10.1042/bj2760471; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	47	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12717	12724		10.1074/jbc.M700788200	http://dx.doi.org/10.1074/jbc.M700788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17289672	hybrid			2022-12-25	WOS:000245942800041
J	Hasegawa, M; Kawasaki, A; Yang, K; Fujimoto, Y; Masumoto, J; Breukink, E; Nunez, G; Fukase, K; Inohara, N				Hasegawa, Mizuho; Kawasaki, Akiko; Yang, Kangkang; Fujimoto, Yukari; Masumoto, Junya; Breukink, Eefjan; Nunez, Gabriel; Fukase, Koichi; Inohara, Naohiro			A role of lipophilic peptidoglycan-related molecules in induction of Nod1-mediated immune responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; INTESTINAL EPITHELIAL-CELLS; BACTERIAL PEPTIDOGLYCAN; HOST RECOGNITION; NOD1 VARIATION; ASSOCIATION; ACTIVATION; RECRUITMENT; CARD4/NOD1; RECEPTOR	Nod1 is an intracellular protein that is involved in recognition of bacterial molecules and whose genetic variation has been linked to several inflammatory diseases. Previous studies suggested that the recognition core of Nod1 stimulatory molecules is gamma-D-glutamyl-meso-diaminopimelic acid ( iE-DAP), but the identity of the major Nod1 stimulatory molecule produced by bacteria remains unknown. Here we show that bacteria produce lipophilic molecules capable of stimulating Nod1. Analysis of synthetic compounds revealed stereoselectivity of the DAP residue and that conjugation of lipophilic acyl residues specifically enhances the Nod1 stimulatory activity of the core iE-DAP. Furthermore, we demonstrate that lipophilic molecules induce and/or enhance the secretion of innate immune mediators from primary mouse mesothelial cells and human monocytic Mono-Mac6 cells, and this effect is mediated through Nod1. These results provide insight into the mechanism of immune recognition via Nod1, which might be useful in the design and testing of novel immunoregulators.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Osaka Univ, Grad Sch Sci, Dept Chem, Toyonaka, Osaka 5600043, Japan; Univ Utrecht, Dept Biochem Membranes, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Osaka University; Utrecht University	Inohara, N (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	ino@umich.edu	Breukink, Eefjan/I-3039-2016; Nuñez, Gabriel/A-7160-2014; Fujimoto, Yukari/M-7282-2014	Breukink, Eefjan/0000-0002-7311-0660; Fujimoto, Yukari/0000-0001-5320-3192				Barnich N, 2005, J CELL BIOL, V170, P21, DOI 10.1083/jcb.200502153; Boughan PK, 2006, J BIOL CHEM, V281, P11637, DOI 10.1074/jbc.M510275200; Breukink E, 2003, J BIOL CHEM, V278, P19898, DOI 10.1074/jbc.M301463200; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; Eder W, 2006, ALLERGY, V61, P1117, DOI 10.1111/j.1398-9995.2006.01128.x; Gao Y, 1998, J ORG CHEM, V63, P2133, DOI 10.1021/jo972133h; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; GOTO T, 1987, IMMUNOSTIMULANTS NOW, P99; Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200; Hasegawa M, 2006, J BIOL CHEM, V281, P29054, DOI 10.1074/jbc.M602638200; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; Hvorup RN, 2003, EUR J BIOCHEM, V270, P799, DOI 10.1046/j.1432-1033.2003.03418.x; Hysi P, 2005, HUM MOL GENET, V14, P935, DOI 10.1093/hmg/ddi087; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Masumoto J, 2006, J EXP MED, V203, P203, DOI 10.1084/jem.20051229; McGovern DPB, 2005, HUM MOL GENET, V14, P1245, DOI 10.1093/hmg/ddi135; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Opitz B, 2006, J IMMUNOL, V176, P484, DOI 10.4049/jimmunol.176.1.484; Park JH, 2007, J IMMUNOL, V178, P2380, DOI 10.4049/jimmunol.178.4.2380; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; Tanabe T, 2006, BBA-MOL BASIS DIS, V1762, P794, DOI 10.1016/j.bbadis.2006.07.006; TOMASIC J, 1980, BIOCHIM BIOPHYS ACTA, V629, P77, DOI 10.1016/0304-4165(80)90266-4; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Weidinger S, 2005, J ALLERGY CLIN IMMUN, V116, P177, DOI 10.1016/j.jaci.2005.02.034	31	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11757	11764		10.1074/jbc.M700846200	http://dx.doi.org/10.1074/jbc.M700846200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322292	hybrid			2022-12-25	WOS:000245941900018
J	Lakshmipathy, SK; Tomic, S; Kaiser, CM; Chang, HC; Genevaux, P; Georgopoulos, C; Barral, JM; Johnson, AE; Hartl, FU; Etchells, SA				Lakshmipathy, Sathish K.; Tomic, Sladjana; Kaiser, Christian M.; Chang, Hung-Chun; Genevaux, Pierre; Georgopoulos, Costa; Barral, Jose M.; Johnson, Arthur E.; Hartl, F. Ulrich; Etchells, Stephanie A.			Identification of nascent chain interaction sites on trigger factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FACTOR-BINDING; POLYPEPTIDE-CHAINS; PROLYL ISOMERASE; RIBOSOME; CHAPERONE; PROTEIN; DNAK; DOMAIN; SPECIFICITY	The role of ribosome-binding molecular chaperones in protein folding is not yet well understood. Trigger factor (TF) is the first chaperone to interact with nascent polypeptides as they emerge from the bacterial ribosome. It binds to the ribosome as a monomer but forms dimers in free solution. Based on recent crystal structures, TF has an elongated shape, with the peptidylproly/cis/trans-isomerase (PPIase) domain and the N-terminal ribosome binding domain positioned at opposite ends of the molecule and the C-terminal domain, which forms two arms, positioned in between. By using site specifically labeled TF proteins, we have demonstrated that all three domains of TF interact with nascent chains during translation. Interactions with the PPIase domain were length-dependent but independent of PPIase activity. Interestingly, with free TF, these same sites were found to be involved in forming the dimer interface, suggesting that dimerization partially occludes TF-nascent chain binding sites. Our data indicate the existence of two regions on TF along which nascent chains can interact, the NC-domains as the main site and the PPIase domain as an auxiliary site.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Ctr Med Univ Geneva, Dept Microbiol & Med Mol, CH-1211 Geneva, Switzerland; Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA	Max Planck Society; University of Geneva; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany.	uhartl@biochem.mpg.de; etchells@biochem.mpg.de	Genevaux, Pierre/A-4851-2015; Johnson, Arthur E/G-3457-2012; Hartl, F. Ulrich/Y-8206-2019	zhang, hong jun/0000-0003-0030-8323; GENEVAUX, Pierre/0000-0001-7539-3126				Agashe VR, 2004, CELL, V117, P199, DOI 10.1016/S0092-8674(04)00299-5; Baram D, 2005, P NATL ACAD SCI USA, V102, P12017, DOI 10.1073/pnas.0505581102; Blaha G, 2003, J MOL BIOL, V326, P887, DOI 10.1016/S0022-2836(02)01436-5; Chin JW, 2002, CHEMBIOCHEM, V3, P1135, DOI 10.1002/1439-7633(20021104)3:11<1135::AID-CBIC1135>3.0.CO;2-M; CROOKE E, 1987, P NATL ACAD SCI USA, V84, P5216, DOI 10.1073/pnas.84.15.5216; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Eisner G, 2003, J CELL BIOL, V163, P35, DOI 10.1083/jcb.200306069; Etchells SA, 2005, J BIOL CHEM, V280, P28118, DOI 10.1074/jbc.M504110200; Ferbitz L, 2004, NATURE, V431, P590, DOI 10.1038/nature02899; Genevaux P, 2004, EMBO REP, V5, P195, DOI 10.1038/sj.embor.7400067; Hesterkamp T, 1997, J BIOL CHEM, V272, P21865, DOI 10.1074/jbc.272.35.21865; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; Hoffmann A, 2006, J BIOL CHEM, V281, P6539, DOI 10.1074/jbc.M512345200; Houben ENG, 2005, J CELL BIOL, V170, P27, DOI 10.1083/jcb.200503035; Kaiser CM, 2006, NATURE, V444, P455, DOI 10.1038/nature05225; Kramer G, 2004, J BACTERIOL, V186, P3777, DOI 10.1128/JB.186.12.3777-3784.2004; Kramer G, 2004, J BIOL CHEM, V279, P14165, DOI 10.1074/jbc.M313635200; Kramer G, 2002, NATURE, V419, P171, DOI 10.1038/nature01047; Kristensen O, 2003, STRUCTURE, V11, P1547, DOI 10.1016/j.str.2003.11.003; Ludlam AV, 2004, P NATL ACAD SCI USA, V101, P13436, DOI 10.1073/pnas.0405868101; Maier R, 2003, J MOL BIOL, V326, P585, DOI 10.1016/S0022-2836(02)01427-4; Maier T, 2005, CURR OPIN STRUC BIOL, V15, P204, DOI 10.1016/j.sbi.2005.03.005; Merz F, 2006, J BIOL CHEM, V281, P31963, DOI 10.1074/jbc.M605164200; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Raine A, 2006, J BIOL CHEM, V281, P28033, DOI 10.1074/jbc.M605753200; Schlunzen F, 2005, STRUCTURE, V13, P1685, DOI 10.1016/j.str.2005.08.007; Scholz C, 1998, J MOL BIOL, V277, P723, DOI 10.1006/jmbi.1997.1604; Schulze-Gahmen U, 2005, ACTA CRYSTALLOGR D, V61, P1343, DOI [10.1107/S090744490502264X, 10.1107/S09074490502264X]; Shimizu Y, 2001, NAT BIOTECHNOL, V19, P751, DOI 10.1038/90802; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; Tomic S, 2006, FEBS LETT, V580, P72, DOI 10.1016/j.febslet.2005.11.050; Tradler T, 1997, FEBS LETT, V407, P184, DOI 10.1016/S0014-5793(97)00345-1; Ullers RS, 2004, P NATL ACAD SCI USA, V101, P7583, DOI 10.1073/pnas.0402398101; Vorderwulbecke S, 2004, FEBS LETT, V559, P181, DOI 10.1016/S0014-5793(04)00052-3	34	57	57	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12186	12193		10.1074/jbc.M609871200	http://dx.doi.org/10.1074/jbc.M609871200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17296610	hybrid			2022-12-25	WOS:000245941900061
J	Schelling, P; Guglielmi, KM; Kirchner, E; Paetzold, B; Dermody, TS; Stehle, T				Schelling, Pierre; Guglielmi, Kristen M.; Kirchner, Eva; Paetzold, Bernhard; Dermody, Terence S.; Stehle, Thilo			The reovirus sigma 1 aspartic acid sandwich - A trimerization motif poised for conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL ADHESION MOLECULE-1; CAPSID PROTEIN MU-1; ATTACHMENT PROTEIN; CRYSTAL-STRUCTURE; LOW-PH; SIALIC-ACID; PARTICLES; RECEPTOR; BINDING; HEMAGGLUTININ	Reovirus attachment protein sigma 1 mediates engagement of receptors on the surface of target cells and undergoes dramatic conformational rearrangements during viral disassembly in the endocytic pathway. The sigma 1 protein is a filamentous, trimeric molecule with a globular beta-barrel head domain. An unusual cluster of aspartic acid residues sandwiched between hydrophobic tyrosines is located at the sigma 1 subunit interface. A 1.75-angstrom structure of the sigma 1 head domain now reveals two water molecules at the subunit interface that are held strictly in position and interact with neighboring residues. Structural and biochemical analyses of mutants affecting the aspartic acid sandwich indicate that these residues and the corresponding chelated water molecules act as a plug to block the free flow of solvent and stabilize the trimer. This arrangement of residues at the sigma 1 head trimer interface illustrates a new protein design motif that may confer conformational mobility during cell entry.	Univ Tubingen, Interfakultares Inst Biochem, D-72076 Tubingen, Germany; Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Elizabeth B Lamb Ctr Pediat Res, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA	Eberhard Karls University of Tubingen; Vanderbilt University; Vanderbilt University; Vanderbilt University	Dermody, TS (corresponding author), Univ Tubingen, Interfakultares Inst Biochem, Hoppe Seyler Str 4, D-72076 Tubingen, Germany.	terry.dermody@vanderbilt.edu; thilo.stehle@uni-tuebingen.de	Ogden, Kristen/AAO-9276-2020	Ogden, Kristen/0000-0002-2670-4335	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067853, T32GM008554] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline; NIGMS NIH HHS [T32 GM08554, R01 GM67853] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baer GS, 1999, J VIROL, V73, P9532, DOI 10.1128/JVI.73.11.9532-9543.1999; Baer GS, 1997, J VIROL, V71, P4921, DOI 10.1128/JVI.71.7.4921-4928.1997; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barton ES, 2001, J BIOL CHEM, V276, P2200, DOI 10.1074/jbc.M004680200; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; Blanco F, 1998, CURR OPIN STRUC BIOL, V8, P107, DOI 10.1016/S0959-440X(98)80017-1; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Campbell JA, 2005, J VIROL, V79, P7967, DOI 10.1128/JVI.79.13.7967-7978.2005; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cavalli A, 2004, BIOPHYS J, V86, P3423, DOI 10.1529/biophysj.103.030825; Chandran K, 2003, J VIROL, V77, P13361, DOI 10.1128/JVI.77.24.13361-13375.2003; Chandran K, 2002, J VIROL, V76, P9920, DOI 10.1128/JVI.76.19.9920-9933.2002; Chappell JD, 1997, J VIROL, V71, P1834, DOI 10.1128/JVI.71.3.1834-1841.1997; Chappell JD, 2000, J VIROL, V74, P8472, DOI 10.1128/JVI.74.18.8472-8479.2000; Chappell JD, 2002, EMBO J, V21, P1, DOI 10.1093/emboj/21.1.1; Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DRYDEN KA, 1993, J CELL BIOL, V122, P1023, DOI 10.1083/jcb.122.5.1023; Ehrlich M, 2004, CELL, V118, P591, DOI 10.1016/j.cell.2004.08.017; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Forrest JC, 2003, J BIOL CHEM, V278, P48434, DOI 10.1074/jbc.M305649200; FRASER RDB, 1990, J VIROL, V64, P2990, DOI 10.1128/JVI.64.6.2990-3000.1990; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karlsson R, 1997, J IMMUNOL METHODS, V200, P121, DOI 10.1016/S0022-1759(96)00195-0; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIBERT ML, 1995, J VIROL, V69, P5057, DOI 10.1128/JVI.69.8.5057-5067.1995; Odegard AL, 2004, J VIROL, V78, P8732, DOI 10.1128/JVI.78.16.8732-8745.2004; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Prota AE, 2003, P NATL ACAD SCI USA, V100, P5366, DOI 10.1073/pnas.0937718100; Roche S, 2006, SCIENCE, V313, P187, DOI 10.1126/science.1127683; SIBANDA BL, 1991, METHOD ENZYMOL, V202, P59; Stehle T, 2004, VIRAL IMMUNOL, V17, P129, DOI 10.1089/0882824041310621; STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987	38	22	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11582	11589		10.1074/jbc.M610805200	http://dx.doi.org/10.1074/jbc.M610805200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303562	Green Published, hybrid			2022-12-25	WOS:000245941500079
J	Agbulut, O; Huet, A; Niederlander, N; Puceat, M; Menasche, P; Coirault, C				Agbulut, Onnik; Huet, Alexis; Niederlander, Nicolas; Puceat, Michel; Menasche, Philippe; Coirault, Catherine			Green fluorescent protein impairs actin-myosin interactions by binding to the actin-binding site of myosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRIATED-MUSCLE; SKELETAL-MUSCLE; MOTOR DOMAIN; CELLS; MODEL; SURFACE; CONTRACTION; EXPRESSION; ALGORITHM; FREQUENCY	Green fluorescent proteins ( GFP) are widely used in biology for tracking purposes. Although expression of GFP is considered to be innocuous for the cells, deleterious effects have been reported. We recently demonstrated that expression of eGFP in muscle impairs its contractile properties ( Agbulut, O., Coirault, C., Niederlander, N., Huet, A., Vicart, P., Hagege, A., Puceat, M., and Menasche, P. ( 2006) Nat. Meth. 3, 331). This prompted us to identify the molecular mechanisms linking eGFP expression to contractile dysfunction and, particularly, to test the hypothesis that eGFP could inhibit actin-myosin interactions. Therefore, we assessed the cellular, mechanical, enzymatic, biochemical, and structural properties of myosin in the presence of eGFP and F-actin. In vitro motility assays, the maximum actin-activated ATPase rate ( V-max) and the associated constant of myosin for actin ( K-m) were determined at 1:0.5, 1:1, and 1:3 myosin: eGFP molar ratios. At a myosin: eGFP ratio of 1: 0.5, there was a nearly 10-fold elevation of K-m. As eGFP concentration increased relative to myosin, the percentage of moving filaments, the myosin-based velocity, and V-max significantly decreased compared with controls. Moreover, myosin co-precipitated with eGFP. Crystal structures of myosin, actin, and GFP indicated that GFP and actin exhibited similar electrostatic surface patterns and the ClusPro docking model showed that GFP bound preferentially to the myosin head and especially to the actin-binding site. In conclusion, our data demonstrate that expression of eGFP in muscle resulted in the binding of eGFP to myosin, thereby disturbing the actin-myosin interaction and in turn the contractile function of the transduced cells. This potential adverse effect of eGFP should be kept in mind when using this marker to track cells following transplantation.	Univ Paris Diderot Paris 7, Dept Biochem, EA300, F-75005 Paris, France; INSERM U421 I Stem, F-91004 Evry, France; Hop Europeen Georges Pompidou, APHP, Dept Cardiovasc Surg, F-75014 Paris, France; Univ Paris 05, Fac Med, F-75014 Paris, France; INSERM U633, F-75014 Paris, France; Univ Paris 07, CRCIL, INSERM U689, F-75010 Paris, France	UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Agbulut, O (corresponding author), 2 Pl Jussieu Case 7006, F-75005 Paris, France.	onnik.agbulut@univ-paris-diderot.fr	Coirault, Catherine/I-2979-2016; Huet, Alexis/AAU-5958-2021; PUCEAT, michel/R-6140-2017; Coirault, Catherine/S-2454-2019	Huet, Alexis/0000-0001-6069-4460; Coirault, Catherine/0000-0002-5594-1057; PUCEAT, michel/0000-0001-9055-7563; Niederlander, Nicolas/0000-0003-1323-8387; Agbulut, Onnik/0000-0003-1923-8871				Agbulut O, 2006, NAT METHODS, V3, P331, DOI 10.1038/nmeth0506-331; Al Attar N, 2003, CARDIOVASC RES, V58, P142, DOI 10.1016/S0008-6363(02)00790-3; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; Bobkov AA, 1996, P NATL ACAD SCI USA, V93, P2285, DOI 10.1073/pnas.93.6.2285; Bobkova EA, 1999, BIOPHYS J, V76, P1001, DOI 10.1016/S0006-3495(99)77264-4; Brazelton TR, 2003, DEV BIOL, V262, P64, DOI 10.1016/S0012-1606(03)00357-9; Chen R, 2003, PROTEINS, V52, P80, DOI 10.1002/prot.10389; Chow D, 2002, J BIOL CHEM, V277, P36799, DOI 10.1074/jbc.M204101200; Coirault C, 2002, AM J RESP CRIT CARE, V165, P250, DOI 10.1164/ajrccm.165.2.2105088; Comeau SR, 2004, NUCLEIC ACIDS RES, V32, pW96, DOI 10.1093/nar/gkh354; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hanazono Y, 1997, HUM GENE THER, V8, P1313, DOI 10.1089/hum.1997.8.11-1313; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; Huang WY, 2000, NAT MED, V6, P482, DOI 10.1038/74914; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Jesaitis AJ, 1999, PROTEIN SCI, V8, P760; Krestel HE, 2004, NEUROBIOL DIS, V17, P310, DOI 10.1016/j.nbd.2004.05.012; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Liu HS, 1999, BIOCHEM BIOPH RES CO, V260, P712, DOI 10.1006/bbrc.1999.0954; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; Mendelson R, 1997, P NATL ACAD SCI USA, V94, P8533, DOI 10.1073/pnas.94.16.8533; Moores SL, 1996, P NATL ACAD SCI USA, V93, P443, DOI 10.1073/pnas.93.1.443; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; SELLERS JR, 1993, METHOD CELL BIOL, V39, P23, DOI 10.1016/S0091-679X(08)60159-4; Smyczynski C, 1997, BIOCHEMISTRY-US, V36, P13201, DOI 10.1021/bi970746i; Spudich JA, 2001, NAT REV MOL CELL BIO, V2, P387, DOI 10.1038/35073086; Srikakulam R, 2004, J CELL SCI, V117, P641, DOI 10.1242/jcs.00899; Tyska MJ, 2000, CIRC RES, V86, P737, DOI 10.1161/01.RES.86.7.737; Wang Q, 2003, J CELL SCI, V116, P4227, DOI 10.1242/jcs.00709; Zielske SP, 2004, MOL THER, V9, P923, DOI 10.1016/j.ymthe.2004.02.017	36	54	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10465	10471		10.1074/jbc.M610418200	http://dx.doi.org/10.1074/jbc.M610418200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289667	hybrid			2022-12-25	WOS:000245941000038
J	Kanayama, T; Arito, M; So, K; Hachimura, S; Inoue, J; Sato, R				Kanayama, Tomohiko; Arito, Mitsumi; So, Kanako; Hachimura, Satoshi; Inoue, Jun; Sato, Ryuichiro			Interaction between sterol regulatory element-binding proteins and liver receptor homolog-1 reciprocally suppresses their transcriptional activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL HETERODIMER PARTNER; CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; BILE-ACID BIOSYNTHESIS; COENZYME-A REDUCTASE; X-RECEPTOR; NUCLEAR RECEPTORS; DIFFERENTIAL REGULATION; PROTEASOME PATHWAY; 2 MECHANISMS; FATTY-ACIDS	In previous studies it was demonstrated that sterol regulatory element-binding proteins ( SREBPs) are able to interact with one of the nuclear receptors, hepatocyte nuclear receptor (HNF)-4, and that this interaction regulates transcriptional activities of these proteins (Misawa, K., Horiba, T., Arimura, N., Hirano, Y., Inoue, J., Emoto, N., Shimano, H., Shimizu, M., and Sato, R. (2003) J. Biol. Chem. 278, 36176 - 36182; Yamamoto, T., Shimano, H., Nakagawa, Y., Ide, T., Yahagi, N., Matsuzaka, T., Nakakuki, M., Takahashi, A., Suzuki, H., Sone, H., Toyoshima, H., Sato, R., and Yamada, N. ( 2004) J. Biol. Chem. 279, 12027 12035). In an attempt to identify other nuclear receptor family members affecting the SREBP transcriptional activities, we found that the liver receptor homolog (LRH)-1 suppresses them. Several types of luciferase assays revealed that coexpression of these two proteins (LRH- 1 and SREBP- 1a, - 1c, or - 2) results in reciprocal inhibition of the transcriptional activity of each protein. It was confirmed that suppression in endogenous LRH- 1 by small interference RNA stimulates the mRNA levels of certain SREBP target genes and that elevation in active SREBPs in the nucleus in response to cholesterol depletion suppresses the LRH- 1 activity. In vitro/ in vivo glutathione S-transferase pulldown experiments demonstrated that the basic helix-loop-helix-leucine zipper domain in SREBP- 2 binds to the ligand-binding domain in LRH- 1. Furthermore, we found that SREBP- 2 interferes with the recruitment of a coactivator of LRH-1, the peroxisome proliferator- activated receptor gamma coactivator-1 alpha, thereby leading to the inhibition of the LRH- 1 transcriptional activity. These results clearly indicate that the interaction between SREBPs and LRH-1 exerts a suppressive influence on their target gene expression responsible for cholesterol and bile acid metabolism.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; Basic Res Activities Innovat Biosci, Tokyo 1050001, Japan	University of Tokyo	Sato, R (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, 1-1-1 Yayoi, Tokyo 1138657, Japan.	aroysato@mail.ecc.u-tokyo.ac.jp	INOUE, Jun/O-7352-2016	INOUE, Jun/0000-0003-4145-3754				Agata Y, 2001, J EXP MED, V193, P873, DOI 10.1084/jem.193.7.873; Agellon LB, 2002, J BIOL CHEM, V277, P20131, DOI 10.1074/jbc.C200105200; Arimura N, 2004, J BIOL CHEM, V279, P10070, DOI 10.1074/jbc.M308522200; Bengoechea-Alonso MT, 2005, P NATL ACAD SCI USA, V102, P11681, DOI 10.1073/pnas.0501494102; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Datta S, 2006, J BIOL CHEM, V281, P807, DOI 10.1074/jbc.M511050200; del Castillo-Olivares A, 2004, J BIOL CHEM, V279, P16813, DOI 10.1074/jbc.M400646200; Delerive P, 2004, MOL ENDOCRINOL, V18, P2378, DOI 10.1210/me.2004-0132; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Hegarty BD, 2005, P NATL ACAD SCI USA, V102, P791, DOI 10.1073/pnas.0405067102; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Iwaki M, 2003, DIABETES, V52, P1655, DOI 10.2337/diabetes.52.7.1655; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kim HJ, 2004, J BIOL CHEM, V279, P28122, DOI 10.1074/jbc.M313302200; Kotzka J, 2004, J BIOL CHEM, V279, P22404, DOI 10.1074/jbc.M401198200; Krylova IN, 2005, CELL, V120, P343, DOI 10.1016/j.cell.2005.01.024; Lee YK, 2006, J BIOL CHEM, V281, P7850, DOI 10.1074/jbc.M509115200; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Li TG, 2006, J BIOL CHEM, V281, P28745, DOI 10.1074/jbc.M605815200; Li Y, 2005, P NATL ACAD SCI USA, V102, P9505, DOI 10.1073/pnas.0501204102; Li Y, 2005, MOL CELL, V17, P491, DOI 10.1016/j.molcel.2005.02.002; Lin JD, 2005, CELL, V120, P261, DOI 10.1016/j.cell.2004.11.043; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; Misawa K, 2003, J BIOL CHEM, V278, P36176, DOI 10.1074/jbc.M302387200; Nakahara M, 2005, J BIOL CHEM, V280, P42283, DOI 10.1074/jbc.M507454200; Ngo TT, 2002, J BIOL CHEM, V277, P33901, DOI 10.1074/jbc.M202135200; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Qin J, 2004, MOL ENDOCRINOL, V18, P2424, DOI 10.1210/me.2004-0009; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Safi R, 2005, CANCER RES, V65, P11762, DOI 10.1158/0008-5472.CAN-05-2792; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Wang DP, 1996, J LIPID RES, V37, P1831; Xiong SB, 2000, P NATL ACAD SCI USA, V97, P3948, DOI 10.1073/pnas.040574197; Xu PL, 2004, MOL ENDOCRINOL, V18, P1887, DOI 10.1210/me.2003-0334; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Zhang YQ, 2003, J LIPID RES, V44, P356, DOI 10.1194/jlr.M200283-JLR200	43	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10290	10298		10.1074/jbc.M700270200	http://dx.doi.org/10.1074/jbc.M700270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283069	hybrid			2022-12-25	WOS:000245941000019
J	Malet, H; Egloff, MP; Selisko, B; Butcher, RE; Wright, PJ; Roberts, M; Gruez, A; Sulzenbacher, G; Vonrhein, C; Bricogne, G; Mackenzie, JM; Khromykh, AA; Davidson, AD; Canard, B				Malet, Helene; Egloff, Marie-Pierre; Selisko, Barbara; Butcher, Rebecca E.; Wright, Peter J.; Roberts, Michael; Gruez, Arnaud; Sulzenbacher, Gerlind; Vonrhein, Clemens; Bricogne, Gerard; Mackenzie, Jason M.; Khromykh, Alexander A.; Davidson, Andrew D.; Canard, Bruno			Crystal structure of the RNA polymerase domain of the West Nile Virus non-structural protein 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; NUCLEAR-LOCALIZATION; MAXIMUM-LIKELIHOOD; VIRAL HELICASE; NS5 PROTEIN; STRAND RNA; DENGUE; TYPE-2; NUCLEOTIDE; MECHANISM	Viruses of the family Flaviviridae are important human and animal pathogens. Among them, the Flaviviruses dengue ( DENV) and West Nile ( WNV) cause regular outbreaks with fatal outcomes. The RNA-dependent RNA polymerase ( RdRp) activity of the non-structural protein 5 ( NS5) is a key activity for viral RNA replication. In this study, crystal structures of enzymatically active and inactive WNV RdRp domains were determined at 3.0- and 2.35-angstrom resolution, respectively. The determined structures were shown to be mostly similar to the RdRps of the Flaviviridae members hepatitis C and bovine viral diarrhea virus, although with unique elements characteristic for the WNVRdRp. Using a reverse genetic system, residues involved in putative interactions between the RNA-cap methyltransferase ( MTase) and the RdRp domain of Flavivirus NS5 were identified. This allowed us to propose a model for the structure of the full-length WNV NS5 by in silico docking of the WNV MTase domain ( modeled from our previously determined structure of the DENV MTase domain) onto the RdRp domain. The Flavivirus RdRp domain structure determined here should facilitate both the design of anti-Flavivirus drugs and structure-function studies of the Flavivirus replication complex in which the multifunctional NS5 protein plays a central role.	CNRS, F-13288 Marseille, France; Univ Aix Marseille 1, F-13288 Marseille, France; Univ Aix Marseille 2, UMR 6098, F-13288 Marseille, France; Monash Univ, Dept Microbiol, Melbourne, Vic 3168, Australia; Global Phasing Ltd, Cambridge CB3 0AX, England; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia; Univ Bristol, Dept Cellular & Mol Med, Bristol BS8 1TD, Avon, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Monash University; Global Phasing Limited; University of Queensland; University of Bristol	Canard, B (corresponding author), CNRS, ESIL Case 925, F-13288 Marseille, France.	bruno.canard@afmb.univ-mrs.fr	Mackenzie, Jason/H-5632-2019; Khromykh, Alexander/X-7200-2018; Sulzenbacher, Gerlind/A-6801-2018	Mackenzie, Jason/0000-0001-6613-8350; Khromykh, Alexander/0000-0001-6206-6935; Sulzenbacher, Gerlind/0000-0003-4844-2820; MALET, Helene/0000-0002-2834-7386; Canard, Bruno/0000-0003-4924-1991				Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; Adachi T, 2002, BBA-PROTEINS PROTEOM, V1601, P38, DOI 10.1016/S1570-9639(02)00433-8; Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bartelma G, 2002, VIROLOGY, V299, P122, DOI 10.1006/viro.2002.1504; Benarroch D, 2004, VIROLOGY, V328, P208, DOI 10.1016/j.virol.2004.07.004; Blanc E, 2004, ACTA CRYSTALLOGR D, V60, P2210, DOI 10.1107/S0907444904016427; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brooks AJ, 2002, J BIOL CHEM, V277, P36399, DOI 10.1074/jbc.M204977200; Bruenn JA, 2003, NUCLEIC ACIDS RES, V31, P1821, DOI 10.1093/nar/gkg277; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCKLEY A, 1992, J GEN VIROL, V73, P1125, DOI 10.1099/0022-1317-73-5-1125; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Choi KH, 2004, P NATL ACAD SCI USA, V101, P4425, DOI 10.1073/pnas.0400660101; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Egloff MP, 2002, EMBO J, V21, P2757, DOI 10.1093/emboj/21.11.2757; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Ferrer-Orta C, 2006, CURR OPIN STRUC BIOL, V16, P27, DOI 10.1016/j.sbi.2005.12.002; Ferrer-Orta C, 2004, J BIOL CHEM, V279, P47212, DOI 10.1074/jbc.M405465200; Gorbalenya AE, 2002, J MOL BIOL, V324, P47, DOI 10.1016/S0022-2836(02)01033-1; Gualano RC, 1998, J GEN VIROL, V79, P437, DOI 10.1099/0022-1317-79-3-437; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guyatt KJ, 2001, J VIROL METHODS, V92, P37, DOI 10.1016/S0166-0934(00)00270-6; Guzman MG, 2002, LANCET INFECT DIS, V2, P33, DOI 10.1016/S1473-3099(01)00171-2; Hall RA, 2002, CURR TOP MICROBIOL, V267, P253; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Johansson M, 2001, J GEN VIROL, V82, P735, DOI 10.1099/0022-1317-82-4-735; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; KAPOOR M, 1995, J BIOL CHEM, V270, P19100, DOI 10.1074/jbc.270.32.19100; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; Khromykh AA, 1999, J VIROL, V73, P10272, DOI 10.1128/JVI.73.12.10272-10280.1999; KOONIN EV, 1991, J GEN VIROL, V72, P2197, DOI 10.1099/0022-1317-72-9-2197; Lanciotti RS, 2002, VIROLOGY, V298, P96, DOI 10.1006/viro.2002.1449; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Leveque VJP, 2003, J VIROL, V77, P9020, DOI 10.1128/JVI.77.16.9020-9028.2003; Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; Nomaguchi M, 2003, J VIROL, V77, P8831, DOI 10.1128/JVI.77.16.8831-8842.2003; O'Farrell D, 2003, J MOL BIOL, V326, P1025, DOI 10.1016/S0022-2836(02)01439-0; O'Reilly EK, 1998, VIROLOGY, V252, P287, DOI 10.1006/viro.1998.9463; Pryor MJ, 1998, J GEN VIROL, V79, P2631, DOI 10.1099/0022-1317-79-11-2631; Ranjith-Kumar CT, 2002, J VIROL, V76, P12526, DOI 10.1128/JVI.76.24.12526-12536.2002; Ranjith-Kumar CT, 2002, J VIROL, V76, P12513, DOI 10.1128/JVI.76.24.12513-12525.2002; Ray D, 2006, J VIROL, V80, P8362, DOI 10.1128/JVI.00814-06; Scherret JH, 2001, EMERG INFECT DIS, V7, P697, DOI 10.3201/eid0704.010418; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Selisko B, 2006, VIROLOGY, V351, P145, DOI 10.1016/j.virol.2006.03.026; Sheldrick GM, 2002, Z KRISTALLOGR, V217, P644, DOI 10.1524/zkri.217.12.644.20662; Steffens S, 1999, J GEN VIROL, V80, P2583, DOI 10.1099/0022-1317-80-10-2583; Tao YZ, 2002, CELL, V111, P733, DOI 10.1016/S0092-8674(02)01110-8; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Thompson AA, 2004, EMBO J, V23, P3462, DOI 10.1038/sj.emboj.7600357; Uchil PD, 2006, J VIROL, V80, P5451, DOI 10.1128/JVI.01982-05; van Dijk AA, 2004, J GEN VIROL, V85, P1077, DOI 10.1099/vir.0.19731-0; WENGLER G, 1993, VIROLOGY, V197, P265, DOI 10.1006/viro.1993.1587; Yon C, 2005, J BIOL CHEM, V280, P27412, DOI 10.1074/jbc.M501393200	63	190	201	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10678	10689		10.1074/jbc.M607273200	http://dx.doi.org/10.1074/jbc.M607273200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287213	Green Published, hybrid			2022-12-25	WOS:000245941000062
J	Gutierrez, J; Paredes, R; Cruzat, F; Hill, DA; van Wijnen, AJ; Lian, JB; Stein, GS; Stein, JL; Imbalzano, AN; Montecino, M				Gutierrez, Jose; Paredes, Roberto; Cruzat, Fernando; Hill, David A.; van Wijnen, Andre J.; Lian, Jane B.; Stein, Gary S.; Stein, Janet L.; Imbalzano, Anthony N.; Montecino, Martin			Chromatin remodeling by SWI/SNF results in nucleosome mobilization to preferential positions in the rat osteocalcin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE OCTAMER; SWI-SNF; SEQUENCE MOTIFS; BINDING PROTEIN; DNA; COMPLEX; TRANSCRIPTION; ORGANIZATION; DISRUPTION; EXPRESSION	Changes in local chromatin structure accompany transcriptional activation of eukaryotic genes. In vivo these changes in chromatin organization can be catalyzed by ATP-dependent chromatin-remodeling complexes, such as SWI/SNF. These complexes alter the tight wrapping of DNA in the nucleosomes and can facilitate the mobilization of the histone octamer to adjacent DNA segments, leaving promoter regulatory elements exposed for transcription factor binding. To gain understanding of how the activity of SWI/SNF complexes may be modulated by the different DNA sequences within a natural promoter, we have reconstituted nucleosomes containing promoter segments of the transcriptionally active cell type-specific osteocalcin (OC) gene and determined how they affect the directional movements of the nucleosomes. Our results indicate that SWI/SNF complexes induce octamer sliding to preferential positions in the OC promoter, leading to a nucleosomal organization that resembles that described in intact cells expressing the OC gene. Our studies demonstrate that the position of the histone octamer is primarily determined by sequences within the OC promoter that include or exclude nucleosomes. We propose that these sequences are critical components of the regulatory mechanisms that mediate expression of this tissue-specific gene.	Univ Concepcion, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Concepcion 4079100, Chile; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA	Universidad de Concepcion; University of Massachusetts System; University of Massachusetts Worcester	Montecino, M (corresponding author), Univ Concepcion, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Barrio Univ S-N,Casilla 160-C, Concepcion 4079100, Chile.	mmonteci@udec.cl	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946; Gutierrez, Jose/0000-0002-0957-2297; Paredes, Roberto/0000-0002-6793-5404	FIC NIH HHS [5R03TW00990] Funding Source: Medline; NIAMS NIH HHS [R01 AR049069] Funding Source: Medline; NIGMS NIH HHS [GM56244] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW000990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056244] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JD, 2001, MOL CELL BIOL, V21, P3830, DOI 10.1128/MCB.21.11.3830-3839.2001; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; BRUKNER I, 1994, J MOL BIOL, V236, P26, DOI 10.1006/jmbi.1994.1115; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; Cao H, 1998, J MOL BIOL, V281, P253, DOI 10.1006/jmbi.1998.1925; Cloutier TE, 2004, MOL CELL, V14, P355, DOI 10.1016/S1097-2765(04)00210-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUBANDGOULET I, 1992, J MOL BIOL, V224, P981, DOI 10.1016/0022-2836(92)90464-U; Fan HY, 2003, MOL CELL, V11, P1311, DOI 10.1016/S1097-2765(03)00192-8; Flaus A, 1998, J MOL BIOL, V275, P427, DOI 10.1006/jmbi.1997.1464; Flaus A, 2003, MOL CELL BIOL, V23, P7767, DOI 10.1128/MCB.23.21.7767-7779.2003; GRABIALAN A, 1996, FEBS LETT, V393, P65; Gutierrez J, 2000, BIOCHEMISTRY-US, V39, P13565, DOI 10.1021/bi0013896; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hill DA, 2000, BIOCHEMISTRY-US, V39, P11649, DOI 10.1021/bi001330z; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Kassabov SR, 2003, MOL CELL, V11, P391, DOI 10.1016/S1097-2765(03)00039-X; Kiyama R, 2002, FEBS LETT, V523, P7, DOI 10.1016/S0014-5793(02)02937-X; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Montecino M, 1996, J CELL BIOCHEM, V63, P221, DOI 10.1002/(SICI)1097-4644(19961101)63:2<221::AID-JCB9>3.0.CO;2-#; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; Peterson CL, 2002, EMBO REP, V3, P319, DOI 10.1093/embo-reports/kvf075; Peterson CL, 1998, J BIOL CHEM, V273, P23641, DOI 10.1074/jbc.273.37.23641; Phelan ML, 2000, MOL CELL BIOL, V20, P6380, DOI 10.1128/MCB.20.17.6380-6389.2000; Ramakrishnan V, 1997, ANNU REV BIOPH BIOM, V26, P83, DOI 10.1146/annurev.biophys.26.1.83; Richmond TJ, 2003, NATURE, V423, P145, DOI 10.1038/nature01595; Sierra J, 2003, MOL CELL BIOL, V23, P3339, DOI 10.1128/MCB.23.9.3339-3351.2003; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; Studitsky VM, 1996, METHOD ENZYMOL, V274, P246; Thastrom A, 2004, J MOL BIOL, V338, P695, DOI 10.1016/j.jmb.2004.03.032; Thastrom A, 1999, J MOL BIOL, V288, P213, DOI 10.1006/jmbi.1999.2686; Villagra A, 2006, J BIOL CHEM, V281, P22695, DOI 10.1074/jbc.M511640200; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang YH, 1996, P NATL ACAD SCI USA, V93, P8863, DOI 10.1073/pnas.93.17.8863; Wang YH, 1996, J MOL BIOL, V263, P511, DOI 10.1006/jmbi.1996.0593; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Young DW, 2005, J CELL BIOCHEM, V94, P720, DOI 10.1002/jcb.20332; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	44	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9445	9457		10.1074/jbc.M609847200	http://dx.doi.org/10.1074/jbc.M609847200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272279	hybrid			2022-12-25	WOS:000245421700017
J	MacKenzie, DA; Schartner, J; Lin, J; Timmel, A; Jennens-Clough, M; Fathman, CG; Seroogy, CM				MacKenzie, Debra A.; Schartner, Jill; Lin, Jack; Timmel, Amanda; Jennens-Clough, Martha; Fathman, C. Garrison; Seroogy, Christine M.			GRAIL is up-regulated in CD4(+) CD25(+) T regulatory cells and is sufficient for conversion of T cells to a regulatory phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; SUPPRESSOR FUNCTION; INDUCTION; TOLERANCE; ANTIGEN; SCURFIN; FOXP3; LYMPHOCYTES; POPULATIONS; MECHANISM	GRAIL (gene related to anergy in lymphocytes) is an ubiquitin-protein isopeptide ligase (E3) ubiquitin ligase necessary for the induction of CD4(+) T cell anergy in vivo. We have extended our previous studies to characterize the expression pattern of GRAIL in other murine CD4(+) T cell types with a described anergic phenotype. These studies revealed that GRAIL expression is increased in naturally occurring (thymically derived) CD4(+) CD25(+) T regulatory cells (mRNA levels 10-fold higher than naive CD25(-) T cells). Further investigation demonstrated that CD25(+) Foxp3(+) antigen-specific T cells were induced after a "tolerizing-administration" of antigen and that GRAIL expression correlated with the CD25(+) Foxp3(+) antigen-specific subset. Lastly, using retroviral transduction, we demonstrated that forced expression of GRAIL in a T cell line was sufficient for conversion of these cells to a regulatory phenotype in the absence of detectable Foxp3. These data demonstrate that GRAIL is differentially expressed in naturally occurring and peripherally induced CD25(+) T regulatory cells and that the expression of GRAIL is linked to their functional regulatory activity.	Univ Wisconsin, Dept Pediat, Div Allergy Immunol Rheumatol, Madison, WI 53792 USA; Stanford Univ, Dept Med, Div Immunol Rheumatol, Stanford, CA 94305 USA	University of Wisconsin System; University of Wisconsin Madison; Stanford University	Seroogy, CM (corresponding author), Univ Wisconsin, Dept Pediat, Div Immunol & Rheumatol, H4-474 CSC,600 Highland Ave, Madison, WI 53792 USA.	cmseroogy@wisc.edu						Anandasabapathy N, 2003, IMMUNITY, V18, P535, DOI 10.1016/S1074-7613(03)00084-0; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; DRESSER DW, 1961, NATURE, V191, P1169, DOI 10.1038/1911169a0; Ermann J, 2001, J IMMUNOL, V167, P4271, DOI 10.4049/jimmunol.167.8.4271; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; GVIN MA, 2006, P NATL ACAD SCI US; Heissmeyer V, 2004, NAT IMMUNOL, V5, P255, DOI 10.1038/ni1047; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Khattri R, 2001, J IMMUNOL, V167, P6312, DOI 10.4049/jimmunol.167.11.6312; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Marie JC, 2005, J EXP MED, V201, P1061, DOI 10.1084/jem.20042276; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nakamura K, 2004, J IMMUNOL, V172, P834, DOI 10.4049/jimmunol.172.2.834; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Pape KA, 1998, J IMMUNOL, V160, P4719; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; SCHWARTZ RH, 1989, COLD SPRING HARB SYM, V54, P605; Seroogy CM, 2004, J IMMUNOL, V173, P79, DOI 10.4049/jimmunol.173.1.79; Soares L, 2004, NAT IMMUNOL, V5, P45, DOI 10.1038/ni1017; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Tanchot C, 2001, J IMMUNOL, V167, P2030, DOI 10.4049/jimmunol.167.4.2030; Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143; Thorstenson KM, 2001, J IMMUNOL, V167, P188, DOI 10.4049/jimmunol.167.1.188	29	57	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9696	9702		10.1074/jbc.M604192200	http://dx.doi.org/10.1074/jbc.M604192200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17259178	hybrid			2022-12-25	WOS:000245421700043
J	Haapasalo, A; Kim, DY; Carey, BW; Turunen, MK; Pettingell, WH; Kovacs, DM				Haapasalo, Annakaisa; Kim, Doo Yeon; Carey, Bryce W.; Turunen, Mari K.; Pettingell, Warren H.; Kovacs, Dora M.			Presenilin/gamma-secretase-mediated cleavage regulates association of leukocyte-common antigen-related (LAR) receptor tyrosine phosphatase with beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; HIPPOCAMPAL CHOLINERGIC INNERVATION; GAMMA-SECRETASE; INTRACELLULAR DOMAIN; DISINTEGRIN-METALLOPROTEASE; NEURITE OUTGROWTH; NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; CYTOPLASMIC DOMAIN; TERMINAL FRAGMENTS	Leukocyte-common antigen-related (LAR) receptor tyrosine phosphatase regulates cell adhesion and formation of functional synapses and neuronal networks. Here we report that LAR is sequentially cleaved by alpha- and presenilin (PS)/gamma-secretases, which also affect signaling and/or degradation of type-I membrane proteins including the Alzheimer disease-related beta-amyloid precursor protein. Similar to the previously characterized PS/gamma-secretase substrates, inhibition of gamma-secretase activity resulted in elevated LAR C-terminal fragment (LAR-CTF) levels in stably LAR-overexpressing Chinese hamster ovary (CHO) cells, human neuroglioma cells, and mouse cortical neurons endogenously expressing LAR. Furthermore, LAR-CTF levels increased in cells lacking functional PS, indicating that gamma-secretase-mediated cleavage of LAR was PS-dependent. Inhibition of alpha-secretase activity by TAPI-1 treatment blocked LAR-CTF accumulation, demonstrating that prior ectodomain shedding was prerequisite for PS/gamma-secretase-mediated cleavage of LAR. Moreover, we identified the product of PS/gamma-secretase cleavage, LAR intracellular domain (LICD), both in vitro and in cells over-expressing full-length (FL) LAR or LAR-CTFs. LAR localizes to cadherin-beta-catenin-based cellular junctions. Assembly and disassembly of these junctions are regulated by tyrosine phosphorylation. We found that endogenous tyrosine-phosphorylated beta-catenin coimmunoprecipitated with LAR in CHO cells. However, when PS/gamma-secretase activity was inhibited, the association between LAR and beta-catenin significantly diminished. In addition to cell adhesion, beta-catenin is involved in transcriptional regulation. We observed that LICD significantly decreased transcription of cyclin D1, one of the beta-catenin target genes. Thus, our results show that PS/gamma-secretase-mediated cleavage of LAR controls LAR-beta-catenin interaction, suggesting an essential role for PS/gamma-secretase in the regulation of LAR signaling.	Massachusetts Gen Hosp, Neurobiol Dis Lab, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Kuopio, Dept Neurol & Neurosci, FIN-70211 Kuopio, Finland	Harvard University; Massachusetts General Hospital; Harvard University; University of Eastern Finland	Kovacs, DM (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,MIND, Neurobiol Dis Lab,Genet & Agine Res Unit,Dept Neu, 114 16th St, Charlestown, MA 02129 USA.	dora_kovacs@hms.harvard.edu		Haapasalo, Annakaisa/0000-0003-0959-2957				Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Anders L, 2006, MOL CELL BIOL, V26, P3917, DOI 10.1128/MCB.26.10.3917-3934.2006; Arasada RR, 2005, J BIOL CHEM, V280, P30783, DOI 10.1074/jbc.M506057200; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Dunah AW, 2005, NAT NEUROSCI, V8, P458, DOI 10.1038/nn1416; Fox AN, 2005, CURR BIOL, V15, P1701, DOI 10.1016/j.cub.2005.08.035; Frade JM, 2005, J NEUROSCI, V25, P1407, DOI 10.1523/JNEUROSCI.3798-04.2005; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Georgakopoulos A, 1999, MOL CELL, V4, P893, DOI 10.1016/S1097-2765(00)80219-1; Gupta-Rossi N, 2004, J CELL BIOL, V166, P73, DOI 10.1083/jcb.200310098; Honkaniemi J, 1998, MOL BRAIN RES, V60, P1, DOI 10.1016/S0169-328X(98)00151-X; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Johnson KG, 2006, NEURON, V49, P517, DOI 10.1016/j.neuron.2006.01.026; Kaufmann N, 2002, NEURON, V34, P27, DOI 10.1016/S0896-6273(02)00643-8; Kim DY, 2005, J BIOL CHEM, V280, P23251, DOI 10.1074/jbc.M412938200; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Ko J, 2003, J NEUROSCI, V23, P1667; Kolkman MJM, 2004, BEHAV BRAIN RES, V154, P171, DOI 10.1016/j.bbr.2004.02.006; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lieber T, 2002, GENE DEV, V16, P209, DOI 10.1101/gad.942302; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Paul S, 2003, CELL MOL LIFE SCI, V60, P2465, DOI 10.1007/s00018-003-3123-7; POT DA, 1991, J BIOL CHEM, V266, P19688; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; Ruhe JE, 2006, CELL SIGNAL, V18, P1515, DOI 10.1016/j.cellsig.2005.12.003; Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; Tsujikawa K, 2002, MOL CANCER RES, V1, P155; Uemura K, 2003, J NEUROSCI RES, V74, P184, DOI 10.1002/jnr.10753; Van der Zee CEEM, 2003, EUR J NEUROSCI, V17, P991, DOI 10.1046/j.1460-9568.2003.02516.x; Van Lieshout EMM, 2001, NEUROSCIENCE, V102, P833, DOI 10.1016/S0306-4522(00)00526-1; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; von Rotz RC, 2004, J CELL SCI, V117, P4435, DOI 10.1242/jcs.01323; Wang X, 2000, ONCOGENE, V19, P2346, DOI 10.1038/sj.onc.1203558; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong HK, 2005, J BIOL CHEM, V280, P23009, DOI 10.1074/jbc.M414648200; Wyszynski M, 2002, NEURON, V34, P39, DOI 10.1016/S0896-6273(02)00640-2; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Xie YM, 2001, J NEUROSCI, V21, P5130, DOI 10.1523/JNEUROSCI.21-14-05130.2001; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang T, 2005, EUR J NEUROSCI, V22, P2159, DOI 10.1111/j.1460-9568.2005.04403.x; Yang T, 2003, J NEUROSCI, V23, P3353; Yeo TT, 1997, J NEUROSCI RES, V47, P348, DOI 10.1002/(SICI)1097-4547(19970201)47:3<348::AID-JNR13>3.0.CO;2-Y; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; YU Q, 1992, ONCOGENE, V7, P1051; ZHANG JS, 1995, J CELL BIOL, V128, P415, DOI 10.1083/jcb.128.3.415; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886	72	43	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9063	9072		10.1074/jbc.M611324200	http://dx.doi.org/10.1074/jbc.M611324200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17259169	hybrid			2022-12-25	WOS:000245780300053
J	Sjolinder, H; Jonsson, AB				Sjolinder, Hong; Jonsson, Ann-Beth			Imaging of Disease Dynamics during Meningococcal Sepsis	PLOS ONE			English	Article								Neisseria meningitidis is a human pathogen that causes septicemia and meningitis with high mortality. The disease progression is rapid and much remains unknown about the disease process. The understanding of disease development is crucial for development of novel therapeutic strategies and vaccines against meningococcal disease. The use of bioluminescent imaging combined with a mouse disease model allowed us to investigate the progression of meningococcal sepsis over time. Injection of bacteria in blood demonstrated waves of bacterial clearance and growth, which selected for Opa-expressing bacteria, indicating the importance of this bacterial protein. Further, N. meningitidis accumulated in the thyroid gland, while thyroid hormone T4 levels decreased. Bacteria reached the mucosal surfaces of the upper respiratory tract, which required expression of the meningococcal PilC1 adhesin. Surprisingly, PilC1 was dispensable for meningococcal growth in blood and for crossing of the blood-brain barrier, indicating that the major role of PilC1 is to interact with mucosal surfaces. This in vivo study reveals disease dynamics and organ targeting during meningococcal disease and presents a potent tool for further investigations of meningococcal pathogenesis and vaccines in vivo. This might lead to development of new strategies to improve the outcome of meningococcal disease in human patients.	[Sjolinder, Hong; Jonsson, Ann-Beth] Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, Uppsala, Sweden	Uppsala University	Jonsson, AB (corresponding author), Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, Uppsala, Sweden.	Ann-Beth.Jonsson@imbim.uu.se			The Swedish Research Council [2004-4831, 2002-6240, 2006-5073, 2006-4112]; Swedish Cancer Society; Magnus Bergvalls Foundation; Ake Wibergs Stiftelse; Swedish Society for Medicine; Torsten och Ragnar Soderbergs Stiftelse; Knut och Alice Wallenbergs Stiftelse; Laerdal Foundation for Acute Medicine; Uppsala University	The Swedish Research Council(Swedish Research Council); Swedish Cancer Society(Swedish Cancer Society); Magnus Bergvalls Foundation; Ake Wibergs Stiftelse; Swedish Society for Medicine; Torsten och Ragnar Soderbergs Stiftelse; Knut och Alice Wallenbergs Stiftelse(Knut & Alice Wallenberg Foundation); Laerdal Foundation for Acute Medicine; Uppsala University	This work was supported by grants from The Swedish Research Council (Dnr 2004-4831, 2002-6240, 2006-5073, 2006-4112), Swedish Cancer Society, Magnus Bergvalls Foundation, Ake Wibergs Stiftelse, Swedish Society for Medicine, Torsten och Ragnar Soderbergs Stiftelse, Knut och Alice Wallenbergs Stiftelse, Laerdal Foundation for Acute Medicine, and Uppsala University.	Albiger B, 2003, INFECT IMMUN, V71, P155, DOI 10.1128/IAI.71.1.155-162.2003; Cattaneo R, 2004, J VIROL, V78, P4385, DOI 10.1128/JVI.78.9.4385-4388.2004; Dehio C, 2000, Subcell Biochem, V33, P61; deVries FP, 1996, INFECT IMMUN, V64, P2998, DOI 10.1128/IAI.64.8.2998-3006.1996; Edwards JL, 2005, CELL MICROBIOL, V7, P1197, DOI 10.1111/j.1462-5822.2005.00547.x; Edwards JL, 2002, CELL MICROBIOL, V4, P571, DOI 10.1046/j.1462-5822.2002.t01-1-00215.x; ELKINS C, 1991, J BACTERIOL, V173, P3911, DOI 10.1128/JB.173.12.3911-3913.1991; Gorringe AR, 2005, VACCINE, V23, P2214, DOI 10.1016/j.vaccine.2005.01.053; Gray-Owen SD, 2003, SCAND J INFECT DIS, V35, P614, DOI 10.1080/00365540310016042; Hackett SJ, 2002, ARCH DIS CHILD, V86, P44, DOI 10.1136/adc.86.1.44; Hobbs MM, 1998, MICROBIOL-UK, V144, P157, DOI 10.1099/00221287-144-1-157; HOLBEIN BE, 1979, INFECT IMMUN, V24, P545, DOI 10.1128/IAI.24.2.545-551.1979; Ilver D, 1998, INFECT IMMUN, V66, P469, DOI 10.1128/IAI.66.2.469-473.1998; Inan M, 2003, SURG TODAY, V33, P24, DOI 10.1007/s005950300004; JERSE AE, 1994, J EXP MED, V179, P911, DOI 10.1084/jem.179.3.911; Johansson L, 2005, J IMMUNOL, V175, P433, DOI 10.4049/jimmunol.175.1.433; Johansson L, 2003, SCIENCE, V301, P373, DOI 10.1126/science.1086476; Kirchner M, 2005, MOL MICROBIOL, V56, P945, DOI 10.1111/j.1365-2958.2005.04600.x; Koomey M, 2001, CURR OPIN MICROBIOL, V4, P53, DOI 10.1016/S1369-5274(00)00164-8; Lipsitch M, 2000, VACCINE, V18, P2895, DOI 10.1016/S0264-410X(00)00046-3; MACKINNON FG, 1992, MICROB PATHOGENESIS, V12, P415, DOI 10.1016/0882-4010(92)90004-8; Massari P, 2003, TRENDS MICROBIOL, V11, P87, DOI 10.1016/S0966-842X(02)00037-9; Merz AJ, 2000, ANNU REV CELL DEV BI, V16, P423, DOI 10.1146/annurev.cellbio.16.1.423; Mezosi E, 2005, J ENDOCRINOL, V185, P121, DOI 10.1677/joe.1.05968; Morand PC, 2004, EMBO J, V23, P2009, DOI 10.1038/sj.emboj.7600200; Mrkic B, 1998, J VIROL, V72, P7420, DOI 10.1128/JVI.72.9.7420-7427.1998; NASSIF X, 1994, P NATL ACAD SCI USA, V91, P3769, DOI 10.1073/pnas.91.9.3769; Rahman M, 1997, MOL MICROBIOL, V25, P11, DOI 10.1046/j.1365-2958.1997.4601823.x; Riley-Vargas RC, 2004, TRENDS IMMUNOL, V25, P496, DOI 10.1016/j.it.2004.07.004; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; Rytkonen A, 2004, J INFECT DIS, V189, P402, DOI 10.1086/381271; SALIT IE, 1986, INFECT IMMUN, V51, P648, DOI 10.1128/IAI.51.2.648-652.1986; SAUKKONEN K, 1988, MICROB PATHOGENESIS, V4, P203, DOI 10.1016/0882-4010(88)90070-8; Szychowska Z, 1998, Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw, V4, P19; Tobiason DM, 2006, PLOS BIOL, V4, P1069, DOI 10.1371/journal.pbio.0040185; Toropainen M, 1999, VACCINE, V17, P2677, DOI 10.1016/S0264-410X(99)00049-3; Zhu DZ, 2005, INFECT IMMUN, V73, P6838, DOI 10.1128/IAI.73.10.6838-6845.2005	37	36	37	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e241	10.1371/journal.pone.0000241	http://dx.doi.org/10.1371/journal.pone.0000241			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311106	Green Submitted, Green Published, gold			2022-12-25	WOS:000207444500020
J	Kang, Y; Hong, JA; Chen, GA; Nguyen, DM; Schrump, DS				Kang, Y.; Hong, J. A.; Chen, G. A.; Nguyen, D. M.; Schrump, D. S.			Dynamic transcriptional regulatory complexes including BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer cells	ONCOGENE			English	Article						lung cancer; epigenetics; NY-ESO-1; BORIS; CTCF; Sp1	GC-RICH DNA; GENE-TRANSCRIPTION; BINDING; FAMILY; IDENTIFICATION; DEREPRESSION; EPIGENETICS; ANTIGEN; DOMAIN; P300	Previously, we reported that the paralogous zinc-finger proteins-CTCF and brother of the regulator of imprinted sites (BORIS), directly contribute to transcriptional regulation of NY-ESO-1 in lung cancer cells. To further examine mechanisms that mediate expression of this cancer-testis gene, we performed software-guided analysis of the NY-ESO-1 promoter region, which revealed several potential Sp1- binding motifs. Sequential 5-aza-2 ' deoxycytidine/ depsipeptide FK228 treatment markedly induced BORIS expression and enhanced nuclear translocation of Sp1 in lung cancer cells. Transient transfection assays using promoter-reporter constructs, as well as gel-shift and chromatin immunoprecipitation experiments revealed that NY-ESO-1 promoter activity coincided with occupancy of the proximal Spi-binding site in lung cancer cells. Mutations within the Sp1 recognition sequence specifi. cally eliminated binding of Sp1 to this motif in vitro, and markedly diminished NY-ESO-1 promoter activity in vivo. siRNA-mediated inhibition of Sp1 expression decreased NY-ESO-1 promoter activity, whereas knock down of CTCF expression augmented NY-ESO-1 transcription in lung cancer cells. Co-immunoprecipitation experiments indicated that Sp1 physically interacts with BORIS but not with CTCF in vivo. Collectively, these. findings suggest that BORIS recruits Sp1 to mediate de-repression of NY-ESO-1 during pulmonary carcinogenesis.	NCI, Ctr Canc Res, Surg Branch, Thorac Oncol Sect, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schrump, DS (corresponding author), NCI, Ctr Canc Res, Surg Branch, Thorac Oncol Sect, Bldg 10,Rm 4-3942,10 Ctr Dr, Bethesda, MD 20892 USA.	David_Schrump@nih.gov			NATIONAL CANCER INSTITUTE [ZIASC010093, Z01BC010519, Z01SC010093] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertini V, 2006, NUCLEIC ACIDS RES, V34, P1721, DOI 10.1093/nar/gkl063; DePlaen E, 1997, GENOMICS, V40, P305, DOI 10.1006/geno.1996.4566; Gnjatic S, 2006, ADV CANCER RES, V95, P1, DOI 10.1016/S0065-230X(06)95001-5; Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823; Hosoi Y, 2004, INT J ONCOL, V25, P461; Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200; Hung JJ, 2006, MOL CELL BIOL, V26, P1770, DOI 10.1128/MCB.26.5.1770-1785.2006; Husmann M, 2000, BIOCHEM J, V352, P763, DOI 10.1042/0264-6021:3520763; James SR, 2006, ONCOGENE, V25, P6975, DOI 10.1038/sj.onc.1209678; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699; Nguyen DM, 2004, CLIN CANCER RES, V10, P1813, DOI 10.1158/1078-0432.CCR-0901-3; Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6; Persengiev SP, 1996, ENDOCRINOLOGY, V137, P638, DOI 10.1210/en.137.2.638; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Schrump DS, 2005, SEMIN ONCOL, V32, P488, DOI 10.1053/j.seminoncol.2005.07.007; Scott GK, 2006, CANCER RES, V66, P1277, DOI 10.1158/0008-5472.CAN-05-3632; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Thomas K, 2005, BIOL REPROD, V72, P898, DOI 10.1095/biolreprod.104.030528; Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Zendman AJW, 2003, J CELL PHYSIOL, V194, P272, DOI 10.1002/jcp.10215; Zhang Y, 2005, MOL CELL BIOL, V25, P7929, DOI 10.1128/MCB.25.18.7929-7939.2005	27	54	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2007	26	30					4394	4403		10.1038/sj.onc.1210218	http://dx.doi.org/10.1038/sj.onc.1210218			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17260018				2022-12-25	WOS:000247620000007
J	Aoudjehane, L; Podevin, P; Scatton, O; Jaffray, P; Dusanter-Fourt, I; Feldmann, G; Massault, PP; Grira, L; Bringuier, A; Dousset, B; Chouzenoux, S; Soubrane, O; Calmus, Y; Conti, F				Aoudjehane, Lynda; Podevin, Philippe; Scatton, Olivier; Jaffray, Patrick; Dusanter-Fourt, Isabelle; Feldmann, Gerard; Massault, Pierre-Philippe; Grira, Lilia; Bringuier, Annie; Dousset, Bertrand; Chouzenoux, Sandrine; Soubrane, Olivier; Calmus, Yvon; Conti, Filomena			Interleukin-4 induces human hepatocyte apoptosis through a Fas-independent pathway	FASEB JOURNAL			English	Article						liver transplantation; IL-4	HEPATITIS-C; LIVER-TRANSPLANTATION; ENDOTHELIAL-CELLS; CYTOKINE PROFILES; MAST-CELLS; T-CELLS; IL-4; EXPRESSION; GENE; ACTIVATION	IL-4 is overexpressed in liver grafts during severe recurrent hepatitis C and rejection. Hepatocyte apoptosis is involved in both these phenomena. We therefore examined the proapoptotic effect of IL-4 on HepG2 cells and human hepatocytes in vitro, together with the underlying mechanisms. We first measured IL-4 receptor expression, STAT6 activation by IL-4, and STAT6 inhibition by an anti-IL-4 antibody or by STAT6 siRNA transfection. We then focused on the pathways involved in IL-4-mediated apoptosis and the role of STAT6 activation in apoptosis initiation. The IL-4 receptor was expressed on both cell types, and STAT6 was activated by IL-4. Both anti- IL-4 and STAT-6 siRNA inhibited this activation. IL- 4 induced apoptosis of both HepG2 cells ( P = 0.008 vs. untreated control) and human hepatocytes ( P< 0.001 vs. untreated control). IL-4 reduced the mitochondrial membrane potential, activated Bid and Bax, and augmented caspase 3, 8, and 9 activity. STAT6 blockade inhibited IL-4- induced apoptosis. Expression of Fas and Fas ligand was unaffected when HepG2 cells and hepatocytes were cultured with IL-4, and Fas/ FasL pathway blockade failed to inhibit IL-4-induced apoptosis. These results show that IL-4 induces apoptosis of human hepatocytes through IL-4 receptor binding, STAT6 activation, decreased mitochondrial membrane potential, and increased caspase activation, independently of the Fas pathway. IL-4 might thus contribute to the progression of severe liver graft damage.	Hop Cochin, APHP, Serv Chirurg, F-75674 Paris 14, France; Univ Paris 05, UPRES 1833, Biol Cellulaire Lab, F-75270 Paris 06, France; Inst Cochin Genet Mol, INSERM U567, Dept Hematol, F-75014 Paris, France; Fac Xavier Bichat, INSERM U327, Biol Cellulaire Lab, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Aoudjehane, L (corresponding author), Hop Cochin, APHP, Serv Chirurg, 27 Rue Faubourg St Jacques, F-75674 Paris 14, France.	filomena.conti@cch.aphp.fr	Dusanter-Fourt, Isabelle/P-4558-2017; Soubrane, Olivier/ABB-4434-2021; Soubrane, Olivier/H-7799-2016	Dusanter-Fourt, Isabelle/0000-0002-9286-1021; Aoudjehane, lynda/0000-0003-4191-0564; Dousset, Bertrand/0000-0003-2526-7345				Bai Li, 2004, Chin J Dig Dis, V5, P175, DOI 10.1111/j.1443-9573.2004.00178.x; Bailey DP, 2004, EXP HEMATOL, V32, P52, DOI 10.1016/j.exphem.2003.10.011; Berenguer M, 2001, J HEPATOL, V35, P666, DOI 10.1016/S0168-8278(01)00179-9; Bertoletti A, 1997, GASTROENTEROLOGY, V112, P193, DOI 10.1016/S0016-5085(97)70235-X; Boleslawski E, 2004, TRANSPLANTATION, V77, P1815, DOI 10.1097/01.tp.0000129914.75547.b3; Bouton LA, 2004, EXP HEMATOL, V32, P1137, DOI 10.1016/j.exphem.2004.09.002; Chaloupka R, 1999, FEBS LETT, V462, P295, DOI 10.1016/S0014-5793(99)01538-0; Conti F, 1999, J HEPATOL, V30, P935, DOI 10.1016/S0168-8278(99)80150-0; Conti F, 2003, TRANSPLANTATION, V76, P210, DOI 10.1097/01.TP.0000067530.95852.67; CONTI F, 1995, TRANSPLANTATION, V60, P1104, DOI 10.1097/00007890-199511270-00008; Curry MP, 2004, TRANSPLANTATION, V78, P955, DOI 10.1097/01.TP.0000140927.63952.58; DELEEUW WJF, 1989, NUCLEIC ACIDS RES, V17, P10137, DOI 10.1093/nar/17.23.10137; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Ethier MF, 2005, FASEB J, V19, P154, DOI 10.1096/fj.05-4031fje; Feray C, 2004, J HEPATOL, V41, P862, DOI 10.1016/j.jhep.2004.09.002; Galka E, 2004, J SURG RES, V122, P14, DOI 10.1016/j.jss.2004.05.004; Gomez-Lechon MJ, 2004, BIOCHEM PHARMACOL, V68, P2427, DOI 10.1016/j.bcp.2004.08.028; Guillot C, 2001, J IMMUNOL, V166, P5225, DOI 10.4049/jimmunol.166.8.5225; Guiter C, 2004, BLOOD, V104, P543, DOI 10.1182/blood-2003-10-3545; Higuchi H, 2003, CURR MOL MED, V3, P483, DOI 10.2174/1566524033479528; HILLAIRE S, 1994, GASTROENTEROLOGY, V107, P781, DOI 10.1016/0016-5085(94)90127-9; Jaruga B, 2003, J IMMUNOL, V171, P3233, DOI 10.4049/jimmunol.171.6.3233; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kim J, 2003, MOL CELLS, V16, P92; Kornberg A, 2005, INT IMMUNOPHARMACOL, V5, P107, DOI 10.1016/j.intimp.2004.09.010; Kountouras J, 2003, J VIRAL HEPATITIS, V10, P335, DOI 10.1046/j.1365-2893.2003.00452.x; Lamboley C, 2000, CELL MOL BIOL, V46, P13; Lee YW, 2000, FEBS LETT, V485, P122, DOI 10.1016/S0014-5793(00)02208-0; Lee YW, 2004, MOL MED, V10, P19, DOI 10.2119/2004-00024.Lee; Li BF, 2006, HEPATOLOGY, V43, P1211, DOI 10.1002/hep.21174; Liu KD, 1998, CURR OPIN IMMUNOL, V10, P271, DOI 10.1016/S0952-7915(98)80165-9; MANGAN DF, 1992, J IMMUNOL, V148, P1812; McPartland JL, 2005, INT J EXP PATHOL, V86, P19, DOI 10.1111/j.0959-9673.2005.00411.x; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Napoli J, 1996, HEPATOLOGY, V24, P759; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Oskeritzian CA, 1999, J IMMUNOL, V163, P5105; OTHMAN SB, HEPATOLOGY, V42, pA483; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PARRY SL, 1994, J IMMUNOL, V152, P2821; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Rajashekhar G, 2003, GYNECOL ONCOL, V91, P101, DOI 10.1016/S0090-8258(03)00397-4; Ramirez F, 1996, J IMMUNOL, V156, P2406; Rippmann JF, 2005, FEBS LETT, V579, P173, DOI 10.1016/j.febslet.2004.11.071; Rivero M, 2002, AM J GASTROENTEROL, V97, P1501, DOI 10.1016/S0002-9270(02)04153-9; Rodrigues DBR, 2005, REV SOC BRAS MED TRO, V38, P483, DOI 10.1590/S0037-86822005000600007; Rudi J, 1998, J CLIN INVEST, V102, P1506, DOI 10.1172/JCI2808; Sasaki Y, 2003, CANCER RES, V63, P8145; Shi YG, 2004, CELL, V117, P855, DOI 10.1016/j.cell.2004.06.007; Shimoda M, 2004, LIVER TRANSPLANT, V10, P1478, DOI 10.1002/lt.20303; TALAL AC, 2004, TRENDS MOL MED, V10, P494; THAI NL, 1995, TRANSPLANTATION, V59, P274; van der Velden VHJ, 1998, CYTOKINE, V10, P803, DOI 10.1006/cyto.1998.0365; Vella V, 2004, J CLIN ENDOCR METAB, V89, P2880, DOI 10.1210/jc.2003-031639; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Wurster AL, 2000, ONCOGENE, V19, P2577, DOI 10.1038/sj.onc.1203485; Zekry A, 2002, LIVER TRANSPLANT, V8, P292, DOI 10.1053/jlts.2002.31655; ZUBER CE, 1990, CELL IMMUNOL, V129, P329, DOI 10.1016/0008-8749(90)90209-A	60	45	47	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1433	1444		10.1096/fj.06-6319com	http://dx.doi.org/10.1096/fj.06-6319com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17283223				2022-12-25	WOS:000246117000019
J	Ellison, TI; Eckert, RL; MacDonald, PN				Ellison, Tara I.; Eckert, Richard L.; MacDonald, Paul N.			Evidence for 1,25-dihydroxyvitamin D-3-independent transactivation by the vitamin D receptor - Uncoupling the receptor and ligand in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; PROTEIN COACTIVATOR COMPLEX; MINERAL ION HOMEOSTASIS; D-DEFICIENCY RICKETS; MEDIATED TRANSCRIPTION; 25-HYDROXYVITAMIN-D 1-ALPHA-HYDROXYLASE; INTERACTING PROTEIN; NUCLEAR-RECEPTOR; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; EPIDERMAL DIFFERENTIATION	The vitamin D endocrine system plays critical although poorly understood roles in skin. Vitamin D receptor (VDR) knock-out (VDRKO) mice have defects in hair follicle cycling and keratinocyte proliferation leading to epidermal thickening, dermal cyst formation, and alopecia. Surprisingly, skin defects are not apparent in mice lacking 25-hydroxyvitamin D 1 alpha-hydroxylase, the enzyme required for 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) hormone biosynthesis. These disparate phenotypes indicate that VDR effects in skin are independent of the 1,25(OH)(2)D-3 ligand. However, cellular or molecular data supporting this hypothesis are lacking. Here, we show transcriptional activation of the vitamin D-responsive 24-hydroxylase promoter by VDR in primary keratinocytes that is independent of the 1,25(OH)(2)D-3 ligand. This activity required functional vitamin D-responsive promoter elements as well as an intact VDR DNA binding domain and thus could not be distinguished from 1,25(OH)(2)D-3-dependent VDR transactivation. The 1,25(OH)(2)D-3-independent activation of VDR was also observed in keratinocytes from 1 alpha-hydroxylase knock-out mice, indicating that it is not due to endogenous 1,25(OH)(2)D-3 production. Mammalian two-hybrid studies showed strong, 1,25(OH)(2)D-3-independent interaction between VDR and retinoid X receptors in primary keratinocytes, indicating that enhanced heterodimerization of these receptors was involved. Indeed, this 1,25(OH)(2)D-3-independent VDR-RXR heterodimerization was sufficient to drive transactivation by VDR(L233S), an inactive ligand binding mutant of VDR that was previously shown to rescue the skin phenotype of VDR null mice. Cumulatively, these studies support the concept that transactivation by VDR in keratinocytes may be uncoupled from the 1,25(OH)(2)D-3 ligand.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Sch Med, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	MacDonald, PN (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, 10900 Euclid Ave, Cleveland, OH 44106 USA.	pnm2@case.edu			NIAMS NIH HHS [P30 AR639750] Funding Source: Medline; NIDDK NIH HHS [R01DK53980] Funding Source: Medline; NIGMS NIH HHS [T32GM 08803] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008803] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akutsu N, 2001, MOL ENDOCRINOL, V15, P1127, DOI 10.1210/me.15.7.1127; Barletta F, 2002, MOL ENDOCRINOL, V16, P301, DOI 10.1210/me.16.2.301; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; Bergman R, 2005, ARCH DERMATOL, V141, P343, DOI 10.1001/archderm.141.3.343; BIKLE DD, 1986, BIOCHEMISTRY-US, V25, P1545, DOI 10.1021/bi00355a013; Bikle DD, 2004, J INVEST DERMATOL, V122, P984, DOI 10.1111/j.0022-202X.2004.22424.x; BLUNT JW, 1968, P NATL ACAD SCI USA, V61, P717, DOI 10.1073/pnas.61.2.717; Brown AJ, 1999, J CELL BIOCHEM, V73, P106, DOI 10.1002/(SICI)1097-4644(19990401)73:1&lt;106::AID-JCB12&gt;3.0.CO;2-Q; Caldelari R, 2000, J INVEST DERMATOL, V114, P1064, DOI 10.1046/j.1523-1747.2000.00960-4.x; Chen CH, 2001, ENDOCRINOLOGY, V142, P5386, DOI 10.1210/en.142.12.5386; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; Chiba N, 2000, J BIOL CHEM, V275, P10719, DOI 10.1074/jbc.275.15.10719; Dardenne O, 2003, BONE, V32, P332, DOI 10.1016/S8756-3282(03)00023-1; Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135; Ellison TI, 2005, MOL ENDOCRINOL, V19, P2309, DOI 10.1210/me.2004-0382; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; GRAY RW, 1972, J BIOL CHEM, V247, P7528; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Jurutka PW, 1996, P NATL ACAD SCI USA, V93, P3519, DOI 10.1073/pnas.93.8.3519; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KNUTSON JC, 1974, BIOCHEMISTRY-US, V13, P1543, DOI 10.1021/bi00704a034; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Li YC, 1998, ENDOCRINOLOGY, V139, P4391, DOI 10.1210/en.139.10.4391; Lu JF, 2005, J INVEST DERMATOL, V124, P778, DOI 10.1111/j.0022-202X.2005.23641.x; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Miller WL, 2000, TRENDS ENDOCRIN MET, V11, P315, DOI 10.1016/S1043-2760(00)00287-3; ONATE SA, 1995, SCIENCE, V270, P1354; Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498; Pinette KV, 2003, MINI-REV MED CHEM, V3, P193, DOI 10.2174/1389557033488204; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; Sakai Y, 2001, J CLIN INVEST, V107, P961, DOI 10.1172/JCI11676; Skorija K, 2005, MOL ENDOCRINOL, V19, P855, DOI 10.1210/me.2004-0415; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; StArnaud R, 1997, J BONE MINER RES, V12, P1552, DOI 10.1359/jbmr.1997.12.10.1552; Sutton ALM, 2003, MOL ENDOCRINOL, V17, P777, DOI 10.1210/me.2002-0363; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698; Vanhooke JL, 2006, P NATL ACAD SCI USA, V103, P75, DOI 10.1073/pnas.0509734103; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391; Zhang C, 2003, J BIOL CHEM, V278, P35325, DOI 10.1074/jbc.M305191200; Zinser GM, 2002, CARCINOGENESIS, V23, P2103, DOI 10.1093/carcin/23.12.2103	49	33	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10953	10962		10.1074/jbc.M609717200	http://dx.doi.org/10.1074/jbc.M609717200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17310066	hybrid			2022-12-25	WOS:000245941500015
J	Kang, JS; Kashtan, CE; Turner, AN; Heidet, L; Hudson, BG; Borza, DB				Kang, Jeong Suk; Kashtan, Clifford E.; Turner, A. Neil; Heidet, Laurence; Hudson, Billy G.; Borza, Dorin-Bogdan			The alloantigenic sites of alpha 3 alpha 4 alpha 5(IV) collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED ALPORT SYNDROME; ANTI-GBM NEPHRITIS; IV COLLAGEN; GOODPASTURE AUTOANTIGEN; RENAL-TRANSPLANTATION; ALPHA-3(IV) COLLAGEN; CRYPTIC EPITOPES; BASEMENT-MEMBRANES; NC1 DOMAINS; ALLOANTIBODIES	Anti-glomerular basement membrane (GBM) antibody nephritis is caused by an autoimmune or alloimmune reaction to the NC1 domains of alpha 3 alpha 4 alpha 5(IV) collagen. Some patients with X-linked Alport syndrome (XLAS) develop post-transplant nephritis mediated by pathogenic anti-GBM alloantibodies to collagen IV chains present in the renal allograft but absent from the tissues of the patient. In this work, the epitopes targeted by alloantibodies from these patients were identified and characterized. All XLAS alloantibodies recognized conformational epitopes in the NC1 domain of alpha 5(IV) collagen, which were mapped using chimeric alpha 1/alpha 5NC1 domains expressed in mammalian cells. Allograft-eluted alloantibodies mainly targeted two conformational alloepitopes mapping to alpha 5NC1 residues 1-45 and 114-168. These regions also encompassed the major epitopes of circulating XLAS alloantibodies, which in some patients additionally targeted alpha 5NC1 residues 169-229. Both kidney-eluted and circulating alloantibodies to alpha 5NC1 distinctively targeted epitopes accessible in the alpha 3 alpha 4 alpha 5NC1 hexamers of human GBM, unlike anti-GBM autoantibodies, which targeted sequestered alpha 3NC1 epitopes. The results identify two immunodominant alpha 5NC1 epitopes as major alloantigenic sites of alpha 3 alpha 4 alpha 5(IV) collagen specifically implicated in the pathogenesis of post-transplant nephritis in XLAS patients. The contrast between the accessibility of these alloepitopes and the crypticity of autoepitopes indicates that distinct molecular forms of antigen may initiate the immunopathogenic processes in the two forms of anti-GBM disease.	Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, Nashville, TN 37232 USA; Univ Minnesota, Sch Med, Dept Pediat, Minneapolis, MN 55455 USA; Univ Edinburgh, MRC, Ctr Inflammat Res, Edinburgh EH16 4TJ, Midlothian, Scotland; Hop Necker Enfants Malad, INSERM, U574, F-75743 Paris 15, France	Vanderbilt University; University of Minnesota System; University of Minnesota Twin Cities; University of Edinburgh; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Borza, DB (corresponding author), Vanderbilt Univ, Sch Med, Div Nephrol, Dept Med, S-3223 MCN, Nashville, TN 37232 USA.	Dorin-Bogdan.Borza@vanderbilt.edu	Borza, Dorin-Bogdan/AAF-2156-2020	Borza, Dorin-Bogdan/0000-0003-4568-279X; Turner, Neil/0000-0003-4547-873X; Hudson, Billy/0000-0002-5420-4100; Heidet, Laurence/0000-0002-1362-5515	NIDDK NIH HHS [P01 DK65123, R37 DK18381] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK065123, R37DK018381] Funding Source: NIH RePORTER; Medical Research Council [G9900991B] Funding Source: researchfish	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		Borza DB, 2000, J BIOL CHEM, V275, P6030, DOI 10.1074/jbc.275.8.6030; Borza DB, 2005, J BIOL CHEM, V280, P27147, DOI 10.1074/jbc.M504050200; Borza DB, 2003, SPRINGER SEMIN IMMUN, V24, P345, DOI 10.1007/s00281-002-0103; Borza DB, 2002, J BIOL CHEM, V277, P40075, DOI 10.1074/jbc.M207769200; Brainwood D, 1998, KIDNEY INT, V53, P762, DOI 10.1046/j.1523-1755.1998.00794.x; Browne G, 2004, KIDNEY INT, V65, P675, DOI 10.1111/j.1523-1755.2004.00428.x; Collins PW, 2006, HAEMOPHILIA, V12, P94, DOI 10.1111/j.1365-2516.2006.01372.x; Dehan P, 1996, NEPHROL DIAL TRANSPL, V11, P1983, DOI 10.1093/oxfordjournals.ndt.a027085; Gluckman J C, 1973, Clin Nephrol, V1, P40; Heidet L, 2000, AM J PATHOL, V156, P1901, DOI 10.1016/S0002-9440(10)65063-8; Hellmark T, 1999, KIDNEY INT, V55, P936, DOI 10.1046/j.1523-1755.1999.055003936.x; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; Hudson BG, 2003, NEW ENGL J MED, V348, P2543, DOI 10.1056/NEJMra022296; KALLURI R, 1995, KIDNEY INT, V47, P1199, DOI 10.1038/ki.1995.170; Kalluri R, 2000, TRANSPLANTATION, V69, P679, DOI 10.1097/00007890-200002270-00038; Kalluri R, 2000, J BIOL CHEM, V275, P20027, DOI 10.1074/jbc.M904549199; KASHTAN C, 1986, J CLIN INVEST, V78, P1035, DOI 10.1172/JCI112658; Kashtan CE, 2006, PEDIATR TRANSPLANT, V10, P651, DOI 10.1111/j.1399-3046.2006.00528.x; Netzer KO, 1999, J BIOL CHEM, V274, P11267, DOI 10.1074/jbc.274.16.11267; Sado Y, 1998, KIDNEY INT, V53, P664, DOI 10.1046/j.1523-1755.1998.00795.x; Sundaramoorthy M, 2002, J BIOL CHEM, V277, P31142, DOI 10.1074/jbc.M201740200; Wang XP, 2005, J AM SOC NEPHROL, V16, P3563, DOI 10.1681/ASN.2005060670	22	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10670	10677		10.1074/jbc.M611892200	http://dx.doi.org/10.1074/jbc.M611892200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17293596	hybrid			2022-12-25	WOS:000245941000061
J	Pescatori, M; Broccolini, A; Minetti, C; Bertini, E; Bruno, C; D'amico, A; Bernardini, C; Mirabella, M; Silvestri, G; Giglio, V; Modoni, A; Pedemonte, M; Tasca, G; Galluzzi, G; Mercuri, E; Tonali, PA; Ricci, E				Pescatori, Mario; Broccolini, Aldobrando; Minetti, Carlo; Bertini, Enrico; Bruno, Claudio; D'amico, Adele; Bernardini, Camilla; Mirabella, Massimiliano; Silvestri, Gabriella; Giglio, Vincenzo; Modoni, Anna; Pedemonte, Marina; Tasca, Giorgio; Galluzzi, Giuliana; Mercuri, Eugenio; Tonali, Pietro A.; Ricci, Enzo			Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression	FASEB JOURNAL			English	Article						microarrays; Duchenne muscular dystrophy; human disease; Wnt, Notch, and BMP signaling	DUCHENNE MUSCULAR-DYSTROPHY; MESSENGER-RNA EXPRESSION; GROWTH-FACTOR-I; SKELETAL-MUSCLE; TISSUE INHIBITORS; TRANSFORMING GROWTH-FACTOR-BETA-1; EXTRACELLULAR-MATRIX; TIME-COURSE; STEM-CELLS; TGF-BETA	Genome-wide gene expression profiling of skeletal muscle from Duchenne muscular dystrophy (DMD) patients has been used to describe muscle tissue alterations in DMD children older than 5 years. By studying the expression profile of 19 patients younger than 2 years, we describe with high resolution the gene expression signature that characterizes DMD muscle during the initial or "presymptomatic" phase of the disease. We show that in the first 2 years of the disease, DMD muscle is already set to express a distinctive gene expression pattern considerably different from the one expressed by normal, age-matched muscle. This "dystrophic" molecular signature is characterized by a coordinate induction of genes involved in the inflammatory response, extracellular matrix (ECM) remodeling and muscle regeneration, and the reduced transcription of those involved in energy metabolism. Despite the lower degree of muscle dysfunction experienced, our younger patients showed abnormal expression of most of the genes reported as differentially expressed in more advanced stages of the disease. By analyzing our patients as a time series, we provide evidence that some genes, including members of three pathways involved in morphogenetic signaling-Wnt, Notch, and BMP-are progressively induced or repressed in the natural history of DMD.	Catholic Univ, Inst Neurol, I-00184 Rome, Italy; Univ Genoa, G Gaslini Inst, Dept Pediat, Neuromuscular Dis Unit, Genoa, Italy; Bambino Gesu Childrens Hosp IRCCS, Unit Mol Med & Pathol, Rome, Italy; Catholic Univ, Inst Anat & Cell Biol, Rome, Italy; St Paolo Hosp, Div Cardiol, Civitavecchia, Italy; St Paolo Hosp, ICU, Civitavecchia, Italy; UILDM, Ctr Neuromuscular Dis, Rome, Italy; ONLUS, Don Gnocchi Fdn, Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Genoa; IRCCS Istituto Giannina Gaslini; IRCCS Bambino Gesu; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Fondazione Don Carlo Gnocchi Onlus	Pescatori, M (corresponding author), Catholic Univ, Inst Neurol, L Go A Gemeilli 8, I-00184 Rome, Italy.	m.pescatori@rm.unicatt.it; ericci@rm.unicatt.it	Broccolini, Aldobrando/ABE-1311-2021; Silvestri, Gabriella/N-6588-2013; Ricci, Enzo/AAC-4448-2020; Silvestri, Gabriella/J-8713-2018; Bertini, Enrico/ABG-1278-2020; Giglio, Vincenzo/AAA-8762-2021; Minetti, Carlo/K-4666-2018; MIRABELLA, Massimiliano/AAC-4016-2020; Bertini, Enrico/A-2284-2014; d'amico, adele/J-9203-2016; Bruno, Claudio/A-3148-2015; Tasca, Giorgio/J-5153-2018	Silvestri, Gabriella/0000-0002-1950-1468; Minetti, Carlo/0000-0002-0640-1804; MIRABELLA, Massimiliano/0000-0002-7783-114X; Bertini, Enrico/0000-0001-9276-4590; d'amico, adele/0000-0003-2438-2624; Bruno, Claudio/0000-0002-3426-2901; Tasca, Giorgio/0000-0003-0849-9144; RICCI, Enzo/0000-0003-3092-3597; Pedemonte, Marina/0000-0001-8410-6918				Arthur MJP, 1999, ALCOHOL CLIN EXP RES, V23, P940, DOI 10.1111/j.1530-0277.1999.tb04208.x; Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Balagopal P, 2006, AM J PHYSIOL-ENDOC M, V290, pE530, DOI 10.1152/ajpendo.00412.2005; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; BERNASCONI P, 1995, J CLIN INVEST, V96, P1137, DOI 10.1172/JCI118101; Bonuccelli G, 2003, AM J PATHOL, V163, P1663, DOI 10.1016/S0002-9440(10)63523-7; Broccolini A, 2004, J NEUROPATH EXP NEUR, V63, P650, DOI 10.1093/jnen/63.6.650; CHELLY J, 1990, CELL, V63, P1239, DOI 10.1016/0092-8674(90)90419-F; Chen YW, 2005, NEUROLOGY, V65, P826, DOI 10.1212/01.wnl.0000173836.09176.c4; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Combaret L, 1996, FEBS LETT, V393, P292, DOI 10.1016/0014-5793(96)00910-6; Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260; Conboy IM, 2003, SCIENCE, V302, P1575, DOI 10.1126/science.1087573; Dahlqvist C, 2003, DEVELOPMENT, V130, P6089, DOI 10.1242/dev.00834; Davis E, 2004, CURR BIOL, V14, P1858, DOI 10.1016/j.cub.2004.09.079; Engvall E, 2003, FASEB J, V17, P1579, DOI 10.1096/fj.02-1215rev; Garces C, 1999, DIFFERENTIATION, V64, P103, DOI 10.1007/s002580050265; Goetsch SC, 2003, PHYSIOL GENOMICS, V14, P261, DOI 10.1152/physiolgenomics.00056.2003; Gosselin LE, 2004, MUSCLE NERVE, V30, P645, DOI 10.1002/mus.20150; Greenberg SA, 2002, NEUROLOGY, V59, P1170, DOI 10.1212/WNL.59.8.1170; GROUNDS MD, 1991, PATHOL RES PRACT, V187, P1; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; Gueders MM, 2006, EUR J PHARMACOL, V533, P133, DOI 10.1016/j.ejphar.2005.12.082; Haslett JN, 2003, NEUROGENETICS, V4, P163, DOI 10.1007/s10048-003-0148-x; Haslett JN, 2002, P NATL ACAD SCI USA, V99, P15000, DOI 10.1073/pnas.192571199; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Honke Kazuya, 1997, No To Hattatsu, V29, P13; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; Katoh M, 2006, INT J MOL MED, V17, P795; KOMINAMI E, 1987, AM J PATHOL, V127, P461; KORN EL, 2003, J STAT PLAN INFER, V124, P2448; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Lee SJ, 2004, ANNU REV CELL DEV BI, V20, P61, DOI 10.1146/annurev.cellbio.20.012103.135836; Lundberg I, 1995, J NEUROIMMUNOL, V63, P9, DOI 10.1016/0165-5728(95)00122-0; Matecki S, 2004, AM J PHYSIOL-REG I, V287, pR961, DOI 10.1152/ajpregu.00146.2004; Messina S, 2006, EXP NEUROL, V198, P234, DOI 10.1016/j.expneurol.2005.11.021; Messina S, 2006, AM J PATHOL, V168, P918, DOI 10.2353/ajpath.2006.050673; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; Muntoni F, 2002, NEUROMUSCULAR DISORD, V12, pS162, DOI 10.1016/S0960-8966(02)00101-3; Musaro A, 2004, P NATL ACAD SCI USA, V101, P1206, DOI 10.1073/pnas.0303792101; Musgrave DS, 2001, BONE, V28, P499, DOI 10.1016/S8756-3282(01)00413-6; NISHIO H, 1990, BRAIN DEV-JPN, V12, P390, DOI 10.1016/S0387-7604(12)80071-4; Oexle K, 2001, NEUROPEDIATRICS, V32, P123, DOI 10.1055/s-2001-16613; Okamoto O, 1999, BIOCHEM J, V337, P537, DOI 10.1042/0264-6021:3370537; Paoni NF, 2002, PHYSIOL GENOMICS, V11, P263, DOI 10.1152/physiolgenomics.00110.2002; Pavlidis P, 2002, J COMPUT BIOL, V9, P401, DOI 10.1089/10665270252935539; Pizon V, 2005, EMBO J, V24, P3781, DOI 10.1038/sj.emboj.7600842; Polesskaya A, 2003, CELL, V113, P841, DOI 10.1016/S0092-8674(03)00437-9; Porter JD, 2004, HUM MOL GENET, V13, P257, DOI 10.1093/hmg/ddh033; Porter JD, 2003, HUM MOL GENET, V12, P1813, DOI 10.1093/hmg/ddg197; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933; Seale P, 2003, CELL CYCLE, V2, P418, DOI 10.4161/cc.2.5.498; Shurin GV, 2005, J IMMUNOL, V174, P5490, DOI 10.4049/jimmunol.174.9.5490; SIMON R, 2003, DESIGN ANAL DNA MICR; SIMON R, BRB ARRAY TOOLS USER, P1012; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; Spencer MJ, 2002, HUM MOL GENET, V11, P2645, DOI 10.1093/hmg/11.21.2645; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Straub V, 1997, CURR OPIN NEUROL, V10, P168, DOI 10.1097/00019052-199704000-00016; t' Hoen PAC, 2006, PHARMACOGENOMICS, V7, P281, DOI 10.2217/14622416.7.3.281; Tagliafico E, 2004, J CELL SCI, V117, P4377, DOI 10.1242/jcs.01291; Tezak Z, 2002, J IMMUNOL, V168, P4154, DOI 10.4049/jimmunol.168.8.4154; Tidball JG, 2000, INT J BIOCHEM CELL B, V32, P1, DOI 10.1016/S1357-2725(99)00095-3; Torrente Y, 2004, J CLIN INVEST, V114, P182, DOI 10.1172/JCI200420325; von Moers A, 2005, ACTA NEUROPATHOL, V109, P285, DOI 10.1007/s00401-004-0941-0; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Winn N, 2002, COLD SPRING HARB SYM, V67, P507, DOI 10.1101/sqb.2002.67.507; YAMAZAKI M, 1994, AM J PATHOL, V144, P221; Yan Z, 2003, J BIOL CHEM, V278, P8826, DOI 10.1074/jbc.M209879200; Zanotti S, 2005, BRAIN, V128, P2546, DOI 10.1093/brain/awh635; Zhou BP, 2003, SEMIN ONCOL, V30, P38, DOI 10.1053/j.seminoncol.2003.08.006; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	76	166	169	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1210	1226		10.1096/fj.06-7285com	http://dx.doi.org/10.1096/fj.06-7285com			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17264171				2022-12-25	WOS:000245650400025
J	Chellaiah, MA; Kuppuswamy, D; Lasky, L; Linder, S				Chellaiah, Meenakshi A.; Kuppuswamy, Dhandapani; Lasky, Larry; Linder, Stefan			Phosphorylation of a Wiscott-Aldrich syndrome protein-associated signal complex is critical in osteoclast bone resorption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHATASE-PEST; CYTOSKELETAL-ASSOCIATED PROTEIN; FOCAL ADHESION KINASE; N-WASP; C-SRC; BETA-3 INTEGRIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ACTIN POLYMERIZATION; INTERACTING PROTEIN; ARP2/3 COMPLEX	The activities of different kinases have been correlated to the phosphorylation of Wiscott-Aldrich syndrome protein (WASP) by studies in multiple cell systems. The purpose of this study was to elucidate the regulatory mechanisms involved in WASP phosphorylation and the resulting sealing ring formation in osteoclasts. The phosphorylation state of WASP and WASP-interacting proteins was determined in osteoclasts treated with osteopontin or expressing either constitutively active or kinase-defective Src by adenovirus-mediated delivery. In vitro kinase analysis of WASP immunoprecipitates exhibited phosphorylation of c-Src, PYK2, WASP, protein-tyrosine phosphatase (PTP)-PEST, and Pro-Ser-Thr phosphatase-interacting protein (PSTPIP). Phosphorylation of these proteins was increased in osteopontin-treated and constitutively active Src-expressing osteoclasts. Pulldown analysis with glutathione S-transferase-fused prohne-rich regions of PTP-PEST revealed coprecipitation of WASP, PYK2, c-Src, and PSTPIP proteins with the N-terminal region (amino acids 294 497) of PTP-PEST. Similarly, interaction of the same signaling proteins, as well as PTP-PEST, was observed with glutathione S-transferase-fused proline-rich regions of WASP. Furthermore, osteopontin stimulation or constitutively active Src expression resulted in serine phosphorylation and inhibition of WASP-associated PTP-PEST. The inhibition of PTP-PEST was accompanied by an increase in tyrosine phosphorylation of WASP and other associated signaling proteins. Experiments with an inhibitor to phosphatase and small interference RNA to PTP-PEST confirmed the involvement of PTP-PEST in sealing ring formation and bone resorption. WASP, which is identified in the sealing ring of resorbing osteoclasts, also demonstrates colocalization with c-Src, PYK2, PSTPIP, and PTP-PEST in immunostaining analyses. Our findings suggest that both tyrosine kinase(s) and the tyrosine phosphatase PTP-PEST coordinate the formation of the sealing ring and thus the bone-resorbing function of osteoclasts.	Univ Maryland, Sch Dent, Dept Biomed Sci, Baltimore, MD 21201 USA; Med Univ S Carolina, Div Cardiol, Cardiac Res Inst, Charleston, SC 29425 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94111 USA; Univ Munich, Inst Prophylaxe & Epidemiol Kreislaufkrankheiten, D-80336 Munich, Germany	University System of Maryland; University of Maryland Baltimore; Medical University of South Carolina; Roche Holding; Genentech; University of Munich	Chellaiah, MA (corresponding author), Univ Maryland, Sch Dent, Dept Biomed Sci, 650 W Baltimore St, Baltimore, MD 21201 USA.	mchellaiah@umaryland.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR046292, R01AR046292] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-48788] Funding Source: Medline; NIAMS NIH HHS [AR46292] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Banin S, 1999, MOL BIOL REP, V26, P173, DOI 10.1023/A:1006954206151; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Bodour K, 2004, J EXP MED, V199, P99, DOI 10.1084/jem.20030976; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood-2003-04-1259; Caron E, 2002, CURR OPIN CELL BIOL, V14, P82, DOI 10.1016/S0955-0674(01)00298-8; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908; Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200; Chellaiah MA, 2000, J BIOL CHEM, V275, P11993, DOI 10.1074/jbc.275.16.11993; Chellaiah MA, 2001, J BIOL CHEM, V276, P47434, DOI 10.1074/jbc.M107494200; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COOPER J A, 1992, P47; Cory GOC, 2003, MOL CELL, V11, P1229, DOI 10.1016/S1097-2765(03)00172-2; Cote JF, 2002, J BIOL CHEM, V277, P2973, DOI 10.1074/jbc.M106428200; Dowbenko D, 1998, J BIOL CHEM, V273, P989, DOI 10.1074/jbc.273.2.989; Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200; Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Gupta A, 2003, J BONE MINER RES, V18, P669, DOI 10.1359/jbmr.2003.18.4.669; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hufner K, 2002, FEBS LETT, V514, P168, DOI 10.1016/S0014-5793(02)02358-X; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Lyons PD, 2001, J BIOL CHEM, V276, P24422, DOI 10.1074/jbc.M011080200; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04-06-0522; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Schulte RJ, 2003, BIOCHEMISTRY-US, V42, P9424, DOI 10.1021/bi034519u; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; Scott MP, 2002, J BIOL CHEM, V277, P28238, DOI 10.1074/jbc.M202783200; Shen Y, 2000, J BIOL CHEM, V275, P1405, DOI 10.1074/jbc.275.2.1405; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; TAYLOR ML, 1989, ANAT EMBRYOL, V180, P427, DOI 10.1007/BF00305117; TETI A, 1991, AM J PHYSIOL, V261, pC1, DOI 10.1152/ajpcell.1991.261.1.C1; Torres E, 2006, J BIOL CHEM, V281, P3513, DOI 10.1074/jbc.M509416200; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; VAANANEN HK, 1995, J CELL SCI, V108, P2729; Violette SM, 2000, CHEM BIOL, V7, P225, DOI 10.1016/S1074-5521(00)00090-9; Willey CD, 2003, J MOL CELL CARDIOL, V35, P671, DOI 10.1016/S0022-2828(03)00112-3; Wu XY, 2004, J BIOL CHEM, V279, P43392, DOI 10.1074/jbc.M408959200; Wu Y, 1998, J BIOL CHEM, V273, P30487, DOI 10.1074/jbc.273.46.30487; Zhang Z, 2002, BONE, V31, P359, DOI 10.1016/S8756-3282(02)00834-7	57	45	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10104	10116		10.1074/jbc.M608957200	http://dx.doi.org/10.1074/jbc.M608957200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17283076	hybrid			2022-12-25	WOS:000245421700084
J	Chen, YG; Wang, Z; Ma, J; Zhang, L; Lu, ZX				Chen, Ye-Guang; Wang, Zhi; Ma, Jing; Zhang, Long; Lu, Zhongxian			Endofin, a FYVE domain protein, interacts with Smad4 and facilitates transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY ENDOSOMES; RECEPTOR INTERNALIZATION; CELL-MEMBRANE; SARA; ACTIVATION; APOPTOSIS; PATHWAYS; BINDING; TRANSDUCTION; ENDOCYTOSIS	Transforming growth factor-beta (TGF-beta) signaling is facilitated by scaffold proteins such as SARA (Smad anchor for receptor activation). Endofin, a member of the FYVE domain protein family, has been suggested to regulate membrane trafficking. In this study, we report that endofin functions as a scaffold protein to facilitate TGF-beta signaling. Overexpression of endofin FYVE domain-deletion mutants inhibited TGF-beta-induced expression of CAGA-luciferase. Knockdown of endogenous endofin expression by RNA interference specifically led to reduction of the transcriptional responses of TGF-beta, but had no effect on BMP-or Wnt1-induced reporter expression. Furthermore, in endofin small interfering RNA-expressing stable cells, TGF-beta-mediated expression of plasminogen activator inhibitor-1 andp21(Cip1) was significantly reduced, and TGF-beta-promoted apoptosis was also impaired. We further showed that endofin could interact with Smad4 and TGF-beta type I receptors. Reduction of endogenous endofin expression resulted in a decrease of TGF-beta-induced Smad2 phosphorylation and Smad2-Smad4 complex formation. Together, our findings suggest that endofin facilitates TGF-beta signaling as a scaffold protein to promote the R-Smad-Smad4 complex formation by bringing Smad4 to the proximity of the receptor complex.	Tsing Hua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Univ Calif Irvine, Coll Med, Dept Med & Biol Chem, Irvine, CA 92697 USA	Tsinghua University; University of California System; University of California Irvine	Chen, YG (corresponding author), Tsing Hua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	ygchen@tsinghua.edu.cn	Zhang, Long/AAT-6571-2021; Lu, ZX/G-4586-2010; Chen, Ye-Guang/L-6998-2019	Zhang, Long/0000-0001-8139-0474; 				Bennett D, 2002, NAT GENET, V31, P419, DOI 10.1038/ng938; Bokel C, 2006, SCIENCE, V314, P1135, DOI 10.1126/science.1132524; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Felici A, 2003, EMBO J, V22, P4465, DOI 10.1093/emboj/cdg428; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Hartung A, 2006, MOL CELL BIOL, V26, P7791, DOI 10.1128/MCB.00022-06; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Inman GJ, 2000, J IMMUNOL, V165, P2500, DOI 10.4049/jimmunol.165.5.2500; Itoh F, 2002, GENES CELLS, V7, P321, DOI 10.1046/j.1365-2443.2002.00519.x; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kunzmann S, 2003, FASEB J, V17, P194, DOI 10.1096/fj.02-0550com; Lu ZX, 2002, J BIOL CHEM, V277, P29363, DOI 10.1074/jbc.M203495200; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Moustakas A, 2001, J CELL SCI, V114, P4359; Ohgushi M, 2005, MOL CELL BIOL, V25, P10017, DOI 10.1128/MCB.25.22.10017-10028.2005; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Ramjaun AR, 2007, ONCOGENE, V26, P970, DOI 10.1038/sj.onc.1209852; Seet LF, 2005, J CELL SCI, V118, P575, DOI 10.1242/jcs.01628; Seet LF, 2004, J BIOL CHEM, V279, P4670, DOI 10.1074/jbc.M311228200; Seet LF, 2001, J BIOL CHEM, V276, P42445, DOI 10.1074/jbc.M105917200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; TEN DP, 2004, TRENDS BIOCHEM SCI, V29, P265; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wang Z, 2004, J VIROL, V78, P7523, DOI 10.1128/JVI.78.14.7523-7527.2004; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Wurthner JU, 2001, J BIOL CHEM, V276, P19495, DOI 10.1074/jbc.M006473200; Yamakawa N, 2002, EMBO J, V21, P1684, DOI 10.1093/emboj/21.7.1684; Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200; Zhang XL, 2005, J BIOL CHEM, V280, P12239, DOI 10.1074/jbc.M413284200; Zhou YL, 2004, MOL ENDOCRINOL, V18, P1818, DOI 10.1210/me.2004-0079	40	52	54	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9688	9695		10.1074/jbc.M611704200	http://dx.doi.org/10.1074/jbc.M611704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272273	hybrid			2022-12-25	WOS:000245421700042
J	Joshi, MB; Dwyer, DM				Joshi, Manju B.; Dwyer, Dennis M.			Molecular and functional analyses of a novel class I secretory nuclease from the human pathogen, Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; EUKARYOTIC HUMAN PATHOGENS; STRAND-SPECIFIC NUCLEASE; PARASITIC PROTOZOA; GENOME SEQUENCE; NUCLEOSIDE TRANSPORTERS; EXTRACELLULAR NUCLEASE; ENDOPLASMIC-RETICULUM; PENICILLIUM-CITRINUM; ASPERGILLUS-ORYZAE	The primitive protozoan pathogen of humans, Leishmania donovani, resides and multiplies in highly restricted micro-environments within their hosts (i.e. as promastigotes in the gut lumen of their sandfly vectors and as amastigotes in the phagolysosomal compartments of infected mammalian macrophages). Like other trypanosomatid parasites, they are purine auxotrophs (i.e. lack the ability to synthesize purines de novo) and therefore are totally dependent upon salvaging these essential nutrients from their hosts. In that context, in this study we identified a unique 35-kDa, dithiothreitol-sensitive nuclease and showed that it was constitutively released/secreted by both promastigote and amastigote developmental forms of this parasite. By using several different molecular approaches, we identified and characterized the structure of LdNuc(s), a gene that encodes this new 35-kDa class I nuclease family member in these organisms. Homologous episomal expression of an epitope-tagged LdNuc(s) chimeric construct was used in conjunction with an anti-LdNuc(s) peptide antibody to delineate the functional and biochemical properties of this unique 35-kDa parasite released/secreted enzyme. Results of coupled immunoprecipitation-enzyme activity analyses demonstrated that this "secretory" enzyme could hydrolyze a variety of synthetic polynucleotides as well as several natural nucleic acid substrates, including RNA and single- and double-stranded DNA. Based on these cumulative observations, we hypothesize that within the micro-environments of its host, this leishmanial "secretory" nuclease could function at a distance away from the parasite to harness (i.e. hydrolyze/access) host-derived nucleic acids to satisfy the essential purine requirements of these organisms. Thus, this enzyme might play an important role(s) in facilitating the survival, growth, and development of this important human pathogen.	NIAID, Cell Biol Sect, Lab Parasit Dis, Div Intramural Res,NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Dwyer, DM (corresponding author), NIAID, Cell Biol Sect, Lab Parasit Dis, Div Intramural Res,NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	ddwyer@niaid.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000745, Z01AI000162, Z01AI000745] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		BATES PA, 1993, FEMS MICROBIOL LETT, V107, P53, DOI 10.1111/j.1574-6968.1993.tb06003.x; Benedik MJ, 1998, FEMS MICROBIOL LETT, V165, P1; BLANK A, 1982, ANAL BIOCHEM, V120, P267, DOI 10.1016/0003-2697(82)90347-5; BROWN PH, 1987, EUR J BIOCHEM, V168, P357, DOI 10.1111/j.1432-1033.1987.tb13427.x; Campbell M, 2003, INFECT IMMUN, V71, P6270, DOI 10.1128/IAI.71.11.6270-6278.2003; Carter NS, 2001, TRENDS PARASITOL, V17, P142, DOI 10.1016/S1471-4922(00)01806-7; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; DEBRABANT A, 1995, MOL BIOCHEM PARASIT, V71, P51, DOI 10.1016/0166-6851(95)00035-Y; Debrabant A, 2000, J BIOL CHEM, V275, P16366, DOI 10.1074/jbc.M908725199; Debrabant A, 2004, INT J PARASITOL, V34, P205, DOI 10.1016/j.ijpara.2003.10.011; Debrabant A, 2001, MOL CELL BIOCHEM, V220, P109, DOI 10.1023/A:1010809420104; Desai NA, 2003, FEMS MICROBIOL REV, V26, P457, DOI 10.1111/j.1574-6976.2003.tb00626.x; Desai NA, 2000, EUR J BIOCHEM, V267, P5123, DOI 10.1046/j.1432-1327.2000.01580.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DWYER DM, 1974, Z PARASITENKD, V43, P227, DOI 10.1007/BF00328879; DWYER DM, 1976, J IMMUNOL, V117, P2081; El-Sayed NM, 2005, SCIENCE, V309, P404, DOI 10.1126/science.1112181; El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631; Farajnia S, 2004, INT J PARASITOL, V34, P899, DOI 10.1016/j.ijpara.2004.03.005; FONG D, 1988, MOL BIOCHEM PARASIT, V31, P97, DOI 10.1016/0166-6851(88)90149-1; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GERBER LD, 1992, J BIOL CHEM, V267, P12168; Ghedin E, 2001, TRAFFIC, V2, P175, DOI 10.1034/j.1600-0854.2001.020304.x; GRAY HB, 1975, NUCLEIC ACIDS RES, V2, P1459, DOI 10.1093/nar/2.9.1459; HAMES BD., 1981, GEL ELECTROPHORESIS, P1; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; Handman E, 2001, CLIN MICROBIOL REV, V14, P229, DOI 10.1128/CMR.14.2.229-243.2001; HASSAN HF, 1986, COMP BIOCHEM PHYS B, V84, P217, DOI 10.1016/0305-0491(86)90209-9; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; IWAMATSU A, 1991, J BIOCHEM-TOKYO, V110, P151, DOI 10.1093/oxfordjournals.jbchem.a123534; Joshi MB, 2005, J BIOL CHEM, V280, P3847, DOI 10.1074/jbc.M412299200; Kar S, 2000, J BIOL CHEM, V275, P37789, DOI 10.1074/jbc.M002149200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landfear SM, 2001, BIOCHEM PHARMACOL, V62, P149, DOI 10.1016/S0006-2952(01)00663-3; Landfear SM, 2004, EUKARYOT CELL, V3, P245, DOI 10.1128/EC.3.2.245-254.2004; Lee BR, 1995, APPL MICROBIOL BIOT, V44, P425; MAEKAWA K, 1991, EUR J BIOCHEM, V200, P651, DOI 10.1111/j.1432-1033.1991.tb16228.x; MCCARTHYBURKE C, 1991, EXP PARASITOL, V73, P385, DOI 10.1016/0014-4894(91)90112-A; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; MUROPASTOR AM, 1992, MOL MICROBIOL, V6, P3021, DOI 10.1111/j.1365-2958.1992.tb01760.x; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Porter-Kelley JM, 2004, TRAFFIC, V5, P868, DOI 10.1111/j.1600-0854.2004.00229.x; PRZYKORSKA A, 1980, EUR J BIOCHEM, V108, P285, DOI 10.1111/j.1432-1033.1980.tb04722.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNEIDER A, 1993, J BIOL CHEM, V268, P21868; Shakarian AM, 2003, MOL CELL BIOCHEM, V245, P31, DOI 10.1023/A:1022851914014; Shakarian AM, 2002, J BIOL CHEM, V277, P17994, DOI 10.1074/jbc.M200114200; Sopwith WF, 2002, INT J PARASITOL, V32, P449, DOI 10.1016/S0020-7519(01)00372-1; STEVENS A, 1960, J BIOL CHEM, V235, P3016; Stiles JK, 1999, ANN TROP MED PARASIT, V93, P781, DOI 10.1080/00034989957781; TAKAHASHI M, 1978, J BIOCHEM-TOKYO, V83, P1521, DOI 10.1093/oxfordjournals.jbchem.a132063; Teasdale RD, 1996, ANNU REV CELL DEV BI, V12, P27, DOI 10.1146/annurev.cellbio.12.1.27; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; *UNICEF UNDP WORLD, 2004, SPEC PROGR RES TRAIN, P19; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Yamage M, 2000, J BIOL CHEM, V275, P36369, DOI 10.1074/jbc.M004036200; Zhang WW, 1996, MOL BIOCHEM PARASIT, V78, P79, DOI 10.1016/S0166-6851(96)02612-6; ZLOTNICK GW, 1987, COMP BIOCHEM PHYS B, V87, P629, DOI 10.1016/0305-0491(87)90063-0	61	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10079	10095		10.1074/jbc.M610770200	http://dx.doi.org/10.1074/jbc.M610770200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276983	hybrid			2022-12-25	WOS:000245421700082
J	Nakamura, K; Moore, R; Negishi, M; Sueyoshi, T				Nakamura, Kouichi; Moore, Rick; Negishi, Masahiko; Sueyoshi, Tatsuya			Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL BETA-OXIDATION; COA DESATURASE 1; GENE-EXPRESSION; XENOBIOTIC RECEPTORS; RESPONSE ELEMENT; ENHANCER MODULE; UGT1A1 GENE; CAR; TRANSCRIPTION; INSULIN	Upon drug activation, the nuclear pregnane X receptor (PXR) regulates not only hepatic drug but also energy metabolism. Using Pxr(-/-) mice, we have now investigated the PXR-mediated repression of lipid metabolism in the fasting livers. Treatment with PXR activator pregnenolone 16 alpha-carbonitrile (PCN) down-regulated the mRNA levels of carnitine palmitoyltransferase 1A (in beta-oxidation) and mitochondrial 3-hydroxy-3-methylglutarate-CoA synthase 2 (in ketogenesis) in wild-type (Pxr(+/+)) mice only. In contrast, the stearoyl-CoA desaturase 1 (in lipogenesis) mRNA was up-regulated in the PCN-treated Pxr(+/+) mice. Reflecting these up- and down-regulations and consistent with decreased energy metabolism, the levels of hepatic triglycerides and of serum 3-hydroxybutylate were increased and decreased, respectively, in the PCN-treated Pxr(+/+) mice. Using gel shift, glutathione S-transferase pull-down and cell-based reporter assays, we then examined whether PXR could cross-talk with the insulin response forkhead factor FoxA2 to repress the transcription of the Cpt1a and Hmgcs2 genes, because FoxA2 activates these genes in fasting liver. PXR directly bound to FoxA2 and repressed its activation of the Cpt1a and Hmgcs2 promoters. Moreover, ChIP assays showed that PCN treatment attenuated the binding of FoxA2 to these promoters in fasting Pxr(+/+) but not Pxr(-/-) mice. These results are consistent with the conclusion that PCN-activated PXR represses FoxA2-mediated transcription of Ctp1a and Hmgcs2 genes in fasting liver.	NIEHS, Pharmacogenet Sect, Lab Reprod & Dev Toxicol, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, Pharmacogenet Sect, Lab Reprod & Dev Toxicol, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928	Intramural NIH HHS [Z01 ES080040-22] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080040] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Allander SV, 1997, ENDOCRINOLOGY, V138, P4291, DOI 10.1210/en.138.10.4291; Bartlett K, 2004, EUR J BIOCHEM, V271, P462, DOI 10.1046/j.1432-1033.2003.03947.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Eaton S, 1996, BIOCHEM J, V320, P345, DOI 10.1042/bj3200345; Fukao T, 2004, PROSTAG LEUKOTR ESS, V70, P243, DOI 10.1016/j.plefa.2003.11.001; Goodwin B, 2002, ANNU REV PHARMACOL, V42, P1, DOI 10.1146/annurev.pharmtox.42.111901.111051; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Grefhorst A, 2005, AM J PHYSIOL-GASTR L, V289, pG592, DOI 10.1152/ajpgi.00063.2005; Hegardt FG, 1999, BIOCHEM J, V338, P569, DOI 10.1042/0264-6021:3380569; Honkakoski P, 2003, ANN MED, V35, P172, DOI 10.1080/07853890310008224; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; Kakizaki S, 2002, DRUG METAB DISPOS, V30, P208, DOI 10.1124/dmd.30.2.208; Kiyosawa N, 2004, ARCH TOXICOL, V78, P435, DOI 10.1007/s00204-004-0565-0; Klaassen CD, 2005, CURR DRUG METAB, V6, P309, DOI 10.2174/1389200054633826; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kobayashi K, 2003, MOL PHARMACOL, V64, P1069, DOI 10.1124/mol.64.5.1069; Kodama S, 2004, MOL CELL BIOL, V24, P7931, DOI 10.1128/MCB.24.18.7931-7940.2004; Laffel L, 1999, DIABETES-METAB RES, V15, P412, DOI 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8; Listenberger LL, 2003, P NATL ACAD SCI USA, V100, P3077, DOI 10.1073/pnas.0630588100; Louet JF, 2001, BIOCHEM SOC T, V29, P310, DOI 10.1042/0300-5127:0290310; Miyazaki M, 2000, J BIOL CHEM, V275, P30132, DOI 10.1074/jbc.M005488200; Mounier C, 2006, CAN J PHYSIOL PHARM, V84, P713, DOI 10.1139/Y05-152; Nyman LR, 2005, MOL GENET METAB, V86, P179, DOI 10.1016/j.ymgme.2005.07.021; Olpin SE, 2004, PROSTAG LEUKOTR ESS, V70, P293, DOI 10.1016/j.plefa.2003.06.003; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Rinaldo P, 2002, ANNU REV PHYSIOL, V64, P477, DOI 10.1146/annurev.physiol.64.082201.154705; Rosenfeld JM, 2003, MOL ENDOCRINOL, V17, P1268, DOI 10.1210/me.2002-0421; Runge-Morris M, 2005, CURR DRUG METAB, V6, P299, DOI 10.2174/1389200054633871; Sonoda J, 2003, CURR DRUG METAB, V4, P59, DOI 10.2174/1389200033336739; Squires EJ, 2004, J BIOL CHEM, V279, P49307, DOI 10.1074/jbc.M407281200; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sugatani J, 2005, METHOD ENZYMOL, V400, P92, DOI 10.1016/S0076-6879(05)00006-6; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Wang HY, 2005, TRENDS MOL MED, V11, P262, DOI 10.1016/j.molmed.2005.04.003; WATERS KM, 1994, J BIOL CHEM, V269, P27773; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Yamamoto Y, 2003, ARCH BIOCHEM BIOPHYS, V409, P207, DOI 10.1016/S0003-9861(02)00456-3; Zhou J, 2006, J BIOL CHEM, V281, P15013, DOI 10.1074/jbc.M511116200	47	143	155	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9768	9776		10.1074/jbc.M610072200	http://dx.doi.org/10.1074/jbc.M610072200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17267396	hybrid, Green Accepted			2022-12-25	WOS:000245421700051
J	Sharma, A; Masri, J; Jo, OD; Bernath, A; Martin, J; Funk, A; Gera, J				Sharma, Anushree; Masri, Janine; Jo, Oak D.; Bernath, Andrew; Martin, Jheralyn; Funk, Alexander; Gera, Joseph			Protein kinase C regulates internal initiation of translation of the GATA-4 mRNA following vasopressin-induced hypertrophy of cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITES; TRANS-ACTING FACTORS; GENE-EXPRESSION; TRANSCRIPTION FACTORS; MEDIATED TRANSLATION; IN-VITRO; PRESSURE-OVERLOAD; AKT ACTIVITY; CYCLIN D1; PHOSPHORYLATION	GATA-4 is a key member of the GATA family of transcription factors involved in cardiac development and growth as well as in cardiac hypertrophy and heart failure. Our previous studies suggest that GATA-4 protein synthesis may be translationally regulated. We report here that the 518-nt long 5'-untransiated region (5'-UTR) of the GATA-4 mRNA, which is predicted to form stable secondary structures (-65 kcal/mol) such as to be inhibitory to cap-dependent initiation, confers efficient translation to monocistronic reporter mRNAs in cell-free extracts. Moreover, uncapped GATA-4 5'-UTR containing monocistronic reporter mRNAs continue to be well translated while capped reporters are insensitive to the inhibition of initiation by cap-analog, suggesting a capin-dependent mechanism of initiation. Utilizing a dicistronic luciferase mRNA reporter containing the GATA-4 5'-UTR within the intercistrionic region, we demonstrate that this leader sequence confers functional internal ribosome entry site (IRES) activity. The activity of the GATA-4 IRES is unaffected in trans - differentiating P19CL6 cells, however, is strongly stimulated immediately following arginine-vasopressin exposure of H9c2 ventricular myocytes. IRES activity is then maintained at submaximal levels during hypertrophic growth of these cells. Supraphysiological Ca2+ levels diminished stimulation of IRES activity immediately following exposure to vasopressin and inhibition of protein kinase C activity utilizing a pseudosubstrate peptide sequence blocked IRES activity during hypertrophy. Thus, our data suggest a mechanism for GATA-4 protein synthesis under conditions of reduced global cap-dependent translation, which is maintained at a submaximal level during hypertrophic growth and point to the regulation of GATA-4 IRES activity by sarco(ER)reticular Ca2+ stores and PKC.	Greater Los Angels Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90048 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gera, J (corresponding author), Greater Los Angels Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA 91343 USA.	gera@ucla.edu		Gera, Joseph/0000-0002-2908-6894	NATIONAL CANCER INSTITUTE [R01CA109312] Funding Source: NIH RePORTER; NCI NIH HHS [CA109312] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aries A, 2004, P NATL ACAD SCI USA, V101, P6975, DOI 10.1073/pnas.0401833101; Bartlett DW, 2006, NUCLEIC ACIDS RES, V34, P322, DOI 10.1093/nar/gkj439; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; Bert AG, 2006, RNA, V12, P1074, DOI 10.1261/rna.2320506; BOSSER R, 1995, MOL CELL BIOL, V15, P661; Brostrom MA, 2000, INT J BIOCHEM CELL B, V32, P993, DOI 10.1016/S1357-2725(00)00037-6; Brostrom MA, 2003, CELL CALCIUM, V34, P345, DOI 10.1016/S0143-4160(03)00127-1; Brostrom MA, 2001, J CELL BIOCHEM, V83, P204, DOI 10.1002/jcb.1219; Byrd MP, 2005, J BIOL CHEM, V280, P18610, DOI 10.1074/jbc.M414014200; CARROLL R, 1993, ANAL BIOCHEM, V212, P17, DOI 10.1006/abio.1993.1284; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Elango N, 2006, J CELL BIOCHEM, V99, P1108, DOI 10.1002/jcb.20909; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gerlitz G, 2002, EUR J BIOCHEM, V269, P2810, DOI 10.1046/j.1432-1033.2002.02974.x; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Grepin C, 1997, DEVELOPMENT, V124, P2387; HabaraOhkubo A, 1996, CELL STRUCT FUNCT, V21, P101, DOI 10.1247/csf.21.101; Han BG, 2002, MOL CELL BIOL, V22, P7372, DOI 10.1128/MCB.22.21.7372-7384.2002; Hasegawa K, 1997, CIRCULATION, V96, P3943; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; HERSHEY J, 2000, PATHWAY MECH INITIAT; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Holcik M, 2005, RNA, V11, P1605, DOI 10.1261/rna.2158605; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; HUANG WY, 1995, GENE, V155, P219, DOI 10.1016/0378-1119(94)00893-W; IDRISS H, 1994, BIOCHEMISTRY-US, V33, P11382, DOI 10.1021/bi00203a037; Komar AA, 2005, J BIOL CHEM, V280, P23425, DOI 10.1074/jbc.R400041200; Krichevsky AM, 1999, J BIOL CHEM, V274, P14295, DOI 10.1074/jbc.274.20.14295; Lancaster AM, 2006, RNA, V12, P894, DOI 10.1261/rna.2342306; Lewis SM, 2005, CELL DEATH DIFFER, V12, P547, DOI 10.1038/sj.cdd.4401602; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; McMullen JR, 2004, CIRCULATION, V109, P3050, DOI 10.1161/01.CIR.0000130641.08705.45; Misquitta CM, 2006, CELL CALCIUM, V40, P329, DOI 10.1016/j.ceca.2006.04.004; Misquitta CM, 2001, MOL CELL BIOCHEM, V224, P53, DOI 10.1023/A:1011982932645; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; Peterkin T, 2005, SEMIN CELL DEV BIOL, V16, P83, DOI 10.1016/j.semcdb.2004.10.003; Pikkarainen S, 2004, CARDIOVASC RES, V63, P196, DOI 10.1016/j.cardiores.2004.03.025; Reilly BA, 1998, J BIOL CHEM, V273, P3747, DOI 10.1074/jbc.273.6.3747; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; Saghir AN, 2001, BIOCHEM J, V356, P557, DOI 10.1042/0264-6021:3560557; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Shioi T, 2003, CIRCULATION, V107, P1664, DOI 10.1161/01.CIR.0000057979.36322.88; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Thoma C, 2004, MOL CELL, V15, P925, DOI 10.1016/j.molcel.2004.08.021; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Van Eden ME, 2004, RNA, V10, P720, DOI 10.1261/rna.5225204; Wada H, 1996, J BIOL CHEM, V271, P8359, DOI 10.1074/jbc.271.14.8359; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	57	17	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9505	9516		10.1074/jbc.M608874200	http://dx.doi.org/10.1074/jbc.M608874200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17284439	hybrid			2022-12-25	WOS:000245421700023
J	Gorlatova, NV; Tale, JM; Elokdah, H; Li, DH; Fan's, K; Warnock, M; Crandall, DL; Lawrence, DA				Gorlatova, Natalia V.; Tale, Jacqueline M.; Elokdah, Hassan; Li, Donghua; Fan's, Kristi; Warnock, Mark; Crandall, David L.; Lawrence, Daniel A.			Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORONARY-ARTERY THROMBOSIS; ADIPOSE-TISSUE DEVELOPMENT; PAI-1 GENE-EXPRESSION; NECROSIS-FACTOR-ALPHA; IN-VIVO; BINDING-SITE; PHARMACOLOGICAL INHIBITION; CARDIOVASCULAR-DISEASE; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS	The inactivation of plasminogen activator inhibitor- 1(PAI-1) by the small molecule PAI-1 inhibitor PAI-039 (tiplaxtinin) has been investigated using enzymatic analysis, direct binding studies, site-directed mutagenesis, and molecular modeling studies. Previously PAI-039 has been shown to exhibit in vivo activity in various animal models, but the mechanism of inhibition is unknown. PAI-039 bound specifically to the active conformation of PAI-1 and exhibited reversible inactivation of PAI-1 in vitro. SDS-PAGE indicated that PAI-039 inactivated PAI-1 predominantly through induction of PAI-1 substrate behavior. Preincubation of PAI-1 with vitronectin, but not bovine serum albumin, blocked PAI-039 activity while analysis of the reciprocal experiment demonstrated that preincubation of PAI-1 with PAI-039 blocked the binding of PAI-1 to vitronectin. Together, these data suggest that the site of interaction of the drug on PAI-1 is inaccessible when PAI-1 is bound to vitronectin and may overlap with the PAI-1 vitronectin binding domain. This was confirmed by site-directed mutagenesis and molecular modeling studies, which suggest that the binding epitope for PAI-039 is localized adjacent to the previously identified interaction site for vitronectin. Thus, these studies provide a detailed characterization of the mechanism of inhibition of PAI-1 by PAI-039 against free, but not vitronectin-bound PAI-1, suggesting for the first time a novel pool of PAl-1 exists that is vulnerable to inhibition by inactivators that bind at the vitronectin binding site.	Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Wyeth Ayerst Res, Cardiovasc & Metab Dis Res, Collegeville, PA 19426 USA; Wyeth Ayerst Res, Chem & Screening Sci, Collegeville, PA 19426 USA; Univ Maryland, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	University of Michigan System; University of Michigan; Pfizer; Pfizer; American Red Cross	Lawrence, DA (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, 7301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dlawrenc@umich.edu		Lawrence, Daniel/0000-0003-3126-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374, P01HL054710, R01HL055747] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55374, HL55747, P01HL54710, P01 HL054710] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BIEMOND BJ, 1995, CIRCULATION, V91, P1175, DOI 10.1161/01.CIR.91.4.1175; Bjorquist P, 1998, BIOCHEMISTRY-US, V37, P1227, DOI 10.1021/bi971554q; Cao CZ, 2006, EMBO J, V25, P1860, DOI 10.1038/sj.emboj.7601082; COLUCCI M, 1985, J CLIN INVEST, V75, P818, DOI 10.1172/JCI111777; Crandall DL, 2006, ARTERIOSCL THROM VAS, V26, P2209, DOI 10.1161/01.ATV.0000235605.51400.9d; Crandall DL, 2004, J THROMB HAEMOST, V2, P1422, DOI 10.1111/j.1538-7836.2004.00829.x; Crandall DL, 2003, BIOCHEM BIOPH RES CO, V311, P904, DOI 10.1016/j.bbrc.2003.10.088; Crandall DL, 2000, J CLIN ENDOCR METAB, V85, P2609, DOI 10.1210/jc.85.7.2609; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; De Taeye B, 2005, CURR OPIN PHARMACOL, V5, P149, DOI 10.1016/j.coph.2005.01.007; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Durand MK, 2004, THROMB HAEMOSTASIS, V91, P438, DOI 10.1160/TH03-12-0784; Egelund R, 2001, J BIOL CHEM, V276, P13077, DOI 10.1074/jbc.M009024200; Elokdah H, 2004, J MED CHEM, V47, P3491, DOI 10.1021/jm049766q; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; FAY WP, 1994, BLOOD, V83, P351; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; Fearns C, 1997, AM J PATHOL, V150, P579; Fogo AB, 2003, J CLIN INVEST, V112, P326, DOI 10.1172/JCI200319375; Folkes A, 2002, BIOORG MED CHEM LETT, V12, P1063, DOI 10.1016/S0960-894X(02)00078-1; Gorlatova NV, 2003, J BIOL CHEM, V278, P16329, DOI 10.1074/jbc.M208420200; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Hennan JK, 2005, J PHARMACOL EXP THER, V314, P710, DOI 10.1124/jpet.105.084129; Horn IR, 1998, THROMB HAEMOSTASIS, V80, P822; Huang YF, 2003, J CLIN INVEST, V112, P379, DOI 10.1172/JCI200318038; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Ingelfinger JR, 2003, NEW ENGL J MED, V349, P2265, DOI 10.1056/NEJMcibr032288; Jensen JK, 2002, FEBS LETT, V521, P91, DOI 10.1016/S0014-5793(02)02830-2; Kannel WB, 2005, LIPIDS, V40, P1215, DOI 10.1007/s11745-005-1488-8; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lawrence DA, 1997, NAT STRUCT BIOL, V4, P339, DOI 10.1038/nsb0597-339; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Leik CE, 2006, J THROMB HAEMOST, V4, P2710, DOI 10.1111/j.1538-7836.2006.02244.x; Lijnen HR, 2005, J THROMB HAEMOST, V3, P1174, DOI 10.1111/j.1538-7836.2005.01390.x; LOSKUTOFF DJ, 1993, THROMB HAEMOSTASIS, V70, P135; LOSKUTOFF DJ, 1991, FIBRINOLYSIS, V5, P197, DOI 10.1016/0268-9499(91)90001-K; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; Minor KH, 2002, J BIOL CHEM, V277, P10337, DOI 10.1074/jbc.M109564200; Naessens D, 2003, J THROMB HAEMOST, V1, P1028, DOI 10.1046/j.1538-7836.2003.00206.x; Podor TJ, 2000, J BIOL CHEM, V275, P19788, DOI 10.1074/jbc.M908079199; PYKE C, 1991, CANCER RES, V51, P4067; Robbie LA, 1997, THROMB HAEMOSTASIS, V77, P510; Robbie LA, 1996, ARTERIOSCL THROM VAS, V16, P539, DOI 10.1161/01.ATV.16.4.539; Rosenberg RD, 1999, NEW ENGL J MED, V340, P1555, DOI 10.1056/NEJM199905203402007; Samad F, 1996, J CLIN INVEST, V97, P37, DOI 10.1172/JCI118404; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; Smith LH, 2006, BLOOD, V107, P132, DOI 10.1182/blood-2005-07-2681; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2004, J BIOL CHEM, V279, P29981, DOI 10.1074/jbc.M401913200; Stefansson S, 2003, CURR PHARM DESIGN, V9, P1545, DOI 10.2174/1381612033454621; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; STEFANSSON S, 2003, SCI STKE, pE24; Uchida Y, 2004, J BIOL CHEM, V279, P4075, DOI 10.1074/jbc.M304222200; Venkatachalam CM, 2003, J MOL GRAPH MODEL, V21, P289, DOI 10.1016/S1093-3263(02)00164-X; Verhamme I, 1999, J BIOL CHEM, V274, P17511, DOI 10.1074/jbc.274.25.17511; Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Weisberg AD, 2005, ARTERIOSCL THROM VAS, V25, P365, DOI 10.1161/01.ATV.0000152356.85791.52; Xu Z, 2004, J BIOL CHEM, V279, P17914, DOI 10.1074/jbc.M314197200; Yepes M., 2006, HEMOSTASIS THROMBOSI, P365; Zhou AW, 2003, NAT STRUCT BIOL, V10, P541, DOI 10.1038/nsb943	67	78	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9288	9296		10.1074/jbc.M611642200	http://dx.doi.org/10.1074/jbc.M611642200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17276980	hybrid			2022-12-25	WOS:000245780300076
J	Popa-Lisseanu, AG; Delgado-Huertas, A; Forero, MG; Rodriguez, A; Arlettaz, R; Ibanez, C				Popa-Lisseanu, Ana G.; Delgado-Huertas, Antonio; Forero, Manuela G.; Rodriguez, Alicia; Arlettaz, Raphael; Ibanez, Carlos			Bats' Conquest of a Formidable Foraging Niche: The Myriads of Nocturnally Migrating Songbirds	PLOS ONE			English	Article								Along food chains, i.e., at different trophic levels, the most abundant taxa often represent exceptional food reservoirs, and are hence the main target of consumers and predators. The capacity of an individual consumer to opportunistically switch towards an abundant food source, for instance, a prey that suddenly becomes available in its environment, may offer such strong selective advantages that ecological innovations may appear and spread rapidly. New predator-prey relationships are likely to evolve even faster when a diet switch involves the exploitation of an unsaturated resource for which few or no other species compete. Using stable isotopes of carbon and nitrogen as dietary tracers, we provide here strong support to the controversial hypothesis that the giant noctule bat Nyctalus lasiopterus feeds on the wing upon the multitude of flying passerines during their nocturnal migratory journeys, a resource which, while showing a predictable distribution in space and time, is only seasonally available. So far, no predator had been reported to exploit this extraordinarily diverse and abundant food reservoir represented by nocturnally migrating passerines.	[Popa-Lisseanu, Ana G.; Forero, Manuela G.; Ibanez, Carlos] CSIC, Estac Biol Donana, E-41080 Seville, Spain; [Delgado-Huertas, Antonio; Rodriguez, Alicia] CSIC, Estac Expt Zaidin, Granada, Spain; [Arlettaz, Raphael] Univ Bern, Inst Zool, Div Conservat Biol, Bern, Switzerland; [Arlettaz, Raphael] Nat Ctr, Valais Field Stn, Swiss Ornithol Inst, Salgesch, Switzerland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Biologica de Donana (EBD); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); University of Bern; Swiss Ornithological Institute	Popa-Lisseanu, AG (corresponding author), CSIC, Estac Biol Donana, E-41080 Seville, Spain.	anapopa@ebd.csic.es	Huertas, Antonio Delgado/F-6866-2011; Arlettaz, Raphaël/O-2182-2016; Ibanez, Carlos/H-7577-2015; Vazquez-Dominguez, Guillermo GVD/L-7818-2014; Rodríguez Sánchez, Alicia/H-7716-2015	Huertas, Antonio Delgado/0000-0002-7240-1570; Arlettaz, Raphaël/0000-0001-6360-5339; Ibanez, Carlos/0000-0003-1181-7641; Rodríguez Sánchez, Alicia/0000-0002-0028-6120	Organismo Autonomo de Parques Nacionales (MMA) of Spain [021/2002]; MEC of Spain; RyC; FPU	Organismo Autonomo de Parques Nacionales (MMA) of Spain; MEC of Spain(Spanish Government); RyC; FPU(Spanish Government)	This research was funded by the Organismo Autonomo de Parques Nacionales (MMA) of Spain, project 021/2002. MEC of Spain supported M. G. F. with a contract RyC and A. G. P- L. with a predoctoral grant of the program FPU.	Arlettaz R, 2001, OIKOS, V95, P105, DOI 10.1034/j.1600-0706.2001.950112.x; Ayliffe LK, 2004, OECOLOGIA, V139, P11, DOI 10.1007/s00442-003-1479-x; BAIRD RW, 1992, OECOLOGIA, V89, P125, DOI 10.1007/BF00319024; Ben-David M, 2001, OECOLOGIA, V127, P180, DOI 10.1007/s004420000570; BenDavid M, 1997, OECOLOGIA, V111, P280, DOI 10.1007/s004420050236; Bontadina F, 2003, FUNCT ECOL, V17, P141, DOI 10.1046/j.1365-2435.2003.00702_1.x; Bruderer B, 1998, J AVIAN BIOL, V29, P499, DOI 10.2307/3677169; BRUDERER B, 1999, P 22 INT ORN C DURB, P1983; CHARNOV EL, 1976, AM NAT, V110, P141, DOI 10.1086/283054; Correia AM, 2001, J ZOOL, V255, P533; Dalerum F, 2005, OECOLOGIA, V144, P647, DOI 10.1007/s00442-005-0118-0; DENIRO MJ, 1978, GEOCHIM COSMOCHIM AC, V42, P495, DOI 10.1016/0016-7037(78)90199-0; Dondini G, 2000, J ZOOL, V251, P233, DOI 10.1111/j.1469-7998.2000.tb00606.x; Hobson KA, 1997, CAN J ZOOL, V75, P1720, DOI 10.1139/z97-799; HOBSON KA, 1992, CONDOR, V94, P181, DOI 10.2307/1368807; HOBSON KA, 1992, CONDOR, V94, P189, DOI 10.2307/1368808; Huin N, 1998, BIRD STUDY, V45, P361, DOI 10.1080/00063659809461108; Ibanez C, 2003, FUNCT ECOL, V17, P143, DOI 10.1046/j.1365-2435.2003.00702_2.x; Ibanez C, 2001, P NATL ACAD SCI USA, V98, P9700, DOI 10.1073/pnas.171140598; Ibanez C., 2004, HDB SAUGETIERE EUROP, VII, P695, DOI DOI 10.1080/0964704X.2013.774246; Inger R, 2006, J ANIM ECOL, V75, P1190, DOI 10.1111/j.1365-2656.2006.01142.x; Jones G, 1996, SYM ZOOL S, P111; Juliano SA, 2005, ECOL LETT, V8, P558, DOI 10.1111/j.1461-0248.2005.00755.x; Kelly JF, 2000, CAN J ZOOL, V78, P1, DOI 10.1139/cjz-78-1-1; Kunz T.H., 1988, P277; MACARTHUR RH, 1966, AM NAT, V100, P377; MacAvoy SE, 2005, CAN J ZOOL, V83, P631, DOI 10.1139/Z05-038; McCutchan JH, 2003, OIKOS, V102, P378, DOI 10.1034/j.1600-0706.2003.12098.x; Miron MLL, 2006, J EXP BIOL, V209, P541, DOI 10.1242/jeb.02016; Moreau R., 1972, PALAEARCTIC AFRICAN; Mroz I, 1996, PHYS REV LETT, V76, P3025, DOI 10.1103/PhysRevLett.76.3025; Munday PL, 2004, CURR BIOL, V14, P1498, DOI 10.1016/j.cub.2004.08.029; NORBERG U M, 1987, Philosophical Transactions of the Royal Society of London B Biological Sciences, V316, P335, DOI 10.1098/rstb.1987.0030; NORBERG UM, 1988, BIOL J LINN SOC, V33, P383, DOI 10.1111/j.1095-8312.1988.tb00451.x; Robbins CT, 2005, OECOLOGIA, V144, P534, DOI 10.1007/s00442-005-0021-8; ROSENZWEIG ML, 1978, BIOL J LINN SOC, V10, P275, DOI 10.1111/j.1095-8312.1978.tb00016.x; RYDELL J, 1994, P ROY SOC B-BIOL SCI, V257, P175, DOI 10.1098/rspb.1994.0112; Simmons NB, 2005, SCIENCE, V307, P527, DOI 10.1126/science.1108871; Sponheimer M, 2006, RAPID COMMUN MASS SP, V20, P1395, DOI 10.1002/rcm.2454; Sweeting CJ, 2005, FUNCT ECOL, V19, P777, DOI 10.1111/j.1365-2435.2005.01019.x; Teeling EC, 2005, SCIENCE, V307, P580, DOI 10.1126/science.1105113; TIESZEN LL, 1983, OECOLOGIA, V57, P32, DOI 10.1007/BF00379558; Vanderklift MA, 2003, OECOLOGIA, V136, P169, DOI 10.1007/s00442-003-1270-z; von Helversen O, 2003, BAT ECOLOGY, P346; Walter H., 1979, ELEONORAS FALCON ADA; West AG, 2004, FUNCT ECOL, V18, P616, DOI 10.1111/j.0269-8463.2004.00862.x; WILSON DS, 1986, AM NAT, V127, P835, DOI 10.1086/284528	47	50	50	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e205	10.1371/journal.pone.0000205	http://dx.doi.org/10.1371/journal.pone.0000205			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299585	Green Submitted, gold, Green Published			2022-12-25	WOS:000207444400006
J	Hill, PC; Jeffries, DJ; Brookes, RH; Fox, A; Jackson-Sillah, D; Lugos, MD; Donkor, SA; de Jong, BC; Corrah, T; Adegbola, RA; McAdam, KP				Hill, Philip C.; Jeffries, David J.; Brookes, Roger H.; Fox, Annette; Jackson-Sillah, Dolly; Lugos, Moses D.; Donkor, Simon A.; de Jong, Bouke C.; Corrah, Tumani; Adegbola, Richard A.; McAdam, Keith P.			Using ELISPOT to Expose False Positive Skin Test Conversion in Tuberculosis Contacts	PLOS ONE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; T-CELLS; INFECTION; DIAGNOSIS; SURVEILLANCE; REVERSION; ASSAY	Background. Repeat tuberculin skin tests may be false positive due to boosting of waned immunity to past mycobacterial exposure. We evaluated whether an ELISPOT test could identify tuberculosis (TB) contacts with boosting of immunity to non-tuberculous mycobacterial exposure. Methodology/Principal Findings. We conducted tuberculin and ELISPOT tests in 1665 TB contacts: 799 were tuberculin test negative and were offered a repeat test after three months. Those with tuberculin test conversion had an ELISPOT, chest X-ray and sputum analysis if appropriate. We compared converters with non-converters, assessed the probability of each of four combinations of ELISPOT results over the two time points and estimated boosting with adjustment for ELISPOT sensitivity and specificity. 704 (72%) contacts had a repeat tuberculin test; 176 (25%) had test conversion, which increased with exposure to a case (p = 0.002), increasing age (p = 0.0006) and BCG scar (p = 0.06). 114 tuberculin test converters had ELISPOT results: 16(14%) were recruitment positive/follow-up positive, 9 (8%) positive/negative, 34 (30%) negative/positive, and 55 (48%) were negative/negative. There was a significant non-linear effect of age for ELISPOT results in skin test converters (p = 0.038). Estimates of boosting ranged from 32%-41% of skin test converters with increasing age. Three converters were diagnosed with TB, two had ELISPOT results: both were positive, including one at recruitment. Conclusions/Significance. We estimate that approximately one third of tuberculin skin test conversion in Gambian TB case contacts is due to boosting of immunity to non-tuberculous mycobacterial exposure. Further longitudinal studies are required to confirm whether ELISPOT can reliably identify case contacts with tuberculin test conversion that would benefit most from prophylactic treatment.	[Hill, Philip C.; Jeffries, David J.; Brookes, Roger H.; Fox, Annette; Jackson-Sillah, Dolly; Lugos, Moses D.; Donkor, Simon A.; de Jong, Bouke C.; Corrah, Tumani; Adegbola, Richard A.; McAdam, Keith P.] MRC Unit, Bacterial Dis Programme, Banjul, Gambia	University of London; London School of Hygiene & Tropical Medicine	Hill, PC (corresponding author), MRC Unit, Bacterial Dis Programme, Banjul, Gambia.	phill@mrc.gm	de Jong, Bouke/A-3636-2013	de Jong, Bouke/0000-0002-1017-4675; Lugos, Moses/0000-0002-4921-2691; Brookes, Roger/0000-0002-5361-0617	Medical Research Council (UK); European Commission; Medical Research Council [MC_U190071468, MC_U190081982] Funding Source: researchfish; MRC [MC_U190071468, MC_U190081982] Funding Source: UKRI	Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); European Commission(European CommissionEuropean Commission Joint Research Centre); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by the Medical Research Council (UK) and the European Commission.	Adegbola RA, 2003, INT J TUBERC LUNG D, V7, P390; Aiken AM, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-66; [Anonymous], 1956, Br Med J, V1, P413; COMSTOCK GW, 1969, AM REV RESPIR DIS, V100, P839; EDWARDS LB, 1953, RESPONSE BCG VACCINA; Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9; Ferrara G, 2006, LANCET, V367, P1328, DOI 10.1016/S0140-6736(06)68579-6; Godkin AJ, 2002, J IMMUNOL, V169, P2210, DOI 10.4049/jimmunol.169.4.2210; Guwatudde D, 2003, AM J EPIDEMIOL, V158, P887, DOI 10.1093/aje/kwg227; Hill PC, 2004, CLIN INFECT DIS, V38, P966, DOI 10.1086/382362; Jeffries DJ, 2006, INT J TUBERC LUNG D, V10, P192; Jeffries DJ, 2004, INT J TUBERC LUNG D, V8, P1095; Kamerbeek J, 1997, J CLIN MICROBIOL, V35, P907, DOI 10.1128/JCM.35.4.907-914.1997; Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100; Levy MZ, 2005, INT J TUBERC LUNG D, V9, P771; Lienhardt C, 2003, AM J RESP CRIT CARE, V168, P448, DOI 10.1164/rccm.200212-1483OC; Menzies D, 1999, AM J RESP CRIT CARE, V159, P15, DOI 10.1164/ajrccm.159.1.9801120; *NAT I HLTH CLIN E, 2006, CLIN GUIDELINE, V33, P1; PALMER CE, 1952, LANCET, V262, P935; Pathan AA, 2001, J IMMUNOL, V167, P5217, DOI 10.4049/jimmunol.167.9.5217; Pouchot J, 1997, ANN INTERN MED, V126, P210, DOI 10.7326/0003-4819-126-3-199702010-00005; Taylor Zachary, 2005, Morbidity and Mortality Weekly Report, V54, P1; TUKEY JW, 1950, AM REV TUBERC PULM, V62, P77; van der Loeff MFS, 2003, AIDS, V17, P1841, DOI [10.1097/00002030-200308150-00014, 10.1097/01.aids.0000076303.76477.49]; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Vekemans J, 2001, INFECT IMMUN, V69, P6554, DOI 10.1128/IAI.69.10.6554-6557.2001; WASZ-HOCKERT O, 1947, Ann Med Intern Fenn, V36, P764	27	27	32	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2007	2	1							e183	10.1371/journal.pone.0000183	http://dx.doi.org/10.1371/journal.pone.0000183			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DH	17264885	Green Published, gold			2022-12-25	WOS:000207444200007
J	Singh, MK; Nicolas, E; Gherraby, W; Dadke, D; Lessin, S; Golemis, EA				Singh, M. K.; Nicolas, E.; Gherraby, W.; Dadke, D.; Lessin, S.; Golemis, E. A.			HEI10 negatively regulates cell invasion by inhibiting cyclin B/Cdk1 and other promotility proteins	ONCOGENE			English	Article						hEI10; Cdk1; cyclin B; migration; invasion; cell cycle	FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; NEUROFIBROMATOSIS TYPE-2; MIGRATION; CANCER; GENE; IDENTIFICATION; PROGRESSION; NF2/MERLIN; EXPRESSION	Human enhancer of invasion, clone 10 ( HEI10) (CCNB1IP1) was. rst described as a RING-finger family ubiquitin ligase that regulates cell cycle by interacting with cyclin B and promoting its degradation. Subsequently, other studies suggested specific upregulation of HEI10 in metastatic melanoma and demonstrated direct interaction between HEI10 and the tumor suppressor Merlin, encoded by the neurofibromatosis 2 gene. These and other results led us to hypothesize that HEI10 also influences the processes of cell migration and metastasis. We here show that cells with depleted HEI10 both migrate more rapidly and invade more effectively than control cells. HEI10 depletion post-transcriptionally increases the expression of a group of promotility regulatory proteins including p130Cas, paxillin, Cdk1 and cyclin B2, but excluding Merlin. Among these, only inhibition of Cdk1/ cyclin B activity specifically reversed the motility and invasion of HEI10-depleted cells. Finally, HEI10 is abundantly transcribed in many human tissues, and particularly abundant in some tumor cell lines, suggesting that it may be commonly involved in coordinating cell cycle with cell migration and invasion.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Golemis, EA (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, W406,333 Cottman Ave, Philadelphia, PA 19111 USA.	ea_golemis@fccc.edu	Singh, Mahendra K./K-6267-2019	Golemis, Erica/0000-0003-3618-3673	NCI NIH HHS [P30 CA006927-44, P30 CA006927, CA-06927, R01 CA063366, R01 CA063366-12, R01 CA63366] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA063366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bouton AH, 1997, HYBRIDOMA, V16, P403, DOI 10.1089/hyb.1997.16.403; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Draviam VM, 2001, J CELL BIOL, V152, P945, DOI 10.1083/jcb.152.5.945; Evans DGR, 2000, J MED GENET, V37, P897, DOI 10.1136/jmg.37.12.897; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Gronholm M, 2006, ONCOGENE, V25, P4389, DOI 10.1038/sj.onc.1209475; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; James MF, 2004, J CELL SCI, V117, P2951, DOI 10.1242/jcs.01156; Juliano R, 2003, NAT CELL BIOL, V5, P589, DOI 10.1038/ncb0703-589; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Manes T, 2003, J CELL BIOL, V161, P817, DOI 10.1083/jcb.200212172; Mine N, 2001, JPN J CANCER RES, V92, P135, DOI 10.1111/j.1349-7006.2001.tb01075.x; Nymark P, 2006, CANCER RES, V66, P5737, DOI 10.1158/0008-5472.CAN-06-0199; Poulikakos PI, 2006, ONCOGENE, V25, P5960, DOI 10.1038/sj.onc.1209587; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; Smith AP, 2004, CANCER BIOL THER, V3, P104, DOI 10.4161/cbt.3.1.661; Toby GG, 2003, MOL CELL BIOL, V23, P2109, DOI 10.1128/MCB.23.6.2109-2122.2003; Wade R, 2006, BIOCHEM J, V393, P565, DOI 10.1042/BJ20051241; Worthylake RA, 2003, J BIOL CHEM, V278, P13578, DOI 10.1074/jbc.M211584200; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	26	25	26	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4825	4832		10.1038/sj.onc.1210282	http://dx.doi.org/10.1038/sj.onc.1210282			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297447	Green Accepted			2022-12-25	WOS:000248170400007
J	He, X; Pool, M; Darcy, KM; Lim, SB; Auersperg, N; Coon, JS; Beck, WT				He, X.; Pool, M.; Darcy, K. M.; Lim, S. B.; Auersperg, N.; Coon, J. S.; Beck, W. T.			Knockdown of polypyrimidine tract-binding protein suppresses ovarian tumor cell growth and invasiveness in vitro	ONCOGENE			English	Article						epithelial ovarian cancer; polypyrimidine tract-binding protein; RNA interference; tissue microarray; tumorigenesis	PERINUCLEOLAR COMPARTMENT; MESSENGER-RNA; HNRNP-I; CANCER; EXPRESSION; RESISTANCE; COMPLEX; ELEMENT; GENE	Polypyrimidine tract-binding protein (PTB) is an RNA-binding protein with multiple functions in the regulation of RNA processing and IRES-mediated translation. We report here overexpression of PTB in a majority of epithelial ovarian tumors revealed by immunoblotting and tissue microarray (TMA) staining. By western blotting, we found that PTB was overexpressed in 17 out of 19 ovarian tumor specimens compared to their matched-normal tissues. By TMA staining, we found PTB expression in 38 out of 44 ovarian cancer cases but only in two out of nine normal adjacent tissues. PTB is also overexpressed in SV40 large T-antigen immortalized ovarian epithelial cells compared to normal human ovarian epithelial cells. Using doxycycline-inducible small interfering RNA technology, we found that knockdown of PTB expression in the ovarian tumor cell line A2780 substantially impaired tumor cell proliferation, anchorageindependent growth and in vitro invasiveness. These results suggest that overexpression of PTB is an important component of the multistep process of tumorigenesis, and might be required for the development and maintenance of epithelial ovarian tumors. Moreover, because of its novel role in tumor cell growth and invasiveness, shown here for the. rst time, PTB may be a novel therapeutic target in the treatment of ovarian cancer.	Univ Illinois, GOG, Core Lab Mol Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Dept Biopharmaceut Sci, Coll Pharm, Chicago, IL 60607 USA; Univ Illinois, Ctr Canc, Chicago, IL 60607 USA; Rush Univ, Ctr Med, Dept Pathol, Chicago, IL USA; Roswell Pk Canc Inst, GOG Stat & Data Ctr, Buffalo, NY USA; Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC V5Z 1M9, Canada	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University; Roswell Park Cancer Institute; University of British Columbia	Beck, WT (corresponding author), Univ Illinois, Dept Biopharmaceut Sci, MC865, 833 S Wood St, Chicago, IL 60612 USA.	WTBeck@uic.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015482] Funding Source: NIH RePORTER; NCRR NIH HHS [C06 RR015482-01, C06RR15482, C06 RR015482] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bast RC, 2005, CLIN CANCER RES, V11, P6103, DOI 10.1158/1078-0432.CCR-04-2213; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; Bushell M, 2006, MOL CELL, V23, P401, DOI 10.1016/j.molcel.2006.06.012; Castelo-Branco P, 2004, MOL CELL BIOL, V24, P4174, DOI 10.1128/MCB.24.10.4174-4183.2004; Cornelis S, 2005, NUCLEIC ACIDS RES, V33, P3095, DOI 10.1093/nar/gki611; Cote CA, 1999, MOL CELL, V4, P431, DOI 10.1016/S1097-2765(00)80345-7; Faustino NA, 2003, GENE DEV, V17, P419, DOI 10.1101/gad.1048803; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; He XL, 2004, CLIN CANCER RES, V10, P4652, DOI 10.1158/1078-0432.CCR-03-0439; Huang S, 1997, J CELL BIOL, V137, P965, DOI 10.1083/jcb.137.5.965; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; JIN W, 1990, NUCLEIC ACIDS RES, V18, P5995, DOI 10.1093/nar/18.20.5995; Jin W, 2000, CANCER RES, V60, P1221; Jin W, 2003, CANCER RES, V63, P6154; Jin X, 2002, ANTICANCER RES, V22, P659; Kamath RV, 2005, CANCER RES, V65, P246; Kasper JS, 2005, J VIROL, V79, P11685, DOI 10.1128/JVI.79.18.11685-11692.2005; Knoch KP, 2004, NAT CELL BIOL, V6, P207, DOI 10.1038/ncb1099; Kosinski PA, 2003, J IMMUNOL, V170, P979, DOI 10.4049/jimmunol.170.2.979; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8; MATERA AG, 1995, J CELL BIOL, V129, P1181, DOI 10.1083/jcb.129.5.1181; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wang ZN, 2003, CANCER RES, V63, P655; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Wollerton MC, 2004, MOL CELL, V13, P91, DOI 10.1016/S1097-2765(03)00502-1; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Zang WQ, 2001, J VIROL, V75, P10779, DOI 10.1128/JVI.75.22.10779-10786.2001	32	97	103	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4961	4968		10.1038/sj.onc.1210307	http://dx.doi.org/10.1038/sj.onc.1210307			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310993	Green Accepted			2022-12-25	WOS:000248322500008
J	Whitwam, T; VanBrocklin, MW; Russo, ME; Haak, PT; Bilgili, D; Resau, JH; Koo, HM; Holmen, SL				Whitwam, T.; VanBrocklin, M. W.; Russo, M. E.; Haak, P. T.; Bilgili, D.; Resau, J. H.; Koo, H-M; Holmen, S. L.			Differential oncogenic potential of activated RAS isoforms in melanocytes	ONCOGENE			English	Article						RAS; MYC; melanocytes; transformation	C-MYC; H-RAS; N-RAS; TUMOR SUPPRESSION; GENE-EXPRESSION; INK4A LOCUS; K-RAS; MELANOMA; PHOSPHORYLATION; GROWTH	RAS genes are mutated in approximately 30% of all human cancers. Interestingly, there exists a strong bias in favor of mutation of only one of the three major RAS genes in tumors of different cellular origins. NRAS mutations occur in approximately 20% of human melanomas, whereas HRAS and KRAS mutations are rare in this disease. To de. ne the mechanism(s) responsible for this preference in melanocytes, we compared the transformation efficiencies of mutant NRAS and KRAS in immortal, non-transformed Ink4a/Arf-deficient melanocytes. NRAS mutation leads to increased cellular proliferation and is potently tumorigenic. In contrast, KRAS mutation does not enhance melanocyte proliferation and is only weakly tumorigenic on its own. Although both NRAS and KRAS activate mitogen-activated protein kinase signaling, only NRAS enhances MYC activity in these cells. Our data suggest that the activity of specific RAS isoforms is context-dependent and provide a possible explanation for the prevalence of NRAS mutations in melanoma. In addition, understanding this mechanism will have important implications for cancer therapies targeting RAS pathways.	Van Andel Res Inst, Mol Med & Virol Grp, Grand Rapids, MI USA; Van Andel Res Inst, Lab Pharmacogenet, Grand Rapids, MI USA; Van Andel Res Inst, Lab Microarray, Grand Rapids, MI USA; No Illinois Univ, Dept Math Sci, De Kalb, IL 60115 USA	Van Andel Institute; Van Andel Institute; Van Andel Institute; Northern Illinois University	Holmen, SL (corresponding author), Nevada Canc Inst, Translat Res Div, 10441 W Twain Ave, Las Vegas, NV 89135 USA.	sholmen@nvcancer.org						Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; AROCA P, 1993, J BIOL CHEM, V268, P25650; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Holmen SL, 2005, CANCER RES, V65, P8250, DOI 10.1158/0008-5472.CAN-05-1173; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kim K, 2002, CANCER RES, V62, P1241; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MAHER J, 1995, ONCOGENE, V11, P1639; Prior IA, 2001, J CELL SCI, V114, P1603; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sviderskaya EV, 2002, JNCI-J NATL CANCER I, V94, P446; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	31	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4563	4570		10.1038/sj.onc.1210239	http://dx.doi.org/10.1038/sj.onc.1210239			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297468				2022-12-25	WOS:000247836100010
J	Darwish, H; Cho, JM; Loignon, M; Alaoui-Jamali, MA				Darwish, H.; Cho, J. M.; Loignon, M.; Alaoui-Jamali, M. A.			Overexpression of SERTAD3, a putative oncogene located within the 19q13 amplicon, induces E2F activity and promotes tumor growth	ONCOGENE			English	Article						SERTAD; 19q13; cell cycle; oncogenesis; E2F	DNA-SEQUENCES; BREAST-CANCER; CELL-LINES; OVARIAN-CANCER; C-MYC; GENE; AMPLIFICATION; PROTEIN; IDENTIFICATION; TRANSFORMATION	The amplified region of chromosome 19q13.1-13.2 has been associated with several cancers. The well-characterized oncogene AKT2 is located in this amplicon. Two members of the same gene family (SERTAD1 and SERTAD3) are also located within this region. We report herein the genomic structure and potential functions of SERTAD3. SERTAD3 has two transcript variants with short mRNA half-lives, and one of the variants is tightly regulated throughout G1 and S phases of the cell cycle. Overexpression of SERTAD3 induces cell transformation in vitro and tumor formation in mice, whereas inhibition of SERTAD3 by small interfering RNA (siRNA) results in a reduction in cell growth rate. Furthermore, luciferase assays based on E2F-1 binding indicate that SERTAD3 increases the activity of E2F, which is reduced by inhibition of SERTAD3 by siRNA. Together, our data support that SERTAD3 contributes to oncogenesis, at least in part, via an E2F-dependent mechanism.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Fac Med, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Segal Comprehens Canc Ctr, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Fac Med, Dept Med, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University; Lady Davis Institute; McGill University	Alaoui-Jamali, MA (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Fac Med, Dept Med, Room E534,3755 Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	moulay.alaoui-jamali@mcgill.ca						Abdullah JM, 2001, BLOOD CELL MOL DIS, V27, P667, DOI 10.1006/bcmd.2001.0434; Alarcon-Vargas D, 2004, J BIOL CHEM, V279, P5008, DOI 10.1074/jbc.M312054200; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BARKER PE, 1982, CANCER GENET CYTOGEN, V5, P81, DOI 10.1016/0165-4608(82)90043-7; Beghini A, 2003, ONCOGENE, V22, P2581, DOI 10.1038/sj.onc.1206336; Bicher A, 1997, GYNECOL ONCOL, V66, P36, DOI 10.1006/gyno.1997.4709; Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; Calgaro S, 2002, GENETICS, V160, P547; Cho JM, 2000, NUCLEIC ACIDS RES, V28, P3478, DOI 10.1093/nar/28.18.3478; Curtis LJ, 1998, GENOMICS, V53, P42, DOI 10.1006/geno.1998.5405; Gupta S, 2003, VIROLOGY, V317, P155, DOI 10.1016/j.virol.2003.08.008; Hiemstra J L, 1994, Prog Clin Biol Res, V385, P51; Hoglund M, 1998, GENE CHROMOSOME CANC, V21, P8; Hsu SIH, 2001, EMBO J, V20, P2273, DOI 10.1093/emboj/20.9.2273; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loignon M, 2002, CARCINOGENESIS, V23, P35, DOI 10.1093/carcin/23.1.35; Luoh SW, 2002, CANCER GENET CYTOGEN, V136, P43, DOI 10.1016/S0165-4608(01)00657-4; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MULERIS M, 1995, GENE CHROMOSOME CANC, V14, P155, DOI 10.1002/gcc.2870140302; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SHILOH Y, 1986, CANCER RES, V46, P5297; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Sugimoto M, 1999, GENE DEV, V13, P3027, DOI 10.1101/gad.13.22.3027; Tang TCM, 2002, CANCER RES, V62, P7157; Thompson G, 1996, J GEOM PHYS, V19, P1, DOI 10.1016/0393-0440(95)00014-3; Wang ZJ, 1999, BRIT J CANCER, V80, P70, DOI 10.1038/sj.bjc.6690323; Yang Xiao-He, 1995, Gene Expression, V4, P195; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Zaharieva BM, 2003, J PATHOL, V201, P603, DOI 10.1002/path.1481	37	31	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2007	26	29					4319	4328		10.1038/sj.onc.1210195	http://dx.doi.org/10.1038/sj.onc.1210195			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17260023				2022-12-25	WOS:000247619900014
J	Pelosi, L; Giacinti, C; Nardis, C; Borsellino, G; Rizzuto, E; Nicoletti, C; Wannenes, F; Battistini, L; Rosenthal, N; Molinaro, M; Musaro, A				Pelosi, Laura; Giacinti, Cristina; Nardis, Chiara; Borsellino, Giovanna; Rizzuto, Emanuele; Nicoletti, Carmine; Wannenes, Francesca; Battistini, Luca; Rosenthal, Nadia; Molinaro, Mario; Musaro, Antonio			Local expression of IGF-1 accelerates muscle regeneration by rapidly modulating inflammatory cytokines and chemokines	FASEB JOURNAL			English	Article						fibrosis; inflammatory response; injury	GROWTH-FACTOR-I; SKELETAL-MUSCLE; TRANSGENE EXPRESSION; PROTEIN; PROLIFERATION; INHIBITION; INJURIES; ISOFORM; CELLS	Muscle regeneration following injury is characterized by myonecrosis accompanied by local inflammation, activation of satellite cells, and repair of injured fibers. The resolution of the inflammatory response is necessary to proceed toward muscle repair, since persistence of inflammation often renders the damaged muscle incapable of sustaining efficient muscle regeneration. Here, we show that local expression of a muscle-restricted insulin-like growth factor (IGF)-1 (mIGF-1) transgene accelerates the regenerative process of injured skeletal muscle, modulating the inflammatory response, and limiting fibrosis. At the molecular level, mIGF-1 expression significantly down-regulated proinflammatory cytokines, such as tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta, and modulated the expression of CC chemokines involved in the recruitment of monocytes/ macrophages. Analysis of the underlying molecular mechanisms revealed that mIGF-1 expression modulated key players of inflammatory response, such as macrophage migration inhibitory factor ( MIF), high mobility group protein-1 ( HMGB1), and transcription NF-kappa B. The rapid restoration of injured mIGF-1 transgenic muscle was also associated with connective tissue remodeling and a rapid recovery of functional properties. By modulating the inflammatory response and reducing fibrosis, supplemental mIGF-1 creates a qualitatively different environment for sustaining more efficient muscle regeneration and repair.	Univ Roma La Sapienza, Dept Histol & Med Embryol, CE BEMM, I-00161 Rome, Italy; Univ Roma La Sapienza, Interuniv Inst Myol, I-00161 Rome, Italy; Santa Lucia Fdn Sci Inst, Neuroimmunol Unit, Rome, Italy; IRCCS San Raffaele, Rome, Italy; EMBL Mouse Biol Program, Monterotondo, Italy; Imperial Coll Sch Med, Natl Heart & Lung Inst, Harefield Heart Sci Ctr, London, England; Edith Cowan Univ, Perth, WA, Australia	Sapienza University Rome; Sapienza University Rome; IRCCS Santa Lucia; IRCCS San Raffaele Pisana; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; European Molecular Biology Laboratory (EMBL); Imperial College London; Edith Cowan University	Musaro, A (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, CE BEMM, Via A Scarpa 14, I-00161 Rome, Italy.	antonio.musaro@uniroma1.it	Battistini, Luca/D-6920-2014; Rizzuto, Emanuele/K-9437-2016; Musaro, Antonio/P-2953-2019; Musarò, Antonio/K-9598-2016; Borsellino, Giovanna/K-3074-2016; Rosenthal, Nadia/O-7009-2015; Battistini, luca/ABE-1882-2021	Battistini, Luca/0000-0002-6488-4891; Rizzuto, Emanuele/0000-0003-2314-6128; Musaro, Antonio/0000-0002-2944-9739; Musarò, Antonio/0000-0002-2944-9739; Borsellino, Giovanna/0000-0002-4227-6481; Rosenthal, Nadia/0000-0002-7599-7365; GIACINTI, Cristina/0000-0002-5596-6967; NICOLETTI, Carmine/0000-0001-5896-2040	Telethon [GSP030543] Funding Source: Medline	Telethon(Fondazione Telethon)		Baker W, 2004, J LEUKOCYTE BIOL, V76, P352, DOI 10.1189/jlb.1102528; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Barton PJR, 2005, CIRCULATION, V112, pI46, DOI 10.1161/01.CIRCULATIONAHA.105.525873; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Cannon JG, 1998, MOL CELL BIOCHEM, V179, P159, DOI 10.1023/A:1006828425418; CANTINI M, 1994, BIOCHEM BIOPH RES CO, V202, P1688, DOI 10.1006/bbrc.1994.2129; CANTINI M, 1995, J NEUROPATH EXP NEUR, V54, P121, DOI 10.1097/00005072-199501000-00014; CHANG MS, 1994, J BIOL CHEM, V269, P25277; Dobrowolny G, 2005, J CELL BIOL, V168, P193, DOI 10.1083/jcb.200407021; DOUGLAS MR, 2002, EXPERT REV MOL MED, P1; Frangogiannis NG, 2003, AM J PHYSIOL-HEART C, V285, pH483, DOI 10.1152/ajpheart.01016.2002; Fraser CC, 2006, CELL CYCLE, V5, P1160, DOI 10.4161/cc.5.11.2773; Hirata A, 2003, AM J PATHOL, V163, P203, DOI 10.1016/S0002-9440(10)63644-9; Hogaboam CM, 1998, KIDNEY INT, V54, P2152, DOI 10.1046/j.1523-1755.1998.00176.x; Huang RP, 2001, J IMMUNOL METHODS, V255, P1, DOI 10.1016/S0022-1759(01)00394-5; Huard J, 2002, J BONE JOINT SURG AM, V84A, P822, DOI 10.2106/00004623-200205000-00022; Jarvinen TAHJ, 2005, AM J SPORT MED, V33, P745, DOI 10.1177/0363546505274714; Konig B, 1999, ANTICANCER RES, V19, P1519; Lescaudron L, 1997, J MUSCLE RES CELL M, V18, P631, DOI 10.1023/A:1018679722112; Merly F, 1999, MUSCLE NERVE, V22, P724, DOI 10.1002/(SICI)1097-4598(199906)22:6<724::AID-MUS9>3.0.CO;2-O; Muller S, 2004, J INTERN MED, V255, P332, DOI 10.1111/j.1365-2796.2003.01296.x; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 2004, P NATL ACAD SCI USA, V101, P1206, DOI 10.1073/pnas.0303792101; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Palumbo R, 2004, BIOCHEM PHARMACOL, V68, P1165, DOI 10.1016/j.bcp.2004.03.048; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Sanz S, 2005, GUT, V54, P134, DOI 10.1136/gut.2003.024505; Sato K, 2003, MUSCLE NERVE, V28, P365, DOI 10.1002/mus.10436; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Summan M, 2003, J INTERF CYTOK RES, V23, P237, DOI 10.1089/107999003321829953; Tidball JG, 2005, AM J PHYSIOL-REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004; TIDBALL JG, 1995, MED SCI SPORT EXER, V27, P1022, DOI 10.1249/00005768-199507000-00011	35	203	211	2	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1393	1402		10.1096/fj.06-7690com	http://dx.doi.org/10.1096/fj.06-7690com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264161				2022-12-25	WOS:000246117000015
J	Campian, JL; Gao, XS; Qian, MW; Eaton, JW				Campian, Jian Li; Gao, Xueshan; Qian, Mingwei; Eaton, John W.			Cytochrome c oxidase activity and oxygen tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SUBUNIT-IV; MITOCHONDRIAL; CELLS; METABOLISM	Most cultured cells and intact animals die under hyperoxic conditions. However, a strain of HeLa cells that proliferates under 80% O-2, termed "HeLa-80," has been derived from wild-type HeLa cells ("HeLa-20") by selection for resistance to step-wise increases of oxygen partial pressure. The tolerance of HeLa-80 cells to hyperoxia is not associated with changes in antioxidant defenses or susceptibility to oxidant-mediated killing. Rather, under both 20 and 80% O-2, mitochondrial reactive oxygen species (ROS) production is similar to 2-fold less in HeLa-80 cells, likely related to a significantly higher cytochrome c oxidase (COX) activity (similar to 2-fold), which may act to deplete upstream electron-rich intermediates responsible for ROS generation. We now report that in HeLa-80 cells elevated COX activity is associated with a >2-fold increase in the regulatory subunit COX Vb, whereas expression levels of other subunits are very close to wild type. Small interfering RNA against Vb selectively lowers COX Vb expression in HeLa-80 cells, increases mitochondrial ROS generation, decreases COX activity 60-80%, and diminishes viability under 80% (but not 20%) O-2. In addition, overexpression of subunit Vb increases COX activity and decreases ROS production in wild-type HeLa-20 cells, along with some increase in tolerance to hyperoxia. Overall, our results indicate that it is possible to make cells tolerant of hyperoxia by manipulation of mitochondrial electron transport. These observations may suggest new pharmaceutical strategies to diminish oxygen-mediated cellular damage.	Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Grp, Louisville, KY 40202 USA	University of Louisville	Eaton, JW (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Grp, 580 S Preston St,Baxter Res Bldg 1,Rm 210, Louisville, KY 40202 USA.	EatonRedox@aol.com			NIDDK NIH HHS [DK58882] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058882] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beauchemin AMJ, 2001, BRAIN RES BULL, V56, P285, DOI 10.1016/S0361-9230(01)00583-4; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Bostek C C, 1989, AANA J, V57, P231; Campian JL, 2004, J BIOL CHEM, V279, P46580, DOI 10.1074/jbc.M406685200; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; Castro L, 2001, NUTRITION, V17, P161, DOI 10.1016/S0899-9007(00)00570-0; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHAPPELL JB, 1964, BIOCHEM J, V90, P225, DOI 10.1042/bj0900225; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; DOWHAN W, 1985, EMBO J, V4, P179, DOI 10.1002/j.1460-2075.1985.tb02334.x; Gerschman R, 2001, Nutrition, V17, P162; Grandjean F, 2002, BIOCHEM PHARMACOL, V63, P823, DOI 10.1016/S0006-2952(01)00865-6; Ho YS, 1998, AM J RESP CELL MOL, V18, P538, DOI 10.1165/ajrcmb.18.4.2959; Holthofer H, 1999, FASEB J, V13, P523, DOI 10.1096/fasebj.13.3.523; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Jarreta D, 2000, CARDIOVASC RES, V45, P860, DOI 10.1016/S0008-6363(99)00388-0; JOENJE H, 1985, LAB INVEST, V52, P420; Jyonouchi H, 1998, AM J RESP CELL MOL, V19, P426, DOI 10.1165/ajrcmb.19.3.2862m; Kruidering M, 1997, J PHARMACOL EXP THER, V280, P638; Lee I, 2002, MOL CELL BIOCHEM, V234, P63, DOI 10.1023/A:1015921513720; Li J, 2004, FREE RADICAL BIO MED, V36, P1460, DOI 10.1016/j.freeradbiomed.2004.03.005; LIGHTOWLERS R, 1991, J BIOL CHEM, V266, P7688; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mantell LL, 2000, MOL GENET METAB, V71, P359, DOI 10.1006/mgme.2000.3046; Morris A H, 1994, New Horiz, V2, P19; O'Donovan DJ, 2000, MOL GENET METAB, V71, P352, DOI 10.1006/mgme.2000.3063; SANDERS SP, 1993, J CLIN INVEST, V91, P46, DOI 10.1172/JCI116198; Slutsky AS, 1999, CHEST, V116, p9S, DOI 10.1378/chest.116.suppl_1.9S-a; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOGNER SW, 1992, ANN PHARMACOTHER, V26, P1554, DOI 10.1177/106002809202601214	30	44	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12430	12438		10.1074/jbc.M604547200	http://dx.doi.org/10.1074/jbc.M604547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17303578	hybrid			2022-12-25	WOS:000245942800011
J	Chen, L; Uchida, K; Endler, A; Shibasaki, F				Chen, Li; Uchida, Kazuyo; Endler, Alexander; Shibasaki, Futoshi			Mammalian tumor suppressor Int6 specifically targets hypoxia inducible factor 2 alpha for degradation by hypoxia- and pVHL-independent regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL PAS DOMAIN; HIPPEL-LINDAU PROTEIN; FACTOR-I; GROWTH-FACTOR; HIF-ALPHA; TRANSACTIVATION DOMAIN; RECEPTOR-2 FLK-1; O-2 HOMEOSTASIS; TRANSGENIC MICE; CANCER-PATIENTS	The hypoxia-inducible factors HIF-1 alpha and HIF-2 alpha are structurally similar as regards their DNA-binding and dimerization domains, but differ in their transactivation domains and, as is shown by experiments using hif-1 alpha(-/-) and hif-2 alpha(-/-) mice, in their functions. This implies that HIF-1 alpha and HIF-2 alpha may have unique target genes. To address this discrepancy and identify HIF-2 alpha-specific target genes, we performed yeast two-hybrid analysis and identified the tumor suppressor Int6/eIF3e/p48 as a novel target gene product involved in HIF-2 alpha regulation. The int6 gene was first identified from a screen in which the mouse mammary tumor virus was employed as an insertional mutagen to identify genes whose functions are critical for breast tumor formation. Here, by using two-hybrid analysis, immunoprecipitation in mammalian cells, and HRE-reporter assays, we report the specific interaction of HIF-2 alpha( but not HIF-1 alpha or HIF-3 alpha) with Int6. The results indicate that the direct interaction of Int6 induces proteasome inhibitor-sensitive HIF-2 alpha degradation. This degradation was clearly observed in renal cell carcinoma 786-O cells, and was found to be both hypoxia-and pVHL-independent. Furthermore, Int6 protein knockdown by int6-siRNA vectors or the dominant-negative mutant Int6-Delta C increased endogenous HIF-2 alpha expression, even under normoxia, and induced sets of critical angiogenic factors comprising vascular endoplasmic growth factor, angiopoietin, and basic fibroblast growth factor mRNA. These results indicate that Int6 is a novel and critical determinant of HIF-2-alpha dependent angiogenesis as well as cancer formation, and that int6-siRNA transfer may be an effective therapeutic strategy in pathological conditions such as heart and brain ischemia, hepatic cirrhosis, and obstructive vessel diseases.	Tokyo Metropolitan Inst Med Sci, Translat Res Project, Bunkyo Ku, Tokyo 1138613, Japan; Tongji Univ, Sch Basic Med, Dept Biol, Shanghai 2000092, Peoples R China	Tokyo Metropolitan Institute of Medical Science; Tongji University	Shibasaki, F (corresponding author), Tokyo Metropolitan Inst Med Sci, Translat Res Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	fshibasa@rinshoken.or.jp						Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bonicalzi ME, 2001, J BIOL CHEM, V276, P1407, DOI 10.1074/jbc.M008295200; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Buttitta F, 2005, CLIN CANCER RES, V11, P3198, DOI 10.1158/1078-0432.CCR-04-2308; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Duan LJ, 2005, CIRCULATION, V111, P2227, DOI 10.1161/01.CIR.0000163580.98098.A3; Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Hara S, 1999, Mol Cell Biol Res Commun, V2, P119, DOI 10.1006/mcbr.1999.0160; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Keith B, 2001, P NATL ACAD SCI USA, V98, P6692, DOI 10.1073/pnas.121494298; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Larcher F, 1998, ONCOGENE, V17, P303, DOI 10.1038/sj.onc.1201928; Maemura K, 1999, J BIOL CHEM, V274, P31565, DOI 10.1074/jbc.274.44.31565; Maina EN, 2005, ONCOGENE, V24, P4549, DOI 10.1038/sj.onc.1208649; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Morris C, 2005, ONCOGENE, V24, P1203, DOI 10.1038/sj.onc.1208268; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; ONARNIM AG, 2003, CURR BIOL, V13, pR323; Ouiddir A, 1999, AM J RESP CELL MOL, V21, P710, DOI 10.1165/ajrcmb.21.6.3751; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sato M, 2002, AM J RESP CELL MOL, V26, P127, DOI 10.1165/ajrcmb.26.1.4319; Scortegagna M, 2003, BLOOD, V102, P1634, DOI 10.1182/blood-2003-02-0448; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Takahashi R, 2004, BIOCHEM BIOPH RES CO, V317, P84, DOI 10.1016/j.bbrc.2004.03.010; Takeda N, 2004, CIRC RES, V95, P146, DOI 10.1161/01.RES.0000134920.10128.b4; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yen HCS, 2003, CELL CYCLE, V2, P81, DOI 10.4161/cc.2.2.340; Yoshimura H, 2004, CLIN CANCER RES, V10, P8554, DOI 10.1158/1078-0432.CCR-0946-03; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yu F, 2001, CANCER RES, V61, P4136	66	50	53	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12707	12716		10.1074/jbc.M700423200	http://dx.doi.org/10.1074/jbc.M700423200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17324924	hybrid			2022-12-25	WOS:000245942800040
J	Lerch-Gaggl, AF; Sun, K; Duncan, SA				Lerch-Gaggl, Alexandra F.; Sun, Kai; Duncan, Stephen A.			Light chain 1 of microtubule-associated protein 1B can negatively regulate the action of Pes1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME BIOGENESIS; CELL-PROLIFERATION; SACCHAROMYCES-CEREVISIAE; MITOTIC APPARATUS; YEAST PESCADILLO; MAMMALIAN-CELLS; BINDING DOMAIN; NERVOUS-SYSTEM; BRCT DOMAIN; RAT-BRAIN	Pes1 was first identified as the locus affected in the zebrafish mutant pescadillo, which exhibits severe defects in gut and liver development. It has since been demonstrated that loss of Pes1 expression in mammals and yeast affects ribosome biogenesis, resulting in a block in cell proliferation. Pes1 contains a BRCA1 C-terminal domain, a structural motif that has been shown to facilitate protein-protein interactions, suggesting that Pes1 has binding partners. We used a yeast two-hybrid screen to identify putative interacting proteins. We found that light chain 1 of the microtubule-associated protein 1B ( Mtap1b-LC1) could partner with Pes1, and deletion analyses revealed a specific interaction of Mtap1b-LC1 with the Pes1 BRCA1 C-terminal domain. We confirmed the integrity of the interaction between Pes1 and Mtap1b-LC1 by co-immunoprecipitation experiments. Protein localization studies in NIH3T3 cells revealed that exogenously expressed Pes1 was typically restricted to nuclei and nucleoli. However, exogenous Pes1 was found predominantly in the cytoplasm in cells that were forced to express Mtap1b-LC1. We also observed that the expression of endogenous Pes1 protein was significantly reduced or undetectable in nuclei when Mtap1b-LC1 was overexpressed, implying that a dynamic interaction exists between the two proteins and that Mtap1b-LC1 has the potential to negatively impact Pes1 function. Finally, we demonstrated that, as is the case when Pes1 expression is depleted by shRNA, overexpression of Mtap1b-LC1 resulted in diminished proliferation of NIH3T3 cells, suggesting that Mtap1b-LC1 has the potential to repress cell proliferation by modulating the nucleolar levels of Pes1.	Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Duncan, SA (corresponding author), Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA.	duncans@mcw.edu		Duncan, Stephen/0000-0002-2507-7827	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060064, R03DK054929] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK060064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CC, 2002, RNA, V8, P150, DOI 10.1017/S1355838202010026; Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; ANDERSON DF, 2002, INT J COMMUTATIVE RI, V1, P11; Battle MA, 2003, BIOCHEMISTRY-US, V42, P7270, DOI 10.1021/bi034081y; Borland G, 2006, MOL PHARMACOL, V69, P374, DOI 10.1124/mol.105.016337; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; CHOU YH, 1995, BIOCHEM BIOPH RES CO, V217, P313, DOI 10.1006/bbrc.1995.2779; Ding JQ, 2002, J CELL BIOL, V158, P427, DOI 10.1083/jcb.200202055; Du YCN, 2002, CELL, V109, P835, DOI 10.1016/S0092-8674(02)00773-0; GOLDMAN RD, 1969, J CELL SCI, V4, P179; HAMILL D, 1994, J CELL BIOL, V127, P973, DOI 10.1083/jcb.127.4.973; HAMMARBACK JA, 1991, NEURON, V7, P129, DOI 10.1016/0896-6273(91)90081-A; Haque J, 2000, GENOMICS, V70, P201, DOI 10.1006/geno.2000.6375; HIROKAWA N, 1985, J CELL BIOL, V101, P1858, DOI 10.1083/jcb.101.5.1858; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Holzel M, 2005, J CELL BIOL, V170, P367, DOI 10.1083/jcb.200501141; Iouk TL, 2001, MOL CELL BIOL, V21, P1260, DOI 10.1128/MCB.21.4.1260-1271.2001; JESSUS C, 1984, CELL DIFFER DEV, V14, P295, DOI 10.1016/0045-6039(84)90018-6; Killian A, 2004, ONCOGENE, V23, P8597, DOI 10.1038/sj.onc.1207845; Kinoshita Y, 2001, J BIOL CHEM, V276, P6656, DOI 10.1074/jbc.M008536200; Lapik YR, 2004, MOL CELL, V15, P17, DOI 10.1016/j.molcel.2004.05.020; Lerch-Gaggl A, 2002, J BIOL CHEM, V277, P45347, DOI 10.1074/jbc.M208338200; LJUNGQUIST S, 1994, MUTAT RES, V314, P177, DOI 10.1016/0921-8777(94)90081-7; LOOMIS PA, 1990, P NATL ACAD SCI USA, V87, P8422, DOI 10.1073/pnas.87.21.8422; Maiorana A, 2004, ONCOGENE, V23, P7116, DOI 10.1038/sj.onc.1207916; Mei X, 2000, BRAIN RES BULL, V53, P801, DOI 10.1016/S0361-9230(00)00416-0; Meixner A, 2000, J CELL BIOL, V151, P1169, DOI 10.1083/jcb.151.6.1169; Oeffinger M, 2002, RNA, V8, P626, DOI 10.1017/S1355838202020022; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; Prisco M, 2004, MOL CELL BIOL, V24, P5421, DOI 10.1128/MCB.24.12.5421-5433.2004; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sakumoto N, 2001, BIOCHEM BIOPH RES CO, V289, P608, DOI 10.1006/bbrc.2001.6021; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; Schaper S, 2001, CURR BIOL, V11, P1885, DOI 10.1016/S0960-9822(01)00584-X; Sikorski EM, 2006, J BIOL CHEM, V281, P24423, DOI 10.1074/jbc.M602287200; SILVER RB, 1980, CELL, V19, P505, DOI 10.1016/0092-8674(80)90525-5; SPECTOR DL, 1984, CHROMOSOMA, V90, P139, DOI 10.1007/BF00292451; SUPRENANT KA, 1993, J CELL SCI, V104, P445; SUPRENANT KA, 1989, CELL MOTIL CYTOSKEL, V14, P401, DOI 10.1002/cm.970140310; SUPRENANT KA, 1993, CELL MOTIL CYTOSKEL, V25, P1, DOI 10.1002/cm.970250102; Togel M, 1998, J CELL BIOL, V143, P695, DOI 10.1083/jcb.143.3.695; Tretyakova I, 2005, J BIOL CHEM, V280, P31981, DOI 10.1074/jbc.M502736200; TUCKER RP, 1990, BRAIN RES REV, V15, P101, DOI 10.1016/0165-0173(90)90013-E; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753	48	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11308	11316		10.1074/jbc.M610977200	http://dx.doi.org/10.1074/jbc.M610977200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308336	hybrid			2022-12-25	WOS:000245941500053
J	Zhu, WZ; Woo, AYH; Yang, DM; Cheng, HP; Crow, MT; Xiao, RP				Zhu, Weizhong; Woo, Anthony Yiu-Ho; Yang, Dongmei; Cheng, Heping; Crow, Michael T.; Xiao, Rui-Ping			Activation of CaMKII delta C is a common intermediate of diverse death stimuli- induced heart muscle cell apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+/CALMODULIN-DEPENDENT PROTEIN-KINASE; CALMODULIN KINASE; CARDIAC MYOCYTES; BETA(1)-ADRENERGIC STIMULATION; PHOSPHOLAMBAN PHOSPHORYLATION; DILATED CARDIOMYOPATHY; DEPENDENT FACILITATION; VENTRICULAR MYOCYTES; CALCIUM-CHANNELS; HYPERTROPHY	Ca2+-calmodulin-dependent protein kinase II ( CaMKII) is expressed in many mammalian cells, with the delta isoform predominantly expressed in cardiomyocytes. Previous studies have shown that inhibition of CaMKII protects cardiomyocytes against beta(1)-adrenergic receptor-mediated apoptosis. However, it is unclear whether activation of CaMKII is sufficient to cause cardiomyocyte apoptosis and whether CaMKII signaling is important in heart muscle cell apoptosis mediated by other stimuli. Here, we specifically enhanced or suppressed CaMKII activity using adenoviral gene transfer of constitutively active ( CA-CaMKII delta C) or dominant negative ( DN-CaMKII delta C) mutants of CaMKII delta C in cultured adult rat cardiomyocytes. Expression of CA-CaMKII delta C promoted cardiomyocyte apoptosis that was associated with increased mitochondrial cytochrome c release and attenuated by co-expression of Bcl-XL. Importantly, isoform-specific suppression of CaMKII delta C with the DN-CaMKII delta C mutant similar to nonselective CaMKII inhibition by the pharmacological inhibitors ( KN-93 or AIP) not only prevented CA-CaMKII delta C-mediated apoptosis but also protected cells from multiple death-inducing stimuli. Thus, activation of CaMKII delta C constitutes a common intermediate by which various death-inducing stimuli trigger cardiomyocyte apoptosis via the primary mitochondrial death pathway.	NIA, Cardiovasc Sci Lab, NIH, Gerontol Res Ctr, Baltimore, MD 21224 USA; Peking Univ, Inst Mol Med, Beijing 100871, Peoples R China; Johns Hopkins Univ, Dept Med, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Peking University; Johns Hopkins University	Xiao, RP (corresponding author), NIA, Cardiovasc Sci Lab, NIH, Gerontol Res Ctr, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	XiaoR@GRC.NIA.NIH.GOV	Woo, Anthony/D-4305-2014; cheng, heping/A-7299-2011; Heping, Cheng/AAE-2680-2019; Yimei, Wang/AAE-4083-2019; Xiao, Rui-Ping/AAE-2629-2019	Woo, Anthony/0000-0003-0662-698X; Heping, Cheng/0000-0002-9604-6702; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000287] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [HL073935] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ai X, 2005, CIRC RES, V97, P1314, DOI 10.1161/01.RES.0000194329.41863.89; Anderson ME, 2004, TRENDS CARDIOVAS MED, V14, P152, DOI 10.1016/j.tcm.2004.02.005; Anderson ME, 1998, J PHARMACOL EXP THER, V287, P996; BASSANI RA, 1995, AM J PHYSIOL-HEART C, V268, pH703, DOI 10.1152/ajpheart.1995.268.2.H703; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BRUCE A, 1983, J BIOL CHEM, V258, P13587; Chen XW, 2005, CIRC RES, V97, P1009, DOI 10.1161/01.RES.0000189270.72915.D1; Crow MT, 2004, CIRC RES, V95, P957, DOI 10.1161/01.RES.0000148632.35500.d9; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Dzhura I, 2000, NAT CELL BIOL, V2, P173, DOI 10.1038/35004052; EDMAN CF, 1994, BBA-MOL CELL RES, V1221, P89, DOI 10.1016/0167-4889(94)90221-6; Grueter CE, 2006, MOL CELL, V23, P641, DOI 10.1016/j.molcel.2006.07.006; Hagemann D, 2000, J BIOL CHEM, V275, P22532, DOI 10.1074/jbc.C000253200; Hoch B, 2000, J CELL BIOCHEM, V79, P293, DOI 10.1002/1097-4644(20001101)79:2<293::AID-JCB120>3.3.CO;2-H; Hoch B, 1999, CIRC RES, V84, P713, DOI 10.1161/01.RES.84.6.713; Jiang H, 2005, FASEB J, V19, pA910; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Maier LS, 2003, CIRC RES, V92, P904, DOI 10.1161/01.RES.0000069685.20258.F1; Ramirez MT, 1997, J BIOL CHEM, V272, P31203, DOI 10.1074/jbc.272.49.31203; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; Sucharov CC, 2006, AM J PHYSIOL-HEART C, V291, pH1299, DOI 10.1152/ajpheart.00017.2006; Vinogradova TM, 2000, CIRC RES, V87, P760, DOI 10.1161/01.RES.87.9.760; Wang W, 2004, CIRC RES, V95, P798, DOI 10.1161/01.RES.0000145361.50017.aa; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; Wu X, 2006, J CLIN INVEST, V116, P675, DOI 10.1172/JCI27374; XIAO RP, 1994, P NATL ACAD SCI USA, V91, P9659, DOI 10.1073/pnas.91.20.9659; Xu XD, 2005, CELL, V120, P59, DOI 10.1016/j.cell.2004.11.036; Yang DM, 2007, CIRC RES, V100, P399, DOI 10.1161/01.RES.0000258022.13090.55; YUAN WL, 1994, AM J PHYSIOL, V267, pH982, DOI 10.1152/ajpheart.1994.267.3.H982; Zhang R, 2005, NAT MED, V11, P409, DOI 10.1038/nm1215; Zhang T, 2004, CARDIOVASC RES, V63, P476, DOI 10.1016/j.cardiores.2004.04.026; Zhang T, 2003, CIRC RES, V92, P912, DOI 10.1161/01.RES.0000069686.31472.C5; Zhang T, 2002, J BIOL CHEM, V277, P1261, DOI 10.1074/jbc.M108525200; Zhou YY, 2000, AM J PHYSIOL-HEART C, V279, pH429; Zhu WD, 2000, J BIOL CHEM, V275, P15239, DOI 10.1074/jbc.275.20.15239; Zhu WZ, 2003, J CLIN INVEST, V111, P617, DOI 10.1172/JCI200316326	38	107	117	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10833	10839		10.1074/jbc.M611507200	http://dx.doi.org/10.1074/jbc.M611507200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17296607	hybrid			2022-12-25	WOS:000245941000077
J	Nag, A; Germaniuk-Kurowska, A; Dimri, M; Sassack, MA; Gurumurthy, CB; Gao, QS; Dimri, G; Band, H; Band, V				Nag, Alo; Germaniuk-Kurowska, Aleksandra; Dimri, Manjari; Sassack, Michael A.; Gurumurthy, Channabasavaiah Basavaraju; Gao, Qingshen; Dimri, Goberdhan; Band, Hamid; Band, Vimla			An essential role of human Ada3 in p53 acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; IN-VIVO; MEDIATED TRANSACTIVATION; HISTONE; COMPLEX; BINDING; MDM2; COACTIVATOR; ACTIVATION; GENE	The p53 tumor suppressor protein functions as a critical component of genotoxic stress response by regulating the expression of effector gene products that control the fate of a cell following DNA damage. Unstressed cells maintain p53 at low levels through regulated degradation, and p53 levels and activity are rapidly elevated upon genotoxic stress. Biochemical mechanisms that control the levels and activity of p53 are therefore of great interest. We and others have recently identified hAda3 (human homologue of yeast alteration/deficiency in activation 3) as a p53-interacting protein and enhancer of p53 activity. Here, we show that endogenous levels of p53 and Ada3 interact with each other, and by using inducible overexpression and short hairpin RNA-mediated knockdown strategies we demonstrate that hAda3 stabilizes p53 protein by promoting its acetylation. Use of a p53 mutant with mutations of known p300/CREB-binding protein acetylation sites demonstrated that hAda3-dependent acetylation is required for increase in p53 stability and target gene induction. Importantly, we demonstrate that endogenous hAda3 is essential for DNA damage-induced acetylation and stabilization of p53 as well as p53 target gene induction. Overall, our results establish hAda3, a component of coactivator complexes that include histone acetyltransferase p300/CREB-binding protein, as a critical mediator of acetylation-dependent stabilization and activation of p53 upon genotoxic stress in mammalian cells.	Northwestern Univ, ENH Res Inst, Div Canc Biol, Evanston, IL 60201 USA; Northwestern Univ, ENH Res Inst, Div Mol Oncol, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Weinberg Coll arts, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60201 USA	Northwestern University; Northwestern University; Northwestern University; Feinberg School of Medicine; Northwestern University	Band, V (corresponding author), Northwestern Univ, ENH Res Inst, Div Canc Biol, 1001 Univ Pl, Evanston, IL 60201 USA.	v-band@northwestern.edu	Gurumurthy, Channabasavaiah B/E-7205-2011; Gurumurthy, Channabasavaiah B/H-8268-2016; Dimri, Goberdhan/AAO-4210-2021	Gurumurthy, Channabasavaiah B/0000-0002-8022-4033; 	NCI NIH HHS [R01 CA095221-01A1, CA99900, R01 CA096986-03, R01 CA096986-01A1, R01 CA096986-02, CA87986, R01 CA095221-04, R01 CA096986-05, CA99163, CA76118, R01 CA095221-03, R01 CA095221-02, CA96844, R01 CA096986-04, R01 CA095221-05, CA81076, CA94143] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095221, R01CA087986, R01CA081076, R01CA099900, R01CA099163, R01CA096986, R01CA096844, R01CA076118, R01CA094143] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Balasubramanian R, 2002, J BIOL CHEM, V277, P7989, DOI 10.1074/jbc.M110849200; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Chao C, 2006, MOL CELL BIOL, V26, P6859, DOI 10.1128/MCB.00062-06; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Forsberg EC, 1997, BIOCHEMISTRY-US, V36, P15918, DOI 10.1021/bi971664x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Maki CG, 1996, CANCER RES, V56, P2649; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Meng GY, 2004, J BIOL CHEM, V279, P54230, DOI 10.1074/jbc.M404482200; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Ou YH, 2005, MOL BIOL CELL, V16, P1684, DOI 10.1091/mbc.E04-08-0689; Pankotai T, 2005, MOL CELL BIOL, V25, P8215, DOI 10.1128/MCB.25.18.8215-8227.2005; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; Roe JS, 2006, MOL CELL, V22, P395, DOI 10.1016/j.molcel.2006.04.006; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Saleh A, 1997, J BIOL CHEM, V272, P5571, DOI 10.1074/jbc.272.9.5571; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200; Zhao Y, 2006, MOL CELL BIOL, V26, P2782, DOI 10.1128/MCB.26.7.2782-2790.2006	45	44	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8812	8820		10.1074/jbc.M610443200	http://dx.doi.org/10.1074/jbc.M610443200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17272277	hybrid, Green Submitted			2022-12-25	WOS:000245780300028
J	Manuylov, NL; Smagulova, FO; Tevosian, SG				Manuylov, N. L.; Smagulova, F. O.; Tevosian, S. G.			Fog2 excision in mice leads to premature mammary gland involution and reduced Esr1 gene expression	ONCOGENE			English	Article						GATA; FOG2; estrogen receptor; transcription factor; mammary; involution	ESTROGEN-RECEPTOR-ALPHA; HUMAN BREAST-CANCER; PROGESTERONE-RECEPTOR; COFACTOR; DIFFERENTIATION; PROTEIN; FAMILY; GATA-3; BCL-2; IDENTIFICATION	The critical role for GATA family proteins in maintaining the normal (non-transformed) cell state is corroborated by the recent findings of mutations or methylation in GATA genes both in primary cancers and tumor lines including breast. Previously, microarray pro. ling studies determined that the highest expression of both GATA3 and ESR1 ( estrogen receptor a) is seen in tumors associated with the most favorable survival outcomes, whereas the lowest expression of GATA3 is detected in tumor subtypes showing the worst outcomes. At this time, genes and pathways that are regulated by GATA3 in the mammary gland are not well defined. We have previously established a requirement for FOG ( Friend Of GATA) cofactors during mouse development. Here we report that in the murine mammary gland Fog2 gene expression is upregulated upon pregnancy and lactation with prominent expression in the epithelial cells of the gland during post-lactational regression. Mammary-specific deletion of Fog2 identified a role for this gene during gland involution; excision of the Fog2 gene leads to the accelerated involution of the gland despite diminished levels of the remodeling enzymes. Importantly, the levels of several genes linked to the control of cancerous transformation in the breast ( Esr1, Prg and Foxa1) are significantly reduced upon Fog2 excision. This implicates FOG2 in the maintenance of epithelial cell differentiation in the mammary gland and in performing a protective role in breast cancer.	Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA; Dartmouth Coll, Sch Med, Norris Cotton Canc Ctr, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Tevosian, SG (corresponding author), Dartmouth Coll, Sch Med, Dept Genet, Hanover, NH 03755 USA.	sergei.g.tevosian@dartmouth.edu	Smagulova, Fatima/K-5459-2015	Smagulova, Fatima/0000-0001-6883-1968				Adameyko II, 2005, DEV DYNAM, V233, P540, DOI 10.1002/dvdy.20368; Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Allar MA, 2004, ENDOCRINOLOGY, V145, P2467, DOI 10.1210/en.2003-1641; Amin DN, 2004, ONCOGENE, V23, P1428, DOI 10.1038/sj.onc.1207257; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Booth BW, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1538; Cantor AB, 2005, SEMIN CELL DEV BIOL, V16, P117, DOI 10.1016/j.semcdb.2004.10.006; Crispino JD, 2005, SEMIN CELL DEV BIOL, V16, P137, DOI 10.1016/j.semcdb.2004.11.002; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Gruvberger S, 2001, CANCER RES, V61, P5979; Han XY, 2003, J BIOL CHEM, V278, P47785, DOI 10.1074/jbc.M309482200; Hoch RV, 1999, INT J CANCER, V84, P122; Huggins GS, 2006, CANCER RES, V66, P1384, DOI 10.1158/0008-5472.CAN-05-2715; Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535-6108(04)00059-5; Kobayashi S, 2006, FASEB J, V20, P800, DOI 10.1096/fj.05-5426fje; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Lacroix M, 2004, MOL CELL ENDOCRINOL, V219, P1, DOI 10.1016/j.mce.2004.02.021; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; Master SR, 2002, MOL ENDOCRINOL, V16, P1185, DOI 10.1210/me.16.6.1185; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Metcalfe AD, 1999, J CELL SCI, V112, P1771; Mundschau G, 2003, BLOOD, V101, P4298, DOI 10.1182/blood-2002-12-3904; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Parikh P, 2005, J AM COLL SURGEONS, V200, P705, DOI 10.1016/j.jamcollsurg.2004.12.025; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polyak K, 2006, CANCER CELL, V9, P151, DOI 10.1016/j.ccr.2006.02.026; Schorr K, 1999, CANCER RES, V59, P2541; Shen DJ, 2005, BIOCHEM BIOPH RES CO, V326, P218, DOI 10.1016/j.bbrc.2004.10.214; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Tevosian SG, 2000, CELL, V101, P729, DOI 10.1016/S0092-8674(00)80885-5; Tevosian SG, 2002, DEVELOPMENT, V129, P4627; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Thangaraju M, 2005, DEVELOPMENT, V132, P4675, DOI 10.1242/dev.02050; Thangaraju M, 2004, ONCOGENE, V23, P2548, DOI 10.1038/sj.onc.1207363; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wechsler J, 2002, NAT GENET, V32, P148, DOI 10.1038/ng955; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Wolf I, 2007, INT J CANCER, V120, P1013, DOI 10.1002/ijc.22389	48	22	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5204	5213		10.1038/sj.onc.1210333	http://dx.doi.org/10.1038/sj.onc.1210333			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17310981				2022-12-25	WOS:000248674200004
J	Hsieh, PC; Chang, JC; Sun, WT; Hsieh, SC; Wang, MC; Wang, FF				Hsieh, P-C; Chang, J-C; Sun, W-T; Hsieh, S-C; Wang, M-C; Wang, F-F			p53 downstream target DDA3 is a novel microtubule-associated protein that interacts with end-binding protein EB3 and activates ss-catenin pathway	ONCOGENE			English	Article						DDA3; microtubule; EB3; p53; ss-catenin	CELL-LINES; GENE; IDENTIFICATION; FAMILY; EXPRESSION; INDUCTION; HOMOLOG; SYSTEM; GROWTH; APC2	We have previously identified mouse DDA3 as a p53-inducible gene. To explore the functional role of DDA3, we screened a mouse brain cDNA library by the yeast two-hybrid assay, and identi. ed the microtubule plus-end binding protein EB3 as a DDA3-interacting protein. Binding of DDA3 to EB3 was veri. ed by glutathione S-transferase (GST) pull-down assay and subcellular colocalization; co-immunoprecipitation further indicated that interaction of these two proteins within cells required intact microtubules. Domains of DDA3-EB3 interaction were mapped by GST pull-down assay to amino acids 118-241 and 242-329 of DDA3 and the N-and C-termini of EB3. Immuno. uorescence analysis revealed colocalization of DDA3 with microtubules in various cell phases, and regions encompassing aa 118-241 and 242-329 contained microtubule-interacting and bundling activities. In vitro microtubule-binding assay showed that DDA3 and EB3 associated directly with microtubules, and cooperated with each other for microtubule binding. In addition, DDA3 bound to the EB3 interacting partner adenomatous polyposis coli 2 (APC2), a homolog of the tumor suppressor APC, which is a component of the beta-catenin destruction complex. Ectopic expression of DDA3 and EB3 enhanced b-catenin-dependent transactivation and cyclin D1 production, whereas knockdown of endogenous DDA3 or EB3 inhibited b-catenin-mediated transactivation and the ability of cells to form colonies. Together, our results identify DDA3 as a novel microtubule-associated protein that binds to EB3, and implicate DDA3 and EB3 in the b-catenin-mediated growth signaling.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Ind Technol Res Inst, Biomed Engn Ctr, Div Biomat & Tissue Engn, Hsinchu, Taiwan	National Yang Ming Chiao Tung University; Industrial Technology Research Institute - Taiwan	Wang, FF (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.	ffwang@ym.edu.tw		HSIEH, SHU-CHEN/0000-0002-0844-7435; Wang, Mei-Chih/0000-0003-0520-9316				Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bu W, 2003, J BIOL CHEM, V278, P49721, DOI 10.1074/jbc.M306194200; Bu W, 2001, ONCOGENE, V20, P3185, DOI 10.1038/sj.onc.1204429; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hanson CA, 2005, GENE, V361, P1, DOI 10.1016/j.gene.2005.07.024; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Honnappa S, 2005, EMBO J, V24, P261, DOI 10.1038/sj.emboj.7600529; Hsieh SC, 2002, ONCOGENE, V21, P3050, DOI 10.1038/sj.onc.1205417; Iwai A, 2004, ONCOGENE, V23, P7593, DOI 10.1038/sj.onc.1208016; Jarrett CR, 2001, CANCER RES, V61, P7978; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Levine Arnold J., 2004, Cell, VS116, pS67, DOI 10.1016/S0092-8674(04)00036-4; Lo PK, 1999, ONCOGENE, V18, P7765, DOI 10.1038/sj.onc.1203167; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nakagawa H, 1998, CANCER RES, V58, P5176; Nakagawa H, 2000, ONCOGENE, V19, P210, DOI 10.1038/sj.onc.1203308; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Ongusaha PP, 2003, EMBO J, V22, P1289, DOI 10.1093/emboj/cdg129; Park WR, 2005, CANCER RES, V65, P1197, DOI 10.1158/0008-5472.CAN-04-3339; Senda Takao, 2005, Anatomical Science International, V80, P121, DOI 10.1111/j.1447-073x.2005.00106.x; SU LK, 1995, CANCER RES, V55, P2972; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; van Es JH, 1999, CURR BIOL, V9, P105, DOI 10.1016/S0960-9822(99)80024-4; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang YH, 2005, ONCOGENE, V24, P6637, DOI 10.1038/sj.onc.1208819	34	37	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4928	4940		10.1038/sj.onc.1210304	http://dx.doi.org/10.1038/sj.onc.1210304			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310996				2022-12-25	WOS:000248322500005
J	Vecchi, M; Nuciforo, P; Romagnoli, S; Confalonieri, S; Pellegrini, C; Serio, G; Quarto, M; Capra, M; Roviaro, GC; Contessini Avesani, E; Corsi, C; Coggi, G; Di Fiore, PP; Bosari, S				Vecchi, M.; Nuciforo, P.; Romagnoli, S.; Confalonieri, S.; Pellegrini, C.; Serio, G.; Quarto, M.; Capra, M.; Roviaro, G. C.; Contessini Avesani, E.; Corsi, C.; Coggi, G.; Di Fiore, P. P.; Bosari, S.			Gene expression analysis of early and advanced gastric cancers	ONCOGENE			English	Article						gastric cancer; early gastric cancer; advanced gastric cancer; gene expression profiling; tissue microarrays	LONG-TERM; MUCOSA; CARCINOGENESIS; METASTASIS; PROFILES; INVASION; CLAUDINS	Gastric carcinoma is one of the major causes of cancer mortality worldwide. Early detection results in excellent prognosis for patients with early cancer (EGC), whereas the prognosis of advanced cancer (AGC) patients remains poor. It is not clear whether EGC and AGC are molecularly distinct, and whether they represent progressive stages of the same tumor or different entities ab initio. Gene expression profiles of EGC and AGC were determined by Affymetrix technology and quantitative polymerase chain reaction. Representative regulated genes were further analysed by in situ hybridization (ISH) on tissue microarrays. Expression analysis allowed the identification of a signature that differentiates AGC from EGC. In addition, comparison with normal gastric mucosa indicated that the majority of alterations associated with EGC are retained in AGC, and that further expression changes mark the transition from EGC to AGC. Finally, ISH analysis showed that representative genes, differentially expressed in the invasive areas of EGC and AGC, are not differentially expressed in the non-invasive areas of the same tumors. Our data are more directly compatible with a progression model of gastric carcinogenesis, whereby EGC and AGC may represent different molecular stages of the same tumor. Finally, the identification of an AGC-specific signature might help devising novel therapeutic strategies for advanced gastric cancer.	Univ Milan, Dipartimento Med Chirurgia & Odontoiatria, Osped San Paolo & Fdn IRCCS Osped Maggiore Policl, Pathol Unit, I-20142 Milan, Italy; IFOM Fdn, Ist FIRC Oncol Mol, Milan, Italy; Univ Milan, Fdn IRCCS Osped Maggiore Policlin Mangiagalli & R, Dipartimento Sci Chirurg, Milan, Italy; AO San Paolo, Dipartimento Chirurg & Special Chirurg, Milan, Italy; Ist Europeo Oncol, Dipartimento Oncol Sperimentale, Milan, Italy; Univ Milan, Dipartimento Med Chirurg & Odontoiatria, Milan, Italy	University of Milan; IFOM - FIRC Institute of Molecular Oncology; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; IRCCS European Institute of Oncology (IEO); University of Milan	Bosari, S (corresponding author), Univ Milan, Dipartimento Med Chirurgia & Odontoiatria, Osped San Paolo & Fdn IRCCS Osped Maggiore Policl, Pathol Unit, I-20142 Milan, Italy.	pierpaolo.difiore@ifom-ieocampus.it; silvano.bosari@unimi.it	Vecchi, Manuela/L-3502-2017; Nuciforo, Paolo/Q-2885-2019; Serio, Gabriella/AAU-4967-2020; Confalonieri, Stefano/AAQ-6786-2020; Di Fiore, Pier Paolo/K-2130-2012; Bosari, Silvano/K-7744-2016	Vecchi, Manuela/0000-0002-2750-9160; Serio, Gabriella/0000-0001-9021-4560; Confalonieri, Stefano/0000-0001-6886-9851; Di Fiore, Pier Paolo/0000-0002-2252-0950; Bosari, Silvano/0000-0002-9744-6951; Nuciforo, Paolo/0000-0003-1380-0990				Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Boussioutas A, 2003, CANCER RES, V63, P2569; Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335; Dicken BJ, 2005, ANN SURG, V241, P27, DOI 10.1097/01.sla.0000149300.28588.23; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Farrell JJ, 2002, J CLIN INVEST, V109, P193, DOI 10.1172/JCI200212529; Hasegawa S, 2002, CANCER RES, V62, P7012; HENDERSON BE, 1990, J NATL CANCER I, V82, P1186, DOI 10.1093/jnci/82.14.1186; Hippo Y, 2001, CANCER RES, V61, P889; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Jinawath N, 2004, ONCOGENE, V23, P6830, DOI 10.1038/sj.onc.1207886; KAJITANI T, 1981, JPN J SURG, V11, P127; Katoh M, 2003, INT J MOL MED, V11, P683; Kim B, 2003, CANCER RES, V63, P8248; Kirikoshi H, 2002, INT J ONCOL, V21, P655; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; LAWRENCE M, 1991, ANN SURG, V213, P327, DOI 10.1097/00000658-199104000-00007; Lee Jong Hoon, 2003, Korean J Gastroenterol, V42, P484; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Meireles SI, 2004, CANCER RES, V64, P1255, DOI 10.1158/0008-5472.CAN-03-1850; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; MULLIN JM, 2004, SCI STKE; Norsett KG, 2004, CANCER LETT, V210, P227, DOI 10.1016/j.canlet.2004.01.022; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Parkin DM, 2004, ONCOGENE, V23, P6329, DOI 10.1038/sj.onc.1207726; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rugge M, 2003, GUT, V52, P1111, DOI 10.1136/gut.52.8.1111; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Tsukuma H, 2000, GUT, V47, P618, DOI 10.1136/gut.47.5.618; TSUKUMA H, 1983, INT J CANCER, V31, P421, DOI 10.1002/ijc.2910310405; Van Itallie CM, 2006, ANNU REV PHYSIOL, V68, P403, DOI 10.1146/annurev.physiol.68.040104.131404; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang CS, 1997, J AM COLL SURGEONS, V185, P476, DOI 10.1016/S1072-7515(97)00076-8; Wang TC, 1998, GASTROENTEROLOGY, V115, P780, DOI 10.1016/S0016-5085(98)70159-3; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yu CD, 2005, WORLD J GASTROENTERO, V11, P2390, DOI 10.3748/wjg.v11.i16.2390	37	60	63	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4284	4294		10.1038/sj.onc.1210208	http://dx.doi.org/10.1038/sj.onc.1210208			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17297478				2022-12-25	WOS:000247619900011
J	Kraveka, JM; Li, L; Szulc, ZM; Bielawski, J; Ogretmen, B; Hannun, YA; Obeid, LM; Bielawska, A				Kraveka, Jacqueline M.; Li, Li; Szulc, Zdzislaw M.; Bielawski, Jacek; Ogretmen, Besim; Hannun, Yusuf A.; Obeid, Lina M.; Bielawska, Alicja			Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE; TELOMERASE ACTIVITY; CERAMIDE; APOPTOSIS; ACTIVATION; INDUCTION; ACID; N-(4-HYDROXYPHENYL)RETINAMIDE; IDENTIFICATION; SPHINGOLIPIDS	The role of dihydroceramide desaturase as a key enzyme in the de novo pathway of ceramide generation was investigated in human neuroblastoma cells (SMS-KCNR). A novel assay using water-soluble analogs of dihydroceramide, dihydroceramidoids (D-erythro-dhCCPS analogs), was used to measure desaturase activity in situ. Conversion of D-erythro-2-N-[12 '-(1 ''-pyridinium)-dodecanoyl]- 4,5-dihydrosphingosine bromide (C-12-dhCCPS) to its 4,5-desaturated counterpart, D-erythro-2-N-[12 '-(1 ''-pyridinium) dodecanoyl]sphingosine bromide (C-12-CCPS), was determined by liquid chromatography/mass spectrometry analysis. The validity of the assay was confirmed using C-8-cyclopropenylceramide, a competitive inhibitor of dihydroceramide desaturase. A human homolog (DEGS-1) of the Drosophila melanogaster des-1 gene was recently identified and reported to have desaturase activity. Transfection of SMS-KCNR cells with small interfering RNA to DEGS-1 significantly blocked the conversion of C-12-dhCCPS to C-12-CCPS. The associated accumulation of endogenous dihydroceramides confirmed DEGS-1 as the main active dihydroceramide desaturase in these cells. The partial loss of DEGS-1 inhibited cell growth, with cell cycle arrest at G(0)/G(1). This was accompanied by a significant decrease in the amount of phosphorylated retinoblastoma protein. This hypophosphorylation was inhibited by tautomycin and not by okadaic acid, suggesting the involvement of protein phosphatase 1. Additionally, we found that treatment of SMS-KCNR cells with fenretinide inhibited desaturase activity in a dose-dependent manner. An increase in dihydroceramides (but not ceramides) paralleled this process as measured by liquid chromatography/mass spectrometry. There were no effects on the mRNA or protein levels of DEGS-1, suggesting that fenretinide acts at the post-translational level as an inhibitor of this enzyme. Tautomycin was also able to block the hypophosphorylation of the retinoblastoma protein observed upon fenretinide treatment. These findings suggest a novel biological function for dihydroceramides.	Med Univ S Carolina, Dept Pediat, Div Hematol Oncol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Kraveka, JM (corresponding author), Med Univ S Carolina, Dept Pediat, Div Hematol Oncol, 135 Rutledge Ave,POB 250558, Charleston, SC 29425 USA.	kravekjm@musc.edu		obeid, lina/0000-0002-0734-0847	NCI NIH HHS [L40 CA110721, K01 CA100767, P01 CA097132] Funding Source: Medline; NCRR NIH HHS [P20 RR017677, C06 RR018823] Funding Source: Medline; NIA NIH HHS [R01 AG016583] Funding Source: Medline; NIDCR NIH HHS [R01 DE016572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA100767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn EH, 2002, EXP BIOL MED, V227, P345, DOI 10.1177/153537020222700507; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Cadena DL, 1997, BIOCHEMISTRY-US, V36, P6960, DOI 10.1021/bi970091l; CARMICHAEL J, 1987, CANCER RES, V47, P943; Causeret C, 2000, LIPIDS, V35, P1117, DOI 10.1007/s11745-000-0627-6; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Clifford JL, 1999, CANCER RES, V59, P14; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DiPietrantonio AM, 1998, INT J CANCER, V78, P53, DOI 10.1002/(SICI)1097-0215(19980925)78:1<53::AID-IJC10>3.0.CO;2-6; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Geeraert L, 1997, BIOCHEM J, V327, P125, DOI 10.1042/bj3270125; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hannun YA, 1997, ADV EXP MED BIOL, V400, P305; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jiang Q, 2004, P NATL ACAD SCI USA, V101, P17825, DOI 10.1073/pnas.0408340102; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Kraveka JM, 2003, ARCH BIOCHEM BIOPHYS, V419, P110, DOI 10.1016/j.abb.2003.08.034; Lee JY, 2000, EXP CELL RES, V261, P303, DOI 10.1006/excr.2000.5028; Lovat PE, 2004, JNCI-J NATL CANCER I, V96, P1288, DOI 10.1093/jnci/djh254; Lovat PE, 2002, CANCER RES, V62, P5158; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Mizutani Y, 2004, FEBS LETT, V563, P93, DOI 10.1016/S0014-5793(04)00274-1; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Omae F, 2004, BIOCHEM J, V379, P687, DOI 10.1042/BJ20031425; Osone S, 2004, INT J CANCER, V112, P219, DOI 10.1002/ijc.20412; Schulz A, 2006, J BIOL CHEM, V281, P2784, DOI 10.1074/jbc.M509483200; Schulze H, 2000, METHOD ENZYMOL, V311, P22; Seville LL, 2005, CURR CANCER DRUG TAR, V5, P159, DOI 10.2174/1568009053765816; Sugiki H, 2000, BRIT J DERMATOL, V143, P1154, DOI 10.1046/j.1365-2133.2000.03882.x; Szulc ZM, 2006, BIOORGAN MED CHEM, V14, P7083, DOI 10.1016/j.bmc.2006.07.016; Tamrakar S, 2000, FRONT BIOSCI-LANDMRK, V5, pD121, DOI 10.2741/Tamrakar; Ternes P, 2002, J BIOL CHEM, V277, P25512, DOI 10.1074/jbc.M202947200; Triola G, 2004, MOL PHARMACOL, V66, P1671, DOI 10.1124/mol.104.003681; Triola G, 2003, J ORG CHEM, V68, P9924, DOI 10.1021/jo030141u; Tserng KY, 2004, BIOCHEM J, V380, P715, DOI 10.1042/BJ20031733; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wang HT, 2001, CANCER RES, V61, P5102; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621	43	127	130	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2007	282	23					16718	16728		10.1074/jbc.M700647200	http://dx.doi.org/10.1074/jbc.M700647200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	174MN	17283068	Green Accepted, hybrid			2022-12-25	WOS:000246946500003
J	Habib, A; Shamseddeen, I; Nasrallah, MS; Antoun, TA; Nemer, G; Bertoglio, J; Badreddine, R; Badr, KF				Habib, Aida; Shamseddeen, Ishraq; Nasrallah, Mona S.; Antoun, Tania Abi; Nemer, Georges; Bertoglio, Jacques; Badreddine, Rami; Badr, Kamal F.			Modulation of COX-2 expression by statins in human monocytic cells	FASEB JOURNAL			English	Article						inflammation; prenylation; prostaglandin; Rac GTPase; NF-kappa B	SMOOTH-MUSCLE-CELLS; PROTEIN HEME OXYGENASE-1; PROSTACYCLIN RECEPTOR; ENDOTHELIAL-CELLS; TRANSCRIPTIONAL ACTIVATION; ATHEROSCLEROTIC PLAQUES; PROSTAGLANDIN E-2; THROMBOXANE A(2); RHO GTPASE; CYCLOOXYGENASE-2	Macrophage cyclooxygenase- 2 ( COX- 2) plays an important role in prostaglandin E-2 and thromboxane A(2) production. Statins are inhibitors of HMG CoA (3-Hydroxy-3-methylglutaryl coenzyme A) reductases and cholesterol synthesis, which block the expression of several inflammatory proteins independent of their capacity to lower endogenous cholesterol. In the present study, we investigated the effect of simvastatin and mevastatin on COX- 2 induction in human monocytic cell line U937 and analyzed the underlying mechanisms. Pretreatment of U937 cells with simvastatin or mevastatin for 24 h resulted in a significant reduction in the lipopolysaccharide (LPS)-dependent induction of prostaglandin E2, thromboxane A2 synthesis, and COX- 2 expression. Mevalonate, the direct metabolite of HMG CoA reductase, and farnesyl pyrophosphate and geranylgeranyl-pyrophosphate, intermediates of the mevalonate pathway, significantly reversed the inhibitory effect of statins on COX-2. An inhibitor of geranylgeranyl transferases, GGTI-286 mimicked the effect of statins on COX- 2 expression. Cytonecrotic factor-1 increased LPS-dependent expression of COX- 2. Treatment of cells with NSC 23766, an inhibitor of Rac, which we demonstrated to block Rac 2 activation, resulted in an inhibition of the LPS-dependent expression of COX- 2. Whereas no effect was obtained with RhoA/C blocker, C3 exoenzyme. Gel retardation experiments and NF kappa B-p65 transcription factor assay showed that simvastatin and NSC 23766 decrease significantly NF-kappa B complex formation. In macrophages, the antiinflammatory effects of statins are mediated in part through the inhibition of COX- 2 and prostanoids. Rac GTPase protein is identified as one of the targets of statins in this regulation.-Habib, A., Shamseddeen, I., Nasrallah, M. S., Antoun, T. A., Nemer, G., Bertoglio, J. Badreddine, R., Badr, K. F. Modulation of COX- 2 expression by statins in human monocytic cells.	Amer Univ Beirut, Dept Biochem, Beirut, Lebanon; Amer Univ Beirut, Dept Internal Med, Beirut, Lebanon; Fac Pharm Chatenay Malabry, INSERM U749, F-92290 Chatenay Malabry, France	American University of Beirut; American University of Beirut; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Habib, A (corresponding author), Amer Univ Beirut, Dept Biochem, POB 11-236, Beirut, Lebanon.	ah31@aub.edu.lb	Nemer, Georges/ABB-5117-2020; Habib, Aida/H-8647-2019; Nemer, Georges/H-7801-2014	Nemer, Georges/0000-0003-2157-5279; Habib, Aida/0000-0001-6027-0043; 				Barbieri SS, 2003, CARDIOVASC RES, V60, P187, DOI 10.1016/S0008-6363(03)00365-1; Barry OP, 1999, J BIOL CHEM, V274, P7545, DOI 10.1074/jbc.274.11.7545; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bishop-Bailey D, 1998, BIOCHEM BIOPH RES CO, V249, P44, DOI 10.1006/bbrc.1998.8966; Bocan Thomas M A, 2002, Curr Opin Investig Drugs, V3, P1312; Bornfeldt KE, 1997, J CLIN INVEST, V100, P875, DOI 10.1172/JCI119603; Cayatte AJ, 2000, ARTERIOSCL THROM VAS, V20, P1724, DOI 10.1161/01.ATV.20.7.1724; Chen JC, 2004, EXP CELL RES, V301, P305, DOI 10.1016/j.yexcr.2004.05.039; Cheng Y, 2006, J CLIN INVEST, V116, P1391, DOI 10.1172/JCI27540; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Cipollone F, 2004, ARTERIOSCL THROM VAS, V24, P1259, DOI 10.1161/01.ATV.0000133192.39901.be; Cipollone F, 2003, CIRCULATION, V107, P1479, DOI 10.1161/01.CIR.0000056530.03783.81; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; Corsini Alberto, 2000, Journal of Cardiovascular Pharmacology and Therapeutics, V5, P161, DOI 10.1177/107424840000500304; CREMINON C, 1995, BBA-LIPID LIPID MET, V1254, P333, DOI 10.1016/0005-2760(94)00196-6; Degraeve F, 2001, J BIOL CHEM, V276, P46849, DOI 10.1074/jbc.M104197200; Demasi M, 2003, J BIOL CHEM, V278, P38607, DOI 10.1074/jbc.M305944200; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Doye A, 2002, CELL, V111, P553, DOI 10.1016/S0092-8674(02)01132-7; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Egan KM, 2005, CIRCULATION, V111, P334, DOI 10.1161/01.CIR.0000153386.95356.78; Fabre JE, 2001, J CLIN INVEST, V107, P603, DOI 10.1172/JCI10881; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; FitzGerald GA, 2001, CLIN EXP RHEUMATOL, V19, pS31; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; FitzGerald GA, 2000, ANN MED, V32, P21; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Gomez-Hernandez A, 2006, J CARDIOVASC PHARM, V47, P60; Gotto AM, 2003, CLIN CARDIOL, V26, pI21; Grosser N, 2004, FREE RADICAL BIO MED, V37, P2064, DOI 10.1016/j.freeradbiomed.2004.09.009; Grosser N, 2004, BIOCHEM BIOPH RES CO, V325, P871, DOI 10.1016/j.bbrc.2004.10.123; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; HABIB A, 1993, J BIOL CHEM, V268, P23448; Hernandez-Presa MA, 2002, ATHEROSCLEROSIS, V160, P49, DOI 10.1016/S0021-9150(01)00547-0; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; JONES DA, 1993, J BIOL CHEM, V268, P9049; Kothapalli D, 2004, J CLIN INVEST, V113, P609, DOI 10.1172/JCI200419097; Laufer S, 2003, CURR OPIN RHEUMATOL, V15, P623, DOI 10.1097/00002281-200309000-00017; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Liao JK, 2004, INT J CLIN PRACT, V58, P41, DOI 10.1111/j.1368-504X.2004.00375.x; Liao JK, 2002, INT J CARDIOL, V86, P5, DOI 10.1016/S0167-5273(02)00195-X; Martel-Pelletier J, 2003, SEMIN ARTHRITIS RHEU, V33, P155, DOI 10.1016/S0049-0172(03)00134-3; Martin-Ventura JL, 2005, STROKE, V36, P1796, DOI 10.1161/01.STR.0000174289.34110.b0; Miggin SM, 2003, J BIOL CHEM, V278, P6947, DOI 10.1074/jbc.M210637200; Moreau V, 2003, MOL CELL BIOL, V23, P6809, DOI 10.1128/MCB.23.19.6809-6822.2003; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; O'Meara SJ, 2005, BIOCHEM J, V386, P177, DOI 10.1042/BJ20041290; O'Meara SJ, 2004, BRIT J PHARMACOL, V143, P318, DOI 10.1038/sj.bjp.0705956; O'Meara SJ, 2004, BRIT J PHARMACOL, V143, P292, DOI 10.1038/sj.bjp.0705947; Ongini E, 2004, P NATL ACAD SCI USA, V101, P8497, DOI 10.1073/pnas.0401996101; Paramo J. A., 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P303, DOI 10.2174/1568006054553381; Penglis PS, 2000, J IMMUNOL, V165, P1605, DOI 10.4049/jimmunol.165.3.1605; PRADELLES P, 1985, ANAL CHEM, V57, P1170, DOI 10.1021/ac00284a003; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Shovman O, 2002, IMMUNOL RES, V25, P271, DOI 10.1385/IR:25:3:271; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; ZHANG SZ, 1990, CELL BIOL TOXICOL, V6, P219	58	39	42	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1665	1674		10.1096/fj.06-6766com	http://dx.doi.org/10.1096/fj.06-6766com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317725				2022-12-25	WOS:000246866500008
J	Nusinow, DA; Hernandez-Munoz, I; Fazzio, TG; Shah, GM; Kraus, WL; Panning, B				Nusinow, Dmitri A.; Hernandez-Munoz, Inmaculada; Fazzio, Thomas G.; Shah, Girish M.; Kraus, W. Lee; Panning, Barbara			Poly(ADP-ribose) polymerase 1 is inhibited by a histone H2A variant, MacroH2A, and contributes to silencing of the inactive X chromosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; CHROMATIN-STRUCTURE; GENE-EXPRESSION; CORE HISTONE; TRANSCRIPTION; NUCLEOSOME; BINDING; PARP-1; DOMAINS; POLY(ADP-RIBOSYL)ATION	Poly(ADP-ribose) polymerase 1 (PARP-1) is a nuclear enzyme that is involved in modulating chromatin structure, regulation of gene expression, and sensing DNA damage. Here, we report that PARP-1 enzymatic activity is inhibited by macroH2A, a vertebrate histone H2A variant that is enriched on facultative heterochromatin. MacroH2A family members have a large C-terminal non-histone domain (NHD) and H2A-like histone domain. MacroH2A1.2 and PARP-1 interact in vivo and in vitro via the NHD. The NHD of each macroH2A family member was sufficient to inhibit PARP-1 enzymatic activity in vitro. The NHD of macroH2A1.2 was a mixed inhibitor of PARP-1 catalytic activity, with affects on both catalytic activity and the substrate binding affinity of PARP-1. Depletion of PARP-1 by RNA interference caused reactivation of a reporter gene on the inactive X chromosome, demonstrating that PARP-1 participates in the maintenance of silencing. These results suggest that one function of macroH2A in gene silencing is to inhibit PARP-1 enzymatic activity, and this may affect PARP-1 association with chromatin.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA; Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain; Univ Laval, CHUL, Res Ctr, Lab Skin Canc Res, Quebec City, PQ G1V 4G2, Canada; Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	University of California System; University of California San Francisco; Laval University; Cornell University	Panning, B (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, Genentech Hall S372B,600 16th St, San Francisco, CA 94158 USA.	bpanning@biochem.ucsf.edu	Nusinow, Dmitri A/K-9129-2013	Nusinow, Dmitri A/0000-0002-0497-1723; Shah, Girish/0000-0002-9291-1164	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM085186, R01GM063671] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK069710] Funding Source: Medline; NIGMS NIH HHS [R01 GM085186, R01 GM63671] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agelopoulos M, 2006, EMBO J, V25, P4843, DOI 10.1038/sj.emboj.7601364; Aguiar RCT, 2005, J BIOL CHEM, V280, P33756, DOI 10.1074/jbc.M505408200; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Angelov D, 2003, MOL CELL, V11, P1033, DOI 10.1016/S1097-2765(03)00100-X; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chadwick BP, 2001, NUCLEIC ACIDS RES, V29, P2699, DOI 10.1093/nar/29.13.2699; Chadwick BP, 2001, HUM MOL GENET, V10, P1101, DOI 10.1093/hmg/10.10.1101; Chakravarthy S, 2005, MOL CELL BIOL, V25, P7616, DOI 10.1128/MCB.25.17.7616-7624.2005; Changolkar LN, 2006, MOL CELL BIOL, V26, P4410, DOI 10.1128/MCB.02258-05; Chu FX, 2006, MOL CELL PROTEOMICS, V5, P194, DOI 10.1074/mcp.M500285-MCP200; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; Costanzi C, 2001, J BIOL CHEM, V276, P21776, DOI 10.1074/jbc.M010919200; Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; de Murcia JMN, 2003, EMBO J, V22, P2255, DOI 10.1093/emboj/cdg206; Doyen CM, 2006, MOL CELL BIOL, V26, P1156, DOI 10.1128/MCB.26.3.1156-1164.2006; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956; Martzen MR, 1999, SCIENCE, V286, P1153, DOI 10.1126/science.286.5442.1153; Ouararhni K, 2006, GENE DEV, V20, P3324, DOI 10.1101/gad.396106; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; PEHRSON JR, 1992, SCIENCE, V257, P1398; Perche PY, 2000, CURR BIOL, V10, P1531, DOI 10.1016/S0960-9822(00)00832-0; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Shah RG, 2005, BIOCHEM BIOPH RES CO, V331, P167, DOI 10.1016/j.bbrc.2005.03.135; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tulin A, 2002, GENE DEV, V16, P2108, DOI 10.1101/gad.1003902; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019	35	95	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12851	12859		10.1074/jbc.M610502200	http://dx.doi.org/10.1074/jbc.M610502200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17322296	hybrid			2022-12-25	WOS:000245942800057
J	Yoon, MK; Kim, HM; Choi, G; Lee, JO; Choi, BS				Yoon, Mi-Kyung; Kim, Ho-Min; Choi, Giltsu; Lee, Jie-Oh; Choi, Byong-Seok			Structural basis for the conformational integrity of the Arabidopsis thaliana HY5 leucine zipper homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BURIED POLAR INTERACTION; COILED-COIL FORMATION; X-RAY-STRUCTURE; DIMERIZATION SPECIFICITY; AMINO-ACIDS; TRANSCRIPTION FACTORS; CRYSTAL-STRUCTURE; ALPHA-HELICES; BZIP PROTEIN; SALT-BRIDGES	The leucine zipper (LZ) domain of the HY5 transcription factor from Arabidopsis thaliana has unique primary structural properties, including major occupation by the Leu residues as well as two buried polar residues in the a positions and a localized distribution of charged and polar residues in the first three heptad repeats. In this study, we solved the crystal structure of the HY5 LZ domain and show that the peculiarities in the primary sequence yield unusual structural characteristics. For example, the HY5 LZ domain exhibits a bipartite charge distribution characterized by a highly negative electrostatic surface potential in its N-terminal half and a nearly neutral potential in its C-terminal half. The LZ N-terminal region also contains two consecutive putative trigger sites for dimerization of the coiled coils. In addition, two buried asparagines at a positions 19 and 33 in the HY5 LZ domain display distinct modes of polar interaction. Whereas Asn19 shows a conformational flip-flop, Asn33 is engaged in a permanent hydrogen bond network. CD spectropolarimetry and analytical ultracentrifugation experiments performed with versions of the HY5 LZ domain containing mutations in the a positions yielded further evidence that position a amino acid residues are crucial for achieving an oligomeric state and maintaining stability. However, a low correlation between position a amino acid preference, core packing geometry, and rotamer conformations suggests that the oligomeric state of the LZ domain is not governed entirely by known structural properties. Taken together, our results suggest structural factors conferring conformational integrity of the HY5 LZ homodimer that are more complicated than proposed previously.	Korea Adv Inst Sci & Technol, Dept Chem, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Natl Creat Res Initiat Ctr, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Lee, JO (corresponding author), Korea Adv Inst Sci & Technol, Dept Chem, 373-1 Guseong Dong, Taejon 305701, South Korea.	jieoh.lee@kaist.ac.kr	Lee, Jie-Oh/AAG-4302-2020; Lee, Jie-Oh/C-1581-2011; Choi, Giltsu/C-1601-2011; Kim, Ho Min/G-2712-2011; Choi, Byong-Seok/C-1937-2011	Lee, Jie-Oh/0000-0001-6519-6049				Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chattopadhyay S, 1998, PLANT CELL, V10, P673, DOI 10.1105/tpc.10.5.673; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; COOPER TM, 1990, BIOPOLYMERS, V30, P657, DOI 10.1002/bip.360300703; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Demeler B, 2005, ANALYTICAL ULTRACENTRIFUGATION: TECHNIQUES AND METHODS, P210; Deppmann CD, 2004, NUCLEIC ACIDS RES, V32, P3435, DOI 10.1093/nar/gkh653; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; Frank S, 2000, J BIOL CHEM, V275, P11672, DOI 10.1074/jbc.275.16.11672; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hao Q, 2003, J APPL CRYSTALLOGR, V36, P1274, DOI 10.1107/S0021889803014031; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HU JC, 1993, PROTEIN SCI, V2, P1072, DOI 10.1002/pro.5560020701; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HURST HC, 1994, PROTEIN PROFILE, V1, P123; Ibarra-Molero B, 2004, J MOL BIOL, V336, P989, DOI 10.1016/j.jmb.2003.12.069; Jakoby M, 2002, TRENDS PLANT SCI, V7, P106, DOI 10.1016/S1360-1385(01)02223-3; Jansson M, 1996, J BIOMOL NMR, V7, P131; JOHN M, 1994, J BIOL CHEM, V269, P16247; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Junius FK, 1996, J BIOL CHEM, V271, P13663, DOI 10.1074/jbc.271.23.13663; JUNIUS FK, 1995, BIOCHEMISTRY-US, V34, P6164, DOI 10.1021/bi00018a020; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; Kammerer RA, 2001, J BIOL CHEM, V276, P13685, DOI 10.1074/jbc.M010492200; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kretsinger JK, 2003, J AM CHEM SOC, V125, P7907, DOI 10.1021/ja029892o; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; Krylov D, 1998, J MOL BIOL, V279, P959, DOI 10.1006/jmbi.1998.1762; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Lavigne P, 1998, J MOL BIOL, V281, P165, DOI 10.1006/jmbi.1998.1914; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; Mackay JP, 1996, BIOCHEMISTRY-US, V35, P4867, DOI 10.1021/bi952761y; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; Mittl PRE, 2000, P NATL ACAD SCI USA, V97, P2562, DOI 10.1073/pnas.97.6.2562; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Oakley MG, 1998, BIOCHEMISTRY-US, V37, P12603, DOI 10.1021/bi981269m; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Oyama T, 1997, GENE DEV, V11, P2983, DOI 10.1101/gad.11.22.2983; POTEKHIN SA, 1994, PROTEIN ENG, V7, P1097, DOI 10.1093/protein/7.9.1097; Spek EJ, 1998, PROTEIN SCI, V7, P2431, DOI 10.1002/pro.5560071121; Steinmetz MO, 1998, EMBO J, V17, P1883, DOI 10.1093/emboj/17.7.1883; Tchan MC, 2000, J BIOL CHEM, V275, P37454, DOI 10.1074/jbc.M004264200; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; Walshaw J, 2001, J MOL BIOL, V307, P1427, DOI 10.1006/jmbi.2001.4545; Whitson SR, 2005, J MOL BIOL, V350, P319, DOI 10.1016/j.jmb.2005.05.002; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zeng X, 1997, P NATL ACAD SCI USA, V94, P3673, DOI 10.1073/pnas.94.8.3673; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365; ZHU BY, 1993, PROTEIN SCI, V2, P383; Zhu H, 2000, J MOL BIOL, V300, P1377, DOI 10.1006/jmbi.2000.3936	60	13	16	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12989	13002		10.1074/jbc.M611465200	http://dx.doi.org/10.1074/jbc.M611465200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17261584	hybrid			2022-12-25	WOS:000245942800069
J	Gorman, MJ; Wang, Y; Jiang, HB; Kanost, MR				Gorman, Maureen J.; Wang, Yang; Jiang, Haobo; Kanost, Michael R.			Manduca sexta hemolymph proteinase 21 activates prophenoloxidase-activating proteinase 3 in an insect innate immune response proteinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOLOTRICHIA-DIOMPHALIA LARVAE; PRO-PHENOL-OXIDASE; IN-VITRO ACTIVATION; COMPLEMENT FACTOR D; SERINE-PROTEASE; COLEOPTERAN INSECT; ANOPHELES-GAMBIAE; TOBACCO HORNWORM; CDNA CLONING; CLIP DOMAINS	Melanization, an insect immune response, requires a set of hemolymph proteins including pathogen recognition proteins that initiate the response, a cascade of mostly unknown serine proteinases, and phenoloxidase. Until now, only initial and final proteinases in the pathways have been conclusively identified. Four such proteinases have been purified from the larval hemolymph of Manduca sexta: hemolymph proteinase 14 ( HP14), which autoactivates in the presence of microbial surface components, and three prophenoloxidase-activating proteinases ( PAP1-3). In this study, we have used two complementary approaches to identify a serine proteinase that activates proPAP3. Partial purification from hemolymph of an activator of proPAP3 resulted in an active fraction with two abundant polypeptides of similar to 32 and similar to 37 kDa. Labeling of these polypeptides with a serine proteinase inhibitor, diisopropyl fluorophosphate, indicated that they were active serine proteinases. N-terminal sequencing revealed that both were cleaved forms of the previously identified hemolymph serine proteinase, HP21. Surprisingly, cleavage of proHP21 had occurred not at the predicted activation site but more N-terminal to it. In vitro reactions carried out with purified HP14 ( which activates proHP21), proHP21, proPAP3, and site-directed mutant forms of the latter two proteinases confirmed that HP21 activates proPAP3 by limited proteolysis. Like the HP21 products purified from hemolymph, HP21 that was activated by HP14 in the in vitro reactions was not cleaved at its predicted activation site.	Kansas State Univ, Dept Biochem, Manhattan, KS 66506 USA; Oklahoma State Univ, Dept Entomol & Plant Pathol, Stillwater, OK 74078 USA	Kansas State University; Oklahoma State University System; Oklahoma State University - Stillwater	Kanost, MR (corresponding author), Kansas State Univ, Dept Biochem, 141 Chalmers Hall, Manhattan, KS 66506 USA.	kanost@ksu.edu	Jiang, Haobo/A-6519-2008	Gorman, Maureen/0000-0003-2005-6223; Jiang, Haobo/0000-0003-1357-1315; Kanost, Michael/0000-0002-6827-0061	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041247, R37GM041247, R01GM058634, R01GM041247] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM041247-18, R01 GM041247, R01 GM058634-09, GM41247, R37 GM041247] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER BC, 1991, BIOCHEM J, V279, P775, DOI 10.1042/bj2790775; Castillejo-Lopez C, 2005, BIOCHEM BIOPH RES CO, V338, P1075, DOI 10.1016/j.bbrc.2005.10.042; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; Gal P, 2005, J BIOL CHEM, V280, P33435, DOI 10.1074/jbc.M506051200; Gupta S, 2005, INSECT BIOCHEM MOLEC, V35, P241, DOI 10.1016/j.ibmb.2004.12.003; Ji CY, 2004, J BIOL CHEM, V279, P34101, DOI 10.1074/jbc.M404584200; Ji CY, 2003, PROTEIN EXPRES PURIF, V29, P235, DOI 10.1016/S1046-5928(03)00020-2; Jiang HB, 2005, INSECT BIOCHEM MOLEC, V35, P931, DOI 10.1016/j.ibmb.2005.03.009; Jiang HB, 2003, INSECT BIOCHEM MOLEC, V33, P1049, DOI 10.1016/S0965-1748(03)00123-1; Jiang HB, 2003, J BIOL CHEM, V278, P3552, DOI 10.1074/jbc.M205743200; Jiang HB, 1998, P NATL ACAD SCI USA, V95, P12220, DOI 10.1073/pnas.95.21.12220; Jing H, 1999, EMBO J, V18, P804, DOI 10.1093/emboj/18.4.804; Kanost Michael R, 2004, Immunol Rev, V198, P97, DOI 10.1111/j.0105-2896.2004.0121.x; Khan AR, 1998, PROTEIN SCI, V7, P815; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; Kwon TH, 2000, EUR J BIOCHEM, V267, P6188, DOI 10.1046/j.1432-1327.2000.01695.x; Leclerc V, 2006, EMBO REP, V7, P231, DOI 10.1038/sj.embor.7400592; Lee SY, 1998, EUR J BIOCHEM, V254, P50, DOI 10.1046/j.1432-1327.1998.2540050.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; LESAVRE PH, 1978, J EXP MED, V148, P1498, DOI 10.1084/jem.148.6.1498; MORGAN PH, 1972, P NATL ACAD SCI USA, V69, P3312, DOI 10.1073/pnas.69.11.3312; NAKAMURA T, 1986, EUR J BIOCHEM, V154, P511, DOI 10.1111/j.1432-1033.1986.tb09427.x; Paskewitz SM, 2006, INSECT BIOCHEM MOLEC, V36, P701, DOI 10.1016/j.ibmb.2006.06.001; Piao S, 2005, EMBO J, V24, P4404, DOI 10.1038/sj.emboj.7600891; Satoh D, 1999, J BIOL CHEM, V274, P7441, DOI 10.1074/jbc.274.11.7441; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; Stubbs MT, 1998, BIOL CHEM, V379, P95; Tang HP, 2006, J BIOL CHEM, V281, P28097, DOI 10.1074/jbc.M601642200; Tong YR, 2005, J BIOL CHEM, V280, P14932, DOI 10.1074/jbc.M500532200; Volanakis JE, 1996, PROTEIN SCI, V5, P553; VOLTZ J, 2006, CELL MICROBIOL, V8, P1392; Volz J, 2005, J BIOL CHEM, V280, P40161, DOI 10.1074/jbc.M506191200; Wang Y, 2006, J BIOL CHEM, V281, P9271, DOI 10.1074/jbc.M513797200; Wang Y, 2004, INSECT BIOCHEM MOLEC, V34, P731, DOI 10.1016/j.ibmb.2004.03.008; Wang Y, 2004, INSECT BIOCHEM MOLEC, V34, P387, DOI 10.1016/j.ibmb.2003.12.005; Yu XQ, 2003, INSECT BIOCHEM MOLEC, V33, P197, DOI 10.1016/S0965-1748(02)00191-1; Zhu YF, 2003, J BIOL CHEM, V278, P46556, DOI 10.1074/jbc.M309682200; Zou Z, 2005, INSECT MOL BIOL, V14, P433, DOI 10.1111/j.1365-2583.2005.00574.x; Zou Z, 2005, J BIOL CHEM, V280, P14341, DOI 10.1074/jbc.M500570200	39	89	93	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11742	11749		10.1074/jbc.M611243200	http://dx.doi.org/10.1074/jbc.M611243200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17317663	hybrid, Green Accepted			2022-12-25	WOS:000245941900016
J	Kuhn, PH; Marjaux, E; Imhof, A; De Strooper, B; Haass, C; Lichtenthaler, SF				Kuhn, Peer-Hendrik; Marjaux, Els; Imhof, Axel; De Strooper, Bart; Haass, Christian; Lichtenthaler, Stefan F.			Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; RECEPTOR-TYPE-II; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; DECOY RECEPTOR; CLEAVAGE; BACE1; EXPRESSION; PRESENILIN; MICE	Ectodomain shedding and intramembrane proteolysis of the amyloid precursor protein ( APP) by alpha-, beta- and gamma-secretase are involved in the pathogenesis of Alzheimer disease ( AD). Increased proteolytic processing and secretion of another membrane protein, the interleukin-1 receptor II ( IL-1R2), have also been linked to the pathogenesis of AD. IL-1R2 is a decoy receptor that may limit detrimental effects of IL-1 in the brain. At present, the proteolytic processing of IL-1R2 remains little understood. Here we show that IL-1R2 can be proteolytically processed in a manner similar to APP. IL-1R2 expressed in human embryonic kidney 293 cells first undergoes ectodomain shedding in an alpha-secretase-like manner, resulting in secretion of the IL-1R2 ectodomain and the generation of an IL-1R2 C-terminal fragment. This fragment undergoes further intramembrane proteolysis by gamma-secretase, leading to the generation of the soluble intracellular domain of IL-1R2. Intramembrane cleavage of IL-1R2 was abolished by a highly specific inhibitor of gamma-secretase and was absent in mouse embryonic fibroblasts deficient in gamma-secretase activity. Surprisingly, the gamma-secretase BACE1 and its homolog BACE2 increased IL-1R2 secretion resulting in C-terminal fragments nearly identical to the ones generated by the alpha-secretase-like cleavage. This suggests that both proteases may act as alternative gamma-secretase-like proteases. Importantly, BACE1 and BACE2 did not cleave several other membrane proteins, demonstrating that both proteases do not contribute to general membrane protein turnover but only cleave specific proteins. This study reveals a similar proteolytic processing of IL-1R2 and APP and may provide an explanation for the increased IL-1R2 secretion observed in AD.	Univ Munich, Adolf Butenandt Inst, D-80336 Munich, Germany; Catholic Univ Louvain, Ctr Human Genet, Dept Mol & Dev Genet, Flanders Interuniv Inst Biotehcnol, B-3000 Louvain, Belgium	University of Munich; Universite Catholique Louvain	Lichtenthaler, SF (corresponding author), Univ Munich, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	Stefan.Lichtenthaler@med.uni-muenchen.de	de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012; Imhof, Axel/AAU-5313-2021; Lichtenthaler, Stefan F/B-6587-2016	De Strooper, Bart/0000-0001-5455-5819; Imhof, Axel/0000-0003-2993-8249; Lichtenthaler, Stefan F/0000-0003-2211-2575; Kuhn, Peer-Hendrik/0000-0001-7891-5102				Allinson TMJ, 2003, J NEUROSCI RES, V74, P342, DOI 10.1002/jnr.10737; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Capell A, 1997, J NEUROCHEM, V69, P2432; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Citron M, 2004, TRENDS PHARMACOL SCI, V25, P92, DOI 10.1016/j.tips.2003.12.004; Cui XL, 2003, J IMMUNOL, V171, P6814, DOI 10.4049/jimmunol.171.12.6814; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; Dominguez D, 2005, J BIOL CHEM, V280, P30797, DOI 10.1074/jbc.M505249200; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Edbauer D, 2002, J BIOL CHEM, V277, P13389, DOI 10.1074/jbc.M111571200; Fluhrer R, 2002, J NEUROCHEM, V81, P1011, DOI 10.1046/j.1471-4159.2002.00908.x; French RA, 1999, J NEUROIMMUNOL, V93, P194, DOI 10.1016/S0165-5728(98)00224-0; FULLER SJ, 1995, BIOCHEMISTRY-US, V34, P8091, DOI 10.1021/bi00025a015; Garlind A, 1999, BRAIN RES, V826, P112, DOI 10.1016/S0006-8993(99)01092-6; Griffin WST, 2000, EXP GERONTOL, V35, P481, DOI 10.1016/S0531-5565(00)00110-8; Gruninger-Leitch F, 2002, J BIOL CHEM, V277, P4687, DOI 10.1074/jbc.M109266200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; HAASS C, 1994, J BIOL CHEM, V269, P17741; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hartwell DW, 1999, THROMB HAEMOSTASIS, V82, P850, DOI 10.1055/s-0037-1615922; Hebert SS, 2006, EMBO REP, V7, P739, DOI 10.1038/sj.embor.7400704; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hu XY, 2006, NAT NEUROSCI, V9, P1520, DOI 10.1038/nn1797; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Kitazume S, 2005, J BIOL CHEM, V280, P8589, DOI 10.1074/jbc.M409417200; Kitazume S, 2003, J BIOL CHEM, V278, P14865, DOI 10.1074/jbc.M206262200; Kopan R, 2004, NAT REV MOL CELL BIO, V5, P499, DOI 10.1038/nrm1406; Lichtenthaler SF, 2003, J BIOL CHEM, V278, P48713, DOI 10.1074/jbc.M303861200; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Lindberg C, 2005, NEUROCHEM INT, V46, P551, DOI 10.1016/j.neuint.2005.01.004; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Ma GZ, 2005, J NEUROSCI RES, V80, P683, DOI 10.1002/jnr.20515; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; Mrak RE, 2001, NEUROBIOL AGING, V22, P903, DOI 10.1016/S0197-4580(01)00287-1; Neumann D, 2000, J IMMUNOL, V165, P3350, DOI 10.4049/jimmunol.165.6.3350; Neumann S, 2006, J BIOL CHEM, V281, P7583, DOI 10.1074/jbc.M508340200; Okochi M, 2002, EMBO J, V21, P5408, DOI 10.1093/emboj/cdf541; Orlando S, 1997, J BIOL CHEM, V272, P31764, DOI 10.1074/jbc.272.50.31764; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Prokop S, 2004, J BIOL CHEM, V279, P23255, DOI 10.1074/jbc.M401789200; Randow F, 2001, NAT CELL BIOL, V3, P891, DOI 10.1038/ncb1001-891; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; Rogers JT, 1999, J BIOL CHEM, V274, P6421, DOI 10.1074/jbc.274.10.6421; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schobel S, 2006, INT J DEV NEUROSCI, V24, P141, DOI 10.1016/j.ijdevneu.2005.11.003; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2003, ANNU REV PHARMACOL, V43, P545, DOI 10.1146/annurev.pharmtox.43.100901.140248; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Stachel SJ, 2004, J MED CHEM, V47, P6447, DOI 10.1021/jm049379g; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Sun XL, 2005, FASEB J, V19, P739, DOI 10.1096/fj.04-3426com; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; Vardy ERLC, 2005, TRENDS MOL MED, V11, P464, DOI 10.1016/j.molmed.2005.08.004; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7; Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong HK, 2005, J BIOL CHEM, V280, P23009, DOI 10.1074/jbc.M414648200; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200	72	122	146	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11982	11995		10.1074/jbc.M700356200	http://dx.doi.org/10.1074/jbc.M700356200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17307738	hybrid			2022-12-25	WOS:000245941900041
J	Hills, R; Mazzarella, R; Fok, K; Liu, M; Nemirovskiy, O; Leone, J; Zack, MD; Arner, EC; Viswanathan, M; Abujoub, A; Muruganandam, A; Sexton, DJ; Bassill, GJ; Sato, AK; Malfait, AM; Tortorella, MD				Hills, Robert; Mazzarella, Richard; Fok, Kam; Liu, Min; Nemirovskiy, Olga; Leone, Joseph; Zack, Marc D.; Arner, Elizabeth C.; Viswanathan, Malini; Abujoub, Aida; Muruganandam, Arumugam; Sexton, Daniel J.; Bassill, Gary J.; Sato, Aaron K.; Malfait, Anne-Marie; Tortorella, Micky D.			Identification of an ADAMTS-4 cleavage motif using phage display leads to the development of fluorogenic peptide substrates and reveals matrilin-3 as a novel substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARTICULAR-CARTILAGE; MATRIX METALLOPROTEINASES; AGGRECANASE-1 ADAMTS-4; OSTEOARTHRITIS; SPECIFICITY; RECOGNITION; DEGRADATION; SEQUENCES; ADAM-TS4; PROTEINS	ADAMTS-4 and ADAMTS-5 are aggrecanases responsible for the breakdown of cartilage aggrecan in osteoarthritis. Multiple ADAMTS-4 cleavage sites have been described in several matrix proteins including aggrecan, versican, and brevican, but no concise predictive cleavage motif has been identified for this protease. By screening a 13-mer peptide library with a diversity of 10(8), we have identified the ADAMTS-4 cleavage motif E-(AFVLMY)-X( 0,1)-( RK)-X( 2,3)-( ST)-(VYIFWMLA), with Glu representing P1. Several 13-mer peptides containing this motif, including DVQEFRGVTAVIR and HNEFRQRETYMVF, were shown to be substrates for ADAMTS-4. These peptides were found to be specific substrates for ADAMTS-4 as they were not cleaved by ADAMTS-5. Modification of these peptides with donor ( 6-FAM) and acceptor ( QSY-9) molecules resulted in the development of fluorescence-based substrates with a K-m of similar to 35 mu M. Furthermore, the role of Glu at P1 and Phe at P1' in binding and catalysis was studied by exploring substitution of these amino acids with the D-isomeric forms. Substitution of P1 with dGlu was tolerable for binding, but not catalysis, whereas substitution of P1' with dPhe precluded both binding and catalysis. Similarly, replacement of Glu with Asp at P1 abolished recognition and cleavage of the peptide. Finally, BLAST results of the ADAMTS-4 cleavage motif identified matrilin-3 as a new substrate for ADAMTS-4. When tested, recombinant ADAMTS-4 effectively cleaved intact matrilin-3 at the predicted motif at Glu435/Ala436 generating two species of 45 and 5 kDa.	Pfizer Global Res & Dev, St Louis, MO 63017 USA; Dynax Corp, Cambridge, MA 02139 USA	Pfizer	Hills, R (corresponding author), 700 Chesterfield Pkwy, Chesterfield, MO 63017 USA.	Robert.L.Hills@Pfizer.com		Malfait, Anne-Marie/0000-0003-1428-0384; Sexton, Daniel J/0000-0001-9604-5948				Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Brazma A, 1996, Proc Int Conf Intell Syst Mol Biol, V4, P34; Chapman KL, 2001, NAT GENET, V28, P393, DOI 10.1038/ng573; Cloutier SM, 2002, EUR J BIOCHEM, V269, P2747, DOI 10.1046/j.1432-1033.2002.02960.x; Collins-Racie LA, 2004, MATRIX BIOL, V23, P219, DOI 10.1016/j.matbio.2004.05.004; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Dickinson SC, 2003, MATRIX BIOL, V22, P267, DOI 10.1016/S0945-053X(03)00034-9; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Glasson SS, 2004, ARTHRITIS RHEUM-US, V50, P2547, DOI 10.1002/art.20558; Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; HUGHES CE, 1995, BIOCHEM J, V305, P799, DOI 10.1042/bj3050799; Karlson L, 2002, J BIOL CHEM, V277, P18579, DOI 10.1074/jbc.M110356200; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LEY CA, 2001, Patent No. 6906176; McCarter JD, 2004, J BACTERIOL, V186, P5919, DOI 10.1128/JB.186.17.5919-5925.2004; Melching LI, 2006, OSTEOARTHR CARTILAGE, V14, P1147, DOI 10.1016/j.joca.2006.05.014; Miller JA, 2003, ANAL BIOCHEM, V314, P260, DOI 10.1016/S0003-2697(02)00638-3; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Pan WJ, 2003, J BIOL CHEM, V278, P27820, DOI 10.1074/jbc.M304436200; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097; Song RH, 2007, ARTHRITIS RHEUM-US, V56, P575, DOI 10.1002/art.22334; Stefansson SE, 2003, AM J HUM GENET, V72, P1448, DOI 10.1086/375556; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tortorella M, 2000, J BIOL CHEM, V275, P25791, DOI 10.1074/jbc.M001065200; Tortorella MD, 2000, J BIOL CHEM, V275, P18566, DOI 10.1074/jbc.M909383199; Tortorella MD, 2004, J BIOL CHEM, V279, P17554, DOI 10.1074/jbc.M313041200; Tortorella MD, 2002, MATRIX BIOL, V21, P499, DOI 10.1016/S0945-053X(02)00069-0; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; Tortorella MD, 2001, OSTEOARTHR CARTILAGE, V9, P539, DOI 10.1053/joca.2001.0427; van der Weyden L, 2006, AM J PATHOL, V169, P515, DOI 10.2353/ajpath.2006.050981; Wagener R, 2005, FEBS LETT, V579, P3323, DOI 10.1016/j.febslet.2005.03.018; WANG Z, 2004, P 50 ANN M ORTH RES; ZENG W, 2004, P 50 ANN M ORTH RES	36	36	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11101	11109		10.1074/jbc.M611588200	http://dx.doi.org/10.1074/jbc.M611588200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311924	hybrid			2022-12-25	WOS:000245941500031
J	Singh, RK; Iyappan, S; Scheffner, M				Singh, Rajesh K.; Iyappan, Saravanakumar; Scheffner, Martin			Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LIGASE; DNA-DAMAGE; EMBRYONIC LETHALITY; P53 DEGRADATION; IN-VIVO; COMPLEX; UBIQUITINATION; DOMAIN; PHOSPHORYLATION; ONCOPROTEIN	Mdm2 is a member of the RING finger family of ubiquitin ligases and is best known for its role in targeting the tumor suppressor p53 for ubiquitination and degradation. Mdm2 can bind to itself and to the structurally related protein MdmX, and these interactions involve the RING finger domain of Mdm2 and MdmX, respectively. In this study, we performed a mutational analysis of the RING finger domain of Mdm2, and we identified several amino acid residues that are important for Mdm2 to exert its ubiquitin ligase function. Mutation of some of these residues interfered with the Mdm2-Mdm2 interaction indicating that a homomeric complex represents the active form of Mdm2. Mutation of other residues did not detectably affect the ability of Mdm2 to interact with itself but reduced the ability of Mdm2 to interact with UbcH5. Remarkably, MdmX efficiently rescued the ubiquitin ligase activity of the latter Mdm2 mutants in vitro and within cells. Because the interaction of Mdm2 with MdmX is more stable than the Mdm2-Mdm2 interaction, this suggests that Mdm2-MdmX complexes play a prominent role in p53 ubiquitination in vivo. Furthermore, we show that, similar to Mdm2, the Mdm2-MdmX complex has Nedd8 ligase activity and that all mutations that affect the ubiquitin ligase activity of Mdm2 also affect its Nedd8 ligase activity. From a mechanistic perspective, this suggests that the actual function of Mdm2 and Mdm2-MdmX, respectively, in p53 ubiquitination and in p53 neddylation is similar for both processes.	Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Konstanz	Scheffner, M (corresponding author), Univ Konstanz, Dept Biol, Box M642, D-78457 Constance, Germany.	martin.scheffner@uni-konstanz.de	Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				Albert TK, 2002, EMBO J, V21, P355, DOI 10.1093/emboj/21.3.355; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Brzovic PS, 2003, P NATL ACAD SCI USA, V100, P5646, DOI 10.1073/pnas.0836054100; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Buchwald G, 2006, EMBO J, V25, P2465, DOI 10.1038/sj.emboj.7601144; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Grier JD, 2006, MOL CELL BIOL, V26, P192, DOI 10.1128/MCB.26.1.192-198.2006; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Hengstermann A, 1998, ONCOGENE, V17, P2933, DOI 10.1038/sj.onc.1202282; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kerscher O, 2006, ANNU REV CELL DEV BI, V22, P159, DOI 10.1146/annurev.cellbio.22.010605.093503; Kostic M, 2006, J MOL BIOL, V363, P433, DOI 10.1016/j.jmb.2006.08.027; Linares LK, 2003, FEBS LETT, V554, P73, DOI 10.1016/S0014-5793(03)01108-6; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; LUNA RMD, 1995, NATURE, V378, P203; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Nuber U, 1996, J BIOL CHEM, V271, P2795, DOI 10.1074/jbc.271.5.2795; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; OPYUROVSKY MV, 2007, EMBO J, V26, P90; Ozkan E, 2005, P NATL ACAD SCI USA, V102, P18890, DOI 10.1073/pnas.0509418102; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Poyurovsky MV, 2003, MOL CELL, V12, P875, DOI 10.1016/S1097-2765(03)00400-3; Saville MK, 2004, J BIOL CHEM, V279, P42169, DOI 10.1074/jbc.M403362200; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Steinman HA, 2005, ONCOGENE, V24, P7935, DOI 10.1038/sj.onc.1208930; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Vander Kooi CW, 2006, BIOCHEMISTRY-US, V45, P121, DOI 10.1021/bi051787e; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Xu Z, 2006, BIOCHEMISTRY-US, V45, P4749, DOI 10.1021/bi0601508; Zhang MH, 2005, MOL CELL, V20, P525, DOI 10.1016/j.molcel.2005.09.023; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	50	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10901	10907		10.1074/jbc.M610879200	http://dx.doi.org/10.1074/jbc.M610879200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17301054	hybrid, Green Published			2022-12-25	WOS:000245941500009
J	Lunn, JA; Jacamo, R; Rozengurt, E				Lunn, J. Adrian; Jacamo, Rodrigo; Rozengurt, Enrique			Preferential phosphorylation of focal adhesion kinase tyrosine 861 is critical for mediating an anti-apoptotic response to hyperosmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER CELLS; SRC FAMILY KINASES; SALTED FOOD-INTAKE; GASTRIC-CANCER; DEPENDENT PHOSPHORYLATION; CORTICAL CYTOSKELETON; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS; PROTEIN	The results presented here demonstrate that focal adhesion kinase ( FAK) Tyr-861 is the predominant tyrosine phosphorylation site stimulated by hyperosmotic stress in a variety of cell types, including epithelial cell lines (ileum-derived IEC-18, colon-derived Caco2, and stomach-derived NCI-N87), FAK null fibroblasts re-expressing FAK, and Src family kinase triple null fibroblasts ( SYF cells) in which c-Src has been restored ( YF cells). We show that hyperosmotic stress-stimulated FAK phosphorylation in epithelial cells is inhibited by Src family kinase inhibitors PP2 and SU6656 and that it does not occur in SYF cells. Unexpectedly, hyperosmotic stress-induced phosphorylation of FAK at Tyr-397, Tyr-576, and most dramatically at Tyr-861 was completely insensitive to the F-actin-disrupting agents, latrunculin A and cytochalasin D. Finally, we show that in FAK null cells exposed to hyperosmotic stress or growth factor withdrawal, re-expression of wild type FAK restored cell survival, whereas re-expression of FAK mutated from tyrosine to phenylalanine at position 861 (FAKY861F) did not. Our results indicate that FAK Tyr- 861 phosphorylation is required for mammalian cell survival of hyperosmotic stress. Furthermore, the results suggest that FAK is an upstream regulator ( rather than downstream effector) of F-actin reorganization in response to hyperosmotic stress. We propose that FAK/c-Src bipartite enzyme is a sensor of cytoplasmic shrinkage, and that the phosphorylation on FAK Tyr-861 by Src and subsequent reorganization of F-actin can initiate an anti- apoptotic signaling pathway that protects cells from hyperosmotic stress.	Univ Calif Los Angeles, Dept Med, David Geffen Sch Med,Digest Dis Res Ctr, Div Digest Dis,CURE, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Dept Med, David Geffen Sch Med,Digest Dis Res Ctr, Div Digest Dis,CURE, 900 Vet Ave,Warren Hall Rm 11-124, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu			NCI NIH HHS [K08CA104039-01] Funding Source: Medline; NIDDK NIH HHS [DK 56930, DK 55003, P30 DK41301] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA104039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, R01DK056930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Bell LM, 2000, J BIOL CHEM, V275, P25262, DOI 10.1074/jbc.M002076200; Bellas RE, 2002, AM J PHYSIOL-LUNG C, V282, pL1135, DOI 10.1152/ajplung.00174.2001; Cary LA, 1996, J CELL SCI, V109, P1787; Chan PC, 1999, J BIOL CHEM, V274, P26901, DOI 10.1074/jbc.274.38.26901; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Di Ciano C, 2002, AM J PHYSIOL-CELL PH, V283, pC850, DOI 10.1152/ajpcell.00018.2002; Di Ciano-Oliveira C, 2003, AM J PHYSIOL-CELL PH, V285, pC555, DOI 10.1152/ajpcell.00086.2003; Duxbury MS, 2004, SURGERY, V135, P555, DOI 10.1016/j.surg.2003.10.017; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Fox JG, 2003, CANCER RES, V63, P942; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Garces CA, 2006, CANCER RES, V66, P1446, DOI 10.1158/0008-5472.CAN-05-1661; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; Gustavsson A, 2004, J BIOL CHEM, V279, P22893, DOI 10.1074/jbc.M309693200; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Ilic D, 1996, EXP CELL RES, V222, P298, DOI 10.1006/excr.1996.0038; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Joossens JV, 1996, INT J EPIDEMIOL, V25, P494, DOI 10.1093/ije/25.3.494; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; Kurenova E, 2004, MOL CELL BIOL, V24, P4361, DOI 10.1128/MCB.24.10.4361-4371.2004; Lewis A, 2002, AM J PHYSIOL-CELL PH, V282, pC271, DOI 10.1152/ajpcell.00427.2001; Lim YM, 2004, J BIOL CHEM, V279, P29060, DOI 10.1074/jbc.M401183200; Lim YM, 2002, J BIOL CHEM, V277, P12735, DOI 10.1074/jbc.M111011200; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Lunn JA, 2004, J BIOL CHEM, V279, P45266, DOI 10.1074/jbc.M314132200; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; QUARONI A, 1981, J NATL CANCER I, V67, P1353; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHILLI R, 1982, GUT, V23, P326, DOI 10.1136/gut.23.4.326; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Sun GQ, 2002, ARCH BIOCHEM BIOPHYS, V397, P11, DOI 10.1006/abbi.2001.2627; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; Tohyama Y, 2004, CURR PHARM DESIGN, V10, P835, DOI 10.2174/1381612043452947; Tsugane S, 2005, CANCER SCI, V96, P1, DOI 10.1111/j.1349-7006.2005.00006.x; Tsugane S, 2004, BRIT J CANCER, V90, P128, DOI 10.1038/sj.bjc.6601511; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; VERNIA P, 1988, DIGEST DIS SCI, V33, P1353, DOI 10.1007/BF01536987; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632; Xia H, 2004, J BIOL CHEM, V279, P33024, DOI 10.1074/jbc.M313265200; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; Zaidel-Bar R, 2005, J CELL SCI, V118, P3997, DOI 10.1242/jcs.02523; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200	62	26	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10370	10379		10.1074/jbc.M607780200	http://dx.doi.org/10.1074/jbc.M607780200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289681	hybrid			2022-12-25	WOS:000245941000027
J	Zhao, YT; He, DH; Zhao, J; Wang, LX; Leff, AR; Spannhake, EW; Georas, S; Natarajan, V				Zhao, Yutong; He, Donghong; Zhao, Jing; Wang, Lixin; Leff, Alan R.; Spannhake, Ernst Wm.; Georas, Steve; Natarajan, Viswanathan			Lysophosphatidic acid induces interleukin-13 (IL-13) receptor alpha 2 expression and inhibits IL-13 signaling in primary human bronchial epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-D; ALPHA-2 CHAIN; GENE-EXPRESSION; ALLERGEN CHALLENGE; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; (IL)-13 RESPONSES; INTERFERON-GAMMA; BINDING SUBUNIT	Interleukin-13 (IL-13), a Th2 cytokine, plays a pivotal role in pathogenesis of bronchial asthma via IL-13 receptor alpha 1 ( IL-13R alpha 1) and IL-4 receptor alpha(IL-4R alpha). Recent studies show that a decoy receptor for IL-13, namely IL-13R alpha 2, mitigates IL-13 signaling and function. This study provides evidence for regulation of IL-13R alpha 2 production and release and IL-13-dependent signaling by lysophosphatidic acid(LPA) in primary cultures of human bronchial epithelial cells( HBEpCs). LPA treatment of HBEpCs in a time dependent fashion increased IL-13R alpha 2 gene expression without altering the mRNA levels of IL-13R alpha 1 and IL-4R alpha. Pretreatment with pertussis toxin (100 ng/ml, 4 h) or transfection of c-Jun small interference RNA or an inhibitor of JNK attenuated LPA-induced IL-13R alpha 2 gene expression and secretion of soluble IL-13R alpha 2. Overexpression of catalytically inactive mutants of phospholipase D(PLD) 1 or 2 attenuated LPA-induced IL-13R alpha 2 gene expression and protein secretion as well as phosphorylation of JNK. Pretreatment of HBEpCs with 1 mu m LPA for 6 h attenuated IL-13 but not IL-4 induced phosphorylation of STAT6. Transfection of HBEpCs with IL-13R alpha 2 small interference RNA blocked the effect of LPA on IL-13-induced phosphorylation of STAT6. Furthermore, pretreatment with LPA (1 mu m, 6 h) attenuated IL-13-induced eotaxin-1 and SOCS-1 gene expression. These results demonstrate that LPA induces IL-13R alpha 2 expression and release via PLD and JNK/AP-1 signal transduction and that pretreatment with LPA down-regulates IL-13 signaling in HBEpCs. Our data suggest a novel mechanism of regulation of IL-13R alpha 2 and IL-13 signaling that may be of physiological relevance to airway inflammation and remodeling.	Berlex Biosci, Dept Gene Technol, Richmond, CA 94806 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Univ Rochester, Dept Med, Div Pulm & Crit Care, Rochester, NY 14627 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Rochester	Zhao, YT (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Care, Ctr Integrat Sci Bldg,Room W403M,929 E 57th St, Chicago, IL 60637 USA.	yzhao@medicine.bsd.uchicago.edu	Wang, Lai-Xi/E-8755-2019; wang, xl/Y-8251-2019		NHLBI NIH HHS [HL71152, R01 HL071152, R01 HL071152-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071152] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi T, 1996, HEPATOLOGY, V24, P1274; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Bodey KJ, 1999, ALLERGY, V54, P1083, DOI 10.1034/j.1398-9995.1999.00889.x; Budnik LT, 2002, BIOL REPROD, V66, P859, DOI 10.1095/biolreprod66.4.859; CAR BD, 1994, AM J RESP CRIT CARE, V149, P655, DOI 10.1164/ajrccm.149.3.8118632; Casas-Gonzalez P, 2003, BBA-MOL CELL BIOL L, V1633, P75, DOI 10.1016/S1388-1981(03)00089-1; Cazzolli R, 2006, IUBMB LIFE, V58, P457, DOI 10.1080/15216540600871142; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; Chou CH, 2005, CARCINOGENESIS, V26, P45, DOI 10.1093/carcin/bgh301; Chun J, 2006, CURR PHARM DESIGN, V12, P161, DOI 10.2174/138161206775193109; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Cummings R, 2004, J BIOL CHEM, V279, P41085, DOI 10.1074/jbc.M404045200; Daines MO, 2002, J BIOL CHEM, V277, P10387, DOI 10.1074/jbc.M108109200; David M, 2001, ONCOGENE, V20, P6660, DOI 10.1038/sj.onc.1204629; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Folkard SG, 1997, EUR RESPIR J, V10, P2097, DOI 10.1183/09031936.97.10092097; Fukushima N, 2001, PROSTAG OTH LIPID M, V64, P21, DOI 10.1016/S0090-6980(01)00105-8; GEORAS SN, 2007, IN PRESS CLIN EXP AL; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Heller NM, 2004, AM J RESP CELL MOL, V31, P573, DOI 10.1165/rcmb.2004-0195OC; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108, DOI 10.1164/ajrccm.165.1.2105051; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HUANG SK, 1995, J IMMUNOL, V155, P2688; Jenkins GM, 2005, CELL MOL LIFE SCI, V62, P2305, DOI 10.1007/s00018-005-5195-z; Kawakami K, 2006, CANCER RES, V66, P4434, DOI 10.1158/0008-5472.CAN-05-1265; Kawakami K, 2001, CANCER GENE THER, V8, P861, DOI 10.1038/sj.cgt.7700373; Kawakami K, 2001, J EXP MED, V194, P1743, DOI 10.1084/jem.194.12.1743; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Kawakami M, 2003, CLIN CANCER RES, V9, P6381; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kogut MH, 2003, INT IMMUNOPHARMACOL, V3, P693, DOI 10.1016/S1567-5769(03)00057-2; Kotowicz K, 1996, INT IMMUNOL, V8, P1915, DOI 10.1093/intimm/8.12.1915; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Malabarba MG, 1996, BIOCHEM J, V319, P865, DOI 10.1042/bj3190865; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Murata T, 1998, INT J MOL MED, V1, P551; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Rahaman SO, 2002, CANCER RES, V62, P1103; Rubenfeld J, 2006, AM J PHYSIOL-LUNG C, V290, pL66, DOI 10.1152/ajplung.00473.2004; Saatian B, 2006, BIOCHEM J, V393, P657, DOI 10.1042/BJ20050791; Siess W, 1999, P NATL ACAD SCI USA, V96, P6931, DOI 10.1073/pnas.96.12.6931; Snyder MD, 2006, TRAFFIC, V7, P993, DOI 10.1111/j.1600-0854.2006.00450.x; Taube C, 2002, J IMMUNOL, V169, P6482, DOI 10.4049/jimmunol.169.11.6482; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Wang LX, 2003, J BIOL CHEM, V278, P39931, DOI 10.1074/jbc.M302896200; Webb DC, 2000, J IMMUNOL, V165, P108, DOI 10.4049/jimmunol.165.1.108; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wood N, 2003, J EXP MED, V197, P703, DOI 10.1084/jem.20020906; Wu AH, 2003, NEURO-ONCOLOGY, V5, P179, DOI 10.1215/S1152851702000510; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu YJ, 2005, CELL CALCIUM, V38, P569, DOI 10.1016/j.ceca.2005.08.001; Yasunaga S, 2003, CYTOKINE, V24, P293, DOI 10.1016/j.cyto.2003.08.006; Zhang JG, 1997, J BIOL CHEM, V272, P9474; Zhao YT, 2005, BIOCHEM J, V385, P493, DOI 10.1042/BJ20041160; Zhao YT, 2006, J BIOL CHEM, V281, P19501, DOI 10.1074/jbc.M511224200; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	60	33	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10172	10179		10.1074/jbc.M611210200	http://dx.doi.org/10.1074/jbc.M611210200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287216	hybrid, Green Accepted			2022-12-25	WOS:000245941000007
J	Huang, Y; Breitwieser, GE				Huang, Ying; Breitwieser, Gerda E.			Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; EXTRACELLULAR CA2+-SENSING RECEPTOR; METABOTROPIC GLUTAMATE RECEPTORS; N-LINKED GLYCOSYLATION; HUMAN CA2+ RECEPTOR; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE DOMAIN; SECONDARY HYPERPARATHYROIDISM; PHARMACOLOGICAL CHAPERONES; AMINOGLYCOSIDE ANTIBIOTICS	The calcium-sensing receptor (CaR), a member of G protein-coupled receptor family C, regulates systemic calcium homeostasis by activating G(q)- and G(i)-linked signaling in the parathyroid, kidney, and intestine. CaR is ubiquitinated by the E3 ligase dorfin and degraded via the endoplasmic reticulum-associated degradation pathway (Huang, Y., Niwa, J., Sobue, G., and Breitwieser, G. E. (2006) J. BioL Chem. 281,11610 -11617). Here we provide evidence for a conformational or functional checkpoint in CaR biogenesis using two complementary approaches. First we characterized the sensitivity of loss- or gain-of-function CaR mutants to proteasome inhibition by MG132. The stabilization of loss-of-function mutants and insensitivity of gain-of-function mutants to MG132 suggests that receptor sensitivity to calcium influences susceptibility to proteasomal degradation. Second, we used the allosteric activator NPS R-568 and antagonist NPS 2143 to promote the active and inactive conformations of wild type CaR, respectively. Overnight culture in NPS R-568 increased expression of CaR, whereas NPS 2143 had the opposite effect. NPS R-568 and NPS 2143 differentially regulated maturation and cell surface expression of wild type CaR, directly affecting maximal signaling responses. NPS R-568 rescued expression of loss-of-function CaR mutants, increasing plasma membrane expression and ERK1/2 phosphorylation in response to 5 mM Ca2+. Disorders of calcium homeostasis caused by CaR mutations may therefore result from altered receptor biogenesis independent of receptor function, i.e. a protein folding disorder. The allosteric modulators NPS R-568 and NPS 2143 not only alter CaR sensitivity to calcium and hence signaling but also modulate receptor expression.	Geisinger Med Clin, Weis Ctr Res, Danville, PA 17822 USA; Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA	Geisinger Medical Center; Syracuse University	Breitwieser, GE (corresponding author), Geisinger Med Clin, Weis Ctr Res, 100 N Acad Ave, Danville, PA 17822 USA.	gebreitwieser@geisinger.edu		Breitwieser, Gerda/0000-0001-9081-0362	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM077563] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM077563] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai M, 1997, J CLIN INVEST, V99, P88, DOI 10.1172/JCI119137; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Baron J, 1996, HUM MOL GENET, V5, P601, DOI 10.1093/hmg/5.5.601; Breitwieser GE, 2004, CELL CALCIUM, V35, P209, DOI 10.1016/j.ceca.2003.10.013; Chakravarthi S, 2006, EMBO REP, V7, P271, DOI 10.1038/sj.embor.7400645; Chattopadhyay N, 2006, MOL GENET METAB, V89, P189, DOI 10.1016/j.ymgme.2006.07.003; Dupre DJ, 2006, J BIOL CHEM, V281, P34561, DOI 10.1074/jbc.M605012200; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; Gama L, 1999, BIOTECHNIQUES, V26, P814, DOI 10.2144/99265bm03; Gama L, 2001, J BIOL CHEM, V276, P39053, DOI 10.1074/jbc.M105662200; Hebert SC, 2006, ANNU REV MED, V57, P349, DOI 10.1146/annurev.med.57.121304.131328; Holstein DM, 2004, J BIOL CHEM, V279, P10060, DOI 10.1074/jbc.M312039200; Hu JX, 2005, J BIOL CHEM, V280, P5113, DOI 10.1074/jbc.M413403200; Hu JX, 2003, TRENDS ENDOCRIN MET, V14, P282, DOI 10.1016/S1043-2760(03)00104-8; Huang Y, 2006, J BIOL CHEM, V281, P11610, DOI 10.1074/jbc.M513552200; Jong YJI, 2005, J BIOL CHEM, V280, P30469, DOI 10.1074/jbc.M501775200; KATZ CL, 1992, ENDOCRINOLOGY, V131, P903, DOI 10.1210/en.131.2.903; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Lindberg JS, 2005, J AM SOC NEPHROL, V16, P800, DOI 10.1681/ASN.2004060512; Mah SJ, 2005, J NEUROSCI, V25, P2215, DOI 10.1523/JNEUROSCI.4573-04.2005; McLarnon SJ, 2002, BIOCHEM BIOPH RES CO, V297, P71, DOI 10.1016/S0006-291X(02)02133-2; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Miedlich S, 2002, J BIOL CHEM, V277, P49691, DOI 10.1074/jbc.M205578200; Miedlich SU, 2004, J BIOL CHEM, V279, P7254, DOI 10.1074/jbc.M307191200; Mizobuchi M, 2004, J AM SOC NEPHROL, V15, P2579, DOI 10.1097/01.ASN.0000141016.20133.33; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Nagano N, 2006, PHARMACOL THERAPEUT, V109, P339, DOI 10.1016/j.pharmthera.2005.06.019; Nemeth EF, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290015; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Petaja-Repo UE, 2002, EMBO J, V21, P1628, DOI 10.1093/emboj/21.7.1628; Petrel C, 2004, J BIOL CHEM, V279, P18990, DOI 10.1074/jbc.M400724200; Petrel C, 2003, J BIOL CHEM, V278, P49487, DOI 10.1074/jbc.M308010200; Pidasheva S, 2006, HUM MOL GENET, V15, P2200, DOI 10.1093/hmg/ddl145; Ramasamy I, 2006, CLIN CHEM LAB MED, V44, P237, DOI 10.1515/CCLM.2006.046; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Sato K, 2002, J CLIN ENDOCR METAB, V87, P3068, DOI 10.1210/jc.87.7.3068; Tfelt-Hansen J, 2005, CRIT REV CL LAB SCI, V42, P35, DOI 10.1080/10408360590886606; Ulloa-Aguirre A, 2004, TRAFFIC, V5, P821, DOI 10.1111/j.1600-0854.2004.00232.x; Wang MH, 2006, J BIOL CHEM, V281, P8864, DOI 10.1074/jbc.M512865200; Watanabe T, 1998, J CLIN ENDOCR METAB, V83, P2497, DOI 10.1210/jc.83.7.2497; Zhang ML, 2005, J BIOL CHEM, V280, P11140, DOI 10.1074/jbc.M412242200	45	88	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9517	9525		10.1074/jbc.M609045200	http://dx.doi.org/10.1074/jbc.M609045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17284438	hybrid			2022-12-25	WOS:000245421700024
J	Kajino, T; Omori, E; Ishii, S; Matsumoto, K; Ninomiya-Tsuji, J				Kajino, Taisuke; Omori, Emily; Ishii, Shunsuke; Matsumoto, Kunihiro; Ninomiya-Tsuji, Jun			TAK1 MAPK kinase kinase mediates transforming growth factor-beta signaling by targeting SnoN oncoprotein for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; RECEPTOR; ACTIVATION; EXPRESSION; CELLS; SMAD3; GENE; SKI; TRANSDUCTION; PATHWAY	Transforming growth factor-beta (TGF-beta) regulates a variety of physiologic processes through essential intracellular mediators Smads. The SnoN oncoprotein is an inhibitor of TGF-beta signaling. SnoN recruits transcriptional repressor complex to block Smad-dependent transcriptional activation of TGF-beta-responsive genes. Following TGF-beta stimulation, SnoN is rapidly degraded, thereby allowing the activation of TGF-beta target genes. Here, we report the role of TAK1 as a SnoN protein kinase. TAK1 interacted with and phosphorylated SnoN, and this phosphorylation regulated the stability of SnoN. Inactivation of TAK1. prevented TGF-beta-induced SnoN degradation and impaired induction of the TGF-beta-responsive genes. These data suggest that TAK1 modulates TGF-beta-dependent cellular responses by targeting SnoN for degradation.	N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; Nagoya Univ, Grad Sch Sci, Dept Biol Mol, Nagoya, Aichi 4648602, Japan; RIKEN, Tsukuba Inst, Genet Mol Lab, Ibaraki 3050074, Japan	University of North Carolina; North Carolina State University; Nagoya University; RIKEN	Ninomiya-Tsuji, J (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA.	Jun_Tsuji@ncsu.edu	Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478; Ninomiya-Tsuji, Jun/0000-0002-5584-0176	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR050972] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM068812] Funding Source: NIH RePORTER; NIAMS NIH HHS [R21 AR050972-02, R21 AR050972, AR050972] Funding Source: Medline; NIGMS NIH HHS [R01 GM068812-04, R01 GM068812, GM068812] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Jadrich JL, 2006, DEVELOPMENT, V133, P1529, DOI 10.1242/dev.02333; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Luo KX, 2004, CURR OPIN GENET DEV, V14, P65, DOI 10.1016/j.gde.2003.11.003; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Ninomiya-Tsuji J, 2003, J BIOL CHEM, V278, P18485, DOI 10.1074/jbc.M207453200; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; PearsonWhite S, 1997, NUCLEIC ACIDS RES, V25, P2930, DOI 10.1093/nar/25.14.2930; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shibuya H, 1998, EMBO J, V17, P1019, DOI 10.1093/emboj/17.4.1019; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	28	34	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9475	9481		10.1074/jbc.M700875200	http://dx.doi.org/10.1074/jbc.M700875200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276978	Green Accepted, hybrid			2022-12-25	WOS:000245421700020
J	Silva, RAGD; Schneeweis, LA; Krishnan, SC; Zhang, XQ; Axelsen, PH; Davidson, WS				Silva, R. A. Gangani D.; Schneeweis, Lumelle A.; Krishnan, Srinivasan C.; Zhang, Xiuqi; Axelsen, Paul H.; Davidson, W. Sean			The structure of apolipoprotein A-II in discoidal high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; ORGANIZATION; ASSOCIATION; PARTICLES	It is well accepted that high levels of high density lipoproteins (HDL) reduce the risk of atherosclerosis in humans. Apolipoprotein A-I (apoA-I) and apoA-II are the first and second most common protein constituents of HDL. Unlike apoA-I, detailed structural models for apoA-II in HDL are not available. Here, we present a structural model of apoA-II in reconstituted HDL (rHDL) based on two well established experimental approaches: chemical cross-linking/mass spectrometry (MS) and internal reflection infrared spectroscopy. Homogeneous apoA-II rHDL were reacted with a cross-linking agent to link proximal lysine residues. Upon trypitic digestion, cross-linked peptides were identified by electrospray mass spectrometry. 14 cross-links were identified and confirmed by tandem mass spectrometry (MS/MS). Infrared spectroscopy indicated a beltlike molecular arrangement for apoA-II in which the protein helices wrap around the lipid bilayer rHDL disc. The cross-links were then evaluated on three potential belt arrangements. The data clearly refute a parallel model but support two antiparallel models, especially a "double hairpin" form. These models form the basis for understanding apoA-II structure in more complex HDL particles.	Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45237 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Mass Spectrometry Applicat Lab, Framingham, MA 01701 USA; Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University System of Ohio; University of Cincinnati; University of Pennsylvania; University of Pennsylvania; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 2120 Galbraith Rd, Cincinnati, OH 45237 USA.	Sean.Davidson@UC.edu		Davidson, William/0000-0003-2756-2989	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067093, R01HL068186] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL67093, R01-HL68186] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allayee H, 2003, CIRC RES, V92, P1262, DOI 10.1161/01.RES.0000075600.87675.16; Axelsen PH, 1996, PROG BIOPHYS MOL BIO, V66, P227, DOI 10.1016/S0079-6107(97)00007-2; BEKAERT ED, 1992, BIOCHIM BIOPHYS ACTA, V1126, P105, DOI 10.1016/0005-2760(92)90223-I; Boucher J, 2004, J LIPID RES, V45, P849, DOI 10.1194/jlr.M300431-JLR200; Castellani LW, 1997, J CLIN INVEST, V100, P464, DOI 10.1172/JCI119554; Clay MA, 2000, J BIOL CHEM, V275, P9019, DOI 10.1074/jbc.275.12.9019; Davidson WS, 2005, CURR OPIN LIPIDOL, V16, P295, DOI 10.1097/01.mol.0000169349.38321.ad; Davidson WS, 2003, J BIOL CHEM, V278, P27199, DOI 10.1074/jbc.M302764200; DECOEN JL, 1988, P NATL ACAD SCI USA, V85, P5669; Durbin DM, 1997, J BIOL CHEM, V272, P31333, DOI 10.1074/jbc.272.50.31333; Escola-Gil JC, 1998, J LIPID RES, V39, P457; Gillard BK, 2005, BIOCHEMISTRY-US, V44, P471, DOI 10.1021/bi048591j; Hedrick CC, 2001, J LIPID RES, V42, P563; Hime NJ, 2006, J LIPID RES, V47, P115, DOI 10.1194/jlr.M500284-JLR200; Jahangiri A, 2005, J LIPID RES, V46, P896, DOI 10.1194/jlr.M400212-JLR200; JONAS A, 1990, J BIOL CHEM, V265, P22123; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Koppaka V, 2001, CELL MOL LIFE SCI, V58, P885, DOI 10.1007/PL00000908; Kruip J, 1997, J BIOL CHEM, V272, P17061, DOI 10.1074/jbc.272.27.17061; Kumar MS, 2002, BIOCHEMISTRY-US, V41, P11681, DOI 10.1021/bi026069w; LUNDKATZ S, 1986, BIOCHEMISTRY-US, V25, P1562, DOI 10.1021/bi00355a016; Maiorano JN, 2004, BIOCHEMISTRY-US, V43, P11717, DOI 10.1021/bi0496642; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MASSEY JB, 1989, BIOCHIM BIOPHYS ACTA, V999, P121, DOI 10.1016/0167-4838(89)90208-2; Panagotopulos SE, 2001, J BIOL CHEM, V276, P42965, DOI 10.1074/jbc.M106462200; Pliszka B, 2001, BIOCHEM BIOPH RES CO, V281, P924, DOI 10.1006/bbrc.2001.4454; Schneeweis LA, 2005, BIOCHEMISTRY-US, V44, P12525, DOI 10.1021/bi050872j; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P8600, DOI 10.1021/bi050421z; Silva RAGD, 2005, BIOCHEMISTRY-US, V44, P2759, DOI 10.1021/bi047717+; SPARKS DL, 1992, J LIPID RES, V33, P123; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912	33	27	27	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9713	9721		10.1074/jbc.M610380200	http://dx.doi.org/10.1074/jbc.M610380200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17264082	hybrid			2022-12-25	WOS:000245421700045
J	von Holst, A; Egbers, U; Prochiantz, A; Faissner, A				von Holst, Alexander; Egbers, Ursula; Prochiantz, Alain; Faissner, Andreas			Neural stem/progenitor cells express 20 Tenascin C isoforms that are differentially regulated by Pax6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGODENDROCYTE PRECURSOR CELLS; ALTERNATIVELY SPLICED REGION; NGF-DEPENDENT SURVIVAL; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; NEURITE OUTGROWTH; GENE-EXPRESSION; SYMPATHETIC NEURONS; TRKA EXPRESSION; MOUSE TENASCIN	Tenascin C (Tnc) is an alternatively spliced, multimodular extracellular matrix glycoprotein present in the ventricular zone of the developing brain. Pax6-deficient small eye (sey) mouse mutants show an altered Tnc expression pattern. Here, we investigated the expression of Tnc isoforms in neural stem/progenitor cells and their regulation by the paired-box transcription factor Pax6. Neural stem/progenitor cells cultured as neurospheres strongly expressed Tnc on the protein level. The Tnc isoform expression in neural stem/progenitor cells was analyzed by reverse transcriptase-PCR and dot blot Southern hybridization: In total, 20 different Tnc isoforms were detected in neurospheres derived from embryonic forebrain cell suspensions. The Tnc isoform containing the fibronectin type III domains A1A4BD is novel and might be neural stem/progenitor cell-specific. Transient overexpression of Pax6 in neurospheres of the medial ganglionic eminence did not alter the total Tnc mRNA expression level but showed a pronounced regulative effect on different Tnc isoforms. The larger Tnc isoforms containing four, five, and six additional alternatively spliced fibronectin type III domains were up-regulated, whereas the small Tnc isoforms without any or with one additional domain were down-regulated. Thus, Pax6 is a homeodomain protein that also modulates the splicing machinery. We conclude that the combinatorial code of Tnc isoform expression in the neural stem/progenitor cell is complex and regulated by Pax6. These findings suggest a functional significance for individual Tnc isoforms in neural stem/progenitor cells.	Ruhr Univ Bochum, Dept Cell Morphol & Mol Neurobiol, D-44780 Bochum, Germany; Ecole Normale Super, CNRS UMR 8542, F-75005 Paris, France	Ruhr University Bochum; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	von Holst, A (corresponding author), Univ Str 150,NDEF 05-339, D-44780 Bochum, Germany.	Alexander.vonHolst@ruhr-uni-bochum.de; Andreas.Faissner@ruhr-uni-bochum.de	Faissner, Andreas/A-5314-2008; von Holst, Alexander/I-3061-2014	Faissner, Andreas/0000-0002-2211-8259; 				Ba-Charvet KTN, 1998, DEVELOPMENT, V125, P4273; Bard JBL, 1998, MECH DEVELOP, V74, P111, DOI 10.1016/S0925-4773(98)00069-0; BARTSCH S, 1992, J NEUROSCI, V12, P736; Campos LS, 2004, DEVELOPMENT, V131, P3433, DOI 10.1242/dev.01199; Carnemolla B, 1999, AM J PATHOL, V154, P1345, DOI 10.1016/S0002-9440(10)65388-6; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; Copertino DW, 1997, P NATL ACAD SCI USA, V94, P1846, DOI 10.1073/pnas.94.5.1846; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; D'Amour KA, 2003, P NATL ACAD SCI USA, V100, P11866, DOI 10.1073/pnas.1834200100; Dirks PB, 2006, NATURE, V444, P687, DOI 10.1038/444687a; DORRIES U, 1994, J NEUROSCI RES, V37, P336, DOI 10.1002/jnr.490370306; Fidler PS, 1999, J NEUROSCI, V19, P8778, DOI 10.1523/JNEUROSCI.19-20-08778.1999; Garcion E, 2004, DEVELOPMENT, V131, P3423, DOI 10.1242/dev.01202; Garcion E, 2001, DEVELOPMENT, V128, P2485; Garwood J, 2004, EUR J NEUROSCI, V20, P2524, DOI 10.1111/j.1460-9568.2004.03727.x; GATES MA, 1995, J COMP NEUROL, V361, P249, DOI 10.1002/cne.903610205; GELLER HM, 1988, J CELL BIOL, V107, P1977, DOI 10.1083/jcb.107.5.1977; Gherzi R, 1997, DNA CELL BIOL, V16, P559, DOI 10.1089/dna.1997.16.559; Gotz M, 1998, NEURON, V21, P1031, DOI 10.1016/S0896-6273(00)80621-2; Gotz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739; Gotz M, 1997, EUR J NEUROSCI, V9, P496, DOI 10.1111/j.1460-9568.1997.tb01627.x; Gotz R, 2005, NAT NEUROSCI, V8, P1169, DOI 10.1038/nn1524; Hack MA, 2005, NAT NEUROSCI, V8, P865, DOI 10.1038/nn1479; Hack MA, 2004, MOL CELL NEUROSCI, V25, P664, DOI 10.1016/j.mcn.2003.12.012; Haubst N, 2004, DEVELOPMENT, V131, P6131, DOI 10.1242/dev.01524; Heins N, 2002, NAT NEUROSCI, V5, P308, DOI 10.1038/nn828; Hu JG, 2004, J NEUROSCI RES, V78, P637, DOI 10.1002/jnr.20317; Joester A, 2001, MATRIX BIOL, V20, P13, DOI 10.1016/S0945-053X(00)00136-0; Joester A, 1999, J BIOL CHEM, V274, P17144, DOI 10.1074/jbc.274.24.17144; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; KAPLONY A, 1991, DEVELOPMENT, V112, P605; Leone DP, 2005, J CELL SCI, V118, P2589, DOI 10.1242/jcs.02396; Meiners S, 2001, J NEUROSCI, V21, P7215, DOI 10.1523/JNEUROSCI.21-18-07215.2001; Mercado MLT, 2004, J NEUROSCI, V24, P238, DOI 10.1523/JNEUROSCI.4519-03.2004; Pinkstaff JK, 1999, J NEUROSCI, V19, P1541; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reynolds BA, 1996, DEV BIOL, V175, P1, DOI 10.1006/dbio.1996.0090; Rigato F, 2002, J NEUROSCI, V22, P6596; Stoykova A, 2000, J NEUROSCI, V20, P8042; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; TUCKER RP, 1993, DEVELOPMENT, V117, P347; von Holst A, 2006, J NEUROSCI, V26, P4082, DOI 10.1523/JNEUROSCI.0422-06.2006; VONHOLST A, 1995, MOL CELL NEUROSCI, V6, P185; vonHolst A, 1997, EUR J NEUROSCI, V9, P2169; Wain HM, 2002, NUCLEIC ACIDS RES, V30, P169, DOI 10.1093/nar/30.1.169; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; Yuasa S, 2001, ARCH HISTOL CYTOL, V64, P119, DOI 10.1679/aohc.64.119	48	70	71	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9172	9181		10.1074/jbc.M608067200	http://dx.doi.org/10.1074/jbc.M608067200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264084	hybrid			2022-12-25	WOS:000245780300064
J	Nizak, C; Fitzhenry, RJ; Kessin, RH				Nizak, Clement; Fitzhenry, Robert J.; Kessin, Richard H.			Exploitation of Other Social Amoebae by Dictyostelium caveatum	PLOS ONE			English	Article								Dictyostelium amoebae faced with starvation trigger a developmental program during which many cells aggregate and form fruiting bodies that consist of a ball of spores held aloft by a thin stalk. This developmental strategy is open to several forms of exploitation, including the remarkable case of Dictyostelium caveatum, which, even when it constitutes 1/10(3) of the cells in an aggregate, can inhibit the development of the host and eventually devour it. We show that it accomplishes this feat by inhibiting a region of cells, called the tip, which organizes the development of the aggregate into a fruiting body. We use live-cell microscopy to define the D. caveatum developmental cycle and to show that D. caveatum amoebae have the capacity to ingest amoebae of other Dictyostelid species, but do not attack each other. The block in development induced by D. caveatum does not affect the expression of specific markers of prespore cell or prestalk cell differentiation, but does stop the coordinated cell movement leading to tip formation. The inhibition mechanism involves the constitutive secretion of a small molecule by D. caveatum and is reversible. Four Dictyostelid species were inhibited in their development, while D. caveatum is not inhibited by its own compound(s). D. caveatum has evolved a predation strategy to exploit other members of its genus, including mechanisms of developmental inhibition and specific phagocytosis.	[Nizak, Clement] Rockefeller Univ, Ctr Phys & Biol, Living Matter Lab, New York, NY 10021 USA; [Fitzhenry, Robert J.; Kessin, Richard H.] Columbia Univ, Dept Anat & Cell Biol, New York, NY USA	Rockefeller University; Columbia University	Nizak, C (corresponding author), CNRS, Spectrometrie Phys Lab, St Martin Dheres, France.	clement.nizak@mail.rockefeller.edu	Nizak, Clement/HGV-1085-2022; Nizak, Clement/L-1334-2013	Nizak, Clement/0000-0002-4591-8240; Nizak, Clement/0000-0002-4591-8240	EMBO; HFSP; Wellcome Trust; Dictyostelium Stock Center; NIH [GM64432-05]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064432] Funding Source: NIH RePORTER	EMBO(European Molecular Biology Organization (EMBO)); HFSP(Human Frontier Science Program); Wellcome Trust(Wellcome TrustEuropean Commission); Dictyostelium Stock Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	C. N. was supported by EMBO and is currently the recipient of a HFSP postdoctoral fellowship. R. J. F. is the recipient of a Wellcome Trust postdoctoral fellowship. We thank Jakob Franke at the Dictyostelium Stock Center and the NIH for support of this facility (GM64432-05).	ABE T, 1994, CELL, V77, P687, DOI 10.1016/0092-8674(94)90053-1; BONNER JT, 1958, J EMBRYOL EXP MORPH, V6, P346; CANNON GJ, 1992, J CELL SCI, V101, P907; Dormann D, 1998, BIOPHYS CHEM, V72, P21, DOI 10.1016/S0301-4622(98)00120-3; DUFFY KTI, 1988, CURR MICROBIOL, V17, P203, DOI 10.1007/BF01589453; GOMER RH, 1987, SCIENCE, V237, P758, DOI 10.1126/science.3039657; Haspel G, 2005, J COMP PHYSIOL A, V191, P529, DOI 10.1007/s00359-005-0620-1; Kessin RH, 2001, DICTYOSTELIUM EVOLUT, pxiv; LEWIS KE, 1986, CAN J MICROBIOL, V32, P79, DOI 10.1139/m86-017; Moore J., 2002, Parasites and the behavior of animals; NICOL A, 1978, J CELL SCI, V32, P377; OLIVE LS, 1961, J PROTOZOOL, V8, P467, DOI 10.1111/j.1550-7408.1961.tb01243.x; Raper KB, 1940, AM J BOT, V27, P436, DOI 10.2307/2436460; Schaap P, 2006, SCIENCE, V314, P661, DOI 10.1126/science.1130670; SIEGERT F, 1995, CURR BIOL, V5, P937, DOI 10.1016/S0960-9822(95)00184-9; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; Thompson CRL, 2004, DEV GROWTH DIFFER, V46, P363; WADDELL DR, 1982, NATURE, V298, P464, DOI 10.1038/298464a0; WADDELL DR, 1985, EXP CELL RES, V159, P323, DOI 10.1016/S0014-4827(85)80006-9; WADDELL DR, 1986, J CELL BIOL, V102, P298, DOI 10.1083/jcb.102.1.298; Zuppinger C, 1997, EUR J PROTISTOL, V33, P396, DOI 10.1016/S0932-4739(97)80051-X	21	10	10	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e212	10.1371/journal.pone.0000212	http://dx.doi.org/10.1371/journal.pone.0000212			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299592	Green Submitted, Green Published, gold			2022-12-25	WOS:000207444400013
J	Winter, SF; Acevedo, VD; Gangula, RD; Freeman, KW; Spencer, DM; Greenberg, NM				Winter, S. F.; Acevedo, V. D.; Gangula, R. D.; Freeman, K. W.; Spencer, D. M.; Greenberg, N. M.			Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2	ONCOGENE			English	Article						FGFR1; prostate; angiogenesis; angiopoietin; transgenic	FIBROBLAST GROWTH-FACTORS; HYPOXIA-INDUCIBLE FACTOR-1; RECEPTOR TYROSINE KINASE; INTRAEPITHELIAL NEOPLASIA; CANCER PROGRESSION; TUMOR ANGIOGENESIS; GENE-EXPRESSION; ANGIOPOIETIN-2; PROMOTER; HYPERPLASIA	The expression of. broblast growth factor receptor (FGFR)-1 correlates with angiogenesis and is associated with prostate cancer (CaP) progression. To more precisely de. ne the molecular mechanisms whereby FGFR1 causes angiogenesis in the prostate we exploited a transgenic mouse model, JOCK-1, in which activation of a conditional FGFR1 allele in the prostate epithelium caused rapid angiogenesis and progressive hyperplasia. By labeling the vasculature in vivo and applying a novel method to measure the vasculature in three dimensions, we were able to observe a signi. cant increase in vascular volume 1 week after FGFR1 activation. Although vessel volume and branching both continued to increase throughout a 6-week period of FGFR1 activation, importantly, we discovered that continued activation of FGFR1 was not required to maintain the new vasculature. Exploring the molecular mediators of the angiogenic phenotype, we observed consistent upregulation of HIF-1 alpha, vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), whereas expression of Ang-1 was lost. Further analysis revealed that loss of Ang-1 expression occurred in the basal epithelium, whereas the increase in Ang-2 expression occurred in the luminal epithelium. Reporter assays con. rmed that the Ang-2 promoter was regulated by FGFR1 signaling and a small molecule inhibitor of FGFR activity, PD173074, could abrogate this response. These. ndings establish a method to follow spontaneous angiogenesis in a conditional autochthonous system, implicate the angiopoietins as downstream effectors of FGFR1 activation in vivo, and suggest that therapies targeting FGFR1 could be used to inhibit neovascularization during initiation and progression of CaP.	Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98109 USA; Baylor Coll Med, Dept Immunol, Houston, TX USA	Fred Hutchinson Cancer Center; Baylor College of Medicine	Greenberg, NM (corresponding author), Fred Hutchinson Canc Res Ctr, Clin Res Div, 1100 Fairview Ave N,D4-100, Seattle, WA 98109 USA.	ngreenberg@fhcrc.org			NCI NIH HHS [CA64851] Funding Source: Medline; NIGMS NIH HHS [R25 GM056929] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM056929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		American Cancer Society, 2006, CANC FACTS FIG 2006; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bicknell R, 2004, ANNU REV PHARMACOL, V44, P219, DOI 10.1146/annurev.pharmtox.44.101802.121650; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Dery MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012; Doll JA, 2001, PROSTATE, V49, P293, DOI 10.1002/pros.10025; Dorkin TJ, 1999, J PATHOL, V189, P564, DOI 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Foster BA, 1999, PROSTATE CANCER P D, V2, P76; Freeman KW, 2003, CANCER RES, V63, P8256; Giri D, 1999, CLIN CANCER RES, V5, P1063; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Hayward SW, 1996, ACTA ANAT, V155, P81; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Huss WJ, 2003, PROSTATE, V54, P8, DOI 10.1002/pros.10163; Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8; Jin CL, 2004, CANCER RES, V64, P4555, DOI 10.1158/0008-5472.CAN-03-3752; Kim I, 2000, J BIOL CHEM, V275, P18550, DOI 10.1074/jbc.M910084199; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; Lind AJ, 2005, PROSTATE, V62, P394, DOI 10.1002/pros.20163; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V289, P801, DOI 10.1006/bbrc.2001.6046; Tait CR, 2004, J PATHOL, V204, P1, DOI 10.1002/path.1618; Thomson AA, 2001, REPRODUCTION, V121, P187, DOI 10.1530/rep.0.1210187; Wang F, 2004, PROSTATE, V58, P1, DOI 10.1002/pros.10311; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P409; Welm BE, 2002, J CELL BIOL, V157, P703, DOI 10.1083/jcb.200107119; Winter SF, 2003, PROSTATE CANCER P D, V6, P204, DOI 10.1038/sj.pcan.4500655; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698; Zhang L, 2003, CANCER RES, V63, P3403	40	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	34					4897	4907		10.1038/sj.onc.1210288	http://dx.doi.org/10.1038/sj.onc.1210288			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17297442				2022-12-25	WOS:000248322500002
J	Baroni, M; Pizzirani, C; Pinotti, M; Ferrari, D; Adinolfi, E; Calzavarini, S; Caruso, P; Bernardi, F; Di Virgilio, F				Baroni, Marcello; Pizzirani, Cinzia; Pinotti, Mirko; Ferrari, Davide; Adinolfi, Elena; Calzavarini, Sara; Caruso, Pierpaolo; Bernardi, Francesco; Di Virgilio, Francesco			Stimulation of P2 (P2X(7)) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles	FASEB JOURNAL			English	Article						coagulation; inflammation; extracellular ATP; purinergic receptors	SHED MEMBRANE MICROPARTICLES; EXTRACELLULAR ATP; ACTIVATION; BLOOD; NUCLEOTIDES; IDENTIFICATION; INFLAMMATION; COAGULATION; THROMBOSIS; EXPRESSION	Receptors for extracellular nucleotides are the focus of increasing attention for their ability to cause release of plasma membrane vesicles ( microparticles, MPs). Here, we show that monocyte-derived human dendritic cells (DCs) stimulated with a P2X(7) receptor (P2X(7)R) agonist undergo a large release of MPs endowed with procoagulant activity. Functional and Western blot studies revealed that MPs contain the membrane-bound form of tissue factor (TF), a glycoprotein acting as essential cofactor of activated factor VII and triggering blood coagulation. Quiescent DCs express the membrane-bound (full length), as well as truncated alternatively spliced TF forms. DC reactivity to anti- TF Abs disappeared almost completely on stimulation with ATP or benzoyl ATP ( BzATP), as shown by immunoblot and confocal microscopy analysis. Concurrently, TF reactivity and activity appeared in the vesicular fraction, indicating that MPs are important carriers for the dissemination of full-length TF form. Activity of MP-bound TF, comparable to that of relipidated recombinant TF, was dose dependently inhibited by the addition of a specific anti- human TF antibody. We infer that a large fraction of this protein, and its procoagulant potential, are "deliverable" after physiological or pathological stimuli. These findings might have implications for triggering and propagating coagulation in healthy and atherosclerotic vessels.-Marcello Baroni, Cinzia Pizzirani, Mirko Pinotti, Davide Ferrari, Elena Adinolfi, Sara Calzavarini, Pierpaolo Caruso, Francesco Bernardi, and Francesco Di Virgilio. Stimulation of P2 ( P2X7) receptors in human dendritic cells induces the release of tissue factor-bearing microparticles.	Univ Ferrara, Interdisciplinary Ctr Study Inflammat, Ferrara, Italy; Univ Ferrara, Dept Biochem, Ferrara, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Ferrara, Italy	University of Ferrara; University of Ferrara; University of Ferrara	Di Virgilio, F (corresponding author), Sect Gen Pathol, Dept Expt & Diagnost Med, Via Borsari 46, I-44100 Ferrara, Italy.	fdv@unife.it	bernardi, francesco/F-5443-2013; Di Virgilio, Francesco/J-3754-2018; Ferrari, Davide/F-5644-2015; Adinolfi, Elena/F-9169-2010; DI VIRGILIO, Francesco/O-4634-2019; Calzavarini, Sara/AAU-9368-2020	Di Virgilio, Francesco/0000-0003-3566-1362; Ferrari, Davide/0000-0002-5727-9204; Adinolfi, Elena/0000-0001-8129-9929; DI VIRGILIO, Francesco/0000-0003-3566-1362; Calzavarini, Sara/0000-0002-7494-2995; Pinotti, Mirko/0000-0002-4114-7055	Telethon [GGP06070] Funding Source: Medline	Telethon(Fondazione Telethon)		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Adinolfi E, 2005, MOL BIOL CELL, V16, P3260, DOI 10.1091/mbc.E04-11-1025; Ahamed J, 2006, P NATL ACAD SCI USA, V103, P13932, DOI 10.1073/pnas.0606411103; Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101; Atkinson B, 2006, BLOOD CELL MOL DIS, V36, P217, DOI 10.1016/j.bcmd.2005.12.025; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bianco F, 2005, J IMMUNOL, V174, P7268, DOI 10.4049/jimmunol.174.11.7268; Biro E, 2003, J THROMB HAEMOST, V1, P2561, DOI 10.1046/j.1538-7836.2003.00456.x; Bogdanov VY, 2003, NAT MED, V9, P458, DOI 10.1038/nm841; Boulanger CM, 2006, HYPERTENSION, V48, P180, DOI 10.1161/01.HYP.0000231507.00962.b5; Burnstock G, 2006, PHARMACOL REV, V58, P58, DOI 10.1124/pr.58.1.5; Campo G, 2006, ARTERIOSCL THROM VAS, V26, P2800, DOI 10.1161/01.ATV.0000247249.82030.94; Carta S, 2006, BLOOD, V108, P1618, DOI 10.1182/blood-2006-03-014126; Cirillo P, 2004, CIRCULATION, V109, P2911, DOI 10.1161/01.CIR.0000129312.43547.08; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Dinarello CA, 2005, J EXP MED, V201, P1355, DOI 10.1084/jem.20050640; DIVIRGILIO F, 1995, IMMUNOL TODAY, V16, P524, DOI 10.1016/0167-5699(95)80045-X; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987; Ferrari D, 2000, FASEB J, V14, P2466, DOI 10.1096/fj.00-0031com; Ferrari D, 2006, J IMMUNOL, V176, P3877, DOI 10.4049/jimmunol.176.7.3877; Fortin JP, 2005, AM J PHYSIOL-HEART C, V288, pH2192, DOI 10.1152/ajpheart.01135.2004; Giesen PLA, 1999, P NATL ACAD SCI USA, V96, P2311, DOI 10.1073/pnas.96.5.2311; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Hathcock J, 2004, SEMIN HEMATOL, V41, P30, DOI 10.1053/j.seminhematol.2003.11.007; Idzko M, 2002, BLOOD, V100, P925, DOI 10.1182/blood.V100.3.925; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; la Sala A, 2002, BLOOD, V99, P1715, DOI 10.1182/blood.V99.5.1715; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mallat Z, 2000, CIRCULATION, V101, P841, DOI 10.1161/01.CIR.101.8.841; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Morel O, 2006, PATHOPHYSIOL HAEMO T, V35, P15, DOI 10.1159/000093538; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; PIZZIRANI C, 2006, IN PRESS BLOOD; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rao LVM, 2005, ARTERIOSCL THROM VAS, V25, P47, DOI 10.1161/01.ATV.0000151624.45775.13; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schnurr M, 2003, BLOOD, V102, P613, DOI 10.1182/blood-2002-12-3745; Schnurr M, 2000, J IMMUNOL, V165, P4704, DOI 10.4049/jimmunol.165.8.4704; Shet AS, 2003, BLOOD, V102, P2678, DOI 10.1182/blood-2003-03-0693; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; Wilkin F, 2002, EUR J IMMUNOL, V32, P2409, DOI 10.1002/1521-4141(200209)32:9<2409::AID-IMMU2409>3.0.CO;2-H; Wong CW, 2006, NAT MED, V12, P950, DOI 10.1038/nm1441; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	48	75	77	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1926	1933		10.1096/fj.06-7238com	http://dx.doi.org/10.1096/fj.06-7238com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314141				2022-12-25	WOS:000246866500033
J	D'Errico, M; Parlanti, E; Teson, M; Degan, P; Lemma, T; Calcagnile, A; Iavarone, I; Jaruga, P; Ropolo, M; Pedrini, AM; Orioli, D; Frosina, G; Zambruno, G; Dizdaroglu, M; Stefanini, M; Dogliotti, E				D'Errico, M.; Parlanti, E.; Teson, M.; Degan, P.; Lemma, T.; Calcagnile, A.; Iavarone, I.; Jaruga, P.; Ropolo, M.; Pedrini, A. M.; Orioli, D.; Frosina, G.; Zambruno, G.; Dizdaroglu, M.; Stefanini, M.; Dogliotti, E.			The role of CSA in the response to oxidative DNA damage in human cells	ONCOGENE			English	Article						cockayne syndrome; DNA repair; keratinocytes; oxidative DNA damage	COCKAYNE-SYNDROME; EXCISION-REPAIR; GENE-PRODUCT; PROTEIN; TRANSCRIPTION; LESIONS; DEFICIENT; PATHWAY	Cockayne syndrome (CS) is a rare genetic disease characterized by severe growth, mental retardation and pronounced cachexia. CS is most frequently due to mutations in either of two genes, CSB and CSA. Evidence for a role of CSB protein in the repair of oxidative DNA damage has been provided recently. Here, we show that CSA is also involved in the response to oxidative stress. CS-A human primary. fibroblasts and keratinocytes showed hypersensitivity to potassium bromate, a specific inducer of oxidative damage. This was associated with inefficient repair of oxidatively induced DNA lesions, namely 8-hydroxyguanine (8-OH-Gua) and (5 ' S)-8,5 '-cyclo 2 '-deoxyadenosine. Expression of the wild-type CSA in the CS-A cell line CS3BE significantly decreased the steady-state level of 8-OH-Gua and increased its repair rate following oxidant treatment. CS-A cell extracts showed normal 8-OH-Gua cleavage activity in an in vitro assay, whereas CS-B cell extracts were con. firmed to be defective. Our data provide the. first in vivo evidence that CSA protein contributes to prevent accumulation of various oxidized DNA bases and underline specific functions of CSB not shared with CSA. These. findings support the hypothesis that defective repair of oxidative DNA damage is involved in the clinical features of CS patients.	Ist Super Sanita, Dept Environm & Primary Prevent, Consiglio Nazl Ricerche, I-00161 Rome, Italy; IRCCS, Ist Dermopat Immacolata, Lab Mol & Cell Biol, Rome, Italy; Ist Nazl Ric Canc, Dept Translat Oncol, I-16132 Genoa, Italy; Univ Maryland Baltimore Cty, Dept Chem & Biochem Engn, Baltimore, MD 21228 USA; Natl Inst Stand & Technol, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA; Ist Genet Mol, Pavia, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Genoa; IRCCS AOU San Martino IST; University System of Maryland; University of Maryland Baltimore County; National Institute of Standards & Technology (NIST) - USA; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR)	Dogliotti, E (corresponding author), Ist Super Sanita, Dept Environm & Primary Prevent, Consiglio Nazl Ricerche, Viale Regina Elena 299, I-00161 Rome, Italy.	dogliott@iss.it	Parlanti, Eleonora/AAC-5978-2021; Zambruno, Giavanna/K-2933-2018; degan, paolo/AAB-4093-2019; Teson, Massimo/GSE-1949-2022; Frosina, Guido/Z-2382-2019; Jaruga, Pawel/M-4378-2015; degan, paolo/AAB-6713-2019	Frosina, Guido/0000-0002-6717-5097; degan, paolo/0000-0003-0855-8896; Jaruga, Pawel/0000-0001-9192-6084; ORIOLI, DONATA/0000-0002-3830-3408; Iavarone, Ivano/0000-0001-5856-9484; Zambruno, Giovanna/0000-0002-1295-056X				Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Brooks PJ, 2002, MUTAT RES-FUND MOL M, V509, P93, DOI 10.1016/S0027-5107(02)00222-1; Cappelli E, 2000, CARCINOGENESIS, V21, P1135, DOI 10.1093/carcin/21.6.1135; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; de Waard H, 2004, MOL CELL BIOL, V24, P7941, DOI 10.1128/MCB.24.18.7941-7948.2004; de Waard H, 2003, DNA REPAIR, V2, P13, DOI 10.1016/S1568-7864(02)00188-X; Degan P, 2005, J CELL BIOCHEM, V94, P460, DOI 10.1002/jcb.20302; Dianov G, 1999, NUCLEIC ACIDS RES, V27, P1365, DOI 10.1093/nar/27.5.1365; ERRICO M, 2005, CANCER RES, V65, P432; ERRICO M, 2007, MUTAT RES, V614, P37; FOURSTERI M, 2006, MOL CELL, V23, P471; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; Jaruga P, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh087; Jaruga P, 2002, BIOCHEMISTRY-US, V41, P3703, DOI 10.1021/bi016004d; Kamiuchi S, 2002, P NATL ACAD SCI USA, V99, P201, DOI 10.1073/pnas.012473199; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Kyng KJ, 2003, ONCOGENE, V22, P1135, DOI 10.1038/sj.onc.1206187; Laine JP, 2006, TRENDS GENET, V22, P430, DOI 10.1016/j.tig.2006.06.006; Lehmann AR, 2003, BIOCHIMIE, V85, P1101, DOI 10.1016/j.biochi.2003.09.010; Licht CL, 2003, AM J HUM GENET, V73, P1217, DOI 10.1086/380399; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; Newman JC, 2006, P NATL ACAD SCI USA, V103, P9613, DOI 10.1073/pnas.0510909103; Osterod M, 2002, ONCOGENE, V21, P8232, DOI 10.1038/sj.onc.1206027; Proietti-De-Santis L, 2006, EMBO J, V25, P1915, DOI 10.1038/sj.emboj.7601071; Spivak G, 2006, DNA REPAIR, V5, P13, DOI 10.1016/j.dnarep.2005.06.017; Tuo J, 2001, J BIOL CHEM, V276, P45772, DOI 10.1074/jbc.M107888200; Tuo JS, 2003, FASEB J, V17, P668, DOI 10.1096/fj.02-0851com; Tuo JS, 2002, DNA REPAIR, V1, P913, DOI 10.1016/S1568-7864(02)00116-7	30	117	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4336	4343		10.1038/sj.onc.1210232	http://dx.doi.org/10.1038/sj.onc.1210232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297471				2022-12-25	WOS:000247620000002
J	Lehner, F; Kulik, U; Klempnauer, J; Borlak, J				Lehner, F.; Kulik, U.; Klempnauer, J.; Borlak, J.			The hepatocyte nuclear factor 6 (HNF6) and FOXA2 are key regulators in colorectal liver metastases	FASEB JOURNAL			English	Article						liver-enriched transcription factors; colon cancer; human liver; hepatocellular carcinoma	ENRICHED TRANSCRIPTION FACTORS; HEPATOCYTE NUCLEAR FACTOR-6; BINDING PROTEIN; DNA-BINDING; EXPRESSION; DIFFERENTIATION; RECRUITMENT; GENETICS; CBP	The molecular causes leading to secondary liver malignancies are unknown. Here we report regulation of major hepatic nuclear factors in human colorectal liver metastases and primary colonic cancer. Notably, the genes coding for HNF6, HNF1 beta, and C/EBP gamma were selectively regulated in liver metastases. We therefore studied protein expression of regulated transcription factors and found unacetylated HNF6 to be a hallmark of colorectal liver metastases. For its known interaction with HNF6, we investigated expression of FOXA2, which we found to be specifically induced in colorectal liver metastases. By electromobility shift assay, we examined DNA binding of disease regulated transcription factors. Essentially, no HNF6 DNA binding was observed. We also searched for sequence variations in the DNA binding domains of HNF6, but did not identify any mutation. Furthermore, we probed for expression of 28 genes targeted by HNF6. Mostly transcript expression was repressed except for tumor growth. In conclusion, we show HNF6 protein expression to be driven by the hepatic environment. Its expression is not observed in healthy colon or primary colonic cancer. HNF6 DNA binding is selectively abrogated through lack of post- translational modification and interaction with FOXA2. Targeting of FOXA2 and HNF6 may therefore enable mechanismbased therapy for colorectal liver metastases.	Fraunhofer Inst Toxicol & Expt Med, D-30625 Hannover, Germany; Hannover Med Sch, Dept Gen Visceral & Transplantat Surg, D-3000 Hannover, Germany	Fraunhofer Gesellschaft; Hannover Medical School	Borlak, J (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Nikolai Fuchs Str 1, D-30625 Hannover, Germany.	borlak@item.fraunhofer.de						Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003; Baglioni S, 2004, AM J MED GENET C, V129C, P35, DOI 10.1002/ajmg.c.30023; Briancon N, 2004, J BIOL CHEM, V279, P33398, DOI 10.1074/jbc.M405312200; Clotman F, 2002, DEVELOPMENT, V129, P1819; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Hayashi Y, 1999, J CLIN PATHOL-MOL PA, V52, P19; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Jain S, 2005, HEPATO-GASTROENTEROL, V52, P1567; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jenny M, 2002, EMBO J, V21, P6338, DOI 10.1093/emboj/cdf649; Jo WS, 2005, SEMIN ONCOL, V32, P11, DOI 10.1053/j.seminoncol.2004.09.034; Kishimoto T, 1998, CELL GROWTH DIFFER, V9, P337; Lannoy VJ, 2000, J BIOL CHEM, V275, P22098, DOI 10.1074/jbc.M000855200; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; Lazarevich N, 2004, HEPATOLOGY, V39, P1038, DOI 10.1002/hep.20155; Lee CS, 2005, NATURE, V435, P944, DOI 10.1038/nature03649; Lemaigre F, 2004, CURR OPIN GENET DEV, V14, P582, DOI 10.1016/j.gde.2004.08.004; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Odom DT, 2004, SCIENCE, V303, P1378, DOI 10.1126/science.1089769; Parviz F, 2003, NAT GENET, V34, P292, DOI 10.1038/ng1175; Rausa FM, 2004, J BIOL CHEM, V279, P43070, DOI 10.1074/jbc.M407472200; Rausa FM, 2003, MOL CELL BIOL, V23, P437, DOI 10.1128/MCB.23.2.437-449.2003; Rubins NE, 2005, MOL CELL BIOL, V25, P7069, DOI 10.1128/MCB.25.16.7069-7077.2005; Schrem H, 2004, PHARMACOL REV, V56, P291, DOI 10.1124/pr.56.2.5; Schrem H, 2002, PHARMACOL REV, V54, P129, DOI 10.1124/pr.54.1.129; van de Velde CJH, 2005, ANN ONCOL, V16, P144, DOI 10.1093/annonc/mdi702; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Xu L, 2001, CANCER RES, V61, P3176; Yoshida Y, 2006, HEPATOLOGY, V43, P276, DOI 10.1002/hep.21044	29	25	27	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1445	1462		10.1096/fj.06-6575com	http://dx.doi.org/10.1096/fj.06-6575com			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17283222				2022-12-25	WOS:000246117000020
J	Berndt, A; Kottke, T; Breitkreuz, H; Dvorsky, R; Hennig, S; Alexander, M; Wolf, E				Berndt, Alex; Kottke, Tilman; Breitkreuz, Helena; Dvorsky, Radovan; Hennig, Sven; Alexander, Michael; Wolf, Eva			A novel photoreaction mechanism for the circadian blue light photoreceptor Drosophila cryptochrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; INDUCED ELECTRON-TRANSFER; ESCHERICHIA-COLI; ARABIDOPSIS CRYPTOCHROME-1; CRYSTAL-STRUCTURE; CHOLINE OXIDASE; FLAVIN RADICALS; ACTION SPECTRUM; CLOCK PROTEIN; PHASE-SHIFTS	Cryptochromes are flavoproteins that are evolutionary related to the DNA photolyases but lack DNA repair activity. Drosophila cryptochrome (dCRY) is a blue light photoreceptor that is involved in the synchronization of the circadian clock with the environmental light-dark cycle. Until now, spectroscopic and structural studies on this and other animal cryptochromes have largely been hampered by difficulties in their recombinant expression. We have therefore established an expression and purification scheme that enables us to purify mg amounts of monomeric dCRY from Sf21 insect cell cultures. Using UV-visible spectroscopy, mass spectrometry, and reversed phase high pressure liquid chromatography, we show that insect cell-purified dCRY contains flavin adenine dinucleotide in its oxidized state (FAD(ox)) and residual amounts of methenyltetrahydrofolate. Upon blue light irradiation, dCRY undergoes a reversible absorption change, which is assigned to the conversion of FAD(ox) to the red anionic FAD(-.) radical. Our findings lead us to propose a novel photoreaction mechanism for dCRY, in which FAD(ox) corresponds to the ground state, whereas the FAD(-.) radical represents the light-activated state that mediates resetting of the Drosophila circadian clock.	Max Planck Inst Mol Physiol, Dept Biol Struct, D-44227 Dortmund, Germany; Res Ctr Julich, IBI 2, D-52425 Julich, Germany; Univ Bielefeld, Dept Chem, D-33615 Bielefeld, Germany	Max Planck Society; Helmholtz Association; Research Center Julich; University of Bielefeld	Wolf, E (corresponding author), Max Planck Inst Mol Physiol, Dept Biol Struct, Otto Hahn Str 11, D-44227 Dortmund, Germany.	eva.wolf@mpi-dortmund.mpg.de	Hennig, Sven/GYU-3381-2022; Kottke, Tilman/B-7102-2011; Dvorsky, Radovan/ABE-3042-2020; Wolf, Eva/G-7340-2014	Kottke, Tilman/0000-0001-8080-9579; Hennig, Sven/0000-0002-8297-6845				Ahmad M, 2002, PLANT PHYSIOL, V129, P774, DOI 10.1104/pp.010969; Brautigam CA, 2004, P NATL ACAD SCI USA, V101, P12142, DOI 10.1073/pnas.0404851101; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Busza A, 2004, SCIENCE, V304, P1503, DOI 10.1126/science.1096973; Cashmore AR, 2003, CELL, V114, P537, DOI 10.1016/j.cell.2003.08.004; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; FRANK KD, 1969, SCIENCE, V163, P688, DOI 10.1126/science.163.3868.688; Froy O, 2002, CURR BIOL, V12, P147, DOI 10.1016/S0960-9822(01)00656-X; Ghanem M, 2006, BIOCHEMISTRY-US, V45, P3437, DOI 10.1021/bi052514m; Ghanem M, 2003, BIOCHEMISTRY-US, V42, P15179, DOI 10.1021/bi035435o; Giovani B, 2003, NAT STRUCT BIOL, V10, P489, DOI 10.1038/nsb933; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; Huang YH, 2006, P NATL ACAD SCI USA, V103, P17701, DOI 10.1073/pnas.0608554103; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; Jung A, 2005, P NATL ACAD SCI USA, V102, P12350, DOI 10.1073/pnas.0500722102; Kottke T, 2006, BIOCHEMISTRY-US, V45, P2472, DOI 10.1021/bi051964b; Lin CT, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-5-220; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; Lin FJ, 2001, MOL CELL BIOL, V21, P7287, DOI 10.1128/MCB.21.21.7287-7294.2001; MALHOTRA K, 1994, BIOCHEMISTRY-US, V33, P8712, DOI 10.1021/bi00195a012; MASSEY V, 1964, FED PROC, V23, P18; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; MEDINA M, 1994, EUR J BIOCHEM, V222, P941, DOI 10.1111/j.1432-1033.1994.tb18943.x; MULLER F, 1987, FREE RADICAL BIO MED, V3, P215, DOI 10.1016/0891-5849(87)90009-8; MULLER F, 1972, EUR J BIOCHEM, V25, P573, DOI 10.1111/j.1432-1033.1972.tb01730.x; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; Okano S, 1999, PHOTOCHEM PHOTOBIOL, V69, P108; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Partch CL, 2005, PHOTOCHEM PHOTOBIOL, V81, P1291, DOI 10.1562/2005-07-08-IR-607; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P7715, DOI 10.1021/bi00485a021; Rosato E, 2001, CURR BIOL, V11, P909, DOI 10.1016/S0960-9822(01)00259-7; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; Sang Y, 2005, PLANT CELL, V17, P1569, DOI 10.1105/tpc.104.029645; Selby CP, 1999, PHOTOCHEM PHOTOBIOL, V69, P105, DOI 10.1562/0031-8655(1999)069<0105:ATMOTP>2.3.CO;2; Shindyalov IN, 1998, PROTEIN ENG, V11, P739, DOI 10.1093/protein/11.9.739; Song SH, 2006, J PHOTOCH PHOTOBIO B, V85, P1, DOI 10.1016/j.jphotobiol.2006.03.007; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Sullivan JA, 2003, DEV BIOL, V260, P289, DOI 10.1016/S0012-1606(03)00212-4; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; UYEDA K, 1963, ANAL BIOCHEM, V6, P100, DOI 10.1016/0003-2697(63)90012-5; Wagner MA, 2000, BIOCHEMISTRY-US, V39, P8813, DOI 10.1021/bi000349z; Worthington EN, 2003, J BIOL CHEM, V278, P39143, DOI 10.1074/jbc.M305792200; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zeugner A, 2005, J BIOL CHEM, V280, P19437, DOI 10.1074/jbc.C500077200; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580; Zhu HS, 2005, CURR BIOL, V15, pR953, DOI 10.1016/j.cub.2005.11.030	52	155	158	4	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13011	13021		10.1074/jbc.M608872200	http://dx.doi.org/10.1074/jbc.M608872200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17298948	hybrid			2022-12-25	WOS:000245942800071
J	Ekberg, J; Schuetz, F; Boase, NA; Conroy, SJ; Manning, J; Kumar, S; Poronnik, P; Adams, DJ				Ekberg, Jenny; Schuetz, Friderike; Boase, Natasha A.; Conroy, Sarah-Jane; Manning, Jantina; Kumar, Sharad; Poronnik, Philip; Adams, David J.			Regulation of the voltage-gated K+ channels KCNQ2/3 and KCNQ3/5 by ubiquitination - Novel role for Nedd4-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL DETERMINANTS; POTASSIUM CHANNELS; LIGASE NEDD4-2; ION CHANNELS; PROTEIN; BRAIN; SUPPRESSION; PHYSIOLOGY; EXPRESSION; INTERACTS	The muscarine-sensitive K+ current (M-current) stabilizes the resting membrane potential in neurons, thus limiting neuronal excitability. The M-current is mediated by heteromeric channels consisting of KCNQ3 subunits in association with either KCNQ2 or KCNQ5 subunits. The role of KCNQ2/3/5 in the regulation of neuronal excitability is well established; however, little is known about the mechanisms that regulate the cell surface expression of these channels. Ubiquitination by the Nedd4/Nedd4-2 ubiquitin ligases is known to regulate a number of membrane ion channels and transporters. In this study, we investigated whether Nedd4/Nedd4-2 could regulate KCNQ2/3/5 channels. We found that the amplitude of the K+ currents mediated by KCNQ2/3 and KCNQ3/5 were reduced by Nedd4-2 (but not Nedd4) in a Xenopus oocyte expression system. Deletion experiments showed that the C-terminal region of the KCNQ3 subunit is required for the Nedd4-2-mediated regulation of the heteromeric channels. Glutathione S-transferase fusion pulldowns and co-immunoprecipitations demonstrated a direct interaction between KCNQ2/3 and Nedd4-2. Furthermore, Nedd4-2 could ubiquitinate KCNQ2/3 in transfected cells. Taken together, these data suggest that Nedd4-2 is potentially an important regulator of M-current activity in the nervous system.	Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Inst Med & Vet Sci, Hanson Inst, Adelaide, SA 5000, Australia	University of Queensland; Hanson Institute; Institute Medical & Veterinary Science Australia	Poronnik, P (corresponding author), Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.	p.poronnik@uq.edu.au; dadams@uq.edu.au	Ekberg, Jenny/AAV-2006-2020; Manning, Jantina/AAP-3810-2020; Adams, David John/K-3578-2019; Adams, David/J-9125-2014; Kumar, Sharad/AAX-7787-2020	Manning, Jantina/0000-0001-9142-6135; Adams, David John/0000-0002-7030-2288; Adams, David/0000-0002-7030-2288; Kumar, Sharad/0000-0001-7126-9814; Ekberg, Jenny/0000-0001-5151-4966; Poronnik, Philip/0000-0002-6246-528X				Abriel H, 2005, PHYSIOLOGY, V20, P398, DOI 10.1152/physiol.00033.2005; Blackburn-Munro G, 2003, EUR J PHARMACOL, V460, P109, DOI 10.1016/S0014-2999(02)02924-2; Boehmer C, 2006, J NEUROCHEM, V97, P911, DOI 10.1111/j.1471-4159.2006.03629.x; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; Calabresi P, 2003, ANN NEUROL, V53, P693, DOI 10.1002/ana.10603; Delmas P, 2005, NAT REV NEUROSCI, V6, P850, DOI 10.1038/nrn1785; DIBBENS LM, 2007, IN PRESS GENES BRAIN; Etxeberria A, 2004, J NEUROSCI, V24, P9146, DOI 10.1523/JNEUROSCI.3194-04.2004; Fotia AB, 2004, J BIOL CHEM, V279, P28930, DOI 10.1074/jbc.M402820200; Fotia AB, 2002, FASEB J, V16, P70, DOI 10.1096/fj.02-0497fje; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gordon E, 2006, BIOPHYS J, V90, P1223, DOI 10.1529/biophysj.105.072504; Gribkoff VK, 2005, EXPERT OPIN INV DRUG, V14, P579, DOI 10.1517/13543784.14.5.579; Gutman GA, 2003, PHARMACOL REV, V55, P583, DOI 10.1124/pr.55.4.9; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Henke G, 2004, J CELL PHYSIOL, V199, P194, DOI 10.1002/jcp.10430; Hettema EH, 2004, EMBO J, V23, P1279, DOI 10.1038/sj.emboj.7600137; Hryciw DH, 2004, J BIOL CHEM, V279, P54996, DOI 10.1074/jbc.M411491200; Itani OA, 2003, AM J PHYSIOL-RENAL, V285, pF916, DOI 10.1152/ajprenal.00203.2003; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; Kanelis V, 2006, STRUCTURE, V14, P543, DOI 10.1016/j.str.2005.11.018; Keleman K, 2005, NAT NEUROSCI, V8, P156, DOI 10.1038/nn1388; Konstas AA, 2002, J BIOL CHEM, V277, P29406, DOI 10.1074/jbc.M203018200; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; KUMAR S, 1994, J BIOL CHEM, V269, P11318; Kuratomi G, 2005, BIOCHEM J, V386, P461, DOI 10.1042/BJ20040738; Kuryshev YA, 2000, AM J PHYSIOL-CELL PH, V278, pC931, DOI 10.1152/ajpcell.2000.278.5.C931; Layfield R, 2001, NEUROPATH APPL NEURO, V27, P171, DOI 10.1046/j.1365-2990.2001.00335.x; Lerche H, 2001, AM J MED GENET, V106, P146, DOI 10.1002/ajmg.1582; Marrion NV, 1997, ANNU REV PHYSIOL, V59, P483, DOI 10.1146/annurev.physiol.59.1.483; Morrione A, 1999, J BIOL CHEM, V274, P24094, DOI 10.1074/jbc.274.34.24094; Myat A, 2002, NEURON, V35, P447, DOI 10.1016/S0896-6273(02)00795-X; Palmada M, 2004, BIOCHEM BIOPH RES CO, V321, P1001, DOI 10.1016/j.bbrc.2004.07.064; Passmore GM, 2003, J NEUROSCI, V23, P7227, DOI 10.1523/JNEUROSCI.23-18-07227.2003; Peters HC, 2005, NAT NEUROSCI, V8, P51, DOI 10.1038/nn1375; Robbins J, 2001, PHARMACOL THERAPEUT, V90, P1, DOI 10.1016/S0163-7258(01)00116-4; Roche JP, 2002, BRIT J PHARMACOL, V137, P1173, DOI 10.1038/sj.bjp.0704989; Schroeder BC, 2000, J BIOL CHEM, V275, P24089, DOI 10.1074/jbc.M003245200; Schroeder BC, 1998, NATURE, V396, P687, DOI 10.1038/25367; Schwake M, 2006, J NEUROSCI, V26, P3757, DOI 10.1523/JNEUROSCI.5017-05.2006; Schwake M, 2003, EMBO REP, V4, P76, DOI 10.1038/sj.embor.embor715; Shearwin-Whyatt L, 2006, BIOESSAYS, V28, P617, DOI 10.1002/bies.20422; Sorkina T, 2006, J NEUROSCI, V26, P8195, DOI 10.1523/JNEUROSCI.1301-06.2006; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Yi JJ, 2005, NEURON, V47, P629, DOI 10.1016/j.neuron.2005.07.008; Yoo D, 2003, J BIOL CHEM, V278, P23066, DOI 10.1074/jbc.M212301200	49	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12135	12142		10.1074/jbc.M609385200	http://dx.doi.org/10.1074/jbc.M609385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322297	hybrid, Green Published			2022-12-25	WOS:000245941900056
J	Baran, Y; Salas, A; Senkal, CE; Gunduz, U; Bielawski, J; Obeid, LM; Ogretmen, B				Baran, Yusuf; Salas, Arelis; Senkal, Can E.; Gunduz, Ufuk; Bielawski, Jacek; Obeid, Lina M.; Ogretmen, Besim			Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; LONGEVITY ASSURANCE GENE-1; HUMAN ACID CERAMIDASE; SPHINGOSINE 1-PHOSPHATE; TYROSINE KINASE; DIHYDROCERAMIDE SYNTHASE; FAMILY-MEMBERS; CANCER-THERAPY; HUMAN HEAD; PROTEIN	In this study, mechanisms of resistance to imatinib-induced apoptosis in human K562 cells were examined. Continuous exposure to stepwise increasing concentrations of imatinib resulted in the selection of K562/IMA-0.2 and -1 cells, which expressed similar to 2.3- and 19-fold resistance, respectively. Measurement of endogenous ceramides by high performance liquid chromatography/mass spectroscopy showed that treatment with imatinib increased the generation of ceramide, mainly C-18-ceramide, which is generated by the human longevity assurance gene 1 (hLASS1), in sensitive, but not in resistant cells. Inhibition of hLASS1 by small interfering RNA partially prevented imatinib-induced cell death in sensitive cells. In reciprocal experiments, overexpression of hLASS1, and not hLASS6, in drug-resistant cells caused a marked increase in imatinib-induced C-18-ceramide generation, and enhanced apoptosis. Interestingly, there were no defects in the levels of mRNA and enzyme activity levels of hLASS1 for ceramide generation in K562/IMA-1 cells. However, expression levels of sphingosine kinase-1 (SK1) and generation of sphingosine 1-phosphate (S1P) were increased significantly in K562/IMA-1 cells, channeling sphingoid bases to the sphingosine kinase pathway. The partial inhibition of SK1 expression by small interference RNA modulated S1P levels and increased sensitivity to imatinib-induced apoptosis in resistant cells. On the other hand, forced expression of SK1 in K562 cells increased the ratio between total S1P/C-18-ceramide levels similar to 6-fold and prevented apoptosis significantly in response to imatinib. Additional data indicated a role for SK1/S1P signaling in the up-regulation of the Bcr-Abl expression at the post-transcriptional level, which suggested a possible mechanism for resistance to imatinib-mediated apoptosis. In conclusion, these data suggest a role for endogenous C-18-ceramide synthesis mainly via hLASS1 in imatinib-induced apoptosis in sensitive cells, whereas in resistant cells, alterations of the balance between the levels of ceramide and S1P by overexpression of SK1 result in resistance to imatinib-induced apoptosis.	Med Univ S Carolina, Div Gen Internal Med, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Ralph H Johnson Vet Adm Hosp, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Middle E Tech Univ, Dept Biol, TR-06531 Ankara, Turkey	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; Middle East Technical University	Ogretmen, B (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, 173 Ashley Ave, Charleston, SC 29425 USA.	ogretmen@musc.edu		obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [P01CA097132, R01CA088932] Funding Source: NIH RePORTER; NCI NIH HHS [CA88932, CA097132] Funding Source: Medline; NIDCR NIH HHS [DE01657] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bektas M, 2005, ONCOGENE, V24, P178, DOI 10.1038/sj.onc.1208019; Buchdunger E, 1996, CANCER RES, V56, P100; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; Davis MD, 2005, J BIOL CHEM, V280, P9833, DOI 10.1074/jbc.M412356200; Deininger Michael, 2005, J Natl Compr Canc Netw, V3, P757; Druker BJ, 2002, TRENDS MOL MED, V8, pS14, DOI 10.1016/S1471-4914(02)02305-5; Foss FW, 2007, BIOORGAN MED CHEM, V15, P663, DOI 10.1016/j.bmc.2006.10.060; Futerman AH, 2004, EMBO REP, V5, P777, DOI 10.1038/sj.embor.7400208; Futerman AH, 2005, TRENDS CELL BIOL, V15, P312, DOI 10.1016/j.tcb.2005.04.006; Galadari S, 2006, BIOCHEM J, V393, P687, DOI 10.1042/BJ20050682; Gambacorti-Passerini CB, 2003, LANCET ONCOL, V4, P75, DOI 10.1016/S1470-2045(03)00979-3; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; He XX, 2003, J BIOL CHEM, V278, P32978, DOI 10.1074/jbc.M301936200; Hegedus T, 2002, BBA-MOL BASIS DIS, V1587, P318, DOI 10.1016/S0925-4439(02)00095-9; Illmer T, 2004, LEUKEMIA, V18, P401, DOI 10.1038/sj.leu.2403257; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; Johnson KR, 2005, J HISTOCHEM CYTOCHEM, V53, P1159, DOI 10.1369/jhc.4A6606.2005; KANTARJIAN HM, 1988, CANCER, V61, P1441, DOI 10.1002/1097-0142(19880401)61:7<1441::AID-CNCR2820610727>3.0.CO;2-C; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kitatani K, 2006, J BIOL CHEM, V281, P36793, DOI 10.1074/jbc.M608137200; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200; Krystal GW, 2001, DRUG RESIST UPDATE, V4, P16, DOI 10.1054/drup.2000.0176; Lahiri S, 2005, J BIOL CHEM, V280, P33735, DOI 10.1074/jbc.M506485200; Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Park JH, 2006, BBA-BIOMEMBRANES, V1758, P2133, DOI 10.1016/j.bbamem.2006.08.019; Pchejetski D, 2005, CANCER RES, V65, P11667, DOI 10.1158/0008-5472.CAN-05-2702; Pewzner-Jung Y, 2006, J BIOL CHEM, V281, P25001, DOI 10.1074/jbc.R600010200; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Riebeling C, 2003, J BIOL CHEM, V278, P43452, DOI 10.1074/jbc.M307104200; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Schulz A, 2006, J BIOL CHEM, V281, P2784, DOI 10.1074/jbc.M509483200; Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Spiegel S, 2002, LEUKEMIA, V16, P1596, DOI 10.1038/sj.leu.2402611; Sultan I, 2006, BIOCHEM J, V393, P513, DOI 10.1042/BJ20051083; Taha TA, 2005, FASEB J, V19, P482, DOI 10.1096/fj.05-4412fje; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Walz C, 2006, CRIT REV ONCOL HEMAT, V57, P145, DOI 10.1016/j.critrevonc.2005.06.007; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xu RJ, 2006, FASEB J, V20, P1813, DOI 10.1096/fj.05-5689com	56	175	191	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10922	10934		10.1074/jbc.M610157200	http://dx.doi.org/10.1074/jbc.M610157200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303574	hybrid, Green Submitted			2022-12-25	WOS:000245941500012
J	Kaustov, L; Lukin, J; Lemak, A; Duan, SL; Ho, M; Doherty, R; Penn, LZ; Arrowsmith, CH				Kaustov, Lilia; Lukin, Jonathan; Lemak, Alexander; Duan, Shili; Ho, Melissa; Doherty, Ryan; Penn, Linda Z.; Arrowsmith, Cheryl H.			The conserved CPH domains of Cul7 and PARC are protein-protein interaction modules that bind the tetramerization domain of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN LIGASE; OLIGOMERIZATION; IDENTIFICATION; COUPLINGS; SYSTEM; FAMILY; CANCER; SITE	Cul7 is a member of the Cullin Ring Ligase ( CRL) family and is required for normal mouse development and cellular proliferation. Recently, a region of Cul7 that is highly conserved in the p53-associated, Parkin-like cytoplasmic protein PARC, was shown to bind p53 directly. Here we identify the CPH domains ( conserved domain within Cul7, PARC, and HERC2 proteins) of both Cul7 and PARC as p53 interaction domains using size exclusion chromatography and NMR spectroscopy. We present the first structure of the evolutionarily conserved CPH domain and provide novel insight into the Cul7-p53 interaction. The NMRstructure of the Cul7-CPH domain reveals a fold similar to peptide interaction modules such as the SH3, Tudor, and KOW domains. The p53 interaction surface of both Cul7 and PARC CPH domains was mapped to a conserved surface distinct from the analogous peptide-binding regions of SH3, KOW, and Tudor domains, suggesting a novel mode of interaction. The CPH domain interaction surface of p53 resides in the tetramerization domain and is formed by residues contributed by at least two subunits.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L5, Canada; Univ Toronto, NE Struct Genom Consortium, Toronto, ON M5G 1L5, Canada; Univ Toronto, Struct Genom Consortium, Toronto, ON M5G 1L5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; Structural Genomics Consortium	Arrowsmith, CH (corresponding author), Rm 4-803,TMDT,MaRS,101 Coll St, Toronto, ON M5G 1L7, Canada.	carrow@uhnres.utoronto.ca		Arrowsmith, Cheryl/0000-0002-4971-3250; Penn, Linda/0000-0001-8133-5459; Kaustov, Lilia/0000-0002-8474-559X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062413] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50-GM62413-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrews P, 2006, ONCOGENE, V25, P4534, DOI 10.1038/sj.onc.1209490; Arai T, 2003, P NATL ACAD SCI USA, V100, P9855, DOI 10.1073/pnas.1733908100; Bhattacharya A, 2007, PROTEINS, V66, P778, DOI 10.1002/prot.21165; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Charier G, 2004, STRUCTURE, V12, P1551, DOI 10.1016/j.str.2004.06.014; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Davison TS, 1998, ONCOGENE, V17, P651, DOI 10.1038/sj.onc.1202062; Davison TS, 2001, J MOL BIOL, V307, P605, DOI 10.1006/jmbi.2001.4450; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Delphin C, 1997, EUR J BIOCHEM, V245, P684, DOI 10.1111/j.1432-1033.1997.t01-1-00684.x; Dias DC, 2002, P NATL ACAD SCI USA, V99, P16601, DOI 10.1073/pnas.252646399; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; Gotz C, 1999, MOL CELL BIOCHEM, V191, P111, DOI 10.1023/A:1006886727248; Grishaev A, 2005, PROTEINS, V61, P36, DOI 10.1002/prot.20457; Grishaev A, 2004, J BIOMOL NMR, V28, P1, DOI 10.1023/B:JNMR.0000012846.56763.f7; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hochrainer K, 2005, GENOMICS, V85, P153, DOI 10.1016/j.ygeno.2004.10.006; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kasper JS, 2006, BIOCHEM BIOPH RES CO, V348, P132, DOI 10.1016/j.bbrc.2006.07.013; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee AS, 2003, J MOL BIOL, V327, P699, DOI 10.1016/S0022-2836(03)00175-X; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; Linge JP, 2003, PROTEINS, V50, P496, DOI 10.1002/prot.10299; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Schwartz AL, 1999, ANNU REV MED, V50, P57; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Steiner T, 2002, EMBO J, V21, P4641, DOI 10.1093/emboj/cdf455; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tjandra N, 1997, NAT STRUCT BIOL, V4, P732, DOI 10.1038/nsb0997-732; Tsunematsu R, 2006, MOL CELL BIOL, V26, P6157, DOI 10.1128/MCB.00595-06; Tugarinov V, 2003, J MOL BIOL, V327, P1121, DOI 10.1016/S0022-2836(03)00238-9; Wagner P, 1995, FEBS LETT, V377, P155, DOI 10.1016/0014-5793(95)01329-6; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; Zweckstetter M, 2001, J AM CHEM SOC, V123, P9490, DOI 10.1021/ja016496h	45	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11300	11307		10.1074/jbc.M611297200	http://dx.doi.org/10.1074/jbc.M611297200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17298945	hybrid			2022-12-25	WOS:000245941500052
J	Xu, K; Zhang, Y; Ilalov, K; Carlson, CS; Feng, JQ; Di Cesare, PE; Liu, CJ				Xu, Ke; Zhang, Yan; Llalov, Kirill; Carlson, Cathy S.; Feng, Jian Q.; Di Cesare, Paul E.; Liu, Chuan-ju			Cartilage oligomeric matrix protein associates with granulin-epithelin precursor (GEP) and potentiates GEP-stimulated chondrocyte proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; HOMOLOGOUS FACTOR 1B; GROWTH-FACTOR PCDGF; CELL-LINE; IN-VITRO; GRANULIN/EPITHELIN PRECURSOR; MYOBLAST DIFFERENTIATION; BONE METABOLISM; GENE-EXPRESSION; SYNOVIAL-FLUID	Mutations in human cartilage oligomeric matrix protein ( COMP) have been linked to the development of pseudoachondroplasia and multiple epiphyseal dysplasia; however, the functions of both wild-type and mutant COMP in the skeletogenesis remain unknown. In an effort to define the biological functions of COMP, a functional genetic screen based on the yeast two-hybrid system was performed. This led to the identification of granulin-epithelin precursor ( GEP), an autocrine growth factor, as a COMP-associated partner. COMP directly binds to GEP both in vitro and in vivo, as revealed by in vitro pull down and co-immunoprecipitation assays. GEP selectively interacts with the epidermal growth factor repeat domain of COMP but not with the other three functional domains of COMP. The granulin A repeat unit of GEP is required and sufficient for association with COMP. COMP co-localizes with GEP predominantly in the pericellular matrix of transfected rat chondrosarcoma cell and primary human chondrocytes. Staining of musculoskeletal tissues of day 19 mouse embryo with antibodies to GEP is restricted to chondrocytes in the lower proliferative and upper hypertrophic zones. Overexpression of GEP stimulates the proliferation of chondrocytes, and this stimulation is enhanced by COMP. In addition, COMP appears to be required for GEP-mediated chondrocyte proliferation, since chondrocyte proliferation induced by GEP is dramatically inhibited by an anti-COMP antibody. findings provide the first evidence linking the association of COMP and GEP and identifying a previously unrecognized growth factor ( i.e. GEP) in cartilage.	NYU, Sch Med, Dept Orthopaed Surg, Hosp Joint Dis, New York, NY 10003 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; Univ Minnesota, Coll Vet Med, Dept Vet Populat Med, St Paul, MN 55108 USA; Texas A&M Univ Syst, Hlth Sci Ctr, Baylor Coll Dent, Dept Biomed Sci, Dallas, TX 75246 USA; Shandong Univ, Sch Med, Inst Pathogen Biol, Jinan 250012, Shandong, Peoples R China	New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; New York University; University of Minnesota System; University of Minnesota Twin Cities; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Shandong University	Liu, CJ (corresponding author), NYU, Sch Med, Dept Orthopaed Surg, 301 E 17th St, New York, NY 10003 USA.	Chuanju.liu@med.nyu.edu	Liu, Chuan-ju/AAT-8165-2021	liu, chuanju/0000-0002-7181-8032; Xu, Ke Kate/0000-0002-2453-4475	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR014099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR052022] Funding Source: NIH RePORTER; NCRR NIH HHS [RR14099] Funding Source: Medline; NIAMS NIH HHS [AR050620, AR052022] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANAKWE OO, 1990, BIOL REPROD, V42, P317, DOI 10.1095/biolreprod42.2.317; BABA T, 1993, MOL REPROD DEV, V34, P233, DOI 10.1002/mrd.1080340302; Barreda DR, 2004, DEV COMP IMMUNOL, V28, P727, DOI 10.1016/j.dci.2003.11.005; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; BRIGGS MD, 1993, GENOMICS, V18, P656, DOI 10.1016/S0888-7543(05)80369-6; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Chen FH, 2005, J BIOL CHEM, V280, P32655, DOI 10.1074/jbc.M504778200; CHEN FHT, 2004, 50 ANN M ORTH RES SO; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; Davidson B, 2004, CANCER-AM CANCER SOC, V100, P2139, DOI 10.1002/cncr.20219; Di Cesare PE, 2000, J ORTHOPAED RES, V18, P713, DOI 10.1002/jor.1100180506; Di Cesare PE, 1999, J ORTHOPAED RES, V17, P437; Di Cesare PE, 2002, MATRIX BIOL, V21, P461, DOI 10.1016/S0945-053X(02)00015-X; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DiCesare PE, 1996, J ORTHOPAED RES, V14, P946, DOI 10.1002/jor.1100140615; DiCesare PE, 1997, FEBS LETT, V412, P249, DOI 10.1016/S0014-5793(97)00789-8; Duke J, 2003, APOPTOSIS, V8, P191, DOI 10.1023/A:1022926811397; Gonzalez EM, 2003, J BIOL CHEM, V278, P38113, DOI 10.1074/jbc.C300310200; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; HECHT JT, 1993, GENOMICS, V18, P661, DOI 10.1016/S0888-7543(05)80370-2; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Hecht JT, 2001, MATRIX BIOL, V20, P251, DOI 10.1016/S0945-053X(01)00136-6; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Hoque M, 2005, J BIOL CHEM, V280, P13648, DOI 10.1074/jbc.M409575200; Hoque M, 2003, MOL CELL BIOL, V23, P1688, DOI 10.1128/MCB.23.5.1688-1702.2003; Hrabal R, 1996, NAT STRUCT BIOL, V3, P747, DOI 10.1038/nsb0996-747; Jones MB, 2003, GYNECOL ONCOL, V88, pS136, DOI 10.1006/gyno.2002.6704; Justen H P, 2000, Mol Cell Biol Res Commun, V3, P165, DOI 10.1006/mcbr.2000.0211; Kipnes J, 2003, OSTEOARTHR CARTILAGE, V11, P442, DOI 10.1016/S1063-4584(03)00055-4; Koelling S, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1922; Kraus VB, 2002, ARTHRITIS RHEUM-US, V46, P420, DOI 10.1002/art.10124; Kuhne SAM, 1998, RHEUMATOL INT, V18, P21, DOI 10.1007/s002960050049; Liu CJ, 2006, FASEB J, V20, P988, DOI 10.1096/fj.05-3877fje; Liu CJ, 2006, J BIOL CHEM, V281, P15800, DOI 10.1074/jbc.M513433200; Liu CJ, 2000, MOL CELL BIOL, V20, P7024, DOI 10.1128/MCB.20.18.7024-7036.2000; Liu CJ, 1999, EMBO J, V18, P2845, DOI 10.1093/emboj/18.10.2845; Liu CJ, 2003, J BIOL CHEM, V278, P1029, DOI 10.1074/jbc.M207074200; Liu CJ, 2002, MOL CELL BIOL, V22, P2893, DOI 10.1128/MCB.22.9.2893-2905.2002; Liu CJ, 2001, J BIOL CHEM, V276, P18925, DOI 10.1074/jbc.M101606200; Lohmander LS, 1999, ARTHRITIS RHEUM, V42, P534, DOI 10.1002/1529-0131(199904)42:3<534::AID-ANR19>3.0.CO;2-J; Lu RQ, 2000, P NATL ACAD SCI USA, V97, P3993, DOI 10.1073/pnas.97.8.3993; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; MANSSON B, 1995, J CLIN INVEST, V95, P1071, DOI 10.1172/JCI117753; Misumi K, 2002, EQUINE VET J, V34, P602, DOI 10.2746/042516402776180205; MORGELIN M, 1992, J BIOL CHEM, V267, P14275; Neidhart M, 1997, BRIT J RHEUMATOL, V36, P1151; Neidhart M, 1996, J RHEUMATOL, V23, P476; Ozbek S, 2002, EMBO J, V21, P5960, DOI 10.1093/emboj/cdf628; Petersson IF, 1998, BRIT J RHEUMATOL, V37, P46; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; SAXNE T, 1992, BRIT J RHEUMATOL, V31, P583; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; Sun XJ, 2004, AM J RESP CELL MOL, V30, P510, DOI 10.1165/rcmb.2003-0266OC; Susic S, 1997, CLIN GENET, V51, P219; Suzuki M, 2002, MOL GENET METAB, V75, P31, DOI 10.1006/mgme.2001.3274; Thornburg NJ, 2004, J VIROL, V78, P12848, DOI 10.1128/JVI.78.23.12848-12856.2004; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; Wang WG, 2003, CLIN CANCER RES, V9, P2221; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Xu SQ, 1998, J BIOL CHEM, V273, P20078, DOI 10.1074/jbc.273.32.20078; Zanocco-Marani T, 1999, CANCER RES, V59, P5331; Zhang HD, 1998, P NATL ACAD SCI USA, V95, P14202, DOI 10.1073/pnas.95.24.14202; ZHOU J, 1993, J BIOL CHEM, V268, P10863; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	70	107	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11347	11355		10.1074/jbc.M608744200	http://dx.doi.org/10.1074/jbc.M608744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307734	hybrid			2022-12-25	WOS:000245941500057
J	Hauser, M; Kauffman, S; Lee, BK; Naider, F; Becker, JM				Hauser, Melinda; Kauffman, Sarah; Lee, Byung-Kwon; Naider, Fred; Becker, Jeffrey M.			The first extracellular loop of the Saccharomyces cerevisiae G protein-coupled receptor Ste2p undergoes a conformational change upon ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR RECEPTOR; C5A RECEPTOR; TRANSMEMBRANE DOMAIN; PHEROMONE RECEPTOR; MATING PHEROMONE; STRUCTURAL BASIS; PEPTIDE ANALOGS; RESIDUES; ACTIVATION; IDENTIFICATION	In this study of the Saccharomyces cerevisiae G protein-coupled receptor Ste2p, we present data indicating that the first extracellular loop (EL1) of the alpha-factor receptor has tertiary structure that limits solvent accessibility and that its conformation changes in a ligand- dependent manner. The substituted cysteine accessibility method was used to probe the solvent exposure of single cysteine residues engineered to replace residues Tyr(101) through Gln(135) of EL1 in the presence and absence of the tridecapeptide alpha-factor and a receptor antagonist. Surprisingly, many residues, especially those at the N-terminal region, were not solvent-accessible, including residues of the binding-competent yet signal transduction- deficient mutants L102C, N105C, S108C, Y111C, and T114C. In striking contrast, two N- terminal residues, Y101C and Y106C, were readily solventaccessible, but upon incubation with alpha-dfactor labeling was reduced, suggesting a pheromone-dependent conformational change limiting solvent accessibility had occurred. Labeling in the presence of the antagonist, which binds Ste2p but does not initiate signal transduction, did not significantly alter reactivity with the Y101C and Y106C receptors, suggesting that the alpha-factor-dependent decrease in solvent accessibility was not because of steric hindrance that prevented the labeling reagent access to these residues. Based on these and previous observations, we propose a model in which the N terminus of EL1 is structured such that parts of the loop are buried in a solvent-inaccessible environment interacting with the extracellular part of the transmembrane domain bundle. This study highlights the essential role of an extracellular loop in activation of a G proteincoupled receptor upon ligand binding.	Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA; CUNY Coll Staten Isl, Dept Chem, Staten Isl, NY 10314 USA; CUNY Coll Staten Isl, Macromol Assemblies Inst, Staten Isl, NY 10314 USA; CUNY Grad Sch & Univ Ctr, Staten Isl, NY 10314 USA	University of Tennessee System; University of Tennessee Knoxville; City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; College of Staten Island (CUNY); City University of New York (CUNY) System; City University of New York (CUNY) Graduate School	Becker, JM (corresponding author), Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA.	jbecker@utk.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022086, R56GM022086, R01GM022087, R56GM022087] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM22087, GM22086] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abel MG, 1998, BBA-MOL CELL RES, V1448, P12, DOI 10.1016/S0167-4889(98)00109-8; Abel MG, 1998, J PEPT RES, V52, P95; Akal-Strader A, 2002, J BIOL CHEM, V277, P30581, DOI 10.1074/jbc.M204089200; AKALSTRADER A, 2004, THESIS U TENNESSEE K, P181; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; Baneres JL, 2005, J BIOL CHEM, V280, P20253, DOI 10.1074/jbc.M412009200; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Burlison JA, 2006, J AM CHEM SOC, V128, P15529, DOI 10.1021/ja065793p; Celic Andjelka, 2003, V237, P105; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Choi Y, 2006, BIOCHEMISTRY-US, V45, P15310, DOI 10.1021/bi0614939; David NE, 1997, J BIOL CHEM, V272, P15553, DOI 10.1074/jbc.272.24.15553; Drews J, 2000, SCIENCE, V287, P1960, DOI 10.1126/science.287.5460.1960; ERIOTOUBARGIOTA E, 1992, BIOCHEMISTRY-US, V31, P551, DOI 10.1021/bi00117a036; Feng YH, 1999, J BIOL CHEM, V274, P35546, DOI 10.1074/jbc.274.50.35546; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 2002, PHARMACOL TOXICOL, V91, P304, DOI 10.1034/j.1600-0773.2002.910607.x; Geva A, 2000, J BIOL CHEM, V275, P35393, DOI 10.1074/jbc.M005602200; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Henry LK, 2002, BIOCHEMISTRY-US, V41, P6128, DOI 10.1021/bi015863z; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hill SJ, 2006, BRIT J PHARMACOL, V147, pS27, DOI 10.1038/sj.bjp.0706455; Javitch JA, 2002, METHOD ENZYMOL, V343, P137; Jenness DD, 1997, MOL CELL BIOL, V17, P6236, DOI 10.1128/MCB.17.11.6236; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Kleinau G, 2007, J BIOL CHEM, V282, P518, DOI 10.1074/jbc.M606176200; Lawson Z, 2004, BIOCHEM SOC T, V32, P1048, DOI 10.1042/BST0321048; Lee BK, 2002, BIOCHEMISTRY-US, V41, P13681, DOI 10.1021/bi026100u; Lee BK, 2001, J BIOL CHEM, V276, P37950; Lee YH, 2006, J BIOL CHEM, V281, P2263, DOI 10.1074/jbc.M509987200; Lin JC, 2004, MOL CELL BIOL, V24, P2041, DOI 10.1128/MCB.24.5.2041-2051.2004; Lin JC, 2003, BIOCHEMISTRY-US, V42, P293, DOI 10.1021/bi026766o; Madabushi S, 2004, J BIOL CHEM, V279, P8126, DOI 10.1074/jbc.M312671200; Mentesana PE, 2001, BIOCHEMISTRY-US, V40, P9685, DOI 10.1021/bi0108507; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Oldenburg KR, 1997, NUCLEIC ACIDS RES, V25, P451, DOI 10.1093/nar/25.2.451; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palczewski K, 2006, ANNU REV BIOCHEM, V75, P743, DOI 10.1146/annurev.biochem.75.103004.142743; POCKLINGTON MJ, 1994, BBA-MOL CELL RES, V1224, P401, DOI 10.1016/0167-4889(94)90275-5; RATHS SK, 1988, J BIOL CHEM, V263, P17333; Ruan KH, 2001, BIOCHEMISTRY-US, V40, P275, DOI 10.1021/bi001867c; Schlyer S, 2006, DRUG DISCOV TODAY, V11, P481, DOI 10.1016/j.drudis.2006.04.008; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Shi L, 2004, P NATL ACAD SCI USA, V101, P440, DOI 10.1073/pnas.2237265100; Son CD, 2005, J PEPT RES, V65, P418, DOI 10.1111/j.1399-3011.2005.00248.X; Son CD, 2004, BIOCHEMISTRY-US, V43, P13193, DOI 10.1021/bi0496889; Stitham J, 2004, BIOCHEMISTRY-US, V43, P8974, DOI 10.1021/bi0496788; Ward SDC, 2006, BIOCHEMISTRY-US, V45, P676, DOI 10.1021/bi051503q	52	37	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10387	10397		10.1074/jbc.M608903200	http://dx.doi.org/10.1074/jbc.M608903200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17293349	hybrid			2022-12-25	WOS:000245941000029
J	Singh, K; Srivastava, A; Patel, SS; Modak, MJ				Singh, Kamalendra; Srivastava, Aashish; Patel, Smita S.; Modak, Mukund J.			Participation of the fingers subdomain of Escherichia coli DNA polymerase I in the strand displacement synthesis of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; CRYSTAL-STRUCTURE; PROTEOLYTIC FRAGMENT; TERNARY COMPLEXES; TEMPLATE-PRIMER; ACTIVE-SITE; REPLICATION; MECHANISM; STABILIZATION; EXONUCLEASE	The replication of the genome requires the removal of RNA primers from the Okazaki fragments and their replacement by DNA. In prokaryotes, this process is completed by DNA polymerase I by means of strand displacement DNA synthesis and 5'-nuclease activity. Here, we demonstrate that the strand displacement DNA synthesis is facilitated by the collective participation of Ser(769), Phe(771), and Arg(841) present in the fingers subdomain of DNA polymerase I. The steady and presteady state kinetic analysis of the properties of appropriate mutant enzymes suggest that: ( a) Ser(769) and Phe(771) together are involved in the strand separation via the formation of a flap structure, and ( b) Arg(841) interacts with the template strand to achieve the optimal strand separation and DNA synthesis. The amino acid residues Ser(769) and Phe(771) are constituents of the O1-helix, which together with O and O2 helices form a 3-helix bundle structure. We note that this 3-helix bundle motif also exists in prokaryotic RNA polymerase. Thus in both DNA and RNA polymerases, this motif may have been adopted to achieve the strand separation function.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Singh, K (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, 185 S Orange Ave, Newark, NJ 07103 USA.	ksingh@umdnj.edu			NIGMS NIH HHS [GM55310, GM 36307] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Joyce CM, 1995, METHOD ENZYMOL, V262, P3; JOYCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P1830, DOI 10.1073/pnas.80.7.1830; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; Li Y, 1999, P NATL ACAD SCI USA, V96, P9491, DOI 10.1073/pnas.96.17.9491; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SETLOW P, 1972, J BIOL CHEM, V247, P232; Singh K, 2003, J BIOL CHEM, V278, P11289, DOI 10.1074/jbc.M211496200; Srivastava A, 2003, BIOCHEMISTRY-US, V42, P3645, DOI 10.1021/bi026699y; Stano NM, 2005, NATURE, V435, P370, DOI 10.1038/nature03615; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Turner RM, 2003, BIOCHEMISTRY-US, V42, P2373, DOI 10.1021/bi026566c; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Yuan YC, 1998, NAT STRUCT BIOL, V5, P959, DOI 10.1038/2934	28	31	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10594	10604		10.1074/jbc.M611242200	http://dx.doi.org/10.1074/jbc.M611242200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17259182	hybrid			2022-12-25	WOS:000245941000053
J	Thompson, BD; Jin, YZ; Wu, KH; Colvirl, RA; Luster, AD; Birnbaumer, L; Wu, MX				Thompson, Brian D.; Jin, Yongzhu; Wu, Kevin H.; Colvirl, Richard A.; Luster, Andrew D.; Birnbaumer, Lutz; Wu, Mei X.			Inhibition of G alpha(i2) activation by G alpha(i3) in CXCR3-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ACUTE ALLOGRAFT-REJECTION; PERTUSSIS-TOXIN; T-CELLS; G-ALPHA-I2(-/-) MICE; MULTIGENE FAMILY; ALPHA-SUBUNIT; BINDING; CXCR3; LYMPHOCYTES	G protein-coupled receptors (GPCRs) convey extracellular stimulation into dynamic intracellular action, leading to the regulation of cell migration and differentiation. T lymphocytes express G alpha(12), and G alpha(i3), two members of the G alpha(i/o). protein family, but whether these two G alpha(i) proteins have distinguishable roles guiding T cell migration remains largely unknown because of a lack of member-specific inhibitors. This study details distinct G alpha(i2) and G alpha(i3) effects on chemokine receptor CXCR3-mediated signaling. Our data showed that Gai, was indispensable for T cell responses to three CXCR3 ligands, CXCL9, CXCL10, and CXCL11, as the lack of G alpha(i2) abolished CXCR3-stimulated migration and guanosine 5'-3-O-(thio)triphosphate (GTP gamma S) incorporation. In sharp contrast, T cells isolated from G alpha(i3) knock-out mice displayed a significant increase in both GTP gamma S incorporation and migration as compared with wild type T cells when stimulated with CXCR3 agonists. The increased GTP gamma S incorporation was blocked by G alpha(i3) protein in a dose-dependent manner. G alpha(i3)-mediated blockade of Gai, activation did not result from Gai3 activation, but instead resulted from competition or steric hindrance of Gai, interaction with the CXCR3 receptor via the N terminus of the second intracellular loop. A mutation in this domain abrogated not only G alpha(i2) activation induced by a CXCR3 agonist but also the interaction of Gai3 to the CXCR3 receptor. These findings reveal for the first time an interplay of Gai proteins in transmitting G protein-coupled receptor signals. This interplay has heretofore been masked by the use of pertussis toxin, a broad inhibitor of the G alpha(i/o) protein family.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02114 USA; NIEHS, Transmembrane Signaling Grp, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Wu, MX (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed,Dept Dermatol, 55 Fruit St,Edwards 222, Boston, MA 02114 USA.	mwu2@partners.org	Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912	Intramural NIH HHS [Z01 ES101643-05] Funding Source: Medline; NIAID NIH HHS [R01 AI050822, AI070785, K02 AI070785, AI050822] Funding Source: Medline; NIAMS NIH HHS [T32 AR007098, T32 AR07098-31] Funding Source: Medline; NIDDK NIH HHS [DK43351, DK074449, R01 DK074449, P30 DK043351] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI070785] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK074449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101643] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; BEALS CR, 1987, P NATL ACAD SCI USA, V84, P7886, DOI 10.1073/pnas.84.22.7886; CHAFFIN KE, 1991, EUR J IMMUNOL, V21, P2565, DOI 10.1002/eji.1830211038; Colvin RA, 2004, J BIOL CHEM, V279, P30219, DOI 10.1074/jbc.M403595200; Cox MA, 2001, MOL PHARMACOL, V59, P707, DOI 10.1124/mol.59.4.707; Duffner U, 2003, EXP HEMATOL, V31, P897, DOI 10.1016/S0301-472X(03)00198-X; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gonsiorek W, 2003, J IMMUNOL METHODS, V273, P15, DOI 10.1016/S0022-1759(02)00415-5; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Hamm HE, 2001, P NATL ACAD SCI USA, V98, P4819, DOI 10.1073/pnas.011099798; Han SB, 2005, IMMUNITY, V22, P343, DOI 10.1016/j.immuni.2005.01.017; Hancock WW, 2001, J EXP MED, V193, P975, DOI 10.1084/jem.193.8.975; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Harrison C, 2003, LIFE SCI, V74, P489, DOI 10.1016/j.lfs.2003.07.005; Haunerland NH, 2004, PROG LIPID RES, V43, P328, DOI 10.1016/j.plipres.2004.05.001; Hornquist CE, 1997, J IMMUNOL, V158, P1068; Huang TT, 2003, INT IMMUNOL, V15, P1359, DOI 10.1093/intimm/dxg135; Hwang JI, 2004, P NATL ACAD SCI USA, V101, P488, DOI 10.1073/pnas.0307549100; Jiang MS, 2002, METHOD ENZYMOL, V344, P277; KASLOW HR, 1992, FASEB J, V6, P2684, DOI 10.1096/fasebj.6.9.1612292; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Khan IA, 2000, IMMUNITY, V12, P483, DOI 10.1016/S1074-7613(00)80200-9; KIM S, 1988, P NATL ACAD SCI USA, V85, P4153, DOI 10.1073/pnas.85.12.4153; Liu LP, 2005, CURR TOP DEV BIOL, V68, P149, DOI 10.1016/S0070-2153(05)68006-4; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Lu B, 1999, EUR J IMMUNOL, V29, P3804, DOI 10.1002/(SICI)1521-4141(199911)29:11<3804::AID-IMMU3804>3.0.CO;2-9; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; PALMER TM, 1995, J BIOL CHEM, V270, P16895, DOI 10.1074/jbc.270.28.16895; Papadakis KA, 2004, CURR ALLERGY ASTHM R, V4, P83, DOI 10.1007/s11882-004-0048-7; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P10686, DOI 10.1074/jbc.270.18.10686; Roberts DJ, 2004, BIOCHEM PHARMACOL, V68, P799, DOI 10.1016/j.bcp.2004.05.044; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Sklar LA, 2000, BIOTECHNIQUES, V28, P976, DOI 10.2144/00285rr03; Smit MJ, 2003, BLOOD, V102, P1959, DOI 10.1182/blood-2002-12-3945; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; SUNYER T, 1989, MOL ENDOCRINOL, V3, P1115, DOI 10.1210/mend-3-7-1115; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Whiting D, 2004, J IMMUNOL, V172, P7417, DOI 10.4049/jimmunol.172.12.7417; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; Wise A, 2002, DRUG DISCOV TODAY, V7, P235, DOI 10.1016/S1359-6446(01)02131-6; Wu JY, 2005, J IMMUNOL, V174, P6122, DOI 10.4049/jimmunol.174.10.6122; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699; Zhang YJ, 2005, INT IMMUNOL, V17, P233, DOI 10.1093/intimm/dxh204; Zhang Z, 2002, J IMMUNOL, V168, P3205, DOI 10.4049/jimmunol.168.7.3205	46	47	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9547	9555		10.1074/jbc.M610931200	http://dx.doi.org/10.1074/jbc.M610931200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17289675	Green Accepted, hybrid			2022-12-25	WOS:000245421700027
J	Adachi, R; Yamaguchi, K; Yagi, H; Sakurai, K; Naiki, H; Goto, Y				Adachi, Rumi; Yamaguchi, Kei-ichi; Yagi, Hisashi; Sakurai, Kazumasa; Naiki, Hironobu; Goto, Yuji			Flow-induced alignment of amyloid protofilaments revealed by linear dichroism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIL FORMATION; BETA(2)-MICROGLOBULIN FRAGMENT; PHYSIOLOGICAL CONDITIONS; PROTEIN; BETA-2-MICROGLOBULIN; ORIENTATION; MATURATION; SUGGESTS	uAmyloid fibrils underlying various serious amyloidoses including Alzheimer and prion diseases form characteristic deposits in which linear fibrils with an unbranched and rigid morphology associate laterally or radially, e.g. radial senile amyloid plaques of amyloid beta. To clarify the formation of these high order amyloid deposits, studying the rheology is important. A 22-residue K3 peptide fragment of beta(2)-microglobulin, a protein responsible for dialysis-related amyloidosis, forms long and homogeneous protofilament-like fibrils in 20% (v/v) 2,2,2-trifluoroethanol and 10 mM HCI (pH similar to 2). Here, using circular dichroism and linear dichroism, we observed the flow-induced alignment of fibrils. Analysis of far- and near-UV linear dichroism spectra suggested that both the net pi-pi transition moment of the backbone carbonyl group and L-b transition moment of the Tyr(26) side chain are oriented in parallel to the fibril axis, revealing the structural details of amyloid protofilaments. Moreover, the intensities of flow-induced circular dichroism or linear dichroism signals depended critically on the length and type of fibrils, suggesting that they are useful for detecting and characterizing amyloid fibrils.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; CREST, Japan Sci & Technol Agcy, Suita, Osaka 5650871, Japan; Univ Fukui, Fac Med Sci, Dept Pathol Sci, Matsuoka, Fukui 9101193, Japan; CREST, Japan Sci & Technol Agcy, Matsuoka, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); University of Fukui; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, Yamadaoka 3-2, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Naiki, Hironobu/G-5599-2014					Chiba T, 2003, J BIOL CHEM, V278, P47016, DOI 10.1074/jbc.M304473200; Dafforn TR, 2004, CURR OPIN STRUC BIOL, V14, P541, DOI 10.1016/j.sbi.2004.08.005; Dafforn TR, 2004, BIOPHYS J, V86, P404, DOI 10.1016/S0006-3495(04)74116-8; DAVIDSSON A, 1980, CHEM PHYS LETT, V70, P313, DOI 10.1016/0009-2614(80)85341-3; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Eakin CM, 2006, NAT STRUCT MOL BIOL, V13, P202, DOI 10.1038/nsmb1068; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Ivanova MI, 2004, P NATL ACAD SCI USA, V101, P10584, DOI 10.1073/pnas.0403756101; Iwata K, 2006, P NATL ACAD SCI USA, V103, P18119, DOI 10.1073/pnas.0607180103; Jahn TR, 2005, AMYLOID PROTEINS: THE BETA SHEET CONFORMATION AND DISEASE, VOLS 1 AND 2, P667, DOI 10.1002/9783527619344.ch26; Jahn TR, 2006, NAT STRUCT MOL BIOL, V13, P195, DOI 10.1038/nsmb1058; Jin LW, 2003, P NATL ACAD SCI USA, V100, P15294, DOI 10.1073/pnas.2534647100; Kihara M, 2005, J BIOL CHEM, V280, P12012, DOI 10.1074/jbc.M411949200; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; Lansbury PT, 2004, NAT MED, V10, pS51, DOI 10.1038/nrn1435; Marrington R, 2004, BIOPHYS J, V87, P2002, DOI 10.1529/biophysj.103.035022; Marrington R, 2006, CHIRALITY, V18, P680, DOI 10.1002/chir.20305; Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680; Ohhashi Y, 2004, J BIOL CHEM, V279, P10814, DOI 10.1074/jbc.M310334200; Petkova AT, 2006, BIOCHEMISTRY-US, V45, P498, DOI 10.1021/bi051952q; Relini A, 2006, J BIOL CHEM, V281, P16521, DOI 10.1074/jbc.M513827200; Rodger A, 2002, PHYS CHEM CHEM PHYS, V4, P4051, DOI 10.1039/b205080n; Rodger A., 1997, CIRCULAR DICHROISM L; Smith JF, 2006, P NATL ACAD SCI USA, V103, P15806, DOI 10.1073/pnas.0604035103; Woody R.W., 1996, CIRCULAR DICHROISM C, P25, DOI DOI 10.1007/978-1-4757-2508-7_2; Yamaguchi K, 2005, J MOL BIOL, V352, P952, DOI 10.1016/j.jmb.2005.07.061; Yamaguchi K, 2006, J MOL BIOL, V363, P279, DOI 10.1016/j.jmb.2006.08.030	29	30	31	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8978	8983		10.1074/jbc.M611738200	http://dx.doi.org/10.1074/jbc.M611738200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264078	hybrid, Green Published			2022-12-25	WOS:000245780300044
J	Huang, GH; Xie, XJ; Han, Y; Fan, LF; Chen, J; Mou, CY; Guo, L; Liu, H; Zhang, QF; Chen, SW; Dong, ML; Liu, JZ; Xu, AL				Huang, Gonghua; Xie, Xiaojin; Han, Yan; Fan, Lifei; Chen, Jie; Mou, Chunyan; Guo, Lei; Liu, Hui; Zhang, Qinfen; Chen, Shangwu; Dong, Meiling; Liu, Jianzhong; Xu, Anlong			The Identification of Lymphocyte-Like Cells and Lymphoid-Related Genes in Amphioxus Indicates the Twilight for the Emergency of Adaptive Immune System	PLOS ONE			English	Article								To seek evidence of a primitive adaptive immune system (AIS) before vertebrate, we examined whether lymphocytes or lymphocyte-like cells and the related molecules participating in the lymphocyte function existed in amphioxus. Anatomical analysis by electron microscopy revealed the presence of lymphocyte-like cells in gills, and these cells underwent morphological changes in response to microbial pathogens that are reminiscent of those of mammalian lymphocytes executing immune response to microbial challenge. In addition, a systematic comparative analysis of our cDNA database of amphioxus identified a large number of genes whose vertebrate counterparts are involved in lymphocyte function. Among these genes, several genes were found to be expressed in the vicinity of the lymphocyte-like cells by in situ hybridization and up-regulated after exposure to microbial pathogens. Our findings in the amphioxus indicate the twilight for the emergency of AIS before the invertebrate-vertebrate transition during evolution.	[Huang, Gonghua; Xie, Xiaojin; Han, Yan; Fan, Lifei; Chen, Jie; Mou, Chunyan; Guo, Lei; Liu, Hui; Zhang, Qinfen; Chen, Shangwu; Dong, Meiling; Liu, Jianzhong; Xu, Anlong] Sun Yat Sen Univ, Coll Life Sci, Open Lab Marine Funct Genom State High Tech Dev P, State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University	Xu, AL (corresponding author), Sun Yat Sen Univ, Coll Life Sci, Open Lab Marine Funct Genom State High Tech Dev P, State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China.	lssxal@mail.sysu.edu.cn			Outstanding Young Scientist Award [39725007]; National Natural Science Foundation of China [30300264]; Ministry of Science and Technology of China [2004AA621030, 2003AA626010]; Ministry of Education, and Key Projects of Commission of Science and Technology of Guangdong Province and Guangzhou City [0107]	Outstanding Young Scientist Award; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Ministry of Education, and Key Projects of Commission of Science and Technology of Guangdong Province and Guangzhou City	"Outstanding Young Scientist Award'' (No. 39725007), and projects (No. 30300264) of National Natural Science Foundation of China, the projects 2004AA621030 and 2003AA626010 of State High-Tech Development Project (863) of the Ministry of Science and Technology of China, Key Project (0107) of Ministry of Education, and Key Projects of Commission of Science and Technology of Guangdong Province and Guangzhou City.	Abi-Rached L, 2002, NAT GENET, V31, P100, DOI 10.1038/ng855; Allam A, 2005, IMMUNOL LETT, V97, P7, DOI 10.1016/j.imlet.2004.09.019; Blair JE, 2005, MOL BIOL EVOL, V22, P2275, DOI 10.1093/molbev/msi225; Cannon JP, 2002, NAT IMMUNOL, V3, P1200, DOI 10.1038/ni849; Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Hagman J, 2005, TRENDS IMMUNOL, V26, P455, DOI 10.1016/j.it.2005.07.001; HAGMAN J, 1991, EMBO J, V10, P3409, DOI 10.1002/j.1460-2075.1991.tb04905.x; Kapitonov VV, 2005, PLOS BIOL, V3, P998, DOI 10.1371/journal.pbio.0030181; Li SG, 2004, J NEUROSCI, V24, P3104, DOI 10.1523/JNEUROSCI.4444-03.2004; Litman GF, 1999, ANNU REV IMMUNOL, V17, P109, DOI 10.1146/annurev.immunol.17.1.109; Marshall AJ, 2002, MOL CELL BIOL, V22, P5479, DOI 10.1128/MCB.22.15.5479-5491.2002; Mayer WE, 2002, P NATL ACAD SCI USA, V99, P14350, DOI 10.1073/pnas.212527499; Mayer WE, 2002, SCAND J IMMUNOL, V55, P162, DOI 10.1046/j.1365-3083.2002.01026.x; Minguillon C, 2003, DEVELOPMENT, V130, P5903, DOI 10.1242/dev.00811; Mou CY, 2002, BIOCHEM BIOPH RES CO, V299, P74, DOI 10.1016/S0006-291X(02)02582-2; Pancer Z, 2004, NATURE, V430, P174, DOI 10.1038/nature02740; RHODES CP, 1982, SCIENCE, V217, P263, DOI 10.1126/science.7089565; Yu CL, 2005, J IMMUNOL, V174, P3493, DOI 10.4049/jimmunol.174.6.3493	20	39	44	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e206	10.1371/journal.pone.0000206	http://dx.doi.org/10.1371/journal.pone.0000206			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299586	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444400007
J	Mols, CMM; Visser, ME				Mols, Christel M. M.; Visser, Marcel E.			Great Tits (Parus major) Reduce Caterpillar Damage in Commercial Apple Orchards	PLOS ONE			English	Article								Alternative ways to control caterpillar pests and reduce the use of pesticides in apple orchards are in the interest of the environment, farmers and the public. Great tits have already been shown to reduce damage under high caterpillar density when breeding in nest boxes in an experimental apple orchard. We tested whether this reduction also occurs under practical conditions of Integrated Pest Management (IPM), as well as Organic Farming (OF), by setting up an area with nest boxes while leaving a comparable area as a control within 12 commercial orchards. We showed that in IPM orchards, but not in OF orchards, in the areas with breeding great tits, apples had 50% of the caterpillar damage of the control areas. Offering nest boxes to attract insectivorous passerines in orchards can thus lead to more limited pesticide use, thereby adding to the natural biological diversity in an agricultural landscape, while also being economically profitable to the fruit growers.	[Mols, Christel M. M.; Visser, Marcel E.] Netherlands Inst Ecol NIOO KNAW, Heteren, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW)	Visser, ME (corresponding author), Netherlands Inst Ecol NIOO KNAW, Heteren, Netherlands.	m.visser@nioo.knaw.nl	Visser, Marcel E/A-9151-2009	Visser, Marcel E/0000-0002-1456-1939	The Technology Foundation STW [3844]	The Technology Foundation STW(Technologiestichting STW)	The Technology Foundation STW (code BBI. 3844), applied science division of NWO and the technology programme of the Ministry of Economic Affairs supported this research. The funders of the research have played no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	BETTS MM, 1955, J ANIM ECOL, V24, P282, DOI 10.2307/1715; BLOMMERS LHM, 1994, ANNU REV ENTOMOL, V39, P213, DOI 10.1146/annurev.en.39.010194.001241; BRUNS H, 1960, BIRD STUDY, V7, P193; Cross JV, 1999, BIOCONTROL SCI TECHN, V9, P277, DOI 10.1080/09583159929569; DEREEDE RH, 1985, ENTOMOL EXP APPL, V37, P263, DOI 10.1007/BF00191658; Gosler A, 1993, GREAT TIT; Kirk David A., 1996, Current Ornithology, V13, P175; Mols CMM, 2005, ARDEA, V93, P259; Mols CMM, 2002, J APPL ECOL, V39, P888, DOI 10.1046/j.1365-2664.2002.00761.x; Naef-Daenzer B, 2000, ANIM BEHAV, V59, P989, DOI 10.1006/anbe.1999.1380; Otvos I. S., 1979, ROLE INSECTIVOROUS B, P341; ROYAMA T, 1966, IBIS, V108, P313, DOI 10.1111/j.1474-919X.1966.tb07348.x; Solomon MG, 2000, BIOCONTROL SCI TECHN, V10, P91, DOI 10.1080/09583150029260; TINBERGEN L., 1960, ARCH NEERLAND ZOOL, V13, P265; VANBALEN JH, 1973, ARDEA, V61, P1	15	43	43	3	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2007	2	2							e202	10.1371/journal.pone.0000202	http://dx.doi.org/10.1371/journal.pone.0000202			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DI	17285148	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444300013
J	Nojima, M; Suzuki, H; Toyota, M; Watanabe, Y; Maruyama, R; Sasaki, S; Sasaki, Y; Mita, H; Nishikawa, N; Yamaguchi, K; Hirata, K; Itoh, F; Tokino, T; Mori, M; Imai, K; Shinomura, Y				Nojima, M.; Suzuki, H.; Toyota, M.; Watanabe, Y.; Maruyama, R.; Sasaki, S.; Sasaki, Y.; Mita, H.; Nishikawa, N.; Yamaguchi, K.; Hirata, K.; Itoh, F.; Tokino, T.; Mori, M.; Imai, K.; Shinomura, Y.			Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer	ONCOGENE			English	Article						SFRP; methylation; gastric cancer; Wnt signaling; apoptosis	BETA-CATENIN GENE; MATRIX METALLOPROTEINASE-7; ABERRANT METHYLATION; ANTAGONIST SFRP1; CYCLIN D1; EXPRESSION; APOPTOSIS; FAMILY; GROWTH; HYPERMETHYLATION	Activation of Wnt signaling has been implicated in gastric tumorigenesis, although mutations in APC (adenomatous polyposis coli), CTNNB1 (beta-catenin) and AXIN are seen much less frequently in gastric cancer (GC) than in colorectal cancer. In the present study, we investigated the relationship between activation of Wnt signaling and changes in the expression of secreted frizzled-related protein (SFRP) family genes in GC. We frequently observed nuclear beta-catenin accumulation (13/15; 87%) and detected the active form of beta-catenin in most (12/16; 75%) GC cell lines. CpG methylation-dependent silencing of SFRP1, SFRP2 and SFRP5 was frequently seen among GC cell lines (SFRP1, 16/16, 100%; SFRP2, 16/16, 100%; SFRP5, 13/16, 81%) and primary GC specimens (SFRP1, 42/46, 91%; SFRP2, 44/46, 96%; SFRP5, 30/46, 65%),and treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine rapidly restored SFRP expression. Ectopic expression of SFRPs downregulated T-cell factor/lymphocyte enhancer factor transcriptional activity, suppressed cell growth and induced apoptosis in GC cells. Analysis of global expression revealed that overexpression of SFRP2 repressed Wnt target genes and induced changes in the expression of numerous genes related to proliferation, growth and apoptosis in GC cells. It thus appears that aberrant SFRP methylation is one of the major mechanisms by which Wnt signaling is activated in GC.	Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Sapporo Med Univ, Dept Publ Hlth, Sapporo, Hokkaido, Japan; Sapporo Med Univ, Dept Mol Biol, Inst Canc Res, Sapporo, Hokkaido, Japan; PRESTO JST, Kawaguchi, Japan; St Marianna Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Kawasaki, Kanagawa, Japan; Sapporo Med Univ, Dept Surg 1, Sapporo, Hokkaido, Japan	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University; Japan Science & Technology Agency (JST); Saint Marianna University; Sapporo Medical University	Suzuki, H (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, S1,W16, Sapporo, Hokkaido 0608543, Japan.	hsuzuki@sapmed.ac.jp	Sasaki, Yasushi/AAA-3079-2019; Tokino, Takashi/AAI-9887-2021	Sasaki, Yasushi/0000-0002-3500-8059; 				Arber N, 1999, HUM PATHOL, V30, P1087, DOI 10.1016/S0046-8177(99)90227-7; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Clements WM, 2002, CANCER RES, V62, P3503; Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; He B, 2005, CANCER RES, V65, P743; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Hollander MC, 2003, ONCOGENE, V22, P3827, DOI 10.1038/sj.onc.1206567; HORII A, 1992, CANCER RES, V52, P3231; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Ii M, 2006, EXP BIOL MED, V231, P20; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; KOPPERT LB, 2000, BRIT J CANCER, V90, P892; Ku Ja-Lok, 2005, Cancer Res Treat, V37, P1, DOI 10.4143/crt.2005.37.1.1; Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881; Liu TH, 2006, CANCER RES, V66, P653, DOI 10.1158/0008-5472.CAN-05-3712; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Murai M, 2005, CLIN CANCER RES, V11, P1021; Naishiro Y, 2001, CANCER RES, V61, P2751; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; Rhee CS, 2002, ONCOGENE, V21, P6598, DOI 10.1038/sj.onc.1205920; Risinger JI, 2005, CANCER RES, V65, P5031, DOI 10.1158/0008-5472.CAN-04-0850; Saikawa Y, 2001, JPN J CANCER RES, V92, P1102, DOI 10.1111/j.1349-7006.2001.tb01065.x; Sasaki Y, 2001, TUMOR BIOL, V22, P123, DOI 10.1159/000050606; Satoh A, 2003, CANCER RES, V63, P8606; Stoehr R, 2004, LAB INVEST, V84, P465, DOI 10.1038/labinvest.3700068; Suriano G, 2005, GENE CHROMOSOME CANC, V42, P238, DOI 10.1002/gcc.20135; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x; Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141	41	182	199	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4699	4713		10.1038/sj.onc.1210259	http://dx.doi.org/10.1038/sj.onc.1210259			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297461				2022-12-25	WOS:000248037900010
J	Kim, MM; Wiederschain, D; Kennedy, D; Hansen, E; Yuan, ZM				Kim, M. M.; Wiederschain, D.; Kennedy, D.; Hansen, E.; Yuan, Z-M			Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP)	ONCOGENE			English	Article						G3BP; p53; MDM2	FUNCTIONAL INACTIVATION; EXPRESSION; GROWTH; DOMAIN; IDENTIFICATION; RNA	Inactivation of the p53 tumor suppressor pathway is a critical step in human tumorigenesis. In addition to mutations, p53 can be functionally silenced through its increased degradation, inhibition of its transcriptional activity and/or its inappropriate subcellular localization. Using a proteomic approach, we have found that members of the Ras network of proteins, Ras-GTPase activating protein-SH3-domain-binding proteins 1 and 2 (G3BP1 and 2), bind to p53 in vitro and in vivo. Our data show that expression of G3BPs leads to the redistribution of p53 from the nucleus to the cytoplasm. The G3BP2 isoform additionally associated with murine double minute 2 (MDM2), a negative regulator of p53. G3BP2 expression resulted in significant reduction in MDM2-mediated p53 ubiquitylation and degradation. Interestingly, MDM2 was also stabilized in G3BP2-expressing cells and its ability to ubiquitylate itself was compromised. Accordingly, short hairpin RNA (shRNA)-mediated knockdown of G3BP2 caused a reduction in MDM2 protein levels. Furthermore, expression of shRNA targeting either G3BP1 or G3BP2 in human cancer cell lines resulted in marked upregulation of p53 levels and activity. Our results suggest that both G3BP isoforms may act as negative regulators of p53.	Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA; Griffith Univ, Sch Biomol & Biomed Sci, Nathan, Qld 4111, Australia	Harvard University; Harvard T.H. Chan School of Public Health; Griffith University	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 665 Huntington Ave, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Kennedy, Hendrick/A-7635-2010	Kennedy, Hendrick/0000-0001-7937-3069	NCI NIH HHS [CA009078, R01CA85679-02] Funding Source: Medline; NIEHS NIH HHS [5P30ES00002, T32ES007155] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009078, R01CA085679] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002, T32ES007155] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Atlas R, 2004, J NEUROCHEM, V89, P613, DOI 10.1111/j.1471-4159.2004.02371.x; Barnes CJ, 2002, CANCER RES, V62, P1251; French J, 2002, HISTOCHEM J, V34, P223, DOI 10.1023/A:1021737413055; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Gu JJ, 2001, CANCER RES, V61, P6703; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; Huang YP, 2005, ONCOGENE, V24, P3819, DOI 10.1038/sj.onc.1208527; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Kennedy D, 2002, J CELL BIOCHEM, V84, P173, DOI 10.1002/jcb.1277; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Liu YX, 2001, CHINESE MED J-PEKING, V114, P35; Molinari AM, 2000, CANCER RES, V60, P2594; Pazman C, 2000, DEVELOPMENT, V127, P1715; Soncini C, 2001, ONCOGENE, V20, P3869, DOI 10.1038/sj.onc.1204553; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Tourriere H, 2003, J CELL BIOL, V160, P823, DOI 10.1083/jcb.200212128; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Zekri L, 2005, MOL CELL BIOL, V25, P8703, DOI 10.1128/MCB.25.19.8703-8716.2005	23	61	65	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4209	4215		10.1038/sj.onc.1210212	http://dx.doi.org/10.1038/sj.onc.1210212			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17297477				2022-12-25	WOS:000247619900003
J	Cayla, C; Todiras, M; Iliescu, R; Saul, VV; Gross, V; Pilz, B; Chai, GX; Merino, VF; Pesquero, JB; Baltatu, OC; Bader, M				Cayla, Cecile; Todiras, Mihail; Iliescu, Radu; Saul, Vera V.; Gross, Volkmar; Pilz, Bernhard; Chai, Guixuan; Merino, Vanessa F.; Pesquero, Joao B.; Baltatu, Ovidiu C.; Bader, Michael			Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension	FASEB JOURNAL			English	Article						bradykinin; blood pressure; endotoxemia	BRADYKININ B-2 RECEPTOR; NITRIC-OXIDE SYNTHASE; NORMAL BLOOD-PRESSURE; AORTIC ENDOTHELIAL-CELLS; KNOCKOUT MICE; CONVERTING-ENZYME; SEPTIC SHOCK; ESCHERICHIA-COLI; ANIMAL-MODELS; B2 RECEPTORS	Kinins play a central role in the modulation of cardiovascular function and in the pathophysiology of inflammation. These peptides mediate their effects by binding to two specific G-protein coupled receptors named B1 and B2. To evaluate the full functional relevance of the kallikrein- kinin system, we generated mice lacking both kinin receptors (B1B2-/-). Because of the close chromosomal position of both kinin receptor genes, B1B2-/- mice could not be obtained by simple breeding of the single knockout lines. Therefore, we inactivated the B1 receptor gene by homologous recombination in embryonic stem cells derived from B2-deficient animals. The B1B2-/- mice exhibited undetectable levels of mRNAs for both receptors and a lack of response to bradykinin (B2 agonist) and des-Arg(9)-bradykinin (B1 agonist), as attested by contractility studies with isolated smooth muscle tissues. B1B2-/- mice are healthy and fertile, and no sign of cardiac abnormality was detected. They are normotensive but exhibit a lower heart rate than controls. Furthermore, kinin receptor deficiency affects the pathogenesis of endotoxin- induced hypotension. While blood pressure decreased markedly in wild-type mice and B2-/- and moderately in B1-/- mice after bacterial lipopolysaccharide ( LPS) injection, blood pressure remained unchanged in B1B2-/- mice. These results clearly demonstrate a pivotal role of kinins and their receptors in hypotension induced by endotoxemia in mice.-Cayla, C., Todiras, M., Iliescu, R., Saul, V. V., Gross, V., Pilz, B., Chai, G., Merino, V. F., Pesquero, J. B., Baltatu, O. C., Bader, M. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; HELIOS Klin, Franz Volhard Clin, D-13092 Berlin, Germany; Univ Fed Sao Paulo, Escola Paulista Med, Dept Biophys, BR-04023062 Sao Paulo, Brazil	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Franz-Volhard Clinical Research Center; Helios Kliniken; Universidade Federal de Sao Paulo (UNIFESP)	Bader, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	mbader@mdc-berlin.de	Todiras, Mihail/AAT-4426-2020; Pesquero, Joao/C-1470-2012; Bader, Michael/K-2124-2013; Baltatu, Ovidiu Constantin/E-5890-2011; Iliescu, Radu/C-5116-2011	Todiras, Mihail/0000-0002-9373-4753; Pesquero, Joao/0000-0002-4507-632X; Baltatu, Ovidiu Constantin/0000-0001-9732-6039; Iliescu, Radu/0000-0002-9124-577X; Bader, Michael/0000-0003-4780-4164				Bae SW, 2003, BIOCHEM BIOPH RES CO, V306, P981, DOI 10.1016/S0006-291X(03)01086-6; BAO G, 1992, HYPERTENSION, V20, P74, DOI 10.1161/01.HYP.20.1.74; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BORKOWSKI JA, 1995, J BIOL CHEM, V270, P13706, DOI 10.1074/jbc.270.23.13706; Cardoso CC, 2004, BIOL CHEM, V385, P295, DOI 10.1515/BC.2004.025; Cecile CA, 2002, INT IMMUNOPHARMACOL, V2, P1721, DOI 10.1016/S1567-5769(02)00175-3; CHULAK C, 1995, BRIT J PHARMACOL, V115, P330, DOI 10.1111/j.1476-5381.1995.tb15881.x; DAMAS J, 1979, BIOMED EXPRESS, V31, P249; DORLEANSJUSTE P, 1989, BRIT J PHARMACOL, V96, P920, DOI 10.1111/j.1476-5381.1989.tb11903.x; Duka A, 2006, AM J PHYSIOL-ENDOC M, V291, pE268, DOI 10.1152/ajpendo.00382.2005; Duka I, 2001, CIRC RES, V88, P275, DOI 10.1161/01.RES.88.3.275; Emanueli C, 1999, CIRCULATION, V100, P2359, DOI 10.1161/01.CIR.100.23.2359; Fein AM, 1997, JAMA-J AM MED ASSOC, V277, P482, DOI 10.1001/jama.277.6.482; Feletou M, 1996, J CARDIOVASC PHARM, V27, P500, DOI 10.1097/00005344-199604000-00008; Figueroa CD, 2001, BIOL REPROD, V64, P1590, DOI 10.1095/biolreprod64.6.1590; FLEMING I, 1992, J CARDIOVASC PHARM, V20, pS135, DOI 10.1097/00005344-199204002-00038; HAYASHI I, 1985, THROMB RES, V39, P313, DOI 10.1016/0049-3848(85)90227-0; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Ignjatovic T, 2004, MOL PHARMACOL, V66, P1310, DOI 10.1124/mol.104.001990; KALTER ES, 1983, J INFECT DIS, V148, P682, DOI 10.1093/infdis/148.4.682; KATORI M, 1989, BRIT J PHARMACOL, V98, P1383, DOI 10.1111/j.1476-5381.1989.tb12688.x; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; LORTIE M, 1992, AM J PHYSIOL, V262, pR72, DOI 10.1152/ajpregu.1992.262.1.R72; Lu JL, 1996, BIOCHEM BIOPH RES CO, V225, P1, DOI 10.1006/bbrc.1996.1121; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Madeddu P, 1997, CIRCULATION, V96, P3570; Maestri R, 2003, HYPERTENSION, V41, P1151, DOI 10.1161/01.HYP.0000064180.55222.DF; MAJIMA M, 1993, HYPERTENSION, V22, P705, DOI 10.1161/01.HYP.22.5.705; Marceau F, 1998, PHARMACOL REV, V50, P357; McLean PG, 2000, CARDIOVASC RES, V48, P194, DOI 10.1016/S0008-6363(00)00184-X; McLean PG, 1999, BRIT J PHARMACOL, V128, P275, DOI 10.1038/sj.bjp.0702743; Meneton P, 2001, P NATL ACAD SCI USA, V98, P2634, DOI 10.1073/pnas.051619598; Milia AF, 2001, HYPERTENSION, V37, P1473, DOI 10.1161/01.HYP.37.6.1473; MINSHALL RD, 1994, CIRC RES, V74, P441, DOI 10.1161/01.RES.74.3.441; Monsees TK, 2002, BIOL REPROD, V67, P1832, DOI 10.1095/biolreprod.102.005207; Morinelli TA, 2001, J PHARMACOL EXP THER, V296, P71; NIES AS, 1968, CIRC RES, V22, P155, DOI 10.1161/01.RES.22.2.155; OTTERBEIN L, 1993, AGENTS ACTIONS, V39, pC125, DOI 10.1007/BF01972742; Pesquero JB, 2006, BIOL CHEM, V387, P119, DOI 10.1515/BC.2006.017; Pesquero JB, 2000, P NATL ACAD SCI USA, V97, P8140, DOI 10.1073/pnas.120035997; Qadri F, 1999, J HYPERTENS, V17, P1265, DOI 10.1097/00004872-199917090-00005; REGOLI D, 1980, PHARMACOL REV, V32, P1; Rhaleb NE, 1999, HYPERTENSION, V33, P329, DOI 10.1161/01.HYP.33.1.329; Robertson E J, 1997, Methods Mol Biol, V75, P173; SALVEMINI D, 1990, P NATL ACAD SCI USA, V87, P2593, DOI 10.1073/pnas.87.7.2593; Schanstra JP, 2003, AM J PHYSIOL-HEART C, V284, pH1904, DOI 10.1152/ajpheart.01150.2002; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Trabold F, 2002, HYPERTENSION, V40, P90, DOI 10.1161/01.HYP.0000021747.43346.95; UENO A, 1995, BRIT J PHARMACOL, V114, P1250, DOI 10.1111/j.1476-5381.1995.tb13340.x; Venema RC, 2002, INT IMMUNOPHARMACOL, V2, P1755, DOI 10.1016/S1567-5769(02)00185-6; Vincent JL, 2000, AM J RESP CRIT CARE, V161, P1781, DOI 10.1164/ajrccm.161.6.9812004; WHALLEY ET, 1992, AGENT ACTION SUPPL, V38, P413; Yang XP, 1997, HYPERTENSION, V30, P735, DOI 10.1161/01.HYP.30.3.735; Yang XP, 2001, CIRC RES, V88, P1072, DOI 10.1161/hh1001.090759	56	80	82	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1689	1698		10.1096/fj.06-7175com	http://dx.doi.org/10.1096/fj.06-7175com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17289925				2022-12-25	WOS:000246866500010
J	Thamilselvan, V; Craig, DH; Basson, MD				Thamilselvan, Vijayalakshmi; Craig, David H.; Basson, Marc D.			FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway	FASEB JOURNAL			English	Article						integrin affinity; membrane translocation; p85 subunit; Akt isoforms; physical forces; mechanotransduction	PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PHOSPHOINOSITIDE 3-KINASE; KINASE-B; INDEPENDENT ACTIVATION; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; PI3 KINASE; IN-VITRO; INTEGRIN	Cancer cell adhesion is traditionally viewed as random, occurring if the cell's receptors match the substrate. Cancer cells are subjected to pressure and shear during growth against a constraining stroma, surgical manipulation, and passage through the venous and lymphatic system. Cells shed into a cavity such as the abdomen postoperatively also experience increased pressure from postoperative edema. Increased extracellular pressure stimulates integrin-mediated cancer cell adhesion via FAK and Src. PI 3- kinase ( PI3K) inhibitors ( LY294002 or wortmannin), Akt inhibitors, or Akt1 siRNA blocked adhesion stimulated by 15 mmHg pressure in SW620 or primary human malignant colonocytes. Pressure activated PI3K, tyrosine-phosphorylated and membrane- translocated the p85 subunit, and phosphorylated Akt. PI3K inhibitor ( LY294002) prevented pressure-stimulated Akt Ser473 and FAK Tyr397, but not FAK576 or Src416 phosphorylation. PP2 inhibited PI3K activity and Akt phosphorylation. FAK siRNA did not affect pressure- induced PI3K activation but blocked Akt phosphorylation. Pressure also stimulated FAK or FAKY397F mutant translocation to the membrane. Akt inhibitor IV blocked pressure- induced Akt and FAK translocation. Pressure activated Src- and PI3K- dependently induced p85 interaction with FAK, and FAK with beta 1 integrin. These results delineate a novel force-activated inside-out Src/ PI3K/FAK/Akt pathway by which cancer cells regulate their own adhesion. These signals may be potential targets for inhibition of metastatic adhesion.-Thamilselvan V., Craig D. H., Basson M. D. FAK association with multiple signal proteins mediates pressure- induced colon cancer cell adhesion via a Src- dependent PI3K/ Akt pathway.	John D Dingell VA Med Ctr, Dept Surg, Detroit, MI 48201 USA; Wayne State Univ, Detroit, MI 48202 USA	Wayne State University	Basson, MD (corresponding author), John D Dingell VA Med Ctr, Dept Surg, 4646 John R St, Detroit, MI 48201 USA.	marc.basson@va.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060771] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK60771] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Balasubramanian S, 2003, J BIOL CHEM, V278, P42214, DOI 10.1074/jbc.M303428200; Barry FA, 2002, J BIOL CHEM, V277, P12874, DOI 10.1074/jbc.M200482200; Basson MD, 2000, J CELL BIOCHEM, V78, P47, DOI 10.1002/(SICI)1097-4644(20000701)78:1<47::AID-JCB5>3.0.CO;2-M; Bongiorno-Borbone L, 2002, J NEUROCHEM, V81, P1212, DOI 10.1046/j.1471-4159.2002.00906.x; Brancaccio M, 2006, CARDIOVASC RES, V70, P422, DOI 10.1016/j.cardiores.2005.12.015; Chan ASH, 1997, J IMMUNOL, V159, P934; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Coffey JC, 2005, J BIOL CHEM, V280, P20968, DOI 10.1074/jbc.M414696200; Conway WC, 2006, J CELL BIOCHEM, V98, P1507, DOI 10.1002/jcb.20819; Cooper CR, 2002, NEOPLASIA, V4, P191, DOI 10.1038/sj.neo.7900224; Cospedal R, 1999, CARDIOVASC RES, V41, P708, DOI 10.1016/S0008-6363(98)00232-6; Crossthwaite AJ, 2004, J NEUROCHEM, V88, P1127, DOI 10.1046/j.1471-4159.2004.02257.x; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Franchini KG, 2000, CIRC RES, V87, P558, DOI 10.1161/01.RES.87.7.558; Gerszten RE, 2001, J BIOL CHEM, V276, P26846, DOI 10.1074/jbc.M011235200; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Gorin Y, 2001, FASEB J, V15, P1909, DOI 10.1096/fj..01-0165com; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Haynes MP, 2003, J BIOL CHEM, V278, P2118, DOI 10.1074/jbc.M210828200; Hunger-Glaser I, 2004, J CELL PHYSIOL, V200, P213, DOI 10.1002/jcp.20018; Itoh N, 2002, CANCER, V94, P3127, DOI 10.1002/cncr.10591; Jin ZG, 2003, CIRC RES, V93, P354, DOI 10.1161/01.RES.0000089257.94002.96; Kang I, 1998, EXP MOL MED, V30, P263, DOI 10.1038/emm.1998.39; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Kim RD, 2001, J SURG RES, V100, P176, DOI 10.1006/jsre.2001.6225; Kinashi T, 1999, J IMMUNOL, V162, P2850; KLIPPEL A, 1993, MOL CELL BIOL, V13, P5560, DOI 10.1128/MCB.13.9.5560; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Koshida R, 2005, ARTERIOSCL THROM VAS, V25, P2548, DOI 10.1161/01.ATV.0000188511.84138.9b; Lezama R, 2005, J NEUROCHEM, V93, P1189, DOI 10.1111/j.1471-4159.2005.03110.x; Ling LX, 1999, J CELL BIOCHEM, V73, P533; Lymn JS, 1999, ARTERIOSCL THROM VAS, V19, P2133, DOI 10.1161/01.ATV.19.9.2133; Masure S, 1999, EUR J BIOCHEM, V265, P353, DOI 10.1046/j.1432-1327.1999.00774.x; Miao H, 2002, BIOCHEM BIOPH RES CO, V292, P892, DOI 10.1006/bbrc.2002.6750; Mohri T, 1999, EXP CELL RES, V253, P533, DOI 10.1006/excr.1999.4720; Morel JCM, 2002, J BIOL CHEM, V277, P34679, DOI 10.1074/jbc.M206337200; Moule SK, 1997, J BIOL CHEM, V272, P7713, DOI 10.1074/jbc.272.12.7713; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; Ortiz PA, 2004, AM J PHYSIOL-RENAL, V287, pF281, DOI 10.1152/ajprenal.00383.2003; Papakonstanti EA, 2003, MOL ENDOCRINOL, V17, P870, DOI 10.1210/me.2002-0253; Pavalko FM, 2003, J CELL PHYSIOL, V194, P194, DOI 10.1002/jcp.10221; Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H; Qin SF, 2003, BIOCHEMISTRY-US, V42, P2995, DOI 10.1021/bi0205911; Resendiz JC, 2003, MOL PHARMACOL, V63, P639, DOI 10.1124/mol.63.3.639; Sasamoto A, 2005, AM J PHYSIOL-CELL PH, V288, pC1012, DOI 10.1152/ajpcell.00314.2004; Sawai H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-37; Sawhney RS, 2004, J BIOL CHEM, V279, P47379, DOI 10.1074/jbc.M402031200; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shen TL, 2001, FEBS LETT, V499, P176, DOI 10.1016/S0014-5793(01)02545-5; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; Siu MKY, 2005, J BIOL CHEM, V280, P25029, DOI 10.1074/jbc.M501049200; Skaletz-Rorowski A, 2003, CARDIOVASC RES, V57, P253, DOI 10.1016/S0008-6363(02)00618-1; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Takahashi N, 1999, CIRC RES, V84, P1194, DOI 10.1161/01.RES.84.10.1194; Tapia JA, 1999, BBA-MOL CELL RES, V1448, P486, DOI 10.1016/S0167-4889(98)00157-8; Thamilselvan V, 2004, GASTROENTEROLOGY, V126, P8, DOI 10.1053/j.gastro.2003.10.078; Thamilselvan V, 2005, CARCINOGENESIS, V26, P1687, DOI 10.1093/carcin/bgi135; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; van Zyp JV, 2006, CANCER BIOL THER, V5, P1169; van Zyp JV, 2004, AM J SURG, V188, P467, DOI 10.1016/j.amjsurg.2004.07.005; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; von Willebrand M, 1998, J BIOL CHEM, V273, P3994, DOI 10.1074/jbc.273.7.3994; Walsh MF, 2003, CELL PHYSIOL BIOCHEM, V13, P135, DOI 10.1159/000071864; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wojciak-Stothard B, 2003, J CELL BIOL, V161, P429, DOI 10.1083/jcb.200210135; Wu X, 2004, BJU INT, V93, P143, DOI 10.1111/j.1464-410X.2004.04574.x; Yap CL, 2002, BLOOD, V99, P151, DOI 10.1182/blood.V99.1.151; Zell T, 1996, J IMMUNOL, V156, P883	76	134	140	3	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1730	1741		10.1096/fj.06-6545com	http://dx.doi.org/10.1096/fj.06-6545com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317726				2022-12-25	WOS:000246866500015
J	Eliyahu, E; Park, JH; Shtraizent, N; He, X; Schuchman, EH				Eliyahu, Efrat; Park, Jae-Ho; Shtraizent, Nataly; He, Xingxuan; Schuchman, Edward H.			Acid ceramidase is a novel factor required for early embryo survival	FASEB JOURNAL			English	Article						apoptosis; oocytes; ceramide	FARBER-DISEASE; MOUSE OOCYTES; SPHINGOLIPIDS; BIOSYNTHESIS; HYDROLYSIS; ACTIVATION; TRANSITION; APOPTOSIS; CLONING; DEATH	Recent studies suggest that the lipid, ceramide, induces the default apoptosis process in eggs. Yet, it is obscure how newly formed embryos overcome this fate. Acid ceramidase ( AC) is a key regulatory enzyme involved in ceramide metabolism, and mutations in the AC gene ( Asah1) result in Farber Lipogranulomatosis, a fatal human genetic disorder. Our previous studies revealed that AC knockout ( Asah1-/-) mice had a lethal phenotype, and herein we reveal the mechanism underlying this observation. A single- cell, polymerase chain reaction ( PCR) genotyping method was developed to analyze individual embryos from Asah1 +/- intercrosses. Combined with Annexin V staining, this genotype analysis demonstrated that Asah1-/- embryos could not survive beyond the 2- cell stage, and underwent apoptotic death. Notably, sphingosine-1-phosphate ( S1P) treatment of early 2- cell embryos from the Asah1 +/- intercrosses rescued Asah1-/- embryos, and enabled their progression from the 2- cell to 4 - 8- cell stage. Quantitative PCR also revealed that expression of the Asah1 gene in healthy embryos was initiated at the 2- cell stage, coincident with embryonic genome activation ( EGA). AC activity and Western blot analyses further demonstrated high expression and activity of the enzyme in normal, unfertilized eggs, which likely provide the protein to newly formed embryos prior to EGA. Based on these observations, we suggest that AC is an essential factor required for embryo survival that functions by removing ceramide from the newly formed embryos, thus inhibiting the default apoptosis pathway.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Schuchman, EH (corresponding author), Mt Sinai Sch Med, Dept Human Genet, 1425 Madison Ave, New York, NY 10029 USA.	edward.schuchman@mssm.edu			NIDDK NIH HHS [R01 DK54830] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054830] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; Chan A, 1998, HISTOCHEM CELL BIOL, V110, P553, DOI 10.1007/s004180050317; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Eliyahu E, 2002, BIOL REPROD, V67, P189, DOI 10.1095/biolreprod67.1.189; FLACH G, 1982, EMBO J, V1, P681, DOI 10.1002/j.1460-2075.1982.tb01230.x; GATT S, 1963, J BIOL CHEM, V238, P3131; GATT S, 1966, J BIOL CHEM, V241, P3724; Gordo AC, 2002, BIOL REPROD, V66, P1828, DOI 10.1095/biolreprod66.6.1828; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HASSLER DF, 1993, ADV LIPID RES, V26, P49; Kattner E, 1997, EUR J PEDIATR, V156, P292, DOI 10.1007/s004310050603; Kerr J. F. R., 1994, CELL BIOL LAB HDB, P319; Koch J, 1996, J BIOL CHEM, V271, P33110, DOI 10.1074/jbc.271.51.33110; Li CM, 1999, GENOMICS, V62, P223, DOI 10.1006/geno.1999.5940; Li CM, 2002, GENOMICS, V79, P218, DOI 10.1006/geno.2002.6686; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Linke, 2001, METABOLIC MOL BASES, P3573; MARSTON JH, 1964, J EXP ZOOL, V155, P237, DOI 10.1002/jez.1401550211; Miao YL, 2005, BIOL REPROD, V73, P1025, DOI 10.1095/biolreprod.105.043703; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; Perez GI, 2005, FASEB J, V19, P860, DOI 10.1096/fj.04-2903fje; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Tarin JJ, 1999, BIOL REPROD, V61, P1347, DOI 10.1095/biolreprod61.5.1347; TELFORD NA, 1990, MOL REPROD DEV, V26, P90, DOI 10.1002/mrd.1080260113; van Lijnschoten G, 2000, PEDIATR DEVEL PATHOL, V3, P597, DOI 10.1007/s100240010107	27	72	84	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1403	1409		10.1096/fj.06-7016com	http://dx.doi.org/10.1096/fj.06-7016com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264167				2022-12-25	WOS:000246117000016
J	Olson, GE; Winfrey, VP; NagDas, SK; Hill, KE; Burk, RF				Olson, Gary E.; Winfrey, Virginia P.; NagDas, Subir K.; Hill, Kristina E.; Burk, Raymond F.			Apolipoprotein E receptor-2 (ApoER2) mediates selenium uptake from selenoprotein P by the mouse testis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPEROXIDE GLUTATHIONE-PEROXIDASE; E RECEPTOR 2; LIPOPROTEIN RECEPTOR; SPERM DEVELOPMENT; RAT PLASMA; PROTEIN; BINDING; SELENOCYSTEINE; REELIN; SPERMATOZOA	Selenium is a micronutrient that is essential for the production of normal spermatozoa. The selenium-rich plasma protein selenoprotein P ( Sepp1) is required for maintenance of testis selenium and for fertility of the male mouse. Sepp1 trafficking in the seminiferous epithelium was studied using conventional methods and mice with gene deletions. Immunocytochemistry demonstrated that Sepp1 is present in vesicle-like structures in the basal region of Sertoli cells, suggesting that the protein is taken up intact. Sepp1 affinity chromatography of a testicular extract followed by mass spectrometry-based identification of bound proteins identified apolipoprotein E receptor 2 ( ApoER2) as a candidate testis Sepp1 receptor. In situ hybridization analysis identified Sertoli cells as the only cell type in the seminiferous epithelium with detectable ApoER2 expression. Testis selenium levels in apoER2(-/-) males were sharply reduced from those in apoER2(-/-) males and were comparable with the depressed levels found in Sepp1(-/-) males. However, liver selenium levels were unchanged by deletion of apoER2. Immunocytochemistry did not detect Sepp1 in the Sertoli cells of apoER2(-/-) males, consistent with a defect in the receptor-mediated Sepp1 uptake pathway. Phase contrast microscopy revealed identical sperm defects in apoER2(-/-) and Sepp1(-/-) mice. Co-immunoprecipitation analysis demonstrated an interaction of testis ApoER2 with Sepp1. These data demonstrate that Sertoli cell ApoER2 is a Sepp1 receptor and a component of the selenium delivery pathway to spermatogenic cells.	Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Div Gastroenterol Hepatol & Nutr, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Olson, GE (corresponding author), Vanderbilt Univ, Dept Cell & Dev Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.	gary.olson@vanderbilt.edu			NICHD NIH HHS [HD044863] Funding Source: Medline; NIEHS NIH HHS [ES02497] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002497, R37ES002497] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Andersen OM, 2003, BIOCHEMISTRY-US, V42, P9355, DOI 10.1021/bi034475p; Andersen OM, 2003, J BIOL CHEM, V278, P23989, DOI 10.1074/jbc.M302157200; Beckett GJ, 2005, J ENDOCRINOL, V184, P455, DOI 10.1677/joe.1.05971; Beffert U, 2005, NEURON, V47, P567, DOI 10.1016/j.neuron.2005.07.007; Brandes C, 2001, J BIOL CHEM, V276, P22160, DOI 10.1074/jbc.M102662200; Burk RF, 2005, ANNU REV NUTR, V25, P215, DOI 10.1146/annurev.nutr.24.012003.132120; BURK RF, 1987, METHOD ENZYMOL, V143, P307; Chittum HS, 1996, ARCH BIOCHEM BIOPHYS, V325, P124, DOI 10.1006/abbi.1996.0015; Driscoll DM, 2003, ANNU REV NUTR, V23, P17, DOI 10.1146/annurev.nutr.23.011702.073318; Foresta C, 2002, BIOL REPROD, V67, P967, DOI 10.1095/biolreprod.102.003822; Guimaraes MJ, 1996, P NATL ACAD SCI USA, V93, P15086, DOI 10.1073/pnas.93.26.15086; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Himeno S, 1996, J BIOL CHEM, V271, P15769, DOI 10.1074/jbc.271.26.15769; Imai H, 2001, BIOL REPROD, V64, P674, DOI 10.1095/biolreprod64.2.674; KANALAS JJ, 1993, J BIOL CHEM, V268, P8188; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Kim HJ, 1998, J BIOCHEM-TOKYO, V124, P451, DOI 10.1093/oxfordjournals.jbchem.a022134; KOH TS, 1983, J ASSOC OFF ANA CHEM, V66, P918; Kohrle J, 2000, BIOL CHEM, V381, P849, DOI 10.1515/BC.2000.107; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; LOW SC, 1995, J BIOL CHEM, V270, P21659, DOI 10.1074/jbc.270.37.21659; Maiorino M, 1999, BIOFACTORS, V10, P251, DOI 10.1002/biof.5520100224; Maiorino M, 2003, BIOL REPROD, V68, P1134, DOI 10.1095/biolreprod.102.007500; May P, 2005, CELL MOL LIFE SCI, V62, P2325, DOI 10.1007/s00018-005-5231-z; Mihara H, 2000, J BIOL CHEM, V275, P6195, DOI 10.1074/jbc.275.9.6195; Moschos MP, 2000, CELL MOL LIFE SCI, V57, P1836, DOI 10.1007/PL00000665; Olson GE, 2005, BIOL REPROD, V73, P201, DOI 10.1095/biolreprod.105.040360; Olson GE, 2004, J BIOL CHEM, V279, P51266, DOI 10.1074/jbc.M410485200; READ R, 1990, J BIOL CHEM, V265, P17899; Schneider WJ, 2003, CELL MOL LIFE SCI, V60, P892, DOI 10.1007/s00018-003-2183-z; SHEEHAN TMT, 1990, CLIN CHEM, V36, P2124; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; URSINI F, 1999, SCIENCE, V277, P225; WILSON DS, 1993, J INORG BIOCHEM, V51, P707, DOI 10.1016/0162-0134(93)85003-Q	37	167	177	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12290	12297		10.1074/jbc.M611403200	http://dx.doi.org/10.1074/jbc.M611403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314095	hybrid			2022-12-25	WOS:000245941900071
J	Ha, SW; Korbas, M; Klepsch, M; Meyer-Klaucke, W; Meyer, O; Svetlitchnyi, V				Ha, Seung-Wook; Korbas, Malgorzata; Klepsch, Mirjam; Meyer-Klaucke, Wolfram; Meyer, Ortwin; Svetlitchnyi, Vitali			Interaction of potassium cyanide with the [Ni-4Fe-5S] active site cluster of CO dehydrogenase from Carboxydothermus hydrogenoformans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; RAY-ABSORPTION SPECTROSCOPY; CLOSTRIDIUM-THERMOACETICUM; RHODOSPIRILLUM-RUBRUM; NICKEL; COMPLEXES; SYNTHASE; ENDOR; AZIDE; LIFE	The Ni-Fe carbon monoxide ( CO) dehydrogenase II ( CODHIICh) from the anaerobic CO-utilizing hydrogenogenic bacterium Carboxydothermus hydrogenoformans catalyzes the oxidation of CO, presumably at the Ni-(mu S-2)-Fe1 subsite of the [ Ni-4S-5S] cluster in the active site. The CO oxidation mechanism proposed on the basis of several CODHIICh crystal structures involved the apical binding of CO at the nickel ion and the activation of water at the Fe1 ion of the cluster. To understand how CO interacts with the active site, we have studied the reactivity of the cluster with potassium cyanide and analyzed the resulting type of nickel coordination by x-ray absorption spectroscopy. Cyanide acts as a competitive inhibitor of reduced CODHIICh with respect to the substrate CO and is therefore expected to mimic the substrate. It inhibits the enzyme reversibly, forming a nickel cyanide. In this reaction, one of the four square-planar sulfur ligands of nickel is replaced by the carbon atom of cyanide, suggesting removal of the mu S-2 from the Ni-(mu S-2)-Fe1 subsite. Upon reactivation of the inhibited enzyme, cyanide is released, and the square-planar coordination of nickel by 4S ligands is recovered, which includes the reformation of the Ni-(mu S-2)-Fe1 bridge. The results are summarized in a model of the CO oxidation mechanism at the [ Ni-4Fe-5S] active site cluster of CODHIICh from C. hydrogenoformans.	Univ Bayreuth, Lehrstuhl Mikrobiol, D-95440 Bayreuth, Germany; Univ Bayreuth, BZMB, D-95440 Bayreuth, Germany; DESY, EMBL, D-22603 Hamburg, Germany	University of Bayreuth; University of Bayreuth; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Svetlitchnyi, V (corresponding author), Univ Bayreuth, Lehrstuhl Mikrobiol, Univ Str 30, D-95440 Bayreuth, Germany.	vitali.svetlitchnyi@uni-bayreuth.de	Meyer-Klaucke, Wolfram/G-1148-2010; Korbas, Malgorzata/B-4024-2009	Korbas, Malgorzata/0000-0003-3064-0132				ANDERSON ME, 1993, J AM CHEM SOC, V115, P12204, DOI 10.1021/ja00078a085; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASTAIN BB, 1968, J AM CHEM SOC, V90, P3994, DOI 10.1021/ja01017a015; COLPAS GJ, 1991, INORG CHEM, V30, P920, DOI 10.1021/ic00005a010; Darnault C, 2003, NAT STRUCT BIOL, V10, P271, DOI 10.1038/nsb912; DeRose VJ, 1998, J AM CHEM SOC, V120, P8767, DOI 10.1021/ja9731480; Dobbek H, 2001, SCIENCE, V293, P1281, DOI 10.1126/science.1061500; Dobbek H, 2004, J AM CHEM SOC, V126, P5382, DOI 10.1021/ja037776v; Dobbek H, 2002, P NATL ACAD SCI USA, V99, P15971, DOI 10.1073/pnas.212640899; Doukov TI, 2002, SCIENCE, V298, P567, DOI 10.1126/science.1075843; Drennan CL, 2001, P NATL ACAD SCI USA, V98, P11973, DOI 10.1073/pnas.211429998; ENSIGN SA, 1989, BIOCHEMISTRY-US, V28, P4973, DOI 10.1021/bi00438a011; Fan Y, 2004, CHEM-EUR J, V10, P1805, DOI 10.1002/chem.200304840; Feng J, 2004, J AM CHEM SOC, V126, P9094, DOI 10.1021/ja048811g; Gnida M, 2003, BIOCHEMISTRY-US, V42, P222, DOI 10.1021/bi026514n; Gu WW, 2004, BIOCHEMISTRY-US, V43, P9029, DOI 10.1021/bi036104e; HALCROW MA, 1994, CHEM REV, V94, P2421, DOI 10.1021/cr00032a008; Hu ZG, 1996, J AM CHEM SOC, V118, P830, DOI 10.1021/ja9528386; Kim EJ, 2004, BIOCHEMISTRY-US, V43, P5728, DOI 10.1021/bi036062u; Korbas M, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2209954; LAX E, 1967, DANS LAX TASCHENBUCH, V1, P1; MEYER O, 1982, J BIOL CHEM, V257, P1333; Ragsdale SW, 2004, CRIT REV BIOCHEM MOL, V39, P165, DOI 10.1080/10409230490496577; Ragsdale SW, 1996, CHEM REV, V96, P2515, DOI 10.1021/cr950058+; Resch M, 2005, J BIOL INORG CHEM, V10, P518, DOI 10.1007/s00775-005-0006-4; Sellmann D, 2000, CHEM-EUR J, V6, P4279, DOI 10.1002/1521-3765(20001201)6:23<4279::AID-CHEM4279>3.0.CO;2-S; Shores MP, 2002, J AM CHEM SOC, V124, P2279, DOI 10.1021/ja011645h; STERN EA, 1993, PHYS REV B, V48, P9825, DOI 10.1103/PhysRevB.48.9825; SVETLICHNY VA, 1991, SYST APPL MICROBIOL, V14, P254, DOI 10.1016/S0723-2020(11)80377-2; Svetlitchnyi V, 2004, P NATL ACAD SCI USA, V101, P446, DOI 10.1073/pnas.0304262101; Svetlitchnyi V, 2001, J BACTERIOL, V183, P5134, DOI 10.1128/JB.183.17.5134-5144.2001; Volbeda A, 2005, DALTON T, P3443, DOI 10.1039/b508403b	33	35	36	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10639	10646		10.1074/jbc.M610641200	http://dx.doi.org/10.1074/jbc.M610641200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17277357	hybrid			2022-12-25	WOS:000245941000058
J	Islam, A; Shen, XY; Hiroi, T; Moss, J; Vaughan, M; Levine, SJ				Islam, Aminul; Shen, Xiaoyan; Hiroi, Toyoko; Moss, Joel; Vaughan, Martha; Levine, Stewart J.			The brefeldin A-inhibited guanine nucleotide-exchange protein, BIG2, regulates the constitutive release of TNFR1 exosome-like vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; ADP-RIBOSYLATION FACTOR; FACTOR-BINDING-PROTEIN; TRANS-GOLGI NETWORK; FACTOR RECEPTOR; ENDOPLASMIC-RETICULUM; RECYCLING ENDOSOMES; CELL-SURFACE; SOLUBLE FORM; TRAFFICKING	The type 1, 55-kDa tumor necrosis factor receptor (TNFR1) is released from cells to the extracellular space where it can bind and modulate TNF bioactivity. Extracellular TNFR1 release occurs by two distinct pathways: the inducible proteolytic cleavage of TNFR1 ectodomains and the constitutive release of full-length TNFR1 in exosome-like vesicles. Regulation of both TNFR1 release pathways appears to involve the trafficking of cytoplasmic TNFRI vesicles. Vesicular trafficking is controlled by ADP-ribosylation factors (ARFs), which are active in the GTP-bound state and inactive when bound to GDP. ARF activation is enhanced by guanine nucleotide-exchange factors that catalyze replacement of GDP by GTP. We investigated whether the brefeldin A (BFA)-inhibited guanine nucleotide-exchange proteins, BIG1 and/or BIG2, are required for TNFRI release from human umbilical vein endothelial cells. Effects of specific RNA interference (RNAi) showed that BIG2, but not BIG1, regulated the release of TNFR1 exosome-like vesicles, whereas neither BIG2 nor BIG1 was required for the IL-1 beta-induced proteolytic cleavage of TNFRI ectodomains. BIG2 co-localized with TNFRI in diffusely distributed cytoplasmic vesicles, and the association between BIG2 and TNFRI was disrupted by BFA. Consistent with the preferential activation of class I ARFs by BIG2, ARF1 and ARF3 participated in the extracellular release of TNFR1 exosome-like vesicles in a nonredundant and additive fashion. We conclude that the association between BIG2 and TNFRI selectively regulates the extracellular release of TNFR1 exosome-like vesicles from human vascular endothelial cells via an ARF1- and ARF3-dependent mechanism.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levine, SJ (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10,Rm 6D03,MSC 1590, Bethesda, MD 20892 USA.	levines@nhlbi.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002544, Z01HL000627, ZIAHL000627, Z01HL002544] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALCH WE, 1992, J BIOL CHEM, V267, P13053; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; Cui XL, 2002, J CLIN INVEST, V110, P515, DOI 10.1172/JCI200213847; DASCHER C, 1994, J BIOL CHEM, V269, P1437; Denzer K, 2000, J CELL SCI, V113, P3365; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; Furman C, 2002, J BIOL CHEM, V277, P7962, DOI 10.1074/jbc.M109149200; Gould SJ, 2003, P NATL ACAD SCI USA, V100, P10592, DOI 10.1073/pnas.1831413100; Hawari FI, 2004, P NATL ACAD SCI USA, V101, P1297, DOI 10.1073/pnas.0307981100; Islam A, 2006, J BIOL CHEM, V281, P6860, DOI 10.1074/jbc.M509397200; LANTZ M, 1990, J CLIN INVEST, V86, P1396, DOI 10.1172/JCI114853; Levine SJ, 2005, AM J PHYSIOL-LUNG C, V289, pL233, DOI 10.1152/ajplung.00469.2004; Levine SJ, 1996, AM J RESP CELL MOL, V14, P254, DOI 10.1165/ajrcmb.14.3.8845176; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; OLSSON I, 1989, EUR J HAEMATOL, V42, P270, DOI 10.1111/j.1600-0609.1989.tb00111.x; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; Sheen VL, 2004, NAT GENET, V36, P69, DOI 10.1038/ng1276; Shen XY, 2006, P NATL ACAD SCI USA, V103, P2635, DOI 10.1073/pnas.0510599103; Shin HW, 2004, MOL BIOL CELL, V15, P5283, DOI 10.1091/mbc.E04-05-0388; Shinotsuka C, 2002, BIOCHEM BIOPH RES CO, V294, P254, DOI 10.1016/S0006-291X(02)00456-4; Shinotsuka C, 2002, J BIOL CHEM, V277, P9468, DOI 10.1074/jbc.M112427200; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Togawa A, 1999, J BIOL CHEM, V274, P12308, DOI 10.1074/jbc.274.18.12308; Volpicelli-Daley LA, 2005, MOL BIOL CELL, V16, P4495, DOI 10.1091/mbc.E04-12-1042; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WALLACH D, 1991, TUMOR NECROSIS FACTO, P47; Wang J, 2003, J BIOL CHEM, V278, P21751, DOI 10.1074/jbc.M212662200; Xu KF, 2005, P NATL ACAD SCI USA, V102, P2784, DOI 10.1073/pnas.0409871102; Yamaji R, 2000, P NATL ACAD SCI USA, V97, P2567, DOI 10.1073/pnas.97.6.2567	41	43	47	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9591	9599		10.1074/jbc.M607122200	http://dx.doi.org/10.1074/jbc.M607122200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276987	hybrid			2022-12-25	WOS:000245421700032
J	Wu, L; Xiao, BT; Jia, XL; Zhang, Y; Lu, SQ; Chen, J; Long, M				Wu, Li; Xiao, Botao; Jia, Xiaoling; Zhang, Yan; Lu, Shouqin; Chen, Juan; Long, Mian			Impact of carrier stiffness and microtopology on two-dimensional kinetics of P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1) interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHILS; BINDING; ADHESION; AFFINITY; RATES	Mechanics and surface microtopology of the molecular carrier influence cell adhesion, but the mechanisms underlying these effects are not well understood. We used a micropipette adhesion frequency assay to quantify how the carrier stiffness and microtopology affected two-dimensional kinetics of interacting adhesion molecules on two apposing surfaces. Interactions of P-selectin with P-selectin glycoprotein ligand-1 (PSGL-1) were used to demonstrate such effects by presenting the molecules on three carrier systems: human red blood cells (RBCs), human promyelocytic leukemia HL-60 cells, and polystyrene beads. Stiffening the carrier alone or in cooperation with roughing the surface lowered the two-dimensional affinity of interacting molecules by reducing the forward rate but not the reverse rate, whereas softening the carrier and roughing the surface had opposing effects in affecting two-dimensional kinetics. In contrast, the soluble antibody bound with similar three-dimensional affinity to surface-anchored P-selectin or PSGL-1 constructs regardless of carrier stiffness and microtopology. These results demonstrate that the carrier stiffness and microtopology of a receptor influences its rate of encountering and binding a surface ligand but does not subsequently affect the stability of binding. This provides new insights into understanding the rolling and tethering mechanism of leukocytes onto endothelium in both physiological and pathological processes.	Chinese Acad Sci, Inst Mech, Natl Micrograv Lab, Beijing 100080, Peoples R China; Chinese Acad Sci, Inst Mech, Ctr Biomech & Bioengn, Beijing 100080, Peoples R China	Chinese Academy of Sciences; Institute of Mechanics, CAS; Chinese Academy of Sciences; Institute of Mechanics, CAS	Long, M (corresponding author), Chinese Acad Sci, Inst Mech, Natl Micrograv Lab, Beijing 100080, Peoples R China.	mlong@imech.ac.cn	Xiao, Botao/F-4667-2010	Xiao, Botao/0000-0002-0785-1006				Chesla SE, 2000, J BIOL CHEM, V275, P10235, DOI 10.1074/jbc.275.14.10235; Chesla SE, 1998, BIOPHYS J, V75, P1553, DOI 10.1016/S0006-3495(98)74074-3; Dumaswala UJ, 1996, BLOOD, V88, P697, DOI 10.1182/blood.V88.2.697.bloodjournal882697; Epperson TR, 2000, J BIOL CHEM, V275, P7839, DOI 10.1074/jbc.275.11.7839; Finger EB, 1996, J IMMUNOL, V157, P5085; GENG JG, 1990, NATURE, V343, P757, DOI 10.1038/343757a0; GRETCH DR, 1987, ANAL BIOCHEM, V163, P270, DOI 10.1016/0003-2697(87)90123-0; Hanley W, 2003, J BIOL CHEM, V278, P10556, DOI 10.1074/jbc.M213233200; Huang J, 2004, J BIOL CHEM, V279, P44915, DOI 10.1074/jbc.M407039200; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; KOFLER R, 1977, J IMMUNOL METHODS, V16, P201, DOI 10.1016/0022-1759(77)90198-3; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; LI SH, 1994, J BIOL CHEM, V269, P4431; Long M, 2001, ANN BIOMED ENG, V29, P935, DOI 10.1114/1.1415529; Long MA, 1999, BIOPHYS J, V76, P1112, DOI 10.1016/S0006-3495(99)77276-0; Long M, 2006, BIOPHYS J, V91, P352, DOI 10.1529/biophysj.106.082909; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; Merkel R, 2001, PHYS REP, V346, P344; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NAGARAJAN S, 1995, J BIOL CHEM, V270, P25762, DOI 10.1074/jbc.270.43.25762; Park EYH, 2002, BIOPHYS J, V82, P1835, DOI 10.1016/S0006-3495(02)75534-3; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; Shao JY, 1998, P NATL ACAD SCI USA, V95, P6797, DOI 10.1073/pnas.95.12.6797; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; Williams TE, 2000, BIOPHYS J, V79, P1858, DOI 10.1016/S0006-3495(00)76435-6; Williams TE, 2001, J BIOL CHEM, V276, P13283, DOI 10.1074/jbc.M010427200; Zhu C, 2002, ANN BIOMED ENG, V30, P305, DOI 10.1114/1.1467923	29	48	54	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9846	9854		10.1074/jbc.M609219200	http://dx.doi.org/10.1074/jbc.M609219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17267403	hybrid, Green Published			2022-12-25	WOS:000245421700059
J	Hou, YZ; Gao, FQ; Wang, QH; Zhao, JF; Flagg, T; Zhang, YD; Deng, XM				Hou, Yongzhong; Gao, Fengqin; Wang, Qinhong; Zhao, Jinfeng; Flagg, Tammy; Zhang, Yangde; Deng, Xingming			Bcl2 impedes DNA mismatch repair by directly regulating the hMSH2-hMSH6 heterodimeric complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERPHASE NUCLEI; EXCISION-REPAIR; PROTEIN; EXPRESSION; APOPTOSIS; CELLS; MICE; PHOSPHORYLATION; RECOMBINATION; SUPPRESSION	Bcl2 has been reported to suppress DNA mismatch repair (MMR) with promotion of mutagenesis, but the mechanism(s) is not fully understood. MutS alpha is the hMSH2-hMSH6 heterodimer that primarily functions to correct mutations that escape the proofreading activity of DNA polymerase. Here we have discovered that Bc12 potently suppresses MMR in association with decreased MutSa activity and increased mutagenesis. Exposure of cells to nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone results in accumulation of Bc12 in the nucleus, which interacts with hMSH6 but not hMSH2 via its BH4 domain. Deletion of the BH4 domain from Bcl2 abrogates the ability of Bcl2 to interact with hMSH6 and is associated with enhanced MMR efficiency and decreased mutation frequency. Overexpression of Bcl2 reduces formation of the hMSH2-hMSH6 complex in cells, and purified Bcl2 protein directly disrupts the hMSH2-hMSH6 complex and suppresses MMR in vitro. Importantly, depletion of endogenous Bcl2 by RNA interference enhances formation of the hMSH2-hMSH6 complex in association with increased MMR and decreased mutagenesis. Thus, Bc12 suppression of MMR may occur in a novel mechanism by directly regulating the heterodimeric hMSH2-hMSH6 complex, which potentially contributes to genetic instability and carcinogenesis.	Univ Florida, Shands Canc Ctr, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Deng, XM (corresponding author), Univ Florida, Shands Canc Ctr, Dept Med, 1376 Mowry Rd,Canc Genet Res Complex,Rm 262,POB 1, Gainesville, FL 32610 USA.	xdeng@ufl.edu	hou, YONGZHONG/K-7771-2013; hou, yongzhong/E-4658-2011	Hou, Yongzhong/0000-0003-2019-8686	NCI NIH HHS [R01 CA112183] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA112183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Castrilli G, 2001, J ORAL PATHOL MED, V30, P305, DOI 10.1034/j.1600-0714.2001.300508.x; Chang IY, 2005, NUCLEIC ACIDS RES, V33, P5073, DOI 10.1093/nar/gki829; CHEBONNELLASSER.C, 1996, ONCOGENE, V13, P1489; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; Deng XM, 2006, MOL CELL BIOL, V26, P4421, DOI 10.1128/MCB.01647-05; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Harfe BD, 2000, ANNU REV GENET, V34, P359, DOI 10.1146/annurev.genet.34.1.359; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hoetelmans RWM, 2000, CELL DEATH DIFFER, V7, P384, DOI 10.1038/sj.cdd.4400664; Jin ZH, 2004, J BIOL CHEM, V279, P40209, DOI 10.1074/jbc.M404056200; Jin ZH, 2006, J BIOL CHEM, V281, P14446, DOI 10.1074/jbc.M511914200; JORQUERA R, 1994, CARCINOGENESIS, V15, P389, DOI 10.1093/carcin/15.2.389; Kaklamanis L, 1996, J PATHOL, V179, P10; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243; Kuo ML, 1999, MOL PHARMACOL, V55, P894; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; Liu YF, 1997, CANCER RES, V57, P1650; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; Mijal RS, 2004, CHEM RES TOXICOL, V17, P424, DOI 10.1021/tx0342417; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Raffoul JJ, 2004, J BIOL CHEM, V279, P18425, DOI 10.1074/jbc.M313983200; ROTH EP, 2005, MOL CELL BIOL, V25, P3596; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Schandl CA, 1999, J HISTOCHEM CYTOCHEM, V47, P151, DOI 10.1177/002215549904700204; Shin KH, 2004, CLIN CANCER RES, V10, P2551, DOI 10.1158/1078-0432.CCR-0669-3; Snowden T, 2004, MOL CELL, V15, P437, DOI 10.1016/j.molcel.2004.06.040; STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Youn CK, 2005, NAT CELL BIOL, V7, P137, DOI 10.1038/ncb1215; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x	36	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9279	9287		10.1074/jbc.M608523200	http://dx.doi.org/10.1074/jbc.M608523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17259174	hybrid			2022-12-25	WOS:000245780300075
J	Onwuegbusi, BA; Rees, JRE; Lao-Sirieix, P; Fitzgerald, RC				Onwuegbusi, Benjamin A.; Rees, Jonathan R. E.; Lao-Sirieix, Pierre; Fitzgerald, Rebecca C.			Selective Loss of TGF beta Smad-Dependent Signalling Prevents Cell Cycle Arrest and Promotes Invasion in Oesophageal Adenocarcinoma Cell Lines	PLOS ONE			English	Article								In cancer, Transforming Growth Factor beta (TGF beta) increases proliferation and promotes invasion via selective loss of signalling pathways. Oesophageal adenocarcinoma arises from Barrett's oesophagus, progresses rapidly and is usually fatal. The contribution of perturbed TGF beta signalling in the promotion of metastasis in this disease has not been elucidated. We therefore investigated the role of TGF beta in Barrett's associated oesophageal adenocarcinoma using a panel of cell lines (OE33, TE7, SEG, BIC, FLO). 4/5 adenocarcinoma cell lines failed to cell cycle arrest, down-regulate c-Myc or induce p21 in response to TGF beta, and modulation of a Smad3/4 specific promoter was inhibited. These hyperproliferative adenocarcinoma cell lines displayed a TGF beta induced increase in the expression of the extracellular matrix degrading proteinases, urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1), which correlated with an invasive cell phenotype as measured by in vitro migration, invasion and cell scattering assays. Inhibiting ERK and JNK pathways significantly reduced PAI and uPA induction and inhibited the invasive cell phenotype. These results suggest that TGF beta Smad-dependent signalling is perturbed in Barrett's carcinogenesis, resulting in failure of growth-arrest. However, TGF beta can promote PAI and uPA expression and invasion through MAPK pathways. These data would support a dual role for TGF beta in oesophageal adenocarcinoma.	[Onwuegbusi, Benjamin A.; Rees, Jonathan R. E.; Lao-Sirieix, Pierre; Fitzgerald, Rebecca C.] Hutchison MRC Res Ctr, MRC Canc Cell Unit, Cambridge, England		Fitzgerald, RC (corresponding author), Hutchison MRC Res Ctr, MRC Canc Cell Unit, Cambridge, England.	rcf@hutchison-mrc.cam.ac.uk		Fitzgerald, Rebecca/0000-0002-3434-3568	Medical Research Council; MRC [MC_U105365007] Funding Source: UKRI; Medical Research Council [MC_U105365007] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The Medical Research Council funded this work.	Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Arts J, 1996, EUR J BIOCHEM, V241, P393, DOI 10.1111/j.1432-1033.1996.00393.x; Bailey T, 1998, AM J PATHOL, V152, P135; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BOTEBORG T, 2000, CELL AGGREGATION ASS, P33; Chazaud B, 2002, AM J PATHOL, V160, P237, DOI 10.1016/S0002-9440(10)64367-2; Chen LQ, 2001, ANN SURG, V234, P172, DOI 10.1097/00000658-200108000-00006; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Duffy MJ, 2002, BIOCHEM SOC T, V30, P207, DOI 10.1042/BST0300207; Edmiston JS, 2005, CANCER RES, V65, P4782, DOI 10.1158/0008-5472.CAN-04-4354; Farina AR, 1998, INT J CANCER, V75, P721; Festuccia C, 2000, INT J CANCER, V85, P407, DOI 10.1002/(SICI)1097-0215(20000201)85:3<407::AID-IJC18>3.0.CO;2-8; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hewin DF, 1996, BRIT J SURG, V83, P1152, DOI 10.1002/bjs.1800830838; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kutz SM, 2001, J CELL SCI, V114, P3905; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; Morrissey D, 1999, CLIN EXP METASTAS, V17, P77; MULDER KM, 1992, J BIOL CHEM, V267, P5029; NAKAMURA T, 1994, CANCER-AM CANCER SOC, V73, P1785, DOI 10.1002/1097-0142(19940401)73:7<1785::AID-CNCR2820730703>3.0.CO;2-0; NERLOV C, 1991, ONCOGENE, V6, P1583; O'Shaughnessy JA, 2002, CLIN CANCER RES, V8, P314; Onwuegbusi BA, 2006, GUT, V55, P764, DOI 10.1136/gut.2005.076430; Providence KM, 2000, J CELL PHYSIOL, V182, P269, DOI 10.1002/(SICI)1097-4652(200002)182:2<269::AID-JCP16>3.0.CO;2-E; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sliva D, 2002, J BIOL CHEM, V277, P3150, DOI 10.1074/jbc.M109579200; Torquati A, 2004, SURGERY, V136, P310, DOI 10.1016/j.surg.2004.05.005; Wang L, 2004, ONCOGENE, V23, P5978, DOI 10.1038/sj.onc.1207802; WESTERHAUSEN DR, 1991, J BIOL CHEM, V266, P1092; Witowsky J, 2003, J BIOL CHEM, V278, P5941, DOI 10.1074/jbc.M212363200; Yang YM, 2003, CLIN CANCER RES, V9, P391; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	36	26	27	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2007	2	1							e177	10.1371/journal.pone.0000177	http://dx.doi.org/10.1371/journal.pone.0000177			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DH	17264880	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444200002
J	Tews, B; Roerig, P; Hartmann, C; Hahn, M; Felsberg, J; Blaschke, B; Sabel, M; Kunitz, A; Toedt, G; Neben, K; Benner, A; von Deimling, A; Reifenberger, G; Lichter, P				Tews, B.; Roerig, P.; Hartmann, C.; Hahn, M.; Felsberg, J.; Blaschke, B.; Sabel, M.; Kunitz, A.; Toedt, G.; Neben, K.; Benner, A.; von Deimling, A.; Reifenberger, G.; Lichter, P.			Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q	ONCOGENE			English	Article						CITED4; gene expression profiling; oligodendroglioma; CpG island; hypermethylation; tumour suppressor gene	PHASE-III TRIAL; ANAPLASTIC OLIGODENDROGLIOMAS; MGMT GENE; EXPRESSION; SUPPRESSOR; CANCER; SURVIVAL; IDENTIFICATION; 19Q13.3; GLIOMAS	Deletions of chromosomal arms 1p and 19q are frequent in oligodendroglial tumours and have been associated with sensitivity to radio- and chemotherapy as well as favourable prognosis. By using microarray-based expression pro. ling, we found that oligodendroglial tumours with 1p and 19q losses showed signi. cantly lower expression of the CBP/p300-interacting transactivator with glutamic acid/ aspartic acid-rich carboxyl-terminal domain 4 gene (CITED4) at 1p34.2 as compared to tumours without 1p and 19q losses. Mutational analysis showed no CITED4 mutations in gliomas. However, 1p and 19q losses as well as low expression of CITED4 transcripts were significantly associated with hypermethylation of the CITED4-associated CpG island. In line with the latter. nding, treatment of CITED4 hypermethylated glioma cell lines with 5-aza-2'-deoxycytidine and trichostatine A resulted in a marked increase of the CITED4 transcript levels. Furthermore, CITED4 hypermethylation was signi. cantly associated with longer recurrence-free and overall survival of patients with oligodendroglial tumours. Taken together, our results indicate that CITED4 is epigenetically silenced in the vast majority of oligodendroglial tumours with 1p and 19q deletions and suggest CITED4 hypermethylation as a novel prognostic marker in oligodendroglioma patients.	Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany; Deutches Krebsforschungszentrum, Div Mol Genet B060, Heidelberg, Germany; Univ Med Berlin, Charite, Dept Neuropathol, Berlin, Germany; Univ Dusseldorf, Dept Neurosurg, D-4000 Dusseldorf, Germany; Deutches Krebsforschungszentrum, Cent Unit Biostat, C060, Heidelberg, Germany	Heinrich Heine University Dusseldorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Reifenberger, G (corresponding author), Univ Dusseldorf, Dept Neuropathol, Moorenstr 5, D-40225 Dusseldorf, Germany.	reifenberger@med.uni-duesseldorf.de	von Deimling, Andreas/F-7774-2013; Reifenberger, Guido/AAE-3599-2019; Hartmann, Christian/D-1882-2010	von Deimling, Andreas/0000-0002-5863-540X; 	PHS HHS [01GS0462, 01GS0463, 01GS0460] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alaminos M, 2005, CANCER RES, V65, P2565, DOI 10.1158/0008-5472.CAN-04-4283; Barbashina V, 2005, CLIN CANCER RES, V11, P1119; Braga D, 2002, CRYSTENGCOMM, V4, P277, DOI 10.1039/b201547a; Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Dong SM, 2002, INT J CANCER, V98, P370, DOI 10.1002/ijc.10204; Felsberg J, 2004, BRAIN PATHOL, V14, P121, DOI 10.1111/j.1750-3639.2004.tb00044.x; Fox SB, 2004, CANCER RES, V64, P6075, DOI 10.1158/0008-5472.CAN-04-0708; Griffin CA, 2006, J NEUROPATH EXP NEUR, V65, P988, DOI 10.1097/01.jnen.0000235122.98052.8f; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jenkins RB, 2006, CANCER RES, V66, P9852, DOI 10.1158/0008-5472.CAN-06-1796; McDonald JM, 2006, CANCER BIOL THER, V5, P300, DOI 10.4161/cbt.5.3.2391; McDonald JM, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-35; Mollemann M, 2005, INT J CANCER, V113, P379, DOI 10.1002/ijc.20575; R Development Core Team, 2005, LANG ENV STAT COMP; Reifenberger G, 2003, J NEUROPATH EXP NEUR, V62, P111, DOI 10.1093/jnen/62.2.111; REIFENBERGER G, 2000, WHO CLASSIFICATION T, P55; Tews B, 2006, INT J CANCER, V119, P792, DOI 10.1002/ijc.21901; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van den Bent MJ, 2006, J CLIN ONCOL, V24, P2715, DOI 10.1200/JCO.2005.04.6078; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Wolf RM, 2003, GENE DEV, V17, P476, DOI 10.1101/gad.1040003	25	32	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					5010	5016		10.1038/sj.onc.1210297	http://dx.doi.org/10.1038/sj.onc.1210297			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17311001				2022-12-25	WOS:000248322500013
J	Weber, ANR; Gangloff, M; Moncrieffe, MC; Hyvert, Y; Imler, JL; Gay, NJ				Weber, Alexander N. R.; Gangloff, Monique; Moncrieffe, Martin C.; Hyvert, Yann; Imler, Jean-Luc; Gay, Nicholas J.			Role of the Spatzle pro-domain in the generation of an active toll receptor ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL-VENTRAL POLARITY; NERVE GROWTH-FACTOR; DROSOPHILA EMBRYO; SIGNALING PATHWAY; INNATE IMMUNITY; CELL FATE; ACTIVATION; PROTEIN; GRADIENT; SEQUENCE	The cytokine Spatzle is the ligand for Drosophila Toll, the prototype of an important family of membrane receptors that function in embryonic patterning and innate immunity. A dimeric precursor of Spatzle is processed by an endoprotease to produce a form (C-106) that cross-links Toll receptor ectodomains and establishes signaling. Here we show that before processing the pro-domain of Spatzle is required for correct biosynthesis and secretion. We mapped two loss-of-function mutations of Spatzle to a discrete site in the pro-domain and showed that the phenotype arises because of a defect in biosynthesis rather than signaling. We also report that the pro-domain and C-106 remain associated after cleavage and that this processed complex signals with the same characteristics as the C-terminal fragment. These results suggest that before activation the determinants on C-106 that bind specifically to Toll are sequestered by the pro-domain and that proteolytic processing causes conformational rearrangements that expose these determinants and enables binding to Toll. Furthermore, we show that the pro-domain is released when the Toll extracellular domain binds to the complex, a finding that has implications for the generation of a signaling-competent Toll dimer.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; CNRS, UPR 9022, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; German Canc Res Ctr, D-69242 Heidelberg, Germany	University of Cambridge; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Helmholtz Association; German Cancer Research Center (DKFZ)	Gay, NJ (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	njg11@mole.bio.cam.ac.uk	Imler, Jean-Luc/GXH-4323-2022	Weber, Alexander/0000-0002-8627-7056; Gangloff, Monique/0000-0001-6131-0115	MRC [G0400007] Funding Source: UKRI; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044220] Funding Source: NIH RePORTER; Medical Research Council [G1000133, G0400007] Funding Source: Medline; NIAID NIH HHS [P01 AI44220] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; CARROLL SB, 1987, DEVELOPMENT, V99, P327; Chang AJ, 2002, DEVELOPMENT, V129, P5635, DOI 10.1242/dev.00161; CHASAN R, 1992, DEVELOPMENT, V115, P607; DeLotto Y, 2001, MOL GEN GENET, V264, P643, DOI 10.1007/s004380000350; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; Dissing M, 2001, EMBO J, V20, P2387, DOI 10.1093/emboj/20.10.2387; DOUGHERTY WG, 1989, VIROLOGY, V172, P145, DOI 10.1016/0042-6822(89)90116-5; Gay NJ, 2006, NAT REV IMMUNOL, V6, P693, DOI 10.1038/nri1916; GIERER A, 1972, KYBERNETIK, V12, P30, DOI 10.1007/BF00289234; He XL, 2004, SCIENCE, V304, P870, DOI 10.1126/science.1095190; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jang IH, 2006, DEV CELL, V10, P45, DOI 10.1016/j.devcel.2005.11.013; Kapust RB, 2001, PROTEIN ENG, V14, P993, DOI 10.1093/protein/14.12.993; Kirk P, 2005, IMMUNITY, V23, P347, DOI 10.1016/j.immuni.2005.09.008; KLIEMANNEL M, 2007, IN PRESS PROTEIN SCI; Lawrence DA, 2001, MOL CELL BIOCHEM, V219, P163, DOI 10.1023/A:1010819716023; LeMosy EK, 2001, P NATL ACAD SCI USA, V98, P5055, DOI 10.1073/pnas.081026598; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Mizuguchi K, 1998, TRENDS BIOCHEM SCI, V23, P239, DOI 10.1016/S0968-0004(98)01216-X; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Morisato D, 2001, DEVELOPMENT, V128, P2309; Moussian B, 2005, CURR BIOL, V15, pR887, DOI 10.1016/j.cub.2005.10.026; Paoletti F, 2006, BIOCHEM SOC T, V34, P605, DOI 10.1042/BST0340605; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Rattenholl A, 2001, J MOL BIOL, V305, P523, DOI 10.1006/jmbi.2000.4295; Rose T, 2003, J BIOL CHEM, V278, P11320, DOI 10.1074/jbc.M211820200; SCHNEIDER DS, 1994, DEVELOPMENT, V120, P1243; STROUD RM, 1977, ANNU REV BIOPHYS BIO, V6, P177, DOI 10.1146/annurev.bb.06.060177.001141; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; Taylor WR, 1997, J MOL BIOL, V269, P902, DOI 10.1006/jmbi.1997.1008; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; Weber ANR, 2005, J BIOL CHEM, V280, P22793, DOI 10.1074/jbc.M502074200; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955	36	39	42	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13522	13531		10.1074/jbc.M700068200	http://dx.doi.org/10.1074/jbc.M700068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17324925	hybrid			2022-12-25	WOS:000246060300041
J	Mellott, TJ; Follettie, MT; Diesl, V; Hill, AA; Lopez-Coviella, I; Blusztajn, JK				Mellott, Tiffany J.; Follettie, Maximillian T.; Diesl, Veronica; Hill, Andrew A.; Lopez-Coviella, Ignacio; Krzysztof Blusztajn, Jan			Prenatal choline availability modulates hippocampal and cerebral cortical gene expression	FASEB JOURNAL			English	Article						microarray; memory; nutrition; development; pregnancy	LONG-TERM POTENTIATION; II MUTANT MICE; PROTEIN-KINASE-II; CALMODULIN-DEPENDENT KINASE; GROWTH-FACTOR-I; DNA METHYLATION; SPLICE VARIANTS; MESSENGER-RNA; RAT-BRAIN; ACETYLCHOLINE-RELEASE	An increased supply of the essential nutrient choline during fetal development [ embryonic day ( E) 11 - 17] in rats causes life-long improvements in memory performance, whereas choline deficiency during this time impairs certain aspects of memory. We analyzed mRNA expression in brains of prenatally choline- deficient, choline- supplemented, or control rats of various ages [ postnatal days ( P) 1 to 34 for hippocampus and E16 to P34 for cortex] using oligonucleotide microarrays and found alterations in gene expression levels evoked by prenatal choline intake that were, in most cases, transient occurring during the P15- P34 period. We selected a subset of genes, encoding signaling proteins, and verified the microarray data by reverse transcriptase- polymerase chain reaction analyses. Prenatally choline- supplemented rats had the highest expression of calcium/ calmodulin ( CaM)- dependent protein kinase ( CaMK) I and insulin- like growth factor ( IGF) II ( Igf2) in the cortex and of the transcription factor Zif268/ EGR1 in the cortex and hippocampus. Prenatally choline deficient rats had the highest expression of CaMKII beta, protein kinase C beta 2, and GABA(B) receptor 1 isoforms c and d in the hippocampus. Similar changes in the expression of the proteins encoded by these genes were observed using immunoblot analyses. These data show that the prenatal supply of choline causes multiple modifications in the developmental patterns of expression of genes known to influence learning and memory and provide molecular correlates for the cognitive changes evoked by altered availability of choline in utero.	Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Wyeth Ayerst Res, Biol Technol, Cambridge, MA USA	Boston University; Boston University; Pfizer	Blusztajn, JK (corresponding author), Boston Univ, Sch Med, Dept Pathol & Lab Med, 715 Albany St,Rm L804, Boston, MA 02118 USA.	jbluszta@bu.edu		Mellott, Tiffany/0000-0003-3287-9374; /0000-0001-8438-3122	NIA NIH HHS [AG-009525] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG009525] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 2003, NUTR NEUROSCI, V6, P129, DOI 10.1080/1028415031000084418; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; Amir-Ahmady B, 2001, J BIOL CHEM, V276, P10514, DOI 10.1074/jbc.M010535200; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BIERI JG, 1977, J NUTR, V107, P1394; Bieri JG., 1980, J NUTR, V110, P1726, DOI [10.1093/jn/110.8.1726, DOI 10.1093/JN/110.8.1726]; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; Bozon B, 2003, NEURON, V40, P695, DOI 10.1016/S0896-6273(03)00674-3; BYRNE MC, 2000, CURRENT PROTOCOLS MO; CARDELL M, 1993, J NEUROCHEM, V61, P1308, DOI 10.1111/j.1471-4159.1993.tb13623.x; Cermak JM, 1998, FASEB J, V12, P349, DOI 10.1096/fasebj.12.3.349; CHAPMAN PF, 1995, NEURON, V14, P591, DOI 10.1016/0896-6273(95)90315-1; Charles KJ, 2001, NEUROSCIENCE, V106, P447, DOI 10.1016/S0306-4522(01)00296-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark SE, 2001, NEUROSCIENCE, V104, P441, DOI 10.1016/S0306-4522(01)00087-2; Craciunescu CN, 2003, J NUTR, V133, P3614, DOI 10.1093/jn/133.11.3614; Davis S, 1998, CR ACAD SCI III-VIE, V321, P97, DOI 10.1016/S0764-4469(97)89808-3; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Eden S, 2001, EMBO J, V20, P3518, DOI 10.1093/emboj/20.13.3518; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FAZELI MS, 1993, J NEUROSCI, V13, P1346; Feil R, 2006, MUTAT RES-FUND MOL M, V600, P46, DOI 10.1016/j.mrfmmm.2006.05.029; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; Fink CC, 2003, NEURON, V39, P283, DOI 10.1016/S0896-6273(03)00428-8; FNB (Food and Nutrition Board) IOM (Institute of Medicine), 1998, DIET REF INT THIAM R; Fritschy JM, 1999, EUR J NEUROSCI, V11, P761, DOI 10.1046/j.1460-9568.1999.00481.x; GARNER SC, 1995, J NUTR, V125, P2851; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; Glazewski S, 1996, SCIENCE, V272, P421, DOI 10.1126/science.272.5260.421; GOLDENRING JR, 1983, J BIOL CHEM, V258, P2632; GOLDENRING JR, 1986, ANN NY ACAD SCI, V466, P457, DOI 10.1111/j.1749-6632.1986.tb38423.x; Gonzalez-Parra S, 2002, HORM RES, V57, P10, DOI 10.1159/000057940; Gordon JA, 1996, NEURON, V17, P491, DOI 10.1016/S0896-6273(00)80181-6; Hall J, 2000, NAT NEUROSCI, V3, P533, DOI 10.1038/75698; He XB, 2001, BIOCHEM BIOPH RES CO, V283, P243, DOI 10.1006/bbrc.2001.4732; Hill AA, 2001, GENOME BIOL, V2; Holley SJ, 2002, DEV BIOL, V244, P319, DOI 10.1006/dbio.2002.0608; Honse Y, 2003, NEUROSCIENCE, V122, P689, DOI 10.1016/S0306-4522(03)00603-1; Ikarashi Y, 1999, BRAIN RES, V816, P238, DOI 10.1016/S0006-8993(98)01163-9; Isomoto S, 1998, BIOCHEM BIOPH RES CO, V253, P10, DOI 10.1006/bbrc.1998.9706; Jones JP, 1999, DEV BRAIN RES, V118, P159, DOI 10.1016/S0165-3806(99)00103-0; Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138; Kar S, 1997, P NATL ACAD SCI USA, V94, P14054, DOI 10.1073/pnas.94.25.14054; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; KONISHI Y, 1994, BRAIN RES, V649, P53, DOI 10.1016/0006-8993(94)91048-0; Kumari M, 2001, J BIOL CHEM, V276, P29764, DOI 10.1074/jbc.M100317200; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; LOCKER J, 1986, CARCINOGENESIS, V7, P1309, DOI 10.1093/carcin/7.8.1309; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; McCann JC, 2006, NEUROSCI BIOBEHAV R, V30, P696, DOI 10.1016/j.neubiorev.2005.12.003; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; Mellott TJ, 2004, FASEB J, V18, P545, DOI 10.1096/fj.03-0877fje; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MILLER LG, 1989, J PHARMACOL EXP THER, V248, P1; Miyashita Y, 1998, NEUROBIOL LEARN MEM, V70, P197, DOI 10.1006/nlme.1998.3848; Mohler H, 2001, LIFE SCI, V68, P2297, DOI 10.1016/S0024-3205(01)01018-9; Montoya D, 2000, NEUROSCI LETT, V296, P85, DOI 10.1016/S0304-3940(00)01660-8; Murrell A, 2001, EMBO REP, V2, P1101, DOI 10.1093/embo-reports/kve248; Nava F, 2001, EUR J PHARMACOL, V430, P261, DOI 10.1016/S0014-2999(01)01163-3; Niculescu MD, 2006, FASEB J, V20, P43, DOI 10.1096/fj.05-4707com; Niculescu MD, 2005, MOL BRAIN RES, V134, P309, DOI 10.1016/j.molbrainres.2004.11.001; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; OCHIISHI T, 1994, BRAIN RES, V659, P179, DOI 10.1016/0006-8993(94)90877-X; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; Oomizu S, 2003, ALCOHOL CLIN EXP RES, V27, P975, DOI 10.1097/01.ALC.0000071743.57855.BE; Paola D, 2000, BIOCHEM BIOPH RES CO, V268, P642, DOI 10.1006/bbrc.2000.2164; Paulsen M, 2001, J PATHOL, V195, P97, DOI 10.1002/path.890; Petrie J, 2001, ALCOHOL CLIN EXP RES, V25, P819, DOI 10.1097/00000374-200106000-00005; Pfaff T, 1999, EUR J NEUROSCI, V11, P2874, DOI 10.1046/j.1460-9568.1999.00704.x; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; RAPPOLEE DA, 1992, GENE DEV, V6, P939, DOI 10.1101/gad.6.6.939; Reinhart B, 2002, MOL CELL BIOL, V22, P2089, DOI 10.1128/MCB.22.7.2089-2098.2002; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Schmitt JM, 2005, J NEUROSCI, V25, P1281, DOI 10.1523/JNEUROSCI.4086-04.2005; Schwarz DA, 2000, J BIOL CHEM, V275, P32174, DOI 10.1074/jbc.M005333200; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SILVA AJ, 1992, COLD SPRING HARB SYM, V57, P527, DOI 10.1101/SQB.1992.057.01.058; Tsujiuchi T, 1999, JPN J CANCER RES, V90, P909, DOI 10.1111/j.1349-7006.1999.tb00834.x; Tucker KL, 2001, NEURON, V30, P649, DOI 10.1016/S0896-6273(01)00325-7; WAINFAN E, 1989, CANCER RES, V49, P4094; Wayman GA, 2004, J NEUROSCI, V24, P3786, DOI 10.1523/JNEUROSCI.3294-03.2004; Weeber EJ, 2000, J NEUROSCI, V20, P5906, DOI 10.1523/JNEUROSCI.20-16-05906.2000; Wei KR, 2001, NEUROREPORT, V12, P833, DOI 10.1097/00001756-200103260-00042; Wei KR, 2001, MOL BRAIN RES, V89, P103, DOI 10.1016/S0169-328X(01)00068-7; Williams CL, 1998, BRAIN RES, V794, P225, DOI 10.1016/S0006-8993(98)00229-7; Zeisel SH, 2004, J AM COLL NUTR, V23, p621S, DOI 10.1080/07315724.2004.10719433; ZEISEL SH, 1995, J NUTR, V125, P3049; Zeisel SH, 2006, ANNU REV NUTR, V26, P229, DOI 10.1146/annurev.nutr.26.061505.111156; Zhang JH, 1998, ENDOCRINOLOGY, V139, P4523, DOI 10.1210/en.139.11.4523	97	35	40	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1311	1323		10.1096/fj.06-6597com	http://dx.doi.org/10.1096/fj.06-6597com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264169				2022-12-25	WOS:000246117000007
J	Textoris-Taube, K; Henklein, P; Pollmann, S; Bergann, T; Weisshoff, H; Seifert, U; Drung, I; Mugge, C; Sijts, A; Kloetzel, PM; Kuckelkorn, U				Textoris-Taube, Kathrin; Henklein, Peter; Pollmann, Sylvie; Bergann, Theresa; Weisshoff, Hardy; Seifert, Ulrike; Drung, Ilse; Muegge, Clemens; Sijts, Alice; Kloetzel, Peter-Michael; Kuckelkorn, Ulrike			The N-terminal flanking region of the TRP2(360-368) melanoma antigen determines proteasome activator PA28 requirement for epitope liberation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOCYTE EPITOPE; CTL EPITOPE; DEGRADATION; EXPRESSION	Proteasomes are known to produce major histocompatibility complex ( MHC) class I ligands from endogenous antigens. The interferon-gamma-inducible proteasome activator PA28 plays an important role in the generation of MHC ligands by proteasomes. Generation of the HLA-A*0201 restricted melanoma antigen TRP2(360-368) by the proteasome has been shown to be dependent on the function of PA28 in vitro and in vivo ( Sun, Y., Sijts, A. J., Song, M., Janek, K., Nussbaum, A. K., Kral, S., Schirle, M., Stevanovic, S., Paschen, A., Schild, H., Kloetzel, P. M., and Schadendorf, D. ( 2002) Cancer Res. 62, 2875-2882). Here we analyzed the role of the epitope sequence environment in determining this PA28 dependence. Experiments using the melanoma TRP2(288-296) epitope and the murine cytomegalovirus-derived pp89 epitope precursor peptide for epitope replacement revealed that the TRP2(360-368) flanking sequences can transfer PA28 dependence onto otherwise PA28 independent epitopes. Moreover, the N-terminal flanking sequence is sufficient to establish PA28 dependence of an epitope by allowing PA28-induced coordinated dual cleavages. These results show that N-terminal flanking sequences strongly influence epitope generation efficiency and that PA28 function is particularly relevant for the generation of normally poorly excised peptide products.	Charite Univ Med Berlin, Inst Biochem, D-10117 Berlin, Germany; Humboldt Univ, Inst Chem, D-12489 Berlin, Germany; Univ Utrecht, Fac Vet Med, Div Infect Dis & Immunol, NL-3584 CL Utrecht, Netherlands	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Utrecht University	Kloetzel, PM (corresponding author), Monbijoustr 2, D-10117 Berlin, Germany.	p-m.kloetzel@charite.de		Sijts, Alice/0000-0003-3815-4788; Kuckelkorn, Ulrike/0000-0002-3085-9161				Beekman NJ, 2000, J IMMUNOL, V164, P1898, DOI 10.4049/jimmunol.164.4.1898; Braun HA, 2005, J BIOL CHEM, V280, P28394, DOI 10.1074/jbc.M502453200; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; GROSS KH, 1988, J MAGN RESON, V76, P87, DOI 10.1016/0022-2364(88)90203-X; Hill CP, 2002, CURR TOP MICROBIOL, V268, P73; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Knuehl C, 2001, J IMMUNOL, V167, P1515, DOI 10.4049/jimmunol.167.3.1515; Kuckelkorn U, 2002, EUR J IMMUNOL, V32, P1368, DOI 10.1002/1521-4141(200205)32:5<1368::AID-IMMU1368>3.0.CO;2-Z; Kuehn L, 1996, ARCH BIOCHEM BIOPHYS, V329, P87, DOI 10.1006/abbi.1996.0195; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Schwarz K, 2000, EUR J IMMUNOL, V30, P3672, DOI 10.1002/1521-4141(200012)30:12<3672::AID-IMMU3672>3.0.CO;2-B; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Seifert U, 2004, J CLIN INVEST, V114, P250, DOI 10.1172/JCI200420985; Shimbara N, 1997, GENES CELLS, V2, P785, DOI 10.1046/j.1365-2443.1997.1610359.x; Stohwasser R, 2003, BIOL CHEM, V384, P39, DOI 10.1515/BC.2003.005; Sun Y, 2002, CANCER RES, V62, P2875; Theobald M, 1998, J EXP MED, V188, P1017, DOI 10.1084/jem.188.6.1017; van Hall T, 2000, J EXP MED, V192, P483, DOI 10.1084/jem.192.4.483	20	17	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12749	12754		10.1074/jbc.M611644200	http://dx.doi.org/10.1074/jbc.M611644200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17308306	hybrid, Green Published			2022-12-25	WOS:000245942800045
J	Islam, MM; Wallin, R; Wynn, RM; Conway, M; Fujii, H; Mobley, JA; Chuang, DT; Hutson, SM				Islam, Mohammad Mainul; Wallin, Reidar; Wynn, R. Max; Conway, Myra; Fujii, Hisao; Mobley, James A.; Chuang, David T.; Hutson, Susan M.			A novel branched-chain amino acid metabolon - Protein-protein interactions in a supramolecular complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-KETOACID DEHYDROGENASE; HUMAN MITOCHONDRIAL; ESCHERICHIA-COLI; ACTIVE-SITES; AMINOTRANSFERASE ISOENZYMES; MULTIENZYME COMPLEX; CRYSTAL-STRUCTURE; BINDING DOMAIN; E1 COMPONENT; CXXC MOTIF	The catabolic pathways of branched-chain amino acids have two common steps. The first step is deamination catalyzed by the vitamin B-6-dependent branched-chain aminotransferase isozymes ( BCATs) to produce branched-chain alpha-keto acids ( BCKAs). The second step is oxidative decarboxylation of the BCKAs mediated by the branched-chain alpha-keto acid dehydrogenase enzyme complex ( BCKD complex). The BCKD complex is organized around a cubic core consisting of 24 lipoate-bearing dihydrolipoyl transacylase ( E2) subunits, associated with the branched-chain alpha-keto acid decarboxylase/ dehydrogenase ( E1), dihydrolipoamide dehydrogenase ( E3), BCKD kinase, and BCKD phosphatase. In this study, we provide evidence that human mitochondrial BCAT ( hBCATm) associates with the E1 decarboxylase component of the rat or human BCKD complex with a K-D of 2.8 mu M. NADH dissociates the complex. The E2 and E3 components do not interact with hBCATm. In the presence of hBCATm, k(cat) values for E1-catalyzed decarboxylation of the BCKAs are enhanced 12-fold. Mutations of hBCATm proteins in the catalytically important CXXC center or E1 proteins in the phosphorylation loop residues prevent complex formation, indicating that these regions are important for the interaction between hBCATm and E1. Our results provide evidence for substrate channeling between hBCATm and BCKD complex and formation of a metabolic unit ( termed branched-chain amino acid metabolon) that can be influenced by the redox state in mitochondria.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA	Wake Forest University; Wake Forest University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Alabama System; University of Alabama Birmingham	Hutson, SM (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.	shutson@wfubmc.edu		Wynn, Richard/0000-0002-1879-2136	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034738, R56DK034738, R01DK026758] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK26758, DK34738] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; Brautigam CA, 2005, J MOL BIOL, V350, P543, DOI 10.1016/j.jmb.2005.05.014; CATE RL, 1980, J BIOL CHEM, V255, P7556; Chang CF, 2006, J BIOL CHEM, V281, P28345, DOI 10.1074/jbc.M605005200; CHUANG DI, 2001, METABOLIC BASIS INHE, P1239; Chuang JL, 2000, METHOD ENZYMOL, V324, P192; Conway ME, 2000, METHOD ENZYMOL, V324, P355; Conway ME, 2004, BIOCHEMISTRY-US, V43, P7356, DOI 10.1021/bi0498050; Conway ME, 2002, BIOCHEMISTRY-US, V41, P9070, DOI 10.1021/bi020200i; DAMUNI Z, 1985, BIOCHEM BIOPH RES CO, V133, P878, DOI 10.1016/0006-291X(85)91217-3; DAMUNI Z, 1984, P NATL ACAD SCI-BIOL, V81, P4335, DOI 10.1073/pnas.81.14.4335; DANSON MJ, 1978, P NATL ACAD SCI USA, V75, P5386, DOI 10.1073/pnas.75.11.5386; Davoodi J, 1998, J BIOL CHEM, V273, P4982, DOI 10.1074/jbc.273.9.4982; FAHIEN LA, 1993, J BIOL CHEM, V268, P17935; Figeys D, 2002, CURR OPIN MOL THER, V4, P210; Frank RAW, 2004, SCIENCE, V306, P872, DOI 10.1126/science.1101030; Fries M, 2003, EUR J BIOCHEM, V270, P861, DOI 10.1046/j.1432-1033.2003.03444.x; Goto M, 2005, J BIOL CHEM, V280, P37246, DOI 10.1074/jbc.M506486200; HALL TR, 1993, J BIOL CHEM, V268, P3092; HARPER AE, 1989, ANN NY ACAD SCI, V573, P267, DOI 10.1111/j.1749-6632.1989.tb15003.x; HARRIS RA, 1994, J NUTR, V124, pS1499, DOI 10.1093/jn/124.suppl_8.1499S; Harris RA, 2004, BIOCHEM BIOPH RES CO, V313, P391, DOI 10.1016/j.bbrc.2003.11.007; HARRIS RA, 1986, ADV ENZYME REGUL, V25, P219, DOI 10.1016/0065-2571(86)90016-6; HARRIS RA, 1985, ARCH BIOCHEM BIOPHYS, V243, P542, DOI 10.1016/0003-9861(85)90531-4; HTUSON SM, 1981, METABOLISM CLIN IMPL, P245; HUTSON SM, 1981, AM J CLIN NUTR, V34, P173, DOI 10.1093/ajcn/34.2.173; HUTSON SM, 1992, J BIOL CHEM, V267, P15681; HUTSON SM, 1978, J BIOL CHEM, V253, P8126; Hutson SM, 2005, J NUTR, V135, p1557S, DOI 10.1093/jn/135.6.1557S; HUTSON SM, 1989, ANN NY ACAD SCI, V573, P230, DOI 10.1111/j.1749-6632.1989.tb15000.x; Hutson SM, 2001, J NUTR, V131, p839S, DOI 10.1093/jn/131.3.839S; Hutson SM, 1998, J NEUROCHEM, V71, P863; ICHIHARA A, 1985, TRANSAMINASES, V2, P430; Kato M, 2006, EMBO J, V25, P5983, DOI 10.1038/sj.emboj.7601444; Kimball SR, 2004, BIOCHEM BIOPH RES CO, V313, P423, DOI 10.1016/j.bbrc.2003.07.014; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li J, 2004, J BIOL CHEM, V279, P32968, DOI 10.1074/jbc.M403611200; Li J, 2007, J BIOL CHEM, V282, P11904, DOI 10.1074/jbc.M610843200; LORIDAN L, 1971, J PEDIATR-US, V78, P53, DOI 10.1016/S0022-3476(71)80263-9; Lynch CJ, 2000, J CELL BIOCHEM, V77, P234, DOI 10.1002/(SICI)1097-4644(20000501)77:2<234::AID-JCB7>3.0.CO;2-I; Lynch CJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE854, DOI 10.1152/ajpendo.00153.2003; Machius M, 2006, STRUCTURE, V14, P287, DOI 10.1016/j.str.2005.10.009; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; MALAISSE WJ, 1984, BIOCHIM BIOPHYS ACTA, V797, P194, DOI 10.1016/0304-4165(84)90122-3; MALAISSE WJ, 1986, ADV ENZYME REGUL, V25, P203, DOI 10.1016/0065-2571(86)90015-4; ODESSEY R, 1974, J BIOL CHEM, V249, P7623; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; Prod'homme M, 2004, CURR OPIN CLIN NUTR, V7, P71, DOI 10.1097/00075197-200401000-00012; REED LJ, 1990, J BIOL CHEM, V265, P8971; Reed LJ, 2001, J BIOL CHEM, V276, P38329, DOI 10.1074/jbc.R100026200; REED LJ, 1985, CURR TOP CELL REGUL, V27, P41; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; Seifert F, 2006, BIOCHEMISTRY-US, V45, P12775, DOI 10.1021/bi061582l; SHIMOMURA Y, 1990, ARCH BIOCHEM BIOPHYS, V283, P293, DOI 10.1016/0003-9861(90)90645-F; Srere PA, 2000, TRENDS BIOCHEM SCI, V25, P150, DOI 10.1016/S0968-0004(00)01550-4; Suryawan A, 1998, AM J CLIN NUTR, V68, P72, DOI 10.1093/ajcn/68.1.72; Sweatt AJ, 2004, J COMP NEUROL, V477, P360, DOI 10.1002/cne.20200; Sweatt AJ, 2004, AM J PHYSIOL-ENDOC M, V286, pE64, DOI 10.1152/ajpendo.00276.2003; TELLER JK, 1990, J BIOL CHEM, V265, P19486; Wynn RM, 2000, METHOD ENZYMOL, V324, P179; Wynn RM, 2004, STRUCTURE, V12, P2185, DOI 10.1016/j.str.2004.09.013; Wynn RM, 2001, J BIOL CHEM, V276, P4168, DOI 10.1074/jbc.M008038200; Wynn RM, 2000, J BIOL CHEM, V275, P30512, DOI 10.1074/jbc.M005075200; Yennawar N, 2001, ACTA CRYSTALLOGR D, V57, P506, DOI 10.1107/S0907444901001925; Yennawar NH, 2006, J BIOL CHEM, V281, P39660, DOI 10.1074/jbc.M607552200; Yennawar NH, 2002, BIOCHEMISTRY-US, V41, P11592, DOI 10.1021/bi020221c; Yoshizawa F, 2004, BIOCHEM BIOPH RES CO, V313, P417, DOI 10.1016/j.bbrc.2003.07.013; Zimmerman LJ, 2005, J PROTEOME RES, V4, P1672, DOI 10.1021/pr050138m	70	81	81	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11893	11903		10.1074/jbc.M700198200	http://dx.doi.org/10.1074/jbc.M700198200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314104	hybrid			2022-12-25	WOS:000245941900032
J	Yamamoto, T; Shimano, H; Inoue, N; Nakagawa, Y; Matsuzaka, T; Takahashi, A; Yahagi, N; Sone, H; Suzuki, H; Toyoshima, H; Yamada, N				Yamamoto, Takashi; Shimano, Hitoshi; Inoue, Noriyuki; Nakagawa, Yoshimi; Matsuzaka, Takashi; Takahashi, Akimitsu; Yahagi, Naoya; Sone, Hirohito; Suzuki, Hiroaki; Toyoshima, Hideo; Yamada, Nobuhiro			Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; LIPOGENIC GENE-EXPRESSION; CHOLESTEROL-METABOLISM; TRANSGENIC MICE; LXR-ALPHA; TRANSCRIPTION FACTOR; ADIPOSE-TISSUE; ACTIVATION; PROMOTER; INHIBITION	Sterol regulatory element-binding protein ( SREBP)-1c is a transcription factor that controls synthesis of fatty acids and triglycerides in the liver and is highly regulated by nutrition and hormones. In the current studies we show that protein kinase A ( PKA), a mediator of glucagon/cAMP, a fasting signaling, suppresses SREBP-1c by modulating the activity of liver X receptor alpha( LXR alpha), a dominant activator of SREBP-1c expression. Activation of PKA repressed LXR-induced SREBP-1c expression both in rat primary hepatocytes and mouse livers. Promoter analyses revealed that the LXR alpha-binding site in the SREBP-1c promoter is responsible for PKA inhibitory effect on SREBP-1c transcription. In vitro and in vivo PKA directly phosphorylated LXR alpha, and the two consensus PKA target sites ( 195, 196 serines and 290, 291 serines) in its ligand binding/heterodimerization domain were crucial for the inhibition of LXR signaling. PKA phosphorylation of LXR alpha caused impaired DNA binding activity by preventing LXR alpha/RXR dimerization and decreased its transcription activity by inhibiting recruitment of coactivator SCR-1 and enhancing recruitment of corepressor NcoR1. These results indicate that LXR alpha is regulated not only by oxysterol derivatives but also by PKA-mediated phosphorylation, which suggests that nutritional regulation of SREBP-1c and lipogenesis could be regulated at least partially through modulation of LXR.	Univ Tsukuba, Dept Internal Med Metab & Endocrinol, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba	Shimano, H (corresponding author), Univ Tsukuba, Dept Internal Med Metab & Endocrinol, Grad Sch Comprehens Human Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	shimano-tky@umin.ac.jp	Yahagi, Naoya/D-2360-2014; Shimano, Hitoshi/V-1761-2019; Sone, Hirohito/ABC-9346-2021; Shimano, Hitoshi/AAI-5648-2020	Yahagi, Naoya/0000-0002-1823-1865; Shimano, Hitoshi/0000-0002-5562-5572; Sone, Hirohito/0000-0003-1263-2817; 				Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Alberti S, 2001, J CLIN INVEST, V107, P565, DOI 10.1172/JCI9794; Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Cao GQ, 2003, J BIOL CHEM, V278, P1131, DOI 10.1074/jbc.M210208200; Castrillo A, 2003, MOL CELL, V12, P805, DOI 10.1016/S1097-2765(03)00384-8; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Chen GX, 2004, P NATL ACAD SCI USA, V101, P11245, DOI 10.1073/pnas.0404297101; Chen MY, 2006, FEBS LETT, V580, P4835, DOI 10.1016/j.febslet.2006.07.074; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Costet P, 2000, J BIOL CHEM, V275, P28240; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Harish S, 2000, BIOCHEM BIOPH RES CO, V279, P853, DOI 10.1006/bbrc.2000.4043; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Hu X, 2003, MOL ENDOCRINOL, V17, P1019, DOI 10.1210/me.2002-0399; Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; Laffitte BA, 2003, P NATL ACAD SCI USA, V100, P5419, DOI 10.1073/pnas.0830671100; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; Matsuzaka T, 2004, DIABETES, V53, P560, DOI 10.2337/diabetes.53.3.560; Ono H, 2003, DIABETES, V52, P2905, DOI 10.2337/diabetes.52.12.2905; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Sone H, 2004, BIOCHEM BIOPH RES CO, V316, P790, DOI 10.1016/j.bbrc.2004.02.121; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Wagner BL, 2003, MOL CELL BIOL, V23, P5780, DOI 10.1128/MCB.23.16.5780-5789.2003; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840; Yamamoto T, 2004, J BIOL CHEM, V279, P12027, DOI 10.1074/jbc.M310333200; Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200; Yoshikawa T, 2001, MOL CELL BIOL, V21, P2991, DOI 10.1128/MCB.21.9.2991-3000.2001; Yu LQ, 2005, J BIOL CHEM, V280, P8742, DOI 10.1074/jbc.M411080200	43	83	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11687	11695		10.1074/jbc.M611911200	http://dx.doi.org/10.1074/jbc.M611911200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17296605	hybrid			2022-12-25	WOS:000245941900010
J	Zeidan, YH; Hannun, YA				Zeidan, Youssef H.; Hannun, Yusuf A.			Activation of acid sphingomyelinase by protein kinase C delta-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; NIEMANN-PICK-DISEASE; LEUKEMIA-CELL LINE; CERAMIDE PRODUCTION; PKC-DELTA; TYROSINE PHOSPHORYLATION; MITOCHONDRIAL-MEMBRANE; CANCER CELLS; TRANSLOCATION; DIFFERENTIATION	Although important for cellular stress signaling pathways, the molecular mechanisms of acid sphingomyelinase (ASMase) activation remain poorly understood. Previous studies showed that treatment of MCF-7 mammary carcinoma cells with the potent protein kinase C (PKC) agonist, phorbol 12-myristate 13-acetate ( PMA), induces a transient drop in sphingomyelin concomitant with an increase in cellular ceramide levels ( Becker, K. P., Kitatani, K., Idkowiak- Baldys, J., Bielawski, J., and Hannun, Y. A. ( 2005) J. Biol. Chem. 280, 2606 - 2612). Here we show that PMA selectively activates ASMase and that ASMase accounts for the majority of PMA- induced ceramide. Pharmacologic inhibition and RNA interference experiments indicated that the novel PKC, PKC delta, is required for ASMase activation. Immunoprecipitation experiments revealed the formation of a novel PKC delta-ASMase complex after PMA stimulation, and PKC delta was able to phosphorylate ASMase in vitro and in cells. Using site-directed mutagenesis, we identify serine 508 as the key residue phosphorylated in response to PMA. Phosphorylation of Ser(508) proved to be an indispensable step for ASMase activation and membrane translocation in response to PMA. The relevance of the proposed mechanism of ASMase regulation is further validated in a model of UV radiation. UV radiation also induced phosphorylation of ASMase at serine 508. Moreover, when transiently overexpressed, ASMase(S508A) blocked the ceramide formation after PMA treatment, suggesting a dominant negative function for this mutant. Taken together, these results establish a novel direct biochemical mechanism for ASMase activation in which PKC delta serves as a key upstream kinase.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 175 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu	Zeidan, Youssef H./H-7578-2019	Zeidan, Youssef H./0000-0002-1951-8585	NCI NIH HHS [P01-CA97132] Funding Source: Medline; NCRR NIH HHS [C06 RR018823] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA097132] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR018823] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; Becker KP, 2005, J BIOL CHEM, V280, P2606, DOI 10.1074/jbc.M409066200; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Charruyer A, 2005, J BIOL CHEM, V280, P19196, DOI 10.1074/jbc.M412867200; Church LD, 2005, J LEUKOCYTE BIOL, V78, P266, DOI 10.1189/jlb.1003456; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Dumitru CA, 2006, ONCOGENE, V25, P5612, DOI 10.1038/sj.onc.1209568; Enomoto A, 2000, CANCER LETT, V155, P137, DOI 10.1016/S0304-3835(00)00422-5; Ferlinz K, 1997, EUR J BIOCHEM, V243, P511, DOI 10.1111/j.1432-1033.1997.511_1a.x; Ferlinz K, 1999, CHEM PHYS LIPIDS, V102, P35, DOI 10.1016/S0009-3084(99)00073-0; Fukunaga M, 2001, BIOCHEM BIOPH RES CO, V289, P573, DOI 10.1006/bbrc.2001.6025; Garzotto M, 1998, CANCER RES, V58, P2260; Ginzburg L, 2005, J NEUROCHEM, V95, P1619, DOI 10.1111/j.1471-4159.2005.03534.x; Giuliano M, 2006, INT J MOL MED, V17, P811; Grant S, 2002, J CLIN INVEST, V109, P717, DOI 10.1172/JCI200215302; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; HURWITZ R, 1994, J BIOL CHEM, V269, P5440; Kajimoto T, 2004, J BIOL CHEM, V279, P12668, DOI 10.1074/jbc.M312350200; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kuemmel TA, 1997, PATHOL RES PRACT, V193, P663, DOI 10.1016/S0344-0338(97)80025-8; Langmann T, 1999, J LIPID RES, V40, P870; Li LW, 1999, MOL CELL BIOL, V19, P8547; Linke T, 2001, BIOL CHEM, V382, P283, DOI 10.1515/BC.2001.035; Liu JH, 2003, CANCER RES, V63, P1153; Liu X, 2006, MOL THER, V14, P627, DOI 10.1016/j.ymthe.2006.07.001; Lovat PE, 2004, JNCI-J NATL CANCER I, V96, P1288, DOI 10.1093/jnci/djh254; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Mimeault M, 2003, PROSTATE, V56, P1, DOI 10.1002/pros.10190; Murate T, 2002, J BIOL CHEM, V277, P9936, DOI 10.1074/jbc.M111594200; Newrzella D, 1996, J BIOL CHEM, V271, P32089, DOI 10.1074/jbc.271.50.32089; Qiu HW, 2003, J BIOL CHEM, V278, P32744, DOI 10.1074/jbc.M303022200; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; Rehman F, 2004, BRIT J CANCER, V91, P1821, DOI 10.1038/sj.bjc.6602212; Rotolo JA, 2005, J BIOL CHEM, V280, P26425, DOI 10.1074/jbc.M414569200; Sawai H, 1997, J BIOL CHEM, V272, P2452; Schissel SL, 1998, J BIOL CHEM, V273, P18250, DOI 10.1074/jbc.273.29.18250; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Sikora J, 2003, ANN HUM GENET, V67, P63, DOI 10.1046/j.1469-1809.2003.00009.x; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Takahashi E, 2006, J RADIAT RES, V47, P19, DOI 10.1269/jrr.47.19; Tettamanti G, 1996, J LIPID MEDIAT CELL, V14, P263, DOI 10.1016/0929-7855(96)00535-4; YAMAGUCHI S, 1977, J BIOL CHEM, V252, P3805; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zeidan YH, 2006, J BIOL CHEM, V281, P24695, DOI 10.1074/jbc.M604713200	56	112	119	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11549	11561		10.1074/jbc.M609424200	http://dx.doi.org/10.1074/jbc.M609424200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303575	hybrid			2022-12-25	WOS:000245941500076
J	de Silva, U; Choudhury, S; Bailey, SL; Harvey, S; Perrino, FW; Hollis, T				de Silva, Udesh; Choudhury, Sumana; Bailey, Suzanna L.; Harvey, Scott; Perrino, Fred W.; Hollis, Thomas			The crystal structure of TREX1 explains the 3 ' nucleotide specificity and reveals a polyproline II helix for protein partnering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; AICARDI-GOUTIERES-SYNDROME; STRAND BREAK REPAIR; PROOFREADING EXONUCLEASE; RECOMBINANT PROTEINS; MICE DEFICIENT; MECHANISM; IDENTIFICATION; CHROMOSOME; SEQUENCES	The TREX1 enzyme processes DNA ends as the major 3'-> 5' exonuclease activity in human cells. Mutations in the TREX1 gene are an underlying cause of the neurological brain disease Aicardi-Goutieres syndrome implicating TREX1 dysfunction in an aberrant immune response. TREX1 action during apoptosis likely prevents autoimmune reaction to DNA that would otherwise persist. To understand the impact of TREX1 mutations identified in patients with Aicardi-Goutieres syndrome on structure and activity we determined the x-ray crystal structure of the dimeric mouse TREX1 protein in substrate and product complexes containing single-stranded DNA and deoxyadenosine monophosphate, respectively. The structures show the specific interactions between the bound nucleotides and the residues lining the binding pocket of the 3' terminal nucleotide within the enzyme active site that account for specificity, and provide the molecular basis for understanding mutations that lead to disease. Three mutant forms of TREX1 protein identified in patients with Aicardi-Goutieres syndrome were prepared and the measured activities show that these specific mutations reduce enzyme activity by 4-35,000-fold. The structure also reveals an 8-amino acid polyproline II helix within the TREX1 enzyme that suggests a mechanism for interactions of this exonuclease with other protein complexes.	Wake Forest Univ Hlth Sci, Dept Biochem, Ctr Struct Biol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University School of Medicine	Hollis, T (corresponding author), Med Ctr Blvd, Winston Salem, NC 27157 USA.	thollis@wfubmc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069962] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM069962] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AICARDI J, 1984, ANN NEUROL, V15, P49, DOI 10.1002/ana.410150109; Alarcon-Riquelme ME, 2006, NAT GENET, V38, P866, DOI 10.1038/ng0806-866; BARNES MH, 1995, GENE, V165, P45, DOI 10.1016/0378-1119(95)00530-J; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Breyer WA, 2000, NAT STRUCT BIOL, V7, P1125; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chowdhury D, 2006, MOL CELL, V23, P133, DOI 10.1016/j.molcel.2006.06.005; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; Crow YJ, 2006, NAT GENET, V38, P917, DOI 10.1038/ng1845; DeRose EF, 2002, BIOCHEMISTRY-US, V41, P94, DOI 10.1021/bi0114170; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Goldsby RE, 2002, P NATL ACAD SCI USA, V99, P15560, DOI 10.1073/pnas.232340999; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Goutieres F, 2005, BRAIN DEV-JPN, V27, P201, DOI 10.1016/j.braindev.2003.12.011; Hamdan S, 2002, STRUCTURE, V10, P535, DOI 10.1016/S0969-2126(02)00738-4; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Inamdar KV, 2002, RADIAT RES, V157, P306, DOI 10.1667/0033-7587(2002)157[0306:ROPDET]2.0.CO;2; Karasinska JM, 2006, CLIN GENET, V70, P457, DOI 10.1111/j.1399-0004.2006.00709_1.x; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lee-Kirsch MA, 2006, AM J HUM GENET, V79, P731, DOI 10.1086/507848; Longacre A, 2003, INT IMMUNOL, V15, P477, DOI 10.1093/intimm/dxg047; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mazur DJ, 2001, J BIOL CHEM, V276, P17022, DOI 10.1074/jbc.M100623200; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; McElhinny SAN, 2006, CELL CYCLE, V5, P958, DOI 10.4161/cc.5.9.2736; Miller H, 1996, BIOCHEMISTRY-US, V35, P12919, DOI 10.1021/bi960326d; Morita M, 2004, MOL CELL BIOL, V24, P6719, DOI 10.1128/MCB.24.15.6719-6727.2004; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Perrino FW, 2004, ADV ENZYME REGUL, V44, P37, DOI 10.1016/j.advenzreg.2003.11.010; Perrino FW, 2005, J BIOL CHEM, V280, P15212, DOI 10.1074/jbc.M500108200; Perry JJP, 2006, NAT STRUCT MOL BIOL, V13, P414, DOI 10.1038/nsmb1088; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Strauss BS, 1997, NUCLEIC ACIDS RES, V25, P806, DOI 10.1093/nar/25.4.806; Taft-Benz SA, 1998, NUCLEIC ACIDS RES, V26, P4005, DOI 10.1093/nar/26.17.4005; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Zarrinpar Ali, 2003, Sci STKE, V2003, pRE8, DOI 10.1126/stke.2003.179.re8	44	82	88	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10537	10543		10.1074/jbc.M700039200	http://dx.doi.org/10.1074/jbc.M700039200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17293595	hybrid			2022-12-25	WOS:000245941000046
J	Hsu, SC; Hung, MC				Hsu, Sheng-Chieh; Hung, Mien-Chie			Characterization of a novel tripartite nuclear localization sequence in the EGFR family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; DEPENDENT PROTEIN-KINASE; RECEPTOR TYROSINE KINASES; IMPORTIN BETA; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; GENE-EXPRESSION; IN-VITRO; PATHWAY; DNA	Aberrant expression of epidermal growth factor receptor ( EGFR) is present in many human tumors. Several reports have shown that EGFR is translocated into the nucleus during liver regeneration and in several types of cells and tissues such as placenta and thyroid. Nuclear EGFR is associated with transcription, DNA synthesis, and DNA repair activity and serves as a prognostic marker in breast carcinoma and oropharyngeal squamous cell cancer. However, the nuclear localization sequence ( NLS) of EGFR has not been extensively examined. In this study, we have shown that the juxtamembrane region of EGFR harbors a putative NLS with three clusters of basic amino acids ( RRRHIVRKRTLRR ( amino acids 645 - 657)) that mediates the nuclear localization of EGFR. We found that this newly characterized tripartite NLS is conserved among the EGFR family members ( EGFR, ErbB2, ErbB3, and ErbB4) and is able to move each to the nucleus. Further, this tripartite NLS could also mediate the nuclear localization of other known cytoplasmic proteins such as pyruvate kinase. We have demonstrated that mutating one of the three basic amino acid clusters ( R or K3A) leads to significant impairment of the nuclear localization of EGFR and that of a green fluorescent protein-pyruvate kinase-NLS reporter protein. Our results show that this tripartite NLS is distinct from the traditional mono- and bipartite NLS and reveal a mechanism that could account for the nuclear localization of membrane receptors.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 79,1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA109311] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672, CA109311] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aifa S, 2005, EXP CELL RES, V302, P108, DOI 10.1016/j.yexcr.2004.08.032; Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; BADER T, 1994, P NATL ACAD SCI USA, V91, P11831, DOI 10.1073/pnas.91.25.11831; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; CAO H, 1995, ENDOCRINOLOGY, V136, P3163, DOI 10.1210/en.136.7.3163; Carpenter G, 2003, CURR OPIN CELL BIOL, V15, P143, DOI 10.1016/S0955-0674(03)00015-2; Casalini P, 2004, J CELL PHYSIOL, V200, P343, DOI 10.1002/jcp.20007; Chen QQ, 2005, CELL RES, V15, P504, DOI 10.1038/sj.cr.7290320; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; CURTIS BM, 1990, J IMMUNOL, V144, P1295; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; Friedmann BJ, 2006, MOL CANCER THER, V5, P209, DOI 10.1158/1535-7163.MCT-05-0239; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Johnson HM, 1998, P SOC EXP BIOL MED, V218, P149; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KAMIO T, 1990, HUM PATHOL, V21, P277, DOI 10.1016/0046-8177(90)90227-V; Larkin J, 2000, J INTERF CYTOK RES, V20, P565, DOI 10.1089/10799900050044769; Liang SH, 1999, ONCOGENE, V18, P2163, DOI 10.1038/sj.onc.1202350; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Lo HW, 2005, CANCER RES, V65, P338; Marti U, 2001, THYROID, V11, P137, DOI 10.1089/105072501300042785; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; Massie C, 2006, NAT REV CANCER, V6, P403, DOI 10.1038/nrc1882; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Orth JD, 2006, CANCER RES, V66, P3603, DOI 10.1158/0008-5472.CAN-05-2916; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Peters Reiner, 2006, V322, P235; Pillai G, 2005, HISTOPATHOLOGY, V46, P209, DOI 10.1111/j.1365-2559.2005.02081.x; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Poon IKH, 2005, TRAFFIC, V6, P173, DOI 10.1111/j.1600-0854.2005.00268.x; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RAKOWICZSZULCZYNSKA EM, 1988, CANCER RES, V48, P7200; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Sardi SP, 2006, CELL, V127, P185, DOI 10.1016/j.cell.2006.07.037; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; TERVAHAUTA A, 1994, INT J GYNECOL PATHOL, V13, P234, DOI 10.1097/00004347-199407000-00007; Truant R, 1999, MOL CELL BIOL, V19, P1210; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; VILLALOBO A, 2003, REV ONCOL, V5, P381; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Yan Duen-Hwa, 2004, V245, P125; Zwaagstra JC, 2000, EXP CELL RES, V258, P121, DOI 10.1006/excr.2000.4905	69	184	195	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10432	10440		10.1074/jbc.M610014200	http://dx.doi.org/10.1074/jbc.M610014200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283074	hybrid			2022-12-25	WOS:000245941000034
J	Johnson, CL; Owen, DM; Gale, M				Johnson, Cynthia L.; Owen, David M.; Gale, Michael, Jr.			Functional and therapeutic analysis of hepatitis C virus NS3 center dot 4A protease control of antiviral immune defense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR-3; NONSTRUCTURAL PROTEIN-3 NS3; NF-KAPPA-B; RIG-I; CRYSTAL-STRUCTURE; ADAPTER PROTEIN; SIGNALING PROTEIN; HELICASE ACTIVITY; BETA PROMOTER; CELL-LINES	Chronic hepatitis C virus ( HCV) infection is a major global public health problem. HCV infection is supported by viral strategies to evade the innate antiviral response wherein the viral NS3.4A protease complex targets and cleaves the interferon promoter stimulator-1 ( IPS-1) adaptor protein to ablate signaling of interferon alpha/beta immune defenses. Here we examined the structural requirements of NS3.4A and the therapeutic potential of NS3.4A inhibitors to control the innate immune response against virus infection. The structural composition of NS3 includes an amino-terminal serine protease domain and a carboxyl-terminal RNA helicase domain. NS3 mutants lacking the helicase domain retained the ability to control virus signaling initiated by retinoic acid-inducible gene-I ( RIG-I) or melanoma differentiation antigen 5 and suppressed the downstream activation of interferon regulatory factor-3 ( IRF-3) and nuclear factor kappa B ( NF-kappa B) through the targeted proteolysis of IPS-1. This regulation was abrogated by truncation of the NS3 protease domain or by point mutations that ablated protease activity. NS3.4A protease control of antiviral immune signaling was due to targeted proteolysis of IPS-1 by the NS3 protease domain and minimal NS4A cofactor. Treatment of HCV-infected cells with an NS3 protease inhibitor prevented IPS-1 proteolysis by the HCV protease and restored RIG-I immune defense signaling during infection. Thus, the NS3.4A protease domain can target IPS-1 for cleavage and is essential for blocking RIG-I signaling to IRF-3 and NF-kappa B, whereas the helicase domain is dispensable for this action. Our results indicate that NS3.4A protease inhibitors have immunomodulatory potential to restore innate immune defenses to HCV infection.	Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gale, M (corresponding author), Univ Texas, SW Med Ctr, Dept Microbiol, Dallas, TX 75390 USA.	Michael.Gale@UTSouthwestern.edu		Owen, David/0000-0002-5724-0342; Monaco, Cynthia/0000-0003-3093-5563; Gale, Michael/0000-0002-6332-7436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060389, U19AI040035] Funding Source: NIH RePORTER; NIAID NIH HHS [U19AI40035, R01AI060389] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; Bartenschlager R, 1999, J VIRAL HEPATITIS, V6, P165, DOI 10.1046/j.1365-2893.1999.00152.x; Borowski P, 1997, J VIROL, V71, P2838, DOI 10.1128/JVI.71.4.2838-2843.1997; Borowski P, 1999, J BIOL CHEM, V274, P30722, DOI 10.1074/jbc.274.43.30722; Brown RS, 2005, NATURE, V436, P973, DOI 10.1038/nature04083; De Francesco R, 1998, ANTIVIR THER, V3, P99; Feld JJ, 2005, NATURE, V436, P967, DOI 10.1038/nature04082; Ferreon JC, 2005, J BIOL CHEM, V280, P20483, DOI 10.1074/jbc.M500422200; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Foy E, 2005, P NATL ACAD SCI USA, V102, P2986, DOI 10.1073/pnas.0408707102; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Fredericksen B, 2002, VIRAL IMMUNOL, V15, P29, DOI 10.1089/088282402317340215; Fukuda K, 2004, BIOCHEM BIOPH RES CO, V325, P670, DOI 10.1016/j.bbrc.2004.10.089; Fukuda K, 2001, Nucleic Acids Res Suppl, P147; Gale M, 2005, NATURE, V436, P939, DOI 10.1038/nature04078; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Gu BH, 2005, PROTEIN PEPTIDE LETT, V12, P315, DOI 10.2174/0929866053765716; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Johnson CL, 2006, TRENDS IMMUNOL, V27, P1, DOI 10.1016/j.it.2005.11.004; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kuang WF, 2004, BIOCHEM BIOPH RES CO, V317, P211, DOI 10.1016/j.bbrc.2004.03.032; Kwong AD, 2000, CURR TOP MICROBIOL, V242, P171; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Lin RT, 2006, J VIROL, V80, P6072, DOI 10.1128/JVI.02495-05; Loo YM, 2006, P NATL ACAD SCI USA, V103, P6001, DOI 10.1073/pnas.0601523103; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Love RA, 1998, CLIN DIAGN VIROL, V10, P151, DOI 10.1016/S0928-0197(98)00036-1; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Moradpour D, 1998, HEPATOLOGY, V28, P192, DOI 10.1002/hep.510280125; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Ni ZJ, 2004, CURR OPIN DRUG DISC, V7, P446; Nishikawa F, 2003, NUCLEIC ACIDS RES, V31, P1935, DOI 10.1093/nar/gkg291; Nomura-Takigawa Y, 2006, J GEN VIROL, V87, P1935, DOI 10.1099/vir.0.81701-0; Pflugheber J, 2002, P NATL ACAD SCI USA, V99, P4650, DOI 10.1073/pnas.062055699; Reed KE, 1998, CURR STUD HEMATOL BL, P1; Rosenberg S, 2001, J MOL BIOL, V313, P451, DOI 10.1006/jmbi.2001.5055; Saha SK, 2006, EMBO J, V25, P3257, DOI 10.1038/sj.emboj.7601220; Saito T, 2007, P NATL ACAD SCI USA, V104, P582, DOI 10.1073/pnas.0606699104; Saito T, 2007, CURR OPIN IMMUNOL, V19, P17, DOI 10.1016/j.coi.2006.11.003; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Sumpter R, 2004, J VIROL, V78, P11591, DOI 10.1128/JVI.78.21.11591-11604.2004; Tan SL, 2004, CURR OPIN PHARMACOL, V4, P465, DOI 10.1016/j.coph.2004.07.003; Taremi SS, 1998, PROTEIN SCI, V7, P2143, DOI 10.1002/pro.5560071011; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wang CF, 2003, J VIROL, V77, P3898, DOI 10.1128/JVI.77.7.3898-3912.2003; Wang CF, 2005, MOL CELL, V18, P425, DOI 10.1016/j.molcel.2005.04.004; Wolk B, 2000, J VIROL, V74, P2293, DOI 10.1128/JVI.74.5.2293-2304.2000; Wyss DF, 2004, J MED CHEM, V47, P2486, DOI 10.1021/jm0305117; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yoneyama M, 2002, J INTERF CYTOK RES, V22, P73, DOI 10.1089/107999002753452674; Zhang C, 2005, J VIROL, V79, P8687, DOI 10.1128/JVI.79.14.8687-8697.2005	60	74	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10792	10803		10.1074/jbc.M610361200	http://dx.doi.org/10.1074/jbc.M610361200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289677	hybrid			2022-12-25	WOS:000245941000073
J	Kinoshita, A; Tsukada, K; Soga, T; Hishiki, T; Ueno, Y; Nakayama, Y; Tomita, M; Suematsu, M				Kinoshita, Ayako; Tsukada, Kosuke; Soga, Tomoyoshi; Hishiki, Takako; Ueno, Yuki; Nakayama, Yoichi; Tomita, Masaru; Suematsu, Makoto			Roles of hemoglobin allostery in hypoxia-induced metabolic alterations in erythrocytes - Simulation and its verification by metabolome analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RED-CELL; ENZYME-KINETIC EQUATIONS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; 2,3-BISPHOSPHOGLYCERATE METABOLISM; GLUCOSE-METABOLISM; MUSCULAR EXERCISE; MASS-SPECTROMETRY; OXYGEN-BINDING; MEMBRANE; BAND-3	When erythrocytes are exposed to hypoxia, hemoglobin ( Hb) stabilizes in the T-state by capturing 2,3-bisphosphoglycerate. This process could reduce the intracellular pool of glycolytic substrates, jeopardizing cellular energetics. Recent observations suggest that hypoxia-induced activation of glycolytic enzymes is correlated with their release from Band III ( BIII) on the cell membrane. Based on these data, we developed a mathematical model of erythrocyte metabolism and compared hypoxia-induced differences in predicted activities of the enzymes, their products, and cellular energetics between models with and without the interaction of Hb with BIII. The models predicted that the allostery-dependent Hb interaction with BIII accelerates consumption of upstream glycolytic substrates such as glucose 6-phosphate and increases downstream products such as phosphoenolpyruvate. This prediction was consistent with metabolomic data from capillary electrophoresis mass spectrometry. The hypoxia-induced alterations in the metabolites resulted from acceleration of glycolysis, as judged by increased conversion of [ C-13] glucose to [ C-13] lactate. The allostery-dependent interaction of Hb with BIII appeared to contribute not only to maintenance of energy charge but also to further synthesis of 2,3-bisphosphoglycerate, which could help sustain stabilization of T-state Hb during hypoxia. Furthermore, such an activation of glycolysis was not observed when Hb was stabilized in R-state by treating the cells with CO. These results suggest that Hb allostery in erythrocytes serves as an O-2-sensing trigger that drives glycolytic acceleration to stabilize intracellular energetics and promote the ability to release O-2 from the cells.	Keio Univ, Inst Adv Biosci, Yamagata 9970017, Japan; Keio Univ, Sch Med, Dept Biochem & Integrat Med Biol, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University	Suematsu, M (corresponding author), Keio Univ, Inst Adv Biosci, Yamagata 9970017, Japan.	msuem@sc.itc.keio.ac.jp	Suematsu, Makoto/I-8135-2013; Soga, Tomoyoshi/B-8105-2014; Suematsu, Makoto/O-5762-2018; Tsukada, Kosuke/C-9986-2014	Suematsu, Makoto/0000-0002-7165-6336; Soga, Tomoyoshi/0000-0001-9502-2509; Suematsu, Makoto/0000-0002-7165-6336; Tsukada, Kosuke/0000-0003-1463-2204; Yachie, Ayako/0000-0003-2032-227X				ATKINSON DE, 1967, J BIOL CHEM, V242, P3239; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; BERGFELD GR, 1992, CARDIOVASC RES, V26, P40, DOI 10.1093/cvr/26.1.40; Campanella ME, 2005, P NATL ACAD SCI USA, V102, P2402, DOI 10.1073/pnas.0409741102; Chu HY, 2006, BIOCHEM J, V400, P143, DOI 10.1042/BJ20060792; COSTA LE, 1976, ACTA PHYSIOL LAT AM, V26, P115; Dash RK, 2004, ANN BIOMED ENG, V32, P1676, DOI 10.1007/s10439-004-7821-6; Ellsworth ML, 2004, MED SCI SPORT EXER, V36, P35, DOI 10.1249/01.MSS.0000106284.80300.B2; Ellsworth ML, 1995, AM J PHYSIOL-HEART C, V269, pH2155, DOI 10.1152/ajpheart.1995.269.6.H2155; HARRIS SJ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P306, DOI 10.1016/0167-4838(90)90242-8; Hauck EF, 2004, J CEREBR BLOOD F MET, V24, P383, DOI 10.1097/00004647-200404000-00003; HIGASHI T, 1979, J BIOL CHEM, V254, P9542; Jagger JE, 2001, AM J PHYSIOL-HEART C, V280, pH2833, DOI 10.1152/ajpheart.2001.280.6.H2833; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; Jensen FB, 2004, ACTA PHYSIOL SCAND, V182, P215, DOI 10.1111/j.1365-201X.2004.01361.x; JOSHI A, 1990, J THEOR BIOL, V142, P69, DOI 10.1016/S0022-5193(05)80013-X; JOSHI A, 1989, J THEOR BIOL, V141, P529, DOI 10.1016/S0022-5193(89)80234-6; JOSHI A, 1990, J THEOR BIOL, V142, P41, DOI 10.1016/S0022-5193(05)80012-8; JOSHI A, 1989, J THEOR BIOL, V141, P515, DOI 10.1016/S0022-5193(89)80233-4; KLIMAN HJ, 1980, J BIOL CHEM, V255, P6314; Komarova SV, 1999, BLOOD CELL MOL DIS, V25, P171, DOI 10.1006/bcmd.1999.0243; LENFANT C, 1968, J CLIN INVEST, V47, P2652, DOI 10.1172/JCI105948; MACPHEE PJ, 1995, AM J PHYSIOL-GASTR L, V269, pG692, DOI 10.1152/ajpgi.1995.269.5.G692; MAGNANI M, 1983, BLOOD, V61, P915; Messana I, 1996, FEBS LETT, V390, P25, DOI 10.1016/0014-5793(96)00624-2; MILLS GC, 1976, P NATL ACAD SCI USA, V73, P2867, DOI 10.1073/pnas.73.8.2867; MOORE LG, 1980, AM J PHYS ANTHROPOL, V53, P11, DOI 10.1002/ajpa.1330530104; Mulquiney PJ, 1999, BIOCHEM J, V342, P581, DOI 10.1042/0264-6021:3420581; Mulquiney PJ, 1999, BIOCHEM J, V342, P567, DOI 10.1042/0264-6021:3420567; MURPHY JR, 1960, J LAB CLIN MED, V55, P286; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; Qian H, 2005, BIOPHYS CHEM, V114, P213, DOI 10.1016/j.bpc.2004.12.001; RAPOPORT TA, 1975, BIOSYSTEMS, V7, P120, DOI 10.1016/0303-2647(75)90049-0; RAPOPORT TA, 1976, BIOCHEM J, V154, P449, DOI 10.1042/bj1540449; SHIMIZU T, 1988, BLOOD, V71, P1130; Soga T, 2002, ANAL CHEM, V74, P2233, DOI 10.1021/ac020064n; Soga T, 2003, J PROTEOME RES, V2, P488, DOI 10.1021/pr034020m; Soga T, 2006, J BIOL CHEM, V281, P16768, DOI 10.1074/jbc.M601876200; Southgate CD, 1996, NAT GENET, V14, P227, DOI 10.1038/ng1096-227; Sprague RS, 1996, AM J PHYSIOL-HEART C, V271, pH2717, DOI 10.1152/ajpheart.1996.271.6.H2717; Suganuma K, 2006, ANTIOXID REDOX SIGN, V8, P1847, DOI 10.1089/ars.2006.8.1847; Takahashi K, 2002, IEEE INTELL SYST, V17, P64, DOI 10.1109/MIS.2002.1039834; Tomita M, 1999, BIOINFORMATICS, V15, P72, DOI 10.1093/bioinformatics/15.1.72; Tsai AG, 2003, PHYSIOL REV, V83, P933, DOI 10.1152/physrev.00034.2002; TSUNESHIGE A, 1987, J BIOCHEM-TOKYO, V101, P695, DOI 10.1093/jb/101.3.695; von Ruckmann B, 2002, BBA-BIOMEMBRANES, V1559, P43, DOI 10.1016/S0005-2736(01)00435-7; WALDER JA, 1984, J BIOL CHEM, V259, P238; YAMAMOTO T, 1994, HORM METAB RES, V26, P504, DOI 10.1055/s-2007-1001744; Yonetani T, 1998, J BIOL CHEM, V273, P20323, DOI 10.1074/jbc.273.32.20323	49	75	76	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10731	10741		10.1074/jbc.M610717200	http://dx.doi.org/10.1074/jbc.M610717200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289676	hybrid			2022-12-25	WOS:000245941000067
J	Sharp, KH; Schneider, S; Cockayne, A; Paoli, M				Sharp, Katherine H.; Schneider, Sabine; Cockayne, Alan; Paoli, Max			Crystal structure of the heme-IsdC complex, the central conduit of the isd iron/heme uptake system in Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC CIRCULAR-DICHROISM; IRON; BINDING; TRANSPORT; ACQUISITION; METABOLISM; PROTEINS; DOMAIN; NEAT; SITE	Pathogens such as Staphylococcus aureus require iron to survive and have evolved specialized proteins to steal heme from their host. IsdC is the central conduit of the Isd ( iron-regulated surface determinant) multicomponent heme uptake machinery; staphylococcal cell-surface proteins such as IsdA, IsdB, and IsdH are thought to funnel their molecular cargo to IsdC, which then mediates the transfer of the iron-containing nutrient to the membrane translocation system IsdDEF. The structure of the heme-IsdC complex reveals a novel heme site within an immunoglobulin-like domain and sheds light on its binding mechanism. The folding topology is reminiscent of the architecture of cytochrome f, cellobiose dehydrogenase, and ethylbenzene dehydrogenase; in these three proteins, the heme is bound in an equivalent position, but interestingly, IsdC features a distinct binding pocket with the ligand located next to the hydrophobic core of the beta-sandwich. The iron is coordinated with a tyrosine surrounded by several non-polar side chains that cluster into a tightly packed proximal side. On the other hand, the distal side is relatively exposed with a short helical peptide segment that acts as a lip clasping onto almost half of the porphyrin plane. This structural feature is argued to play a role in the mechanism of binding and release by switching to an open conformation and thus loosening the interactions holding the heme. The structure of the heme-IsdC complex provides a template for the understanding of other proteins, such as IsdA, IsdB, and IsdH, that contain the same heme-binding module as IsdC, known as the NEAT ( near transporter) domain.	Univ Nottingham, Sch Pharm, Nottingham NG7 2RD, England; Univ Nottingham, Inst Infect Immun & Inflammat, Ctr Biomol Sci, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham	Paoli, M (corresponding author), Univ Nottingham, Sch Pharm, Univ Pk, Nottingham NG7 2RD, England.	max.paoli@nottingham.ac.uk	Schneider, Sabine/G-2908-2013	Schneider, Sabine/0000-0003-1054-8689				Abraham BD, 2001, BIOCHEMISTRY-US, V40, P2251, DOI 10.1021/bi002121h; Andrade MA, 2002, GENOME BIOL, V3; Andrews SC, 2003, FEMS MICROBIOL REV, V27, P215, DOI 10.1016/S0168-6445(03)00055-X; Arnoux P, 1999, NAT STRUCT BIOL, V6, P516; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BROWETT WR, 1979, BIOCHIM BIOPHYS ACTA, V577, P291, DOI 10.1016/0005-2795(79)90033-3; Chan ACK, 2006, J MOL BIOL, V362, P1108, DOI 10.1016/j.jmb.2006.08.001; Chi YI, 2000, BIOCHEMISTRY-US, V39, P7689, DOI 10.1021/bi000090k; Clarke SR, 2006, J INFECT DIS, V193, P1098, DOI 10.1086/501471; Clarke SR, 2004, MOL MICROBIOL, V51, P1509, DOI 10.1111/j.1365-2958.2003.03938.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans W, 1997, CHEM BRIT, V33, P22; Faraldo-Gomez JD, 2003, NAT REV MOL CELL BIO, V4, P105, DOI 10.1038/nrm1015; Friedman DB, 2006, PLOS PATHOG, V2, P777, DOI 10.1371/journal.ppat.0020087; Grigg JC, 2007, MOL MICROBIOL, V63, P139, DOI 10.1111/j.1365-2958.2006.05502.x; Hallberg BM, 2000, STRUCT FOLD DES, V8, P79, DOI 10.1016/S0969-2126(00)00082-4; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; Kloer DP, 2006, STRUCTURE, V14, P1377, DOI 10.1016/j.str.2006.07.001; Kuklin NA, 2006, INFECT IMMUN, V74, P2215, DOI 10.1128/IAI.74.4.2215-2223.2006; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Mack J, 2004, BIOCHEM BIOPH RES CO, V320, P781, DOI 10.1016/j.bbrc.2004.06.025; Maresso AW, 2006, BIOMETALS, V19, P193, DOI 10.1007/s10534-005-4863-7; Martinez GL, 2000, J ELECTRON MATER, V29, P325, DOI 10.1007/s11664-000-0072-x; Mazmanian SK, 2003, SCIENCE, V299, P906, DOI 10.1126/science.1081147; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ochsner UA, 2000, MICROBIOL-UK, V146, P185, DOI 10.1099/00221287-146-1-185; Painter J, 2006, J APPL CRYSTALLOGR, V39, P109, DOI 10.1107/S0021889805038987; Paoli M, 1999, NAT STRUCT BIOL, V6, P926; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; Pilpa RM, 2006, J MOL BIOL, V360, P435, DOI 10.1016/j.jmb.2006.05.019; Posey JE, 2000, SCIENCE, V288, P1651, DOI 10.1126/science.288.5471.1651; Schneider S, 2006, J BIOL CHEM, V281, P32606, DOI 10.1074/jbc.M607516200; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Skaar EP, 2004, MICROBES INFECT, V6, P390, DOI 10.1016/j.micinf.2003.12.008; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; Stojiljkovic I, 2002, DNA CELL BIOL, V21, P281, DOI 10.1089/104454902753759708; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Vliet AHM, 2002, FEMS MICROBIOL REV, V26, P173, DOI 10.1111/j.1574-6976.2002.tb00609.x; Vermeiren CL, 2006, BIOCHEMISTRY-US, V45, P12867, DOI 10.1021/bi0607711; Vonrhein Clemens, 2007, Methods Mol Biol, V364, P215, DOI 10.1385/1-59745-266-1:215	42	105	112	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10625	10631		10.1074/jbc.M700234200	http://dx.doi.org/10.1074/jbc.M700234200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287214	hybrid			2022-12-25	WOS:000245941000056
J	Pagano, JM; Farley, BM; McCoig, LM; Ryder, SP				Pagano, John M.; Farley, Brian M.; McCoig, Lisa M.; Ryder, Sean P.			Molecular basis of RNA recognition by the embryonic polarity determinant MEX-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS EMBRYOS; GLP-1 MESSENGER-RNA; ZINC-FINGER DOMAIN; CAENORHABDITIS-ELEGANS; TRANSLATIONAL REGULATION; GERMLINE SPECIFICATION; PIE-1 PROTEIN; CELL POLARITY; BINDING; TRISTETRAPROLIN	Embryonic development requires maternal proteins and RNA. In Caenorhabditis elegans, a gradient of CCCH tandem zinc finger (TZF) proteins coordinates axis polarization and germline differentiation. These proteins govern expression from maternal mRNAs by an unknown mechanism. Here we show that the TZF protein MEX-5, a primary anterior determinant, is an RNA-binding protein that recognizes linear RNA sequences with high affinity but low specificity. The minimal binding site is a tract of six or more uridines within a 9-13-nucleotide window. This sequence is remarkably abundant in the 3'-untranslated region of C. elegans transcripts, demonstrating that MEX-5 alone cannot specify mRNA target selection. In contrast, human TZF homologs tristetraprolin and ERF-2 bind with high specificity to UUAUUUAUU elements. We show that mutation of a single amino acid in each MEX-5 zinc finger confers tristetraprolin-like specificity to this protein. We propose that divergence of this discriminator residue modulates the RNA-binding specificity in this protein class. This residue is variable in nematode TZF proteins, but is invariant in other metazoans. Therefore, the divergence of TZF proteins and their critical role in early development is likely a nematode-specific adaptation.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Ryder, SP (corresponding author), 364 Plantat St,Lazare Res Bldg,Rm 906, Worcester, MA 01605 USA.	sean.ryder@umassmed.edu		Farley, Brian/0000-0002-8400-9306				Alliegro MC, 2006, P NATL ACAD SCI USA, V103, P9034, DOI 10.1073/pnas.0602859103; Asaoka-Taguchi M, 1999, NAT CELL BIOL, V1, P431, DOI 10.1038/15666; Auweter SD, 2006, NUCLEIC ACIDS RES, V34, P4943, DOI 10.1093/nar/gkl620; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; BRENNER S, 1974, GENETICS, V77, P71; Brewer BY, 2004, J BIOL CHEM, V279, P27870, DOI 10.1074/jbc.M402551200; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Cuenca AA, 2003, DEVELOPMENT, V130, P1255, DOI 10.1242/dev.00284; Curtis D, 1997, EMBO J, V16, P834, DOI 10.1093/emboj/16.4.834; D'Agostino I, 2006, DEV BIOL, V292, P244, DOI 10.1016/j.ydbio.2005.11.046; DeRenzo C, 2003, NATURE, V424, P685, DOI 10.1038/nature01887; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; Dsouza M, 1997, TRENDS GENET, V13, P497, DOI 10.1016/S0168-9525(97)01347-4; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; Forbes A, 1998, DEVELOPMENT, V125, P679; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Goldstein B, 1996, DEVELOPMENT, V122, P1467; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Huang NN, 2002, DEVELOPMENT, V129, P747; Hudson BP, 2004, NAT STRUCT MOL BIOL, V11, P257, DOI 10.1038/nsmb738; Johnstone O, 2001, ANNU REV GENET, V35, P365, DOI 10.1146/annurev.genet.35.102401.090756; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; Lai WS, 2006, MOL CELL BIOL, V26, P9196, DOI 10.1128/MCB.00945-06; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LEVITAN DJ, 1994, P NATL ACAD SCI USA, V91, P6108, DOI 10.1073/pnas.91.13.6108; LIN S, 1972, J MOL BIOL, V72, P671, DOI 10.1016/0022-2836(72)90184-2; Maduro MF, 2005, DEV BIOL, V285, P510, DOI 10.1016/j.ydbio.2005.06.022; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Ogura K, 2003, DEVELOPMENT, V130, P2495, DOI 10.1242/dev.00469; Pellettieri J, 2002, SCIENCE, V298, P1946, DOI 10.1126/science.1072162; Pitt JN, 2000, DEV BIOL, V219, P315, DOI 10.1006/dbio.2000.9607; Rambo RP, 2004, BIOCHEMISTRY-US, V43, P6486, DOI 10.1021/bi049912u; Reese KJ, 2000, MOL CELL, V6, P445, DOI 10.1016/S1097-2765(00)00043-5; REINES SA, 1974, NUCLEIC ACIDS RES, V1, P767, DOI 10.1093/nar/1.6.767; Ryder SP, 2004, RNA, V10, P1449, DOI 10.1261/rna.7780504; Schubert CM, 2000, MOL CELL, V5, P671, DOI 10.1016/S1097-2765(00)80246-4; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Seydoux G, 2006, CELL, V127, P891, DOI 10.1016/j.cell.2006.11.016; Tabara H, 1999, DEVELOPMENT, V126, P1; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Tenlen JR, 2006, GENETICS, V174, P1933, DOI 10.1534/genetics.105.052621; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; Wallenfang MR, 2000, NATURE, V408, P89, DOI 10.1038/35040562; WEEKS KM, 1992, BIOCHEMISTRY-US, V31, P10281, DOI 10.1021/bi00157a015; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	50	78	79	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8883	8894		10.1074/jbc.M700079200	http://dx.doi.org/10.1074/jbc.M700079200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264081	hybrid			2022-12-25	WOS:000245780300035
J	Chang, KC; Unsinger, J; Davis, CG; Schwulst, SJ; Muenzer, JT; Strasser, A; Hotchkiss, RS				Chang, Katherine C.; Unsinger, Jacqueline; Davis, Christopher G.; Schwulst, Steven J.; Muenzer, Jared T.; Strasser, Andreas; Hotchkiss, Richard S.			Multiple triggers of cell death in sepsis: death receptor and mitochondrial-mediated apoptosis	FASEB JOURNAL			English	Article						endotoxin; necrosis; cytokines	BH3-ONLY PROTEINS PUMA; IMPROVES SURVIVAL; LYMPHOCYTE APOPTOSIS; FAS LIGAND; BCL-2; INHIBITION; DEPLETION; MICE; BIM; PATHOPHYSIOLOGY	Lymphocyte apoptosis plays a central role in the pathophysiology of sepsis. Lymphocyte apoptosis was examined in mice with defective death receptor pathways due to transgenic expression of a dominant negative mutant of Fas-associated death domain (FADD-DN) or Bid(-/-) and in mice with defective mitochondrial-mediated pathways due to loss of Bim(-/-), Puma(-/-), or Noxa(-/-). FADD-DN transgenic and Bid(-/-) mice had significant albeit incomplete protection, and this protection was associated with increased survival. Surprisingly, splenic B cells were also protected in FADD-DN mice although transgene expression was confined to T cells, providing evidence for an indirect protective mechanism. Bim(-/-) provided virtually complete protection against lymphocyte apoptosis whereas Puma(-/-) and Noxa(-/-) mice had modest or no protection, respectively. Bim(-/-) mice had improved survival, and adoptive transfer of splenocytes from Bim(-/-) mice into Rag 1(-/-) mice demonstrated that this was a lymphocyte intrinsic effect. The improved survival was associated with decreased interleukin (IL) -10 and IL-6 cytokines. Collectively, these data indicate that numerous death stimuli are generated during sepsis, and it therefore appears unlikely that blocking a single "trigger" can inhibit apoptosis. If siRNA becomes practical therapeutically, proapoptotic proteins would be potential targets.	Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Walter & Eliza Hall Inst Med Res, Dept Immunol, Melbourne, Vic 3050, Australia	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Walter & Eliza Hall Institute	Hotchkiss, RS (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, 660 S Euclid, St Louis, MO 63110 USA.	hotchkir@msnotes.wustl.edu	Strasser, Andreas/C-7581-2013	Strasser, Andreas/0000-0002-5020-4891	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055194, R01GM044118, R37GM044118] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM55194, GM44118] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Chen SH, 2005, NEW GENERAT COMPUT, V23, P3, DOI 10.1007/BF03037645; Chung CS, 2003, J LEUKOCYTE BIOL, V74, P344, DOI 10.1189/jlb.0102006; Chung CS, 1998, ARCH SURG-CHICAGO, V133, P1213, DOI 10.1001/archsurg.133.11.1213; Chung CS, 2001, SURGERY, V130, P339, DOI 10.1067/msy.2001.116540; Coopersmith CM, 2002, JAMA-J AM MED ASSOC, V287, P1716, DOI 10.1001/jama.287.13.1716; Creagh EM, 2001, BIOCHEM SOC T, V29, P696, DOI 10.1042/0300-5127:0290696; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Felmet KA, 2005, J IMMUNOL, V174, P3765, DOI 10.4049/jimmunol.174.6.3765; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Green DR, 2000, NATURE, V405, P28, DOI 10.1038/35011175; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Hiramatsu M, 1997, SHOCK, V7, P247, DOI 10.1097/00024382-199704000-00002; Hotchkiss RS, 2006, J IMMUNOL, V176, P5471, DOI 10.4049/jimmunol.176.9.5471; Hotchkiss RS, 2005, J IMMUNOL, V174, P5110, DOI 10.4049/jimmunol.174.8.5110; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hotchkiss RS, 1999, J IMMUNOL, V162, P4148; Hotchkiss RS, 1999, P NATL ACAD SCI USA, V96, P14541, DOI 10.1073/pnas.96.25.14541; Hotchkiss RS, 2003, SCAND J INFECT DIS, V35, P585, DOI 10.1080/00365540310015692; Hotchkiss RS, 2000, J IMMUNOL, V164, P3675, DOI 10.4049/jimmunol.164.7.3675; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Hotchkiss RS, 2002, J IMMUNOL, V168, P2493, DOI 10.4049/jimmunol.168.5.2493; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Iwata A, 2003, J IMMUNOL, V171, P3136, DOI 10.4049/jimmunol.171.6.3136; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Le Tulzo Y, 2002, SHOCK, V18, P487, DOI 10.1097/00024382-200212000-00001; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; Murphy SL, 1998, NATL VITAL STAT REP, V48, P1; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Oberholzer A, 2005, SHOCK, V23, P488, DOI 10.1097/01.shk.0000163802.46355.59; Oberholzer C, 2001, FASEB J, V15, P879, DOI 10.1096/fj.00-058rev; Oberholzer C, 2001, P NATL ACAD SCI USA, V98, P11503, DOI 10.1073/pnas.181338198; Opferman JT, 2003, NAT IMMUNOL, V4, P410, DOI 10.1038/ni0503-410; Pellegrini M, 2003, P NATL ACAD SCI USA, V100, P14175, DOI 10.1073/pnas.2336198100; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Rathmell JC, 1998, IMMUNOL CELL BIOL, V76, P387, DOI 10.1046/j.1440-1711.1998.00774.x; Remick DG, 2002, SHOCK, V17, P463, DOI 10.1097/00024382-200206000-00004; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Su X, 1998, J IMMUNOL, V160, P5288; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Toti P, 2004, AM J CLIN PATHOL, V122, P765, DOI 10.1309/RV6E9BMC9954A2WU; van Dissel JT, 1998, LANCET, V351, P950, DOI 10.1016/S0140-6736(05)60606-X; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Weaver JGR, 2004, FASEB J, V18, P1185, DOI 10.1096/fj.03-1230com; Wei QQ, 2006, AM J PHYSIOL-RENAL, V290, pF35, DOI 10.1152/ajprenal.00184.2005; Wesche DE, 2005, J LEUKOCYTE BIOL, V78, P325, DOI 10.1189/jlb.0105017; Wesche-Soldato DE, 2005, BLOOD, V106, P2295, DOI 10.1182/blood-2004-10-4086; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	60	122	132	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2007	21	3					708	719		10.1096/fj.06-6805com	http://dx.doi.org/10.1096/fj.06-6805com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	142YE	17307841				2022-12-25	WOS:000244686400010
J	Fahlgren, N; Howell, MD; Kasschau, KD; Chapman, EJ; Sullivan, CM; Cumbie, JS; Givan, SA; Law, TF; Grant, SR; Dangl, JL; Carrington, JC				Fahlgren, Noah; Howell, Miya D.; Kasschau, Kristin D.; Chapman, Elisabeth J.; Sullivan, Christopher M.; Cumbie, Jason S.; Givan, Scott A.; Law, Theresa F.; Grant, Sarah R.; Dangl, Jeffery L.; Carrington, James C.			High-Throughput Sequencing of Arabidopsis microRNAs: Evidence for Frequent Birth and Death of MIRNA Genes	PLOS ONE			English	Article								In plants, microRNAs (miRNAs) comprise one of two classes of small RNAs that function primarily as negative regulators at the posttranscriptional level. Several MIRNA genes in the plant kingdom are ancient, with conservation extending between angiosperms and the mosses, whereas many others are more recently evolved. Here, we use deep sequencing and computational methods to identify, profile and analyze non-conserved MIRNA genes in Arabidopsis thaliana. 48 non-conserved MIRNA families, nearly all of which were represented by single genes, were identified. Sequence similarity analyses of miRNA precursor foldback arms revealed evidence for recent evolutionary origin of 16 MIRNA loci through inverted duplication events from protein-coding gene sequences. Interestingly, these recently evolved MIRNA genes have taken distinct paths. Whereas some non-conserved miRNAs interact with and regulate target transcripts from gene families that donated parental sequences, others have drifted to the point of non-interaction with parental gene family transcripts. Some young MIRNA loci clearly originated from one gene family but form miRNAs that target transcripts in another family. We suggest that MIRNA genes are undergoing relatively frequent birth and death, with only a subset being stabilized by integration into regulatory networks.	[Fahlgren, Noah; Howell, Miya D.; Kasschau, Kristin D.; Chapman, Elisabeth J.; Sullivan, Christopher M.; Cumbie, Jason S.; Givan, Scott A.; Carrington, James C.] Oregon State Univ, Dept Bot & Plant Pathol, Ctr Genome Res & Biocomp, Corvallis, OR 97331 USA; [Fahlgren, Noah; Chapman, Elisabeth J.] Oregon State Univ, Mol & Cellular Biol Grad Program, Corvallis, OR 97331 USA; [Law, Theresa F.; Grant, Sarah R.; Dangl, Jeffery L.] Univ N Carolina, Dept Biol, Chapel Hill, NC USA	Oregon State University; Oregon State University; University of North Carolina; University of North Carolina Chapel Hill	Carrington, JC (corresponding author), Oregon State Univ, Dept Bot & Plant Pathol, Ctr Genome Res & Biocomp, Corvallis, OR 97331 USA.	carrington@cgrb.oregonstate.edu	Carrington, James C/A-4656-2012; Fahlgren, Noah/D-4404-2011	Carrington, James C/0000-0003-3572-129X; Fahlgren, Noah/0000-0002-5597-4537; Givan, Scott/0000-0002-0630-8589	National Science Foundation [MCB-0618433]; National Institutes of Health [AI43288]; U. S. Department of Agriculture [2005-35319-15280]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043288, R21AI043288, R37AI043288] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U. S. Department of Agriculture(United States Department of Agriculture (USDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by grants from the National Science Foundation 2010 Project (MCB-0618433), the National Institutes of Health (AI43288), and the U. S. Department of Agriculture (2005-35319-15280).	Allen E, 2005, CELL, V121, P207, DOI 10.1016/j.cell.2005.04.004; Allen E, 2004, NAT GENET, V36, P1282, DOI 10.1038/ng1478; Axtell MJ, 2006, CELL, V127, P565, DOI 10.1016/j.cell.2006.09.032; Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562; Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874; Chan SWL, 2005, NAT REV GENET, V6, P351, DOI 10.1038/nrg1601; Chu CY, 2006, PLOS BIOL, V4, P1122, DOI 10.1371/journal.pbio.0040210; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Gasciolli V, 2005, CURR BIOL, V15, P1494, DOI 10.1016/j.cub.2005.07.024; Guddeti S, 2005, CELL RES, V15, P631, DOI 10.1038/sj.cr.7290333; Hall TMT, 2005, STRUCTURE, V13, P1403, DOI 10.1016/j.str.2005.08.005; Hammond SM, 2005, FEBS LETT, V579, P5822, DOI 10.1016/j.febslet.2005.08.079; Henderson IR, 2006, NAT GENET, V38, P721, DOI 10.1038/ng1804; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; Jiang DH, 2006, CELL RES, V16, P507, DOI 10.1038/sj.cr.7310062; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; John Bino, 2006, V342, P101, DOI 10.1385/1-59745-123-1:101; Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286; Jones-Rhoades MW, 2006, ANNU REV PLANT BIOL, V57, P19, DOI 10.1146/annurev.arplant.57.032905.105218; Jones-Rhoades MW, 2004, MOL CELL, V14, P787, DOI 10.1016/j.molcel.2004.05.027; Jurka J, 2005, CYTOGENET GENOME RES, V110, P462, DOI 10.1159/000084979; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; Kasschau KD, 2007, PLOS BIOL, V5, P479, DOI 10.1371/journal.pbio.0050057; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lindow M, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-119; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311; Lu C, 2005, SCIENCE, V309, P1567, DOI 10.1126/science.1114112; Lu C, 2006, GENOME RES, V16, P1276, DOI 10.1101/gr.5530106; Lu SF, 2005, PLANT CELL, V17, P2186, DOI 10.1105/tpc.105.033456; Maher C, 2006, GENOME RES, V16, P510, DOI 10.1101/gr.4680506; Mallory AC, 2006, NAT GENET, V38, pS31, DOI 10.1038/ng1791; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Nakano M, 2006, NUCLEIC ACIDS RES, V34, pD731, DOI 10.1093/nar/gkj077; Navarro L, 2006, SCIENCE, V312, P436, DOI 10.1126/science.1126088; Noma K, 2004, NAT GENET, V36, P1174, DOI 10.1038/ng1452; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Palatnik JF, 2003, NATURE, V425, P257, DOI 10.1038/nature01958; Peragine A, 2004, GENE DEV, V18, P2368, DOI 10.1101/gad.1231804; Rajagopalan R, 2006, GENE DEV, V20, P3407, DOI 10.1101/gad.1476406; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Schwab R, 2005, DEV CELL, V8, P517, DOI 10.1016/j.devcel.2005.01.018; Slotkin RK, 2005, NAT GENET, V37, P641, DOI 10.1038/ng1576; Sunkar R, 2004, PLANT CELL, V16, P2001, DOI 10.1105/tpc.104.022830; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Tran RK, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r90; Vazquez F, 2004, MOL CELL, V16, P69, DOI 10.1016/j.molcel.2004.09.028; Wang Y, 2006, BIOINFORMATICS, V22, P2585, DOI 10.1093/bioinformatics/btl437; Xie ZX, 2005, PLANT PHYSIOL, V138, P2145, DOI 10.1104/pp.105.062943; Xie ZX, 2005, P NATL ACAD SCI USA, V102, P12984, DOI 10.1073/pnas.0506426102; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; Yoshikawa M, 2005, GENE DEV, V19, P2164, DOI 10.1101/gad.1352605	57	897	1005	3	99	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e219	10.1371/journal.pone.0000219	http://dx.doi.org/10.1371/journal.pone.0000219			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299599	Green Submitted, gold, Green Published			2022-12-25	WOS:000207444400020
J	Haase, D; Meister, M; Muley, T; Hess, J; Teurich, S; Schnabel, P; Hartenstein, B; Angel, P				Haase, D.; Meister, M.; Muley, T.; Hess, J.; Teurich, S.; Schnabel, P.; Hartenstein, B.; Angel, P.			FRMD3, a novel putative tumour suppressor in NSCLC	ONCOGENE			English	Article						protein 4.1; lung cancer; ferm containing 3; apoptosis	PROTEIN 4.1B; EXPRESSION; GROWTH; CANCER; DAL-1; MENINGIOMA; GENE; DOMAIN; MEMBER; MERLIN	Lung cancer including non-small cell lung carcinoma (NSCLC) represents a leading cause of cancer death in Western countries. Yet, understanding its pathobiology to improve early diagnosis and therapeutic strategies is still a major challenge of today's biomedical research. We analyzed a set of differentially regulated genes that were identifi. ed in skin cancer by a comprehensive microarray study, for their expression in NSCLC. We found that ferm domain containing protein 3 (FRMD3), a member of the protein 4.1 superfamily, is expressed in normal lung tissue but silenced in 54 out of 58 independent primary NSCLC tumours compared to patient-matched normal lung tissue. FRMD3 overexpression in different epithelial cell lines resulted in a decreased clonogenicity as measured by colony formation assay. Although cell attachment capabilities and cell proliferation rate remained unchanged, this phenotype was most likely owing to induced apoptosis. Our data identify FRMD3 as a novel putative tumour suppressor gene suggesting an important role in the origin and progression of lung cancer.	Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control A100, D-69120 Heidelberg, Germany; Thoraxklin Heidelberg GmbH, Sekt Translat Forschung, Heidelberg, Germany; Univ Hosp, Dept Gen Pathol, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Hartenstein, B (corresponding author), Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control A100, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	b.hartenstein@dkfz.de	Hess, Jochen/ABE-1144-2021	Hess, Jochen/0000-0003-3493-1711				Breitenbach U, 2001, J INVEST DERMATOL, V117, P634, DOI 10.1046/j.0022-202x.2001.01437.x; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; Forgacs Eva, 2001, Pathology and Oncology Research, V7, P6; Gerber MA, 2006, CANCER RES, V66, P5295, DOI 10.1158/0008-5472.CAN-05-1628; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Gutmann DH, 2001, NEUROBIOL DIS, V8, P266, DOI 10.1006/nbdi.2000.0376; Gutmann DH, 2000, HUM MOL GENET, V9, P1495, DOI 10.1093/hmg/9.10.1495; Hanada T, 2003, J BIOL CHEM, V278, P34445, DOI 10.1074/jbc.M305209200; Huang S, 2001, EUR J CLIN INVEST, V31, P907, DOI 10.1046/j.1365-2362.2001.00892.x; Hummerich L, 2006, ONCOGENE, V25, P111, DOI 10.1038/sj.onc.1209016; Jiang W, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-4; Kuns R, 2005, ONCOGENE, V24, P6502, DOI 10.1038/sj.onc.1208813; Mao XL, 2003, CANCER RES, V63, P7979; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Ni XH, 2003, J HUM GENET, V48, P101, DOI 10.1007/s100380300015; Panani AD, 2006, CANCER LETT, V239, P1, DOI 10.1016/j.canlet.2005.06.030; Perry A, 2000, J NEUROPATH EXP NEUR, V59, P872, DOI 10.1093/jnen/59.10.872; Rapp UR, 2003, ADV ENZYME REGUL, V43, P183, DOI 10.1016/S0065-2571(03)00002-5; Robb VA, 2003, NEUROBIOL DIS, V13, P191, DOI 10.1016/S0969-9961(03)00071-8; Robb VA, 2005, ONCOGENE, V24, P1946, DOI 10.1038/sj.onc.1208335; Robb VA, 2004, ONCOGENE, V23, P3589, DOI 10.1038/sj.onc.1207445; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Shaw AT, 2005, CLIN CANCER RES, V11, p4999S, DOI 10.1158/1078-0432.CCR-05-9005; Sherman LS, 2001, TRENDS CELL BIOL, V11, P442, DOI 10.1016/S0962-8924(01)02128-6; Singh V, 2004, ONCOGENE, V23, P7761, DOI 10.1038/sj.onc.1208057; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Tran YK, 1999, CANCER RES, V59, P35; Yageta M, 2002, CANCER RES, V62, P5129	28	23	26	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4464	4468		10.1038/sj.onc.1210225	http://dx.doi.org/10.1038/sj.onc.1210225			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17260017				2022-12-25	WOS:000247620000014
J	Saita, Y; Takagi, T; Kitahara, K; Usui, M; Miyazono, K; Ezura, Y; Nakashima, K; Kurosawa, H; Ishii, S; Noda, M				Saita, Yoshitomo; Takagi, Tsuyoshi; Kitahara, Keiichiro; Usui, Michihiko; Miyazono, Kohei; Ezura, Yoichi; Nakashima, Kazuhisa; Kurosawa, Hisashi; Ishii, Shunsuke; Noda, Masaki			Lack of Schnurri-2 expression associates with reduced bone remodeling and osteopenia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR; NEGATIVE REGULATION; SIGNALING PATHWAY; MINERAL DENSITY; GENE; DIFFERENTIATION; OSTEOBLASTS; MASS; OSTEOPOROSIS	Regulation of bone remodeling determines the levels of bone mass and its imbalance causes major skeletal diseases such as osteoporosis. A zinc finger protein, Schnurri-2 (SHN-2), was recently demonstrated to regulate bone morphogenetic protein-dependent adipogenesis and lymphogenesis. However, the role of SHN-2 in bone is not known. Here, we investigated the effects of Shn-2 deficiency on bone metabolism and cell function in Shn-2-null mice. Lack of SHN-2 expression reduced bone remodeling by suppressing both osteoblastic bone formation and osteoclastic bone resorption activities in vivo. Shn-2 deficiency suppressed osterix and osteocalcin expression as well as in vitro mineralization. Conversely, Shn-2 overexpression enhanced osteocalcin promoter activity and bone morphogenetic protein-dependent osteoblastic differentiation. Shn-2 deficiency suppressed Nfatc1 and c-fos expression leading to reduction of tartrate-resistant acid phosphatase-positive cell development in vivo as well as in the cultures of bone marrow cells. These studies demonstrate that SHN-2 regulates the activities of critical transcription factors required for normal bone remodeling.	Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pharmacol, Chiyoda Ku, Tokyo 1010062, Japan; RIKEN, Genet Mol Lab, Tsukuba Inst, Ibaraki 3050074, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan; Juntendo Univ, Sch Med, Dept Orthoped, Tokyo 1138421, Japan; Tokyo Med & Dent Univ, 21st Century Ctr Excellence Program Frontier Res, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Adv Bone & Joint Sci Integrated Act Initiat JSPS, Tokyo 1010062, Japan; Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1010062, Japan	Tokyo Medical & Dental University (TMDU); RIKEN; University of Tokyo; Juntendo University; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Noda, M (corresponding author), Tokyo Med & Dent Univ, Inst Med Res, Dept Mol Pharmacol, Chiyoda Ku, 3-10 Kanda Surugadai,2 Chome, Tokyo 1010062, Japan.	noda.mph@mri.tmd.ac.jp	Ishii, Shunsuke/A-5271-2016; Ezura, Yoichi/L-9485-2016	Ishii, Shunsuke/0000-0002-6530-2478; Usui, Michihiko/0000-0002-5208-1848; Nakashima, Kazuhisa/0000-0003-0491-2149				Affolter M, 2001, EMBO J, V20, P3298, DOI 10.1093/emboj/20.13.3298; ARORA K, 1995, CELL, V81, P781, DOI 10.1016/0092-8674(95)90539-1; Bleul CC, 2005, J IMMUNOL, V175, P5213, DOI 10.4049/jimmunol.175.8.5213; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Dai H, 2000, DEV BIOL, V227, P373, DOI 10.1006/dbio.2000.9901; Durr U, 2004, EUR J BIOCHEM, V271, P1135, DOI 10.1111/j.1432-1033.2004.04017.x; Epstein S, 2005, MAYO CLIN PROC, V80, P379, DOI 10.4065/80.3.379; Felsenberg D, 2005, CLIN THER, V27, P1, DOI 10.1016/j.clinthera.2004.12.020; Gardner JC, 2005, J CLIN ENDOCR METAB, V90, P6392, DOI 10.1210/jc.2005-1235; GRIEDER NC, 1995, CELL, V81, P791, DOI 10.1016/0092-8674(95)90540-5; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660; Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200; HOGAN B, 1994, MANIPULATING MOUSE E, P379; Jin WZ, 2006, DEV CELL, V10, P461, DOI 10.1016/j.devcel.2006.02.016; Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313; Kimura MY, 2005, J EXP MED, V201, P397, DOI 10.1084/jem.20040733; Kitahara K, 2003, ENDOCRINOLOGY, V144, P2132, DOI 10.1210/en.2002-220996; Klein RF, 2004, SCIENCE, V303, P229, DOI 10.1126/science.1090985; Lecanda F, 1997, J CELL BIOCHEM, V67, P386, DOI 10.1002/(SICI)1097-4644(19971201)67:3<386::AID-JCB10>3.3.CO;2-5; Maeda Y, 2004, J CELL BIOCHEM, V93, P337, DOI 10.1002/jcb.20154; Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004; Marty T, 2000, NAT CELL BIOL, V2, P745, DOI 10.1038/35036383; Morinobu M, 2005, J EXP MED, V201, P961, DOI 10.1084/jem.20041097; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; Okamoto M, 2006, J BONE MINER RES, V21, P1022, DOI 10.1359/JBMR.060411; Oukka M, 2004, J EXP MED, V199, P15, DOI 10.1084/jem.20030421; PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071; Salingcarnboriboon R, 2003, EXP CELL RES, V287, P289, DOI 10.1016/S0014-4827(03)00107-1; Shen ZJ, 2002, J BIOL CHEM, V277, P29840, DOI 10.1074/jbc.M203157200; STAEHLINGHAMPTON K, 1995, DEVELOPMENT, V121, P3393; Takagi T, 2001, NAT IMMUNOL, V2, P1048, DOI 10.1038/ni728; Takeuchi Y, 2002, J BIOL CHEM, V277, P49011, DOI 10.1074/jbc.M207804200; Tsuji K, 2004, J BONE MINER RES, V19, P1481, DOI 10.1359/JBMR.040601; Udagawa Y, 2000, GENES CELLS, V5, P359, DOI 10.1046/j.1365-2443.2000.00328.x; Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006; Wu LC, 2002, GENE EXPRESSION, V10, P137, DOI 10.3727/000000002783992479; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Zelzer E, 2003, NATURE, V423, P343, DOI 10.1038/nature01659	42	29	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12907	12915		10.1074/jbc.M611203200	http://dx.doi.org/10.1074/jbc.M611203200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17311925	hybrid			2022-12-25	WOS:000245942800062
J	Sanchez-Magraner, L; Viguera, AR; Garcia-Pacios, M; Garcillan, MP; Arrondo, JLR; de la Cruz, F; Goni, FM; Ostolaza, H				Sanchez-Magraner, Lissete; Viguera, Ana R.; Garcia-Pacios, Marcos; Garcillan, M. Pilar; Arrondo, Jose-Luis R.; de la Cruz, Fernando; Goni, Felix M.; Ostolaza, Helena			The calcium-binding c-terminal domain of Escherichia coli alpha-hemolysin is a major determinant in the surface-active properties of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE TOXIN; CRYSTAL-STRUCTURE; PSEUDOMONAS-AERUGINOSA; INFRARED-SPECTROSCOPY; ALKALINE PROTEASE; SELF-AGGREGATION; LIPID-BILAYERS; TARGET-CELLS; INSERTION; RECEPTOR	alpha-Hemolysin ( HlyA) from Escherichia coli is a protein toxin ( 1024 amino acids) that targets eukaryotic cell membranes, causing loss of the permeability barrier. HlyA consists of two main regions, an N-terminal domain rich in amphipathic helices, and a C-terminal Ca2+-binding domain containing a Gly- and Asp-rich nonapeptide repeated in tandem 11-17 times. The latter is called the RTX domain and gives its name to the RTX protein family. It had been commonly assumed that membrane interaction occurred mainly if not exclusively through the amphipathic helix domain. However, we have cloned and expressed the C-terminal region of HlyA, containing the RTX domain plus a few stabilizing sequences, and found that it is a potent surface-active molecule. The isolated domain binds Ca2+ with about the same affinity ( apparent K-0.5 approximate to 150 mu M) as the parent protein HlyA, and Ca2+ binding induces in turn a more compact folding with an increased proportion of beta-sheet structure. Both with and without Ca2+ the C-terminal region of HlyA can interact with lipid monolayers spread at an air-water interface. However, the C-terminal domain by itself is devoid of membrane lytic properties. The present results can be interpreted in the light of our previous studies that involved in receptor binding a peptide in the C-terminal region of HlyA. We had also shown experimentally the distinction between reversible membrane adsorption and irreversible lytic insertion of the toxin. In this context, the present data allow us to propose that both major domains of HlyA are directly involved in membrane-toxin interaction, the nonapeptide repeat, calcium-binding RTX domain being responsible for the early stages of HlyA docking to the target membrane.	Univ Basque Country, Unidad Biofis, Ctr Mixto, CSIC,EHU, Bilbao 48080, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain; Univ Cantabria, CSIC, Dept Biol Mol, Unidad Asociada Ctr Invest Biol, Santander 39011, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria	Ostolaza, H (corresponding author), Univ Basque Country, Unidad Biofis, Ctr Mixto, CSIC,EHU, Aptdo 644, Bilbao 48080, Spain.	gbzoseth@ehu.es	Garcillan, Maria Pilar/L-3125-2014; Viguera, Ana R/L-8248-2014; de la Cruz, Fernando/L-2812-2014; Garcillán-Barcia, María Pilar/G-5812-2016; Goni, Felix M/M-5425-2015	Viguera, Ana R/0000-0002-7688-8099; de la Cruz, Fernando/0000-0003-4758-6857; Garcillán-Barcia, María Pilar/0000-0001-7058-5428; Goni, Felix M/0000-0001-6270-9216; OSTOLAZA ECHABE, ELENA AMAYA/0000-0003-2933-9975				Arrondo JLR, 1999, PROG BIOPHYS MOL BIO, V72, P367, DOI 10.1016/S0079-6107(99)00007-3; ARRONDO JLR, 1993, PROG BIOPHYS MOL BIO, V59, P23, DOI 10.1016/0079-6107(93)90006-6; Bakas L, 1996, BIOPHYS J, V71, P1869, DOI 10.1016/S0006-3495(96)79386-4; Bauche C, 2006, J BIOL CHEM, V281, P16914, DOI 10.1074/jbc.M601594200; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BAUMANN U, 1994, J MOL BIOL, V242, P244, DOI 10.1006/jmbi.1994.1576; Cortajarena AL, 2003, J BIOL CHEM, V278, P19159, DOI 10.1074/jbc.M208552200; Cortajarena AL, 2001, J BIOL CHEM, V276, P12513, DOI 10.1074/jbc.M006792200; Dalla Serra M, 1999, BIOCHEM BIOPH RES CO, V263, P516, DOI 10.1006/bbrc.1999.1400; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; FELMLEE T, 1988, P NATL ACAD SCI USA, V85, P5269, DOI 10.1073/pnas.85.14.5269; Goni FM, 1998, BRAZ J MED BIOL RES, V31, P1019, DOI 10.1590/S0100-879X1998000800002; Hamada K, 1996, J BIOCHEM, V119, P844, DOI 10.1093/oxfordjournals.jbchem.a021320; Holland IB, 2005, MOL MEMBR BIOL, V22, P29, DOI 10.1080/09687860500042013; Hyland C, 2001, J BACTERIOL, V183, P5364, DOI 10.1128/JB.183.18.5364-5370.2001; Lally ET, 1997, J BIOL CHEM, V272, P30463, DOI 10.1074/jbc.272.48.30463; Ligi F, 1998, COMP BIOCHEM PHYS B, V121, P265, DOI 10.1016/S0305-0491(98)10099-8; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; Marsh D, 1996, BBA-REV BIOMEMBRANES, V1286, P183, DOI 10.1016/S0304-4157(96)00009-3; Martin C, 2004, J BACTERIOL, V186, P3760, DOI 10.1128/JB.186.12.3760-3765.2004; MIYATAKE H, 1995, J BIOCHEM, V118, P474, DOI 10.1093/oxfordjournals.jbchem.a124932; Moayeri M, 1997, INFECT IMMUN, V65, P2233, DOI 10.1128/IAI.65.6.2233-2239.1997; OSTOLAZA H, 1995, EUR J BIOCHEM, V228, P39, DOI 10.1111/j.1432-1033.1995.tb20225.x; OSTOLAZA H, 1991, FEBS LETT, V280, P195, DOI 10.1016/0014-5793(91)80291-A; Sanchez-Magraner L, 2006, J BIOL CHEM, V281, P5461, DOI 10.1074/jbc.M512897200; Soloaga A, 1998, BIOCHEMISTRY-US, V37, P6387, DOI 10.1021/bi9730994; Soloaga A, 1999, MOL MICROBIOL, V31, P1013, DOI 10.1046/j.1365-2958.1999.01225.x; Stanley P, 1998, MICROBIOL MOL BIOL R, V62, P309, DOI 10.1128/MMBR.62.2.309-333.1998; Valeva A, 2005, J BIOL CHEM, V280, P36657, DOI 10.1074/jbc.M507690200; Welch RA, 2001, CURR TOP MICROBIOL, V257, P85	30	47	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11827	11835		10.1074/jbc.M700547200	http://dx.doi.org/10.1074/jbc.M700547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17324923	hybrid			2022-12-25	WOS:000245941900025
J	Girnita, L; Shenoy, SK; Sehat, B; Vasilcanu, R; Vasilcanu, D; Girnita, A; Lefkowitz, RJ; Larsson, O				Girnita, Leonard; Shenoy, Sudha K.; Sehat, Bita; Vasilcanu, Radu; Vasilcanu, Daiana; Girnita, Ada; Lefkowitz, Robert J.; Larsson, Olle			beta-Arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; PROTEIN-COUPLED RECEPTORS; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; G1 PHASE; GROWTH; INSULIN; UBIQUITINATION; SIGNAL; ENDOCYTOSIS; EXPRESSION	beta-Arrestin1, which regulates many aspects of seven transmembrane receptor (7TMR) biology, has also been shown to serve as an adaptor, which brings Mdm2, an E3 ubiquitin ligase to the insulin-like growth factor-1 receptor (IGF-1R), leading to its proteasome- dependent destruction. Here we demonstrate that IGF-1R stimulation also leads to ubiquitination of beta-arrestin1, which regulates vesicular trafficking and activation of ERK1/2. This beta-arrestin1-dependent ERK activity can occur even when the classical tyrosine kinase signaling is impaired. siRNA- mediated suppression of beta-arrestin1 in human melanoma cells ablates IGF-1-stimulated ERK and prolongs the G1 phase of the cell cycle. These data suggest that beta-arrestin-dependent ERK signaling by the IGF-1R regulates cell cycle progression and may thus be an important regulator of the growth of normal and malignant cells.	Karolinska Hosp, Dept Pathol & Oncol, Div Cellular & Mol Tumor Pathol, CCK, SE-17176 Stockholm, Sweden; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Karolinska Institutet; Karolinska University Hospital; Duke University; Howard Hughes Medical Institute; Duke University	Girnita, L (corresponding author), Karolinska Hosp, Dept Pathol & Oncol, Div Cellular & Mol Tumor Pathol, CCK, R8-04, SE-17176 Stockholm, Sweden.	Leonard.Girnita@ki.se; Olle.Larsson@ki.se	Girnita, Ada/AAC-4518-2020; Lefkowitz, Robert/AAW-2649-2021; Shenoy, Sudha/AAN-4075-2021; Girnita, Leonard/A-4168-2008	Shenoy, Sudha/0000-0002-2565-4663; Girnita, Leonard/0000-0003-0280-9500	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037, R01HL080525, R01HL070631] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL080525, HL16037, HL70631] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2003, P NATL ACAD SCI USA, V100, P1740, DOI 10.1073/pnas.262789099; Ahn SK, 2004, J BIOL CHEM, V279, P35518, DOI 10.1074/jbc.M405878200; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BASERGA R, 1995, CANCER RES, V55, P249; Carter RS, 2005, J BIOL CHEM, V280, P43272, DOI 10.1074/jbc.M508656200; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dews M, 2000, ENDOCRINOLOGY, V141, P1289, DOI 10.1210/en.141.4.1289; Fredriksson R, 2003, MOL PHARMACOL, V63, P1256, DOI 10.1124/mol.63.6.1256; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; Lefkowitz RJ, 2004, TRENDS PHARMACOL SCI, V25, P413, DOI 10.1016/j.tips.2004.06.006; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Lin FT, 1998, J BIOL CHEM, V273, P31640, DOI 10.1074/jbc.273.48.31640; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McMasters KM, 1996, ONCOGENE, V13, P1731; Perroy J, 2004, NAT METHODS, V1, P203, DOI 10.1038/NMETH722; Reiter E, 2006, TRENDS ENDOCRIN MET, V17, P159, DOI 10.1016/j.tem.2006.03.008; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2005, J BIOL CHEM, V280, P15315, DOI 10.1074/jbc.M412418200; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tohgo A, 2003, J BIOL CHEM, V278, P6258, DOI 10.1074/jbc.M212231200; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Ulfarsson E, 2005, CLIN CANCER RES, V11, P4674, DOI 10.1158/1078-0432.CCR-05-0129; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Yamamoto T, 2006, CURR BIOL, V16, P1171, DOI 10.1016/j.cub.2006.04.044	42	106	112	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11329	11338		10.1074/jbc.M611526200	http://dx.doi.org/10.1074/jbc.M611526200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303558	hybrid			2022-12-25	WOS:000245941500055
J	Hobbs, MD; Sakai, A; Cox, MM				Hobbs, Michael D.; Sakai, Akiko; Cox, Michael M.			SSB protein limits RecOR binding onto single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECF; STALLED REPLICATION FORKS; PHAGE-LAMBDA ORF; GENETIC-RECOMBINATION; C-TERMINUS; DEINOCOCCUS-RADIODURANS; CRYSTAL-STRUCTURE; HOMOLOGOUS RECOMBINATION; FUNCTIONAL INTERACTION; RAD51 RECOMBINASE	The RecO and RecR proteins form a complex that promotes the nucleation of RecA protein filaments onto SSB protein-coated single-stranded DNA ( ssDNA). However, even when RecO and RecR proteins are provided at optimal concentrations, the loading of RecA protein is surprisingly slow, typically proceeding with a lag of 10 min or more. The rate-limiting step in RecOR-promoted RecA nucleation is the binding of RecOR protein to ssDNA, which is inhibited by SSB protein despite the documented interaction between RecO and SSB. Full activity of RecOR is seen only when RecOR is preincubated with ssDNA prior to the addition of SSB. The slow binding of RecOR to SSB-coated ssDNA involves the C terminus of SSB. When an SSB variant that lacks the C-terminal 8 amino acids is used, the capacity of RecOR to facilitate RecA loading onto the ssDNA is largely abolished. The results are used in an expanded model for RecOR action.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu	SAKAI, AKIKO/AAC-9814-2020	SAKAI, AKIKO/0000-0002-1258-1725	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052725, T32GM007215] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM007215, GM52725] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya N, 2002, J MOL BIOL, V318, P1251, DOI 10.1016/S0022-2836(02)00053-0; ALONSO JC, 1993, J BIOL CHEM, V268, P1424; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Bernstein DA, 2004, P NATL ACAD SCI USA, V101, P8575, DOI 10.1073/pnas.0401331101; BIANCO PR, 1998, FRONT BIOSCI, V3, P560; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; Cadman CJ, 2004, NUCLEIC ACIDS RES, V32, P6378, DOI 10.1093/nar/gkh980; Carrasco B, 2005, NUCLEIC ACIDS RES, V33, P3942, DOI 10.1093/nar/gki713; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Curth U, 1996, NUCLEIC ACIDS RES, V24, P2706, DOI 10.1093/nar/24.14.2706; DAVIS RW, 1980, ADV BACTERIAL GENET, P116; Drees JC, 2004, J BIOL CHEM, V279, P52991, DOI 10.1074/jbc.M409050200; Drees JC, 2004, MOL CELL, V15, P789, DOI 10.1016/j.molcel.2004.08.026; Eggington JM, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-2; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; Gasior SL, 2001, P NATL ACAD SCI USA, V98, P8411, DOI 10.1073/pnas.121046198; Genschel J, 2000, BIOL CHEM, V381, P183, DOI 10.1515/BC.2000.025; Gulbis JM, 2004, EUR J BIOCHEM, V271, P439, DOI 10.1046/j.1432-1033.2003.03944.x; Handa P, 2001, J BIOL CHEM, V276, P16992, DOI 10.1074/jbc.M100393200; Honda M, 2006, J BIOL CHEM, V281, P18549, DOI 10.1074/jbc.M512658200; Kantake N, 2002, P NATL ACAD SCI USA, V99, P15327, DOI 10.1073/pnas.252633399; Kinebuchi T, 1997, BIOCHEMISTRY-US, V36, P6732, DOI 10.1021/bi961647s; KOLODNER R, 1985, J BACTERIOL, V163, P1060, DOI 10.1128/JB.163.3.1060-1066.1985; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8461, DOI 10.1073/pnas.151260698; LAVERY PE, 1988, J MOL BIOL, V203, P861, DOI 10.1016/0022-2836(88)90112-X; Lee BI, 2004, EMBO J, V23, P2029, DOI 10.1038/sj.emboj.7600222; Leiros I, 2005, EMBO J, V24, P906, DOI 10.1038/sj.emboj.7600582; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; Liu YL, 2000, EMBO REP, V1, P85, DOI 10.1093/embo-reports/kvd002; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; LUISIDELUCA C, 1994, J MOL BIOL, V236, P124, DOI 10.1006/jmbi.1994.1123; Lusetti SL, 2006, MOL CELL, V21, P41, DOI 10.1016/j.molcel.2005.11.011; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2004, J BIOL CHEM, V279, P55073, DOI 10.1074/jbc.M410371200; Lusetti SL, 2004, J BIOL CHEM, V279, P30037, DOI 10.1074/jbc.M403064200; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; Ma YJ, 2004, J BIOL CHEM, V279, P19035, DOI 10.1074/jbc.M311738200; MADIRAJU MVVS, 1988, P NATL ACAD SCI USA, V85, P6592, DOI 10.1073/pnas.85.18.6592; MADIRAJU MVVS, 1992, BIOCHEMISTRY-US, V31, P10529, DOI 10.1021/bi00158a016; Maxwell KL, 2005, P NATL ACAD SCI USA, V102, P11260, DOI 10.1073/pnas.0503399102; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MOREAU PL, 1988, J BACTERIOL, V170, P2493, DOI 10.1128/jb.170.6.2493-2500.1988; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; Richard DJ, 2004, NUCLEIC ACIDS RES, V32, P1065, DOI 10.1093/nar/gkh259; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROCHA EPC, 2005, PLOS GENET; Savvides SN, 2004, PROTEIN SCI, V13, P1942, DOI 10.1110/ps.04661904; SAWITZKE JA, 1992, GENETICS, V130, P7; SAWITZKE JA, 1994, J BACTERIOL, V176, P6730, DOI 10.1128/JB.176.21.6730-6737.1994; Schlacher K, 2006, CHEM REV, V106, P406, DOI 10.1021/cr0404951; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; SMITH GR, 1989, GENOME, V31, P520, DOI 10.1139/g89-100; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; UMEZU K, 1993, P NATL ACAD SCI USA, V90, P3875, DOI 10.1073/pnas.90.9.3875; UMEZU K, 1994, J BIOL CHEM, V269, P30005; Walker GC, 2000, BACTERIAL STRESS RESPONSES, P131; WANG TCV, 1993, MUTAT RES, V294, P157, DOI 10.1016/0921-8777(93)90024-B; Webb BL, 1997, CELL, V91, P347, DOI 10.1016/S0092-8674(00)80418-3; Webb BL, 1999, J BIOL CHEM, V274, P15367, DOI 10.1074/jbc.274.22.15367; Webb BL, 1995, J BIOL CHEM, V270, P31397, DOI 10.1074/jbc.270.52.31397; WHITBY MC, 1995, MOL GEN GENET, V246, P174, DOI 10.1007/BF00294680; Witte G, 2003, NUCLEIC ACIDS RES, V31, P4434, DOI 10.1093/nar/gkg498; Yasuda T, 2001, EMBO J, V20, P1192, DOI 10.1093/emboj/20.5.1192; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	81	67	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11058	11067		10.1074/jbc.M611007200	http://dx.doi.org/10.1074/jbc.M611007200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17272275	hybrid			2022-12-25	WOS:000245941500026
J	Dhawan, L; Liu, B; Blaxall, BC; Taubman, MB				Dhawan, Latika; Liu, Bin; Blaxall, Burns C.; Taubman, Mark B.			A novel role for the glucocorticoid receptor in the regulation of monocyte chemoattractant protein-1 mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; CHOLESTEROL-FED RABBITS; BALLOON ARTERIAL INJURY; GENE-EXPRESSION; ATHEROSCLEROTIC LESIONS; MACROPHAGE ACCUMULATION; NEOINTIMAL HYPERPLASIA; INTIMAL HYPERPLASIA; MCP-1 DEFICIENCY; DNA-BINDING	Monocyte chemoattractant protein-1 (MCP-1) plays an important role in attracting monocytes to sites of inflammation and is the dominant mediator of macrophage accumulation in atherosclerotic plaques. We have previously shown that glucocorticoids inhibit the secretion of MCP-1 in arterial smooth muscle cells (SMC) by markedly decreasing MCP-1 mRNA stability. We now report that the destabilization of MCP-1 mRNA is mediated by the glucocorticoid receptor (GR). The GR antagonist, RU486, blocked the effect of the glucocorticoid dexamethasone (Dex) on MCP-1 mRNA stability in SMC culture. Using a previously reported in vitro mRNA gel shift and stability assay, antibodies to the GR blocked the ability of cytoplasmic extracts from Dex-treated SMC to decay MCP-1 mRNA. Recombinant human GR (rhGR) bound in a concentration dependent manner to in vitro transcribed MCP-1 mRNA, whereas other members of the steroid hormone receptor family did not. Binding of GR to MCP-1 mRNA was specific as it was not found to bind other mRNAs. Immunoprecipitation of GR in extracts from Dex-treated SMC followed by real-time reverse transcription-PCR demonstrated that endogenous GR was bound specifically to MCP-1 mRNA. The addition of exogenous rhGR blocked the ability of extracts from Dex-treated SMC to degrade MCP-1 mRNA, suggesting that exogenous rhGR can compete with an endogenous GR-containing degradative complex. These data suggest a novel role for the GR in binding to and facilitating mRNA degradation. These results provide novel insights into GR function and may provide a new approach to attenuate the inflammatory response mediated by MCP-1.	Univ Rochester, Sch Med & Dent, Rochester, NY 14620 USA; Univ Rochester, Cardiovasc Res Inst, Rochester, NY 14620 USA	University of Rochester; University of Rochester	Taubman, MB (corresponding author), Univ Rochester, Sch Med & Dent, 601 Elmwood Ave,Box 678 CVRI, Rochester, NY 14620 USA.	mark_taubman@urmc.rochester.edu	Blaxall, Burns/ABD-8289-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL077789, R01HL077669] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL77669, P01 HL77789] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alcorn JL, 2004, AM J PHYSIOL-LUNG C, V286, pL767, DOI 10.1152/ajplung.00280.2003; ALI M, 1987, J BIOL CHEM, V262, P6778; ASAI K, 1993, ARTERIOSCLER THROMB, V13, P892, DOI 10.1161/01.ATV.13.6.892; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERK BC, 1991, J AM COLL CARDIOL, V17, pB111; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; Cooper JAD, 1998, AM J RESP CELL MOL, V18, P521, DOI 10.1165/ajrcmb.18.4.2786; DAVIES GJ, 1995, EUR HEART J, V16, P31, DOI 10.1093/eurheartj/16.suppl_I.31; de Silanes IL, 2005, MOL CELL BIOL, V25, P9520, DOI 10.1128/MCB.25.21.9520-9531.2005; Egashira K, 2002, CIRC RES, V90, P1167, DOI 10.1161/01.RES.0000020561.03244.7E; Furukawa Y, 1999, CIRC RES, V84, P306, DOI 10.1161/01.RES.84.3.306; Gao ZL, 2003, CHEM REV, V103, P3733, DOI 10.1021/cr020474b; Garcia-Gras EA, 2000, J BIOL CHEM, V275, P22001, DOI 10.1074/jbc.M001048200; Gosling J, 1999, J CLIN INVEST, V103, P773, DOI 10.1172/JCI5624; Gu L, 1999, Chem Immunol, V72, P7, DOI 10.1159/000058723; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Kim WJH, 2003, BIOCHEM BIOPH RES CO, V310, P936, DOI 10.1016/j.bbrc.2003.09.088; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Libby P, 1996, CURR OPIN LIPIDOL, V7, P330, DOI 10.1097/00041433-199610000-00012; Liu B, 2006, J MOL CELL CARDIOL, V41, P160, DOI 10.1016/j.yjmcc.2006.03.426; MCGUIRE J, 1988, ANN NY ACAD SCI, V548, P283, DOI 10.1111/j.1749-6632.1988.tb18816.x; NAITO M, 1992, J NUTR SCI VITAMINOL, V38, P255, DOI 10.3177/jnsv.38.255; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Newton R, 2000, THORAX, V55, P603, DOI 10.1136/thorax.55.7.603; OLIVER N, 1983, CELL, V33, P287, DOI 10.1016/0092-8674(83)90357-4; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; Poon M, 1999, MOL CELL BIOL, V19, P6471; POON M, 1991, J BIOL CHEM, V266, P22375; Poon M, 1999, LAB INVEST, V79, P1369; Poon M, 2001, ATHEROSCLEROSIS, V155, P371, DOI 10.1016/S0021-9150(00)00605-5; Poon M, 1996, AM J PATHOL, V149, P307; Pype JL, 1999, AM J RESP CELL MOL, V21, P528, DOI 10.1165/ajrcmb.21.4.3660; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; Roque M, 2002, ARTERIOSCL THROM VAS, V22, P554, DOI 10.1161/hq0402.105720; ROSSINI GP, 1987, BIOCHEM BIOPH RES CO, V147, P1188, DOI 10.1016/S0006-291X(87)80195-X; RUSSOMARIE F, 1992, J NEUROIMMUNOL, V40, P281, DOI 10.1016/0165-5728(92)90144-A; Sakai M, 1999, ARTERIOSCL THROM VAS, V19, P1726, DOI 10.1161/01.ATV.19.7.1726; SLAVIN J, 1995, GROWTH FACTORS, V12, P151, DOI 10.3109/08977199509028961; Stellato Cristiana, 2004, Proc Am Thorac Soc, V1, P255, DOI 10.1513/pats.200402-015MS; Steube Klaus G., 2000, Molecular Cell Biology Research Communications, V3, P60, DOI 10.1006/mcbr.2000.0190; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; TYMOCZKO JL, 1985, BIOCHIM BIOPHYS ACTA, V846, P193, DOI 10.1016/0167-4889(85)90065-5; VanPut DJM, 1995, EUR J PHARMACOL, V294, P753, DOI 10.1016/0014-2999(95)00635-4; Wang JM, 1999, AM J PHYSIOL-LUNG C, V276, pL175, DOI 10.1152/ajplung.1999.276.1.L175; Wysocki SJ, 1996, J CELL BIOCHEM, V62, P303, DOI 10.1002/(SICI)1097-4644(199609)62:3<303::AID-JCB1>3.0.CO;2-V; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YU XH, 1992, P NATL ACAD SCI USA, V89, P6953, DOI 10.1073/pnas.89.15.6953	50	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10146	10152		10.1074/jbc.M605925200	http://dx.doi.org/10.1074/jbc.M605925200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17276989	hybrid			2022-12-25	WOS:000245941000004
J	Duurkens, RH; Tol, MB; Geertsma, ER; Permentier, HP; Slotboom, DJ				Duurkens, Ria H.; Tol, Menno B.; Geertsma, Eric R.; Permentier, Hjalmar P.; Slotboom, Dirk Jan			Flavin binding to the high affinity riboflavin transporter RibU	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTOCOCCUS-LACTIS; 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE; SCHIZOSACCHAROMYCES-POMBE; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; GENE-EXPRESSION; PROTEIN; BIOSYNTHESIS; MEMBRANE; SYSTEMS	The first biochemical and spectroscopic characterization of a purified membrane transporter for riboflavin ( vitamin B-2) is presented. The riboflavin transporter RibU from the bacterium Lactococcus lactis was overexpressed, solubilized, and purified. The purified transporter was bright yellow when the cells had been cultured in rich medium. We used a detergent- compatible matrix- assisted laser desorption ionization time-of-flight mass spectrometry method ( Cadene, M., and Chait, B. T. ( 2000) Anal. Chem. 72, 5655 - 5658) to show that the source of the yellow color was riboflavin that had been co-purified with the transporter. The method appears generally applicable for substrate identification of purified membrane proteins. Substrate- free RibU was produced by expressing the protein in cells cultured in chemically defined medium. Riboflavin, FMN, and roseoflavin bound to RibU with high affinity and 1: 1 stoichiometry ( K-d for riboflavin is 0.6 nM), but FAD did not bind to the transporter. The absorption spectrum of riboflavin changed dramatically when the substrate bound to RibU. Well resolved bands appeared at 441, 464, and 486 nm, indicating a hydrophobic binding pocket. The fluorescence of riboflavin was almost completely quenched upon binding to RibU, and also the tryptophan fluorescence of the transporter was quenched when flavins bound. The results indicate that riboflavin is stacked with one or more tryptophan residues in the binding pocket of RibU. Mutagenesis experiments showed that Trp-68 was involved directly in the riboflavin binding. The structural properties of the binding site and mechanistic consequences of the exceptionally high affinity of RibU for its substrate are discussed in relation to soluble riboflavin- binding proteins of known structure.	Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands	University of Groningen	Slotboom, DJ (corresponding author), Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	d.j.slotboom@rug.nl	Permentier, Hjalmar P/H-4190-2016	Permentier, Hjalmar P/0000-0001-7317-8887; Geertsma, Eric R./0000-0002-2789-5444				Bacher A, 2000, ANNU REV NUTR, V20, P153, DOI 10.1146/annurev.nutr.20.1.153; Bieger B, 2003, STRUCTURE, V11, P375, DOI 10.1016/S0969-2126(03)00048-0; BOWMAN BB, 1989, ANNU REV NUTR, V9, P187, DOI 10.1146/annurev.nu.09.070189.001155; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burgess C, 2004, APPL ENVIRON MICROB, V70, P5769, DOI 10.1128/AEM.70.10.5769-5777.2004; Burgess CM, 2006, J BACTERIOL, V188, P2752, DOI 10.1128/JB.188.8.2752-2760.2006; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; CECCHINI G, 1979, J BIOL CHEM, V254, P7295; CHOI JD, 1980, ARCH BIOCHEM BIOPHYS, V204, P41, DOI 10.1016/0003-9861(80)90005-3; Eitinger T, 2000, ARCH MICROBIOL, V173, P1, DOI 10.1007/s002030050001; Fischer M, 2002, EUR J BIOCHEM, V269, P519, DOI 10.1046/j.0014-2956.2001.02674.x; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; Gerhardt S, 2002, J MOL BIOL, V318, P1317, DOI 10.1016/S0022-2836(02)00116-X; GHISLA S, 1986, BIOCHEM J, V239, P1; HARBURY HA, 1959, P NATL ACAD SCI USA, V45, P1708, DOI 10.1073/pnas.45.12.1708; Kreneva RA, 2000, RUSS J GENET+, V36, P972; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; MOLENAAR D, 1993, J BACTERIOL, V175, P5438, DOI 10.1128/JB.175.17.5438-5444.1993; Monaco HL, 1997, EMBO J, V16, P1475, DOI 10.1093/emboj/16.7.1475; NISHIKIMI M, 1973, J BIOCHEM, V73, P1233, DOI 10.1093/oxfordjournals.jbchem.a130196; Ohashi Y, 2003, CURR ORG CHEM, V7, P1605, DOI 10.2174/1385272033486288; OTTO MK, 1981, P NATL ACAD SCI-BIOL, V78, P266, DOI 10.1073/pnas.78.1.266; Reihl P, 2005, J BIOL CHEM, V280, P39809, DOI 10.1074/jbc.M505002200; Sahin-Toth M, 2000, BIOCHEMISTRY-US, V39, P5097, DOI 10.1021/bi0000263; van der Heide T, 2000, P NATL ACAD SCI USA, V97, P7102, DOI 10.1073/pnas.97.13.7102; Veldhuis G, 2004, BIOPHYS J, V86, P1959, DOI 10.1016/S0006-3495(04)74259-9; VELDHUIS G, 2006, THESIS U GRONINGEN; WHITE HB, 1988, ANNU REV NUTR, V8, P279, DOI 10.1146/annurev.nu.08.070188.001431; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	29	75	78	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10380	10386		10.1074/jbc.M608583200	http://dx.doi.org/10.1074/jbc.M608583200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289680	hybrid			2022-12-25	WOS:000245941000028
J	Meray, RK; Lansbury, PT				Meray, Robin K.; Lansbury, Peter T., Jr.			Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL HYDROLASES; DEUBIQUITINATING ENZYMES; CONFORMATIONAL PLASTICITY; BINDING PROTEINS; STRUCTURAL BASIS; CELL APOPTOSIS; BETA-ARRESTIN; IN-VIVO; PGP 9.5; SUBSTRATE	Deubiquitinating enzymes ( DUBs) are negative regulators of protein ubiquitination and play an important role in ubiquitin-dependent processes. Recent studies have found that diverse cellular mechanisms are employed to control the activity of DUBs. Ubiquitin C-terminal hydrolase-L1 ( UCH-L1) is a highly expressed neuronal DUB linked to Parkinson disease; however, little is known about its specific functions or modes of regulation. Here, we demonstrate that UCH-L1 is post-translationally modified by monoubiquitin in cells, at lysine residues near the active site. This modification restricts enzyme activity by preventing binding to ubiquitinated targets, and permanent monoubiquitination, as mimicked by a ubiquitin-UCH-L1 fusion, inhibits UCH-L1 in its capacity to increase free ubiquitin levels in cells. Interestingly, UCH-L1 catalyzes its own deubiquitination in an intramolecular manner, thereby regulating the lifetime of this modification. Our results illustrate monoubiquitination as a reversible regulatory mechanism for DUB activity involving auto-deubiquitination.	Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Cambridge, MA 02139 USA	Harvard University; Harvard University; Brigham & Women's Hospital	Lansbury, PT (corresponding author), Ctr Neurol Dis, 65 Landsdowne St,4th Floor, Cambridge, MA 02139 USA.	plansbury@rics.bwh.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS047420] Funding Source: NIH RePORTER; NINDS NIH HHS [R21NS047420] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Burbea M, 2002, NEURON, V35, P107, DOI 10.1016/S0896-6273(02)00749-3; Caballero OL, 2002, ONCOGENE, V21, P3003, DOI 10.1038/sj.onc.1205390; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; Das C, 2006, P NATL ACAD SCI USA, V103, P4675, DOI 10.1073/pnas.0510403103; DiAntonio A, 2004, ANNU REV NEUROSCI, V27, P223, DOI 10.1146/annurev.neuro.27.070203.144317; DICKSON DW, 1994, ACTA NEUROPATHOL, V87, P269; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; Facheris M, 2005, NEUROSCI LETT, V381, P131, DOI 10.1016/j.neulet.2005.02.008; Gong B, 2006, CELL, V126, P775, DOI 10.1016/j.cell.2006.06.046; Harada T, 2004, AM J PATHOL, V164, P59, DOI 10.1016/S0002-9440(10)63096-9; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hibi K, 1999, AM J PATHOL, V155, P711, DOI 10.1016/S0002-9440(10)65169-3; Hoeller D, 2006, NAT CELL BIOL, V8, P163, DOI 10.1038/ncb1354; Huang TT, 2006, NAT CELL BIOL, V8, P339, DOI 10.1038/ncb1378; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Johnston SC, 1999, EMBO J, V18, P3877, DOI 10.1093/emboj/18.14.3877; Kwon J, 2004, AM J PATHOL, V165, P1367, DOI 10.1016/S0002-9440(10)63394-9; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Larsen CN, 1998, BIOCHEMISTRY-US, V37, P3358, DOI 10.1021/bi972274d; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Luchansky SJ, 2006, BIOCHEMISTRY-US, V45, P14717, DOI 10.1021/bi061406c; Machida YJ, 2006, MOL CELL, V23, P589, DOI 10.1016/j.molcel.2006.06.024; Miller SLH, 2004, J BIOL CHEM, V279, P33528, DOI 10.1074/jbc.M313097200; Misaghi S, 2005, J BIOL CHEM, V280, P1512, DOI 10.1074/jbc.M410770200; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Nishikawa K, 2003, BIOCHEM BIOPH RES CO, V304, P176, DOI 10.1016/S0006-291X(03)00555-2; Osaka H, 2003, HUM MOL GENET, V12, P1945, DOI 10.1093/hmg/ddg211; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Reiley W, 2005, MOL CELL BIOL, V25, P3886, DOI 10.1128/MCB.25.10.3886-3895.2005; Satoh J, 2001, J NEUROL SCI, V189, P113, DOI 10.1016/S0022-510X(01)00555-X; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Shen CL, 2005, J BIOL CHEM, V280, P35967, DOI 10.1074/jbc.M505220200; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shenoy SK, 2005, J BIOL CHEM, V280, P15315, DOI 10.1074/jbc.M412418200; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Xue SF, 2006, BRAIN RES, V1087, P28, DOI 10.1016/j.brainres.2006.02.121; Yamazaki T, 2002, CLIN CANCER RES, V8, P192; Zhu QZ, 2005, EXP CELL RES, V307, P436, DOI 10.1016/j.yexcr.2005.03.031	48	78	81	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10567	10575		10.1074/jbc.M611153200	http://dx.doi.org/10.1074/jbc.M611153200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17259170	hybrid			2022-12-25	WOS:000245941000050
J	Hernandez, E; Leite, MF; Guerra, MT; Kruglov, EA; Bruna-Romero, O; Rodrigues, MA; Gomes, DA; Giordano, FJ; Dranoff, JA; Nathanson, MH				Hernandez, Erick; Leite, M. Fatima; Guerra, Mateus T.; Kruglov, Emma A.; Bruna-Romero, Oscar; Rodrigues, Michele A.; Gomes, Dawidson A.; Giordano, Frank J.; Dranoff, Jonathan A.; Nathanson, Michael H.			Spatial distribution of inositol 1,4,5-trisphosphate receptor isoforms shapes Ca2+ waves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOCYTE COUPLETS; PANCREATIC ACINAR-CELLS; BILE-DUCT EPITHELIA; GENE-EXPRESSION; XENOPUS OOCYTES; CALCIUM WAVES; TRISPHOSPHATE RECEPTOR; LIVER; OSCILLATIONS; VASOPRESSIN	Cytosolic Ca2+ is a versatile second messenger that can regulate multiple cellular processes simultaneously. This is accomplished in part through Ca2+ waves and other spatial patterns of Ca2+ signals. To investigate the mechanism responsible for the formation of Ca2+ waves, we examined the role of inositol 1,4,5-trisphosphate receptor (InsP3R) isoforms in Ca2+ wave formation. Ca2+ signals were examined in hepatocytes, which express the type I and II InsP3R in a polarized fashion, and in AR4-2J cells, a nonpolarized cell line that expresses type I and II InsP3R in a ratio similar to what is found in hepatocytes but homogeneously throughout the cell. Expression of type I or II InsP3R was selectively suppressed by isoform-specific DNA antisense in an adenoviral delivery system, which was delivered to AR4-2J cells in culture and to hepatocytes in vivo. Loss of either isoform inhibited Ca2+ signals to a similar extent in AR4-2J cells. In contrast, loss of the basolateral type I InsP3R decreased the sensitivity of hepatocytes to vasopressin but had little effect on the initiation or spread of Ca2+ waves across hepatocytes. Loss of the apical type II isoform caused an even greater decrease in the sensitivity of hepatocytes to vasopressin and resulted in Ca2+ waves that were much slower and delayed in onset. These findings provide evidence that the apical concentration of type II InsP3Rs is essential for the formation of Ca2+ waves in hepatocytes. The subcellular distribution of InsP3R isoforms may critically determine the repertoire of spatial patterns of Ca2+ signals.	Yale Univ, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Dept Med, New Haven, CT 06520 USA; Univ Fed Minas Gerais, Dept Physiol & Biophys, BR-31270901 Belo Horizonte, MG, Brazil	Yale University; Yale University; Universidade Federal de Minas Gerais	Nathanson, MH (corresponding author), Yale Univ, Sch Med, Rm TAC S241D,1 Gilbert St, New Haven, CT 06520 USA.	michael.nathanson@yale.edu	de Fatima Leite, Maria/AAK-2555-2021; BRUNA-ROMERO, OSCAR/B-3918-2010; Gomes, Dawidson Assis/O-1372-2013	BRUNA-ROMERO, OSCAR/0000-0002-8855-4969; Gomes, Dawidson Assis/0000-0001-7714-991X	FIC NIH HHS [R03 TW001451, TW01451] Funding Source: Medline; NIDDK NIH HHS [DK57751, R01 DK045710-06A2, R01 DK061747, DK34989, DK07356, DK45710, DK61747, R01 DK045710, P30 DK034989-169004, P01 DK057751, P01 DK057751-01A1, P30 DK034989, T32 DK007356] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001451] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007356, R01DK045710, P30DK034989, P01DK057751, R01DK061747, R29DK045710] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GAUTAM A, 1987, HEPATOLOGY, V7, P216, DOI 10.1002/hep.1840070203; Gilland E, 1999, P NATL ACAD SCI USA, V96, P157, DOI 10.1073/pnas.96.1.157; GRAF J, 1984, P NATL ACAD SCI-BIOL, V81, P6516, DOI 10.1073/pnas.81.20.6516; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hattori M, 2004, J BIOL CHEM, V279, P11967, DOI 10.1074/jbc.M311456200; Hirata K, 1999, INVEST OPHTH VIS SCI, V40, P2046; Hirata K, 1998, P NATL ACAD SCI USA, V95, P8381, DOI 10.1073/pnas.95.14.8381; Hirata K, 2002, HEPATOLOGY, V36, P284, DOI 10.1053/jhep.2002.34432; Hirata K, 2002, GASTROENTEROLOGY, V122, P1088, DOI 10.1053/gast.2002.32363; Ito K, 1997, EMBO J, V16, P242, DOI 10.1093/emboj/16.2.242; JOSEPH SK, 1994, J BIOL CHEM, V269, P5673; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LEITE MF, 2001, LIVER BIOL PATHOBIOL, P537; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Lu CY, 1996, J MOL CELL CARDIOL, V28, P1703, DOI 10.1006/jmcc.1996.0160; Marchant J, 1999, EMBO J, V18, P5285, DOI 10.1093/emboj/18.19.5285; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Morel JL, 2003, ARTERIOSCL THROM VAS, V23, P1567, DOI 10.1161/01.ATV.0000089013.82552.5D; Nathanson MH, 1999, J EXP BIOL, V202, P3049; NATHANSON MH, 1992, J BIOL CHEM, V267, P23282; Nathanson MH, 1996, AM J PHYSIOL-REG I, V270, pR561, DOI 10.1152/ajpregu.1996.270.3.R561; Nathanson MH, 1999, GASTROENTEROLOGY, V116, P1176, DOI 10.1016/S0016-5085(99)70021-1; NATHANSON MH, 1995, AM J PHYSIOL-GASTR L, V269, pG167, DOI 10.1152/ajpgi.1995.269.1.G167; NATHANSON MH, 1992, MOL BIOL CELL, V3, P113, DOI 10.1091/mbc.3.1.113; NATHANSON MH, 1994, AM J PHYSIOL, V267, pG338, DOI 10.1152/ajpgi.1994.267.3.G338; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Onoue H, 2000, BIOCHEM BIOPH RES CO, V267, P928, DOI 10.1006/bbrc.1999.2065; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; PARYS JB, 1995, CELL CALCIUM, V18, P353, DOI 10.1016/0143-4160(95)90051-9; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; ROBBGASPERS LD, 1995, J BIOL CHEM, V270, P8102, DOI 10.1074/jbc.270.14.8102; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; Shibao K, 2003, GASTROENTEROLOGY, V125, P1175, DOI 10.1016/S0016-5085(03)01201-0; Sugiyama T, 1996, J HISTOCHEM CYTOCHEM, V44, P1237, DOI 10.1177/44.11.8918898; Swillens S, 1999, P NATL ACAD SCI USA, V96, P13750, DOI 10.1073/pnas.96.24.13750; Tordjmann T, 1998, EMBO J, V17, P4695, DOI 10.1093/emboj/17.16.4695; Tordjmann T, 1997, EMBO J, V16, P5398, DOI 10.1093/emboj/16.17.5398; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; YAO Y, 1995, J PHYSIOL-LONDON, V482, P533, DOI 10.1113/jphysiol.1995.sp020538; Yule DI, 1997, J BIOL CHEM, V272, P9093	51	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10057	10067		10.1074/jbc.M700746200	http://dx.doi.org/10.1074/jbc.M700746200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17284437	Green Accepted, hybrid			2022-12-25	WOS:000245421700080
J	Liu, SW; Jing, WG; Cheung, B; Lu, H; Sun, J; Yan, XX; Niu, JK; Farmar, J; Wu, SG; Jiang, SB				Liu, Shuwen; Jing, Weiguo; Cheung, Byron; Lu, Hong; Sun, Jane; Yan, Xuxia; Niu, Jinkui; Farmar, James; Wu, Shuguang; Jiang, Shibo			HIV gp41 C-terminal heptad repeat contains multifunctional domains - Relation to mechanisms of action of anti-HIV peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; 6-HELIX BUNDLE FORMATION; ENV-MEDIATED FUSION; MEMBRANE-FUSION; ENVELOPE GLYCOPROTEIN; INHIBITORY-ACTION; ENTRY INHIBITORS; COILED-COIL; BINDING; CONFORMATION	T20 (Fuzeon), a novel anti-human immunodeficiency virus (HIV) drug, is a peptide derived from HIV-1 gp41 C-terminal heptad repeat (CHR). Its mechanism of action has not yet been defined. We applied Pepscan strategy to determine the relationship between functional domains and mechanisms of action of five 36-mer overlapping peptides with a shift of five amino acids (aa): CHR-1 (aa 623-658), C36 (aa 628-663), CHR-3 (aa 633-668), T20 (aa 638 - 673), and CHR-5 (aa 643- 678). C36 is a peptide with addition of two aa to the N terminus of C34. Peptides CHR-1 and C36 contain N-terminal heptad repeat (NHR)- and pocket-binding domains. They inhibited HIV-1 fusion by interacting with gp41 NHR, forming stable six-helix bundles and blocking gp41 core formation. Peptide T20 containing partial NHR- and lipid-binding domains, but lacking pocket-binding domain, blocked viral fusion by binding its N- and C-terminal sequences with gp41 NHR and cell membrane, respectively. Peptide CHR-3, which is located in the middle between C36 and T20, overlaps > 86% of the sequences of these two peptides, and lacks pocket- and lipid-binding domains, exhibited marginal anti-HIV-1 activity. These results suggest that T20 and C36 contain different functional domains, through which they inhibit HIV-1 entry with distinct mechanisms of action. The multiple functional domains in gp41 CHR and their binding partners may serve as targets for rational design of new anti-HIV-1 drugs and vaccines.	So Med Univ, Sch Pharmaceut Sci, Guangzhou 510515, Peoples R China; New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10021 USA	Southern Medical University - China; New York Blood Center	Liu, SW (corresponding author), So Med Univ, Sch Pharmaceut Sci, Guangzhou 510515, Peoples R China.	liusw269@gmail.com; sjiang@nybloodcenter.org	Jiang, Shibo/L-4500-2014	Jiang, Shibo/0000-0001-8283-7135; Liu, Shuwen/0000-0001-6346-5006	NIAID NIH HHS [R01 AI46221] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046221] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Armand-Ugon M, 2003, ANTIVIR RES, V59, P137, DOI 10.1016/S0166-3542(03)00071-8; Baldwin CE, 2004, J VIROL, V78, P12428, DOI 10.1128/JVI.78.22.12428-12437.2004; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHOU TC, 1991, CALCUSYN; Cohen FS, 2004, J MEMBRANE BIOL, V199, P1, DOI 10.1007/s00232-004-0669-8; Dwyer JJ, 2003, BIOCHEMISTRY-US, V42, P4945, DOI 10.1021/bi027283n; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Gallo SA, 2006, J BIOL CHEM, V281, P18787, DOI 10.1074/jbc.M602422200; Hildinger M, 2001, J VIROL, V75, P3038, DOI 10.1128/JVI.75.6.3038-3042.2001; Hong LA, 2003, J VIROL METHODS, V107, P155, DOI 10.1016/S0166-0934(02)00213-6; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; JIANG S, 2000, P SOC PHOTO-OPT INS, V3926, P212, DOI DOI 10.1117/12.380514; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jiang SB, 2004, ANTIMICROB AGENTS CH, V48, P4349, DOI 10.1128/AAC.48.11.4349-4359.2004; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kilby JM, 2003, NEW ENGL J MED, V348, P2228, DOI 10.1056/NEJMra022812; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; Liu SW, 2005, J BIOL CHEM, V280, P11259, DOI 10.1074/jbc.M411141200; Liu SW, 2003, PEPTIDES, V24, P1303, DOI 10.1016/j.peptides.2003.07.013; Liu SW, 2003, J BIOMOL SCREEN, V8, P685, DOI 10.1177/1087057103259155; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100; MOORE JP, 1993, VIRAL FUSION MECHANI, P233; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Peisajovich SG, 2003, J BIOL CHEM, V278, P21012, DOI 10.1074/jbc.M212773200; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; Schibli DJ, 2001, BIOCHEMISTRY-US, V40, P9570, DOI 10.1021/bi010640u; Shnaper S, 2004, J BIOL CHEM, V279, P18526, DOI 10.1074/jbc.M304950200; Shu W, 2000, J BIOL CHEM, V275, P1839, DOI 10.1074/jbc.275.3.1839; Trivedi VD, 2003, PROTEIN ENG, V16, P311, DOI 10.1093/proeng/gzg036; Veiga AS, 2004, J AM CHEM SOC, V126, P14758, DOI 10.1021/ja0459882; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wexler-Cohen Y, 2006, J BIOL CHEM, V281, P9005, DOI 10.1074/jbc.M512475200; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1995, AIDS RES HUM RETROV, V11, P323, DOI 10.1089/aid.1995.11.323; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	43	123	137	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9612	9620		10.1074/jbc.M609148200	http://dx.doi.org/10.1074/jbc.M609148200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276993	hybrid			2022-12-25	WOS:000245421700034
J	Ohnuma, K; Uchiyama, M; Yamochi, T; Nishibashi, K; Hosono, O; Takahashi, N; Kina, S; Tanaka, H; Lin, X; Dang, NH; Morimoto, C				Ohnuma, Kei; Uchiyama, Masahiko; Yamochi, Tadanori; Nishibashi, Kunika; Hosono, Osamu; Takahashi, Nozomu; Kina, Shinichiro; Tanaka, Hirotoshi; Lin, Xin; Dang, Nam H.; Morimoto, Chikao			Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DIPEPTIDYL PEPTIDASE-IV; ANTIGEN-PRESENTING CELLS; MAGUK FAMILY; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; PERIPHERAL-BLOOD; SURFACE-MOLECULE; SYNOVIAL-FLUID; PROTEIN-KINASE	CD26 is a widely distributed 110-kDa cell surface glycoprotein with an important role in T-cell costimulation. We demonstrated previously that CD26 binds to caveolin-1 in antigen-presenting cells, and following exogenous CD26 stimulation, Tollip and IRAK-1 disengage from caveolin-1 in antigen-presenting cells. IRAK-1 is then subsequently phosphorylated to up-regulate CD86 expression, resulting in subsequent T-cell proliferation. However, it is unclear whether caveolin-1 is a costimulatory ligand for CD26 in T-cells. Using soluble caveolin-1-Fc fusion protein, we now show that caveolin-1 is the costimulatory ligand for CD26, and that ligation of CD26 by caveolin-1 induces T-cell proliferation and NF-kappa B activation in a T-cell receptor/CD3-dependent manner. We also demonstrated that the cytoplasmic tail of CD26 interacts with CARMAI in T-cells, resulting in signaling events that lead to NF-kappa B activation. Ligation of CD26 by caveolin-1 recruits a complex consisting of CD26, CARMAI, Bcl10, and I kappa B kinase to lipid rafts. Taken together, our findings provide novel insights into the regulation of T-cell costimulation via the CD26 molecule.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Nevada Canc Inst, Dept Hematol Malignancies, Las Vegas, NV 89135 USA	University of Tokyo; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Diego	Morimoto, C (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	morimoto@ims.u-tokyo.ac.jp						Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Che TJ, 2004, J BIOL CHEM, V279, P15870, DOI 10.1074/jbc.M310599200; Chen CY, 2003, B MATH BIOL, V65, P933, DOI 10.1016/S0092-8240(03)00055-7; Chien CH, 2004, J BIOL CHEM, V279, P52338, DOI 10.1074/jbc.M406185200; CICCIMARRA F, 1976, J CLIN INVEST, V57, P1386, DOI 10.1172/JCI108407; Collins AV, 2002, IMMUNITY, V17, P201, DOI 10.1016/S1074-7613(02)00362-X; DANG NH, 1990, J IMMUNOL, V145, P3963; DANG NH, 1990, J IMMUNOL, V144, P4092; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Dong RP, 1998, MOL IMMUNOL, V35, P13, DOI 10.1016/S0161-5890(98)00015-7; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; EGUCHI K, 1989, J IMMUNOL, V142, P4233; FLEISCHER B, 1994, IMMUNOL TODAY, V15, P180, DOI 10.1016/0167-5699(94)90316-6; FOX DA, 1984, J IMMUNOL, V133, P1250; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Gerli R, 1996, CLIN IMMUNOL IMMUNOP, V80, P31, DOI 10.1006/clin.1996.0091; Hara H, 2004, J EXP MED, V200, P1167, DOI 10.1084/jem.20032246; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Hegen M, 1997, IMMUNOLOGY, V90, P257, DOI 10.1046/j.1365-2567.1997.00053.x; Ishii T, 2001, P NATL ACAD SCI USA, V98, P12138, DOI 10.1073/pnas.211439098; Kahne T, 1999, INT J MOL MED, V4, P3; Lee KY, 2005, SCIENCE, V308, P114, DOI 10.1126/science.1107107; Lin X, 2004, SEMIN IMMUNOL, V16, P429, DOI 10.1016/j.smim.2004.08.022; MARGUET D, 1992, J BIOL CHEM, V267, P2200; Mizokami A, 1996, J RHEUMATOL, V23, P2022; Morimoto C, 1998, IMMUNOL REV, V161, P55, DOI 10.1111/j.1600-065X.1998.tb01571.x; MORIMOTO C, 1989, J IMMUNOL, V143, P3430; MUSCAT C, 1994, CLIN EXP IMMUNOL, V98, P252; NANUS DM, 1993, P NATL ACAD SCI USA, V90, P7069, DOI 10.1073/pnas.90.15.7069; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohnuma K, 2005, MOL CELL BIOL, V25, P7743, DOI 10.1128/MCB.25.17.7743-7757.2005; Ohnuma K, 2004, P NATL ACAD SCI USA, V101, P14186, DOI 10.1073/pnas.0405266101; Ohnuma K, 2002, IMMUNOLOGY, V107, P325, DOI 10.1046/j.1365-2567.2002.01510.x; Ohnuma K, 2001, J IMMUNOL, V167, P6745, DOI 10.4049/jimmunol.167.12.6745; Rasmussen HB, 2003, NAT STRUCT BIOL, V10, P19, DOI 10.1038/nsb882; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Tanaka J, 1999, BIOCHEM BIOPH RES CO, V264, P938, DOI 10.1006/bbrc.1999.1617; TANAKA T, 1994, P NATL ACAD SCI USA, V91, P3082, DOI 10.1073/pnas.91.8.3082; TANAKA T, 1993, P NATL ACAD SCI USA, V90, P4586, DOI 10.1073/pnas.90.10.4586; TANAKA T, 1992, J IMMUNOL, V149, P481; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; von Bonin A, 1998, IMMUNOL REV, V161, P43; vonBonin A, 1997, IMMUNOL LETT, V55, P179, DOI 10.1016/S0165-2478(97)02705-3; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wegener E, 2006, MOL CELL, V23, P13, DOI 10.1016/j.molcel.2006.05.027; Yan SL, 2003, EUR J IMMUNOL, V33, P1519, DOI 10.1002/eji.200323469; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	53	94	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10117	10131		10.1074/jbc.M609157200	http://dx.doi.org/10.1074/jbc.M609157200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17287217	hybrid			2022-12-25	WOS:000245421700085
J	Cudilo, E; Al Naemi, H; Marmorstein, L; Baldwin, AL				Cudilo, Elizabeth; Al Naemi, Hamda; Marmorstein, Lihua; Baldwin, Ann L.			Knockout Mice: Is It Just Genetics? Effect of Enriched Housing on Fibulin-4(+/-) Mice	PLOS ONE			English	Article								Background. Fibulin-4 is an extracellular matrix protein expressed by vascular smooth muscle cells that is essential for maintaining arterial integrity. Fibulin-4(-/-) mice die just before birth due to arterial hemorrhage, but fibulin-4(+/-) mice appear to be outwardly normal. Experiments were therefore performed to determine whether fibulin-4(+/-) mice display arterial pathologies on a microscopic scale. After preliminary experiments were performed, a second purpose developed, which was to test the hypothesis that any observed pathologies would be ameliorated by housing the animals in enriched cages. Methodology. Fibulin-4(+/-) and wild-type mice were housed either four/cage in standard cages or two per cage in larger cages, each cage containing a tunnel and a wheel. After three weeks the mice were sacrificed, and the aortas perfusion-fixed and excised for light and electron microscopy. Principle Findings. When the mice were in standard cages, localized regions of disorganized extracellular matrix and collagen fibers consistently appeared between some of the medial smooth muscle cells in the fibulin-4(+/-) mice. In the wild-type mice, the smooth muscle cells were closely connected to each other and the media was more compact. The number of disorganized regions per square mm was significantly greater for fibulin-4(+/-) mice (172 +/- 43 (SEM)) than for wild-type mice (15 +/- 8) (p<0.01, n = 8). When the mice were in enriched cages, the fibulin-4(+/-) mice showed significantly fewer disorganized regions than those in standard cages (35 +/- 12) (p<0.05, n = 8). The wild type mice also showed fewer disorganized regions (3 +/- 2), but this difference was not significant. Conclusions. These results indicate that arterial pathologies manifested in fibulin-4(+/-) mice can be reduced by enriching the housing conditions, and imply that appropriate environments may counteract the effects of some genetic deficiencies.	[Cudilo, Elizabeth; Baldwin, Ann L.] Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA; [Al Naemi, Hamda] Univ Qatar, Doha, Qatar; [Marmorstein, Lihua] Univ Arizona, Dept Ophthalmol & Vis Sci, Tucson, AZ USA	University of Arizona; Qatar University; University of Arizona	Baldwin, AL (corresponding author), Univ Arizona, Coll Med, Dept Physiol, Tucson, AZ 85724 USA.	abaldwin@u.arizona.edu			National Center for Research Resources (NCRR) [RR017358]; National Center for Complementary and Alternative Medicine (NCCAM) [P20AT00774]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P20AT000774] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR017358] Funding Source: NIH RePORTER	National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Center for Complementary and Alternative Medicine (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This research was supported by the National Center for Research Resources (NCRR) grant RR017358 and the National Center for Complementary and Alternative Medicine (NCCAM) P20AT00774. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NCCAM.	Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; Chu Mon-Li, 2004, Birth Defects Res C Embryo Today, V72, P25, DOI 10.1002/bdrc.20003; Collod G, 1996, EUR J HUM GENET, V4, P292; Collod-Beroud G, 2002, EUR J HUM GENET, V10, P673, DOI 10.1038/sj.ejhg.5200876; Crabbe JC, 1999, SCIENCE, V284, P1670, DOI 10.1126/science.284.5420.1670; DAVIS EC, 1993, CELL TISSUE RES, V272, P211, DOI 10.1007/BF00302726; Gilbert SF, 2005, J BIOSCIENCES, V30, P65, DOI 10.1007/BF02705151; Hucthagowder V, 2006, AM J HUM GENET, V78, P1075, DOI 10.1086/504304; HUMASON GL, 1979, ANIMAL TISSUE TECHNI, P147; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Lin CH, 2005, P NATL ACAD SCI USA, V102, P14877, DOI 10.1073/pnas.0506785102; McLaughlin PJ, 2006, MOL CELL BIOL, V26, P1700, DOI 10.1128/MCB.26.5.1700-1709.2006; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Restivo L, 2005, P NATL ACAD SCI USA, V102, P11557, DOI 10.1073/pnas.0504984102; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Sing CF, 2003, ARTERIOSCL THROM VAS, V23, P1190, DOI 10.1161/01.ATV.0000075081.51227.86; SOSAMELGAREJO JA, 1989, J PATHOL, V157, P213, DOI 10.1002/path.1711570307; Spires TL, 2004, J NEUROSCI, V24, P2270, DOI 10.1523/JNEUROSCI.1658-03.2004; Tsuda T, 2001, DEV DYNAM, V222, P89, DOI 10.1002/dvdy.1172; Yanagisawa H, 2002, NATURE, V415, P168, DOI 10.1038/415168a	20	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e229	10.1371/journal.pone.0000229	http://dx.doi.org/10.1371/journal.pone.0000229			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311093	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444500010
J	Tabatabaei-Zavareh, N; Vlasova, A; Greenwood, CP; Takei, F				Tabatabaei-Zavareh, Nooshin; Vlasova, Anastasia; Greenwood, Chelsea Pamela; Takei, Fumio			Characterization of Developmental Pathway of Natural Killer Cells from Embryonic Stem Cells In Vitro	PLOS ONE			English	Article								In vitro differentiation of embryonic stem (ES) cells is often used to study hematopoiesis. However, the differentiation pathway of lymphocytes, in particular natural killer (NK) cells, from ES cells is still unclear. Here, we used a multi-step in vitro ES cell differentiation system to study lymphocyte development from ES cells, and to characterize NK developmental intermediates. We generated embryoid bodies (EBs) from ES cells, isolated CD34(+) EB cells and cultured them on OP9 stroma with a cocktail of cytokines to generate cells we termed ES-derived hematopoietic progenitors (ES-HPs). EB cell subsets, as well as ES-HPs derived from EBs, were tested for NK, T, B and myeloid lineage potentials using lineage specific cultures. ES-HPs derived from CD34(+) EBs differentiated into NK cells when cultured on OP9 stroma with IL-2 and IL-15, and into T cells on Delta-like 1-transduced OP9 (OP9-DL1) with IL-7 and Flt3-L. Among CD34(+) EB cells, NK and T cell potentials were detected in a CD45(-) subset, whereas CD45(+) EB cells had myeloid but not lymphoid potentials. Limiting dilution analysis of ES-HPs generated from CD34(+) CD45(-) EB cells showed that CD45(+) Mac-1(-) Ter119(-) ES-HPs are highly enriched for NK progenitors, but they also have T, B and myeloid potentials. We concluded that CD45(-) CD34(+) EB cells have lymphoid potential, and they differentiate into more mature CD45+ Lin(-) hematopoietic progenitors that have lymphoid and myeloid potential. NK progenitors among ES-HPs are CD122(-) and they rapidly acquire CD122 as they differentiate along the NK lineage.	[Takei, Fumio] Univ British Columbia, Terry Fox Lab, British Columbia Canc Res Ctr, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Takei, F (corresponding author), Univ British Columbia, Terry Fox Lab, British Columbia Canc Res Ctr, Vancouver, BC V5Z 1M9, Canada.	ftakei@bccrc.ca		Takei, Fumio/0000-0002-3620-5046	National Cancer Institute of Canada; Canadian Institute of Health Research	National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by grants from the National Cancer Institute of Canada and the Canadian Institute of Health Research.	Balciunaite G, 2005, EUR J IMMUNOL, V35, P1292, DOI 10.1002/eji.200425822; Baumann CI, 2004, BLOOD, V104, P1010, DOI 10.1182/blood-2004-03-0989; Bertrand JY, 2005, P NATL ACAD SCI USA, V102, P134, DOI 10.1073/pnas.0402270102; Ceredig R, 2002, NAT REV IMMUNOL, V2, P888, DOI 10.1038/nri937; Cho SK, 1999, P NATL ACAD SCI USA, V96, P9797, DOI 10.1073/pnas.96.17.9797; de Pooter RF, 2003, BLOOD, V102, P1649, DOI 10.1182/blood-2003-01-0224; Douagi I, 2002, BLOOD, V99, P463, DOI 10.1182/blood.V99.2.463; Freud AG, 2006, J EXP MED, V203, P1033, DOI 10.1084/jem.20052507; Huang JX, 2005, J IMMUNOL, V175, P4858, DOI 10.4049/jimmunol.175.8.4858; Ikawa T, 1999, J EXP MED, V190, P1617, DOI 10.1084/jem.190.11.1617; Ikawa T, 2004, BLOOD, V103, P530, DOI 10.1182/blood-2003-06-1797; Kim S, 2002, NAT IMMUNOL, V3, P523, DOI 10.1038/ni796; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Lanier LL, 2005, ANNU REV IMMUNOL, V23, P225, DOI 10.1146/annurev.immunol.23.021704.115526; Lian RH, 2002, J IMMUNOL, V168, P4980, DOI 10.4049/jimmunol.168.10.4980; Maeda M, 2005, J IMMUNOL, V175, P4426, DOI 10.4049/jimmunol.175.7.4426; Masuda K, 2005, J IMMUNOL, V174, P2525, DOI 10.4049/jimmunol.174.5.2525; Miller CL, 1997, BLOOD, V89, P1214, DOI 10.1182/blood.V89.4.1214; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nakayama N, 1998, BLOOD, V91, P2283, DOI 10.1182/blood.V91.7.2283.2283_2283_2295; NEWMAN PJ, 1994, ANN NY ACAD SCI, V714, P165, DOI 10.1111/j.1749-6632.1994.tb12041.x; POTOCNIK AJ, 1994, EMBO J, V13, P5274, DOI 10.1002/j.1460-2075.1994.tb06861.x; Rosmaraki EE, 2001, EUR J IMMUNOL, V31, P1900, DOI 10.1002/1521-4141(200106)31:6<1900::AID-IMMU1900>3.0.CO;2-M; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Schmitt TM, 2004, NAT IMMUNOL, V5, P410, DOI 10.1038/ni1055; Veinotte LL, 2006, BLOOD, V107, P2673, DOI 10.1182/blood-2005-07-2797; Wang Y, 2005, P NATL ACAD SCI USA, V102, P19081, DOI 10.1073/pnas.0506127102; Yokota T, 2006, DEVELOPMENT, V133, P2041, DOI 10.1242/dev.02349; Zuniga-Pflucker JC, 2004, NAT REV IMMUNOL, V4, P67, DOI 10.1038/nri1257	30	17	18	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e232	10.1371/journal.pone.0000232	http://dx.doi.org/10.1371/journal.pone.0000232			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311098	gold, Green Published			2022-12-25	WOS:000207444500013
J	Fayos, J; Fayos, C				Fayos, Jose; Fayos, Carolina			Wind Data Mining by Kohonen Neural Networks	PLOS ONE			English	Article								Time series of Circulation Weather Type (CWT), including daily averaged wind direction and vorticity, are self-classified by similarity using Kohonen Neural Networks (KNN). It is shown that KNN is able to map by similarity all 7300 five-day CWT sequences during the period of 1975-94, in London, United Kingdom. It gives, as a first result, the most probable wind sequences preceding each one of the 27 CWT Lamb classes in that period. Inversely, as a second result, the observed diffuse correlation between both five-day CWT sequences and the CWT of the 6(th) day, in the long 20-year period, can be generalized to predict the last from the previous CWT sequence in a different test period, like 1995, as both time series are similar. Although the average prediction error is comparable to that obtained by forecasting standard methods, the KNN approach gives complementary results, as they depend only on an objective classification of observed CWT data, without any model assumption. The 27 CWT of the Lamb Catalogue were coded with binary three-dimensional vectors, pointing to faces, edges and vertex of a "wind-cube,'' so that similar CWT vectors were close.	[Fayos, Jose] CSIC, Inst Quim Fis Rocasolano, Dept Cristalog, Madrid, Spain; [Fayos, Carolina] Raytheon Informat Solut, Silver Spring, MD USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	Fayos, J (corresponding author), CSIC, Inst Quim Fis Rocasolano, Dept Cristalog, Madrid, Spain.	xpepe@iqfr.csic.es		Fayos, Jose/0000-0002-9303-2268	Spanish MEC [CTQ2005-02058/BQU]	Spanish MEC(Spanish Government)	J. Fayos thanks the Spanish MEC for support under project CTQ2005-02058/BQU.	BRIFFA KR, 1995, ANAL CLIMATE VARIABI, P122; CAWLEY GC, 1996, P INT C ART NEUR NET, V96, P281; Chen DL, 2000, INT J CLIMATOL, V20, P1067, DOI 10.1002/1097-0088(200008)20:10&lt;1067::AID-JOC528&gt;3.0.CO;2-Q; DAVIES TD, 1991, INT J CLIMATOL, V11, P795; HULME M, 1993, CLIM DYNAM, V9, P95, DOI 10.1007/BF00210012; Jenkinson A.F., 1977, SYNOPTIC CLIMATOLOGY; JONES PD, 1993, INT J CLIMATOL, V13, P655, DOI 10.1002/joc.3370130606; Kohonen T., 1995, SERIES INFORM SCI, V30; Kretzschmar R, 2004, J APPL METEOROL, V43, P727, DOI 10.1175/2057.1; Lamb H., 1972, GEOPHYS MEMOIRS, V116; LAMB HH, 1950, Q J ROY METEOR SOC, V76, P393, DOI 10.1002/qj.49707633005; Marzban C, 1998, WEATHER FORECAST, V13, P151, DOI 10.1175/1520-0434(1998)013<0151:ANNFDW>2.0.CO;2; Ultsch A, 2002, INFORM SCIENCES, V144, P91, DOI 10.1016/S0020-0255(02)00203-7	13	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e210	10.1371/journal.pone.0000210	http://dx.doi.org/10.1371/journal.pone.0000210			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299590	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444400011
J	Nikolaidis, N; Chalkia, D; Watkins, DN; Barrow, RK; Snyder, SH; van Rossum, DB; Patterson, RL				Nikolaidis, Nikolas; Chalkia, Dimitra; Watkins, D. Neil; Barrow, Roxanne K.; Snyder, Solomon H.; van Rossum, Damian B.; Patterson, Randen L.			Ancient Origin of the New Developmental Superfamily DANGER	PLOS ONE			English	Article								Developmental proteins play a pivotal role in the origin of animal complexity and diversity. We report here the identification of a highly divergent developmental protein superfamily (DANGER), which originated before the emergence of animals (similar to 850 million years ago) and experienced major expansion-contraction events during metazoan evolution. Sequence analysis demonstrates that DANGER proteins diverged via multiple mechanisms, including amino acid substitution, intron gain and/or loss, and recombination. Divergence for DANGER proteins is substantially greater than for the prototypic member of the superfamily (Mab-21 family) and other developmental protein families (e. g., WNT proteins). DANGER proteins are widely expressed and display species-dependent tissue expression patterns, with many members having roles in development. DANGER1A, which regulates the inositol trisphosphate receptor, promotes the differentiation and outgrowth of neuronal processes. Regulation of development may be a universal function of DANGER family members. This family provides a model system to investigate how rapid protein divergence contributes to morphological complexity.	[Nikolaidis, Nikolas; Chalkia, Dimitra; van Rossum, Damian B.; Patterson, Randen L.] Penn State Univ, Dept Biol, University Pk, PA 16802 USA; [Watkins, D. Neil] Johns Hopkins Univ, Sch Med, Sidney Kimmel Canc Inst, Baltimore, MD USA; [Barrow, Roxanne K.; Snyder, Solomon H.] Johns Hopkins Univ, Solomon H Snyder Dept Neurosci, Sch Med, Baltimore, MD USA; [Snyder, Solomon H.] Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Baltimore, MD USA; [Snyder, Solomon H.] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Nikolaidis, N (corresponding author), Penn State Univ, Dept Biol, University Pk, PA 16802 USA.	nxn7@psu.edu; rlp25@psu.edu	Chalkia, Dimitra/J-3793-2016; Watkins, David N/I-6113-2013	Chalkia, Dimitra/0000-0003-4780-544X; van Rossum, Damian/0000-0003-1011-2586	SEARLE; PSU; Eberly College of Sciences; Huck Institute; USPHS [MH 68830, MH 18501]; Research Scientist Award [DA 00074]; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH068830, R01MH018501, R37MH018501] Funding Source: NIH RePORTER	SEARLE; PSU; Eberly College of Sciences; Huck Institute; USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); Research Scientist Award; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by the SEARLE award and start-up monies from PSU (RLP), a Fellowship from the Eberly College of Sciences and the Huck Institute (DVR), USPHS grant Conte Center grant MH 68830 and MH 18501 (SHS) and Research Scientist Award DA 00074 (SHS).	Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AVISE JC, 1999, PHYLOGEOGRAPHY HIST; Ayala FJ, 1998, P NATL ACAD SCI USA, V95, P606, DOI 10.1073/pnas.95.2.606; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bi WM, 2002, GENOME RES, V12, P713, DOI 10.1101/gr.73702; Bird M, 1998, J ANAT, V193, P503, DOI 10.1046/j.1469-7580.1998.19340503.x; Brandenberger R, 2004, NAT BIOTECHNOL, V22, P707, DOI 10.1038/nbt971; Brosius J, 1999, GENETICA, V107, P209, DOI 10.1023/A:1004018519722; Carroll S. B., 2004, DNA DIVERSITY MOL GE; Carroll SB, 2001, NATURE, V409, P1102, DOI 10.1038/35059227; Carson-Walter EB, 1998, ONCOGENE, V17, P367, DOI 10.1038/sj.onc.1201938; CHOW KL, 1995, DEVELOPMENT, V121, P3615; Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Davidson EH, 2006, SCIENCE, V311, P796, DOI 10.1126/science.1113832; Eichler EE, 2003, SCIENCE, V301, P793, DOI 10.1126/science.1086132; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Gregory TR, 2004, GENE, V324, P15, DOI 10.1016/j.gene.2003.09.030; Heanue TA, 2006, P NATL ACAD SCI USA, V103, P6919, DOI 10.1073/pnas.0602152103; Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051; King N, 2003, SCIENCE, V301, P361, DOI 10.1126/science.1083853; Ko MSH, 2000, DEVELOPMENT, V127, P1737; Kopczynski CC, 1998, P NATL ACAD SCI USA, V95, P9973, DOI 10.1073/pnas.95.17.9973; Korf I., 2003, BLAST; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Kusserow A, 2005, NATURE, V433, P156, DOI 10.1038/nature03158; Lau GTC, 2001, BIOCHEM BIOPH RES CO, V280, P1378, DOI 10.1006/bbrc.2001.4290; LI WH, 1991, FUNDAMENTALS MOL EVO; Lim J, 2006, CELL, V125, P801, DOI 10.1016/j.cell.2006.03.032; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Mariani M, 1999, HUM MOL GENET, V8, P2397, DOI 10.1093/hmg/8.13.2397; Nei M, 2005, ANNU REV GENET, V39, P121, DOI 10.1146/annurev.genet.39.073003.112240; Ovcharenko I, 2004, GENOME RES, V14, P472, DOI 10.1101/gr.2129504; Patterson RL, 2005, TRENDS BIOCHEM SCI, V30, P688, DOI 10.1016/j.tibs.2005.10.005; Peterson KJ, 2004, P NATL ACAD SCI USA, V101, P6536, DOI 10.1073/pnas.0401670101; Prado FL, 2003, CURR GENET, V42, P185, DOI 10.1007/s00294-002-0346-3; Prud'homme B, 2002, CURR BIOL, V12, P1395, DOI 10.1016/S0960-9822(02)01068-0; Qian XZ, 2001, MOL CELL BIOL, V21, P1613, DOI 10.1128/MCB.21.5.1613-1620.2001; Ranwez V, 2001, MOL BIOL EVOL, V18, P1103, DOI 10.1093/oxfordjournals.molbev.a003881; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schmidt HA, 2002, BIOINFORMATICS, V18, P502, DOI 10.1093/bioinformatics/18.3.502; Schwartz S, 2000, GENOME RES, V10, P577, DOI 10.1101/gr.10.4.577; Schwartz S, 2003, GENOME RES, V13, P103, DOI 10.1101/gr.809403; Shaw CJ, 2005, HUM GENET, V116, P1, DOI 10.1007/s00439-004-1204-9; Stevens-Kroef MJPL, 2000, CANCER GENET CYTOGEN, V116, P119, DOI 10.1016/S0165-4608(99)00119-3; Technau U, 2005, TRENDS GENET, V21, P633, DOI 10.1016/j.tig.2005.09.007; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van Rossum DB, 2006, J BIOL CHEM, V281, P37111, DOI 10.1074/jbc.M608760200; van Rossum DB, 2005, NATURE, V434, P99, DOI 10.1038/nature03340; Wong RLY, 2002, TERATOLOGY, V65, P70, DOI 10.1002/tera.10018; Wong YM, 2002, MECH DEVELOP, V113, P149, DOI 10.1016/S0925-4773(02)00012-6; Yamada R, 2004, DEV BIOL, V274, P295, DOI 10.1016/j.ydbio.2004.07.016; Yamada R, 2003, DEVELOPMENT, V130, P1759, DOI 10.1242/dev.00399; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yeh RF, 2001, GENOME RES, V11, P803, DOI 10.1101/gr.175701; Zika R, 2004, NUCLEIC ACIDS RES, V32, pW48, DOI 10.1093/nar/gkh358	59	14	14	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e204	10.1371/journal.pone.0000204	http://dx.doi.org/10.1371/journal.pone.0000204			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17301879	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444400005
J	van Gils, JA; Munster, VJ; Radersma, R; Liefhebber, D; Fouchier, RAM; Klaassen, M				van Gils, Jan A.; Munster, Vincent J.; Radersma, Reinder; Liefhebber, Daan; Fouchier, Ron A. M.; Klaassen, Marcel			Hampered Foraging and Migratory Performance in Swans Infected with Low-Pathogenic Avian Influenza A Virus	PLOS ONE			English	Article							BODY CONDITION; BIRDS; SURVEILLANCE; CALIFORNIA; EVOLUTION; H6N2; SIZE	It is increasingly acknowledged that migratory birds, notably waterfowl, play a critical role in the maintenance and spread of influenza A viruses. In order to elucidate the epidemiology of influenza A viruses in their natural hosts, a better understanding of the pathological effects in these hosts is required. Here we report on the feeding and migratory performance of wild migratory Bewick's swans (Cygnus columbianus bewickii Yarrell) naturally infected with low-pathogenic avian influenza (LPAI) A viruses of subtypes H6N2 and H6N8. Using information on geolocation data collected from Global Positioning Systems fitted to neck-collars, we show that infected swans experienced delayed migration, leaving their wintering site more than a month after uninfected animals. This was correlated with infected birds travelling shorter distances and fuelling and feeding at reduced rates. The data suggest that LPAI virus infections in wild migratory birds may have higher clinical and ecological impacts than previously recognised.	[van Gils, Jan A.; Radersma, Reinder; Liefhebber, Daan; Klaassen, Marcel] Netherlands Inst Ecol NIOO KNAW, Ctr Limnol, Dept Plant Anim Interact, Nieuwersluis, Netherlands; [Munster, Vincent J.; Fouchier, Ron A. M.] Erasmus MC, Dept Virol, Rotterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); Erasmus University Rotterdam; Erasmus MC	van Gils, JA (corresponding author), Univ Bristol, Sch Biol Sci, Woodland Rd, Bristol, Avon, England.	j.vangils@nioo.knaw.nl	Munster, Vincent/I-7607-2018; van Gils, Jan/B-5544-2008; Klaassen, Marcel/B-4325-2008; Fouchier, Ron A/A-1911-2014	Munster, Vincent/0000-0002-2288-3196; van Gils, Jan/0000-0002-4132-8243; Klaassen, Marcel/0000-0003-3907-9599; Fouchier, Ron A/0000-0001-8095-2869	Royal Netherlands Academy of Arts and Sciences	Royal Netherlands Academy of Arts and Sciences	Royal Netherlands Academy of Arts and Sciences	Alexander DJ, 2000, VET MICROBIOL, V74, P3, DOI 10.1016/S0378-1135(00)00160-7; Both C, 2005, GLOBAL CHANGE BIOL, V11, P1606, DOI 10.1111/j.1365-2486.2005.01038.x; BOWLER JM, 1994, ARDEA, V82, P241; Choudhury S, 1996, IBIS, V138, P700, DOI 10.1111/j.1474-919X.1996.tb04772.x; Coleman JT, 2002, WATERBIRDS, V25, P346; Evans M.E., 1978, Wildfowl, V29, P118; Fouchier RAM, 2003, AVIAN DIS, V47, P857, DOI 10.1637/0005-2086-47.s3.857; Fouchier RAM, 2005, J VIROL, V79, P2814, DOI 10.1128/JVI.79.5.2814-2822.2005; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; Hedenstrom A, 1997, J THEOR BIOL, V189, P227, DOI 10.1006/jtbi.1997.0505; Hoffmann E, 2001, ARCH VIROL, V146, P2275, DOI 10.1007/s007050170002; KIDA H, 1980, INFECT IMMUN, V30, P547; Kinde H, 2003, AVIAN DIS, V47, P1214, DOI 10.1637/0005-2086-47.s3.1214; Klaassen M, 2006, J APPL ECOL, V43, P92, DOI 10.1111/j.1365-2664.2005.01109.x; Kokko H, 1999, J ANIM ECOL, V68, P940, DOI 10.1046/j.1365-2656.1999.00343.x; Krauss S, 2004, VECTOR-BORNE ZOONOT, V4, P177, DOI 10.1089/vbz.2004.4.177; Madsen J, 2006, J AVIAN BIOL, V37, P283, DOI 10.1111/j.2006.0908-8857.03555.x; Martin P., 1993, MEASURING BEHAV, V2nd, DOI [10.1017/CBO9781139168342, DOI 10.1017/CBO9781139168342]; Munster VJ, 2006, VACCINE, V24, P6729, DOI 10.1016/j.vaccine.2006.05.060; Munster VJ, 2005, EMERG INFECT DIS, V11, P1545, DOI 10.3201/eid1110.050546; Nolet BA, 1998, J AVIAN BIOL, V29, P574, DOI 10.2307/3677178; Olsen B, 2006, SCIENCE, V312, P384, DOI 10.1126/science.1122438; Piersma T, 2003, TRENDS ECOL EVOL, V18, P228, DOI 10.1016/S0169-5347(03)00036-3; Rees E. C., 1996, PARTNERSHIPS BIRDS S, P118; Rees EC, 2006, BEWICKS SWAN; RISING JD, 1989, AUK, V106, P666; Sedinger JS, 1997, CONDOR, V99, P314, DOI 10.2307/1369937; Spackman E, 2005, VIRUS RES, V114, P89, DOI 10.1016/j.virusres.2005.05.013; *SYST SOFTW, 2000, SYSTAT VERS 10; VANGILS JA, BASED DISSECTI UNPUB; Viney ME, 2005, TRENDS ECOL EVOL, V20, P665, DOI 10.1016/j.tree.2005.10.003; Wallensten A, 2006, ANTARCT SCI, V18, P353, DOI 10.1017/S095410200600040X; WEBSTER RG, 1978, VIROLOGY, V84, P268, DOI 10.1016/0042-6822(78)90247-7; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; Woolcock PR, 2003, AVIAN DIS, V47, P872, DOI 10.1637/0005-2086-47.s3.872	35	170	181	1	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2007	2	1							e184	10.1371/journal.pone.0000184	http://dx.doi.org/10.1371/journal.pone.0000184			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DH	17264886	Green Submitted, Green Published, gold			2022-12-25	WOS:000207444200008
J	Akdemir, F; Christich, A; Sogame, N; Chapo, J; Abrams, JM				Akdemir, F.; Christich, A.; Sogame, N.; Chapo, J.; Abrams, J. M.			p53 directs focused genomic responses in Drosophila	ONCOGENE			English	Article						apoptosis; p53; radiation; Drosophila; cell death	RIBONUCLEOTIDE REDUCTASE GENE; CELL-DEATH; DNA-DAMAGE; CASPASE DRONC; APOPTOSIS; MELANOGASTER; PROTEINS; SMAC/DIABLO; ACTIVATION; PATHWAYS	p53 is a fundamental determinant of cancer susceptibility and other age-related pathologies. Similar to mammalian counterparts, Drosophila p53 integrates stress signals and elicits apoptotic responses that maintain genomic stability. To illuminate core-adaptive functions controlled by this gene family, we examined the Drosophila p53 regulatory network at a genomic scale. In development, the absence of p53 impacted constitutive expression for a surprisingly broad scope of genes. By contrast, stimulus-dependent responses governed by Drosophila p53 were limited in scope. The vast majority of stress responders were induced and p53 dependent (RIPD) genes. The signature set of 29 'high stringency' RIPD genes identified here were enriched for intronless loci, with a non-uniform distribution that includes a recently evolved cluster unique to Drosophila melanogaster. Two RIPD genes, with known and unknown biochemical activities, were functionally examined. One RIPD gene, designated XRP1, maintains genome stability after genotoxic challenge and prevents cell proliferation upon induced expression. A second gene, RnrL, is an apoptogenic effector required for caspase activation in a model of p53-dependent killing. Together, these studies identify ancient and convergent features of the p53 regulatory network.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Abrams, JM (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA.	John.Abrams@utsouthwestern.edu	akdemir, fatih/AAR-5764-2021	AKDEMIR, FATIH/0000-0003-3023-9453	PHS HHS [R01G-M072124] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Bae BI, 2005, NEURON, V47, P29, DOI 10.1016/j.neuron.2005.06.005; Bauer JH, 2005, CURR BIOL, V15, P2063, DOI 10.1016/j.cub.2005.10.051; Blanchette M, 2004, MOL CELL, V14, P775, DOI 10.1016/j.molcel.2004.06.012; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen P, 2004, CELL DEATH DIFFER, V11, P704, DOI 10.1038/sj.cdd.4401406; Chew SK, 2004, DEV CELL, V7, P897, DOI 10.1016/j.devcel.2004.09.016; Colombani J, 2006, CURR BIOL, V16, P1453, DOI 10.1016/j.cub.2006.05.059; COURGEON AM, 1972, NATURE-NEW BIOL, V238, P250, DOI 10.1038/newbio238250a0; Daish TJ, 2004, DEV CELL, V7, P909, DOI 10.1016/j.devcel.2004.09.018; Dorstyn L, 1999, P NATL ACAD SCI USA, V96, P4307, DOI 10.1073/pnas.96.8.4307; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Kauppila S, 2003, ONCOGENE, V22, P4860, DOI 10.1038/sj.onc.1206715; Lee CY, 2003, CURR BIOL, V13, P350, DOI 10.1016/S0960-9822(03)00085-X; Lee JH, 2003, FEBS LETT, V550, P5, DOI 10.1016/S0014-5793(03)00771-3; Lu WJ, 2006, CELL DEATH DIFFER, V13, P909, DOI 10.1038/sj.cdd.4401922; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774; Nordstrom W, 2000, CELL DEATH DIFFER, V7, P1035, DOI 10.1038/sj.cdd.4400766; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Sakharkar MK, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-67; Sharpless NE, 2002, CELL, V110, P9, DOI 10.1016/S0092-8674(02)00818-8; Sogame N, 2003, P NATL ACAD SCI USA, V100, P4696, DOI 10.1073/pnas.0736384100; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012	30	61	62	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5184	5193		10.1038/sj.onc.1210328	http://dx.doi.org/10.1038/sj.onc.1210328			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17310982				2022-12-25	WOS:000248674200002
J	Wakasugi, T; Izumi, H; Uchiumi, T; Suzuki, H; Arao, T; Nishio, K; Kohno, K				Wakasugi, T.; Izumi, H.; Uchiumi, T.; Suzuki, H.; Arao, T.; Nishio, K.; Kohno, K.			ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes	ONCOGENE			English	Article						ZNF143; p73; Rad51; FEN-1; cisplatin; DNA repair	BOX-BINDING-PROTEIN; CANCER-CELL-LINES; DRUG-RESISTANCE; DAMAGING AGENTS; EXPRESSION; ACTIVATOR; YB-1; STAF	Zinc-finger protein 143 ( ZNF143) is a human homolog of Xenopus transcriptional activator staf that is involved in selenocystyl tRNA transcription. We previously showed that ZNF143 expression is induced by treatment with DNA-damaging agents and that it preferentially binds to cisplatin-modified DNA. In this study, the potential function of ZNF143 was investigated. ZNF143 was overexpressed in cisplatin-resistant cells. ZNF143 knockdown in prostate cancer caused increased sensitivity for cisplatin, but not for oxaliplatin, etoposide and vincristine. We also showed that ZNF143 is associated with tumor suppressor gene product p73 but not with p53.p73 could stimulate the binding of ZNF143 to both ZNF143 binding site and cisplatin-modified DNA, and modulate the function of ZNF143. We provide a direct evidence that both Rad51 and flap endonuclease-1 are target genes of ZNF143 and overexpressed in cisplatin-resistant cells. Taken together, these experiments demonstrate that an interplay of ZNF143, p73 and ZNF143 target genes is involved in DNA repair gene expression and cisplatin resistance.	Univ Occupat & Environm Hlth, Sch Med, Dept Biol Mol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Otorhinolaryngol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Kinki Univ, Sch Med, Dept Genome Biol, Osaka, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Kindai University (Kinki University)	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Biol Mol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp						Altaha R, 2004, INT J MOL MED, V14, P959; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; FUJII R, 1994, JPN J CANCER RES, V85, P426, DOI 10.1111/j.1349-7006.1994.tb02376.x; Imamura T, 2001, J BIOL CHEM, V276, P7534, DOI 10.1074/jbc.M008143200; Ise T, 1999, CANCER RES, V59, P342; Ishiguchi H, 2004, INT J CANCER, V111, P900, DOI 10.1002/ijc.20358; Izumi H, 2003, BIOCHEM J, V373, P713, DOI 10.1042/BJ20021902; Keshelava N, 2001, CANCER RES, V61, P6185; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Kohno K, 2005, EUR J CANCER, V41, P2577, DOI 10.1016/j.ejca.2005.08.007; Kuwano M, 2004, MOL CANCER THER, V3, P1485; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; Myslinski E, 1998, J BIOL CHEM, V273, P21998, DOI 10.1074/jbc.273.34.21998; Ohga T, 1996, CANCER RES, V56, P4224; Raymond E, 2002, MOL CANCER THER, V1, P227; Rincon JC, 1998, NUCLEIC ACIDS RES, V26, P4846, DOI 10.1093/nar/26.21.4846; Schaub M, 1997, EMBO J, V16, P173, DOI 10.1093/emboj/16.1.173; Spiro C, 2003, MOL CELL BIOL, V23, P6063, DOI 10.1128/MCB.23.17.6063-6074.2003; Sugaya M, 2002, CHEST, V122, P282, DOI 10.1378/chest.122.1.282; Tanabe M, 2003, CANCER RES, V63, P8592; TEW KD, 1994, CANCER RES, V54, P4313; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Uramoto H, 2003, BIOCHEM J, V371, P301, DOI 10.1042/BJ20021646; Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200; Vikhanskaya F, 2001, CANCER RES, V61, P935; Wood RD, 2005, MUTAT RES-FUND MOL M, V577, P275, DOI 10.1016/j.mrfmmm.2005.03.007; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7	31	47	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5194	5203		10.1038/sj.onc.1210326	http://dx.doi.org/10.1038/sj.onc.1210326			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17297437				2022-12-25	WOS:000248674200003
J	Jiang, WQ; Zhong, ZH; Henson, JD; Reddel, RR				Jiang, W-Q; Zhong, Z-H; Henson, J. D.; Reddel, R. R.			Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference	ONCOGENE			English	Article						telomeres; alternative lengthening of telomeres; ALT-associated PML bodies; PML; siRNA; methionine restriction	PROMYELOCYTIC LEUKEMIA BODIES; LARGE-BODY FORMATION; TUMOR-CELL-LINES; DNA-DAMAGE; MAMMALIAN-CELLS; METABOLIC DEFECT; PROTEIN COMPLEX; NUCLEAR-BODIES; CANCER-CELLS; HUMAN RAP1	Telomerase-negative cancer cells can maintain their telomeres by a recombination-mediated alternative lengthening of telomeres (ALT) process. We reported previously that sequestration of MRE11/RAD50/NBS1 complexes represses ALT-mediated telomere length maintenance, and suppresses formation of ALT-associated promyelocytic leukemia (PML) bodies (APBs). APBs are PML bodies containing telomeric DNA and telomere-binding proteins, and are observed only in a small fraction of cells within asynchronously dividing ALT-positive cell populations. Here, we report that methionine restriction caused a reversible arrest in G(0)/G(1) phase of the cell cycle and reversible induction of APB formation in most cells within an ALT-positive population. We combined methionine restriction with RNA interference to test whether the following proteins are required for APB formation: PML body-associated proteins, PML and Sp100; telomere-associated proteins, TRF1, TRF2, TIN2 and RAP1; and DNA repair proteins, MRE11, RAD50, NBS1 and 53BP1. APB formation was not decreased by depletion of Sp100 (as reported previously) or of 53BP1, although 53BP1 partially colocalizes with APBs. Depletion of the other proteins suppressed APB formation. Because of the close linkage between ALT-mediated telomere maintenance and ability to form APBs, the eight proteins identified by this screen as being required for APB formation are also likely to be required for the ALT mechanism. Oncogene	Childrens Med Res Inst, Canc Res Unit, Westmead, NSW 2145, Australia	Children's Medical Research Institute - Australia	Reddel, RR (corresponding author), Childrens Med Res Inst, Canc Res Unit, 214 Hawkesbury Rd, Westmead, NSW 2145, Australia.	rreddel@cmri.usyd.edu.au	Henson, Jeremy/ABD-3494-2021; Reddel, Roger R/A-6635-2014	Reddel, Roger R/0000-0002-6302-6107; Henson, Jeremy/0000-0002-1594-9310				Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; Brachner A, 2006, CANCER RES, V66, P3584, DOI 10.1158/0008-5472.CAN-05-2839; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cerone MA, 2005, ONCOGENE, V24, P7893, DOI 10.1038/sj.onc.1208934; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Fasching CL, 2005, CANCER RES, V65, P2722, DOI 10.1158/0008-5472.CAN-04-2881; GERDES J, 1984, J IMMUNOL, V133, P1710; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Grobelny JV, 2000, J CELL SCI, V113, P4577; HALPERN BC, 1974, P NATL ACAD SCI USA, V71, P1133, DOI 10.1073/pnas.71.4.1133; Henson JD, 2005, CLIN CANCER RES, V11, P217; Houghtaling BR, 2004, CURR BIOL, V14, P1621, DOI 10.1016/j.cub.2004.08.052; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jiang WQ, 2005, MOL CELL BIOL, V25, P2708, DOI 10.1128/MCB.25.7.2708-2721.2005; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; JUDDE JG, 1989, CANCER RES, V49, P4859; Kamei H, 1996, EXP CELL RES, V224, P302, DOI 10.1006/excr.1996.0140; Kamei H, 1997, EXP CELL RES, V237, P207, DOI 10.1006/excr.1997.3790; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kim S, 2004, J BIOL CHEM, V279, P43799, DOI 10.1074/jbc.M408650200; Lei M, 2001, J CELL SCI, V114, P1447; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Li BB, 2003, MOL BIOL CELL, V14, P5060, DOI 10.1091/mbc.e03-06-0403; Lu S, 2000, NUTR CANCER, V38, P123, DOI 10.1207/S15327914NC381_17; Marciniak RA, 2005, CANCER RES, V65, P2730, DOI 10.1158/0008-5472.CAN-04-2888; MECHAM JO, 1983, BIOCHEM BIOPH RES CO, V117, P429, DOI 10.1016/0006-291X(83)91218-4; Molenaar C, 2003, EMBO J, V22, P6631, DOI 10.1093/emboj/cdg633; Moran-Jones K, 2005, NUCLEIC ACIDS RES, V33, P486, DOI 10.1093/nar/gki203; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nabetani A, 2004, J BIOL CHEM, V279, P25849, DOI 10.1074/jbc.M312652200; O'Connor MS, 2004, J BIOL CHEM, V279, P28585, DOI 10.1074/jbc.M312913200; Pavillard V, 2004, BIOCHEM PHARMACOL, V67, P1587, DOI 10.1016/j.bcp.2004.01.006; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Silverman J, 2004, GENE DEV, V18, P2108, DOI 10.1101/gad.1216004; SMYTH CM, 1993, PATHOLOGY, V25, P388, DOI 10.3109/00313029309090865; Stavropoulos DJ, 2002, HUM MOL GENET, V11, P3135, DOI 10.1093/hmg/11.25.3135; STERN PH, 1986, J NATL CANCER I, V76, P629, DOI 10.1093/jnci/76.4.629; STERN PH, 1984, IN VITRO CELL DEV B, V20, P663; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tarsounas M, 2004, CELL, V117, P337, DOI 10.1016/S0092-8674(04)00337-X; TISDALE MJ, 1980, BRIT J CANCER, V42, P121, DOI 10.1038/bjc.1980.210; Toouli CD, 2002, ONCOGENE, V21, P128, DOI 10.1038/sj.onc.1205014; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu GK, 2003, CANCER RES, V63, P2589; Xu LF, 2004, J CELL BIOL, V167, P819, DOI 10.1083/jcb.200408181; Xu ZX, 2003, MOL CELL BIOL, V23, P4247, DOI 10.1128/MCB.23.12.4247-4256.2003; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Ye JZS, 2004, J BIOL CHEM, V279, P47264, DOI 10.1074/jbc.M409047200; Ye JZS, 2004, NAT GENET, V36, P618, DOI 10.1038/ng1360; Yeager TR, 1999, CANCER RES, V59, P4175; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zhu XD, 2003, MOL CELL, V12, P1489, DOI 10.1016/S1097-2765(03)00478-7	65	86	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4635	4647		10.1038/sj.onc.1210260	http://dx.doi.org/10.1038/sj.onc.1210260			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297460				2022-12-25	WOS:000248037900004
J	Miller, SL; Antico, G; Raghunath, PN; Tomaszewski, JE; Clevenger, CV				Miller, S. L.; Antico, G.; Raghunath, P. N.; Tomaszewski, J. E.; Clevenger, C. V.			Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells	ONCOGENE			English	Article						prolactin; breast neoplasms; invasion; Vav2; Rac; paxillin	FOCAL ADHESION KINASE; RHO-GTPASES; BINDING PROTEIN; V-SRC; PAXILLIN; GROWTH; ACTIN; VAV2; ACTIVATION; CDC42	Prolactin (PRL) stimulates the cytoskeletal re-organization and motility of breast cancer cells. During PRL receptor signaling, Vav2 becomes phosphorylated and activated, an event regulated by the serine/ threonine kinase Nek3. Given the regulatory role of Vav2, the function of Nek3 in PRL-mediated motility and invasion was examined. Overexpression of Nek3 in Chinese hamster ovary transfectants potentiated cytoskeletal re-organization in response to PRL. In contrast, downregulation of Nek3 expression by small-interfering RNA (siRNA) attenuated PRL-mediated cytoskeletal reorganization, activation of GTPase Rac1, cell migration and invasion of T47D cells. In addition, PRL stimulation induced an interaction between Nek3 and paxillin and significantly increased paxillin serine phosphorylation, whereas Nek3 siRNA-transfected cells showed a marked reduction in paxillin phosphorylation. Analysis of breast tissue microarrays also demonstrated a significant up-regulation of Nek3 expression in malignant versus normal specimens. These data suggest that Nek3 contributes to PRL-mediated breast cancer motility through mechanisms involving Rac1 activation and paxillin phosphorylation.	Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol & Chem, New York, NY 10021 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Northwestern University; Memorial Sloan Kettering Cancer Center; University of Pennsylvania	Clevenger, CV (corresponding author), Northwestern Univ, Dept Pathol, Lurie 4-107,303 E Super St, Chicago, IL 60611 USA.	clevenger@northwestern.edu			NATIONAL CANCER INSTITUTE [R01CA069294, R01CA092265] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA69294, R01CA92265] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; Beningo KA, 2001, J CELL BIOL, V153, P881, DOI 10.1083/jcb.153.4.881; BHATAVDEKAR JM, 1990, CANCER, V65, P2028, DOI 10.1002/1097-0142(19900501)65:9&lt;2028::AID-CNCR2820650924&gt;3.0.CO;2-9; Bouzahzah B, 2001, MOL MED, V7, P816, DOI 10.1007/BF03401974; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Canbay E, 1997, BIOCHEM J, V324, P231, DOI 10.1042/bj3240231; CLEVENGER CV, 1990, P NATL ACAD SCI USA, V87, P6460, DOI 10.1073/pnas.87.16.6460; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; de Oca PM, 2005, LAB INVEST, V85, P633, DOI 10.1038/labinvest.3700256; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DeMali KA, 2003, CURR OPIN CELL BIOL, V15, P572, DOI 10.1016/S0955-0674(03)00109-1; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gao J, 1999, CELL SIGNAL, V11, P205, DOI 10.1016/S0898-6568(98)00067-9; Gordon LA, 2003, INT J CANCER, V106, P8, DOI 10.1002/ijc.11172; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HOLTKAMP W, 1984, INT J CANCER, V34, P323, DOI 10.1002/ijc.2910340307; HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; ILLC D, 1995, NATURE, V377, P539; INOUE T, 1993, J CELL PHYSIOL, V156, P212, DOI 10.1002/jcp.1041560128; Kline JB, 2001, MOL ENDOCRINOL, V15, P832, DOI 10.1210/me.15.5.832; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; LISSONI P, 1995, ONCOLOGY, V52, P439; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; Miller SL, 2005, MOL ENDOCRINOL, V19, P939, DOI 10.1210/me.2004-0443; NAWROCKI RB, 2001, INT J CANCER, V93, P644; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 2000, J CELL SCI, V113, P3673; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roy S, 2002, J CELL BIOCHEM, V84, P377, DOI 10.1002/jcb.10025; Rycyzyn MA, 2002, P NATL ACAD SCI USA, V99, P6790, DOI 10.1073/pnas.092160699; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Salcedo R, 2002, CLIN CANCER RES, V8, P2655; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SCHUPP G, 1996, COMPRAIL 96 COMPUTER, V2, P13; Tanaka K, 1999, J BIOL CHEM, V274, P13491, DOI 10.1074/jbc.274.19.13491; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; TURNER CE, 1994, J CELL SCI, V107, P1583; Yoneda T, 1997, J CLIN INVEST, V99, P2509, DOI 10.1172/JCI119435	48	58	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4668	4678		10.1038/sj.onc.1210264	http://dx.doi.org/10.1038/sj.onc.1210264			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297458				2022-12-25	WOS:000248037900007
J	Yan, Y; Black, CP; Cowan, KH				Yan, Y.; Black, C. P.; Cowan, K. H.			Irradiation-induced G2/M checkpoint response requires ERK1/2 activation	ONCOGENE			English	Article						ATM/ATR; Cdc2; Cdc25A/C; Chk1; ERK1/2; irradiation and wee1	DNA-DAMAGE CHECKPOINT; CELL-CYCLE ARREST; 14-3-3 PROTEIN-BINDING; IONIZING-RADIATION; TYROSINE PHOSPHORYLATION; CDC25 PHOSPHATASES; S-PHASE; KINASE; CHK1; ATR	Following DNA damage, cells undergo G2/M cell cycle arrest, allowing time for DNA repair. G2/M checkpoint activation involves activation of Wee1 and Chk1 kinases and inhibition of Cdc25A and Cdc25C phosphatases, which results in inhibition of Cdc2 kinase. Results presented in this report indicate that gamma-irradiation (IR) exposure of MCF-7 cells resulted in extracellular signal regulated protein kinase 1 and 2 (ERK1/2) activation and induction of G2/M arrest. Furthermore, inhibition of ERK1/2 signaling resulted in >= 85% attenuation in IR-induced G2/M arrest and concomitant diminution of IR-induced activation of ataxia telangiectasia mutated-and rad3-related (ATR), Chk1 and Wee1 kinases as well as phosphorylation of Cdc25A-Thr506, Cdc25C-Ser216 and Cdc2-Tyr15. Moreover, incubation of cells with caffeine, which inhibits ataxia telangiectasia mutated (ATM)/ATR, or transfection of cells with short interfering RNA targeting ATR abrogated IR-induced Chk1 phosphorylation and G2/M arrest but had no effect on IR-induced ERK1/2 activation. In contrast, inhibition of ERK1/2 signaling resulted in marked attenuation in IR-induced ATR activity with little, if any, effect on IR-induced ATM activation. These results implicate IR-induced ERK1/2 activation as an important regulator of G2/M checkpoint response to IR in MCF-7 cells.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Cowan, KH (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr,ECI 6010, Omaha, NE 68198 USA.	kcowan@unmc.edu						Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; Ahn JY, 2000, CANCER RES, V60, P5934; Bulavin DV, 2003, NAT CELL BIOL, V5, P545, DOI 10.1038/ncb994; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cui W, 2000, MOL CARCINOGEN, V29, P219, DOI 10.1002/1098-2744(200012)29:4<219::AID-MC1004>3.0.CO;2-D; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; KHARBANDA S, 1994, CANCER RES, V54, P1412; Koundrioukoff S, 2004, DNA REPAIR, V3, P969, DOI 10.1016/j.dnarep.2004.03.010; Kristjansdottir K, 2004, CHEM BIOL, V11, P1043, DOI 10.1016/j.chembiol.2004.07.007; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Nagasawa H, 1998, CANCER RES, V58, P2036; O'Connell MJ, 2005, J CELL SCI, V118, P1, DOI 10.1242/jcs.01626; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sarkaria JN, 1999, CANCER RES, V59, P4375; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Ward I, 2004, CURR TOP DEV BIOL, V63, P1, DOI 10.1016/S0070-2153(04)63001-8; Wellbrock C, 2002, J BIOL CHEM, V277, P6443, DOI 10.1074/jbc.M110684200; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu Bo, 2004, Methods Mol Biol, V281, P283; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	34	81	85	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4689	4698		10.1038/sj.onc.1210268	http://dx.doi.org/10.1038/sj.onc.1210268			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297454				2022-12-25	WOS:000248037900009
J	Staub, J; Chien, J; Pan, Y; Qian, X; Narita, K; Aletti, G; Scheerer, M; Roberts, LR; Molina, J; Shridhar, V				Staub, J.; Chien, J.; Pan, Y.; Qian, X.; Narita, K.; Aletti, G.; Scheerer, M.; Roberts, L. R.; Molina, J.; Shridhar, V.			Epigenetic silencing of HSulf-1 in ovarian cancer: implications in chemoresistance	ONCOGENE			English	Article						methylation; histone modification; tumor suppressor; chemoresponse; apoptosis	HISTONE-DEACETYLASE INHIBITORS; H3 LYSINE-9 METHYLATION; IN-VIVO; CHROMATIN IMMUNOPRECIPITATION; TUMOR-GROWTH; CPG ISLANDS; GENE; HYPERMETHYLATION; CHEMOTHERAPY; CARCINOMA	To investigate the mechanism by which HSulf-1 expression is downregulated in ovarian cancer, DNA methylation and histone acetylation of HSulf-1 was analysed in ovarian cancer cell lines and primary tumors. Treatment of OV207 and SKOV3 by 5-aza-2'-deoxycytidine resulted in increased transcription of HSulf-1. Sequence analysis of bisulfi. te-modi. ed genomic DNA from ovarian cell lines and primary tumors without HSulf-1 expression revealed an increase in the frequency of methylation of 12 CpG sites in exon 1A. Chromatin immunoprecipitation assays showed an increase in histone H3 methylation in cell lines without HSulf-1 expression. To assess the signi. cance of HSulf-1 downregulation in ovarian cancer, OV167 and OV202 cells were transfected with HS ulf-1 siRNA. Downregulation of HSulf-1 expression in OV167 and OV202 cells lead to an attenuation of cisplatin-induced cytotoxicity. Moreover, patients with ovari an tumors expressing higher levels of HSulf-1 showed a 90% response rate (27/30) to chemotherapy compared to a response rate of 63% (19/30) in those with weak or moderate levels (P = 0.0146, chi(2) test). Collectively, these data indicate that HSulf-1 is epigenetically silenced in ovarian cancer and that epigenetic therapy targeting HSulf-1 might sensitize ovarian tumors to conventional. first-line therapies.	Mayo Coll Med, Div Expt Pathol, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin, Coll Med, Div Med Oncol, Dept Oncol, Rochester, MN USA; Mayo Clin, Coll Med, Dept Med, Div Gastroenterol & Hepatol, Rochester, MN USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Shridhar, V (corresponding author), Mayo Coll Med, Div Expt Pathol, Dept Lab Med & Pathol, 200 1st St SW,2-46 Stabile, Rochester, MN 55905 USA.	shridhar.vijayalakshmi@mayo.edu	Seal, Sudipta/A-7698-2012; Aletti, Giovanni/AAM-9781-2020; Narita, Keishi/E-3539-2010; Chien, Jeremy/AID-8939-2022	Narita, Keishi/0000-0002-7602-8523; Roberts, Lewis/0000-0001-7885-8574; Aletti, Giovanni/0000-0003-4602-5601; Chien, Jeremy/0000-0003-4744-8374	NCI NIH HHS [CA106954-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batch C, 2004, AM J OBSTET GYNECOL, V191, P1552, DOI 10.1016/j.agoj.2004.05.025; Blagosklonny MV, 2002, MOL CANCER THER, V1, P937; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Dai YM, 2005, J BIOL CHEM, V280, P40066, DOI 10.1074/jbc.M508136200; Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2; Esteller M, 2002, J NATL CANCER I, V94, P26; Fujii S, 2003, HUM MOL GENET, V12, P1791, DOI 10.1093/hmg/ddg204; Galm O, 2002, GENOME RES, V12, P153, DOI 10.1101/gr.202501; Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Han JW, 2000, CANCER RES, V60, P6068; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Katsaros D, 2004, GYNECOL ONCOL, V94, P685, DOI 10.1016/j.ygyno.2004.06.018; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; Kopelovich L, 2003, JNCI-J NATL CANCER I, V95, P1747, DOI 10.1093/jnci/dig109; Lai JP, 2006, GASTROENTEROLOGY, V130, P2130, DOI 10.1053/j.gastro.2006.02.056; Lai JP, 2004, ONCOGENE, V23, P1439, DOI 10.1038/sj.onc.1207258; Lai JP, 2004, GASTROENTEROLOGY, V126, P231, DOI 10.1053/j.gastro.2003.09.043; Lai JP, 2003, J BIOL CHEM, V278, P23107, DOI 10.1074/jbc.M302203200; LaVoie HA, 2005, MOL CELL ENDOCRINOL, V243, P12, DOI 10.1016/j.mce.2005.09.005; Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Narita K, 2006, CANCER RES, V66, P6025, DOI 10.1158/0008-5472.CAN-05-3582; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; Plumb JA, 2000, CANCER RES, V60, P6039; Qian X, 2004, DIAGN MOL PATHOL, V13, P9, DOI 10.1097/00019606-200403000-00002; Seidl S, 2004, CANCER-AM CANCER SOC, V100, P2598, DOI 10.1002/cncr.20295; Shridhar V, 2001, CANCER RES, V61, P4258; Strathdee G, 2005, GYNECOL ONCOL, V97, P898, DOI 10.1016/j.ygyno.2005.03.023; Terasawa K, 2004, CLIN CANCER RES, V10, P2000, DOI 10.1158/1078-0432.CCR-0932-03; Xing MZ, 2004, CANCER RES, V64, P1664, DOI 10.1158/0008-5472.CAN-03-3242; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yang QW, 2003, CANCER RES, V63, P6299; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	43	89	95	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4969	4978		10.1038/sj.onc.1210300	http://dx.doi.org/10.1038/sj.onc.1210300			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310998	Green Published			2022-12-25	WOS:000248322500009
J	Moschos, SJ; Smith, AP; Mandic, M; Athanassiou, C; Watson-Hurst, K; Jukic, DM; Edington, HD; Kirkwood, JM; Becker, D				Moschos, S. J.; Smith, A. P.; Mandic, M.; Athanassiou, C.; Watson-Hurst, K.; Jukic, D. M.; Edington, H. D.; Kirkwood, J. M.; Becker, D.			SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas	ONCOGENE			English	Article						melanoma; molecular profiling; Ubc9; apoptosis; chemotherapy	UBIQUITIN-CONJUGATING ENZYME; TUMOR-SUPPRESSOR; HUMAN HOMOLOG; EXPRESSION; PROTEIN; GROWTH; GENE; NORMALIZATION; ASSOCIATION; SUMOYLATION	Although patients diagnosed with melanoma of <= 1.00mm thickness have a relatively good cure rate, the prognosis for patients with locally advanced and metastatic melanoma is grave. The discovery of new and effective therapies for this disease depends in large part on molecular studies that will resolve why advanced-stage melanoma is refractory to conventional chemotherapy and radiation therapy. To identify genes that have important functions in advanced-stage melanomas, in particular, in melanoma-infiltrated lymph nodes, which are not well characterized at the molecular level, we generated a LongSAGE library from a melanoma-positive lymph node, and subjected melanoma-infiltrated lymph nodes to protein expression profiling. The data document that the molecular signature of melanoma, which has spread to regional lymph nodes, is very similar to the molecular signature of primary melanomas. Equally important, we provide evidence that the ubiquitin-conjugating enzyme, Ubc9, is expressed at high levels in melanoma-positive lymph nodes, and that it plays a crucial role in preventing advanced-stage melanomas from undergoing chemotherapy-induced apoptosis.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Dermatol, Pittsburgh, PA 15213 USA; Automated Cell Inc, Pittsburgh, PA USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Becker, D (corresponding author), Univ Pittsburgh, Dept Pathol, HCC Res Pavil,Suite 1 46A,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	dbecker@pitt.edu			NCATS NIH HHS [UL1 TR000005] Funding Source: Medline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER	NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))		Balch CM, 2004, CA-CANCER J CLIN, V54, P131, DOI 10.3322/canjclin.54.3.131; Balch CM, 2000, CANCER-AM CANCER SOC, V88, P1484, DOI 10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Edwards D, 2003, BIOINFORMATICS, V19, P825, DOI 10.1093/bioinformatics/btg083; Hayashi T, 2002, EXP CELL RES, V280, P212, DOI 10.1006/excr.2002.5634; Herlyn M, 2006, INT J CANCER, V118, P523, DOI 10.1002/ijc.21605; HERLYN M, 1987, CANCER RES, V47, P3057; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Johnson EW, 1997, J BACK MUSCULOSKELET, V9, P3, DOI 10.3233/BMR-1997-9102; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Lin JY, 2004, FEBS LETT, V573, P15, DOI 10.1016/j.febslet.2004.07.059; Lin X, 2003, J BIOL CHEM, V278, P31043, DOI 10.1074/jbc.C300112200; McDonald SL, 2004, CANCER BIOL THER, V3, P110, DOI 10.4161/cbt.3.1.662; Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210; Mo YY, 2004, CANCER RES, V64, P2793, DOI 10.1158/0008-5472.CAN-03-2410; Nacerddine K, 2005, DEV CELL, V9, P769, DOI 10.1016/j.devcel.2005.10.007; Perlis C, 2004, ONCOLOGIST, V9, P182, DOI 10.1634/theoncologist.9-2-182; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Rizos H, 2005, CELL CYCLE, V4, P597, DOI 10.4161/cc.4.4.1588; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Smith AP, 2005, CANCER BIOL THER, V4, P1018, DOI 10.4161/cbt.4.9.2165; Smith AP, 2004, CANCER BIOL THER, V3, P104, DOI 10.4161/cbt.3.1.661; Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102; Tashiro K, 1997, P NATL ACAD SCI USA, V94, P7862, DOI 10.1073/pnas.94.15.7862; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Ungureanu D, 2003, BLOOD, V102, P3311, DOI 10.1182/blood-2002-12-3816; Valesky M, 2002, MOL MED, V8, P103, DOI 10.1007/BF03402080; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WANG E, 2004, J TRANSL MED, V15, P34; Wang YP, 1996, CELL GROWTH DIFFER, V7, P1733; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Wang ZY, 1996, J BIOL CHEM, V271, P24811, DOI 10.1074/jbc.271.40.24811; Watanabe TK, 1996, CYTOGENET CELL GENET, V72, P86, DOI 10.1159/000134169; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Xu WD, 2000, EXP CELL RES, V255, P135, DOI 10.1006/excr.2000.4803; Yasugi T, 1996, NUCLEIC ACIDS RES, V24, P2005, DOI 10.1093/nar/24.11.2005	39	67	73	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4216	4225		10.1038/sj.onc.1210216	http://dx.doi.org/10.1038/sj.onc.1210216			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17297476				2022-12-25	WOS:000247619900004
J	Ghosh, M; Loper, R; Ghomashchi, F; Tucker, DE; Bonventre, JV; Gelb, MH; Leslie, CC				Ghosh, Moumita; Loper, Robyn; Ghomashchi, Farideh; Tucker, Dawn E.; Bonventre, Joseph V.; Gelb, Michael H.; Leslie, Christina C.			Function, activity, and membrane targeting of cytosolic phospholipase A(2)zeta in mouse lung fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; SMOOTH-MUSCLE-CELLS; GROUP-IIA; GROUP-IV; MAMMALIAN-CELLS; GROUP-X; PHOSPHORYLATION SITES; EICOSANOID PRODUCTION; NUCLEAR-ENVELOPE; BINDING DOMAIN	Group IVA cytosolic phospholipase A(2) ( cPLA(2)alpha) initiates eicosanoid production; however, this pathway is not completely ablated in cPLA(2)alpha(-/-) lung fibroblasts stimulated with A23187 or serum. cPLA(2)alpha(-/-) fibroblasts preferentially released arachidonic acid, but A23187-stimulated cPLA(2)alpha(-/-) fibroblasts nonspecifically released multiple fatty acids. Arachidonic acid release from cPLA2 alpha(-/-) fibroblasts was inhibited by the cPLA(2)alpha inhibitors pyrrolidine-2 ( IC50, 0.03 mu M) and Wyeth-1 ( IC50, 0.1 mu M), implicating another C2 domain-containing group IV PLA(2). cPLA(2)alpha(-/-) fibroblasts contain cPLA(2)beta and cPLA(2)zeta but not cPLA(2)epsilon or cPLA(2)delta. Purified cPLA(2)zeta exhibited much higher lysophospholipase and PLA(2) activity than cPLA(2)beta and was potently inhibited by pyrrolidine-2 and Wyeth-1, which did not inhibit cPLA(2)beta. In contrast to cPLA(2)beta, cPLA(2)zeta expressed in Sf9 cells mediated A23187-induced arachidonic acid release, which was inhibited by pyrrolidine-2 and Wyeth-1. cPLA(2)zeta exhibits specific activity, inhibitor sensitivity, and low micromolar calcium dependence similar to cPLA(2)alpha and has been identified as the PLA(2) responsible for calcium-induced fatty acid release and prostaglandin E-2 production from cPLA(2)alpha(-/-) lung fibroblasts. In response to ionomycin, EGFP-cPLA(2)zeta translocated to ruffles and dynamic vesicular structures, whereas EGFP-cPLA(2)alpha translocated to the Golgi and endoplasmic reticulum, suggesting distinct mechanisms of regulation for the two enzymes.	Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, Denver, CO 80206 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA; Univ Colorado, Sch Med, Dept Pathol, Aurora, CO 80045 USA; Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA	National Jewish Health; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Leslie, CC (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Cell Biol Program, 1400 Jackson St, Denver, CO 80206 USA.	lesliec@njc.org		gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL50040, HL34303, R01 HL050040, P01 HL034303, HL61378, R01 HL050040-14, R01 HL061378] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, R01HL061378, R01HL050040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; Chiba H, 2004, J BIOL CHEM, V279, P12890, DOI 10.1074/jbc.M305801200; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; DECARVALHO MGS, 1995, J BIOL CHEM, V270, P20439, DOI 10.1074/jbc.270.35.20439; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Downey P, 2001, AM J PHYSIOL-RENAL, V280, pF607, DOI 10.1152/ajprenal.2001.280.4.F607; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Ghosh M, 2004, AM J RESP CELL MOL, V30, P91, DOI 10.1165/rcmb.2003-0005OC; Ghosh M, 2006, J BIOL CHEM, V281, P16615, DOI 10.1074/jbc.M601770200; Ghosh M, 2006, PROG LIPID RES, V45, P487, DOI 10.1016/j.plipres.2006.05.003; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; Girotti M, 2004, J BIOL CHEM, V279, P19113, DOI 10.1074/jbc.M313867200; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; Jenkins CM, 2003, BIOCHEMISTRY-US, V42, P11798, DOI 10.1021/bi034611q; Jenkins CM, 2002, J BIOL CHEM, V277, P32807, DOI 10.1074/jbc.M202568200; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; Leslie CC, 2004, BIOCHEM CELL BIOL, V82, P1, DOI 10.1139/o03-080; Leslie Christina C, 2004, Methods Mol Biol, V284, P229; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Mounier CM, 2004, J BIOL CHEM, V279, P25024, DOI 10.1074/jbc.M313019200; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Ni Z, 2006, J BIOL CHEM, V281, P16245, DOI 10.1074/jbc.M513874200; Ohto T, 2005, J BIOL CHEM, V280, P24576, DOI 10.1074/jbc.M413711200; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pickard RT, 1999, J BIOL CHEM, V274, P8823, DOI 10.1074/jbc.274.13.8823; Seno K, 2000, J MED CHEM, V43, P1041, DOI 10.1021/jm9905155; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Song CZ, 1999, J BIOL CHEM, V274, P17063, DOI 10.1074/jbc.274.24.17063; Stewart A, 2002, J BIOL CHEM, V277, P29526, DOI 10.1074/jbc.M204856200; Tucker DE, 2005, J LIPID RES, V46, P2122, DOI 10.1194/jlr.M500230-JLR200; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Vitale A, 2005, DEV BIOL, V282, P374, DOI 10.1016/j.ydbio.2005.03.018; Wong DA, 2002, J EXP MED, V196, P349, DOI 10.1084/jem.20011443; Yokota Y, 1999, BBA-MOL CELL BIOL L, V1438, P213, DOI 10.1016/S1388-1981(99)00053-0	45	47	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11676	11686		10.1074/jbc.M608458200	http://dx.doi.org/10.1074/jbc.M608458200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17293613	Green Accepted, hybrid			2022-12-25	WOS:000245941900009
J	Hill, KE; Zhou, JD; Austin, LM; Motley, AK; Ham, AJL; Olson, GE; Atkins, JF; Gesteland, RF; Burk, RF				Hill, Kristina E.; Zhou, Jiadong; Austin, Lori M.; Motley, Amy K.; Ham, Amy-Joan L.; Olson, Gary E.; Atkins, John F.; Gesteland, Raymond F.; Burk, Raymond F.			The selenium-rich C-terminal domain of mouse selenoprotein P is necessary for the supply of selenium to brain and testis but not for the maintenance of whole body selenium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; UGA CODONS; RAT PLASMA; PROTEIN; EXPRESSION; INSERTION; DELETION; ACID; GENE; SELENOCYSTEINES	Selenoprotein P (Sepp1) has two domains with respect to selenium content: the N-terminal, selenium-poor domain and the C-terminal, selenium-rich domain. To assess domain function, mice with deletion of the C-terminal domain have been produced and compared with Sepp1(-/-) and Sepp1(-)/(-) mice. All mice studied were males fed a semipurified diet with defined selenium content. The Sepp1 protein in the plasma of mice with the C-terminal domain deleted was determined by mass spectrometry to terminate after serine 239 and thus was designated Sepp1 Delta 240 - 361. Plasma Sepp1 and selenium concentrations as well as glutathione peroxidase activity were determined in the three types of mice. Glutathione peroxidase and Sepp1(Delta 240-361) accounted for over 90% of the selenium in the plasma of Sepp1(Delta 240-361) mice. Calculations using results from Sepp1(-/-) mice revealed that Sepp1, with a potential for containing 10 selenocysteine residues, contained an average of 5 selenium atoms per molecule, indicating that shortened and/or selenium-depleted forms of the protein were present in these wild-type mice. Sepp1(Delta 240 - 361) mice had low brain and testis selenium concentrations that were similar to those in Sepp1(-/-) mice but they better maintained their whole body selenium. Sepp1(Delta 240-361) mice had depressed fertility, even when they were fed a high selenium diet, and their spermatozoa were defective and morphologically indistinguishable from those of selenium-deficient mice. Neurological dysfunction and death occurred when Sepp1(Delta 240-361) mice were fed selenium-deficient diet. These phenotypes were similar to those of Sepp1(-/-) mice but had later onset or were less severe. The results of this study demonstrate that the C terminus of Sepp1 is critical for the maintenance of selenium in brain and testis but not for the maintenance of whole body selenium.	Vanderbilt Univ, Div Gastroenterol Hepatol & Nutr, Dept Med, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell & Dev Biol, Sch Med, Nashville, TN 37232 USA; Univ Utah, Eccles Inst Human Genet, Salt Lake City, UT 84112 USA; Natl Univ Ireland Univ Coll Cork, Biosci Inst, Cork, Ireland	Vanderbilt University; Vanderbilt University; Vanderbilt University; Utah System of Higher Education; University of Utah; University College Cork	Burk, RF (corresponding author), Vanderbilt Univ Sch Med, 1030C Med Res Bldg 4, Nashville, TN 37232 USA.	raymond.burk@vanderbilt.edu		Atkins, John/0000-0001-7933-0165	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, R01ES002497, R37ES002497] Funding Source: NIH RePORTER; NICHD NIH HHS [HD44863] Funding Source: Medline; NIEHS NIH HHS [ES02497, ES00267] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Burk RF, 2006, BBA-GEN SUBJECTS, V1760, P1789, DOI 10.1016/j.bbagen.2006.08.010; Burk RF, 2005, ANNU REV NUTR, V25, P215, DOI 10.1146/annurev.nutr.24.012003.132120; Chittum HS, 1996, ARCH BIOCHEM BIOPHYS, V325, P124, DOI 10.1006/abbi.1996.0015; DENG CX, 1993, MOL CELL BIOL, V13, P2134, DOI 10.1128/MCB.13.4.2134; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Greer JM, 2002, NEURON, V33, P23, DOI 10.1016/S0896-6273(01)00564-5; Hansen BT, 2005, J PROTEOME RES, V4, P358, DOI 10.1021/pr0498234; Hill KE, 2003, J BIOL CHEM, V278, P13640, DOI 10.1074/jbc.M300755200; Hill KE, 2004, J NUTR, V134, P157, DOI 10.1093/jn/134.1.157; HILL KE, 1991, J BIOL CHEM, V266, P10050; Himeno S, 1996, J BIOL CHEM, V271, P15769, DOI 10.1074/jbc.271.26.15769; Howard MT, 2005, EMBO J, V24, P1596, DOI 10.1038/sj.emboj.7600642; Koga M, 1998, BIOL REPROD, V58, P261, DOI 10.1095/biolreprod58.1.261; KOH TS, 1983, J ASSOC OFF ANA CHEM, V66, P918; Kryukov GV, 2000, GENES CELLS, V5, P1049, DOI 10.1046/j.1365-2443.2000.00392.x; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Ma SG, 2003, BIOCHEMISTRY-US, V42, P9703, DOI 10.1021/bi0346300; Ma SG, 2002, J BIOL CHEM, V277, P12749, DOI 10.1074/jbc.M111462200; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; Olson GE, 2005, BIOL REPROD, V73, P201, DOI 10.1095/biolreprod.105.040360; READ R, 1990, J BIOL CHEM, V265, P17899; SAIJOH K, 1995, MOL BRAIN RES, V30, P301, DOI 10.1016/0169-328X(94)00007-2; Saito Y, 2004, BIOCHEM J, V381, P841, DOI 10.1042/BJ20040328; Schweizer U, 2005, BIOCHEM J, V386, P221, DOI 10.1042/BJ20041973; SHEEHAN TMT, 1990, CLIN CHEM, V36, P2124; Stoytcheva Z, 2006, MOL CELL BIOL, V26, P9177, DOI 10.1128/MCB.00856-06; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Xia YM, 2005, AM J CLIN NUTR, V81, P829, DOI 10.1093/ajcn/81.4.829; Yang XG, 2000, BBA-GEN SUBJECTS, V1474, P390, DOI 10.1016/S0304-4165(00)00035-0	30	82	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10972	10980		10.1074/jbc.M700436200	http://dx.doi.org/10.1074/jbc.M700436200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311913	hybrid			2022-12-25	WOS:000245941500017
J	Baker, BY; Epand, RF; Epand, RM; Miller, WL				Baker, Bo Y.; Epand, Raquel F.; Epand, Richard M.; Miller, Walter L.			Cholesterol binding does not predict activity of the steroidogenic acute regulatory protein, StAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOID ADRENAL-HYPERPLASIA; MOLTEN-GLOBULE; MITOCHONDRIAL-MEMBRANE; SYNTHETIC MEMBRANES; CELLS; MECHANISM; GENE; TRANSPORT; COMPLEX; IMPORT	Steroidogenic acute regulatory protein ( StAR) stimulates adrenal and gonadal steroidogenesis by increasing the influx of cholesterol into mitochondria, where it is converted to pregnenolone to initiate steroidogenesis. StAR acts on the outer mitochondrial membrane where each molecule stimulates the mitochondrial import of several hundred molecules of cholesterol, but the precise mechanism of the action of StAR remains uncertain. StAR has a sterol-binding pocket that can accommodate one molecule of cholesterol. Direct assays show that StAR can bind cholesterol with stoichiometry approaching 1: 1, and several disease- causing mutants with decreased or absent activity have correspondingly decreased cholesterol binding. We show that the StAR mutant R182L, which causes severe disease and is devoid of measurable activity in transfected cells or with isolated steroidogenic mitochondria, nevertheless, can bind as much [C-14]- or NBD-cholesterol as wild-type StAR under equilibrium conditions and can transfer cholesterol between liposomes in vitro. Similarly, the artificial mutant S195A had 46.5% of the activity of wild-type StAR but bound cholesterol indistinguishably from wild- type. Competition assays showed that the rate of binding (t(1/2on)) for R182L was only 36% of the wild- type and the rate of dissociation (t(1/2off)) was 57% of wild- type, whereas the t(1/2on) and t(1/2off) for S195A and S195D were essentially the same for wild- type. These data indicate that cholesterol binding and transfer activities are distinct from its activity to induce steroidogenesis. StAR appears to act by other mechanisms in addition to cholesterol binding.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada	University of California System; University of California San Francisco; University of California System; University of California San Francisco; McMaster University	Miller, WL (corresponding author), Univ Calif San Francisco, Dept Pediat, Room HSE1427, San Francisco, CA 94143 USA.	wlmlab@ucsf.edu	, Richard/R-2316-2019; Baker, Bo/C-1466-2010; Miller, Walter L/J-3696-2012	, Richard/0000-0002-9602-9558; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037922] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37922] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Artemenko IP, 2001, J BIOL CHEM, V276, P46583, DOI 10.1074/jbc.M107815200; Baker BY, 2006, J CLIN ENDOCR METAB, V91, P4781, DOI 10.1210/jc.2006-1565; Baker BY, 2005, J BIOL CHEM, V280, P41753, DOI 10.1074/jbc.M510241200; Bose HS, 2000, BIOCHEMISTRY-US, V39, P11722, DOI 10.1021/bi000911l; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Bose HS, 2000, J CLIN ENDOCR METAB, V85, P3636, DOI 10.1210/jc.85.10.3636; Chen X, 2005, J CLIN ENDOCR METAB, V90, P835, DOI 10.1210/jc.2004-1323; Christensen K, 2001, J BIOL CHEM, V276, P17044, DOI 10.1074/jbc.M100903200; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; Ewing TJA, 1997, J COMPUT CHEM, V18, P1175, DOI 10.1002/(SICI)1096-987X(19970715)18:9<1175::AID-JCC6>3.0.CO;2-O; Fleury A, 2004, J STEROID BIOCHEM, V91, P259, DOI 10.1016/j.jsbmb.2004.04.010; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; Hauet T, 2005, MOL ENDOCRINOL, V19, P540, DOI 10.1210/me.2004-0307; Im YJ, 2005, NATURE, V437, P154, DOI 10.1038/nature03923; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; Li H, 2001, MOL ENDOCRINOL, V15, P2211, DOI 10.1210/me.15.12.2211; Li XM, 2002, J CELL BIOL, V157, P63, DOI 10.1083/jcb.200201037; Li ZG, 2006, J ORG CHEM, V71, P1718, DOI 10.1021/jo052029x; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Mathieu AP, 2002, J MOL ENDOCRINOL, V29, P327, DOI 10.1677/jme.0.0290327; Miller WL, 2007, MOL ENDOCRINOL, V21, P589, DOI 10.1210/me.2006-0303; Miller WL, 1999, J STEROID BIOCHEM, V69, P131, DOI 10.1016/S0960-0760(98)00153-8; Miller WL, 1997, J MOL ENDOCRINOL, V19, P227, DOI 10.1677/jme.0.0190227; Murcia M, 2006, J LIPID RES, V47, P2614, DOI 10.1194/jlr.M600232-JLR200; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; PON LA, 1986, J BIOL CHEM, V261, P3309; Raychaudhuri S, 2006, J CELL BIOL, V173, P107, DOI 10.1083/jcb.200510084; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Romanowski MJ, 2002, P NATL ACAD SCI USA, V99, P6949, DOI 10.1073/pnas.052140699; Shaw JE, 2006, BIOPHYS J, V90, P2170, DOI 10.1529/biophysj.105.073510; Soccio RE, 2005, J BIOL CHEM, V280, P19410, DOI 10.1074/jbc.M501778200; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Song MS, 2001, BIOCHEM J, V356, P151, DOI 10.1042/0264-6021:3560151; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Tuckey RC, 2002, J BIOL CHEM, V277, P47123, DOI 10.1074/jbc.M206965200; West LA, 2001, ENDOCRINOLOGY, V142, P502, DOI 10.1210/en.142.1.502; Yaworsky DC, 2005, J BIOL CHEM, V280, P2045, DOI 10.1074/jbc.M410937200	46	61	61	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10223	10232		10.1074/jbc.M611221200	http://dx.doi.org/10.1074/jbc.M611221200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17301050	hybrid			2022-12-25	WOS:000245941000012
J	Hellbusch, CC; Sperandio, M; Frommhold, D; Yakubenia, S; Wild, MK; Popovici, D; Vestweber, D; Grone, HJ; von Figura, K; Lubke, T; Korner, C				Hellbusch, Christina C.; Sperandio, Markus; Frommhold, David; Yakubenia, Sviatlana; Wild, Martin K.; Popovici, Diana; Vestweber, Dietmar; Grone, Hermann-Josef; von Figura, Kurt; Lubke, Torben; Korner, Christian			Golgi GDP-fucose transporter-deficient mice mimic congenital disorder of glycosylation IIc/leukocyte adhesion deficiency II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-SELECTIN; GLYCOPROTEIN SYNDROME; FUCT-VII; DEFECT; IDENTIFICATION; FUCOSYLATION; RECRUITMENT; INTEGRINS; MUTATION; REVEALS	Modification of glycoproteins by the attachment of fucose residues is widely distributed in nature. The importance of fucosylation has recently been underlined by identification of the monogenetic inherited human disease "congenital disorder of glycosylation IIc," also termed "leukocyte adhesion deficiency II." Due to defective Golgi GDP-fucose transporter ( SLC35C1) activity, patients show a hypofucosylation of glycoproteins and present clinically with mental and growth retardation, persistent leukocytosis, and severe infections. To investigate effects induced by the loss of fucosylated structures in different organs, we generated a mouse model for the disease by inactivating the Golgi GDP-transporter gene ( Slc35c1). Lectin binding studies revealed a tremendous reduction of fucosylated glycoconjugates in tissues and isolated cells from Slc35c1(-/-) mice. Fucose treatment of cells from different organs led to partial normalization of the fucosylation state of glycoproteins, thereby indicating an alternative GDP-fucose transport mechanism. Slc35c1-deficient mice presented with severe growth retardation, elevated postnatal mortality rate, dilatation of lung alveoles, and hypocellular lymph nodes. In vitro and in vivo leukocyte adhesion and rolling assays revealed a severe impairment of P-, E-, and L-selectin ligand function. The diversity of these phenotypic aspects demonstrates the broad general impact of fucosylation in the mammalian organism.	Univ Childrens Hosp, Dept Pediat, Div Inborn Metab Dis, D-69120 Heidelberg, Germany; Univ Childrens Hosp, Dept Pediat, Sect Neonatol, D-69120 Heidelberg, Germany; Max Planck Inst Mol Biomed, D-48149 Munster, Germany; German Canc Res Ctr, Dept Cellular & Mol Pathol, D-69120 Heidelberg, Germany; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Abt Biochem 2, D-37073 Gottingen, Germany	Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Max Planck Society; Helmholtz Association; German Cancer Research Center (DKFZ); University of Gottingen	Korner, C (corresponding author), Univ Childrens Hosp, Dept Pediat, Div Inborn Metab Dis, Neuenheimer Feld 153, D-69120 Heidelberg, Germany.	christian.koerner@med.uni-heidelberg.de	Lübke, Torben/B-6019-2012	Lubke, Torben/0000-0002-3342-0090; Vestweber, Dietmar/0000-0002-3517-732X; Sperandio, Markus/0000-0002-7689-3613				BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; BRANDLI AW, 1988, J BIOL CHEM, V263, P16283; CUMMINGS RD, 1994, METHOD ENZYMOL, V230, P66; Domino SE, 2001, MOL CELL BIOL, V21, P8336, DOI 10.1128/MCB.21.24.8336-8345.2001; Gotsch U, 1997, J CELL SCI, V110, P583; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Helmus Y, 2006, BLOOD, V107, P3959, DOI 10.1182/blood-2005-08-3334; Hidalgo A, 2003, BLOOD, V101, P1705, DOI 10.1182/blood-2002-09-2840; HOGAN B, 1986, MANIPULATING MOUSE E, P188; HOGAN B, 1994, MANIPULATING MOUSE E, P89; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Klyscz T, 1997, BIOMED TECH, V42, P168, DOI 10.1515/bmte.1997.42.6.168; Korner C, 1999, J LEUKOCYTE BIOL, V66, P95; Korner C, 1998, GLYCOCONJUGATE J, V15, P499, DOI 10.1023/A:1006939104442; KRAKOWER CA, 1951, AMA ARCH PATHOL, V51, P629; Kudo T, 2004, MOL CELL BIOL, V24, P4221, DOI 10.1128/MCB.24.10.4221-4228.2004; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LEY K, 1988, PFLUG ARCH EUR J PHY, V412, P93, DOI 10.1007/BF00583736; LEY K, 1989, AM J PHYSIOL, V256, pH85, DOI 10.1152/ajpheart.1989.256.1.H85; LIPOWSKY HH, 1978, MICROVASC RES, V15, P93, DOI 10.1016/0026-2862(78)90009-2; Long DS, 2004, P NATL ACAD SCI USA, V101, P10060, DOI 10.1073/pnas.0402937101; Lowe JB, 1997, KIDNEY INT, V51, P1418, DOI 10.1038/ki.1997.194; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/ng0501-73; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; Luo Y, 2005, J BIOL CHEM, V280, P11289, DOI 10.1074/jbc.M414574200; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Marquardt T, 1999, J PEDIATR-US, V134, P681, DOI 10.1016/S0022-3476(99)70281-7; Marquardt T, 1999, BLOOD, V94, P3976, DOI 10.1182/blood.V94.12.3976.424k06_3976_3985; Martinez-Duncker I, 2003, GLYCOBIOLOGY, V13, p1C, DOI 10.1093/glycob/cwg113; MEREDITH MJ, 1988, CELL BIOL TOXICOL, V4, P405, DOI 10.1007/BF00117769; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; Sears P, 1998, CELL MOL LIFE SCI, V54, P223, DOI 10.1007/s000180050146; Shi SL, 2003, P NATL ACAD SCI USA, V100, P5234, DOI 10.1073/pnas.0831126100; Smith ML, 2003, BIOPHYS J, V85, P637, DOI 10.1016/S0006-3495(03)74507-X; Smith PL, 2002, J CELL BIOL, V158, P801, DOI 10.1083/jcb.200203125; Sperandio M, 2001, J IMMUNOL, V167, P2268, DOI 10.4049/jimmunol.167.4.2268; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; Staudacher E, 1999, BBA-GEN SUBJECTS, V1473, P216, DOI 10.1016/S0304-4165(99)00181-6; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Wagner N, 1996, NATURE, V382, P366, DOI 10.1038/382366a0; Wang XC, 2005, P NATL ACAD SCI USA, V102, P15791, DOI 10.1073/pnas.0507375102; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4	48	55	55	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10762	10772		10.1074/jbc.M700314200	http://dx.doi.org/10.1074/jbc.M700314200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17276979	hybrid			2022-12-25	WOS:000245941000070
J	Bruneau, E; Akaaboune, M				Bruneau, Emile; Akaaboune, Mohammed			The dynamics of the rapsyn scaffolding protein at individual acetylcholine receptor clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC-FAMILY KINASES; NEUROMUSCULAR-JUNCTIONS; POSTSYNAPTIC PROTEINS; REQUIRES RAPSYN; IN-VIVO; PHOSPHORYLATION; AGRIN; TRAFFICKING; STARGAZIN; PSD-95	Rapsyn, a cytoplasmic receptor-associated protein, is required for the clustering of acetylcholine receptors (AChRs). Although AChR dynamics have been extensively studied, little is known about the dynamics of rapsyn. Here, we used a rapsyn-green fluorescent protein (GFP) fusion protein and quantitative fluorescent imaging to study the dynamics of rapsyn in transfected C2C12 myotubes. First, we found that rapsyn-GFP expression at clusters did not alter AChR aggregation, function, or turnover. Quantification of rapsyn immunofluorescence indicated that the expression of rapsyn-GFP proteins at clusters does not increase the overall rapsyn density compared with untransfected myotube clusters. Using time lapse imaging and fluorescence recovery after photobleaching, we demonstrated that the recovery of rapsyn-GFP fluorescence at clusters was very fast, with a halftime of about similar to 1.5 h (similar to 3 times faster than AChRs). Inhibition of protein kinase C significantly altered receptor insertion, but it had no effect on rapsyn insertion. When cells were treated with the broad spectrum kinase inhibitor staurosporine, receptor insertion was decreased even further. However, inhibition of protein kinase A had no effect on insertion of either rapsyn or receptors. Finally, when cells were treated with neural agrin, rapsyn and AChRs were both directed away from preexisting clusters and accumulated together in new small clusters. These results demonstrate the remarkable dynamism of rapsyn, which may underlie the stability and maintenance of the postsynaptic scaffold and suggest that the insertion of different postsynaptic proteins may be operating independently.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Program Neurosci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Akaaboune, M (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, 830 N Univ Ave, Ann Arbor, MI 48109 USA.	makaabou@umich.edu		Bruneau, Emile/0000-0001-7294-8675	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS056748, R01NS047332] Funding Source: NIH RePORTER; NINDS NIH HHS [NS047332, NS056748] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AEL DE, 2002, CELL, V108, P849; Akaaboune M, 2002, NEURON, V34, P865, DOI 10.1016/S0896-6273(02)00739-0; Akaaboune M, 1999, SCIENCE, V286, P503, DOI 10.1126/science.286.5439.503; APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; Brune JN, 2006, GEOLOGY, V34, P137, DOI 10.1130/G22127.1; Bruneau EG, 2005, DEV BIOL, V288, P248, DOI 10.1016/j.ydbio.2005.09.041; Cai CL, 2006, J BIOL CHEM, V281, P4267, DOI 10.1074/jbc.M505886200; Carroll RC, 2002, TRENDS NEUROSCI, V25, P571, DOI 10.1016/S0166-2236(02)02272-5; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Choi J, 2002, J BIOL CHEM, V277, P12359, DOI 10.1074/jbc.M200528200; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Ferns M, 1996, J CELL BIOL, V132, P937, DOI 10.1083/jcb.132.5.937; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FRAIL DE, 1989, NEURON, V2, P1077, DOI 10.1016/0896-6273(89)90232-8; Fuhrer C, 1999, J NEUROSCI, V19, P6405; Fuhrer C, 1996, J BIOL CHEM, V271, P32474, DOI 10.1074/jbc.271.50.32474; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Gervasio OL, 2005, J PHYSIOL-LONDON, V562, P673, DOI 10.1113/jphysiol.2004.077685; Grady RM, 2003, J CELL BIOL, V160, P741, DOI 10.1083/jcb.200209045; Henley JM, 2003, NEUROSCI RES, V45, P243, DOI 10.1016/S0168-0102(02)00229-8; Kim EJ, 2004, NAT REV NEUROSCI, V5, P771, DOI 10.1038/nrn1517; Kummer TT, 2004, J CELL BIOL, V164, P1077, DOI 10.1083/jcb.200401115; Lanuza MA, 2002, J NEUROSCI RES, V67, P607, DOI 10.1002/jnr.10122; Marangi PA, 2001, EMBO J, V20, P7060, DOI 10.1093/emboj/20.24.7060; Marangi PA, 2002, J CELL BIOL, V157, P883, DOI 10.1083/jcb.200202110; Marchand S, 2002, J NEUROSCI, V22, P8891; Marchand S, 2000, J NEUROSCI, V20, P521, DOI 10.1523/JNEUROSCI.20-02-00521.2000; McConville J, 2002, CURR OPIN PHARMACOL, V2, P296, DOI 10.1016/S1471-4892(02)00156-X; Mittaud P, 2001, J BIOL CHEM, V276, P14505, DOI 10.1074/jbc.M007024200; Mohamed AS, 1999, J BIOL CHEM, V274, P20529, DOI 10.1074/jbc.274.29.20529; Mohamed AS, 2001, J NEUROSCI, V21, P3806, DOI 10.1523/JNEUROSCI.21-11-03806.2001; Moransard M, 2003, J BIOL CHEM, V278, P7350, DOI 10.1074/jbc.M210865200; Muller JS, 2006, NEUROLOGY, V67, P1159, DOI 10.1212/01.wnl.0000233837.79459.40; NOAKES PG, 1993, DEV BIOL, V155, P275, DOI 10.1006/dbio.1993.1025; Ohno K, 2002, AM J HUM GENET, V70, P875, DOI 10.1086/339465; Ono F, 2001, J NEUROSCI, V21, P5439, DOI 10.1523/JNEUROSCI.21-15-05439.2001; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; Rasse TM, 2005, NAT NEUROSCI, V8, P898, DOI 10.1038/nn1484; Rutter AR, 2000, J NEUROCHEM, V75, P2501, DOI 10.1046/j.1471-4159.2000.0752501.x; Sadasivam G, 2005, J NEUROSCI, V25, P10479, DOI 10.1523/JNEUROSCI.2103-05.2005; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Schnell E, 2002, P NATL ACAD SCI USA, V99, P13902, DOI 10.1073/pnas.172511199; Sharma K, 2006, MOL CELL NEUROSCI, V31, P702, DOI 10.1016/j.mcn.2006.01.010; Si JT, 1998, LIFE SCI, V62, P1497, DOI 10.1016/S0024-3205(98)00096-4; Turney SG, 1996, J NEUROSCI METH, V64, P199, DOI 10.1016/0165-0270(95)00135-2; VALENZUELA IMP, 2005, J BIOL CHEM, V280, P31801; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661; Wang JQ, 2005, MOL NEUROBIOL, V32, P237, DOI 10.1385/MN:32:3:237	49	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9932	9940		10.1074/jbc.M608714200	http://dx.doi.org/10.1074/jbc.M608714200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17283077	Green Published, hybrid			2022-12-25	WOS:000245421700068
J	Moncoq, K; Trieber, CA; Young, HS				Moncoq, Karine; Trieber, Catharine A.; Young, Howard S.			The molecular basis for cyclopiazonic acid inhibition of the sarcoplasmic reticulum calcium pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING; PHOSPHORYL TRANSFER; CRYSTAL-STRUCTURE; ACTIVE-SITE; CA2+-ATPASE; CA2+; THAPSIGARGIN; MECHANISM; RESIDUES; PROTEIN	The sarcoplasmic reticulum Ca2+-ATPase is essential for calcium reuptake in the muscle contraction-relaxation cycle. Here we present structures of a calcium-free state with bound cyclopiazonic acid (CPA) and magnesium fluoride at 2.65 angstrom resolution and a calcium-free state with bound CPA and ADP at 3.4 angstrom resolution. In both structures, CPA occupies the calcium access channel delimited by transmembrane segments M1-M4. Inhibition of Ca2+-ATPase is stabilized by a polar pocket that surrounds the tetramic acid of CPA and a hydrophobic platform that cradles the inhibitor. The calcium pump residues involved include Gln(56), Leu(61), Val(62), and Asn(101). We conclude that CPA inhibits the calcium pump by blocking the calcium access channel and immobilizing a subset of transmembrane helices. In the E2(CPA) structure, ADP is bound in a distinct orientation within the nucleotide binding pocket. The adenine ring is sandwiched between Arg(489) of the nucleotide-binding domain and Arg(678) of the phosphorylation domain. This mode of binding conforms to an adenine recognition motif commonly found in ATP-dependent proteins.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta	Young, HS (corresponding author), Univ Alberta, Dept Biochem, Bldg 327, Edmonton, AB T6G 2H7, Canada.	hyoung@ualberta.ca		Trieber, Catharine/0000-0002-1336-1126; Young, Howard/0000-0002-5990-8422				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Biot C, 2003, J AM CHEM SOC, V125, P13988, DOI 10.1021/ja035223e; Denessiouk KA, 2001, PROTEINS, V44, P282, DOI 10.1002/prot.1093; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; HOLZAPFE.CW, 1968, TETRAHEDRON, V24, P2101, DOI 10.1016/0040-4020(68)88113-X; Inesi G, 2006, BIOCHEMISTRY-US, V45, P13769, DOI 10.1021/bi061255d; Jensen AML, 2006, EMBO J, V25, P2305, DOI 10.1038/sj.emboj.7601135; Kimura K, 1996, J BIOL CHEM, V271, P28933, DOI 10.1074/jbc.271.46.28933; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LU YZ, 1994, BIOCHEMISTRY-US, V33, P5056, DOI 10.1021/bi00183a008; Ma HL, 1999, BIOCHEMISTRY-US, V38, P15522, DOI 10.1021/bi991523q; Mao LS, 2003, J AM CHEM SOC, V125, P14216, DOI 10.1021/ja036096p; MARTINS OB, 1985, J BIOL CHEM, V260, P6776; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Missiaen L, 2002, J BIOL CHEM, V277, P6898, DOI 10.1074/jbc.M110939200; Moller JV, 2005, CURR OPIN STRUC BIOL, V15, P387, DOI 10.1016/j.sbi.2005.06.005; MURPHY AJ, 1976, BIOCHEM BIOPH RES CO, V70, P1048, DOI 10.1016/0006-291X(76)91008-1; Obara K, 2005, P NATL ACAD SCI USA, V102, P14489, DOI 10.1073/pnas.0506222102; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; Picard M, 2006, J BIOL CHEM, V281, P3360, DOI 10.1074/jbc.M511385200; RAESS BU, 1985, MOL PHARMACOL, V27, P444; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Reddy LG, 2003, BIOCHEMISTRY-US, V42, P4585, DOI 10.1021/bi026995a; RILEY RT, 1992, TOXICOL APPL PHARM, V114, P261, DOI 10.1016/0041-008X(92)90076-5; ROSS DC, 1991, J BIOL CHEM, V266, P4613; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Soler F, 1998, BIOCHEMISTRY-US, V37, P4266, DOI 10.1021/bi971455c; Sorensen TLM, 2004, SCIENCE, V304, P1672, DOI 10.1126/science.1099366; Sousa MC, 1998, BIOCHEMISTRY-US, V37, P15392, DOI 10.1021/bi981510x; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; Stewart RC, 1998, BIOCHEMISTRY-US, V37, P12269, DOI 10.1021/bi980970n; STOKES D, 2003, ANNU REV BIOPH BIOM, V32, P425; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; Tetko IV, 2005, J COMPUT AID MOL DES, V19, P453, DOI 10.1007/s10822-005-8694-y; Toyoshima C, 2004, NATURE, V430, P529, DOI 10.1038/nature02680; Toyoshima C, 2004, ANNU REV BIOCHEM, V73, P269, DOI 10.1146/annurev.biochem.73.011303.073700; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Venkatesh PK, 2005, MYCOPATHOLOGIA, V159, P393, DOI 10.1007/s11046-004-6271-x; WARREN GB, 1974, P NATL ACAD SCI USA, V71, P622, DOI 10.1073/pnas.71.3.622; Wilson DM, 2002, ADV EXP MED BIOL, V504, P3; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wootton LL, 2006, J BIOL CHEM, V281, P6970, DOI 10.1074/jbc.M510978200; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; Young HS, 2004, J MEMBRANE BIOL, V198, P55, DOI 10.1007/s00232-004-0666-y; Young HS, 2001, J MOL BIOL, V308, P231, DOI 10.1006/jmbi.2001.4558; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	53	110	111	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9748	9757		10.1074/jbc.M611653200	http://dx.doi.org/10.1074/jbc.M611653200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17259168	hybrid			2022-12-25	WOS:000245421700049
J	Suzuki, T; Nishi, T; Nagino, T; Sasaki, K; Aizawa, K; Kada, N; Sawaki, D; Munemasa, Y; Matsumura, T; Muto, S; Sata, M; Miyagawa, K; Horikoshi, M; Nagai, R				Suzuki, Toru; Nishi, Toshiya; Nagino, Tomoko; Sasaki, Kana; Aizawa, Kenichi; Kada, Nanae; Sawaki, Daigo; Munemasa, Yoshiko; Matsumura, Takayoshi; Muto, Shinsuke; Sata, Masataka; Miyagawa, Kiyoshi; Horikoshi, Masami; Nagai, Ryozo			Functional interaction between the transcription factor Kruppel-like factor 5 and poly(ADP-ribose) polymerase-1 in cardiovascular apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; ACETYLATION; P300; MICE; EXPRESSION; REGULATOR; PATHWAY; PROTEIN; REPAIR; DOMAIN	Kruppel-like factor 5 (KLF5) is a transcription factor important in regulation of the cardiovascular response to external stress. KLF5 regulates pathological cell growth, and its acetylation is important for this effect. Its mechanisms of action, however, are still unclear. Analysis in KLF5-deficient mice showed that KLF5 confers apoptotic resistance in vascular lesions. Mechanistic analysis further showed that it specifically interacts with poly(ADP-ribose) polymerase-1 (PARP-1), a nuclear enzyme important in DNA repair and apoptosis. KLF5 interacted with a proteolytic fragment of PARP-1, and acetylation of KLF5 under apoptotic conditions increased their affinity. Moreover, KLF5 wild-type (but not a non-acetylatable point mutant) inhibited apoptosis as induced by the PARP-1 fragment. Collectively, we have found that KLF5 regulates apoptosis and targets PARP-1, and further, for acetylation to regulate these effects. Our findings thus implicate functional interaction between the transcription factor KLF5 and PARP-1 in cardiovascular apoptosis.	Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Clin Bioinformat, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Radiat Biol, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Lab Dev Biol, Bunkyo Ku, Tokyo 1138655, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Suzuki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	torusuzu-tky@umin.ac.jp; nagai-tky@umin.ac.jp	SAWAKI, Daigo/T-6871-2018	SAWAKI, Daigo/0000-0003-1417-2033; Nishi, Toshiya/0000-0002-9451-2423; Suzuki, Toru/0000-0002-8371-664X				Aizawa K, 2004, J BIOL CHEM, V279, P70, DOI 10.1074/jbc.M306621200; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Hoshino Y, 2000, CIRCULATION, V102, P2528, DOI 10.1161/01.CIR.102.20.2528; Kim JW, 2000, J CELL SCI, V113, P955; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Miyamoto S, 2006, CIRCULATION, V113, P679, DOI 10.1161/CIRCULATIONAHA.105.585182; Miyamoto S, 2003, MOL CELL BIOL, V23, P8528, DOI 10.1128/MCB.23.23.8528-8541.2003; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Olson EN, 2004, NAT MED, V10, P467, DOI 10.1038/nm0504-467; Sata M, 2000, J MOL CELL CARDIOL, V32, P2097, DOI 10.1006/jmcc.2000.1238; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Shindo T, 2002, NAT MED, V8, P856, DOI 10.1038/nm738; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Suzuki T, 2005, TRENDS CARDIOVAS MED, V15, P125, DOI 10.1016/j.tcm.2005.04.003; Suzuki T, 2005, ARTERIOSCL THROM VAS, V25, P1135, DOI 10.1161/01.ATV.0000165656.65359.23; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Suzuki T, 2003, J BIOL CHEM, V278, P28758, DOI 10.1074/jbc.M302228200; Suzuki T, 1998, J BIOCHEM, V124, P389, DOI 10.1093/oxfordjournals.jbchem.a022124; Torigoe T, 2005, J BIOL CHEM, V280, P1179, DOI 10.1074/jbc.M410499200; Towbin JA, 2002, NATURE, V415, P227, DOI 10.1038/415227a; von Kobbe C, 2004, NUCLEIC ACIDS RES, V32, P4003, DOI 10.1093/nar/gkh721; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; Watanabe N, 1999, CIRC RES, V85, P182, DOI 10.1161/01.RES.85.2.182; Yang L, 2003, CANCER RES, V63, P6815; Yung TMC, 2001, J BIOL CHEM, V276, P11279, DOI 10.1074/jbc.M008044200; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9	32	25	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9895	9901		10.1074/jbc.M608098200	http://dx.doi.org/10.1074/jbc.M608098200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17283079	hybrid			2022-12-25	WOS:000245421700064
J	Blanvillain, S; Meyer, D; Boulanger, A; Lautier, M; Guynet, C; Denance, N; Vasse, J; Lauber, E; Arlat, M				Blanvillain, Servane; Meyer, Damien; Boulanger, Alice; Lautier, Martine; Guynet, Catherine; Denance, Nicolas; Vasse, Jacques; Lauber, Emmanuelle; Arlat, Matthieu			Plant Carbohydrate Scavenging through TonB-Dependent Receptors: A Feature Shared by Phytopathogenic and Aquatic Bacteria	PLOS ONE			English	Article							CAMPESTRIS PV. CAMPESTRIS; MULTIPLE SEQUENCE ALIGNMENT; MEMBRANE TRANSPORTER FECA; COMPLETE GENOME SEQUENCE; GRAM-NEGATIVE BACTERIA; SOLANACEARUM-HRP GENES; III SECRETION SYSTEM; GYP DOMAIN PROTEIN; XANTHOMONAS-CAMPESTRIS; OUTER-MEMBRANE	TonB-dependent receptors (TBDRs) are outer membrane proteins mainly known for the active transport of iron siderophore complexes in Gram-negative bacteria. Analysis of the genome of the phytopathogenic bacterium Xanthomonas campestris pv. campestris (Xcc), predicts 72 TBDRs. Such an overrepresentation is common in Xanthomonas species but is limited to only a small number of bacteria. Here, we show that one Xcc TBDR transports sucrose with a very high affinity, suggesting that it might be a sucrose scavenger. This TBDR acts with an inner membrane transporter, an amylosucrase and a regulator to utilize sucrose, thus defining a new type of carbohydrate utilization locus, named CUT locus, involving a TBDR for the transport of substrate across the outer membrane. This sucrose CUT locus is required for full pathogenicity on Arabidopsis, showing its importance for the adaptation to host plants. A systematic analysis of Xcc TBDR genes and a genome context survey suggested that several Xcc TBDRs belong to other CUT loci involved in the utilization of various plant carbohydrates. Interestingly, several Xcc TBDRs and CUT loci are conserved in aquatic bacteria such as Caulobacter crescentus, Colwellia psychrerythraea, Saccharophagus degradans, Shewanella spp., Sphingomonas spp. or Pseudoalteromonas spp., which share the ability to degrade a wide variety of complex carbohydrates and display TBDR overrepresentation. We therefore propose that TBDR overrepresentation and the presence of CUT loci designate the ability to scavenge carbohydrates. Thus CUT loci, which seem to participate to the adaptation of phytopathogenic bacteria to their host plants, might also play a very important role in the biogeochemical cycling of plant-derived nutrients in marine environments. Moreover, the TBDRs and CUT loci identified in this study are clearly different from those characterized in the human gut symbiont Bacteroides thetaiotaomicron, which allow glycan foraging, suggesting a convergent evolution of TBDRs in Proteobacteria and Bacteroidetes.	[Blanvillain, Servane; Meyer, Damien; Boulanger, Alice; Lautier, Martine; Guynet, Catherine; Denance, Nicolas; Vasse, Jacques; Lauber, Emmanuelle; Arlat, Matthieu] INRA, CNRS, Lab Interact Plantes Microorganismes, UMR2594 441, F-31326 Castanet Tolosan, France; [Lautier, Martine; Arlat, Matthieu] Univ Toulouse 3, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Lauber, E (corresponding author), INRA, CNRS, Lab Interact Plantes Microorganismes, UMR2594 441, F-31326 Castanet Tolosan, France.	elauber@toulouse.inra.fr; arlat@toulouse.inra.fr	Guynet, Catherine/A-4815-2011; Denancé, Nicolas/I-1554-2019; Boulanger, Alice/E-6279-2019; Lauber, Emmanuelle/ABB-3077-2021; Arlat, Matthieu/CAH-3310-2022; MEYER, Damien F/G-2607-2013; Guynet, Catherine/GPX-0917-2022; Denancé, Nicolas/C-7008-2015	Denancé, Nicolas/0000-0003-0173-3970; Boulanger, Alice/0000-0001-5918-9547; Lauber, Emmanuelle/0000-0001-5933-4476; MEYER, Damien F/0000-0003-2735-176X; Denancé, Nicolas/0000-0003-0173-3970; Arlat, Matthieu/0000-0001-6196-4856	Ministere de la Recherche et de l'Enseignement Superieur; Departement Sante des Plantes et Environnement de L'Institut National de la Recherche Agronomique	Ministere de la Recherche et de l'Enseignement Superieur; Departement Sante des Plantes et Environnement de L'Institut National de la Recherche Agronomique	S. Blanvillain, D. Meyer and A. Boulanger were supported by grants from the Ministere de la Recherche et de l'Enseignement Superieur. We gratefully acknowledge financial support from the Departement Sante des Plantes et Environnement de L'Institut National de la Recherche Agronomique.	AHMER BMM, 1995, J BACTERIOL, V177, P4742, DOI 10.1128/jb.177.16.4742-4747.1995; Aldon D, 2000, EMBO J, V19, P2304, DOI 10.1093/emboj/19.10.2304; Alvarez A. M., 2000, MECH RESISTANCE PLAN, P21, DOI [10.1007/978-94-011-3937-3_2, DOI 10.1007/978-94-011-3937-3_2]; Angot A, 2006, P NATL ACAD SCI USA, V103, P14620, DOI 10.1073/pnas.0509393103; Anzai Y, 2000, INT J SYST EVOL MICR, V50, P1563, DOI 10.1099/00207713-50-4-1563; ARLAT M, 1991, MOL PLANT MICROBE IN, V4, P593, DOI 10.1094/MPMI-4-593; Aso Y, 2006, NAT BIOTECHNOL, V24, P188, DOI 10.1038/nbt1181; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; BAGG A, 1987, BIOCHEMISTRY-US, V26, P5471, DOI 10.1021/bi00391a039; Baichoo N, 2002, J BACTERIOL, V184, P5826, DOI 10.1128/JB.184.21.5826-5832.2002; Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkt1223, 10.1093/nar/gkp985, 10.1093/nar/gkr1065]; Bauer M, 2006, ENVIRON MICROBIOL, V8, P2201, DOI 10.1111/j.1462-2920.2006.01152.x; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bogs J, 2000, J BACTERIOL, V182, P5351, DOI 10.1128/JB.182.19.5351-5358.2000; BRADBEER C, 1976, J BACTERIOL, V128, P99, DOI 10.1128/JB.128.1.99-104.1976; Braun V, 1997, ARCH MICROBIOL, V167, P325, DOI 10.1007/s002030050451; Braun V, 2005, FEMS MICROBIOL REV, V29, P673, DOI 10.1016/j.femsre.2004.10.001; Brito B, 2002, MOL PLANT MICROBE IN, V15, P109, DOI 10.1094/MPMI.2002.15.2.109; Brown JS, 2001, MOL MICROBIOL, V40, P572, DOI 10.1046/j.1365-2958.2001.02414.x; Bryson K, 2005, NUCLEIC ACIDS RES, V33, pW36, DOI 10.1093/nar/gki410; Cartron ML, 2006, BIOMETALS, V19, P143, DOI 10.1007/s10534-006-0003-2; Cases I, 2005, INT MICROBIOL, V8, P213; Chimento DP, 2003, NAT STRUCT BIOL, V10, P394, DOI 10.1038/nsb914; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Cubero J, 2004, INT J SYST EVOL MICR, V54, P429, DOI 10.1099/ijs.0.02784-0; Cunnac S, 2004, MOL MICROBIOL, V53, P115, DOI 10.1111/j.1365-2958.2004.04118.x; Cunnac S, 2004, J BACTERIOL, V186, P2309, DOI 10.1128/JB.186.8.2309-2318.2004; da Silva ACR, 2002, NATURE, V417, P459, DOI 10.1038/417459a; DELORENZO V, 1987, J BACTERIOL, V169, P2624, DOI 10.1128/jb.169.6.2624-2630.1987; DELORENZO V, 1988, J MOL BIOL, V203, P875, DOI 10.1016/0022-2836(88)90113-1; DIGROLAM.PM, 1971, J BACTERIOL, V106, P745, DOI 10.1128/JB.106.3.745-750.1971; Dombrecht B, 2001, MOL PLANT MICROBE IN, V14, P426, DOI 10.1094/MPMI.2001.14.3.426; Dow JM, 2003, P NATL ACAD SCI USA, V100, P10995, DOI 10.1073/pnas.1833360100; DOW JM, 1990, APPL ENVIRON MICROB, V56, P2994, DOI 10.1128/AEM.56.10.2994-2998.1990; Dsouza M, 1997, TRENDS GENET, V13, P497, DOI 10.1016/S0168-9525(97)01347-4; Escolar L, 1998, J MOL BIOL, V283, P537, DOI 10.1006/jmbi.1998.2119; Faure D, 2001, J MOL MICROB BIOTECH, V3, P467; Fenselau S, 1995, MOL PLANT MICROBE IN, V8, P845, DOI 10.1094/MPMI-8-0845; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Galperin MY, 2004, ENVIRON MICROBIOL, V6, P552, DOI 10.1111/j.1462-2920.2004.00633.x; GOUGH CL, 1990, GENE, V89, P53, DOI 10.1016/0378-1119(90)90205-6; HANTKE K, 1987, MOL GEN GENET, V210, P135, DOI 10.1007/BF00337769; Hashidoko Y, 2005, BIOSCI BIOTECH BIOCH, V69, P1427, DOI 10.1271/bbb.69.1427; Hashimoto W, 2005, BIOCHEMISTRY-US, V44, P13783, DOI 10.1021/bi050873b; Hashimoto W, 2005, BIOSCI BIOTECH BIOCH, V69, P673, DOI 10.1271/bbb.69.673; Hottes AK, 2004, J BACTERIOL, V186, P1448, DOI 10.1128/JB.186.5.1448-1461.2004; Huang BX, 2004, J BACTERIOL, V186, P4387, DOI 10.1128/JB.186.13.4387-4389.2004; HUYNH TV, 1989, SCIENCE, V245, P1374, DOI 10.1126/science.2781284; Ireland MME, 2002, MOL MICROBIOL, V45, P1029, DOI 10.1046/j.1365-2958.2002.03071.x; JAHREIS K, 1993, MOL MICROBIOL, V9, P195, DOI 10.1111/j.1365-2958.1993.tb01681.x; JEFFERSON RA, 1987, EMBO J, V6, P3901; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; Kim HS, 2004, J BACTERIOL, V186, P411, DOI 10.1128/JB.186.2.411-418.2004; Koebnik R, 2005, TRENDS MICROBIOL, V13, P343, DOI 10.1016/j.tim.2005.06.005; Koebnik R, 1993, Trends Microbiol, V1, P201, DOI 10.1016/0966-842X(93)90092-6; Koebnik R, 2006, J BACTERIOL, V188, P7652, DOI 10.1128/JB.00795-06; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee BM, 2005, NUCLEIC ACIDS RES, V33, P577, DOI 10.1093/nar/gki206; Leveau JHJ, 2001, P NATL ACAD SCI USA, V98, P3446, DOI 10.1073/pnas.061629598; Lima WC, 2005, OMICS, V9, P160, DOI 10.1089/omi.2005.9.160; Llamas MA, 2006, J BACTERIOL, V188, P1882, DOI 10.1128/JB.188.5.1882-1891.2006; Loprasert S, 1999, GENE, V239, P251, DOI 10.1016/S0378-1119(99)00412-6; LUNDRIGAN MD, 1986, J BIOL CHEM, V261, P797; Marenda M, 1998, MOL MICROBIOL, V27, P437, DOI 10.1046/j.1365-2958.1998.00692.x; Marx CJ, 2002, BIOTECHNIQUES, V33, P1062, DOI 10.2144/02335rr01; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; Mercier J, 2000, APPL ENVIRON MICROB, V66, P369, DOI 10.1128/AEM.66.1.369-374.2000; Mey AR, 2005, INFECT IMMUN, V73, P8167, DOI 10.1128/IAI.73.12.8167-8178.2005; Meyer D, 2005, MOL PLANT PATHOL, V6, P327, DOI 10.1111/j.1364-3703.2005.00287.x; Meyer D, 2006, J BACTERIOL, V188, P4903, DOI 10.1128/JB.00180-06; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Molloy MP, 2002, PROTEOMICS, V2, P899, DOI 10.1002/1615-9861(200207)2:7<899::AID-PROT899>3.0.CO;2-Y; Morales CQ, 2005, MOL PLANT MICROBE IN, V18, P477, DOI 10.1094/MPMI-18-0477; Neugebauer H, 2005, J BACTERIOL, V187, P8300, DOI 10.1128/JB.187.24.8300-8311.2005; Nierman WC, 2001, P NATL ACAD SCI USA, V98, P4136, DOI 10.1073/pnas.061029298; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; Noel L, 2001, MOL MICROBIOL, V41, P1271, DOI 10.1046/j.1365-2958.2001.02567.x; Ochiai H, 2005, JARQ-JPN AGR RES Q, V39, P275, DOI 10.6090/jarq.39.275; Oke V, 1999, MOL MICROBIOL, V32, P837, DOI 10.1046/j.1365-2958.1999.01402.x; Papa R, 2006, EXTREMOPHILES, V10, P483, DOI 10.1007/s00792-006-0525-0; Paquelin A, 2001, MOL MICROBIOL, V42, P995, DOI 10.1046/j.1365-2958.2001.02628.x; Pawelek PD, 2006, SCIENCE, V312, P1399, DOI 10.1126/science.1128057; Phadke ND, 2001, PROTEOMICS, V1, P705, DOI 10.1002/1615-9861(200104)1:5<705::AID-PROT705>3.3.CO;2-E; Postle K, 2003, MOL MICROBIOL, V49, P869, DOI 10.1046/j.1365-2958.2003.03629.x; Puhler A, 2004, CURR OPIN PLANT BIOL, V7, P137, DOI 10.1016/j.pbi.2004.01.009; Qian W, 2005, GENOME RES, V15, P757, DOI 10.1101/gr.3378705; Reid SJ, 2005, APPL MICROBIOL BIOT, V67, P312, DOI 10.1007/s00253-004-1885-y; Ryan RP, 2006, P NATL ACAD SCI USA, V103, P6712, DOI 10.1073/pnas.0600345103; SCHMID K, 1982, J BACTERIOL, V151, P68, DOI 10.1128/JB.151.1.68-76.1982; SCHULEIN K, 1991, MOL MICROBIOL, V5, P2233, DOI 10.1111/j.1365-2958.1991.tb02153.x; SCHWYN B, 1987, ANAL BIOCHEM, V160, P47, DOI 10.1016/0003-2697(87)90612-9; Seliger SS, 2001, MOL MICROBIOL, V39, P801, DOI 10.1046/j.1365-2958.2001.02273.x; Shipman JA, 2000, J BACTERIOL, V182, P5365, DOI 10.1128/JB.182.19.5365-5372.2000; Shultis DD, 2006, SCIENCE, V312, P1396, DOI 10.1126/science.1127694; Slater H, 2000, MOL MICROBIOL, V38, P986, DOI 10.1046/j.1365-2958.2000.02196.x; Somers E, 2000, MOL GEN GENET, V263, P1038, DOI 10.1007/PL00008692; Sonnenburg JL, 2005, SCIENCE, V307, P1955, DOI 10.1126/science.1109051; SPRENGER GA, 1988, J GEN MICROBIOL, V134, P1635; STRUYVE M, 1991, J MOL BIOL, V218, P141, DOI 10.1016/0022-2836(91)90880-F; Subramoni S, 2005, MOL PLANT MICROBE IN, V18, P644, DOI 10.1094/MPMI-18-0644; Tanabe T, 2003, J BACTERIOL, V185, P6938, DOI 10.1128/JB.185.23.6938-6949.2003; TANG JL, 1990, MOL GEN GENET, V222, P157, DOI 10.1007/BF00283038; Thieme F, 2005, J BACTERIOL, V187, P7254, DOI 10.1128/JB.187.21.7254-7266.2005; Thijs G, 2002, J COMPUT BIOL, V9, P447, DOI 10.1089/10665270252935566; Thijs G, 2001, BIOINFORMATICS, V17, P1113, DOI 10.1093/bioinformatics/17.12.1113; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsuge S, 2006, J BACTERIOL, V188, P4158, DOI 10.1128/JB.00006-06; Van Gelder P, 2001, PROTEIN ENG, V14, P943, DOI 10.1093/protein/14.11.943; VAUTERIN L, 1995, INT J SYST BACTERIOL, V45, P472, DOI 10.1099/00207713-45-3-472; Wan XF, 2004, J BACTERIOL, V186, P8385, DOI 10.1128/JB.186.24.8385-8400.2004; WEICKERT MJ, 1992, J BIOL CHEM, V267, P15869; Wiggerich HG, 2000, MICROBIOL-UK, V146, P1053, DOI 10.1099/00221287-146-5-1053; Wiggerich HG, 1997, J BACTERIOL, V179, P7103, DOI 10.1128/jb.179.22.7103-7110.1997; Williams P. H., 1980, Plant Disease, V64, P736, DOI 10.1094/PD-64-736; WILSON M, 1994, APPL ENVIRON MICROB, V60, P4468, DOI 10.1128/AEM.60.12.4468-4477.1994; Xu J, 2003, P NATL ACAD SCI USA, V100, P10452, DOI 10.1073/pnas.1734063100; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029; Yue WW, 2003, J MOL BIOL, V332, P353, DOI 10.1016/S0022-2836(03)00855-6; Zhao QX, 2002, J BACTERIOL, V184, P1503, DOI 10.1128/JB.184.6.1503-1513.2002; Zou LF, 2006, APPL ENVIRON MICROB, V72, P6212, DOI 10.1128/AEM.00511-06	123	237	246	2	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e224	10.1371/journal.pone.0000224	http://dx.doi.org/10.1371/journal.pone.0000224			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311090	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444500005
J	Chang, DLF; Qiu, W; Ying, H; Zhang, Y; Chen, CY; Xiao, ZXJ				Chang, D. L. F.; Qiu, W.; Ying, H.; Zhang, Y.; Chen, C-Y; Xiao, Z-X J.			ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2	ONCOGENE			English	Article						ARF; retinoblastoma protein; MDM2; cell; cycle; cancer	TUMOR-SUPPRESSOR; INK4A LOCUS; C-ABL; EXON 1-BETA; NUCLEOLAR LOCALIZATION; SELECTIVE DELETION; DEPENDENT KINASES; NUCLEAR EXPORT; STABILIZES P53; G(1) CONTROL	The INK4a/ARF locus, encoding two tumor suppressor proteins, p16(INK4a) and p14(ARF) (ARF), plays key roles in many cellular processes including cell proliferation, apoptosis, cellular senescence and differentiation. Inactivation of INK4a/ARF is one of the most frequent events during human cancer development. Although p16(INK4a) is a critical component in retinoblastoma protein (Rb)-mediated growth regulatory pathway, p14ARF plays a pivotal role in the activation of p53 upon oncogenic stress signals. A body of evidence indicates that ARF also possesses growth suppression functions independent of p53, the mechanism of which is not well understood. We have recently shown that MDM2 interacts with Rb and promotes proteasome-dependent Rb degradation. In this study, we show that ARF disrupts MDM2 -Rb interaction resulting in Rb accumulation. Wild-type ARF, but not ARF mutant defective in MDM2 interaction, stabilizes Rb and inhibits colony foci formation independent of p53. In addition, ablation of Rb impairs ARF function in growth suppression. Thus, this study demonstrates that ARF plays a direct role in regulation of Rb and suggests that inactivation of ARF may lead to defects in both p53 and Rb pathways in human cancer development.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Grad Program Mol Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University	Xiao, ZXJ (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St,K-423, Boston, MA 02118 USA.	jxiao@bu.edu	Ying, Haoqiang/AAK-4325-2020					Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Boyer SN, 1996, CANCER RES, V56, P4620; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Carness KH, 2000, ISSUES SCI TECHNOL, V16, P19; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dias SS, 2006, ONCOGENE, V25, P6666, DOI 10.1038/sj.onc.1209671; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Groth A, 2000, J BIOL CHEM, V275, P27473; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Modestou M, 2001, CANCER RES, V61, P3145; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Pan W, 2003, ONCOGENE, V22, P5496, DOI 10.1038/sj.onc.1206857; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Viswanathan M, 2001, ORAL ONCOL, V37, P341, DOI 10.1016/S1368-8375(00)00112-3; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Wang IJ, 2001, MOL VIS, V7, P20; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Ying HQ, 2006, CELL CYCLE, V5, P506, DOI 10.4161/cc.5.5.2515; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	56	12	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4627	4634		10.1038/sj.onc.1210254	http://dx.doi.org/10.1038/sj.onc.1210254			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297463				2022-12-25	WOS:000248037900003
J	Huang, P; Senga, T; Hamaguchi, M				Huang, P.; Senga, T.; Hamaguchi, M.			A novel role of phospho-beta-catenin in microtubule regrowth at centrosome	ONCOGENE			English	Article						phospho-beta-catenin; microtubule regrowth; centrosome	WNT-SIGNALING PATHWAY; TUMOR-SUPPRESSOR; MITOTIC SPINDLE; CELL-CYCLE; PROTEIN; KINASE; CANCER; IDENTIFICATION; LOCALIZATION; PROGRESSION	beta-Catenin is a biologically important molecule playing critical roles in both cell adhesion and transcriptional regulation in the Wnt pathway. Here, we show that phospho-beta-atenin (phosphorylated at Ser33/37/Thr41), which is reported to be degraded immediately after its phosphorylation, accumulated in the centrosome. Whereas phospho- mimicking mutant, S33/37/T41E-beta-catenin, could local ize to the centrosome, S33A-beta-catenin that lacks the phosphorylation site lost its localization to the centrosome. Phospho-beta-catenin localized mai nly to mother centrosome during the interphase and was recruited to daughter centrosome in M-phase. Depletion of beta-catenin with small interfering RNA or inhibition of its phosphorylation by LiCl treatment caused disruption of radial microtubule (MT) array and retardation of the MT regrowth during the recovery from nocodazole treatment. In addition, these treatments increased the frequency of mono-astral MT reorganization. Furthermore, overexpression of the nonphosphorylatable beta-catenin, but not the phospho-mimicking beta-catenin, markedly disrupted radial MT array and repressed the MT regrowth. In contrast, phospho-mimicking beta-atenin localized to both of the duplicated centrosomes with aberrant larger and denser radial MTs array formation. In addition, some of the cells overexpressing phospho-mimicking beta-catenin had mul tiple centrosomes. Taken together, this study demonstrates a novel role of phospho-beta-catenin in MT organization at the centrosomes.	Nagoya Univ, Grad Sch Med, Dept Oncol, Div Canc Biol,Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University	Hamaguchi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Oncol, Div Canc Biol,Showa Ku, 65 Tsurumaicho, Nagoya, Aichi 4668550, Japan.	mhamagu@med.nagoya-u.ac.jp						Amin ARMR, 2003, CANCER RES, V63, P6334; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; Ciani L, 2004, J CELL BIOL, V164, P243, DOI 10.1083/jcb.200309096; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Harwood A, 2003, NAT CELL BIOL, V5, P275, DOI 10.1038/ncb0403-275; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kaplan DD, 2004, J BIOL CHEM, V279, P10829, DOI 10.1074/jbc.C400035200; Kielhorn E, 2003, INT J CANCER, V103, P652, DOI 10.1002/ijc.10893; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; Ligon LA, 2001, NAT CELL BIOL, V3, P913, DOI 10.1038/ncb1001-913; Liu YZ, 2001, ONCOGENE, V20, P5908, DOI 10.1038/sj.onc.1204738; Lucas FR, 1998, J CELL SCI, V111, P1351; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Olmeda D, 2003, MOL BIOL CELL, V14, P2844, DOI 10.1091/mbc.E03-01-0865; Ou YY, 2002, J CELL SCI, V115, P1825; Pellman D, 2001, SCIENCE, V291, P2555, DOI 10.1126/science.1057337; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; Reinacher-Schick A, 2001, J CELL BIOL, V152, P491, DOI 10.1083/jcb.152.3.491; Sadot E, 2002, J CELL SCI, V115, P2771; Sluder G, 2004, CURR OPIN CELL BIOL, V16, P49, DOI 10.1016/j.ceb.2003.11.006; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P44, DOI 10.1073/pnas.0137044100; Wakefield JG, 2003, J CELL SCI, V116, P637, DOI 10.1242/jcs.00273; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	28	87	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4357	4371		10.1038/sj.onc.1210217	http://dx.doi.org/10.1038/sj.onc.1210217			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17260019				2022-12-25	WOS:000247620000004
J	Sun, S; Liu, YM; Lipsky, S; Cho, M				Sun, Shan; Liu, Yaoming; Lipsky, Samantha; Cho, Michael			Physical manipulation of calcium oscillations facilitates osteodifferentiation of human mesenchymal stem cells	FASEB JOURNAL			English	Article						Ca2+; oscillation; hMSCs; electrical stimulation	NONINVASIVE ELECTRICAL STIMULUS; 3-DIMENSIONAL COLLAGEN GEL; HUMAN FIBROBLAST MIGRATION; CA2+ SIGNALING PATHWAYS; GENE-EXPRESSION; STIMULATION; RESPONSES; DIFFERENTIATION; ORGANIZATION; ACTIVATION	The role of cytosolic calcium oscillation has long been recognized in the regulation of cellular and molecular interactions. Information embedded in calcium oscillation can provide molecular cues for cell behavior such as cell differentiation. Although calcium dynamics are versatile and likely to depend on the cell type, the calcium dynamics in human mesenchymal stem cells ( hMSCs) and its role in differentiation are yet to be fully elucidated. In the present study we characterized the calcium oscillation profiles in hMSCs before and after subjecting the cells to the osteoinductive factors. Our findings indicate that the calcium spikes decreased rapidly with osteodifferentiation to a level observed in terminally differentiated human osteoblasts. In addition, the calcium oscillations appear to serve as a bidirectional signal during hMSC differentiation. While an altered calcium oscillation pattern may be an indicator for hMSC differentiation, it is also likely to be involved in directing hMSC differentiation. Treatment of hMSCs with a noninvasive electrical stimulation, for example, not only altered the calcium oscillations but also facilitated osteodifferentiation. Regulation of calcium oscillation by external physical stimulation could amplify hMSC differentiation into a tissue- specific lineage and may offer an alternate biotechnology to harness the unique properties of stem cells.	Univ Illinois, Dept Bioengn, Chicago, IL 60607 USA; Univ Illinois, Dept Chem, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Cho, M (corresponding author), Univ Illinois, Dept Bioengn, 851 S Morgan St,M-C 063, Chicago, IL 60607 USA.	mcho@uic.edu		Cho, Myoung Rae/0000-0002-8191-8045	NIBIB NIH HHS [EB006067] Funding Source: Medline; NIGMS NIH HHS [GM060741] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB006067] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060741] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aaron RK, 1996, J ORTHOP RES, V14, P582, DOI 10.1002/jor.1100140412; Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001; Blum JS, 2001, J CELL BIOCHEM, V80, P532, DOI 10.1002/1097-4644(20010315)80:4<532::AID-JCB1007>3.0.CO;2-B; Chawla S, 2002, EUR J PHARMACOL, V447, P131, DOI 10.1016/S0014-2999(02)01837-X; Cho MR, 2002, IEEE T PLASMA SCI, V30, P1504, DOI 10.1109/TPS.2002.804200; Cho MR, 1999, FASEB J, V13, P677, DOI 10.1096/fasebj.13.6.677; CHO MR, 2002, FRONTIERS BIOSCI, V7, P1; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; den Dekker E, 2001, THROMB HAEMOSTASIS, V86, P1106; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Ducibella T, 2002, DEV BIOL, V250, P280, DOI 10.1006/dbio.2002.0788; Dupont G, 2000, BBA-MOL CELL RES, V1498, P134, DOI 10.1016/S0167-4889(00)00090-2; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; HARBERD N, 2002, MOL BIOL CELL, P862; Jones J E, 1998, Eur J Dent Educ, V2, P42, DOI 10.1111/j.1600-0579.1998.tb00035.x; Kawano S, 2003, CELL CALCIUM, V34, P145, DOI 10.1016/S0143-4160(03)00069-1; Kawano S, 2002, CELL CALCIUM, V32, P165, DOI 10.1016/S0143416002001240; Khatib L, 2004, FASEB J, V18, P1903, DOI 10.1096/fj.04-1814fje; Kimura K, 1998, J BIOTECHNOL, V63, P55, DOI 10.1016/S0168-1656(98)00075-3; Lehmann U, 2001, METHODS, V25, P409, DOI 10.1006/meth.2001.1263; Li YJ, 2004, J ORTHOP RES, V22, P1283, DOI 10.1016/j.orthres.2004.04.002; LIU Y, 2005, ANN M BIOM ENG SOC B; Luttrell LM, 2002, CAN J PHYSIOL PHARM, V80, P375, DOI 10.1139/Y02-045; Marhl M, 2000, BIOSYSTEMS, V57, P75, DOI 10.1016/S0303-2647(00)00090-3; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; ROBINSON KR, 1985, J CELL BIOL, V101, P2023, DOI 10.1083/jcb.101.6.2023; Rodriguez JP, 2004, J CELL BIOCHEM, V93, P721, DOI 10.1002/jcb.20234; RONDE P, 2000, BIOCHIM BIOPHYS ACTA, V1498, P272; Salasznyk RM, 2004, J BIOMED BIOTECHNOL, P24, DOI 10.1155/S1110724304306017; Sauer H, 1999, J CELL BIOCHEM, V75, P710, DOI 10.1002/(SICI)1097-4644(19991215)75:4<710::AID-JCB16>3.0.CO;2-Z; SAVIOGALIMBERTI E, 2005, AM J PHYSIOL, V290, pH613; Short B, 2003, ARCH MED RES, V34, P565, DOI 10.1016/j.arcmed.2003.09.007; Sun S, 2004, TISSUE ENG, V10, P1558, DOI 10.1089/ten.2004.10.1558; Sun S, 2004, TISSUE ENG, V10, P1548, DOI 10.1089/1076327042500193; Sun S, 2006, BIOELECTROCHEMISTRY, V69, P133, DOI 10.1016/j.bioelechem.2005.11.007; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; TAYLOR DL, 1975, BIOL BULL, V149, P448; Torihashi S, 2002, J BIOL CHEM, V277, P19191, DOI 10.1074/jbc.M201728200; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Yanagida E, 2004, CELL CALCIUM, V36, P135, DOI 10.1016/j.ceca.2004.01.022; Zhao M, 2004, J CELL SCI, V117, P397, DOI 10.1242/jcs.00868; Zhuang HM, 1997, BIOCHEM BIOPH RES CO, V237, P225, DOI 10.1006/bbrc.1997.7118	44	147	156	0	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1472	1480		10.1096/fj.06-7153com	http://dx.doi.org/10.1096/fj.06-7153com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264165				2022-12-25	WOS:000246117000022
J	Sjostrand, D; Carlsson, J; Paratcha, G; Persson, B; Ibanez, CF				Sjostrand, Dan; Carlsson, Jonas; Paratcha, Gustavo; Persson, Bengt; Ibanez, Carlos F.			Disruption of the GDNF binding site in NCAM dissociates ligand binding and homophilic cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; NEUROTROPHIC FACTOR; MOLECULE NCAM; RET; DOMAINS; FAMILY; GFR-ALPHA-1; ACTIVATION; IDENTIFICATION; SPECIFICITY	Most plasma membrane proteins are capable of sensing multiple cell-cell and cell-ligand interactions, but the extent to which this functional versatility is founded on their modular design is less clear. We have identified the third immunoglobulin domain of the Neural Cell Adhesion Molecule ( NCAM) as the necessary and sufficient determinant for its interaction with Glial Cell Line-derived Neurotrophic Factor ( GDNF). Four charged contacts were identified by molecular modeling as the main contributors to binding energy. Their mutation abolished GDNF binding to NCAM but left intact the ability of NCAM to mediate cell adhesion, indicating that the two functions are genetically separable. The GDNF-NCAM interface allows complex formation with the GDNF family receptor alpha 1, shedding light on the molecular architecture of a multicomponent GDNF receptor.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Linkoping Univ, IFM Bioinformat, S-58183 Linkoping, Sweden	Karolinska Institutet; Karolinska Institutet; Linkoping University	Ibanez, CF (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden.	carlos.ibanez@ki.se	Almlöf, Jonas/E-1608-2017	Almlöf, Jonas/0000-0002-1211-9821; Persson, Bengt/0000-0003-3165-5344; Paratcha, Gustavo/0000-0002-0804-4433				Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Albach C, 2004, ANAL BIOANAL CHEM, V378, P1129, DOI 10.1007/s00216-003-2383-2; Anders J, 2001, J BIOL CHEM, V276, P35808, DOI 10.1074/jbc.M104968200; Atkins AR, 2004, J BIOL CHEM, V279, P49633, DOI 10.1074/jbc.M409159200; Baloh RH, 2000, J BIOL CHEM, V275, P3412, DOI 10.1074/jbc.275.5.3412; Baloh RH, 1998, P NATL ACAD SCI USA, V95, P5801, DOI 10.1073/pnas.95.10.5801; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; Barker RA, 2006, LANCET NEUROL, V5, P285, DOI 10.1016/S1474-4422(06)70386-6; BECKER JW, 1989, P NATL ACAD SCI USA, V86, P1088, DOI 10.1073/pnas.86.3.1088; Davies AM, 1997, NEURON, V19, P485; de Graaff E, 2001, GENE DEV, V15, P2433, DOI 10.1101/gad.205001; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Eigenbrot C, 1997, NAT STRUCT BIOL, V4, P435, DOI 10.1038/nsb0697-435; Eketjall S, 1999, EMBO J, V18, P5901, DOI 10.1093/emboj/18.21.5901; Gardell LR, 2003, NAT MED, V9, P1383, DOI 10.1038/nm944; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; HALL AK, 1987, J CELL BIOL, V104, P1579, DOI 10.1083/jcb.104.6.1579; Iwase T, 2005, J NEUROCHEM, V94, P1488, DOI 10.1111/j.1471-4159.2005.03290.x; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Johnson CP, 2004, P NATL ACAD SCI USA, V101, P6963, DOI 10.1073/pnas.0307567100; Ledda F, 2007, NAT NEUROSCI, V10, P293, DOI 10.1038/nn1855; Leppanen VM, 2004, EMBO J, V23, P1452, DOI 10.1038/sj.emboj.7600174; Liedtke S, 2001, GLYCOBIOLOGY, V11, P373, DOI 10.1093/glycob/11.5.373; Natarajan D, 2002, DEVELOPMENT, V129, P5151; OWENS GC, 1987, P NATL ACAD SCI USA, V84, P294, DOI 10.1073/pnas.84.1.294; Paratcha G, 2006, MOL CELL NEUROSCI, V31, P505, DOI 10.1016/j.mcn.2005.11.007; Paratcha G, 2003, CELL, V113, P867, DOI 10.1016/S0092-8674(03)00435-5; Sainio K, 1997, DEVELOPMENT, V124, P4077; Scott RP, 2001, J BIOL CHEM, V276, P1450, DOI 10.1074/jbc.M006157200; SMALL SJ, 1987, J CELL BIOL, V105, P2335, DOI 10.1083/jcb.105.5.2335; Soroka V, 2003, STRUCTURE, V11, P1291, DOI 10.1016/j.str.2003.09.006; Taraviras S, 1999, DEVELOPMENT, V126, P2785; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Trupp M, 1998, MOL CELL NEUROSCI, V11, P47, DOI 10.1006/mcne.1998.0667; Wang XQ, 2006, STRUCTURE, V14, P1083, DOI 10.1016/j.str.2006.05.010; Wieland JA, 2005, J BIOL CHEM, V280, P41037, DOI 10.1074/jbc.M503975200	37	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12734	12740		10.1074/jbc.M701588200	http://dx.doi.org/10.1074/jbc.M701588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17322291	hybrid			2022-12-25	WOS:000245942800043
J	Ivanovic, T; Agosto, MA; Chandran, K; Nibert, ML				Ivanovic, Tijana; Agosto, Melina A.; Chandran, Kartik; Nibert, Max L.			A role for molecular chaperone Hsc70 in reovirus outer capsid disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ENTRY; MAMMALIAN REOVIRUSES; NONENVELOPED VIRUS; PROTEIN MU-1; PUTATIVE AUTOCLEAVAGE; PEPTIDE-BINDING; PARTICLES; ATPASE; POLYOMAVIRUS; ACTIVATION	After crossing the cellular membrane barrier during cell entry, most animal viruses must undergo further disassembly before initiating viral gene expression. In many cases, these disassembly mechanisms remain poorly defined. For this report, we examined a final step in disassembly of the mammalian reovirus outer capsid: cytoplasmic release of the central, delta fragment of membrane penetration protein mu 1 to yield the transcriptionally active viral core particle. An in vitro assay with reticulocyte lysate recapitulated the release of intact delta molecules. Requirements for activity in this system were shown to include a protein factor, ATP, and Mg2+ and K+ ions, consistent with involvement of a molecular chaperone such as Hsc70. Immunodepletion of Hsc70 and Hsp70 impaired delta release, which was then rescued by addition of purified Hsc70. Hsc70 was associated with released delta molecules not only in the lysate but also during cell entry. We conclude that Hsc70 plays a defined role in reovirus outer capsid disassembly, during or soon after membrane penetration, to prepare the entering particle for gene expression and replication.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Harvard Univ, Training Program Virol, Boston, MA 02115 USA; Harvard Univ, Training Programs Biol & Biomed Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard University	Nibert, ML (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	mnibert@hms.harvard.edu	Chandran, Kartik/I-2232-2012	Agosto, Melina/0000-0002-3647-1926	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046440, T32AI007245, F31AI064142] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007226] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI046440, R01 AI46440, T32 AI07245, F31 AI064142, F31 AI064142-01] Funding Source: Medline; NIGMS NIH HHS [T32 GM07226] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agosto MA, 2006, P NATL ACAD SCI USA, V103, P16496, DOI 10.1073/pnas.0605835103; BODKIN DK, 1989, J VIROL, V63, P4676, DOI 10.1128/JVI.63.11.4676-4681.1989; BORSA J, 1973, J VIROL, V11, P552, DOI 10.1128/JVI.11.4.552-564.1973; BORSA J, 1981, VIROLOGY, V111, P191, DOI 10.1016/0042-6822(81)90664-4; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Broering TJ, 2005, J VIROL, V79, P6194, DOI 10.1128/JVI.79.10.6194-6206.2005; Chandran K, 2003, J VIROL, V77, P13361, DOI 10.1128/JVI.77.24.13361-13375.2003; Chandran K, 2003, TRENDS MICROBIOL, V11, P374, DOI 10.1016/S0966-842X(03)00178-1; Chandran K, 2002, J VIROL, V76, P9920, DOI 10.1128/JVI.76.19.9920-9933.2002; Chromy LR, 2006, J VIROL, V80, P5086, DOI 10.1128/JVI.80.10.5086-5091.2006; CRIPE TP, 1995, J VIROL, V69, P7807, DOI 10.1128/JVI.69.12.7807-7813.1995; FLAHERTY KM, 1994, J BIOL CHEM, V269, P12899; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; FURLONG DB, 1988, J VIROL, V62, P246, DOI 10.1128/JVI.62.1.246-256.1988; Glotzer JB, 2000, NATURE, V407, P207, DOI 10.1038/35025102; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; Guerrero CA, 2002, J VIROL, V76, P4096, DOI 10.1128/JVI.76.8.4096-4102.2002; Gurer C, 2002, J VIROL, V76, P4666, DOI 10.1128/JVI.76.9.4666-4670.2002; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; JOKLIK WK, 1972, VIROLOGY, V49, P700, DOI 10.1016/0042-6822(72)90527-2; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Morimoto RI, 2002, CELL, V110, P281, DOI 10.1016/S0092-8674(02)00860-7; Nibert ML, 2005, J MOL BIOL, V345, P461, DOI 10.1016/j.jmb.2004.10.026; NIBERT ML, 1991, J VIROL, V65, P1960, DOI 10.1128/JVI.65.4.1960-1967.1991; NIBERT ML, 1992, J VIROL, V66, P6408, DOI 10.1128/JVI.66.11.6408-6418.1992; OBRIEN MC, 1995, J BIOL CHEM, V270, P2247, DOI 10.1074/jbc.270.5.2247; Odegard AL, 2004, J VIROL, V78, P8732, DOI 10.1128/JVI.78.16.8732-8745.2004; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Perez-Vargas J, 2006, J VIROL, V80, P3322, DOI 10.1128/JVI.80.7.3322-3331.2006; PRASAD K, 1994, J BIOL CHEM, V269, P6931; SAGARA J, 1992, VIROLOGY, V190, P845, DOI 10.1016/0042-6822(92)90923-D; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; STURZENBECKER LJ, 1987, J VIROL, V61, P2351, DOI 10.1128/JVI.61.8.2351-2361.1987; Sullivan CS, 2001, VIROLOGY, V287, P1, DOI 10.1006/viro.2001.1038; Young JC, 2003, TRENDS BIOCHEM SCI, V28, P541, DOI 10.1016/j.tibs.2003.08.009; Zarate S, 2003, J VIROL, V77, P7254, DOI 10.1128/JVI.77.13.7254-7260.2003	36	51	60	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12210	12219		10.1074/jbc.M610258200	http://dx.doi.org/10.1074/jbc.M610258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17284448	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000245941900064
J	Partridge, JD; Sanguinetti, G; Dibden, DP; Roberts, RE; Poole, RK; Green, J				Partridge, Jonathan D.; Sanguinetti, Guido; Dibden, David P.; Roberts, Ruth E.; Poole, Robert K.; Green, Jeffrey			Transition of Escherichia coli from aerobic to micro-aerobic conditions involves fast and slow reacting regulatory components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDASE CYDAB OPERON; OUTER-MEMBRANE; SACCHAROMYCES-CEREVISIAE; ANAEROBIC GROWTH; GENE-EXPRESSION; FNR PROTEIN; TRANSCRIPTION; ACTIVATION; ARCA; ROLES	Understanding life at a systems level is a major aim of biology. The bacterium Escherichia coli offers one of the best opportunities to achieve this goal. It is a metabolically versatile bacterium able to respond to changes in oxygen availability. This ability is a crucial component of its lifestyle, allowing it to thrive in aerobic external environments and under the oxygen-starved conditions of a host gut. The controlled growth conditions of chemostat culture were combined with transcript profiling to investigate transcriptome dynamics during the transition from aerobic to micro-aerobic conditions. In addition to predictable changes in transcripts encoding proteins of central metabolism, the abundances of transcripts involved in homeostasis of redox-reactive metals ( Cu and Fe), and cell envelope stress were significantly altered. To gain further insight into the responses of the regulatory networks, the activities of key transcription factors during the transition to micro-aerobic conditions were inferred using a probabilistic modeling approach, which revealed that the response of the direct oxygen sensor FNR was rapid and overshot, whereas the indirect oxygen sensor ArcA reacted more slowly. Similarly, the cell envelope stress sensors RpoE and CpxR reacted rapidly and more slowly, respectively. Thus, it is suggested that combining rapid and slow reacting components in regulatory networks might be a feature of systems in which a signal is perceived by two or more functionally related transcription factors controlling overlapping regulons.	Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Dept Comp Sci, Sheffield S1 4DP, S Yorkshire, England	University of Sheffield; University of Sheffield	Green, J (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	jeff.green@sheffield.ac.uk	Partridge, Jonathan/GSD-6795-2022	Partridge, Jonathan/0000-0003-2536-5404	BBSRC [BB/F003463/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/F003463/1, P19192] Funding Source: Medline	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Anderson LA, 2000, J BACTERIOL, V182, P7035, DOI 10.1128/JB.182.24.7035-7043.2000; COMPAN I, 1994, MOL MICROBIOL, V11, P955, DOI 10.1111/j.1365-2958.1994.tb00374.x; Constantinidou C, 2006, J BIOL CHEM, V281, P4802, DOI 10.1074/jbc.M512312200; Cotter PA, 1997, MOL MICROBIOL, V25, P605, DOI 10.1046/j.1365-2958.1997.5031860.x; Covert MW, 2004, NATURE, V429, P92, DOI 10.1038/nature02456; Danese PN, 1997, GENE DEV, V11, P1183, DOI 10.1101/gad.11.9.1183; Dartigalongue C, 2001, J BIOL CHEM, V276, P20866, DOI 10.1074/jbc.M100464200; De Wulf P, 2002, J BIOL CHEM, V277, P26652, DOI 10.1074/jbc.M203487200; Dmello R, 1996, MICROBIOL-UK, V142, P755, DOI 10.1099/00221287-142-4-755; Evans C. G. T., 1970, METHODS MICROBIOLOGY, V2, DOI [10.1016/S0580-9517(08)70227-7, DOI 10.1016/S0580-9517(08)70227-7]; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Georgellis D, 2001, SCIENCE, V292, P2314, DOI 10.1126/science.1059361; Govantes F, 2000, MOL MICROBIOL, V38, P1061, DOI 10.1046/j.1365-2958.2000.02215.x; GREEN J, 1998, MOL MICROBIOL, P17; Guest John R., 1996, P317; Hayes A, 2002, METHODS, V26, P281, DOI 10.1016/S1046-2023(02)00032-4; Hondorp ER, 2004, PLOS BIOL, V2, P1738, DOI 10.1371/journal.pbio.0020336; Hong HD, 2006, J BIOL CHEM, V281, P7568, DOI 10.1074/jbc.M512365200; Hoskisson PA, 2005, MICROBIOL-SGM, V151, P3153, DOI 10.1099/mic.0.27924-0; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; Kang YS, 2005, J BACTERIOL, V187, P1135, DOI 10.1128/JB.187.3.1135-1160.2005; Khoroshilova N, 1997, P NATL ACAD SCI USA, V94, P6087, DOI 10.1073/pnas.94.12.6087; King T, 2005, FEMS MICROBIOL LETT, V244, P323, DOI 10.1016/j.femsle.2005.02.002; King T, 2004, J BACTERIOL, V186, P5614, DOI 10.1128/JB.186.17.5614-5620.2004; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; Marshall FA, 2001, MOL MICROBIOL, V39, P747, DOI 10.1046/j.1365-2958.2001.02262.x; Miller JH., 1972, EXPT MOL GENETICS; Nandi B, 2005, MICROBIOL-SGM, V151, P2975, DOI 10.1099/mic.0.27995-0; Outten FW, 2001, J BIOL CHEM, V276, P30670, DOI 10.1074/jbc.M104122200; Partridge JD, 2006, J BIOL CHEM, V281, P27806, DOI 10.1074/jbc.M603450200; Pilsl H, 1999, J BACTERIOL, V181, P3578, DOI 10.1128/JB.181.11.3578-3581.1999; Piper MDW, 2002, J BIOL CHEM, V277, P37001, DOI 10.1074/jbc.M204490200; Rhodius VA, 2006, PLOS BIOL, V4, P43, DOI 10.1371/journal.pbio.0040002; Salmon KA, 2005, J BIOL CHEM, V280, P15084, DOI 10.1074/jbc.M414030200; Sambrook J, 2001, MOL CLONING LAB MANU; SAWERS G, 1993, MOL MICROBIOL, V10, P737, DOI 10.1111/j.1365-2958.1993.tb00944.x; Wagner AFV, 2001, BIOCHEM BIOPH RES CO, V285, P456, DOI 10.1006/bbrc.2001.5186; Wainwright LM, 2005, MICROBIOL-SGM, V151, P4079, DOI 10.1099/mic.0.28266-0; WING HJ, 1995, J BACTERIOL, V177, P6704, DOI 10.1128/jb.177.23.6704-6710.1995; Wyborn NR, 2002, MICROBIOL-SGM, V148, P1015, DOI 10.1099/00221287-148-4-1015; Yamamoto K, 2005, MOL MICROBIOL, V56, P215, DOI 10.1111/j.1365-2958.2005.04532.x	42	101	102	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11230	11237		10.1074/jbc.M700728200	http://dx.doi.org/10.1074/jbc.M700728200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307737	hybrid			2022-12-25	WOS:000245941500045
J	Vecchiarelli, AG; Schumacher, MA; Funnell, BE				Vecchiarelli, Anthony G.; Schumacher, Maria A.; Funnell, Barbara E.			P1 partition complex assembly involves several modes of protein-DNA recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; P7 PLASMID PARTITION; PARB PROTEIN; DAUGHTER CELLS; BINDING; SITE; RECOMBINATION; SEGREGATION; SPECIFICITY; CENTROMERE	Assembly of P1 plasmid partition complexes at the partition site, parS, is nucleated by a dimer of P1 ParB and Escherichia coli integration host factor (IHF), which promotes loading of more ParB dimers and the pairing of plasmids during the cell cycle. ParB binds several copies of two distinct recognition motifs, known as A- and B-boxes, which flank a bend in parS created by IHF binding. The recent crystal structure of ParB bound to a partial parS site revealed two relatively independent DNA-binding domains and raised the question of how a dimer of ParB recognizes its complicated arrangement of recognition motifs when it loads onto the full parS site in the presence of IHF. In this study, we addressed this question by examining ParB binding activities to parS mutants containing different combinations of the A- and B- box motifs in parS. Binding was measured to linear and supercoiled DNA in electrophoretic and filter binding assays, respectively. ParB showed preferences for certain motifs that are dependent on position and on plasmid topology. In the simplest arrangement, one motif on either side of the bend was sufficient to form a complex, although affinity differed depending on the motifs. Therefore, a ParB dimer can load onto parS in different ways, so that the initial ParB-IHF-parS complex consists of a mixture of different orientations of ParB. This arrangement supports a model in which parS motifs are available for inter-as well as intramolecular parS recognition.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Toronto; University of Texas System; UTMD Anderson Cancer Center	Funnell, BE (corresponding author), Univ Toronto, Dept Mol & Med Genet, Rm 4182,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	b.funnell@utoronto.ca	Vecchiarelli, Anthony/H-5978-2019	Vecchiarelli, Anthony/0000-0002-6198-3245; Funnell, Barbara/0000-0002-1828-6567	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074815] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM074815] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIEK DP, 1994, P NATL ACAD SCI USA, V91, P8027, DOI 10.1073/pnas.91.17.8027; Biswas T, 2005, NATURE, V435, P1059, DOI 10.1038/nature03657; Bouet JY, 2000, J BIOL CHEM, V275, P8213, DOI 10.1074/jbc.275.11.8213; Bouet JY, 1999, EMBO J, V18, P1415, DOI 10.1093/emboj/18.5.1415; Davis MA, 1996, MOL MICROBIOL, V21, P1029, DOI 10.1046/j.1365-2958.1996.721423.x; DAVIS MA, 1988, EMBO J, V7, P1881, DOI 10.1002/j.1460-2075.1988.tb03021.x; DAVIS MA, 1990, EMBO J, V9; Edgar R, 2001, MOL MICROBIOL, V42, P1363, DOI 10.1046/j.1365-2958.2001.02717.x; Erdmann N, 1999, P NATL ACAD SCI USA, V96, P14905, DOI 10.1073/pnas.96.26.14905; Funnell BE, 2004, PLASMID BIOLOGY, P81; FUNNELL BE, 1993, J BIOL CHEM, V268, P3616; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; FUNNELL BE, 1994, BIOCHIMIE, V76, P924, DOI 10.1016/0300-9084(94)90017-5; Hayes F, 2006, NAT REV MICROBIOL, V4, P133, DOI 10.1038/nrmicro1342; HAYES F, 1994, J MOL BIOL, V243, P190, DOI 10.1006/jmbi.1994.1646; HAYES F, 1994, MOL MICROBIOL, V11, P249, DOI 10.1111/j.1365-2958.1994.tb00305.x; Higgins NP, 2004, PLASMID BIOLOGY, P181; KANAAR R, 1992, CURR OPIN STRUC BIOL, V2, P369, DOI DOI 10.1016/0959-440X(92)90227-X; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; LARSSON A, 1991, J IMMUNOL METHODS, V137, P253, DOI 10.1016/0022-1759(91)90031-A; Li YF, 2002, MOL MICROBIOL, V46, P63, DOI 10.1046/j.1365-2958.2002.03156.x; Ma YM, 2001, BIOCHEMISTRY-US, V40, P9638, DOI 10.1021/bi010932v; MARTIN KA, 1991, J BACTERIOL, V173, P3630, DOI 10.1128/JB.173.12.3630-3634.1991; NASH HA, 1987, J BACTERIOL, V169, P4124, DOI 10.1128/jb.169.9.4124-4127.1987; Radman-Livaja M, 2006, CURR OPIN STRUC BIOL, V16, P42, DOI 10.1016/j.sbi.2005.12.003; Radnedge L, 1996, EMBO J, V15, P1155, DOI 10.1002/j.1460-2075.1996.tb00454.x; Reichheld SE, 2006, J MOL BIOL, V361, P382, DOI 10.1016/j.jmb.2006.06.035; Rodionov O, 2004, MOL MICROBIOL, V52, P1215, DOI 10.1111/j.1365-2958.2004.04055.x; Rodionov O, 1999, SCIENCE, V283, P546, DOI 10.1126/science.283.5401.546; Schumacher MA, 2005, NATURE, V438, P516, DOI 10.1038/nature04149; Surtees JA, 1999, J BACTERIOL, V181, P5898, DOI 10.1128/JB.181.19.5898-5908.1999; Surtees JA, 2001, J BIOL CHEM, V276, P12385, DOI 10.1074/jbc.M009370200	32	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10944	10952		10.1074/jbc.M611250200	http://dx.doi.org/10.1074/jbc.M611250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308337	hybrid			2022-12-25	WOS:000245941500014
J	Rass, U; Ahel, I; West, SC				Rass, Ulrich; Ahel, Ivan; West, Stephen C.			Actions of aprataxin in multiple DNA repair pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK REPAIR; HISTIDINE TRIAD SUPERFAMILY; PROTEIN APRATAXIN; ATAXIA; GENE; MUTATIONS; APRAXIA; DAMAGE	Mutations in the Aptx gene lead to a neurological disorder known as ataxia oculomotor apraxia-1. The product of Aptx is Aprataxin (Aptx), a DNA-binding protein that resolves abortive DNA ligation intermediates. Aprataxin catalyzes the nucleophilic release of adenylate groups covalently linked to 5' phosphate termini, resulting in termini that can again serve as substrates for DNA ligases. Here we show that Aprataxin acts preferentially on adenylated nicks and double-strand breaks rather than on single-stranded DNA. Moreover, we show that whereas the catalytic activity of Aptx resides within the HIT domain, the C-terminal zinc finger domain provides stabilizing contacts that lock the enzyme onto its high affinity AMP-DNA target site. Both domains are therefore required for efficient AMP-DNA hydrolase activity. Additionally, we find a role for Aprataxin in base excision repair, specifically in the removal of adenylates that arise from abortive ligation reactions that take place at incised abasic sites in DNA. We suggest that Aprataxin may have a general proofreading function in DNA repair, removing DNA adenylates as they arise during single-strand break repair, double-strand break repair, and in base excision repair.	Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England	Cancer Research UK	West, SC (corresponding author), Canc Res UK, London Res Inst, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.	stephen.west@cancer.org.uk		Rass, Ulrich/0000-0001-9275-9062; West, Stephen/0000-0001-8848-9418; Ahel, Ivan/0000-0002-9446-3756				Ahel I, 2006, NATURE, V443, P713, DOI 10.1038/nature05164; Barnes DE, 2004, ANNU REV GENET, V38, P445, DOI 10.1146/annurev.genet.38.072902.092448; Bogenhagen DF, 1998, J BIOL CHEM, V273, P7888, DOI 10.1074/jbc.273.14.7888; Boorstein RJ, 2001, J BIOL CHEM, V276, P41991, DOI 10.1074/jbc.M106953200; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Caldecott KW, 2001, BIOESSAYS, V23, P447, DOI 10.1002/bies.1063; Clements PM, 2004, DNA REPAIR, V3, P1493, DOI 10.1016/j.dnarep.2004.06.017; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; GOFFIN C, 1987, NUCLEIC ACIDS RES, V15, P875; Gueven N, 2004, HUM MOL GENET, V13, P1081, DOI 10.1093/hmg/ddh122; Kijas AW, 2006, J BIOL CHEM, V281, P13939, DOI 10.1074/jbc.M507946200; Le Ber I, 2003, BRAIN, V126, P2761, DOI 10.1093/brain/awg283; Luo H, 2004, MOL CELL BIOL, V24, P8356, DOI 10.1128/MCB.24.19.8356-8365.2004; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; Mosesso P, 2005, CELL MOL LIFE SCI, V62, P485, DOI 10.1007/s00018-004-4441-0; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Sano Y, 2004, ANN NEUROL, V55, P241, DOI 10.1002/ana.10808; Seidle HF, 2005, J BIOL CHEM, V280, P20927, DOI 10.1074/jbc.M502889200; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002	19	70	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9469	9474		10.1074/jbc.M611489200	http://dx.doi.org/10.1074/jbc.M611489200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276982	Green Accepted, hybrid			2022-12-25	WOS:000245421700019
J	Shang, X; Moon, SY; Zheng, Y				Shang, Xun; Moon, Sun Young; Zheng, Yi			p200 RhoGAP promotes cell proliferation by mediating cross-talk between Ras and Rho signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; C-SRC; TRANSFORMATION; FAMILY; DOMAIN; CDC42; RAC1; P190; RECEPTOR; CANCER	p200 RhoGAP, a member of the Rho GTPase-activating protein (RhoGAP) family, was previously implicated in the regulation of neurite outgrowth through its RhoGAP activity. Here we show that ectopic expression of p200 RhoGAP stimulates fibroblast cell proliferation and cell cycle progression, leading to transformation. The morphology of the foci induced by p200 RhoGAP is distinct from that formed by Rac or Rho activation but similar to that induced by oncogenic Ras, raising the possibility that p200 RhoGAP may engage Ras signaling. Expression of p200 RhoGAP results in a significant increase of Ras-GTP and the activation of two downstream signaling pathways of Ras, ERK1/2 and phosphatidylinositol 3-kinase. Inhibition of Ras or ERK1/2, but not phosphatidylinositol 3-kinase, effectively suppresses the foci formation induced by p200 RhoGAP, suggesting that the Ras-ERK pathway is required for p200 RhoGAP-mediated cell transformation. p200 RhoGAP co-localizes with p120 RasGAP in cells and forms a complex with p120 RasGAP, and this interaction is mediated by the C-terminal region and the Src homology 3 domain of p200 RhoGAP and p120 RasGAP, respectively. Mutations of p200 RhoGAP that disrupt interaction with p120 RasGAP abolish its Ras activation and cell transforming activities. Interestingly, the RhoGAP activity of the N-terminal RhoGAP domain in p200 RhoGAP is also required for its full transforming activity, and expression of a dominant negative RhoA mutant that blocks RhoA cycling between the GDP- and GTP-bound states suppresses p200 RhoGAP transformation. These results suggest that a Rho GTPase-activating protein may have a positive input to cell proliferation and provide evidence that p200 RhoGAP can mediate cross-talks between Ras- and Rho-regulated signaling pathways in cell growth regulation.	Univ Cincinnati, Childrens Hosp, Med Ctr, Childrens Hosp Res Fdn,Div Expt Hematol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Zheng, Y (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Childrens Hosp Res Fdn,Div Expt Hematol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	yi.zheng@chmcc.org	Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074	NATIONAL CANCER INSTITUTE [R01CA105117] Funding Source: NIH RePORTER; NCI NIH HHS [CA105117] Funding Source: Medline; NIGMS NIH HHS [GM53943] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fort P, 1999, Prog Mol Subcell Biol, V22, P159; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hu KQ, 1997, EMBO J, V16, P473, DOI 10.1093/emboj/16.3.473; Jaffe AB, 2003, SCIENCE, V302, P1690, DOI 10.1126/science.1092874; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kozma R, 1996, MOL CELL BIOL, V16, P5069; KRISHAN A, 1975, J CELL BIOL, V66, P188, DOI 10.1083/jcb.66.1.188; Li R, 1997, J BIOL CHEM, V272, P32830, DOI 10.1074/jbc.272.52.32830; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Moon SY, 2003, J BIOL CHEM, V278, P4151, DOI 10.1074/jbc.M207789200; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; Nakamura T, 2002, MOL CELL BIOL, V22, P8721, DOI 10.1128/MCB.22.24.8721-8734.2002; Nakazawa T, 2003, MOL BIOL CELL, V14, P2921, DOI 10.1091/mbc.e02-09-0623; Nasu-Nishimura Y, 2006, GENES CELLS, V11, P607, DOI 10.1111/j.1365-2443.2006.00966.x; Okabe T, 2003, J BIOL CHEM, V278, P9920, DOI 10.1074/jbc.M208872200; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ridley A, 2000, NATURE, V406, P466, DOI 10.1038/35020170; Roof RW, 2000, FEBS LETT, V472, P117, DOI 10.1016/S0014-5793(00)01439-3; Roof RW, 1998, MOL CELL BIOL, V18, P7052, DOI 10.1128/MCB.18.12.7052; Shang X, 2003, J BIOL CHEM, V278, P45903, DOI 10.1074/jbc.M304514200; Tcherkezian J, 2005, MOL CELL BIOL, V25, P6314, DOI 10.1128/MCB.25.15.6314-6329.2005; VAN AL, 1997, GENE DEV, V11, P2295; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Wang DZM, 1997, CANCER RES, V57, P2478; Wang JB, 2005, J BIOL CHEM, V280, P22883, DOI 10.1074/jbc.M414375200; Wolf RM, 2003, GENE DEV, V17, P476, DOI 10.1101/gad.1040003; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Yuan BZ, 1998, CANCER RES, V58, P2196; Zhao CM, 2003, J BIOL CHEM, V278, P34641, DOI 10.1074/jbc.M304594200; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	42	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8801	8811		10.1074/jbc.M609375200	http://dx.doi.org/10.1074/jbc.M609375200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17272280	hybrid			2022-12-25	WOS:000245780300027
J	Vinci, CR; Clarke, SG				Vinci, Chris R.; Clarke, Steven G.			Recognition of age-damaged (R,S)-adenosyl-L-methionine by two methyltransferases in the yeast Saccharomyces cervisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; S-ADENOSYLMETHIONINE; 1-AMINOCYCLOPROPANE-1-CARBOXYLATE SYNTHASE; PROTEIN METHYLATION; SULFONIUM CENTER; TRANS-ACONITATE; SPECIFICITY; REPAIR; CONFIGURATION; BIOSYNTHESIS	The biological methyl donor S-adenosylmethionine (AdoMet) can exist in two diastereoisomeric states with respect to its sulfonium ion. The S configuration, (SS)-AdoMet, is the only form that is produced enzymatically as well as the only form used in almost all biological methylation reactions. Under physiological conditions, however, the sulfonium ion can spontaneously racemize to the R form, producing (R,S)AdoMet. As of yet, (R,S)-AdoMet has no known physiological function and may inhibit cellular reactions. In this study, we found two Saccharomyces cerevisiae enzymes that are capable of recognizing (R,S)-AdoMet and using it to methylate homocysteine to form methionine. These enzymes are the products of the SAM4 and MHT1 genes, identified previously as homocysteine methyltransferases dependent upon AdoMet and S-methylmethionine, respectively. We found here that Sam4 recognizes both (S,S)- and (R,S)-AdoMet, but that its activity is much higher with the R,S form. Mht1 reacts with only the R,S form of AdoMet, whereas no activity is seen with the SS form. R,S-Specific homocysteine methyltransferase activity is also shown here to occur in extracts of A rabidopsis thaliana, Drosophila melanogaster, and Caenorhabditis elegans, but has not been detected in several tissue extracts of Mus musculus. Such activity may function to prevent the accumulation of (R,S)-AdoMet in these organisms.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, SG (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	clarke@mbi.ucla.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018000] Funding Source: NIH RePORTER; NIA NIH HHS [AG018000] Funding Source: Medline; NIGMS NIH HHS [GM026020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Banerjee R, 1997, METHOD ENZYMOL, V281, P189; BEAUDOUIN C, 1993, J NEUROCHEM, V61, P928, DOI 10.1111/j.1471-4159.1993.tb03604.x; Bentley R, 2005, CHEM SOC REV, V34, P609, DOI 10.1039/b418284g; BORCHARDT RT, 1976, J MED CHEM, V19, P1099, DOI 10.1021/jm00231a004; Bottiglieri T, 2002, AM J CLIN NUTR, V76, p1151S, DOI 10.1093/ajcn/76.5.1151S; Cai H, 2001, BIOCHEMISTRY-US, V40, P2210, DOI 10.1021/bi0022902; Cannon LM, 2002, ANAL BIOCHEM, V308, P358, DOI 10.1016/S0003-2697(02)00267-1; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Castro C, 2004, BIOCHEMISTRY-US, V43, P5341, DOI 10.1021/bi049821x; Clarke S, 2003, AGEING RES REV, V2, P263, DOI 10.1016/S1568-1637(03)00011-4; CORNFORTH JW, 1977, J AM CHEM SOC, V99, P7292, DOI 10.1021/ja00464a032; CREASON GL, 1985, PHYTOCHEMISTRY, V24, P1151, DOI 10.1016/S0031-9422(00)81092-4; DELAHABA G, 1959, J AM CHEM SOC, V81, P3975, DOI 10.1021/ja01524a039; Evans JC, 2002, STRUCTURE, V10, P1159, DOI 10.1016/S0969-2126(02)00796-7; Fellner T, 2003, METHOD ENZYMOL, V366, P187; Fontecave M, 2004, TRENDS BIOCHEM SCI, V29, P243, DOI 10.1016/j.tibs.2004.03.007; Friguet B, 2006, FEBS LETT, V580, P2910, DOI 10.1016/j.febslet.2006.03.028; Garrow TA, 2006, FASEB J, V20, pA606; Garrow TA, 1996, J BIOL CHEM, V271, P22831, DOI 10.1074/jbc.271.37.22831; GRUESORENSEN G, 1984, J CHEM SOC PERK T 1, P1091, DOI 10.1039/p19840001091; Hanna GM, 2004, PHARMAZIE, V59, P251; Hernebring M, 2006, P NATL ACAD SCI USA, V103, P7700, DOI 10.1073/pnas.0510944103; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; Jarrett JT, 2003, CURR OPIN CHEM BIOL, V7, P174, DOI 10.1016/S1367-5931(03)00022-X; Jiracek J, 2006, J MED CHEM, V49, P3982, DOI 10.1021/jm050885v; KAGAN RM, 1995, BIOCHEMISTRY-US, V34, P10794, DOI 10.1021/bi00034a012; LAUBLE H, 1994, J MOL BIOL, V237, P437, DOI 10.1006/jmbi.1994.1246; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Loenen WAM, 2006, BIOCHEM SOC T, V34, P330, DOI 10.1042/BST0340330; Lombard DB, 2005, CELL, V120, P497, DOI 10.1016/j.cell.2005.01.028; LOUGHLIN RE, 1964, J BIOL CHEM, V239, P2888; LOWENSON JD, 1991, J BIOL CHEM, V266, P19396; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; McCarthy DL, 2001, BIOCHEMISTRY-US, V40, P12276, DOI 10.1021/bi011050z; Miranda TB, 2004, FEBS LETT, V577, P181, DOI 10.1016/j.febslet.2004.09.080; Neuhierl B, 1999, J BIOL CHEM, V274, P5407, DOI 10.1074/jbc.274.9.5407; Peariso K, 1998, J AM CHEM SOC, V120, P8410, DOI 10.1021/ja980581g; Porras-Yakushi TR, 2005, J BIOL CHEM, V280, P34590, DOI 10.1074/jbc.M507672200; Ranocha P, 2000, J BIOL CHEM, V275, P15962, DOI 10.1074/jbc.M001116200; Ranocha P, 2001, PLANT J, V25, P575, DOI 10.1046/j.1365-313x.2001.00988.x; REBHOLZ KL, 1994, ARCH BIOCHEM BIOPHYS, V312, P227, DOI 10.1006/abbi.1994.1303; SATOH S, 1989, PLANT PHYSIOL, V91, P1036, DOI 10.1104/pp.91.3.1036; Schubert HL, 2003, TRENDS BIOCHEM SCI, V28, P329, DOI 10.1016/S0968-0004(03)00090-2; SHAPIRO SK, 1964, J BIOL CHEM, V239, P1551; Thomas D, 2000, J BIOL CHEM, V275, P40718, DOI 10.1074/jbc.M005967200; Urdiales JL, 2001, EUR J GASTROEN HEPAT, V13, P1015, DOI 10.1097/00042737-200109000-00003; Veiga-Da-Cunha M, 2006, BIOCHEM J, V399, P257, DOI 10.1042/BJ20060684; Villa ST, 2006, PHYSIOL PLANTARUM, V128, P581, DOI 10.1111/j.1399-3054.2006.00772.x; WU SE, 1983, BIOCHEMISTRY-US, V22, P2828, DOI 10.1021/bi00281a009; ZAPPIA V, 1969, BIOCHIM BIOPHYS ACTA, V178, P185, DOI 10.1016/0005-2744(69)90147-8	52	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8604	8612		10.1074/jbc.M610029200	http://dx.doi.org/10.1074/jbc.M610029200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264075	hybrid			2022-12-25	WOS:000245780300006
J	Zhang, CK; Ng, KL; Li, JD; He, F; Anderson, DJ; Sun, YE; Zhou, QY				Zhang, Chengkang; Ng, Kwan L.; Li, Jia-Da; He, Fei; Anderson, David J.; Sun, Yi E.; Zhou, Qun-Yong			Prokineticin 2 is a target gene of proneural basic helix-loop-helix factors for olfactory bulb neurogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; ADULT MAMMALIAN BRAIN; SUBVENTRICULAR ZONE; MIGRATION; EXPRESSION; RECEPTORS; NEURONS; CELLS; IDENTIFICATION; PROGENITORS	Prokineticin 2, a cysteine-rich secreted protein, regulates diverse biological functions including the neurogenesis of olfactory bulb. Here we show that the PK2 gene is a functional target gene of proneural basic helix-loop-helix (bHLH) factors. Neurogenin 1 and MASH1 activate PK2 transcription by binding to E-box motifs on the PK2 promoter with the same set of E-boxes critical for another pair of bHLH factors, CLOCK and BMAL1, in the regulation of circadian clock. Our results establish PK2 as a common functional target gene for different bHLH transcriptional factors in mediating their respective functions.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Calif Los Angeles, Dept Psychiat, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biobehav Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Pharmacol, Los Angeles, CA 90095 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of California System; University of California Irvine; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Zhou, QY (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.	qzhou@uci.edu	ZHANG, CHENGKANG/A-8141-2008	Li, Jia-Da/0000-0002-4236-3518; Zhang, Chengkang/0000-0002-3746-2095				Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Cheng MY, 2006, J COMP NEUROL, V498, P796, DOI 10.1002/cne.21087; Cheng MY, 2002, NATURE, V417, P405, DOI 10.1038/417405a; Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Ge WH, 2006, P NATL ACAD SCI USA, V103, P1319, DOI 10.1073/pnas.0510419103; Hand R, 2005, NEURON, V48, P45, DOI 10.1016/j.neuron.2005.08.032; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; LeCouter J, 2004, P NATL ACAD SCI USA, V101, P16813, DOI 10.1073/pnas.0407697101; LeCouter J, 2003, P NATL ACAD SCI USA, V100, P2685, DOI 10.1073/pnas.0337667100; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Lin DCH, 2002, J BIOL CHEM, V277, P19276, DOI 10.1074/jbc.M202139200; Lledo PM, 2006, NAT REV NEUROSCI, V7, P179, DOI 10.1038/nrn1867; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Ma QF, 1999, GENE DEV, V13, P1717, DOI 10.1101/gad.13.13.1717; Murray RC, 2003, J NEUROSCI, V23, P1769; Ng KL, 2005, SCIENCE, V308, P1923, DOI 10.1126/science.1112103; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Pattyn A, 2004, NAT NEUROSCI, V7, P589, DOI 10.1038/nn1247; RICHARDSON A, 2001, PROTOCOLS NEURAL CEL, P173; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Zhang CK, 2005, BIOCHEM J, V386, P161, DOI 10.1042/BJ20041514	29	32	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2007	282	10					6917	6921		10.1074/jbc.C600290200	http://dx.doi.org/10.1074/jbc.C600290200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	148NC	17259180	hybrid, Green Accepted			2022-12-25	WOS:000245080900002
J	Jiu, M; Zhou, XP; Tong, L; Xu, J; Yang, X; Wan, FH; Liu, SS				Jiu, Min; Zhou, Xue-Ping; Tong, Lin; Xu, Jing; Yang, Xiao; Wan, Fang-Hao; Liu, Shu-Sheng			Vector-Virus Mutualism Accelerates Population Increase of an Invasive Whitefly	PLOS ONE			English	Article							BEMISIA-TABACI HOMOPTERA; GRAIN APHID HOMOPTERA; SPOTTED WILT VIRUS; NON-B-BIOTYPE; GENETIC DIVERSITY; FRANKLINIELLA-OCCIDENTALIS; LIFE-HISTORY; TOMATO; TRANSMISSION; ALEYRODIDAE	The relationships between plant viruses, their herbivore vectors and host plants can be beneficial, neutral, or antagonistic, depending on the species involved. This variation in relationships may affect the process of biological invasion and the displacement of indigenous species by invaders when the invasive and indigenous organisms occur with niche overlap but differ in the interactions. The notorious invasive B biotype of the whitefly complex Bemisia tabaci entered China in the late 1990s and is now the predominant or only biotype in many regions of the country. Tobacco curly shoot virus (TbCSV) and Tomato yellow leaf curl China virus (TYLCCNV) are two whitefly-transmitted begomoviruses that have become widespread recently in south China. We compared the performance of the invasive B and indigenous ZHJ1 whitefly biotypes on healthy, TbCSV-infected and TYLCCNV-infected tobacco plants. Compared to its performance on healthy plants, the invasive B biotype increased its fecundity and longevity by 12 and 6 fold when feeding on TbCSV-infected plants, and by 18 and 7 fold when feeding on TYLCCNV-infected plants. Population density of the B biotype on TbCSV- and TYLCCNV-infected plants reached 2 and 13 times that on healthy plants respectively in 56 days. In contrast, the indigenous ZHJ1 performed similarly on healthy and virus-infected plants. Virus-infection status of the whiteflies per se of both biotypes showed limited effects on performance of vectors on cotton, a nonhost plant of the viruses. The indirect mutualism between the B biotype whitefly and these viruses via their host plants, and the apparent lack of such mutualism for the indigenous whitefly, may contribute to the ability of the B whitefly biotype to invade, the displacement of indigenous whiteflies, and the disease pandemics of the viruses associated with this vector.	[Jiu, Min; Tong, Lin; Xu, Jing; Yang, Xiao; Liu, Shu-Sheng] Zhejiang Univ, Inst Insect Sci, Hangzhou 310003, Zhejiang, Peoples R China; [Zhou, Xue-Ping] Zhejiang Univ, Inst Biotechnol, Hangzhou 310003, Zhejiang, Peoples R China; [Wan, Fang-Hao] Chinese Acad Agr Sci, Inst Plant Protect, Beijing, Peoples R China	Zhejiang University; Zhejiang University; Chinese Academy of Agricultural Sciences; Institute of Plant Protection, CAAS	Liu, SS (corresponding author), Zhejiang Univ, Inst Insect Sci, Hangzhou 310003, Zhejiang, Peoples R China.	shshliu@zju.edu.cn	yang, xiao/K-8509-2013; Liu, Shu-Sheng/D-2300-2013; xu, jing/GRR-8698-2022	Yang, Xiao/0000-0002-2351-4827	National Basic Research and Development Program of China [2002CB111403]; Zhejiang Agricultural Science and Technology Key Research Project [2005C12008-02]	National Basic Research and Development Program of China(National Basic Research Program of China); Zhejiang Agricultural Science and Technology Key Research Project	This study was funded by the National Basic Research and Development Program of China (2002CB111403) and Zhejiang Agricultural Science and Technology Key Research Project (2005C12008-02).	*APPL BIOST INC, 2002, BIOMSTAT STAT SOFTW; Belliure B, 2005, ECOL LETT, V8, P70, DOI 10.1111/j.1461-0248.2004.00699.x; BROWN JK, 1995, ANNU REV ENTOMOL, V40, P511, DOI 10.1146/annurev.en.40.010195.002455; CASTLE SJ, 1993, ENTOMOL EXP APPL, V69, P51, DOI 10.1007/BF02380673; Chu D, 2006, FLA ENTOMOL, V89, P168, DOI 10.1653/0015-4040(2006)89[168:TIOTEQ]2.0.CO;2; COHEN S, 1966, PHYTOPATHOLOGY, V56, P1127; Colvin J, 2006, ADV VIRUS RES, V67, P419, DOI 10.1016/S0065-3527(06)67011-5; Colvin J, 2004, PLANT PATHOL, V53, P577, DOI 10.1111/j.0032-0862.2004.01062.x; COSTA HS, 1991, ENVIRON ENTOMOL, V20, P1102, DOI 10.1093/ee/20.4.1102; COSTA HS, 1993, INSECT SCI APPL, V14, P255, DOI 10.1017/S1742758400014703; Cui XF, 2004, J VIROL, V78, P13966, DOI 10.1128/JVI.78.24.13966-13974.2004; De Barro PJ, 2000, MOL PHYLOGENET EVOL, V16, P29, DOI 10.1006/mpev.1999.0768; De Barro PJ, 2005, MOL ECOL, V14, P3695, DOI 10.1111/j.1365-294X.2005.02700.x; De Barro PJ, 2005, B ENTOMOL RES, V95, P193, DOI 10.1079/BER2004351; DEANGELIS JD, 1993, ENVIRON ENTOMOL, V22, P1308, DOI 10.1093/ee/22.6.1308; Fauquet CM, 2005, ARCH VIROL, V150, P2151, DOI 10.1007/s00705-005-0583-0; FERERES A, 1989, ENVIRON ENTOMOL, V18, P388, DOI 10.1093/ee/18.3.388; Frohlich DR, 1999, MOL ECOL, V8, P1683, DOI 10.1046/j.1365-294x.1999.00754.x; Jimenez-Martinez ES, 2004, J ECON ENTOMOL, V97, P203, DOI 10.1603/0022-0493-97.2.203; Jiu M, 2006, J PHYTOPATHOL, V154, P587, DOI 10.1111/j.1439-0434.2006.01151.x; Johnson SN, 2003, OECOLOGIA, V134, P388, DOI 10.1007/s00442-002-1139-6; KENNEDY JS, 1951, NATURE, V168, P825, DOI 10.1038/168825a0; Kluth S, 2002, OECOLOGIA, V133, P193, DOI 10.1007/s00442-002-1016-3; Li ZH, 2005, PHYTOPATHOLOGY, V95, P902, DOI 10.1094/PHYTO-95-0902; Li Zheng-Xi, 2005, Insect Science, V12, P421, DOI 10.1111/j.1744-7917.2005.00053.x; Lima LHC, 2002, GENET MOL BIOL, V25, P217, DOI 10.1590/S1415-47572002000200016; Lin Ke-Jian, 2003, Acta Ecologica Sinica, V23, P870; Luo Chen, 2002, Acta Entomologica Sinica, V45, P759; Maris PC, 2004, PHYTOPATHOLOGY, V94, P706, DOI 10.1094/PHYTO.2004.94.7.706; McKenzie CL, 2004, FLA ENTOMOL, V87, P403, DOI 10.1653/0015-4040(2004)087[0403:AESOBT]2.0.CO;2; McKenzie CL, 2002, FLA ENTOMOL, V85, P367, DOI 10.1653/0015-4040(2002)085[0367:EOTMVT]2.0.CO;2; McKenzie CL, 2002, ARCH INSECT BIOCHEM, V49, P203, DOI 10.1002/arch.10020; MEHTA P, 1994, J ECON ENTOMOL, V87, P1291, DOI 10.1093/jee/87.5.1291; Morales FJ, 2001, CROP PROT, V20, P825, DOI 10.1016/S0261-2194(01)00114-4; Morse JG, 2006, ANNU REV ENTOMOL, V51, P67, DOI 10.1146/annurev.ento.51.110104.151044; Oliveira MRV, 2001, CROP PROT, V20, P709, DOI 10.1016/S0261-2194(01)00108-9; Perring Thomas M., 1996, P3; Perring TM, 2001, CROP PROT, V20, P725, DOI 10.1016/S0261-2194(01)00109-0; Polston JE, 1997, PLANT DIS, V81, P1358, DOI 10.1094/PDIS.1997.81.12.1358; Qiu Bao-Li, 2003, Acta Entomologica Sinica, V46, P605; QUIROZ C, 1991, J ECON ENTOMOL, V84, P1920, DOI 10.1093/jee/84.6.1920; Rekha AR, 2005, ENTOMOL EXP APPL, V117, P221, DOI 10.1111/j.1570-7458.2005.00352.x; Ribeiro SG, 2003, ARCH VIROL, V148, P281, DOI 10.1007/s00705-002-0917-0; Roca E, 1997, PLANT PATHOL, V46, P407, DOI 10.1046/j.1365-3059.1997.d01-29.x; Rubinstein G, 1997, J GEN VIROL, V78, P2683, DOI 10.1099/0022-1317-78-10-2683; Seal SE, 2006, CRIT REV PLANT SCI, V25, P23, DOI 10.1080/07352680500365257; Stout MJ, 2006, ANNU REV ENTOMOL, V51, P663, DOI 10.1146/annurev.ento.51.110104.151117; Wijkamp I, 1996, ENTOMOL EXP APPL, V81, P285, DOI 10.1007/BF00187037; Wu XX, 2003, PROG NAT SCI-MATER, V13, P276, DOI 10.1360/03jz9049; Xie Y, 2002, CHINESE SCI BULL, V47, P197, DOI 10.1360/02tb9047; Zang LS, 2006, ENTOMOL EXP APPL, V121, P221, DOI 10.1111/j.1570-8703.2006.00482.x; Zang Lian-Sheng, 2005, Acta Entomologica Sinica, V48, P742; Zang Lian-Sheng, 2005, Chinese Bulletin of Entomology, V42, P329; Zang LianSheng, 2005, Biodiversity Science, V13, P181, DOI 10.1360/biodiv.040202; Zhang LP, 2005, J APPL ENTOMOL, V129, P121, DOI 10.1111/j.1439-0418.2005.00950.x; Zhou XP, 2003, J GEN VIROL, V84, P237, DOI 10.1099/vir.0.18608-0	56	233	284	1	84	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2007	2	1							e182	10.1371/journal.pone.0000182	http://dx.doi.org/10.1371/journal.pone.0000182			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DH	17264884	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444200006
J	Luxenburg, C; Geblinger, D; Klein, E; Anderson, K; Hanein, D; Geiger, B; Addadi, L				Luxenburg, Chen; Geblinger, Dafna; Klein, Eugenia; Anderson, Karen; Hanein, Dorit; Geiger, Benny; Addadi, Lia			The Architecture of the Adhesive Apparatus of Cultured Osteoclasts: From Podosome Formation to Sealing Zone Assembly	PLOS ONE			English	Article							CELL-SUBSTRATUM ADHESIONS; VITRONECTIN RECEPTOR; ACTIN-CYTOSKELETON; BONE-RESORPTION; ORGANIZATION; DEFICIENCY; INTEGRIN; GELSOLIN	Background. Osteoclasts are bone-degrading cells, which play a central role in physiological bone remodeling. Unbalanced osteoclast activity is largely responsible for pathological conditions such as osteoporosis. Osteoclasts develop specialized adhesion structures, the so-called podosomes, which subsequently undergo dramatic reorganization into sealing zones. These ring-like adhesion structures, which delimit the resorption site, effectively seal the cell to the substrate forming a diffusion barrier. The structural integrity of the sealing zone is essential for the cell ability to degrade bone, yet its structural organization is poorly understood. Principal Findings. Combining high-resolution scanning electron microscopy with fluorescence microscopy performed on the same sample, we mapped the molecular architecture of the osteoclast resorptive apparatus from individual podosomes to the sealing zone, at an unprecedented resolution. Podosomes are composed of an actin-bundle core, flanked by a ring containing adhesion proteins connected to the core via dome-like radial actin fibers. The sealing zone, hallmark of bone-resorbing osteoclasts, consists of a dense array of podosomes communicating through a network of actin filaments, parallel to the substrate and anchored to the adhesive plaque domain via radial actin fibers. Significance. The sealing zone of osteoclasts cultured on bone is made of structural units clearly related to individual podosomes. It differs from individual or clustered podosomes in the higher density and degree of inter-connectivity of its building blocks, thus forming a unique continuous functional structure connecting the cell to its extracellular milieu. Through this continuous structure, signals reporting on the substrate condition may be transmitted to the whole cell, modulating the cell response under physiological and pathological conditions.	[Luxenburg, Chen; Geblinger, Dafna; Addadi, Lia] Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; [Luxenburg, Chen; Geiger, Benny] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; [Klein, Eugenia] Weizmann Inst Sci, Chem Res Support Unit, IL-76100 Rehovot, Israel; [Anderson, Karen; Hanein, Dorit] Burnham Inst Med Res, Infect Dis & Cell Adhes Programs, La Jolla, CA USA	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Sanford Burnham Prebys Medical Discovery Institute	Addadi, L (corresponding author), Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel.	lia.addadi@weizmann.ac.il			National Institute of General Medical Sciences (NIGMS), National Institutes of Health Cell Migration Consortium [U54 GM64346]; Women's Health Research Center, WIS; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346] Funding Source: NIH RePORTER	National Institute of General Medical Sciences (NIGMS), National Institutes of Health Cell Migration Consortium(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Women's Health Research Center, WIS; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by grants from the National Institute of General Medical Sciences (NIGMS), National Institutes of Health Cell Migration Consortium, Grant U54 GM64346 (BG and DH). CL was funded in part by the Women's Health Research Center, WIS.	Akisaka T, 2001, J BONE MINER RES, V16, P1248, DOI 10.1359/jbmr.2001.16.7.1248; Akisaka T, 2006, J ELECTRON MICROSC, V55, P53, DOI 10.1093/jmicro/dfl012; AVNUR Z, 1981, J MOL BIOL, V153, P361, DOI 10.1016/0022-2836(81)90283-7; Calle Y, 2004, BLOOD, V103, P3552, DOI 10.1182/blood-2003-04-1259; Chellaiah M, 2000, J CELL BIOL, V148, P665, DOI 10.1083/jcb.148.4.665; Chiusaroli R, 2004, MOL BIOL CELL, V15, P234, DOI 10.1091/mbc.e03-04-0207; Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02-07-0389; Evans JG, 2003, J CELL BIOL, V161, P697, DOI 10.1083/jcb.200212037; GAVAZZI I, 1989, J CELL SCI, V94, P85; Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008; Lakkakorpi PT, 1996, MICROSC RES TECHNIQ, V33, P171, DOI 10.1002/(SICI)1097-0029(19960201)33:2<171::AID-JEMT7>3.0.CO;2-W; LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817; LAKKAKORPI PT, 1993, J CELL SCI, V104, P663; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Luxenburg C, 2006, EUR J CELL BIOL, V85, P203, DOI 10.1016/j.ejcb.2005.11.002; LUXENBURG C, 2006, J CELL SCI; MARCHISIO PC, 1984, J CELL BIOL, V99, P1696, DOI 10.1083/jcb.99.5.1696; NERMUT MV, 1991, EXP CELL RES, V193, P382, DOI 10.1016/0014-4827(91)90111-7; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; Pfaff M, 2001, J CELL SCI, V114, P2775; Rodan GA, 2003, CANCER, V97, P726, DOI 10.1002/cncr.11147; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04-06-0522; Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Teti A, 1999, J BONE MINER RES, V14, P2107, DOI 10.1359/jbmr.1999.14.12.2107; TROTTER JA, 1981, EXP CELL RES, V132, P235, DOI 10.1016/0014-4827(81)90099-9; Vaananen HK, 2000, J CELL SCI, V113, P377; VAANANEN HK, 1995, J CELL SCI, V108, P2729; Weiner S, 1998, ANNU REV MATER SCI, V28, P271, DOI 10.1146/annurev.matsci.28.1.271; ZALLONE AZ, 1989, CONNECT TISSUE RES, V20, P143, DOI 10.3109/03008208909023882; ZAMBONINZALLONE A, 1989, EXP CELL RES, V182, P645, DOI 10.1016/0014-4827(89)90266-8; ZAMBONINZALLONE A, 1988, J BONE MINER RES, V3, P517; Zamir E, 1999, J CELL SCI, V112, P1655	36	218	221	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2007	2	1							e179	10.1371/journal.pone.0000179	http://dx.doi.org/10.1371/journal.pone.0000179			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DH	17264882	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444200004
J	de Koning, JP; Wakabayashi, Y; Nagase, H; Mao, JH; Balmain, A				de Koning, J. P.; Wakabayashi, Y.; Nagase, H.; Mao, J-H; Balmain, A.			Convergence of congenic mapping and allele-specific alterations in tumors for the resolution of the Skts1 skin tumor susceptibility locus	ONCOGENE			English	Article						congenic; LOH; allele-specific; skin; papilloma; susceptibility	GENETIC ALTERATIONS; MODIFIER LOCI; MOUSE MODELS; LUNG-CANCER; MICE; IDENTIFICATION; RETINOBLASTOMA; CHROMOSOME-7; RESISTANCE; CANDIDATE	Although several familial cancer genes with high-penetrance mutations have been identified, the major genetic component of susceptibility to sporadic cancers is attributable to low-penetrance alleles. These 'weak' tumor susceptibility genes do not segregate as single Mendelian traits and are therefore difficult to find in studies of human populations. Previously, we have proposed that a combination of germline mapping and analysis of allele-specific imbalance in tumors may be used to re. ne the locations of susceptibility genes using mouse models of cancer. Here, we have used linkage analysis and congenic mouse strains to map the major skin tumor susceptibility locus Skts1 within a genetic interval of 0.9 cM on proximal chromosome 7. This interval lies in an apparent recombination cold spot, and corresponds to a physical distance of about 15 Mb. We therefore, used patterns of allele-specific imbalances in tumors from backcross and congenic mice to re. ne the location of Skts1. We demonstrate that this single tumor modi. er locus has a dramatic effect on the allelic preference for imbalance on chromosome 7, with at least 90% of tumors from the congenics showing preferential gain of markers on the chromosome carrying the susceptibility variant. Importantly, these alterations enabled us to re. ne the location of Skts1 at higher resolution than that attained using the congenic mice. We conclude that low-penetrance susceptibility genes can have strong effects on patterns of allele-specific somatic genetic changes in tumors, and that analysis of the directionality of these somatic events provides an important and rapid route to identification of germline genetic variants that confer increased cancer risk.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Roswell Pk Canc Inst, Dept Canc, Buffalo, NY 14263 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Roswell Park Cancer Institute	Balmain, A (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 2340 Sutter St,Room S-227, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu	Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021	NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Demant P, 2003, NAT REV GENET, V4, P721, DOI 10.1038/nrg1157; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dragani TA, 2003, CANCER RES, V63, P3011; Ewart-Toland A, 2005, CARCINOGENESIS, V26, P1368, DOI 10.1093/carcin/bgi085; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fijneman RJA, 1996, NAT GENET, V14, P465, DOI 10.1038/ng1296-465; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Hienonen T, 2006, INT J CANCER, V118, P505, DOI 10.1002/ijc.21344; KEMP CJ, 1993, CANCER RES, V53, P6022; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Legare ME, 2000, GENOMICS, V70, P62, DOI 10.1006/geno.2000.6368; Mao JH, 2003, CURR OPIN GENET DEV, V13, P14, DOI 10.1016/S0959-437X(03)00005-4; Mao JH, 2006, P NATL ACAD SCI USA, V103, P8125, DOI 10.1073/pnas.0602581103; Nagase H, 2003, CANCER RES, V63, P4849; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Saran A, 2004, ONCOGENE, V23, P4130, DOI 10.1038/sj.onc.1207565; Silver L.M., 1995, MOUSE GENETICS CONCE; To MD, 2006, NAT GENET, V38, P926, DOI 10.1038/ng1836; VOGEL SN, 1994, INFECT IMMUN, V62, P4454, DOI 10.1128/IAI.62.10.4454-4459.1994; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185	28	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4171	4178		10.1038/sj.onc.1210206	http://dx.doi.org/10.1038/sj.onc.1210206			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17311004				2022-12-25	WOS:000247252700012
J	Knobloch, J; Shaughnessy, JD; Ruther, U				Knobloch, Juergen; Shaughnessy, John D., Jr.; Ruether, Ulrich			Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway	FASEB JOURNAL			English	Article						limb truncations; microphthalmia; teratogenic mechanism; programmed cell death	APICAL ECTODERMAL RIDGE; PROGRAMMED CELL-DEATH; BETA-CATENIN; TERATOGENIC ACTIVITY; HEAD INDUCTION; CHICK EMBRYO; P53; DICKKOPF-1; MECHANISM; ACTIVATION	Thalidomide, a sedative originally used to treat morning sickness and now used to treat leprosy and multiple myeloma, is also a teratogen that induces birth defects in humans such as limb truncations and microphthalmia. However, the teratogenic mechanism of action of this drug remains obscure. Thalidomide induces limb and eye defects in the chicken embryo at an EC50 of 50 mu g/kg egg wt and apoptosis in primary human embryonic fibroblasts ( HEFs) at an EC50 of 8.9 mu M. Using these model systems, we demonstrate by semiquantitative reverse transcriptase- polymerase chain reaction and whole- mount in situ hybridization that thalidomide- induced oxidative stress enhances signaling through bone morphogenetic proteins ( Bmps). This leads to up- regulation of the Bmp target gene and Wnt antagonist Dickkopf1 ( Dkk1) with subsequent inhibition of canonical Wnt/beta-catenin signaling and increased cell death as shown by trypan blue and terminal deoxynucleotidyl transferase- mediated nick end labeling staining. Thalidomide- induced cell death was dramatically reduced in HEFs and in embryonic limb buds by the use of inhibitors against Bmps, Dkk1, and Gsk3 beta, a beta-catenin antagonist acting downstream of Dkk1 in the Wnt pathway. Most interestingly, blocking of Dkk1 or Gsk3 beta dramatically counteracts thalidomideinduced limb truncations and microphthalmia. From this, we conclude that perturbing of Bmp/ Dkk1/ Wnt signaling is central to the teratogenic effects of thalidomide.	Univ Dusseldorf, Inst Entwicklungs & Mol Biol Tiere, D-40225 Dusseldorf, Germany; Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Donna D & Donald M Lambert Lab Myeloma Genet, Little Rock, AR 72205 USA	Heinrich Heine University Dusseldorf; University of Arkansas System; University of Arkansas Medical Sciences	Knobloch, J (corresponding author), Univ Dusseldorf, Inst Entwicklungs & Mol Biol Tiere, Univ Str 1, D-40225 Dusseldorf, Germany.	ruether@uni-duesseldorf.de		Knobloch, Jurgen/0000-0001-6868-0055	NCI NIH HHS [CA-55819, CA-97513] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055819, R33CA097513] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn K, 2001, DEVELOPMENT, V128, P4449; Aslan M, 2003, ANTIOXID REDOX SIGN, V5, P781, DOI 10.1089/152308603770380089; Barthel A, 2005, BIOL CHEM, V386, P207, DOI 10.1515/BC.2005.026; Beck HN, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-12; BLASCHKE G, 1979, ARZNEIMITTEL-FORSCH, V29-2, P1640; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chiarugi P, 2005, FREE RADICAL RES, V39, P353, DOI 10.1080/10715760400027987; COILA S, 2007, IN PRESS BLOOD; DEBOCK CA, 1963, NATURE, V199, P1204, DOI 10.1038/1991204a0; FABRO S, 1964, LIFE SCI, V3, P987, DOI 10.1016/0024-3205(64)90109-2; FABRO S, 1965, NATURE, V208, P1208, DOI 10.1038/2081208a0; FABRO S, 1967, NATURE, V215, P296, DOI 10.1038/215296a0; Francis JM, 2000, J BIOL CHEM, V275, P39137, DOI 10.1074/jbc.M007212200; Franz Wolfgang, 2000, PERSPEKTIVEN WIRTSCH, V1, P53, DOI DOI 10.1111/1468-2516.00005; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; Hagen T, 2004, BIOCHEM J, V379, P471, DOI 10.1042/BJ20031749; Hansen JM, 2004, ANTIOXID REDOX SIGN, V6, P1, DOI 10.1089/152308604771978291; KEMPER F, 1962, LANCET, V2, P836; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; KNOCHE B, 1994, J CHROMATOGR A, V666, P235, DOI 10.1016/0021-9673(94)80385-4; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LENZ W, 1988, TERATOLOGY, V38, P203, DOI 10.1002/tera.1420380303; Maass M, 2000, HERZ, V25, P68, DOI 10.1007/PL00001953; Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067; Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010; MELLIN GW, 1962, NEW ENGL J MED, V267, P1238, DOI 10.1056/NEJM196212132672407; Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534-5807(01)00041-7; NEWMAN LM, 1993, REPROD TOXICOL, V7, P359, DOI 10.1016/0890-6238(93)90025-3; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; Pizette S, 1999, DEVELOPMENT, V126, P883; Qiang YW, 2003, ONCOGENE, V22, P1536, DOI 10.1038/sj.onc.1206239; SAUNDERS JW, 1972, ANN NY ACAD SCI, V193, P29, DOI 10.1111/j.1749-6632.1972.tb27821.x; Schardein J., 1993, CHEM INDUCED BIRTH D; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Shin SY, 2004, CANCER LETT, V212, P225, DOI 10.1016/j.canlet.2004.03.003; SMITHELLS RW, 1992, J MED GENET, V29, P716, DOI 10.1136/jmg.29.10.716; Stephens TD, 2000, BIOCHEM PHARMACOL, V59, P1489, DOI 10.1016/S0006-2952(99)00388-3; Trousse F, 2001, J NEUROSCI, V21, P1292; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wells Peter G, 2005, Toxicol Appl Pharmacol, V207, P354, DOI 10.1016/j.taap.2005.01.061; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wolpert L, 2002, INT J DEV BIOL, V46, P869; WOLPERT L, 1979, J EMBRYOL EXP MORPH, V50, P175; Yamamoto M, 1996, CANCER-AM CANCER SOC, V77, P1628, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1628::AID-CNCR31>3.3.CO;2-Z; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191; Zuzarte-Luis V, 2004, DEV BIOL, V272, P39, DOI 10.1016/j.ydbio.2004.04.015; ZWILLING E, 1955, J EXP ZOOL, V128, P423, DOI 10.1002/jez.1401280304	50	95	97	0	34	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1410	1421		10.1096/fj.06-7603com	http://dx.doi.org/10.1096/fj.06-7603com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17283219				2022-12-25	WOS:000246117000017
J	Voskoboynik, A; Simon-Blecher, N; Soen, Y; Rinkevich, B; De Tomaso, AW; Ishizuka, KJ; Weissman, IL				Voskoboynik, Ayelet; Simon-Blecher, Noa; Soen, Yoav; Rinkevich, Baruch; De Tomaso, Anthony W.; Ishizuka, Katherine J.; Weissman, Irving L.			Striving for normality: whole body regeneration through a series of abnormal generations	FASEB JOURNAL			English	Article						vascular budding; blastogenesis; development; tunicate	ASCIDIAN BOTRYLLUS-SCHLOSSERI; BILATERAL ASYMMETRY; STEM-CELLS; BUDS; POLARITY; PALLEAL; DEATH	Embryogenesis and asexual reproduction are commonly considered to be coordinated developmental processes, which depend on accurate progression through a defined sequence of developmental stages. Here we report a peculiar developmental scenario in a simple chordate, Botryllus schlosseri, wherein a normal colony of individuals ( zooids and buds) is regenerated from the vasculature ( vascular budding) through a sequence of morphologically abnormal developmental stages. Vascular budding was induced by surgically removing buds and zooids from B. schlosseri colonies, leaving only the vasculature and the tunic that connects them. In vivo imaging and histological sections showed that the timing and morphology of developing structures during vascular budding deviated significantly from other asexual reproduction modes ( the regular asexual reproduction mode in this organism and vascular budding in other botryllid species). Subsequent asexual reproduction cycles exhibited gradual regaining of normal developmental patterns, eventually leading to regeneration of a normal colony. The conversion into a normal body form suggests the activation of an alternative pathway of asexual reproduction, which involves gradual regaining of normal positional information. It presents a powerful model for studying the specification of the same body plan by different developmental programs.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Hopkins Marine Stn, Dept Biol, Pacific Grove, CA USA; Natl Inst Oceanog Oceanog & Limnol Res, Haifa, Israel; Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University; Bar Ilan University; Stanford University	Voskoboynik, A (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	ayeletv@stanford.edu	Palmer, Theo/GSI-6635-2022		NIDDK NIH HHS [R01 DK054762, R01-DK54762] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054762] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANCROFT FW, 1903, MARK ANNIVERSARY, V8, P147; Berrill N.J., 1975, P241; Berrill NJ, 1941, BIOL BULL-US, V80, P185, DOI 10.2307/1537596; Berrill NJ, 1941, BIOL BULL-US, V80, P169, DOI 10.2307/1537595; BERRILL NJ, 1950, TUNICATA ACCOUNT BRI, P1; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brien P., 1968, Advances in Morphogenesis, V7, P151; BURIGHEI P, 1976, Bollettino di Zoologia, V43, P293; Burighel P, 1997, MICROSCOPICAL ANATOM, V15, P221; Delsuc F, 2006, NATURE, V439, P965, DOI 10.1038/nature04336; DESANTO RS, 1969, J ULTRA MOL STRUCT R, V28, P259, DOI 10.1016/S0022-5320(69)90084-7; FREEMAN G, 1971, J EXP ZOOL, V178, P433, DOI 10.1002/jez.1401780403; FUJIMOTO H, 1976, J MORPHOL, V150, P607, DOI 10.1002/jmor.1051500302; FUKUMOTO M, 1971, DEV GROWTH DIFFER, V13, P73; GILBERT SF, 2000, DEV BIOL, P121; GRETCHEN LH, 1967, ANIMAL TISSUE TECHNI, P14; IZZARD CS, 1973, J MORPHOL, V139, P1, DOI 10.1002/jmor.1051390102; Laird DJ, 2005, CELL, V123, P1351, DOI 10.1016/j.cell.2005.10.026; LAUZON RJ, 1992, DEV DYNAM, V194, P71, DOI 10.1002/aja.1001940109; LAUZON RJ, 1993, CELL TISSUE RES, V272, P115, DOI 10.1007/BF00323577; Manni L, 2006, BIOESSAYS, V28, P902, DOI 10.1002/bies.20462; MILKMAN R, 1967, BIOL BULL, V132, P229, DOI 10.2307/1539891; MILKMAN R, 1961, BIOL BULL, V121, P376; MILLAR RH, 1971, ADV MAR BIOL, V9, P1, DOI 10.1016/S0065-2881(08)60341-7; Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542; MUKAI H, 1976, Science Reports of the Faculty of Education Gunma University, V25, P61; NAKAUCHI M, 1974, Reports of the Usa Marine Biological Station, V21, P29; NAKAUCHI M, 1974, Reports of the Usa Marine Biological Station, V21, P19; NAKAUCHI M, 1978, BIOL BULL, V154, P453, DOI 10.2307/1541071; Nakauchi M., 1990, Advances in Invertebrate Reproduction, V5, P49; NAKAUCHI M, 1986, ADV INVERTEBRATE REP, P49; OKA H, 1957, BIOL BULL, V112, P225, DOI 10.2307/1539200; OKA H, 1959, BIOL BULL, V117, P340, DOI 10.2307/1538913; Okuyama M, 2001, ZOOL SCI, V18, P261, DOI 10.2108/zsj.18.261; RINKEVICH B, 1995, P NATL ACAD SCI USA, V92, P7695, DOI 10.1073/pnas.92.17.7695; RINKEVICH B, 1987, BIOL BULL, V173, P474, DOI 10.2307/1541694; Rinkevich B., 1996, INVERTEBRATE CELL CU, P1; ROBERTSON EJ, 1987, TERATOCARCINOMAS EMB, P1; Rossi DJ, 2006, CELL, V125, P229, DOI 10.1016/j.cell.2006.04.006; SABBADIN A, 1982, AM ZOOL, V22, P765; Sabbadin A., 1956, Rendiconti Accad Lincei (8), V20, P659; SABBADIN A, 1975, DEV BIOL, V46, P79, DOI 10.1016/0012-1606(75)90088-3; SATOH N, 1994, DEV BIOL ASCIDIANS, P169; Tiozzo S, 2005, DEV DYNAM, V232, P468, DOI 10.1002/dvdy.20250; Watanabe H., 1953, SCI REP TOKYO BUNRIK, V7, P183; WATKINS MJ, 1958, BIOL BULL, V115, P147, DOI 10.2307/1539101; WOLPERT L, 2001, PRINCIPLES DEV	47	56	57	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1335	1344		10.1096/fj.06-7337com	http://dx.doi.org/10.1096/fj.06-7337com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17289924				2022-12-25	WOS:000246117000009
J	Hong, S; Wang, LC; Gao, X; Kuo, YL; Liu, BY; Merling, R; Kung, HJ; Shih, HM; Giam, CZ				Hong, Sohee; Wang, Ling-Chi; Gao, Xiang; Kuo, Yu-Liang; Liu, Baoying; Merling, Randall; Kung, Hsing-Jien; Shih, Hsiu-Ming; Giam, Chou-Zen			Heptad repeats regulate protein phosphatase 2A recruitment to I-kappa B kinase gamma/NF-kappa B essential modulator and are targeted by human T-lymphotropic virus type 1 tax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-GAMMA; PERSISTENT ACTIVATION; TRANSFORMING PROTEIN; COMPLEX ACTIVITY; TNF-ALPHA; NEMO; UBIQUITINATION; PHOSPHORYLATION; OLIGOMERIZATION; IDENTIFICATION	The switching on-and-off of I-kappa B kinase (IKK) and NF-kappa B occurs rapidly after signaling. How activated IKK becomes down-regulated is not well understood. Here we show that following tumor necrosis factor-alpha stimulation, protein phosphatase 2A (PP2A) association with IKK is increased. A heptad repeat in IKK gamma, helix 2 (HLX2), mediates PP2A recruitment. Two other heptad repeats downstream of HLX2, termed coiled-coil region 2 (CCR2) and leucine zipper (LZ), bind HLX2 and negatively regulate HLX2 interaction with PP2A. HTLV-1 transactivator Tax also binds HLX2, and this interaction is enhanced by CCR2 but reduced by LZ. In the presence of Tax, PP2A-IKK gamma binding is greatly strengthened. Interestingly, peptides spanning CCR2 and/or LZ disrupt IKK gamma Tax and IKK gamma-PP2A interactions and potently inhibit NF-kappa B activation by Tax and tumor necrosis factor-alpha. We propose that when IKK is resting, HLX2, CCR2, and LZ form a helical bundle in which HLX2 is sequestered. The HLX2-CCR2-LZ bundle becomes unfolded by signal-induced modifications of IKK gamma or after Tax binding. In this conformation, IKK becomes activated. IKK gamma then recruits PP2A via the exposed HLX2 domain for rapid down-regulation of IKK. Tax-PP2A interaction, however, renders PP2A inactive, thus maintaining Tax-PP2A-IKK in an active state. Finally, CCR2 and LZ possibly inhibit IKK activation by stabilizing the HLX2-CCR2-LZ bundle.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA; Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 115, Taiwan; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	Uniformed Services University of the Health Sciences - USA; National Health Research Institutes - Taiwan; University of California System; University of California Davis	Giam, CZ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	cgiam@usuhs.mil	Kung, Hsing-Jien/C-7651-2013; Shih, Hsiu-Ming/S-7023-2018					Agou F, 2004, J BIOL CHEM, V279, P54248, DOI 10.1074/jbc.M406423200; Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Cheong R, 2006, J BIOL CHEM, V281, P2945, DOI 10.1074/jbc.M510085200; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Filipe-Santos O, 2006, J EXP MED, V203, P1745, DOI 10.1084/jem.20060085; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Iha H, 2003, ONCOGENE, V22, P8912, DOI 10.1038/sj.onc.1207058; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kray AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McDonnell AV, 2006, BIOINFORMATICS, V22, P356, DOI 10.1093/bioinformatics/bti797; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; Shih HM, 1996, P NATL ACAD SCI USA, V93, P13896, DOI 10.1073/pnas.93.24.13896; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; SUNG SSJ, 1992, J EXP MED, V176, P897, DOI 10.1084/jem.176.3.897; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6	35	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12119	12126		10.1074/jbc.M610392200	http://dx.doi.org/10.1074/jbc.M610392200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314097	hybrid			2022-12-25	WOS:000245941900054
J	Wu, ATH; Sutovsky, P; Manandhar, G; Xu, W; Katayama, M; Day, BN; Park, KW; Yi, YJ; Xi, YW; Prather, RS; Oko, R				Wu, Alexander T. H.; Sutovsky, Peter; Manandhar, Gaurishankar; Xu, Wei; Katayama, Mika; Day, Billy N.; Park, Kwang-Wook; Yi, Young-Joo; Xi, Yan Wei; Prather, Randall S.; Oko, Richard			PAWP, a sperm-specific WW domain-binding protein, promotes meiotic resumption and pronuclear development during fertilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YES-ASSOCIATED PROTEIN; TRIGGERS CA2+ OSCILLATIONS; PROLINE-RICH MOTIFS; PERINUCLEAR THECA; OOCYTE ACTIVATION; CELL-CYCLE; BOVINE SPERMIOGENESIS; BETA-DYSTROGLYCAN; PHOSPHOLIPASE-C; LIDDLE SYNDROME	We report a novel alkaline extractable protein of the sperm head that exclusively resides in the post-acrosomal sheath region of the perinuclear theca (PT) and is expressed and assembled in elongating spermatids. It is a protein that shares sequence homology to the N-terminal half of WW domain-binding protein 2, while the C-terminal half is unique and rich in proline. A functional PPXY consensus binding site for group-I WW domain-containing proteins, and numerous unique repeating motifs, YGXPPXG, are identified in the proline-rich region. Considering these molecular characteristics, we designated this protein PAWP for postacrosomal sheath WW domain-binding protein. Microinjection of recombinant PAWP or alkaline PT extract into metaphase II-arrested porcine, bovine, macaque, and Xenopus oocytes induced a high rate of pronuclear formation, which was prevented by co-injection of a competitive PPXY motif containing peptide derived from PAWP but not by co-injection of the point-mutated peptide. Intracytoplasmic sperm injection (ICSI) of porcine oocytes combined with co-injection of the competitive PPXY peptide or an anti-recombinant PAWP antiserum prevented pronuclear formation and arrested fertilization. Conversely, co-injection of the modified PPXY peptide, when the tyrosine residue of PPXY was either phosphorylated or substituted with phenylalanine, did not prevent ICSI-induced fertilization. This study uncovers a group IWW domain module signal transduction event within the fertilized egg that appears compulsory for meiotic resumption and pronuclear development during egg activation and provides compelling evidence that a PPXY motif of sperm-contributed PAWP can trigger these events.	Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada; Univ Missouri, Dept Anim Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Obstet & Gynecol, Columbia, MO 65211 USA; Univ Ottawa, Dept Biol, Ctr Adv Res Environm Genom, Ottawa, ON K1N 6N5, Canada	Queens University - Canada; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of Ottawa	Oko, R (corresponding author), Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada.	ro3@post.queensu.ca	Prather, Randall S/B-4528-2012	Sutovsky, Peter/0000-0002-9231-2823; Prather, Randall/0000-0002-6012-4035; Wu, Alexander/0000-0002-0178-6530				Abeydeera LR, 1997, BIOL REPROD, V57, P729, DOI 10.1095/biolreprod57.4.729; Adenot PG, 1997, DEVELOPMENT, V124, P4615; Aul RB, 2002, DEV BIOL, V242, P268, DOI 10.1006/dbio.2002.0575; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Cox LJ, 2002, REPRODUCTION, V124, P611, DOI 10.1530/rep.0.1240611; Dhananjayan SC, 2006, MOL ENDOCRINOL, V20, P2343, DOI 10.1210/me.2005-0533; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Espanel X, 2001, J BIOL CHEM, V276, P14514, DOI 10.1074/jbc.M008568200; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Heid HW, 2002, EXP CELL RES, V279, P177, DOI 10.1006/excr.2002.5603; Herrada G, 1997, J CELL SCI, V110, P1543; Heyers S, 2000, MOL CELL ENDOCRINOL, V166, P51, DOI 10.1016/S0303-7207(00)00297-5; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; Ilsley JL, 2001, CELL SIGNAL, V13, P625, DOI 10.1016/S0898-6568(01)00188-7; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kimura Y, 1998, BIOL REPROD, V58, P1407, DOI 10.1095/biolreprod58.6.1407; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; Kurokawa M, 2005, DEV BIOL, V285, P376, DOI 10.1016/j.ydbio.2005.06.029; Lecuyer C, 2000, BIOL REPROD, V63, P1801, DOI 10.1095/biolreprod63.6.1801; Ma CQ, 2006, CURR BIOL, V16, P214, DOI 10.1016/j.cub.2005.11.067; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; OKO R, 1995, MICROSC RES TECHNIQ, V32, P520, DOI 10.1002/jemt.1070320605; OKO R, 1994, BIOL REPROD, V50, P1000, DOI 10.1095/biolreprod50.5.1000; OKO R, 2001, ANDROLOGY 21 CENTURY, P37; Perry ACF, 1999, BIOL REPROD, V60, P747, DOI 10.1095/biolreprod60.3.747; Rousseaux-Preost R, 2003, BIOCHEM BIOPH RES CO, V303, P182, DOI 10.1016/S0006-291X(03)00317-6; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Saunders CM, 2002, DEVELOPMENT, V129, P3533; Schultz RM, 2002, HUM REPROD UPDATE, V8, P323, DOI 10.1093/humupd/8.4.323; Sette C, 2002, EMBO J, V21, P5386, DOI 10.1093/emboj/cdf553; Sette C, 1997, DEVELOPMENT, V124, P2267; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Sutovsky P, 1999, HUM REPROD, V14, P2301, DOI 10.1093/humrep/14.9.2301; Sutovsky P, 1998, J CELL SCI, V111, P2841; Sutovsky P, 1997, DEV BIOL, V188, P75, DOI 10.1006/dbio.1997.8618; Sutovsky P, 2003, MICROSC RES TECHNIQ, V61, P362, DOI 10.1002/jemt.10350; Swann K, 2004, REPRODUCTION, V127, P431, DOI 10.1530/rep.1.00169; Talmor-Cohen A, 2004, REPRODUCTION, V127, P455, DOI 10.1530/rep.1.00104; Tovich PR, 2004, BIOL REPROD, V71, P1182, DOI 10.1095/biolreprod.104.030445; Tovich PR, 2003, J BIOL CHEM, V278, P32431, DOI 10.1074/jbc.M303786200; VONBULOW M, 1995, EXP CELL RES, V219, P407, DOI 10.1006/excr.1995.1246; Whitaker M, 2006, PHYSIOL REV, V86, P25, DOI 10.1152/physrev.00023.2005; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551	45	129	138	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12164	12175		10.1074/jbc.M609132200	http://dx.doi.org/10.1074/jbc.M609132200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17289678	hybrid			2022-12-25	WOS:000245941900059
J	Jansen, S; Callewaert, N; Dewerte, I; Andries, M; Ceulemans, H; Bollen, M				Jansen, Silvia; Callewaert, Nico; Dewerte, Isabelle; Andries, Maria; Ceulemans, Hugo; Bollen, Mathieu			An essential oligomannosidic glycan chain in the catalytic domain of autotaxin, a secreted lysophospholipase-D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHATIDIC ACID; NUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE; I-ALPHA/AUTOTAXIN; N-GLYCOSYLATION; PROTEIN; IDENTIFICATION; MOTILITY; CELLS; PYROPHOSPHATASES/PHOSPHODIESTERASES; PHOSPHODIESTERASE	Autotaxin/NPP2, a secreted lysophospholipase-D, promotes cell proliferation, survival, and motility by generating the signaling molecule lysophosphatidic acid. Here we show that ectonucleotide pyrophosphatase/phosphodiesterase 2 ( NPP2) is N-glycosylated on Asn-53, Asn-410, and Asn-524. Mutagenesis and deglycosylation experiments revealed that only the glycosylation of Asn-524 is essential for the expression of the catalytic and motility-stimulating activities of NPP2. The N-glycan on Asn-524 was identified as Man(8/9)GlcNAc(2), which is rarely present on mature eukaryotic glycoproteins. Additional studies show that this Asn-524-linked glycan is not accessible to alpha-1,2-mannosidase, suggesting that its non-reducing termini are buried inside the folded protein. Consistent with a structural role for the Asn-524-linked glycan, only the mutation of Asn-524 augmented the sensitivity of NPP2 to proteolysis and increased its mobility during Blue Native PAGE. Asn-524 is phylogenetically conserved and maps to the catalytic domain of NPP2, but a structural model of this domain suggests that Asn-524 is remote from the catalytic site. Our study defines an essential role for the Asn-524-linked glycan chain of NPP2.	Katholieke Univ Leuven, Fac Med, Lab Biosignaling & Therapeut, Dept Mol Cellular Biol, B-3000 Louvain, Belgium; Univ Ghent VIB, Unit Mol Glycobiol, DMBRVIB & LProbe, B-9052 Ghent, Belgium	KU Leuven; Flanders Institute for Biotechnology (VIB); Ghent University	Bollen, M (corresponding author), Katholieke Univ Leuven, Afdeling Biochem, Campus Gasthuisberg,Here Str 49, B-3000 Louvain, Belgium.	Mathieu.Bollen@med.kuleuven.be	Nabi, Ambreen/AED-3676-2022	Nabi, Ambreen/0000-0003-1899-363X; Callewaert, Nico/0000-0003-2069-6917; Ceulemans, Hugo/0000-0002-7059-4399				Baumforth KRN, 2005, BLOOD, V106, P2138, DOI 10.1182/blood-2005-02-0471; Cimpean A, 2004, BIOCHEM J, V381, P71, DOI 10.1042/BJ20040465; Clark RAC, 1998, J NEUROCHEM, V70, P2594; Fischer DJ, 2001, MOL PHARMACOL, V60, P776; Fox MA, 2004, MOL CELL NEUROSCI, V27, P140, DOI 10.1016/j.mcn.2004.06.002; Fox MA, 2003, MOL CELL NEUROSCI, V23, P507, DOI 10.1016/S1044-7431(03)00073-3; Gijsbers R, 2003, BIOCHEM J, V371, P321, DOI 10.1042/BJ20021943; Gijsbers R, 2001, J BIOL CHEM, V276, P1361, DOI 10.1074/jbc.M007552200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hama K, 2004, J BIOL CHEM, V279, P17634, DOI 10.1074/jbc.M313927200; Hoelzinger DB, 2005, NEOPLASIA, V7, P7, DOI 10.1593/neo.04535; HORSTKORTE R, 1993, J CELL BIOL, V121, P1409, DOI 10.1083/jcb.121.6.1409; Jansen S, 2005, J CELL SCI, V118, P3081, DOI 10.1242/jcs.02438; Koike S, 2006, GENES CELLS, V11, P133, DOI 10.1111/j.1365-2443.2006.00924.x; Laroy W, 2006, NAT PROTOC, V1, P397, DOI 10.1038/nprot.2006.60; Maras M, 2000, J BIOTECHNOL, V77, P255, DOI 10.1016/S0168-1656(99)00222-9; Meerson NR, 2000, J CELL SCI, V113, P4193; Moolenaar WH, 2004, BIOESSAYS, V26, P870, DOI 10.1002/bies.20081; OBE Y, 2003, BIOCHEM BIOPH RES CO, V308, P719; Roth J, 2002, CHEM REV, V102, P285, DOI 10.1021/cr000423j; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SKIPPER R, 1989, J HISTOTECHNOL, V12, P303; Stefan C, 2005, TRENDS BIOCHEM SCI, V30, P542, DOI 10.1016/j.tibs.2005.08.005; STRACKE ML, 1995, MELANOMA RES, V5, P203, DOI 10.1097/00008390-199508000-00001; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Tanaka M, 2006, J BIOL CHEM, V281, P25822, DOI 10.1074/jbc.M605142200; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Tyagarajan K, 1997, BIOCHEMISTRY-US, V36, P10200, DOI 10.1021/bi9706125; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2005, J BIOL CHEM, V280, P21155, DOI 10.1074/jbc.M413183200; van Meeteren LA, 2006, MOL CELL BIOL, V26, P5015, DOI 10.1128/MCB.02419-05; Wu J, 2005, BIOCHEM J, V386, P153, DOI 10.1042/BJ20041455; Yang SY, 2002, CLIN EXP METASTAS, V19, P603, DOI 10.1023/A:1020950420196; Zalatan JG, 2006, BIOCHEMISTRY-US, V45, P9788, DOI 10.1021/bi060847t	34	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11084	11091		10.1074/jbc.M611503200	http://dx.doi.org/10.1074/jbc.M611503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307740	hybrid			2022-12-25	WOS:000245941500029
J	Umeda-Kameyama, Y; Tsuda, M; Ohkura, C; Matsuo, T; Namba, Y; Ohuchi, Y; Aigaki, T				Umeda-Kameyama, Yumi; Tsuda, Manabu; Ohkura, Chiaki; Matsuo, Takashi; Namba, Yoshio; Ohuchi, Yasuyoshi; Aigaki, Toshiro			Thioredoxin suppresses Parkin-associated endothelin receptor-like receptor-induced neurotoxicity and extends longevity in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SYNUCLEIN; PROTEIN; STRESS; MODEL; DISEASE; CELLS; DEGENERATION; DEGRADATION; SUBSTRATE; APOPTOSIS	Parkin-associated endothelin receptor-like receptor ( Pael-R) is a substrate of the E3 ubiquitin ligase Parkin, which has been implicated in the pathogenesis of Parkinson disease. Misexpression of human Pael-R in Drosophila has been shown to induce selective loss of dopaminergic neurons, a symptom of Parkinson disease. Using this model, we investigated whether thioredoxin ( TRX), an evolutionarily conserved antioxidant and molecular chaperone, could suppress the neurotoxicity induced by Pael-R. The Drosophila genome contains three TRX-encoding genes, namely TrxT, Trx-2, and dhd. When each of the TRX genes was overexpressed together with Pael-R in all neurons, the number of dopaminergic neurons and level of locomotor activity were significantly increased compared with control flies. To assess the role of the antioxidant activity of TRX in this context, we generated redox-defective mutants, TrxT( C35A) and TrxT( D26A/K57I), and coexpressed each of them with Pael-R. The mutants suppressed the Pael-R neurotoxicity similarly to wild-type TrxT, although the extent of the rescue was slightly reduced for the locomotor activity. We confirmed that both mutants remained active as chaperones, suggesting that this activity may be the major cause of the suppression. In the absence of Pael-R, overexpression of TRX in all neurons increased the level of locomotor activity in aged flies and extended the mean longevity by 15%. Furthermore, overexpression of TRX suppressed neurotoxicity in a Drosophila model of Machado-Joseph disease expressing polyglutamine. These results establish that Drosophila TRX can function as an anti-aging agent and as a suppressor of Pael-R- and polyglutamine-induced neurotoxicity.	Tokyo Metropolitan Univ, Dept Biol Sci, Hachioji, Tokyo 1920397, Japan; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan; Japan Biol Informat Consortium, Tokyo 1358073, Japan	Tokyo Metropolitan University; University of Tokyo	Aigaki, T (corresponding author), Tokyo Metropolitan Univ, Dept Biol Sci, 1-1 Minami Osawa, Hachioji, Tokyo 1920397, Japan.	aigaki-toshiro@c.metro-u.ac.jp	Matsuo, Takashi/AAR-8291-2021	Matsuo, Takashi/0000-0002-4185-6740				Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Auluck PK, 2005, J BIOL CHEM, V280, P2873, DOI 10.1074/jbc.M412106200; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bauer H, 2002, J BIOL CHEM, V277, P17457, DOI 10.1074/jbc.M200636200; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cha GH, 2005, P NATL ACAD SCI USA, V102, P10345, DOI 10.1073/pnas.0500346102; Chan HYE, 2000, CELL DEATH DIFFER, V7, P1075, DOI 10.1038/sj.cdd.4400757; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; ENDOH M, 1993, BIOCHEM BIOPH RES CO, V192, P760, DOI 10.1006/bbrc.1993.1479; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; GIBB WRG, 1988, NEUROLOGY, V38, P1402, DOI 10.1212/WNL.38.9.1402; Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100; Haywood AFM, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-14; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HORI K, 1994, BRAIN RES, V652, P304, DOI 10.1016/0006-8993(94)90241-0; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kern R, 2003, BIOCHEM J, V371, P965, DOI 10.1042/BJ20030093; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Koutsillieri E, 2002, J NEUROL S2, V249, P1, DOI DOI 10.1007/S00415-002-1201-7; Le Bourg E, 1999, EXP GERONTOL, V34, P157, DOI 10.1016/S0531-5565(98)00077-1; Lee SJ, 2003, J BIOL CHEM, V278, P44552, DOI 10.1074/jbc.M304517200; Liu YM, 2002, CIRC RES, V90, P1259, DOI 10.1161/01.RES.0000022160.64355.62; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; Neckameyer WS, 2000, NEUROBIOL AGING, V21, P145, DOI 10.1016/S0197-4580(99)00109-8; Nishinaka Y, 2001, REDOX REP, V6, P289, DOI 10.1179/135100001101536427; Olzmann JA, 2004, J BIOL CHEM, V279, P8506, DOI 10.1074/jbc.M311017200; Pesah Y, 2004, DEVELOPMENT, V131, P2183, DOI 10.1242/dev.01095; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Quigney DJ, 2003, BRAIN RES, V993, P133, DOI 10.1016/j.brainres.2003.09.004; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SALZ HK, 1994, GENETICS, V136, P1075; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shin YG, 2005, J BIOL CHEM, V280, P23727, DOI 10.1074/jbc.M503326200; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; SPINA MB, 1989, P NATL ACAD SCI USA, V86, P1398, DOI 10.1073/pnas.86.4.1398; Sulzer D, 1999, NEUROTOX RES, V1, P181, DOI 10.1007/BF03033289; Svensson MJ, 2003, CHROMOSOMA, V112, P133, DOI 10.1007/s00412-003-0253-5; Van Duijn CM, 2001, AM J HUM GENET, V69, P505; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Whitworth AJ, 2005, P NATL ACAD SCI USA, V102, P8024, DOI 10.1073/pnas.0501078102; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	49	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11180	11187		10.1074/jbc.M700937200	http://dx.doi.org/10.1074/jbc.M700937200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17301052	hybrid			2022-12-25	WOS:000245941500039
J	Takahashi, H; Arai, M; Takenawa, T; Sota, H; Xie, QH; Wakura, M				Takahashi, Hisashi; Arai, Munehito; Takenawa, Tatsuyuki; Sota, Hiroyuki; Xie, Qui Hong; Wakura, Masahiro			Stabilization of hyperactive dihydrofolate reductase by cyanocysteine-mediated backbone cyclization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; GLOBULAR-PROTEINS; IN-VIVO; UNPROTECTED PEPTIDES; THERMAL-DENATURATION; PYROCOCCUS-FURIOSUS; CRYSTAL-STRUCTURES; SUBSTRATE BINDING; SULFHYDRYL GROUPS	Stabilization of an enzyme while maintaining its activity has been a major challenge in protein chemistry. Although it is difficult to simultaneously improve stability and activity of a protein by amino acid substitutions due to the activity-stability trade-off, backbone cyclization by connecting the N and C termini with a linker is promising as a general method of stabilizing a protein without affecting its activity. Recently, we created a hyperactive, methionine- and cysteine-free mutant of dihydrofolate reductase from Escherichia coli, called ANLYF, by introducing seven amino acid substitutions, which, however, destabilized the protein. Here we show that ANLYF is stabilized without a loss of its high activity by a novel backbone cyclization method for unprotected proteins. The method is based on the in vitro cyanocysteine-mediated intramolecular ligation reaction, which can be conducted with relatively high efficiency by a simple procedure and under mild conditions. We also show that the reversibility of thermal denaturation is highly improved by the cyclization. Thus, activity and stability of the protein can be separately improved by amino acid substitutions and backbone cyclization, respectively. We suggest that the cyanocysteine-mediated cyclization method is complementary to the intein-mediated cyclization method in stabilizing a protein without affecting its activity.	Natl Inst Adv Ind Sci & Technol, Prot Design Res Grp, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Wakura, M (corresponding author), Natl Inst Adv Ind Sci & Technol, Prot Design Res Grp, Inst Biol Resources & Funct, Tsukuba Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	masa-iwakura@aist.go.jp	Takenawa, Tatsuyuki/M-5439-2018; Arai, Munehito/A-1258-2012	Takenawa, Tatsuyuki/0000-0001-5642-0117; Arai, Munehito/0000-0002-1223-2242				Aita T, 2001, PROTEIN ENG, V14, P633, DOI 10.1093/protein/14.9.633; Anfinsen C B, 1975, Adv Protein Chem, V29, P205, DOI 10.1016/S0065-3233(08)60413-1; Arai M, 2005, J MOL BIOL, V347, P337, DOI 10.1016/j.jmb.2005.01.033; Arai M, 2003, J MOL BIOL, V329, P779, DOI 10.1016/S0022-2836(03)00511-4; Arai M, 2003, J MOL BIOL, V328, P273, DOI 10.1016/S0022-2836(03)00212-2; Arnold FH, 2001, NATURE, V409, P253, DOI 10.1038/35051731; ARNOLD FH, 2000, ADV PROTEIN CHEM, V55, P1; Beadle BM, 2002, J MOL BIOL, V321, P285, DOI 10.1016/S0022-2836(02)00599-5; BETZ SF, 1993, PROTEIN SCI, V2, P1551, DOI 10.1002/pro.5560021002; Blakley R.L., 1984, FOLATES PTERINS, V1, P191; Blaschke UK, 2000, METHOD ENZYMOL, V328, P478, DOI 10.1016/S0076-6879(00)28414-0; BOLIN JT, 1982, J BIOL CHEM, V257, P13650; BYSTROFF C, 1990, BIOCHEMISTRY-US, V29, P3263, DOI 10.1021/bi00465a018; Camarero JA, 1998, ANGEW CHEM INT EDIT, V37, P347, DOI 10.1002/(SICI)1521-3773(19980216)37:3<347::AID-ANIE347>3.0.CO;2-5; Camarero JA, 1999, J AM CHEM SOC, V121, P5597, DOI 10.1021/ja990929n; Camarero JA, 2001, J MOL BIOL, V308, P1045, DOI 10.1006/jmbi.2001.4631; Camarero JA, 1997, CHEM COMMUN, P1369, DOI 10.1039/a702083j; Cantor C., 1980, BIOPHYS CHEM; CATSIMPOOLAS N, 1966, J BIOL CHEM, V241, P1790; Daly NL, 2000, J BIOL CHEM, V275, P19068, DOI 10.1074/jbc.M000450200; Declerck N, 2003, PROTEIN ENG, V16, P287, DOI 10.1093/proeng/gzg032; Deechongkit S, 2002, J AM CHEM SOC, V124, P4980, DOI 10.1021/ja0123608; DEGANI Y, 1971, J ORG CHEM, V36, P2727; DEGANI Y, 1974, BIOCHEMISTRY-US, V13, P1, DOI 10.1021/bi00698a001; Eijsink VGH, 2004, J BIOTECHNOL, V113, P105, DOI 10.1016/j.jbiotec.2004.03.026; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FLORY PJ, 1956, J AM CHEM SOC, V78, P5222, DOI 10.1021/ja01601a025; FRIEDEN C, 1990, P NATL ACAD SCI USA, V87, P4413, DOI 10.1073/pnas.87.12.4413; Gangopadhyay JP, 2003, BBA-GEN SUBJECTS, V1619, P193, DOI 10.1016/S0304-4165(02)00495-6; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOLDENBERG DP, 1983, J MOL BIOL, V165, P407, DOI 10.1016/S0022-2836(83)80265-4; Gonzalez C, 2000, P NATL ACAD SCI USA, V97, P11221, DOI 10.1073/pnas.210301097; Guo CY, 2004, PROTEIN EXPRES PURIF, V37, P361, DOI 10.1016/j.pep.2004.06.037; HILLCOAT BL, 1967, ANAL BIOCHEM, V21, P178, DOI 10.1016/0003-2697(67)90179-0; Ishihama Y, 1999, TETRAHEDRON LETT, V40, P3415, DOI 10.1016/S0040-4039(99)00504-3; Iwai H, 1999, FEBS LETT, V459, P166, DOI 10.1016/S0014-5793(99)01220-X; Iwai H, 2001, J BIOL CHEM, V276, P16548, DOI 10.1074/jbc.M011639200; Iwakura M, 2006, J BIOL CHEM, V281, P13234, DOI 10.1074/jbc.M508823200; IWAKURA M, 1995, J BIOCHEM, V117, P480, DOI 10.1093/oxfordjournals.jbchem.a124733; IWAKURA M, 1992, J BIOCHEM-TOKYO, V111, P37, DOI 10.1093/oxfordjournals.jbchem.a123715; Iwakura M, 2000, NAT STRUCT BIOL, V7, P580, DOI 10.1038/76811; Iwakura M, 1996, J BIOCHEM-TOKYO, V119, P414; Iwakura M, 2001, PROTEIN ENG, V14, P583, DOI 10.1093/protein/14.8.583; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; JENNINGS PA, 1993, BIOCHEMISTRY-US, V32, P3783, DOI 10.1021/bi00065a034; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korkegian A, 2005, SCIENCE, V308, P857, DOI 10.1126/science.1107387; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING LAB MANU; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; MATSUMURA M, 1991, METHOD ENZYMOL, V202, P336; MEIERING EM, 1992, J MOL BIOL, V225, P585, DOI 10.1016/0022-2836(92)90387-Y; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; MORRISON JF, 1988, BIOCHEMISTRY-US, V27, P5499, DOI 10.1021/bi00415a017; Ogasahara K, 1998, BIOCHEMISTRY-US, V37, P17537, DOI 10.1021/bi9814585; Ota M, 2003, J MOL BIOL, V327, P1053, DOI 10.1016/S0022-2836(03)00207-9; Pace C N, 1986, Methods Enzymol, V131, P266; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; Pfeil W., 1998, PROTEIN STABILITY FO; POLAND DC, 1965, BIOPOLYMERS, V3, P379, DOI 10.1002/bip.1965.360030404; Press W. H., 1992, ART SCI COMPUTING; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P586, DOI 10.1021/bi962337c; Schnell JR, 2004, ANNU REV BIOPH BIOM, V33, P119, DOI 10.1146/annurev.biophys.33.110502.133613; SCHREIBER C, 1994, STRUCTURE, V2, P945, DOI 10.1016/S0969-2126(94)00096-4; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Siebold C, 2002, BIOPHYS CHEM, V96, P163, DOI 10.1016/S0301-4622(02)00012-1; Sota H, 1998, ANAL CHEM, V70, P2019, DOI 10.1021/ac9713666; Sun ZY, 2005, PROTEIN EXPRES PURIF, V43, P26, DOI 10.1016/j.pep.2005.05.005; Sydor JR, 2002, BIOCONJUGATE CHEM, V13, P707, DOI 10.1021/bc025534z; Takenawa T, 1998, J BIOCHEM-TOKYO, V123, P1137; THORNTON JM, 1983, J MOL BIOL, V167, P443, DOI 10.1016/S0022-2836(83)80344-1; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; TSUNASAWA S, 1987, J BIOCHEM, V101, P111, DOI 10.1093/oxfordjournals.jbchem.a121882; UWAJIMA T, 1990, BIOCHEM BIOPH RES CO, V171, P684, DOI 10.1016/0006-291X(90)91200-C; Valiyaveetil FI, 2002, J AM CHEM SOC, V124, P9113, DOI 10.1021/ja0266722; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; Wang XJ, 2002, J MOL BIOL, V320, P85, DOI 10.1016/S0022-2836(02)00400-X; Xu MQ, 2001, METHODS, V24, P257, DOI 10.1006/meth.2001.1187; Zhou HX, 2003, J MOL BIOL, V332, P257, DOI 10.1016/S0022-2836(03)00886-6	82	15	16	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9420	9429		10.1074/jbc.M610983200	http://dx.doi.org/10.1074/jbc.M610983200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17264073	hybrid			2022-12-25	WOS:000245421700014
J	Tani, M; Hannun, YA				Tani, Motohiro; Hannun, Yusuf A.			Neutral sphingomyelinase 2 is palmitoylated on multiple cysteine residues - Role of palmitoylation in subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NECROSIS-FACTOR-ALPHA; SIGNALING PROTEINS; BACILLUS-CEREUS; PHOSPHOLIPASE-C; ACID-RESIDUES; DISTINCT POOL; CELL-SURFACE; ACTIVATION; EXPRESSION	The neutral sphingomyelinases (nSMases) are considered major candidates for mediating the stress-induced production of ceramide. nSMase2, which has two hydrophobic segments near the NH2-terminal region, has been reported to be located at the plasma membrane and play important roles in ceramide-mediated signaling. In this study, we found that nSMase2 is palmitoylated on multiple cysteine residues via thioester bonds. Site-directed mutagenesis of cysteine residues to alanine indicated that two cysteine clusters of the enzyme are multiply palmitoylated; one cluster is located between the two hydrophobic segments, and the second one is located in the middle of the catalytic region of the protein. When overexpressed in the confluent phase of MCF-7 cells, wild-type nSMase2 was strictly localized in the plasma membranes, and the cysteine mutants of each palmitoylated cysteine cluster were seen not only at the plasma membrane but also in some punctate structures. Furthermore, mutation of all potential palmitoylation sites resulted in a dramatic reduction in the plasma membrane distribution and an increase in the punctate structures. The palmitoylation-deficient mutant was directed to lysosomes and rapidly degraded. Palmitoylation had no effect on enzyme activity but affected membrane-association properties of the protein. Finally, the catalytic region of nSMase2 where palmitoylation occurs was found to be localized at the inner leaflet of the plasma membrane. In summary, the results from this study reveal for the first time the palmitoylation of nSMase2 via thioester bonds and its importance in the subcellular localization and stability of this protein.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu		Tani, Motohiro/0000-0003-4316-8260	NIGMS NIH HHS [GM43825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrami L, 2006, J CELL BIOL, V172, P309, DOI 10.1083/jcb.200507067; Ago H, 2006, J BIOL CHEM, V281, P16157, DOI 10.1074/jbc.M601089200; Aubin I, 2005, NAT GENET, V37, P803, DOI 10.1038/ng1603; BARENHOLZ Y, 1980, BIOCHIM BIOPHYS ACTA, V604, P129, DOI 10.1016/0005-2736(80)90572-6; Clarke CJ, 2007, J BIOL CHEM, V282, P1384, DOI 10.1074/jbc.M609216200; Clarke CJ, 2006, BIOCHEMISTRY-US, V45, P11247, DOI 10.1021/bi061307z; De Palma C, 2006, ARTERIOSCL THROM VAS, V26, P99, DOI 10.1161/01.ATV.0000194074.59584.42; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hayashi Y, 1997, J BIOL CHEM, V272, P18082, DOI 10.1074/jbc.272.29.18082; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; Jana A, 2004, J BIOL CHEM, V279, P51451, DOI 10.1074/jbc.M404635200; Jiang LW, 2002, TRENDS CELL BIOL, V12, P362, DOI 10.1016/S0962-8924(02)02322-X; Karakashian AA, 2004, FASEB J, V18, P968, DOI 10.1096/fj.03-0875fje; Krut O, 2006, J BIOL CHEM, V281, P13784, DOI 10.1074/jbc.M511306200; Lane SR, 1997, J NEUROCHEM, V69, P1864; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Levy M, 2006, BIOCHEM BIOPH RES CO, V344, P900, DOI 10.1016/j.bbrc.2006.04.013; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200; Marchesini N, 2004, BIOCHEM CELL BIOL, V82, P27, DOI 10.1139/o03-091; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; Miura GI, 2006, CELL CYCLE, V5, P1184, DOI 10.4161/cc.5.11.2804; Nagata Y, 2006, J CELL BIOL, V174, P245, DOI 10.1083/jcb.200605028; Okamoto Y, 2003, BIOCHEMISTRY-US, V42, P7855, DOI 10.1021/bi0341354; Openshaw AEA, 2005, J BIOL CHEM, V280, P35011, DOI 10.1074/jbc.M506800200; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Rodrigues-Lima F, 2000, J BIOL CHEM, V275, P28316; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smotrys JE, 2004, ANNU REV BIOCHEM, V73, P559, DOI 10.1146/annurev.biochem.73.011303.073954; Staub O, 2006, PHYSIOL REV, V86, P669, DOI 10.1152/physrev.00020.2005; Stoffel W, 2005, P NATL ACAD SCI USA, V102, P4554, DOI 10.1073/pnas.0406380102; TAMURA H, 1995, BIOCHEM J, V309, P757, DOI 10.1042/bj3090757; Tani M, 2004, J BIOL CHEM, V279, P29351, DOI 10.1074/jbc.M404012200; Tani M, 2007, CELL SIGNAL, V19, P229, DOI 10.1016/j.cellsig.2006.07.001; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Valdez-Taubas J, 2005, EMBO J, V24, P2524, DOI 10.1038/sj.emboj.7600724; Van Itallie CM, 2005, J CELL SCI, V118, P1427, DOI 10.1242/jcs.01735; VENIEN C, 1988, BIOCHIM BIOPHYS ACTA, V942, P159, DOI 10.1016/0005-2736(88)90285-4; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Zhang P, 1997, J BIOL CHEM, V272, P9609; Zumbansen M, 2002, MOL CELL BIOL, V22, P3633, DOI 10.1128/MCB.22.11.3633-3638.2002	45	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					10047	10056		10.1074/jbc.M611249200	http://dx.doi.org/10.1074/jbc.M611249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272284	hybrid			2022-12-25	WOS:000245421700079
J	Tarze, A; Dauplais, M; Grigoras, I; Lazard, M; Ha-Duong, NT; Barbier, F; Blanquet, S; Plateau, P				Tarze, Agathe; Dauplais, Marc; Grigoras, Ioana; Lazard, Myriam; Ha-Duong, Nguyet-Thanh; Barbier, Frederique; Blanquet, Sylvain; Plateau, Pierre			Extracellular production of hydrogen selenide accounts for thiol-assisted toxicity of selenite against Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GROWTH-INHIBITION; BRUSH-BORDER MEMBRANE; ESCHERICHIA-COLI; SODIUM SELENITE; SUPEROXIDE-DISMUTASE; SMALL-INTESTINE; D-CYSTEINE; GLUTATHIONE; CELLS; MECHANISM	Administration of selenium in humans has anticarcinogenic effects. However, the boundary between cancer-protecting and toxic levels of selenium is extremely narrow. The mechanisms of selenium toxicity need to be fully understood. In Saccharomyces cerevisiae, selenite in the millimolar range is well tolerated by cells. Here we show that the lethal dose of selenite is reduced to the micromolar range by the presence of thiols in the growth medium. Glutathione and selenite spontaneously react to produce several selenium-containing compounds (selenodiglutathione, glutathioselenol, hydrogen selenide, and elemental selenium) as well as reactive oxygen species. We studied which compounds in the reaction pathway between glutathione and sodium selenite are responsible for this toxicity. Involvement of selenodiglutathione, elemental selenium, or reactive oxygen species could be ruled out. In contrast, extracellular formation of hydrogen selenide can fully explain the exacerbation of selenite toxicity by thiols. Indeed, direct production of hydrogen selenide with D-cysteine desulfhydrase induces high mortality. Selenium uptake by S. cerevisiae is considerably enhanced in the presence of external thiols, most likely through internalization of hydrogen selenide. Finally, we discuss the possibility that selenium exerts its toxicity through consumption of intracellular reduced glutathione, thus leading to severe oxidative stress.	Ecole Polytech, Dept Biol, CNRS, UMR 7654,Lab Biochim, F-91128 Palaiseau, France; CNRS, Serv Cent Anal, USR 59, F-69390 Vernaison, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS)	Plateau, P (corresponding author), Ecole Polytech, Dept Biol, CNRS, UMR 7654,Lab Biochim, F-91128 Palaiseau, France.	plateau@bioc.polytechnique.fr	Grigoras, Ioana/G-4426-2011; Ha-Duong, Nguyet-Thanh/N-5907-2018; Tarze, Agathe/R-4379-2018	Grigoras, Ioana/0000-0003-2547-8935; Lazard, Myriam/0000-0002-7154-1352; Tarze, Agathe/0000-0001-6101-069X; Bessueille, Frederique/0000-0002-3786-6225				ANJARIA KB, 1988, MUTAT RES, V204, P605, DOI 10.1016/0165-1218(88)90063-8; ANUNDI I, 1984, ACTA PHARMACOL TOX, V54, P273; Bansal M. P., 2002, Journal of Medicinal Food, V5, P85, DOI 10.1089/109662002760178168; Bansal MP, 1999, BIOL TRACE ELEM RES, V70, P21, DOI 10.1007/BF02783846; BATIST G, 1986, CANCER RES, V46, P5482; Bebien M, 2002, J BACTERIOL, V184, P1556, DOI 10.1128/JB.184.6.1556-1564.2002; Bendich A, 2001, DIETARY REFERENCE IN, DOI [10.1016/s0899-9007(00)00596-7, DOI 10.1016/S0899-9007(00)00596-7]; BERGMEYER HU, 1955, BIOCHEM Z, V327, P255; BJORNSTEDT M, 1995, METHOD ENZYMOL, V252, P209; Bjornstedt M, 1996, BIOCHEMISTRY-US, V35, P8511, DOI 10.1021/bi9528762; Bronzetti G, 2001, MUTAT RES-GEN TOX EN, V496, P105, DOI 10.1016/S1383-5718(01)00213-3; BYARD JL, 1969, ARCH BIOCHEM BIOPHYS, V130, P556, DOI 10.1016/0003-9861(69)90070-8; CAFFREY PB, 1991, MOL PHARMACOL, V39, P281; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Combs GF, 1998, PHARMACOL THERAPEUT, V79, P179, DOI 10.1016/S0163-7258(98)00014-X; COSTE H, 1987, J BIOL CHEM, V262, P12096; de Leon CAP, 2002, J APPL MICROBIOL, V92, P602, DOI 10.1046/j.1365-2672.2002.01562.x; DELAMOTTEGUERY F, 1991, EUR J BIOCHEM, V196, P287; Diwadkar-Navsariwala V, 2004, J NUTR, V134, P2899, DOI 10.1093/jn/134.11.2899; Diwadkar-Navsariwala V, 2006, P NATL ACAD SCI USA, V103, P8179, DOI 10.1073/pnas.0508218103; DUDLEY H. C., 1941, Journal of Industrial Hygiene and Toxicology, V23, P470; Eghbal MA, 2004, TOXICOLOGY, V203, P69, DOI 10.1016/j.tox.2004.05.020; FALCONE G, 1963, J BACTERIOL, V85, P754, DOI 10.1128/JB.85.4.754-762.1963; GANTHER HE, 1971, BIOCHEMISTRY-US, V10, P4089, DOI 10.1021/bi00798a013; GANTHER HE, 1968, BIOCHEMISTRY-US, V7, P2898, DOI 10.1021/bi00848a029; GANTHER HE, 1987, J AM COLL TOXICOL, V5, P1; Gharieb MM, 2004, MYCOL RES, V108, P1415, DOI 10.1017/S0953756204001418; Gharieb MM, 2004, BIOMETALS, V17, P183, DOI 10.1023/B:BIOM.0000018402.22057.62; HIREL PH, 1988, BIOCHIMIE, V70, P773, DOI 10.1016/0300-9084(88)90107-1; HSIEH HS, 1977, BIOCHIM BIOPHYS ACTA, V497, P205; Imura N., 1989, SE BIOL MED, P70, DOI [10.1007/978-3-642-74421-1_14, DOI 10.1007/978-3-642-74421-1_14]; IVES DJG, 1948, J CHEM SOC, P766, DOI 10.1039/jr9480000766; JAMIESON DJ, 1992, J BACTERIOL, V174, P6678, DOI 10.1128/JB.174.20.6678-6681.1992; JIANG XR, 1992, LEUKEMIA RES, V16, P347, DOI 10.1016/0145-2126(92)90136-U; Kessi J, 2004, J BIOL CHEM, V279, P50662, DOI 10.1074/jbc.M405887200; KICE JL, 1980, J AM CHEM SOC, V102, P4448, DOI 10.1021/ja00533a025; Kim TS, 2003, BIOCHEM PHARMACOL, V66, P2301, DOI 10.1016/j.bcp.2003.08.021; KITAHARA J, 1993, ARCH TOXICOL, V67, P497, DOI 10.1007/BF01969921; Kobayashi Y, 2001, J CHROMATOGR B, V760, P73, DOI 10.1016/S0378-4347(01)00252-3; KRAMER GF, 1988, MUTAT RES, V201, P169, DOI 10.1016/0027-5107(88)90123-6; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; KUCHAN MJ, 1991, CANCER LETT, V57, P181, DOI 10.1016/0304-3835(91)90213-2; KUCHAN MJ, 1992, CANCER RES, V52, P1091; Leblondel G, 2001, BIOL TRACE ELEM RES, V83, P191, DOI 10.1385/BTER:83:3:191; LIN Y, 1993, BIOCHEM PHARMACOL, V45, P429, DOI 10.1016/0006-2952(93)90080-G; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469; MCCONNELL KP, 1952, J BIOL CHEM, V195, P277; Mihara H, 2000, J BIOL CHEM, V275, P6195, DOI 10.1074/jbc.275.9.6195; MYKKANEN HM, 1990, J NUTR, V120, P882, DOI 10.1093/jn/120.8.882; NAGASAWA T, 1985, EUR J BIOCHEM, V153, P541, DOI 10.1111/j.1432-1033.1985.tb09335.x; Ogra Y, 2002, J CHROMATOGR B, V767, P301, DOI 10.1016/S1570-0232(01)00581-5; ONEIL MJ, 2001, MERCK INDEX ENCY CHE, P1512; Painter EP, 1941, CHEM REV, V28, P179, DOI 10.1021/cr60090a001; Park YC, 2004, BIOL TRACE ELEM RES, V98, P143, DOI 10.1385/BTER:98:2:143; Pinson B, 2000, MOL MICROBIOL, V36, P679, DOI 10.1046/j.1365-2958.2000.01890.x; PITTMAN RW, 1949, J CHEM SOC, P1811, DOI 10.1039/jr9490001811; Rayman MP, 2004, BRIT J NUTR, V92, P557, DOI 10.1079/BJN20041251; Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9; ROSIN MP, 1981, CANCER LETT, V13, P7, DOI 10.1016/0304-3835(81)90080-X; Schrauzer Gerhard Norbert, 2003, Adv Food Nutr Res, V47, P73, DOI 10.1016/S1043-4526(03)47002-2; Seko Y, 1997, BIOMED ENVIRON SCI, V10, P333; Seo YR, 2002, ONCOGENE, V21, P3663, DOI 10.1038/sj.onc.1205468; SHAMBERGER RJ, 1969, CAN MED ASSOC J, V100, P682; Shen HM, 2000, FREE RADICAL BIO MED, V28, P1115, DOI 10.1016/S0891-5849(00)00206-9; Shen HM, 2001, FREE RADICAL BIO MED, V30, P9, DOI 10.1016/S0891-5849(00)00421-4; SLONIMSKI PP, 1949, ANN I PASTEUR PARIS, V76, P510; Soutourina J, 2001, J BIOL CHEM, V276, P40864, DOI 10.1074/jbc.M102375200; SPALLHOLZ JE, 1994, FREE RADICAL BIO MED, V17, P45, DOI 10.1016/0891-5849(94)90007-8; Sutherland MW, 1997, FREE RADICAL RES, V27, P283, DOI 10.3109/10715769709065766; Suzuki KT, 2006, TOXICOL APPL PHARM, V217, P43, DOI 10.1016/j.taap.2006.07.006; WHITING RF, 1980, MUTAT RES, V78, P159, DOI 10.1016/0165-1218(80)90095-6; WOLFFRAM S, 1989, J NUTR, V119, P706, DOI 10.1093/jn/119.5.706; YU SY, 1985, BIOL TRACE ELEM RES, V7, P21, DOI 10.1007/BF02916544; Zuo L, 2004, ANN HEMATOL, V83, P751, DOI 10.1007/s00277-004-0920-5	74	99	105	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8759	8767		10.1074/jbc.M610078200	http://dx.doi.org/10.1074/jbc.M610078200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17261587	hybrid			2022-12-25	WOS:000245780300022
J	Le Foll, B; Wertheim, C; Goldberg, SR				Le Foll, Bernard; Wertheim, Carrie; Goldberg, Steven R.			High Reinforcing Efficacy of Nicotine in Non-Human Primates	PLOS ONE			English	Article							CONDITIONED PLACE PREFERENCES; PROGRESSIVE RATIO SCHEDULE; ADMINISTER PURE NICOTINE; DOPAMINE D-3 RECEPTOR; MONOAMINE-OXIDASE; INTRAVENOUS NICOTINE; DRAMATICALLY INCREASES; FIXED-RATIO; BEHAVIOR; DRUG	Although tobacco appears highly addictive in humans, there has been persistent controversy about the ability of its psychoactive ingredient nicotine to induce self-administration behavior in laboratory animals, bringing into question nicotine's role in reinforcing tobacco smoking. Because of ethical difficulties in inducing nicotine dependence in naive human subjects, we explored reinforcing effects of nicotine in experimentally-naive non-human primates given access to nicotine for periods of time up to two years. Five squirrel monkeys with no experimental history were allowed to intravenously self-administer nicotine by pressing one of two levers. The number of presses on the active lever needed to obtain each injection was fixed (fixed-ratio schedule) or increased progressively with successive injections during the session (progressive-ratio schedule), allowing evaluation of both reinforcing and motivational effects of nicotine under conditions of increasing response cost. Over time, a progressive shift toward high rates of responding on the active lever, but not the inactive lever, developed. The monkeys' behavior was clearly directed toward nicotine self-administration, rather than presentation of environmental stimuli associated with nicotine injection. Both schedules of reinforcement revealed a high motivation to self-administer nicotine, with monkeys continuing to press the lever when up to 600 lever-presses were needed for each injection of nicotine. Thus, nicotine, by itself, in the absence of behavioral or drug-exposure history, is a robust and highly effective reinforcer of drug-taking behavior in a non-human primate model predictive of human behavior. This supports the use of nicotinic ligands for the treatment of smokers, and this novel preclinical model offers opportunities to test future medications for the treatment of nicotine dependence.	[Le Foll, Bernard; Wertheim, Carrie; Goldberg, Steven R.] NIDA, Preclin Pharmacol Sect, NIH, Dept Hlth & Human Serv, Baltimore, MD 20892 USA; [Le Foll, Bernard] Ctr Addict & Mental Hlth, Translat Addict Res Lab, Toronto, ON, Canada; [Le Foll, Bernard] Univ Toronto, Toronto, ON, Canada	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA); University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto	Le Foll, B (corresponding author), NIDA, Preclin Pharmacol Sect, NIH, Dept Hlth & Human Serv, Baltimore, MD 20892 USA.	bernard_lefoll@camh.net	Le Foll, Bernard/K-2952-2014	Le Foll, Bernard/0000-0002-6406-4973	Intramural Research Program of the National Institute on Drug Abuse; National Institutes of Health; Department of Health and Human Services; NATIONAL INSTITUTE ON DRUG ABUSE [ZIFDA000001, Z02DA000001, Z01DA000001, ZIADA000001] Funding Source: NIH RePORTER	Intramural Research Program of the National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Health and Human Services; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was supported by the Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services.	Agatsuma S, 2006, HUM MOL GENET, V15, P2721, DOI 10.1093/hmg/ddl206; ATOR NA, 1983, PHARMACOL BIOCHEM BE, V19, P993, DOI 10.1016/0091-3057(83)90406-9; BELLUZZI JD, 2004, NEUROPSYCHOPHARMACOL; Bruijnzeel AW, 2003, SYNAPSE, V50, P20, DOI 10.1002/syn.10242; Caggiula AR, 2001, PHARMACOL BIOCHEM BE, V70, P515, DOI 10.1016/S0091-3057(01)00676-1; Caggiula AR, 2002, PHYSIOL BEHAV, V77, P683, DOI 10.1016/S0031-9384(02)00918-6; Cohen C, 2005, NEUROPSYCHOPHARMACOL, V30, P145, DOI 10.1038/sj.npp.1300541; Corrigall W A, 1999, Nicotine Tob Res, V1, P11, DOI 10.1080/14622299050011121; Dar R, 2004, PSYCHOPHARMACOLOGY, V173, P18, DOI 10.1007/s00213-004-1781-2; Dar R, 2002, ADDICT RES THEORY, V10, P545, DOI 10.1080/1606635021000041753; DELAGARZA R, 1987, DRUG ALCOHOL DEPEN, V19, P17, DOI 10.1016/0376-8716(87)90083-4; DENEAU GA, 1967, ANN NY ACAD SCI, V142, P277, DOI 10.1111/j.1749-6632.1967.tb13730.x; Donny EC, 1999, PSYCHOPHARMACOLOGY, V147, P135, DOI 10.1007/s002130051153; Donny EC, 2003, PSYCHOPHARMACOLOGY, V169, P68, DOI 10.1007/s00213-003-1473-3; Donny EC, 2000, PSYCHOPHARMACOLOGY, V151, P392, DOI 10.1007/s002130000497; Fowler JS, 1996, NATURE, V379, P733, DOI 10.1038/379733a0; Fowler JS, 1996, P NATL ACAD SCI USA, V93, P14065, DOI 10.1073/pnas.93.24.14065; Garrett BE, 2001, J PHARMACOL EXP THER, V296, P486; GLOWA JR, 1983, SCIENCE, V220, P333; GOLDBERG SR, 1973, J PHARMACOL EXP THER, V186, P18; GOLDBERG SR, 1981, SCIENCE, V214, P573; GOLDBERG SR, 1983, PHARMACOL BIOCHEM BE, V19, P1011, DOI 10.1016/0091-3057(83)90408-2; GOLDBERG SR, 2005, PSYCHOPHARMACOLOGY B; Goldstein MG, 2000, CLIN PRACTICE GUIDEL; Griffiths R, 1979, ADV BEHAV PHARMACOL, V2, P163; Grigson PS, 1997, BEHAV NEUROSCI, V111, P129, DOI 10.1037/0735-7044.111.1.129; Guillem K, 2005, J NEUROSCI, V25, P8593, DOI 10.1523/JNEUROSCI.2139-05.2005; Harvey DM, 2004, PSYCHOPHARMACOLOGY, V175, P134, DOI 10.1007/s00213-004-1818-6; HENNINGFIELD JE, 1985, J PHARMACOL EXP THER, V234, P1; HENNINGFIELD JE, 1983, PHARMACOL BIOCHEM BE, V19, P1021, DOI 10.1016/0091-3057(83)90409-4; Hill R. T., 1970, AMPHETAMINE RELATED, P781; Justinova Z, 2003, PSYCHOPHARMACOLOGY, V169, P135, DOI 10.1007/s00213-003-1484-0; Laviolette SR, 2003, MOL PSYCHIATR, V8, P50, DOI 10.1038/sj.mp.4001197; Le Foll B, 2006, BEHAV PHARMACOL, V17, P195; Le Foll B, 2005, TRENDS PHARMACOL SCI, V26, P287, DOI 10.1016/j.tips.2005.04.005; Le Foll B, 2005, J PHARMACOL EXP THER, V312, P875, DOI 10.1124/jpet.104.077974; Le Foll B, 2005, NEUROPSYCHOPHARMACOL, V30, P720, DOI 10.1038/sj.npp.1300622; Le Foll B, 2005, PSYCHOPHARMACOLOGY, V178, P481, DOI 10.1007/s00213-004-2021-5; Le Foll B, 2006, PSYCHOPHARMACOLOGY, V184, P367, DOI 10.1007/s00213-005-0155-8; Le Foll B, 2005, NEUROPHARMACOLOGY, V49, P525, DOI 10.1016/j.neuropharm.2005.04.022; Le Foll B, 2004, NEUROREPORT, V15, P2139, DOI 10.1097/00001756-200409150-00028; Manzardo AM, 2002, BRAIN RES, V924, P10, DOI 10.1016/S0006-8993(01)03215-2; Markou A, 2004, ANN NY ACAD SCI, V1025, P491, DOI 10.1196/annals.1316.061; Olausson P, 2004, PSYCHOPHARMACOLOGY, V171, P173, DOI 10.1007/s00213-003-1575-y; Olausson P, 2003, NEUROPSYCHOPHARMACOL, V28, P1264, DOI 10.1038/sj.npp.1300173; Paterson NE, 2004, PSYCHOPHARMACOLOGY, V172, P179, DOI 10.1007/s00213-003-1637-1; Perkins KA, 2004, PSYCHOPHARMACOLOGY, V175, P256, DOI 10.1007/s00213-004-1930-7; ROBERTS DCS, 1993, PSYCHOPHARMACOLOGY, V111, P215, DOI 10.1007/BF02245526; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P397, DOI 10.1007/BF02247412; Samaha AN, 2005, TRENDS PHARMACOL SCI, V26, P82, DOI 10.1016/j.tips.2004.12.007; SANNERUD CA, 1994, EUR J PHARMACOL, V271, P461, DOI 10.1016/0014-2999(94)90807-9; SLIFER BL, 1985, PHARMACOL BIOCHEM BE, V22, P61, DOI 10.1016/0091-3057(85)90487-3; Soria R, 1996, PSYCHOPHARMACOLOGY, V128, P221, DOI 10.1007/s002130050129; SPEALMAN RD, 1982, J PHARMACOL EXP THER, V223, P402; SPEAR DJ, 1991, PHARMACOL BIOCHEM BE, V38, P411, DOI 10.1016/0091-3057(91)90300-Q; STOLERMAN IP, 1991, TRENDS PHARMACOL SCI, V12, P467, DOI 10.1016/0165-6147(91)90638-9; Tanda G, 2000, NAT NEUROSCI, V3, P1073, DOI 10.1038/80577; Villegier AS, 2006, NEUROPSYCHOPHARMACOL, V31, P1704, DOI 10.1038/sj.npp.1300987; Wakasa Yoshio, 1995, Japanese Journal of Psychopharmacology, V15, P53; WEST R, 1992, PSYCHOPHARMACOLOGY, V108, P408, DOI 10.1007/BF02247413; YANAGITA T, 1977, PREDICTING DEPENDENC, P231	61	55	55	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e230	10.1371/journal.pone.0000230	http://dx.doi.org/10.1371/journal.pone.0000230			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311094	gold, Green Submitted, Green Published			2022-12-25	WOS:000207444500011
J	Qian, J; Steigerwald, K; Combs, KA; CBarton, M; Groden, J				Qian, J.; Steigerwald, K.; Combs, K. A.; CBarton, M.; Groden, J.			Caspase cleavage of the APC tumor suppressor and release of an amino-terminal domain is required for the transcription-independent function of APC in apoptosis	ONCOGENE			English	Article						APC; apoptosis; transcription; independent-caspase; colon cancer	ADENOMATOUS POLYPOSIS; PROTEIN	The adenomatous polyposis coli (APC) tumor suppressor is inactivated by mutation in most colorectal tumors. APC is a component of the Wnt signaling pathway and is best known for its ability to downregulate beta-catenin and consequent effects on transcriptional regulation. Previous work demonstrated that APC accelerates apoptosis-associated caspase activity independently of transcription, and suggested novel tumor suppressor functions of APC. In this work, we have mapped the APC apoptosis-accelerating region to amino acids (aa) 1-760 by testing a series of nonoverlapping APC segments. Interestingly, this segment corresponds to a stable group II caspase cleavage product of APC released during apoptosis that includes the aminoterminal aa1-777. Mutation of the APC aspartic acid residue at position 777 to an alanine completely abolished in vitro cleavage of APC by a recombinant group II caspase and rendered the full-length protein unable to accelerate apoptosis in vitro. A truncated APC protein associated with familial and sporadic colorectal cancer, also unable to accelerate apoptosis in vitro and in vivo, is resistant to group II caspase cleavage. These results demonstrate that cleavage of APC and the subsequent release of an aminoterminal segment are necessary for the transcriptionindependent mechanism of APC-mediated apoptosis.	Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University System of Ohio; Ohio State University; University System of Ohio; University of Cincinnati; University of Texas System; UTMD Anderson Cancer Center	Groden, J (corresponding author), Ohio State Univ, Coll Med, Dept Mol Virol Immunol & Med Genet, 400 W 12th St, Columbus, OH 43210 USA.	joanna.groden@osumc.edu	Zhang, Spring/K-2787-2013	Barton, Michelle/0000-0002-4042-1374	NATIONAL CANCER INSTITUTE [R15CA063517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053683] Funding Source: NIH RePORTER; NCI NIH HHS [CA 63517] Funding Source: Medline; NIGMS NIH HHS [R01 GM053683, R01 GM053683-07A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; Browne SJ, 1998, CELL DEATH DIFFER, V5, P206, DOI 10.1038/sj.cdd.4400331; FASSCHON DM, 1997, J CELL BIOL, V137, P1117; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; GRODEN J, 1993, AM J HUM GENET, V52, P263; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lillard-Wetherell K, 2004, HUM MOL GENET, V13, P1919, DOI 10.1093/hmg/ddh193; NEWMEYER DD, 1994, CELL, V79, P453; Steigerwald K, 2005, MOL CANCER RES, V3, P78, DOI 10.1158/1541-7786.MCR-03-0189; Webb SJ, 1999, FASEB J, V13, P339, DOI 10.1096/fasebj.13.2.339	11	17	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4872	4876		10.1038/sj.onc.1210265	http://dx.doi.org/10.1038/sj.onc.1210265			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297457				2022-12-25	WOS:000248170400012
J	Hausherr, A; Tavares, R; Schaffer, M; Obermeier, A; Miksch, C; Mitina, O; Ellwart, J; Hallek, M; Krause, G				Hausherr, A.; Tavares, R.; Schaeffer, M.; Obermeier, A.; Miksch, C.; Mitina, O.; Ellwart, J.; Hallek, M.; Krause, G.			Inhibition of IL-6-dependent growth of myeloma cells by an acidic peptide repressing the gp130-mediated activation of Src family kinases	ONCOGENE			English	Article						myeloma; interleukin-6 signalling; gp130; membrane-permeant peptide; Src family kinases	MULTIPLE-MYELOMA; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; BCR-ABL; IN-VIVO; PROTEIN; RECEPTOR; HCK; INTERLEUKIN-6; SURVIVAL	An acidic domain (AD) of gp130 was previously found to interact with the Src family kinase (SFK) Hck. Here, the in. uence of myristoylated peptides derived from this AD was assessed in the mouse myeloma cell line, 7TD1. The IL-6-dependent growth of 7TD1 c ells was reduced by similar to 75%, if 100 mu M of myristoylated 18mer peptide (18AD) was included in the growth medium, but was unaffected by a control peptide with scrambled sequence (18sc). A similar differential inhibition by peptides 18AD and 18sc was observed for the erythropoietin-dependent growth of BaF-EH cells expressing chimeric erythropoietin receptor-gp130 and human Hck and for the human myeloma cell line INA-6. While the peptide 18AD concentration inhibiting 50% was similar to 30 mu M in 7TD1 and BaF-EH cells, peptide 18AD did not signifi. cantly inhibit growth of IL-6-independent MM1. S myeloma and OKT1 hybridoma cells or of BaF-EH cells supplied with IL-3. Treatment with 100 mu M peptide 18AD caused the same degree or 60% of apoptosis induction as IL-6 deprivation in 7TD1 or INA-6 cells, respectively. Co-immunoprecipitation experiments revealed that peptide 18AD interfered with the association of Hck and gp130 in 7TD1 lysates in a concentration-dependent manner. IL-6-treatment of INA-6 cells induced the kinase activities of Fyn, Lyn and Hck, but not Src, and the IL-6-induced SFK activities were inhibited by peptide 18AD. Expression in 7TD1 cells of a kinase-inactive Hck mutant (K269R) elicited a dominant-negative effect on cell number increases providing further evidence that SFKs are required for gp130 signalling in myeloma cells.	Univ Hosp Cologne, Clin Internal Med 1, D-50923 Cologne, Germany; GSF, Natl Res Ctr Environm & Hlth, Clin Cooperat Grp Gene Therapy, Munich, Germany; GRELUX GmbH, Martinsried, Germany; SIREEN AG, Martinsried, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Munich, Germany	University of Cologne; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Krause, G (corresponding author), Univ Hosp Cologne, Clin Internal Med 1, Kerpener Str 62, D-50923 Cologne, Germany.	guenter.krause@uk-koeln.de	Hallek, Michael/Y-3191-2019; Krause, Günter/A-1858-2012	Hallek, Michael/0000-0002-7425-4455; Krause, Günter/0000-0003-3905-0921				Adachi T, 1999, J IMMUNOL, V162, P1496; Adachi T, 1999, J IMMUNOL, V163, P939; Ancey C, 2003, J BIOL CHEM, V278, P16968, DOI 10.1074/jbc.C300081200; Boehning D, 2005, P NATL ACAD SCI USA, V102, P1466, DOI 10.1073/pnas.0409650102; Brocke-Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood-2003-04-1048; Burger R, 2001, Hematol J, V2, P42, DOI 10.1038/sj.thj.6200075; Chatterjee M, 2002, BLOOD, V100, P3311, DOI 10.1182/blood-2002-01-0102; Contri A, 2005, J CLIN INVEST, V115, P369, DOI 10.1172/JC1200522094; Cote S, 2002, CYTOKINE, V20, P113, DOI 10.1006/cyto.2002.1988; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; Dasgupta P, 2000, LIFE SCI, V66, P1557, DOI 10.1016/S0024-3205(00)00476-8; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; French JD, 2000, ACTA ONCOL, V39, P777; Georgii-Hemming P, 1999, BLOOD, V93, P1724, DOI 10.1182/blood.V93.5.1724.405k21_1724_1731; Greenstein S, 2003, EXP HEMATOL, V31, P271, DOI 10.1016/S0301-472X(03)00023-7; Hallek M, 1997, EXP HEMATOL, V25, P1367; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ishihara K, 2002, CYTOKINE GROWTH F R, V13, P357, DOI 10.1016/S1359-6101(02)00027-8; Kardinal C, 2000, FASEB J, V14, P1529, DOI 10.1096/fj.14.11.1529; Kelemen BR, 2002, J BIOL CHEM, V277, P8741, DOI 10.1074/jbc.M108459200; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Laszlo GS, 2003, J BIOL CHEM, V278, P27750, DOI 10.1074/jbc.M303670200; Manfredini R, 2003, PEPTIDES, V24, P1207, DOI 10.1016/j.peptides.2003.06.005; Neumann C, 1996, EUR J IMMUNOL, V26, P379, DOI 10.1002/eji.1830260217; Niv MY, 2004, J BIOL CHEM, V279, P1242, DOI 10.1074/jbc.M306723200; Ogata A, 1997, J IMMUNOL, V159, P2212; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Podar K, 2004, J BIOL CHEM, V279, P21658, DOI 10.1074/jbc.M305783200; Podar K, 2003, J BIOL CHEM, V278, P5794, DOI 10.1074/jbc.M208636200; Posern G, 1998, ONCOGENE, V16, P1903, DOI 10.1038/sj.onc.1201714; Schaeffer M, 2001, MOL CELL BIOL, V21, P8068, DOI 10.1128/MCB.21.23.8068-8081.2001; Schulze WX, 2004, J BIOL CHEM, V279, P10756, DOI 10.1074/jbc.M309909200; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Trikha M, 2003, CLIN CANCER RES, V9, P4653; Warmuth M, 2003, BLOOD, V101, P664, DOI 10.1182/blood-2002-01-0288; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260	44	20	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	34					4987	4998		10.1038/sj.onc.1210306	http://dx.doi.org/10.1038/sj.onc.1210306			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310994				2022-12-25	WOS:000248322500011
J	Narla, G; Kremer-Tal, S; Matsumoto, N; Zhao, X; Yao, S; Kelley, K; Tarocchi, M; Friedman, SL				Narla, G.; Kremer-Tal, S.; Matsumoto, N.; Zhao, X.; Yao, S.; Kelley, K.; Tarocchi, M.; Friedman, S. L.			In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma	ONCOGENE			English	Article						KLF6; Kruppel-like factor; tumor-suppressor gene; p21; haploinsufficiency	KRUPPEL-LIKE FACTOR-6; TRANSCRIPTION FACTOR KLF6; CELL LUNG-CANCER; PROSTATE-CANCER; EXPRESSION; PROGRESSION; ACTIVATION; HAPLOINSUFFICIENCY; INHIBITOR; PROMOTER	Kruppel-like factor (KLF) 6 is a tumor-suppressor gene functionally inactivated by loss of heterozygosity, somatic mutation and/or alternative splicing that generates a dominant-negative splice form, KLF6-SV1. Wild-type KLF6 (wtKLF6) expression is decreased in many human malignancies, which correlates with reduced patient survival. Additionally, loss of the KLF6 locus in the absence of somatic mutation in the remaining allele occurs in a number of human cancers, raising the possibility that haploinsuffi. ciency of the KLF6 gene alone contributes to cellular growth dysregulation and tumorigenesis. Our earlier studies identified the cyclin-dependent kinase inhibitor p21 as a transcriptional target of the KLF6 gene in cultured cells, but not in vivo. To address this issue, we have generated two genetic mouse models to de. ne the in vivo role of KLF6 in regulating cell proliferation and p21 expression. Transgenic overexpression of KLF6 in the liver resulted in a runted phenotype with decreased body and liver size, with evidence of decreased hepatocyte proliferation, increased p21 and reduced proliferating cell nuclear antigen expression. In contrast, mice with targeted deletion of one KLF6 allele (KLF6+/-) display increased liver mass with reduced p21 expression, compared to wild type littermates. Moreover, in primary hepatocellular carcinoma samples, there is a significant correlation between wtKLF6 and p21 mRNA expression. Combined, these data suggest that haploinsuffi. ciency of the KLF6 gene may regulate cellular proliferation in vivo through decreased transcriptional activation of the cyclin- dependent kinase inhibitor p21.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Div Liver Dis, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Div Hematol Oncol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Friedman, SL (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Box 1123,1425 Madison Ave,Room 11-70, New York, NY 10029 USA.	scott.friedman@mssm.edu	Narla, Goutham/AAZ-5710-2020	Narla, Goutham/0000-0003-4098-4203; TAROCCHI, MIRKO/0000-0002-7767-5116	NIDDK NIH HHS [DK37340] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberici P, 2006, ONCOGENE, V25, P1841, DOI 10.1038/sj.onc.1209226; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Boyault S, 2005, HEPATOLOGY, V41, P681, DOI 10.1002/hep.20588; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen Han-kui, 2002, Ai Zheng, V21, P1047; Cho YG, 2005, ONCOGENE, V24, P4588, DOI 10.1038/sj.onc.1208670; Difeo A, 2006, ONCOGENE, V25, P6026, DOI 10.1038/sj.onc.1209611; Difeo A, 2006, CLIN CANCER RES, V12, P3730, DOI 10.1158/1078-0432.CCR-06-0054; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; KREMERTAL S, 2006, J HEPATOL       1127; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; MATSUMOTO N, 2006, HEPATOLOGY, V107, P1357; Narla G, 2005, CANCER RES, V65, P1213, DOI 10.1158/0008-5472.CAN-04-4249; Narla G, 2003, AM J PATHOL, V162, P1047, DOI 10.1016/S0002-9440(10)63901-6; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Pan Xiu-cheng, 2006, J Zhejiang Univ Sci B, V7, P830, DOI 10.1631/jzus.2006.B0830; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Slavin DA, 2004, ONCOGENE, V23, P8196, DOI 10.1038/sj.onc.1208020; Song J, 2006, J GASTROEN HEPATOL, V21, P1286, DOI 10.1111/j.1440-1746.2006.04445.x; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Walthall K, 2005, BIRTH DEFECTS RES B, V74, P132, DOI 10.1002/bdrb.20040; Wang Shao-ping, 2004, Zhonghua Wai Ke Za Zhi, V42, P1258; Warke VG, 2003, J BIOL CHEM, V278, P14812, DOI 10.1074/jbc.M300787200; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245	36	64	71	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4428	4434		10.1038/sj.onc.1210223	http://dx.doi.org/10.1038/sj.onc.1210223			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297474				2022-12-25	WOS:000247620000010
J	Johnson, J; Albarani, V; Nguyen, M; Goldman, M; Willems, F; Aksoy, E				Johnson, Jolyn; Albarani, Valentina; Nguyen, Muriel; Goldman, Michel; Willems, Fabienne; Aksoy, Ezra			Protein kinase C alpha is involved in interferon regulatory factor 3 activation and type I interferon-beta synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; TOLL-LIKE RECEPTOR-3; NF-KAPPA-B; REGULATORY FACTOR-3; TRANSCRIPTION FACTORS; GENE-EXPRESSION; DENDRITIC CELLS; VIRUS INDUCTION; ANTIVIRAL RESPONSE; SIGNALING PATHWAY	Protein kinase C ( PKC) isoforms are critically involved in the regulation of innate immune responses. Herein, we investigated the role of conventional PKC alpha in the regulation of IFN-beta gene expression mediated by the Toll-like receptor 3 ( TLR3) signaling pathway. Inhibition of conventional PKC ( cPKC) activity in monocyte-derived dendritic cells or TLR3-expressing cells by an isoform-specific inhibitor, Go "6976, selectively inhibited IFN-beta synthesis induced by double-stranded RNA polyinosine-polycytidylic acid. Furthermore, reporter gene assays confirmed that PKC alpha regulates IFN-beta promoter activity, since overexpression of dominant negative PKC alpha but not PKC beta(I) repressed interferon regulatory factor 3 ( IRF-3)-dependent but not NF-kappa B-mediated promoter activity upon TLR3 engagement in HEK 293 cells. Dominant negative PKC alpha inhibited IRF-3 transcriptional activity mediated by overexpression of TIR domain-containing adapter inducing IFN-beta and Tank-binding kinase-1. Additional biochemical analysis demonstrated that Go "6976-treated dendritic cells exhibited IRF-3 phosphorylation, dimerization, nuclear translocation, and DNA binding activity analogous to their control counterparts in response to polyinosine-polycytidylic acid. In contrast, co-immunoprecipitation experiments revealed that TLR3-induced cPKC activity is essential for mediating the interaction of IRF-3 but not p65/RelA with the coactivator CREB-binding protein. Furthermore, PKC alpha knockdown with specific small interfering RNA inhibited IFN-beta expression and down-regulated IRF-3-dependent promoter activity, establishing PKC alpha as a component of TLR3 signaling that regulates IFN-beta gene expression by targeting IRF-3-CREB-binding protein interaction. Finally, we analyzed the involvement of cPKCs in other signaling pathways leading to IFN-beta synthesis. These experiments revealed that cPKCs play a role in the synthesis of IFN-beta induced via both TLR-dependent and -independent pathways.	Univ Libre Bruxelles, Inst Med Immunol, B-6041 Charleroi, Belgium	Universite Libre de Bruxelles	Willems, F (corresponding author), Univ Libre Bruxelles, Inst Med Immunol, 8 Rue Adrienne Bolland, B-6041 Charleroi, Belgium.	fwillems@ulb.ac.be	Aksoy, Ezra/ABH-1337-2021	Aksoy, Ezra/0000-0002-6962-1572				Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Aksoy E, 2002, EUR J IMMUNOL, V32, P3040, DOI 10.1002/1521-4141(200211)32:11<3040::AID-IMMU3040>3.0.CO;2-M; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Bach JF, 2005, NAT MED, V11, P120, DOI 10.1038/nm0205-120; Banchereau J, 2004, IMMUNITY, V20, P539, DOI 10.1016/S1074-7613(04)00108-6; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Falvo JV, 2000, MOL CELL BIOL, V20, P4814, DOI 10.1128/MCB.20.13.4814-4825.2000; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; GESSANI S, 1989, J INTERFERON RES, V9, P543, DOI 10.1089/jir.1989.9.543; Goriely S, 2001, J IMMUNOL, V166, P2141, DOI 10.4049/jimmunol.166.3.2141; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Juang YT, 1998, P NATL ACAD SCI USA, V95, P9837, DOI 10.1073/pnas.95.17.9837; Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200; Kariko K, 2004, J IMMUNOL, V172, P6545, DOI 10.4049/jimmunol.172.11.6545; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kontny E, 2000, J LEUKOCYTE BIOL, V67, P249, DOI 10.1002/jlb.67.2.249; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Lin CH, 2001, MOL CELL, V8, P581, DOI 10.1016/S1097-2765(01)00333-1; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McGettrick AF, 2006, P NATL ACAD SCI USA, V103, P9196, DOI 10.1073/pnas.0600462103; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Mochly-Rosen D, 1998, FASEB J, V12, P35; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Panne D, 2004, EMBO J, V23, P4384, DOI 10.1038/sj.emboj.7600453; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Servant MJ, 2003, J BIOL CHEM, V278, P9441, DOI 10.1074/jbc.M209851200; Servant MJ, 2001, J BIOL CHEM, V276, P355, DOI 10.1074/jbc.M007790200; Shapira L, 1997, BIOCHEM BIOPH RES CO, V240, P629, DOI 10.1006/bbrc.1997.7717; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; SHINJI H, 1994, J IMMUNOL, V153, P5760; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Spitaler M, 2004, NAT IMMUNOL, V5, P785, DOI 10.1038/ni1097; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Tan SL, 2003, BIOCHEM J, V376, P545, DOI 10.1042/BJ20031406; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; THACORE HR, 1990, J GEN VIROL, V71, P2833, DOI 10.1099/0022-1317-71-12-2833; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Theofilopoulos AN, 2005, ANNU REV IMMUNOL, V23, P307, DOI 10.1146/annurev.immunol.23.021704.115843; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yoneyama M, 1998, EMBO J, V17, P1087, DOI 10.1093/emboj/17.4.1087; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	62	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					15022	15032		10.1074/jbc.M700421200	http://dx.doi.org/10.1074/jbc.M700421200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17296604	hybrid			2022-12-25	WOS:000246589000041
J	Moseley, JB; Bartolini, F; Okada, K; Wen, Y; Gundersen, GG; Goode, BL				Moseley, James B.; Bartolini, Francesca; Okada, Kyoko; Wen, Ying; Gundersen, Gregg G.; Goode, Bruce L.			Regulated binding of adenomatous polyposis coli protein to actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; MICROTUBULES IN-VIVO; FORMIN PROTEINS; CROSS-LINKING; APC PROTEIN; EB1; ASSOCIATION; FILAMENTS; ENDS; LOCALIZATION	Adenomatous polyposis coli ( APC) protein is a large tumor suppressor that is truncated in most colorectal cancers. The carboxyl-terminal third of APC protein mediates direct interactions with microtubules and the microtubule plus-end tracking protein EB1. In addition, APC has been localized to actin-rich regions of cells, but the mechanism and functional significance of this localization have remained unclear. Here we show that purified carboxyl-terminal basic domain of human APC protein ( APC-basic) bound directly to and bundled actin filaments and associated with actin stress fibers in microinjected cells. Actin filaments and microtubules competed for binding to APC-basic, but APC-basic also could cross-link actin filaments and microtubules at specific concentrations, suggesting a possible role in cytoskeletal cross-talk. APC interactions with actin in vitro were inhibited by its ligand EB1, and co-microinjection of EB1 prevented APC association with stress fibers. Point mutations in EB1 that disrupted APC binding relieved the inhibition in vitro and restored APC localization to stress fibers in vivo, demonstrating that EB1-APC regulation is direct. Because tumor formation and metastasis involve coordinated changes in the actin and microtubule cytoskeletons, this novel function for APC and its regulation by EB1 may have direct implications	Brandeis Univ, Rosentiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA	Brandeis University; Brandeis University; Columbia University; Columbia University	Goode, BL (corresponding author), Brandeis Univ, Rosentiel Basic Med Sci Res Ctr, 415 South St, Waltham, MA 02454 USA.	goode@brandeis.edu			NIGMS NIH HHS [GM63691, R01 GM062939, GM062939] Funding Source: Medline; Telethon [GFP03006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062939, R01GM063691] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; Barth AIM, 2002, J CELL SCI, V115, P1583; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; BROWN SS, 1979, J CELL BIOL, V80, P499, DOI 10.1083/jcb.80.2.499; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Deka J, 1998, EUR J BIOCHEM, V253, P591, DOI 10.1046/j.1432-1327.1998.2530591.x; ERICKSON HP, 1976, P NATL ACAD SCI USA, V73, P2813, DOI 10.1073/pnas.73.8.2813; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; GRIFFITH LM, 1982, J BIOL CHEM, V257, P9135; JACOBS M, 1975, NATURE, V257, P707, DOI 10.1038/257707a0; Jones EW, 2002, METHOD ENZYMOL, V351, P127; Kita K, 2006, MOL BIOL CELL, V17, P2331, DOI 10.1091/mbc.E05-06-0498; Kreitzer G, 1999, MOL BIOL CELL, V10, P1105, DOI 10.1091/mbc.10.4.1105; Langford KJ, 2006, CELL MOTIL CYTOSKEL, V63, P483, DOI 10.1002/cm.20139; Langford KJ, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-3; LEE JC, 1978, BIOCHEMISTRY-US, V17, P2783, DOI 10.1021/bi00607a013; Li ZY, 2005, CANCER RES, V65, P5195, DOI 10.1158/0008-5472.CAN-04-4609; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; McCartney BM, 2006, DEVELOPMENT, V133, P2407, DOI 10.1242/dev.02398; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Mogensen MM, 2002, J CELL BIOL, V157, P1041, DOI 10.1083/jcb.200203001; Moseley JB, 2005, J BIOL CHEM, V280, P28023, DOI 10.1074/jbc.M503094200; Moseley JB, 2006, METHOD ENZYMOL, V406, P215, DOI 10.1016/S0076-6879(06)06016-2; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Oshima H, 1997, CANCER RES, V57, P1644; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Slep KC, 2005, J CELL BIOL, V168, P587, DOI 10.1083/jcb.200410114; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SU LK, 1995, CANCER RES, V55, P2972; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Wolff J, 1998, BIOCHEMISTRY-US, V37, P10722, DOI 10.1021/bi980400n; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	45	83	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12661	12668		10.1074/jbc.M610615200	http://dx.doi.org/10.1074/jbc.M610615200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17293347	hybrid			2022-12-25	WOS:000245942800035
J	Hait, NC; Bellamy, A; Milstien, S; Kordula, T; Spiegel, S				Hait, Nitai C.; Bellamy, Andrea; Milstien, Sheldon; Kordula, Tomasz; Spiegel, Sarah			Sphingosine kinase type 2 activation by ERK-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOMODULATORY DRUG FTY720; PLASMA-MEMBRANE; GROWTH-FACTOR; FUNCTIONAL-CHARACTERIZATION; DEPENDENT TRANSLOCATION; CELL-PROLIFERATION; MOLECULAR-CLONING; BINDING SITE; PROTEIN; SPHINGOSINE-1-PHOSPHATE	Sphingosine 1-phosphate ( S1P), a potent lipid mediator, is a ligand for a family of five G protein-coupled receptors ( S1P1-5) that have been shown to regulate a variety of biological responses important for cancer progression. The cellular level of S1P is low and tightly regulated in a spatio-temporal manner through its synthesis catalyzed by two sphingosine kinases, denoted SphK1 and SphK2. Many stimuli activate and translocate SphK1 to the plasma membrane by mechanisms that are dependent on its phosphorylation. Much less is known about activation of SphK2. Here we demonstrate that epidermal growth factor ( EGF) as well as the protein kinase C activator, phorbol ester, induce rapid phosphorylation of hSphK2 which was markedly reduced by inhibition of MEK1/ERK pathway. Down-regulation of ERK1 blocked EGF-induced phosphorylation of SphK2. Recombinant ERK1 phosphorylated hSphK2 in vitro and increased its enzymatic activity. ERK1 also was found to be in a complex with hSphK2 in vivo. Site-directed mutagenesis indicated that hSphK2 is phosphorylated on Ser-351 and Thr-578 by ERK1 and that phosphorylation of these residues is important for EGF-stimulated migration of MDA-MB-453 cells. These studies provide the first clues to the mechanism of agonist-mediated SphK2 activation and enhance understanding of the regulation of SphK2 activity by phosphorylation and its role in movement of human breast cancer cells toward EGF.	Virginia Commonwealth Univ, Sch Med, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Richmond, VA 23298 USA; NIMH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	Virginia Commonwealth University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem, 1101 E Marshall St,2-011 Sanger Hall,Box 980614, Richmond, VA 23298 USA.	sspiegel@vcu.edu			NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [Z01MH001039] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01CA61774] Funding Source: Medline; NIGMS NIH HHS [R37GM043880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allende ML, 2004, J BIOL CHEM, V279, P52487, DOI 10.1074/jbc.M406512200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Cyster JG, 2005, ANNU REV IMMUNOL, V23, P127, DOI 10.1146/annurev.immunol.23.021704.115628; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007; Hla T, 2005, SCIENCE, V309, P1682, DOI 10.1126/science.1118340; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kappos L, 2006, NEW ENGL J MED, V355, P1124, DOI 10.1056/NEJMoa052643; Kharel Y, 2005, J BIOL CHEM, V280, P36865, DOI 10.1074/jbc.M506293200; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kohno M, 2006, MOL CELL BIOL, V26, P7211, DOI 10.1128/MCB.02341-05; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200; Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200; Milstien S, 2006, CANCER CELL, V9, P148, DOI 10.1016/j.ccr.2006.02.025; Mizugishi K, 2005, MOL CELL BIOL, V25, P11113, DOI 10.1128/MCB.25.24.11113-11121.2005; Okada T, 2005, J BIOL CHEM, V280, P36318, DOI 10.1074/jbc.M504507200; Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Stahelin RV, 2005, J BIOL CHEM, V280, P43030, DOI 10.1074/jbc.M507574200; Sutherland CM, 2006, J BIOL CHEM, V281, P11693, DOI 10.1074/jbc.M601042200; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Tedesco-Silva H, 2005, TRANSPLANTATION, V79, P1553, DOI 10.1097/01.TP.0000121761.02129.A6; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Urtz N, 2004, MOL CELL BIOL, V24, P8765, DOI 10.1128/MCB.24.19.8765-8777.2004; Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c; Wattenberg BW, 2006, J LIPID RES, V47, P1128, DOI 10.1194/jlr.R600003-JLR200; Zemann B, 2006, BLOOD, V107, P1454, DOI 10.1182/blood-2005-07-2628	40	120	122	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12058	12065		10.1074/jbc.M609559200	http://dx.doi.org/10.1074/jbc.M609559200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17311928	hybrid			2022-12-25	WOS:000245941900048
J	Harrison, D; Hussain, SA; Combs, AC; Ervasti, JM; Yurchenco, PD; Hohenester, E				Harrison, David; Hussain, Sadaf-Ahmahni; Combs, Ariana C.; Ervasti, James M.; Yurchenco, Peter D.; Hohenester, Erhard			Crystal structure and cell surface anchorage sites of laminin alpha 1LG4-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-DYSTROGLYCAN BINDING; SULFATIDE BINDING; RECEPTOR; CHAIN; HEPARIN; MODULE; DOMAIN; REQUIREMENTS; PERLECAN	The laminin G-like ( LG) domains of laminin-111, a glycoprotein widely expressed during embryogenesis, provide cell anchoring and receptor binding sites that are involved in basement membrane assembly and cell signaling. We now report the crystal structure of the laminin alpha 1LG4-5 domains and provide a mutational analysis of heparin, alpha-dystroglycan, and galactosyl-sulfatide binding. The two domains of alpha 1LG4-5 are arranged in a V-shaped fashion similar to that observed with laminin alpha 2 LG4-5 but with a substantially different interdomain angle. Recombinant alpha 1LG4-5 binding to heparin, alpha-dystroglycan, and sulfatides was dependent upon both shared and unique contributions from basic residues distributed in several clusters on the surface of LG4. For heparin, the greatest contribution was detected from two clusters, (RKR)-R-2719 and (KRK)-K-2791. Binding to alpha-dystroglycan was particularly dependent on basic residues within (RKR)-R-2719, (2831)RAR, and (KDR)-K-2858. Binding to galactosyl-sulfatide was most affected by mutations in (2831)RAR and (2766)KGRTK but not in (RKR)-R-2719. The combined analysis of structure and activities reveal differences in LG domain interactions that should enable dissection of biological roles of different laminin ligands.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, Div Cell & Mol Biol, London SW7 2AZ, England; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	Imperial College London; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Wisconsin System; University of Wisconsin Madison	Hohenester, E (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, Div Cell & Mol Biol, Prince Consort Rd, London SW7 2AZ, England.	e.hohenester@imperial.ac.uk	Ervasti, James/AAZ-4786-2020	Yurchenco, Peter/0000-0003-0387-2317	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036425] Funding Source: NIH RePORTER; BBSRC [BB/D524840/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D524840/1, BBD5248401] Funding Source: Medline; NIDDK NIH HHS [R37-DK36425, R37 DK036425] Funding Source: Medline; Wellcome Trust [054334] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Combs AC, 2005, BIOCHEM J, V390, P303, DOI 10.1042/BJ20050375; DEUTZMANN R, 1988, EUR J BIOCHEM, V177, P35, DOI 10.1111/j.1432-1033.1988.tb14342.x; Ervasti JM, 1997, J BIOL CHEM, V272, P22315, DOI 10.1074/jbc.272.35.22315; Hohenester E, 1999, MOL CELL, V4, P783, DOI 10.1016/S1097-2765(00)80388-3; Hozumi K, 2006, J BIOL CHEM, V281, P32929, DOI 10.1074/jbc.M605708200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li S, 2002, J CELL BIOL, V157, P1279, DOI 10.1083/jcb.200203073; Li SH, 2005, J CELL BIOL, V169, P179, DOI 10.1083/jcb.200501098; McDearmon EL, 2003, J BIOL CHEM, V278, P44868, DOI 10.1074/jbc.M307026200; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; Miner JH, 2004, DEVELOPMENT, V131, P2247, DOI 10.1242/dev.01112; Sasaki T, 2002, EXP CELL RES, V275, P185, DOI 10.1006/excr.2002.5499; Scheele S, 2005, P NATL ACAD SCI USA, V102, P1502, DOI 10.1073/pnas.0405095102; Smirnov SP, 2002, J BIOL CHEM, V277, P18928, DOI 10.1074/jbc.M201880200; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Sugita S, 2001, J CELL BIOL, V154, P435, DOI 10.1083/jcb.200105003; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Tseng CN, 2003, J BIOL CHEM, V278, P17236, DOI 10.1074/jbc.M300282200; Weir ML, 2006, J CELL SCI, V119, P4047, DOI 10.1242/jcs.03103; Wizemann H, 2003, J MOL BIOL, V332, P635, DOI 10.1016/S0022-2836(03)00848-9; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; Yurchenco PD, 2004, MATRIX BIOL, V22, P521, DOI 10.1016/j.matbio.2003.10.006; Yurchenco PD, 2002, METHOD CELL BIOL, V69, P111, DOI 10.1016/S0091-679X(02)69010-7	33	53	53	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11573	11581		10.1074/jbc.M610657200	http://dx.doi.org/10.1074/jbc.M610657200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307732	Green Accepted, hybrid			2022-12-25	WOS:000245941500078
J	Heinz, K; Marx, A				Heinz, Kathrin; Marx, Andreas			Lesion bypass activity of DNA polymerase a from the extremely radioresistant organism Deinococcus radiodurans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXONUCLEASE ACTIVITY; REPLICATION; FIDELITY; RESISTANT; RADIATION; GENOME; REPAIR; SPECIFICITY; MANGANESE	The bacterium Deinococcus radiodurans survives extremely high exposure to ionizing radiation and extended periods of desiccation. Radiation at the survival doses is known to cause numerous DNA damage, such as hundreds of double strand breaks and single strand breaks, as well as damage of the nucleobases. The mechanisms of D. radiodurans to survive the depicted threats are still only beginning to be understood. DNA polymerase A (PolA) has been shown to be crucially involved in irradiation resistance mechanisms of D. radiodurans. We expressed and characterized the DNA polymerase domain of PolA for the first time in vitro. The obtained enzyme is able to efficiently catalyze DNA-dependent DNA synthesis requiring Mg(II) as divalent metal ion. Additionally, strand displacement synthesis of the DNA polymerase, which is required in several repair processes, could be detected. We further found that DNA polymerase function of PolA is modulated by the presence of Mn(II). Whereas proceeding DNA synthesis of PolA was blocked by certain DNA damage that occurs through radiation of DNA, bypass was facilitated by Mn(II). Our results suggest an enzyme modulator function of Mn(II). These observations parallel reports that D. radiodurans accumulates intracellular Mn(II) in cases of irradiation and that the level of irradiation protection correlates with Mn(II) concentrations.	Univ Konstanz, Dept Chem, Chair Organ Chem Cellular Chem, D-78457 Constance, Germany	University of Konstanz	Marx, A (corresponding author), Univ Str 10, D-78457 Constance, Germany.	andreas.marx@uni-konstanz.de						ANDERSON AW, 1956, FOOD TECHNOL-CHICAGO, V10, P575; BARNES WM, 1992, GENE, V112, P29, DOI 10.1016/0378-1119(92)90299-5; Battista JR, 1999, TRENDS MICROBIOL, V7, P362, DOI 10.1016/S0966-842X(99)01566-8; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; Blasius M, 2006, MOL MICROBIOL, V60, P165, DOI 10.1111/j.1365-2958.2006.05077.x; CHOU FI, 1990, J BACTERIOL, V172, P2029, DOI 10.1128/jb.172.4.2029-2035.1990; Cox MM, 2005, NAT REV MICROBIOL, V3, P882, DOI 10.1038/nrmicro1264; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Daly MJ, 2004, SCIENCE, V306, P1025, DOI 10.1126/science.1103185; DIAZ A, 1992, MOL MICROBIOL, V6, P3009, DOI 10.1111/j.1365-2958.1992.tb01759.x; Englander J, 2004, J BACTERIOL, V186, P5973, DOI 10.1128/jb.186.18.5973-5977.2004; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GUTMAN PD, 1993, J BACTERIOL, V175, P3581, DOI 10.1128/jb.175.11.3581-3590.1993; GUTMAN PD, 1994, MUTAT RES, V314, P87, DOI 10.1016/0921-8777(94)90064-7; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; JOYCE CM, 1984, J BACTERIOL, V158, P636, DOI 10.1128/JB.158.2.636-643.1984; Kornberg A., 1991, DNA REPLICATION; KUNKEL TA, 1979, J BIOL CHEM, V254, P5718; Lecointe F, 2004, MOL MICROBIOL, V53, P1721, DOI 10.1111/j.1365-2958.2004.04233.x; Levin-Zaidman S, 2003, SCIENCE, V299, P254, DOI 10.1126/science.1077865; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; Makarova KS, 2001, MICROBIOL MOL BIOL R, V65, P44, DOI 10.1128/MMBR.65.1.44-79.2001; Mattimore V, 1996, J BACTERIOL, V178, P633, DOI 10.1128/jb.178.3.633-637.1996; MILDVAN AS, 1972, CRIT REV BIOCH, V6, P219; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; MOORE PD, 1981, P NATL ACAD SCI-BIOL, V78, P110, DOI 10.1073/pnas.78.1.110; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; RABKIN SD, 1983, P NATL ACAD SCI-BIOL, V80, P1541, DOI 10.1073/pnas.80.6.1541; Scharer OD, 2003, ANGEW CHEM INT EDIT, V42, P2946, DOI 10.1002/anie.200200523; SETLOW P, 1972, J BIOL CHEM, V247, P224; SIROVER MA, 1976, SCIENCE, V194, P1434, DOI 10.1126/science.1006310; SIROVER MA, 1979, J BIOL CHEM, V254, P107; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; Villani G, 2002, NUCLEIC ACIDS RES, V30, P3323, DOI 10.1093/nar/gkf463; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Zahradka K, 2006, NATURE, V443, P569, DOI 10.1038/nature05160	38	17	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10908	10914		10.1074/jbc.M611404200	http://dx.doi.org/10.1074/jbc.M611404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303573	Green Submitted, hybrid			2022-12-25	WOS:000245941500010
J	Justino, MC; Almeida, CC; Teixeira, M; Saraiva, LM				Justino, Marta C.; Almeida, Claudia C.; Teixeira, Miguel; Saraiva, Ligia M.			Escherichia coli di-iron YtfE protein is necessary for the repair of stress-damaged iron-sulfur clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; NITRIC-OXIDE; CYSTEINE DESULFURASE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; ACONITASE; BIOGENESIS; MECHANISMS; OPERON; INACTIVATION	DNA microarray experiments showed that the expression of the Escherichia coli ytfE gene is highly increased upon exposure to nitric oxide. We also reported that deletion of ytfE significantly alters the phenotype of E. coli, generating a strain with enhanced susceptibility to nitrosative stress and defective in the activity of several iron- sulfur- containing proteins. In this work, it is shown that the E. coli ytfE confers protection against oxidative stress. Furthermore, we found that the damage of the [ 4Fe-4S](2+) clusters of aconitase B and fumarase A caused by exposure to hydrogen peroxide and nitric oxide stress occurs at higher rates in the absence of ytfE. The ytfE null mutation also abolished the recovery of aconitase and fumarase activities, which is observed in wild type E. coli once the stress is scavenged. Notably, upon the addition of purified holo- YtfE protein to the mutant cell extracts, the enzymatic activities of fumarase and aconitase are fully recovered and at rates similar to the wild type strain. We concluded that YtfE is critical for the repair of iron- sulfur clusters damaged by oxidative and nitrosative stress conditions.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780157 Oeiras, Portugal	Universidade Nova de Lisboa	Saraiva, LM (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Ave Republ, P-2780157 Oeiras, Portugal.	lst@itqb.unl.pt	Teixeira, Miguel/M-1509-2019; Saraiva, Ligia M/H-8537-2012; DE ALMEIDA, CARLOS CAETANO/K-4265-2016; Teixeira, Miguel/A-9098-2011	Teixeira, Miguel/0000-0003-4124-6237; Saraiva, Ligia M/0000-0002-0675-129X; DE ALMEIDA, CARLOS CAETANO/0000-0002-3215-5731; Teixeira, Miguel/0000-0003-4124-6237; Justino, Marta/0000-0002-9310-9456				Barras F, 2005, ADV MICROB PHYSIOL, V50, P41, DOI 10.1016/S0065-2911(05)50002-X; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Bodenmiller DM, 2006, J BACTERIOL, V188, P874, DOI 10.1128/JB.188.3.874-881.2006; Bradbury AJ, 1996, MICROBIOL-SGM, V142, P389, DOI 10.1099/13500872-142-2-389; Djaman O, 2004, J BIOL CHEM, V279, P44590, DOI 10.1074/jbc.M406487200; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; Fontecave M, 2005, J BIOL INORG CHEM, V10, P713, DOI 10.1007/s00775-005-0025-1; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Han D, 2005, BIOCHEMISTRY-US, V44, P11986, DOI 10.1021/bi0509393; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; Imlay JA, 2006, MOL MICROBIOL, V59, P1073, DOI 10.1111/j.1365-2958.2006.05028.x; Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518; Johnson DC, 2006, J BACTERIOL, V188, P7551, DOI 10.1128/JB.00596-06; Justino MC, 2006, FEMS MICROBIOL LETT, V257, P278, DOI 10.1111/j.1574-6968.2006.00179.x; Justino MC, 2005, J BIOL CHEM, V280, P2636, DOI 10.1074/jbc.M411070200; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Kiley PJ, 2003, CURR OPIN MICROBIOL, V6, P181, DOI 10.1016/S1369-5274(03)00039-0; Lee JH, 2004, MOL MICROBIOL, V51, P1745, DOI 10.1111/j.1365-2958.2003.03946.x; Loiseau L, 2003, J BIOL CHEM, V278, P38352, DOI 10.1074/jbc.M305953200; MASSEY V, 1953, BIOCHEM J, V53, P72, DOI 10.1042/bj0530072; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; Mukhopadhyay P, 2004, P NATL ACAD SCI USA, V101, P745, DOI 10.1073/pnas.0307741100; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Outten FW, 2004, MOL MICROBIOL, V52, P861, DOI 10.1111/j.1365-2958.2004.04025.x; Rogers PA, 2003, DNA REPAIR, V2, P809, DOI 10.1016/S1568-7864(03)00065-X; Rogers PA, 2001, J BIOL CHEM, V276, P30980, DOI 10.1074/jbc.M101037200; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Varghese S, 2003, J BACTERIOL, V185, P221, DOI 10.1128/JB.185.1.221-230.2003; Woodmansee AN, 2002, METHOD ENZYMOL, V349, P3, DOI 10.1016/S0076-6879(02)49316-0; WOODS SA, 1988, BIOCHIM BIOPHYS ACTA, V954, P14, DOI 10.1016/0167-4838(88)90050-7; Yang WY, 2002, J BIOL CHEM, V277, P12868, DOI 10.1074/jbc.M109485200; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	39	99	104	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10352	10359		10.1074/jbc.M610656200	http://dx.doi.org/10.1074/jbc.M610656200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289666	hybrid			2022-12-25	WOS:000245941000025
J	Salamat-Miller, N; Fang, JW; Seidel, CW; Assenov, Y; Albrecht, M; Middaugh, CR				Salamat-Miller, Nazila; Fang, Jianwen; Seidel, Christopher W.; Assenov, Yassen; Albrecht, Mario; Middaugh, C. Russell			A network-based analysis of polyanion-binding proteins utilizing human protein arrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; INTRINSIC DISORDER; SULFATED GLYCOSAMINOGLYCANS; HEPARAN-SULFATE; SCALE; DATABASE; CELLS; SITES; PHOSPHORYLATION; COMPLEXES	The existence of interactions between many cellular proteins and various polyanionic surfaces within a cell is now well established. The functional role of such interactions, however, remains to be clearly defined. The existence of protein arrays, with a large selection of different kinds of proteins, provides a way to better address a number of aspects of this question. We have therefore investigated the interaction between five cellular polyanions (actin, tubulin, heparin, heparan sulfate, and DNA) and similar to 5,000 human proteins using protein microarrays in an attempt to better understand the functional nature of such interaction(s). We demonstrate that a large number of polyanion-binding proteins exist that contain multiple positively charged regions, are often disordered, are involved in phosphorylation processes, and appear to play a role in protein-protein interaction networks. Considering the crowded nature of cellular interiors, we propose that polyanion-binding proteins interact with a wide variety of polyanionic surfaces in cells in a functionally significant manner.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Univ Kansas, Bioinformat Core Facil, Lawrence, KS 66047 USA; Stowers Inst Med Res, Kansas City, MO 64110 USA; Max Planck Inst Informat, D-66123 Saarbrucken, Germany	University of Kansas; University of Kansas; Stowers Institute for Medical Research; Max Planck Society	Middaugh, CR (corresponding author), Univ Kansas, Dept Pharmaceut Chem, 2030 Becker Dr, Lawrence, KS 66047 USA.	middaugh@ku.edu	Albrecht, Mario/B-6694-2008	Albrecht, Mario/0000-0002-3103-9624	NCRR NIH HHS [P20 RR016475] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016475] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Albert R, 2005, J CELL SCI, V118, P4947, DOI 10.1242/jcs.02714; Apgar J, 2000, BIOPHYS J, V79, P1095, DOI 10.1016/S0006-3495(00)76363-6; Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Brimacombe DB, 1999, BIOCHEM J, V342, P605, DOI 10.1042/0264-6021:3420605; Chantalat S, 2003, MOL BIOL CELL, V14, P2357, DOI 10.1091/mbc.E02-10-0693; Conrad H. E., 1998, HEPARIN BINDING PROT; DABORA JM, 1991, J BIOL CHEM, V266, P23637; Dedmon MM, 2002, P NATL ACAD SCI USA, V99, P12681, DOI 10.1073/pnas.202331299; Deleault NR, 2005, J BIOL CHEM, V280, P26873, DOI 10.1074/jbc.M503973200; Diella F, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-79; Dunker AK, 2002, BIOCHEMISTRY-US, V41, P6573, DOI 10.1021/bi012159+; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Fang JW, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-277; Fitzgerald J, 2000, BRAIN RES, V877, P110, DOI 10.1016/S0006-8993(00)02692-5; Hasegawa M, 1997, J BIOL CHEM, V272, P33118, DOI 10.1074/jbc.272.52.33118; Hileman RE, 1998, BIOESSAYS, V20, P156, DOI 10.1002/(SICI)1521-1878(199802)20:2<156::AID-BIES8>3.3.CO;2-#; Iakoucheva LM, 2002, J MOL BIOL, V323, P573, DOI 10.1016/S0022-2836(02)00969-5; Jones LS, 2004, MOL CELL PROTEOMICS, V3, P746, DOI 10.1074/mcp.R400008-MCP200; Kueltzo LA, 2000, J BIOL CHEM, V275, P33213, DOI 10.1074/jbc.M002476200; Kueltzo LA, 2000, EXPERT OPIN INV DRUG, V9, P2039, DOI 10.1517/13543784.9.9.2039; Kurakin A, 2005, DEV GENES EVOL, V215, P46, DOI 10.1007/s00427-004-0448-7; Li JP, 2005, P NATL ACAD SCI USA, V102, P6473, DOI 10.1073/pnas.0502287102; Linding R, 2003, STRUCTURE, V11, P1453, DOI 10.1016/j.str.2003.10.002; Liu JG, 2006, BIOCHEMISTRY-US, V45, P6873, DOI 10.1021/bi0602718; MACH H, 1993, BIOCHEMISTRY-US, V32, P7703, DOI 10.1021/bi00081a015; Manna T, 2001, J BIOL CHEM, V276, P39742, DOI 10.1074/jbc.M104061200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Medalia O, 2002, SCIENCE, V298, P1209, DOI 10.1126/science.1076184; Minton AP, 2001, J BIOL CHEM, V276, P10577, DOI 10.1074/jbc.R100005200; Miteva MA, 2005, NUCLEIC ACIDS RES, V33, pW372, DOI 10.1093/nar/gki365; Mitsi M, 2006, BIOCHEMISTRY-US, V45, P10319, DOI 10.1021/bi060974p; Mulder NJ, 2005, NUCLEIC ACIDS RES, V33, pD201, DOI 10.1093/nar/gki106; O'Brien KP, 2005, NUCLEIC ACIDS RES, V33, pD476, DOI 10.1093/nar/gki107; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Pokholok DK, 2006, SCIENCE, V313, P533, DOI 10.1126/science.1127677; Remm M, 2001, J MOL BIOL, V314, P1041, DOI 10.1006/jmbi.2000.5197; Rentzeperis D, 1999, NAT STRUCT BIOL, V6, P569; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Salamat-Miller N, 2006, MOL CELL PROTEOMICS, V5, P2263, DOI 10.1074/mcp.M600240-MCP200; Samanta MP, 2003, P NATL ACAD SCI USA, V100, P12579, DOI 10.1073/pnas.2132527100; Schweitzer B, 2003, PROTEOMICS, V3, P2190, DOI 10.1002/pmic.200300610; Sedlak E, 1998, BIOPOLYMERS, V46, P145, DOI 10.1002/(SICI)1097-0282(199809)46:3<145::AID-BIP2>3.0.CO;2-L; Spitzer JJ, 2005, TRENDS BIOCHEM SCI, V30, P536, DOI 10.1016/j.tibs.2005.08.002; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Tang C, 2006, NATURE, V444, P383, DOI 10.1038/nature05201; TEMPLETON DM, 1988, INT J BIOL MACROMOL, V10, P131, DOI 10.1016/0141-8130(88)90038-4; TSAI PK, 1993, PHARMACEUT RES, V10, P649, DOI 10.1023/A:1018939228201; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; VOLKIN DB, 1993, ARCH BIOCHEM BIOPHYS, V300, P30, DOI 10.1006/abbi.1993.1005; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x; WOLLIN A, 1973, Thrombosis Research, V2, P377, DOI 10.1016/0049-3848(73)90048-0; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551; YU Q, 1995, BIOTECHNIQUES, V19, P122	56	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10153	10163		10.1074/jbc.M610957200	http://dx.doi.org/10.1074/jbc.M610957200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17276992	hybrid			2022-12-25	WOS:000245941000005
J	Wright, CW; Rumble, JM; Duckett, CS				Wright, Casey W.; Rumble, Julie M.; Duckett, Colin S.			CD30 activates both the canonical and alternative NF-kappa B pathways in anaplastic large cell lymphoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; REED-STERNBERG CELLS; NEGATIVE SELECTION; NF-KAPPA-B1 P105; HODGKINS-LYMPHOMA; TNF RECEPTOR-1; FACTOR FAMILY; CYCLE ARREST; T-CELLS; NPM-ALK	CD30 is a member of the tumor necrosis factor receptor superfamily whose expression is up-regulated on anaplastic large cell lymphoma ( ALCL) and Hodgkin lymphoma ( HL) cells. Many different outcomes of CD30 stimulation have been reported, including cell cycle arrest, apoptosis, and activation of the prosurvival transcription factor, NF-kappa B, although this last activity is much less well defined in ALCL cells. In order to better understand the signaling properties of CD30 in cancer, we established a system for the stimulation of CD30 with its physiological ligand. Using this system, CD30 was stimulated on ALCL and HL cells, and the subsequent CD30 signaling properties were characterized. We show that a fraction of ALCL cells rapidly underwent apoptosis following CD30 stimulation, whereas HL cells were unaffected. The surviving ALCL cells exhibited robust activation of both the canonical and alternative NF-kappa B pathways as measured by nuclear translocation of RelA, p50, RelB, and p52, and this culminated in the transactivation of classical NF-kappa B-responsive genes. With prolonged CD30 stimulation, ALCL cells underwent cell cycle arrest that correlated with expression of the cell cycle inhibitor p21(waf1). Furthermore, p21(waf1) expression and cell cycle arrest were found to depend predominantly on the canonical NF-kappa B pathway, since it was reversed byRNAinterference- mediated suppression of RelA. In contrast, suppression of the p100/ p52 NF-kappa B subunit had little effect on p21(waf1). These data reveal that in ALCL cells, in contrast to other cell types, CD30 stimulation elicits p21(waf1)-mediated arrest through the canonical but not the alternative NF-kappa B pathway.	Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Mol Mech Dis Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Duckett, CS (corresponding author), Univ Michigan, Dept Pathol, 2057 BSRB, Ann Arbor, MI 48109 USA.	colind@umich.edu		Wright, Casey/0000-0002-9512-1264; Duckett, Colin/0000-0001-9413-2263	NHLBI NIH HHS [T32 HL07517] Funding Source: Medline; NIAID NIH HHS [T32 AI007413-12] Funding Source: Medline; NIGMS NIH HHS [GM067827] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067827] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizawa S, 1997, J BIOL CHEM, V272, P2042; Amakawa R, 1996, CELL, V84, P551, DOI 10.1016/S0092-8674(00)81031-4; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Chiarle R, 1999, CLIN IMMUNOL, V90, P157, DOI 10.1006/clim.1998.4636; Chiarle R, 1999, J IMMUNOL, V163, P194; Croft M, 2003, NAT REV IMMUNOL, V3, P609, DOI 10.1038/nri1148; DELPRETE G, 1995, J EXP MED, V182, P1655, DOI 10.1084/jem.182.6.1655; DeYoung AL, 2000, J IMMUNOL, V165, P6170, DOI 10.4049/jimmunol.165.11.6170; Duckett CS, 1997, MOL CELL BIOL, V17, P1535, DOI 10.1128/MCB.17.3.1535; Duckett CS, 1997, GENE DEV, V11, P2810, DOI 10.1101/gad.11.21.2810; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Harper J.V., 2005, CELL CYCLE CONTROL, P113; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Horie R, 2004, CANCER CELL, V5, P353, DOI 10.1016/S1535-6108(04)00084-4; Hubinger G, 2001, ONCOGENE, V20, P590, DOI 10.1038/sj.onc.1204128; Hubinger G, 1999, EXP HEMATOL, V27, P1796, DOI 10.1016/S0301-472X(99)00116-2; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Levi E, 2001, BLOOD, V98, P1630, DOI 10.1182/blood.V98.5.1630; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Mir SS, 2000, BLOOD, V96, P4307; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Nishikori M, 2005, CANCER SCI, V96, P487, DOI 10.1111/j.1349-7006.2005.00078.x; Nonaka M, 2005, ONCOGENE, V24, P3976, DOI 10.1038/sj.onc.1208564; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; STEIN H, 1985, BLOOD, V66, P848; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Watanabe M, 2005, CANCER RES, V65, P7628, DOI 10.1158/0008-5472.CAN-05-0925; Younes A, 1999, INT J BIOL MARKER, V14, P135, DOI 10.1177/172460089901400303; Younes A, 2003, CANCER-AM CANCER SOC, V98, P458, DOI 10.1002/cncr.11524; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yu QY, 2005, ONCOGENE, V24, P7114, DOI 10.1038/sj.onc.1208853; Zheng B, 2003, BLOOD, V102, P1019, DOI 10.1182/blood-2002-11-3507; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	43	56	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10252	10262		10.1074/jbc.M608817200	http://dx.doi.org/10.1074/jbc.M608817200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17261581	hybrid			2022-12-25	WOS:000245941000015
J	Losasso, C; Cretaio, E; Palle, K; Pattarello, L; Bjornsti, MA; Benedetti, P				Losasso, Carmen; Cretaio, Erica; Palle, Komaraiah; Pattarello, Luca; Bjornsti, Mary-Ann; Benedetti, Piero			Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAMPTOTHECIN RESISTANCE; SINGLE MUTATION; ACTIVE-SITE; YEAST; SENSITIVITY; DOMAIN; RELAXATION; MECHANISMS; BINDING; ENZYME	Eukaryotic DNA topoisomerase I (Top1p) catalyzes changes in DNA topology via the formation of a covalent enzyme-DNA intermediate, which is reversibly stabilized by the anticancer agent camptothecin (CPT). Crystallographic studies of the 70-kDa C terminus of human Top1p bound to duplex DNA describe a monomeric protein clamp circumscribing the DNA helix. The structures, which lack the N-terminal domain, comprise the conserved clamp, an extended linker domain, and the conserved C-terminal active site Tyr domain. CPT bound to the covalent Top1p-DNA complex limits linker flexibility, allowing structural determination of this domain. We previously reported that mutation of Ala 653 to Pro in the linker increases the rate of enzyme-catalyzed DNA religation, thereby rendering Top1A653Pp resistant to CPT (Fiorani, P., Bruselles, A., Falconi, M., Chillemi, G., Desideri, A., and Benedetti P. (2003) J. Biol. Chem. 278, 43268 - 43275). Molecular dynamics studies suggested mutation-induced increases in linker flexibility alter Top1p catalyzed DNA religation. To address the functional consequences of linker flexibility on enzyme catalysis and drug sensitivity, we investigated the interactions of the A653P linker mutation with a self-poisoning T718A mutation within the active site of Top1p. The A653P mutation suppressed the lethal phenotype of Top1T718Ap in yeast, yet did not restore enzyme sensitivity to CPT. However, the specific activity of the double mutant was decreased in vivo and in vitro, consistent with a decrease in DNA binding. These findings support a model where changes in the flexibility or orientation of the linker alter the geometry of the active site and thereby the kinetics of DNA cleavage/religation catalyzed by Top1p.	Univ Padua, Dept Biol, I-35131 Padua, Italy; St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38104 USA	University of Padua; St Jude Children's Research Hospital	Benedetti, P (corresponding author), Univ Padua, Dept Biol, Via U Bassi 58-B, I-35131 Padua, Italy.	pietro.benedetti@unipd.it	losasso, carmen/C-2928-2013; Losasso, Carmen/AAC-9790-2022; Losasso, Carmen/AAC-9734-2022	losasso, carmen/0000-0002-8234-1292; Losasso, Carmen/0000-0002-8234-1292; Losasso, Carmen/0000-0002-8234-1292; Cretaio, Erica/0000-0001-9654-5563	NATIONAL CANCER INSTITUTE [R01CA058755, P30CA021765, R01CA111542] Funding Source: NIH RePORTER; NCI NIH HHS [CA111542, CA21765, CA58755] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENEDETTI P, 1993, CANCER RES, V53, P4343; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chillemi G, 2005, NUCLEIC ACIDS RES, V33, P3339, DOI 10.1093/nar/gki642; Chillemi G, 2004, BIOPHYS J, V87, P4087, DOI 10.1529/biophysj.104.044925; Colley WC, 2004, J BIOL CHEM, V279, P54069, DOI 10.1074/jbc.M409764200; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; Fiorani P, 1999, MOL PHARMACOL, V56, P1105, DOI 10.1124/mol.56.6.1105; Fiorani P, 2003, J BIOL CHEM, V278, P43268, DOI 10.1074/jbc.M303899200; Fiorani P, 2000, METH MOL B, V95, P291; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; Hann CL, 1998, J BIOL CHEM, V273, P31519, DOI 10.1074/jbc.273.47.31519; Horie K, 2002, ONCOGENE, V21, P7913, DOI 10.1038/sj.onc.1205917; Ireton GC, 2000, J BIOL CHEM, V275, P25820, DOI 10.1074/jbc.M002144200; Jacquiau HR, 2005, J BIOL CHEM, V280, P23566, DOI 10.1074/jbc.M500947200; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; KAISER C, 1994, METHODS YEAST GENETI, P133; KAUH EA, 1995, P NATL ACAD SCI USA, V92, P6299, DOI 10.1073/pnas.92.14.6299; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KNAB AM, 1995, J BIOL CHEM, V270, P6141, DOI 10.1074/jbc.270.11.6141; Koster DA, 2005, NATURE, V434, P671, DOI 10.1038/nature03395; LEVIN NA, 1993, GENETICS, V133, P799; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Li TK, 2003, CANCER RES, V63, P8400; MCCONAUGHY BL, 1981, BIOCHIM BIOPHYS ACTA, V655, P1, DOI 10.1016/0005-2787(81)90059-9; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Pommier Y, 2003, MUTAT RES-FUND MOL M, V532, P173, DOI 10.1016/j.mrfmmm.2003.08.016; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Reid RJD, 1998, BBA-GENE STRUCT EXPR, V1400, P289, DOI 10.1016/S0167-4781(98)00142-0; Rodriguez-Galindo C, 2000, MED PEDIATR ONCOL, V35, P385, DOI 10.1002/1096-911X(20001001)35:4<385::AID-MPO1>3.0.CO;2-E; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; van Waardenburg RCAM, 2006, MOL CELL BIOL, V26, P4958, DOI 10.1128/MCB.00160-06; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Woo MH, 2003, P NATL ACAD SCI USA, V100, P13767, DOI 10.1073/pnas.2235886100	44	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9855	9864		10.1074/jbc.M608200200	http://dx.doi.org/10.1074/jbc.M608200200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17276985	hybrid			2022-12-25	WOS:000245421700060
J	Persson, M; Letts, JA; Hosseini-Maaf, B; Borisova, SN; Palcic, MM; Evans, SV; Olsson, ML				Persson, Mattias; Letts, James A.; Hosseini-Maaf, Bahram; Borisova, Svetlana N.; Palcic, Monica M.; Evans, Stephen V.; Olsson, Martin L.			Structural effects of naturally occurring human blood group B galactosyltransferase mutations adjacent to the DXD motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DONOR SUBSTRATE-SPECIFICITY; SINGLE-POINT MUTATION; MOLECULAR-GENETIC ANALYSIS; ENZYME-ACTIVITY; GROUP SYSTEM; GROUP-A; GLYCOSYLTRANSFERASES; BETA-1,4-GALACTOSYLTRANSFERASE-I; MUTAGENESIS; PROTEINS	Human blood group A and B antigens are produced by two closely related glycosyltransferase enzymes. An N-acetylgalactosaminyltransferase (GTA) utilizes UDP-GalNAc to extend H antigen acceptors (Fuc alpha(1-2)Gal beta-OR) producing A antigens, whereas a galactosyltransferase (GTB) utilizes UDP-Gal as a donor to extend H structures producing B antigens. GTA and GTB have a characteristic (DVD213)-D-211 motif that coordinates to a Mn2+ ion shown to be critical in donor binding and catalysis. Three GTB mutants, M214V, M214T, and M214R, with alterations adjacent to the (211)DVD213 motif have been identified in blood banking laboratories. From serological phenotyping, individuals with the M214R mutation show the B,1 variant expressing very low levels of B antigens, whereas those with M214T and M214V mutations give rise to A(weak)B phenotypes. Kinetic analysis of recombinant mutant GTB enzymes revealed that M214R has a 1200-fold decrease in k(cat) compared with wild type GTB. The crystal structure of M214R showed that DVD motif coordination to Mn2+ was disrupted by Arg-214 causing displacement of the metal by a water molecule. Kinetic characterizations of the M214T and M214V mutants revealed they both had GTA and GTB activity consistent with the serology. The crystal structure of the M214T mutant showed no change in DVD coordination to Mn2+. Instead a critical residue, Met-266, which is responsible for determining donor specificity, had adopted alternate conformations. The conformation with the highest occupancy opens up the active site to accommodate the larger A-specific donor, UDP-GalNAc, accounting for the dual specificity.	Carlsberg Lab, DK-2500 Copenhagen, Denmark; Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada; Lund Univ, Div Hematol & Transfus Med, Dept Lab Med, SE-22185 Lund, Sweden; Univ Lund Hosp, Blood Ctr, SE-22185 Lund, Sweden	University of Victoria; Lund University; Lund University; Skane University Hospital	Palcic, MM (corresponding author), Carlsberg Lab, Gamle Carlsberg Vej 10, DK-2500 Copenhagen, Denmark.	monica@crc.dk; Martin_L.Olsson@med.lu.se	Letts, James Anthony/AAN-6632-2020	Letts, James Anthony/0000-0002-9864-3586; Olsson, Martin L/0000-0003-1647-9610; Evans, Stephen/0000-0002-0366-4027				Angulo J, 2006, J AM CHEM SOC, V128, P13529, DOI 10.1021/ja063550r; Blumenfeld OO, 2004, HUM MUTAT, V23, P8, DOI 10.1002/humu.10296; Breton C, 2006, GLYCOBIOLOGY, V16, p29R, DOI 10.1093/glycob/cwj016; Busch C, 1998, J BIOL CHEM, V273, P19566, DOI 10.1074/jbc.273.31.19566; Butterfoss GL, 2003, PROTEIN SCI, V12, P2719, DOI 10.1110/ps.03273303; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Davies GJ, 2005, CURR OPIN STRUC BIOL, V15, P637, DOI 10.1016/j.sbi.2005.10.008; Deng ZH, 2005, VOX SANG, V89, P251, DOI 10.1111/j.1423-0410.2005.00697.x; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; Gotting C, 2004, J BIOL CHEM, V279, P42566, DOI 10.1074/jbc.M401340200; Gulberti S, 2003, J BIOL CHEM, V278, P32219, DOI 10.1074/jbc.M207899200; Hancock SM, 2006, CURR OPIN CHEM BIOL, V10, P509, DOI 10.1016/j.cbpa.2006.07.015; Hu YN, 2002, CHEM BIOL, V9, P1287, DOI 10.1016/S1074-5521(02)00295-8; Jank T, 2005, J BIOL CHEM, V280, P37833, DOI 10.1074/jbc.M506836200; Kubo A, 2004, ARCH BIOCHEM BIOPHYS, V429, P198, DOI 10.1016/j.abb.2004.06.021; Lee HJ, 2005, J BIOL CHEM, V280, P525, DOI 10.1074/jbc.M410245200; Li JG, 2001, GLYCOBIOLOGY, V11, P217, DOI 10.1093/glycob/11.3.217; Marcus SL, 2003, J BIOL CHEM, V278, P12403, DOI 10.1074/jbc.M212002200; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ogasawara K, 1996, BLOOD, V88, P2732, DOI 10.1182/blood.V88.7.2732.bloodjournal8872732; Olsson ML, 2001, BLOOD, V98, P1585, DOI 10.1182/blood.V98.5.1585; Ouzzine M, 2002, J BIOL CHEM, V277, P25439, DOI 10.1074/jbc.M201912200; Pak JE, 2006, J BIOL CHEM, V281, P26693, DOI 10.1074/jbc.M603534200; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; Patenaude SI, 2002, NAT STRUCT BIOL, V9, P685, DOI 10.1038/nsb832; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Qasba PK, 2005, TRENDS BIOCHEM SCI, V30, P53, DOI 10.1016/j.tibs.2004.11.005; Rajagopal S, 2005, FEBS J, V272, P1819, DOI 10.1111/j.1742-4658.2005.04604.x; Ramakrishnan B, 2005, BIOCHEMISTRY-US, V44, P3202, DOI 10.1021/bi0479454; Ramakrishnan B, 2002, J BIOL CHEM, V277, P20833, DOI 10.1074/jbc.M111183200; Roubinet F, 2002, TRANSFUSION, V42, P239, DOI 10.1046/j.1537-2995.2002.00030.x; Seltsam A, 2003, BLOOD, V102, P3035, DOI 10.1182/blood-2003-03-0955; Seto NOL, 1999, EUR J BIOCHEM, V259, P770, DOI 10.1046/j.1432-1327.1999.00086.x; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Yamamoto F, 1996, J BIOL CHEM, V271, P10515, DOI 10.1074/jbc.271.18.10515; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0	38	17	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9564	9570		10.1074/jbc.M610998200	http://dx.doi.org/10.1074/jbc.M610998200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17259183	hybrid			2022-12-25	WOS:000245421700029
J	Miller, S; Kastner, S; Krijnse-Locker, J; Buhler, S; Bartenschlager, R				Miller, Sven; Kastner, Stefan; Krijnse-Locker, Jacomine; Buehler, Sandra; Bartenschlager, Ralf			The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WEST-NILE-VIRUS; RNA REPLICATION; NS3 PROTEIN; NS2B-3 PROTEINASE; FLAVIVIRUS KUNJIN; NS4B PROTEIN; STRANDED-RNA; IDENTIFICATION; INTERFERON; CURVATURE	Dengue virus (DV) is a positive sense RNA virus replicating in the cytoplasm in membranous compartments that are induced by viral infection. The non-structural protein (NS) 4A is one of the least characterized DV proteins. It is highly hydrophobic with its C-terminal region (designated 2K fragment) serving as a signal sequence for the translocation of the adjacent NS4B into the endoplasmic reticulum (ER) lumen. In this report, we demonstrate that NS4A associates with membranes via 4 internal hydrophobic regions, which are all able to mediate membrane targeting of a cytosolic reporter protein. We also developed a model for the membrane topology of NS4A in which the N-terminal third of NS4A localizes to the cytoplasm, while the remaining part contains three transmembrane segments, with the C-terminal end localized in the ER lumen. Subcellular localization experiments in DV-infected cells revealed that NS4A resides primarily in ER-derived cytoplasmic dot-like structures that also contain dsRNA and other DV proteins, suggesting that NS4A is a component of the membrane-bound viral replication complex (RC). Interestingly, the individual expression of DV NS4A lacking the 2K fragment resulted in the induction of cytoplasmic membrane alterations resembling virus-induced structures, whereas expression of full-length NS4A does not induce comparable membrane alterations. Thus, proteolytic removal of the 2K peptide appears to be important for induction of membrane alterations that may harbor the viral RC. These results shed new light on the role of NS4A in the DV replication cycle and provide a model of how this protein induces membrane rearrangements and how this property may be regulated.	Univ Heidelberg, Dept Mol Virol, D-69120 Heidelberg, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL)	Buhler, S (corresponding author), Univ Heidelberg, Dept Mol Virol, Bergheimer Str 58, D-69120 Heidelberg, Germany.	sandra_sparacio@med.uni-heidelberg.de; ralf_bartenschlager@med.uni-heidelberg.de	Locker, Jacomine Krijnse/E-1009-2016; Locker, Jacomine Krijnse/AAX-1185-2020; Bartenschlager, Ralf/L-2582-2015	Bartenschlager, Ralf/0000-0001-5601-9307				AMBERG SM, 1994, J VIROL, V68, P3794, DOI 10.1128/JVI.68.6.3794-3802.1994; AnandaRao R, 2005, VIRUS RES, V112, P60, DOI 10.1016/j.virusres.2005.03.022; Appel N, 2005, J VIROL, V79, P3187, DOI 10.1128/JVI.79.5.3187-3194.2005; BONIFACINO JS, 2000, CHARACTERIZATION CEL; CAHOUR A, 1992, J VIROL, V66, P1535, DOI 10.1128/JVI.66.3.1535-1542.1992; CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245; CHU PWG, 1992, ARCH VIROL, V125, P177, DOI 10.1007/BF01309636; CHU PWG, 1992, J VIROL METHODS, V37, P219, DOI 10.1016/0166-0934(92)90049-J; CLEAVES GR, 1979, VIROLOGY, V96, P159, DOI 10.1016/0042-6822(79)90181-8; FALGOUT B, 1991, J VIROL, V65, P2467, DOI 10.1128/JVI.65.5.2467-2475.1991; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P466; Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0; Guo JT, 2005, J VIROL, V79, P1343, DOI 10.1128/JVI.79.3.1343-1350.2005; Kaariainen L, 2002, PROG NUCLEIC ACID RE, V71, P187, DOI 10.1016/S0079-6603(02)71044-1; KOONIN EV, 1993, J GEN VIROL, V74, P733, DOI 10.1099/0022-1317-74-4-733; LEARY K, 1980, J ULTRA MOL STRUCT R, V72, P123, DOI 10.1016/S0022-5320(80)90050-7; LIN C, 1993, J VIROL, V67, P2327, DOI 10.1128/JVI.67.4.2327-2335.1993; Lindenbach BD, 1999, J VIROL, V73, P4611, DOI 10.1128/JVI.73.6.4611-4621.1999; Lindenbach BD, 1997, J VIROL, V71, P9608, DOI 10.1128/JVI.71.12.9608-9617.1997; Liu WJ, 2005, J VIROL, V79, P1934, DOI 10.1128/JVI.79.3.1934-1942.2005; Mackenzie J, 2005, TRAFFIC, V6, P967, DOI 10.1111/j.1600-0854.2005.00339.x; Mackenzie JM, 1998, VIROLOGY, V245, P203, DOI 10.1006/viro.1998.9156; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; MILLER S, 2006, J BIOL CHEM; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; Munoz-Jordan JL, 2005, J VIROL, V79, P8004, DOI 10.1128/JVI.79.13.8004-8013.2005; Munoz-Jordan JL, 2003, P NATL ACAD SCI USA, V100, P14333, DOI 10.1073/pnas.2335168100; Muylaert IR, 1997, J VIROL, V71, P291, DOI 10.1128/JVI.71.1.291-298.1997; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; NG ML, 1989, ARCH VIROL, V106, P103, DOI 10.1007/BF01311042; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; Roosendaal J, 2006, J VIROL, V80, P4623, DOI 10.1128/JVI.80.9.4623-4632.2006; SAMBROOK J, 2001, MOL CLONIGN LAB MANU; Tan BH, 1996, VIROLOGY, V216, P317, DOI 10.1006/viro.1996.0067; Umareddy I, 2006, J GEN VIROL, V87, P2605, DOI 10.1099/vir.0.81844-0; WARRENER P, 1993, J VIROL, V67, P989, DOI 10.1128/JVI.67.2.989-996.1993; WENGLER G, 1991, J GEN VIROL, V72, P851, DOI 10.1099/0022-1317-72-4-851; Westaway EG, 1997, J VIROL, V71, P6650, DOI 10.1128/JVI.71.9.6650-6661.1997; Yu GY, 2006, J VIROL, V80, P6013, DOI 10.1128/JVI.00053-06; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	41	320	327	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8873	8882		10.1074/jbc.M609919200	http://dx.doi.org/10.1074/jbc.M609919200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17276984	hybrid			2022-12-25	WOS:000245780300034
J	Mamane, Y; Petroulakis, E; Martineau, Y; Sato, TA; Larsson, O; Rajasekhar, VK; Sonenberg, N				Mamane, Yael; Petroulakis, Emmanuel; Martineau, Yvan; Sato, Taka-Aki; Larsson, Ola; Rajasekhar, Vinagolu K.; Sonenberg, Nahum			Epigenetic Activation of a Subset of mRNAs by eIF4E Explains Its Effects on Cell Proliferation	PLOS ONE			English	Article							RIBOSOMAL-PROTEIN GENES; CAP-BINDING PROTEIN; TRANSLATIONAL CONTROL; ORNITHINE-DECARBOXYLASE; INITIATION FACTOR-4E; SECONDARY STRUCTURE; NONCODING REGION; EXPRESSION; CANCER; GROWTH	Background. Translation deregulation is an important mechanism that causes aberrant cell growth, proliferation and survival. eIF4E, the mRNA 5' capbinding protein, plays a major role in translational control. To understand how eIF4E affects cell proliferation and survival, we studied mRNA targets that are translationally responsive to eIF4E. Methodology/ Principal Findings. Microarray analysis of polysomal mRNA from an eIF4E-inducible NIH 3T3 cell line was performed. Inducible expression of eIF4E resulted in increased translation of defined sets of mRNAs. Many of the mRNAs are novel targets, including those that encode large- and small-subunit ribosomal proteins and cell growth-related factors. In addition, there was augmented translation of mRNAs encoding antiapoptotic proteins, which conferred resistance to endoplasmic reticulum-mediated apoptosis. Conclusions/Significance. Our results shed new light on the mechanisms by which eIF4E prevents apoptosis and transforms cells. Downregulation of eIF4E and its downstream targets is a potential therapeutic option for the development of novel anticancer drugs.	[Mamane, Yael; Petroulakis, Emmanuel; Martineau, Yvan; Sonenberg, Nahum] McGill Univ, Dept Biochem, McGill Canc Ctr, Montreal, PQ, Canada; [Sato, Taka-Aki] Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY USA; [Larsson, Ola] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Rajasekhar, Vinagolu K.] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA	McGill University; Columbia University; University of Minnesota System; University of Minnesota Twin Cities; Memorial Sloan Kettering Cancer Center	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, McGill Canc Ctr, Montreal, PQ, Canada.	nahum.sonenberg@mcgill.ca	Larsson, Ola/F-8151-2013; Martineau, Yvan/G-2387-2017	Martineau, Yvan/0000-0002-0575-4085; Vinagolu, Rajasekhar/0000-0002-7364-2675; Larsson, Ola/0000-0003-1412-1308	National Cancer Institute of Canada (NCIC); McGill University; Association pour la Recherche sur le Cancer (France); Swedish Research Council; CIHR; Howard Hughes Medical Institute (HHMI) International Scholar	National Cancer Institute of Canada (NCIC)(Canadian Cancer Society (CCS)); McGill University; Association pour la Recherche sur le Cancer (France)(Fondation ARC pour la Recherche sur le Cancer); Swedish Research Council(Swedish Research CouncilEuropean Commission); CIHR(Canadian Institutes of Health Research (CIHR)); Howard Hughes Medical Institute (HHMI) International Scholar(Howard Hughes Medical Institute)	This research was supported by a grant from the National Cancer Institute of Canada (NCIC). Y. Mamane is a recipient of a fellowship from the NCIC. E. P. was supported by a Fellowship from the Cancer Research Society and a Chemical Biology Fellowship from McGill University. Y. Martineau is a recipient of a postdoctoral fellowship from Association pour la Recherche sur le Cancer (France) and a Canadian Institute of Health Research (CIHR) Cancer Consortium Training Award from McGill University. O. Larsson is supported by a postdoctoral fellowship from the Swedish Research Council. N.S. is a CIHR distinguished scientist and a Howard Hughes Medical Institute (HHMI) International Scholar.	Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bassoe CF, 1998, LEUKEMIA RES, V22, P329, DOI 10.1016/S0145-2126(97)00178-1; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909; Ferraiuolo MA, 2004, P NATL ACAD SCI USA, V101, P4118, DOI 10.1073/pnas.0400933101; FERRARI S, 1990, CANCER RES, V50, P5825; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gradi A, 1998, P NATL ACAD SCI USA, V95, P11089, DOI 10.1073/pnas.95.19.11089; GRAFF JR, 1995, INT J CANCER, V60, P255; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Grzmil M, 2006, J PATHOL, V208, P340, DOI 10.1002/path.1902; Hamilton TL, 2006, BIOCHEM SOC T, V34, P12, DOI 10.1042/BST0340012; HAMMOND ML, 1991, GENE DEV, V5, P1723, DOI 10.1101/gad.5.9.1723; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; Hong NA, 2000, DEV BIOL, V220, P76, DOI 10.1006/dbio.2000.9615; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; Khaleghpour K, 1999, MOL CELL BIOL, V19, P4302; Kinzy TG, 2000, COLD SPRING HARBOR M, V39, P973; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Larsson O, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-129; LARSSON O, 2006, NUCL ACIDS RES; Larsson O, 2006, NAT BIOTECHNOL, V24, P1322, DOI 10.1038/nbt1106-1322; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li SN, 2004, J BIOL CHEM, V279, P21312, DOI 10.1074/jbc.M312467200; Loging WT, 1999, CANCER EPIDEM BIOMAR, V8, P1011; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; MAO XH, 1992, J BIOL CHEM, V267, P20444; MATHEWS MB, 2007, TRANSLATIONAL CONTRO; Mignone F, 2005, NUCLEIC ACIDS RES, V33, pD141, DOI 10.1093/nar/gki021; Morand EF, 2005, INTERN MED J, V35, P419, DOI 10.1111/j.1445-5994.2005.00853.x; Nadano D, 2000, JPN J CANCER RES, V91, P802, DOI 10.1111/j.1349-7006.2000.tb01017.x; Oridate N, 2005, CANCER BIOL THER, V4, P318, DOI 10.4161/cbt.4.3.1504; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; Preiss T, 2003, NAT STRUCT BIOL, V10, P1039, DOI 10.1038/nsb1015; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; RUVINSKY I, 2006, TRENDS BIOCH SCI; SantaCruz DJ, 1997, J CUTAN PATHOL, V24, P533, DOI 10.1111/j.1600-0560.1997.tb01457.x; SCHNEIDER R, 2007, TRANSLATIONAL CONTRO; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shantz LM, 1996, CANCER RES, V56, P3265; Shi YQ, 2004, EXP CELL RES, V296, P337, DOI 10.1016/j.yexcr.2004.02.009; Shimizu T, 2005, J DERMATOL SCI, V37, P65, DOI 10.1016/j.jdermsci.2004.08.007; Stromberg T, 2004, BLOOD, V103, P3138, DOI 10.1182/blood-2003-05-1543; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Thompson B., 2007, TRANSLATIONAL CONTRO; Tomonaga T, 2003, CANCER RES, V63, P3511; Trempat P, 2004, LEUKEMIA LYMPHOMA, V45, P2001, DOI 10.1080/10428190410001713189; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Uechi T, 2001, GENOMICS, V72, P223, DOI 10.1006/geno.2000.6470; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wettenhall JM, 2004, BIOINFORMATICS, V20, P3705, DOI 10.1093/bioinformatics/bth449; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; NUCL ACIDS RES, V34, pD322	86	171	177	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e242	10.1371/journal.pone.0000242	http://dx.doi.org/10.1371/journal.pone.0000242			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311107	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444500021
J	Zhou, TS; Zhang, JJ; Yuan, ZJ; Xu, AL				Zhou, Tianshou; Zhang, Jiajun; Yuan, Zhanjiang; Xu, Anlong			External Stimuli Mediate Collective Rhythms: Artificial Control Strategies	PLOS ONE			English	Article								The artificial intervention of biological rhythms remains an exciting challenge. Here, we proposed artificial control strategies that were developed to mediate the collective rhythms emerging in multicellular structures. Based on noisy repressilators and by injecting a periodic control amount to the extracellular medium, we introduced two typical kinds of control models. In one, there are information exchanges among cells, where signaling molecules receive the injected stimulus that freely diffuses toward/from the intercellular medium. In the other, there is no information exchange among cells, but signaling molecules also receive the stimulus that directionally diffuses into each cell from the common environment. We uncovered physical mechanisms for how the stimulus induces, enhances or ruins collective rhythms. We found that only when the extrinsic period is close to an integer multiplicity of the averaged intrinsic period can the collective behaviors be induced/enhanced; otherwise, the stimulus possibly ruins the achieved collective behaviors. Such entrainment properties of these oscillators to external signals would be exploited by realistic living cells to sense external signals. Our results not only provide a new perspective to the understanding of the interplays between extrinsic stimuli and intrinsic physiological rhythms, but also would lead to the development of medical therapies or devices.	[Zhou, Tianshou; Zhang, Jiajun; Yuan, Zhanjiang] Sun Yat Sen Univ, Sch Math & Computat Sci, Guangzhou 510275, Guangdong, Peoples R China; [Zhou, Tianshou; Xu, Anlong] Sun Yat Sen Univ, State Key Lab Biocontrol, Sch Life Sci, Guangzhou 510275, Guangdong, Peoples R China; [Zhou, Tianshou; Xu, Anlong] Sun Yat Sen Univ, Guangzhou Ctr Bioinformat, Sch Life Sci, Guangzhou 510275, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Zhou, TS (corresponding author), Sun Yat Sen Univ, Sch Math & Computat Sci, Guangzhou 510275, Guangdong, Peoples R China.	mcszhtsh@mail.sysu.edu.cn		Zhang, Jiajun/0000-0001-7107-4814	Natural Science Foundation of Guangdong Province [50033047]; National Distinguished Ph.D. Theses Grant [200521]	Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Distinguished Ph.D. Theses Grant	Natural Science Foundation of Guangdong Province (No. 50033047); National Distinguished Ph.D. Theses Grant (200521)	Bassler BL, 1999, CURR OPIN MICROBIOL, V2, P582, DOI 10.1016/S1369-5274(99)00025-9; CHEN W, 1993, GENE, V130, P15, DOI 10.1016/0378-1119(93)90341-Y; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; Garcia-Ojalvo J, 2004, P NATL ACAD SCI USA, V101, P10955, DOI 10.1073/pnas.0307095101; GLASS L, 1994, PHYS REV E, V50, P5077, DOI 10.1103/PhysRevE.50.5077; Goldbeter A., 1996, BIOCH OSCILLATIONS C; Hasty J, 2002, NATURE, V420, P224, DOI 10.1038/nature01257; Hasty J, 2001, CHAOS, V11, P207, DOI 10.1063/1.1345702; Kaplan DT, 1996, PHYS REV LETT, V76, P4074, DOI 10.1103/PhysRevLett.76.4074; Kuramoto Y., 2003, CHEM OSCILLATION WAV; KURAMOTO Y, 1984, CHEM OSCILLATION WAV, P62; Lai YC, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.214101; Lebiedz D, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.108303; Liu B, 2005, INT J BIFURCAT CHAOS, V15, P517, DOI 10.1142/S0218127405012338; McMillen D, 2002, P NATL ACAD SCI USA, V99, P679, DOI 10.1073/pnas.022642299; Osipov GV, 1997, PHYS REV E, V55, P2353, DOI 10.1103/PhysRevE.55.2353; Ozbudak EM, 2002, NAT GENET, V31, P69, DOI 10.1038/ng869; Paulsson J, 2001, Q REV BIOPHYS, V34, P1, DOI 10.1017/S0033583501003663; Pikovsky AS, 1996, EUROPHYS LETT, V34, P165, DOI 10.1209/epl/i1996-00433-3; Schultz TF, 2003, SCIENCE, V301, P326, DOI 10.1126/science.1085935; Simon PM, 2000, J APPL PHYSIOL, V89, P760, DOI 10.1152/jappl.2000.89.2.760; Tang SY, 2003, INT J BIFURCAT CHAOS, V13, P973, DOI 10.1142/S0218127403007011; Volfson D, 2006, NATURE, V439, P861, DOI 10.1038/nature04281; Wagemakers A, 2006, CHAOS, V16, DOI 10.1063/1.2173048; Zhou TS, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.178103	28	19	21	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e231	10.1371/journal.pone.0000231	http://dx.doi.org/10.1371/journal.pone.0000231			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311095	gold, Green Submitted, Green Published			2022-12-25	WOS:000207444500012
J	Ma, X; Kalakonda, S; Srinivasula, SM; Reddy, SP; Platanias, LC; Kalvakolanu, DV				Ma, X.; Kalakonda, S.; Srinivasula, S. M.; Reddy, S. P.; Platanias, L. C.; Kalvakolanu, D. V.			GRIM-19 associates with the serine protease HtrA2 for promoting cell death	ONCOGENE			English	Article						cytokines; vitamins; cancer; cell death; growth; suppression	RETINOIC ACID; TUMOR-DEVELOPMENT; CASPASE ACTIVITY; IFN-GAMMA; APOPTOSIS; INHIBITOR; OMI/HTRA2; MITOCHONDRIA; REGULATOR; INTERACTS	We have isolated a novel interferon (IFN)-retinoid regulated cell death regulatory protein genes associated with retinoid-IFN-induced mortality (GRIM)-19 earlier. To understand its mechanism of action, we have employed a yeast-two-hybrid screen and identified serine protease HtrA2 as its binding partner. GRIM-19 physically interacts with HtrA2 and augments cell death in an IFN/all-trans retinoic acid (RA)-dependent manner. In the presence of GRIM-19, the HtrA2-driven destruction of the antiapoptotic protein X-linked inhibitor of apoptosis (XIAP) is augmented. These interactions were disrupted by an human herpes virus-8 (HHV-8)-coded oncoprotein, vIRF1, and conferred resistance to IFN/RA-induced cell death. These data show a critical role of HtrA2 in a cytokine-induced cell death response for the. rst time and its inhibition by a viral protein.	Univ Maryland, Greenbaum Canc Ctr, Dept Microbiol & Immunol, Sch Med, Baltimore, MD 21201 USA; NCI, Lab Immune Cell Biol, Bethesda, MD 20892 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; Northwestern Univ, Sch Med, Lurie Canc Ctr, Div Hematol & Oncol, Chicago, IL 60611 USA	University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Kalvakolanu, DV (corresponding author), Univ Maryland, Greenbaum Canc Ctr, Dept Microbiol & Immunol, Sch Med, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA105005] Funding Source: NIH RePORTER; NCI NIH HHS [CA105005] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; CHOMIENNE C, 1990, BLOOD, V76, P1710; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Gresser I, 2002, CYTOKINE GROWTH F R, V13, P111, DOI 10.1016/S1359-6101(01)00035-1; Gupta S, 2004, J BIOL CHEM, V279, P45844, DOI 10.1074/jbc.M404940200; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hu JD, 2002, J INTERF CYTOK RES, V22, P1017, DOI 10.1089/107999002760624242; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; Jin SK, 2003, GENE DEV, V17, P359, DOI 10.1101/gad.1047003; Kalvakolanu DV, 2004, CYTOKINE GROWTH F R, V15, P169, DOI 10.1016/j.cytogfr.2004.01.002; KALVAKOLANU DV, 2002, ENCY CANC, V2, P511; Kuninaka S, 2005, ONCOGENE, V24, P5287, DOI 10.1038/sj.onc.1208682; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Seo T, 2002, J VIROL, V76, P8797, DOI 10.1128/JVI.76.17.8797-8807.2002; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	28	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4842	4849		10.1038/sj.onc.1210287	http://dx.doi.org/10.1038/sj.onc.1210287			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297443				2022-12-25	WOS:000248170400009
J	Kawada, K; Hosogi, H; Sonoshita, M; Sakashita, H; Manabe, T; Shimahara, Y; Sakai, Y; Takabayashi, A; Oshima, M; Taketo, MM				Kawada, K.; Hosogi, H.; Sonoshita, M.; Sakashita, H.; Manabe, T.; Shimahara, Y.; Sakai, Y.; Takabayashi, A.; Oshima, M.; Taketo, M. M.			Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes	ONCOGENE			English	Article						CXCR3; colon cancer; lymph node; metastasis	COLORECTAL-CANCER; ENDOTHELIAL-CELLS; BREAST-CANCER; IFN-GAMMA; EPITHELIAL-CELLS; CUTTING EDGE; PIVOTAL ROLE; T-CELLS; EXPRESSION; CC	Chemokines and their receptors are essential for leukocyte trafficking, and also implicated in cancer metastasis to specific organs. We have recently demonstrated that CXCR3 plays a critical role in metastasis of mouse melanoma cells to lymph nodes. Here, we show that some human colon cancer cell lines express CXCR3 constitutively. We constructed cells that expressed CXCR3 cDNA (`DLD-1-CXCR3'), and compared with nonexpressing controls by rectal transplantation in nude mice. Although both cell lines disseminated to lymph nodes at similar frequencies at 2 weeks, DLD-1-CXCR3 expanded more rapidly than the control in 4 weeks. In 6 weeks, 59% of mice inoculated with DLD1-CXCR3 showed macroscopic metastasis in para-aortic lymph nodes, whereas only 14% of those with the control (P < 0.05). In contrast, metastasis to the liver or lung was rare, and unaffected by CXCR3 expression. In clinical colon cancer samples, we found expression of CXCR3 in 34% cases, most of which had lymph node metastasis. Importantly, patients with CXCR3-positive cancer showed significantly poorer prognosis than those without CXCR3, or those expressing CXCR4 or CCR7. These results indicate that activation of CXCR3 with its ligands stimulates colon cancer metastasis preferentially to the draining lymph nodes with poorer prognosis.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan; Kyoto Univ, Grad Sch Med, Dept Clin Pathol, Kyoto, Japan; Kitano Hosp, Inst Med, Osaka, Japan	Kyoto University; Kyoto University; Kyoto University; Kitano Hospital	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp	Hosogi, Hisahiro/AAK-2585-2020; SONOSHITA, MASAHIRO/Q-1571-2019; Oshima, Masanobu/F-9958-2014; Sonoshita, Masahiro/AAE-5516-2019	SONOSHITA, MASAHIRO/0000-0003-2890-336X; Oshima, Masanobu/0000-0002-3304-0004; 				Amichay D, 1996, J IMMUNOL, V157, P4511; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Dijkstra IM, 2004, J IMMUNOL, V172, P2744, DOI 10.4049/jimmunol.172.5.2744; Dwinell MB, 2001, GASTROENTEROLOGY, V120, P49, DOI 10.1053/gast.2001.20914; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; Flatmark K, 2004, EUR J CANCER, V40, P1593, DOI 10.1016/j.ejca.2004.02.023; FLEMING JB, 1997, AJCC CANC STAGING MA, P83; GATTASS CR, 1994, J EXP MED, V179, P1373, DOI 10.1084/jem.179.4.1373; Janatpour MJ, 2001, J EXP MED, V194, P1375, DOI 10.1084/jem.194.9.1375; Jordan NJ, 1999, J CLIN INVEST, V104, P1061, DOI 10.1172/JCI6685; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kashtan H, 1992, Surg Oncol, V1, P251, DOI 10.1016/0960-7404(92)90072-S; Kawada K, 2004, CANCER RES, V64, P4010, DOI 10.1158/0008-5472.CAN-03-1757; Kim J, 2005, J CLIN ONCOL, V23, P2744, DOI 10.1200/JCO.2005.07.078; Luther SA, 2000, P NATL ACAD SCI USA, V97, P12694, DOI 10.1073/pnas.97.23.12694; Mancardi S, 2003, IMMUNOLOGY, V108, P523, DOI 10.1046/j.1365-2567.2003.01613.x; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Mashino K, 2002, CANCER RES, V62, P2937; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Ninomiya I, 2004, INT J CANCER, V112, P135, DOI 10.1002/ijc.20360; Ochsenbein AF, 2001, NATURE, V411, P1058, DOI 10.1038/35082583; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Poggi A, 2004, BLOOD, V103, P2205, DOI 10.1182/blood-2003-08-2928; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Saeki H, 1999, J IMMUNOL, V162, P2472; Schimanski CC, 2005, CLIN CANCER RES, V11, P1743, DOI 10.1158/1078-0432.CCR-04-1195; Soejima K, 2001, J IMMUNOL, V167, P6576, DOI 10.4049/jimmunol.167.11.6576; Soto H, 1998, P NATL ACAD SCI USA, V95, P8205, DOI 10.1073/pnas.95.14.8205; Tannenbaum CS, 1998, J IMMUNOL, V161, P927; Trentin L, 1999, J CLIN INVEST, V104, P115, DOI 10.1172/JCI7335; Tsutsumi S, 2001, CANCER LETT, V169, P77, DOI 10.1016/S0304-3835(00)00622-4; Vicari AP, 2000, J IMMUNOL, V165, P1992, DOI 10.4049/jimmunol.165.4.1992; Vlahakis SR, 2002, J IMMUNOL, V169, P5546, DOI 10.4049/jimmunol.169.10.5546; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Walser TC, 2006, CANCER RES, V66, P7701, DOI 10.1158/0008-5472.CAN-06-0709; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Yoneyama H, 2002, J EXP MED, V195, P1257, DOI 10.1084/jem.20011983; Zeelenberg IS, 2003, CANCER RES, V63, P3833; Zhang R, 1997, ONCOGENE, V14, P1607, DOI 10.1038/sj.onc.1200957	44	180	191	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4679	4688		10.1038/sj.onc.1210267	http://dx.doi.org/10.1038/sj.onc.1210267			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297455				2022-12-25	WOS:000248037900008
J	Kohonen-Corish, MRJ; Sigglekow, ND; Susanto, J; Chapuis, PH; Bokey, EL; Dent, OF; Chan, C; Lin, BPC; Seng, TJ; Laird, PW; Young, J; Leggett, BA; Jass, JR; Sutherland, RL				Kohonen-Corish, M. R. J.; Sigglekow, N. D.; Susanto, J.; Chapuis, P. H.; bokey, E. L.; Dent, O. F.; Chan, C.; Lin, B. P. C.; Seng, T. J.; Laird, P. W.; Young, J.; Leggett, B. A.; Jass, J. R.; Sutherland, R. L.			Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer	ONCOGENE			English	Article						mutated in colorectal cancer (MCC); promoter hypermethylation; serrated polyps; clinico-pathologic correlations	NF-KAPPA-B; MICROSATELLITE INSTABILITY; SERRATED POLYPS; DNA METHYLATION; BRAF MUTATION; COLON-CANCER; K-RAS; PHENOTYPE; MCC; HYPERMETHYLATION	The mutated in colorectal cancer (MCC) gene is in close linkage with the adenomatous polyposis coli (APC) gene on chromosome 5, in a region of frequent loss of heterozygosity in colorectal cancer. The role of MCC in carcinogenesis, however, has not been extensively analysed, and functional studies are emerging, which implicate it as a candidate tumor suppressor gene. The aim of this study was to examine loss of MCC expression due to promoter hypermethylation and its clinicopathologic signifi. cance in colorectal cancer. Correspondence of MCC methylation with gene silencing was demonstrated using bisulfi. te sequencing, reverse transcription-polymerase chain reaction and Western blotting. MCC methylation was detected in 45-52% of 187 primary colorectal cancers. There was a striking association with CDKN2A methylation (P < 0.0001), the CpG island methylator phenotype ( P < 0.0001) and the BRAF V600E mutation (P < 0.0001). MCC methylation was also more common (P = 0.0084) in serrated polyps than in adenomas. In contrast, there was no association with APC methylation or KRAS mutations. This study demonstrates for the. first time that MCC methylation is a frequent change during colorectal carcinogenesis. Furthermore, MCC methylation is significantly associated with a distinct spectrum of precursor lesions, which are suggested to give rise to cancers via the serrated neoplasia pathway.	Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Univ New S Wales, Fac Med, St Vincents Clin Sch, Kensington, NSW 2033, Australia; Concord Hosp, Dept Colorectal Surg, Sydney, NSW, Australia; Univ Sydney, Sydney, NSW, Australia; Concord Hosp, Dept Anat Pathol, Sydney, NSW, Australia; USC Norris Comprehens Canc Ctr, Los Angeles, CA USA; Queensland Inst Med Res, Mol Canc Epidemiol Lab, Herston, Qld, Australia; Royal Brisbane & Womens Hosp Fdn, Conjoint Gastroenterol Lab, Brisbane, Qld, Australia; Queensland Inst Med Res, Brisbane, Qld 4006, Australia; McGill Univ, Dept Pathol, Montreal, PQ, Canada	Garvan Institute of Medical Research; University of New South Wales Sydney; Concord Repatriation General Hospital; University of Sydney; Concord Repatriation General Hospital; University of Southern California; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; QIMR Berghofer Medical Research Institute; McGill University	Kohonen-Corish, MRJ (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	m.corish@garvan.org.au	Laird, Peter W/G-8683-2012; Young, Joanne P/B-9981-2011; Sutherland, Robert L/A-8378-2008; Young, Joanne P/H-7774-2014; Kohonen-Corish, Maija/Q-9763-2019; Leggett, Barbara A/D-3579-2011	Laird, Peter W/0000-0001-9117-3641; Kohonen-Corish, Maija/0000-0002-4073-1479; Leggett, Barbara/0000-0003-2062-7380	NCI NIH HHS [R01 CA075090, R01 CA118699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075090, R01CA118699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Esteller M, 2000, CANCER RES, V60, P2368; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ikenoue T, 2003, CANCER RES, V63, P8132; Jass JR, 2005, NAT CLIN PRACT ONCOL, V2, P398, DOI 10.1038/ncponc0248; Jass JR, 2000, GUT, V47, P43, DOI 10.1136/gut.47.1.43; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; Kohonen-Corish MRJ, 2005, J CLIN ONCOL, V23, P2318, DOI 10.1200/JCO.2005.00.109; Matsumine A, 1996, J BIOL CHEM, V271, P10341, DOI 10.1074/jbc.271.17.10341; Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; O'Brien MJ, 2004, AM J SURG PATHOL, V28, P423, DOI 10.1097/00000478-200404000-00001; Rashid A, 2001, AM J PATHOL, V159, P1129, DOI 10.1016/S0002-9440(10)61789-0; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Samowitz WS, 2005, GASTROENTEROLOGY, V129, P837, DOI 10.1053/j.gastro.2005.06.020; Senda T, 1999, J HISTOCHEM CYTOCHEM, V47, P1149, DOI 10.1177/002215549904700907; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Ward RL, 2003, J CLIN ONCOL, V21, P3729, DOI 10.1200/JCO.2003.03.123; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Wynter CVA, 2004, GUT, V53, P573, DOI 10.1136/gut.2003.030841	28	59	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4435	4441		10.1038/sj.onc.1210210	http://dx.doi.org/10.1038/sj.onc.1210210			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17260021				2022-12-25	WOS:000247620000011
J	Matus, M; Lewin, G; Stumpel, F; Buchwalow, IB; Schneider, MD; Schutz, G; Schmitz, W; Muller, FU				Matus, Marek; Lewin, Geertje; Stuempel, Frank; Buchwalow, Igor B.; Schneider, Michael D.; Schuetz, Guenther; Schmitz, Wilhelm; Mueller, Frank U.			Cardiomyocyte-specific inactivation of transcription factor CREB in mice	FASEB JOURNAL			English	Article						Cre-loxP system; knockout mice; cAMP responsive element binding protein; heart	ELEMENT-BINDING PROTEIN; CONGESTIVE-HEART-FAILURE; RESPONSE ELEMENT; CYCLIC-AMP; CARDIAC MYOCYTES; NUCLEAR-PROTEIN; TRANSGENIC MICE; GENE-TRANSCRIPTION; SOMATOSTATIN GENE; TARGETED MUTATION	The transcription factor cAMP response element (CRE)-binding protein (CREB, Creb1) plays a critical role in regulating gene expression in response to activation of the cAMP-dependent signaling pathway, which is implicated in the pathophysiology of heart failure. Using the Cre-loxP system, we generated mice with a cardiomyocyte- specific inactivation of CREB and studied in this model whether CREB is critical for cardiac function. CREB-deficient mice were viable and displayed neither changes in cardiac morphology nor alterations of basal or isoproterenol-stimulated left ventricular function in vivo or of important cardiac regulatory proteins. Since CREB was proposed as a negative regulator of cardiomyocyte apoptosis by enhancing the expression of the antiapoptotic protein Bcl-2, we analyzed the fragmentation of DNA, the activity of caspases 3/7 and the expression of Bcl-2 and did not observe any differences between CREB-deficient and CREB- normal hearts. Our results suggest that the presence of CREB is not critical for normal cardiac function in mice.-Matus M., Lewin G., Stumpel F., Buchwalow I. B., Schneider M. D., Schutz G., Schmitz W., and Muller F. U. Cardiomyocyte-specific inactivation of transcription factor CREB in mice.	Univ Munster, Inst Pharmacol & Toxicol, D-48129 Munster, Germany; Univ Munster, Inst Pathol, D-48129 Munster, Germany; Baylor Coll Med, Ctr Cardiovasc Dev, Dept Med, Houston, TX USA; German Canc Res Ctr, Div Mol Biol Cell 1, Heidelberg, Germany	University of Munster; University of Munster; Baylor College of Medicine; Helmholtz Association; German Cancer Research Center (DKFZ)	Muller, FU (corresponding author), Univ Munster, Inst Pharmacol & Toxicol, Domagkstr 12, D-48129 Munster, Germany.	mullerf@uni-muenster.de		Schneider, Michael/0000-0001-9645-1938				Agah R, 1997, J CLIN INVEST, V100, P169, DOI 10.1172/JCI119509; Antos CL, 2003, J BIOL CHEM, V278, P28930, DOI 10.1074/jbc.M303113200; Backs J, 2006, CIRC RES, V98, P15, DOI 10.1161/01.RES.0000197782.21444.8f; Blendy JA, 1996, EMBO J, V15, P1098, DOI 10.1002/j.1460-2075.1996.tb00447.x; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Buchwalow IB, 2004, NITRIC OXIDE-BIOL CH, V10, P203, DOI 10.1016/j.niox.2004.04.004; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; Colucci WS, 1997, AM J CARDIOL, V80, pL15, DOI 10.1016/S0002-9149(97)00845-X; Colucci WS., 1997, HEART DIS TXB CARDIO, P394; Felker GM, 2001, AM HEART J, V142, P932, DOI 10.1067/mhj.2001.119611; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Freeland K, 2001, MOL BRAIN RES, V92, P98, DOI 10.1016/S0169-328X(01)00158-9; GOLDSPINK PH, 1994, CIRC RES, V74, P1042, DOI 10.1161/01.RES.74.6.1042; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Gusterson RJ, 2003, J BIOL CHEM, V278, P6838, DOI 10.1074/jbc.M211762200; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; Husse B, 2005, BIOCHEM BIOPH RES CO, V334, P1260, DOI 10.1016/j.bbrc.2005.06.206; Isoda T, 2003, FASEB J, V17, P144, DOI 10.1096/fj.01-0981com; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mantamadiotis T, 2002, NAT GENET, V31, P47, DOI 10.1038/ng882; Mantamadiotis T, 1998, BIOTECHNIQUES, V25, P968, DOI 10.2144/98256bm07; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mehrhof FB, 2001, CIRCULATION, V104, P2088, DOI 10.1161/hc4201.097133; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MULLER FU, 1995, CIRCULATION, V92, P2041, DOI 10.1161/01.CIR.92.8.2041; Muller FU, 1998, FASEB J, V12, P1191; Muller FU, 2005, J BIOL CHEM, V280, P6906, DOI 10.1074/jbc.M407864200; Muller FU, 2004, CELL DEATH DIFFER, V11, P485, DOI 10.1038/sj.cdd.4401383; Muller FU, 2002, FASEB J, V16, P103, DOI 10.1096/fj.02-0486fje; Muller FU, 2001, CARDIOVASC RES, V52, P95, DOI 10.1016/S0008-6363(01)00361-3; OFIR R, 1991, GENE EXPRESSION, V1, P55; Oike Y, 1999, BLOOD, V93, P2771; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; UNG AL, 2000, GENES REV, V14, P272; Yanazume T, 2003, MOL CELL BIOL, V23, P3593, DOI 10.1128/MCB.23.10.3593-3606.2003; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4	49	21	21	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1884	1892		10.1096/fj.06-7915com	http://dx.doi.org/10.1096/fj.06-7915com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17307839				2022-12-25	WOS:000246866500029
J	Kaufman, L; Yang, GZ; Hayashi, K; Ashby, JR; Huang, L; Ross, MJ; Klotman, ME; Klotman, PE				Kaufman, Lewis; Yang, Guozhe; Hayashi, Kayo; Ashby, James R.; Huang, Li; Ross, Michael J.; Klotman, Mary E.; Klotman, Paul E.			The homophilic adhesion molecule sidekick-1 contributes to augmented podocyte aggregation in HIV-associated nephropathy	FASEB JOURNAL			English	Article						HIVAN; pseudocrescent; collapsing glomerulopathy	GLOMERULAR SLIT DIAPHRAGM; IDIOPATHIC COLLAPSING GLOMERULOPATHY; TIGHT JUNCTION PROTEIN; CELL-CELL ADHESION; ACTIN CYTOSKELETON; PHENOTYPE; NEPHRIN; DEDIFFERENTIATION; SUSCEPTIBILITY; PROLIFERATION	The collapsing glomerulopathy of HIV-associated nephropathy (HIVAN) is characterized by podocyte dedifferentiation and proliferation. In affected glomeruli, proliferating podocytes adhere in aggregates to form glomerular pseudocrescents and fill an enlarged Bowman's space. Previously, we reported that sidekick-1 (sdk-1), an adhesion molecule of the immunoglobulin superfamily, was highly up-regulated in HIV-1 transgenic podocytes. In the current work, we explore how sdk-1 overexpression contributes to HIVAN pathogenesis. Murine podocytes infected with HIV-1 virus expressed significantly more sdk-1 than control-infected cells. Podocytes stably transfected with an sdk-1 expression construct grew in large aggregates with a simplified morphology characterized by a disorganized actin cytoskeleton, changes similar to podocytes in HIVAN. In contrast to controls, HIV-1 infected podocytes adhered to stably transfected sdk-1 podocyte aggregates in mixing studies. Furthermore, substrate-released cell sheets of wild-type podocytes were readily dissociated by mechanical stress, whereas HIV-1 podocytes remained in aggregates. The number of HIV-1 podocyte aggregates was significantly reduced in cells expressing a short hairpin RNA (shRNA) construct specific for sdk-1 compared with cells expressing control shRNA. Finally, in a HIVAN mouse model, sdk-1 protein was detected in podocytes in collapsed glomerular tufts and in glomerular pseudocrescents. These findings suggest that sdk-1 is an important mediator of cellular adhesion in HIV-infected podocytes and may contribute to podocyte clustering that is characteristic of pseudocrescent formation in HIVAN.	Mt Sinai Sch Med, Div Nephrol, New York, NY 10029 USA; Mt Sinai Sch Med, Div Infect Dis, New York, NY 10029 USA; Juntendo Univ, Sch Med, Div Nephrol, Tokyo 113, Japan	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Juntendo University	Kaufman, L (corresponding author), Mt Sinai Sch Med, Div Nephrol, Box 1243,1 Gustave L Levy Pl, New York, NY 10029 USA.	lewis.kaufman@mssm.edu	klotman, mary e/A-1921-2016		NIDDK NIH HHS [K08 DK070530, P01 DK056492] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK070530, P01DK056492] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bariety J, 2005, KIDNEY INT, V68, P1109, DOI 10.1111/j.1523-1755.2005.00503.x; Bariety J, 2003, J AM SOC NEPHROL, V14, pS42, DOI 10.1097/01.ASN.0000067651.34743.B0; Bariety J, 1998, KIDNEY INT, V53, P918, DOI 10.1111/j.1523-1755.1998.00845.x; Barisoni L, 2002, MICROSC RES TECHNIQ, V57, P254, DOI 10.1002/jemt.10084; Barisoni L, 1999, J AM SOC NEPHROL, V10, P51; Barisoni L, 2000, KIDNEY INT, V58, P137, DOI 10.1046/j.1523-1755.2000.00149.x; Barisoni L, 2000, KIDNEY INT, V58, P173, DOI 10.1046/j.1523-1755.2000.00152.x; Bruggeman LA, 2000, J AM SOC NEPHROL, V11, P2079, DOI 10.1681/ASN.V11112079; Bruggeman LA, 1997, J CLIN INVEST, V100, P84, DOI 10.1172/JCI119525; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Ciani L, 2003, MOL CELL BIOL, V23, P3575, DOI 10.1128/MCB.23.10.3575-3582.2003; Fedorova E, 2006, J GENE MED, V8, P414, DOI 10.1002/jgm.861; Fogo AB, 2003, SEMIN NEPHROL, V23, P161, DOI 10.1053/snep.2003.50015; Gharavi AG, 2004, P NATL ACAD SCI USA, V101, P2488, DOI 10.1073/pnas.0308649100; Hayashi K, 2005, FASEB J, V19, P614, DOI 10.1096/fj.04-2947fje; He JCJ, 2004, J CLIN INVEST, V114, P643, DOI 10.1172/JCI200421004; Hirabayashi S, 2005, LAB INVEST, V85, P1528, DOI 10.1038/labinvest.3700347; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Huber TB, 2003, J BIOL CHEM, V278, P13417, DOI 10.1074/jbc.C200678200; Huen AC, 2002, J CELL BIOL, V159, P1005, DOI 10.1083/jcb.200206098; Husain M, 2005, AIDS, V19, P1975, DOI 10.1097/01.aids.0000191918.42110.27; Husain M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000019642.55998.69; Jones N, 2006, NATURE, V440, P818, DOI 10.1038/nature04662; Kaufman L, 2004, J AM SOC NEPHROL, V15, P1721, DOI 10.1097/01.ASN.0000128975.28958.C2; Khoshnoodi J, 2003, AM J PATHOL, V163, P2337, DOI 10.1016/S0002-9440(10)63590-0; Kim JM, 2003, SCIENCE, V300, P1298, DOI 10.1126/science.1081068; Liu G, 2003, J CLIN INVEST, V112, P209, DOI 10.1172/JCI200318242; Marras D, 2002, NAT MED, V8, P522, DOI 10.1038/nm0502-522; Monahan M, 2001, SEMIN NEPHROL, V21, P394, DOI 10.1053/snep.2001.23771; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Nguyen DNT, 1997, DEVELOPMENT, V124, P3303; Oh J, 2004, PEDIATR NEPHROL, V19, P130, DOI 10.1007/s00467-003-1367-y; Patek CE, 2003, HUM MOL GENET, V12, P2379, DOI 10.1093/hmg/ddg240; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; Ross MJ, 2006, J AM SOC NEPHROL, V17, P996, DOI 10.1681/ASN.2005070692; Ross MJ, 2002, J AM SOC NEPHROL, V13, P2997, DOI 10.1097/01.ASN.0000040750.40907.99; Schwartz EJ, 2001, J AM SOC NEPHROL, V12, P1677, DOI 10.1681/ASN.V1281677; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI200112849; Silberberg M, 2005, AM J PHYSIOL-RENAL, V288, pF1153, DOI 10.1152/ajprenal.00008.2005; Yamagata M, 2002, CELL, V110, P649, DOI 10.1016/S0092-8674(02)00910-8; Yang Y, 2002, NEPHRON, V91, P416, DOI 10.1159/000064281; Zheng ZY, 2005, P NATL ACAD SCI USA, V102, P2502, DOI 10.1073/pnas.0409786102	43	25	26	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1367	1375		10.1096/fj.06-7191com	http://dx.doi.org/10.1096/fj.06-7191com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17307840				2022-12-25	WOS:000246117000012
J	Methe, H; Groothuis, A; Sayegh, MH; Edelman, ER				Methe, Heiko; Groothuis, Adam; Sayegh, Mohamed H.; Edelman, Elazer R.			Matrix adherence of endothelial cells attenuates immune reactivity: induction of hyporesponsiveness in allo- and xenogeneic models	FASEB JOURNAL			English	Article						three-dimensional collagen matrices; T cells; tolerance; suppression; anergy; rodent	CD8(+) T-CELLS; INTERFERON-GAMMA; CULTURE; ANTIGEN; ATHEROSCLEROSIS; TRANSPLANTATION; INFLAMMATION; STIMULATION; EXPRESSION; MOLECULES	Endothelial integrity regulates vascular tone, luminal patency, and the immune reactivity to tissue grafts. Endothelial dysfunction is the first marker and site of disease initiation and severity. It has long been known that endothelial biochemical function is density dependent, and we have recently shown that endothelial immunobiology is anchorage dependent. Matrix-embedded endothelial cells (EC) establish a controlled anchorage state and are not only immune protected but also induce a system immune protective state. We now define this aspect of vascular and immune biology in detail. The in vitro immune response of allogeneic splenocytes ( proliferation, lytic activity, and cytokine expression) on exposure to aortic EC was significantly reduced if EC were embedded within three-dimensional collagen matrices (3D- EC; P < 0.005) to an even greater extent than EC that had reached confluence as monolayers on tissue culture plates ( EC-TCPS). Splenocyte reactivity was enhanced with repeated exposure to EC-TCPS but minimally if preexposed to 3D- EC ( P < 0.002). 3D- EC induced significantly greater differentiation of splenocytes into CD4(+) CD25(+) Foxp3(+) regulatory T cells than EC-TCPS ( P < 0.02). The reduced response to 3D- EC and potential protective effect to subsequent exposure were confirmed in vivo. Repeated exposure of immunecompetent mice to injections of xenogeneic EC-TCPS induced vigorous host immunity. In contrast, prior implantation of 3D-EC induced hyporesponsiveness toward subsequent injection of EC- TCPS with reduced humoral response, decreased lytic activity, and lower frequency of effector splenocytes ( P < 0.001). EC interaction with its matrix determines phenotype, viability, and biosecretory potential. We now show that this microenvironmental interaction also influences endothelialmediated activation of allo- and xenogeneic immune cells. 3D matrix- embedding limits the ability of EC to initiate adaptive immunity, and initial exposure to 3D-EC confers hyporesponsiveness to subsequent exposure to immunogeneic EC. These effects transcended the traditional control that confluence imposes on EC and reflects perhaps even higher order control. Our findings might offer novel insights to endothelialmediated diseases and potential cell- based therapies. -	MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Transplantat Res Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiovasc, Boston, MA USA	Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Methe, H (corresponding author), MIT, Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave,Bldg 56-322, Cambridge, MA 02139 USA.	hmethe@mit.edu		Sayegh, Mohamed/0000-0002-2847-588X	NHLBI NIH HHS [HL-49039] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cappellesso S, 2002, TRANSPL IMMUNOL, V10, P293, DOI 10.1016/S0966-3274(02)00073-4; CENTRA M, 1992, FASEB J, V6, P3117, DOI 10.1096/fasebj.6.12.1521742; Choi J, 2004, ANNU REV IMMUNOL, V22, P683, DOI 10.1146/annurev.immunol.22.012703.104639; Cid Maria C, 2004, Curr Rheumatol Rep, V6, P184, DOI 10.1007/s11926-004-0067-3; Denton M D, 2000, Pediatr Transplant, V4, P252, DOI 10.1034/j.1399-3046.2000.00031.x; Edelman DB, 2005, EXP NEUROL, V192, P1, DOI 10.1016/j.expneurol.2004.10.005; Gould DS, 1999, IMMUNOL TODAY, V20, P77, DOI 10.1016/S0167-5699(98)01394-2; Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430; Harada H, 2003, J CLIN INVEST, V112, P234, DOI 10.1172/JCI200317008; Kern A, 2001, J INVEST DERMATOL, V117, P112, DOI 10.1046/j.0022-202x.2001.01386.x; Koglin J, 2000, CIRCULATION, V101, P1034, DOI 10.1161/01.CIR.101.9.1034; Krupnick AS, 2005, J IMMUNOL, V175, P6265, DOI 10.4049/jimmunol.175.10.6265; LaGier AJ, 2006, HUM IMMUNOL, V67, P568, DOI 10.1016/j.humimm.2006.04.013; Lee DY, 2004, J BIOMAT SCI-POLYM E, V15, P753, DOI 10.1163/156856204774196144; Limmer A, 2000, NAT MED, V6, P1348, DOI 10.1038/82161; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Marelli-Berg FM, 2000, J IMMUNOL, V165, P4182, DOI 10.4049/jimmunol.165.8.4182; McMillan D E, 1997, Vasc Med, V2, P132; Methe H, 2005, CIRCULATION, V112, pI89, DOI 10.1161/01.CIRCULATIONAHA.105.524991; Methe H, 2005, J HEART LUNG TRANSPL, V24, P833, DOI 10.1016/j.healun.2004.05.014; NATHAN A, 1995, P NATL ACAD SCI USA, V92, P8130, DOI 10.1073/pnas.92.18.8130; Nugent HM, 1999, CIRC RES, V84, P384, DOI 10.1161/01.RES.84.4.384; Nugent HM, 2003, CIRC RES, V92, P1068, DOI 10.1161/01.RES.0000073844.41372.38; Nugent HM, 2001, J SURG RES, V99, P228, DOI 10.1006/jsre.2001.6198; NUGENT MA, 1993, CIRC RES, V73, P1051, DOI 10.1161/01.RES.73.6.1051; Papagianni A, 2003, NEPHROL DIAL TRANSPL, V18, P113, DOI 10.1093/ndt/18.1.113; Perez VL, 1998, CELL IMMUNOL, V189, P31, DOI 10.1006/cimm.1998.1362; Raines EW, 2000, INT J EXP PATHOL, V81, P173, DOI 10.1046/j.1365-2613.2000.00155.x; ROBSON SC, 1995, INT ARCH ALLERGY IMM, V106, P305, DOI 10.1159/000236861; Rosemblatt M, 2004, CURR PHARM DESIGN, V10, P109, DOI 10.2174/1381612043453487; Sasaki T, 2002, CYTOTHERAPY, V4, P285, DOI 10.1080/146532402320219808; Schleicher E, 1996, KIDNEY BLOOD PRESS R, V19, P305, DOI 10.1159/000174091; Siebers U, 1997, ANN NY ACAD SCI, V831, P304; Simeonovic CJ, 1999, CELL TRANSPLANT, V8, P365, DOI 10.1177/096368979900800404; Singh NP, 2003, TRANSPLANTATION, V75, P586, DOI 10.1097/01.TP.0000052594.83318.68; Stegemann JP, 2003, EXP CELL RES, V283, P146, DOI 10.1016/S0014-4827(02)00041-1; Turesson C, 2004, CURR PHARM DESIGN, V10, P129, DOI 10.2174/1381612043453414; Valujskikh A, 2003, CURR OPIN IMMUNOL, V15, P493, DOI 10.1016/S0952-7915(03)00110-9; Wang H, 2000, NAT MED, V6, P549, DOI 10.1038/75029; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WREN SM, 1993, TRANSPLANTATION, V56, P905, DOI 10.1097/00007890-199310000-00025; Zhai Y, 2002, J IMMUNOL, V169, P1270, DOI 10.4049/jimmunol.169.3.1270	42	15	16	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1515	1526		10.1096/fj.06-7051com	http://dx.doi.org/10.1096/fj.06-7051com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264166				2022-12-25	WOS:000246117000026
J	Zhang, Y; Deng, Q; Barbieri, JT				Zhang, Yue; Deng, Qing; Barbieri, Joseph T.			Intracellular localization of type III-delivered Pseudomonas ExoS with endosome vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AERUGINOSA EXOENZYME-S; GTPASE-ACTIVATING PROTEIN; TRANS-GOLGI NETWORK; IMPORTANT VIRULENCE MECHANISM; PLASMA-MEMBRANE; ADP-RIBOSYLATION; IN-VIVO; TERMINAL DOMAIN; EARLY/RECYCLING ENDOSOMES; EUKARYOTIC CELLS	ExoS (453 amino acids) is a bi-functional type III cytotoxin produced by Pseudomonas aeruginosa. Residues 96-219 include the Rho GTPase- activating protein (RhoGAP) domain, and residues 234-453 include the 14-3-3-dependent ADP-ribosyltransferase domain. Earlier studies also identified an N-terminal domain (termed the membrane localization domain) that comprises residues 51-77 and includes a novel leucine-rich motif that targets ExoS to the perinuclear region of cultured cells. There is limited information on how ExoS or other type III cytotoxins enter and target intracellular host proteins. Type III-delivered ExoS localized to both plasma membrane and perinuclear region, whereas ExoS(Delta MLD) was localized to the cytosol. Plasma membrane localization of ExoS was transient and had a half-life of similar to 20 min. Type III-delivered ExoS co-immunoprecipitated 14-3-3 proteins and Rab9, Rab6, and Rab5. Immunofluorescence experiments showed that ExoS colocalized with Rab9, Rab6, and Rab5. Fluorescent energy transfer was detected between ExoS and 14-3-3 proteins but not between ExoS and Rabs proteins. Together, these results indicate that type III-delivered ExoS localizes on the host endosomes and utilizes multiple pathways to traffic from the plasma membrane to the perinuclear region of intoxicated host cells.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Barbieri, JT (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	jtb01@mcw.edu	Deng, Qing/AAC-1123-2020; Deng, Qing/G-3923-2011	Deng, Qing/0000-0002-9254-9951; 	NIAID NIH HHS [AI030162] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030162] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHNERTHILGER G, 1992, BIOCHEM J, V284, P321, DOI 10.1042/bj2840321; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Balleine RL, 2000, GENE CHROMOSOME CANC, V29, P48, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1005>3.0.CO;2-O; Barbieri JT, 2000, INT J MED MICROBIOL, V290, P381; Benabdillah R, 2004, MICROB PATHOGENESIS, V36, P247, DOI 10.1016/j.micpath.2003.12.006; BODEY GP, 1983, REV INFECT DIS, V5, P279; Boutros R, 2003, J MOL BIOL, V332, P675, DOI 10.1016/S0022-2836(03)00944-6; Carroll KS, 2001, SCIENCE, V292, P1373, DOI 10.1126/science.1056791; Centonze VE, 2003, METHOD ENZYMOL, V360, P542; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; COBURN J, 1991, INFECT IMMUN, V59, P4259, DOI 10.1128/IAI.59.11.4259-4262.1991; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Del Nery E, 2006, TRAFFIC, V7, P394, DOI 10.1111/j.1600-0854.2006.00395.x; Deleuil F, 2003, CELL MICROBIOL, V5, P53, DOI 10.1046/j.1462-5822.2003.00236.x; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; Frithz-Lindsten E, 1998, MOL MICROBIOL, V29, P1155, DOI 10.1046/j.1365-2958.1998.00994.x; Ganesan AK, 1998, J BIOL CHEM, V273, P7332, DOI 10.1074/jbc.273.13.7332; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Henriksson ML, 2002, BIOCHEM J, V367, P617, DOI 10.1042/BJ20020714; Henriksson ML, 2002, EUR J BIOCHEM, V269, P4921, DOI 10.1046/j.1432-1033.2002.03191.x; Hoja MR, 2000, EXP CELL RES, V259, P239, DOI 10.1006/excr.2000.4948; IGLEWSKI BH, 1978, P NATL ACAD SCI USA, V75, P3211, DOI 10.1073/pnas.75.7.3211; Iversen TG, 2001, MOL BIOL CELL, V12, P2099, DOI 10.1091/mbc.12.7.2099; Kirkham M, 2005, J CELL BIOL, V168, P465, DOI 10.1083/jcb.200407078; Krall R, 2004, J BIOL CHEM, V279, P2747, DOI 10.1074/jbc.M301963200; Krall R, 2002, INFECT IMMUN, V70, P360, DOI 10.1128/IAI.70.1.360-367.2002; KULICH SM, 1995, INFECT IMMUN, V63, P1; Lencer WI, 2005, BBA-MOL CELL RES, V1746, P314, DOI 10.1016/j.bbamcr.2005.07.007; Letzelter M, 2006, EMBO J, V25, P3223, DOI 10.1038/sj.emboj.7601202; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Mallard F, 2002, J CELL BIOL, V156, P653, DOI 10.1083/jcb.200110081; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; Massol RH, 2004, MOL BIOL CELL, V15, P3631, DOI 10.1091/mbc.E04-04-0283; McDonald C, 2003, J BIOL CHEM, V278, P18514, DOI 10.1074/jbc.M301226200; MELBY EL, 1991, J CELL BIOCHEM, V47, P251, DOI 10.1002/jcb.240470311; MENDELSON MH, 1994, CLIN INFECT DIS, V18, P886, DOI 10.1093/clinids/18.6.886; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Pederson KJ, 1998, MOL MICROBIOL, V30, P751, DOI 10.1046/j.1365-2958.1998.01106.x; Pederson KJ, 1999, MOL MICROBIOL, V32, P393, DOI 10.1046/j.1365-2958.1999.01359.x; Pederson KJ, 2002, MOL MICROBIOL, V46, P1381, DOI 10.1046/j.1365-2958.2002.03256.x; Pederson KJ, 2000, MOL MICROBIOL, V37, P287, DOI 10.1046/j.1365-2958.2000.01990.x; Persson C, 1999, MOL MICROBIOL, V33, P828, DOI 10.1046/j.1365-2958.1999.01529.x; Rabin SDP, 2006, INFECT IMMUN, V74, P2552, DOI 10.1128/IAI.74.5.2552-2561.2006; RIEDERER MA, 1994, J CELL BIOL, V125, P573, DOI 10.1083/jcb.125.3.573; Riese MJ, 2002, J BIOL CHEM, V277, P12082, DOI 10.1074/jbc.M109039200; Riese MJ, 2002, INFECT IMMUN, V70, P2230, DOI 10.1128/IAI.70.4.2230-2232.2002; Rodman JS, 2000, J CELL SCI, V113, P183; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; Sandvig K, 2002, ANNU REV CELL DEV BI, V18, P1, DOI 10.1146/annurev.cellbio.18.011502.142107; SCHWEIZER HP, 1991, GENE, V97, P109, DOI 10.1016/0378-1119(91)90016-5; Skrzypek E, 1998, MOL MICROBIOL, V30, P1051, DOI 10.1046/j.1365-2958.1998.01135.x; Smith DC, 2006, TRAFFIC, V7, P379, DOI 10.1111/j.1600-0854.2006.00391.x; Stirling FR, 2006, CELL MICROBIOL, V8, P1294, DOI 10.1111/j.1462-5822.2006.00710.x; Sun JJ, 2003, J BIOL CHEM, V278, P32794, DOI 10.1074/jbc.M304290200; Utskarpen A, 2006, TRAFFIC, V7, P663, DOI 10.1111/j.1600-0854.2006.00418.x; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743; Willumsen BM, 1996, ONCOGENE, V13, P1901; Yahr TL, 1997, J BACTERIOL, V179, P7165, DOI 10.1128/jb.179.22.7165-7168.1997; Zhang Y, 2005, INFECT IMMUN, V73, P7938, DOI 10.1128/IAI.73.12.7938-7945.2005	64	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13022	13032		10.1074/jbc.M606305200	http://dx.doi.org/10.1074/jbc.M606305200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17311921	hybrid			2022-12-25	WOS:000245942800072
J	Akoachere, M; Squires, RC; Nour, AM; Angelov, L; Brojatsch, J; Abel-Santos, E				Akoachere, Monique; Squires, Raynal C.; Nour, Adel M.; Angelov, Ludmyl; Brojatsch, Jurgen; Abel-Santos, Ernesto			Identification of an in vivo inhibitor of Bacillus anthracis spore germination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOSPORES REQUIRES; CEREUS-T; RESISTANCE; RECEPTORS; ENZYMES; TOXINS; HEAT	Germination of Bacillus anthracis spores into the vegetative form is an essential step in anthrax pathogenicity. This process can be triggered in vitro by the common germinants inosine and alanine. Kinetic analysis of B. anthracis spore germination revealed synergy and a sequential mechanism between inosine and alanine binding to their cognate receptors. Because inosine is a critical germinant in vitro, we screened inosine analogs for the ability to block in vitro germination of B. anthracis spores. Seven analogs efficiently blocked this process in vitro. This led to the identification of 6-thioguanosine, which also efficiently blocked spore germination in macrophages and prevented killing of these cells mediated by B. anthracis spores. 6-Thioguanosine shows potential as an anti-anthrax therapeutic agent.	Univ Nevada, Dept Chem, Las Vegas, NV 89154 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Nevada System of Higher Education (NSHE); University of Nevada Las Vegas; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Brojatsch, J (corresponding author), Univ Nevada, Dept Chem, 4505 Maryland Pwy,Box 454003, Las Vegas, NV 89154 USA.	brojatsc@aecom.yu.edu		brojatsch, jurgen/0000-0002-7424-365X	NIAID NIH HHS [AI057158] Funding Source: Medline; PHS HHS [1R01AIGM053212] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U54AI057158] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alileche A, 2006, CELL CYCLE, V5, P100, DOI 10.4161/cc.5.1.2283; Alileche A, 2005, PLOS PATHOG, V1, P150, DOI 10.1371/journal.ppat.0010019; Banks DJ, 2005, CELL MICROBIOL, V7, P1173, DOI 10.1111/j.1462-5822.2005.00545.x; BARANKIEWICZ J, 1985, EUR J IMMUNOL, V15, P627, DOI 10.1002/eji.1830150618; Bonuccelli G, 2005, AM J PHYSIOL-CELL PH, V288, pC1402, DOI 10.1152/ajpcell.00582.2004; BOSCHWITZ H, 1983, J BACTERIOL, V153, P700, DOI 10.1128/JB.153.2.700-708.1983; BOSCHWITZ H, 1985, J BACTERIOL, V164, P302, DOI 10.1128/JB.164.1.302-309.1985; Brittingham KC, 2005, J IMMUNOL, V174, P5545, DOI 10.4049/jimmunol.174.9.5545; Cheng HC, 2001, J PHARMACOL TOX MET, V46, P61, DOI 10.1016/S1056-8719(02)00166-1; Cortezzo DE, 2004, J APPL MICROBIOL, V96, P725, DOI 10.1111/j.1365-2672.2004.02196.x; Coulthard S, 2005, INVEST NEW DRUG, V23, P523, DOI 10.1007/s10637-005-4020-8; Derijks LJJ, 2003, EUR J GASTROEN HEPAT, V15, P63, DOI 10.1097/00042737-200301000-00011; Dixon TC, 2000, CELL MICROBIOL, V2, P453, DOI 10.1046/j.1462-5822.2000.00067.x; Fisher N, 2005, J BACTERIOL, V187, P8055, DOI 10.1128/JB.187.23.8055-8062.2005; FOSTER SJ, 1986, BIOCHEM J, V237, P865, DOI 10.1042/bj2370865; FRANCIS JE, 1991, J MED CHEM, V34, P2570, DOI 10.1021/jm00112a035; Guidi-Rontani C, 1999, MOL MICROBIOL, V31, P9, DOI 10.1046/j.1365-2958.1999.01137.x; Guidi-Rontani C, 2001, MOL MICROBIOL, V42, P931, DOI 10.1046/j.1365-2958.2001.02695.x; Hanna PC, 1999, TRENDS MICROBIOL, V7, P180, DOI 10.1016/S0966-842X(99)01507-3; HILLS GM, 1949, BIOCHEM J, V45, P353, DOI 10.1042/bj0450353; Hornstra LM, 2006, APPL ENVIRON MICROB, V72, P44, DOI 10.1128/AEM.72.1.44-53.2006; Ireland JAW, 2002, J BACTERIOL, V184, P1296, DOI 10.1128/JB.184.5.1296-1303.2002; Ireland JAW, 2002, INFECT IMMUN, V70, P5870, DOI 10.1128/IAI.70.10.5870-5872.2002; Kaina B, 2004, CYTOGENET GENOME RES, V104, P77, DOI 10.1159/000077469; Massa M R, 1975, Nuovi Ann Ig Microbiol, V26, P450; MITCHELL C, 1986, FEMS MICROBIOL LETT, V34, P211; Moayeri M, 2003, J CLIN INVEST, V112, P670, DOI [10.1172/JCI200317991, 10.1172/JCI17991]; Mock M, 2003, CELL MICROBIOL, V5, P15, DOI 10.1046/j.1462-5822.2003.00253.x; Moir A, 2002, CELL MOL LIFE SCI, V59, P403, DOI 10.1007/s00018-002-8432-8; Nicholson WL, 2000, MICROBIOL MOL BIOL R, V64, P548, DOI 10.1128/MMBR.64.3.548-572.2000; Presta M, 1999, CANCER RES, V59, P2417; Read TD, 2003, NATURE, V423, P81, DOI 10.1038/nature01586; RODBARD D, 1974, CLIN CHEM, V20, P1255; Segel IH., 1993, ENZYME KINETICS BEHA; Setlow P, 2006, J APPL MICROBIOL, V101, P514, DOI 10.1111/j.1365-2672.2005.02736.x; SPLITTST.DF, 1966, J BACTERIOL, V92, P995, DOI 10.1128/JB.92.4.995-1001.1966; Tournier JN, 2006, B ACAD NAT MED PARIS, V190, P155, DOI 10.1016/S0001-4079(19)33358-8; TRUJILLO R, 1970, APPL MICROBIOL, V20, P620, DOI 10.1128/AEM.20.4.620-623.1970; WARREN SC, 1968, BIOCHIM BIOPHYS ACTA, V170, P341, DOI 10.1016/0304-4165(68)90014-7; Weiner M, 2003, J BACTERIOL, V185, P1462, DOI 10.1128/JB.185.4.1462-1464.2003; Weiner MA, 2003, INFECT IMMUN, V71, P3954, DOI 10.1128/IAI.71.7.3954-3959.2003; WOESE CR, 1968, P NATL ACAD SCI USA, V59, P869, DOI 10.1073/pnas.59.3.869; WOLGAMOT.GD, 1971, CAN J MICROBIOL, V17, P1043, DOI 10.1139/m71-165; YOUSTEN AA, 1975, CAN J MICROBIOL, V21, P1192, DOI 10.1139/m75-178	44	56	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12112	12118		10.1074/jbc.M611432200	http://dx.doi.org/10.1074/jbc.M611432200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17296608	hybrid			2022-12-25	WOS:000245941900053
J	Seong, HA; Jung, H; Ha, H				Seong, Hyun-A; Jung, Haiyoung; Ha, Hyunjung			NM23-H1 tumor suppressor physically interacts with serine-threonine kinase receptor-associated protein, a transforming growth factor-beta (TGF-beta) receptor-interacting protein, and negatively regulates TGF-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-DIPHOSPHATE KINASE; MIGRATION INHIBITORY FACTOR; X-RAY STRUCTURE; IN-VITRO; IDENTIFICATION; METASTASIS; ENZYME; CELLS; GENE; DIFFERENTIATION	NM23-H1 is a member of the NM23/NDP kinase gene family and a putative metastasis suppressor. Previously, a screen for NM23-H1-interacting proteins that could potentially modulate its activity identified serine-threonine kinase receptor-associated protein (STRAP), a transforming growth factor (TGF)-beta receptor-interacting protein. Through the use of cysteine to serine amino acid substitution mutants of NM23-H1 (C4S, C109S, and C145S) and STRAP (C152S, C270S, and C152S/C270S), we demonstrated that the association between these two proteins is dependent on Cys(145) of NM23-H1 and Cys(152) and Cys(270) of STRAP but did not appear to involve Cys(4) and Cys(109) of NM23-H1, suggesting that a disulfide linkage involving Cys(145) of NM23-H1 and Cys(152) or Cys(270) of STRAP mediates complex formation. The interaction was dependent on the presence of dithiothreitol or beta-mercaptoethanol but not H2O2. Ectopic expression of wild-type NM23-H1, but not NM23-H1(C145S), negatively regulated TGF-beta signaling in a dose-dependent manner, enhanced stable association between the TGF-beta receptor and Smad7, and prevented nuclear translocation of Smad3. Similarly, wild-type NM23-H1 inhibited TGF-beta induced apoptosis and growth inhibition, whereas NM23H1(C145S) had no effect. Knockdown of NM23-H1 by small interfering RNA stimulated TGF-beta signaling. Coexpression of wild-type STRAP, but not STRAP(C152S/C270S), significantly stimulated NM23-H1-induced growth of HaCaT cells. These results suggest that the direct interaction of NM23-H1 and STRAP is important for the regulation of TGF-beta-dependent biological activity as well as NM23-H1 activity.	Chungbuk Natl Univ, Dept Biochem, Sch Life Sci, Res Ctr Bioresource & Hlth,Biotechnol Res Inst, Cheongju 361763, South Korea	Chungbuk National University	Ha, H (corresponding author), Chungbuk Natl Univ, Dept Biochem, Sch Life Sci, Res Ctr Bioresource & Hlth,Biotechnol Res Inst, Cheongju 361763, South Korea.	hyunha@chungbuk.ac.kr						Blum G, 2003, J BIOL CHEM, V278, P40442, DOI 10.1074/jbc.M305490200; CHIADMI M, 1993, STRUCTURE, V1, P283, DOI 10.1016/0969-2126(93)90016-A; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Datta PK, 1998, J BIOL CHEM, V273, P34671, DOI 10.1074/jbc.273.52.34671; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; Engel M, 1998, J BIOL CHEM, V273, P20058, DOI 10.1074/jbc.273.32.20058; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; Gervasi F, 1996, CELL GROWTH DIFFER, V7, P1689; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HOWLETT AR, 1994, J NATL CANCER I, V86, P1838, DOI 10.1093/jnci/86.24.1838; Ishikawa N, 2003, J BIOENERG BIOMEMBR, V35, P7, DOI 10.1023/A:1023433504713; Jung H, 2001, J BIOL CHEM, V276, P15504, DOI 10.1074/jbc.M009620200; KANTOR JD, 1993, CANCER RES, V53, P1971; KIMURA N, 1988, J BIOL CHEM, V263, P4647; Kimura N, 2000, J BIOENERG BIOMEMBR, V32, P309, DOI 10.1023/A:1005549315846; Komachi K, 1997, MOL CELL BIOL, V17, P6023, DOI 10.1128/MCB.17.10.6023; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; Leung SM, 1997, J BIOL CHEM, V272, P2607, DOI 10.1074/jbc.272.5.2607; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Lombardi D, 2003, J BIOENERG BIOMEMBR, V35, P67, DOI 10.1023/A:1023445907439; Ma DQ, 2002, J BIOL CHEM, V277, P1560, DOI 10.1074/jbc.M108359200; Michelotti EF, 1997, J BIOL CHEM, V272, P22526, DOI 10.1074/jbc.272.36.22526; Morera S, 1995, STRUCTURE, V3, P1307, DOI 10.1016/S0969-2126(01)00268-4; Nosaka K, 1998, BIOCHEM BIOPH RES CO, V243, P342, DOI 10.1006/bbrc.1997.8097; Otero AD, 1997, J BIOL CHEM, V272, P14690, DOI 10.1074/jbc.272.23.14690; Otero AD, 2000, J BIOENERG BIOMEMBR, V32, P269, DOI 10.1023/A:1005589029959; Paravicini G, 1996, BIOCHEM BIOPH RES CO, V227, P82, DOI 10.1006/bbrc.1996.1471; Postel EH, 2003, P NATL ACAD SCI USA, V100, P13247, DOI 10.1073/pnas.2333230100; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; Postel EH, 2000, P NATL ACAD SCI USA, V97, P14194, DOI 10.1073/pnas.97.26.14194; Prasad N, 2000, BIOCHEMISTRY-US, V39, P6929, DOI 10.1021/bi000387i; Rochdi MD, 2004, J BIOL CHEM, V279, P18981, DOI 10.1074/jbc.M312621200; Samant RS, 2001, CLIN EXP METASTAS, V18, P683, DOI 10.1023/A:1013124725690; Seong HA, 2005, J BIOL CHEM, V280, P42897, DOI 10.1074/jbc.M507539200; Seong HA, 2003, J BIOL CHEM, V278, P9655, DOI 10.1074/jbc.M207478200; Song EJ, 2000, BIOCHEMISTRY-US, V39, P10090, DOI 10.1021/bi000267a; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Timmons L, 1997, ADV GENET, V35, P207, DOI 10.1016/S0065-2660(08)60451-4; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; Yao KS, 2005, CLIN CANCER RES, V11, P7264, DOI 10.1158/1078-0432.CCR-05-0135; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	43	63	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12075	12096		10.1074/jbc.M609832200	http://dx.doi.org/10.1074/jbc.M609832200			22	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314099	hybrid			2022-12-25	WOS:000245941900050
J	Gassanov, N; Jankowski, M; Danalache, B; Wang, D; Grygorczyk, R; Hoppe, UC; Gutkowska, J				Gassanov, Natig; Jankowski, Marek; Danalache, Bogdan; Wang, Donghao; Grygorczyk, Ryszard; Hoppe, Uta C.; Gutkowska, Jolanta			Arginine vasopressin-mediated cardiac differentiation - Insights into the role of its receptors and nitric oxide signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; INDUCED RELEASE; ES CELLS; EXPRESSION; CARDIOMYOCYTES; SYNTHASE; ATRIAL; SSR149415	Despite the existence of a functional arginine vasopressin ( AVP) system in the adult heart and evidence that AVP induces myogenesis, its significance in cardiomyogenesis is currently unknown. In the present study, we hypothesized a role for AVP in cardiac differentiation of D3 and lineage-specific embryonic stem ( ES) cells expressing green fluorescent protein under the control of atrial natriuretic peptide ( Anp) or myosin light chain-2V ( Mlc-2V) promoters. Furthermore, we investigated the nitric oxide ( NO) involvement in AVP-mediated pathways. AVP exposure increased the number of beating embryoid bodies, fluorescent cells, and expression of Gata-4 and other cardiac genes. V1a and V2 receptors ( V1aR and V2R) differentially mediated these effects in transgenic ES cells, and exhibited a distinct developmentally regulated mRNA expression pattern. A NO synthase inhibitor, L-NAME, powerfully antagonized the AVP-induced effects on cardiogenic differentiation, implicating NO signaling in AVP-mediated pathways. Indeed, AVP elevated the mRNA and protein levels of endothelial NO synthase ( eNOS) through V2R stimulation. Remarkably, increased beating activity was found in AVP-treated ES cells with down-regulated eNOS expression, indicating the significant involvement of additional pathways in cardiomyogenic effects of AVP. Finally, patch clamp recordings revealed specific AVP-induced changes of action potentials and increased L-type Ca2+ ( I-Ca,I- L) current densities in differentiated ventricular phenotypes. Thus, AVP promotes cardiomyocyte differentiation of ES cells and involves Gata-4 and NO signaling. AVP-induced action potential prolongation appears likely to be linked to the increased I-Ca,I- L current in ventricular cells. In conclusion, this report provides new evidence for the essential role of the AVP system in ES cell-derived cardiomyogenesis.	Univ Cologne, Dept Internal Med 3, D-50924 Cologne, Germany; Univ Montreal, CHUM Hotel Dieu, Res Ctr, Montreal, PQ H2W 1T8, Canada	University of Cologne; Universite de Montreal	Gutkowska, J (corresponding author), Pavillon Mason,3850 St Urbain, Montreal, PQ H2W 1T8, Canada.	jolanta.gutkowska@umontreal.ca	Jankowski, Marek/AAF-7643-2019; Danalache, Bogdan Alexandru 1/B-3958-2010	Jankowski, Marek/0000-0002-1245-0733; Grygorczyk, Ryszard/0000-0002-9798-7651				Bani-Yaghoub M, 2004, DEVELOPMENT, V131, P4287, DOI 10.1242/dev.01295; Bernat A, 1997, J PHARMACOL EXP THER, V282, P597; Bloch W, 1999, CARDIOVASC RES, V43, P675, DOI 10.1016/S0008-6363(99)00160-1; Chini B, 1996, FEBS LETT, V397, P201, DOI 10.1016/S0014-5793(96)01135-0; Gassanov N, 2006, CELL CALCIUM, V39, P175, DOI 10.1016/j.ceca.2005.10.008; Gassanov N, 2004, FASEB J, V18, P1710, DOI 10.1096/fj.04-1619fje; Griffante C, 2005, BRIT J PHARMACOL, V146, P744, DOI 10.1038/sj.bjp.0706383; Hay DC, 2004, STEM CELLS, V22, P225, DOI 10.1634/stemcells.22-2-225; Hescheler J, 1997, CARDIOVASC RES, V36, P149, DOI 10.1016/S0008-6363(97)00193-4; Hirata Y, 1997, HYPERTENSION, V29, P58, DOI 10.1161/01.HYP.29.1.58; Holmes CL, 2003, CRIT CARE, V7, P427, DOI 10.1186/cc2337; Hupf H, 1999, CIRC RES, V84, P365, DOI 10.1161/01.RES.84.3.365; Jankowski M, 2001, P NATL ACAD SCI USA, V98, P11765, DOI 10.1073/pnas.201394198; Kanno S, 2004, P NATL ACAD SCI USA, V101, P12277, DOI 10.1073/pnas.0401557101; Kaufmann JE, 2000, J CLIN INVEST, V106, P107, DOI 10.1172/JCI9516; Kaufmann JE, 2003, J THROMB HAEMOST, V1, P821, DOI 10.1046/j.1538-7836.2003.00197.x; Kofidis T, 2004, STEM CELLS, V22, P1239, DOI 10.1634/stemcells.2004-0127; Kolossov E, 1998, J CELL BIOL, V143, P2045, DOI 10.1083/jcb.143.7.2045; Krumenacker JS, 2006, NITRIC OXIDE-BIOL CH, V14, P1, DOI 10.1016/j.niox.2005.06.010; Lagumdzija A, 2005, PEPTIDES, V26, P1661, DOI 10.1016/j.peptides.2005.02.007; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Laugwitz KL, 1999, CIRCULATION, V99, P925, DOI 10.1161/01.CIR.99.7.925; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; McDevitt TC, 2005, J MOL CELL CARDIOL, V39, P865, DOI 10.1016/j.yjmcc.2005.09.007; Menard C, 1999, J BIOL CHEM, V274, P29063, DOI 10.1074/jbc.274.41.29063; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moore JC, 2004, INT J DEV BIOL, V48, P47, DOI 10.1387/ijdb.15005574; Mouillac B, 1995, ADV EXP MED BIOL, V395, P301; Muller M, 2000, FASEB J, V14, P2540, DOI 10.1096/fj.00-0002com; Nakamura Y, 2000, EUR J PHARMACOL, V391, P39, DOI 10.1016/S0014-2999(99)00775-X; NERVI C, 1995, CELL GROWTH DIFFER, V6, P81; Oshikawa S, 2004, MOL PHARMACOL, V65, P623, DOI 10.1124/mol.65.3.623; Paquin J, 2002, P NATL ACAD SCI USA, V99, P9550, DOI 10.1073/pnas.152302499; Park F, 1998, HYPERTENSION, V32, P896, DOI 10.1161/01.HYP.32.5.896; Scicchitano BM, 2005, MOL BIOL CELL, V16, P3632, DOI 10.1091/mbc.E05-01-0055; Scicchitano BM, 2002, MOL ENDOCRINOL, V16, P1407, DOI 10.1210/me.16.6.1407; Serradeil-Le Gal C, 2002, J PHARMACOL EXP THER, V300, P1122; SUGIMOTO T, 1994, J BIOL CHEM, V269, P27088; Tahara A, 2005, PHARMACOL RES, V51, P275, DOI 10.1016/j.phrs.2004.09.006; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; XU YJ, 1991, CIRC RES, V69, P239, DOI 10.1161/01.RES.69.1.239; ZHANG ST, 1995, CIRC RES, V76, P592, DOI 10.1161/01.RES.76.4.592; Zou GM, 2003, BIOL CELL, V95, P365, DOI 10.1016/S0248-4900(03)00079-0	43	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11255	11265		10.1074/jbc.M610769200	http://dx.doi.org/10.1074/jbc.M610769200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17298949	hybrid			2022-12-25	WOS:000245941500048
J	Lasbury, ME; Merali, S; Durant, PJ; Tschang, D; Ray, CA; Lee, CH				Lasbury, Mark E.; Merali, Salim; Durant, Pamela J.; Tschang, Dennis; Ray, Chad A.; Lee, Chao-Hung			Polyamine-mediated apoptosis of alveolar macrophages during Pneumocystis pneumonia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHOALVEOLAR LAVAGE FLUID; NF-KAPPA-B; CARINII-PNEUMONIA; BORDETELLA-PERTUSSIS; CYTOLOGICAL EXAMINATION; INCREASED EXPRESSION; PHAGOCYTIC-ACTIVITY; CASPASE ACTIVATION; HYDROGEN-PEROXIDE; CYTOCHROME-C	The number of alveolar macrophages is decreased during Pneumocystis pneumonia (Pcp), partly because of activation of apoptosis in these cells. This apoptosis occurs in both rat and mouse models of Pcp. Bronchoalveolar lavage (BAL) fluids from Pneumocystis-infected animals were found to contain high levels of polyamines, including spermidine, N1-acetylspermine, and N-1-acetylspermidine. These BAL fluids and exogenous polyamines were able to induce apoptosis in alveolar macrophages. Apoptosis of alveolar macrophages during infection, after incubation with BAL fluids from Pneumocystis-infected animals, or after incubation with polyamines was marked by an increase in intracellular reactive oxygen species, activation of caspases-3 and -9, DNA fragmentation, and leakage of mitochondrial cytochrome c into the cytoplasm. When polyamines were depleted from the BAL fluids of infected animals, the ability of these BAL fluids to induce apoptosis was lost. Interestingly, the apoptosis inducing activity of the polyamine-depleted BAL fluids was restored when polyamines were added back. The results of this study suggested that Pneumocystis infection results in accumulation of high levels of polyamines in the lung. These polyamines activate apoptosis of alveolar macrophages, perhaps because of the ROS that are produced during polyamine metabolism.	Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Amgen Inc, Dept Pharmacokinet & Drug Metab, Thousand Oaks, CA 91320 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Amgen	Lasbury, ME (corresponding author), Indiana Univ, Sch Med, Dept Pathol & Lab Med, 1120 S Dr,Fesler Hall,Rm 406, Indianapolis, IN 46202 USA.	melasbur@iupui.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI062259] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL65170] Funding Source: Medline; NIAID NIH HHS [R01 AI062259] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Atochina EN, 2000, AM J PHYSIOL-LUNG C, V278, pL599, DOI 10.1152/ajplung.2000.278.3.L599; Atochina EN, 2001, J LAB CLIN MED, V137, P429, DOI 10.1067/mlc.2001.115220; Balcewicz-Sablinska MK, 1998, J IMMUNOL, V161, P2636; BARTLETT MS, 1988, J CLIN MICROBIOL, V26, P1100, DOI 10.1128/JCM.26.6.1100-1102.1988; BARTLETT MS, 1994, CLIN DIAGN LAB IMMUN, V1, P511, DOI 10.1128/CDLI.1.5.511-516.1994; BARTLETT MS, 1992, DIAGN MICR INFEC DIS, V15, P129, DOI 10.1016/0732-8893(92)90036-S; Beers MF, 1999, J LAB CLIN MED, V133, P423, DOI 10.1016/S0022-2143(99)90019-7; Benfield TL, 1997, CHEST, V111, P1193, DOI 10.1378/chest.111.5.1193; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen Y, 2003, CANCER RES, V63, P3619; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; FLEURY J, 1985, ACTA CYTOL, V29, P721; FLEURYFEITH J, 1989, CHEST, V95, P1198, DOI 10.1378/chest.95.6.1198; Fraser IP, 2000, MICROBES INFECT, V2, P1305, DOI 10.1016/S1286-4579(00)01283-1; GAJDUSEK DC, 1957, PEDIATRICS, V19, P543; Gobert AP, 2002, J IMMUNOL, V168, P4692, DOI 10.4049/jimmunol.168.9.4692; Goebel S, 1999, MED MICROBIOL IMMUN, V187, P221, DOI 10.1007/s004300050096; Goebel Stefan, 1998, Tokai Journal of Experimental and Clinical Medicine, V23, P351; Gueirard P, 1998, INFECT IMMUN, V66, P1718, DOI 10.1128/IAI.66.4.1718-1725.1998; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HAMPERL H, 1956, AM J PATHOL, V32, P1; Hawel L, 2002, ANAL BIOCHEM, V311, P127, DOI 10.1016/S0003-2697(02)00423-2; Keane J, 1997, INFECT IMMUN, V65, P298, DOI 10.1128/IAI.65.1.298-304.1997; KHELEF N, 1995, FEMS MICROBIOL LETT, V134, P27, DOI 10.1016/0378-1097(95)00375-F; Klingler K, 1997, INFECT IMMUN, V65, P5272, DOI 10.1128/IAI.65.12.5272-5278.1997; Kolls JK, 1999, J IMMUNOL, V162, P2890; Koziel H, 1998, J CLIN INVEST, V102, P1332, DOI 10.1172/JCI560; Kuramoto N, 2003, BRAIN RES, V967, P170, DOI 10.1016/S0006-8993(02)04268-3; Lasbury ME, 2006, J IMMUNOL, V176, P6443, DOI 10.4049/jimmunol.176.11.6443; Lasbury ME, 2003, J EUKARYOT MICROBIOL, V50, P637, DOI 10.1111/j.1550-7408.2003.tb00662.x; Lasbury ME, 2004, INFECT IMMUN, V72, P2140, DOI 10.1128/IAI.72.4.2140-2147.2004; Lasbury ME, 2003, INFECT IMMUN, V71, P4943, DOI 10.1128/IAI.71.9.4943-4952.2003; Lasbury ME, 2003, CLIN DIAGN LAB IMMUN, V10, P293, DOI 10.1128/CDLI.10.2.293-302.2003; LAURSEN AL, 1993, J INFECT DIS, V168, P1466, DOI 10.1093/infdis/168.6.1466; MATSUMOTO Y, 1989, J PROTOZOOL, V36, pS21, DOI 10.1111/j.1550-7408.1989.tb05814.x; Merali S, 1999, J BIOL CHEM, V274, P21017, DOI 10.1074/jbc.274.30.21017; Merali S, 1996, J CHROMATOGR B, V675, P321, DOI 10.1016/0378-4347(95)00363-0; Merali S, 1996, ANTIMICROB AGENTS CH, V40, P973, DOI 10.1128/AAC.40.4.973; Meyer TF, 1999, CLIN INFECT DIS, V28, P433, DOI 10.1086/515160; Molestina RE, 2003, J CELL SCI, V116, P4359, DOI 10.1242/jcs.00683; Muller A, 1999, EMBO J, V18, P339, DOI 10.1093/emboj/18.2.339; NIELSEN H, 1987, ACTA PATH MICRO IM C, V95, P81; OHNO Y, 1985, J BIOL CHEM, V260, P8438; ORIORDAN DM, 1995, J CLIN INVEST, V95, P2699, DOI 10.1172/JCI117972; Payne TM, 2003, J CELL SCI, V116, P4345, DOI 10.1242/jcs.00756; Pollard KJ, 1999, EMBO J, V18, P5622, DOI 10.1093/emboj/18.20.5622; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532, DOI 10.1152/jappl.1986.60.2.532; ROGEL A, 1992, J BIOL CHEM, V267, P22599; SADAGHDAR H, 1992, CHEST, V102, P63, DOI 10.1378/chest.102.1.63; Shah N, 1999, BIOCHEMISTRY-US, V38, P14763, DOI 10.1021/bi991291v; Skelly M, 2003, LANCET, V361, P1267, DOI 10.1016/S0140-6736(03)12984-4; SMITH RL, 1988, CHEST, V93, P60, DOI 10.1378/chest.93.1.60; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Stefanelli C, 1999, FEBS LETT, V451, P95, DOI 10.1016/S0014-5793(99)00549-9; Stefanelli C, 2000, BIOCHEM J, V347, P875, DOI 10.1042/0264-6021:3470875; Stefanelli C, 2002, FEBS LETT, V527, P223, DOI 10.1016/S0014-5793(02)03242-8; SU TH, 1994, ANNU REV MED, V45, P261, DOI 10.1146/annurev.med.45.1.261; Sukumaran SK, 2004, INFECT IMMUN, V72, P6012, DOI 10.1128/IAI.72.10.6012-6022.2004; Tang X, 2000, INFECT IMMUN, V68, P4720, DOI 10.1128/IAI.68.8.4720-4724.2000; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; YOUNG JA, 1986, J CLIN PATHOL, V39, P945, DOI 10.1136/jcp.39.9.945; YOUNG JA, 1984, J CLIN PATHOL, V37, P390, DOI 10.1136/jcp.37.4.390; YOUNG KR, 1985, ANN INTERN MED, V103, P522, DOI 10.7326/0003-4819-103-4-522; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	67	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11009	11020		10.1074/jbc.M611686200	http://dx.doi.org/10.1074/jbc.M611686200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17314093	hybrid			2022-12-25	WOS:000245941500021
J	Muylaert, I; Elias, P				Muylaert, Isabella; Elias, Per			Knockdown of DNA ligase IV/XRCC4 by RNA interference inhibits herpes simplex virus type I DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT LIGATION; REPAIR PROTEINS; GENOME; RECOMBINATION; CIRCULARIZATION; MUTATIONS; GENE; LIFE	Herpes simplex virus has a linear double-stranded DNA genome with directly repeated terminal sequences needed for cleavage and packaging of replicated DNA. In infected cells, linear genomes rapidly become endless. It is currently a matter of discussion whether the endless genomes are circles supporting rolling circle replication or arise by recombination of linear genomes forming concatemers. Here, we have examined the role of mammalian DNA ligases in the herpes simplex virus, type I (HSV-1) life cycle by employing RNA interference (RNAi) in human 1BR.3.N fibroblasts. We find that RNAi-mediated knockdown of DNA ligase IV and its co-factor XRCC4 causes a hundred-fold reduction of virus yield, a small plaque phenotype, and reduced DNA synthesis. The effect is specific because RNAi against DNA ligase I or DNA ligase III fail to reduce HSV-1 replication. Furthermore, RNAi against DNA ligase IV and XRCC4 does not affect replication of adenovirus. In addition, high multiplicity infections of HSV-1 in human DNA ligase IV-deficient cells reveal a pronounced delay of production of infectious virus. Finally, we demonstrate that formation of endless genomes is inhibited by RNAi-mediated depletion of DNA ligase IV and XRCC4. Our results suggests that DNA ligase IV/XRCC4 serves an important role in the replication cycle of herpes viruses and is likely to be required for the formation of the endless genomes early during productive infection.	Gothenburg Univ, Inst Biomed, Dept Med Biochem & Cell Biol, SE-40530 Gothenburg, Sweden	University of Gothenburg	Elias, P (corresponding author), Gothenburg Univ, Inst Biomed, Dept Med Biochem & Cell Biol, Box 440, SE-40530 Gothenburg, Sweden.	per.elias@medkem.gu.se						Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; BARNES DE, 1992, CELL, V69, P495, DOI 10.1016/0092-8674(92)90450-Q; Bentley DJ, 2002, J CELL SCI, V115, P1551; CALDECOTT KW, 1994, MOL CELL BIOL, V14, P68, DOI 10.1128/MCB.14.1.68; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Falkenberg M, 2000, P NATL ACAD SCI USA, V97, P3896, DOI 10.1073/pnas.97.8.3896; GARBER DA, 1993, VIROLOGY, V197, P459, DOI 10.1006/viro.1993.1612; Girard PM, 2004, HUM MOL GENET, V13, P2369, DOI 10.1093/hmg/ddh274; Goldstein JN, 1998, VIROLOGY, V244, P442, DOI 10.1006/viro.1998.9129; Hammarsten O, 1996, J VIROL, V70, P4523, DOI 10.1128/JVI.70.7.4523-4529.1996; Jackson SA, 2003, P NATL ACAD SCI USA, V100, P7871, DOI 10.1073/pnas.1230643100; Kysela B, 2005, P NATL ACAD SCI USA, V102, P1877, DOI 10.1073/pnas.0401179102; Kysela B, 2003, J BIOL CHEM, V278, P22466, DOI 10.1074/jbc.M303273200; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; Lilley CE, 2005, P NATL ACAD SCI USA, V102, P5844, DOI 10.1073/pnas.0501916102; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103; Martin IV, 2002, GENOME BIOL, V3; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Pascal JM, 2004, NATURE, V432, P473, DOI 10.1038/nature03082; Pitcher RS, 2006, MOL CELL, V23, P743, DOI 10.1016/j.molcel.2006.07.009; POFFENBERGER KL, 1985, J VIROL, V53, P587, DOI 10.1128/JVI.53.2.587-595.1985; Porter IM, 2004, J GEN VIROL, V85, P583, DOI 10.1099/vir.0.19657-0; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Sandri-Goldin RM, 2003, P NATL ACAD SCI USA, V100, P7428, DOI 10.1073/pnas.1432875100; Schildgen O, 2005, J VIROL, V79, P7273, DOI 10.1128/JVI.79.11.7273-7278.2005; Severini A, 2003, VIROLOGY, V314, P443, DOI 10.1016/S0042-6822(03)00451-3; Shirata N, 2005, J BIOL CHEM, V280, P30336, DOI 10.1074/jbc.M500976200; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Strang BL, 2005, J VIROL, V79, P12487, DOI 10.1128/JVI.79.19.12487-12494.2005; Su YH, 2002, J GEN VIROL, V83, P2943, DOI 10.1099/0022-1317-83-12-2943; Su YH, 2006, J VIROL, V80, P11589, DOI 10.1128/JVI.01869-06; Taylor TJ, 2004, J VIROL, V78, P5856, DOI 10.1128/JVI.78.11.5856-5866.2004; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; WEBER PC, 1988, CELL, V54, P369, DOI 10.1016/0092-8674(88)90200-0; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003; Wilkinson DE, 2004, J VIROL, V78, P4783, DOI 10.1128/JVI.78.9.4783-4796.2004; Yao XD, 1997, J VIROL, V71, P6842, DOI 10.1128/JVI.71.9.6842-6849.1997; Yao XD, 2001, J BIOL CHEM, V276, P2905, DOI 10.1074/jbc.M005627200	44	46	49	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10865	10872		10.1074/jbc.M611834200	http://dx.doi.org/10.1074/jbc.M611834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17296606	hybrid			2022-12-25	WOS:000245941500005
J	Weyer, K; Boldt, HB; Poulsen, CB; Kjaer-Sorensen, K; Gyrup, C; Oxvig, C				Weyer, Kathrin; Boldt, Henning B.; Poulsen, Christine B.; Kjaer-Sorensen, Kasper; Gyrup, Claus; Oxvig, Claus			A substrate specificity-determining unit of three Lin12-Notch repeat modules is formed in trans within the pappalysin-1 dimer and requires a sequence stretch C-terminal to the third module	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-PROTEIN-A; MAJOR BASIC-PROTEIN; PHYSIOLOGICAL INHIBITOR; PROTEOLYTIC ACTIVATION; DROSOPHILA NOTCH; PAPP-A; DOMAIN; PROFORM; COMPLEX; EXPRESSION	Members of the pappalysin family of metzincin metalloproteinases, pregnancy-associated plasma protein-A (PAPP-A, pappalysin-1) and PAPP-A2 (pappalysin-2), regulate the bioavailability of insulin-like growth factors (IGFs) by specific proteolytic inactivation of IGF-binding proteins (IGFBPs). PAPP-A cleaves IGFBP-4 and IGFBP-5, whereas PAPP-A2 cleaves only IGFBP-5. The pappalysins contain three Lin12-Notch repeat (LNR1-3) modules, previously considered unique to the Notch receptor family in which they function to regulate receptor cleavage. In contrast to the Notch receptor where three LNR modules are tandemly arranged, LNR3 is separated by more than 1000 residues from LNR1-2 in the pappalysin sequence. Each of the three LNR modules of PAPP-A is required for proteolysis of IGFBP-4, but not IGFBP-5. However, we here find that a C-terminal truncated variant of PAPP-A, which lacks LNR3 and therefore activity against IGFBP-4, cleaves IGFBP-4 when co-expressed with a PAPP-A variant, which is mutated in the active site. This suggests that LNR3 from the inactive subunit interacts in trans with LNR1-2 of the truncated PAPP-A subunit to form a functional trimeric LNR unit. We also show that formation of such a functional LNR unit depends on dimerization, as dissociation of a mutated non-covalent PAPP-A dimer results in reduced activity against IGFBP-4, but not IGFBP-5. Using PAPP-A/PAPP-A2 chimeras, we demonstrate that PAPP-A2 LNR1-2, but not LNR3, are functionally conserved with respect to IGFBP proteolysis. Additionally, we find that a sequence stretch C-terminal to LNR3 and single residues (Asp(1521), Arg(1529), and Asp(1530)) within this are required for LNR functionality.	Univ Aarhus, Dept Mol Biol, DK-8000 Aarhus, Denmark	Aarhus University	Oxvig, C (corresponding author), Gustav Wieds Vej 10C, DK-8000 Aarhus, Denmark.	co@mb.au.dk	Kjaer-Sorensen, Kasper/AAF-1457-2020	Oxvig, Claus/0000-0002-4715-9719; Weyer, Kathrin/0000-0002-8473-7987				Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Boldt HB, 2004, J BIOL CHEM, V279, P38525, DOI 10.1074/jbc.M405222200; Boldt HB, 2001, BIOCHEM J, V358, P359, DOI 10.1042/0264-6021:3580359; Boldt HB, 2006, PROTEIN EXPRES PURIF, V48, P261, DOI 10.1016/j.pep.2006.01.024; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Chen BK, 2003, J CLIN ENDOCR METAB, V88, P4465, DOI 10.1210/jc.2003-030193; Conover CA, 2004, DEVELOPMENT, V131, P1187, DOI 10.1242/dev.00997; Conover CA, 2001, ENDOCRINOLOGY, V142, P2155, DOI 10.1210/en.142.5.2155; Cosin-Sales J, 2004, CIRCULATION, V109, P1724, DOI 10.1161/01.CIR.0000124716.67921.D2; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Giudice LC, 2002, J CLIN ENDOCR METAB, V87, P2359, DOI 10.1210/jc.87.5.2359; Glerup S, 2005, J BIOL CHEM, V280, P9823, DOI 10.1074/jbc.M413228200; Gomis-Ruth FX, 2003, MOL BIOTECHNOL, V24, P157, DOI 10.1385/MB:24:2:157; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kashiwagi M, 2004, J BIOL CHEM, V279, P10109, DOI 10.1074/jbc.M312123200; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; KRISTENSEN T, 1994, BIOCHEMISTRY-US, V33, P1592, DOI 10.1021/bi00172a040; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laursen LS, 2002, J BIOL CHEM, V277, P47225, DOI 10.1074/jbc.M209155200; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Lieber T, 2002, GENE DEV, V16, P209, DOI 10.1101/gad.942302; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overgaard MT, 2000, J BIOL CHEM, V275, P31128, DOI 10.1074/jbc.M001384200; Overgaard MT, 2003, J BIOL CHEM, V278, P2106, DOI 10.1074/jbc.M208777200; Overgaard MT, 2001, J BIOL CHEM, V276, P21849, DOI 10.1074/jbc.M102191200; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; OXVIG C, 2004, HDB PROTEOLYTIC ENZY, P754; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Qin QP, 1997, CLIN CHEM, V43, P2323; Rand MD, 2000, MOL CELL BIOL, V20, P1825, DOI 10.1128/MCB.20.5.1825-1835.2000; REBAY I, 1993, CELL, V74, P319, DOI 10.1016/0092-8674(93)90423-N; Sanchez-Irizarry C, 2004, MOL CELL BIOL, V24, P9265, DOI 10.1128/MCB.24.21.9265-9273.2004; Smith GCS, 2002, NATURE, V417, P916, DOI 10.1038/417916a; STOCKER W, 1995, PROTEIN SCI, V4, P823; Tallant C, 2006, J BIOL CHEM, V281, P17920, DOI 10.1074/jbc.M600907200; Vardar D, 2003, BIOCHEMISTRY-US, V42, P7061, DOI 10.1021/bi034156y; Wald NJ, 1999, NEW ENGL J MED, V341, P461, DOI 10.1056/NEJM199908123410701; Weyer K, 2004, EUR J BIOCHEM, V271, P1525, DOI 10.1111/j.1432-1033.2004.04061.x	43	30	30	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10988	10999		10.1074/jbc.M607903200	http://dx.doi.org/10.1074/jbc.M607903200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17314100	hybrid			2022-12-25	WOS:000245941500019
J	Jiang, LI; Collins, J; Davis, R; Lin, KM; DeCamp, D; Roach, T; Hsueh, R; Rebres, RA; Ross, EM; Taussig, R; Fraser, I; Sternweis, PC				Jiang, Lily I.; Collins, Julie; Davis, Richard; Lin, Keng-Mean; DeCamp, Dianne; Roach, Tamara; Hsueh, Robert; Rebres, Robert A.; Ross, Elliott M.; Taussig, Ronald; Fraser, Iain; Sternweis, Paul C.			Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G(13) pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; MULTIPLE SIGNALING PATHWAYS; PROTEIN-COUPLED RECEPTORS; RESONANCE ENERGY-TRANSFER; BETA-GAMMA-SUBUNITS; ADENYLYL-CYCLASE; FLUORESCENT INDICATORS; EPAC ACTIVATION; CROSS-TALK; CELL-LINE	Regulation of intracellular cyclic adenosine 3',5'-monophosphate ( cAMP) is integral in mediating cell growth, cell differentiation, and immune responses in hematopoietic cells. To facilitate studies of cAMP regulation we developed a BRET ( (b) under bar ioluminescence (r) under bar esonance (e) under bar nergy (t) under bar ransfer) sensor for cAMP, CAMYEL ( (cAMP) under bar sensor using (Y) under bar FP-(E) under bar pac-R (L) under bar uc), which can quantitatively and rapidly monitor intracellular concentrations of cAMP in vivo. This sensor was used to characterize three distinct pathways for modulation of cAMP synthesis stimulated by presumed G(s)-dependent receptors for isoproterenol and prostaglandin E-2. Whereas two ligands, uridine 5'-diphosphate and complement C5a, appear to use known mechanisms for augmentation of cAMP via G(q)/calcium and G(i), the action of sphingosine 1-phosphate ( S1P) is novel. In these cells, S1P, a biologically active lysophospholipid, greatly enhances increases in intracellular cAMP triggered by the ligands for G(s)-coupled receptors while having only a minimal effect by itself. The enhancement of cAMP by S1P is resistant to pertussis toxin and independent of intracellular calcium. Studies with RNAi and chemical perturbations demonstrate that the effect of S1P is mediated by the S1P(2) receptor and the heterotrimeric G(13) protein. Thus in these macrophage cells, all four major classes of G proteins can regulate intracellular cAMP.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Calif San Francisco, Vet Adm Med Ctr, San Francisco, CA 94121 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); California Institute of Technology	Jiang, LI (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	lily.jiang@utsouthwestern.edu; paul.sternweis@utsouthwestern.edu	Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, U54GM062114] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 62114, U54 GM062114, U54 GM062114-07, R01 GM030355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bos JL, 2003, NAT REV MOL CELL BIO, V4, P733, DOI 10.1038/nrm1197; Boute N, 2002, TRENDS PHARMACOL SCI, V23, P351, DOI 10.1016/S0165-6147(02)02062-X; BRASS LF, 1992, BIOCHEM J, V281, P73, DOI 10.1042/bj2810073; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Castro A, 2005, MED RES REV, V25, P229, DOI 10.1002/med.20020; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chin KV, 2002, ANN NY ACAD SCI, V968, P49, DOI 10.1111/j.1749-6632.2002.tb04326.x; DiPilato LM, 2004, P NATL ACAD SCI USA, V101, P16513, DOI 10.1073/pnas.0405973101; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Haslauer M, 1998, MOL PHARMACOL, V53, P837; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Houslay MD, 1997, TRENDS BIOCHEM SCI, V22, P217, DOI 10.1016/S0968-0004(97)01050-5; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Lania A, 2001, EUR J ENDOCRINOL, V145, P543, DOI 10.1530/eje.0.1450543; Lerner A, 2006, BIOCHEM J, V393, P21, DOI 10.1042/BJ20051368; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MacKenzie SJ, 2002, BRIT J PHARMACOL, V136, P421, DOI 10.1038/sj.bjp.0704743; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Movsesian MA, 2005, CURR TOP DEV BIOL, V68, P25, DOI 10.1016/S0070-2153(05)68002-7; Nagai T, 2004, P NATL ACAD SCI USA, V101, P10554, DOI 10.1073/pnas.0400417101; Natarajan M, 2006, NAT CELL BIOL, V8, P571, DOI 10.1038/ncb1418; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006-291X(02)02671-2; Ponsioen B, 2004, EMBO REP, V5, P1176, DOI 10.1038/sj.embor.7400290; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Rehmann H, 2006, NATURE, V439, P625, DOI 10.1038/nature04468; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Rosen H, 2005, NAT REV IMMUNOL, V5, P560, DOI 10.1038/nri1650; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; SINGER WD, 1994, J BIOL CHEM, V269, P19796; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; Sunahara Roger K, 2002, Mol Interv, V2, P168, DOI 10.1124/mi.2.3.168; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TURNER JT, 1992, J PHARMACOL EXP THER, V263, P708; Wang HB, 2003, MOL PHARMACOL, V63, P463, DOI 10.1124/mol.63.3.463; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345; Zhao AZ, 2002, NAT NEUROSCI, V5, P727, DOI 10.1038/nn885	47	221	228	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10576	10584		10.1074/jbc.M609695200	http://dx.doi.org/10.1074/jbc.M609695200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283075	Green Accepted, hybrid			2022-12-25	WOS:000245941000051
J	Maertens, B; Hopkins, D; Franzke, CW; Keene, DR; Bruckner-Tuderman, L; Greenspan, DS; Koch, M				Maertens, Barbara; Hopkins, Delana; Franzke, Claus-Werner; Keene, Douglas R.; Bruckner-Tuderman, Leena; Greenspan, Daniel S.; Koch, Manuel			Cleavage and oligomerization of gliomedin, a transmembrane collagen required for node of Ranvier formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; OPEN-ANGLE GLAUCOMA; OLFACTOMEDIN-DOMAIN; XIII COLLAGEN; MOLECULAR-CLONING; ADHESION PROTEIN; HUMAN MYOCILIN; FURIN; EXPRESSION; GLYCOPROTEIN	Gliomedin, which has been implicated as a major player in genesis of the nodes of Ranvier, contains two collagenous domains and an olfactomedin-like domain and belongs to the group of type II transmembrane collagens that includes collagens XIII and XVII and ectodysplasin A. One characteristic of this protein family is that constituent proteins can exist in both transmembrane and soluble forms. Recently, gliomedin expressed at the tips of Schwann cell microvilli was found to bind axonal adhesion molecules neurofascin and NrCAM in interactions essential for Na+-channel clustering at the nodes of Ranvier in myelinating peripheral nerves. Interestingly, exogenously added olfactomedin domain was found to have the same effect as intact gliomedin. Here we analyze the tissue form of gliomedin and demonstrate that the molecule not only exists as full-length gliomedin but also as a soluble form shed from the cell surface in a furin-dependent manner. In addition, gliomedin can be further proteolytically processed by bone morphogenetic protein 1/Tolloid-like enzymes, resulting in release of the olfactomedin domain from the collagen domains. Interestingly, the later cleavage induces formation of higher order, insoluble molecular aggregates that may play important roles in Na+-channel clustering.	Univ Cologne, Fac Med, Ctr Biochem, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Dept Dermatol, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Ctr Mol Med Cologne, D-50931 Cologne, Germany; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Program Mol & Cellular Pharmacol, Madison, WI 53706 USA; Univ Freiburg, Dept Dermatol, D-79104 Freiburg, Germany; Shriners Hosp Children, Res Ctr, Portland, OR 97239 USA	University of Cologne; University of Cologne; University of Cologne; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Freiburg	Koch, M (corresponding author), Univ Cologne, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	Manuel.Koch@uni-koeln.de	Koch, Manuel/AAG-9914-2021	Koch, Manuel/0000-0002-2962-7814; Greenspan, Daniel/0000-0001-8096-7446	NIGMS NIH HHS [R01 GM71679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aroca-Aguilar JD, 2005, J BIOL CHEM, V280, P21043, DOI 10.1074/jbc.M501340200; Barembaum M, 2000, NAT CELL BIOL, V2, P219, DOI 10.1038/35008643; Bosio A, 1998, J NEUROCHEM, V70, P308; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; Eshed Y, 2005, NEURON, V47, P215, DOI 10.1016/j.neuron.2005.06.026; Feltri ML, 2005, J PERIPHER NERV SYST, V10, P128, DOI 10.1111/j.1085-9489.2005.0010204.x; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; Franzke CW, 2005, J BIOL CHEM, V280, P4005, DOI 10.1074/jbc.R400034200; Furutani Y, 2005, BIOCHEM J, V389, P675, DOI 10.1042/BJ20050120; GARTEN W, 1994, BIOCHIMIE, V76, P217, DOI 10.1016/0300-9084(94)90149-X; Ge Gaoxiang, 2006, Birth Defects Research, V78, P47, DOI 10.1002/bdrc.20060; Ge GX, 2005, MOL CELL BIOL, V25, P5846, DOI 10.1128/MCB.25.14.5846-5858.2005; Girault JA, 2002, CURR OPIN NEUROBIOL, V12, P476, DOI 10.1016/S0959-4388(02)00370-7; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Henrich S, 2005, J MOL BIOL, V345, P211, DOI 10.1016/j.jmb.2004.10.050; Henrich S, 2003, NAT STRUCT BIOL, V10, P520, DOI 10.1038/nsb941; Hillier BJ, 2006, ACTA CRYSTALLOGR F, V62, P16, DOI 10.1107/S1744309105038996; Hillier BJ, 2003, J CELL BIOL, V160, P597, DOI 10.1083/jcb.200210053; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Koch M, 2004, J BIOL CHEM, V279, P22514, DOI 10.1074/jbc.M400536200; Kubota R, 1997, GENOMICS, V41, P360, DOI 10.1006/geno.1997.4682; Kubota R, 1998, BIOCHEM BIOPH RES CO, V242, P396, DOI 10.1006/bbrc.1997.7972; Lambert S, 1997, J NEUROSCI, V17, P7025; Latvanlehto A, 2003, J BIOL CHEM, V278, P37590, DOI 10.1074/jbc.M305974200; Loria PM, 2004, J NEUROSCI, V24, P2191, DOI 10.1523/JNEUROSCI.5462-03.2004; Moreno TA, 2005, DEV BIOL, V288, P434, DOI 10.1016/j.ydbio.2005.09.050; Myllyharju J, 2004, TRENDS GENET, V20, P33, DOI 10.1016/j.tig.2003.11.004; Nagy I, 2003, BIOCHEM BIOPH RES CO, V302, P554, DOI 10.1016/S0006-291X(03)00198-0; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nguyen TD, 1998, J BIOL CHEM, V273, P6341, DOI 10.1074/jbc.273.11.6341; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Ricard CS, 2005, EXP EYE RES, V81, P501, DOI 10.1016/j.exer.2005.06.014; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; SNYDER DA, 1991, BIOCHEMISTRY-US, V30, P9143, DOI 10.1021/bi00102a004; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Torrado M, 2002, HUM MOL GENET, V11, P1291, DOI 10.1093/hmg/11.11.1291; Tsuda H, 2002, NEURON, V33, P515, DOI 10.1016/S0896-6273(02)00590-1; Vabnick I, 1996, J NEUROSCI, V16, P4914; Vaisanen MR, 2004, BIOCHEM J, V380, P685, DOI 10.1042/BJ20031974; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; WAXMAN SG, 1993, ANN NEUROL, V33, P121, DOI 10.1002/ana.410330202; YOKOE H, 1993, P NATL ACAD SCI USA, V90, P4655, DOI 10.1073/pnas.90.10.4655	46	73	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10647	10659		10.1074/jbc.M611339200	http://dx.doi.org/10.1074/jbc.M611339200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17293346	hybrid			2022-12-25	WOS:000245941000059
J	Stauffer, D; Chang, B; Huang, J; Dunn, A; Thayer, M				Stauffer, Daniel; Chang, Bill; Huang, Jing; Dunn, Andrew; Thayer, Mathew			p300/CREB-binding protein interacts with ATR and is required for the DNA replication checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DAMAGE CHECKPOINT; S-PHASE; HISTONE ACETYLTRANSFERASE; COACTIVATOR P300; KINASE ATR; GENE; ACETYLATION; P53; ACTIVATION	The highly related acetyltransferases, p300 and CREB-binding protein (CBP) are coactivators of signal-responsive transcriptional activation. In addition, recent evidence suggests that p300/CBP also interacts directly with complexes that mediate DNA replication and repair. In this report, we show that loss of p300/CBP in mammalian cells results in a defect in the cell cycle arrest induced by stalled DNA replication. We demonstrate that complexes containing p300/CBP and ATR can be detected in mammalian cells, and that the downstream kinase CHK1 fails to be phosphorylated in response to stalled DNA replication in cells that lack p300/CBP. These observations broaden the roles for the p300/CBP acetyltransferases to include the modulation of chromatin structure and function during DNA metabolic events as well as for transcription.	Oregon Hlth & Sci Univ, Dept Biochem, Portland, OR 97201 USA	Oregon Health & Science University	Thayer, M (corresponding author), 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	thayerm@ohsu.edu		Chang, Bill/0000-0003-3783-1820	NATIONAL CANCER INSTITUTE [R01CA097021, R01CA104693] Funding Source: NIH RePORTER; NCI NIH HHS [CA97021, CA104693] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Ariumi Y, 2005, J VIROL, V79, P2973, DOI 10.1128/JVI.79.5.2973-2978.2005; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chan HM, 2001, J CELL SCI, V114, P2363; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Friedrich-Heineken F, 2005, J MOL BIOL, V353, P980, DOI 10.1016/j.jmb.2005.09.018; Garcia-Muse T, 2005, EMBO J, V24, P4345, DOI 10.1038/sj.emboj.7600896; Goodman RH, 2000, GENE DEV, V14, P1553; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hasan S, 2002, MOL CELL, V10, P1213, DOI 10.1016/S1097-2765(02)00745-1; Hasan S, 2001, MOL CELL, V7, P1221, DOI 10.1016/S1097-2765(01)00272-6; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Ho CC, 2006, CANCER RES, V66, P2233, DOI 10.1158/0008-5472.CAN-05-1790; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Kung AL, 2000, GENE DEV, V14, P272; Kuninger D, 2004, HUM GENE THER, V15, P1287, DOI 10.1089/hum.2004.15.1287; Liu QH, 2000, GENE DEV, V14, P1448; Livengood JA, 2002, J BIOL CHEM, V277, P9054, DOI 10.1074/jbc.M108870200; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Naryzhny SN, 2004, J BIOL CHEM, V279, P20194, DOI 10.1074/jbc.M312850200; Nayak BK, 2002, ONCOGENE, V21, P7226, DOI 10.1038/sj.onc.1205889; Pichierri P, 2004, BIOESSAYS, V26, P306, DOI 10.1002/bies.10411; Pichierri P, 2003, ONCOGENE, V22, P1491, DOI 10.1038/sj.onc.1206169; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Sharma S, 2004, MOL BIOL CELL, V15, P734, DOI 10.1091/mbc.E03-08-0567; Shiomi Y, 2002, GENES CELLS, V7, P861, DOI 10.1046/j.1365-2443.2002.00566.x; Sibon OCM, 1999, CURR BIOL, V9, P302, DOI 10.1016/S0960-9822(99)80138-9; Smolik S, 2007, MOL CELL BIOL, V27, P135, DOI 10.1128/MCB.01283-06; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang J, 2005, MOL CELL BIOL, V25, P9910, DOI 10.1128/MCB.25.22.9910-9919.2005; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	58	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9678	9687		10.1074/jbc.M609261200	http://dx.doi.org/10.1074/jbc.M609261200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272271	hybrid			2022-12-25	WOS:000245421700041
J	Umate, P; Schwenkert, S; Karbat, I; Dal Bosco, C; Mlcochova, L; Volz, S; Zer, H; Herrmann, RG; Ohad, I; Meurer, J				Umate, Pavan; Schwenkert, Serena; Karbat, Izhar; Dal Bosco, Cristina; Mlcochova, Lada; Volz, Stefanie; Zer, Hagit; Herrmann, Reinhold G.; Ohad, Itzhak; Meurer, Joerg			Deletion of PsbM in tobacco alters the Q(B) site properties and the electron flow within photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-HARVESTING-COMPLEX; MOLECULAR-MASS SUBUNITS; THERMO-LUMINESCENCE; CHLAMYDOMONAS-REINHARDTII; PROTEIN-PHOSPHORYLATION; CHARGE ACCUMULATION; CYTOCHROME B(559); CRYSTAL-STRUCTURE; PLASTOQUINONE; OXIDATION	Photosystem II, the oxygen-evolving complex of photosynthetic organisms, includes an intriguingly large number of low molecular weight polypeptides, including PsbM. Here we describe the first knock-out of psbM using a transplastomic, reverse genetics approach in a higher plant. Homoplastomic Delta psbM plants exhibit photoautotrophic growth. Biochemical, biophysical, and immunological analyses demonstrate that PsbM is not required for biogenesis of higher order photosystem 11 complexes. However, photosystem 11 is highly light-sensitive, and its activity is significantly decreased in ApsbM, whereas kinetics of plastid protein synthesis, reassembly of photosystem 11, and recovery of its activity are comparable with the wild type. Unlike wild type, phosphorylation of the reaction center proteins D1 and D2 is severely reduced, whereas the redox-controlled phosphorylation of photosystem 11 light-harvesting complex is reversely regulated in ApsbM plants because of accumulation of reduced plastoquinone in the dark and a limited photosystem II-mediated electron transport in the light. Charge recombination in ApsbM measured by thermoluminescence oscillations significantly differs from the 2/6 patterns in the wild type. A simulation program of thermoluminescence oscillations indicates a higher Q(B)/Q(B)(-) ratio in dark-adapted mutant thylakoids relative to the wild type. The interaction of the Q(A)/Q(B) sites estimated by shifts in the maximal thermoluminescence emission temperature of the Q band, induced by binding of different herbicides to the Q(B) site, is changed indicating alteration of the activation energy for back electron flow. We conclude that PsbM is primarily involved in the interaction of the redox components important for the electron flow within, outward, and backward to photosystem II.	Univ Munich, Dept Biol 1, D-80638 Munich, Germany; Tel Aviv Univ, Dept Plant Sci, George S Wise Fac Life Sci, IL-69978 Tel Aviv, Israel; Hebrew Univ Jerusalem, Even Ari Ctr Photosynthesis Res, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Biol Chem, Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	University of Munich; Tel Aviv University; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Meurer, J (corresponding author), Univ Munich, Dept Biol 1, Menzingerstr 67, D-80638 Munich, Germany.	joerg.meurer@lrz.uni-muenchen.de	Meurer, Jörg/F-8479-2010; Schwenkert, Serena/F-8564-2012	Meurer, Jörg/0000-0003-2973-9514; Dal Bosco, Cristina/0000-0002-0280-5369				Adir N, 2003, PHOTOSYNTH RES, V76, P343, DOI 10.1023/A:1024969518145; Allen JF, 2005, CURR BIOL, V15, pR929, DOI 10.1016/j.cub.2005.10.061; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; Bondarava N, 2003, J BIOL CHEM, V278, P13554, DOI 10.1074/jbc.M212842200; Clausen J, 2004, BBA-BIOENERGETICS, V1655, P184, DOI 10.1016/j.bbabio.2003.06.001; CORANA A, 1987, ACM T MATH SOFTWARE, V13, P262, DOI 10.1145/29380.29864; Dekker JP, 2005, BBA-BIOENERGETICS, V1706, P12, DOI 10.1016/j.bbabio.2004.09.009; DEMETER S, 1984, BIOCHIM BIOPHYS ACTA, V764, P24, DOI 10.1016/0005-2728(84)90136-1; DEVAULT D, 1983, P NATL ACAD SCI-BIOL, V80, P983, DOI 10.1073/pnas.80.4.983; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; Ducruet JM, 2003, J EXP BOT, V54, P2419, DOI 10.1093/jxb/erg268; Feild TS, 1998, PLANT PHYSIOL, V116, P1209, DOI 10.1104/pp.116.4.1209; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Gomez SM, 2002, MOL CELL PROTEOMICS, V1, P46, DOI 10.1074/mcp.M100007-MCP200; Granvogl B, 2006, PROTEOMICS, V6, P3681, DOI 10.1002/pmic.200500924; Hankamer B, 2001, J STRUCT BIOL, V135, P262, DOI 10.1006/jsbi.2001.4405; Haumann M, 2005, SCIENCE, V310, P1019, DOI 10.1126/science.1117551; Ikeuchi M, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL III, P297; IKEUCHI M, 1989, FEBS LETT, V253, P178, DOI 10.1016/0014-5793(89)80954-8; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kashino Y, 2002, BIOCHEMISTRY-US, V41, P8004, DOI 10.1021/bi026012+; KLESS H, 1993, Z NATURFORSCH C, V48, P185; KLUGHAMMER C, 1994, PLANTA, V192, P261, DOI 10.1007/BF01089043; Koop HU, 1996, PLANTA, V199, P193, DOI 10.1007/BF00196559; Krieger-Liszkay A, 1998, BIOCHEMISTRY-US, V37, P17339, DOI 10.1021/bi9822628; Liu ZF, 2004, NATURE, V428, P287, DOI 10.1038/nature02373; Loll B, 2005, NATURE, V438, P1040, DOI 10.1038/nature04224; Lunde C, 2000, NATURE, V408, P613, DOI 10.1038/35046121; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; Minagawa J, 2004, PHOTOSYNTH RES, V82, P241, DOI 10.1007/s11120-004-2079-2; Munekage Y, 2002, CELL, V110, P361, DOI 10.1016/S0092-8674(02)00867-X; Nelson N, 2004, NAT REV MOL CELL BIO, V5, P971, DOI 10.1038/nrm1525; Nelson N, 2006, ANNU REV PLANT BIOL, V57, P521, DOI 10.1146/annurev.arplant.57.032905.105350; Ohad I, 2004, BIOCHEMISTRY-US, V43, P2297, DOI 10.1021/bi0348260; Ohnishi N, 2007, J BIOL CHEM, V282, P7107, DOI 10.1074/jbc.M606763200; Ossenbuhl F, 2006, PLANT CELL, V18, P2236, DOI 10.1105/tpc.106.043646; Peng LW, 2006, PLANT CELL, V18, P955, DOI 10.1105/tpc.105.037689; Regel RE, 2001, J BIOL CHEM, V276, P41473, DOI 10.1074/jbc.M102007200; Rochaix JD, 2001, PLANT PHYSIOL, V125, P142, DOI 10.1104/pp.125.1.142; Ruban AV, 2006, J BIOL CHEM, V281, P14981, DOI 10.1074/jbc.M511415200; RUTHERFORD AW, 1984, P NATL ACAD SCI-BIOL, V81, P1107, DOI 10.1073/pnas.81.4.1107; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; Rutherford AW, 2001, TRENDS BIOCHEM SCI, V26, P648, DOI 10.1016/S0968-0004(01)01953-3; Schreiber U., 1998, P320; SCHUSTER G, 1988, EUR J BIOCHEM, V177, P411, DOI 10.1111/j.1432-1033.1988.tb14390.x; Schwenkert S, 2006, J BIOL CHEM, V281, P34227, DOI 10.1074/jbc.M604888200; Shi LX, 2004, BBA-BIOENERGETICS, V1608, P75, DOI 10.1016/j.bbabio.2003.12.004; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; SUGIURA M, 1986, PLANT SCI, V44, P211, DOI 10.1016/0168-9452(86)90093-2; Swiatek M, 2003, CURR GENET, V43, P45, DOI 10.1007/s00294-003-0369-4; Swiatek M, 2003, MOL GENET GENOMICS, V268, P699, DOI 10.1007/s00438-002-0791-1; Swiatek M, 2001, PLANT CELL, V13, P1347, DOI 10.1105/tpc.13.6.1347; Szilard A, 2005, PHOTOSYNTH RES, V84, P15, DOI 10.1007/s11120-004-7161-2; Thornton LE, 2005, ADV PHOTO RESPIRAT, V22, P121; Vass I, 2003, PHOTOSYNTH RES, V76, P303, DOI 10.1023/A:1024989519054; Vener AV, 1997, P NATL ACAD SCI USA, V94, P1585, DOI 10.1073/pnas.94.4.1585; Vrettos JS, 2002, PHILOS T R SOC B, V357, P1395, DOI 10.1098/rstb.2002.1136; WHITMARSH I, 1996, OXYGENIC PHOTOSYNTHE, P249; ZER H, 1994, J BIOL CHEM, V269, P17670; Zer H, 1999, P NATL ACAD SCI USA, V96, P8277, DOI 10.1073/pnas.96.14.8277; Zer H, 2003, BIOCHEMISTRY-US, V42, P728, DOI 10.1021/bi020451r	61	34	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9758	9767		10.1074/jbc.M608117200	http://dx.doi.org/10.1074/jbc.M608117200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17261590	Green Published, hybrid			2022-12-25	WOS:000245421700050
J	Raffi, M; Siegel, RM				Raffi, Milena; Siegel, Ralph M.			A Functional Architecture of Optic Flow in the Inferior Parietal Lobule of the Behaving Monkey	PLOS ONE			English	Article							MULTIPLE-STIMULUS DISPLAYS; VISUAL ASSOCIATION CORTEX; NEURONAL RESPONSES; MACAQUE MONKEY; AREA 7A; HEADING PERCEPTION; POLYSENSORY AREA; PRELUNATE GYRUS; RHESUS-MONKEY; CORTICAL MAPS	The representation of navigational optic flow across the inferior parietal lobule was assessed using optical imaging of intrinsic signals in behaving monkeys. The exposed cortex, corresponding to the dorsal-most portion of areas 7a and dorsal prelunate (DP), was imaged in two hemispheres of two rhesus monkeys. The monkeys actively attended to changes in motion stimuli while fixating. Radial expansion and contraction, and rotation clockwise and counter-clockwise optic flow stimuli were presented concentric to the fixation point at two angles of gaze to assess the interrelationship between the eye position and optic flow signal. The cortical response depended upon the type of flow and was modulated by eye position. The optic flow selectivity was embedded in a patchy architecture within the gain field architecture. All four optic flow stimuli tested were represented in areas 7a and DP. The location of the patches varied across days. However the spatial periodicity of the patches remained constant across days at,950 and 1100 mm for the two animals examined. These optical recordings agree with previous electrophysiological studies of area 7a, and provide new evidence for flow selectivity in DP and a fine scale description of its cortical topography. That the functional architectures for optic flow can change over time was unexpected. These and earlier results also from inferior parietal lobule support the inclusion of both static and dynamic functional architectures that define association cortical areas and ultimately support complex cognitive function.	[Raffi, Milena; Siegel, Ralph M.] Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA	Rutgers State University Newark; Rutgers State University New Brunswick	Siegel, RM (corresponding author), Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA.	axon@cortex.rutgers.edu	Raffi, Milena/AAU-9845-2020	RAFFI, MILENA/0000-0002-7467-5591	Whitehall Foundation; NIH/NEI [EY09223, EY014657]; NEI/NCRR [RR12873]; Programma Marco Polo; VIII Tornata of University of Bologna; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012873] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009223, R03EY014657] Funding Source: NIH RePORTER	Whitehall Foundation; NIH/NEI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)NIH National Center for Research Resources (NCRR)); Programma Marco Polo; VIII Tornata of University of Bologna; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Supported by the Whitehall Foundation, NIH/NEI EY09223, NIH/NEI EY014657, and NEI/NCRR RR12873 to RMS. A travel grant to Milena Raffi was funded by Programma Marco Polo, VIII Tornata of University of Bologna.	ANDERSEN RA, 1985, J COMP NEUROL, V232, P443, DOI 10.1002/cne.902320403; ANDERSEN RA, 1989, ANNU REV NEUROSCI, V12, P377, DOI 10.1146/annurev.neuro.12.1.377; ANDERSEN RA, 1990, J COMP NEUROL, V296, P65, DOI 10.1002/cne.902960106; Anderson KC, 1999, J NEUROSCI, V19, P2681; Arieli A, 2002, J NEUROSCI METH, V116, P15, DOI 10.1016/S0165-0270(02)00022-5; ARNSTEN AFT, 1984, BRAIN RES, V306, P9, DOI 10.1016/0006-8993(84)90351-2; Batschelet E, 1981, CIRCULAR STAT BIOL; Birbaumer N, 1997, J NEUROSCI, V17, P5503; Britten KH, 2002, CEREB CORTEX, V12, P692, DOI 10.1093/cercor/12.7.692; Britten KH, 1998, VISUAL NEUROSCI, V15, P553; Britten KH, 1998, NAT NEUROSCI, V1, P59, DOI 10.1038/259; BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; Buchner H, 1999, NEUROSCI LETT, V260, P57, DOI 10.1016/S0304-3940(98)00948-3; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; Butefisch CM, 2000, P NATL ACAD SCI USA, V97, P3661, DOI 10.1073/pnas.050350297; CAVADA C, 1991, NEUROSCIENCE, V42, P683, DOI 10.1016/0306-4522(91)90037-O; CAVADA C, 1989, J COMP NEUROL, V287, P393, DOI 10.1002/cne.902870402; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; Constantinidis C, 2001, CEREB CORTEX, V11, P581, DOI 10.1093/cercor/11.7.581; Constantinidis C, 2001, CEREB CORTEX, V11, P592, DOI 10.1093/cercor/11.7.592; Cossart R, 2003, NATURE, V423, P283, DOI 10.1038/nature01614; Crick F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/nn0203-119; CRICK FHC, 1979, SCI AM, V241, P219, DOI 10.1038/scientificamerican0979-219; Critchley M., 1953, PARIETAL LOBES; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995; Duann JR, 2002, NEUROIMAGE, V15, P823, DOI 10.1006/nimg.2001.1049; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1346, DOI 10.1152/jn.1991.65.6.1346; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Geesaman BJ, 1997, CEREB CORTEX, V7, P749, DOI 10.1093/cercor/7.8.749; Golmayo L, 2003, NEUROSCIENCE, V119, P597, DOI 10.1016/S0306-4522(03)00031-9; GRAZIANO MSA, 1994, J NEUROSCI, V14, P54; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; Heider B, 2005, CEREB CORTEX, V15, P460, DOI 10.1093/cercor/bhh148; HOF PR, 1995, J COMP NEUROL, V352, P161, DOI 10.1002/cne.903520202; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; KARNI A, 1995, NATURE, V377, P155; Kleinfeld D, 2005, PLOS BIOL, V3, P1685, DOI 10.1371/journal.pbio.0030355; Kondo H, 1999, EUR J NEUROSCI, V11, P4197, DOI 10.1046/j.1460-9568.1999.00844.x; LAGAE L, 1994, J NEUROPHYSIOL, V71, P1597, DOI 10.1152/jn.1994.71.5.1597; LI CY, 1989, BRAIN RES, V496, P307, DOI 10.1016/0006-8993(89)91078-0; LONGUETHIGGINS HC, 1980, PROC R SOC SER B-BIO, V208, P385, DOI 10.1098/rspb.1980.0057; MAGUIRE WM, 1984, J NEUROSCI, V4, P1690; Malonek D, 1997, P NATL ACAD SCI USA, V94, P14826, DOI 10.1073/pnas.94.26.14826; Marr D., 1982, VISION; Menning H, 2000, NEUROREPORT, V11, P817, DOI 10.1097/00001756-200003200-00032; Merchant H, 2003, J NEUROPHYSIOL, V90, P675, DOI 10.1152/jn.00331.2003; Merchant H, 2001, J NEUROPHYSIOL, V86, P1937, DOI 10.1152/jn.2001.86.4.1937; MOTTER BC, 1987, J NEUROSCI, V7, P154; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; PERRONE JA, 1994, VISION RES, V34, P2917, DOI 10.1016/0042-6989(94)90060-4; PHINNEY RE, 1996, ABSTRSOCNEUROSCI, V22, P1693; Pigarev IN, 2001, EXP BRAIN RES, V136, P108, DOI 10.1007/s002210000566; Polley DB, 1999, NEURON, V24, P623, DOI 10.1016/S0896-6273(00)81117-4; Raffi M, 2004, SYNTH LIBR, V324, P3; Raffi M, 2005, J NEUROSCI, V25, P5171, DOI 10.1523/JNEUROSCI.5201-04.2005; Read HL, 1997, CEREB CORTEX, V7, P647, DOI 10.1093/cercor/7.7.647; Rossini PM, 2000, BRAIN RES REV, V33, P131, DOI 10.1016/S0169-328X(00)00090-5; Shtoyerman E, 2000, J NEUROSCI, V20, P8111; Siegel R M, 1990, J Cogn Neurosci, V2, P306, DOI 10.1162/jocn.1990.2.4.306; SIEGEL RM, 1988, NATURE, V331, P259, DOI 10.1038/331259a0; Siegel RM, 2003, J NEUROPHYSIOL, V90, P1279, DOI 10.1152/jn.01179.2002; Siegel RM, 1997, CEREBR CORT, V12, P499; Siegel RM, 1997, CEREB CORTEX, V7, P327, DOI 10.1093/cercor/7.4.327; SIEGEL RM, 2006, CEREB CORTEX; Spengler F, 1997, NEUROSCI LETT, V232, P151, DOI 10.1016/S0304-3940(97)00602-2; SPORNS O, 1989, P NATL ACAD SCI USA, V86, P7265, DOI 10.1073/pnas.86.18.7265; STEINMETZ MA, 1987, J NEUROSCI, V7, P177; Stettler DD, 2002, NEURON, V36, P739, DOI 10.1016/S0896-6273(02)01029-2; TANAKA K, 1986, J NEUROSCI, V6, P134; ULLMAN S, 1979, PROC R SOC SER B-BIO, V203, P405, DOI 10.1098/rspb.1979.0006; VAINA LM, 1994, INVEST OPHTH VIS SCI, V35, P1438; VAINA LM, 2000, INT REV NEUROBIOL, P293; van Essen D.C., 1985, P259	74	24	24	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2007	2	2							e200	10.1371/journal.pone.0000200	http://dx.doi.org/10.1371/journal.pone.0000200			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DI	17285147	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444300012
J	Belgacem, YH; Martin, JR				Belgacem, Yesser Hadj; Martin, Jean-Rene			Hmgcr in the Corpus Allatum Controls Sexual Dimorphism of Locomotor Activity and Body Size via the Insulin Pathway in Drosophila	PLOS ONE			English	Article								The insulin signaling pathway has been implicated in several physiological and developmental processes. In mammals, it controls expression of 3-Hydroxy-3-Methylglutaryl CoA Reductase (HMGCR), a key enzyme in cholesterol biosynthesis. In insects, which can not synthesize cholesterol de novo, the HMGCR is implicated in the biosynthesis of juvenile hormone (JH). However, the link between the insulin pathway and JH has not been established. In Drosophila, mutations in the insulin receptor (InR) decrease the rate of JH synthesis. It is also known that both the insulin pathway and JH play a role in the control of sexual dimorphism in locomotor activity. In studies here, to demonstrate that the insulin pathway and HMGCR are functionally linked in Drosophila, we first show that hmgcr mutation also disrupts the sexual dimorphism. Similarly to the InR, HMGCR is expressed in the corpus allatum(ca), which is the gland where JH biosynthesis occurs. Two p[hmgcr-GAL4] lines were therefore generated where RNAi was targeted specifically against the HMGCR or the InR in the ca. We found that RNAi-HMGCR blocked HMGCR expression, while the RNAi-InR blocked both InR and HMGCR expression. Each RNAi caused disruption of sexual dimorphism and produced dwarf flies at specific rearing temperatures. These results provide evidence: (i) that HMGCR expression is controlled by the InR and (ii) that InR and HMGCR specifically in the ca, are involved in the control of body size and sexual dimorphism of locomotor activity.	[Belgacem, Yesser Hadj; Martin, Jean-Rene] CNRS, Neurobiol Cellulaire & Mol Lab, Unite UPR 9040, Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Martin, JR (corresponding author), CNRS, Neurobiol Cellulaire & Mol Lab, Unite UPR 9040, Gif Sur Yvette, France.	jean-rene.martin@inaf.cnrs-gif.fr			French Ministry of Research and Education; CNRS	French Ministry of Research and Education; CNRS(Centre National de la Recherche Scientifique (CNRS))	This work (J.R. Martin) was supported by the French Ministry of Research and Education (ACI: Action Concertee Incitative: Biologie du Developpement et Physiologie Integrative) and by the CNRS (ATIPE-Neurobiologie), France.	ADAMSON ED, 1993, J CELL BIOCHEM, V53, P280, DOI 10.1002/jcb.240530403; Araki E, 1994, Nihon Rinsho, V52, P2659; AZROLAN NI, 1989, BIOCHEM J, V258, P421, DOI 10.1042/bj2580421; Belgacem YH, 2002, P NATL ACAD SCI USA, V99, P15154, DOI 10.1073/pnas.232244199; Belgacem YH, 2006, J NEUROBIOL, V66, P19, DOI 10.1002/neu.20193; Belles X, 2005, ANNU REV ENTOMOL, V50, P181, DOI 10.1146/annurev.ento.50.071803.130356; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Butler AA, 2001, ANNU REV PHYSIOL, V63, P141, DOI 10.1146/annurev.physiol.63.1.141; Cagen LM, 2005, BIOCHEM J, V385, P207, DOI 10.1042/BJ20040162; Cao C, 2001, CELL TISSUE RES, V304, P317, DOI 10.1007/s004410100367; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; CLAYTON RB, 1964, J LIPID RES, V5, P3; Colombani J, 2005, SCIENCE, V310, P667, DOI 10.1126/science.1119432; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Dauwalder B, 2002, GENE DEV, V16, P2879, DOI 10.1101/gad.1010302; Deshpande G, 2005, DEV CELL, V9, P629, DOI 10.1016/j.devcel.2005.09.014; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; Duncan RE, 2005, CANCER EPIDEM BIOMAR, V14, P1897, DOI 10.1158/1055-9965.EPI-05-0027; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; Flatt T, 2005, BIOESSAYS, V27, P999, DOI 10.1002/bies.20290; Foufelle Fabienne, 2001, Journal de la Societe de Biologie, V195, P243; Gatti S, 2000, CURR BIOL, V10, P667, DOI 10.1016/S0960-9822(00)00517-0; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2849, DOI 10.1001/jama.256.20.2849; Ikeya T, 2002, CURR BIOL, V12, P1293, DOI 10.1016/S0960-9822(02)01043-6; IRONS M, 1994, AM J MED GENET, V50, P347, DOI 10.1002/ajmg.1320500409; Isabel G, 2005, AM J PHYSIOL-REG I, V288, pR531, DOI 10.1152/ajpregu.00158.2004; Ito K, 1998, LEARN MEMORY, V5, P52; Kunte AS, 2006, CELL METAB, V3, P439, DOI 10.1016/j.cmet.2006.04.011; LAKSHMANAN M R, 1973, Biochemical and Biophysical Research Communications, V50, P704, DOI 10.1016/0006-291X(73)91301-6; Lee GH, 2004, GENETICS, V167, P311, DOI 10.1534/genetics.167.1.311; LI AC, 1988, J LIPID RES, V29, P781; Martin JR, 2004, BEHAV PROCESS, V67, P207, DOI 10.1016/j.beproc.2004.04.003; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Ness GC, 2000, P SOC EXP BIOL MED, V224, P8, DOI 10.1046/j.1525-1373.2000.22359.x; Osborne AR, 2004, BIOCHEM BIOPH RES CO, V318, P814, DOI 10.1016/j.bbrc.2004.04.105; PENHOS JC, 1968, METABOLISM, V17, P246, DOI 10.1016/0026-0495(68)90127-3; Plosker GL, 1996, DRUGS, V51, P433, DOI 10.2165/00003495-199651030-00011; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shingleton AW, 2005, PLOS BIOL, V3, P1607, DOI 10.1371/journal.pbio.0030289; SINGER II, 1984, P NATL ACAD SCI-BIOL, V81, P5556, DOI 10.1073/pnas.81.17.5556; Song JB, 2003, SCIENCE, V300, P502, DOI 10.1126/science.1081203; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Takahashi Y, 1997, ENDOCRINOLOGY, V138, P741, DOI 10.1210/en.138.2.741; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Theopold U, 1996, P NATL ACAD SCI USA, V93, P1195, DOI 10.1073/pnas.93.3.1195; Thorpe JL, 2004, DEV CELL, V6, P295, DOI 10.1016/S1534-5807(04)00032-2; Tschape JA, 2002, EMBO J, V21, P6367, DOI 10.1093/emboj/cdf636; Tu MP, 2005, GEN COMP ENDOCR, V142, P347, DOI 10.1016/j.ygcen.2005.02.009; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Van Doren M, 1998, NATURE, V396, P466, DOI 10.1038/24871; Waddell S, 2000, CELL, V103, P805, DOI 10.1016/S0092-8674(00)00183-5; Wang D, 1997, J BIOL CHEM, V272, P26367, DOI 10.1074/jbc.272.42.26367; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; Wu Q, 2005, NAT NEUROSCI, V8, P1350, DOI 10.1038/nn1540; Wu Q, 2005, P NATL ACAD SCI USA, V102, P13289, DOI 10.1073/pnas.0501914102; YAO KM, 1993, J NEUROBIOL, V24, P723, DOI 10.1002/neu.480240604	64	80	82	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2007	2	1							e187	10.1371/journal.pone.0000187	http://dx.doi.org/10.1371/journal.pone.0000187			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DH	17264888	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444200011
J	Fleisig, HB; Orazio, N; Liang, H; Tyler, AF; Adams, HP; Weitzman, MD; Nagarajan, L				Fleisig, H. B.; Orazio, N. I.; Liang, H.; Tyler, A. F.; Adams, H. P.; Weitzman, M. D.; Nagarajan, L.			Adenoviral E1B55K oncoprotein sequesters candidate leukemia suppressor sequence-specific single-stranded DNA-binding protein 2 into aggresomes	ONCOGENE			English	Article						SSBP2; E1B55K; direct interaction; colocalization; aggresomes	TRANSCRIPTIONAL REPRESSION; 55-KILODALTON PROTEIN; CELL-TRANSFORMATION; E1B-55K ONCOPROTEIN; E4ORF6 PROTEINS; NUCLEAR EXPORT; INFECTED CELLS; MRE11 COMPLEX; P53; GENE	Sequence-specific single-stranded DNA-binding protein 2 (SSBP2) is a candidate tumor suppressor for human acute myelogenous leukemia (AML). Inducible expression of SSBP2 causes growth arrest and partial differentiation in AML cells. Here, we report that the adenoviral oncoprotein E1B55K directly binds to endogenous SSBP2 protein and sequesters it into juxtanuclear bodies in adenovirally transformed human embryonic kidney (HEK) 293 cells. Similarly, transient expression of E1B55K in IMR90 fibroblasts and HeLa cells result in the formation of juxtanuclear bodies containing SSBP2. When nuclear export of E1B55K is prevented, SSBP2 remains associated with E1B55K in nuclear foci. A requirement for intact microtubules to retain the integrity of the juxtanuclear bodies suggests them to be E1B55K containing aggresomes. The adenoviral E1B55K protein has been shown to localize to the Mre11 complex and p53 to aggresome structures; together with the viral E4orf6 protein, E1B55K recruits a cellular E3 ubiquitin ligase that induces degradation of Mre11 and p53. However, our present studies reveal that E1B55K does not degrade SSBP2. These data demonstrate that E1B55K targets the candidate leukemia suppressor SSBP2 and suggest that subverting its function may contribute to cell transformation by viral oncoproteins.	MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Div Biol, Grad Program, San Diego, CA 92103 USA	University of Texas System; UTMD Anderson Cancer Center; Salk Institute; University of California System; University of California San Diego	Nagarajan, L (corresponding author), MD Anderson Canc Ctr, Dept Mol Genet, Box 1006,1515 Holcombe Blvd, Houston, TX 77030 USA.	lnagaraj@mdanderson.org			NCI NIH HHS [T32 CA064041, CA16672, CA97093] Funding Source: Medline; NHLBI NIH HHS [HL074449] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, T32CA064041, R01CA097093] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074449] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Araujo FD, 2005, J VIROL, V79, P11382, DOI 10.1128/JVI.79.17.11382-11391.2005; Bayarsaihan D, 1996, BIOCHEM J, V314, P293, DOI 10.1042/bj3140293; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Castro P, 2002, GENOMICS, V80, P78, DOI 10.1006/geno.2002.6805; Cathomen T, 2000, J VIROL, V74, P11407, DOI 10.1128/JVI.74.23.11407-11412.2000; Chen L, 2002, P NATL ACAD SCI USA, V99, P14320, DOI 10.1073/pnas.212532399; Dobner T, 2001, CURR TOP MICROBIOL, V259, P25; Dosch T, 2001, J VIROL, V75, P5677, DOI 10.1128/JVI.75.12.5677-5683.2001; Endter C, 2005, ONCOGENE, V24, P55, DOI 10.1038/sj.onc.1208170; Endter C, 2004, CURR TOP MICROBIOL, V273, P163; Felsani A, 2006, ONCOGENE, V25, P5277, DOI 10.1038/sj.onc.1209621; Flint SJ, 2003, CURR TOP MICROBIOL, V272, P287; Goardon N, 2006, EMBO J, V25, P357, DOI 10.1038/sj.emboj.7600934; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kratzer F, 2000, ONCOGENE, V19, P850, DOI 10.1038/sj.onc.1203395; Liang H, 2005, ONCOGENE, V24, P2625, DOI 10.1038/sj.onc.1208167; Liu Y, 2005, J VIROL, V79, P14004, DOI 10.1128/JVI.79.22.14004-14016.2005; Martin MED, 1998, J VIROL, V72, P3146, DOI 10.1128/JVI.72.4.3146-3154.1998; Nishioka N, 2005, DEVELOPMENT, V132, P2535, DOI 10.1242/dev.01844; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; ORNELLES DA, 1991, J VIROL, V65, P424, DOI 10.1128/JVI.65.1.424-429.1991; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; SARNOW P, 1982, VIROLOGY, V120, P510, DOI 10.1016/0042-6822(82)90054-X; Schuh AH, 2005, MOL CELL BIOL, V25, P10235, DOI 10.1128/MCB.25.23.10235-10250.2005; STEEGE MW, 1998, PROVEN PRACTICE PREV, V1, P4; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; van Meyel DJ, 2003, DEVELOPMENT, V130, P1915, DOI 10.1242/dev.00389; Weitzman MD, 2005, ONCOGENE, V24, P7686, DOI 10.1038/sj.onc.1209063; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Wu LT, 2006, BIOCHEM BIOPH RES CO, V339, P977, DOI 10.1016/j.bbrc.2005.11.098; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; Zhao LY, 2003, J VIROL, V77, P11809, DOI 10.1128/JVI.77.21.11809-11821.2003	41	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4797	4805		10.1038/sj.onc.1210281	http://dx.doi.org/10.1038/sj.onc.1210281			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17311003				2022-12-25	WOS:000248170400004
J	Ott, RG; Simma, O; Kollmann, K; Weisz, E; Zebedin, EM; Schorpp-Kistner, M; Heller, G; Zochbauer, S; Wagner, EF; Freissmuth, M; Sexl, V				Ott, R. G.; Simma, O.; Kollmann, K.; Weisz, E.; Zebedin, E. M.; Schorpp-Kistner, M.; Heller, G.; Zoechbauer, S.; Wagner, E. F.; Freissmuth, M.; Sexl, V.			JunB is a gatekeeper for B-lymphoid leukemia	ONCOGENE			English	Article						JunB; bcr/abl; AP-1; leukemia	CHRONIC MYELOID-LEUKEMIA; CYCLIN-DEPENDENT KINASE; MICE LACKING JUNB; C-JUN; TUMOR-DEVELOPMENT; CELL LYMPHOMAS; EXPRESSION; PHOSPHORYLATION; METHYLATION; GAMMA	Loss of JunB has been observed in human leukemia and lymphoma, but it remains unknown, whether this loss is relevant to disease progression. Here, we investigated the consequences of JunB de. ciency using Abelson-induced B- lymphoid leukemia as a model system. Mice de. cient in JunB expression succumbed to Abelson-induced leukemia with increased incidence and significantly reduced latency. Similarly, bcr/abl p185-transformed JunB-deficient (junBD/D) cells induced leukemia in RAG2(-/-) mice displaying a more malignant phenotype. These observations indicated that cell intrinsic effects within the junBD/D tumor cells accounted for the accelerated leukemia development. Indeed, explantated bcr/abl p185 transformed junBD/D cells proliferated faster than the control cells. The proliferative advantage emerged slowly after the initial transformation process and was associated with increased expression levels of the cell cycle kinase cdk6 and with decreased levels of the cell cycle inhibitor p16INK4a. These alterations were due to irreversible reprogramming of the cell, because - once established - accelerated disease induced by junBD/D cells was not reverted by re-introducing JunB. Consistent with this observation, we found that the p16 promoter was methylated. Thus, JunB functions as a gatekeeper during tumor evolution. In its absence, transformed leukemic cells acquire an enhanced proliferative capacity, which presages a more malignant disease.	MUV, Inst Pharmacol, Vienna, Austria; MUV, Dept Oncol, Vienna, Austria; DKFZ, German Canc Res Ctr, Vienna, Austria; IMP, Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Sexl, V (corresponding author), Dept Pharmacol, Waehringerstr 13A, A-1090 Vienna, Austria.	sexl@meduniwien.ac.at	heller, gerwin/E-6521-2011; Zöchbauer-Müller, Sabine/B-8399-2012; Sexl, Veronika/B-8657-2016	heller, gerwin/0000-0001-8742-5631; Zöchbauer-Müller, Sabine/0000-0002-6777-1729; Wagner, Erwin F/0000-0001-7872-0196; Freissmuth, Michael/0000-0001-9398-1765; Kollmann, Karoline/0000-0002-7937-4245; Sexl, Veronika/0000-0001-9363-0412				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Corcoran MM, 1999, ONCOGENE, V18, P6271, DOI 10.1038/sj.onc.1203033; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Mao X, 2002, GENE CHROMOSOME CANC, V35, P144, DOI 10.1002/gcc.10104; Mao X, 2003, BLOOD, V101, P1513, DOI 10.1182/blood-2002-08-2434; Marique T, 2001, J THEOR BIOL, V209, P3, DOI 10.1006/jtbi.2000.2237; Markevich NI, 2004, J CELL BIOL, V164, P353, DOI 10.1083/jcb.200308060; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2004, CELL, V119, P431, DOI 10.1016/j.cell.2004.10.010; Rassidakis GZ, 2005, MODERN PATHOL, V18, P1365, DOI 10.1038/modpathol.3800419; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Szremska AP, 2003, BLOOD, V102, P4159, DOI 10.1182/blood-2003-03-0915; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wolff L, 2003, ONCOGENE, V22, P9265, DOI 10.1038/sj.onc.1207092; WU JX, 1990, ONCOGENE, V5, P989; Yang MY, 2003, BLOOD, V101, P3205, DOI 10.1182/blood-2002-05-1598	35	18	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4863	4871		10.1038/sj.onc.1210285	http://dx.doi.org/10.1038/sj.onc.1210285			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297445				2022-12-25	WOS:000248170400011
J	Schniewind, B; Groth, S; Muerkoster, SS; Sipos, B; Schaefer, H; Kalthoff, H; Fandrich, F; Ungefroren, H				Schniewind, B.; Groth, S.; Mueerkoester, S. Sebens; Sipos, B.; Schaefer, H.; Kalthoff, H.; Faendrich, F.; Ungefroren, H.			Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function	ONCOGENE			English	Article						TGF-beta; pancreatic carcinoma; ALK5; smad; metastasis	GROWTH-FACTOR-BETA; CANCER-CELLS; BREAST-CANCER; TRANSCRIPTIONAL REPRESSION; MESENCHYMAL TRANSITION; MAMMARY TUMORIGENESIS; ENHANCED EXPRESSION; SIGNALING PATHWAY; BONE METASTASIS; C-MYC	In the present study, we have analysed the effects of transforming growth factor-beta (TGF-beta) signaling on the growth behavior of pancreatic carcinoma cells in vitro and on their tumorigenicity in vivo. Ectopic expression of dominant-negative mutants of the TGF-beta type II receptor or type 1 receptor/activin receptor-like kinase 5(ALK5) in TGF-beta-sensitive pancreatic ductal adenocarcinoma PANC-1 cells prevented the TGF-beta-induced activation of transfected Smad-responsive reporter genes and growth arrest. The growth-inhibitory effect was mimicked by stable expression of kinase-active ALK5( A LK5- T204D), and was dependent on ALK5's ability to activate Smad signaling, as a ALK5-derived mutant with an intact kinase domain but deficient in its ability to activate Smads (RImL45) failed to suppress proliferation in the absence of added TGF-beta. Moreover, this mutant often displayed opposite effects to those of ALK5-TD and blocked various ligand-induced responses in vitro, indicating that it acts in a dominant-negative fashion to inhibit endogenous wild-type receptors. ALK5-TD-, but not RImL45-TD-transduced cells underwent epithelial-to-mesenchymal transition, exhibited a higher ratio of thrombospondin-1 to vascular endothelial growth factor-A expression and upregulated various metastasis-associated genes. Upon orthotopic transplantation of PANC-1 clones into immunodeficient mice, ALK5-TD, but not RImL45-TD, greatly reduced tumor size and induced the formation of liver metastases in otherwise non-metastatic PANC-1 cells. These results suggest a causal, dominant role for the endogenous Smad2/3 signaling pathway in the tumor suppressor and prometastatic activities of TGF-beta in pancreatic tumor cells.	UKSH, Dept Gen Surg & Thorac Surg, Kiel, Germany; Dept Med 1, Lab Mol Gastroenterol & Hepatol, Kiel, Germany; Dept Pathol, Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Ungefroren, H (corresponding author), Univ Hosp Kiel, Arnold Heller Str 7, D-24105 Kiel, Germany.	hungefroren@chirurgie-sh.de	Sebens, Susanne/C-1222-2010; Ungefroren, Hendrik/E-2933-2010; Kalthoff, Holger/B-1618-2010; Schäfer, Heiner/C-1055-2011; Faendrich, Fred/B-1705-2010					Arnold NB, 2005, J BIOL CHEM, V280, P21858, DOI 10.1074/jbc.M500583200; Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO;2-B; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Bottinger EP, 1997, CANCER RES, V57, P5564; Chen WB, 2002, J BIOL CHEM, V277, P36118, DOI 10.1074/jbc.M203709200; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Dai JL, 1998, CANCER RES, V58, P4592; Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Duda DG, 2003, ONCOGENE, V22, P6857, DOI 10.1038/sj.onc.1206751; Ellenrieder V, 2001, INT J CANCER, V93, P204, DOI 10.1002/ijc.1330; Ellenrieder V, 2001, CANCER RES, V61, P4222; Fensterer H, 2004, GENE CHROMOSOME CANC, V39, P224, DOI 10.1002/gcc.20000; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FRIESS H, 1993, CANCER RES, V53, P2704; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Goggins M, 1998, CANCER RES, V58, P5329; Grau AM, 1997, CANCER RES, V57, P3929; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Iglesias M, 2000, ONCOGENE, V19, P4134, DOI 10.1038/sj.onc.1203764; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Javelaud D, 2005, ONCOGENE, V24, P5742, DOI 10.1038/sj.onc.1208928; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2006, J CELL BIOCHEM, V98, P1380, DOI 10.1002/jcb.20928; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kuang CZ, 2006, P NATL ACAD SCI USA, V103, P1858, DOI 10.1073/pnas.0508977103; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; Muraoka-Cook RS, 2006, ONCOGENE, V25, P3408, DOI 10.1038/sj.onc.1208964; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Nakagawa T, 2004, KIDNEY INT, V66, P605, DOI 10.1111/j.1523-1755.2004.00780.x; Nicolas FJ, 2003, ONCOGENE, V22, P3698, DOI 10.1038/sj.onc.1206420; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peng BL, 2002, CLIN CANCER RES, V8, P3628; Reiss M, 1997, BREAST CANCER RES TR, V45, P81, DOI 10.1023/A:1005865812918; Rowland-Goldsmith MA, 2002, MOL CANCER THER, V1, P161; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Ungefroren H, 2005, J BIOL CHEM, V280, P2644, DOI 10.1074/jbc.M411925200; UNGEFROREN H, 2007, INT J CANC; Voss M, 1999, INT J ONCOL, V14, P93; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	56	47	49	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4850	4862		10.1038/sj.onc.1210272	http://dx.doi.org/10.1038/sj.onc.1210272			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297450				2022-12-25	WOS:000248170400010
J	Wikman, H; Ruosaari, S; Nymark, P; Sarhadi, V; Saharinen, J; Vanhala, E; Karjalainen, A; Hollmen, J; Knuutila, S; Anttila, S				Wikman, H.; Ruosaari, S.; Nymark, P.; Sarhadi, V. K.; Saharinen, J.; Vanhala, E.; Karjalainen, A.; Hollmen, J.; Knuutila, S.; Anttila, S.			Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer	ONCOGENE			English	Article						lung cancer; asbestos; microarrays; microsatellite; analysis	CELL-LINES; ADENOCARCINOMA; DNA; IDENTIFICATION; WORKERS; EXPOSURE; SMOKING; TISSUE; BLOOD	Asbestos is a pulmonary carcinogen known to give rise to DNA and chromosomal damage, but the exact carcinogenic mechanisms are still largely unknown. In this study, gene expression arrays were performed on lung tumor samples from 14 heavily asbestos-exposed and 14 non-exposed patients matched for other characteristics. Using a two-step statistical analysis, 47 genes were revealed that could differentiate the tumors of asbestos-exposed from those of non-exposed patients. To identify asbestos-associated regions with DNA copy number and expressional changes, the gene expression data were combined with comparative genomic hybridization microarray data. As a result, a combinatory pro. le of DNA copy number aberrations and expressional changes significantly associated with asbestos exposure was obtained. Asbestos-related areas were detected in 2p21-p16.3, 3p21.31, 5q35.2-q35.3, 16p13.3, 19p13.3-p13.1 and 22q12.3-q13.1. The most prominent of these, 19p13, was further characterized by microsatellite analysis in 62 patients for the differences in allelic imbalance (AI) between the two groups of lung tumors. 79% of the exposed and 45% of the non-exposed patients (P = 0.008) were found to be carriers of AI in their lung tumors. In the exposed group, AI in 19p was prevalent regardless of the histological tumor type. In adenocarcinomas, AI in 19p appeared to occur independently of the asbestos exposure.	Finnish Inst Occupat Hlth, FI-00250 Helsinki, Finland; Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, Hamburg, Germany; Aalto Univ, Lab Comp & Informat Sci, FIN-02150 Espoo, Finland; Univ Helsinki, Dept Pathol, Haartman Inst, Helsinki, Finland; Univ Helsinki, Cent Hosp, HUSLAB, Helsinki, Finland; Natl Publ Hlth Inst, Dept Mol Med, Biomedicum, Helsinki, Finland	Finnish Institute of Occupational Health; University of Hamburg; University Medical Center Hamburg-Eppendorf; Aalto University; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; University of Helsinki	Anttila, S (corresponding author), Finnish Inst Occupat Hlth, Topeliuksenkatu 41aA, FI-00250 Helsinki, Finland.	sisko.anttila@ttl.fi	Nymark, Penny/AAC-9890-2019; Nymark, Penny/B-5246-2014	Nymark, Penny/0000-0002-3435-7775; Wikman, Harriet/0000-0001-6862-0888				Balsara BR, 2002, ONCOGENE, V21, P6877, DOI 10.1038/sj.onc.1205836; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Bossolasco M, 1999, MOL CARCINOGEN, V26, P189, DOI 10.1002/(SICI)1098-2744(199911)26:3<189::AID-MC8>3.0.CO;2-T; Dano L, 2000, GENE CHROMOSOME CANC, V29, P1, DOI 10.1002/1098-2264(2000)9999:9999<000::AID-GCC1000>3.3.CO;2-S; De Rienzo A, 2000, Clin Ter, V151, P433; FATMA N, 1991, BRIT J IND MED, V48, P103; Gupta N, 2005, BBA-MOL BASIS DIS, V1741, P215, DOI 10.1016/j.bbadis.2005.04.002; Hellstrom I, 2003, CANCER RES, V63, P3695; Hoang JM, 1997, CANCER RES, V57, P300; Hyman E, 2002, CANCER RES, V62, P6240; Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178; KARJALAINEN A, 1993, AM J IND MED, V23, P461, DOI 10.1002/ajim.4700230309; KARJALAINEN A, 1997, ADV ENV CONTROL TECH, P127; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Marczynski B, 2000, MUTAT RES-GEN TOX EN, V468, P195, DOI 10.1016/S1383-5718(00)00053-X; MARCZYNSKI B, 1994, HUM EXP TOXICOL, V13, P3, DOI 10.1177/096032719401300102; Marsit CJ, 2004, CANCER RES, V64, P8702, DOI 10.1158/0008-5472.CAN-04-2558; Medina PP, 2005, HUM MOL GENET, V14, P973, DOI 10.1093/hmg/ddi091; Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0; Nymark P, 2006, CANCER RES, V66, P5737, DOI 10.1158/0008-5472.CAN-06-0199; Radak Z, 2005, CANCER LETT, V219, P191, DOI 10.1016/j.canlet.2004.07.008; Reisman DN, 2003, CANCER RES, V63, P560; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; Sakakura C, 2005, INT J CANCER, V113, P221, DOI 10.1002/ijc.20551; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; SELIKOFF IJ, 1968, J AMER MED ASSOC, V204, P106, DOI 10.1001/jama.204.2.106; Shukla A, 2003, INT J BIOCHEM CELL B, V35, P1198, DOI 10.1016/S1357-2725(02)00315-1; Shukla A, 2003, FREE RADICAL BIO MED, V34, P1117, DOI 10.1016/S0891-5849(03)00060-1; Takamochi K, 2004, LUNG CANCER, V46, P271, DOI 10.1016/j.lungcan.2004.05.001; Upadhyay D, 2003, EXP BIOL MED, V228, P650, DOI 10.1177/153537020322800602; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726	33	35	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4730	4737		10.1038/sj.onc.1210270	http://dx.doi.org/10.1038/sj.onc.1210270			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297452				2022-12-25	WOS:000248037900014
J	Li, X; Deng, W; Lobo-Ruppert, SM; Ruppert, JM				Li, X.; Deng, W.; Lobo-Ruppert, S. M.; Ruppert, J. M.			Gli1 acts through Snail and E-cadherin to promote nuclear signaling by beta-catenin	ONCOGENE			English	Article						Hedgehog; Snail; Gli1; E-cadherin; beta-catenin; epithelial-mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITION; BASAL-CELL CARCINOMA; STEM-CELLS; C-MYC; TUMOR-SUPPRESSOR; CANCER CELLS; WNT; TRANSFORMATION; ADHESION; EXPRESSION	The Hedgehog pathway transcription factor Gli1 induces transformation of epithelial cells via induction of Snail, a repressor of E-cadherin (E-cad). E-cad is normally complexed with beta-catenin at the cell membrane. Loss of E-cad during developmental epithelial-mesenchymal transitions can switch beta-catenin from its role at adherens junctions to its role in nuclear transcription. During tumorigenesis it is unclear which pathways trigger this switch. In the current study, gain- and loss-of-function approaches identified E-cad as a selective inhibitor of transformation by Gli1, and Snail knockdown was rescued by downregulation of E-cad. Gli1 induced relocalization of beta-catenin from the cell membrane to the nucleus. The ability of wild-type or mutant alleles of E-cad to modulate transformation by Gli1 correlated with their ability to regulate localization of beta-catenin. Inhibition of Wnt-beta-catenin signaling by dominant negative Tcf4 selectively blocked in vitro transformation by Gli1. In Gli1-transgenic mice, infiltrating skin tumor cells expressed active, unphosphorylated beta-catenin. Our studies identify E-cad as a selective suppressor of transformation by Gli1 and point to the Sonic Hedgehog-Gli1 pathway as a key regulator of the beta-catenin switch in epithelial cells and cancers.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Ruppert, JM (corresponding author), Univ Alabama, Sch Med, Dept Med, Room 570 WTI, Birmingham, AL 35294 USA.	mruppert@uab.edu			NCI NIH HHS [CA094030, R01 CA094030, CA065686, R29 CA065686, R01 CA065686, R01 CA094030-05] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065686, R29CA065686, R01CA094030] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi T, 2006, GUT, V55, P991, DOI 10.1136/gut.2005.080333; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Ascano JM, 2003, J BIOL CHEM, V278, P8771, DOI 10.1074/jbc.M211427200; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bienz M, 2005, CURR BIOL, V15, pR64, DOI 10.1016/j.cub.2004.12.058; Bonifas JM, 2001, J INVEST DERMATOL, V116, P739, DOI 10.1046/j.1523-1747.2001.01315.x; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; El-Bahrawy M, 2003, BRIT J DERMATOL, V148, P964, DOI 10.1046/j.1365-2133.2003.05240.x; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huang CC, 2005, CANCER BIOL THER, V4, P1401, DOI 10.4161/cbt.4.12.2355; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; Kolligs FT, 2000, GENE DEV, V14, P1319; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Li X, 2006, ONCOGENE, V25, P609, DOI 10.1038/sj.onc.1209077; Louro ID, 2002, CANCER RES, V62, P5867; Louro ID, 1999, CELL GROWTH DIFFER, V10, P503; Mullor JL, 2001, CURR BIOL, V11, P769, DOI 10.1016/S0960-9822(01)00229-9; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Saldanha G, 2004, BRIT J DERMATOL, V151, P157, DOI 10.1111/j.1365-2133.2004.06048.x; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; van de Wetering M, 2001, CANCER RES, V61, P278; van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	38	117	129	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4489	4498		10.1038/sj.onc.1210241	http://dx.doi.org/10.1038/sj.onc.1210241			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297467	Green Accepted			2022-12-25	WOS:000247836100003
J	Oh, J; Kim, JG; Jeon, E; Yoo, CH; Moon, JS; Rhee, S; Hwang, I				Oh, Jonghee; Kim, Jung-Gun; Jeon, Eunkyung; Yoo, Chang-Hyuk; Moon, Jae Sun; Rhee, Sangkee; Hwang, Ingyu			Amyloidogenesis of type III-dependent harpins from plant pathogenic bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; LEAF APOPLASTIC FLUID; HYPERSENSITIVE RESPONSE; BIOLOGICAL-ACTIVITY; HYDROPHOBIC PROTEINS; ERWINIA-AMYLOVORA; IRON-DEFICIENCY; HRP PATHWAY; ELICITOR; FORMS	Harpins are heat-stable, glycine-rich type III-secreted proteins produced by plant pathogenic bacteria, which cause a hypersensitive response (HR) when infiltrated into the intercellular space of tobacco leaves; however, the biochemical mechanisms by which harpins cause plant cell death remain unclear. In this study, we determined the biochemical characteristics of HpaG, the first harpin identified from a Xanthomonas species, under plant apoplast-like conditions using electron microscopy and circular dichroism spectroscopy. We found that His(6)-HpaG formed biologically active spherical oligomers, protofibrils, and beta-sheet-rich fibrils, whereas the null HR mutant His(6)HpaG(L50P) did not. Biochemical analysis and HR assay of various forms of HpaG demonstrated that the transition from an beta-helix to beta-sheet-rich fibrils is important for the biological activity of protein. The fibrillar form of His(6)-HpaG is an amyloid protein based on positive staining with Congo red to produce green birefringence under polarized light, increased protease resistance, and beta-sheet fibril structure. Other harpins, such as HrpN from Erwinia amylovora and HrpZ from Pseudomonas syringae pv. syringae, also formed curvilinear protofibrils or fibrils under plant apoplast-like conditions, suggesting that amyloidogenesis is a common feature of harpins. Missense and deletion mutagenesis of HpaG indicated that the rate of HpaG fibril formation is modulated by a motif present in the C terminus. The plant cytotoxicity of HpaG is unique among the amyloid-forming proteins that occur in several microorganisms. Structural and morphological analogies between HpaG and disease-related amyloidogenic proteins, such as A beta protein, suggest possible common biochemical characteristics in the induction of plant and animal cell death.	Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea; Seoul Natl Univ, Ctr Agr Biomat, Seoul 151921, South Korea; Korea Res Biosci & Biotechnol, Plant Genome Res Ctr, Taejon 305633, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Hwang, I (corresponding author), Seoul Natl Univ, Dept Agr Biotechnol, Seoul 151921, South Korea.	ingyu@snu.ac.kr						Ahmad M, 2001, MOL PLANT MICROBE IN, V14, P1223, DOI 10.1094/MPMI.2001.14.10.1223; Alfano JR, 1996, MOL MICROBIOL, V19, P715, DOI 10.1046/j.1365-2958.1996.415946.x; Alfano JR, 2004, ANNU REV PHYTOPATHOL, V42, P385, DOI 10.1146/annurev.phyto.42.040103.110731; ARLAT M, 1994, EMBO J, V13, P543, DOI 10.1002/j.1460-2075.1994.tb06292.x; BARETTINO D, 1994, NUCLEIC ACIDS RES, V22, P541, DOI 10.1093/nar/22.3.541; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; BAUER DW, 1995, MOL PLANT MICROBE IN, V8, P484, DOI 10.1094/MPMI-8-0484; Bieler S, 2005, J BIOL CHEM, V280, P26880, DOI 10.1074/jbc.M502031200; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chapman MR, 2002, SCIENCE, V295, P851, DOI 10.1126/science.1067484; Charkowski AO, 1998, J BACTERIOL, V180, P5211, DOI 10.1128/JB.180.19.5211-5217.1998; Claessen D, 2003, GENE DEV, V17, P1714, DOI 10.1101/gad.264303; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Fandrich M, 2003, P NATL ACAD SCI USA, V100, P15463, DOI 10.1073/pnas.0303758100; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Greenberg JT, 1996, P NATL ACAD SCI USA, V93, P12094, DOI 10.1073/pnas.93.22.12094; Greenberg JT, 1997, ANNU REV PLANT PHYS, V48, P525, DOI 10.1146/annurev.arplant.48.1.525; HE SY, 1993, CELL, V73, P1255, DOI 10.1016/0092-8674(93)90354-S; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Hoyos ME, 1996, MOL PLANT MICROBE IN, V9, P608, DOI 10.1094/MPMI-9-0608; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kim JF, 1998, J BACTERIOL, V180, P5203, DOI 10.1128/JB.180.19.5203-5210.1998; Kim JG, 2004, J BACTERIOL, V186, P6239, DOI 10.1128/JB.186.18.6239-6247.2004; Kim JG, 2003, J BACTERIOL, V185, P3155, DOI 10.1128/JB.185.10.3155-3166.2003; King CY, 1997, P NATL ACAD SCI USA, V94, P6618, DOI 10.1073/pnas.94.13.6618; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Kourie JI, 2002, CLIN EXP PHARMACOL P, V29, P741, DOI 10.1046/j.1440-1681.2002.03737.x; Kourie JI, 2000, AM J PHYSIOL-CELL PH, V278, pC1063, DOI 10.1152/ajpcell.2000.278.6.C1063; Lee J, 2001, P NATL ACAD SCI USA, V98, P289, DOI 10.1073/pnas.011265298; Lopez-Millan AF, 2000, PLANT PHYSIOL, V124, P873, DOI 10.1104/pp.124.2.873; Lopez-Millan AF, 2001, J EXP BOT, V52, P1489, DOI 10.1093/jexbot/52.360.1489; Masison DC, 1997, P NATL ACAD SCI USA, V94, P12503, DOI 10.1073/pnas.94.23.12503; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Pike SM, 1998, PHYSIOL MOL PLANT P, V53, P39, DOI 10.1006/pmpp.1998.0167; Qahwash I, 2003, J BIOL CHEM, V278, P23187, DOI 10.1074/jbc.M213298200; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Racape J, 2005, MOL MICROBIOL, V58, P1406, DOI 10.1111/j.1365-2958.2004.04910.x; Resende CG, 2003, MOL MICROBIOL, V49, P1005, DOI 10.1046/j.1365-2958.2003.03608.x; SCHULTE R, 1992, PLANT CELL, V4, P79, DOI 10.1105/tpc.4.1.79; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Thompson A, 2000, J NEUROSCI RES, V62, P293, DOI 10.1002/1097-4547(20001015)62:2<293::AID-JNR14>3.0.CO;2-Y; Tossi A, 2000, BIOPOLYMERS, V55, P4; Vila M, 2003, NAT REV NEUROSCI, V4, P365, DOI 10.1038/nrn1100; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; Wengelnik K, 1996, J BACTERIOL, V178, P1061, DOI 10.1128/jb.178.4.1061-1069.1996; Wickner RB, 2004, GENE DEV, V18, P470, DOI 10.1101/gad.1177104	48	85	91	1	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13601	13609		10.1074/jbc.M602576200	http://dx.doi.org/10.1074/jbc.M602576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17314101	hybrid			2022-12-25	WOS:000246060300049
J	Grubina, R; Huang, Z; Shiva, S; Joshi, MS; Azarov, I; Basu, S; Ringwood, LA; Jiang, A; Hogg, N; Kim-Shapiro, DB; Gladwin, MT				Grubina, Rozalina; Huang, Zhi; Shiva, Sruti; Joshi, Mahesh S.; Azarov, Ivan; Basu, Swati; Ringwood, Lorna A.; Jiang, Alice; Hogg, Neil; Kim-Shapiro, Daniel B.; Gladwin, Mark T.			Concerted nitric oxide formation and release from the simultaneous reactions of nitrite with deoxy- and oxyhemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; BLOOD-FLOW REGULATION; S-NITROSOHEMOGLOBIN; AUTOCATALYTIC OXIDATION; ISCHEMIA-REPERFUSION; HYPOXIC CONDITIONS; LIGAND-BINDING; OXYGEN-BINDING; HEMOGLOBIN; NO	Recent studies reveal a novel role for hemoglobin as an allosterically regulated nitrite reductase that may mediate nitric oxide (NO)-dependent signaling along the physiological oxygen gradient. Nitrite reacts with deoxyhemoglobin in an allosteric reaction that generates NO and oxidizes deoxyhemoglobin to methemoglobin. NO then reacts at a nearly diffusion-limited rate with deoxyhemoglobin to form iron-nitrosyl-hemoglobin, which to date has been considered a highly stable adduct and, thus, not a source of bioavailable NO. However, under physiological conditions of partial oxygen saturation, nitrite will also react with oxyhemoglobin, and although this complex autocatalytic reaction has been studied for a century, the interaction of the oxy- and deoxy-reactions and the effects on NO disposition have never been explored. We have now characterized the kinetics of hemoglobin oxidation and NO generation at a range of oxygen partial pressures and found that the deoxy-reaction runs in parallel with and partially inhibits the oxy-reaction. In fact, intermediates in the oxy-reaction oxidize the heme iron of iron nitrosyl hemoglobin, a product of the deoxy-reaction, which releases NO from the iron-nitrosyl. This oxidative denitrosylation is particularly striking during cycles of hemoglobin deoxygenation and oxygenation in the presence of nitrite. These chemistries may contribute to the oxygen-dependent disposition of nitrite in red cells by limiting oxidative inactivation of nitrite by oxyhemoglobin, promoting nitrite reduction to NO by deoxyhemoglobin, and releasing free NO from iron-nitrosyl-hemoglobin.	NHLBI, Vasc Med Branch, Dept Crit Care Med, Ctr Clin,NIH, Bethesda, MD 20892 USA; Howard Hughes Med Inst, Natl Inst Hlth, Res Scholars Program, Bethesda, MD 20814 USA; NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA; Wake Forest Univ, Dept Phys, Winston Salem, NC 27109 USA; Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Heart Lung & Blood Institute (NHLBI); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Wake Forest University; Medical College of Wisconsin	Gladwin, MT (corresponding author), NHLBI, Vasc Med Branch, Dept Crit Care Med, Ctr Clin,NIH, Bldg 10 CRC,Rm 5-5140,10 Ctr Dr, Bethesda, MD 20892 USA.	mgladwin@nih.gov	Kim-Shapiro, Daniel/HGA-2682-2022	Azarov, Ivan/0000-0002-9886-3298	Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [HL58091, R37 HL058091, R01 HL058091, HL078706] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL058091, R01HL058091, R29HL058091, K02HL078706] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angelo M, 2006, P NATL ACAD SCI USA, V103, P8366, DOI 10.1073/pnas.0600942103; Boccini F, 2006, J PHYS CHEM A, V110, P3927, DOI 10.1021/jp056452l; Brooks J, 1937, PROC R SOC SER B-BIO, V123, P368, DOI 10.1098/rspb.1937.0057; Bryan NS, 2005, NAT CHEM BIOL, V1, P290, DOI 10.1038/nchembio734; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI12761; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; Castello PR, 2006, CELL METAB, V3, P277, DOI 10.1016/j.cmet.2006.02.011; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Crawford JH, 2006, BLOOD, V107, P566, DOI 10.1182/blood-2005-07-2668; DOYLE MP, 1981, J BIOL CHEM, V256, P2393; Duranski MR, 2005, J CLIN INVEST, V115, P1232, DOI 10.1172/JCI200522493; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Ford PC, 2005, CHEM REV, V105, P2439, DOI 10.1021/cr0307289; Gardner PR, 2005, J INORG BIOCHEM, V99, P247, DOI 10.1016/j.jinorgbio.2004.10.003; Gautier C, 2006, BIOCHEM BIOPH RES CO, V341, P816, DOI 10.1016/j.bbrc.2006.01.031; Gladwin MT, 2002, J BIOL CHEM, V277, P27818, DOI 10.1074/jbc.M203236200; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P11482, DOI 10.1073/pnas.97.21.11482; Gladwin MT, 2000, P NATL ACAD SCI USA, V97, P9943, DOI 10.1073/pnas.180155397; Gladwin MT, 2004, FREE RADICAL BIO MED, V36, P707, DOI 10.1016/j.freeradbiomed.2003.11.032; Gladwin MT, 2005, NAT CHEM BIOL, V1, P308, DOI 10.1038/nchembio1105-308; Godber BLJ, 2000, J BIOL CHEM, V275, P7757, DOI 10.1074/jbc.275.11.7757; Hataishi R, 2006, AM J PHYSIOL-HEART C, V291, pH379, DOI 10.1152/ajpheart.01172.2005; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; Herold S, 2006, INORG CHEM, V45, P6933, DOI 10.1021/ic060469g; Huang KT, 2005, J BIOL CHEM, V280, P31126, DOI 10.1074/jbc.M501496200; Huang KT, 2006, BLOOD, V107, P2602, DOI 10.1182/blood-2005-10-4104; Huang Z, 2005, J CLIN INVEST, V115, P2099, DOI 10.1172/JCI24650; Huang Z, 2003, BIOPHYS J, V85, P2374, DOI 10.1016/S0006-3495(03)74661-X; Hunter CJ, 2004, NAT MED, V10, P1122, DOI 10.1038/nm1109; Jeffers A, 2005, COMP BIOCHEM PHYS A, V142, P130, DOI 10.1016/j.cbpb.2005.04.016; Keszler A, 2006, FREE RADICAL BIO MED, V40, P507, DOI 10.1016/j.freeradbiomed.2005.09.005; Kim-Shapiro DB, 2005, J INORG BIOCHEM, V99, P237, DOI 10.1016/j.jinorgbio.2004.10.034; Kim-Shapiro DB, 2004, FREE RADICAL BIO MED, V36, P402, DOI 10.1016/j.freeradbiomed.2003.10.030; KOSAKA H, 1982, BIOCHIM BIOPHYS ACTA, V702, P237; Kozlov AV, 2005, ANTIOXID REDOX SIGN, V7, P515, DOI 10.1089/ars.2005.7.515; Li HT, 2001, J BIOL CHEM, V276, P24482, DOI 10.1074/jbc.M011648200; Lissi E, 1998, FREE RADICAL BIO MED, V24, P1535, DOI 10.1016/S0891-5849(98)00004-5; Luchsinger BP, 2003, P NATL ACAD SCI USA, V100, P461, DOI 10.1073/pnas.0233287100; Luchsinger BP, 2005, J INORG BIOCHEM, V99, P912, DOI 10.1016/j.jinorgbio.2004.12.010; Lundberg JO, 2005, ARTERIOSCL THROM VAS, V25, P915, DOI 10.1161/01.ATV.0000161048.72004.c2; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; McMahon TJ, 2002, NAT MED, V8, P711, DOI 10.1038/nm718; McMahon TJ, 2000, J BIOL CHEM, V275, P16738, DOI 10.1074/jbc.M000532200; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; Modin A, 2001, ACTA PHYSIOL SCAND, V171, P9, DOI 10.1046/j.1365-201x.2001.171001009.x; MORRIS RJ, 1980, J BIOL CHEM, V255, P8050; Nagababu E, 2003, J BIOL CHEM, V278, P46349, DOI 10.1074/jbc.M307572200; Nohl H, 2000, ACTA BIOCHIM POL, V47, P913, DOI 10.18388/abp.2000_3946; Piknova B, 2005, J BIOL CHEM, V280, P40583, DOI 10.1074/jbc.M506292200; Roche CJ, 2006, J BIOL CHEM, V281, P36874, DOI 10.1074/jbc.M603914200; SHIVA S, 2007, IN PRESS CIRC RES; Singel DJ, 2005, ANNU REV PHYSIOL, V67, P99, DOI 10.1146/annurev.physiol.67.060603.090918; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Tsuchiya K, 2005, AM J PHYSIOL-HEART C, V288, pH2163, DOI 10.1152/ajpheart.00525.2004; Wang Y, 1995, Adv Pharmacol, V34, P71; Webb A, 2004, P NATL ACAD SCI USA, V101, P13683, DOI 10.1073/pnas.0402927101; Xu XL, 2003, P NATL ACAD SCI USA, V100, P11303, DOI 10.1073/pnas.2033883100; Yonetani T, 1998, J BIOL CHEM, V273, P20323, DOI 10.1074/jbc.273.32.20323; ZWEIER JL, 1995, NAT MED, V1, P804, DOI 10.1038/nm0895-804	60	128	130	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12916	12927		10.1074/jbc.M700546200	http://dx.doi.org/10.1074/jbc.M700546200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17322300	hybrid			2022-12-25	WOS:000245942800063
J	Han, YP; Yan, CL; Zhou, L; Qin, L; Tsukamoto, H				Han, Yuan-Ping; Yan, Chunli; Zhou, Ling; Qin, Lan; Tsukamoto, Hidekazu			A matrix metalloproteinase-9 activation cascade by hepatic stellate cells in trans-differentiation in the three-dimensional extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; NECROSIS FACTOR-ALPHA; NF-KAPPA-B; RAT-LIVER; HUMAN SKIN; PROTEOLYTIC ACTIVATION; INFLAMMATORY CYTOKINES; MEDIATED INDUCTION; GROWTH-FACTORS; KUPFFER CELLS	Hepatic stellate cells (HSCs) undergo myofibroblastic transdifferentiation in liver fibrogenesis. We previously showed that dual stimulation with three-dimensional type-I collagen and interleukin-1 (IL-1) synergistically induces HSC trans-differentiation in a manner dependent on the activation of matrix metallopreinase-9 (MMP-9). The present study is aimed to determine the mechanism of MMP-9 activation in this model. The pro-MMP-9-converting activities expressed by trans-differentiating HSCs are characterized as secreted factors that are sensitive to MMP inhibitor and have apparent molecular masses of 50 and 25 kDa. This is in sharp contrast to the pro-MMP-9 activator from mouse and human skin, which is a chymotrypsin-like proteinase. Among multiple MMPs induced in HSCs by the dual stimulation, MMP-13 is most conspicuously up-regulated and meets all criteria as the pro-MMP-9 activator. HSC cultured in three- dimensional type-I collagen, but not in Matrigel, IL-1 induces expression of MMP-13 and its matured form at 50 and 25 kDa, respectively. In vitro reconstitution experiment proves that MMP-13, but not its zymogen, activates pro-MMP-9. Further, short hairpin RNA targeting MMP-13 abolishes proMMP-9 activation and HSC trans-differentiation. We further demonstrate that pro-MMP-13 activation is facilitated with a membrane-associated factor, inhibited with tissue inhibitor of metalloproteinase-2, and abolished with short hairpin RNA against MMP-14. Moreover, pro-MMP-13 is also activated by a secreted factor, which is absorbed by gelatin-Sepharose and reconstituted with MMP-9. Thus, IL-1-induced trans-differentiation of HSCs in three-dimensional extracellular matrix is facilitated by an MMP activation cascade (MMP-14 > MMP13 > MMP-9) and a positive feedback loop of MMP-9 > MMP13, suggesting their critical roles in liver injury and repair.	Univ So Calif, Keck Sch Med, Dept Surg, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Han, YP (corresponding author), Univ So Calif, Keck Sch Med, Dept Surg, 2011 Zonal Ave,HMR 813, Los Angeles, CA 90033 USA.	yhan@surgery.usc.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R24AA012885, P50AA011999] Funding Source: NIH RePORTER; NIAAA NIH HHS [P50 AA11999, R24 AA012885, R24AA12885, P50 AA011999] Funding Source: Medline; NIAMS NIH HHS [AR051558, R01 AR051558, R01 AR051558-01] Funding Source: Medline; NIDDK NIH HHS [DK069418, R01 DK069418-01, R01 DK069418] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; Benyon RC, 2001, SEMIN LIVER DIS, V21, P373, DOI 10.1055/s-2001-17552; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Corbel M, 2001, INFLAMM RES, V50, P129, DOI 10.1007/s000110050736; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DELEEUW AM, 1984, HEPATOLOGY, V4, P392; Dreier R, 2004, EXP CELL RES, V297, P303, DOI 10.1016/j.yexcr.2004.02.027; Fang KC, 1997, J BIOL CHEM, V272, P25628, DOI 10.1074/jbc.272.41.25628; Fang KC, 1996, J CLIN INVEST, V97, P1589, DOI 10.1172/JCI118583; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; Friedman SL, 1999, SEMIN LIVER DIS, V19, P129, DOI 10.1055/s-2007-1007105; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; FRIEDMAN SL, 1985, P NATL ACAD SCI USA, V82, P8681, DOI 10.1073/pnas.82.24.8681; FRIEDMAN SL, 1987, ANAL BIOCHEM, V161, P207, DOI 10.1016/0003-2697(87)90673-7; GEERTS A, 1989, J HEPATOL, V9, P59, DOI 10.1016/0168-8278(89)90076-7; Geerts A, 2001, SEMIN LIVER DIS, V21, P311, DOI 10.1055/s-2001-17550; GRESSNER AM, 1990, SEMIN LIVER DIS, V10, P30, DOI 10.1055/s-2008-1040455; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Hahn-Dantona E, 1999, ANN NY ACAD SCI, V878, P372, DOI 10.1111/j.1749-6632.1999.tb07696.x; Han YP, 2005, SURGERY, V138, P932, DOI 10.1016/j.surg.2005.05.003; Han YP, 2004, J BIOL CHEM, V279, P4820, DOI 10.1074/jbc.M310999200; Han YP, 2002, J BIOL CHEM, V277, P27319, DOI 10.1074/jbc.M202842200; Han YP, 2001, J BIOL CHEM, V276, P22341, DOI 10.1074/jbc.M010839200; Han YP, 2001, J CELL SCI, V114, P131; Han YP, 2006, J GASTROEN HEPATOL, V21, pS88, DOI 10.1111/j.1440-1746.2006.04586.x; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; HERBST H, 1991, VIRCHOWS ARCH B, V60, P295, DOI 10.1007/BF02899560; Ikeda K, 2002, J BIOL CHEM, V277, P19206, DOI 10.1074/jbc.M201078200; Itoh Y, 2006, MOL BIOL CELL, V17, P5390, DOI 10.1091/mbc.e06-08-0740; JEZEQUEL AM, 1987, J HEPATOL, V5, P174, DOI 10.1016/S0168-8278(87)80570-6; JOHNSON JD, 1993, P NATL ACAD SCI USA, V90, P5677, DOI 10.1073/pnas.90.12.5677; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knittel T, 1999, J HEPATOL, V30, P48, DOI 10.1016/S0168-8278(99)80007-5; Knittel T, 2000, HISTOCHEM CELL BIOL, V113, P443; Kossakowska AE, 1998, AM J PATHOL, V153, P1895, DOI 10.1016/S0002-9440(10)65703-3; Lemjabbar H, 1999, AM J RESP CELL MOL, V20, P903, DOI 10.1165/ajrcmb.20.5.3260; MATSUOKA M, 1989, LIVER, V9, P71; MILANI S, 1994, AM J PATHOL, V144, P528; MINATO Y, 1983, HEPATOLOGY, V3, P559; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKANOUE T, 1983, ARCH PATHOL LAB MED, V107, P459; OKAZAKI I, 1974, NATURE, V252, P49, DOI 10.1038/252049a0; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; SATO H, 1993, J BIOL CHEM, V268, P23460; Selvarajan S, 2001, NAT CELL BIOL, V3, P267, DOI 10.1038/35060059; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; TAKAHARA T, 1988, LAB INVEST, V59, P509; Tchougounova E, 2005, J BIOL CHEM, V280, P9291, DOI 10.1074/jbc.M410396200; TSUKADA S, 2006, CLIN CHIM ACTA, V364, P33, DOI DOI 10.1016/J.CCA.2005.06.014; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; Uchinami H, 2006, HEPATOLOGY, V44, P420, DOI 10.1002/hep.21268; Wake K, 1980, Int Rev Cytol, V66, P303; Watanabe T, 2001, J HEPATOL, V35, P465, DOI 10.1016/S0168-8278(01)00177-5	56	70	73	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12928	12939		10.1074/jbc.M700554200	http://dx.doi.org/10.1074/jbc.M700554200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17322299	Green Accepted, hybrid			2022-12-25	WOS:000245942800064
J	Budman, J; Kim, SA; Chu, G				Budman, Joe; Kim, Sunny A.; Chu, Gilbert			Processing of DNA for nonhomologous end-joining is controlled by kinase activity and XRCC4/Ligase IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; POLYMERASE-LAMBDA; LIGASE-IV; MAMMALIAN-CELLS; COMPLEX; KU; AUTOPHOSPHORYLATION	Nonhomologous end-joining ( NHEJ) repairs DNA double-strand breaks created by ionizing radiation and V(D)J recombination. To repair the broken ends, NHEJ processes noncompatible ends into a ligatable form but suppresses processing of compatible ends. It is not known how NHEJ controls polymerase and nuclease activities to act exclusively on noncompatible ends. Here, we analyzed processing independently of ligation by using a two-stage assay with extracts that recapitulated the properties of NHEJ in vivo. Processing of noncompatible ends required wortmannin-sensitive kinase activity. Since DNA-dependent protein kinase catalytic subunit ( DNA-PKcs) brings the ends together before undergoing activation of its kinase, this suggests that processing occurred after synapsis of the ends. Surprisingly, all polymerase and most nuclease activity required XRCC4/Ligase IV. This suggests a mechanism for how NHEJ suppresses processing to optimize the preservation of DNA sequence.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University; Stanford University	Chu, G (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR Bldg,Rm 1145,269 Campus Dr, Stanford, CA 94305 USA.	chu@stanford.edu						Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; Bredemeyer AL, 2006, NATURE, V442, P466, DOI 10.1038/nature04866; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Budman J, 2005, EMBO J, V24, P849, DOI 10.1038/sj.emboj.7600563; Budman J, 2006, METHOD ENZYMOL, V408, P430, DOI 10.1016/S0076-6879(06)08027-X; Calsou P, 1999, J BIOL CHEM, V274, P7848, DOI 10.1074/jbc.274.12.7848; Capp JP, 2006, NUCLEIC ACIDS RES, V34, P2998, DOI 10.1093/nar/gkl380; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chappell C, 2002, EMBO J, V21, P2827, DOI 10.1093/emboj/21.11.2827; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Fan W, 2004, BIOCHEM BIOPH RES CO, V323, P1328, DOI 10.1016/j.bbrc.2004.09.002; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; Goodarzi AA, 2006, EMBO J, V25, P3880, DOI 10.1038/sj.emboj.7601255; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahajan KN, 2002, MOL CELL BIOL, V22, P5194, DOI 10.1128/MCB.22.14.5194-5202.2002; McElhinny SAN, 2005, MOL CELL, V19, P357, DOI 10.1016/j.molcel.2005.06.012; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; OKADA T, 1994, J BIOL CHEM, V269, P3563; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Sarkaria JN, 1998, CANCER RES, V58, P4375; Schlissel MS, 1998, MOL CELL BIOL, V18, P2029, DOI 10.1128/MCB.18.4.2029; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003; Weterings E, 2003, NUCLEIC ACIDS RES, V31, P7238, DOI 10.1093/nar/gkg889; Yoo S, 1999, NUCLEIC ACIDS RES, V27, P4679, DOI 10.1093/nar/27.24.4679; Zhang YB, 2001, MOL CELL BIOL, V21, P7995, DOI 10.1128/MCB.21.23.7995-8006.2001	38	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11950	11959		10.1074/jbc.M610058200	http://dx.doi.org/10.1074/jbc.M610058200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17272270	hybrid			2022-12-25	WOS:000245941900038
J	Cabello, N; Remelli, R; Canela, L; Soriguera, A; Mallol, J; Canela, EI; Robbins, MJ; Lluis, C; Franco, R; McIlhinney, RAJ; Ciruela, F				Cabello, Nuria; Remelli, Rosaria; Canela, Laia; Soriguera, Ana; Mallol, Josefa; Canela, Enric I.; Robbins, Melanie J.; Lluis, Carme; Franco, Rafael; McIlhinney, R. A. Jeffrey; Ciruela, Francisco			Actin-binding protein alpha-actinin-1 interacts with the metabotropic glutamate receptor type 5b and modulates the cell surface expression and function of the receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-DEPENDENT INACTIVATION; ALPHA-ACTININ; NMDA-RECEPTOR; FILAMIN-A; MASS-SPECTROMETRY; KINASE-II; TYPE-1-ALPHA RECEPTOR; SENSING RECEPTOR; ADENOSINE A(2A); PLASMA-MEMBRANE	Receptors for neurotransmitters require scaffolding proteins for membrane microdomain targeting and for regulating receptor function. Using a yeast two-hybrid screen, alpha-actinin-1, a major F-actin cross-linking protein, was identified as a binding partner for the C-terminal domain of metabotropic glutamate receptor type 5b (mGlu(5b) receptor). Co-expression, co-immunoprecipitation, and pull-down experiments showed a close and specific interaction between mGlu(5b) receptor and alpha-actinin-1 in both transfected HEK293 cells and rat striatum. The interaction of alpha-actinin-1 with mGlu(5b) receptor modulated the cell surface expression of the receptor. This was dependent on the binding of alpha-actinin-1 to the actin cytoskeleton. In addition, the alpha-actinin-1/mGlu(5b) receptor interaction regulated receptor-mediated activation of the mitogen-activated protein kinase pathway. Together, these findings indicate that there is an alpha-actinin-1-dependent mGlu(5b) receptor association with the actin cytoskeleton modulating receptor cell surface expression and functioning.	Univ Barcelona, Fac Biol, Inst Invest Biomed August Pi Sunyer, E-08028 Barcelona, Spain; Univ Barcelona, Fac Biol, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England; GlaxoSmithKline, Psychiat Ctr Excellence Drug Discovery, Dept Schizophrenia & Bipolar Neurophysiol & Pharm, Harlow CM19 5AW, Essex, England	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; GlaxoSmithKline	Ciruela, F (corresponding author), Univ Barcelona, Fac Biol, Inst Invest Biomed August Pi Sunyer, Avda Diagonal 645, E-08028 Barcelona, Spain.	fciruela@ub.edu	Franco, Rafael/C-3694-2015; Mallol, Josefa/I-4194-2015; Ciruela, F./A-5096-2013; Canela, Enric I./M-8726-2013	Franco, Rafael/0000-0003-2549-4919; Mallol, Josefa/0000-0002-2479-4162; Ciruela, F./0000-0003-0832-3739; Canela, Enric I./0000-0003-4992-7440	Medical Research Council [MC_U138162357] Funding Source: Medline; MRC [MC_U138162357] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Attucci S, 2001, BRIT J PHARMACOL, V132, P799, DOI 10.1038/sj.bjp.0703904; Au YH, 2004, STRUCTURE, V12, P611, DOI 10.1016/j.str.2004.02.019; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; Benquet P, 2002, J NEUROSCI, V22, P9679; Bouhamdan M, 2006, J NEUROSCI, V26, P2522, DOI 10.1523/JNEUROSCI.4083-05.2006; Burgueno J, 2004, EXP CELL RES, V300, P23, DOI 10.1016/j.yexcr.2004.06.013; Burgueno J, 2003, J BIOL CHEM, V278, P37545, DOI 10.1074/jbc.M302809200; Burgueno J, 2003, J NEUROCHEM, V86, P785, DOI 10.1046/j.1471-4159.2003.01842.x; Canals M, 2003, J BIOL CHEM, V278, P46741, DOI 10.1074/jbc.M306451200; CASADO V, 1990, J NEUROSCI RES, V26, P461, DOI 10.1002/jnr.490260409; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Chan WY, 2001, MOL CELL NEUROSCI, V17, P577, DOI 10.1006/mcne.2001.0965; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Ciruela F, 1997, FEBS LETT, V418, P83, DOI 10.1016/S0014-5793(97)01353-7; Ciruela F, 1999, BIOCHEM J, V341, P795, DOI 10.1042/0264-6021:3410795; Ciruela F, 2004, ANAL CHEM, V76, P5354, DOI 10.1021/ac049295f; Ciruela F, 2005, J MOL NEUROSCI, V26, P277, DOI 10.1385/JMN:26:2-3:277; Cukovic D, 2001, FEBS LETT, V498, P87, DOI 10.1016/S0014-5793(01)02505-4; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; Dunah AW, 2000, MOL BRAIN RES, V79, P77, DOI 10.1016/S0169-328X(00)00102-9; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Enz R, 2002, FEBS LETT, V514, P184, DOI 10.1016/S0014-5793(02)02361-X; Faulkner G, 1999, J CELL BIOL, V146, P465, DOI 10.1083/jcb.146.2.465; Ferre S, 2002, P NATL ACAD SCI USA, V99, P11940, DOI 10.1073/pnas.172393799; Heidinger V, 2002, J NEUROSCI, V22, P5452; Hjalm G, 2001, J BIOL CHEM, V276, P34880, DOI 10.1074/jbc.M100784200; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Huang CF, 2006, FEBS LETT, V580, P1795, DOI 10.1016/j.febslet.2006.02.035; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kremerskothen J, 2002, BIOCHEM BIOPH RES CO, V295, P678, DOI 10.1016/S0006-291X(02)00734-9; Krupp JJ, 1999, J NEUROSCI, V19, P1165; LAZARIDES E, 1975, CELL, V6, P289, DOI 10.1016/0092-8674(75)90180-4; Leinweber BD, 1999, BIOCHEM J, V344, P117, DOI 10.1042/0264-6021:3440117; Li M, 2000, MOL PHARMACOL, V57, P446, DOI 10.1124/mol.57.3.446; Lin RW, 2002, PHARMACOLOGY, V66, P173, DOI 10.1159/000065531; Lin RW, 2001, P NATL ACAD SCI USA, V98, P5258, DOI 10.1073/pnas.011538198; Lujan R, 2001, NEUROREPORT, V12, P1285, DOI 10.1097/00001756-200105080-00046; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Marti A, 1997, J BIOL CHEM, V272, P2620, DOI 10.1074/jbc.272.5.2620; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; Minakami R, 1997, J BIOL CHEM, V272, P20291, DOI 10.1074/jbc.272.32.20291; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Nakagawa T, 2004, NEUROPHARMACOLOGY, V47, P734, DOI 10.1016/j.neuropharm.2004.07.022; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Onoprishvili I, 2003, MOL PHARMACOL, V64, P1092, DOI 10.1124/mol.64.5.1092; Otey CA, 2004, CELL MOTIL CYTOSKEL, V58, P104, DOI 10.1002/cm.20007; Peng JM, 2004, J BIOL CHEM, V279, P21003, DOI 10.1074/jbc.M400103200; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Pisani A, 1997, BRIT J PHARMACOL, V120, P1007, DOI 10.1038/sj.bjp.0700999; Robison AJ, 2005, J BIOL CHEM, V280, P39316, DOI 10.1074/jbc.M508189200; Robison AJ, 2005, J BIOL CHEM, V280, P35329, DOI 10.1074/jbc.M502191200; Romano C, 2002, NEUROSCIENCE, V111, P693, DOI 10.1016/S0306-4522(02)00042-8; Rycroft BK, 2004, J PHYSIOL-LONDON, V557, P795, DOI 10.1113/jphysiol.2003.059212; Sarrio S, 2000, MOL CELL BIOL, V20, P5164, DOI 10.1128/MCB.20.14.5164-5174.2000; Seck T, 2003, J BIOL CHEM, V278, P10408, DOI 10.1074/jbc.M209655200; Sessoms-Sikes S, 2005, MOL CELL NEUROSCI, V29, P139, DOI 10.1016/j.mcn.2005.01.006; Sorimachi H, 1997, J MOL BIOL, V270, P688, DOI 10.1006/jmbi.1997.1145; TRAVE G, 1995, EUR J BIOCHEM, V227, P35, DOI 10.1111/j.1432-1033.1995.tb20357.x; Ugolini A, 1997, NEUROPHARMACOLOGY, V36, P1047, DOI 10.1016/S0028-3908(97)00103-2; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Walikonis RS, 2001, J NEUROSCI, V21, P423, DOI 10.1523/JNEUROSCI.21-02-00423.2001; Wirkner K, 2007, CEREB CORTEX, V17, P621, DOI 10.1093/cercor/bhk012; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Yang L, 2004, J NEUROSCI, V24, P10846, DOI 10.1523/JNEUROSCI.2496-04.2004; Young P, 1998, EMBO J, V17, P1614, DOI 10.1093/emboj/17.6.1614; Zhang ML, 2005, J BIOL CHEM, V280, P11140, DOI 10.1074/jbc.M412242200; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; Zhou Q, 2001, J CELL BIOL, V155, P605, DOI 10.1083/jcb.200107092; Zimmermann T, 2002, FEBS LETT, V531, P245, DOI 10.1016/S0014-5793(02)03508-1	70	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12143	12153		10.1074/jbc.M608880200	http://dx.doi.org/10.1074/jbc.M608880200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17311919	hybrid, Green Published			2022-12-25	WOS:000245941900057
J	Cottrell, GS; Padilla, B; Pikios, S; Roosterman, D; Steinhoff, M; Grady, EF; Bunnett, NW				Cottrell, Graeme S.; Padilla, Benjamin; Pikios, Stella; Roosterman, Dirk; Steinhoff, Martin; Grady, Eileen F.; Bunnett, Nigel W.			Post-endocytic sorting of calcitonin receptor-like receptor and receptor activity-modifying protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; BETA(2)-ADRENERGIC RECEPTOR; NEUROKININ-1 RECEPTOR; COUPLED RECEPTOR; MEDIATES UBIQUITINATION; BINDING-SPECIFICITY; DOWN-REGULATION; BETA-ARRESTIN; SPINAL-CORD; RAB GTPASES	Calcitonin receptor-like receptor ( CLR) and the receptor activity-modifying protein 1 ( RAMP1) comprise a receptor for calcitonin gene-related peptide ( CGRP). Although CGRP induces endocytosis of CLR/RAMP1, little is known about post-endocytic sorting of these proteins. We observed that the duration of stimulation with CGRP markedly affected post-endocytic sorting of CLR/RAMP1. In HEK and SK-N-MC cells, transient stimulation ( 10(-7) M CGRP, 1 h), induced CLR/RAMP1 recycling with similar kinetics ( 2-6 h), demonstrated by labeling receptors in living cells with antibodies to extracellular epitopes. Recycling of CLR/RAMP1 correlated with resensitization of CGRP-induced increases in [ Ca2+](i). Cycloheximide did not affect resensitization, but bafilomycin A(1), an inhibitor of vacuolar H+-ATPases, abolished resensitization. Recycling CLR and RAMP1 were detected in endosomes containing Rab4a and Rab11a, and expression of GTPase-defective Rab4aS22N and Rab11aS25N inhibited resensitization. After sustained stimulation ( 10(-7) M CGRP,> 2 h), CLR/RAMP1 trafficked to lysosomes. RAMP1 was degraded similar to 4-fold more rapidly than CLR ( RAMP1, 45% degradation, 5 h; CLR, 54% degradation, 16 h), determined by Western blotting. Inhibitors of lysosomal, but not proteasomal, proteases prevented degradation. Sustained stimulation did not induce detectable mono- or polyubiquitination of CLR or RAMP1, determined by immunoprecipitation and Western blotting. Moreover, a RAMP1 mutant lacking the only intracellular lysine ( RAMP1K142R) internalized and was degraded normally. Thus, after transient stimulation with CGRP, CLR and RAMP1 traffic from endosomes to the plasma membrane, which mediates resensitization. After sustained stimulation, CLR and RAMP1 traffic from endosomes to lysosomes by ubiquitin-independent mechanisms, where they are degraded at different rates.	Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Interdisziplinares Zentrum Klin Forsch Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Munster, Ludwig Boltzmann Inst Cell Immunobiol Skin, D-48149 Munster, Germany	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Munster	Bunnett, NW (corresponding author), Univ Calif San Francisco, Dept Surg, 521 Parnassus Ave, San Francisco, CA 94143 USA.	nigel.bunnett@ucsf.edu	Steinhoff, Martin/F-6312-2013	Bunnett, Nigel W./0000-0003-3367-0644; Cottrell, Graeme/0000-0001-9098-7627; Steinhoff, Martin/0000-0002-7090-2187	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052388, R56DK043207, R01DK039957, R01DK043207, R01DK057840, R37DK039957] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52388, DK57840, DK39957, DK43207] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; AMARA SG, 1985, SCIENCE, V229, P1094, DOI 10.1126/science.2994212; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Bomberger JM, 2005, J BIOL CHEM, V280, P23926, DOI 10.1074/jbc.M501751200; Bomberger JM, 2005, J BIOL CHEM, V280, P9297, DOI 10.1074/jbc.M413786200; Brain SD, 2004, PHYSIOL REV, V84, P903, DOI 10.1152/physrev.00037.2003; Christopoulos G, 1999, MOL PHARMACOL, V56, P235, DOI 10.1124/mol.56.1.235; Cottrell GS, 2006, J BIOL CHEM, V281, P27773, DOI 10.1074/jbc.M603369200; Cottrell GS, 2005, J COMP NEUROL, V490, P239, DOI 10.1002/cne.20669; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Fraser NJ, 1999, MOL PHARMACOL, V55, P1054, DOI 10.1124/mol.55.6.1054; Garland AM, 1996, MOL PHARMACOL, V49, P438; GIBSON SJ, 1984, J NEUROSCI, V4, P3101, DOI 10.1523/jneurosci.04-12-03101.1984; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hilaire S, 2001, J BIOL CHEM, V276, P42182, DOI 10.1074/jbc.M107323200; Hislop JN, 2004, J BIOL CHEM, V279, P22522, DOI 10.1074/jbc.M311062200; Hunyady L, 2002, J CELL BIOL, V157, P1211, DOI 10.1083/jcb.200111013; Jacob C, 2005, J BIOL CHEM, V280, P16076, DOI 10.1074/jbc.M500109200; Kuwasako K, 2000, J BIOL CHEM, V275, P29602, DOI 10.1074/jbc.M004534200; Kuwasako K, 2006, J BIOL CHEM, V281, P7205, DOI 10.1074/jbc.M511147200; Kuwasako K, 2003, J BIOL CHEM, V278, P22623, DOI 10.1074/jbc.M302571200; Kuwasako K, 2002, FEBS LETT, V519, P113, DOI 10.1016/S0014-5793(02)02721-7; Li JG, 2003, J PHARMACOL EXP THER, V305, P531, DOI 10.1124/jpet.102.045559; LONGMORE J, 1994, EUR J PHARMACOL, V265, P53, DOI 10.1016/0014-2999(94)90222-4; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Marchese A, 2003, DEV CELL, V5, P709, DOI 10.1016/S1534-5807(03)00321-6; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Mohrmann K, 1999, MOL MEMBR BIOL, V16, P81, DOI 10.1080/096876899294797; NJUKI F, 1993, CLIN SCI, V85, P385, DOI 10.1042/cs0850385; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Olesen J, 2004, NEW ENGL J MED, V350, P1104, DOI 10.1056/NEJMoa030505; Roosterman D, 2004, J BIOL CHEM, V279, P30670, DOI 10.1074/jbc.M402479200; ROSENFELD MG, 1984, SCIENCE, V225, P1315, DOI 10.1126/science.6089345; Schmidlin F, 2003, AM J PHYSIOL-CELL PH, V285, pC945, DOI 10.1152/ajpcell.00541.2002; Schmidlin F, 2001, J BIOL CHEM, V276, P25427, DOI 10.1074/jbc.M101688200; Seachrist JL, 2000, J BIOL CHEM, V275, P27221; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Tanowitz M, 2002, J BIOL CHEM, V277, P50219, DOI 10.1074/jbc.C200536200; VanRossum D, 1997, NEUROSCI BIOBEHAV R, V21, P649, DOI 10.1016/S0149-7634(96)00023-1	40	64	65	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12260	12271		10.1074/jbc.M606338200	http://dx.doi.org/10.1074/jbc.M606338200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17310067	hybrid			2022-12-25	WOS:000245941900069
J	Hung, CL; Liu, JH; Chiu, WC; Huang, SW; Hwang, JK; Wang, WC				Hung, Chiu-Lien; Liu, Jia-Hsin; Chiu, Wei-Chun; Huang, Shao-Wei; Hwang, Jenn-Kang; Wang, Wen-Ching			Crystal structure of Helicobacter pylori formamidase AmiF reveals a cysteine-glutamate-lysine catalytic triad	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ACID AMIDOHYDROLASE; ALIPHATIC AMIDASE; SERINE PROTEASES; SEQUENCE; PROGRAM; PURIFICATION; DYNAMICS	Helicobacter pylori AmiF formamidase that hydrolyzes formamide to produce formic acid and ammonia belongs to a member of the nitrilase superfamily. The crystal structure of AmiF was solved to 1.75 angstrom resolution using single-wavelength anomalous dispersion methods. The structure consists of a homohexamer related by 3-fold symmetry in which each subunit has an alpha-beta-beta-alpha four-layer architecture characteristic of the nitrilase superfamily. One exterior alpha layer faces the solvent, whereas the other one associates with that of the neighbor subunit, forming a tight alpha-beta-beta-alpha-alpha-beta-beta-alpha dimer. The apo and liganded crystal structures of an inactive mutant C166S were also determined to 2.50 and 2.30 angstrom, respectively. These structures reveal a small formamide-binding pocket that includes Cys(166), Glu(60), and Lys(133) catalytic residues, in which Cys166 acts as a nucleophile. Analysis of the liganded AmiF and N-carbamoyl D-amino acid amidohydrolase binding pockets reveals a common Cys-Glu-Lys triad, another conserved glutamate, and different subsets of ligand-binding residues. Molecular dynamic simulations show that the conserved triad has minimal fluctuations, catalyzing the hydrolysis of a specific nitrile or amide in the nitrilase superfamily efficiently.	Natl Chiao Tung Univ, Inst Bioinformat, Hsinchu 300, Taiwan; Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu 300, Taiwan; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan	National Yang Ming Chiao Tung University; National Tsing Hua University; National Tsing Hua University	Hwang, JK (corresponding author), Natl Chiao Tung Univ, Inst Bioinformat, Hsinchu 300, Taiwan.	jkhwang@faculty.nctu.edu.tw; wcwang@life.nthu.edu.tw	Wang, Wen-Ching/ABI-2253-2020	Wang, Wen-Ching/0000-0002-7422-3667				Bahar I, 1997, FOLD DES, V2, P173, DOI 10.1016/S1359-0278(97)00024-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BORK P, 1994, PROTEIN SCI, V3, P1344, DOI 10.1002/pro.5560030821; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bury-Mone S, 2004, MOL MICROBIOL, V53, P623, DOI 10.1111/j.1365-2958.2004.04137.x; Chen CY, 2003, J BIOL CHEM, V278, P26194, DOI 10.1074/jbc.M302384200; Chiu WC, 2006, J MOL BIOL, V359, P741, DOI 10.1016/j.jmb.2006.03.063; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; EICHINGE.BE, 1972, MACROMOLECULES, V5, P496, DOI 10.1021/ma60028a028; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Grifantini R, 1996, J BIOL CHEM, V271, P9326, DOI 10.1074/jbc.271.16.9326; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holm L, 1999, NUCLEIC ACIDS RES, V27, P244, DOI 10.1093/nar/27.1.244; Ikenaka Y, 1998, BIOSCI BIOTECH BIOCH, V62, P1672, DOI 10.1271/bbb.62.1672; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; Kumaran D, 2003, PROTEINS, V52, P283, DOI 10.1002/prot.10417; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nakai T, 2000, STRUCTURE, V8, P729, DOI 10.1016/S0969-2126(00)00160-X; OGAWA J, 1993, EUR J BIOCHEM, V212, P685, DOI 10.1111/j.1432-1033.1993.tb17706.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pace HC, 2000, CURR BIOL, V10, P907, DOI 10.1016/S0960-9822(00)00621-7; Pace HC, 2001, GENOME BIOL, V2; Sakai N, 2004, PROTEINS, V57, P869, DOI 10.1002/prot.20259; Skouloubris S, 2001, MOL MICROBIOL, V40, P596, DOI 10.1046/j.1365-2958.2001.02400.x; Skouloubris S, 1997, MOL MICROBIOL, V25, P989, DOI 10.1111/j.1365-2958.1997.mmi536.x; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Vliet AHM, 2004, INFECT IMMUN, V72, P766, DOI 10.1128/IAI.72.2.766-773.2004; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Wang WC, 2001, J MOL BIOL, V306, P251, DOI 10.1006/jmbi.2000.4380; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001; WILLISON JC, 1993, FEMS MICROBIOL LETT, V104, P1; Yang LW, 2005, STRUCTURE, V13, P893, DOI 10.1016/j.str.2005.03.015; YANG W, 1990, J BIOL CHEM, V265, P13553	42	40	40	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12220	12229		10.1074/jbc.M609134200	http://dx.doi.org/10.1074/jbc.M609134200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17307742	hybrid			2022-12-25	WOS:000245941900065
J	Wagner, JR; Zhang, JR; Brunzelle, JS; Vierstra, RD; Forest, KT				Wagner, Jeremiah R.; Zhang, Junrui; Brunzelle, Joseph S.; Vierstra, Richard D.; Forest, Katrina T.			High resolution structure of Deinococcus bacteriophytochrome yields new insights into phytochrome architecture and evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; X-RAY-SCATTERING; HISTIDINE KINASES; CPH1 PHYTOCHROME; CHROMOPHORE; DOMAIN; CYANOBACTERIAL; REVEALS; SYNECHOCYSTIS; MODEL	Phytochromes are red/far red light photochromic photoreceptors that direct many photosensory behaviors in the bacterial, fungal, and plant kingdoms. They consist of an N-terminal domain that covalently binds a bilin chromophore and a C-terminal region that transmits the light signal, often through a histidine kinase relay. Using x-ray crystallography, we recently solved the first three-dimensional structure of a phytochrome, using the chromophore-binding domain of Deinococcus radiodurans bacterial phytochrome assembled with its chromophore, biliverdin IX alpha. Now, by engineering the crystallization interface, we have achieved a significantly higher resolution model. This 1.45 angstrom resolution structure helps identify an extensive buried surface between crystal symmetry mates that may promote dimerization in vivo. It also reveals that upon ligation of the C3(2) carbon of biliverdin to Cys(24), the chromophore A-ring assumes a chiral center at C2, thus becoming 2(R),3(E)-phytochromobilin, a chemistry more similar to that proposed for the attached chromophores of cyanobacterial and plant phytochromes than previously appreciated. The evolution of bacterial phytochromes to those found in cyanobacteria and higher plants must have involved greater fitness using more reduced bilins, such as phycocyanobilin, combined with a switch of the attachment site from a cysteine near the N terminus to one conserved within the cGMP phosphodiesterase/adenyl cyclase/FhlA domain. From analysis of site-directed mutants in the D. radiodurans phytochrome, we show that this bilin preference was partially driven by the change in binding site, which ultimately may have helped photosynthetic organisms optimize shade detection. Collectively, these three-dimensional structural results better clarify bilin/protein interactions and help explain how higher plant phytochromes evolved from prokaryotic progenitors.	Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Northwestern Univ, Life Sci Collaborat Access Team, Argonne, IL 60439 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Northwestern University	Vierstra, RD (corresponding author), Univ Wisconsin, Dept Genet, 425-G Henry Mall, Madison, WI 53706 USA.	vierstra@wisc.edu; forest@bact.wisc.edu	Zhang, Junrui/J-2684-2012					Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; Book AJ, 2005, PLANT PHYSIOL, V138, P1046, DOI 10.1104/pp.104.057406; Borucki B, 2005, J BIOL CHEM, V280, P34358, DOI 10.1074/jbc.M505493200; CHERRY JR, 1993, PLANT CELL, V5, P565, DOI 10.1105/tpc.5.5.565; Cramer P, 1997, FEBS LETT, V405, P373, DOI 10.1016/S0014-5793(97)00217-2; Dasgupta S, 1997, PROTEINS, V28, P494, DOI 10.1002/(SICI)1097-0134(199708)28:4<494::AID-PROT4>3.0.CO;2-A; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; EDGERTON MD, 1992, PLANT CELL, V4, P161, DOI 10.1105/tpc.4.2.161; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esteban B, 2005, BIOCHEMISTRY-US, V44, P450, DOI 10.1021/bi0484365; Evans K, 2006, J MOL BIOL, V364, P655, DOI 10.1016/j.jmb.2006.09.045; Fischer AJ, 2005, BIOCHEMISTRY-US, V44, P15203, DOI 10.1021/bi051633z; FOREST K, 1992, CURR OPIN STRUC BIOL, V2, P576; Froehlich AC, 2005, EUKARYOT CELL, V4, P2140, DOI 10.1128/EC.4.12.2140-2152.2005; Garrard SM, 2001, PROTEIN EXPRES PURIF, V21, P412, DOI 10.1006/prep.2001.1392; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Inomata K, 2006, J BIOL CHEM, V281, P28162, DOI 10.1074/jbc.M603983200; JONES AM, 1989, PHOTOCHEM PHOTOBIOL, V49, P479, DOI 10.1111/j.1751-1097.1989.tb09198.x; JONES AM, 1986, BIOCHEMISTRY-US, V25, P2987, DOI 10.1021/bi00358a038; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Jorissen HJMM, 2002, EUR J BIOCHEM, V269, P2662, DOI 10.1046/j.1432-1033.2002.02928.x; Karniol B, 2005, BIOCHEM J, V392, P103, DOI 10.1042/BJ20050826; Karniol B, 2004, J BACTERIOL, V186, P445, DOI 10.1128/JB.186.2.445-453.2004; KIEFHABER T, 1992, J MOL BIOL, V224, P231, DOI 10.1016/0022-2836(92)90586-9; Krall L, 2000, P NATL ACAD SCI USA, V97, P8169, DOI 10.1073/pnas.140520097; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; Lamparter T, 2003, J BIOL CHEM, V278, P33786, DOI 10.1074/jbc.M305563200; Lamparter T, 2002, P NATL ACAD SCI USA, V99, P11628, DOI 10.1073/pnas.152263999; Lamparter T, 1997, P NATL ACAD SCI USA, V94, P11792, DOI 10.1073/pnas.94.22.11792; Mallam AL, 2005, J MOL BIOL, V346, P1409, DOI 10.1016/j.jmb.2004.12.055; Matsushita T, 2003, NATURE, V424, P571, DOI 10.1038/nature01837; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy F., 2006, PHOTOMORPHOGENESIS P, P65; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otto H, 2003, BIOCHEMISTRY-US, V42, P5885, DOI 10.1021/bi026946y; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park CM, 2000, BIOCHEMISTRY-US, V39, P6349, DOI 10.1021/bi992916s; Quail PH, 2002, NAT REV MOL CELL BIO, V3, P85, DOI 10.1038/nrm728; Rockwell NC, 2006, ANNU REV PLANT BIOL, V57, P837, DOI 10.1146/annurev.arplant.56.032604.144208; Rohmer T, 2006, J PHYS CHEM B, V110, P20580, DOI 10.1021/jp062454+; Strauss HM, 2005, FEBS LETT, V579, P3970, DOI 10.1016/j.febslet.2005.06.025; TERRY MJ, 1993, J BIOL CHEM, V268, P26099; TOKUTOMI S, 1989, FEBS LETT, V247, P139, DOI 10.1016/0014-5793(89)81257-8; Vierstra RD, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P171, DOI 10.1002/352760510X.ch8; Virnau P, 2006, PLOS COMPUT BIOL, V2, P1074, DOI 10.1371/journal.pcbi.0020122; von Stetten D, 2007, J BIOL CHEM, V282, P2116, DOI 10.1074/jbc.M608878200; Wagner JR, 2005, NATURE, V438, P325, DOI 10.1038/nature04118; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wu SH, 2000, BIOCHEMISTRY-US, V39, P13487, DOI 10.1021/bi001123z; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	53	195	205	0	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12298	12309		10.1074/jbc.M611824200	http://dx.doi.org/10.1074/jbc.M611824200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322301	hybrid			2022-12-25	WOS:000245941900072
J	Ogawa, C; Usui, K; Aoki, M; Ito, F; Itoh, M; Kai, C; Kanamori-Katayama, M; Hayashizaki, Y; Suzuki, H				Ogawa, Chihiro; Usui, Kengo; Aoki, Makoto; Ito, Fuyu; Itoh, Masayoshi; Kai, Chikatoshi; Kanamori-Katayama, Mutsumi; Hayashizaki, Yoshihide; Suzuki, Harukazu			Gemin2 plays an important role in stabilizing the survival of motor neuron complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL MUSCULAR-ATROPHY; SMN COMPLEX; GENE-PRODUCT; U SNRNPS; PROTEIN; COMPONENT; IDENTIFICATION; LOCALIZATION; EXPRESSION; ZPR1	The survival of motor neuron ( SMN) protein, responsible for the neurodegenerative disease spinal muscular atrophy ( SMA), oligomerizes and forms a stable complex with seven other major components, the Gemin proteins. Besides the SMN protein, Gemin2 is a core protein that is essential for the formation of the SMN complex, although the mechanism by which it drives formation is unclear. We have found a novel interaction, a Gemin2 self-association, using the mammalian two-hybrid system and the in vitro pull-down assays. Using in vitro dissociation assays, we also found that the self-interaction of the amino-terminal SMN protein, which was confirmed in this study, became stable in the presence of Gemin2. In addition, Gemin2 knockdown using small interference RNA treatment revealed a drastic decrease in SMN oligomer formation and in the assembly activity of spliceosomal small nuclear ribonucleoprotein ( snRNP). Taken together, these results indicate that Gemin2 plays an important role in snRNP assembly through the stabilization of the SMN oligomer/complex via novel self-interaction. Applying the results/techniques to amino-terminal SMN missense mutants that were recently identified from SMA patients, we successfully showed that amino-terminal self-association, Gemin2 binding, the stabilization effect of Gemin2, and snRNP assembly activity were all lowered in the mutant SMN( D44V), suggesting that instability of the amino-terminal SMN self-association may cause SMA in patients carrying this allele.	RIKEN, Yokohama Inst, Genom Sci Ctr, Genome Explorat Res Grp,Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Yokohama City Univ, Int Grad Sch Arts & Sci, Div Genom Informat Resource Supramol Biol, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Japan Sci & Technol Agcy, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; RIKEN, Wako Inst, Discovery Res Inst, Genome Sci Lab, Wako, Saitama 3510198, Japan	RIKEN; Yokohama City University; Japan Science & Technology Agency (JST); RIKEN	Suzuki, H (corresponding author), RIKEN, Yokohama Inst, Genom Sci Ctr, Genome Explorat Res Grp,Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	rgscerg@gsc.riken.jp	Usui, Kengo/A-7203-2016; Hayashizaki, Yoshihide/N-6590-2015; Itoh, Masayoshi/N-5363-2015; Suzuki, Harukazu/N-9553-2015	Itoh, Masayoshi/0000-0002-1772-318X; Suzuki, Harukazu/0000-0002-8087-0836				Baccon J, 2002, J BIOL CHEM, V277, P31957, DOI 10.1074/jbc.M203478200; Battle DJ, 2006, MOL CELL, V23, P273, DOI 10.1016/j.molcel.2006.05.036; Burghes AHM, 1997, AM J HUM GENET, V61, P9, DOI 10.1086/513913; Campbell L, 2000, HUM MOL GENET, V9, P1093, DOI 10.1093/hmg/9.7.1093; Carissimi C, 2006, J BIOL CHEM, V281, P8126, DOI 10.1074/jbc.M512243200; Carissimi C, 2006, J BIOL CHEM, V281, P37009, DOI 10.1074/jbc.M607505200; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Charroux B, 2000, J CELL BIOL, V148, P1177, DOI 10.1083/jcb.148.6.1177; Charroux B, 1999, J CELL BIOL, V147, P1181, DOI 10.1083/jcb.147.6.1181; Crawford TO, 1996, NEUROBIOL DIS, V3, P97, DOI 10.1006/nbdi.1996.0010; Feng WQ, 2005, HUM MOL GENET, V14, P1605, DOI 10.1093/hmg/ddi168; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Gangwani L, 2005, MOL CELL BIOL, V25, P2744, DOI 10.1128/MCB.25.7.2744-2756.2005; Gangwani L, 2001, NAT CELL BIOL, V3, P376, DOI 10.1038/35070059; Gubitz AK, 2004, EXP CELL RES, V296, P51, DOI 10.1016/j.yexcr.2004.03.022; Gubitz AK, 2002, J BIOL CHEM, V277, P5631, DOI 10.1074/jbc.M109448200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hua Y, 2004, CELL MOL LIFE SCI, V61, P2658, DOI 10.1007/s00018-004-4300-z; Jablonka S, 2002, P NATL ACAD SCI USA, V99, P10126, DOI 10.1073/pnas.152318699; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Ma YL, 2005, STRUCTURE, V13, P883, DOI 10.1016/j.str.2005.03.014; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Mouaikel J, 2003, EMBO REP, V4, P616, DOI 10.1038/sj.embor.embor863; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Narayanan U, 2004, MOL CELL, V16, P223, DOI 10.1016/j.molcel.2004.09.024; Ogino S, 2004, EXPERT REV MOL DIAGN, V4, P15, DOI 10.1586/14737159.4.1.15; Paushkin S, 2002, CURR OPIN CELL BIOL, V14, P305, DOI 10.1016/S0955-0674(02)00332-0; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 2002, J BIOL CHEM, V277, P7540, DOI 10.1074/jbc.M110141200; Rochette CF, 1997, NEUROGENETICS, V1, P141, DOI 10.1007/s100480050021; Shpargel KB, 2005, P NATL ACAD SCI USA, V102, P17372, DOI 10.1073/pnas.0508947102; Sun Y, 2005, HUM MUTAT, V25, P64, DOI 10.1002/humu.20111; Suzuki H, 2001, GENOME RES, V11, P1758, DOI 10.1101/gr.180101; Suzuki H, 2004, BIOTECHNIQUES, V37, P918, DOI 10.2144/04376BM06; Terns MP, 2001, CURR BIOL, V11, pR862, DOI 10.1016/S0960-9822(01)00517-6; Wan LL, 2005, MOL CELL BIOL, V25, P5543, DOI 10.1128/MCB.25.13.5543-5551.2005; Wirth B, 2006, HUM GENET, V119, P422, DOI 10.1007/s00439-006-0156-7; Yong JS, 2004, TRENDS CELL BIOL, V14, P226, DOI 10.1016/j.tcb.2004.03.010; Young PJ, 2000, HUM MOL GENET, V9, P2869, DOI 10.1093/hmg/9.19.2869; ZERRES K, 1995, ARCH NEUROL-CHICAGO, V52, P518, DOI 10.1001/archneur.1995.00540290108025	43	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11122	11134		10.1074/jbc.M609297200	http://dx.doi.org/10.1074/jbc.M609297200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308308	hybrid			2022-12-25	WOS:000245941500033
J	van der Veer, E; Ho, C; O'Neil, C; Barbosa, N; Scott, R; Cregan, SP; Pickering, JG				van der Veer, Eric; Ho, Cynthia; O'Neil, Caroline; Barbosa, Nicole; Scott, Robert; Cregan, Sean P.; Pickering, J. Geoffrey			Extension of human cell lifespan by nicotinamide phosphoribosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; COLONY-ENHANCING FACTOR; NAD BIOSYNTHESIS; APOPTOSIS; SIRT1; P53; ATHEROSCLEROSIS; INHIBITION; ACTIVATION; EXPRESSION	Extending the productive lifespan of human cells could have major implications for diseases of aging, such as atherosclerosis. We identified a relationship between aging of human vascular smooth muscle cells (SMCs) and nicotinamide phosphoribosyltransferase (Nampt/PBEF/Visfatin), the rate-limiting enzyme for NAD(+) salvage from nicotinamide. Replicative senescence of SMCs was preceded by a marked decline in the expression and activity of Nampt. Furthermore, reducing Nampt activity with the antagonist FK866 induced premature senescence in SMCs, assessed by serial quantification of the proportion of cells with senescence-associated beta-galactosidase activity. In contrast, introducing the Nampt gene into aging human SMCs delayed senescence and substantially lengthened cell lifespan, together with enhanced resistance to oxidative stress. Nampt-mediated SMClifespan extension was associated with increased activity of the NAD(+)-dependent longevity enzyme SIRT1 and was abrogated in Nampt-overexpressing cells transduced with a dominant-negative form of SIRT1 (H363Y). Nampt overexpression also reduced the fraction of p53 that was acetylated on lysine 382, a target of SIRT1, suppressed an age-related increase in p53 expression, and increased the rate of p53 degradation. Moreover, add-back of p53 with recombinant adenovirus blocked the anti-aging effects of Nampt. These data indicate that Nampt is a longevity protein that can add stress-resistant life to human SMCs by optimizing SIRT1-mediated p53 degradation.	Univ Western Ontario, London Hlth Sci Ctr, Dept Med Cardiol, London, ON N6A 5K8, Canada; Univ Western Ontario, London Hlth Sci Ctr, Dept Biochem, London, ON N6A 5K8, Canada; Univ Western Ontario, London Hlth Sci Ctr, Dept Med Biophys, London, ON N6A 5K8, Canada; Univ Western Ontario, London Hlth Sci Ctr, Dept Biol, London, ON N6A 5K8, Canada; Univ Western Ontario, Robarts Res Inst, London, ON N6A 5K8, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario)	Pickering, JG (corresponding author), London Hlth Sci Ctr, 339 Windermere Rd, London, ON N6A 5A5, Canada.	gpickering@robarts.ca	Pickering, J. Geoffrey/G-3341-2011; Cregan, Sean/M-3205-2013	Pickering, J. Geoffrey/0000-0001-6474-3274; 				Al-Shali KZ, 2004, ARTERIOSCL THROM VAS, V24, P1591, DOI 10.1161/01.ATV.0000136392.59656.8b; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Araki T, 2004, SCIENCE, V305, P1010, DOI 10.1126/science.1098014; Bauer JH, 2006, AGING CELL, V5, P437, DOI 10.1111/j.1474-9726.2006.00228.x; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Cregan SP, 2000, GENE THER, V7, P1200, DOI 10.1038/sj.gt.3301208; de Boer VCJ, 2006, MECH AGEING DEV, V127, P618, DOI 10.1016/j.mad.2006.02.007; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fera E, 2004, J BIOL CHEM, V279, P35573, DOI 10.1074/jbc.M400711200; Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243; Hasmann M, 2003, CANCER RES, V63, P7436; Jia SH, 2004, J CLIN INVEST, V113, P1318, DOI [10.1172/JCI19930, 10.1172/JCI200419930]; Khan JA, 2006, NAT STRUCT MOL BIOL, V13, P582, DOI 10.1038/nsmb1105; Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58; Li SH, 2001, CIRC RES, V89, P517, DOI 10.1161/hh1801.097165; Matthews C, 2006, CIRC RES, V99, P156, DOI 10.1161/01.RES.0000233315.38086.bc; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Revollo JR, 2004, J BIOL CHEM, V279, P50754, DOI 10.1074/jbc.M408388200; Rocnik EF, 2002, J BIOL CHEM, V277, P38571, DOI 10.1074/jbc.M206689200; Rongvaux A, 2002, EUR J IMMUNOL, V32, P3225, DOI 10.1002/1521-4141(200211)32:11<3225::AID-IMMU3225>3.0.CO;2-L; van der Veer E, 2005, CIRC RES, V97, P25, DOI 10.1161/01.RES.0000173298.38808.27; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Yang HY, 2006, EXP GERONTOL, V41, P718, DOI 10.1016/j.exger.2006.06.003	25	251	257	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10841	10845		10.1074/jbc.C700018200	http://dx.doi.org/10.1074/jbc.C700018200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307730	hybrid			2022-12-25	WOS:000245941500002
J	Adlerz, L; Holback, S; Multhaup, G; Iverfeldt, K				Adlerz, Linda; Holback, Sofia; Multhaup, Gerd; Iverfeldt, Kerstin			IGF-1-induced processing of the amyloid precursor protein family is mediated by different signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; HUMAN NEUROBLASTOMA-CELLS; CYCLIN-DEPENDENT KINASE-5; RETINOIC-ACID; ALZHEIMERS-DISEASE; IGF-I; INSULIN; APLP2; BRAIN; APP	The mammalian amyloid precursor protein (APP) protein family consists of the APP and the amyloid precursor-like proteins 1 and 2 (APLP1 and APLP2). The neurotoxic amyloid ss-peptide (A ss) originates from APP, which is the only member of this protein family implicated in Alzheimer disease. However, the three homologous proteins have been proposed to be processed in similar ways and to have essential and overlapping functions. Therefore, it is also important to take into account the effects on the processing and function of the APP- like proteins in the development of therapeutic drugs aimed at decreasing the production of A ss. Insulin and insulin-like growth factor-1 (IGF-1) have been shown to regulate APP processing and the levels of A ss in the brain. In the present study, we show that IGF-1 increases alpha-secretase processing of endogenous APP and also increases ectodomain shedding of APLP1 and APLP2 in human SH-SY5Y neuroblastoma cells. We also investigated the role of different IGF-1-induced signaling pathways, using specific inhibitors for phosphatidylinositol 3- kinase and mitogenactivated protein kinase (MAPK). Our results indicate that phosphatidylinositol 3-kinase is involved in ectodomain shedding of APP and APLP1, but not APLP2, and that MAPK is involved only in the ectodomain shedding of APLP1.	Univ Stockholm, Dept Neurochem, SE-10691 Stockholm, Sweden; Free Univ Berlin, Inst Chem & Biochem, D-14195 Berlin, Germany	Stockholm University; Free University of Berlin	Iverfeldt, K (corresponding author), Univ Stockholm, Dept Neurochem, SE-10691 Stockholm, Sweden.	kerstin@neurochem.su.se						Adlerz L, 2003, MOL BRAIN RES, V119, P62, DOI 10.1016/j.molbrainres.2003.08.014; ALLSOP D, 1983, BRAIN RES, V259, P348, DOI 10.1016/0006-8993(83)91273-8; Beckman M, 1997, NEUROSCI LETT, V221, P73, DOI 10.1016/S0304-3940(96)13292-4; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Cappai R, 1999, FEBS LETT, V442, P95, DOI 10.1016/S0014-5793(98)01635-4; Carro E, 2006, NEUROBIOL AGING, V27, P1250, DOI 10.1016/j.neurobiolaging.2005.06.015; Carro E, 2004, EUR J PHARMACOL, V490, P127, DOI 10.1016/j.ejphar.2004.02.050; Carro E, 2002, NAT MED, V8, P1390, DOI 10.1038/nm793; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; Dupont J, 2003, RECENT PROG HORM RES, V58, P325, DOI 10.1210/rp.58.1.325; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; Eggert S, 2004, J BIOL CHEM, V279, P18146, DOI 10.1074/jbc.M311601200; Endres K, 2005, FEBS J, V272, P5808, DOI 10.1111/j.1742-4658.2005.04976.x; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Han P, 2005, J NEUROSCI, V25, P11542, DOI 10.1523/JNEUROSCI.3831-05.2005; Heber S, 2000, J NEUROSCI, V20, P7951; Holback S, 2005, J NEUROCHEM, V95, P1059, DOI 10.1111/j.1471-4159.2005.03440.x; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim B, 2004, ONCOGENE, V23, P130, DOI 10.1038/sj.onc.1206924; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; Lee JH, 2004, J NEUROCHEM, V91, P634, DOI 10.1111/j.1471-4159.2004.02770.x; Leyssen M, 2005, EMBO J, V24, P2944, DOI 10.1038/sj.emboj.7600757; Li QM, 2004, J BIOL CHEM, V279, P10542, DOI 10.1074/jbc.M310001200; Liu F, 2003, FEBS LETT, V547, P193, DOI 10.1016/S0014-5793(03)00714-2; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; LORENT K, 1995, NEUROSCIENCE, V65, P1009, DOI 10.1016/0306-4522(94)00555-J; LUO LQ, 1992, NEURON, V9, P595, DOI 10.1016/0896-6273(92)90024-8; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Mattsson MEK, 1990, GROWTH FACTORS, V2, P251, DOI 10.3109/08977199009078013; Navarro I, 1999, COMP BIOCHEM PHYS B, V122, P137, DOI 10.1016/S0305-0491(98)10163-3; Paliga K, 1997, EUR J BIOCHEM, V250, P354, DOI 10.1111/j.1432-1033.1997.0354a.x; Pastorino L, 2004, MOL CELL NEUROSCI, V25, P642, DOI 10.1016/j.mcn.2003.12.013; REFOLO LM, 1989, BIOCHEM BIOPH RES CO, V164, P664, DOI 10.1016/0006-291X(89)91511-8; Ryder J, 2003, BIOCHEM BIOPH RES CO, V312, P922, DOI 10.1016/j.bbrc.2003.11.014; Sakai T, 2006, CELL BIOL INT, V30, P952, DOI 10.1016/j.cellbi.2006.06.018; Solano DC, 2000, FASEB J, V14, P1015, DOI 10.1096/fasebj.14.7.1015; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; Vardy ERLC, 2005, TRENDS MOL MED, V11, P464, DOI 10.1016/j.molmed.2005.08.004; Wang DS, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/58406; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; Watanabe T, 2005, J AM GERIATR SOC, V53, P1748, DOI 10.1111/j.1532-5415.2005.53524.x; WEBSTER MT, 1995, BIOCHEM J, V310, P95, DOI 10.1042/bj3100095; Xu KP, 2001, AM J PHYSIOL-CELL PH, V281, pC603, DOI 10.1152/ajpcell.2001.281.2.C603	46	61	68	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10203	10209		10.1074/jbc.M611183200	http://dx.doi.org/10.1074/jbc.M611183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17301053	hybrid			2022-12-25	WOS:000245941000010
J	Gleason, CE; Lu, DH; Witters, LA; Newgard, CB; Birnbaum, MJ				Gleason, Catherine E.; Lu, Danhong; Witters, Lee A.; Newgard, Christopher B.; Birnbaum, Morris J.			The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; STIMULATED INSULIN-SECRETION; CHAIN AMINO-ACIDS; P70 S6 KINASE; MAMMALIAN TARGET; GLUCOSE-HOMEOSTASIS; SIGNALING PATHWAY; SKELETAL-MUSCLE; GENE-EXPRESSION; PHAS-I	The AMP- activated protein kinase ( AMPK) is a central regulator of the energy status of the cell, based on its unique ability to respond directly to fluctuations in the ratio of AMP: ATP. Because glucose and amino acids stimulate insulin release from pancreatic beta- cells by the regulation of metabolic intermediates, AMPK represents an attractive candidate for control of beta- cell function. Here, we show that inhibition of AMPK in beta- cells by high glucose inversely correlates with activation of the mammalian Target of Rapamycin ( mTOR) pathway, another cellular sensor for nutritional conditions. Forced activation of AMPK by AICAR, phenformin, or oligomycin significantly blocked phosphorylation of p70S6K, a downstream target of mTOR, in response to the combination of glucose and amino acids. Amino acids also suppressed the activity of AMPK, and this at a minimum required the presence of leucine and glutamine. It is unlikely that the ability of AMPK to sense both glucose and amino acids plays a role in regulation of insulin secretion, as inhibition of AMPK by amino acids did not influence insulin secretion. Moreover, activation of AMPK by AICAR or phenformin did not antagonize glucose- stimulated insulin secretion, and insulin secretion was also unaffected in response to suppression ofAMPKactivity by expression of a dominant negative AMPK construct ( K45R). Taken together, these results suggest that the inhibition ofAMPKactivity by glucose and amino acids might be an important component of the mechanism for nutrientstimulated mTOR activity but not insulin secretion in the beta- cell.	Univ Penn, Howard Hughes Med Inst, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19104 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27704 USA; Duke Univ, Med Ctr, Dept Med & Biochem, Durham, NC 27704 USA; Dartmouth Coll, Dept Med, Dartmouth Med Sch, Hanover, NH 03755 USA; Dartmouth Coll, Dept Biochem, Dartmouth Med Sch, Hanover, NH 03755 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; Duke University; Duke University; Duke University; Dartmouth College; Dartmouth College; Dartmouth College	Birnbaum, MJ (corresponding author), Univ Penn, Howard Hughes Med Inst, Sch Med, 415 Curie Blvd,CRB Room 320, Philadelphia, PA 19104 USA.	birnbaum@mail.med.upenn.edu		Birnbaum, Morris/0000-0001-9972-8680	NIDDK NIH HHS [DK42583, DK019525, DK049210] Funding Source: Medline; NIGMS NIH HHS [T32-GM07229] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, P01DK049210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007229] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahren B, 2005, CURR MOL MED, V5, P275, DOI 10.2174/1566524053766004; Akkan A G, 1994, Diabetes Res, V25, P13; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Bolea S, 1997, PFLUG ARCH EUR J PHY, V433, P699, DOI 10.1007/s004240050334; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Browne GJ, 2004, J BIOL CHEM, V279, P12220, DOI 10.1074/jbc.M309773200; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chan AYM, 2004, J BIOL CHEM, V279, P32771, DOI 10.1074/jbc.M403528200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Doyle ME, 2003, PHARMACOL REV, V55, P105, DOI 10.1124/pr.55.1.7; FAHIEN LA, 1988, J BIOL CHEM, V263, P13610; Gomez E, 2004, J BIOL CHEM, V279, P53937, DOI 10.1074/jbc.M408682200; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Hurley RL, 2006, J BIOL CHEM, V281, P36662, DOI 10.1074/jbc.M606676200; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Jensen MV, 2006, J BIOL CHEM, V281, P22342, DOI 10.1074/jbc.M604350200; Kimball S R, 2001, Prog Mol Subcell Biol, V26, P155; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Krause U, 2002, EUR J BIOCHEM, V269, P3751, DOI 10.1046/j.1432-1033.2002.03074.x; Leclerc I, 2004, DIABETES, V53, pS67, DOI 10.2337/diabetes.53.suppl_3.S67; Leclerc I, 2004, AM J PHYSIOL-ENDOC M, V286, pE1023, DOI 10.1152/ajpendo.00532.2003; MacDonald MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE1, DOI 10.1152/ajpendo.00218.2004; Malaisse W J, 1994, Diabetes Res, V25, P25; MAY ME, 1989, DIABETES METAB REV, V5, P227, DOI 10.1002/dmr.5610050303; McDaniel ML, 2002, DIABETES, V51, P2877, DOI 10.2337/diabetes.51.10.2877; Meijer AJ, 2004, BIOCHEM BIOPH RES CO, V313, P397, DOI 10.1016/j.bbrc.2003.07.012; MORTIMORE GE, 1987, J BIOL CHEM, V262, P16322; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; NEWGARD CB, 2001, SUBSTRATE CONTROL IN, P125; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Raile K, 2005, DIABETOLOGIA, V48, P1798, DOI 10.1007/s00125-005-1860-x; Reiter AK, 2005, AM J PHYSIOL-ENDOC M, V288, pE980, DOI 10.1152/ajpendo.00333.2004; Rutter GA, 2003, BIOCHEM J, V375, P1, DOI 10.1042/BJ20030048; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; SENER A, 1981, EUR J CLIN INVEST, V11, P455, DOI 10.1111/j.1365-2362.1981.tb02013.x; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; SWENNE I, 1992, DIABETOLOGIA, V35, P193, DOI 10.1007/BF00400917; Viollet B, 2003, BIOCHEM SOC T, V31, P216, DOI 10.1042/bst0310216; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Xavier GD, 2003, BIOCHEM J, V371, P761; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Xu G, 2001, DIABETES, V50, P353, DOI 10.2337/diabetes.50.2.353; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; Yoshizawa F, 2004, BIOCHEM BIOPH RES CO, V313, P417, DOI 10.1016/j.bbrc.2003.07.013; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	57	149	154	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10341	10351		10.1074/jbc.M610631200	http://dx.doi.org/10.1074/jbc.M610631200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287212	hybrid			2022-12-25	WOS:000245941000024
J	Ritter, E; Elgeti, M; Hofmann, KP; Bartl, FJ				Ritter, Eglof; Elgeti, Matthias; Hofmann, Klaus Peter; Bartl, Franz J.			Deactivation and proton transfer in light-induced metarhodopsin II/metarhodopsin III conversion - A time-resolved fourier transform infrared spectroscopic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MI-MII EQUILIBRIUM; ARRESTIN-RHODOPSIN INTERACTIONS; PROTEIN-COUPLED RECEPTOR; FTIR SPECTROSCOPY; SIGNALING STATES; RECOMBINANT MEMBRANES; RETINAL CHROMOPHORE; VISUAL EXCITATION; BOVINE RHODOPSIN; PH-DEPENDENCE	Vertebrate rhodopsin shares with other retinal proteins the 11-cis-retinal chromophore and the light-induced 11-cis/trans isomerization triggering its activation pathway. However, only in rhodopsin the retinylidene Schiff base bond to the apoprotein is eventually hydrolyzed, making a complex regeneration pathway necessary. Metabolic regeneration cannot be short-cut, and light absorption in the active metarhodopsin ( Meta) II intermediate causes anti/syn isomerization around the retinylidene linkage rather than reversed trans/cis isomerization. A new deactivating pathway is thereby triggered, which ends in the Meta III "retinal storage" product. Using time-resolved Fourier transform infrared spectroscopy, we show that the identified steps of receptor activation, including Schiff base deprotonation, protein structural changes, and proton uptake by the apoprotein, are all reversed. However, Schiff base reprotonation is much faster than the activating deprotonation, whereas the protein structural changes are slower. The final proton release occurs with pK approximate to 4.5, similar to the pK of a free Glu residue and to the pK at which the isolated opsin apoprotein becomes active. A forced deprotonation, equivalent to the forced protonation in the activating pathway, which occurs against the unfavorable pH of the medium, is not observed. This explains properties of the final Meta III product, which displays much higher residual activity and is less stable than rhodopsin arising from regeneration with 11-cis-retinal. We propose that the anti/syn conversion can only induce a fast reorientation and distance change of the Schiff base but fails to build up the full set of dark ground state constraints, presumably involving the Glu(134)/Arg(135) cluster.	Univ Med Berlin, Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany; Humboldt Univ, Zentrum Biophys & Bioinformat, D-10015 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Bartl, FJ (corresponding author), Univ Med Berlin, Charite, Inst Med Phys & Biophys, Charitepl 1, D-10098 Berlin, Germany.	franz.bartl@charite.de						ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; ARNIS S, 1994, J BIOL CHEM, V269, P23879; ATTWOOD PV, 1980, FEBS LETT, V119, P323, DOI 10.1016/0014-5793(80)80281-X; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; Bartl FJ, 2001, J BIOL CHEM, V276, P30161, DOI 10.1074/jbc.M101506200; Bartl FJ, 2005, J BIOL CHEM, V280, P34259, DOI 10.1074/jbc.M505260200; Bartl FJ, 2007, PHYS CHEM CHEM PHYS, V9, P1648, DOI 10.1039/b616365c; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; Calvert PD, 2006, TRENDS CELL BIOL, V16, P560, DOI 10.1016/j.tcb.2006.09.001; COOPER A, 1979, NATURE, V282, P531, DOI 10.1038/282531a0; Crognale MA, 1999, VISION RES, V39, P707, DOI 10.1016/S0042-6989(98)00140-0; Dickopf S, 1998, BIOCHEMISTRY-US, V37, P16888, DOI 10.1021/bi981879m; Fahmy K, 1998, BIOPHYS J, V75, P1306, DOI 10.1016/S0006-3495(98)74049-4; Fahmy K, 2000, BIOCHEMISTRY-US, V39, P10607, DOI 10.1021/bi000912d; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gartner W., 2000, HDB BIOL PHYS, V3, P297; GIBSON NJ, 1990, BIOCHEM BIOPH RES CO, V169, P1028, DOI 10.1016/0006-291X(90)91997-7; GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040; GIBSON NJ, 1991, BIOCHEM BIOPH RES CO, V176, P915, DOI 10.1016/S0006-291X(05)80273-6; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; Hofmann K P, 2001, Z Med Phys, V11, P217; HOFMANN KP, 1992, J BIOL CHEM, V267, P15701; HUBBARD R, 1952, SCIENCE, V115, P60, DOI 10.1126/science.115.2977.60; HUBBARD R, 1952, J GEN PHYSIOL, V36, P269, DOI 10.1085/jgp.36.2.269; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; Kim JE, 2001, BIOCHEMISTRY-US, V40, P13774, DOI 10.1021/bi0116137; KROFP A, 1967, VISION RES, V7, P811, DOI 10.1016/0042-6989(67)90001-6; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; LANYI JK, 1992, ACTA PHYSIOL SCAND, V146, P245; Ludeke S, 2005, J MOL BIOL, V353, P345, DOI 10.1016/j.jmb.2005.08.039; Mahalingam M, 2006, BIOCHEMISTRY-US, V45, P15624, DOI 10.1021/bi061970n; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; Mendez A, 2003, J NEUROSCI, V23, P3124; Meyer CK, 2000, J BIOL CHEM, V275, P19713, DOI 10.1074/jbc.M000603200; MONTAG ED, 1987, VISION RES, V27, P2153, DOI 10.1016/0042-6989(87)90129-5; Nishimura S, 1998, BIOCHEMISTRY-US, V37, P15816, DOI 10.1021/bi981451n; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Parkes JH, 1999, BIOCHEMISTRY-US, V38, P6862, DOI 10.1021/bi9827666; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; Patel AB, 2005, J MOL BIOL, V347, P803, DOI 10.1016/j.jmb.2005.01.069; PAULSEN R, 1975, VISION RES, V15, P1325, DOI 10.1016/0042-6989(75)90184-4; Ritter E, 2004, J BIOL CHEM, V279, P48102, DOI 10.1074/jbc.M406857200; Sachs K, 2000, METHOD ENZYMOL, V315, P238; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; Siebert F, 1995, ISRAEL J CHEM, V35, P309; SIEBERT F, 1983, EUR J BIOCHEM, V136, P119, DOI 10.1111/j.1432-1033.1983.tb07714.x; Sommer ME, 2006, VISION RES, V46, P4532, DOI 10.1016/j.visres.2006.08.031; Sommer ME, 2006, J BIOL CHEM, V281, P9407, DOI 10.1074/jbc.M510037200; Sommer ME, 2005, J BIOL CHEM, V280, P6861, DOI 10.1074/jbc.M411341200; Vogel R, 2003, BIOCHEMISTRY-US, V42, P9863, DOI 10.1021/bi034684+; Vogel R, 2001, J BIOL CHEM, V276, P38487, DOI 10.1074/jbc.M105423200; Vogel R, 2005, BIOCHEMISTRY-US, V44, P11684, DOI 10.1021/bi0508587; Vogel R, 2000, BIOCHEMISTRY-US, V39, P8895, DOI 10.1021/bi000852b; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230; YOSHIZAWA T, 1963, NATURE, V197, P1279, DOI 10.1038/1971279a0; Zimmermann K, 2004, J BIOL CHEM, V279, P48112, DOI 10.1074/jbc.M406856200	60	13	13	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10720	10730		10.1074/jbc.M610658200	http://dx.doi.org/10.1074/jbc.M610658200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287211	hybrid			2022-12-25	WOS:000245941000066
J	Dinh, M; Grunberger, D; Ho, HD; Tsing, SY; Shaw, D; Lee, S; Barnett, J; Hill, RJ; Swinney, DC; Bradshaw, JM				Dinh, Marie; Grunberger, Dorit; Ho, Hoangdung; Tsing, Stan Y.; Shaw, David; Lee, Simon; Barnett, Jim; Hill, Ronald J.; Swinney, David C.; Bradshaw, J. Michael			Activation mechanism and steady state kinetics of Bruton's tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DEVELOPMENT; X-LINKED AGAMMAGLOBULINEMIA; TEC FAMILY KINASES; PHOSPHORYL TRANSFER; CATALYTIC MECHANISM; PROTEIN-KINASES; BTK FUNCTION; SH3 DOMAIN; MAP KINASE; AUTOPHOSPHORYLATION	Bruton's tyrosine kinase (BTK) is a member of the Tec nonreceptor tyrosine kinase family that is involved in regulating B cell proliferation. To better understand the enzymatic mechanism of the Tec family of kinases, the kinetics of BTK substrate phosphorylation were characterized using a radioactive enzyme assay. We first examined whether autophosphorylation regulates BTK activity. Western blotting with a phosphospecific antibody revealed that BTK rapidly autophosphorylates at Tyr(551) within its activation loop in vitro. Examination of a Y55 IF BTK mutant indicated that phosphorylation of Tyr(551) causes a 10-fold increase in BTK activity. We then proceeded to characterize the steady state kinetic mechanism of BTK. Varying the concentrations of ATP and S1 peptide (biotin-Aca-AAAEEIYGEI-NH2) revealed that BTK employs a ternary complex mechanism with K-mATP = 84 +/- 20 mu m and K-mS1 = 37 +/- 8 mu m. Inhibition studies were also performed to examine the order of substrate binding. The inhibitors ADP and staurosporine were both found to be competitive with ATP and non-competitive with S1, indicating binding of ATP and S1 to BTK is either random or ordered with ATP binding first. Negative cooperativity was also found between the S1 and ATP binding sites. Unlike ATP site inhibitors, substrate analog inhibitors did not inhibit BTK at concentrations less than 1 mm, suggesting that BTK may employ a "substrate clamping" type of kinetic mechanism whereby the substrate K-d is weaker than K-m. This investigation of BTK provides the first detailed kinetic characterization of a Tec family kinase.	Roche Palo Alto LLC, Dept Biochem Pharmacol, Palo Alto, CA 94304 USA; Roche Palo Alto LLC, Dept Mol & Prot Sci, Palo Alto, CA 94304 USA; Roche Palo Alto LLC, Dept Inflammat Autoimmun & Transplantat Therapy A, Palo Alto, CA 94304 USA	Roche Holding; Roche Holding; Roche Holding	Bradshaw, JM (corresponding author), 3431 Hillview Ave,Mailstop R2-101, Palo Alto, CA 94304 USA.	Michael.bradshaw@roche.com						BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Berg LJ, 2005, ANNU REV IMMUNOL, V23, P549, DOI 10.1146/annurev.immunol.22.012703.104743; Boerner RJ, 1995, BIOCHEMISTRY-US, V34, P16419, DOI 10.1021/bi00050a024; Chen GJ, 2000, BIOCHEMISTRY-US, V39, P2079, DOI 10.1021/bi9919495; COLE PA, 1994, J BIOL CHEM, V269, P30880; Copeland R. A., 2005, EVALUATION ENZYME IN; Dal Porto JM, 2004, MOL IMMUNOL, V41, P599, DOI 10.1016/j.molimm.2004.04.008; Desiderio S, 1997, CURR OPIN IMMUNOL, V9, P534, DOI 10.1016/S0952-7915(97)80107-0; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Kendall RL, 1999, J BIOL CHEM, V274, P6453, DOI 10.1074/jbc.274.10.6453; Kurosaki T, 1997, J BIOL CHEM, V272, P15595, DOI 10.1074/jbc.272.25.15595; Levitzki A, 2006, ANNU REV BIOCHEM, V75, P93, DOI 10.1146/annurev.biochem.75.103004.142657; Lewis CM, 2001, CURR OPIN IMMUNOL, V13, P317, DOI 10.1016/S0952-7915(00)00221-1; Lieser SA, 2005, BBA-PROTEINS PROTEOM, V1754, P191, DOI 10.1016/j.bbapap.2005.07.024; Lieser SA, 2005, J BIOL CHEM, V280, P7769, DOI 10.1074/jbc.M411736200; Lindvall JM, 2005, IMMUNOL REV, V203, P200, DOI 10.1111/j.0105-2896.2005.00225.x; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Parast CV, 1998, BIOCHEMISTRY-US, V37, P16788, DOI 10.1021/bi981291f; Park H, 1996, IMMUNITY, V4, P515, DOI 10.1016/S1074-7613(00)80417-3; Partik G, 1999, J CANCER RES CLIN, V125, P379, DOI 10.1007/s004320050290; POSNER I, 1992, J BIOL CHEM, V267, P20638; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Segel I.H., 1975, ENZYME KINETICS; Smith CIE, 2001, BIOESSAYS, V23, P436, DOI 10.1002/bies.1062; Takesono A, 2002, J CELL SCI, V115, P3039; Trauger JW, 2002, BIOCHEMISTRY-US, V41, P8948, DOI 10.1021/bi0258243; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Vassilev AO, 2006, CURR DRUG TARGETS, V7, P327, DOI 10.2174/138945006776054997; Vassilev AO, 2004, CURR PHARM DESIGN, V10, P1757, DOI 10.2174/1381612043384475; Vihinen M, 2000, FRONT BIOSCI-LANDMRK, V5, pD917, DOI 10.2741/vihinen; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; WILDEN PA, 1992, J BIOL CHEM, V267, P16660; Wu H, 2003, BIOCHEMISTRY-US, V42, P1129, DOI 10.1021/bi026857l	40	37	42	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8768	8776		10.1074/jbc.M609920200	http://dx.doi.org/10.1074/jbc.M609920200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264076	hybrid			2022-12-25	WOS:000245780300023
J	Taricani, L; Wang, TSF				Taricani, Lorena; Wang, Teresa S. F.			Rad4(TopBP1) associates with Srr2, an Spc1 MAPK-regulated protein, in response to environmental stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATF1 TRANSCRIPTION FACTOR; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; S-PHASE; KINASE; ACTIVATION; EXPRESSION; TOPBP1; PHOSPHORYLATION; REPLICATION	Rad4(TopBP1) is a scaffold in a protein complex containing both replication proteins and checkpoint proteins and plays essential roles in both replication and checkpoint responses. We have previously identified four novel fission yeast mutants of rad4(+TopBP1) to explore how Rad4(TopBP1), a single protein, can play multiple roles in genomic integrity maintenance. Among the four novel mutants, rad4-c17(TopBP1) is a thermosensitive mutant. Here, we characterized rad4-c17(TopBP1) and identified a rad4-c17(TopBP1) allele specific suppressor named srr2(+) (suppressor of Rad4(TopBP1) R2 domain). srr2(+) has previously been identified as an environmental stress-responsive gene (GenBank (TM) accession number AL049644.1, locus spcc191.01). srr2(+) null cells are sensitive to hydroxyurea (HU) at elevated temperatures. Deletion of srr2(+) in rad4-c17(TopBP1) exacerbates the HU sensitivity of the mutant. Overexpression of srr2(+) suppresses the rad4-c17(TopBP1) mutant sensitivity to temperature and HU and restores the compromised ability of rad4-c17(TopBP1) to activating Cds1 kinase in response to HU treatment. Furthermore, stress-activated MAPK, Spc1 (also known as StyI or Phh1), induces the expression and phosphorylation of the Srr2 protein. Significantly, environmental stress induces co-precipitation of Srr2 protein with Rad4(TopBP1), and the co-precipitation is compromised in the rad4-c17(TopBP1) mutant. These results have led us to propose a model; Rad4(TopBP1) exists in a large protein complex to coordinate genomic perturbations with checkpoint responses to maintain genomic integrity. In addition, when cells experience environmental stress, Rad4(TopBP1) associates with Srr2, an Spc1 MAPK-responsive protein, to survive the stress, potentially by providing a link of the Spc1 MAPK response to checkpoint responses.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Wang, TSF (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.	tswang@stanford.edu			NATIONAL CANCER INSTITUTE [R01CA054415] Funding Source: NIH RePORTER; NCI NIH HHS [CA54415] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Degols G, 1996, MOL CELL BIOL, V16, P2870; Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Furuya K, 2004, GENE DEV, V18, P1154, DOI 10.1101/gad.291104; Garcia V, 2005, DNA REPAIR, V4, P1227, DOI 10.1016/j.dnarep.2005.04.001; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Kim JE, 2005, MOL CELL BIOL, V25, P10907, DOI 10.1128/MCB.25.24.10907-10915.2005; Kumagai A, 2006, CELL, V124, P943, DOI 10.1016/j.cell.2005.12.041; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Rhind N, 1998, MOL CELL BIOL, V18, P3782, DOI 10.1128/MCB.18.7.3782; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sawin KE, 1998, J CELL BIOL, V142, P457, DOI 10.1083/jcb.142.2.457; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; Shiozaki K, 1998, MOL BIOL CELL, V9, P1339, DOI 10.1091/mbc.9.6.1339; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Taricani L, 2002, J BIOL CHEM, V277, P10562, DOI 10.1074/jbc.M110686200; Taricani L, 2001, NUCLEIC ACIDS RES, V29, P3030, DOI 10.1093/nar/29.14.3030; Taricani L, 2006, MOL BIOL CELL, V17, P3456, DOI 10.1091/mbc.E06-01-0056; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x	25	2	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8793	8800		10.1074/jbc.M609282200	http://dx.doi.org/10.1074/jbc.M609282200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17272281	hybrid			2022-12-25	WOS:000245780300026
J	Yap, LL; Samoilova, RI; Gennis, RB; Dikanov, SA				Yap, Lai Lai; Samoilova, Rimma I.; Gennis, Robert B.; Dikanov, Sergei A.			Characterization of mutants that change the hydrogen bonding of the semiquinone radical at the Q(H) site of the cytochrome bo(3) from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; NUCLEAR-QUADRUPOLE RESONANCE; ECHO ENVELOPE MODULATION; PRIMARY ACCEPTOR QUINONE; UBIQUINONE BINDING-SITE; Q(H)(CENTER-DOT-) UBISEMIQUINONE; BOUND UBIQUINONE; REACTION CENTERS; PHOTOSYSTEM-II; SPIN SYSTEMS	The cytochrome bo(3) ubiquinol oxidase catalyzes the two-electron oxidation of ubiquinol in the cytoplasmic membrane of Escherichia coli, and reduces O-2 to water. This enzyme has a high affinity quinone binding site (Q(H)), and the quinone bound to this site acts as a cofactor, necessary for rapid electron transfer from substrate ubiquinol, which binds at a separate site (Q(L)), to heme b. Previous pulsed EPR studies have shown that a semiquinone at the Q(H) site formed during the catalytic cycle is a neutral species, with two strong hydrogen bonds to Asp-75 and either Arg-71 or Gln-101. In the current work, pulsed EPR studies have been extended to two mutants at the Q(H) site. The D75E mutation has little influence on the catalytic activity, and the pattern of hydrogen bonding is similar to the wild type. In contrast, the D75H mutant is virtually inactive. Pulsed EPR revealed significant structural changes in this mutant. The hydrogen bond to Arg-71 or Gln-101 that is present in both the wild type and D75E mutant oxidases is missing in the D75H mutant. Instead, the D75H has a single, strong hydrogen bond to a histidine, likely His-75. The D75H mutant stabilizes an anionic form of the semiquinone as a result of the altered hydrogen bond network. Either the redistribution of charge density in the semiquinone species, or the altered hydrogen bonding network is responsible for the loss of catalytic function.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Clin Vet Med, Urbana, IL 61801 USA; Russian Acad Sci, Inst Chem Kinet & Combust, Novosibirsk 630090, Russia	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Russian Academy of Sciences; Voevodsky Institute of Chemical Kinetics & Combustion SB RAS	Gennis, RB (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.	r-gennis@uiuc.edu; dikanov@uiuc.edu	Samoilova, Rimma Ivanovna/T-7956-2017	Samoilova, Rimma Ivanovna/0000-0002-1649-1487	FIC NIH HHS [1 R03 TW 01495] Funding Source: Medline; NCRR NIH HHS [S10-RR15878] Funding Source: Medline; NIGMS NIH HHS [GM62954] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001495] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062954] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; ASHBY CIH, 1978, J AM CHEM SOC, V100, P6057, DOI 10.1021/ja00487a014; ASTASHKIN AV, 1995, J CHEM PHYS, V102, P5583, DOI 10.1063/1.469289; Deligiannakis Y, 1999, J AM CHEM SOC, V121, P7653, DOI 10.1021/ja984209c; DIKANOV SA, 1995, J MAGN RESON SER A, V116, P125, DOI 10.1006/jmra.1995.1199; DIKANOV SA, 1982, CHEM PHYS LETT, V90, P149, DOI 10.1016/0009-2614(82)83630-0; EDMONDS DT, 1973, J MAGN RESON, V12, P134, DOI 10.1016/0022-2364(73)90136-4; Flores M, 2003, CHEM PHYS, V294, P401, DOI 10.1016/S0301-0104(03)00321-5; Grimaldi S, 2003, BIOCHEMISTRY-US, V42, P5632, DOI 10.1021/bi034010z; Grimaldi S, 2001, BIOCHEMISTRY-US, V40, P1037, DOI 10.1021/bi001641+; Hastings SF, 2000, EUR J BIOCHEM, V267, P5638, DOI 10.1046/j.1432-1327.2000.01643.x; Hellwig P, 1999, BIOCHEMISTRY-US, V38, P14683, DOI 10.1021/bi991267h; Hellwig P, 2002, BIOCHEMISTRY-US, V41, P10675, DOI 10.1021/bi012146w; Hellwig P, 2001, BIOCHEMISTRY-US, V40, P1077, DOI 10.1021/bi002154x; HOFER P, 1986, CHEM PHYS LETT, V132, P279, DOI 10.1016/0009-2614(86)80124-5; HUNT MJ, 1976, J MAGN RESON, V22, P295, DOI 10.1016/0022-2364(76)90304-8; HUNT MJ, 1975, CHEM PHYS LETT, V34, P473, DOI 10.1016/0009-2614(75)85542-4; JIANG F, 1990, J AM CHEM SOC, V112, P9035, DOI 10.1021/ja00181a002; Joela H, 1997, ACTA CHEM SCAND, V51, P233, DOI 10.3891/acta.chem.scand.51-0233; Kobayashi K, 2000, BIOCHEMISTRY-US, V39, P15620, DOI 10.1021/bi0014094; Lendzian F, 1996, BER BUNSEN PHYS CHEM, V100, P2036, DOI 10.1002/bbpc.19961001219; Lubitz W, 1999, APPL MAGN RESON, V17, P1, DOI 10.1007/BF03162067; MACMILLAN F, 1995, MAGN RESON CHEM, V33, P581; MCCONNELL HM, 1956, J CHEM PHYS, V24, P764, DOI 10.1063/1.1742605; MCDOWELL CA, 1986, J MAGN RESON, V69, P283, DOI 10.1016/0022-2364(86)90079-X; MIMS WB, 1978, J CHEM PHYS, V69, P4921, DOI 10.1063/1.436479; Mogi T, 1999, FEBS LETT, V457, P223, DOI 10.1016/S0014-5793(99)01047-9; Musser SM, 1997, BIOCHEMISTRY-US, V36, P894, DOI 10.1021/bi961723r; OMALLEY PJ, 1986, J AM CHEM SOC, V108, P3995, DOI 10.1021/ja00274a024; Puustinen A, 1996, P NATL ACAD SCI USA, V93, P1545, DOI 10.1073/pnas.93.4.1545; REIJERSE EJ, 1991, J CHEM PHYS, V95, P836, DOI 10.1063/1.461091; Rumbley JN, 1997, BBA-PROTEIN STRUCT M, V1340, P131, DOI 10.1016/S0167-4838(97)00036-8; SAMOILOVA RI, 1994, J CHEM SOC P1, V2, P609; Schultz BE, 1998, BIOCHEMISTRY-US, V37, P4160, DOI 10.1021/bi971714y; Schweiger A., 2001, PRINCIPLES PULSE ELE, P359; Sinnecker S, 2004, J AM CHEM SOC, V126, P3280, DOI 10.1021/ja0392014; Spoyalov AP, 1996, CHEM PHYS LETT, V263, P715, DOI 10.1016/S0009-2614(96)01255-9; Tsubaki M, 2000, J INORG BIOCHEM, V82, P19, DOI 10.1016/S0162-0134(00)00140-9; Veselov AV, 2000, BIOCHEMISTRY-US, V39, P3169, DOI 10.1021/bi9926835; Wiertz FGM, 2004, FEBS LETT, V575, P127, DOI 10.1016/j.febslet.2004.08.048; Yap LL, 2006, J BIOL CHEM, V281, P16879, DOI 10.1074/jbc.M602544200	42	27	28	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8777	8785		10.1074/jbc.M611595200	http://dx.doi.org/10.1074/jbc.M611595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17267395	hybrid			2022-12-25	WOS:000245780300024
J	Xia, XH				Xia, Xuhua			The+4G Site in Kozak Consensus Is Not Related to the Efficiency of Translation Initiation	PLOS ONE			English	Article								The optimal context for translation initiation in mammalian species is GCCRCCaugG (where R = purine and "aug'' is the initiation codon), with the -3R and +4G being particularly important. The presence of +4G has been interpreted as necessary for efficient translation initiation. Accumulated experimental and bioinformatic evidence has suggested an alternative explanation based on amino acid constraint on the second codon, i.e., amino acid Ala or Gly are needed as the second amino acid in the nascent peptide for the cleavage of the initiator Met, and the consequent overuse of Ala and Gly codons (GCN and GGN) leads to the +4G consensus. I performed a critical test of these alternative hypotheses on +4G based on 34169 human protein-coding genes and published gene expression data. The result shows that the prevalence of +4G is not related to translation initiation. Among the five G-starting codons, only alanine codons (GCN), and glycine codons (GGN) to a much smaller extent, are overrepresented at the second codon, whereas the other three codons are not overrepresented. While highly expressed genes have more +4G than lowly expressed genes, the difference is caused by GCN and GGN codons at the second codon. These results are inconsistent with +4G being needed for efficient translation initiation, but consistent with the proposal of amino acid constraint hypothesis.	Univ Ottawa, Dept Biol, Ottawa, ON, Canada	University of Ottawa	Xia, XH (corresponding author), Univ Ottawa, Dept Biol, Ottawa, ON, Canada.	xxia@uottawa.ca	Xia, Xuhua/E-5264-2010	Xia, Xuhua/0000-0002-3092-7566	Discovery, Strategic Research, and Research Tools; Natural Science and Engineering Research Council of Canada	Discovery, Strategic Research, and Research Tools; Natural Science and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	This project is supported by the Discovery, Strategic Research, and Research Tools and Instruments Grants from the Natural Science and Engineering Research Council of Canada.	Bentham M, 2006, J GEN VIROL, V87, P563, DOI 10.1099/vir.0.81200-0; Breuer S, 2006, BIOCHEMISTRY-US, V45, P2339, DOI 10.1021/bi052052c; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; CIGAN AM, 1987, GENE, V59, P1; Coghlan A, 2000, YEAST, V16, P1131, DOI 10.1002/1097-0061(20000915)16:12<1131::AID-YEA609>3.0.CO;2-F; de Vries JS, 2006, PLANT J, V45, P31, DOI 10.1111/j.1365-313X.2005.02590.x; Dinel S, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni025; Duret L, 2002, CURR OPIN GENET DEV, V12, P640, DOI 10.1016/S0959-437X(02)00353-2; Farazi TA, 2001, J BIOL CHEM, V276, P39501, DOI 10.1074/jbc.R100042200; FLINTA C, 1986, EUR J BIOCHEM, V154, P193, DOI 10.1111/j.1432-1033.1986.tb09378.x; Frottin F, 2006, MOL CELL PROTEOMICS, V5, P2336, DOI 10.1074/mcp.M600225-MCP200; Futcher B, 1999, MOL CELL BIOL, V19, P7357; GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055; Griffin TJ, 2002, MOL CELL PROTEOMICS, V1, P323, DOI 10.1074/mcp.M200001-MCP200; GRUNERT S, 1994, EMBO J, V13, P3618, DOI 10.1002/j.1460-2075.1994.tb06669.x; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Harkins S, 2005, J VIROL, V79, P987, DOI 10.1128/JVI.79.2.987-996.2005; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; IKEMURA T, 1981, J MOL BIOL, V151, P389, DOI 10.1016/0022-2836(81)90003-6; Kozak M, 2003, BLOOD, V101, P1202, DOI 10.1182/blood-2002-10-3194; KOZAK M, 1991, GENE EXPRESSION, V1, P117; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZAK M, 2001, SCI STKE, pPE1; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; Plotkin JB, 2004, P NATL ACAD SCI USA, V101, P12588, DOI 10.1073/pnas.0404957101; Provitera P, 2006, BIOPHYS CHEM, V119, P23, DOI 10.1016/j.bpc.2005.08.008; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Robert-Seilaniantz A, 2006, MOL PLANT MICROBE IN, V19, P130, DOI 10.1094/MPMI-19-0130; Rowe DC, 2006, P NATL ACAD SCI USA, V103, P6299, DOI 10.1073/pnas.0510041103; Sakurai N, 2006, J BIOL CHEM, V281, P14288, DOI 10.1074/jbc.M510338200; Semon M, 2006, MOL BIOL EVOL, V23, P523, DOI 10.1093/molbev/msj053; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SHINE J, 1975, EUR J BIOCHEM, V57, P221, DOI 10.1111/j.1432-1033.1975.tb02294.x; Tats A, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-28; Tian Q, 2004, MOL CELL PROTEOMICS, V3, P960, DOI 10.1074/mcp.M400055-MCP200; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Vilas GL, 2006, P NATL ACAD SCI USA, V103, P6542, DOI 10.1073/pnas.0600824103; Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371; XIA X, DATA ANAL MOL BIOL E; Xia XH, 2005, GENE, V345, P13, DOI 10.1016/j.gene.2004.11.019; Xia XH, 1998, GENETICS, V149, P37; ZAR JH, BIOSTATISTICAL AANAL	47	28	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2007	2	2							e188	10.1371/journal.pone.0000188	http://dx.doi.org/10.1371/journal.pone.0000188			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DI	17285142	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444300001
J	Chen, M; Rahman, L; Voeller, D; Kastanos, E; Yang, SX; Feigenbaum, L; Allegra, C; Kaye, FJ; Steeg, P; Zajac-Kaye, M				Chen, M.; Rahman, L.; Voeller, D.; Kastanos, E.; Yang, S. X.; Feigenbaum, L.; Allegra, C.; Kaye, F. J.; Steeg, P.; Zajac-Kaye, M.			Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas	ONCOGENE			English	Article						thymidylate synthase; transgenic model; islet cell adenoma; endocrine pancreas	DEPENDENT KINASE INHIBITORS; GENE-EXPRESSION; BREAST-CANCER; DNA-SYNTHESIS; MOUSE MODEL; C-MYC; K-RAS; P53; MICE; 5-FLUOROURACIL	Thymidylate synthase ( TS) is an essential enzyme for DNA synthesis and repair and elevated levels of TS have been identified as an important prognostic biomarker for colorectal cancer and several other common human malignancies. In addition, TS gene expression has been linked with cell-cycle regulation and cell proliferation through the ability of retinoblastoma protein to repress the transcriptional activation of E2F target genes such as TS. Therefore, overproduction of TS could participate in the progression to a neoplastic phenotype. Consistent with this model, a recent study has suggested that ectopic TS express ion can induce a transformed phenotype in mammalian cells. To investigate the role of deregulated TS activity in tumor development, we generated transgenic mice that express high levels of catalytically active human TS( hTS) exclusively in the pancreas and low levels of hTS in multiple other tissues. Analyses of pancreatic tissue in TS transgenic mice revealed abnormalities within the endocrine pancreas, ranging from pancreatic islet hyperplasia to the detection of islet cell tumors. Overexpression of hTS in murine islets provides a new model to study genetic alterations associated with the progression from normal cells to hyperplasia to islet cell tumors, and suggests that this mouse model may be useful for regulating TS activity in vivo for development of cancer prevention and new therapies.	Ctr Canc Res, Mol Therapeut Program, Bethesda, MD USA; Natl Clin Target Validat Lab, Div Canc Treatment & Diag, Bethesda, MD USA; NCI, Frederick Canc Res, Lab Anim Sci, Frederick, MD 21701 USA; NCI, Genet Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zajac-Kaye, M (corresponding author), NCI, NIH, Bldg 37 RM 1122,37 Convent Dr, Bethesda, MD 20892 USA.	kayem@exchange.nih.gov	kaye, frederic/E-2437-2011		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC007256, ZIASC007256] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; Allegra CJ, 2003, J CLIN ONCOL, V21, P241, DOI 10.1200/JCO.2003.05.044; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Angus SP, 2002, J BIOL CHEM, V277, P44376, DOI 10.1074/jbc.M205911200; Banerjee D, 1998, CANCER RES, V58, P4292; Bertino JR, 2003, CLIN CANCER RES, V9, P1235; Casanovas O, 2005, ONCOGENE, V24, P6597, DOI 10.1038/sj.onc.1208823; Chu E, 1996, Cancer Treat Res, V87, P175; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Edler D, 2000, CLIN CANCER RES, V6, P1378; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; Johnston PG, 1997, JNCI-J NATL CANCER I, V89, P308, DOI 10.1093/jnci/89.4.308; JOHNSTON PG, 1995, CANCER RES, V55, P1407; JOHNSTON PG, 1993, BIOCHEM PHARMACOL, V45, P2483, DOI 10.1016/0006-2952(93)90230-T; Lewis BC, 2003, GENE DEV, V17, P3127, DOI 10.1101/gad.1140403; Martinez A, 2001, J ENDOCRINOL, V170, P503, DOI 10.1677/joe.0.1700503; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; NAVALGUND LG, 1980, J BIOL CHEM, V255, P7386; PAVELIC K, 1995, J PATHOL, V177, P395, DOI 10.1002/path.1711770410; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pestalozzi BC, 1997, J CLIN ONCOL, V15, P1923, DOI 10.1200/JCO.1997.15.5.1923; Rahman L, 2004, CANCER CELL, V5, P341, DOI 10.1016/S1535-6108(04)00080-7; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Sato T, 2000, HEPATO-GASTROENTEROL, V47, P875; Shintani Y, 2003, INT J CANCER, V104, P790, DOI 10.1002/ijc.11014; Takimoto Chris H, 2005, Cancer Chemother Biol Response Modif, V22, P1; Voeller DM, 2002, BIOCHEM BIOPH RES CO, V297, P24, DOI 10.1016/S0006-291X(02)02080-6; Wang EH, 1998, CANCER RES, V58, P4417; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Yang SX, 2005, CLIN CANCER RES, V11, P6226, DOI 10.1158/1078-0432.CCR-05-0270; Zhan Y, 2000, DNA CELL BIOL, V19, P639, DOI 10.1089/10445490050199045	35	20	23	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4817	4824		10.1038/sj.onc.1210273	http://dx.doi.org/10.1038/sj.onc.1210273			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297449				2022-12-25	WOS:000248170400006
J	Minami, Y; Shimamura, T; Shah, K; LaFramboise, T; Glatt, KA; Liniker, E; Borgman, CL; Haringsma, HJ; Feng, W; Weir, BA; Lowell, AM; Lee, JC; Wolf, J; Shapiro, GI; Wong, KK; Meyerson, M; Thomas, RK				Minami, Y.; Shimamura, T.; Shah, K.; LaFramboise, T.; Glatt, K. A.; Liniker, E.; Borgman, C. L.; Haringsma, H. J.; Feng, W.; Weir, B. A.; Lowell, A. M.; Lee, J. C.; Wolf, J.; Shapiro, G. I.; Wong, K-K; Meyerson, M.; Thomas, R. K.			The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272	ONCOGENE			English	Article						lung cancer; targeted therapy; oncogene mutation; ERBB2; Her-2; kinase inhibitors	GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; ACQUIRED-RESISTANCE; KINASE DOMAIN; CELL-LINES; BCR-ABL; GEFITINIB; MUTATIONS; ERLOTINIB; ADENOCARCINOMAS	Mutations in the ERBB2 gene were recently found in approximately 2% of primary non-small cell lung cancer (NSCLC) specimens; however, little is known about the functional consequences and the relevance to responsiveness to targeted drugs for most of these mutations. Here, we show tha t the major lung cancer-derived ERBB2 mutants, including the most frequent mutation, A775insYVMA, lead to oncogenic transformation in a cellular assay. Murine cells transformed with these mutants were relatively resistant to the reversible epidermal growth factor receptor (EGFR) inhibitor erlotinib, resembling the resistant phenotype found in cells carrying the homologous mutations in exon 20 of EGFR. However, the same cells were highly sensitive to the irreversible dual-specificity EGFR/ERBB2 kinase inhibitor HKI-272, as were those overexpressing wild-type ERBB2. Finally, the NSCLC cell line, Calu-3, overexpressing wild-type ERBB2 owing to a high-level amplification of the ERBB2 gene were highly sensitive to HKI-272. These results provide a rationale for treatment of patients with ERBB2-mutant or ERBB2-amplified lung tumors with HKI-272.	Univ Cologne, Klaus Joachim Zulch Labs, Max Planck Soc, D-50931 Cologne, Germany; Univ Cologne, Fac Med, D-50931 Cologne, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Cambridge, MA 02138 USA; MIT, Broad Inst, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Univ Cologne, Ctr Integrated Oncol, Dept Internal Med 1, D-5000 Cologne 41, Germany; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA	Max Planck Society; University of Cologne; University of Cologne; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Brigham & Women's Hospital; University of Cologne; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Thomas, RK (corresponding author), Univ Cologne, Klaus Joachim Zulch Labs, Max Planck Soc, Gleueler Str 50, D-50931 Cologne, Germany.	geoffrey_Shapiro@dfci.harvard.edu; kwong1@partners.org; matthew_meyerson@dfci.harvard.edu; roman.thomas@nf.mpg.de	Meyerson, Matthew L/E-7123-2012		NATIONAL CANCER INSTITUTE [P20CA090578] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA90578] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; JIANG J, 2004, BLOOD; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Kobayashi S, 2005, CANCER RES, V65, P7096, DOI 10.1158/0008-5472.CAN-05-1346; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Perez-Soler R, 2004, J CLIN ONCOL, V22, P3238, DOI 10.1200/JCO.2004.11.057; PIERCE JH, 1991, ONCOGENE, V6, P1189; Rabindran SK, 2005, CANCER LETT, V227, P9, DOI 10.1016/j.canlet.2004.11.015; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Shimamura T, 2006, CANCER RES, V66, P6487, DOI 10.1158/0008-5472.CAN-06-0971; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	26	86	93	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					5023	5027		10.1038/sj.onc.1210292	http://dx.doi.org/10.1038/sj.onc.1210292			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17311002				2022-12-25	WOS:000248322500015
J	Barbieri, SS; Weksler, BB				Barbieri, Silvia S.; Weksler, Babette B.			Tobacco smoke cooperates with interleukin-1 beta to alter beta-catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase-2 expression in vitro and in vivo	FASEB JOURNAL			English	Article						endothelial cells; inflammation; signal transduction	FACTOR-KAPPA-B; CIGARETTE-SMOKE; GENE-EXPRESSION; NITRIC-OXIDE; ACTIVATION; NICOTINE; KINASE; TARGET; CANCER; MACROPHAGES	Cigarette smoking affects all phases of atherosclerosis from endothelial dysfunction to acute occlusive clinical events. We explored activation by exposure to tobacco smoke of two genes, beta-catenin and COX-2, that play key roles in inflammation and vascular remodeling events. Using both in vivo and in vitro smoke exposure, we determined that tobacco smoke (TS) induced nuclear beta-catenin accumulation and COX-2 expression and activity and moreover interacted with IL-1 beta to enhance these effects. Exposure of cardiac endothelial cells to tobacco smoke plus IL-1 beta (TS/ IL-1 beta) enhanced permeability of endothelial monolayers and disrupted membrane VE-cadherin/beta-catenin complexes, decreased beta-catenin phosphorylation, and increased phosphorylation of GSK-3 beta, Akt, and EGFR. Transfection of endothelial cells with beta-catenin-directed small interferring RNA (siRNA) suppressed TS/ IL-1 beta-mediated effects on COX-2 modulation. Inhibitors of EGFR and phosphatidylinositol- 3-kinase also abolished both the TS/ IL-1 beta-mediated modulation of the Akt/GSK-3 beta/beta-catenin pathway and enhancement of COX-2 expression. Moreover, increased levels of Akt and GSK-3 beta phosphorylation, nuclear beta-catenin accumulation, COX-2 expression, and IL-1 beta were observed in cardiovascular tissue of ApoE(-/-) mice exposed to cigarette smoke daily for 2 wk. Our results suggest a novel mechanism by which cigarette smoking can induce proinflammatory and proatherosclerotic effects in vascular tissue.-Barbieri, S. S., Weksler, B. B. Tobacco smoke cooperates with interleukin-1 beta to alter beta- catenin trafficking in vascular endothelium resulting in increased permeability and induction of cyclooxygenase- 2 expression in vitro and in vivo.	Cornell Univ, Weill Med Coll, Div Hematol Med Oncol, New York, NY 10021 USA; Univ Milan, Dept Pharmacol Sci, I-20122 Milan, Italy	Cornell University; University of Milan	Weksler, BB (corresponding author), Cornell Univ, Weill Med Coll, Div Hematol Med Oncol, 1300 York Ave, New York, NY 10021 USA.	babette@med.cornell.edu	Barbieri, Silvia Stella/K-2130-2018	Barbieri, Silvia Stella/0000-0002-7486-2637	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055627] Funding Source: NIH RePORTER; NHLBI NIH HHS [R0-1 HL-55627] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047; Araki Y, 2003, CANCER RES, V63, P728; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bernhard D, 2005, FASEB J, V19, P1096, DOI 10.1096/fj.04-3192com; Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4; Cipollone F, 2005, ARTERIOSCL THROM VAS, V25, P1925, DOI 10.1161/01.ATV.0000177814.41505.41; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Forster C, 2005, J PHYSIOL-LONDON, V565, P475, DOI 10.1113/jphysiol.2005.084038; George SJ, 2004, TRENDS CARDIOVAS MED, V14, P100, DOI 10.1016/j.tcm.2003.12.008; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Inoue M, 1998, CIRCULATION, V98, P2108, DOI 10.1161/01.CIR.98.20.2108; Khan TA, 2005, CIRCULATION, V112, pI196, DOI 10.1161/CIRCULATIONAHA.104.526053; Kim SJ, 2002, BIOCHEM BIOPH RES CO, V296, P221, DOI 10.1016/S0006-291X(02)00824-0; Knight-Lozano CA, 2002, CIRCULATION, V105, P849, DOI 10.1161/hc0702.103977; Lau PP, 2006, ARTERIOSCL THROM VAS, V26, P143, DOI 10.1161/01.ATV.0000193510.19000.10; LODGE PA, 1992, TRANSPLANT P, V24, P2816; Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1; Moncada S, 1997, ANN NY ACAD SCI, V811, P60, DOI 10.1111/j.1749-6632.1997.tb51989.x; Moraitis D, 2005, CANCER RES, V65, P664; Norvell SM, 2004, CALCIFIED TISSUE INT, V75, P396, DOI 10.1007/s00223-004-0213-y; Pichiule P, 2004, J BIOL CHEM, V279, P12171, DOI 10.1074/jbc.M305146200; PITTILO RM, 1990, INT J EXP PATHOL, V71, P573; Ryder MI, 2002, ORAL MICROBIOL IMMUN, V17, P331, DOI 10.1034/j.1399-302X.2002.170601.x; Sheu ML, 2004, MOL PHARMACOL, V66, P187, DOI 10.1124/mol.66.1.187; Shin VY, 2004, TOXICOL APPL PHARM, V195, P103, DOI 10.1016/j.taap.2003.10.009; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sigala F, 2003, EUR J VASC ENDOVASC, V26, P523, DOI 10.1016/S1078-5884(03)00342-3; Skurk C, 2005, CIRC RES, V96, P308, DOI 10.1161/01.RES.0000156273.30274.f7; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Stemme V, 2000, EUR J VASC ENDOVASC, V20, P146, DOI 10.1053/ejvs.2000.1145; Uruno A, 2004, HYPERTENS RES, V27, P887, DOI 10.1291/hypres.27.887; Wang YJ, 2004, INT IMMUNOPHARMACOL, V4, P1675, DOI 10.1016/j.intimp.2004.07.028; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Zennou V, 2001, NAT BIOTECHNOL, V19, P446, DOI 10.1038/88115	38	71	74	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1831	1843		10.1096/fj.06-7557com	http://dx.doi.org/10.1096/fj.06-7557com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317723				2022-12-25	WOS:000246866500025
J	Tan, DX; Manchester, LC; Di Mascio, P; Martinez, GR; Prado, FM; Reiter, RJ				Tan, Dun-Xian; Manchester, Lucien C.; Di Mascio, Paolo; Martinez, Glaucia R.; Prado, Fernanda M.; Reiter, Russel J.			Novel rhythms of N-1-acetyl-N-2-formyl-5-methoxykynuramine and its precursor melatonin in water hyacinth: importance for phytoremediation	FASEB JOURNAL			English	Article						plant; AFMK; circadian rhythm; antioxidant	EICHHORNIA-CRASSIPES; INDUSTRIAL EFFLUENTS; REACTIVE OXYGEN; EDIBLE PLANTS; ANTIOXIDANT; NITROGEN; PROTECTION; VITAMIN; ORGANS	N-1-acetyl- N-2-formyl-5-methoxykynuramine (AMFK) is a major metabolite of melatonin in mammals. To investigate whether AFMK exists in plants, an aquatic plant, water hyacinth, was used. To achieve this, LC/MS/MS with a deuterated standard was employed. AFMK was identified in any plant for the first time. Both it and its precursor, melatonin, were rhythmic with peaks during the late light phase. These novel rhythms indicate that these molecules do not serve as the chemical signal of darkness as in animals but may relate to processes of photosynthesis or photoprotection. These possibilities are supported by higher production of melatonin and AFMK in plants grown in sunlight (10,000-15,000 mu W/ cm(2)) compared to those grown under artificial light (400-450 mu W/ cm2). Melatonin and AFMK, as potent free radical scavengers, may assist plants in coping with harsh environmental insults, including soil and water pollutants. High levels of melatonin and AFMK in water hyacinth may explain why this plant more easily tolerates environmental pollutants, including toxic chemicals and heavy metals and is successfully used in phytoremediation. These novel findings could lead to improvements in the phytoremediative capacity of plants by either stimulating endogenous melatonin synthesis or by adding melatonin to water/soil in which they are grown.-Dun-Xian Tan, Lucien C. Manchester, Paolo Di Mascio, Glaucia R. Martinez, Fernanda M. Prado, and Russel J. Reiter. Novel rhythms of N-1-acetyl-N-2- formyl- 5- methoxykynuramine and its precursor melatonin in water hyacinth: importance for phytoremediation.	Univ Texas, Hlth Sci Ctr, Dept Struct & Cellular Biol, San Antonio, TX 78229 USA; St Marys Univ, Dept Biol Sci, San Antonio, TX USA; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508 Sao Paulo, Brazil	University of Texas System; University of Texas Health San Antonio; Universidade de Sao Paulo	Reiter, RJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Struct & Cellular Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	reiter@uthscsa.edu	Di Mascio, Paolo/D-1264-2014; tan, dun-xian/E-3610-2010; Martinez, Glaucia Regina/I-3110-2016	Di Mascio, Paolo/0000-0003-4125-8350; Martinez, Glaucia Regina/0000-0002-2628-4406				Afreen F, 2006, J PINEAL RES, V41, P108, DOI 10.1111/j.1600-079X.2006.00337.x; Arnao MB, 2007, J PINEAL RES, V42, P147, DOI 10.1111/j.1600-079X.2006.00396.x; Balzer I, 1996, BOT ACTA, V109, P180, DOI 10.1111/j.1438-8677.1996.tb00560.x; BEHRMANN G, 1997, BIOMETEOROLOGY, V14, P258; Chen GF, 2003, LIFE SCI, V73, P19, DOI 10.1016/S0024-3205(03)00252-2; Conti A, 2002, TREATISE ON PINEAL GLAND AND MELATONIN, P105; Cuzzocrea S, 1999, FASEB J, V13, P1930, DOI 10.1096/fasebj.13.14.1930; DUBBELS R, 1995, J PINEAL RES, V18, P28, DOI 10.1111/j.1600-079X.1995.tb00136.x; Hardeland R, 2005, ENDOCRINE, V27, P119, DOI 10.1385/ENDO:27:2:119; Hardeland R, 2004, RECENT ADV ENDOCRINO, P21; HATTORI A, 1995, BIOCHEM MOL BIOL INT, V35, P627; Hernandez-Ruiz J, 2005, J PINEAL RES, V39, P137, DOI 10.1111/j.1600-079X.2005.00226.x; Iriti M, 2006, MED HYPOTHESES, V67, P833, DOI 10.1016/j.mehy.2006.03.049; JAMIL K, 1987, J ENVIRON SCI HEAL B, V22, P103; Jayaweera MW, 2004, WATER SCI TECHNOL, V50, P217, DOI 10.2166/wst.2004.0379; Karbownik M, 2001, CELL BIOL TOXICOL, V17, P33, DOI 10.1023/A:1010903130693; Kim CY, 2000, TOHOKU J EXP MED, V191, P241, DOI 10.1620/tjem.191.241; Kolar J, 2005, J PINEAL RES, V39, P333, DOI 10.1111/j.1600-079X.2005.00276.x; Lei XY, 2004, J PINEAL RES, V36, P126, DOI 10.1046/j.1600-079X.2003.00106.x; Manchester LC, 2000, LIFE SCI, V67, P3023, DOI 10.1016/S0024-3205(00)00896-1; Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002; Misbahuddin M, 2002, ARCH ENVIRON HEALTH, V57, P516, DOI 10.1080/00039890209602082; MUELLER U, 2000, EUR J CELL BIOL S50, V79, P98; Mueller U., 1999, STUDIES ANTIOXIDANTS, P140; Murch SJ, 2000, PLANT CELL REP, V19, P698, DOI 10.1007/s002990000206; POEGGELER B, 1991, Naturwissenschaften, V78, P268; Qi WB, 2000, ENVIRON HEALTH PERSP, V108, P399, DOI 10.2307/3454379; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; Reiter RJ, 2001, NUTR REV, V59, P286, DOI 10.1111/j.1753-4887.2001.tb07018.x; REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303-7207(91)90087-9; Riddle SG, 2002, ENVIRON SCI TECHNOL, V36, P1965, DOI 10.1021/es010603q; Semak I, 2005, BIOCHEMISTRY-US, V44, P9300, DOI 10.1021/bi050202d; Sener G, 2003, PHARMACOL TOXICOL, V93, P290, DOI 10.1111/j.1600-0773.2003.pto930607.x; Singhal V, 2003, BIORESOURCE TECHNOL, V86, P221, DOI 10.1016/S0960-8524(02)00178-5; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Tan DX, 2003, J PINEAL RES, V34, P249, DOI 10.1034/j.1600-079X.2003.00037.x; Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137; Tan DX, 1993, ENDOCR J, V1, P57; Trivedy RK, 2002, WATER SCI TECHNOL, V45, P329, DOI 10.2166/wst.2002.0442; Van Tassel DL, 2001, J PINEAL RES, V31, P8, DOI 10.1034/j.1600-079X.2001.310102.x; Wolf K, 2001, J PLANT PHYSIOL, V158, P1491, DOI 10.1078/0176-1617-00561; Xia HL, 2006, BIORESOURCE TECHNOL, V97, P1050, DOI 10.1016/j.biortech.2005.04.039	46	165	175	5	67	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1724	1729		10.1096/fj.06-7745com	http://dx.doi.org/10.1096/fj.06-7745com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314136				2022-12-25	WOS:000246866500014
J	Chiellini, G; Frascarelli, S; Ghelardoni, S; Carnicelli, V; Tobias, SC; DeBarber, A; Brogioni, S; Ronca-Testoni, S; Cerbai, E; Grandy, DK; Scanlan, TS; Zucchi, R				Chiellini, Grazia; Frascarelli, Sabina; Ghelardoni, Sandra; Carnicelli, Vittoria; Tobias, Sandra C.; DeBarber, Andrea; Brogioni, Simona; Ronca-Testoni, Simonetta; Cerbai, Elisabetta; Grandy, David K.; Scanlan, Thomas S.; Zucchi, Riccardo			Cardiac effects of 3-iodothyronamine: a new aminergic system modulating cardiac function	FASEB JOURNAL			English	Article						thyronamines; signal transduction; G protein-coupled receptors; myocardial function	PHOSPHOTYROSINE PHOSPHATASE; ACETYLCHOLINE CONCENTRATION; RAT; RECEPTOR; HEART; IDENTIFICATION; PROLIFERATION; ISCHEMIA; AGONISTS; TISSUES	3-iodothyronamine T(1)AM is a novel endogenous thyroid hormone derivative that activates the G protein-coupled receptor known as trace anime-associated receptor 1 (TAAR1). In the isolated working rat heart and in rat cardiomyocytes, T(1)AM produced a reversible, dose-dependent negative inotropic effect (e.g., 27 +/- 5, 51 +/- 3, and 65 +/- 2% decrease in cardiac output at 19, 25, and 38 mu M concentration, respectively). An independent negative chronotropic effect was also observed. The hemodynamic effects of T(1)AM were remarkably increased in the presence of the tyrosine kinase inhibitor genistein, whereas they were attenuated in the presence of the tyrosine phosphatase inhibitor vanadate. No effect was produced by inhibitors of protein kinase A, protein kinase C, calcium-calmodulin kinase II, phosphatidylinositol-3-kinase, or MAP kinases. Tissue cAMP levels were unchanged. In rat ventricular tissue, Western blot experiments with antiphosphotyrosine antibodies showed reduced phosphorylation of microsomal and cytosolic proteins after perfusion with synthetic T(1)AM; reverse transcriptase-polymerase chain reaction experiments revealed the presence of transcripts for at least 5 TAAR subtypes; specific and saturable binding of [I-125] T(1)AM was observed, with a dissociation constant in the low micromolar range ( 5 mu M); and endogenous T(1)AM was detectable by tandem mass spectrometry. In conclusion, our findings provide evidence for the existence of a novel aminergic system modulating cardiac function.	Univ Pisa, Dip Sci Uomo & Ambiente, I-56126 Pisa, Italy; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Oregon Hlth & Sci Univ, Dept Physiol & Pharmacol, Portland, OR USA; Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR USA; Univ Florence, Dipartimento Farmacol, Florence, Italy	University of Pisa; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Oregon Health & Science University; Oregon Health & Science University; University of Florence	Zucchi, R (corresponding author), Univ Pisa, Dip Sci Uomo & Ambiente, Via Roma 55, I-56126 Pisa, Italy.	r.zucchi@med.unipi.it	Cerbai, Elisabetta/J-2663-2013; Zucchi, Riccardo/AAC-8963-2022; Chiellini, Grazia/AAC-5877-2022	Cerbai, Elisabetta/0000-0001-7839-1361; ZUCCHI, RICCARDO/0000-0002-6450-3788	NIDDK NIH HHS [DK-52798] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK052798, R01DK052798] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bers D.M., 2001, EXCITATION CONTRACTI, V2nd ed.; Bian JS, 1998, J MOL CELL CARDIOL, V30, P2103, DOI 10.1006/jmcc.1998.0774; Borowsky B, 2001, P NATL ACAD SCI USA, V98, P8966, DOI 10.1073/pnas.151105198; Bunzow JR, 2001, MOL PHARMACOL, V60, P1181, DOI 10.1124/mol.60.6.1181; CERBAI E, 1994, J PHYSIOL-LONDON, V481, P585, DOI 10.1113/jphysiol.1994.sp020465; COTE P, 1974, CARDIOVASC RES, V8, P721, DOI 10.1093/cvr/8.6.721; DEUSSEN A, 1988, CIRC RES, V63, P240, DOI 10.1161/01.RES.63.1.240; FORTIER PA, 1985, CAN J PHYSIOL PHARM, V63, P1429, DOI 10.1139/y85-235; FRANK JS, 1974, J CELL BIOL, V60, P586, DOI 10.1083/jcb.60.3.586; GANGULY PK, 1986, CIRC RES, V59, P684, DOI 10.1161/01.RES.59.6.684; GOTZSCHE LBH, 1994, EUR J ENDOCRINOL, V130, P281, DOI 10.1530/eje.0.1300281; GUENDKER C, 2001, ENDOCRINOLOGY, V142, P2369; Hart ME, 2006, J MED CHEM, V49, P1101, DOI 10.1021/jm0505718; Imai A, 1996, CANCER, V77, P132, DOI 10.1002/(SICI)1097-0142(19960101)77:1<132::AID-CNCR22>3.0.CO;2-5; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; Kubovcakova L, 2004, NEUROSCIENCE, V126, P375, DOI 10.1016/j.neuroscience.2004.04.005; Lindemann L, 2005, GENOMICS, V85, P372, DOI 10.1016/j.ygeno.2004.11.010; Lizotte E, 2005, ANAL BIOCHEM, V345, P47, DOI 10.1016/j.ab.2005.07.001; Massa A, 2004, ANN NY ACAD SCI, V1030, P264, DOI 10.1196/annals.1329.033; Micutkova L, 2004, ANN NY ACAD SCI, V1018, P424, DOI 10.1196/annals.1296.052; Milanes MV, 2000, N-S ARCH PHARMACOL, V361, P61, DOI 10.1007/s002109900165; Miyakawa M, 2006, SYNTHETIC COMMUN, V36, P891, DOI 10.1080/00397910500466074; NOMURA A, 1990, LIFE SCI, V47, P135, DOI 10.1016/0024-3205(90)90226-H; ODA RP, 1987, AM J PHYSIOL, V252, pH125, DOI 10.1152/ajpheart.1987.252.1.H125; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; PAGE E, 1978, AM J PHYSIOL, V235, pC147, DOI 10.1152/ajpcell.1978.235.5.C147; Petrone A, 2000, J CELL SCI, V113, P2345; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Scanlan TS, 2004, NAT MED, V10, P638, DOI 10.1038/nm1051; SCHRODERVANDERELST JP, 1990, ENDOCRINOLOGY, V127, P1656; Shah KR, 1995, INT J CARDIOL, V52, P101, DOI 10.1016/0167-5273(95)02457-8; Stangl V, 2002, CARDIOVASC RES, V53, P12, DOI 10.1016/S0008-6363(01)00420-5; Wassen FWJS, 2002, ENDOCRINOLOGY, V143, P2812, DOI 10.1210/en.143.7.2812; Younes A, 2005, AM J PHYSIOL-HEART C, V289, pH1652, DOI 10.1152/ajpheart.01110.2004; ZUCCHI R, 1994, CIRC RES, V74, P271, DOI 10.1161/01.RES.74.2.271; Zucchi R, 2002, FASEB J, V16, P1976, DOI 10.1096/fj.02-0402fje	37	99	102	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1597	1608		10.1096/fj.06-7474com	http://dx.doi.org/10.1096/fj.06-7474com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17284482				2022-12-25	WOS:000246117000034
J	Liu, M; Yang, YB; Gu, CF; Yue, YP; Wu, KK; Wu, JG; Zhu, Y				Liu, Mo; Yang, Yongbo; Gu, Chunfang; Yue, Yinpu; Wu, Kenneth K.; Wu, Jianguo; Zhu, Ying			Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calciumindependent protein kinase C pathways	FASEB JOURNAL			English	Article						COX; SARS-CoV; spike protein; transcriptional activation	NF-KAPPA-B; ENDOPLASMIC-RETICULUM STRESS; SIGNAL-TRANSDUCTION PATHWAY; VIRUS-INFECTION; SUBCELLULAR-LOCALIZATION; COX-2 EXPRESSION; NUCLEAR-FACTOR; ACTIVATION; CELLS; MAPK	We have previously shown that the nucleocapsid protein of SARS-associated coronavirus (SARS-CoV) activated cyclooxygenase-2 (COX-2) expression ( 1). In this study, we identified another viral protein, the spike of SARS-CoV, which played an important role in virus-stimulated COX-2 expression after screening all genes from the SARS-CoV genome. We found that an upstream calcium-dependent PKC isozyme PKC alpha that modulates the downstream ERK/ NF-kappa B pathway through an influx of extracellular Ca2+ is induced by the spike protein of SARS-CoV. The ERK/NF-kappa B was identified to be involved in the activation of COX-2 promoter and production of COX-2 protein in HEK293T cells. We also demonstrated that another unusual pathway, the calcium-independent PI3K/PKC epsilon/JNK/CREB pathway, functioned in cooperation with the calcium-dependent pathway to induce COX-2 expression upon stimulation by spike protein. This pathway can be blocked by PKC epsilon-specific, small interfering RNA, PI3K/JNK kinase-specific inhibitors as well as dominant negative JNK. PKC epsilon-specific siRNA also attenuated the phosphorylation of JNK. Our results provide evidence that helps us understand the function of SRAS-CoV spike protein in SARS pathogenesis.	Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China; Univ Texas, Hlth Sci Ctr, Vasc Biol Res Ctr, Inst Mol Med, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Div Hematol, Houston, TX USA	Wuhan University; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	Zhu, Y (corresponding author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.	wu9988@vip.sina.com; yingzhu@whu.edu.cn	Wu, Jianguo/G-6267-2010; liu, mo/E-2087-2014; Wu, Kenneth Kun-Yu/B-1070-2010	Wu, Jianguo/0000-0002-1182-3024; Wu, Jianguo/0000-0002-8326-2895				Bosco D, 2001, DIABETES, V50, P1039, DOI 10.2337/diabetes.50.5.1039; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Choi SH, 2006, J BIOL CHEM, V281, P7468, DOI 10.1074/jbc.M512438200; Choudhury GG, 2004, J BIOL CHEM, V279, P27399, DOI 10.1074/jbc.M403530200; Corasaniti MT, 2003, TOXICOL LETT, V139, P213, DOI 10.1016/S0378-4274(02)00436-8; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Dolganiuc A, 2003, J IMMUNOL, V170, P5615, DOI 10.4049/jimmunol.170.11.5615; Eickmann M, 2003, SCIENCE, V302, P1504; Esteban V, 2005, CIRC RES, V96, P965, DOI 10.1161/01.RES.0000166326.91395.74; Hinz B, 2002, J PHARMACOL EXP THER, V300, P367, DOI 10.1124/jpet.300.2.367; Hung JH, 2004, J BIOL CHEM, V279, P46384, DOI 10.1074/jbc.M403568200; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Jijon HB, 2002, AM J PHYSIOL-CELL PH, V283, pC31, DOI 10.1152/ajpcell.00113.2001; Khoo S, 2003, J BIOL CHEM, V278, P32969, DOI 10.1074/jbc.M301198200; Kim H, 2005, J BIOL CHEM, V280, P21237, DOI 10.1074/jbc.M413842200; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Lawrence A, 1999, BRIT DENT J, V1, P2; MARTIN JT, 2003, AM J RESP CRIT CARE, V169, P239; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; Nal B, 2005, J GEN VIROL, V86, P1423, DOI 10.1099/vir.0.80671-0; Neurath MF, 1998, GUT, V43, P856, DOI 10.1136/gut.43.6.856; Nunez O, 2004, GUT, V53, P1665, DOI 10.1136/gut.2003.038364; Pavio N, 2003, J VIROL, V77, P3578, DOI 10.1128/JVI.77.6.3578-3585.2003; Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498; Pratt PF, 2003, J BIOL CHEM, V278, P51928, DOI 10.1074/jbc.M309256200; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; Simmons G, 2004, P NATL ACAD SCI USA, V101, P4240, DOI 10.1073/pnas.0306446101; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Su HL, 2002, J VIROL, V76, P4162, DOI 10.1128/JVI.76.9.4162-4171.2002; Syeda F, 2006, J BIOL CHEM, V281, P11792, DOI 10.1074/jbc.M509292200; Wang HC, 2003, AM J PATHOL, V163, P2441, DOI 10.1016/S0002-9440(10)63599-7; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Yan XH, 2006, INT J BIOCHEM CELL B, V38, P1417, DOI 10.1016/j.biocel.2006.02.003; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199; Zhu JZ, 2005, J BIOL CHEM, V280, P8617, DOI 10.1074/jbc.M413539200; Zhu Y, 2005, VIRUS GENES, V30, P93, DOI 10.1007/s11262-004-4586-9; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	37	60	64	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1586	1596		10.1096/fj.06-6589com	http://dx.doi.org/10.1096/fj.06-6589com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17267381				2022-12-25	WOS:000246117000033
J	Vandeput, F; Combettes, L; Mills, SJ; Backers, K; Wohlkonig, A; Parys, JB; De Smedt, H; Missiaen, L; Dupont, G; Potter, BVL; Erneux, C				Vandeput, Fabrice; Combettes, Laurent; Mills, Stephen J.; Backers, Katrien; Wohlkonig, Alexandre; Parys, Jan B.; De Smedt, Humbert; Missiaen, Ludwig; Dupont, Genevieve; Potter, Barry V. L.; Erneux, Christophe			Biphenyl 2,3 ',4,5 ',6-pentakisphosphate, a novel inositol polyphosphate surrogate, modulates Ca2+ responses in rat hepatocytes	FASEB JOURNAL			English	Article						inositol 5-phosphatase; SHIP2; Ins(1,4,5) P-3 receptor; Ca2+ signaling; benzene polyphosphates	PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; 1,4,5-TRISPHOSPHATE 3-KINASE; 5-PHOSPHATASE ACTIVITY; METABOLIZING ENZYMES; SHIP2; OSCILLATIONS; CALCIUM; DOMAIN; BRAIN; CELLS	Benzene polyphosphates containing phosphate groups on one ring are Ins( 1,4,5) P-3 5-phosphatase inhibitors when evaluated against type-I Ins( 1,4,5) P-3 5- phosphatase. A novel biphenyl derivative, biphenyl 2,3', 4,5', 6- pentakisphosphate, with five phosphate groups on two rings was synthesized: It inhibited the activity of two inositol 5- phosphatases: type I and SHIP2 with Ins( 1,3,4,5) P-4 as substrate. The inhibition was competitive with respect to the substrate. IC50 value measured in rat hepatocytes, which contains the native Ins( 1,4,5) P-3 5- phosphatase, was in the micromolar range at 1.0 mu M Ins( 1,4,5) P-3 as substrate. Biphenyl 2,3', 4,5', 6- pentakisphosphate did not affect the activity of Ins( 1,4,5) P-3 3- kinase A in the 5 - 100 mu M range. Surprisingly, experimental evidence supports an effect of biphenyl 2,3', 4,5', 6- pentakisphosphate at the level of the Ins( 1,4,5) P-3 receptor. Finally, when injected into rat hepatocytes, the analog affected the frequency of Ca2+ oscillations in a positive or negative way depending on its concentration. At very high concentrations of the analog, Ca2+ oscillations were even suppressed. These data were interpreted as a dual effect of the biphenyl 2,3', 4,5', 6- pentakisphosphate on cytosolic [ Ca2+] increases: an activation effect through an increase in Ins( 1,4,5) P-3 level via Ins( 1,4,5) P-3 5- phosphatase inhibition and an inhibitory effect, which was exerted directly on the Ins( 1,4,5) P-3 receptor. Thus, our data show for the first time that the frequency of Ca2+ oscillations in response to a Ca2+- mobilizing agonist can be controlled by inhibitors of type-I Ins( 1,4,5) P-3 5- phosphatase.	Univ Libre Bruxelles, IRIBHM, B-1070 Brussels, Belgium; Univ Paris 11, INSERM UMR S757, Orsay, France; Univ Bath, Dept Pharm & Pharmacol, Wolfson Lab Med Chem, Bath BA2 7AY, Avon, England; Inst Biol, CNRS UMR8161, Lille, France; Katholieke Univ Leuven, Dept Mol Cell Biol, Fysiol Lab, Louvain, Belgium; Univ Libre Bruxelles, Fac Sci, Brussels, Belgium	Universite Libre de Bruxelles; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Bath; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); KU Leuven; Universite Libre de Bruxelles	Erneux, C (corresponding author), Univ Libre Bruxelles, IRIBHM, Campus Erasme,Bldg C,808 Route Lennik, B-1070 Brussels, Belgium.	cerneux@ulb.ac.be	Potter, Barry VL/A-1845-2012; Potter, Barry/AAX-4781-2020; Combettes, Laurent/L-1842-2013	Combettes, Laurent/0000-0002-1376-4574; Wohlkonig, Alexandre/0000-0003-3103-5022; Parys, Jan/0000-0002-3591-4967	Wellcome Trust [060554] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Blero D, 2005, FEBS J, V272, P2512, DOI 10.1111/j.1742-4658.2005.04672.x; Blero D, 2001, BIOCHEM BIOPH RES CO, V282, P839, DOI 10.1006/bbrc.2001.4639; Bultynck G, 2004, BIOCHEM J, V381, P87, DOI 10.1042/BJ20040072; Chi YL, 2004, J BIOL CHEM, V279, P44987, DOI 10.1074/jbc.M406416200; Clair C, 2001, J CELL SCI, V114, P1999; Clement S, 2001, NATURE, V409, P92, DOI 10.1038/35051094; DeSmedt F, 1997, J BIOL CHEM, V272, P17367, DOI 10.1074/jbc.272.28.17367; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; DOWNES CP, 1982, BIOCHEM J, V203, P169, DOI 10.1042/bj2030169; Dupont G, 2003, FEBS LETT, V534, P101, DOI 10.1016/S0014-5793(02)03789-4; Dupont G, 1997, CELL CALCIUM, V22, P321, DOI 10.1016/S0143-4160(97)90017-8; ERNEUX C, 1986, BIOCHEM BIOPH RES CO, V134, P351, DOI 10.1016/0006-291X(86)90570-X; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; ERNEUX C, 1985, MOL CELL ENDOCRINOL, V43, P123, DOI 10.1016/0303-7207(85)90075-9; ERNEUX C, 1991, TRENDS PHARMACOL SCI, V12, P174, DOI 10.1016/0165-6147(91)90539-5; Frederick JP, 2005, P NATL ACAD SCI USA, V102, P8454, DOI 10.1073/pnas.0503706102; Fujii M, 2005, J BIOL CHEM, V280, P1156, DOI 10.1074/jbc.M412006200; Hermosura MC, 2000, NATURE, V408, P735, DOI 10.1038/35047115; MAILLEUX P, 1991, J NEUROCHEM, V56, P345, DOI 10.1111/j.1471-4159.1991.tb02601.x; Miller GJ, 2004, MOL CELL, V15, P703, DOI 10.1016/j.molcel.2004.08.005; Mills SJ, 2006, CHEMBIOCHEM, V7, P1696, DOI 10.1002/cbic.200600125; Mitchell CA, 2002, IUBMB LIFE, V53, P25, DOI 10.1080/15216540210815; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Pesesse X, 1998, FEBS LETT, V437, P301, DOI 10.1016/S0014-5793(98)01255-1; Poinas A, 2005, CHEMBIOCHEM, V6, P1449, DOI 10.1002/cbic.200400443; POITRAS M, 1993, EUR J PHARM-MOLEC PH, V244, P203, DOI 10.1016/0922-4106(93)90145-Y; Riley AM, 1997, ANGEW CHEM INT EDIT, V36, P1472, DOI 10.1002/anie.199714721; Rowe T, 2006, ASSAY DRUG DEV TECHN, V4, P175, DOI 10.1089/adt.2006.4.175; Sleeman MW, 2005, NAT MED, V11, P199, DOI 10.1038/nm1178; Speed CJ, 1999, J CELL SCI, V112, P669; STOREY DJ, 1984, NATURE, V312, P374, DOI 10.1038/312374a0; TAKAZAWA K, 1988, BIOCHEM BIOPH RES CO, V153, P632, DOI 10.1016/S0006-291X(88)81142-2; Tordjmann T, 1997, EMBO J, V16, P5398, DOI 10.1093/emboj/16.17.5398; Vandeput F, 2006, CELL SIGNAL, V18, P2193, DOI 10.1016/j.cellsig.2006.05.010; Vanlingen S, 2001, BIOCHEM PHARMACOL, V61, P803, DOI 10.1016/S0006-2952(01)00540-8; VERJANS B, 1994, BIOCHEM J, V300, P85, DOI 10.1042/bj3000085	36	26	27	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1481	1491		10.1096/fj.06-7691com	http://dx.doi.org/10.1096/fj.06-7691com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264160				2022-12-25	WOS:000246117000023
J	Zhao, YT; Katzman, RB; Delmolino, LM; Bhat, I; Zhang, Y; Gurumurthy, CB; Germaniuk-Kurowska, A; Reddi, HV; Solomon, A; Zeng, MS; Kung, A; Ma, H; Gao, QS; Dimri, G; Stanculescu, A; Miele, L; Wu, LZ; Griffin, JD; Wazer, DE; Band, H; Band, V				Zhao, Yongtong; Katzman, Rebecca B.; Delmolino, Laurie M.; Bhat, Ishfaq; Zhang, Ying; Gurumurthy, Channabasavaiah B.; Germaniuk-Kurowska, Aleksandra; Reddi, Honey V.; Solomon, Aharon; Zeng, Mu-Sheng; Kung, Aisha; Ma, Hui; Gao, Qingshen; Dimri, Goberdhan; Stanculescu, Adina; Miele, Lucio; Wu, Lizi; Griffin, James D.; Wazer, David E.; Band, Hamid; Band, Vimla			The Notch regulator MAML1 interacts with p53 and functions as a coactivator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; TUMOR-SUPPRESSOR; DNA-DAMAGE; HUMAN ADA3; TRANSCRIPTIONAL COACTIVATORS; MEDIATED TRANSACTIVATION; CELL FATE; MASTERMIND; APOPTOSIS; TUMORIGENESIS	Members of the evolutionarily conserved Mastermind (MAM) protein family, including the three related mammalian Master-mind-like (MAML) proteins MAML1-3, function as crucial coactivators of Notch-mediated transcriptional activation. Given the recent evidence of cross-talk between the p53 and Notch signal transduction pathways, we have investigated whether MAML1 may also be a transcriptional coactivator of p53. Indeed, we show here that MAML1 is able to interact with p53. We show that MAML1-p53 interaction involves the N-terminal region of MAML1 and the DNA-binding domain of p53, and we use a chromatin immunoprecipitation assay to show that MAML1 is part of the activator complex that binds to native p53-response elements within the promoter of the p53 target genes. Overexpression of wild-type MAML1 as well as a mutant, defective in Notch signaling, enhanced the p53-dependent gene induction in mammalian cells, whereas MAML1 knockdown reduced the p53-dependent gene expression. MAML1 increases the half-life of p53 protein and enhances its phosphorylation/acetylation upon DNA damage of cells. Finally, RNA interference-mediated knockdown of the single Caenorhabditis elegans MAML homolog, Lag-3, led to substantial abrogation of p53-mediated germ-cell apoptotic response to DNA damage and markedly reduced the expression of Ced-13 and Egl-1, downstream pro-apoptotic targets of the C. elegans p53 homolog Cep-1. Thus, we present evidence for a novel coactivator function of MAML1 for p53, independent of its function as a coactivator of Notch signaling pathway.	Northwestern Univ, Feinberg Sch Med, ENH Res Inst, Div Canc Biol,Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, ENH Res Inst, Div Mol Oncol,Dept Med, Evanston, IL 60201 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60201 USA; Tufts Univ New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA; Loyola Univ, Med Ctr, Breast Canc Program, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Pharmacol & Expt Therapeut, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Tufts Medical Center; Loyola University Chicago; Loyola University Chicago; Harvard University; Dana-Farber Cancer Institute	Band, V (corresponding author), Northwestern Univ, Feinberg Sch Med, ENH Res Inst, Div Canc Biol,Dept Med, 1001 Univ Pl, Evanston, IL 60201 USA.	v-band@northwestern.edu	Gurumurthy, Channabasavaiah B/H-8268-2016; Gurumurthy, Channabasavaiah B/E-7205-2011	Gurumurthy, Channabasavaiah B/0000-0002-8022-4033; Miele, Lucio/0000-0002-5853-7287; zeng, musheng/0000-0003-3509-5591	NATIONAL CANCER INSTITUTE [R01CA081076, T32CA070085, R01CA097148, R01CA076118, R01CA096986, R01CA099900, R01CA087986, R01CA096844, R01CA095221, R01CA094143, R01CA099163] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA70085, R01 CA095221-05, R01 CA097148, R01 CA096986-05, R01 CA096986-02, R01 CA096986-01A1, R01 CA095221-01A1, CA81076, R01 CA096986-04, CA94143, R01 CA095221-02, R01 CA095221-04, CA87986, CA99900, R01 CA096986-03, CA96844, R01 CA095221-03, CA76118, CA99163] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BRENNER S, 1974, GENETICS, V77, P71; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Christova R, 2002, NAT CELL BIOL, V4, P79, DOI 10.1038/ncb733; Coutts AS, 2005, BIOCHEM BIOPH RES CO, V331, P778, DOI 10.1016/j.bbrc.2005.03.150; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; DORMAN JB, 1995, GENETICS, V141, P1399; Doyle TG, 2000, P NATL ACAD SCI USA, V97, P7877, DOI 10.1073/pnas.97.14.7877; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Grabher C, 2006, NAT REV CANCER, V6, P347, DOI 10.1038/nrc1880; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lathion S, 2003, CANCER RES, V63, P8687; Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Meng GY, 2004, J BIOL CHEM, V279, P54230, DOI 10.1074/jbc.M404482200; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Nair P, 2003, J VIROL, V77, P7106, DOI 10.1128/JVI.77.12.7106-7112.2003; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Schumacher B, 2005, CELL DEATH DIFFER, V12, P153, DOI 10.1038/sj.cdd.4401539; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Shen HX, 2006, GENE DEV, V20, P675, DOI 10.1101/gad.1383706; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wang T, 2001, EMBO J, V20, P6404, DOI 10.1093/emboj/20.22.6404; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wu LZ, 2004, SEMIN CANCER BIOL, V14, P348, DOI 10.1016/j.semcancer.2004.04.014; Yang XD, 2004, DEV BIOL, V269, P81, DOI 10.1016/j.ydbio.2004.01.014; Zeng MS, 2002, J BIOL CHEM, V277, P45611, DOI 10.1074/jbc.M208447200	49	62	70	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11969	11981		10.1074/jbc.M608974200	http://dx.doi.org/10.1074/jbc.M608974200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17317671	hybrid, Green Submitted			2022-12-25	WOS:000245941900040
J	Bertola, A; Bonnafous, S; Cormont, M; Anty, R; Tanti, JF; Tran, A; Le Marchand-Brustel, Y; Gual, P				Bertola, Adeline; Bonnafous, Stephanie; Cormont, Mireille; Anty, Rodolphe; Tanti, Jean-Francois; Tran, Albert; Le Marchand-Brustel, Yannick; Gual, Philippe			Hepatocyte growth factor induces glucose uptake in 3T3-L1 adipocytes through A Gab1/phosphatidylinositol 3-kinase/Glut4 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY LIVER-DISEASE; ADIPOSE-TISSUE; INSULIN; MET; EXPRESSION; ADIPOKINES; SECRETION; CANCER; LEADS; GAB1	Adipose tissue is a source of hepatocyte growth factor ( HGF), and circulating HGF levels have been associated with elevated body mass index in human. However, the effects of HGF on adipocyte functions have not yet been investigated. We show here that in 3T3-L1 adipocytes HGF stimulates the phosphatidylinositol (PI) 3-kinase-dependent protein kinase B (PKB) activity, AS160 phosphorylation, Glut4 translocation, and consequently, glucose uptake. The initial steps involved in HGF- and insulin-induced glucose uptake are different. HGF enhanced the tyrosine phosphorylation of Gab1, leading to the recruitment of the p85-regulated subunit of PI 3-kinase, whereas p85 was exclusively recruited by IRS1 in response to insulin. In adipocytes rendered insulin-resistant by a long-lasting tumor necrosis factor alpha treatment, the protein level of Gab1 was strongly decreased, and HGF- stimulated PKB activation and glucose uptake were also altered. Moreover, treatment of 3T3-L1 adipocytes with thiazolidinedione, an anti- diabetic drug, enhanced the expression of both HGF and its receptor. These data provide the first evidence that in vitro HGF promotes glucose uptake through a Gab1/PI 3-kinase/ PKB/ AS160 pathway which was altered in tumor necrosis factor alpha-treated adipocytes.	INSERM, U568, Fac Med, F-06107 Nice 02, France; Univ Nice, F-06107 Nice, France; CHU, Federat Hepatol, F-06202 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Gual, P (corresponding author), INSERM, U568, Fac Med, Ave Valombrose, F-06107 Nice 02, France.	gual@unice.fr	Gual, Philippe/P-9833-2019; Gual, Philippe/M-8787-2017	Gual, Philippe/0000-0001-7393-8356; Gual, Philippe/0000-0001-7393-8356; Tanti, Jean-Francois/0000-0003-1782-1318; CORMONT, Mireille/0000-0001-6918-2410; Anty, Rodolphe/0000-0002-8053-1957; Anty, Rodolphe/0000-0001-8194-9805; Bertola, Adeline/0000-0002-4885-8423				Arner P, 2003, TRENDS ENDOCRIN MET, V14, P137, DOI 10.1016/S1043-2760(03)00024-9; Bard-Chapeau EA, 2005, NAT MED, V11, P567, DOI 10.1038/nm1227; Bell LN, 2006, AM J PHYSIOL-ENDOC M, V291, pE843, DOI 10.1152/ajpendo.00174.2006; Comoglio PM, 2001, NAT CELL BIOL, V3, pE161, DOI 10.1038/35083116; Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI23621; Dugani CB, 2005, EMBO REP, V6, P1137, DOI 10.1038/sj.embor.7400584; Fain JN, 2004, ENDOCRINOLOGY, V145, P2273, DOI 10.1210/en.2003-1336; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Galimi F, 2001, J IMMUNOL, V166, P1241, DOI 10.4049/jimmunol.166.2.1241; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Gual P, 2003, J BIOL CHEM, V278, P26550, DOI 10.1074/jbc.M212273200; Gual P, 2002, J BIOL CHEM, V277, P43980, DOI 10.1074/jbc.M203042200; Gual P, 2003, DIABETES METAB, V29, P566, DOI 10.1016/S1262-3636(07)70071-X; Guerre-Millo M, 2004, DIABETES METAB, V30, P13, DOI 10.1016/S1262-3636(07)70084-8; Haukeland JW, 2006, J HEPATOL, V44, P1167, DOI 10.1016/j.jhep.2006.02.011; Hiratsuka A, 2005, J CLIN ENDOCR METAB, V90, P2927, DOI 10.1210/jc.2004-1588; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Janez A, 2000, J BIOL CHEM, V275, P26870; Kaplan O, 2000, NEOPLASIA, V2, P365, DOI 10.1038/sj.neo.7900103; Kataoka H, 2003, CANCER METAST REV, V22, P223, DOI 10.1023/A:1023051500010; Kato Y, 1998, J PEDIATR SURG, V33, P13, DOI 10.1016/S0022-3468(98)90351-7; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Mari M, 2006, J CELL SCI, V119, P1297, DOI 10.1242/jcs.02850; NAKAMURA Y, 1995, BIOCHEM BIOPH RES CO, V215, P483, DOI 10.1006/bbrc.1995.2490; Pagano C, 2006, J CLIN ENDOCR METAB, V91, P1081, DOI 10.1210/jc.2005-1056; Patel N, 2006, PFLUG ARCH EUR J PHY, V451, P499, DOI 10.1007/s00424-005-1475-6; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; Rehman J, 2003, J AM COLL CARDIOL, V41, P1408, DOI 10.1016/S0735-1097(03)00231-6; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Roccisana J, 2005, DIABETES, V54, P2090, DOI 10.2337/diabetes.54.7.2090; Rosario M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1; Saiki A, 2006, INT J OBESITY, V30, P1676, DOI 10.1038/sj.ijo.0803316; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Swierczynski J, 2005, OBES SURG, V15, P803, DOI 10.1381/0960892054222678; Tomita K, 2004, GASTROENTEROLOGY, V126, P873, DOI 10.1053/j.gastro.2003.12.008; WANG M, 2006, AM J PHYSIOL-REG I, V29, pE880	38	36	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10325	10332		10.1074/jbc.M611770200	http://dx.doi.org/10.1074/jbc.M611770200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284447	hybrid			2022-12-25	WOS:000245941000022
J	Huang, JS; Dong, L; Kozasa, T; Le Breton, GC				Huang, Jin-Sheng; Dong, Lanlan; Kozasa, Tohru; Le Breton, Guy C.			Signaling through G alpha(13) switch region I is essential for protease-activated receptor 1-mediated human platelet shape change, aggregation, and secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPDUCIN-BASED INTERVENTION; ENDOTHELIAL-CELL MIGRATION; THROMBOXANE A(2) RECEPTORS; INTACT HUMAN-PLATELETS; BETA-GAMMA-SUBUNITS; G-ALPHA-Q; PHOSPHOLIPASE-C; INTEGRIN ALPHA(IIB)BETA(3); MOLECULAR-MECHANISM; THROMBIN RECEPTORS	This study investigated the involvement of G alpha(13) switch region I (SRI) in protease-activated receptor 1 (PAR1)-mediated platelet function and signaling. To this end, myristoylated peptides representing the G alpha(13) SRI (Myr-G(13)SRI(pep)) and its random counterpart were evaluated for their effects on PAR1 activation. Initial studies demonstrated that (Myr-G(13)SRI(pep)) and Myr-G(13)SRI(Random-pep) pep were equally taken up by human platelets and did not interfere with PAR1-ligand interaction. Subsequent experiments revealed that Myr-G(13)SRI(pep) specifically bound to platelet RhoA guanine nucleotide exchange factor (p115RhoGEF) and blocked PAR1-mediated RhoA activation in platelets and human embryonic kidney cells. These results suggest a direct interaction of G alpha(13) SRI with p115RhoGEF and a mechanism for Myr-G13SRIpep inhibition of RhoA activation. Platelet function studies demonstrated that Myr-G13SRIpep specifically inhibited PAR1- stimulated shape change, aggregation, and secretion in a dose-dependent manner but did not inhibit platelet activation induced by either ADP or A23187. It was also found that Myr-G(13)SRI(pep) inhibited low dose, but not high dose, thrombin-induced aggregation. Additional experiments showed that PAR1- mediated calcium mobilization was partially blocked by Myr-G(13)SRI(pep) but not by the Rho kinase inhibitor Y-27632. Finally, Myr-G(13)SRI(pep) effectively inhibited PAR1-induced stress fiber formation and cell contraction in endothelial cells. Collectively, these results suggest the following: 1) interaction of G alpha(13) SRI with p115RhoGEF is required for G13-mediated RhoA activation in platelets; 2) signaling through the G(13) pathway is critical for PAR1- mediated human platelet functional changes and low dose thrombin-induced aggregation; and 3) G13 signaling elicits calcium mobilization in human platelets through a Rho kinase-independent mechanism.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Le Breton, GC (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,MC 868, Chicago, IL 60612 USA.	gcl@uic.edu			NHLBI NIH HHS [HL-24530-23] Funding Source: Medline; NIGMS NIH HHS [GM061454] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024530] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061454] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562; Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; Brass LF, 2003, CHEST, V124, p18S, DOI 10.1378/chest.124.3_suppl.18S; BRASS LF, 1987, J CLIN INVEST, V79, P1269, DOI 10.1172/JCI112947; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Covic L, 2002, NAT MED, V8, P1161, DOI 10.1038/nm760; D'Ursi AM, 2006, MOL PHARMACOL, V69, P727, DOI 10.1124/mol.105.017715; Djellas Y, 1999, J BIOL CHEM, V274, P14325, DOI 10.1074/jbc.274.20.14325; Dorsam RT, 2002, J BIOL CHEM, V277, P47588, DOI 10.1074/jbc.M208778200; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; FEINBERG H, 1974, J LAB CLIN MED, V84, P926; Flaumenhaft R, 2005, BLOOD, V105, P3879, DOI 10.1182/blood-2004-04-1392; Freissmuth M, 1999, TRENDS PHARMACOL SCI, V20, P237, DOI 10.1016/S0165-6147(99)01337-1; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; HAMILTON JR, 2004, J THROMB HAEMOST, V2, P1538; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; Huang JS, 2006, CELL SIGNAL, V18, P564, DOI 10.1016/j.cellsig.2005.06.011; Huang JS, 2004, CELL SIGNAL, V16, P521, DOI 10.1016/j.cellsig.2003.10.008; JHON DY, 1993, J BIOL CHEM, V268, P6654; Kahn ML, 1999, J CLIN INVEST, V103, P879, DOI 10.1172/JCI6042; KATTELMAN EJ, 1986, THROMB RES, V41, P471, DOI 10.1016/0049-3848(86)91692-0; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kim S, 2002, BLOOD, V99, P3629, DOI 10.1182/blood.V99.10.3629; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Kuliopulos A, 2003, LIFE SCI, V74, P255, DOI 10.1016/j.lfs.2003.09.012; Lee BS, 2005, RAPID COMMUN MASS SP, V19, P1545, DOI 10.1002/rcm.1956; Leng LJ, 1998, BLOOD, V91, P4206, DOI 10.1182/blood.V91.11.4206.411k30_4206_4215; Manganello JM, 2003, J BIOL CHEM, V278, P124, DOI 10.1074/jbc.M209219200; Manganello JM, 1999, J BIOL CHEM, V274, P28003, DOI 10.1074/jbc.274.39.28003; Marinissen MJ, 2003, J BIOL CHEM, V278, P46814, DOI 10.1074/jbc.M305709200; Mazzoni MR, 2000, MOL PHARMACOL, V58, P226, DOI 10.1124/mol.58.1.226; Meigs TE, 2005, J BIOL CHEM, V280, P18049, DOI 10.1074/jbc.M500445200; Moers A, 2004, J BIOL CHEM, V279, P45354, DOI 10.1074/jbc.M408962200; Moers A, 2003, NAT MED, V9, P1418, DOI 10.1038/nm943; Murugappan S, 2005, BLOOD, V106, P550, DOI 10.1182/blood-2004-12-4866; MUSTARD JF, 1975, AM J PHYSIOL, V228, P1757, DOI 10.1152/ajplegacy.1975.228.6.1757; Nakamura S, 2004, MOL PHARMACOL, V66, P1029, DOI 10.1124/mol.104.002287; Nieswandt B, 2002, J BIOL CHEM, V277, P39493, DOI 10.1074/jbc.M207256200; OBRIAN CA, 1991, INVEST NEW DRUG, V9, P169, DOI 10.1007/BF00175084; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Otterdal K, 2001, THROMB RES, V103, P411, DOI 10.1016/S0049-3848(01)00334-6; PARK DG, 1993, J BIOL CHEM, V268, P4573; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; RINK TJ, 1988, EXPERIENTIA, V44, P97, DOI 10.1007/BF01952188; Simoncini T, 2006, MOL ENDOCRINOL, V20, P1756, DOI 10.1210/me.2005-0259; Suzuki Y, 1999, BLOOD, V93, P3408, DOI 10.1182/blood.V93.10.3408.410k37_3408_3417; Vaidyula VR, 2003, BRIT J HAEMATOL, V121, P491, DOI 10.1046/j.1365-2141.2003.04296.x; Vogt S, 2003, J BIOL CHEM, V278, P28743, DOI 10.1074/jbc.M304570200; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Watanabe Y, 2001, BLOOD, V97, P3798, DOI 10.1182/blood.V97.12.3798	55	29	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10210	10222		10.1074/jbc.M605678200	http://dx.doi.org/10.1074/jbc.M605678200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17298951	hybrid			2022-12-25	WOS:000245941000011
J	Storozhenko, S; Navarrete, O; Ravanel, S; De Brouwer, V; Chaerle, P; Zhang, GF; Bastien, O; Lambert, W; Rebeille, F; Van Der Straeten, D				Storozhenko, Sergei; Navarrete, Oscar; Ravanel, Stephane; De Brouwer, Veerle; Chaerle, Peter; Zhang, Guo-Fang; Bastien, Olivier; Lambert, Willy; Rebeille, Fabrice; Van Der Straeten, Dominique			Cytosolic hydroxymethyldihydropterin pyrophosphokinase/dihydropteroate synthase from Arabidopsis thaliana - A specific role in early development and stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; P-AMINOBENZOATE BRANCH; CELL-FREE-EXTRACTS; FOLIC-ACID; FOLATE SYNTHESIS; ENDOTHELIAL FUNCTION; HIGHER-PLANTS; BIOSYNTHESIS; DIHYDROPTEROATE; MITOCHONDRIA	In plants, 6-hydroxymethyl-7, 8-dihydropterin pyrophosphokinase/7, 8-dihydropteroate synthase ( mitHPPK/DHPS) is a bifunctional mitochondrial enzyme, which catalyzes the first two consecutive steps of tetrahydrofolate biosynthesis. Mining the Arabidopsis genome data base has revealed a second gene encoding a protein that lacks a potential transit peptide, suggesting a cytosolic localization of the isoenzyme ( cytHPPK/DHPS). When the N-terminal part of the cytHPPK/DHPS was fused to green fluorescent protein, the fusion protein appeared only in the cytosol, confirming the above prediction. Functionality of cytHPPK/DHPS was addressed by two parallel approaches: first, the cytHPPK/DHPS was able to rescue yeast mutants lacking corresponding activities; second, recombinant cytHPPK/DHPS expressed and purified from Escherichia coli displayed both HPPK and DHPS activities in vitro. In contrast to mitHPPK/DHPS, which was ubiquitously expressed, the cytHPPK/DHPS gene was exclusively expressed in reproductive tissue, more precisely in developing seeds as revealed by histochemical analysis of a transgenic cytHPPK/DHPS promoter-GUS line. In addition, it was observed that expression of cytHPPK/DHPS mRNA was induced by salt stress, suggesting a potential role of the enzyme in stress response. This was supported by the phenotype of a T-DNA insertion mutant in the cytHPPK/DHPS gene, resulting in lower germination rates as compared with the wild-type upon application of oxidative and osmotic stress.	Univ Ghent, Dept Mol Genet, Unit Plant Hormone Signaling & Bioimaging, B-9000 Ghent, Belgium; CEA Grenoble, Lab Physiol Cellulaire Vegetale, Dept Dynam Cellulaire, F-38054 Grenoble 9, France; Univ Ghent, Toxicol Lab, B-9000 Ghent, Belgium	Ghent University; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Ghent University	Van Der Straeten, D (corresponding author), Univ Ghent, Dept Mol Genet, Unit Plant Hormone Signaling & Bioimaging, KL Ledeganckstr 35, B-9000 Ghent, Belgium.	dominique.vanderstraeten@ugent.be	Bastien, Olivier/B-9723-2008; Van Der Straeten, Dominique/E-7385-2016	Van Der Straeten, Dominique/0000-0002-7755-1420; Chaerle, Peter/0000-0002-8216-0299; Ravanel, Stephane/0000-0001-9475-4222				APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Basset G, 2002, P NATL ACAD SCI USA, V99, P12489, DOI 10.1073/pnas.192278499; Basset GJC, 2004, PLANT J, V40, P453, DOI 10.1111/j.1365-313X.2004.02231.x; Basset GJC, 2004, P NATL ACAD SCI USA, V101, P1496, DOI 10.1073/pnas.0308331100; Baxter CJ, 2007, PLANT PHYSIOL, V143, P312, DOI 10.1104/pp.106.090431; Bayly AM, 2002, FEMS MICROBIOL LETT, V213, P189; Beeckman T., 1994, Plant Molecular Biology Reporter, V12, P37, DOI 10.1007/BF02668662; Bowers JE, 2003, NATURE, V422, P433, DOI 10.1038/nature01521; BROWN GM, 1961, J BIOL CHEM, V236, P2534; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Doshi SN, 2001, ARTERIOSCL THROM VAS, V21, P1196, DOI 10.1161/hq0701.092000; EVANS IH, 1976, GENETIC FUNCTION MIT, P209; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Goyer A, 2004, PLANT PHYSIOL, V135, P103, DOI 10.1104/pp.103.038430; Guldener U, 2004, MOL BIOL CELL, V15, P3811, DOI 10.1091/mbc.E03-09-0680; Hanson AD, 2002, CURR OPIN PLANT BIOL, V5, P244, DOI 10.1016/S1369-5266(02)00249-2; Hanson AD, 2001, ANNU REV PLANT PHYS, V52, P119, DOI 10.1146/annurev.arplant.52.1.119; He XL, 2005, GENETICS, V169, P1157, DOI 10.1534/genetics.104.037051; IWAI K, 1968, J VITAMINOL, V14, P160, DOI 10.5925/jnsv1954.14.160; Jabrin S, 2003, PLANT PHYSIOL, V131, P1431, DOI 10.1104/pp.016915; Karimi M, 2002, TRENDS PLANT SCI, V7, P193, DOI 10.1016/S1360-1385(02)02251-3; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Magome H, 2004, PLANT J, V37, P720, DOI 10.1111/j.1365-313X.2003.01998.x; Mouillon JM, 2002, BIOCHEM J, V363, P313, DOI 10.1042/0264-6021:3630313; Neuburger M, 1996, J BIOL CHEM, V271, P9466, DOI 10.1074/jbc.271.16.9466; Orsomando G, 2006, PLANT J, V46, P426, DOI 10.1111/j.1365-313X.2006.02685.x; Orsomando G, 2005, J BIOL CHEM, V280, P28877, DOI 10.1074/jbc.M504306200; Ravanel S, 2001, P NATL ACAD SCI USA, V98, P15360, DOI 10.1073/pnas.261585098; Rebeille F, 1997, EMBO J, V16, P947, DOI 10.1093/emboj/16.5.947; Scott J, 2000, J SCI FOOD AGR, V80, P795, DOI [10.1002/(SICI)1097-0010(20000515)80:7&lt;795::AID-JSFA599&gt;3.0.CO;2-K, 10.1002/(SICI)1097-0010(20000515)80:7<795::AID-JSFA599>3.0.CO;2-K]; Seki M, 2002, PLANT J, V31, P279, DOI 10.1046/j.1365-313X.2002.01359.x; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Storozhenko S, 2005, TRENDS FOOD SCI TECH, V16, P271, DOI 10.1016/j.tifs.2005.03.007; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Verhaar MC, 1999, CIRCULATION, V100, P335, DOI 10.1161/01.CIR.100.4.335; Wang RC, 2003, PLANT PHYSIOL, V132, P556, DOI 10.1104/pp.103.021253; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zhang GF, 2005, J CHROMATOGR A, V1078, P59, DOI 10.1016/j.chroma.2005.04.085; Zhu JK, 2001, TRENDS PLANT SCI, V6, P66, DOI 10.1016/S1360-1385(00)01838-0	41	28	33	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10749	10761		10.1074/jbc.M701158200	http://dx.doi.org/10.1074/jbc.M701158200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289662	hybrid, Green Published			2022-12-25	WOS:000245941000069
J	Tanaka, S; Ishii, K; Kasai, K; Yoon, SO; Saeki, Y				Tanaka, Shigeru; Ishii, Ken; Kasai, Kazue; Yoon, Sung Ok; Saeki, Yoshinaga			Neural expression of G protein-coupled receptors GPR3, GPR6, and GPR12 up-regulates cyclic AMP levels and promotes neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; MOLECULAR-CLONING; CHROMOSOMAL LOCALIZATION; AXONAL REGENERATION; NEURONAL SURVIVAL; MEIOTIC ARREST; GROWTH-FACTOR; CAMP; INHIBITION; OOCYTES	Cyclic AMP regulates multiple neuronal functions, including neurite outgrowth and axonal regeneration. GPR3, GPR6, and GPR12 make up a family of constitutively active G protein-coupled receptors ( GPCRs) that share greater than 50% identity and 65% similarity at the amino acid level. They are highly expressed in the central nervous system, and their expression in various cell lines results in constitutive stimulation of cAMP production. When the constitutively active GPCRs were overexpressed in rat cerebellar granule neurons in culture, the transfected neurons exhibited significantly enhanced neurite outgrowth and overcame growth inhibition caused by myelin-associated glycoprotein. GPR12-mediated neurite outgrowth was the most prominent and was shown to depend on G(s) and cAMP-dependent protein kinase. Moreover, the GPR12-mediated rescue from myelin- associated glycoprotein inhibition was attributable to cAMP-dependent protein kinase-mediated inhibition of the small GTPase, RhoA. Among the three receptors, GPR3 was revealed to be enriched in the developing rat cerebellar granule neurons. When the endogenous GPR3 was knocked down, significant reduction of neurite growth was observed, which was reversed by expression of either GPR3 or GPR12. Taken together, our results indicate that expression of the constitutively active GPCRs up-regulates cAMP production in neurons, stimulates neurite outgrowth, and counteracts myelin inhibition. Further characterization of the GPCRs in developing and injured mammalian neurons should provide insights into how basal cAMP levels are regulated in neurons and could establish a firm scientific foundation for applying receptor biology to treatment of various neurological disorders.	Ohio State Univ, Med Ctr, Dept Neurol Surg, Dardinger Lab Neurooncol & Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Neurobiol, Columbus, OH 43210 USA; Keio Univ, Sch Med, Dept Orthopaed Surg, Tokyo 1608582, Japan	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Keio University	Saeki, Y (corresponding author), Ohio State Univ, Med Ctr, Dept Neurol Surg, Dardinger Lab Neurooncol & Neurosci, 385B Wiseman Hall CCC,400 W 12th Ave, Columbus, OH 43210 USA.	saeki.6@osu.edu	Tanaka, Shigeru/O-3908-2015; Yoon, Sung Ok/C-5992-2012	Tanaka, Shigeru/0000-0003-3247-9098; 	NINDS NIH HHS [R21 NS44514] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS044514] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Berlot CH, 2002, J BIOL CHEM, V277, P21080, DOI 10.1074/jbc.M201330200; Bhatt DH, 2004, SCIENCE, V305, P254, DOI 10.1126/science.1098439; Bresnick JN, 2003, ASSAY DRUG DEV TECHN, V1, P239, DOI 10.1089/15406580360545053; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Cai DM, 2002, NEURON, V35, P711, DOI 10.1016/S0896-6273(02)00826-7; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; EGGERICKX D, 1995, BIOCHEM J, V309, P837, DOI 10.1042/bj3090837; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Freudzon L, 2005, J CELL BIOL, V171, P255, DOI 10.1083/jcb.200506194; Gao Y, 2003, J NEUROSCI, V23, P11770; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HEIBER M, 1995, DNA CELL BIOL, V14, P25, DOI 10.1089/dna.1995.14.25; Hinckley M, 2005, DEV BIOL, V287, P249, DOI 10.1016/j.ydbio.2005.08.019; Ignatov A, 2003, BIOCHEM BIOPH RES CO, V311, P329, DOI 10.1016/j.bbrc.2003.10.006; Ignatov A, 2003, J NEUROSCI, V23, P907; IISMAA TP, 1994, GENOMICS, V24, P391, DOI 10.1006/geno.1994.1635; Kao HT, 2002, NAT NEUROSCI, V5, P431, DOI 10.1038/nn840; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; Komuro H, 2003, CELL MOL LIFE SCI, V60, P1084, DOI 10.1007/s00018-003-2248-z; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; Leclere PG, 2005, J NEUROSCI METH, V142, P137, DOI 10.1016/j.jneumeth.2004.08.012; Ledent C, 2005, P NATL ACAD SCI USA, V102, P8922, DOI 10.1073/pnas.0503840102; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; LIESI P, 1983, NATURE, V306, P265, DOI 10.1038/306265a0; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; MARCHESE A, 1994, GENOMICS, V23, P609, DOI 10.1006/geno.1994.1549; Mehlmann LM, 2004, SCIENCE, V306, P1947, DOI 10.1126/science.1103974; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Qiu J, 2002, PROG BRAIN RES, V137, P381; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; RYDEL RE, 1988, P NATL ACAD SCI USA, V85, P1257, DOI 10.1073/pnas.85.4.1257; SAEKI Y, 1993, FEBS LETT, V336, P317, DOI 10.1016/0014-5793(93)80828-I; Saeki Yoshinaga, 2003, Methods Mol Med, V76, P51; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SONG ZH, 1995, GENOMICS, V28, P347, DOI 10.1006/geno.1995.1154; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Wang Q, 1998, J NEUROSCI, V18, P4973; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9	46	87	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10506	10515		10.1074/jbc.M700911200	http://dx.doi.org/10.1074/jbc.M700911200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284443	hybrid			2022-12-25	WOS:000245941000043
J	Wohlwend, D; Strasser, A; Dickmanns, A; Doenecke, D; Ficner, R				Wohlwend, Daniel; Strasser, Anja; Dickmanns, Achim; Doenecke, Detlef; Ficner, Ralf			Thermodynamic analysis of H1 nuclear import - Receptor tuning of importin beta/importin7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; PROTEIN IMPORT; LOCALIZATION SIGNAL; STRUCTURAL BASIS; MAMMALIAN-CELLS; BETA; ALPHA; COMPLEX; RANGTP; DOMAIN	The nuclear import of H1 linker histones is mediated by a heterodimer of transport receptors, known as importin beta and importin7. Interestingly, both importins separately interact with H1, but only as a dimer they facilitate the translocation through the nuclear pore. We identified the H1 binding site of importin7, comprising two extended acidic loops near the C terminus of importin7. The analysis of the H1 import complex assembly by means of isothermal titration calorimetry revealed that the formation of a receptor heterodimer in vitro is an enthalpy-driven process, whereas subsequent binding of H1 to the heterodimer is entropy-driven. Furthermore, we show that the importin beta binding domain of importin7 plays a key role in the activation of importin7 by importin beta. This process is allosterically regulated by importin beta and accounts for a specific tuning of the activity of the importin beta center dot importin7 heterodimer. The results presented here provide new insights into cellular strategies to even energy balances in nuclear import and point toward a general regulation of importin beta-related nuclear import processes.	Univ Gottingen, Abt Mol Strukturbiol, Inst Microbiol & Genet, D-37077 Gottingen, Germany; Univ Gottingen, GZMB, D-37077 Gottingen, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ Gottingen, Inst Biochem & Mol Zellbiol, Abt Mol Biol, D-37073 Gottingen, Germany	University of Gottingen; University of Gottingen; European Molecular Biology Laboratory (EMBL); University of Gottingen	Ficner, R (corresponding author), Univ Gottingen, Abt Mol Strukturbiol, Inst Microbiol & Genet, Justus Von Liebig Weg 11, D-37077 Gottingen, Germany.	rficner@gwdg.de						ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Bauerle M, 2002, J BIOL CHEM, V277, P32480, DOI 10.1074/jbc.M202765200; Bednenko J, 2003, J CELL BIOL, V162, P391, DOI 10.1083/jcb.200303085; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Conti E, 2006, CURR OPIN STRUC BIOL, V16, P237, DOI 10.1016/j.sbi.2006.03.010; Conti Elena, 2002, Results Probl Cell Differ, V35, P93; Fassati A, 2003, EMBO J, V22, P3675, DOI 10.1093/emboj/cdg357; Fried H, 2003, CELL MOL LIFE SCI, V60, P1659, DOI 10.1007/s00018-003-3070-3; Fukuhara N, 2004, J BIOL CHEM, V279, P2176, DOI 10.1074/jbc.M309112200; Gorlich D, 1997, J CELL BIOL, V138, P65, DOI 10.1083/jcb.138.1.65; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Harreman MT, 2003, J BIOL CHEM, V278, P21361, DOI 10.1074/jbc.M301114200; Harreman MT, 2003, J BIOL CHEM, V278, P5854, DOI 10.1074/jbc.M210951200; Huber J, 2002, J CELL BIOL, V156, P467, DOI 10.1083/jcb.200108114; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; JOHN J, 1988, J BIOL CHEM, V263, P11792; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; Lee SJ, 2005, NATURE, V435, P693, DOI 10.1038/nature03578; Madrid AS, 2006, CHROMOSOMA, V115, P98, DOI 10.1007/s00412-005-0043-3; Matsuura Y, 2004, NATURE, V432, P872, DOI 10.1038/nature03144; MELCHIOR F, 1995, METHOD ENZYMOL, V257, P279; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Tyler JK, 2002, EUR J BIOCHEM, V269, P2268, DOI 10.1046/j.1432-1033.2002.02890.x	29	11	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10707	10719		10.1074/jbc.M610409200	http://dx.doi.org/10.1074/jbc.M610409200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17259172	hybrid			2022-12-25	WOS:000245941000065
J	Rajala, A; Anderson, RE; Ma, JX; Lem, J; Al-Ubaidi, MR; Rajala, RVS				Rajala, Ammaji; Anderson, Robert E.; Ma, Jian-Xing; Lem, Janis; Al-Ubaidi, Muayyad R.; Rajala, Raju V. S.			G-protein-coupled receptor rhodopsin regulates the phosphorylation of retinal insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR EXPRESSION; TYROSINE PHOSPHORYLATION; CELL-DEATH; PHOTORECEPTOR DEGENERATION; SIGNALING PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; ROD PHOTORECEPTORS; IMPAIRED INSULIN; BOUND PROTEIN-14	We have shown previously that phosphoinositide 3-kinase in the retina is activated in vivo through light-induced tyrosine phosphorylation of the insulin receptor (IR). The light effect is localized to photoreceptor neurons and is independent of insulin secretion (Rajala, R. V., McClellan, M. E., Ash, J. D., and Anderson, R. E. (2002) J. Biol. Chem, 277,43319 - 43326). These results suggest that there exists a cross-talk between phototransduction and other signal transduction pathways. In this study, we examined the stage of phototransduction that is coupled to the activation of the IR. We studied IR phosphorylation in mice lacking the rod-specific a-subunit of transducin to determine if phototransduction events are required for IR activation. To confirm that light-induced tyrosine phosphorylation of the IR is signaled through bleachable rhodopsin, we examined IR activation in retinas from RPE65(-/-) mice that are deficient in opsin chromophore. We observed that IR phosphorylation requires the photobleaching of rhodopsin but not transducin signaling. To determine whether the light-dependent activation of IR is mediated through the rod or cone transduction pathway, we studied the IR activation in mice lacking opsin, a mouse model of pure cone function. No light-dependent activation of the IR was found in the retinas of these mice. We provide evidence for the existence of a light-mediated IR pathway in the retina that is different from the known insulin-mediated pathway in nonneuronal tissues. These results suggest that IR phosphorylation in rod photoreceptors is signaled through the G-protein-coupled receptor rhodopsin. This is the first study demonstrating that rhodopsin can initiate signaling pathway(s) in addition to its classical photortransduction.	Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dean A McGee Eye Inst, Oklahoma City, OK 73104 USA; Tufts Univ New England Med Ctr, Dept Ophthalmol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Tufts Medical Center; Tufts University	Rajala, RVS (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, 608 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	raju-rajala@ouhsc.edu	Gimenez, Luis E Diaz/D-9291-2011		NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017703] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY012190, R01EY000871, R01EY016507, R01EY004149] Funding Source: NIH RePORTER; NCRR NIH HHS [RR17703, P20 RR017703] Funding Source: Medline; NEI NIH HHS [EY016507, EY04149, P30 EY012190, EY00871, EY12190] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alfinito PD, 2002, P NATL ACAD SCI USA, V99, P5655, DOI 10.1073/pnas.072557799; ARSHAVSKY VY, 2003, SCI STKE, pE43; Balasubramanian N, 2003, CURR BIOL, V13, P1306, DOI 10.1016/S0960-9822(03)00511-6; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; BASINGER S, 1976, SCIENCE, V194, P1074, DOI 10.1126/science.1086510; Bell MW, 2000, J NEUROCHEM, V75, P2006, DOI 10.1046/j.1471-4159.2000.0752006.x; Bell MW, 1999, J NEUROCHEM, V73, P2331, DOI 10.1046/j.1471-4159.1999.0732331.x; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; BROEKHUYSE RM, 1985, CURR EYE RES, V4, P613, DOI 10.3109/02713688508999993; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang HY, 2000, SCIENCE, V290, P1978, DOI 10.1126/science.290.5498.1978; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; COOK B, 1995, INVEST OPHTH VIS SCI, V36, P990; Cooney GJ, 2004, EMBO J, V23, P582, DOI 10.1038/sj.emboj.7600082; CUATRECASAS P, 1973, P NATL ACAD SCI USA, V70, P485, DOI 10.1073/pnas.70.2.485; D'Mello SR, 1997, J NEUROSCI, V17, P1548; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; de la Monte SM, 2005, J ALZHEIMERS DIS, V7, P45; de la Monte SM, 2004, J ALZHEIMERS DIS, V6, P231; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Fain GL, 2001, PHYSIOL REV, V81, P117, DOI 10.1152/physrev.2001.81.1.117; Ghalayini AJ, 1998, EXP EYE RES, V66, P817, DOI 10.1006/exer.1998.0498; Ghalayini AJ, 2002, J BIOL CHEM, V277, P1469, DOI 10.1074/jbc.M011432200; Hamada J, 2004, FEBS LETT, V557, P204, DOI 10.1016/S0014-5793(03)01493-5; Hardie RC, 2003, CURR BIOL, V13, pR775, DOI 10.1016/j.cub.2003.09.021; HOLLYFIELD JG, 1979, INVEST OPHTH VIS SCI, V18, P117; Hong DH, 2003, INVEST OPHTH VIS SCI, V44, P2413, DOI 10.1167/iovs.02-1206; Jaissle GB, 2001, INVEST OPHTH VIS SCI, V42, P506; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; Kasahara T, 2002, J NEUROSCI, V22, P7321; Lee SJ, 2003, NEURON, V39, P121, DOI 10.1016/S0896-6273(03)00390-8; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; Lev S, 1999, MOL CELL BIOL, V19, P2278; Li F, 2003, INVEST OPHTH VIS SCI, V44, P4968, DOI 10.1167/iovs.03-0140; Li GY, 2007, J NEUROSCI, V27, P203, DOI 10.1523/JNEUROSCI.0445-06.2007; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; *NIH, 1985, GUID CAR US LAB AN; Nouaille S, 2006, EMBO REP, V7, P512, DOI 10.1038/sj.embor.7400668; Nouaille S, 2006, BIOCHEM PHARMACOL, V72, P1355, DOI 10.1016/j.bcp.2006.07.018; ORGANISCIAK DT, 1991, EXP EYE RES, V53, P773, DOI 10.1016/0014-4835(91)90113-S; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; Peng YW, 1997, P NATL ACAD SCI USA, V94, P1995, DOI 10.1073/pnas.94.5.1995; PENN JS, 1987, EXP EYE RES, V44, P779, DOI 10.1016/S0014-4835(87)80041-6; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; RAJALA RV, 2006, INVEST OPHTH VIS SCI, V47, P52; Rajala RVS, 2005, BIOCHEMISTRY-US, V44, P15461, DOI 10.1021/bi0513148; Rajala RVS, 2005, BIOCHEMISTRY-US, V44, P7929, DOI 10.1021/bi0500271; Rajala RVS, 2004, BIOCHEMISTRY-US, V43, P5637, DOI 10.1021/bi035913v; Rajala RVS, 2003, MOL NEUROBIOL, V28, P123, DOI 10.1385/MN:28:2:123; Rajala RVS, 2002, J BIOL CHEM, V277, P43319, DOI 10.1074/jbc.M206355200; Rajala RVS, 2001, INVEST OPHTH VIS SCI, V42, P3110; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Reiter CEN, 2006, DIABETES, V55, P1148, DOI 10.2337/diabetes.55.04.06.db05-0744; Reiter CEN, 2003, AM J PHYSIOL-ENDOC M, V285, pE763, DOI 10.1152/ajpendo.00507.2002; Reiter CEN, 2003, PROG RETIN EYE RES, V22, P545, DOI 10.1016/S1350-9462(03)00035-1; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schubert M, 2004, P NATL ACAD SCI USA, V101, P3100, DOI 10.1073/pnas.0308724101; SMITH HG, 1982, METHOD ENZYMOL, V81, P57; Sokolov M, 2004, J BIOL CHEM, V279, P19149, DOI 10.1074/jbc.M311058200; Sokolov M, 2002, NEURON, V34, P95, DOI 10.1016/S0896-6273(02)00636-0; Song JB, 2003, SCIENCE, V300, P502, DOI 10.1126/science.1081203; Spear N, 1997, J NEUROCHEM, V69, P53; Steen E, 2005, J ALZHEIMERS DIS, V7, P63, DOI 10.3233/jad-2005-7107; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Strissel KJ, 2005, J BIOL CHEM, V280, P29250, DOI 10.1074/jbc.M501789200; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Woodruff ML, 2002, J PHYSIOL-LONDON, V542, P843, DOI 10.1113/jphysiol.2001.013987; Yi XJ, 2005, J NEUROSCI, V25, P1240, DOI 10.1523/JNEUROSCI.3664-04.2005; Yu XR, 2004, J BIOL CHEM, V279, P13086, DOI 10.1074/jbc.M313283200; Zheng LX, 2006, INVEST OPHTH VIS SCI, V47, P5583, DOI 10.1167/iovs.06-0163; ZIMMERMAN WF, 1982, METHOD ENZYMOL, V81, P52	78	37	38	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9865	9873		10.1074/jbc.M608845200	http://dx.doi.org/10.1074/jbc.M608845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272282	hybrid			2022-12-25	WOS:000245421700061
J	Yueh, MF; Tukey, RH				Yueh, Mei-Fei; Tukey, Robert H.			Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NRF2; ANTIOXIDANT RESPONSE ELEMENT; ARYL-HYDROCARBON RECEPTOR; GLUTAMATE-CYSTEINE LIGASE; OXIDATIVE STRESS; X-RECEPTOR; UDP-GLUCURONOSYLTRANSFERASES; HEPATIC EXPRESSION; NUCLEAR RECEPTOR; AH RECEPTOR	The formation of beta-D-glucopyranosides (glucuronides) by the UDP-glucuronosyltransferases (UGTs) is a significant metabolic pathway that facilitates the elimination of small hydrophobic molecules such as drugs, dietary constituents, steroids, and bile acids. We elucidate here that an anti-oxidative response leads to induction of UGT1A1 through the Nrf2-Keap1 pathway. When human HepG2 cells were treated with the prooxidants tent-butylhydroquinone and beta-naphthoflavone, cellular UGT1A1 glucuronidation activities were increased. The induction of UGT1A1 proceeded following the overexpression of Nrf2 and was blocked following overexpression of Keap1, demonstrating that Keap1 suppresses Nrf2 activation of the UGT1A1 gene. Loss of function analysis for Nrf2 conducted by small interfering RNA revealed that induction of UGT1A1 was not seen in Nrf2 knock-out cells. To examine the contribution of oxidants toward the regulation of human UGT1A1 in vivo, transgenic mice bearing the human UGT1 locus (Tg-UGT1) were treated with tert-butylhydroquinone. Human UGT1A1 was markedly increased in small and large intestines as well as in liver. Gene mapping experiments including transfections of UGT1A1 reporter gene constructs into HepG2 cells coupled with functional analysis of Nrf2 expression and binding to antioxidant-response elements (ARE) resulted in identification of an ARE in the phenobarbital-response enhancer module region of the UGT1A1 gene. The ARE flanks the recently identified Ah receptor xenobiotic-responsive element. The results suggest that Nrf2-Keap1-dependent UGT1A1 induction by prooxidants might represent a key adaptive response to cellular oxidative stress that defends against a variety of environmental insults, including electrophile attacks and chemical carcinogenesis.	Univ Calif San Diego, Lab Environm Toxicol, Dept Biochem & Chem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Tukey, RH (corresponding author), Univ Calif San Diego, Lab Environm Toxicol, Dept Biochem & Chem, Leichtag Biomed Res Bldg,9500 Gilman Dr, La Jolla, CA 92093 USA.	rtukey@ucsd.edu			NIEHS NIH HHS [ES10337] Funding Source: Medline; NIGMS NIH HHS [GM49135] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049135] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS NH, 1993, CHEM-BIOL INTERACT, V86, P255, DOI 10.1016/0009-2797(93)90101-4; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Auyeung DJ, 2003, MOL PHARMACOL, V63, P119, DOI 10.1124/mol.63.1.119; BANSAL SK, 1980, ANAL BIOCHEM, V109, P321, DOI 10.1016/0003-2697(80)90655-7; Barbier O, 2003, J BIOL CHEM, V278, P32852, DOI 10.1074/jbc.M305361200; Barbier O, 2003, J BIOL CHEM, V278, P13975, DOI 10.1074/jbc.M300749200; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chen SJ, 2005, J BIOL CHEM, V280, P37547, DOI 10.1074/jbc.M506683200; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Frank C, 2003, J BIOL CHEM, V278, P43299, DOI 10.1074/jbc.M305186200; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gregory PA, 2004, TOXICOL APPL PHARM, V199, P354, DOI 10.1016/j.taap.2004.01.008; Holtzclaw WD, 2004, ADV ENZYME REGUL, V44, P335, DOI 10.1016/j.advenzreg.2003.11.013; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jain AK, 2006, J BIOL CHEM, V281, P12132, DOI 10.1074/jbc.M511198200; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kwak MK, 2001, MUTAT RES-FUND MOL M, V480, P305, DOI 10.1016/S0027-5107(01)00190-7; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Ma Q, 2004, BIOCHEM J, V377, P205, DOI 10.1042/BJ20031123; Mackenzie PI, 2005, PHARMACOGENET GENOM, V15, P677, DOI 10.1097/01.fpc.0000173483.13689.56; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Nioi P, 2003, BIOCHEM J, V374, P337, DOI 10.1042/BJ20030754; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; Ritter JK, 1999, HEPATOLOGY, V30, P476, DOI 10.1002/hep.510300205; Strassburg CP, 1997, MOL PHARMACOL, V52, P212, DOI 10.1124/mol.52.2.212; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Sugatani J, 2005, MOL PHARMACOL, V67, P845, DOI 10.1124/mol.104.007161; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Verreault M, 2006, HEPATOLOGY, V44, P368, DOI 10.1002/hep.21259; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Xu CJ, 2006, MOL CANCER THER, V5, P1918, DOI 10.1158/1535-7163.MCT-05-0497; Yang HP, 2002, J BIOL CHEM, V277, P35232, DOI 10.1074/jbc.M203812200; Yang HP, 2001, BIOCHEM J, V357, P447, DOI 10.1042/0264-6021:3570447; Yueh MF, 2005, METHOD ENZYMOL, V400, P75, DOI 10.1016/S0076-6879(05)00005-4; Yueh MF, 2003, J BIOL CHEM, V278, P15001, DOI 10.1074/jbc.M300645200	42	112	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8749	8758		10.1074/jbc.M610790200	http://dx.doi.org/10.1074/jbc.M610790200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17259171	hybrid			2022-12-25	WOS:000245780300021
J	Nielsen, JS; Graves, ML; Chelliah, S; Vogl, AW; Roskelley, CD; McNagny, KM				Nielsen, Julie S.; Graves, Marcia L.; Chelliah, Shierley; Vogl, A. Wayne; Roskelley, Calvin D.; McNagny, Kelly M.			The CD34-Related Molecule Podocalyxin Is a Potent Inducer of Microvillus Formation	PLOS ONE			English	Article								Background. Podocalyxin is a CD34-related transmembrane protein involved in hematopoietic cell homing, kidney morphogenesis, breast cancer progression, and epithelial cell polarization. Although this sialomucin has been shown to block cell adhesion, the mechanisms involved remain enigmatic. It has, however, been postulated that the adaptor proteins NHERF-1 and 2 could regulate apical targeting of Podocalyxin by linking it to the actin cytoskeleton. Principal Findings. Here, in contrast, we find that full-length Podocalyxin acts to recruit NHERF-1 to the apical domain. Moreover, we show that ectopic expression of Podocalyxin in epithelial cells leads to microvillus formation along an expanded apical domain that extends laterally to the junctional complexes. Removal of the C-terminal PDZ-binding domain of Podocalyxin abolishes NHERF-1 recruitment but, surprisingly, has no effect on the formation of microvilli. Instead, we find that the extracellular domain and transmembrane region of Podocalyxin are sufficient to direct recruitment of filamentous actin and ezrin to the plasma membrane and induce microvillus formation. Conclusions/Significance. Our data suggest that this single molecule can modulate NHERF localization and, independently, act as a key orchestrator of apical cell morphology, thereby lending mechanistic insights into its multiple roles as a polarity regulator, tumor progression marker, and anti-adhesin.	[Nielsen, Julie S.; Chelliah, Shierley; McNagny, Kelly M.] Univ British Columbia, Biomed Res Ctr, Vancouver, BC, Canada; [Graves, Marcia L.; Vogl, A. Wayne; Roskelley, Calvin D.] Univ British Columbia, Dept Cellular & Physiol Sci, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia	McNagny, KM (corresponding author), Univ British Columbia, Biomed Res Ctr, Vancouver, BC, Canada.	Kelly@brc.ubc.ca	Roskelley, Calvin D/F-4630-2011; McNagny, Kelly/P-5239-2014	McNagny, Kelly/0000-0003-4737-3499	NSERC Canada Graduate Scholarship; UBC Graduate Fellowship; MSFHR; CIHR [MT-15477]; CBCRA [15322]	NSERC Canada Graduate Scholarship(Natural Sciences and Engineering Research Council of Canada (NSERC)); UBC Graduate Fellowship; MSFHR(Michael Smith Foundation for Health Research); CIHR(Canadian Institutes of Health Research (CIHR)); CBCRA	JSN is a recipient of an NSERC Canada Graduate Scholarship; MLG is a recipient of a UBC Graduate Fellowship; KMM is an MSFHR scholar. This work was funded by CIHR grant #MT-15477 and CBCRA grant #15322.	Alexander WS, 2006, P NATL ACAD SCI USA, V103, P16442, DOI 10.1073/pnas.0607872103; ANDREWS PM, 1979, KIDNEY INT, V15, P376, DOI 10.1038/ki.1979.49; Berndt C, 2004, CELL BIOL INT, V28, P829, DOI 10.1016/j.cellbi.2004.08.003; Cleton-Jansen AM, 2002, BREAST CANCER RES, V4, P5, DOI 10.1186/bcr416; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; D'Alterio C, 2005, J CELL BIOL, V171, P549, DOI 10.1083/jcb.200507072; DEKAN G, 1990, AM J PATHOL, V137, P913; DEKAN G, 1991, P NATL ACAD SCI USA, V88, P5398, DOI 10.1073/pnas.88.12.5398; Doyonnas R, 2005, BLOOD, V105, P4170, DOI 10.1182/blood-2004-10-4077; Doyonnas R, 2001, J EXP MED, V194, P13, DOI 10.1084/jem.194.1.13; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; Gelberg H, 1996, LAB INVEST, V74, P907; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; KERJASCHKI D, 1984, J CELL BIOL, V98, P1591, DOI 10.1083/jcb.98.4.1591; Kershaw DB, 1997, J BIOL CHEM, V272, P15708, DOI 10.1074/jbc.272.25.15708; Li Y, 2002, AM J PHYSIOL-RENAL, V282, pF1129, DOI 10.1152/ajprenal.00131.2001; Loomis PA, 2003, J CELL BIOL, V163, P1045, DOI 10.1083/jcb.200309093; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; MCNAGNY KM, 1992, LEUKEMIA, V6, P975; McNagny KM, 1997, J CELL BIOL, V138, P1395, DOI 10.1083/jcb.138.6.1395; Meder D, 2005, J CELL BIOL, V168, P303, DOI 10.1083/jcb.200407072; Miettinen A, 1999, AM J PATHOL, V154, P813, DOI 10.1016/S0002-9440(10)65328-X; Morales FC, 2004, P NATL ACAD SCI USA, V101, P17705, DOI 10.1073/pnas.0407974101; Orlando RA, 2001, J AM SOC NEPHROL, V12, P1589, DOI 10.1681/ASN.V1281589; Revenu C, 2004, NAT REV MOL CELL BIO, V5, P635, DOI 10.1038/nrm1437; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; SAWADA H, 1986, AM J PATHOL, V125, P309; Schmieder S, 2004, J AM SOC NEPHROL, V15, P2289, DOI 10.1097/01.ASN.0000135968.49899.E8; SCHNABEL E, 1989, EUR J CELL BIOL, V48, P313; Scholl FG, 1999, J CELL SCI, V112, P4601; SEILER MW, 1977, LAB INVEST, V36, P48; SEILER MW, 1975, SCIENCE, V189, P390, DOI 10.1126/science.1145209; Serrador JM, 2002, J BIOL CHEM, V277, P10400, DOI 10.1074/jbc.M110694200; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Somasiri A, 2004, CANCER RES, V64, P5068, DOI 10.1158/0008-5472.CAN-04-0240; Takeda T, 2000, MOL BIOL CELL, V11, P3219, DOI 10.1091/mbc.11.9.3219; Takeda T, 2001, J CLIN INVEST, V108, P289, DOI 10.1172/JCI12539; Tan PC, 2006, STEM CELLS, V24, P1150, DOI 10.1634/stemcells.2005-0426; Vitureira N, 2005, GENE EXPR PATTERNS, V5, P349, DOI 10.1016/j.modgep.2004.10.002; Weinman EJ, 2001, J CLIN INVEST, V108, P185, DOI 10.1172/JCI13518; WEINMAN EJ, 2005, ANN REV PHYSL; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	44	62	70	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e237	10.1371/journal.pone.0000237	http://dx.doi.org/10.1371/journal.pone.0000237			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311105	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444500018
J	Tenaillon, O; Silander, OK; Uzan, JP; Chao, L				Tenaillon, Olivier; Silander, Olin K.; Uzan, Jean-Philippe; Chao, Lin			Quantifying Organismal Complexity using a Population Genetic Approach	PLOS ONE			English	Article							EVOLUTION; FITNESS; ADAPTATION; EPISTASIS; SIZE; REPLICATION; MUTATIONS; MELTDOWN; CHANCE; TESTS	Background. Various definitions of biological complexity have been proposed: the number of genes, cell types, or metabolic processes within an organism. As knowledge of biological systems has increased, it has become apparent that these metrics are often incongruent. Methodology. Here we propose an alternative complexity metric based on the number of genetically uncorrelated phenotypic traits contributing to an organism's fitness. This metric, phenotypic complexity, is more objective than previous suggestions, as complexity is measured from a fundamental biological perspective, that of natural selection. We utilize a model linking the equilibrium fitness (drift load) of a population to phenotypic complexity. We then use results from viral evolution experiments to compare the phenotypic complexities of two viruses, the bacteriophage X174 and vesicular stomatitis virus, and to illustrate the consistency of our approach and its applicability. Conclusions/Significance. Because Darwinian evolution through natural selection is the fundamental element unifying all biological organisms, we propose that our metric of complexity is potentially a more relevant metric than others, based on the count of artificially defined set of objects.	[Tenaillon, Olivier] Univ Denis Diderot Paris VII, Fac Med Xavier Bichat, INSERM, U722, Paris, France; [Tenaillon, Olivier; Silander, Olin K.; Chao, Lin] Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; [Silander, Olin K.] ETH, ETH Zentrum NW, Zurich, Switzerland; [Uzan, Jean-Philippe] Univ Paris 06, CNRS, Inst Astrophys Paris, UMR 7095, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Diego; Swiss Federal Institutes of Technology Domain; ETH Zurich; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Sorbonne Universite	Tenaillon, O (corresponding author), Univ Denis Diderot Paris VII, Fac Med Xavier Bichat, INSERM, U722, Paris, France.	Olivier.Tenaillon@bichat.inserm.fr	Tenaillon, Olivier/L-9857-2017	Silander, Olin/0000-0003-4105-8316; Tenaillon, Olivier/0000-0002-3796-1601	Agence Nationale de la Recherche [ANR-05-JCJC0136-01]; NIH	Agence Nationale de la Recherche(French National Research Agency (ANR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	OT was funded by the Agence Nationale de la Recherche (ANR-05-JCJC0136-01). OS was partially funded by an NIH training grant. LC was funded by an NIH grant.	Adami C, 2000, P NATL ACAD SCI USA, V97, P4463, DOI 10.1073/pnas.97.9.4463; Bonhoeffer S, 2004, SCIENCE, V306, P1547, DOI 10.1126/science.1101786; Bose S, 2003, J GEN VIROL, V84, P1687, DOI 10.1099/vir.0.19074-0; Bull JJ, 1997, GENETICS, V147, P1497; Burch CL, 2004, GENETICS, V167, P559, DOI 10.1534/genetics.103.021196; Burch CL, 1999, GENETICS, V151, P921; Carroll SB, 2001, NATURE, V409, P1102, DOI 10.1038/35059227; Elena SF, 1997, NATURE, V390, P395, DOI 10.1038/37108; Estes S, 2004, GENETICS, V166, P1269, DOI 10.1534/genetics.166.3.1269; Fisher R.A., 1930, GENETICAL THEORY NAT; Fong SS, 2005, GENOME RES, V15, P1365, DOI 10.1101/gr.3832305; Fong SS, 2004, NAT GENET, V36, P1056, DOI 10.1038/ng1432; Hartl DL, 1998, GENETICA, V102-3, P525, DOI 10.1023/A:1017071901530; Martin G, 2006, EVOLUTION, V60, P893; McShea DW, 1996, EVOLUTION, V50, P477, DOI 10.1111/j.1558-5646.1996.tb03861.x; NOVELLA IS, 1995, J VIROL, V69, P2869, DOI 10.1128/JVI.69.5.2869-2872.1995; Orr HA, 2000, EVOLUTION, V54, P13, DOI 10.1111/j.0014-3820.2000.tb00002.x; Pearson H, 2006, NATURE, V441, P398, DOI 10.1038/441398a; Poon A, 2000, EVOLUTION, V54, P1467, DOI 10.1111/j.0014-3820.2000.tb00693.x; Reynolds MG, 2000, GENETICS, V156, P1471; Sanjuan R, 2004, P NATL ACAD SCI USA, V101, P15376, DOI 10.1073/pnas.0404125101; Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178; Sella G, 2005, P NATL ACAD SCI USA, V102, P9541, DOI 10.1073/pnas.0501865102; SHLOMAI J, 1981, J BIOL CHEM, V256, P5233; SILANDER OK, 2007, PLOS BIOL IN PRESS; Szathmary E, 2001, SCIENCE, V292, P1315, DOI 10.1126/science.1060852; TRAVISANO M, 1995, SCIENCE, V267, P87, DOI 10.1126/science.7809610; Wagner GP, 1996, EVOLUTION, V50, P967, DOI 10.1111/j.1558-5646.1996.tb02339.x; WAGNER GP, 1990, EVOLUTION, V44, P715, DOI 10.1111/j.1558-5646.1990.tb05950.x; Welch JJ, 2003, EVOLUTION, V57, P1723, DOI 10.1554/02-673; Whitlock MC, 2003, ANN ZOOL FENN, V40, P169; Woods R, 2006, P NATL ACAD SCI USA, V103, P9107, DOI 10.1073/pnas.0602917103	33	49	50	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e217	10.1371/journal.pone.0000217	http://dx.doi.org/10.1371/journal.pone.0000217			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299597	Green Published, gold			2022-12-25	WOS:000207444400018
J	Meary, D; Kitromilides, E; Mazens, K; Graff, C; Gentaz, E				Meary, David; Kitromilides, Elenitsa; Mazens, Karine; Graff, Christian; Gentaz, Edouard			Four-Day-Old Human Neonates Look Longer at Non-Biological Motions of a Single Point-of-Light	PLOS ONE			English	Article							INFANT SENSITIVITY; BIOLOGICAL MOTION; PERCEPTION; VELOCITY; REPRESENTATION; SPEED; MODEL	Background. Biological motions, that is, the movements of humans and other vertebrates, are characterized by dynamic regularities that reflect the structure and the control schemes of the musculo-skeletal system. Early studies on the development of the visual perception of biological motion showed that infants after three months of age distinguished between biological and non-biological locomotion. Methodology/Principal Findings. Using single point-light motions that varied with respect to the "two-third-power law" of motion generation and perception, we observed that four-day-old human neonates looked longer at non-biological motions than at biological motions when these were simultaneously presented in a standard preferential looking paradigm. Conclusion/Significance. This result can be interpreted within the "violation of expectation" framework and can indicate that neonates' motion perception-like adults'-is attuned to biological kinematics.	[Meary, David; Kitromilides, Elenitsa; Mazens, Karine; Graff, Christian; Gentaz, Edouard] Univ Pierre Mendes France, CNRS, UMR 5105, Psychol & NeuroCognit Lab, Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite de Savoie	Gentaz, E (corresponding author), Univ Pierre Mendes France, CNRS, UMR 5105, Psychol & NeuroCognit Lab, Grenoble, France.	edouard.gentaz@upmf-grenoble.fr			Fyssen Foundation; Region Rhone-Alpes; CNRS	Fyssen Foundation; Region Rhone-Alpes(Region Auvergne-Rhone-Alpes); CNRS(Centre National de la Recherche Scientifique (CNRS))	The research was supported by Fyssen Foundation, Region Rhone-Alpes and CNRS grants.	BERTENTHAL BI, 1987, J EXP PSYCHOL HUMAN, V13, P577, DOI 10.1037/0096-1523.13.4.577; BERTENTHAL BI, 1984, J EXP CHILD PSYCHOL, V37, P213, DOI 10.1016/0022-0965(84)90001-8; Cashon CH, 2000, INFANCY, V1, P429, DOI 10.1207/S15327078IN0104_4; Dannemiller JL, 2000, J EXP CHILD PSYCHOL, V76, P253, DOI 10.1006/jecp.1999.2551; deSperati C, 1997, J NEUROSCI, V17, P3932; Fadiga L, 2000, INT J PSYCHOPHYSIOL, V35, P165, DOI 10.1016/S0167-8760(99)00051-3; Flanagan JR, 2003, NATURE, V424, P769, DOI 10.1038/nature01861; FOX R, 1982, SCIENCE, V218, P486, DOI 10.1126/science.7123249; Grezes J, 2001, HUM BRAIN MAPP, V12, P1, DOI 10.1002/1097-0193(200101)12:1<1::AID-HBM10>3.0.CO;2-V; HAITH MM, 1966, J EXP CHILD PSYCHOL, V3, P235, DOI 10.1016/0022-0965(66)90067-1; Hespos SJ, 2001, COGNITION, V78, P207, DOI 10.1016/S0010-0277(00)00118-9; JOHANSSON G, 1973, PERCEPT PSYCHOPHYS, V14, P201, DOI 10.3758/BF03212378; JOHANSSON G, 1976, PSYCHOL RES-PSYCH FO, V38, P379, DOI 10.1007/BF00309043; Kim IK, 1999, DEVELOPMENTAL SCI, V2, P339, DOI 10.1111/1467-7687.00080; Pack CC, 2001, NATURE, V409, P1040, DOI 10.1038/35059085; Perrone JA, 2002, VISION RES, V42, P1035, DOI 10.1016/S0042-6989(02)00029-9; Pollick FE, 1997, VISION RES, V37, P347, DOI 10.1016/S0042-6989(96)00116-2; Priebe NJ, 2003, J NEUROSCI, V23, P5650; Reisbeck TE, 1999, VISION RES, V39, P3267, DOI 10.1016/S0042-6989(99)00017-6; SCHWARTZ AB, 1994, SCIENCE, V265, P540, DOI 10.1126/science.8036499; Streri A, 2003, SOMATOSENS MOT RES, V20, P13, DOI 10.1080/0899022031000083799; VIVIANI P, 1989, PERCEPT PSYCHOPHYS, V46, P266, DOI 10.3758/BF03208089; VIVIANI P, 1992, J EXP PSYCHOL HUMAN, V18, P603, DOI 10.1037/0096-1523.18.3.603; Viviani P, 2002, ATTENTION PERFORM, V19, P406; VIVIANI P, 1991, J EXP PSYCHOL HUMAN, V17, P198, DOI 10.1037/0096-1523.17.1.198; VIVIANI P, 1992, TUTORIALS MOTOR BEHA, V2, P229; Wang SH, 2004, COGNITION, V93, P167, DOI 10.1016/j.cognition.2003.09.012; Wickelgren EA, 2001, J EXP PSYCHOL HUMAN, V27, P942, DOI 10.1037//-1523.27.4.942	29	31	31	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2007	2	1							e186	10.1371/journal.pone.0000186	http://dx.doi.org/10.1371/journal.pone.0000186			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DH	17264887	Green Published, gold			2022-12-25	WOS:000207444200010
J	Garzon, R; Pichiorri, F; Palumbo, T; Visentini, M; Aqeilan, R; Cimmino, A; Wang, H; Sun, H; Volinia, S; Alder, H; Calin, GA; Liu, CG; Andreeff, M; Croce, CM				Garzon, R.; Pichiorri, F.; Palumbo, T.; Visentini, M.; Aqeilan, R.; Cimmino, A.; Wang, H.; Sun, H.; Volinia, S.; Alder, H.; Calin, G. A.; Liu, C-G; Andreeff, M.; Croce, C. M.			MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia	ONCOGENE			English	Article						microRNAs; promyelocytic leukemia; NF-kappa B	NF-KAPPA-B; RAR-ALPHA; ACTIVATION; APOPTOSIS; BINDING; CELLS	MicroRNAs (miRNAs) are small non-coding RNAs of 19-25 nucleotides that are involved in the regulation of critical cell processes such as apoptosis, cell proliferation and differentiation. However, little is known about the role of miRNAs in granulopoiesis. Here, we report the expression of miRNAs in acute promyelocytic leukemia patients and cell lines during all-trans-retinoic acid (ATRA) treatment by using a miRNA microarrays platform and quantitative real time-polymerase chain reaction (qRT-PCR). We found upregulation of miR-15a, miR-15b, miR-16-1, let-7a-3, let-7c, let-7d, miR-223, miR-342 and miR-107, whereas miR-181b was downregulated. Among the upregulated miRNAs, miR-107 is predicted to target NFI-A, a gene that has been involved in a regulatory loop involving miR-223 and C/EBPa during granulocytic differentiation. Indeed, we have confirmed that miR-107 targets NF1-A. To get insights about ATRA regulation of miRNAs, we searched for ATRA-modulated transcription factors binding sites in the upstream genomic region of the let-7a-3/let-7b cluster and identified several putative nuclear factor-kappa B (NF-kappa B) consensus elements. The use of reporter gene assays, chromatin immunoprecipitation and site-directed mutagenesis revealed that one proximal NF-kappa B binding site is essential for the transactivation of the let-7a-3/let-7b cluster. Finally, we show that ATRA downregulation of RAS and Bcl2 correlate with the activation of known miRNA regulators of those proteins, let-7a and miR-15a/miR-16-1, respectively.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Catania, Dept Expt & Clin Pharmacol, I-95124 Catania, Italy; Univ Roma La Sapienza, Div Clin Immunol, I-00161 Rome, Italy; Univ Texas, MD Anderson Canc Ctr, Dept Blood & Bone Marrow Transplantat, Sect Mol Hematol & Therapy, Houston, TX 77030 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Catania; Sapienza University Rome; University of Texas System; UTMD Anderson Cancer Center	Croce, CM (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Wiseman Hall,Room 445C,400 12th Ave, Columbus, OH 43210 USA.	Carlo.Croce@osumc.edu	Wang, Huating/C-6719-2014; Young, Richard A/F-6495-2012; Aqeilan, Rami/R-4443-2016; Sun, Hao/J-9964-2013; Calin, George/E-9390-2011; sun, hao/GRS-7732-2022; Volinia, Stefano/AAA-9264-2019; Aqeilan, Rami/AAT-7785-2020; Volinia, Stefano/A-3029-2010; Garzon, Ramiro/E-3104-2011; Sun, Hao/T-5576-2019; VISENTINI, MARCELLA/K-4161-2016	Wang, Huating/0000-0001-5474-2905; Young, Richard A/0000-0001-8855-8647; Aqeilan, Rami/0000-0002-6034-023X; Sun, Hao/0000-0002-5547-9501; Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Sun, Hao/0000-0002-5547-9501; Cimmino, Amelia/0000-0002-0004-9299; VISENTINI, MARCELLA/0000-0002-4053-6091; Calin, George/0000-0001-6704-5615	NCI NIH HHS [P01CA76259, P01CA81534, P01 CA055164, P01CA16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA076259, P01CA081534, P01CA055164] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bowen DT, 2005, BLOOD, V106, P2113, DOI 10.1182/blood-2005-03-0867; BRUEL A, 1995, LEUKEMIA, V9, P1173; Chan IT, 2006, BLOOD, V108, P1708, DOI 10.1182/blood-2006-04-015040; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Dresios J, 2005, P NATL ACAD SCI USA, V102, P1865, DOI 10.1073/pnas.0409764102; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; KURLAND JF, 2001, J BIOCH CHEM, V30, P45380; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Mathieu J, 2005, ONCOGENE, V24, P7145, DOI 10.1038/sj.onc.1208889; Meani N, 2005, ONCOGENE, V24, P3358, DOI 10.1038/sj.onc.1208498; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mori N, 1999, BLOOD, V93, P2360; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; PRIEL IP, 2005, MOL CANC RESER, V3, P585; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000	26	283	319	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2007	26	28					4148	4157		10.1038/sj.onc.1210186	http://dx.doi.org/10.1038/sj.onc.1210186			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17260024				2022-12-25	WOS:000247252700010
J	Briggs, GS; McEwan, PA; Yu, J; Moore, T; Emsley, J; Lloyd, RG				Briggs, Geoffrey S.; McEwan, Paul A.; Yu, Jing; Moore, Timothy; Emsley, Jonas; Lloyd, Robert G.			Ring structure of the Escherichia coli DNA-binding protein RdgC associated with recombination and replication fork repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT GROWTH; RECA; BETA; STRAINS; CLAMP	The DNA-binding protein, RdgC, is associated with recombination and replication fork repair in Escherichia coli and with the virulence- associated, pilin antigenic variation mediated by RecA and other recombination proteins in Neisseria species. We solved the structure of the E. coli protein and refined it to 2.4 angstrom. RdgC crystallizes as a dimer with a head-to-head, tail-to-tail organization forming a ring with a 30 angstrom diameter hole at the center. The protein fold is unique and reminiscent of a horseshoe with twin gates closing the open end. The central hole is lined with positively charged residues and provides a highly plausible DNA binding channel consistent with the nonspecific mode of binding detected in vitro and with the ability of RdgC to modulate RecA function in vivo.	Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England; Univ Nottingham, Ctr Biomol Sci, Sch Pharm, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham	Lloyd, RG (corresponding author), Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England.	bob.lloyd@nottingham.ac.uk	emsley, jonas/A-8509-2016	emsley, jonas/0000-0002-8949-8030; mcewan, paul/0000-0001-6097-1528; Briggs, Geoff/0000-0002-4149-8752; Yu, Jing/0000-0001-8001-8494	MRC [G9806167] Funding Source: UKRI; Medical Research Council [G9806167] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cox MM, 2007, NAT REV MOL CELL BIO, V8, P127, DOI 10.1038/nrm2099; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Drees JC, 2006, J BIOL CHEM, V281, P4708, DOI 10.1074/jbc.M513592200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; EVANS P, 1993, CCP4 DARESBURY STUDY, P114; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Leslie AGW, 1992, JOINT CCP4 ESF EAMCB, V26; Mahdi AA, 2006, GENE DEV, V20, P2135, DOI 10.1101/gad.382306; Mehr IJ, 2000, GENETICS, V154, P523; Moore T, 2004, J BACTERIOL, V186, P870, DOI 10.1128/JB.186.3.870-874.2004; Moore T, 2003, EMBO J, V22, P735, DOI 10.1093/emboj/cdg048; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Ryder L, 1996, GENETICS, V143, P1101; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tessmer I, 2005, J MOL BIOL, V350, P254, DOI 10.1016/j.jmb.2005.04.043; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999	24	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12353	12357		10.1074/jbc.C700023200	http://dx.doi.org/10.1074/jbc.C700023200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17308310	hybrid			2022-12-25	WOS:000245942800002
J	Cowart, LA; Hannun, YA				Cowart, L. Ashley; Hannun, Yusuf A.			Selective substrate supply in the regulation of yeast de novo sphingolipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STRESS RESPONSE; MEMBRANE H+-ATPASE; LONG-CHAIN BASES; SACCHAROMYCES-CEREVISIAE; SERINE PALMITOYLTRANSFERASE; PLASMA-MEMBRANE; INDUCE APOPTOSIS; FREE SPHINGOSINE; PALMITIC ACID; STEARIC-ACID	The heat stress response of Saccharomyces cerevisiae is characterized by transient cell cycle arrest, altered gene expression, degradation of nutrient permeases, trehalose accumulation, and translation initiation of heat shock proteins. Importantly heat stress also induces de novo sphingolipid synthesis upon which many of these subprograms of the heat stress response depend. Despite extensive data addressing the roles for sphingolipids in heat stress, the mechanism( s) by which heat induces sphingolipid synthesis remains unknown. This study was undertaken to determine the events and/or factors required for heat stress-induced sphingolipid synthesis. Data presented indicate that heat does not directly alter the in vitro activity of serine palmitoyltransferase ( SPT), the enzyme responsible for initiating de novo sphingolipid synthesis. Moreover deletion of the small peptide Tsc3p, which is thought to maximize SPT activity, specifically reduced production of C-20 sphingolipid species by over 70% but did not significantly decrease overall sphingoid base production. In contrast, the fatty-acid synthase inhibitor cerulenin nearly completely blocked sphingoid base production after heat, indicating a requirement for endogenous fatty acids for heat-mediated sphingoid base synthesis. Consistent with this, genetic studies show that fatty acid import does not contribute to heat-induced de novo synthesis under normal conditions. Interestingly the absence of medium serine also ameliorated heat-induced sphingoid base production, indicating a requirement for exogenous serine for the response, and consistent with this finding, disruption of synthesis of endogenous serine did not affect heat-induced sphingolipid synthesis. Serine uptake assays indicated that heat increased serine uptake from medium by 100% during the first 10 min of heat stress. Moreover treatments that increase serine uptake in the absence of heat including acute medium acidification and glucose treatment also enhanced de novo sphingoid base synthesis equivalent to that induced by heat stress. These data agree with findings from mammalian systems that availability of substrates is a key determinant of flux through sphingolipid synthesis. Moreover data presented here indicate that SPT activity can be driven by several factors that increase serine uptake in the absence of heat. These findings may provide insights into the many systems in which de novo synthesis is increased in the absence of elevated in vitro SPT activity.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.	hannun@musc.edu			NIGMS NIH HHS [GM63265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albers E, 2003, J BIOL CHEM, V278, P10264, DOI 10.1074/jbc.M211692200; Aouida M, 2005, J BIOL CHEM, V280, P24267, DOI 10.1074/jbc.M503071200; Assimacopoulos-Jeannet F, 2004, INT J OBESITY, V28, pS53, DOI 10.1038/sj.ijo.0802857; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chavez JA, 2003, ARCH BIOCHEM BIOPHYS, V419, P101, DOI 10.1016/j.abb.2003.08.020; Chung N, 2000, J BIOL CHEM, V275, P17229, DOI 10.1074/jbc.C000229200; Chung NJ, 2001, J BIOL CHEM, V276, P35614, DOI 10.1074/jbc.M105653200; Cowart LA, 2006, BIOCHEM J, V393, P733, DOI 10.1042/BJ20050643; Cowart LA, 2003, J BIOL CHEM, V278, P30328, DOI 10.1074/jbc.M300656200; Dickson RC, 2000, METHOD ENZYMOL, V311, P3; Dickson RC, 1997, J BIOL CHEM, V272, P30196, DOI 10.1074/jbc.272.48.30196; Dickson RC, 2006, PROG LIPID RES, V45, P447, DOI 10.1016/j.plipres.2006.03.004; Ferguson-Yankey SR, 2002, YEAST, V19, P573, DOI 10.1002/yea.861; Gable K, 2000, J BIOL CHEM, V275, P7597, DOI 10.1074/jbc.275.11.7597; Gasch Audrey P, 2002, Funct Integr Genomics, V2, P181, DOI 10.1007/s10142-002-0058-2; Goossens A, 2000, MOL CELL BIOL, V20, P7654, DOI 10.1128/MCB.20.20.7654-7661.2000; Grilley MM, 1998, J BIOL CHEM, V273, P11062, DOI 10.1074/jbc.273.18.11062; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hans MA, 2003, BIOTECHNOL BIOENG, V82, P143, DOI 10.1002/bit.10553; Inuzuka M, 2005, J BIOL CHEM, V280, P35776, DOI 10.1074/jbc.M505712200; Jenkins GM, 1997, J BIOL CHEM, V272, P32566, DOI 10.1074/jbc.272.51.32566; Jenkins GM, 2002, J BIOL CHEM, V277, P42572, DOI 10.1074/jbc.M207346200; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; KOTYK A, 1994, J MEMBRANE BIOL, V138, P29; Lecchi S, 2005, BIOCHEMISTRY-US, V44, P16624, DOI 10.1021/bi051555f; Lu ZH, 2003, BIOCHEM BIOPH RES CO, V303, P1002, DOI 10.1016/S0006-291X(03)00449-2; Meier KD, 2006, MOL BIOL CELL, V17, P1164, DOI 10.1091/mbc.E05-11-1039; MERRILL AH, 1988, BIOCHEMISTRY-US, V27, P340, DOI 10.1021/bi00401a051; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; Monaghan E, 2002, YEAST, V19, P659, DOI 10.1002/yea.864; Moskvina E, 1999, MOL MICROBIOL, V32, P1263, DOI 10.1046/j.1365-2958.1999.01438.x; Mu YM, 2001, ENDOCRINOLOGY, V142, P3590, DOI 10.1210/en.142.8.3590; Nagura M, 2004, LIPIDS, V39, P43, DOI 10.1007/s11745-004-1200-z; Obeid LA, 2002, BBA-MOL CELL BIOL L, V1585, P163, DOI 10.1016/S1388-1981(02)00337-2; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2001, DRUG RESIST UPDATE, V4, P368, DOI 10.1054/drup.2001.0225; Perry DK, 2002, BBA-MOL CELL BIOL L, V1585, P146, DOI 10.1016/S1388-1981(02)00335-9; PINTO WJ, 1992, J BACTERIOL, V174, P2575, DOI 10.1128/jb.174.8.2575-2581.1992; PIPER PW, 1993, FEMS MICROBIOL REV, V11, P339, DOI 10.1016/0168-6445(93)90005-T; REICH JG, 1981, ENERGY METABOLISM CE; SAHEKI S, 1985, ANAL BIOCHEM, V148, P277, DOI 10.1016/0003-2697(85)90229-5; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; SCHIRCH L, 1982, ADV ENZYMOL RAMB, V53, P83; Shimabukuro M, 1998, J BIOL CHEM, V273, P32487, DOI 10.1074/jbc.273.49.32487; Sims KJ, 2004, BIOCHEM CELL BIOL, V82, P45, DOI 10.1139/o03-086; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; SOPHIANOPOULOU V, 1995, FEMS MICROBIOL REV, V16, P53, DOI 10.1016/0168-6445(94)00091-C; SYCHROVA H, 1985, FEBS LETT, V183, P21, DOI 10.1016/0014-5793(85)80945-5; VANDERREST ME, 1995, MICROBIOL REV, V59, P304, DOI 10.1128/MMBR.59.2.304-322.1995; VIEGAS CA, 1995, APPL ENVIRON MICROB, V61, P1904, DOI 10.1128/AEM.61.5.1904-1909.1995; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235; Zou ZY, 2003, J BIOL CHEM, V278, P16414, DOI 10.1074/jbc.M210557200	52	60	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12330	12340		10.1074/jbc.M700685200	http://dx.doi.org/10.1074/jbc.M700685200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322298	hybrid			2022-12-25	WOS:000245941900075
J	Loh, E; Choe, J; Loeb, LA				Loh, Ern; Choe, Juno; Loeb, Lawrence A.			Highly tolerated amino acid substitutions increase the fidelity of Escherichia coli DNA polymerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KLENOW FRAGMENT; ACTIVE-SITE; DEOXYRIBONUCLEIC ACID; NUCLEOTIDE SELECTION; REPLICATION FIDELITY; BIOCHEMICAL BASIS; O-HELIX; MUTANTS; MUTATIONS; MECHANISM	Fidelity of DNA synthesis, catalyzed by DNA polymerases, is critical for the maintenance of the integrity of the genome. Mutant polymerases with elevated accuracy ( antimutators) have been observed, but these mainly involve increased exonuclease proofreading or large decreases in polymerase activity. We have determined the tolerance of DNA polymerase for amino acid substitutions in the active site and in different segments of E. coli DNA polymerase I and have determined the effects of these substitutions on the fidelity of DNA synthesis. We established a DNA polymerase I mutant library, with random substitutions throughout the polymerase domain. This random library was first selected for activity. The essentiality of DNA polymerases and their sequence and structural conservation suggests that few amino acid substitutions would be tolerated. However, we report that two-thirds of single base substitutions were tolerated without loss of activity, and plasticity often occurs at evolutionarily conserved regions. We screened 408 members of the active library for alterations in fidelity of DNA synthesis in Escherichia coli expressing the mutant polymerases and carrying a second plasmid containing a beta-lactamase reporter. Mutation frequencies varied from 1/1000- to 1000-fold greater compared with wild type. Mutations that produced an antimutator phenotype were distributed throughout the polymerase domain, with 12% clustered in the M-helix. We confirmed that a single mutation in this segment results in increased base discrimination. Thus, this work identifies the M-helix as a determinant of fidelity and suggests that polymerases can tolerate many substitutions that alter fidelity without incurring major changes in activity.	Univ Washington, Joseph Gottstein Mem Canc Res Lab, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Joseph Gottstein Mem Canc Res Lab, Dept Pathol, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NCI NIH HHS [CA102029] Funding Source: Medline; NIA NIH HHS [AG01751] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Beard WA, 2003, STRUCTURE, V11, P489, DOI 10.1016/S0969-2126(03)00051-0; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Camps M, 2003, P NATL ACAD SCI USA, V100, P9727, DOI 10.1073/pnas.1333928100; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; Ciccarelli FD, 2006, SCIENCE, V311, P1283, DOI 10.1126/science.1123061; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DONLIN MJ, 1994, BIOCHEMISTRY-US, V33, P14908, DOI 10.1021/bi00253a030; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; EGER BT, 1991, BIOCHEMISTRY-US, V30, P1441, DOI 10.1021/bi00219a039; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; FIJALKOWSKA IJ, 1993, GENETICS, V134, P1023; GILLIN FD, 1976, J BIOL CHEM, V251, P5225; Glick E, 2002, BIOTECHNIQUES, V33, P1136, DOI 10.2144/02335dd08; Goldsby RE, 2001, NAT MED, V7, P638, DOI 10.1038/88963; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guo HH, 2004, P NATL ACAD SCI USA, V101, P9205, DOI 10.1073/pnas.0403255101; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Johnson SJ, 2003, P NATL ACAD SCI USA, V100, P3895, DOI 10.1073/pnas.0630532100; Joyce CM, 2004, BIOCHEMISTRY-US, V43, P14317, DOI 10.1021/bi048422z; Kim TW, 2005, P NATL ACAD SCI USA, V102, P15803, DOI 10.1073/pnas.0505113102; KORNBERG A, 1956, BIOCHIM BIOPHYS ACTA, V21, P197, DOI 10.1016/0006-3002(56)90127-5; Kornberg A., 1992, DNA REPLICATION; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Loh E, 2005, DNA REPAIR, V4, P1390, DOI 10.1016/j.dnarep.2005.09.006; Marini F, 2003, J BIOL CHEM, V278, P32014, DOI 10.1074/jbc.M305646200; MARKIEWICZ P, 1994, J MOL BIOL, V240, P421, DOI 10.1006/jmbi.1994.1458; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Miller JH, 1999, J BACTERIOL, V181, P1576, DOI 10.1128/JB.181.5.1576-1584.1999; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MUZYCZKA N, 1972, J BIOL CHEM, V247, P7116; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; Patel PH, 2001, J BIOL CHEM, V276, P5044, DOI 10.1074/jbc.M008701200; PETRUSKA J, 1986, P NATL ACAD SCI USA, V83, P1559, DOI 10.1073/pnas.83.6.1559; Plosky BS, 2004, CURR OPIN GENET DEV, V14, P113, DOI 10.1016/j.gde.2004.02.002; Rattray AJ, 2003, ANNU REV GENET, V37, P31, DOI 10.1146/annurev.genet.37.042203.132748; REHAKRANTZ LJ, 1977, J MOL BIOL, V116, P99, DOI 10.1016/0022-2836(77)90121-8; Sharief FS, 1999, GENOMICS, V59, P90, DOI 10.1006/geno.1999.5843; Shinkai A, 2001, J BIOL CHEM, V276, P46759, DOI 10.1074/jbc.M104780200; Shinkai A, 2001, J BIOL CHEM, V276, P18836, DOI 10.1074/jbc.M011472200; Singh K, 2003, J BIOL CHEM, V278, P11289, DOI 10.1074/jbc.M211496200; Summerer D, 2005, ANGEW CHEM INT EDIT, V44, P4712, DOI 10.1002/anie.200500047; Suzuki M, 2000, J BIOL CHEM, V275, P32728, DOI 10.1074/jbc.M000097200; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Turner RM, 2003, BIOCHEMISTRY-US, V42, P2373, DOI 10.1021/bi026566c; WITKIN EM, 1992, J BACTERIOL, V174, P4166, DOI 10.1128/jb.174.12.4166-4168.1992; Yoshikuni Y, 2006, NATURE, V440, P1078, DOI 10.1038/nature04607; Zheng WJ, 2005, STRUCTURE, V13, P565, DOI 10.1016/j.str.2005.01.017	60	37	66	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12201	12209		10.1074/jbc.M611294200	http://dx.doi.org/10.1074/jbc.M611294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17301051	hybrid			2022-12-25	WOS:000245941900063
J	Oktay, Y; Dioum, E; Matsuzaki, S; Ding, K; Yan, LJ; Haller, RG; Szweda, LI; Garcia, JA				Oktay, Yavuz; Dioum, Elhadji; Matsuzaki, Satoshi; Ding, Kan; Yan, Liang-Jun; Haller, Ronald G.; Szweda, Luke I.; Garcia, Joseph A.			Hypoxia-inducible factor 2 alpha regulates expression of the mitochondrial aconitase chaperone protein frataxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; ALPHA-KETOGLUTARATE DEHYDROGENASE; REDOX-DEPENDENT MODULATION; HYPOXIA-INDUCIBLE FACTOR; OXIDATIVE DAMAGE; HYDROGEN-PEROXIDE; MAMMALIAN-CELLS; TUMOR-CELLS; MUTANT MICE; IRON	Mice lacking Epas1, encoding the transcription factor Hypoxia-inducible Factor 2 alpha (HIF-2 alpha), exhibit an apparent mitochondrial disease state. Similarities between knock-outs of Epas1 and of Sod2, encoding the mitochondrial antioxidant enzyme manganese superoxide dismutase, led to the identification of Sod2 as a HIF-2 alpha target gene. However, Sod2 levels in Epas1(-/-) liver are intermediate between that of Sod(-/-) and Sod2(-/-) mice, which have subtle or severe phenotypes, respectively. This suggests that additional HIF-2 alpha target genes besides Sod2 contribute to the Epas1(-/-) mitochondrial disease state. To define the nature of the mitochondrial defect in Epas1(-/-) liver, we performed biophysical, biochemical, and molecular studies. In the setting of decreased Sod2 levels and increased oxidative stress, we found reduced respiration, sensitized mitochondrial permeability transition pore opening, intact electron transport chain activities, and impaired mitochondrial aconitase activity. Mitochondrial aconitase protein levels were preserved, whereas mRNA and protein levels for frataxin, the oxidative stress-regulated mitochondrial aconitase chaperone protein, were markedly reduced in Epas1(-/-) livers. The mouse Fxn promoter was preferentially activated by HIF-2 alpha through a consensus HIF-responsive enhancer element. In summary, the studies reveal that Fxn, like Sod2, is a nuclear-encoded, mitochondrial-localized HIF-2 alpha target gene required for optimal mitochondrial homeostasis. These findings expand upon the previously defined role of HIF-2 alpha in the cellular response to oxidative stress and identify a novel link of HIF-2 alpha with mitochondrial homeostasis.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Inst Exercise & Environm Med, Dallas, TX 75231 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Arlington; Oklahoma Medical Research Foundation	Garcia, JA (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joseph.garcia@utsouthwestern.edu	Oktay, Yavuz/G-4794-2015	Oktay, Yavuz/0000-0002-0158-2693; Garcia, Joseph/0000-0002-5621-7538; , Kan/0000-0003-3485-8200; Yan, Liang-Jun/0000-0002-5815-5430	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067154] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL067154] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200; Armstrong JS, 2004, BIOESSAYS, V26, P894, DOI 10.1002/bies.20071; AZZI A, 1975, BIOCHEM BIOPH RES CO, V65, P597, DOI 10.1016/S0006-291X(75)80188-4; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Boveris A, 2002, METHOD ENZYMOL, V349, P280, DOI 10.1016/S0076-6879(02)49342-1; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bulteau AL, 2005, P NATL ACAD SCI USA, V102, P5987, DOI 10.1073/pnas.0501519102; Bulteau AL, 2004, SCIENCE, V305, P242, DOI 10.1126/science.1098991; Bulteau AL, 2003, BIOCHEMISTRY-US, V42, P14846, DOI 10.1021/bi0353979; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; FISCHER JC, 1985, CLIN CHIM ACTA, V153, P23, DOI 10.1016/0009-8981(85)90135-4; Fiske CH, 1925, J BIOL CHEM, V66, P375; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; Gong YQ, 2005, AM J PHYSIOL-CELL PH, V288, pC1023, DOI 10.1152/ajpcell.00443.2004; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Greene E, 2005, GENOMICS, V85, P221, DOI 10.1016/j.ygeno.2004.10.013; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Humphries KM, 1998, BIOCHEMISTRY-US, V37, P15835, DOI 10.1021/bi981512h; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098; KREBS HA, 1952, BIOCHEM J, V52, P527, DOI 10.1042/bj0520527; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LEE CP, 1995, BBA-MOL BASIS DIS, V1271, P21, DOI 10.1016/0925-4439(95)00005-O; LEE CP, 1968, EUR J BIOCHEM, V3, P385, DOI 10.1111/j.1432-1033.1967.tb19541.x; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Matecki S, 2002, AM J RESP CELL MOL, V26, P239, DOI 10.1165/ajrcmb.26.2.4581; Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Munnich A, 1996, EUR J PEDIATR, V155, P262; Nulton-Persson AC, 2003, BIOCHEMISTRY-US, V42, P4235, DOI 10.1021/bi027370f; Nulton-Persson AC, 2001, J BIOL CHEM, V276, P23357, DOI 10.1074/jbc.M100320200; O'Neill HA, 2005, BIOCHEMISTRY-US, V44, P537, DOI 10.1021/bi048459j; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; RACKER E, 1950, BIOCHIM BIOPHYS ACTA, V4, P211, DOI 10.1016/0006-3002(50)90026-6; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sadek HA, 2004, BIOCHEMISTRY-US, V43, P8494, DOI 10.1021/bi049803f; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Schroedl C, 2002, AM J PHYSIOL-LUNG C, V283, pL922, DOI 10.1152/ajplung.00014.2002; Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266; SRERE PA, 1969, METHOD ENZYMOL, V13, P245; Stehling O, 2004, HUM MOL GENET, V13, P3007, DOI 10.1093/hmg/ddh324; Sturm B, 2005, J BIOL CHEM, V280, P6701, DOI 10.1074/jbc.M408717200; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; TAYLOR RW, 1997, ORGANELLE DIS, P341; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Wharton DC., 1967, METHOD ENZYMOL, P245; Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510; Yan LJ, 2002, EMBO J, V21, P5164, DOI 10.1093/emboj/cdf528	57	67	67	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11750	11756		10.1074/jbc.M611133200	http://dx.doi.org/10.1074/jbc.M611133200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17322295	hybrid			2022-12-25	WOS:000245941900017
J	Tsytsykova, AV; Falvo, JV; Schmidt-Supprian, M; Courtois, G; Thanos, D; Goldfeld, AE				Tsytsykova, Alla V.; Falvo, James V.; Schmidt-Supprian, Marc; Courtois, Gilles; Thanos, Dimitris; Goldfeld, Anne E.			Post-induction, stimulus-specific regulation of tumor necrosis factor mRNA expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NF-KAPPA-B; FACTOR-ALPHA GENE; BRUTONS TYROSINE KINASE; HUMAN MONOCYTIC CELLS; CREB-BINDING-PROTEIN; TOLL-LIKE RECEPTORS; ACTIVATED T-CELLS; IFN-BETA-GENE; TRANSCRIPTION FACTOR; DNA-BINDING	The tumor necrosis factor ( TNF) gene is activated by multiple extracellular signals in a stimulus- and cell type-specific fashion. Based on the presence of kappa B-like DNA motifs in the region upstream of the TNF gene, some have proposed a direct role for NF-kappa B in lipopolysaccharide ( LPS)-induced TNF gene transcription in cells of the monocyte/macrophage lineage. However, we have previously demonstrated a general and critical role for a minimal TNF promoter region bearing only one of the kappa B-like motifs, kappa 3, which is bound by nuclear factor of activated T cell proteins in lymphocytes and fibroblasts in response to multiple stimuli and Ets proteins in LPS-stimulated macrophages. Here, in an effort to resolve these contrasting findings, we used a combination of site-directed mutagenesis of the TNF promoter, quantitative DNase I footprinting, and analysis of endogenous TNF mRNA production in response to multiple stimuli under conditions that inhibit NF-kappa B activation ( using the proteasome inhibitor lactacystin and using cells lacking either functional NF-kappa B essential modulator, which is the I kappa B kinase regulatory subunit, or the Nemo gene itself). We find that TNF mRNA production in response to ionophore is NF-kappa B-independent, but inhibition of NF-kappa B activation attenuates virus- and LPS-induced TNF mRNA levels after initial induction. We conclude that induction of TNF gene transcription by virus or LPS does not depend upon NF-kappa B binding to the proximal promoter; rather, a stimulus- specific post-induction mechanism involving NF-kappa B, yet to be characterized, is involved in the maintenance of maximal TNF mRNA levels.	CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Hop St Louis, INSERM, F-75015 Paris, France; Biomed Sci Res Ctr Alexander Fleming, Inst Mol Biol & Genet, Athens, Greece; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Alexander Fleming Biomedical Sciences Research Center; Columbia University	Goldfeld, AE (corresponding author), CBR Inst Biomed Res, 800 Huntington Ave, Boston, MA 02115 USA.	goldfeld@cbrinstitute.org	Schmidt-Supprian, Marc/F-5893-2011; Goldfeld, Anne/AAF-1818-2019; Thanos, Dimitris/AAE-5720-2019	Schmidt-Supprian, Marc/0000-0002-8543-6166; COURTOIS, Gilles/0000-0003-3117-9595	NIGMS NIH HHS [GM076685] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076685] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADERKA D, 1986, J IMMUNOL, V136, P2938; Aggarwal B.B., 1995, HUMAN CYTOKINES THEI; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Andreakos E, 2004, BLOOD, V103, P2229, DOI 10.1182/blood-2003-04-1356; Baer M, 1998, MOL CELL BIOL, V18, P5678, DOI 10.1128/MCB.18.10.5678; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P3274, DOI 10.1073/pnas.0511113103; Barthel R, 2003, MOL CELL BIOL, V23, P526, DOI 10.1128/MCB.23.2.526-533.2003; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Beinke S, 2004, MOL CELL BIOL, V24, P9658, DOI 10.1128/MCB.24.21.9658-9667.2004; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Berkowitz B, 2002, J BIOL CHEM, V277, P24694, DOI 10.1074/jbc.M200006200; BEUTLER B, 1991, J CLIN INVEST, V87, P1336, DOI 10.1172/JCI115137; Bohuslav J, 1998, J CLIN INVEST, V102, P1645, DOI 10.1172/JCI3877; BOUSSIOTIS VA, 1994, P NATL ACAD SCI USA, V91, P7007, DOI 10.1073/pnas.91.15.7007; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Cho JH, 2005, P NATL ACAD SCI USA, V102, P2350, DOI 10.1073/pnas.0409856102; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; de Diego RP, 2006, J ALLERGY CLIN IMMUN, V117, P1462, DOI 10.1016/j.jaci.2006.01.037; Diaz B, 2000, J INTERF CYTOK RES, V20, P741, DOI 10.1089/10799900050116453; Doyle SL, 2005, J BIOL CHEM, V280, P23496, DOI 10.1074/jbc.C500053200; DROUET C, 1991, J IMMUNOL, V147, P1694; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Escalante CR, 2002, STRUCTURE, V10, P383, DOI 10.1016/S0969-2126(02)00723-2; Falvo JV, 2000, P NATL ACAD SCI USA, V97, P3925, DOI 10.1073/pnas.97.8.3925; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; Frankenberger M, 1997, IMMUNOBIOLOGY, V198, P81, DOI 10.1016/S0171-2985(97)80029-0; GEPPERT TD, 1994, MOL MED, V1, P93; GOLDFELD AE, 1992, P NATL ACAD SCI USA, V89, P12198, DOI 10.1073/pnas.89.24.12198; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Horwood NJ, 2006, J IMMUNOL, V176, P3635, DOI 10.4049/jimmunol.176.6.3635; Horwood NJ, 2003, J EXP MED, V197, P1603, DOI 10.1084/jem.20021845; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; Jefferies CA, 2004, IMMUNOL LETT, V92, P15, DOI 10.1016/j.imlet.2003.11.017; Jefferies CA, 2003, J BIOL CHEM, V278, P26258, DOI 10.1074/jbc.M301484200; Kastenbauer S, 1999, INFECT IMMUN, V67, P1553; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kuprash DV, 1999, J IMMUNOL, V162, P4045; KUPRASH DV, 1995, ONCOGENE, V11, P97; Leung JY, 2000, P NATL ACAD SCI USA, V97, P6614, DOI 10.1073/pnas.97.12.6614; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277; Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632; MAINS PE, 1983, SOMAT CELL GENET, V9, P699, DOI 10.1007/BF01539475; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; Mukhopadhyay S, 2002, J IMMUNOL, V168, P2914, DOI 10.4049/jimmunol.168.6.2914; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; O'Donnell PM, 2002, J INTERF CYTOK RES, V22, P539, DOI 10.1089/10799900252982016; OETH P, 1995, BLOOD, V86, P4144, DOI 10.1182/blood.V86.11.4144.bloodjournal86114144; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SHANNON MF, 1990, MOL CELL BIOL, V10, P2950, DOI 10.1128/MCB.10.6.2950; Steer JH, 2000, J BIOL CHEM, V275, P18432, DOI 10.1074/jbc.M906304199; Swantek JL, 1999, J BIOL CHEM, V274, P11667, DOI 10.1074/jbc.274.17.11667; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TREDE NS, 1995, J IMMUNOL, V155, P902; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Tsytsykova AV, 2000, J EXP MED, V192, P581, DOI 10.1084/jem.192.4.581; Tsytsykova AV, 2002, MOL CELL BIOL, V22, P2620, DOI 10.1128/MCB.22.8.2620-2631.2002; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; van der Bruggen T, 1999, INFECT IMMUN, V67, P3824, DOI 10.1128/IAI.67.8.3824-3829.1999; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yie JM, 1999, EMBO J, V18, P3074, DOI 10.1093/emboj/18.11.3074; ZIEGLERHEITBROCK HWL, 1993, J IMMUNOL, V151, P6986	102	27	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11629	11638		10.1074/jbc.M611418200	http://dx.doi.org/10.1074/jbc.M611418200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17303559	hybrid			2022-12-25	WOS:000245941900004
J	Chen, WJ; Lam, SS; Srinath, H; Schiffer, CA; Royer, WE; Lin, K				Chen, Weijun; Lam, Suvana S.; Srinath, Hema; Schiffer, Celia A.; Royer, William E., Jr.; Lin, Kai			Competition between Ski and CREB-binding protein for binding to Smad proteins in transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; CRYSTAL-STRUCTURE; CELL-MEMBRANE; CO-REPRESSOR; RECEPTOR; ONCOPROTEIN; ACTIVATION; PHOSPHORYLATION; DOMAIN; COACTIVATORS	The family of Smad proteins mediates transforming growth factor-beta (TGF-beta) signaling in cell growth and differentiation. Smads repress or activate TGF-beta signaling by interacting with corepressors ( e. g. Ski) or coactivators ( e. g. CREB-binding protein (CBP)), respectively. Specifically, Ski has been shown to interfere with the interaction between Smad3 and CBP. However, it is unclear whether Ski competes with CBP for binding to Smads and whether they can interact with Smad3 at the same binding surface on Smad3. We investigated the interactions among purified constructs of Smad, Ski, and CBP in vitro by size-exclusion chromatography, isothermal titration calorimetry, and mutational studies. Here, we show that Ski-(16 - 192) interacted directly with a homotrimer of receptor-regulated Smad protein ( R-Smad), e. g. Smad2 or Smad3, to form a hexamer; Ski-( 16 - 192) interacted with an R- Smad . Smad4 heterotrimer to form a pentamer. CBP-(1941 - 1992) was also found to interact directly with an R- Smad homotrimer to form a hexamer and with an R- Smad . Smad4 heterotrimer to form a pentamer. Moreover, these domains of Ski and CBP competed with each other for binding to Smad3. Our mutational studies revealed that domains of Ski and CBP interacted with Smad3 at a portion of the binding surface of the Smad anchor for receptor activation. Our results suggest that Ski negatively regulates TGF-beta signaling by replacing CBP in R-Smad complexes. Our working model suggests that Smad protein activity is delicately balanced by Ski and CBP in the TGF-beta pathway.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Chen, WJ (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, 364 Plantat St, Worcester, MA 01605 USA.	Weijun.Chen@umassmed.edu; William.Royer@umassmed.edu	Chen, Wei/GZK-7348-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056080] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 056080, R01 AI056080] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1997, EMBO J, V16, P3912, DOI 10.1093/emboj/16.13.3912; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Inoue Y, 2007, ONCOGENE, V26, P500, DOI 10.1038/sj.onc.1209826; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Miyazono K, 2000, CYTOKINE GROWTH F R, V11, P15, DOI 10.1016/S1359-6101(99)00025-8; Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Qin B, 1999, STRUCTURE, V7, P1493, DOI 10.1016/S0969-2126(00)88340-9; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Warner DR, 2003, CELL SIGNAL, V15, P235, DOI 10.1016/S0898-6568(02)00082-7; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zheng GX, 1997, ONCOGENE, V15, P459, DOI 10.1038/sj.onc.1201205	38	28	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11365	11376		10.1074/jbc.M700186200	http://dx.doi.org/10.1074/jbc.M700186200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17283070	hybrid			2022-12-25	WOS:000245941500059
J	Lee, WL; Cosio, G; Ireton, K; Grinstein, S				Lee, Warren L.; Cosio, Gabriela; Ireton, Keith; Grinstein, Sergio			Role of CrkII in Fc gamma receptor-mediated phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; ADAPTER PROTEINS; APOPTOTIC CELLS; RHO-GTPASES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHATIDYLSERINE RECEPTOR; RAC-GEF; ACTIVATION; MEMBRANE; COMPLEX	Phagocytosis of IgG-opsonized pathogens by Fc gamma receptors requires extensive remodeling of the actin cytoskeleton, a process regulated by the small GTPase Rac. Vav was thought to be the guanine nucleotide exchange factor responsible for the activation of Rac, but recent evidence indicates that Fc gamma receptor-mediated phagocytosis is unaffected in macrophages lacking all three isoforms of Vav. We therefore tested whether another GEF, DOCK180, participates in Fc gamma receptor-initiated phagocytosis. DOCK180 associates with the adaptor protein Crk, which mediates recruitment of the GEF to sites of tyrosine phosphorylation. CrkII and DOCK180 were found to accumulate at the phagocytic cup. Knockdown of Crk or DOCK180 in murine macrophages using small interfering RNA inhibited phagocytosis of IgG-opsonized particles. Moreover, transfection of dominant negative CrkII prevented both recruitment of DOCK180 and the activation of Rac at the phagocytic cup. This is the first report of a role for either Crk or DOCK180 in Fc gamma receptor-mediated phagocytosis. The Crk-DOCK180 complex is involved in the clearance of apoptotic cells, which unlike the ingestion of IgG-opsonized particles, is an anti-inflammatory process. The finding that CrkII-DOCK180 is also responsible, at least in part, for the effects of Fc gamma receptors implies that additional, parallel pathways must account for the associated pro-inflammatory effect.	Hosp Sick Children, Programme Cell Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Interdept Div Crit Care Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Div Respirol, Toronto, ON M5S 1A8, Canada; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; State University System of Florida; University of Central Florida	Grinstein, S (corresponding author), Hosp Sick Children, Programme Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.ca		Lee, Warren/0000-0002-1788-6587				Akakura S, 2005, J CELL PHYSIOL, V204, P344, DOI 10.1002/jcp.20288; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Buday L, 1999, BBA-REV BIOMEMBRANES, V1422, P187, DOI 10.1016/S0304-4157(99)00005-2; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Castellano F, 2000, J CELL SCI, V113, P2955; Cote JF, 2005, NAT CELL BIOL, V7, P797, DOI 10.1038/ncb1280; Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Garcia-Garcia E, 2002, J LEUKOCYTE BIOL, V72, P1092; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Gu HH, 2003, J CELL BIOL, V161, P1151, DOI 10.1083/jcb.200212158; Hall AB, 2006, IMMUNITY, V24, P305, DOI 10.1016/j.immuni.2006.02.005; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Henson PM, 2001, NAT REV MOL CELL BIO, V2, P627, DOI 10.1038/35085094; Hoppe AD, 2004, MOL BIOL CELL, V15, P3509, DOI 10.1091/mbc.E03-11-0847; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; Maderna P, 2003, BBA-MOL BASIS DIS, V1639, P141, DOI 10.1016/j.bbadis.2003.09.004; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; Patel JC, 2002, MOL BIOL CELL, V13, P1215, DOI 10.1091/mbc.02-01-0002; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Scott CC, 2005, J CELL BIOL, V169, P139, DOI 10.1083/jcb.200412162; Sun H, 2005, CELL MICROBIOL, V7, P443, DOI 10.1111/j.1462-5822.2004.00475.x; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Wang XC, 2003, SCIENCE, V302, P1563, DOI 10.1126/science.1087641; YAMAMOTO K, 1984, J EXP MED, V159, P405, DOI 10.1084/jem.159.2.405	37	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11135	11143		10.1074/jbc.M700823200	http://dx.doi.org/10.1074/jbc.M700823200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308335	hybrid			2022-12-25	WOS:000245941500034
J	Lippert, U; Diao, D; Barak, NN; Ferrari, DM				Lippert, Undine; Diao, Daojun; Barak, Naomi N.; Ferrari, David M.			Conserved structural and functional properties of D-domain containing redox-active and -inactive protein disulfide isomerase-related protein chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING SITE; RETICULUM-LUMENAL PROTEIN; QUALITY-CONTROL; B' DOMAIN; ERP29; FAMILY; IDENTIFICATION; LOCALIZATION; MEMBER; WIND	The structure and mode of binding of the endoplasmic reticulum protein disulfide isomerase-related proteins to their substrates is currently a focus of intensive research. We have recently determined the crystal structure of the Drosophila melanogaster protein disulfide isomerase-related protein Wind and have described two essential substrate binding sites within the protein, one within the thioredoxin b-domain and another within the C-terminal D-domain. Although a mammalian ortholog of Wind ( ERp29/28) is known, conflicting interpretations of its structure and putative function have been postulated. Here, we have provided evidence indicating that ERp29 is indeed similar in both structure and function to its Drosophila ortholog. Using a site-directed mutagenesis approach, we have demonstrated that homodimerization of the b-domains is significantly reduced in vitro upon replacement of key residues at the predicted dimerization interface. Investigation of Wind-ERp29 fusion constructs showed that mutants of the D-domain of ERp29 prevent transport of a substrate protein ( Pipe) in a manner consistent with the presence of a discrete, conserved peptide binding site in the D-domain. Finally, we have highlighted the general applicability of these findings by showing that the D-domain of a redox-active disulfide isomerase, from the slime mold Dictyostelium discoideum, can also functionally replace the Wind D-domain in vivo.	Max Planck Res Unit Enzymol Prot Folding, D-06120 Halle, Germany; Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany; Univ Gottingen, Dept Cardiol & Pneumol, D-37075 Gottingen, Germany	Max Planck Society; Max Planck Society; University of Gottingen	Ferrari, DM (corresponding author), Max Planck Res Unit Enzymol Prot Folding, Weinbergweg 22, D-06120 Halle, Germany.	ferrari@enzyme-halle.mpg.de						Barnewitz K, 2004, J BIOL CHEM, V279, P39829, DOI 10.1074/jbc.M406839200; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Darby NJ, 1998, J MOL BIOL, V276, P239, DOI 10.1006/jmbi.1997.1504; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Ferrari DM, 1998, EUR J BIOCHEM, V255, P570, DOI 10.1046/j.1432-1327.1998.2550570.x; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; FERRARI DM, 1999, ISOLATION CHARACTERI; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Hermann VM, 2005, J BIOL CHEM, V280, P13529, DOI 10.1074/jbc.M410889200; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Kleizen B, 2004, CURR OPIN CELL BIOL, V16, P343, DOI 10.1016/j.ceb.2004.06.012; Liepinsh E, 2001, STRUCTURE, V9, P457, DOI 10.1016/S0969-2126(01)00607-4; Ma QJ, 2003, J BIOL CHEM, V278, P44600, DOI 10.1074/jbc.M307966200; Mayer M, 2003, J MOL BIOL, V330, P137, DOI 10.1016/S0022-2836(03)00556-4; Mkrtchiana S, 1998, FEBS LETT, V431, P322, DOI 10.1016/S0014-5793(98)00786-8; Molinari M, 2004, MOL CELL, V13, P125, DOI 10.1016/S1097-2765(03)00494-5; Monnat J, 2000, MOL BIOL CELL, V11, P3469, DOI 10.1091/mbc.11.10.3469; Monnat J, 1997, FEBS LETT, V418, P357, DOI 10.1016/S0014-5793(97)01415-4; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Sargsyan E, 2002, J BIOL CHEM, V277, P17009, DOI 10.1074/jbc.M200539200; Sen J, 2000, DEVELOPMENT, V127, P5541; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; van Anken E, 2005, CRIT REV BIOCHEM MOL, V40, P191, DOI 10.1080/10409230591008161	26	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11213	11220		10.1074/jbc.M604440200	http://dx.doi.org/10.1074/jbc.M604440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17296603	hybrid, Green Published			2022-12-25	WOS:000245941500043
J	Shalak, V; Guigou, L; Kaminska, M; Wautier, MP; Wautier, JL; Mirande, M				Shalak, Vyacheslav; Guigou, Ludovic; Kaminska, Monika; Wautier, Marie-Paule; Wautier, Jean-Luc; Mirande, Marc			Characterization of p43(ARF), a derivative of the p43 component of multiaminoacyl-tRNA synthetase complex released during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-POLYPEPTIDE-II; ENDOTHELIAL-CELLS; MULTISYNTHETASE COMPLEX; CYTOKINE; PROTEIN; TRANSLATION; MECHANISMS; EXPRESSION; PRECURSOR; DOMAIN	In human, nine aminoacyl tRNA synthetases are associated with the three auxiliary proteins, p18, p38, and p43, to form a stable multiprotein complex. The p43 component, which has a potent tRNA binding capacity, is associated to the complex via its N-terminal moiety. This protein is also the precursor of the endothelial monocyte-activating polypeptide II (p43(EMAPII), corresponding to the C-terminal moiety of p43), a cytokine generated during apoptosis. Here we examined the cellular pathway that, starting from the p43 subunit of the complex, leads to this extracellular cytokine. We identified a new intermediate in this pathway, named p43(ARF) for Apoptosis-released Factor. This intermediate is produced in cellulo by proteolytic cleavage of endogenous p43 and is rapidly recovered in the culture medium. This p43 derivative was purified from the medium of human U937 cells subjected to serum starvation. It contains 40 additional N-terminal amino acid residues as compared with the cytokine p43(EMAPII) and may be generated by a member of the matrix metalloproteinase family. Recombinant p43(ARF) is a monomer in solution and binds tRNA with a K-d of similar to 6 nM, 30-fold lower than that of p43. Highly purified p43(ARF) or p43(EMAPII) do not stimulate the expression of E-selectin by human umbilical vein endothelial cells. Our results suggest that the cleavage of p43 and its cellular delocalization, and thus the release of this tRNA binding subunit from the complex, is one of the molecular mechanisms leading to the shut down of protein synthesis in apoptosis.	CNRS, Lab Enzymol & Biochim Struct, F-91190 Gif Sur Yvette, France; Univ Paris 07, Inst Natl Transfus Sanguine, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite	Mirande, M (corresponding author), CNRS, Lab Enzymol & Biochim Struct, 1 Ave Terrasse, F-91190 Gif Sur Yvette, France.	Marc.Mirande@lebs.cnrs-gif.fr	Shalak, Vyacheslav F/D-3707-2015; wautier, marie/ABC-4444-2020; Wautier, Jean-Luc/T-9851-2019	Shalak, Vyacheslav F/0000-0001-6114-6482; WAUTIER, Marie-Paule/0000-0002-9353-5180; WAUTIER, Jean-Luc/0000-0001-6826-2312				Agou F, 1996, J BIOL CHEM, V271, P29295, DOI 10.1074/jbc.271.46.29295; BAFFY G, 1993, J BIOL CHEM, V268, P6511; Barnett G, 2000, CANCER RES, V60, P2850; DELOMENIE C, 1993, EXP CELL RES, V207, P122, DOI 10.1006/excr.1993.1170; Guigou L, 2004, BIOCHEMISTRY-US, V43, P4592, DOI 10.1021/bi036150e; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Kaminska M, 2001, BIOCHEMISTRY-US, V40, P14309, DOI 10.1021/bi015670b; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P25106; KAO J, 1994, J BIOL CHEM, V269, P9774; KERJAN P, 1994, BBA-GEN SUBJECTS, V1199, P293, DOI 10.1016/0304-4165(94)90009-4; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Ko YG, 2001, J BIOL CHEM, V276, P23028, DOI 10.1074/jbc.M101544200; Lee YN, 2004, IMMUNITY, V20, P145, DOI 10.1016/S1074-7613(04)00020-2; Liu J, 2006, EXP CELL RES, V312, P2231, DOI 10.1016/j.yexcr.2006.03.024; MIRANDE M, 2003, AMINOACYL TRNA SYNTH, P298; Morley SJ, 2005, CELL DEATH DIFFER, V12, P571, DOI 10.1038/sj.cdd.4401591; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Norcum MT, 2000, J BIOL CHEM, V275, P17921, DOI 10.1074/jbc.C000266200; Park SG, 2002, J BIOL CHEM, V277, P45243, DOI 10.1074/jbc.M207934200; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; POPENKO VI, 1994, EUR J CELL BIOL, V65, P60; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; Renault L, 2001, EMBO J, V20, P570, DOI 10.1093/emboj/20.3.570; Saelens X, 2005, J CELL BIOL, V168, P545, DOI 10.1083/jcb.200407162; Saelens X, 2001, J BIOL CHEM, V276, P41620, DOI 10.1074/jbc.M103674200; Sampath P, 2004, CELL, V119, P195, DOI 10.1016/j.cell.2004.09.030; Schwarz MA, 1999, J EXP MED, V190, P341, DOI 10.1084/jem.190.3.341; Shalak V, 2001, J BIOL CHEM, V276, P23769, DOI 10.1074/jbc.M100489200; WAUTIER JL, 1981, NEW ENGL J MED, V305, P237, DOI 10.1056/NEJM198107303050501; Wautier MP, 1999, CELL BIOL TOXICOL, V15, P153, DOI 10.1023/A:1007629403123; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403	32	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10935	10943		10.1074/jbc.M611737200	http://dx.doi.org/10.1074/jbc.M611737200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303557	hybrid			2022-12-25	WOS:000245941500013
J	Piao, SF; Kim, S; Kim, JH; Park, JW; Lee, BL; Ha, NC				Piao, Shunfu; Kim, Seulki; Kim, Jung Hyun; Park, Ji Won; Lee, Bok Leul; Ha, Nam-Chul			Crystal structure of the serine protease domain of prophenoloxidase activating factor-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTALLOGRAPHIC ANALYSIS; COLEOPTERAN INSECT; BINDING; PROTEINASE; REFINEMENT; THROMBIN; MODELS; SYSTEM; TOLL	A family of serine proteases ( SPs) mediates the proteolytic cascades of embryonic development and immune response in invertebrates. These proteases, called easter-type SPs, consist of clip and chymotrypsin-like SP domains. The SP domain of easter-type proteases differs from those of typical SPs in its primary structure. Herein, we report the first crystal structure of the SP domain of easter-type proteases, presented as that of prophenoloxidase activating factor ( PPAF)-I in zymogen form. This structure reveals several important structural features including a bound calcium ion, an additional loop with a unique disulfide linkage, a canyon-like deep active site, and an exposed activation loop. We subsequently show the role of the bound calcium and the proteolytic susceptibility of the activation loop, which occurs in a clip domain-independent manner. Based on biochemical study in the presence of heparin, we suggest that PPAF-III, highly homologous to PPAF-I, contains a surface patch that is responsible for enhancing the catalytic activity through interaction with a nonsubstrate region of a target protein. These results provide insights into an activation mechanism of easter-type proteases in proteolytic cascades, in comparison with the well studied blood coagulation enzymes in mammals.	Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea; Pusan Natl Univ, Res Inst Drug Dev, Pusan 609735, South Korea	Pusan National University; Pusan National University	Ha, NC (corresponding author), Pusan Natl Univ, Coll Pharm, Pusan 609735, South Korea.	hnc@pusan.ac.kr						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BODE W, 1983, J MOL BIOL, V164, P237, DOI 10.1016/0022-2836(83)90077-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Jang IH, 2006, DEV CELL, V10, P45, DOI 10.1016/j.devcel.2005.11.013; Jing H, 1999, EMBO J, V18, P804, DOI 10.1093/emboj/18.4.804; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim MS, 2002, J BIOL CHEM, V277, P39999, DOI 10.1074/jbc.M205508200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Kwon TH, 2000, EUR J BIOCHEM, V267, P6188, DOI 10.1046/j.1432-1327.2000.01695.x; Lee SY, 1998, EUR J BIOCHEM, V257, P615, DOI 10.1046/j.1432-1327.1998.2570615.x; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Lu DS, 1999, J MOL BIOL, V292, P361, DOI 10.1006/jmbi.1999.3089; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; O'Brien D., 1993, NATURAL IMMUNE SYSTE, P257; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pechik I, 2006, BIOCHEMISTRY-US, V45, P3588, DOI 10.1021/bi0525369; Pechik I, 2004, P NATL ACAD SCI USA, V101, P2718, DOI 10.1073/pnas.0303440101; Piao S, 2005, EMBO J, V24, P4404, DOI 10.1038/sj.emboj.7600891; Piao S, 2005, BBA-PROTEINS PROTEOM, V1752, P103, DOI 10.1016/j.bbapap.2005.05.008; Piao SF, 2006, ACTA CRYSTALLOGR F, V62, P771, DOI 10.1107/S1744309106025851; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; Rose T, 2003, J BIOL CHEM, V278, P11320, DOI 10.1074/jbc.M211820200; Ross J, 2003, GENE, V304, P117, DOI 10.1016/S0378-1119(02)01187-3; SIPOS T, 1970, BIOCHEMISTRY-US, V9, P2766, DOI 10.1021/bi00816a003; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WANG DC, 1985, J MOL BIOL, V185, P595, DOI 10.1016/0022-2836(85)90074-9	32	25	30	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10783	10791		10.1074/jbc.M611556200	http://dx.doi.org/10.1074/jbc.M611556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287215	hybrid			2022-12-25	WOS:000245941000072
J	Fischer, T; Lu, L; Haigler, HT; Langen, R				Fischer, Torsten; Lu, Lucy; Haigler, Harry T.; Langen, Ralf			Annexin B12 is a sensor of membrane curvature and undergoes major curvature-dependent structural changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY CRYSTALLOGRAPHY; MILDLY ACIDIC PH; CRYSTAL-STRUCTURE; HELICAL HAIRPIN; BAR DOMAIN; PHOSPHATIDYLCHOLINE VESICLES; PHOSPHOLIPID-VESICLES; TRANSMEMBRANE HELIX; V BINDING; CALCIUM	The regulation of membrane curvature plays an important role in many membrane trafficking and fusion events. Recent studies have begun to identify some of the proteins involved in controlling and sensing the curvature of cellular membranes. A mechanistic understanding of these processes is limited, however, as structural information for the membrane-bound forms of these proteins is scarce. Here, we employed a combination of biochemical and biophysical approaches to study the interaction of annexin B12 with membranes of different curvatures. We observed selective and Ca2+-independent binding of annexin B12 to negatively charged vesicles that were either highly curved or that contained lipids with negative intrinsic curvature. This novel curvature-dependent membrane interaction induced major structural rearrangements in the protein and resulted in a backbone fold that was different from that of the well characterized Ca2+-dependent membrane-bound form of annexin B12. Following curvature-dependent membrane interaction, the protein retained a predominantly a-helical structure but EPR spectroscopy studies of nitroxide side chains placed at selected sites on annexin B12 showed that the protein underwent inside-out refolding that brought previously buried hydrophobic residues into contact with the membrane. These structural changes were reminiscent of those previously observed following Ca2+- independent interaction of annexins with membranes at mildly acidic pH, yet they occurred at neutral pH in the presence of curved membranes. The present data demonstrate that annexin B12 is a sensor of membrane curvature and that membrane curvature can trigger large scale conformational changes. We speculate that membrane curvature could be a physiological signal that induces the previously reported Ca2+-independent membrane interaction of annexins in vivo.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90033 USA	University of California System; University of California Irvine; University of Southern California	Haigler, HT (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.	hhaigler@uci.edu; langen@usc.edu	Haigler, Harry/C-3788-2011		NIGMS NIH HHS [GM 55651, GM 63915] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063915, R01GM055651] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Antonny B, 1997, J BIOL CHEM, V272, P30848, DOI 10.1074/jbc.272.49.30848; Avila-Sakar AJ, 1998, BBA-PROTEIN STRUCT M, V1387, P103, DOI 10.1016/S0167-4838(98)00111-3; Babiychuk EB, 2000, J CELL BIOL, V150, P1113, DOI 10.1083/jcb.150.5.1113; Bigay J, 2005, EMBO J, V24, P2244, DOI 10.1038/sj.emboj.7600714; Bigay J, 2003, NATURE, V426, P563, DOI 10.1038/nature02108; Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; Crowley JJ, 2005, MOL PHARMACOL, V68, P4, DOI 10.1124/mol.105.012971; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020; Gallop JL, 2006, EMBO J, V25, P2898, DOI 10.1038/sj.emboj.7601174; Gennis R. B., 1989, BIOMEMBRANES MOL STR, DOI [10.1007/978-1-4757-2065-5, DOI 10.1007/978-1-4757-2065-5]; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; Golczak Marcin, 2001, FASEB Journal, V15, P1083; GREENHUT SF, 1986, J BIOL CHEM, V261, P3670; Hegde BG, 2006, BIOCHEMISTRY-US, V45, P934, DOI 10.1021/bi052143+; Hofmann A, 2000, J BIOL CHEM, V275, P8072, DOI 10.1074/jbc.275.11.8072; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; Huang H, 2001, BIOCHEMISTRY-US, V40, P4169, DOI 10.1021/bi002346s; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Isas JM, 2005, BIOCHEMISTRY-US, V44, P16435, DOI 10.1021/bi051751m; Isas JM, 2004, J BIOL CHEM, V279, P32492, DOI 10.1074/jbc.M402568200; Isas JM, 2003, J BIOL CHEM, V278, P30227, DOI 10.1074/jbc.M301228200; Isas JM, 2000, BIOCHEMISTRY-US, V39, P3015, DOI 10.1021/bi9922401; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Jost M, 1997, J CELL SCI, V110, P221; Kim YE, 2005, J BIOL CHEM, V280, P32398, DOI 10.1074/jbc.M505017200; Kohler G, 1997, BIOCHEMISTRY-US, V36, P8189, DOI 10.1021/bi9703960; Ladokhin AS, 2005, BIOCHEMISTRY-US, V44, P3402, DOI 10.1021/bi047805u; Ladokhin AS, 2002, BIOCHEMISTRY-US, V41, P13617, DOI 10.1021/bi0264418; Lambert O, 2004, J BIOL CHEM, V279, P10872, DOI 10.1074/jbc.M313657200; Langen R, 1998, J BIOL CHEM, V273, P22453, DOI 10.1074/jbc.273.35.22453; Langen R, 1998, P NATL ACAD SCI USA, V95, P14060, DOI 10.1073/pnas.95.24.14060; Lecat S, 2000, J CELL SCI, V113, P2607; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; MACHIDA K, 1980, BIOCHIM BIOPHYS ACTA, V596, P201, DOI 10.1016/0005-2736(80)90355-7; Masuda M, 2006, EMBO J, V25, P2889, DOI 10.1038/sj.emboj.7601176; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; McMahon HT, 2005, NATURE, V438, P590, DOI 10.1038/nature04396; MEERS P, 1994, BIOCHEMISTRY-US, V33, P5829, DOI 10.1021/bi00185a022; MEERS P, 1993, BIOCHEMISTRY-US, V32, P5411, DOI 10.1021/bi00071a016; MEERS P, 1993, BIOCHEMISTRY-US, V32, P11711, DOI 10.1021/bi00094a030; Mukhopadhyay P, 2004, BIOPHYS J, V86, P1601, DOI 10.1016/S0006-3495(04)74227-7; Oling F, 2000, J MOL BIOL, V304, P561, DOI 10.1006/jmbi.2000.4183; Patel DR, 2001, BIOCHEMISTRY-US, V40, P7054, DOI 10.1021/bi010345+; Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586; REEVES JP, 1969, J CELL PHYSIOL, V73, P49, DOI 10.1002/jcp.1040730108; Rescher U, 2004, J CELL SCI, V117, P2631, DOI 10.1242/jcs.01245; Rety S, 2005, J MOL BIOL, V345, P1131, DOI 10.1016/j.jmb.2004.11.015; Rosengarth A, 1998, FEBS LETT, V438, P279, DOI 10.1016/S0014-5793(98)01318-0; Seaton B. A., 1996, ANNEXINS MOL STRUCTU; Sopkova J, 1998, BIOCHEMISTRY-US, V37, P11962, DOI 10.1021/bi980773o; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Turpin E, 1998, BBA-MOL CELL RES, V1402, P115, DOI 10.1016/S0167-4889(97)00151-1; van den Brink-van der Laan E, 2001, BIOCHEMISTRY-US, V40, P9677, DOI 10.1021/bi002903a; VOGES D, 1994, J MOL BIOL, V238, P199, DOI 10.1006/jmbi.1994.1281; Weissenhorn W, 2005, J MOL BIOL, V351, P653, DOI 10.1016/j.jmb.2005.06.013; WENG XW, 1993, PROTEIN SCI, V2, P448; Zanotti G, 1998, BIOCHEM J, V329, P101, DOI 10.1042/bj3290101	64	19	20	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9996	10004		10.1074/jbc.M611180200	http://dx.doi.org/10.1074/jbc.M611180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17267400	hybrid			2022-12-25	WOS:000245421700074
J	Macleod, ET; Darby, AC; Maudlin, I; Welburn, SC				Macleod, Ewan Thomas; Darby, Alistair Charles; Maudlin, Ian; Welburn, Sue Christina			Factors Affecting Trypanosome Maturation in Tsetse Flies	PLOS ONE			English	Article								Trypanosoma brucei brucei infections which establish successfully in the tsetse fly midgut may subsequently mature into mammalian infective trypanosomes in the salivary glands. This maturation is not automatic and the control of these events is complex. Utilising direct in vivo feeding experiments, we report maturation of T. b. brucei infections in tsetse is regulated by antioxidants as well as environmental stimuli. Dissection of the maturation process provides opportunities to develop transmission blocking vaccines for trypanosomiasis. The present work suggests L-cysteine and/or nitric oxide are necessary for the differentiation of trypanosome midgut infections in tsetse.	[Macleod, Ewan Thomas; Darby, Alistair Charles; Maudlin, Ian; Welburn, Sue Christina] Univ Edinburgh, Ctr Infect Dis, Coll Med & Vet Med, Easter Bush Vet Ctr, Roslin, Midlothian, Scotland	University of Edinburgh	Welburn, SC (corresponding author), Univ Edinburgh, Ctr Infect Dis, Coll Med & Vet Med, Easter Bush Vet Ctr, Roslin, Midlothian, Scotland.	sue.welburn@ed.ac.uk	Darby, Alistair/I-6485-2012; macleod, ewan/AAG-1005-2019	Darby, Alistair/0000-0002-3786-6209; macleod, ewan/0000-0002-5517-0619; Welburn, Susan/0000-0002-9903-7086	Wellcome Trust	Wellcome Trust(Wellcome TrustEuropean Commission)	The financial support of the Wellcome Trust is gratefully acknowledged. The funders played no part in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	BASS KE, 1991, MOL BIOCHEM PARASIT, V44, P261, DOI 10.1016/0166-6851(91)90012-U; BURTON V, 1988, MOL CELL BIOL, V8, P3550, DOI 10.1128/MCB.8.8.3550; DALE C, 1995, PARASITOLOGY, V111, P187, DOI 10.1017/S0031182000064933; DENLINGER DL, 1984, COMP BIOCHEM PHYS C, V77, P233, DOI 10.1016/0742-8413(84)90006-9; Dipeolu O O, 1974, Acta Trop, V32, P185; DUSZENKO M, 1992, MOL BIOCHEM PARASIT, V50, P269, DOI 10.1016/0166-6851(92)90224-8; Fairbairn H., 1948, Tropical Diseases Bulletin London, V45, P1; GLAZENBURG EJ, 1984, BIOCHEM PHARMACOL, V33, P625, DOI 10.1016/0006-2952(84)90318-6; Ha EM, 2005, DEV CELL, V8, P125, DOI 10.1016/j.devcel.2004.11.007; Hao ZG, 2003, INSECT BIOCHEM MOLEC, V33, P1155, DOI 10.1016/j.ibmb.2003.07.001; Kumar S, 2003, P NATL ACAD SCI USA, V100, P14139, DOI 10.1073/pnas.2036262100; MACLEOD ET, 2007, PARASITOLOG IN PRESS; MACLEOD ET, 2005, THESIS U EDINBURGH; MAUDLIN I, 1987, TROP MED PARASITOL, V38, P167; MAUDLIN I, 1984, Z PARASITENKD, V70, P11, DOI 10.1007/BF00929570; MAUDLIN I, 1988, TROP MED PARASITOL, V39, P56; MAUDLIN I, 1989, ANN TROP MED PARASIT, V83, P431, DOI 10.1080/00034983.1989.11812368; Milligan PJM, 1995, EXP PARASITOL, V81, P409, DOI 10.1006/expr.1995.1132; MOLOO SK, 1985, ANN TROP MED PARASIT, V79, P223, DOI 10.1080/00034983.1985.11811911; OKOTH JO, 1986, ANN TROP MED PARASIT, V80, P459, DOI 10.1080/00034983.1986.11812048; OTIENO LH, 1983, ACTA TROP, V40, P113; PHELPS RJ, 1969, J APPL ECOL, V6, P323, DOI 10.2307/2401546; Van den Abbeele J, 1999, PARASITOLOGY, V118, P469, DOI 10.1017/S0031182099004217; WELBURN SC, 1987, ANN TROP MED PARASIT, V81, P453, DOI 10.1080/00034983.1987.11812144; Welburn SC, 1997, MED VET ENTOMOL, V11, P286, DOI 10.1111/j.1365-2915.1997.tb00408.x; WELBURN SC, 1989, MED VET ENTOMOL, V3, P141, DOI 10.1111/j.1365-2915.1989.tb00489.x; Welburn SC, 1995, EXP PARASITOL, V81, P404, DOI 10.1006/expr.1995.1131; Whitten MMA, 2001, EXP PARASITOL, V98, P44, DOI 10.1006/expr.2001.4615; Xing RE, 2006, BIOORGAN MED CHEM, V14, P1706, DOI 10.1016/j.bmc.2005.10.018	29	30	31	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e239	10.1371/journal.pone.0000239	http://dx.doi.org/10.1371/journal.pone.0000239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17318257	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444500019
J	Janhunen, P; Kaartokallio, H; Oksanen, I; Lehto, K; Lehto, H				Janhunen, Pekka; Kaartokallio, Hermanni; Oksanen, Ilona; Lehto, Kirsi; Lehto, Harry			Biological Feedbacks as Cause and Demise of Neoproterozoic Icehouse: Astrobiological Prospects for Faster Evolution and Importance of Cold Conditions	PLOS ONE			English	Article							SNOWBALL EARTH; ICE SHELF; CARBON; ECOLOGY; CLIMATE; CYANOBACTERIA; ECOSYSTEMS; INITIATION; METHANE; ORIGIN	Several severe glaciations occurred during the Neoproterozoic eon, and especially near its end in the Cryogenian period (630-850 Ma). While the glacial periods themselves were probably related to the continental positions being appropriate for glaciation, the general coldness of the Neoproterozoic and Cryogenian as a whole lacks specific explanation. The Cryogenian was immediately followed by the Ediacaran biota and Cambrian Metazoan, thus understanding the climate-biosphere interactions around the Cryogenian period is central to understanding the development of complex multicellular life in general. Here we present a feedback mechanism between growth of eukaryotic algal phytoplankton and climate which explains how the Earth system gradually entered the Cryogenian icehouse from the warm Mesoproterozoic greenhouse. The more abrupt termination of the Cryogenian is explained by the increase in gaseous carbon release caused by the more complex planktonic and benthic foodwebs and enhanced by a diversification of metazoan zooplankton and benthic animals. The increased ecosystem complexity caused a decrease in organic carbon burial rate, breaking the algal-climatic feedback loop of the earlier Neoproterozoic eon. Prior to the Neoproterozoic eon, eukaryotic evolution took place in a slow timescale regulated by interior cooling of the Earth and solar brightening. Evolution could have proceeded faster had these geophysical processes been faster. Thus, complex life could theoretically also be found around stars that are more massive than the Sun and have main sequence life shorter than 10 Ga. We also suggest that snow and glaciers are, in a statistical sense, important markers for conditions that may possibly promote the development of complex life on extrasolar planets.	[Janhunen, Pekka] Univ Helsinki, Dept Phys Sci, Helsinki, Finland; [Janhunen, Pekka] Finnish Meteorol Inst, FIN-00101 Helsinki, Finland; [Kaartokallio, Hermanni] Finnish Inst Marine Res, Helsinki, Finland; [Oksanen, Ilona] Univ Helsinki, Dept Appl Chem & Microbiol, Helsinki, Finland; [Oksanen, Ilona] Univ Stockholm, Dept Bot, S-10691 Stockholm, Sweden; [Lehto, Kirsi; Lehto, Harry] Nord Inst Theoret Phys NORDITA, Copenhagen, Denmark; [Lehto, Kirsi] Univ Turku, Dept Biol, SF-20500 Turku, Finland; [Lehto, Harry] Univ Turku, Tuorla Observ, Turku, Finland	University of Helsinki; Finnish Meteorological Institute; University of Helsinki; Stockholm University; Nordic Institute for Theoretical Physics; University of Turku; University of Turku	Janhunen, P (corresponding author), Univ Helsinki, Dept Phys Sci, Helsinki, Finland.	pekka.janhunen@fmi.fi	Kaartokallio, Hermanni/D-1143-2010	Janhunen, Pekka/0000-0001-5650-8039				Bartley JK, 2004, GEOLOGY, V32, P129, DOI 10.1130/G19939.1; Bodiselitsch B, 2005, SCIENCE, V308, P239, DOI 10.1126/science.1104657; Butterfield NJ, 1997, PALEOBIOLOGY, V23, P247, DOI 10.1017/S009483730001681X; Chandler MA, 2000, J GEOPHYS RES-ATMOS, V105, P20737, DOI 10.1029/2000JD900221; Deynoux M., 2004, EARTHS GLACIAL RECOR; Falkowski PG, 1998, SCIENCE, V281, P200, DOI 10.1126/science.281.5374.200; Fedonkin Mikhail A., 2003, Paleontological Research, V7, P9, DOI 10.2517/prpsj.7.9; HAN TM, 1992, SCIENCE, V257, P232, DOI 10.1126/science.1631544; Hayes JM, 1999, CHEM GEOL, V161, P103, DOI 10.1016/S0009-2541(99)00083-2; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Hyde WT, 2000, NATURE, V405, P425, DOI 10.1038/35013005; Kasting JF, 2005, PRECAMBRIAN RES, V137, P119, DOI 10.1016/j.precamres.2005.03.002; Kharecha P, 2005, GEOBIOLOGY, V3, P53, DOI 10.1111/j.1472-4669.2005.00049.x; KNOLL AH, 1994, P NATL ACAD SCI USA, V91, P6743, DOI 10.1073/pnas.91.15.6743; Knoll AH, 1996, NATURE, V382, P111, DOI 10.1038/382111a0; Kopp RE, 2005, P NATL ACAD SCI USA, V102, P11131, DOI 10.1073/pnas.0504878102; Lenton TM, 2002, PHILOS T R SOC B, V357, P683, DOI 10.1098/rstb.2001.1014; Olcott AN, 2005, SCIENCE, V310, P471, DOI 10.1126/science.1115769; Pavlov AA, 2003, GEOLOGY, V31, P87, DOI 10.1130/0091-7613(2003)031<0087:MRPA>2.0.CO;2; Rothman DH, 2003, P NATL ACAD SCI USA, V100, P8124, DOI 10.1073/pnas.0832439100; Schrag DP, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000219; Shaviv NirJ., 2003, GSA TODAY, V137, P4, DOI DOI 10.1130/1052-5173(2003)013; STAL LJ, 1995, NEW PHYTOL, V131, P1, DOI 10.1111/j.1469-8137.1995.tb03051.x; STANLEY SM, 1973, P NATL ACAD SCI USA, V70, P1486, DOI 10.1073/pnas.70.5.1486; Tajika E, 2003, EARTH PLANET SC LETT, V214, P443, DOI 10.1016/S0012-821X(03)00396-0; Tomitani A, 2006, P NATL ACAD SCI USA, V103, P5442, DOI 10.1073/pnas.0600999103; Vincent WF, 2000, NATURWISSENSCHAFTEN, V87, P137, DOI 10.1007/s001140050692; Vincent WF, 2004, CRYOBIOLOGY, V48, P103, DOI 10.1016/j.cryobiol.2004.01.006; WALKER JCG, 1981, J GEOPHYS RES-OCEANS, V86, P9776, DOI 10.1029/JC086iC10p09776; Yoon HS, 2004, MOL BIOL EVOL, V21, P809, DOI 10.1093/molbev/msh075	30	3	3	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e214	10.1371/journal.pone.0000214	http://dx.doi.org/10.1371/journal.pone.0000214			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299594	Green Published, gold, Green Submitted			2022-12-25	WOS:000207444400015
J	Ke, Y; Wu, D; Princen, F; Nguyen, T; Pang, Y; Lesperance, J; Muller, WJ; Oshima, RG; Feng, GS				Ke, Y.; Wu, D.; Princen, F.; Nguyen, T.; Pang, Y.; Lesperance, J.; Muller, W. J.; Oshima, R. G.; Feng, G-S			Role of Gab2 in mammary tumorigenesis and metastasis	ONCOGENE			English	Article						Gab2; mammary tumor; metastasis; signal transduction; cell migration; scaffolding protein	HUMAN BREAST-CANCER; DOCKING PROTEIN GAB2; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; GROWTH-FACTOR; INDUCTION; KINASE; ACTIVATION; EXPRESSION; MIGRATION	Overexpression of the adaptor/scaffolding protein Gab2 has been detected in primary human breast cancer cells and cell lines, although its functional signifi. cance in breast carcinogenesis is not fully understood. Here, we show a requirement for Gab2 in promoting mammary tumor metastasis. Although Gab2 expression levels were elevated in mammary tumors induced by the Neu (ErbB-2) oncogene, homozygous deletion of Gab2 in mice had only a modest effect on the initiation of Neu-induced mammary tumors. Notably, ablation of Gab2 severely suppressed lung metastasis. Gab2-deficient cancer cells displayed normal Akt activities, and their proliferative rate in vitro was similar to control cells. However, Gab2(-/-) cancer cells exhibited decreased migration and impaired Erk activation, and the defects were rescued by re-introduction of Gab2 into Gab2(-/-) cells. These. ndings suggest that although Gab2 overexpression may confer growth advantage to tumor cells, the functional requirement for Gab2 in mammary tumor initiation/growth may be dispensable, and that Gab2 may have a prominent role in promoting mammary tumor metastasis.	Burnham Inst Med Res, Ctr Canc, La Jolla, CA 92037 USA; Royal Victoria Hosp, Mol Oncol Grp, Montreal, PQ, Canada	Sanford Burnham Prebys Medical Discovery Institute; McGill University; Royal Victoria Hospital	Feng, GS (corresponding author), Burnham Inst Med Res, Ctr Canc, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gfeng@burnham.org			NCI NIH HHS [CA78606, CA102583] Funding Source: Medline; NHLBI NIH HHS [HL66208] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA102583, R01CA078606] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abassi YA, 2004, J IMMUNOL METHODS, V292, P195, DOI 10.1016/j.jim.2004.06.022; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Liu Y, 2002, FEBS LETT, V515, P1, DOI 10.1016/S0014-5793(02)02425-0; Meng SS, 2005, BIOCHEM J, V391, P143, DOI 10.1042/BJ20050229; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Slamon D, 2001, SEMIN ONCOL, V28, P13, DOI 10.1053/sonc.2001.22812; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Xing JZ, 2005, CHEM RES TOXICOL, V18, P154, DOI 10.1021/tx049721s; Yamada K, 2001, CYTOGENET CELL GENET, V94, P39, DOI 10.1159/000048780; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Zhang EE, 2004, P NATL ACAD SCI USA, V101, P16064, DOI 10.1073/pnas.0405041101; Zhao MS, 1999, INTERNET J CHEM, V2	24	69	71	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	34					4951	4960		10.1038/sj.onc.1210315	http://dx.doi.org/10.1038/sj.onc.1210315			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310989				2022-12-25	WOS:000248322500007
J	Roche, KC; Rocha, S; Bracken, CP; Perkins, ND				Roche, K. C.; Rocha, S.; Bracken, C. P.; Perkins, N. D.			Regulation of ATR-dependent pathways by the FHA domain containing protein SNIP1	ONCOGENE			English	Article						p53; NF-kappa B; ARF; checkpoint kinases; DNA damage	NF-KAPPA-B; ARF TUMOR-SUPPRESSOR; DNA-DAMAGE; PHOSPHORYLATION EVENTS; CELL-CYCLE; P53; EXPRESSION; BINDING; CHK1; ACTIVATION	The forkhead associated (FHA) domain-containing protein Smad nuclear interacting protein 1 (SNIP1) has multiple cellular functions, including the ability to interact with DNA-binding transcription factors and transcriptional coactivators. Moreover, we have demonstrated previously that SNIP1 regulates cyclin D1 expression and promoter activity. Here, we identify a new function for SNIP1 as a regulator of ATR checkpoint kinase-dependent pathways in human U-2 OS osteosarcoma cells: SNIP1 is required for p53 induction in response to ultraviolet light treatment and selectively regulates the phosphorylation of known ATR target proteins, including p53, Chk1 and the histone variant H2AX. These activities are independent of its ability to regulate cyclin D1 expression. Significantly, SNIP1 is also required for ATR-dependent functions of the human p14(ARF) tumour suppressor, including its ability to modulate the activity of the RelA(p65) NF-kappa B subunit. This, together with its other described functions, suggests that SNIP1 could have an important role during tumorigenesis and cancer therapy.	Univ Dundee, Coll Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland; Univ Galway, Dept Biochem, Genome Stabil Lab, Galway, Ireland	University of Dundee; Ollscoil na Gaillimhe-University of Galway	Perkins, ND (corresponding author), Univ Dundee, Coll Life Sci, Div Gene Regulat & Express, MSI WTB JBC Complex,Dow St, Dundee DD1 5EH, Scotland.	n.d.perkins@dundee.ac.uk		Rocha, Sonia/0000-0002-2413-4981; Bracken, Cameron/0000-0001-7722-625X				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Durocher D, 2002, FEBS LETT, V513, P58, DOI 10.1016/S0014-5793(01)03294-X; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Jowsey PA, 2004, J BIOL CHEM, V279, P55562, DOI 10.1074/jbc.M411021200; Kim RH, 2001, J BIOL CHEM, V276, P46297, DOI 10.1074/jbc.M103819200; Kim RH, 2000, GENE DEV, V14, P1605; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Lin WC, 2001, GENE DEV, V15, P1833; Lowndes NF, 2005, CURR BIOL, V15, pR99, DOI 10.1016/j.cub.2005.01.029; Motoyama N, 2004, CURR OPIN GENET DEV, V14, P11, DOI 10.1016/j.gde.2003.12.003; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Roche KC, 2004, ONCOGENE, V23, P8185, DOI 10.1038/sj.onc.1208025; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Wang Y, 2003, P NATL ACAD SCI USA, V100, P15387, DOI 10.1073/pnas.2536810100	25	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4523	4530		10.1038/sj.onc.1210233	http://dx.doi.org/10.1038/sj.onc.1210233			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17260016				2022-12-25	WOS:000247836100006
J	Partlow, KC; Chen, JJ; Brant, JA; Neubauer, AM; Meyerrose, TE; Creer, MH; Nolta, JA; Caruthers, SD; Lanza, GM; Wickline, SA				Partlow, Kathryn C.; Chen, Junjie; Brant, Jason A.; Neubauer, Anne M.; Meyerrose, Todd E.; Creer, Michael H.; Nolta, Jan A.; Caruthers, Shelton D.; Lanza, Gregory M.; Wickline, Samuel A.			F-19 magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons	FASEB JOURNAL			English	Article						endothelial progenitor cells; nanoparticles; contrast agent	ENDOTHELIAL PROGENITOR CELLS; UMBILICAL-CORD BLOOD; MESENCHYMAL STEM-CELLS; IN-VITRO; NANOPARTICLES; TISSUE; DIFFERENTIATION; IDENTIFICATION; ANGIOGENESIS; DEPENDENCE	MRI has been employed to elucidate the migratory behavior of stem/progenitor cells noninvasively in vivo with traditional proton (H-1) imaging of iron oxide nanoparticle- labeled cells. Alternatively, we demonstrate that fluorine (F-19) MRI of cells labeled with different types of liquid perfluorocarbon ( PFC) nanoparticles produces unique and sensitive cell markers distinct from any tissue background signal. To define the utility for cell tracking, mononuclear cells harvested from human umbilical cord blood were grown under proendothelial conditions and labeled with nanoparticles composed of two distinct PFC cores ( perfluorooctylbromide and perfluoro-15-crown-5 ether). The sensitivity for detecting and imaging labeled cells was defined on 11.7T ( research) and 1.5T ( clinical) scanners. Stem/progenitor cells (CD34(+) CD133(+) CD31(+)) readily internalized PFC nanoparticles without aid of adjunctive labeling techniques, and cells remained functional in vivo. PFC-labeled cells exhibited distinct F-19 signals and were readily detected after both local and intravenous injection. PFC nanoparticles provide an unequivocal and unique signature for stem/progenitor cells, enable spatial cell localization with F-19 MRI, and permit quantification and detection of multiple fluorine signatures via F-19 MR spectroscopy. This method should facilitate longitudinal investigation of cellular events in vivo for multiple cell types simultaneously.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63103 USA; St Louis Univ, Sch Med, Dept Lab Med, St Louis, MO 63103 USA; Philips Med Syst, Andover, MA USA	Washington University (WUSTL); Saint Louis University; Saint Louis University; Philips; Philips Healthcare	Wickline, SA (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8215,660 S Euclid Ave, St Louis, MO 63110 USA.	saw@howdy.wustl.edu	Chen, Junjie/E-8095-2010; CHEN, JUNJIE/HHM-8428-2022	Partlow, Kathryn/0000-0002-3476-2527; Brant, Jason/0000-0002-3492-0679; Nolta, Jan/0000-0003-4576-8542	NCI NIH HHS [CO-37007, U54-CA-119342] Funding Source: Medline; NHLBI NIH HHS [HL-073646, HL-078631] Funding Source: Medline; NIDDK NIH HHS [R01 DK061848, R01 DK053041-08, R01 DK061848-06A1, R01 DK053041] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U54CA119342] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053041, R01DK061848] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahrens ET, 2005, NAT BIOTECHNOL, V23, P983, DOI 10.1038/nbt1121; Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9; Aoki M, 2004, STEM CELLS, V22, P994, DOI 10.1634/stemcells.22-6-994; Arbab AS, 2006, STEM CELLS, V24, P671, DOI 10.1634/stemcells.2005-0017; Arbab Ali Syed, 2004, Mol Imaging, V3, P24, DOI 10.1162/153535004773861697; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bulte JWM, 2004, CURR PHARM BIOTECHNO, V5, P567; Caruthers SD, 2006, INVEST RADIOL, V41, P305, DOI 10.1097/01.rli.0000199281.60135.6a; Coulombel L, 2004, ONCOGENE, V23, P7210, DOI 10.1038/sj.onc.1207941; Cunningham CH, 2005, MAGNET RESON MED, V53, P999, DOI 10.1002/mrm.20477; Daldrup-Link HE, 2005, EUR RADIOL, V15, P4, DOI 10.1007/s00330-004-2526-7; DARDZINSKI BJ, 1994, MAGNET RESON MED, V32, P88, DOI 10.1002/mrm.1910320112; Eggermann J, 2003, CARDIOVASC RES, V58, P478, DOI 10.1016/S0008-6363(03)00252-9; Fan CL, 2003, ACTA PHARMACOL SIN, V24, P212; Frank JA, 2003, RADIOLOGY, V228, P480, DOI 10.1148/radiol.2281020638; Gratama JW, 1998, CYTOMETRY, V34, P128, DOI 10.1002/(SICI)1097-0320(19980615)34:3<128::AID-CYTO3>3.0.CO;2-D; Hill JM, 2003, CIRCULATION, V108, P1009, DOI 10.1161/01.CIR.0000084537.66419.7A; Iwaguro H, 2005, METH MOLEC MED, V112, P239; Kim SW, 2006, STEM CELLS, V24, P1620, DOI 10.1634/stemcells.2005-0365; Kraitchman DL, 2003, CIRCULATION, V107, P2290, DOI 10.1161/01.CIR.0000070931.62772.4E; KRUGLUGER W, 1993, J PERIODONTAL RES, V28, P145, DOI 10.1111/j.1600-0765.1993.tb01062.x; Lanza GM, 1996, CIRCULATION, V94, P3334, DOI 10.1161/01.CIR.94.12.3334; Lanza GM, 2005, CURR TOP DEV BIOL, V70, P57, DOI 10.1016/S0070-2153(05)70003-X; Liu JW, 2006, STEM CELLS, V24, P199, DOI 10.1634/stemcells.2004-0364; Marsh JN, 2002, J ACOUST SOC AM, V112, P2858, DOI 10.1121/1.1517251; Mason RP, 1996, NMR BIOMED, V9, P125, DOI 10.1002/(SICI)1099-1492(199605)9:3<125::AID-NBM405>3.0.CO;2-F; Morawski AM, 2004, MAGN RESON MED, V52, P1255, DOI 10.1002/mrm.20287; Naruse K, 2005, DIABETES, V54, P1823, DOI 10.2337/diabetes.54.6.1823; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Stroh A, 2005, NEUROIMAGE, V24, P635, DOI 10.1016/j.neuroimage.2004.09.014; van den Bos EJ, 2003, CELL TRANSPLANT, V12, P743, DOI 10.3727/000000003108747352; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Walczak P, 2005, MAGN RESON MED, V54, P769, DOI 10.1002/mrm.20701	33	233	256	0	81	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1647	1654		10.1096/fj.06-6505com	http://dx.doi.org/10.1096/fj.06-6505com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17284484				2022-12-25	WOS:000246866500006
J	Herzig, S; Khan, IFY; Grundemann, D; Matthes, J; Ludwig, A; Michels, G; Hoppe, UC; Chaudhuri, D; Schwartz, A; Yue, DT; Hullin, R				Herzig, Stefan; Khan, Ismail F. Y.; Gruendemann, Dirk; Matthes, Jan; Ludwig, Andreas; Michels, Guido; Hoppe, Uta C.; Chaudhuri, Dipayan; Schwartz, Arnold; Yue, David T.; Hullin, Roger			Mechanism of Ca(v)1.2 channel modulation by the amino terminus of cardiac beta(2)-subunits	FASEB JOURNAL			English	Article						cardiac electrophysiology; calcium channel subunit; dihydropyridine	SENSITIVE CALCIUM-CHANNEL; GATED CA2+ CHANNELS; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; HUMAN HEART; SUBCELLULAR-LOCALIZATION; SPLICE VARIANTS; DOMAIN; CLONING; BINDING	L- type calcium channels are composed of a pore, alpha(1c) ( Ca(v)1.2), and accessory beta- and alpha(2)delta-subunits. The beta(2)-subunit core structure was recently resolved at high resolution, providing important information on many functional aspects of channel modulation. In this study we reveal differential novel effects of five beta(2)-subunits isoforms expressed in human heart (beta(2a-e)) on the single L- type calcium channel current. These splice variants differ only by amino- terminal length and amino acid composition. Single- channel modulation by beta(2)-subunit isoforms was investigated in HEK293 cells expressing the recombinant L- type ion conducting pore. All beta(2)- subunits increased open probability, availability, and peak current with a highly consistent rank order (beta(2a) approximate to beta(2b) > beta(2e) approximate to beta(2c) > beta(2d)). We show graded modulation of some transition rates within and between deep- closed and inactivated states. The extent of modulation correlates strongly with the length of amino- terminal domains. Two mutant beta(2)-subunits that imitate the natural span related to length confirm this conclusion. The data show that the length of amino termini is a relevant physiological mechanism for channel closure and inactivation, and that natural alternative splicing exploits this principle for modulation of the gating properties of calcium channels.	Univ Cologne, Dept Pharmacol, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med, Cologne, Germany; Univ Erlangen Nurnberg, Inst Expt & Clin Pharmacol & Toxicol, Erlangen, Germany; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Univ Cincinnati, Inst Mol Pharmacol & Biophys, Cincinnati, OH USA; Univ Hosp, Swiss Heart Ctr Bern, Dept Cardiol, Bern, Switzerland	University of Cologne; University of Cologne; University of Erlangen Nuremberg; Johns Hopkins University; University System of Ohio; University of Cincinnati; University of Bern; University Hospital of Bern	Herzig, S (corresponding author), Univ Cologne, Dept Pharmacol, Gleueler Str 24, D-50931 Cologne, Germany.	stefan.herzig@uni-koeln.de	Matthes, Jan/AAF-1229-2020; Gründemann, Dirk/AAD-2217-2022	Matthes, Jan/0000-0003-2754-1555; Herzig, Stefan/0000-0001-8107-5204; Chaudhuri, Dipayan/0000-0003-0605-7334	NHLBI NIH HHS [R01 HL079599-01, T32 HL07382-30] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079599, T32HL007382] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Birnbaumer L, 1998, J BIOENERG BIOMEMBR, V30, P357, DOI 10.1023/A:1021989622656; CASTELLANO A, 1994, BIOCHEM SOC T, V22, P483, DOI 10.1042/bst0220483; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; Chien AJ, 1998, J BIOL CHEM, V273, P23590, DOI 10.1074/jbc.273.36.23590; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Erhardt JA, 1998, J BIOL CHEM, V273, P35222, DOI 10.1074/jbc.273.52.35222; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; Felix R, 1999, RECEPTOR CHANNEL, V6, P351; Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003; Freise D, 1999, BIOL CHEM, V380, P897, DOI 10.1515/BC.1999.110; Groner F, 2004, BIOCHEM BIOPH RES CO, V314, P878, DOI 10.1016/j.bbrc.2003.12.174; Grundemann D, 1996, BIOTECHNIQUES, V21, P898; Grundemann D, 1997, J BIOL CHEM, V272, P10408; Haase H, 1996, J MOL MED-JMM, V74, P99; Harry JB, 2004, J BIOL CHEM, V279, P46367, DOI 10.1074/jbc.M409523200; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hullin R, 1999, CIRCULATION, V100, P155, DOI 10.1161/01.CIR.100.2.155; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; Ludwig A, 1997, J NEUROSCI, V17, P1339; Michels G, 2002, MOL PHARMACOL, V61, P682, DOI 10.1124/mol.61.3.682; MITTERDORFER J, 1994, FEBS LETT, V352, P141, DOI 10.1016/0014-5793(94)00938-4; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 2002, MOL PHARMACOL, V62, P485, DOI 10.1124/mol.62.3.485; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; Schroder F, 1998, CIRCULATION, V98, P969, DOI 10.1161/01.CIR.98.10.969; SCHULTZ D, 1993, P NATL ACAD SCI USA, V90, P6228, DOI 10.1073/pnas.90.13.6228; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; Splawski I, 2004, CELL, V119, P19, DOI 10.1016/j.cell.2004.09.011; SuhKim H, 1996, MOL PHARMACOL, V50, P1330; Takahashi SX, 2005, J GEN PHYSIOL, V126, P365, DOI 10.1085/jgp.200509354; Takahashi SX, 2003, BIOPHYS J, V84, P3007, DOI 10.1016/S0006-3495(03)70027-7; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Vendel AC, 2006, J NEUROSCI, V26, P2635, DOI 10.1523/JNEUROSCI.0067-06.2006; Walker D, 1998, J BIOL CHEM, V273, P2361, DOI 10.1074/jbc.273.4.2361; Wei S, 2000, CIRC RES, V86, P175, DOI 10.1161/01.RES.86.2.175; Yue DT, 2004, NEURON, V42, P357, DOI 10.1016/S0896-6273(04)00259-4	46	29	29	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1527	1538		10.1096/fj.06-7377com	http://dx.doi.org/10.1096/fj.06-7377com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17289923				2022-12-25	WOS:000246117000027
J	Blundell, CD; Mahoney, DJ; Cordell, MR; Almond, A; Kahmann, JD; Perczel, A; Taylor, JD; Campbell, ID; Day, AJ				Blundell, Charles D.; Mahoney, David J.; Cordell, Martin R.; Almond, Andrew; Kahmann, Jan D.; Perczel, Andras; Taylor, Jonathan D.; Campbell, Iain D.; Day, Anthony J.			Determining the molecular basis for the pH-dependent interaction between the link module of human TSG-6 and hyaluronan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTER-ALPHA-INHIBITOR; FACTOR-STIMULATED GENE-6; EXTRACELLULAR-MATRIX; PROTEIN TSG-6; ESCHERICHIA-COLI; CHROMOSOMAL LOCALIZATION; INDUCED ARTHRITIS; CELL-INTERACTIONS; BINDING-PROTEINS; HEAVY-CHAINS	TSG-6 is an inflammation-associated hyaluronan (HA)-binding protein that has anti-inflammatory and protective functions in arthritis and asthma as well as a critical role in mammalian ovulation. The interaction between TSG-6 and HA is pH-dependent, with a marked reduction in affinity on increasing the pH from 6.0 to 8.0. Here we have investigated the mechanism underlying this pH dependence using a combined approach of site-directed mutagenesis, NMR, isothermal titration calorimetry and microtiter plate assays. Analysis of single-site mutants of the TSG-6 Link module indicated that the loss in affinity above pH 6.0 is mediated by the change in ionization state of a histidine residue (His(4)) that is not within the HA-binding site. To understand this in molecular terms, the pH-dependent folding profile and the pK(a) values of charged residues within the Link module were determined using NMR. These data indicated that His(4) makes a salt bridge to one side-chain oxygen atom of a buried aspartate residue (Asp(89)), whereas the other oxygen is simultaneously hydrogen-bonded to a key HA-binding residue (Tyr(12)). This molecular network transmits the change in ionization state of His(4) to the HA-binding site, which explains the loss of affinity at high pH. In contrast, simulations of the pH affinity curves indicate that another histidine residue, His(45), is largely responsible for the gain in affinity for HA between pH 3.5 and 6.0. The pH-dependent interaction of TSG-6 with HA (and other ligands) provides a means of differentially regulating the functional activity of this protein in different tissue microenvironments.	Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ Oxford, MRC, Immunochem Unit, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Eotvos Lorand Univ, Inst Chem, Prot Modelling Grp, H-1117 Budapest, Hungary; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester; University of Oxford; University of Oxford; Eotvos Lorand University; Hungarian Academy of Sciences; University of Manchester	Day, AJ (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	anthony.day@manchester.ac.uk	Taylor, Jonathan/A-1416-2013; Day, Anthony/O-1658-2015	Taylor, Jonathan/0000-0003-0119-433X; Day, Anthony/0000-0002-1415-3134; Almond, Andrew/0000-0001-7471-6333; Taylor, Jonathan/0000-0002-9797-3989; Blundell, Charles/0000-0002-1439-9126	Wellcome Trust [058154, 063822/Z/01/Z] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; Blundell C. D., 2002, HYALURONAN, P161; Blundell CD, 2005, J BIOL CHEM, V280, P18189, DOI 10.1074/jbc.M414343200; Blundell CD, 2003, J BIOL CHEM, V278, P49261, DOI 10.1074/jbc.M309623200; Blundell CD, 2006, BIOCHEM J, V396, P487, DOI 10.1042/BJ20060085; Blundell CD, 2006, ANAL BIOCHEM, V353, P236, DOI 10.1016/j.ab.2006.03.013; Cao TV, 2004, MICROCIRCULATION, V11, P615, DOI 10.1080/10739680490503438; Carrette O, 2001, BIOL REPROD, V65, P301, DOI 10.1095/biolreprod65.1.301; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Day AJ, 2005, TRENDS IMMUNOL, V26, P637, DOI 10.1016/j.it.2005.09.009; Day AJ, 1998, WENN GR INT, V72, P141; Day AJ, 2001, CURR OPIN STRUC BIOL, V11, P617, DOI 10.1016/S0959-440X(00)00256-6; FENG P, 1993, J BIOL CHEM, V268, P9387; Forteza R, 2007, AM J RESP CELL MOL, V36, P20, DOI 10.1165/rcmb.2006-0018OC; Fulop C, 1997, GENE, V202, P95, DOI 10.1016/S0378-1119(97)00459-9; Fulop C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422; Getting SJ, 2002, J BIOL CHEM, V277, P51068, DOI 10.1074/jbc.M205121200; Glant TT, 2002, ARTHRITIS RHEUM-US, V46, P2207, DOI 10.1002/art.10555; Kahmann JD, 1997, PROTEIN EXPRES PURIF, V9, P315, DOI 10.1006/prep.1996.0694; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Kuznetsova SA, 2005, J BIOL CHEM, V280, P30899, DOI 10.1074/jbc.M500701200; Kuznetsova SA, 2006, J CELL SCI, V119, P4499, DOI 10.1242/jcs.03171; LADBURY JE, 1993, BIOCHEMISTRY-US, V32, P7526, DOI 10.1021/bi00080a026; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; Lesley J, 2004, J BIOL CHEM, V279, P25745, DOI 10.1074/jbc.M313319200; Mahoney DJ, 2005, J BIOL CHEM, V280, P27044, DOI 10.1074/jbc.M502068200; Mahoney DJ, 2001, GLYCOBIOLOGY, V11, P1025, DOI 10.1093/glycob/11.12.1025; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Maroudas A., 1980, JOINTS SYNOVIAL FLUI, P239; Milner CM, 2006, BIOCHEM SOC T, V34, P446, DOI 10.1042/BST0340446; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Mindrescu C, 2002, ARTHRITIS RHEUM, V46, P2453, DOI 10.1002/art.10503; Mukhopadhyay D, 2001, ARCH BIOCHEM BIOPHYS, V394, P173, DOI 10.1006/abbi.2001.2552; Nentwich HA, 2002, J BIOL CHEM, V277, P15354, DOI 10.1074/jbc.M110765200; Ochsner SA, 2003, ENDOCRINOLOGY, V144, P4376, DOI 10.1210/en.2003-0487; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; PELTON JG, 1993, PROTEIN SCI, V2, P543; Pickford AR, 2001, EMBO J, V20, P1519, DOI 10.1093/emboj/20.7.1519; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; Sanggaard KW, 2005, J BIOL CHEM, V280, P11936, DOI 10.1074/jbc.M409016200; SIMKIN PA, 1992, J RHEUMATOL, V19, P1017; Szanto S, 2004, ARTHRITIS RHEUM-US, V50, P3012, DOI 10.1002/art.20655; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Wisniewski HG, 2005, J BIOL CHEM, V280, P14476, DOI 10.1074/jbc.M411734200; WISNIEWSKI HG, 1993, J IMMUNOL, V151, P6593; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200	54	28	33	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12976	12988		10.1074/jbc.M611713200	http://dx.doi.org/10.1074/jbc.M611713200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17307731	hybrid			2022-12-25	WOS:000245942800068
J	Fox, TE; Houck, KL; O'Neill, SM; Nagarajan, M; Stover, TC; Pomianowski, PT; Unal, O; Yun, JK; Naides, SJ; Kester, M				Fox, Todd E.; Houck, Kristy L.; O'Neill, Sean M.; Nagarajan, Murali; Stover, Thomas C.; Pomianowski, Pawel T.; Unal, Onur; Yun, Jong K.; Naides, Stanley J.; Kester, Mark			Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROTUMOR CELL-LINES; SIGNAL-TRANSDUCTION; ARACHIDONIC-ACID; DOMAIN; RAS; INHIBITION; SUPPRESSOR; COMPLEX; BINDING; DIGLYCERIDES	We have previously demonstrated that hexanoyl-D-erythrosphingosine ( C-6-ceramide), an anti-mitogenic cell-permeable lipid metabolite, limited vascular smooth muscle growth by abrogating trauma-induced Akt activity in a stretch injury model of neointimal hyperplasia. Furthermore, ceramide selectively and directly activated protein kinase C zeta ( PKC zeta) to suppress Akt-dependent mitogenesis. To further analyze the interaction between ceramide and PKC zeta, the ability of ceramide to localize within highly structured lipid microdomains ( rafts) and activate PKC zeta was investigated. Using rat aorta vascular smooth muscle cells ( A7r5), we now demonstrate that C-6-ceramide treatment results in an increased localization and phosphorylation of PKC zeta within caveolin-enriched lipid microdomians to inactivate Akt. In addition, ceramide specifically reduced the association of PKC zeta with 14-3-3, a scaffold protein localized to less structured regions within membranes. Pharmacological disruption of highly structured lipid microdomains resulted in abrogation of ceramide-activated, PKC zeta-dependent Akt inactivation, whereas molecular strategies suggest that ceramide-dependent PKC zeta phosphorylation of Akt3 at Ser(34) was necessary for ceramide-induced vascular smooth muscle cell growth arrest. Taken together, these data demonstrate that structured membrane microdomains are necessary for ceramide-induced activation of PKC zeta and resultant diminished Akt activity, leading to vascular smooth muscle cell growth arrest.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol H078, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kester, M (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol H078, Hershey, PA 17033 USA.	mkester@psu.edu	Kester, Mark/ABG-4615-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076789, R01HL066371] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL76789, R01HL66371] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200; BRIDGES D, 2005, SCI STKE, pRE10, DOI DOI 10.1126/STKE.2962005RE10; Bridges D, 2004, SCI STKE, pre10; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Charles R, 2000, CIRC RES, V87, P282, DOI 10.1161/01.RES.87.4.282; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Christian AE, 1997, J LIPID RES, V38, P2264; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Goswami R, 2005, J NEUROSCI RES, V81, P541, DOI 10.1002/jnr.20550; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; Heinrich M, 2000, ADV EXP MED BIOL, V477, P305; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; Huwiler A, 2001, FASEB J, V15, P7; Kaga S, 1998, J IMMUNOL, V160, P4182; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Kilkus J, 2003, J NEUROSCI RES, V72, P65, DOI 10.1002/jnr.10549; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leroy I, 2005, CELL SIGNAL, V17, P1149, DOI 10.1016/j.cellsig.2004.12.013; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Mandal A, 1997, J BIOL CHEM, V272, P20306, DOI 10.1074/jbc.272.32.20306; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Powell DJ, 2003, MOL CELL BIOL, V23, P7794, DOI 10.1128/MCB.23.21.7794-7808.2003; Rosenfeldt HM, 2001, BIOCHEM SOC T, V29, P836, DOI 10.1042/0300-5127:0290836; Ruvolo PP, 2001, J BIOL CHEM, V276, P11754, DOI 10.1074/jbc.M011400200; Sandirasegarane L, 2001, BIOCHEM BIOPH RES CO, V283, P158, DOI 10.1006/bbrc.2001.4739; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stratford S, 2004, J BIOL CHEM, V279, P36608, DOI 10.1074/jbc.M406499200; Tanabe F, 1998, BIOCHEM BIOPH RES CO, V242, P129, DOI 10.1006/bbrc.1997.7934; Wang GH, 2005, J BIOL CHEM, V280, P26415, DOI 10.1074/jbc.M501492200; Wang YM, 1999, J NEUROSCI RES, V55, P293, DOI 10.1002/(SICI)1097-4547(19990201)55:3<293::AID-JNR4>3.3.CO;2-0; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263	39	134	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12450	12457		10.1074/jbc.M700082200	http://dx.doi.org/10.1074/jbc.M700082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17308302	hybrid			2022-12-25	WOS:000245942800013
J	Steiner, T; Lamerz, AC; Hess, P; Breithaupt, C; Krapp, S; Bourenkov, G; Huber, R; Gerardy-Schahn, R; Jacob, U				Steiner, Thomas; Lamerz, Anne-Christin; Hess, Petra; Breithaupt, Constanze; Krapp, Stephan; Bourenkov, Gleb; Huber, Robert; Gerardy-Schahn, Rita; Jacob, Uwe			Open and closed structures of the UDP-glucose pyrophosphorylase from Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; POTATO-TUBER; BIOCHEMICAL-CHARACTERIZATION; PURIFICATION; TRANSLATION; RESIDUES; CLONING; CDNA	Uridine diphosphate-glucose pyrophosphorylase (UGPase) represents a ubiquitous enzyme, which catalyzes the formation of UDP-glucose, a key metabolite of the carbohydrate pathways of all organisms. In the protozoan parasite Leishmania major, which causes a broad spectrum of diseases and is transmitted to humans by sand fly vectors, UGPase represents a virulence factor because of its requirement for the synthesis of cell surface glycoconjugates. Here we present the crystal structures of the L. major UGPase in its uncomplexed apo form (open conformation) and in complex with UDP-glucose (closed conformation). The UGPase consists of three distinct domains. The N-terminal domain exhibits species-specific differences in length, which might permit distinct regulation mechanisms. The central catalytic domain resembles a Rossmann-fold and contains key residues that are conserved in many nucleotidyltransferases. The C-terminal domain forms a left-handed parallel beta-helix (L beta H), which represents a rarely observed structural element. The presented structures together with mutagenesis analyses provide a basis for a detailed analysis of the catalytic mechanism and for the design of species-specific UGPase inhibitors.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Hannover Med Sch, Abt Zellulare Chem, Zentrum Biochem, D-30625 Hannover, Germany; DESY, MPG, ASMB, Grp Prot Dynam, D-22603 Hamburg, Germany; Salzburg Univ, Forschungszentrum Biowissensch & Gesundheit, A-5020 Salzburg, Austria; Cardiff Univ, Sch Biosci & Chem, Cardiff CF10 3TL, Wales	Max Planck Society; Hannover Medical School; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; Salzburg University; Cardiff University	Steiner, T (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18, D-82152 Martinsried, Germany.	steiner@biochem.mpg.de	Bourenkov, Gleb P/C-7794-2017	Bourenkov, Gleb P/0000-0002-2617-5920				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Bonofiglio L, 2005, CURR MICROBIOL, V51, P217, DOI 10.1007/s00284-005-4466-0; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang HY, 1996, EUR J BIOCHEM, V236, P723, DOI 10.1111/j.1432-1033.1996.t01-1-00723.x; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; ELLING L, 1994, J BIOTECHNOL, V34, P157, DOI 10.1016/0168-1656(94)90085-X; FloresDiaz M, 1997, J BIOL CHEM, V272, P23784, DOI 10.1074/jbc.272.38.23784; Geisler M, 2004, PLANT MOL BIOL, V56, P783, DOI 10.1007/s11103-004-4953-x; Genevaux P, 1999, ARCH MICROBIOL, V172, P1, DOI 10.1007/s002030050732; Jin XS, 2005, EMBO J, V24, P694, DOI 10.1038/sj.emboj.7600551; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATSUBE T, 1991, BIOCHEMISTRY-US, V30, P8546, DOI 10.1021/bi00099a008; Krapp S, 2003, J MOL BIOL, V334, P625, DOI 10.1016/j.jmb.2003.09.080; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamerz AC, 2006, J BIOL CHEM, V281, P16314, DOI 10.1074/jbc.M600076200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu GA, 1996, PROTEIN DATA BANK Q, V78, P10; Martz F, 2002, BIOCHEM J, V367, P295, DOI 10.1042/BJ20020772; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Naderer T, 2004, CURR MOL MED, V4, P649, DOI 10.2174/1566524043360069; NAKANO K, 1989, J BIOCHEM-TOKYO, V106, P528, DOI 10.1093/oxfordjournals.jbchem.a122886; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; ORDIN L, 1968, PLANT PHYSIOL, V43, P473, DOI 10.1104/pp.43.3.473; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; PENG HL, 1993, FEBS LETT, V329, P153, DOI 10.1016/0014-5793(93)80213-E; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Roeben A, 2006, J MOL BIOL, V364, P551, DOI 10.1016/j.jmb.2006.08.079; Rutter J, 2002, CELL, V111, P17, DOI 10.1016/S0092-8674(02)00974-1; Sacks DL, 2000, P NATL ACAD SCI USA, V97, P406, DOI 10.1073/pnas.97.1.406; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sivaraman J, 2002, J BIOL CHEM, V277, P44214, DOI 10.1074/jbc.M206932200	36	42	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					13003	13010		10.1074/jbc.M609984200	http://dx.doi.org/10.1074/jbc.M609984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17303565	hybrid			2022-12-25	WOS:000245942800070
J	Lande-Diner, L; Zhang, JM; Ben-Porath, I; Amariglio, N; Keshet, I; Hecht, M; Azuara, V; Fisher, AG; Rechavi, G; Cedar, H				Lande-Diner, Laura; Zhang, Jianmin; Ben-Porath, Ittai; Amariglio, Ninette; Keshet, Ilana; Hecht, Merav; Azuara, Veronique; Fisher, Amanda G.; Rechavi, Gideon; Cedar, Howard			Role of DNA methylation in stable gene repression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-STRUCTURE; DEVELOPMENTAL PATTERN; TRANSCRIPTION; DEMETHYLATION; INHIBITION; OCT-3/4	A large fraction of the animal genome is maintained in a transcriptionally repressed state throughout development. By generating viable Dnmt1(-/-) mouse cells we have been able to study the effect of DNA methylation on both gene expression and chromatin structure. Our results confirm that the underlying methylation pattern has a profound effect on histone acetylation and is the major effector of me-H3(K4) in the animal genome. We demonstrate that many methylated genes are subject to additional repression mechanisms that also impact on histone acetylation, and the data suggest that late replication timing may play an important role in this process.	Hebrew Univ Jerusalem, Sch Med, Dept Cellular Biochem & Human Genet, IL-91120 Jerusalem, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Ctr Canc Res, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Safra Childrens Hosp, IL-69978 Tel Aviv, Israel; Hammersmith Hosp, Lymphocytes Dev Grp, MRC,Sch Med, Clin Sci Ctr,Imperial Coll, London W12 0NN, England	Hebrew University of Jerusalem; Chaim Sheba Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Imperial College London	Cedar, H (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Cellular Biochem & Human Genet, IL-91120 Jerusalem, Israel.	cedar@md.huji.ac.il		Azuara, Veronique/0000-0003-4608-3713	MRC [MC_U120027516] Funding Source: UKRI; Medical Research Council [MC_U120027516] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Azuara V, 2003, NAT CELL BIOL, V5, P668, DOI 10.1038/ncb1006; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; De Smet C, 1999, MOL CELL BIOL, V19, P7327; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; Feldman N, 2006, NAT CELL BIOL, V8, P188, DOI 10.1038/ncb1353; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gidekel S, 2002, J BIOL CHEM, V277, P34521, DOI 10.1074/jbc.M203338200; Goren A, 2003, NAT REV MOL CELL BIO, V4, P25, DOI 10.1038/nrm1008; Gribnau J, 2003, GENE DEV, V17, P759, DOI 10.1101/gad.1059603; GRUENBAUM Y, 1981, FEBS LETT, V124, P67, DOI 10.1016/0014-5793(81)80055-5; Hashimshony T, 2003, NAT GENET, V34, P187, DOI 10.1038/ng1158; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Hiratani I, 2004, P NATL ACAD SCI USA, V101, P16861, DOI 10.1073/pnas.0406687101; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Lande-Diner L, 2004, COLD SPRING HARB SYM, V69, P131, DOI 10.1101/sqb.2004.69.131; LANDEDINER L, 2005, NAT REV GENET, V6, P648; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Perry P, 2004, CELL CYCLE, V3, P1645; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; REYNAUD C, 1992, CANCER LETT, V61, P255, DOI 10.1016/0304-3835(92)90296-8; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Walsh CP, 1998, NAT GENET, V20, P116, DOI 10.1038/2413; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Zhang JM, 2002, NATURE, V420, P198, DOI 10.1038/nature01150	40	110	117	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12194	12200		10.1074/jbc.M607838200	http://dx.doi.org/10.1074/jbc.M607838200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17311920	hybrid			2022-12-25	WOS:000245941900062
J	Rickman, C; Medine, CN; Bergmann, A; Duncan, RR				Rickman, Colin; Medine, Claire N.; Bergmann, Axel; Duncan, Rory R.			Functionally and spatially distinct modes of munc18-syntaxin 1 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE FUSION; SNARE COMPLEX-FORMATION; REGULATED EXOCYTOSIS; CRYSTAL-STRUCTURE; MEMBRANE-FUSION; VPS45P BINDS; PC12 CELLS; SYNTAXIN; PROTEIN; MUNC18	Eukaryotic membrane trafficking is a conserved process under tight temporal and spatial regulation in which the fusion of membranes is driven by the formation of the ternary SNARE complex. Syntaxin 1a, a core component of the exocytic SNARE complex in neurons and neuroendocrine cells, is regulated directly by munc18-1, its cognate Sec1p/munc18 ( SM) protein. SM proteins show remarkable structural conservation throughout evolution, indicating a common binding mechanism and function. However, SM proteins possess disparate binding mechanisms and regulatory effects with munc18-1, the major brain isoform, classed as atypical in both its binding specificity and its mode. We now show that munc18-1 interacts with syntaxin 1a through two mechanistically distinct modes of binding, both in vitro and in living cells, in contrast to current models. Furthermore, these functionally divergent interactions occur at distinct cellular locations. These findings provide a molecular explanation for the multiple, spatially distinct roles of munc18-1.	Univ Edinburgh, Ctr Integrat Physiol, Edinburgh EH8 9XD, Midlothian, Scotland; Becker & Hickl GmbH, D-12277 Berlin, Germany	University of Edinburgh; Becker & Hickl	Duncan, RR (corresponding author), Univ Edinburgh, Ctr Integrat Physiol, George Sq, Edinburgh EH8 9XD, Midlothian, Scotland.	rory.duncan@ed.ac.uk		Rickman, Colin/0000-0001-8938-524X; Duncan, Rory/0000-0003-0693-910X	Wellcome Trust [074146] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200; Bracher A, 2002, EMBO J, V21, P6114, DOI 10.1093/emboj/cdf608; Bracher A, 2000, STRUCTURE, V8, P685, DOI 10.1016/S0969-2126(00)00156-8; BRENNER S, 1974, GENETICS, V77, P71; Bryant NJ, 2001, EMBO J, V20, P3380, DOI 10.1093/emboj/20.13.3380; Burgoyne RD, 2003, PHYSIOL REV, V83, P581, DOI 10.1152/physrev.00031.2002; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Carpp LN, 2006, J CELL BIOL, V173, P927, DOI 10.1083/jcb.200512024; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Dulubova I, 2002, EMBO J, V21, P3620, DOI 10.1093/emboj/cdf381; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Duncan RR, 2004, J MICROSC-OXFORD, V215, P1, DOI 10.1111/j.0022-2720.2004.01343.x; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Grabowski R, 1997, FEBS LETT, V411, P169, DOI 10.1016/S0014-5793(97)00720-5; Graham ME, 1997, J NEUROCHEM, V69, P2369; HARRISON SD, 1994, NEURON, V13, P555, DOI 10.1016/0896-6273(94)90025-6; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Hu K, 2002, NATURE, V415, P646, DOI 10.1038/415646a; Kweon DH, 2002, BIOCHEMISTRY-US, V41, P5449, DOI 10.1021/bi0256476; Latham CF, 2006, TRAFFIC, V7, P1408, DOI 10.1111/j.1600-0854.2006.00474.x; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Nichols BJ, 1998, EUR J CELL BIOL, V77, P263, DOI 10.1016/S0171-9335(98)80084-8; NOVICK P, 1979, P NATL ACAD SCI USA, V76, P1858, DOI 10.1073/pnas.76.4.1858; Peng RW, 2002, J CELL BIOL, V157, P645, DOI 10.1083/jcb.200202006; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Rickman C, 2005, CHEM BIOL, V12, P545, DOI 10.1016/j.chembiol.2005.03.004; Rickman C, 2006, MOL BIOL CELL, V17, P283, DOI 10.1091/mbc.E05-07-0620; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rizzo MA, 2004, NAT BIOTECHNOL, V22, P445, DOI 10.1038/nbt945; Rowe J, 1999, J CELL SCI, V112, P1865; Schutz D, 2005, EUR J NEUROSCI, V21, P2419, DOI 10.1111/j.1460-9568.2005.04095.x; Scott BL, 2004, J CELL BIOL, V167, P75, DOI 10.1083/jcb.200405018; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Toonen RFG, 2003, TRENDS CELL BIOL, V13, P177, DOI 10.1016/S0962-8924(03)00031-X; Toonen RF, 2006, EMBO J, V25, P3725, DOI 10.1038/sj.emboj.7601256; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zilly FE, 2006, PLOS BIOL, V4, P1789, DOI 10.1371/journal.pbio.0040330	40	100	105	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12097	12103		10.1074/jbc.M700227200	http://dx.doi.org/10.1074/jbc.M700227200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17264080	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000245941900051
J	Yang, B; Chen, KY; Zhang, C; Huang, S; Zhang, H				Yang, Bin; Chen, Keyang; Zhang, Chune; Huang, Sophia; Zhang, Hui			Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE TRANSCRIPTION; NONPERMISSIVE CELLS; INHIBITOR PROTEIN; POTENT INHIBITORS; VIF PROTEIN; VIRAL-DNA; VPR; REPLICATION; INFECTION	Cellular cytidine deaminases APOBEC3 family is a group of potent inhibitors for many exogenous and endogenous retroviruses. It has been demonstrated that they induce G to A hypermutations in the nascent retroviral DNA, resulting from the cytosine ( C) to uracil ( U) conversions in minus-stranded viral DNA. In this report, we have demonstrated that the result of C to U conversion in minus-stranded DNA of human immunodeficiency virus type 1 ( HIV-1) could trigger a degradation of nascent viral DNA mediated by uracil DNA glycosylases-2 ( UNG2) and apurinic/apyrimidinic endonuclease ( APE). Since antiviral activity of APOBEC3G is partially affected by UNG2 inhibitor Ugi or UNG2-specific short-interfering RNA in virus-producing cells but not target cells, the virion-associated UNG2 most likely mediates this process. Interestingly, as APE-specific short-interfering RNA can also partially inhibit the anti-HIV-1 activity of APOBEC3G in virus-producing cells but not in target cells and APE molecules can be detected within HIV-1 virions, it seems that the required APE is also virion-associated. Furthermore, the in vitro cleavage experiment using uracil-containing single-stranded DNA as a template has demonstrated that the uracil-excising catalytic activity of virion-associated UNG2 can remove dU from the uracil-containing viral DNA and leave an abasic site, which could be further cleaved by virion-associated APE. Based upon our observations, we propose that the degradation of APOBEC3G-edited viral DNA mediated by virion-associated UNG2 and APE during or after reverse transcription could be partially responsible for the potent anti-HIV-1 effect by APOBEC3G in the absence of vif.	Thomas Jefferson Univ, Ctr Human Virol, Div Infect Dis, Dept Med, Philadelphia, PA 19107 USA	Jefferson University	Zhang, H (corresponding author), Thomas Jefferson Univ, Ctr Human Virol, Div Infect Dis, Dept Med, JAH334,1020 Locust St, Philadelphia, PA 19107 USA.	hui.zhang@jefferson.edu	Yang, Bin/W-7014-2019; Yang, Bin/J-4044-2015	Yang, Bin/0000-0003-1180-6184; Yang, Bin/0000-0003-4110-1513	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI047720, R01AI047720, R01AI058798] Funding Source: NIH RePORTER; NIAID NIH HHS [AI047720, AI058798] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acharya N, 2003, MICROBIOL-SGM, V149, P1647, DOI 10.1099/mic.0.26228-0; Acharya N, 2002, J MOL BIOL, V321, P579, DOI 10.1016/S0022-2836(02)00654-X; BENNETT SE, 1992, J BIOL CHEM, V267, P22512; Bishop KN, 2006, J VIROL, V80, P8450, DOI 10.1128/JVI.00839-06; Bishop KN, 2004, CURR BIOL, V14, P1392, DOI 10.1016/j.cub.2004.06.057; Bogerd HP, 2006, NUCLEIC ACIDS RES, V34, P89, DOI 10.1093/nar/gkj416; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; Chen KY, 2006, J VIROL, V80, P7645, DOI 10.1128/JVI.00206-06; Chen RX, 2004, J BIOL CHEM, V279, P28419, DOI 10.1074/jbc.M403875200; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; DOEHLE BP, 2005, VIROLOGY, V80, P12102; Dornadula G, 2000, J VIROL, V74, P2594, DOI 10.1128/JVI.74.6.2594-2602.2000; Esnault C, 2005, NATURE, V433, P430, DOI 10.1038/nature03238; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; Handa P, 2002, NUCLEIC ACIDS RES, V30, P3086, DOI 10.1093/nar/gkf425; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Holmes RK, 2007, J BIOL CHEM, V282, P2587, DOI 10.1074/jbc.M607298200; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; Iwatani Y, 2006, J VIROL, V80, P5992, DOI 10.1128/JVI.02680-05; Jarmuz A, 2002, GENOMICS, V79, P285, DOI 10.1006/geno.2002.6718; Kaiser SM, 2006, J VIROL, V80, P875, DOI 10.1128/JVI.80.2.875-882.2006; Krokan HE, 2002, ONCOGENE, V21, P8935, DOI 10.1038/sj.onc.1205996; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mansky LM, 2000, J VIROL, V74, P7039, DOI 10.1128/JVI.74.15.7039-7047.2000; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Navaratnam N, 2006, INT J HEMATOL, V83, P195, DOI 10.1532/IJH97.06032; Navarro F, 2005, VIROLOGY, V333, P374, DOI 10.1016/j.virol.2005.01.011; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Noguchi C, 2005, HEPATOLOGY, V41, P626, DOI 10.1002/hep.20580; Petersen-Mahrt SK, 2003, J BIOL CHEM, V278, P19583, DOI 10.1074/jbc.C300114200; Pion M, 2006, J EXP MED, V203, P2887, DOI 10.1084/jem.20061519; Priet S, 2005, MOL CELL, V17, P479, DOI 10.1016/j.molcel.2005.01.016; Rosler C, 2005, HEPATOLOGY, V42, P301, DOI 10.1002/hep.20801; Sasada A, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-32; Schrofelbauer B, 2005, J VIROL, V79, P10978, DOI 10.1128/JVI.79.17.10978-10987.2005; Selig L, 1999, J VIROL, V73, P592, DOI 10.1128/JVI.73.1.592-600.1999; Selig L, 1997, J VIROL, V71, P4842, DOI 10.1128/JVI.71.6.4842-4846.1997; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Shindo K, 2003, J BIOL CHEM, V278, P44412, DOI 10.1074/jbc.C300376200; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; Turelli P, 2004, SCIENCE, V303, P1829, DOI 10.1126/science.1092066; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; WANG ZG, 1991, GENE, V99, P31; Willetts KE, 1999, J VIROL, V73, P1682, DOI 10.1128/JVI.73.2.1682-1688.1999; Yu Q, 2004, J BIOL CHEM, V279, P53379, DOI 10.1074/jbc.M408802200; Yu Q, 2004, NAT STRUCT MOL BIOL, V11, P435, DOI 10.1038/nsmb758; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707; Zhang H, 1996, J VIROL, V70, P2809, DOI 10.1128/JVI.70.5.2809-2824.1996; ZHANG H, 1993, AIDS RES HUM RETROV, V9, P1287, DOI 10.1089/aid.1993.9.1287; Zheng YH, 2004, J VIROL, V78, P6073, DOI 10.1128/JVI.78.11.6073-6076.2004	52	111	114	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11667	11675		10.1074/jbc.M606864200	http://dx.doi.org/10.1074/jbc.M606864200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17272283	hybrid			2022-12-25	WOS:000245941900008
J	Zhao, TB; Zhang, HL; Guo, YM; Fan, ZS				Zhao, Tongbiao; Zhang, Honglian; Guo, Yuming; Fan, Zusen			Granzyme K directly processes bid to release cytochrome c and endonuclease g leading to mitochondria-dependent cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRANULE SERINE PROTEASES; ASSEMBLY PROTEIN SET; DNA FRAGMENTATION; IN-VIVO; PERMEABILITY TRANSITION; MEDIATED APOPTOSIS; TUMOR-SUPPRESSOR; ACTIVATED DNASE; KILLER-CELLS; A-DEFICIENT	Granule-mediated cytolysis is the major pathway for killer lymphocytes to kill pathogens and tumor cells. Little is known about how granzyme K functions in killer lymphocyte-mediated cytolysis. We previously showed that human GzmK triggers rapid cell death independently of caspase activation with single-stranded DNA nicks, similar to GzmA. In this study we found that GzmK can induce rapid reactive oxygen species generation and collapse of mitochondrial inner membrane potential (Delta psi(m)). Blockade of reactive oxygen species production by antioxidant N-acetylcysteine or superoxide scavenger Tiron inhibits GzmK-induced cell death. Moreover GzmK targets mitochondria by cleaving Bid to generate its active form tBid, which disrupts the outer mitochondrial membrane leading to the release of cytochrome c and endonuclease G. Thus, we showed herein that GzmK-induced caspase-independent death occurs through Bid-dependent mitochondrial damage that is different from GzmA.	Chinese Acad Sci, Natl Lab Biomacromol, Beijing 100101, Peoples R China; Chinese Acad Sci, Ctr Infect & Immun, Inst Biophys, Beijing 100101, Peoples R China	Chinese Academy of Sciences; Chinese Academy of Sciences; Institute of Biophysics, CAS	Fan, ZS (corresponding author), Chinese Acad Sci, Natl Lab Biomacromol, 15 Datun Rd, Beijing 100101, Peoples R China.	fanz@moon.ibp.ac.cn	Zhao, Tongbiao/C-5761-2011	Zhao, Tongbiao/0000-0003-1429-5818				Alimonti JB, 2001, J BIOL CHEM, V276, P6974, DOI 10.1074/jbc.M008444200; Bade B, 2005, EUR J IMMUNOL, V35, P2940, DOI 10.1002/eji.200526249; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barry M, 2000, MOL CELL BIOL, V20, P3781, DOI 10.1128/MCB.20.11.3781-3794.2000; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bratke K, 2005, EUR J IMMUNOL, V35, P2608, DOI 10.1002/eji.200526122; Carter CRD, 1996, CELL IMMUNOL, V172, P235, DOI 10.1006/cimm.1996.0238; Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davis JE, 2001, EUR J IMMUNOL, V31, P39, DOI 10.1002/1521-4141(200101)31:1<39::AID-IMMU39>3.0.CO;2-1; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Fan ZS, 2002, MOL CELL BIOL, V22, P2810, DOI 10.1128/MCB.22.8.2810-2820.2002; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Fan ZS, 2005, CELL MOL IMMUNOL, V2, P259; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Grossman WJ, 2003, CURR OPIN IMMUNOL, V15, P544, DOI 10.1016/S0952-7915(03)00099-2; HAMEED A, 1988, J IMMUNOL, V141, P3142; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lieberman J, 2003, CURR OPIN IMMUNOL, V15, P553, DOI 10.1016/S0952-7915(03)00108-0; Lu HX, 2006, J IMMUNOL, V177, P1171, DOI 10.4049/jimmunol.177.2.1171; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacDonald G, 1999, J EXP MED, V189, P131, DOI 10.1084/jem.189.1.131; Martinvalet D, 2005, IMMUNITY, V22, P355, DOI 10.1016/j.immuni.2005.02.004; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Shresta S, 1997, J BIOL CHEM, V272, P20236, DOI 10.1074/jbc.272.32.20236; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zhao T, 2007, CELL DEATH DIFFER, V14, P489, DOI 10.1038/sj.cdd.4402040; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	45	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12104	12111		10.1074/jbc.M611006200	http://dx.doi.org/10.1074/jbc.M611006200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17308307	hybrid			2022-12-25	WOS:000245941900052
J	Lu, HH; Pannicke, U; Schwarz, K; Lieber, MR				Lu, Haihui; Pannicke, Ulrich; Schwarz, Klaus; Lieber, Michael R.			Length-dependent binding of human XLF to DNA and stimulation of XRCC4 center dot DNA ligase IV activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMBINED IMMUNE-DEFICIENCY; CLASS SWITCH RECOMBINATION; KINASE CATALYTIC SUBUNIT; END-JOINING FACTOR; V(D)J RECOMBINATION; XRCC4 PROTEIN; COMPLEX; INTERACTS; CERNUNNOS; MECHANISM	An XRCC4-like factor, called XLF or Cernunnos, was recently identified as another important factor in the non-homologous DNA end joining ( NHEJ) process. NHEJ is the major pathway for the repair of double-strand DNA breaks. The similarity in the putative secondary structures of XLF and XRCC4 as well as the association of XLF with XRCC4.DNA ligase IV in vivo suggested a role in the final ligation step of NHEJ. Here, we find that purified XLF directly interacts with purified XRCC4.DNA ligase IV complex and stimulates the ligase complex in a direct assay for ligation activity. Purified XLF has DNA binding activity, but this binding is dependent on DNA length in a manner most consistent with orientation of the C-terminal alpha helices parallel to the DNA helix. To better understand the function of XLF, we purified an XLF mutant ( R57G), which was identified in patients with NHEJ deficiency and severe combined immunodeficiency. Surprisingly, the mutant protein retained its ability to stimulate XRCC4.DNA ligase IV but failed to translocate to the nucleus, and this appears to be the basis for the NHEJ defect in this patient.	Univ Ulm, Dept Transfus Med, Inst Clin Transfus Med & Immunogenet, D-89081 Ulm, Germany; Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90089 USA; Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem, Los Angeles, CA 90089 USA; Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Biol, Los Angeles, CA 90089 USA; Kenneth Norris Jr Comprehens Canc Ctr, Dept Biol Sci, Los Angeles, CA 90089 USA; Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA	Ulm University	Schwarz, K (corresponding author), Univ Ulm, Dept Transfus Med, Inst Clin Transfus Med & Immunogenet, D-89081 Ulm, Germany.	klaus.schwarz@medizin.uni-ulm.de; lieber@usc.edu	Pannicke, Ulrich/D-7348-2014	Lieber, Michael/0000-0001-8809-0909; Lieber, Michael/0000-0003-3700-6345				Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Callebaut I, 2006, J BIOL CHEM, V281, P13857, DOI 10.1074/jbc.C500473200; Drouet J, 2006, J BIOL CHEM, V281, P27784, DOI 10.1074/jbc.M603047200; Dudley DD, 2005, ADV IMMUNOL, V86, P43, DOI 10.1016/S0065-2776(04)86002-4; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hentges P, 2006, J BIOL CHEM, V281, P37517, DOI 10.1074/jbc.M608727200; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Lieber MR, 2006, DNA REPAIR, V5, P1234, DOI 10.1016/j.dnarep.2006.05.013; Ma YM, 2004, MOL CELL, V16, P701, DOI 10.1016/j.molcel.2004.11.017; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Pavlicek A, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-15; Robins P, 1996, J BIOL CHEM, V271, P24257, DOI 10.1074/jbc.271.39.24257; Schwarz K, 2003, BIOESSAYS, V25, P1061, DOI 10.1002/bies.10344; Tomkinson AE, 2006, CHEM REV, V106, P687, DOI 10.1021/cr040498d	18	85	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11155	11162		10.1074/jbc.M609904200	http://dx.doi.org/10.1074/jbc.M609904200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17317666	hybrid			2022-12-25	WOS:000245941500036
J	Mazon, H; Gabor, K; Leys, D; Heck, AJR; van der Oost, J; van den Heuvel, RHH				Mazon, Hortense; Gabor, Krisztina; Leys, David; Heck, Albert J. R.; van der Oost, John; van den Heuvel, Robert H. H.			Transcriptional activation by CprK1 is regulated by protein structural changes induced by effector binding and redox state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROMOLECULAR COMPLEXES; REDUCTIVE DEHALOGENASE; CONFORMATIONAL-CHANGES; LIMITED PROTEOLYSIS; MASS-SPECTROMETRY; SP-NOV; FLIGHT; DEHALORESPIRATION; HALORESPIRATION; PURIFICATION	The transcriptional activator CprK1 from Desulfitobacterium-hafniense, a member of the ubiquitous cAMP receptor protein/fumarate nitrate reduction regulatory protein family, activates transcription of genes encoding proteins involved in reductive dehalogenation of chlorinated aromatic compounds. 3-Chloro-4-hydroxyphenylacetate is a known effector for CprK1, which interacts tightly with the protein, and induces binding to a specific DNA sequence ("dehalobox," TTAAT--ATTAA) located in the promoter region of chlorophenol reductive dehalogenase genes. Despite the availability of recent x-ray structures of two CprK proteins in distinct states, the mechanism by which CprK1 activates transcription is poorly understood. In the present study, we have investigated the mechanism of CprK1 activation and its effector specificity. By using macromolecular native mass spectrometry and DNA binding assays, analogues of 3-chloro-4-hydroxypheny-lacetate that have a halogenated group at the ortho position and a chloride or acetic acid group at the para position were found to be potent effectors for CprK1. By using limited proteolysis it was demonstrated that CprK1 requires a cascade of structural events to interact with dehalobox dsDNA. Upon reduction of the intermolecular disulfide bridge in oxidized CprK1, the protein becomes more dynamic, but this alone is not sufficient for DNA binding. Activation of CprK1 is a typical example of allosteric regulation; the binding of a potent effector molecule to reduced CprK1 induces local changes in the N-terminal effector binding domain, which subsequently may lead to changes in the hinge region and as such to structural changes in the DNA binding domain that are required for specific DNA binding.	Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Wageningen & Res Ctr, Microbiol Lab, NL-6703 CT Wageningen, Netherlands; Univ Manchester, Manchester Interdisciplinary Bioctr, Fac Life Sci, Manchester M60 1QD, Lancs, England	Utrecht University; Utrecht University; Wageningen University & Research; University of Manchester	van den Heuvel, RHH (corresponding author), Organon Int BV, NL-5340 BH Oss, Netherlands.	r.h.h.vandenheuvel@chem.uu.nl	van+der+Oost, John/Y-2548-2019; Heck, Albert/D-7098-2011	Heck, Albert/0000-0002-2405-4404	Biotechnology and Biological Sciences Research Council [BB/C00521X/1] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Akashi S, 2006, MED RES REV, V26, P339, DOI 10.1002/med.20051; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandes HK, 1998, ARCH BIOCHEM BIOPHYS, V352, P130, DOI 10.1006/abbi.1998.0580; Christiansen N, 1998, FEBS LETT, V436, P159, DOI 10.1016/S0014-5793(98)01114-4; Christiansen N, 1996, INT J SYST BACTERIOL, V46, P442, DOI 10.1099/00207713-46-2-442; Clark A.R., 1996, ENZYMOLOGY LABFAX, P199; Eiting M, 2005, MOL MICROBIOL, V56, P433, DOI 10.1111/j.1365-2958.2005.04561.x; El Fantroussi S, 1998, BIOTECHNOL PROGR, V14, P167, DOI 10.1021/bp980011k; Fic E, 2006, BIOCHEMISTRY-US, V45, P373, DOI 10.1021/bi051586a; Gabor K, 2006, J BACTERIOL, V188, P2604, DOI 10.1128/JB.188.7.2604-2613.2006; Green J, 2001, ADV MICROB PHYSIOL, V44, P1, DOI 10.1016/S0065-2911(01)44010-0; Hanson CL, 2004, J BIOL CHEM, V279, P24907, DOI 10.1074/jbc.R300037200; Harman JG, 2001, BBA-PROTEIN STRUCT M, V1547, P1, DOI 10.1016/S0167-4838(01)00187-X; Holliger C, 1998, FEMS MICROBIOL REV, V22, P383, DOI 10.1016/S0168-6445(98)00030-8; Joyce MG, 2006, J BIOL CHEM, V281, P28318, DOI 10.1074/jbc.M602654200; Krutchinsky AN, 1998, J AM SOC MASS SPECTR, V9, P569, DOI 10.1016/S1044-0305(98)00027-0; Loo JA, 1997, MASS SPECTROM REV, V16, P1; MADSEN T, 1992, APPL ENVIRON MICROB, V58, P2874, DOI 10.1128/AEM.58.9.2874-2878.1992; McDonald C, 2005, ANAL CHIM ACTA, V534, P3, DOI 10.1016/j.aca.2004.04.017; Myers SL, 2006, RAPID COMMUN MASS SP, V20, P1628, DOI 10.1002/rcm.2482; Pop SM, 2004, J BIOL CHEM, V279, P49910, DOI 10.1074/jbc.M409435200; Pop SM, 2006, J BIOL CHEM, V281, P26382, DOI 10.1074/jbc.M602158200; Robinson CV, 1996, J AM CHEM SOC, V118, P8646, DOI 10.1021/ja960211x; Rogniaux H, 2001, ANAL BIOCHEM, V291, P48, DOI 10.1006/abio.2000.4975; Smidt H, 2004, ANNU REV MICROBIOL, V58, P43, DOI 10.1146/annurev.micro.58.030603.123600; Smidt H, 2000, J BACTERIOL, V182, P5683, DOI 10.1128/JB.182.20.5683-5691.2000; Sobott F, 2005, PHILOS T R SOC A, V363, P379, DOI 10.1098/rsta.2004.1498; Tahallah N, 2001, RAPID COMMUN MASS SP, V15, P596, DOI 10.1002/rcm.275; UTKIN I, 1995, APPL ENVIRON MICROB, V61, P346, DOI 10.1128/AEM.61.1.346-351.1995; UTKIN I, 1994, INT J SYST BACTERIOL, V44, P612, DOI 10.1099/00207713-44-4-612; van de Pas BA, 1999, J BIOL CHEM, V274, P20287, DOI 10.1074/jbc.274.29.20287; van den Heuvel RH, 2004, CURR OPIN CHEM BIOL, V8, P519, DOI 10.1016/j.cbpa.2004.08.006; Villemur R, 2002, CAN J MICROBIOL, V48, P697, DOI 10.1139/w02-057; WEBER IT, 1987, J BIOL CHEM, V262, P5630; WENDT H, 1995, PROTEIN SCI, V4, P1563, DOI 10.1002/pro.5560040814	35	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11281	11290		10.1074/jbc.M611177200	http://dx.doi.org/10.1074/jbc.M611177200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303561	Green Published, hybrid			2022-12-25	WOS:000245941500050
J	Naji, S; Grunberg, S; Thomm, M				Naji, Souad; Gruenberg, Sebastian; Thomm, Michael			The RPB7 orthologue E ' is required for transcriptional activity of a reconstituted archaeal core enzyme at low temperatures and stimulates open complex formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TFIIE-ALPHA; IN-VITRO; BASAL TRANSCRIPTION; PYROCOCCUS-FURIOSUS; ABC TRANSPORTER; INITIATION; PROMOTER; SUBUNIT; REGULATOR	RNA polymerases from Archaea and Eukaryotes consist of a core enzyme associated with a dimeric E'F ( Rpb7/Rpb4) sub-complex but the functional contribution of the two subunit subcomplexes to the transcription process is poorly understood. Here we report the reconstitution of the 11-subunit RNA polymerase and of the core enzyme from the hyperthermophilic Archaeon Pyrococcus furiosus. The core enzyme showed significant activity between 70 and 80 degrees C but was almost inactive at 60 degrees C. E' stimulated the activity of the core enzyme at 60 degrees C, dramatically suggesting an important role of this subunit at low growth temperatures. Subunit F did not contribute significantly to catalytic activity. Permanganate footprinting at low temperatures dissected the contributions of the core enzyme, subunit E', and of archaeal TFE to open complex formation. Opening in the -2 and -4 region could be achieved by the core enzyme, subunit E' stimulated bubble formation in general and opening at the upstream end of the transcription bubble was preferably stimulated by TFE. Analyses of the kinetic stabilities of open complexes revealed an unexpected E'-independent role of TFE in the stabilization of open complexes.	Univ Regensburg, Lehrstuhl Mikrobiol, D-93053 Regensburg, Germany; Univ Regensburg, Archaeenzentrum, D-93053 Regensburg, Germany	University of Regensburg; University of Regensburg	Thomm, M (corresponding author), Univ Str 31, D-93053 Regensburg, Germany.	michael.thomm@biologie.uni-regensburg.de		Grunberg, Sebastian/0000-0002-5694-0574				Armache KJ, 2005, J BIOL CHEM, V280, P7131, DOI 10.1074/jbc.M413038200; Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Bell SD, 1999, MOL CELL, V4, P971, DOI 10.1016/S1097-2765(00)80226-9; Bell SD, 1998, TRENDS MICROBIOL, V6, P222, DOI 10.1016/S0966-842X(98)01281-5; Bell SD, 2001, CURR OPIN MICROBIOL, V4, P208, DOI 10.1016/S1369-5274(00)00190-9; Bell SD, 2001, EMBO REP, V2, P133, DOI 10.1093/embo-reports/kve021; Bushnell DA, 2003, P NATL ACAD SCI USA, V100, P6969, DOI 10.1073/pnas.1130601100; Choder M, 2004, TRENDS BIOCHEM SCI, V29, P674, DOI 10.1016/j.tibs.2004.10.007; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Darcy TJ, 1999, J BACTERIOL, V181, P4424, DOI 10.1128/JB.181.14.4424-4429.1999; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; Forget D, 2004, MOL CELL BIOL, V24, P1122, DOI 10.1128/MCB.24.3.1122-1131.2004; Geiduschek EP, 2005, MOL MICROBIOL, V56, P1397, DOI 10.1111/j.1365-2958.2005.04627.x; Goede B, 2006, J BIOL CHEM, V281, P30581, DOI 10.1074/jbc.M605209200; Goodchild A, 2004, MOL MICROBIOL, V53, P309, DOI 10.1111/j.1365-2958.2004.04130.x; Hanzelka BL, 2001, J BACTERIOL, V183, P1813, DOI 10.1128/JB.183.5.1813-1818.2001; Hausner W, 1996, J BIOL CHEM, V271, P30144, DOI 10.1074/jbc.271.47.30144; Hethke C, 1996, NUCLEIC ACIDS RES, V24, P2369, DOI 10.1093/nar/24.12.2369; Jasiak AJ, 2006, MOL CELL, V23, P71, DOI 10.1016/j.molcel.2006.05.013; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; Lee SJ, 2005, MOL MICROBIOL, V57, P1797, DOI 10.1111/j.1365-2958.2005.04804.x; Lee SJ, 2003, J BIOL CHEM, V278, P983, DOI 10.1074/jbc.M210236200; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; Meinhart A, 2003, J BIOL CHEM, V278, P48267, DOI 10.1074/jbc.M307874200; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; Orlicky SM, 2001, J BIOL CHEM, V276, P10097, DOI 10.1074/jbc.M003165200; Ouhammouch M, 2004, J BIOL CHEM, V279, P51719, DOI 10.1074/jbc.C400446200; Peyroche E, 2002, P NATL ACAD SCI USA, V99, P14670, DOI 10.1073/pnas.232580799; SADHALE PP, 1994, MOL CELL BIOL, V14, P6164, DOI 10.1128/MCB.14.9.6164; Shpakovski GV, 1999, BIOORG KHIM+, V25, P791; Siaut M, 2003, MOL CELL BIOL, V23, P195, DOI 10.1128/MCB.23.1.195-205.2003; Spitalny P, 2003, J BIOL CHEM, V278, P30497, DOI 10.1074/jbc.M303633200; Thomm M, 1996, FEMS MICROBIOL REV, V18, P159; THOMM M, 2006, ARCHAEA EVOLUTION PH, P185; Todone F, 2001, MOL CELL, V8, P1137, DOI 10.1016/S1097-2765(01)00379-3; Toulokhonov I, 2006, J MOL BIOL, V361, P644, DOI 10.1016/j.jmb.2006.06.071; Vierke G, 2003, J BIOL CHEM, V278, P18, DOI 10.1074/jbc.M209250200; Werner F, 2000, NUCLEIC ACIDS RES, V28, P4299, DOI 10.1093/nar/28.21.4299; Werner F, 2005, MOL CELL BIOL, V25, P8344, DOI 10.1128/MCB.25.18.8344-8355.2005; Werner F, 2002, MOL CELL, V10, P635, DOI 10.1016/S1097-2765(02)00629-9; WETTACH J, 1995, P NATL ACAD SCI USA, V92, P472, DOI 10.1073/pnas.92.2.472; Zaros C, 2005, MOL MICROBIOL, V55, P104, DOI 10.1111/j.1365-2958.2004.04375.x	42	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11047	11057		10.1074/jbc.M611674200	http://dx.doi.org/10.1074/jbc.M611674200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311916	hybrid			2022-12-25	WOS:000245941500025
J	Taguchi, N; Ishihara, N; Jofuku, A; Oka, T; Mihara, K				Taguchi, Naoko; Ishihara, Naotada; Jofuku, Akihiro; Oka, Toshihiko; Mihara, Katsuyoshi			Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT OPTIC ATROPHY; MAMMALIAN-CELLS; OUTER-MEMBRANE; BUDDING YEAST; FUSION; PROTEIN; MORPHOLOGY; INHERITANCE; DIVISION; CYCLE	Organelles are inherited to daughter cells beyond dynamic changes of the membrane structure during mitosis. Mitochondria are dynamic entities, frequently dividing and fusing with each other, during which dynamin-related GTPase Drp1 is required for the fission reaction. In this study, we analyzed mitochondrial dynamics in mitotic mammalian cells. Although mitochondria in interphase HeLa cells are long tubular network structures, they are fragmented in early mitotic phase, and the filamentous network structures are subsequently reformed in the daughter cells. In marked contrast, tubular mitochondrial structures are maintained during mitosis in Drp1 knockdown cells, indicating that the mitochondrial fragmentation in mitosis requires mitochondrial fission by Drp1. Drp1 was specifically phosphorylated in mitosis by Cdk1/cyclin B on Ser-585. Exogenous expression of unphosphorylated mutant Drp1(S585A) led to reduced mitotic mitochondrial fragmentation. These results suggest that phosphorylation of Drp1 on Ser-d585 promotes mitochondrial fission in mitotic cells.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Mihara, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	mihara@cell.med.kyushu-u.ac.jp		Ishihara, Naotada/0000-0002-6305-7149				Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Barni S, 1996, BIOTECH HISTOCHEM, V71, P66, DOI 10.3109/10520299609117135; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Boldogh IR, 2001, TRAFFIC, V2, P368, DOI 10.1034/j.1600-0854.2001.002006368.x; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2004, CURR TOP DEV BIOL, V59, P119, DOI 10.1016/S0070-2153(04)59005-1; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150; Gorsich SW, 2004, MOL BIOL CELL, V15, P4369, DOI 10.1091/mbc.E03-12-0875; Griffin EE, 2005, J CELL BIOL, V170, P237, DOI 10.1083/jcb.200503148; Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359; Hetzer MW, 2005, ANNU REV CELL DEV BI, V21, P347, DOI 10.1146/annurev.cellbio.21.090704.151152; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0; Itoh T, 2004, EMBO J, V23, P2520, DOI 10.1038/sj.emboj.7600271; Jofuku A, 2005, BIOCHEM BIOPH RES CO, V333, P650, DOI 10.1016/j.bbrc.2005.05.154; Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046; Karbowski M, 2001, J CELL SCI, V114, P281; Karren MA, 2005, J CELL BIOL, V171, P291, DOI 10.1083/jcb.200506158; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Margineantu DH, 2002, MITOCHONDRION, V1, P425, DOI 10.1016/S1567-7249(02)00006-5; Mozdy AD, 2003, NAT REV MOL CELL BIO, V4, P468, DOI 10.1038/nrm1125; Naylor K, 2006, J BIOL CHEM, V281, P2177, DOI 10.1074/jbc.M507943200; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nishijima H, 1997, J CELL BIOL, V138, P1105, DOI 10.1083/jcb.138.5.1105; Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; POSAKONY JW, 1977, J CELL BIOL, V74, P468, DOI 10.1083/jcb.74.2.468; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Shepard KA, 1999, J CELL BIOL, V144, P711, DOI 10.1083/jcb.144.4.711; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Solomaha E, 2005, J BIOL CHEM, V280, P23147, DOI 10.1074/jbc.M501745200; Stojanovski D, 2004, J CELL SCI, V117, P1201, DOI 10.1242/jcs.01058; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; Tan TC, 2003, NAT CELL BIOL, V5, P701, DOI 10.1038/ncb1020; Tomizawa K, 2003, J CELL BIOL, V163, P813, DOI 10.1083/jcb.200308110; Uchiyama K, 2003, J CELL BIOL, V161, P1067, DOI 10.1083/jcb.200303048; Westermann B, 2003, BBA-MOL CELL RES, V1641, P195, DOI 10.1016/S0167-4889(03)00091-0; Wong ED, 2000, J CELL BIOL, V151, P341, DOI 10.1083/jcb.151.2.341; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	49	830	859	3	54	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11521	11529		10.1074/jbc.M607279200	http://dx.doi.org/10.1074/jbc.M607279200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17301055	hybrid			2022-12-25	WOS:000245941500073
J	Necula, M; Kayed, R; Milton, S; Glabe, CG				Necula, Mihaela; Kayed, Rakez; Milton, Saskia; Glabe, Charles G.			Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							TAU-FILAMENT FORMATION; ATOMIC-FORCE MICROSCOPY; FIBRILS IN-VITRO; ALZHEIMERS-DISEASE; A-BETA; CONGO RED; ALPHA-SYNUCLEIN; PROTEIN FIBRILLOGENESIS; TEMPERATURE-DEPENDENCE; INSULIN FIBRILLATION	Alzheimer disease is characterized by the abnormal aggregation of amyloid beta peptide into extracellular fibrillar deposits known as amyloid plaques. Soluble oligomers have been observed at early time points preceding fibril formation, and these oligomers have been implicated as the primary pathological species rather than the mature fibrils. A significant issue that remains to be resolved is whether amyloid oligomers are an obligate intermediate on the pathway to fibril formation or represent an alternate assembly pathway that may or may not lead to fiber formation. To determine whether amyloid beta oligomers are obligate intermediates in the fibrillization pathway, we characterized the mechanism of action of amyloid beta aggregation inhibitors in terms of oligomer and fibril formation. Based on their effects, the small molecules segregated into three distinct classes: compounds that inhibit oligomerization but not fibrillization, compounds that inhibit fibrillization but not oligomerization, and compounds that inhibit both. Several compounds selectively inhibited oligomerization at substoichiometric concentrations relative to amyloid beta monomer, with some active in the low nanomolar range. These results indicate that oligomers are not an obligate intermediate in the fibril formation pathway. In addition, these data suggest that small molecule inhibitors are useful for clarifying the mechanisms underlying protein aggregation and may represent potential therapeutic agents that target fundamental disease mechanisms.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Glabe, CG (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, 3438 McGaugh Hall, Irvine, CA 92697 USA.	cglabe@uci.edu			NINDS NIH HHS [NS-38298] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038298] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad A, 2005, J BIOL CHEM, V280, P42669, DOI 10.1074/jbc.M504298200; Ahmad A, 2004, J BIOL CHEM, V279, P14999, DOI 10.1074/jbc.M313134200; Anguiano M, 2002, BIOCHEMISTRY-US, V41, P11338, DOI 10.1021/bi020314u; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Blackley HKL, 2000, J MOL BIOL, V298, P833, DOI 10.1006/jmbi.2000.3711; Bloom GS, 2005, BBA-MOL BASIS DIS, V1739, P116, DOI 10.1016/j.bbadis.2004.08.008; Bohrmann B, 2000, J STRUCT BIOL, V130, P232, DOI 10.1006/jsbi.2000.4241; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAMILLERI P, 1994, FEBS LETT, V341, P256, DOI 10.1016/0014-5793(94)80467-2; Chen YR, 2006, J BIOL CHEM, V281, P24414, DOI 10.1074/jbc.M602363200; Cheng X, 2005, ANAL CHEM, V77, P7012, DOI 10.1021/ac050556a; Chien P, 2004, ANNU REV BIOCHEM, V73, P617, DOI 10.1146/annurev.biochem.72.121801.161837; Chirita C, 2004, BIOCHEMISTRY-US, V43, P2879, DOI 10.1021/bi036094h; Chirita CN, 2005, BIOCHEMISTRY-US, V44, P5862, DOI 10.1021/bi0500123; Chirita CN, 2004, BIOCHEMISTRY-US, V43, P1704, DOI 10.1021/bi036034b; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; D'Andrea MR, 2003, NEUROSCI LETT, V342, P114, DOI 10.1016/S0304-3940(03)00252-0; De Felice FG, 2004, FASEB J, V18, P1366, DOI 10.1096/fj.04-1764com; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Dobson CM, 2003, NATURE, V426, P884, DOI 10.1038/nature02261; Esler WP, 1997, NAT BIOTECHNOL, V15, P258, DOI 10.1038/nbt0397-258; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; Ferrao-Gonzales AD, 2005, J BIOL CHEM, V280, P34747, DOI 10.1074/jbc.M501651200; Glabe CC, 2005, SUB CELL BIOCHEM, V38, P167; Glabe CG, 2004, TRENDS BIOCHEM SCI, V29, P542, DOI 10.1016/j.tibs.2004.08.009; Glabe CG, 2006, NEUROBIOL AGING, V27, P570, DOI 10.1016/j.neurobiolaging.2005.04.017; Gorman PM, 2003, J MOL BIOL, V325, P743, DOI 10.1016/S0022-2836(02)01279-2; Gosal WS, 2005, J MOL BIOL, V351, P850, DOI 10.1016/j.jmb.2005.06.040; Gosal WS, 2004, BIOMACROMOLECULES, V5, P2408, DOI 10.1021/bm049659d; Green JD, 2004, J BIOL CHEM, V279, P12206, DOI 10.1074/jbc.M312452200; Grudzielanek S, 2006, J MOL BIOL, V356, P497, DOI 10.1016/j.jmb.2005.11.075; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Hepler RW, 2006, BIOCHEMISTRY-US, V45, P15157, DOI 10.1021/bi061850f; Howlett D, 1997, FEBS LETT, V417, P249, DOI 10.1016/S0014-5793(97)01290-8; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; Howlett DR, 1999, BIOCHEM J, V343, P419, DOI 10.1042/0264-6021:3430419; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; Hurshman AR, 2004, BIOCHEMISTRY-US, V43, P7365, DOI 10.1021/bi049621l; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kaylor J, 2005, J MOL BIOL, V353, P357, DOI 10.1016/j.jmb.2005.08.046; Kim YS, 2003, J BIOL CHEM, V278, P10842, DOI 10.1074/jbc.M212540200; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Klunk WE, 2001, LIFE SCI, V69, P1471, DOI 10.1016/S0024-3205(01)01232-2; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Kuner P, 2000, J BIOL CHEM, V275, P1673, DOI 10.1074/jbc.275.3.1673; Kusumoto Y, 1998, P NATL ACAD SCI USA, V95, P12277, DOI 10.1073/pnas.95.21.12277; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 2002, J BIOL CHEM, V277, P42881, DOI 10.1074/jbc.M206593200; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Li J, 2004, FASEB J, V18, P962, DOI 10.1096/fj.03-0770fje; Lomakin A, 1997, P NATL ACAD SCI USA, V94, P7942, DOI 10.1073/pnas.94.15.7942; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Modler AJ, 2003, J MOL BIOL, V325, P135, DOI 10.1016/S0022-2836(02)01175-0; Morozova-Roche LA, 2004, BIOCHEMISTRY-US, V43, P9610, DOI 10.1021/bi0494121; Naiki H, 1998, BIOCHEMISTRY-US, V37, P17882, DOI 10.1021/bi980550y; Naiki H, 1996, LAB INVEST, V74, P374; Necula M, 2005, BIOCHEMISTRY-US, V44, P10227, DOI 10.1021/bi050387o; Necula M, 2004, ANAL BIOCHEM, V329, P238, DOI 10.1016/j.ab.2004.02.023; Netland EE, 1998, NEUROBIOL AGING, V19, P201, DOI 10.1016/S0197-4580(98)00047-5; Nilsson KPR, 2005, BIOCHEMISTRY-US, V44, P3718, DOI 10.1021/bi047402u; Nybo M, 1999, SCAND J IMMUNOL, V49, P219; Oddo S, 2006, J BIOL CHEM, V281, P1599, DOI 10.1074/jbc.M507892200; Ono K, 2004, J NEUROSCI RES, V75, P742, DOI 10.1002/jnr.20025; Ono K, 2004, BBA-MOL BASIS DIS, V1690, P193, DOI 10.1016/j.bbadis.2004.06.008; Padrick SB, 2002, BIOCHEMISTRY-US, V41, P4694, DOI 10.1021/bi0160462; Pappolla M, 1998, J BIOL CHEM, V273, P7185, DOI 10.1074/jbc.273.13.7185; Pertinhez TA, 2002, FEBS LETT, V529, P193, DOI 10.1016/S0014-5793(02)03333-1; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Podlisny MB, 1998, BIOCHEMISTRY-US, V37, P3602, DOI 10.1021/bi972029u; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; POLLACK SJ, 1995, NEUROSCI LETT, V197, P211, DOI 10.1016/0304-3940(95)11939-T; Porat Y, 2004, BIOCHEMISTRY-US, V43, P14454, DOI 10.1021/bi048582a; Sabate R, 2005, LANGMUIR, V21, P6944, DOI 10.1021/la050472x; Sabate R, 2005, INT J BIOL MACROMOL, V35, P9, DOI 10.1016/j.ijbiomac.2004.11.001; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Skovronsky DM, 2000, P NATL ACAD SCI USA, V97, P7609, DOI 10.1073/pnas.97.13.7609; Smith DL, 2001, NEUROBIOL DIS, V8, P1017, DOI 10.1006/nbdi.2001.0438; SOREGHAN B, 1994, J BIOL CHEM, V269, P28551; Souillac PO, 2003, BIOCHEMISTRY-US, V42, P8094, DOI 10.1021/bi034652m; Souillac PO, 2002, J BIOL CHEM, V277, P12666, DOI 10.1074/jbc.M109229200; Taniguchi S, 2005, J BIOL CHEM, V280, P7614, DOI 10.1074/jbc.M408714200; Tomiyama T, 1996, J BIOL CHEM, V271, P6839, DOI 10.1074/jbc.271.12.6839; TOMIYAMA T, 1994, BIOCHEM BIOPH RES CO, V204, P76, DOI 10.1006/bbrc.1994.2428; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wang J, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-1; Williams AD, 2005, P NATL ACAD SCI USA, V102, P7115, DOI 10.1073/pnas.0408582102; Wood SJ, 1996, J BIOL CHEM, V271, P4086; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Yao ZX, 2001, BRAIN RES, V889, P181, DOI 10.1016/S0006-8993(00)03131-0; Yu JX, 2002, J MOL NEUROSCI, V19, P51, DOI 10.1007/s12031-002-0010-x; Zhu M, 2004, J BIOL CHEM, V279, P26846, DOI 10.1074/jbc.M403129200	106	557	575	1	174	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10311	10324		10.1074/jbc.M608207200	http://dx.doi.org/10.1074/jbc.M608207200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284452	hybrid			2022-12-25	WOS:000245941000021
J	Schumacher, MA; Mansoor, A; Funnell, BE				Schumacher, Maria A.; Mansoor, Andre; Funnell, Barbara E.			Structure of a four-way bridged ParB-DNA complex provides insight into P1 segrosome assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMID PARTITION COMPLEX; INTEGRATION HOST FACTOR; ESCHERICHIA-COLI; BACTERIAL SEGROSOME; PROTEIN; SPECIFICITY; BINDING; SITE; CENTROMERE; DOMAINS	The plasmid partition process is essential for plasmid propagation and is mediated by par systems, consisting of centromere-like sites and two proteins, ParA and ParB. In the first step of partition by the archetypical P1 system, ParB binds a complicated centromere-like site to form a large nucleoprotein segrosome. ParB is a dimeric DNA-binding protein that can bridge between both A-boxes and B-boxes located on the centromere. Its helix-turn-helix domains bind A-boxes and the dimer domain binds B-boxes. Binding of the first ParB dimer nucleates the remaining ParB molecules onto the centromere site, which somehow leads to the formation of a condensed segrosome superstructure. To further understand this unique DNA spreading capability of ParB, we crystallized and determined the structure of a 1: 2 ParB-(142-333):A3-B2-box complex to 3.35 angstrom resolution. The structure reveals a remarkable four-way, protein-DNA bridged complex in which both ParB helix-turn-helix domains simultaneously bind adjacent A-boxes and the dimer domain bridges between two B-boxes. The multibridging capability and the novel dimer domain-B-box interaction, which juxtaposes the DNA sites close in space, suggests a mechanism for the formation of the wrapped solenoid-like segrosome superstructure. This multibridging capability of ParB is likely critical in its partition complex formation and pairing functions.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97239 USA; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Texas System; UTMD Anderson Cancer Center; Oregon Health & Science University; University of Toronto	Schumacher, MA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Unit 1000,1515 Holcombe Blvd, Houston, TX 77030 USA.	maschuma@mdanderson.org		Funnell, Barbara/0000-0002-1828-6567	NIGMS NIH HHS [GM074815] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074815] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Biswas T, 2005, NATURE, V435, P1059, DOI 10.1038/nature03657; Bouet JY, 2000, J BIOL CHEM, V275, P8213, DOI 10.1074/jbc.275.11.8213; Bradley CM, 2005, NAT STRUCT MOL BIOL, V12, P935, DOI 10.1038/nsmb989; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Davey MJ, 1997, J BIOL CHEM, V272, P15286, DOI 10.1074/jbc.272.24.15286; DAVIS MA, 1990, EMBO J, V9, P991, DOI 10.1002/j.1460-2075.1990.tb08201.x; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Edgar R, 2001, MOL MICROBIOL, V42, P1363, DOI 10.1046/j.1365-2958.2001.02717.x; Erdmann N, 1999, P NATL ACAD SCI USA, V96, P14905, DOI 10.1073/pnas.96.26.14905; Fung E, 2001, EMBO J, V20, P4901, DOI 10.1093/emboj/20.17.4901; Funnell BE, 2005, PLASMID, V53, P119, DOI 10.1016/j.plasmid.2004.12.009; FUNNELL BE, 1988, J BACTERIOL, V170, P954, DOI 10.1128/JB.170.2.954-960.1988; FUNNELL BE, 1993, J BIOL CHEM, V268, P3616; FUNNELL BE, 1991, J BIOL CHEM, V266, P14328; FUNNELL BE, 1988, P NATL ACAD SCI USA, V85, P6657, DOI 10.1073/pnas.85.18.6657; FUNNELL BE, 1994, BIOCHIMIE, V76, P924, DOI 10.1016/0300-9084(94)90017-5; FUNNELL BE, 2004, PLASMID BIOL; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hayes F, 2006, NAT REV MICROBIOL, V4, P133, DOI 10.1038/nrmicro1342; HAYES F, 1993, P NATL ACAD SCI USA, V90, P9228, DOI 10.1073/pnas.90.19.9228; HAYES F, 1994, J MOL BIOL, V243, P190, DOI 10.1006/jmbi.1994.1646; Hayes F, 2006, TRENDS BIOCHEM SCI, V31, P247, DOI 10.1016/j.tibs.2006.03.002; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khare D, 2004, NAT STRUCT MOL BIOL, V11, P656, DOI 10.1038/nsmb773; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lobocka M, 1996, J MOL BIOL, V259, P366, DOI 10.1006/jmbi.1996.0326; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MARTIN KA, 1991, J BACTERIOL, V173, P3630, DOI 10.1128/JB.173.12.3630-3634.1991; PRENTKI P, 1977, MOL GEN GENET, V152, P71, DOI 10.1007/BF00264942; Radnedge L, 1998, EMBO J, V17, P6076, DOI 10.1093/emboj/17.20.6076; Radnedge L, 1996, EMBO J, V15, P1155, DOI 10.1002/j.1460-2075.1996.tb00454.x; Rodionov O, 2004, MOL MICROBIOL, V52, P1215, DOI 10.1111/j.1365-2958.2004.04055.x; Rodionov O, 1999, SCIENCE, V283, P546, DOI 10.1126/science.283.5401.546; Schumacher MA, 2005, NATURE, V438, P516, DOI 10.1038/nature04149; Surtees JA, 2003, CURR TOP DEV BIOL, V56, P145, DOI 10.1016/S0070-2153(03)01010-X; Surtees JA, 1999, J BACTERIOL, V181, P5898, DOI 10.1128/JB.181.19.5898-5908.1999; Surtees JA, 2001, J BIOL CHEM, V276, P12385, DOI 10.1074/jbc.M009370200; Vlieghe D, 1999, ACTA CRYSTALLOGR D, V55, P1495, DOI 10.1107/S0907444999007933	40	25	25	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10456	10464		10.1074/jbc.M610603200	http://dx.doi.org/10.1074/jbc.M610603200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17293348	hybrid			2022-12-25	WOS:000245941000037
J	Duffy, HS; Iacobas, I; Hotchkiss, K; Hirst-Jensen, BJ; Bosco, A; Dandachi, N; Dermietzel, R; Sorgen, PL; Spray, DC				Duffy, Heather S.; Iacobas, Ionela; Hotchkiss, Kylie; Hirst-Jensen, Bethany J.; Bosco, Alejandra; Dandachi, Nadine; Dermietzel, Rolf; Sorgen, Paul L.; Spray, David C.			The gap junction protein connexin32 interacts with the Src homology 3/Hook domain of discs large homolog 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C6 GLIOMA-CELLS; POSSIBLE MECHANISM; EXPRESSION; COLOCALIZATION; IDENTIFICATION; COMMUNICATION; TRANSCRIPTION; MEMBRANE; ELEMENTS; GROWTH	Scaffolding of membrane proteins is a common strategy for forming complexes of proteins, including some connexins, within membrane microdomains. Here we describe studies indicating that Cx32 interacts with a PDZ-containing scaffolding protein, Dlgh1 (Discs Large homolog 1). Initial screens of liver lysates using antibody arrays indicated an interaction between Cx32 and Dlgh1 that was confirmed using coimmunoprecipitation studies. Yeast two-hybrid complementation determined that the Cx32 bound via interaction with the SH3/Hook domain of Dlgh1. Confocal microscopy of liver sections revealed that Cx32 and Dlgh1 could colocalize in hepatocyte membranes in wild type mice. Examination of levels and localization of Dlgh1 in livers from Cx32 null mice indicate that, in the absence of Cx32, Dlgh1 was decreased, and the remainder was translocated from the hepatocyte membrane to the nucleus with some remaining in cytoplasmic compartments. This translocation was confirmed by Western blots comparing Dlgh1 levels in nuclear extracts from wild type and Cx32 null murine livers. Using SKHep cells stably transfected with Cx32 under the control of a tet-off promoter, we found that acute removal of Cx32 led to a decrease of membrane-localized Dlgh1 and an increase in the nuclear localization of this tumor suppressor protein. Together, these results suggest that loss of Cx32 alters the levels, localization, and interactions of the tumor suppressor protein Dlgh1, events known in other systems to alter cell cycle and increase tumorigenicity.	Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Univ Nebraska, Dept Biochem & Mol Biol, Omaha, NE 68918 USA; Univ Bochum, Dept Neurosci & Mol Brain Res, D-44780 Bochum, Germany	Columbia University; Yeshiva University; Albert Einstein College of Medicine; University of Nebraska System; Ruhr University Bochum	Duffy, HS (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pharmacol, 630 W 168th St, New York, NY 10032 USA.	hsd2102@columbia.edu		BOSCO, ALEJANDRA/0000-0003-3743-5414; Spray, David/0000-0001-8368-5073	NIDDK NIH HHS [DK41918] Funding Source: Medline; NIGMS NIH HHS [R01 GM072631] Funding Source: Medline; PHS HHS [M072631] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072631] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad S, 2001, EUR J BIOCHEM, V268, P4544, DOI 10.1046/j.1432-1327.2001.02380.x; Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; Costes SV, 2004, BIOPHYS J, V86, P3993, DOI [10.1529/biophysj.103.038422, 10.1529/biophysi.103.038422]; Dagli MLZ, 2004, CARCINOGENESIS, V25, P483, DOI 10.1093/carcin/bgh050; Dang XT, 2003, MOL CELL BIOCHEM, V242, P35, DOI 10.1023/A:1021152709313; Duffy HS, 2002, J PHYSIOL-PARIS, V96, P243, DOI 10.1016/S0928-4257(02)00012-8; Duffy HS, 2005, PRACTICAL METHODS IN CARDIOVASCULAR RESEARCH, P916, DOI 10.1007/3-540-26574-0_46; Fishman GI, 1995, CELL ADHES COMMUN, V3, P353, DOI 10.3109/15419069509081019; Fu CT, 2004, J BIOL CHEM, V279, P36943, DOI 10.1074/jbc.M403952200; Funke L, 2005, ANNU REV BIOCHEM, V74, P219, DOI 10.1146/annurev.biochem.74.082803.133339; Gellhaus A, 2004, J BIOL CHEM, V279, P36931, DOI 10.1074/jbc.M404073200; Hirschi KK, 1996, CELL GROWTH DIFFER, V7, P861; Hsueh YP, 2006, CURR MED CHEM, V13, P1915, DOI 10.2174/092986706777585040; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Kojima T, 1999, BIOCHEM BIOPH RES CO, V266, P222, DOI 10.1006/bbrc.1999.1778; Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922; Lauf U, 2002, P NATL ACAD SCI USA, V99, P10446, DOI 10.1073/pnas.162055899; Lin JHC, 2002, J NEUROSCI, V22, P4302, DOI 10.1523/JNEUROSCI.22-11-04302.2002; Naus CCG, 2002, CAN J PHYSIOL PHARM, V80, P136, DOI 10.1139/Y02-009; Naus CCG, 2000, BRAIN RES REV, V32, P259, DOI 10.1016/S0165-0173(99)00087-9; Neijssen J, 2005, NATURE, V434, P83, DOI 10.1038/nature03290; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; Penes MC, 2005, EUR J NEUROSCI, V22, P404, DOI 10.1111/j.1460-9568.2005.04225.x; Peracchia C, 2000, J BIOL CHEM, V275, P26220, DOI 10.1074/jbc.M004007200; PITTS JD, 1988, BRIT J CANCER, V58, P52; Scemes E, 2000, J NEUROSCI, V20, P1435; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Stains Joseph P, 2005, Birth Defects Res C Embryo Today, V75, P72, DOI 10.1002/bdrc.20034; Stains JP, 2005, MOL BIOL CELL, V16, P64, DOI 10.1091/mbc.E04-04-0339; Stains JP, 2003, J BIOL CHEM, V278, P24377, DOI 10.1074/jbc.M212554200; Suadicani SO, 2003, GLIA, V42, P160, DOI 10.1002/glia.10197; Temme A, 1997, CURR BIOL, V7, P713, DOI 10.1016/S0960-9822(06)00302-2; Valiunas V, 2005, J PHYSIOL-LONDON, V568, P459, DOI 10.1113/jphysiol.2005.090985; Xu X, 2001, CELL COMMUN ADHES, V8, P321, DOI 10.3109/15419060109080746	34	54	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9789	9796		10.1074/jbc.M605261200	http://dx.doi.org/10.1074/jbc.M605261200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17284442	hybrid			2022-12-25	WOS:000245421700053
J	Hoos, MD; Ahmed, M; Smith, SO; van Nostrand, WE				Hoos, Michael D.; Ahmed, Mahiuddin; Smith, Steven O.; van Nostrand, William E.			Inhibition of familial cerebral amyloid angiopathy mutant amyloid beta-protein fibril assembly by myelin basic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE BRAIN; HUMAN APOLIPOPROTEIN-E; DUTCH-TYPE; A-BETA; PRECURSOR PROTEIN; TRANSGENIC MICE; MUSCLE-CELLS; IN-VITRO; HEMORRHAGE	Deposition of fibrillar amyloid beta-protein (A beta) in the brain is a prominent pathological feature of Alzheimer disease and related disorders, including familial forms of cerebral amyloid angiopathy (CAA). Mutant forms of A beta, including Dutch- and Iowa-type A beta, which are responsible for familial CAA, deposit primarily as fibrillar amyloid along the cerebral vasculature and are either absent or present only as diffuse non-fibrillar plaques in the brain parenchyma. Despite the lack of parenchymal fibril formation in vivo, these CAA mutant A beta peptides exhibit a markedly increased rate and extent of fibril formation in vitro compared with wild-type A beta. Based on these conflicting observations, we sought to determine whether brain parenchymal factors that selectively interact with and modulate CAA mutant A beta fibril assembly exist. Using a combination of immunoaffinity chromatography and mass spectrometry, we identified myelin basic protein (MBP) as a prominent brain parenchymal factor that preferentially binds to CAA mutant A beta compared with wild-type A beta. Surface plasmon resonance measurements confirmed that MBP bound more tightly to Dutch/Iowa CAA double mutant A beta than to wild-type A beta. Using a combination of biochemical and ultrastructural techniques, we found that MBP inhibited the fibril assembly of CAA mutant A beta. Together, these findings suggest a possible role for MBP in regulating parenchymal fibrillar A beta deposition in familial CAA.	SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	van Nostrand, WE (corresponding author), SUNY Stony Brook, Dept Med, HSC T-15-083, Stony Brook, NY 11794 USA.	William.VanNostrand@stonybrook.edu	Smith, Steven/HDM-9496-2022		NIA NIH HHS [R01 AG027317] Funding Source: Medline; NIGMS NIH HHS [T32 GM008444] Funding Source: Medline; NINDS NIH HHS [NS35781] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027317] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abdo WF, 2006, NEUROLOGY, V67, P474, DOI 10.1212/01.wnl.0000227891.25592.8c; Aleshkov S, 1997, BIOCHEMISTRY-US, V36, P10571, DOI 10.1021/bi9626362; Attems J, 2004, ACTA NEUROPATHOL, V107, P83, DOI 10.1007/s00401-003-0796-9; Bailey TL, 2004, NEUROL RES, V26, P573, DOI 10.1179/016164104225016272; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Beems T, 2003, ACTA NEUROCHIR, V145, P37, DOI 10.1007/s00701-002-1019-1; Bentley NM, 2002, BIOCHEM J, V366, P273, DOI 10.1042/BJ20020207; BERLET HH, 1994, NEUROSCI LETT, V179, P75, DOI 10.1016/0304-3940(94)90938-5; Bornebroek M, 1996, ALZ DIS ASSOC DIS, V10, P224, DOI 10.1097/00002093-199601040-00008; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAMPAGNONI AT, 1993, J BIOL CHEM, V268, P4930; CHAN KC, 1988, BIOCHEM BIOPH RES CO, V152, P1468, DOI 10.1016/S0006-291X(88)80451-0; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; CHOU FCH, 1976, J BIOL CHEM, V251, P2671; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; Cotman SL, 2000, MOL CELL NEUROSCI, V15, P183, DOI 10.1006/mcne.1999.0816; Davis J, 1996, P NATL ACAD SCI USA, V93, P2996, DOI 10.1073/pnas.93.7.2996; Davis J, 2004, J BIOL CHEM, V279, P20296, DOI 10.1074/jbc.M312946200; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Deane R, 2003, NAT MED, V9, P907, DOI 10.1038/nm890; DeMattos RB, 2002, P NATL ACAD SCI USA, V99, P10843, DOI 10.1073/pnas.162228299; Esiri MM, 2001, LANCET, V357, P169; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; Givogri MI, 2000, J NEUROSCI RES, V59, P153, DOI 10.1002/(SICI)1097-4547(20000115)59:2<153::AID-JNR1>3.3.CO;2-6; Grabowski TJ, 2001, ANN NEUROL, V49, P697, DOI 10.1002/ana.1009; HENDRIKSL, 1992, NAT GENET, V1, P218; Hill CMD, 2005, BIOCHEM BIOPH RES CO, V329, P362, DOI 10.1016/j.bbrc.2005.01.151; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Jellinger KA, 2002, J NEURAL TRANSM, V109, P813, DOI 10.1007/s007020200068; John V, 2003, J MED CHEM, V46, P4625, DOI 10.1021/jm030247h; Kakio A, 2001, J BIOL CHEM, V276, P24985, DOI 10.1074/jbc.M100252200; KAMINO K, 1992, AM J HUM GENET, V51, P998; KAWAI M, 1993, BRAIN RES, V623, P142, DOI 10.1016/0006-8993(93)90021-E; Kokubo H, 2005, BRAIN RES, V1031, P222, DOI 10.1016/j.brainres.2004.10.041; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; Maat-Schieman MLC, 2004, ACTA NEUROPATHOL, V107, P389, DOI 10.1007/s00401-004-0824-4; MAATSCHIEMAN MLC, 1992, ACTA NEUROPATHOL, V84, P674, DOI 10.1007/BF00227745; MaatSchieman MLC, 1997, J NEUROPATH EXP NEUR, V56, P273, DOI 10.1097/00005072-199703000-00006; Manelli AM, 2004, J MOL NEUROSCI, V23, P235, DOI 10.1385/JMN:23:3:235; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Mastrangelo IA, 2006, J MOL BIOL, V358, P106, DOI 10.1016/j.jmb.2006.01.042; MATSUBARA E, 1995, J BIOL CHEM, V270, P7563, DOI 10.1074/jbc.270.13.7563; Melchor JP, 2000, J NEUROCHEM, V74, P2209, DOI 10.1046/j.1471-4159.2000.0742209.x; Miravalle L, 2000, J BIOL CHEM, V275, P27110; MOSCARELLO MA, 1990, PROG CLIN BIOL RES, V336, P25; Mucke L, 2000, AM J PATHOL, V157, P2003, DOI 10.1016/S0002-9440(10)64839-0; Natte R, 2001, ANN NEUROL, V50, P765, DOI 10.1002/ana.10040; Pillot T, 1999, J NEUROCHEM, V72, P230, DOI 10.1046/j.1471-4159.1999.0720230.x; PIROLLET F, 1992, BIOCHEMISTRY-US, V31, P8849, DOI 10.1021/bi00152a022; Polverini E, 2004, J STRUCT BIOL, V148, P353, DOI 10.1016/j.jsb.2004.08.004; Potter H, 2001, NEUROBIOL AGING, V22, P923, DOI 10.1016/S0197-4580(01)00308-6; Pribyl TM, 1996, J COMP NEUROL, V374, P342, DOI 10.1002/(SICI)1096-9861(19961021)374:3<342::AID-CNE3>3.0.CO;2-1; PRIBYL TM, 1993, P NATL ACAD SCI USA, V90, P10695, DOI 10.1073/pnas.90.22.10695; Richter-Landsberg C, 2000, J NEUROSCI RES, V59, P11, DOI 10.1002/(SICI)1097-4547(20000101)59:1<11::AID-JNR2>3.0.CO;2-O; ROTH HJ, 1987, J NEUROSCI RES, V17, P321, DOI 10.1002/jnr.490170402; ROZEMULLER AJM, 1993, AM J PATHOL, V142, P1449; SANAN DA, 1994, J CLIN INVEST, V94, P860, DOI 10.1172/JCI117407; Schwarzman AL, 2004, AMYLOID, V11, P1, DOI 10.1080/13506120410001667458; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shin Y, 2002, ANN NY ACAD SCI, V977, P245, DOI 10.1111/j.1749-6632.2002.tb04822.x; SMITH R, 1992, J NEUROCHEM, V59, P1589, DOI 10.1111/j.1471-4159.1992.tb10989.x; Stine WB, 2003, J BIOL CHEM, V278, P11612, DOI 10.1074/jbc.M210207200; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; Tagliavini F., 1999, ALZHEIMERS REP, V2, pS28; Thal DR, 2003, J NEUROPATH EXP NEUR, V62, P1287, DOI 10.1093/jnen/62.12.1287; Tosic M, 2002, GLIA, V37, P219, DOI 10.1002/glia.10028; Tsuzuki K, 2000, NEUROSCI LETT, V281, P171, DOI 10.1016/S0304-3940(00)00834-X; VAN BROECKHOVEN C, 1990, SCIENCE, V248, P1120, DOI 10.1126/science.1971458; Van Nostrand WE, 2001, J BIOL CHEM, V276, P32860, DOI 10.1074/jbc.M104135200; VANDUINEN SG, 1987, P NATL ACAD SCI USA, V84, P5991; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Verbeek MM, 1997, J NEUROCHEM, V68, P1135; Vinters Harry V, 2003, Adv Neurol, V92, P105; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; WATTENDORFF AR, 1995, J NEUROL NEUROSUR PS, V59, P699; WISNIEWSKI HM, 1994, AMYLOID, V1, P8, DOI 10.3109/13506129409148619; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; WOOD DD, 1989, J BIOL CHEM, V264, P5121; Yamamoto N, 2005, FEBS LETT, V579, P2185, DOI 10.1016/j.febslet.2005.03.013; Yang DS, 2001, AMYLOID, V8, P10; Zand R, 1998, BIOCHEMISTRY-US, V37, P2441, DOI 10.1021/bi972347t	83	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9952	9961		10.1074/jbc.M603494200	http://dx.doi.org/10.1074/jbc.M603494200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17259179	hybrid			2022-12-25	WOS:000245421700070
J	Phartiyal, P; Jones, EMC; Robertson, GA				Phartiyal, Pallavi; Jones, Eugenia M. C.; Robertson, Gail A.			Heteromeric assembly of human ether-a-go-go-related gene (hERG) 1a/1b channels occurs cotranslationally via N-terminal interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG QT SYNDROME; DEFECTIVE PROTEIN TRAFFICKING; GATED POTASSIUM CHANNELS; K+ CHANNEL; ENDOPLASMIC-RETICULUM; CARDIAC-ARRHYTHMIA; I-KR; PHARMACOLOGICAL RESCUE; SURFACE EXPRESSION; MUTANT CHANNELS	Alternate transcripts of the human ether-A-go-go-related gene (hERG1) encode two subunits, hERG 1a and 1b, which form potassium channels regulating cardiac repolarization, neuronal firing frequency, and neoplastic cell growth. The la and 1b subunits are identical except for their unique, cytoplasmic N termini, and they readily co-assemble in heterologous and native systems. We tested the hypothesis that interactions of nascent N termini promote heteromeric assembly of 1a and 1b subunits. We found that 1a and 1b N-terminal fragments bind in a direct and dose-dependent manner. hERG1 hetero-oligomerization occurs in the endoplasmic reticulum where co-expression of N-terminal fragments with hERG1 subunits disrupted oligomerization and core glycosylation. The disruption of core glycosylation, a cotranslational event, allows us to pinpoint these N-terminal interactions to the earliest steps in biogenesis. Thus, N-terminal interactions mediate hERG 1a/1b assembly, a process whose perturbation may represent a new mechanism for disease.	Univ Wisconsin, Satellite Labs, Dept Physiol, Madison, WI 53711 USA; Univ Wisconsin, Satellite Labs, Cellular & Mol Biol Program, Madison, WI 53711 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Robertson, GA (corresponding author), Univ Wisconsin, Satellite Labs, Dept Physiol, 601 Sci Dr, Madison, WI 53711 USA.	robertson@physiology.wisc.edu		Robertson, Gail/0000-0003-4694-5790	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081780] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL081780] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson CL, 2006, CIRCULATION, V113, P365, DOI 10.1161/CIRCULATIONAHA.105.570200; Arcangeli A, 2004, BIOCHEM SOC T, V32, P826, DOI 10.1042/BST0320826; Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; Arcangeli Annarosa, 2005, V266, P225; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; Bianchi L, 1998, CANCER RES, V58, P815; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; Cherubini A, 2005, MOL BIOL CELL, V16, P2972, DOI 10.1091/mbc.E04-10-0940; COVARRUBIAS M, 1995, J BIOL CHEM, V270, P19408, DOI 10.1074/jbc.270.33.19408; Crociani O, 2003, J BIOL CHEM, V278, P2947, DOI 10.1074/jbc.M210789200; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; Deutsch C, 2003, NEURON, V40, P265, DOI 10.1016/S0896-6273(03)00506-3; Deutsch C, 2002, ANNU REV PHYSIOL, V64, P19, DOI 10.1146/annurev.physiol.64.081501.155934; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Farrelly AM, 2003, AM J PHYSIOL-GASTR L, V284, pG883, DOI 10.1152/ajpgi.00394.2002; Ficker E, 2000, J MOL CELL CARDIOL, V32, P2327, DOI 10.1006/jmcc.2000.1263; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; Fitzgerald PT, 2005, HEART RHYTHM, V2, pS30, DOI 10.1016/j.hrthm.2005.08.007; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; Gong QM, 2005, J BIOL CHEM, V280, P19419, DOI 10.1074/jbc.M502327200; Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002; Green WN, 1999, J GEN PHYSIOL, V113, P163, DOI 10.1085/jgp.113.2.163; Gullo F, 2002, FASEB J, V16, P330, DOI 10.1096/fj.02-0200fje; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; January CT, 2000, J CARDIOVASC ELECTR, V11, P1413, DOI 10.1046/j.1540-8167.2000.01413.x; Jenke M, 2003, EMBO J, V22, P395, DOI 10.1093/emboj/cdg035; Jones EMC, 2004, J BIOL CHEM, V279, P44690, DOI 10.1074/jbc.M408344200; Jordan M, 2004, METHODS, V33, P136, DOI 10.1016/j.ymeth.2003.11.011; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kosolapov A, 2003, J BIOL CHEM, V278, P4305, DOI 10.1074/jbc.M209422200; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; Lees-Miller JP, 2003, MOL CELL BIOL, V23, P1856, DOI 10.1128/MCB.23.6.1856-1862.2003; LeesMiller JP, 1997, CIRC RES, V81, P719; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; London B, 1997, CIRC RES, V81, P870; Lu JL, 2001, BIOCHEMISTRY-US, V40, P10934, DOI 10.1021/bi010763e; Lu JL, 2001, BIOCHEMISTRY-US, V40, P13288, DOI 10.1021/bi0107647; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; Ohya S, 2002, AM J PHYSIOL-CELL PH, V283, pC866, DOI 10.1152/ajpcell.00099.2002; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Pillozzi S, 2002, LEUKEMIA, V16, P1791, DOI 10.1038/sj.leu.2402572; Rajamani S, 2002, CIRCULATION, V105, P2830, DOI 10.1161/01.CIR.0000019513.50928.74; Robertson GA, 2006, HANDB EXP PHARMACOL, V171, P349; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; Roti ECR, 2002, J BIOL CHEM, V277, P47779, DOI 10.1074/jbc.M206638200; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sato Y, 2002, P NATL ACAD SCI USA, V99, P60, DOI 10.1073/pnas.012399799; SHAHLA V, 1992, CELL, V68, P23; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; Smith GAM, 2002, J BIOL CHEM, V277, P18528, DOI 10.1074/jbc.M200592200; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Tu L, 2000, BIOCHEMISTRY-US, V39, P824, DOI 10.1021/bi991740r; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; WIRTH PJ, 1995, J CHROMATOGR A, V698, P123, DOI 10.1016/0021-9673(94)00879-E; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	64	51	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9874	9882		10.1074/jbc.M610875200	http://dx.doi.org/10.1074/jbc.M610875200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272276	hybrid			2022-12-25	WOS:000245421700062
J	Feng, Q; Sekula, D; Muller, R; Freemantle, SJ; Dmitrovsky, E				Feng, Q.; Sekula, D.; Muller, R.; Freemantle, S. J.; Dmitrovsky, E.			Uncovering residues that regulate cyclin D1 proteasomal degradation	ONCOGENE			English	Article						cyclin D1; all-trans-retinoic acid; ubiquitination	N-TERMINAL UBIQUITINATION; NUCLEAR-LOCALIZATION; RETINOIC ACID; PHOSPHORYLATION; PROTEOLYSIS; CANCER; SIGNAL; TARGET; UBE1L; PREVENTION	Cyclin D1 regulates G1 cell-cycle progression and is aberrantly expressed in carcinogenesis. Proteasomal degradation of cyclin D1 was highlighted as a cancer chemopreventive mechanism. To understand this mechanism better, residues responsible for degradation and ubiquitination of cyclin D1 were investigated. Eighteen lysines in cyclin D1 had single, double or multiple mutations engineered before transfection into BEAS-2B human bronchial epithelial (HBE) cells to evaluate stabilities after all-trans-retinoic acid (RA) or cycloheximide treatments. Specific mutations stabilized cyclin D1, including substitutions of lysines surrounding the cyclin box domain that inhibited RA-mediated degradation and extended the cyclin D1 half-life. Mutation of all cyclin D1 lysines blocked polyubiquitination. N-terminus (but not C-terminus) modification stabilized cyclin D1. Ubiquitination resistant mutants preferentially localized cyclin D1 to the nucleus, directly implicating subcellular localization in regulating cyclin D1 degradation. Taken together, these findings uncover specific residues conferring ubiquitination of cyclin D1. These provide a mechanistic basis for proteasomal degradation of cyclin D1.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Univ Marburg, IMT, Marburg, Germany; Dartmouth Med Sch, Dept Med, Hanover, NH USA; Dartmouth Med Sch, Norris Cotton Canc Ctr, Hanover, NH USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA	Dartmouth College; Philipps University Marburg; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Dmitrovsky, E (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.	Ethan.Dmitrovsky@Dartmouth.EDU	Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248	NATIONAL CANCER INSTITUTE [R01CA087546, R01CA111422] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111422, R01 CA087546] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Aggarwal BB, 2004, ANTICANCER RES, V24, P2783; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Batonnet S, 2004, J BIOL CHEM, V279, P5413, DOI 10.1074/jbc.M310315200; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016/j.tcb.2004.01.004; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coulombe P, 2004, MOL CELL BIOL, V24, P6140, DOI 10.1128/MCB.24.14.6140-6150.2004; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DMITROVSKY E, 2002, ENCY CANC, P449; Dragnev KH, 2005, J CLIN ONCOL, V23, P8757, DOI 10.1200/JCO.2005.01.9521; Dragnev KH, 2004, CLIN CANCER RES, V10, P2570, DOI 10.1158/1078-0432.CCR-03-0271; Dragnev KH, 2001, ANN NY ACAD SCI, V952, P13, DOI 10.1111/j.1749-6632.2001.tb02724.x; Fung TK, 2005, CELL CYCLE, V4, P1411, DOI 10.4161/cc.4.10.2046; Germain D, 2000, J BIOL CHEM, V275, P12074, DOI 10.1074/jbc.275.16.12074; Gladden AB, 2005, J CELL BIOCHEM, V96, P906, DOI 10.1002/jcb.20613; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kitareewan S, 2002, P NATL ACAD SCI USA, V99, P3806, DOI 10.1073/pnas.052011299; Klotzbucher A, 1996, EMBO J, V15, P3053, DOI 10.1002/j.1460-2075.1996.tb00668.x; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Lu FM, 2003, CANCER RES, V63, P7056; Ma Y, 2005, CANCER RES, V65, P6476, DOI 10.1158/0008-5472.CAN-05-0370; Patel MI, 2005, CLIN CANCER RES, V11, P1999, DOI 10.1158/1078-0432.CCR-04-1877; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Petty WJ, 2003, LUNG CANCER, V41, pS155, DOI 10.1016/S0169-5002(03)00159-4; Pitha-Rowe I, 2004, CANCER RES, V64, P8109, DOI 10.1158/0008-5472.CAN-03-3938; Pitha-Rowe I, 2004, J BIOL CHEM, V279, P18178, DOI 10.1074/jbc.M309259200; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Solomon DA, 2003, J BIOL CHEM, V278, P30339, DOI 10.1074/jbc.M303969200; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Zwicker J, 1999, ONCOGENE, V18, P19, DOI 10.1038/sj.onc.1202286	38	26	28	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5098	5106		10.1038/sj.onc.1210309	http://dx.doi.org/10.1038/sj.onc.1210309			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310991				2022-12-25	WOS:000248487400008
J	Lue, H; Thiele, M; Franz, J; Dahl, E; Speckgens, S; Leng, L; Fingerle-Rowson, G; Bucala, R; Luscher, B; Bernhagen, J				Lue, H.; Thiele, M.; Franz, J.; Dahl, E.; Speckgens, S.; Leng, L.; Fingerle-Rowson, G.; Bucala, R.; Luscher, B.; Bernhagen, J.			Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity	ONCOGENE			English	Article						MIF; JAB1; apoptosis; survival; Akt pathway; cytokine	HUMAN BREAST-CANCER; COP9 SIGNALOSOME; PROTEIN-KINASE; SIGNALING PATHWAY; PI3K/AKT PATHWAY; PTEN EXPRESSION; REGULATORY ROLE; TUMOR-GROWTH; CYTOKINE; BINDING	The phosphoinositide-3-kinase (PI3K)/Akt signaling pathway plays an important role in cell survival and the development of cancer. Macrophage migration inhibitory factor (MIF) is a critical in. ammatory cytokine that was recently associated with tumorigenesis and that potently inhibits apoptosis. This may involve inhibition of p53-dependent genes, but the initiating molecular mechanism of how MIF controls survival/apoptosis is unknown. Here, we show that MIF prevents apoptosis and promotes tumor cell survival by directly activating the Akt pathway. MIF enhanced Akt activity in primary and immortalized. broblasts (MEF and NIH/3T3), HeLa cervix carcinoma cells and various breast cancer cell lines. Activation was abolished by kinase inhibitors Ly294002 and PP2 and in Src/Yes/Fyn(SYF)(-/-) and CD74(-/-)(MEFs), while being enhanced in CD74-overexpressing MEFs, demonstrating that the MIF-induced Akt pathway encompasses signaling through the MIF receptor CD74 and the upstream kinases Src and PI3K. Akt was activated by exogenous rMIF and autocrine MIF action, as revealed by experiments in MIF-/- MEFs and antibody blockade. siRNA knockdown of CSN5/JAB1, a tumor marker and MIF-binding protein, showed that JAB1 controls autocrine MIF-mediated Akt signaling by inhibition of MIF secretion. Akt activation by MIF led to phosphorylation of the proapoptotic proteins BAD and Foxo3a. Apoptosis inhibition by MIF was functionally associated with Akt activation as it was abolished by overexpression of the Akt pathway inhibitor PTEN and occurred independently of p53. This was shown by studying DNA damage-induced apoptosis in. broblasts, the Fas death pathway in HeLa cells that do not express functional p53, and etoposide-induced apoptosis in breast carcinoma cells expressing mutant p53. Importantly, dependence of breast cancer cell survival on MIF correlated with Akt activation and the PTEN status of these cells. Thus, MIF can directly promote cell survival through activation of the PI3K/Akt pathway and this effect is critical for tumor cell survival.	Univ Hosp, Rhein Westfal TH Aachen, Dept Biochem & Mol Cell Biol, Inst Biochem, D-52074 Aachen, Germany; Univ Hosp, Rhein Westfal TH Aachen, Inst Pathol, D-52074 Aachen, Germany; Univ Hosp, Rhein Westfal TH Aachen, Dept Biochem & Mol Biol, D-52074 Aachen, Germany; Yale Univ, Sch Med, Dept Pathol & Med, New Haven, CT USA; Univ Hosp Cologne, Med Clin 1, Cologne, Germany	RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; RWTH Aachen University Hospital; Yale University; University of Cologne	Bernhagen, J (corresponding author), Univ Hosp, Rhein Westfal TH Aachen, Dept Biochem & Mol Cell Biol, Inst Biochem, Pauwelsstr 30, D-52074 Aachen, Germany.	jbernhagen@ukaachen.de	Luscher, Bernhard/A-7330-2011	Luscher, Bernhard/0000-0002-9622-8709	NIAID NIH HHS [AI43210] Funding Source: Medline; NIAMS NIH HHS [AR49610] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049610] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adler AS, 2006, NAT GENET, V38, P421, DOI 10.1038/ng1752; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Amin MA, 2006, BLOOD, V107, P2252, DOI 10.1182/blood-2005-05-2011; Amin MA, 2003, CIRC RES, V93, P321, DOI 10.1161/01.RES.0000087641.56024.DA; Bando H, 2002, JPN J CANCER RES, V93, P389, DOI 10.1111/j.1349-7006.2002.tb01269.x; Bech-Otschir D, 2002, J CELL SCI, V115, P467; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Burger-Kentischer A, 2005, FEBS LETT, V579, P1693, DOI 10.1016/j.febslet.2005.01.080; Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Calandra T, 2003, NAT REV IMMUNOL, V3, P791, DOI 10.1038/nri1200; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; deGraffenried LA, 2004, ANN ONCOL, V15, P1510, DOI 10.1093/annonc/mdh388; Fingerle-Rowson G, 2003, P NATL ACAD SCI USA, V100, P9354, DOI 10.1073/pnas.1533295100; Flieger O, 2003, FEBS LETT, V551, P78, DOI 10.1016/S0014-5793(03)00900-1; Hagemann T, 2005, J IMMUNOL, V175, P1197, DOI 10.4049/jimmunol.175.2.1197; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Lue HQ, 2006, CELL SIGNAL, V18, P688, DOI 10.1016/j.cellsig.2005.06.013; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2004, CELL SIGNAL, V16, P13, DOI 10.1016/j.cellsig.2003.07.002; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029; Nguyen MT, 2003, J IMMUNOL, V170, P3337, DOI 10.4049/jimmunol.170.6.3337; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Osoegawa A, 2006, CANCER, V107, P154, DOI 10.1002/cncr.21961; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Schober A, 2004, CIRCULATION, V109, P380, DOI 10.1161/01.CIR.0000109201.72441.09; Shi XR, 2006, IMMUNITY, V25, P595, DOI 10.1016/j.immuni.2006.08.020; Shimizu T, 1999, BIOCHEM BIOPH RES CO, V264, P751, DOI 10.1006/bbrc.1999.1584; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Takahashi N, 1998, MOL MED, V4, P707, DOI 10.1007/BF03401765; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Wolf DA, 2003, NAT CELL BIOL, V5, P1029, DOI 10.1038/ncb1203-1029; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123	49	270	285	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5046	5059		10.1038/sj.onc.1210318	http://dx.doi.org/10.1038/sj.onc.1210318			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310986				2022-12-25	WOS:000248487400003
J	Bubman, D; Guasparri, I; Cesarman, E				Bubman, D.; Guasparri, I.; Cesarman, E.			Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen	ONCOGENE			English	Article						KSHV; HHV-8; PEL; c-Myc; LANA	GLYCOGEN-SYNTHASE KINASE-3; CELLULAR GENE-EXPRESSION; EPSTEIN-BARR-VIRUS; BURKITT-LYMPHOMA; DNA-SEQUENCES; TRANSACTIVATION DOMAIN; CELLS; PHOSPHORYLATION; MUTATIONS; ONCOGENE	Primary effusion lymphoma (PEL) is a rare subtype of non-Hodgkin's lymphoma, which is associated with infection by Kaposi's sarcoma herpesvirus (KSHV)/ human herpesvirus-8. The c-Myc transcription factor plays an important role in cellular proliferation, differentiation and apoptosis. Lymphomas frequently have deregulated c-Myc expression owing to chromosomal translocations, ampli. cations or abnormal stabilization. However, no structural abnormalities were found in the c-myc oncogene in PEL. Given that c-Myc is often involved in lymphomagenesis, we hypothesized that it is deregulated in PEL. We report that PEL cells have abnormally stable c-Myc protein. The turnover of c-Myc protein is stringently regulated by post-transcriptional modi. cations, including phosphorylation of c-Myc threonine 58 (T58) by glycogen synthase kinase-3 beta (GSK-3b). Our data show that the impaired c-Myc degradation in PEL cells is associated with a signi. cant underphosphorylation of c-Myc T58. The KSHV latency-associated nuclear antigen (LANA) is responsible for this deregulation. Overexpression of LANA in human embryonic kidney 293 or peripheral blood B cells leads to post-transcriptional deregulation of c-Myc protein. Conversely, when LANA is eliminated from PEL cells using RNA interference, GSK-3bmediated c-Myc T58 phosphorylation is restored. The presence of c-Myc and LANA in GSK-3 beta-containing complexes in PEL cells further con. rms the signi. cance of these interactions in naturally KSHV-infected cells.	Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Dept Pathol & Lab Med, New York, NY USA	Cornell University; Cornell University	Cesarman, E (corresponding author), Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, 1300 york Ave,Room C410, New York, NY 10021 USA.	ecesarm@med.cornell.edu			NATIONAL CANCER INSTITUTE [R01CA068939] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA068939] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An FQ, 2005, J BIOL CHEM, V280, P3862, DOI 10.1074/jbc.M407435200; An JB, 2004, BLOOD, V103, P222, DOI 10.1182/blood-2003-05-1538; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dominguez-Sola D, 2004, NAT CELL BIOL, V6, P288, DOI 10.1038/ncb0404-288; Fakhari FD, 2006, J CLIN INVEST, V116, P735, DOI 10.1172/JCI26190; Fan W, 2005, J VIROL, V79, P1244, DOI 10.1128/JVI.79.2.1244-1251.2005; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Gaidano G, 2003, BLOOD, V102, P1833, DOI 10.1182/blood-2002-11-3606; Gaidano G, 1996, ACTA HAEMATOL-BASEL, V95, P193; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Hayward S. D., 2006, SCI STKE, V335, pre4; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Horenstein MG, 1997, BLOOD, V90, P1186, DOI 10.1182/blood.V90.3.1186; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; Knight JS, 2001, J BIOL CHEM, V276, P22971, DOI 10.1074/jbc.M101890200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; PAPAS TS, 1985, NATURE, V318, P237, DOI 10.1038/318237a0; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; Polakis P, 2000, GENE DEV, V14, P1837; PULVERER BJ, 1994, ONCOGENE, V9, P59; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Renne R, 2001, J VIROL, V75, P458, DOI 10.1128/JVI.75.1.458-468.2001; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SOULIER J, 1995, BLOOD, V86, P1275; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; YANO T, 1993, ONCOGENE, V8, P2741; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	50	86	87	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4979	4986		10.1038/sj.onc.1210299	http://dx.doi.org/10.1038/sj.onc.1210299			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310999				2022-12-25	WOS:000248322500010
J	Beck, JG; Mathieu, D; Loudet, C; Buchoux, S; Dufourc, EJ				Beck, Johannes G.; Mathieu, Damien; Loudet, Cecile; Buchoux, Sebastien; Dufourc, Erick J.			Plant sterols in "rafts": a better way to regulate membrane thermal shocks	FASEB JOURNAL			English	Article						2H-NMR; cholesterol; ergosterol; sitosterol; stigmasterol; sphingomyelin; glucosylcerebroside; dipalmitoylphosphatidylcholine; order parameters	NUCLEAR-MAGNETIC-RESONANCE; DIFFERENTIAL SCANNING CALORIMETRY; LIQUID-ORDERED PHASE; SOLID-STATE H-2-NMR; MODEL MEMBRANES; BILAYER-MEMBRANES; LIPID RAFTS; DIPALMITOYLPHOSPHATIDYLCHOLINE BILAYERS; NEUTRON-DIFFRACTION; DOMAINS RAFTS	Specialized lipid domains ( rafts) that are generally enriched in sterols and sphingolipids, are most likely present in cell membranes of animals, plants and fungi. While cholesterol and ergosterol are predominant in vertebrates and fungi, plants possess complex sterol profiles, dominated by sitosterol and stigmasterol in Arabidopsis thaliana. Fully hydrated model membranes of composition approaching those found in rafts of mammals, fungi and plants were investigated by means of solid-state H-2-NMR, using deuterated dipalmitoylphosphatidylcholine (H-2(62)-DPPC). The dynamics of such membranes was determined through measuring of membrane ordering or disordering properties. The presence of the liquid-ordered, lo, phase, which may be an indicator of rigid sterol-sphingolipid domains, was detected in all binary or ternary mixtures of all sterols investigated. Of great interest, the dynamics of ternary mixtures mimicking rafts in plants ( phytosterol/ glucosylcerebroside/ DPPC), showed a lesser temperature sensitivity to thermal shocks, on comparing to systems mimicking rafts in mammals and fungi. This effect was particularly marked with sitosterol. The presence of an ethyl group branched on the alkyl chain of sitosterol and stigmasterol is proposed as reinforcing the membrane cohesion by additional attractive van der Waals interactions with the alkyl chains of sphingolipids and phospholipids. As a side result, the elevated resolution of NMR spectra in the presence of sitosterol also suggests domains of smaller size than with other sterols. Finally, the role of phytosterols in maintaining plant membranes in a state of dynamics less sensitive to temperature shocks is discussed.-Johannes G. Beck, Damien Mathieu, Cecile Loudet, Sebastien Buchoux and Erick J. Dufourc. Plant sterols in "rafts": a better way to regulate membrane thermal shocks.	Univ Bordeaux 1, CNRS UMR 5248, CBMN, ENITAB,IECB, F-33607 Pessac, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite de Bordeaux	Dufourc, EJ (corresponding author), Univ Bordeaux 1, CNRS UMR 5248, CBMN, ENITAB,IECB, 2 Rue Robert Escarpit, F-33607 Pessac, France.	e.dufourc@iecb.u-bordeaux.fr	DUFOURC, Erick Joel/AAA-4992-2020; Buchoux, Sébastien/B-1822-2010	DUFOURC, Erick Joel/0000-0002-8221-9326; Buchoux, Sébastien/0000-0002-1544-2093				Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Aussenac F, 2003, BIOCHEMISTRY-US, V42, P1383, DOI 10.1021/bi026717b; Bacia K, 2005, P NATL ACAD SCI USA, V102, P3272, DOI 10.1073/pnas.0408215102; BLOOM M, 1981, CHEM PHYS LETT, V80, P198, DOI 10.1016/0009-2614(81)80089-9; BLOOM M, 1978, BIOCHEMISTRY-US, V17, P5750, DOI 10.1021/bi00619a024; Bouvier-Nave P, 1998, EUR J BIOCHEM, V256, P88, DOI 10.1046/j.1432-1327.1998.2560088.x; BouvierNave P, 1997, EUR J BIOCHEM, V246, P518, DOI 10.1111/j.1432-1033.1997.t01-1-00518.x; BURNETT LJ, 1971, J CHEM PHYS, V55, P5829, DOI 10.1063/1.1675758; Cevc G., 1993, PHOSPHOLIPIDS HDB, V2ZxaucDNWHcC; DAVIS JH, 1976, CHEM PHYS LETT, V42, P390, DOI 10.1016/0009-2614(76)80392-2; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; Douliez JP, 1996, J PHYS CHEM-US, V100, P18450, DOI 10.1021/jp961220v; DOULIEZ JP, 1995, BIOPHYS J, V68, P1727, DOI 10.1016/S0006-3495(95)80350-4; DUFOURC EJ, 1992, BIOPHYS J, V61, P42, DOI 10.1016/S0006-3495(92)81814-3; DUFOURC EJ, 1984, BIOCHEMISTRY-US, V23, P6063; DUFOURC EJ, 2002, LIPID DOMAINS BIOL M, V139; FLORINE KI, 1987, BIOCHEMISTRY-US, V26, P2978, DOI 10.1021/bi00385a004; Hsueh YW, 2005, BIOPHYS J, V88, P1799, DOI 10.1529/biophysj.104.051375; JARRELL HC, 1981, BIOPHYS J, V34, P451, DOI 10.1016/S0006-3495(81)84862-X; Kost B, 1999, J CELL BIOL, V145, P317, DOI 10.1083/jcb.145.2.317; LENZ BR, 1980, BIOCHEMISTRY-US, V19, P1943; LEONARD A, 1992, PROG COLL POL SCI S, V89, P315; LEONARD A, 1991, BIOCHIMIE, V73, P1295, DOI 10.1016/0300-9084(91)90092-F; Leonard A, 2001, LANGMUIR, V17, P2019, DOI 10.1021/la001382p; Leonard A., 1993, B MAGN RESON, V15, P124; LEYDI C, 2001, BIOPHYS J, V80, P1819; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; MARINOV R, 1995, J CHIM PHYS PCB, V92, P1727, DOI 10.1051/jcp/1995921727; MCMULLEN TPW, 1995, BBA-BIOMEMBRANES, V1234, P90, DOI 10.1016/0005-2736(94)00266-R; Mongrand S, 2004, J BIOL CHEM, V279, P36277, DOI 10.1074/jbc.M403440200; Peng LC, 2002, SCIENCE, V295, P147, DOI 10.1126/science.1064281; POTT T, 1995, BIOPHYS J, V68, P965, DOI 10.1016/S0006-3495(95)80272-9; RANCE M, 1982, BIOCHIM BIOPHYS ACTA, V688, P191, DOI 10.1016/0005-2736(82)90594-6; RUBENSTEIN JR, 1979, P NATL ACAD SCI USA, V76, P15, DOI 10.1073/pnas.76.1.15; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; Schaeffer A, 2001, PLANT J, V25, P605, DOI 10.1046/j.1365-313x.2001.00994.x; Schaller H, 2004, PLANT PHYSIOL BIOCH, V42, P465, DOI 10.1016/j.plaphy.2004.05.012; Schaller H, 2003, PROG LIPID RES, V42, P163, DOI 10.1016/S0163-7827(02)00047-4; Schrick K, 2002, PLANT J, V31, P61, DOI 10.1046/j.1365-313X.2002.01333.x; SEELIG J, 1977, Q REV BIOPHYS, V10, P353, DOI 10.1017/S0033583500002948; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 2002, J CLIN INVEST, V110, P597, DOI 10.1172/JCI200216390; STERNIN E, 1983, J MAGN RESON, V55, P274, DOI 10.1016/0022-2364(83)90239-1; STOCKTON GW, 1976, CHEM PHYS LIPIDS, V17, P251, DOI 10.1016/0009-3084(76)90070-0; STOCKTON GW, 1976, BIOCHEMISTRY-US, V15, P955; STOHRER J, 1991, J CHEM PHYS, V95, P672, DOI 10.1063/1.461417; Subczynski WK, 2003, BBA-BIOMEMBRANES, V1610, P231, DOI 10.1016/S0005-2736(03)00021-X; TAMPE R, 1991, BIOCHEMISTRY-US, V30, P4909, DOI 10.1021/bi00234a011; Vie V, 1998, LANGMUIR, V14, P4574, DOI 10.1021/la980203p; VIST MR, 1990, BIOCHEMISTRY-US, V29, P451, DOI 10.1021/bi00454a021; Wang TY, 2000, BIOPHYS J, V79, P1478, DOI 10.1016/S0006-3495(00)76399-5; WEISZ K, 1992, BIOCHEMISTRY-US, V31, P1100, DOI 10.1021/bi00119a019; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v	55	124	127	1	33	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2007	21	8					1714	1723		10.1096/fj.06-7809com	http://dx.doi.org/10.1096/fj.06-7809com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317727				2022-12-25	WOS:000246866500013
J	Dogra, C; Changotra, H; Wedhas, N; Qin, X; Wergedal, JE; Kumar, A				Dogra, Charu; Changotra, Harish; Wedhas, Nia; Qin, Xuezhong; Wergedal, Jon E.; Kumar, Ashok			TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine	FASEB JOURNAL			English	Article						skeletal muscle atrophy; atrogin-1; MuRF1; NF-kappa B; Akt	TUMOR-NECROSIS-FACTOR; FACTOR-KAPPA-B; UBIQUITIN LIGASES; MYOGENIC DIFFERENTIATION; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; PROTEIN LOSS; PATHWAY; ACTIVATION; ATROPHY	TWEAK cytokine has been implicated in several biological responses including inflammation, angiogenesis, and osteoclastogenesis. We have investigated the role of TWEAK in regulating skeletal muscle mass. Addition of soluble TWEAK protein to cultured myotubes reduced the mean myotube diameter and enhanced the degradation of specific muscle proteins such as CK and MyHCf. The effect of TWEAK on degradation of MyHCf was stronger than its structural homologue, TNF-alpha. TWEAK increased the ubiquitination of MyHCf and the transcript levels of atrogin-1 and MuRF1 ubiquitin ligases. TWEAK inhibited phosphorylation of Akt kinase and its downstream targets GSK-3 beta, FOXO1, mTOR, and p70S6K. Furthermore, TWEAK increased the activation of NF-kappa beta transcription factor in myotubes. Adenoviral- mediated overexpression of I kappa B alpha Delta N (a degradation-resistant mutant of NF-kappa B inhibitory protein I kappa alpha) in myotubes blocked the TWEAK-induced degradation of MyHCf. Chronic administration of TWEAK in mice resulted in reduced body and skeletal muscle weight with an associated increase in the activity of ubiquitin-proteasome system and NF-kappa B. Finally, muscle-specific transgenic overexpression of TWEAK decreased the body and skeletal muscle weight in mice. Collectively, our data suggest that TWEAK induces skeletal muscle atrophy through inhibition of the PI3K/ Akt signaling pathway and activation of the ubiquitin-proteasome and NF-kappa B systems. -Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J. E., Kumar, A. TNF- related weak inducer of apoptosis ( TWEAK) is a potent skeletal muscle-wasting cytokine.	Jerry L Pettis Mem Vet Adm Med Ctr, Lab Skeletal Muscle Physiol & Neurobiol, Loma Linda, CA 92357 USA; Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA; Loma Linda Univ, Sch Med, Loma Linda, CA USA	Loma Linda University	Kumar, A (corresponding author), Jerry L Pettis Mem Vet Adm Med Ctr, Lab Skeletal Muscle Physiol & Neurobiol, 11201 Benton St 151, Loma Linda, CA 92357 USA.	ashok.kumar2@va.gov	Changotra, Harish/H-2105-2011	Changotra, Harish/0000-0002-1465-5257; Kumar, Ashok/0000-0001-8571-2848	NIA NIH HHS [R01 AG129623, R01 AG029623, R01 AG029623-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG029623] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acharyya S, 2004, J CLIN INVEST, V114, P370, DOI 10.1172/jci200420174; Argiles JM, 2005, INT J BIOCHEM CELL B, V37, P1609, DOI 10.1016/j.biocel.2005.03.007; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Broussard SR, 2004, J IMMUNOL, V172, P7713, DOI 10.4049/jimmunol.172.12.7713; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Cao PR, 2005, INT J BIOCHEM CELL B, V37, P2088, DOI 10.1016/j.biocel.2004.11.010; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Desplat-Jego S, 2002, J NEUROIMMUNOL, V133, P116, DOI 10.1016/S0165-5728(02)00368-5; Dogra C, 2006, J BIOL CHEM, V281, P10327, DOI 10.1074/jbc.M511131200; Dogra C, 2006, J CELL PHYSIOL, V208, P575, DOI 10.1002/jcp.20696; Du J, 2000, J BIOL CHEM, V275, P19661, DOI 10.1074/jbc.M907258199; Filippatos GS, 2005, CURR OPIN CLIN NUTR, V8, P249, DOI 10.1097/01.mco.0000165002.08955.5b; Franch HA, 2005, CURR OPIN CLIN NUTR, V8, P271, DOI 10.1097/01.mco.0000165005.01331.45; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Haddad F, 2005, J APPL PHYSIOL, V98, P911, DOI 10.1152/japplphysiol.01026.2004; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Ho DH, 2004, CANCER RES, V64, P8968, DOI 10.1158/0008-5472.CAN-04-1879; Hunter RB, 2004, J CLIN INVEST, V114, P1504, DOI 10.1172/JCI200421696; Hunter RB, 2002, FASEB J, V16, P529, DOI 10.1096/fj.01-0866com; Jackman RW, 2004, AM J PHYSIOL-CELL PH, V287, pC834, DOI 10.1152/ajpcell.00579.2003; Jakubowski A, 2005, J CLIN INVEST, V115, P2330, DOI 10.1172/JCI23486; Jefferson LS, 1999, INT J BIOCHEM CELL B, V31, P191, DOI 10.1016/S1357-2725(98)00141-1; Kawakita T, 2005, INT J ONCOL, V26, P87; Kawakita T, 2004, BIOCHEM BIOPH RES CO, V318, P726, DOI 10.1016/j.bbrc.2004.04.084; Kim J, 2004, GENES CELLS, V9, P399, DOI 10.1111/j.1356-9597.2004.00731.x; Kronqvist P, 2002, AM J PATHOL, V161, P1535, DOI 10.1016/S0002-9440(10)64431-8; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Kumar A, 2005, J BIOL CHEM, V280, P37782, DOI 10.1074/jbc.M505278200; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lecker SH, 1999, J CLIN INVEST, V104, P1411, DOI 10.1172/JCI7300; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Li YP, 2003, FASEB J, V17, P1048, DOI 10.1096/fj.02-0759com; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Lin TA, 1996, J BIOL CHEM, V271, P30199, DOI 10.1074/jbc.271.47.30199; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Maecker H, 2005, CELL, V123, P931, DOI 10.1016/j.cell.2005.09.022; Marsters SA, 1998, CURR BIOL, V8, P525, DOI 10.1016/S0960-9822(98)70204-0; Miller SM, 1998, MOL BIOL CELL, V9, p292A; Nader GA, 2005, INT J BIOCHEM CELL B, V37, P1985, DOI 10.1016/j.biocel.2005.02.026; Nakayama M, 2003, J IMMUNOL, V170, P341, DOI 10.4049/jimmunol.170.1.341; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Perper SJ, 2006, J IMMUNOL, V177, P2610, DOI 10.4049/jimmunol.177.4.2610; Polek TC, 2003, J BIOL CHEM, V278, P32317, DOI 10.1074/jbc.M302518200; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Potrovita I, 2004, J NEUROSCI, V24, P8237, DOI 10.1523/JNEUROSCI.1089-04.2004; Reid MB, 2005, AM J PHYSIOL-REG I, V288, pR1423, DOI 10.1152/ajpregu.00545.2004; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Saas P, 2000, GLIA, V32, P102, DOI 10.1002/1098-1136(200010)32:1<102::AID-GLIA100>3.0.CO;2-U; Sacheck JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE591, DOI 10.1152/ajpendo.00073.2004; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3; Semov A, 2002, FASEB J, V16, P899, DOI 10.1096/fj.01-1002fje; Sharma R, 2002, INT J CARDIOL, V85, P161, DOI 10.1016/S0167-5273(02)00244-9; Spate U, 2004, CURR OPIN CLIN NUTR, V7, P265, DOI 10.1097/01.mco.0000126344.88494.de; Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; Wedhas N, 2005, FASEB J, V19, P1986, DOI 10.1096/fj.05-4198com; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Xu HR, 2004, BIOCHEM BIOPH RES CO, V318, P422, DOI 10.1016/j.bbrc.2004.04.036	69	168	178	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1857	1869		10.1096/fj.06-7537com	http://dx.doi.org/10.1096/fj.06-7537com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314137	Green Accepted			2022-12-25	WOS:000246866500027
J	Hasshoff, M; Bohnisch, C; Tonn, D; Hasert, B; Schulenburg, H				Hasshoff, Martin; Boehnisch, Claudia; Tonn, Daniela; Hasert, Barbara; Schulenburg, Hinrich			The role of Caenorhabditis elegans insulin-like signaling in the behavioral avoidance of pathogenic Bacillus thuringiensis	FASEB JOURNAL			English	Article						immune system; host-pathogen evolution	TOLL-LIKE RECEPTORS; LIFE-SPAN; STRESS RESISTANCE; NATURAL VARIATION; LONGEVITY; MUTANTS; DAF-2; RECOGNITION; DROSOPHILA; SEROTONIN	Pathogens cause damage, and their elimination requires activation of the costly immune response. A highly economic defense strategy should thus be the behavioral avoidance of pathogens, as manifested in humans by all aspects of hygiene or revulsion at pathogen-rich material. Despite its potential importance, behavioral defenses have as yet received only little attention in biomedical research-in stark contrast to the physiological immune system. In the present study, the genetics of such behavioral defenses are elucidated in a simple model organism, the nematode Caenorhabditis elegans. We show for the first time that mutations in the insulin-like receptor (ILR) pathway lead to two distinct behavioral responses against pathogenic strains of the Gram-positive bacterium Bacillus thuringiensis ( BT), including the physical evasion of pathogens and their reduced oral uptake. Since this pathway also contributes to nematode stress resistance, the results surprisingly reveal a genetic link between physiological and behavioral defenses. Considering that many signaling pathways have conserved their functions across evolution, including the ILR pathway, this signaling cascade may represent an interesting candidate regulator for behavioral defenses in more complex organisms, including humans.-Hasshoff M., Bohnisch C., Tonn D., Hasert B., Schulenburg H. The role of Caenorhabditis elegans insulin-like signaling in the behavioral avoidance of pathogenic Bacillus thuringiensis.	Univ Tubingen, Inst Zool, Dept Anim Evolutionary Ecol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Schulenburg, H (corresponding author), Univ Tubingen, Inst Zool, Dept Anim Evolutionary Ecol, Morgenstelle 28, D-72076 Tubingen, Germany.	hinrich.schulenburg@uni-tuebingen.de	Schulenburg, Hinrich/A-3886-2009					Aballay A, 2000, CURR BIOL, V10, P1539, DOI 10.1016/S0960-9822(00)00830-7; Barriere A, 2005, CURR BIOL, V15, P1176, DOI 10.1016/j.cub.2005.06.022; Barsyte D, 2001, FASEB J, V15, P627, DOI 10.1096/fj.99-0966com; Beale E, 2006, APPL ENVIRON MICROB, V72, P5135, DOI 10.1128/AEM.00611-06; Bluher M, 2003, SCIENCE, V299, P572, DOI 10.1126/science.1078223; Bowie AG, 2005, MOL IMMUNOL, V42, P859, DOI 10.1016/j.molimm.2004.11.007; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; Couillault C, 2004, NAT IMMUNOL, V5, P488, DOI 10.1038/ni1060; Curtis V, 2004, P ROY SOC B-BIOL SCI, V271, pS131, DOI 10.1098/rsbl.2003.0144; Curtis V, 2001, PERSPECT BIOL MED, V44, P17, DOI 10.1353/pbm.2001.0001; Estevez AO, 2006, DEV BIOL, V298, P32, DOI 10.1016/j.ydbio.2006.06.005; Finch CE, 2001, ANNU REV GENOM HUM G, V2, P435, DOI 10.1146/annurev.genom.2.1.435; Fisher R. A., 1954, STAT METHODS RES WOR, DOI DOI 10.1007/BF01603396; Garsin DA, 2003, SCIENCE, V300, P1921, DOI 10.1126/science.1080147; Gems D, 2005, MECH AGEING DEV, V126, P381, DOI 10.1016/j.mad.2004.09.001; Gems D, 1998, GENETICS, V150, P129; Griffitts JS, 2005, BIOESSAYS, V27, P614, DOI 10.1002/bies.20239; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Haber M, 2005, MOL BIOL EVOL, V22, P160, DOI 10.1093/molbev/msh264; Halaschek-Wiener J, 2005, GENOME RES, V15, P603, DOI 10.1101/gr.3274805; HAMILTON WD, 1982, SCIENCE, V218, P384, DOI 10.1126/science.7123238; HART BL, 1990, NEUROSCI BIOBEHAV R, V14, P273, DOI 10.1016/S0149-7634(05)80038-7; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hodgkin J, 1997, GENETICS, V146, P149; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Imler JL, 2004, J ENDOTOXIN RES, V10, P241, DOI 10.1179/096805104225005887; Katic M, 2005, CELL MOL LIFE SCI, V62, P320, DOI 10.1007/s00018-004-4297-y; Kavaliers M, 2005, NEUROSCI BIOBEHAV R, V29, P1347, DOI 10.1016/j.neubiorev.2005.04.011; Kavaliers M, 2005, ANIM BEHAV, V70, P693, DOI 10.1016/j.anbehav.2004.12.016; Kavaliers M, 2005, TRENDS PARASITOL, V21, P423, DOI 10.1016/j.pt.2005.07.008; Kavaliers M, 2003, GENES BRAIN BEHAV, V2, P220, DOI 10.1034/j.1601-183X.2003.00021.x; LEYNS F, 1995, FUND APPL NEMATOL, V18, P211; Liang B, 2006, CELL METAB, V4, P429, DOI 10.1016/j.cmet.2006.11.004; Lithgow GJ, 2002, MECH AGEING DEV, V123, P765, DOI 10.1016/S0047-6374(01)00422-5; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; McElwee JJ, 2004, J BIOL CHEM, V279, P44533, DOI 10.1074/jbc.M406207200; Moore J., 2002, PARASITES BEHAV ANIM; Murakami S, 2006, EXP GERONTOL, V41, P1014, DOI 10.1016/j.exger.2006.06.061; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; OH SW, 2006, IN PRESS NAT GENET; Pasare C, 2004, MICROBES INFECT, V6, P1382, DOI 10.1016/j.micinf.2004.08.018; PRADEL E, 2007, IN PRESS P NATL ACAD; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Rubio-Godoy M, 2007, MED HYPOTHESES, V68, P61, DOI 10.1016/j.mehy.2006.06.036; Schmid-Hempel P, 2003, TRENDS ECOL EVOL, V18, P27, DOI 10.1016/S0169-5347(02)00013-7; Schulenburg H, 2004, IMMUNOL REV, V198, P36, DOI 10.1111/j.0105-2896.2004.0125.x; Schulenburg H, 2004, PARASITOLOGY, V128, P433, DOI 10.1017/S003118200300461X; Sicard M, 2007, ENVIRON MICROBIOL, V9, P12, DOI 10.1111/j.1462-2920.2006.01099.x; Sivasundar A, 2005, CURR BIOL, V15, P1598, DOI 10.1016/j.cub.2005.08.034; Smith MP, 2002, FEMS MICROBIOL LETT, V210, P181, DOI 10.1111/j.1574-6968.2002.tb11178.x; Sokal RR, 1995, BIOMETRY; Stiernagle T., 1999, C ELEGANS PRACTICAL, P51; Tan MW, 1999, P NATL ACAD SCI USA, V96, P715, DOI 10.1073/pnas.96.2.715; Troemel ER, 2006, PLOS GENET, V2, P1725, DOI 10.1371/journal.pgen.0020183; Vellai T, 2006, GENETICS, V174, P309, DOI 10.1534/genetics.106.061499; Wu Q, 2005, NAT NEUROSCI, V8, P1350, DOI 10.1038/nn1540; YOOK K, 2007, IN PRESS GENETICS; Zhang Y, 2005, NATURE, V438, P179, DOI 10.1038/nature04216	59	54	58	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1801	1812		10.1096/fj.06-6551com	http://dx.doi.org/10.1096/fj.06-6551com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314144				2022-12-25	WOS:000246866500022
J	Rousseau, K; Kauser, S; Pritchard, LE; Warhurst, A; Oliver, RL; Slominski, A; Wei, ET; Thody, AJ; Tobin, DJ; White, A				Rousseau, Karine; Kauser, Sobia; Pritchard, Lynn E.; Warhurst, Anne; Oliver, Robert L.; Slominski, Andrzej; Wei, Edward T.; Thody, Anthony J.; Tobin, Desmond J.; White, Anne			Proopiomelanocortin (POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis	FASEB JOURNAL			English	Article						alpha-MSH; hair follicle melanocytes; CRH receptors	CORTICOTROPIN-RELEASING HORMONE; 2-SITE IMMUNORADIOMETRIC ASSAY; CULTURED HUMAN MELANOCYTES; HAIR-FOLLICLE MELANOCYTES; PROHORMONE CONVERTASES 1; CANCER CELL-LINES; BETA-ENDORPHIN; HUMAN SKIN; MELANOCORTIN-1 RECEPTOR; CEREBROSPINAL-FLUID	Proopiomelanocortin ( POMC) can be processed to ACTH and melanocortin peptides. However, processing is incomplete in some tissues, leading to POMC precursor release from cells. This study examined POMC processing in human skin and the effect of POMC on the melanocortin-1 receptor (MC-1R) and melanocyte regulation. POMC was secreted by both human epidermal keratinocytes ( from 5 healthy donors) and matched epidermal melanocytes in culture. Much lower levels of alpha-MSH were secreted and only by the keratinocytes. Neither cell type released ACTH. Cell extracts contained significantly more ACTH than POMC, and alpha-MSH was detected only in keratinocytes. Nevertheless, the POMC processing components, prohormone convertases 1, 2 and regulatory protein 7B2, were detected in melanocytes and keratinocytes. In contrast, hair follicle melanocytes secreted both POMC and alpha-MSH, and this was enhanced in response to corticotrophin-releasing hormone ( CRH) acting primarily through the CRH receptor 1. In cells stably transfected with the MC-1R, POMC stimulated cAMP, albeit with a lower potency than ACTH, alpha-MSH, and beta-MSH. POMC also increased melanogenesis and dendricity in human pigment cells. This release of POMC from skin cells and its functional activity at the MC-1R highlight the importance of POMC processing as a key regulatory event in the skin. Rousseau, K., Kauser, S., Pritchard, L. E., Warhurst, A., Oliver, R. L., Slominski, A., Wei, E. T., Thody, A. J., Tobin, D. J., White, A. Proopiomelanocortin ( POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis.	Univ Manchester, Fac Life Sci & Med, Manchester M13 9PT, Lancs, England; Univ Manchester, Fac Human Sci, Manchester M13 9PT, Lancs, England; Univ Bradford, Bradford, W Yorkshire, England; Univ Tennessee Hlth Sci, Dept Pathol & Lab Med, Memphis, TN USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA USA; Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England	University of Manchester; University of Manchester; University of Bradford; University of Tennessee System; University of Tennessee Health Science Center; University of California System; University of California Berkeley; Newcastle University - UK	White, A (corresponding author), Univ Manchester, Fac Life Sci & Med, Stopford Bldg, Manchester M13 9PT, Lancs, England.	anne.white@manchester.ac.uk	White, Anne/G-7717-2015; Tobin, Desmond/A-5228-2009	White, Anne/0000-0002-7686-2884; Slominski, Andrzej/0000-0001-8963-3995; Tobin, Desmond/0000-0003-4566-9392	NIAMS NIH HHS [AR047079, R01 AR047079-03, R01 AR047079-02, R01 AR047079, R01 AR047079-01A2] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047079] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABDELMALEK Z, 1995, P NATL ACAD SCI USA, V92, P1789, DOI 10.1073/pnas.92.5.1789; ANCANS J, 2002, MECH SUNTANNING; BERTAGNA XY, 1978, P NATL ACAD SCI USA, V75, P5160, DOI 10.1073/pnas.75.10.5160; BHARDWAJ RS, 1994, ARCH DERMATOL RES, V287, P85, DOI 10.1007/BF00370724; Bicknell AB, 2001, CELL, V105, P903, DOI 10.1016/S0092-8674(01)00403-2; Bohm MB, 2005, ENDOCRINOLOGY, V146, P4635, DOI 10.1210/en.2005-0665; BUFFEY JA, 1994, BRIT J DERMATOL, V131, P836, DOI 10.1111/j.1365-2133.1994.tb08586.x; Chakraborty AK, 1996, BBA-MOL CELL RES, V1313, P130, DOI 10.1016/0167-4889(96)00063-8; CROSBY SR, 1988, J CLIN ENDOCR METAB, V67, P1272, DOI 10.1210/jcem-67-6-1272; Dumermuth E, 1998, METHODS, V16, P188, DOI 10.1006/meth.1998.0666; GIBSON S, 1994, J CLIN ENDOCR METAB, V78, P835, DOI 10.1210/jc.78.4.835; HUNT G, 1995, PIGM CELL RES, V8, P202, DOI 10.1111/j.1600-0749.1995.tb00664.x; HUNT G, 1994, J CELL SCI, V107, P205; HUNT G, 1994, J ENDOCRINOL, V140, pR1, DOI 10.1677/joe.0.140R001; Ito N, 2005, FASEB J, V19, P1332, DOI 10.1096/fj.04-1968fje; Kadekaro AL, 2003, ANN NY ACAD SCI, V994, P359, DOI 10.1111/j.1749-6632.2003.tb03200.x; Kauser S, 2005, ENDOCRINOLOGY, V146, P532, DOI 10.1210/en.2004-1145; Kauser S, 2004, J INVEST DERMATOL, V123, P184, DOI 10.1111/j.0022-202X.2004.22724.x; Kauser S, 2003, J INVEST DERMATOL, V120, P1073, DOI 10.1046/j.1523-1747.2003.12242.x; Kauser S, 2006, FASEB J, V20, P882, DOI 10.1096/fj.05-5257com; KAUTSKY MB, 1995, J INVEST DERMATOL, V104, P545, DOI 10.1111/1523-1747.ep12606058; Krude H, 1998, NAT GENET, V19, P155, DOI 10.1038/509; LERNER AB, 1961, NATURE, V189, P176, DOI 10.1038/189176a0; Mazurkiewicz JE, 2000, J HISTOCHEM CYTOCHEM, V48, P905, DOI 10.1177/002215540004800703; MOUNTJOY KG, 1994, MOL CELL ENDOCRINOL, V102, pR7, DOI 10.1016/0303-7207(94)90113-9; Peters EMJ, 2000, J INVEST DERMATOL, V114, P430, DOI 10.1046/j.1523-1747.2000.00913.x; Pritchard LE, 2004, J ENDOCRINOL, V180, P183, DOI 10.1677/joe.0.1800183; Pritchard LE, 2003, ENDOCRINOLOGY, V144, P760, DOI 10.1210/en.2002-220866; Pritchard LE, 2002, J ENDOCRINOL, V172, P411, DOI 10.1677/joe.0.1720411; RAY DW, 1995, J CLIN ENDOCR METAB, V80, P2430, DOI 10.1210/jc.80.8.2430; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; Schiller M, 2001, J INVEST DERMATOL, V117, P227, DOI 10.1046/j.0022-202x.2001.01412.x; SLOMINSKI A, 1992, LIFE SCI, V50, P1103, DOI 10.1016/0024-3205(92)90347-R; Slominski A, 2005, AM J PHYSIOL-ENDOC M, V288, pE701, DOI 10.1152/ajpendo.00519.2004; Slominski A, 1998, J CLIN ENDOCR METAB, V83, P1020, DOI 10.1210/jc.83.3.1020; SLOMINSKI A, 1993, MOL CELL ENDOCRINOL, V93, pC1, DOI 10.1016/0303-7207(93)90131-3; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; Slominski A, 2004, ENDOCRINOLOGY, V145, P941, DOI 10.1210/en.2003-0851; Slominski A, 2005, J NEUROIMMUNOL, V162, P97, DOI 10.1016/j.jneuroim.2005.01.014; Slominski A, 1999, HUM PATHOL, V30, P208, DOI 10.1016/S0046-8177(99)90278-2; Slominski A, 2006, FRONT BIOSCI-LANDMRK, V11, P2230, DOI 10.2741/1966; STEWART MF, 1989, BRIT J CANCER, V60, P20, DOI 10.1038/bjc.1989.212; Thody AJ, 1998, PIGM CELL RES, V11, P265, DOI 10.1111/j.1600-0749.1998.tb00735.x; THODY AJ, 1983, PEPTIDES, V4, P813, DOI 10.1016/0196-9781(83)90072-4; TOBIN DJ, 1995, J INVEST DERMATOL, V104, P86, DOI 10.1111/1523-1747.ep12613573; TSIGOS C, 1995, J DIABETES COMPLICAT, V9, P92, DOI 10.1016/1056-8727(94)00024-I; Wakamatsu K, 1997, PIGM CELL RES, V10, P288, DOI 10.1111/j.1600-0749.1997.tb00688.x; Wei ET, 1998, PEPTIDES, V19, P1183, DOI 10.1016/S0196-9781(98)00085-0; White A, 1998, CLIN ENDOCRINOL, V48, P251, DOI 10.1046/j.1365-2265.1998.00451.x; WHITE A, 1989, J MOL ENDOCRINOL, V3, P65, DOI 10.1677/jme.0.0030065; WHITE A, 1987, CLIN ENDOCRINOL, V26, P41, DOI 10.1111/j.1365-2265.1987.tb03637.x; Wintzen M, 1996, J INVEST DERMATOL, V106, P673, DOI 10.1111/1523-1747.ep12345496	52	121	128	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1844	1856		10.1096/fj.06-7398com	http://dx.doi.org/10.1096/fj.06-7398com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317724	Green Accepted			2022-12-25	WOS:000246866500026
J	Boucher, N; Dacheux, D; Giroud, C; Baltz, T				Boucher, Nathalie; Dacheux, Denis; Giroud, Christiane; Baltz, Theo			An essential cell cycle-regulated nucleolar protein relocates to the mitotic spindle where it is involved in mitotic progression in Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORM; RNA INTERFERENCE; RIBOSOME BIOGENESIS; BINDING PROTEIN; GENE-EXPRESSION; PROCYCLIC FORM; AURORA KINASE; CYTOKINESIS; HOMOLOG; MITOSIS	TbNOP86 and TbNOP66 are two novel nucleolar proteins isolated in Trypanosoma brucei. They share 92.6% identity, except for an additional C-terminal domain of TbNOP86 of 182 amino acids in length. Both proteins are found in Trypanosomatidae, but similarity to other eukaryotic proteins could not be found. TbNOP86 and TbNOP66 are expressed at similar level in procyclic and bloodstream forms, although the relative level of expression of TbNOP66 is 11 times lower. TbNOP86 undergoes post-translational modifications, as it is found predominantly at 110 kDa compared with the predicted 86 kDa. Immunofluorescence of overexpressed ty-tagged TbNOP86 and TbNOP66 showed that both proteins accumulated in the nucleolus of G(1) cells. This was confirmed by the co-localization of an endogenous TbNOP86-myc with the nucleolar protein Nopp140. TbNOP86-ty localization is cell cycle-regulated, because it co-localizes with the mitotic spindle in mitotic cells. TbNOP86 is required for mitotic progression in both life stages as depleted cells are enriched in the G2/M phase. In procyclic cells, a reduced growth rate is accompanied by an accumulation of zoids (0N1K), 2N1K, and multinucleated cells (xNyK). The 2N1K cells are blocked in late mitosis as nucleolar segregation is completed. TbNOP86 depletion in bloodstream form caused a drastic growth inhibition producing cells bearing two kinetoplasts and an enlarged nucleus (1N*2K), followed by an accumulation of 2N2K cells with connected nuclei and xNyK cells. These studies of TbNOP86 provide a more comprehensive account of proteins involved in mitotic events in trypanosomes and should lead to the identification of partners with similar function.	Univ Bordeaux 2, UMR 5234, CNRS, Lab Microbiol Cellulaire & Mol, F-33076 Bordeaux, France; Univ Bordeaux 2, UMR 5234, CNRS, Lab Pathogenet, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux	Boucher, N (corresponding author), Univ Bordeaux 2, UMR 5234, CNRS, Lab Microbiol Cellulaire & Mol, F-33076 Bordeaux, France.	nathalie.boucher@parasitmol.u-bordeaux2.fr	Dacheux, Denis/AGF-5359-2022	DACHEUX, Denis/0000-0002-9956-4839				Andersen JS, 2005, NATURE, V433, P77, DOI 10.1038/nature03207; Bakalara N, 2000, J BIOL CHEM, V275, P8863, DOI 10.1074/jbc.275.12.8863; BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; Berriman M, 2005, SCIENCE, V309, P416, DOI 10.1126/science.1112642; Blanc JF, 2005, PROTEOMICS, V5, P3778, DOI 10.1002/pmic.200401194; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; Das A, 1996, J BIOL CHEM, V271, P15675, DOI 10.1074/jbc.271.26.15675; Dubessay P, 2006, MOL MICROBIOL, V59, P1162, DOI 10.1111/j.1365-2958.2005.05013.x; Durand-Dubief M, 2003, BMC BIOL, V1, DOI 10.1186/1741-7007-1-2; Elias MCQB, 2001, MOL BIOCHEM PARASIT, V112, P79, DOI 10.1016/S0166-6851(00)00349-2; Ersfeld K, 1997, SCIENCE, V276, P611, DOI 10.1126/science.276.5312.611; Hammarton TC, 2005, MOL MICROBIOL, V56, P104, DOI 10.1111/j.1365-2958.2005.04542.x; Hammarton TC, 2003, J BIOL CHEM, V278, P22877, DOI 10.1074/jbc.M300813200; Harlow E., 1988, ANTIBODIES LAB MANUA; Hoek M, 2000, J CELL SCI, V113, P3959; Jensen BC, 2005, EUKARYOT CELL, V4, P30, DOI 10.1128/EC.4.1.30-35.2005; Jensen BC, 2003, J BIOL CHEM, V278, P32204, DOI 10.1074/jbc.M304198200; Jensen BC, 2007, MOL BIOCHEM PARASIT, V151, P28, DOI 10.1016/j.molbiopara.2006.10.002; Kaiser BK, 2002, MOL BIOL CELL, V13, P2289, DOI 10.1091/mbc.01-11-0535; Kelly S, 2006, EUKARYOT CELL, V5, P876, DOI 10.1128/EC.5.5.876-879.2006; Kumar P, 2006, EUKARYOT CELL, V5, P92, DOI 10.1128/EC.5.1.92-102.2006; Kumar P, 2005, J BIOL CHEM, V280, P31783, DOI 10.1074/jbc.M504326200; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; Li B, 2005, MOL CELL BIOL, V25, P5011, DOI 10.1128/MCB.25.12.5011-5021.2005; Li ZY, 2006, EUKARYOT CELL, V5, P1026, DOI 10.1128/EC.00129-06; Li ZY, 2003, J BIOL CHEM, V278, P20652, DOI 10.1074/jbc.M301635200; McKean PG, 2003, CURR OPIN MICROBIOL, V6, P600, DOI 10.1016/j.mib.2003.10.010; Nazar RN, 2004, IUBMB LIFE, V56, P457, DOI 10.1080/15216540400010867; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Oberholzer M, 2006, MOL BIOCHEM PARASIT, V145, P117, DOI 10.1016/j.molbiopara.2005.09.002; Ogbadoyi E, 2000, CHROMOSOMA, V108, P501, DOI 10.1007/s004120050402; Park JH, 2002, MOL BIOCHEM PARASIT, V119, P97, DOI 10.1016/S0166-6851(01)00407-8; Ploubidou A, 1999, J CELL SCI, V112, P4641; Pradel LC, 2006, J CELL SCI, V119, P1852, DOI 10.1242/jcs.02900; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; Rothberg KG, 2006, J BIOL CHEM, V281, P9781, DOI 10.1074/jbc.M600133200; SASSE R, 1988, J CELL SCI, V90, P577; SEYFANG A, 1993, EUR J BIOCHEM, V214, P593, DOI 10.1111/j.1432-1033.1993.tb17958.x; Trautmann S, 2004, DEV CELL, V7, P755, DOI 10.1016/j.devcel.2004.10.006; Tu XM, 2006, J BIOL CHEM, V281, P9677, DOI 10.1074/jbc.M511504200; Tu XM, 2004, J BIOL CHEM, V279, P20519, DOI 10.1074/jbc.M312862200; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WIRTZ E, 1995, SCIENCE, V268, P1179, DOI 10.1126/science.7761835; WOODWARD R, 1990, J CELL SCI, V95, P49	47	13	13	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13780	13790		10.1074/jbc.M700780200	http://dx.doi.org/10.1074/jbc.M700780200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17322293	hybrid			2022-12-25	WOS:000246060300068
J	van Bergeijk, J; Rydel-Konecke, K; Grothe, C; Claus, P				van Bergeijk, Jeroen; Rydel-Koenecke, Katharina; Grothe, Claudia; Claus, Peter			The spinal muscular atrophy gene product regulates neurite outgrowth: Importance of the C terminus	FASEB JOURNAL			English	Article						survival of motoneuron; neurodegeneration; actin; PC12 cells	NEURON SMN PROTEIN; FIBROBLAST GROWTH FACTOR-2; MOLECULAR ANALYSIS; ACTIN-FILAMENT; MESSENGER-RNA; COILED BODIES; NUCLEAR GEMS; CAJAL BODIES; 20S COMPLEX; SURVIVAL	Spinal muscular atrophy is a neurodegenerative disease accompanied by a loss of motoneurons. Either mutations or deletions in the survival of motoneuron ( SMN) gene are responsible for this defect. SMN is an assembly protein for RNA- protein complexes in the nucleus and is also found in axons of neurons. However, it is unclear which dysfunctions of SMN are important for disease progression. In this study we analyzed the contributions of different SMN regions for localization and neuronal differentiation associated with outgrowth of neurites. Suppression of endogenous SMN protein levels significantly decreased the growth of neurites. Down- regulation of the interacting protein gemin2 had the opposite effect. Surprisingly, selective overexpression of the SMN C- terminal domain promoted neurite outgrowth similar to fulllength protein and could rescue the SMN knock- down effects. The knock- down led to a significant change in the G-/F-actin ratio, indicating a role for SMN in actin dynamics. Therefore, our data suggest a functional role for SMN in microfilament metabolism in axons of motoneurons.	Hannover Med Sch, Dept Neuroanat, D-30625 Hannover, Germany; ZSN Hannover, Ctr Syst Neurosci, Hannover, Germany	Hannover Medical School	Claus, P (corresponding author), Hannover Med Sch, Dept Neuroanat, OE 4140,Carl Neuberg Str 1, D-30625 Hannover, Germany.	claus.peter@mh-hannover.de	Claus, Peter/A-7978-2008	Claus, Peter/0000-0003-3824-9445				Anderson K, 2003, CURR OPIN NEUROL, V16, P595, DOI 10.1097/00019052-200310000-00005; Briese M, 2005, BIOESSAYS, V27, P946, DOI 10.1002/bies.20283; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Campbell L, 1997, AM J HUM GENET, V61, P40, DOI 10.1086/513886; Carissimi C, 2006, J BIOL CHEM, V281, P8126, DOI 10.1074/jbc.M512243200; Cifuentes-Diaz C, 2001, J CELL BIOL, V152, P1107, DOI 10.1083/jcb.152.5.1107; Cifuentes-Diaz C, 2002, HUM MOL GENET, V11, P1439, DOI 10.1093/hmg/11.12.1439; Claus P, 2003, J BIOL CHEM, V278, P479, DOI 10.1074/jbc.M206056200; Claus P, 2004, BIOCHEM J, V384, P559, DOI 10.1042/BJ20040801; Coovert DD, 1997, HUM MOL GENET, V6, P1205, DOI 10.1093/hmg/6.8.1205; Da Silva JS, 2003, J CELL BIOL, V162, P1267, DOI 10.1083/jcb.200304021; Fan L, 2002, HUM MOL GENET, V11, P1605, DOI 10.1093/hmg/11.14.1605; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Giesemann T, 1999, J BIOL CHEM, V274, P37908, DOI 10.1074/jbc.274.53.37908; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROTHE C, 1992, J NEUROSCI RES, V32, P317, DOI 10.1002/jnr.490320304; Gubitz AK, 2004, EXP CELL RES, V296, P51, DOI 10.1016/j.yexcr.2004.03.022; Haastert K, 2005, J NEUROSCI METH, V142, P275, DOI 10.1016/j.jneumeth.2004.09.003; HAHNEN E, 1995, HUM MOL GENET, V4, P1927, DOI 10.1093/hmg/4.10.1927; Hebert MD, 2001, GENE DEV, V15, P2720, DOI 10.1101/gad.908401; Huber K, 1997, J COMP NEUROL, V382, P189; Jablonka S, 2004, J NEUROBIOL, V58, P272, DOI 10.1002/neu.10313; Jablonka S, 2001, HUM MOL GENET, V10, P497, DOI 10.1093/hmg/10.5.497; Kalil K, 2005, CURR OPIN NEUROBIOL, V15, P521, DOI 10.1016/j.conb.2005.08.005; Kuhn TB, 2000, J NEUROBIOL, V44, P126, DOI 10.1002/1097-4695(200008)44:2<126::AID-NEU4>3.0.CO;2-Z; Le TT, 2005, HUM MOL GENET, V14, P845, DOI 10.1093/hmg/ddi078; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LINDENBAUM MH, 1988, J BIOL CHEM, V263, P5662; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; McAndrew PE, 1997, AM J HUM GENET, V60, P1411, DOI 10.1086/515465; McWhorter ML, 2003, J CELL BIOL, V162, P919, DOI 10.1083/jcb.200303168; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Meister G, 2002, TRENDS CELL BIOL, V12, P472, DOI 10.1016/S0962-8924(02)02371-1; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Monani UR, 1999, HUM MOL GENET, V8, P1177, DOI 10.1093/hmg/8.7.1177; Navascues J, 2004, CHROMOSOMA, V112, P398, DOI 10.1007/s00412-004-0285-5; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, CURR BIOL, V11, P1079, DOI 10.1016/S0960-9822(01)00316-5; Pellizzoni L, 2002, SCIENCE, V298, P1775, DOI 10.1126/science.1074962; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; RODRIGUES NR, 1995, HUM MOL GENET, V4, P631, DOI 10.1093/hmg/4.4.631; Rossoll W, 2002, HUM MOL GENET, V11, P93, DOI 10.1093/hmg/11.1.93; Rossoll W, 2003, J CELL BIOL, V163, P801, DOI 10.1083/jcb.200304128; Sharma A, 2005, EXP CELL RES, V309, P185, DOI 10.1016/j.yexcr.2005.05.014; Terns MP, 2001, CURR BIOL, V11, pR862, DOI 10.1016/S0960-9822(01)00517-6; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; van Bergeijk J, 2006, CHEM BIOL DRUG DES, V67, P244, DOI 10.1111/j.1747-0285.2006.00369.x; Wang J, 2001, J BIOL CHEM, V276, P45387, DOI 10.1074/jbc.M105059200; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003; Young PJ, 2000, HUM MOL GENET, V9, P2869, DOI 10.1093/hmg/9.19.2869; Young PJ, 2001, EXP CELL RES, V265, P252, DOI 10.1006/excr.2001.5186; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858; Zhang HLL, 2003, J NEUROSCI, V23, P6627; Zheng JQ, 2001, J NEUROSCI, V21, P9291, DOI 10.1523/JNEUROSCI.21-23-09291.2001; Zigmond SH, 2004, CURR TOP DEV BIOL, V63, P145, DOI 10.1016/S0070-2153(04)63005-5	61	50	50	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1492	1502		10.1096/fj.06-7136com	http://dx.doi.org/10.1096/fj.06-7136com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17317728				2022-12-25	WOS:000246117000024
J	Cannistraro, VJ; Taylor, JS				Cannistraro, Vincent J.; Taylor, John-Stephen			Ability of polymerase eta and T7 DNA polymerase to bypass bulge structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; SYN THYMINE DIMER; CRYSTAL-STRUCTURE; ERROR-PRONE; CIS-SYN; SULFOLOBUS-SOLFATARICUS; REPLICATION FIDELITY; PHOSPHATE BACKBONE; INSERTION OPPOSITE; REACTION-MECHANISM	DNA misalignment occurs in homopolymer tracts during replication and can lead to frameshift mutations. Polymerase ( pol) recognition of primer-templates containing bulge structures and the transmission of a bulge through a polymerase binding site or replication complex are important components of frameshift mutagenesis. In this report, we describe the interaction of the catalytic core of pol eta with primer-templates containing bulge structures by single round primer extension. We found that pol eta could stabilize a frayed primer terminus, which enhances its ability to extend primer-templates containing bulges. Based on methylphosphonate-DNA mapping, pol eta interacts with the single strand template but not appreciably with the template strand of the DNA stem greater than two nucleotides from the primer terminus. These latter characteristics, combined with the ability to stabilize a frayed primer terminus, may explain why primer-templates containing template bulges are extended so efficiently by pol eta. Although pol eta could accommodate large bulges and continue synthesis without obstruction, bulge structures in the template, but not in the primer, caused termination of the T7 DNA replication complex. Terminations occurred when the template bulge neared the helix-loop-helix domain of the polymerase thumb. Terminations were not observed, however, when bulge structures approached the site of interaction of the DNA with the extended thumb and thioredoxin. At low temperature, however, terminations did occur at this site.	Washington Univ, Dept Chem, St Louis, MO 63103 USA	Washington University (WUSTL)	Taylor, JS (corresponding author), Washington Univ, Dept Chem, 1 Brookings Dr,Campus Box 1134, St Louis, MO 63103 USA.	taylor@wuchem.wustl.edu	Taylor, John-Stephen/AAA-3218-2020	Taylor, John-Stephen/0000-0002-8615-7257	NATIONAL CANCER INSTITUTE [R37CA040463, R01CA040463] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40463, R01 CA040463, R01 CA040463-23] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bassett E, 2002, DNA REPAIR, V1, P1003, DOI 10.1016/S1568-7864(02)00150-7; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; Brieba LG, 2004, EMBO J, V23, P3452, DOI 10.1038/sj.emboj.7600354; Cannistraro VJ, 1999, BBA-PROTEIN STRUCT M, V1433, P170, DOI 10.1016/S0167-4838(99)00136-3; Cannistraro VJ, 2004, J BIOL CHEM, V279, P18288, DOI 10.1074/jbc.M400282200; CANNISTRARO VJ, 1994, J MOL BIOL, V243, P930, DOI 10.1006/jmbi.1994.1693; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fortune JM, 2005, J BIOL CHEM, V280, P29980, DOI 10.1074/jbc.M505236200; Fortune JM, 2006, NUCLEIC ACIDS RES, V34, P4335, DOI 10.1093/nar/gkl403; Garcia-Diaz M, 2006, CELL, V124, P331, DOI [10.1016/j.cell.2005.10.039, 10.1016/j.cel.2005.10.039]; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Hamelberg D, 2002, NUCLEIC ACIDS RES, V30, P3615, DOI 10.1093/nar/gkf472; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Hwang HS, 2005, BIOCHEMISTRY-US, V44, P4850, DOI 10.1021/bi048244+; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Kokoska RJ, 2003, J BIOL CHEM, V278, P50537, DOI 10.1074/jbc.M308515200; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Kroutil LC, 1996, BIOCHEMISTRY-US, V35, P1046, DOI 10.1021/bi952178h; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; Lam WC, 1999, BIOCHEMISTRY-US, V38, P2661, DOI 10.1021/bi9820762; Lam WC, 1998, BIOCHEMISTRY-US, V37, P1513, DOI 10.1021/bi9720181; LEBLANC DA, 1991, BIOCHEMISTRY-US, V30, P4042, DOI 10.1021/bi00230a031; Lee JB, 2006, NATURE, V439, P621, DOI 10.1038/nature04317; Li Y, 2004, NAT STRUCT MOL BIOL, V11, P784, DOI 10.1038/nsmb792; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Ling H, 2003, NATURE, V424, P1083, DOI 10.1038/nature01919; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; MASKER W, 1993, MUTAT RES, V301, P235, DOI 10.1016/0165-7992(93)90063-2; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Matsuda T, 2001, J MOL BIOL, V312, P335, DOI 10.1006/jmbi.2001.4937; MORDEN KM, 1990, BIOCHEMISTRY-US, V29, P8835, DOI 10.1021/bi00489a047; Okonogi TM, 2002, P NATL ACAD SCI USA, V99, P4156, DOI 10.1073/pnas.072067799; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; ROSEN MA, 1992, BIOCHEMISTRY-US, V31, P4004, DOI 10.1021/bi00131a016; Schweitzer M, 1999, J BIOMOL STRUCT DYN, V16, P1177, DOI 10.1080/07391102.1999.10508326; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Smith CA, 1998, J BIOL CHEM, V273, P21933, DOI 10.1074/jbc.273.34.21933; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; StraussSoukup JK, 1997, BIOCHEMISTRY-US, V36, P8692, DOI 10.1021/bi9705467; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; Sun LP, 2000, BIOCHEMISTRY-US, V39, P14603, DOI 10.1021/bi001446v; TABOR S, 1987, J BIOL CHEM, V262, P16212; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Turner RM, 2003, BIOCHEMISTRY-US, V42, P2373, DOI 10.1021/bi026566c; Uijon SN, 2004, STRUCTURE, V12, P1395, DOI 10.1016/j.str.2004.05.011; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	58	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11188	11196		10.1074/jbc.M608478200	http://dx.doi.org/10.1074/jbc.M608478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303570	hybrid			2022-12-25	WOS:000245941500040
J	Kooijman, EE; Tieleman, DP; Testerink, C; Munnik, T; Rijkers, DTS; Burger, KNJ; de Kruijff, B				Kooijman, Edgar E.; Tieleman, D. Peter; Testerink, Christa; Munnik, Teun; Rijkers, Dirk T. S.; Burger, Koert N. J.; de Kruijff, Ben			An electrostatic/hydrogen bond switch as the basis for the specific interaction of phosphatidic acid with proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; ALPHA-HELICAL PEPTIDES; LYSOPHOSPHATIDIC ACID; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-D; PHOSPHOGLUCOSE ISOMERASE; HYDROPHOBIC MISMATCH; CATALYTIC MECHANISM; MOLECULAR-DYNAMICS; ESCHERICHIA-COLI	Phosphatidic acid ( PA) is a minor but important phospholipid that, through specific interactions with proteins, plays a central role in several key cellular processes. The simple yet unique structure of PA, carrying just a phosphomonoester head group, suggests an important role for interactions with the positively charged essential residues in these proteins. We analyzed by solid- state magic angle spinning P-31 NMR and molecular dynamics simulations the interaction of low concentrations of PA in model membranes with positively charged side chains of membrane- interacting peptides. Surprisingly, lysine and arginine residues increase the charge of PA, predominantly by forming hydrogen bonds with the phosphate of PA, thereby stabilizing the protein-lipid interaction. Our results demonstrate that this electrostatic/ hydrogen bond switch turns the phosphate of PA into an effective and preferred docking site for lysine and arginine residues. In combination with the special packing properties of PA, PA may well be nature's preferred membrane lipid for interfacial insertion of positively charged membrane protein domains.	Univ Utrecht, Bijvoet Ctr, Dept Biochem Membranes, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Univ Amsterdam, Swammerdam Inst Life Sci, Sect Plant Physiol, NL-1098 SM Amsterdam, Netherlands; Univ Utrecht, Dept Med Chem, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Dept Biochem Physiol, Inst Biomembranes, NL-3584 CH Utrecht, Netherlands	Utrecht University; University of Calgary; University of Amsterdam; Utrecht University; Utrecht University	Kooijman, EE (corresponding author), Kent State Univ, Dept Phys, Smith Hall 105, Kent, OH 44242 USA.	e.e.kooijman@gmail.com	Munnik, Teun/N-2778-2019; Tieleman, D. Peter/A-4790-2011; Munnik, Teun/G-8624-2012	Munnik, Teun/0000-0002-4919-4913; Tieleman, D. Peter/0000-0001-5507-0688; Munnik, Teun/0000-0002-4919-4913; Rijkers, Dirk T.S./0000-0002-8874-7576; Testerink, Christa/0000-0001-6738-115X				Aleshin AE, 1998, STRUCTURE, V6, P39, DOI 10.1016/S0969-2126(98)00006-9; Aliste MP, 2003, BIOCHEMISTRY-US, V42, P8976, DOI 10.1021/bi027001j; Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Athenstaedt K, 1999, EUR J BIOCHEM, V266, P1, DOI 10.1046/j.1432-1327.1999.00822.x; Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Bravo J, 2001, MOL CELL, V8, P829, DOI 10.1016/S1097-2765(01)00372-0; Brink-van der Laan EV, 2004, BBA-BIOMEMBRANES, V1666, P275, DOI 10.1016/j.bbamem.2004.06.010; Bruno IJ, 2002, ACTA CRYSTALLOGR B, V58, P389, DOI 10.1107/S0108768102003324; Burger KNJ, 2000, BIOCHEMISTRY-US, V39, P12485, DOI 10.1021/bi000971r; *CCDC, 1994, VIST PROGR AN DISPL; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; de Planque MRR, 2002, BIOCHEMISTRY-US, V41, P8396, DOI 10.1021/bi0257686; de Planque MRR, 2001, BIOCHEMISTRY-US, V40, P5000, DOI 10.1021/bi000804r; DEKRUIJFF B, 1985, BIOCHIM BIOPHYS ACTA, V820, P295, DOI 10.1016/0005-2736(85)90124-5; Deol SS, 2006, BIOPHYS J, V90, P822, DOI 10.1529/biophysj.105.071407; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; Ellson CD, 2002, J CELL SCI, V115, P1099; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Freyberg Z, 2003, TRENDS CELL BIOL, V13, P540, DOI 10.1016/j.tcb.2003.08.004; Ghosh S, 2003, J BIOL CHEM, V278, P45690, DOI 10.1074/jbc.M302933200; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HAUSER H, 1989, P NATL ACAD SCI USA, V86, P5351, DOI 10.1073/pnas.86.14.5351; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; Kooijman EE, 2005, BIOCHEMISTRY-US, V44, P17007, DOI 10.1021/bi0518794; Kooijman EE, 2005, BIOCHEMISTRY-US, V44, P2097, DOI 10.1021/bi0478502; Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x; KOTER M, 1978, BIOCHIM BIOPHYS ACTA, V514, P255, DOI 10.1016/0005-2736(78)90296-1; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Lee AG, 2004, BBA-BIOMEMBRANES, V1666, P62, DOI 10.1016/j.bbamem.2004.05.012; Lee DC, 2003, J BIOL CHEM, V278, P31412, DOI 10.1074/jbc.M213154200; Lee JH, 2005, PROTEIN SCI, V14, P727, DOI 10.1110/ps.041070205; Lee SA, 2005, P NATL ACAD SCI USA, V102, P13052, DOI 10.1073/pnas.0503900102; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Loewen CJR, 2004, SCIENCE, V304, P1644, DOI 10.1126/science.1096083; Lynch KR, 2002, BBA-MOL CELL BIOL L, V1582, P289, DOI 10.1016/S1388-1981(02)00183-X; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; Oliva G, 1995, STRUCTURE, V3, P1323, DOI 10.1016/S0969-2126(01)00270-2; Powl AM, 2005, BIOCHEMISTRY-US, V44, P5873, DOI 10.1021/bi047439e; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Rizzo MA, 2000, J BIOL CHEM, V275, P23911, DOI 10.1074/jbc.M001553200; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Sardar VM, 2002, BBA-MOL CELL BIOL L, V1582, P309, DOI 10.1016/S1388-1981(02)00185-3; Solomons JTG, 2004, J MOL BIOL, V342, P847, DOI 10.1016/j.jmb.2004.07.085; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; Zimmerberg J, 2006, NAT REV MOL CELL BIO, V7, P9, DOI 10.1038/nrm1784	55	180	184	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11356	11364		10.1074/jbc.M609737200	http://dx.doi.org/10.1074/jbc.M609737200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17277311	hybrid, Green Published			2022-12-25	WOS:000245941500058
J	Sato, Y; Okuyama, S; Hori, K				Sato, Yuichiro; Okuyama, Satomi; Hori, Kanji			Primary structure and carbohydrate binding specificity of a potent anti-HIV lectin isolated from the filamentous cyanobacterium Oscillatoria agardhii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRESH-WATER CYANOBACTERIUM; MYXOBACTERIAL HEMAGGLUTININ; CONCANAVALIN-A; MICROCYSTIS-AERUGINOSA; INACTIVATING PROTEIN; MYXOCOCCUS-XANTHUS; PLANT-LECTINS; CYANOVIRIN-N; MANNOSE; RECOGNITION	The primary structure of a lectin, designated Oscillatoria agardhii agglutinin (OAA), isolated from the freshwater cyanobacterium O. agardhii NIES-204 was determined by the combination of Edman degradation and electron spray ionization-mass spectrometry. OAA is a polypeptide (M-r 13,925) consisting of two tandem repeats. Interestingly, each repeat sequence of OAA showed a high degree of similarity to those of a myxobacterium, Myxococcus xanthus hemagglutinin, and a marine red alga Eucheuma serra lectin. A systematic binding assay with pyridylaminated oligosaccharides revealed that OAA exclusively binds to high mannose (HM)-typeN-glycans but not to other N-glycans, including complex types, hybrid types, and the pentasaccharide core or oligosaccharides from glycolipids. OAA did not interact with any of free mono- and oligomannoses that are constituents of the branched oligomannosides. These results suggest that the core disaccharide, GlcNAc-GlcNAc, is also essential for binding to OAA. The binding activity of OAA to HM type N-glycans was dramatically decreased when alpha 1 - 2 Man was attached to alpha 1 - 3 Man branched from the alpha 1 - 6 Man of the pentasaccharide core. This specificity of OAA for HM- type oligosaccharides is distinct from other HM- binding lectins. Kinetic analysis with an HM heptasaccharide revealed that OAA possesses two carbohydrate binding sites per molecule, with an association constant of 2.41 x 10(8) M-1. Furthermore, OAA potently inhibits human immunodeficiency virus replication in MT-4 cells (EC50 = 44.5 nM). Thus, we have found a novel lectin family sharing similar structure and carbohydrate binding specificity among bacteria, cyanobacteria, and marine algae.	Hiroshima Univ, Grad Sch Biosphere Sci, Higashihiroshima 7398528, Japan	Hiroshima University	Hori, K (corresponding author), Hiroshima Univ, Grad Sch Biosphere Sci, Kagamiyama 1-4-4, Higashihiroshima 7398528, Japan.	kanhori@hiroshima-u.ac.jp						BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; Balzarini J, 2004, J VIROL, V78, P10617, DOI 10.1128/JVI.78.19.10617-10627.2004; Balzarini J, 2005, J BIOL CHEM, V280, P41005, DOI 10.1074/jbc.M508801200; Barre A, 1996, PLANT PHYSIOL, V112, P1531, DOI 10.1104/pp.112.4.1531; Barre A, 2001, BIOCHIMIE, V83, P645, DOI 10.1016/S0300-9084(01)01315-3; Bewley CA, 1998, NAT STRUCT BIOL, V5, P571, DOI 10.1038/828; Bokesch HR, 2003, BIOCHEMISTRY-US, V42, P2578, DOI 10.1021/bi0205698; Botos I, 2002, J BIOL CHEM, V277, P34336, DOI 10.1074/jbc.M205909200; Calarese DA, 2005, P NATL ACAD SCI USA, V102, P13372, DOI 10.1073/pnas.0505763102; Chisholm JRM, 1996, NATURE, V381, P382, DOI 10.1038/381382a0; CUMSKY M, 1979, P NATL ACAD SCI USA, V76, P5505, DOI 10.1073/pnas.76.11.5505; CUMSKY MG, 1981, J BIOL CHEM, V256, P2596; Dam TK, 1998, J BIOL CHEM, V273, P5528, DOI 10.1074/jbc.273.10.5528; Dworkin M, 1996, MICROBIOL REV, V60, P70, DOI 10.1128/MMBR.60.1.70-102.1996; Fourans A, 2004, FEMS MICROBIOL ECOL, V51, P55, DOI 10.1016/j.femsec.2004.07.012; Gupta D, 1996, EUR J BIOCHEM, V242, P320, DOI 10.1111/j.1432-1033.1996.0320r.x; Hartley MR, 2004, BBA-PROTEINS PROTEOM, V1701, P1, DOI 10.1016/j.bbapap.2004.06.004; Hester G, 1996, J MOL BIOL, V262, P516, DOI 10.1006/jmbi.1996.0532; HORI K, 1990, HYDROBIOLOGIA, V204, P561, DOI 10.1007/BF00040287; Jimbo M, 2000, BIOCHEM BIOPH RES CO, V273, P499, DOI 10.1006/bbrc.2000.2961; KATOH H, 1993, J BIOCHEM-TOKYO, V113, P118, DOI 10.1093/oxfordjournals.jbchem.a123994; Kawakubo A, 1999, J APPL PHYCOL, V11, P149, DOI 10.1023/A:1008062127564; Kawakubo AL, 1997, J APPL PHYCOL, V9, P331, DOI 10.1023/A:1007915006334; Kehr JC, 2006, MOL MICROBIOL, V59, P893, DOI 10.1111/j.1365-2958.2005.05001.x; Liener I.E., 1986, LECTINS PROPERTIES F; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; MEGA T, 1992, J BIOCHEM-TOKYO, V111, P396, DOI 10.1093/oxfordjournals.jbchem.a123768; MISQUITH S, 1994, J BIOL CHEM, V269, P30393; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; NELSON DR, 1981, J BIOL CHEM, V256, P2589; Ng KKS, 2002, J BIOL CHEM, V277, P16088, DOI 10.1074/jbc.M200493200; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; ROMEO JM, 1986, P NATL ACAD SCI USA, V83, P6332, DOI 10.1073/pnas.83.17.6332; Sato Y, 2000, COMP BIOCHEM PHYS B, V125, P169, DOI 10.1016/S0305-0491(99)00164-9; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; Skvortsov IM, 1998, FEMS MICROBIOL LETT, V165, P223, DOI 10.1111/j.1574-6968.1998.tb13150.x; Tateno H, 2003, J BIOL CHEM, V278, P10891, DOI 10.1074/jbc.M211840200; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Williams DC, 2005, J BIOL CHEM, V280, P29269, DOI 10.1074/jbc.M504642200; Yamaguchi M, 1999, BIOCHEM BIOPH RES CO, V265, P703, DOI 10.1006/bbrc.1999.1749	41	84	87	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11021	11029		10.1074/jbc.M701252200	http://dx.doi.org/10.1074/jbc.M701252200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17314091	hybrid, Green Submitted			2022-12-25	WOS:000245941500022
J	Herman, RE; Badders, D; Fuller, M; Makienko, EG; Houston, ME; Quay, SC; Johnson, PH				Herman, Richard E.; Badders, Douglas; Fuller, Mark; Makienko, Ekaterina G.; Houston, Michael E., Jr.; Quay, Steven C.; Johnson, Paul H.			The Trp cage motif as a scaffold for the display of a randomized peptide library on bacteriophage T7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGE DISPLAY; BINDING-PROTEINS; SEQUENCE; LIGANDS; STREPTAVIDIN; SUPPRESSION; MOLECULES; FINGERS; LEADS	Phage libraries displaying linear or disulfide-constrained pephdes often yield weak binders, upon screening against a target, and must be optimized to improve affinity. The disadvantages of libraries based on larger complex proteins, such as single chain antibodies, have stimulated interest in the development of smaller nonimmunoglobulin protein scaffolds. A promising candidate is the Trp cage motif, a 20-residue C-terminal sequence of exendin-4. Amino acid substitution within the Trp cage resulted in a 20-mer peptide recognized as an ultrafast cooperative folding miniprotein, with ideal characteristics for the discovery of small structured nonimmunoglobulin motifs having a stable tertiary structure. Although we were unable to display the Trp cage on M13 phage, successful display was achieved using the lytic T7 phage. Interestingly, mutations were observed at a frequency dependent on display valency. A Trp cage library designed with randomized amino acids at seven solvent-exposed positions was developed from 1.6 X 10(9) primary clones in T7Select10-3b. DNA sequencing of 109 library clones revealed 38% mutants and 16% truncations by TAG codons at randomized positions. Amino acid frequencies were largely within expected bounds and DIVAA analysis revealed that the library had an average diversity of 0.67. Utility of the library was demonstrated by identification of HPQ containing Trp cage miniproteins, which bound streptavidin, and AAADPYAQWLQSMGPHSGRPPPR, which bound to human bronchial epithelial cells. A high complexity library based on the Trp cage miniprotein has demonstrated potential for identifying novel cell and protein binding peptides that could be used for the delivery of therapeutic molecules or as target-specific therapeutic agents.	Nastech Pharmaceut Co Inc, Bothell, WA 98021 USA		Johnson, PH (corresponding author), Nastech Pharmaceut Co Inc, 3830 Monte Villa PKwy, Bothell, WA 98021 USA.	pjohnson@nastech.com		Quay, Steven Carl/0000-0002-0363-7651				ANDERSEN NH, 2001, PEPTIDES WAVE FUTURE, P406; BEAUCAGE SL, 1992, TETRAHEDRON, V48, P2223, DOI 10.1016/S0040-4020(01)88752-4; Binz HK, 2005, NAT BIOTECHNOL, V23, P1257, DOI 10.1038/nbt1127; Castagnoli L, 2001, COMB CHEM HIGH T SCR, V4, P121; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; DENNIS MS, 1995, J BIOL CHEM, V270, P25411, DOI 10.1074/jbc.270.43.25411; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; EDELMANN P, 1987, MOL GEN GENET, V207, P517, DOI 10.1007/BF00331625; EDGAR RS, 1963, METHODOLOGY BASIC GE, P19; Friesen WJ, 1998, NAT STRUCT BIOL, V5, P543, DOI 10.1038/794; GIEBEL LB, 1995, BIOCHEMISTRY-US, V34, P15430, DOI 10.1021/bi00047a006; GOMEZ J, 1995, J MOL BIOL, V252, P337, DOI 10.1006/jmbi.1995.0501; KATZ BA, 1995, BIOCHEMISTRY-US, V34, P15421, DOI 10.1021/bi00047a005; Krotz AH, 1997, TETRAHEDRON LETT, V38, P3875, DOI 10.1016/S0040-4039(97)00798-3; Krumpe LRH, 2006, PROTEOMICS, V6, P4210, DOI 10.1002/pmic.200500606; LADNER RC, 1995, TRENDS BIOTECHNOL, V13, P426, DOI 10.1016/S0167-7799(00)88997-0; Ladner RC, 2001, CURR OPIN BIOTECH, V12, P406, DOI 10.1016/S0958-1669(00)00235-4; Lin JC, 2004, J AM CHEM SOC, V126, P13679, DOI 10.1021/ja047265o; Lowman HB, 1997, ANNU REV BIOPH BIOM, V26, P401, DOI 10.1146/annurev.biophys.26.1.401; MACRINA FL, 1978, PLASMID, V1, P417, DOI 10.1016/0147-619X(78)90056-2; Marvin DA, 1998, CURR OPIN STRUC BIOL, V8, P150, DOI 10.1016/S0959-440X(98)80032-8; MILLER JH, 1983, J MOL BIOL, V164, P59, DOI 10.1016/0022-2836(83)90087-6; Nakamura GR, 2001, BIOCHEMISTRY-US, V40, P9828, DOI 10.1021/bi0109360; Neidigh JW, 2001, BIOCHEMISTRY-US, V40, P13188, DOI 10.1021/bi010902s; Neidigh JW, 2002, NAT STRUCT BIOL, V9, P425, DOI 10.1038/nsb798; *NEW ENGL BIOL INC, 2002, INSTR MAN PH D C7C P; Qiu LL, 2002, J AM CHEM SOC, V124, P12952, DOI 10.1021/ja0279141; RAPOZA MP, 1993, J BACTERIOL, V175, P1856, DOI 10.1128/JB.175.6.1856-1859.1993; REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Steiner D, 2006, NAT BIOTECHNOL, V24, P823, DOI 10.1038/nbt1218; Uchiyama F, 2005, J BIOSCI BIOENG, V99, P448, DOI 10.1263/jbb.99.448	32	25	29	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9813	9824		10.1074/jbc.M610722200	http://dx.doi.org/10.1074/jbc.M610722200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17264074	hybrid			2022-12-25	WOS:000245421700056
J	Kim, SY; Levenson, JM; Korsmeyer, S; Sweatt, JD; Schumacher, A				Kim, Se Young; Levenson, Jonathan M.; Korsmeyer, Stanley; Sweatt, J. David; Schumacher, Armin			Developmental regulation of Eed complex composition governs a switch in global histone modification in brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP PROTEIN EED; H3 LYSINE-27 METHYLATION; INACTIVE X-CHROMOSOME; EMBRYONIC STEM-CELLS; POLYCOMB-GROUP GENE; MLL-MUTANT MICE; METHYLTRANSFERASE ACTIVITY; MAMMALIAN TRITHORAX; RESPONSE ELEMENTS; BINDING PROTEIN	Originally discovered as epigenetic regulators of developmental gene expression, the Polycomb (PcG) and trithorax (trxG) group of proteins form distinct nuclear complexes governing post-translational modification of histone tails. This study identified a novel, developmentally regulated interface between Eed and Mll, pivotal constituents of PcG and trxG pathways, respectively, in mouse brain. Although the PcG proteins Eed and EzH2 (Enhancer of Zeste protein-2) engaged in a common complex during neurodevelopment, Eed associated with the trxG protein Mll upon brain maturation. Comprehensive analysis of multiple histone modifications revealed differential substrate specificity of the novel Eed-Mll complex in adult brain compared with the developmental Eed-EzH2 complex. Newborn brain from eed heterozygotes and eed;Mll double heterozygotes exhibited decreased trimethylation at lysine 27 of histone H3, as well as hyperacetylation of histone H4. In contrast, adult hippocampus from Mll heterozygotes was remarkable for decreased acetylation of histone H4, which restored to wild-type levels in eed;Mll double heterozygotes. A physiological role for the Eed-Mll complex in adult brain was evident from complementary defects in synaptic plasticity in eed and Mll mutant hippocampi. These results support the notion that developmental regulation of complex composition bestows the predominant Eed complex with the chromatin remodeling activity conducive for gene regulation during neurodevelopment and adult brain function. Thus, this study suggests dynamic regulation of chromatin complex composition as a molecular mechanism to coopt constituents of developmental pathways into the regulation of neuronal memory formation in adult brain.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol & Med,Dana Farber Canc Inst, Boston, MA 02115 USA	Baylor College of Medicine; Baylor College of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute	Schumacher, A (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	armins@bcm.tmc.edu		Sweatt, J. David/0000-0003-3567-485X				Alarcon JM, 2004, NEURON, V42, P947, DOI 10.1016/j.neuron.2004.05.021; Ayton P, 2001, GENESIS, V30, P201, DOI 10.1002/gene.1066; Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048; Bloyer S, 2003, DEV BIOL, V261, P426, DOI 10.1016/S0012-1606(03)00314-2; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; Chwang WB, 2006, LEARN MEMORY, V13, P322, DOI 10.1101/lm.152906; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Deschamps J, 1999, INT J DEV BIOL, V43, P635; FAUST C, 1995, DEVELOPMENT, V121, P273; Faust C, 1998, DEVELOPMENT, V125, P4495; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Grimaud C, 2006, CHROMOSOME RES, V14, P363, DOI 10.1007/s10577-006-1069-y; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; Hsieh JJD, 2003, MOL CELL BIOL, V23, P186, DOI 10.1128/MCB.23.1.186-194.2003; Kalantry S, 2006, NAT CELL BIOL, V8, P195, DOI 10.1038/ncb1351; Kalantry S, 2006, PLOS GENET, V2, P656, DOI 10.1371/journal.pgen.0020066; Kim SY, 2006, DEVELOPMENT, V133, P4957, DOI 10.1242/dev.02677; Korzus E, 2004, NEURON, V42, P961, DOI 10.1016/j.neuron.2004.06.002; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; Mager J, 2003, NAT GENET, V33, P502, DOI 10.1038/ng1125; Mak W, 2002, CURR BIOL, V12, P1016, DOI 10.1016/S0960-9822(02)00892-8; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Mok H, 2004, DEVELOPMENT, V131, P4871, DOI 10.1242/dev.01342; Montgomery ND, 2005, CURR BIOL, V15, P942, DOI 10.1016/j.cub.2005.04.051; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Poux S, 2001, GENE DEV, V15, P2509, DOI 10.1101/gad.208901; Ringrose L, 2003, DEV CELL, V5, P759, DOI 10.1016/S1534-5807(03)00337-X; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; Silva J, 2003, DEV CELL, V4, P481, DOI 10.1016/S1534-5807(03)00068-6; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Tillib S, 1999, MOL CELL BIOL, V19, P5189; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; Wang JB, 2001, NAT GENET, V28, P371, DOI 10.1038/ng574; Wang JB, 2002, MAMM GENOME, V13, P493, DOI 10.1007/s00335-002-2182-7; Wood MA, 2005, LEARN MEMORY, V12, P111, DOI 10.1101/lm.86605; Xia ZB, 2003, P NATL ACAD SCI USA, V100, P8342, DOI 10.1073/pnas.1436338100; Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; Yu BD, 1998, P NATL ACAD SCI USA, V95, P10632, DOI 10.1073/pnas.95.18.10632; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	60	57	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9962	9972		10.1074/jbc.M608722200	http://dx.doi.org/10.1074/jbc.M608722200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17259173	hybrid			2022-12-25	WOS:000245421700071
J	Krig, SR; Jin, VX; Bieda, MC; O'Geen, H; Yaswen, P; Green, R; Farnham, PJ				Krig, Sheryl R.; Jin, Victor X.; Bieda, Mark C.; O'Geen, Henriette; Yaswen, Paul; Green, Roland; Farnham, Peggy J.			Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING SITES; CHROMOSOMAL REGION; BREAST-CANCER; CO-REPRESSOR; DNA-BINDING; TRANSCRIPTION; CTBP; SEQUENCES; GENOME; COREPRESSOR	It has been proposed that ZNF217, which is amplified at 20q13 in various tumors, plays a key role during neoplastic transformation. ZNF217 has been purified in complexes that contain repressor proteins such as CtBP2, suggesting that it acts as a transcriptional repressor. However, the function of ZNF217 has not been well characterized due to a lack of known target genes. Using a global chromatin immunoprecipitation (ChIP)-chip approach, we identified thousands of ZNF217 binding sites in three tumor cell lines (MCF7, SW480, and Ntera2). Further analysis of ZNF217 in Ntera2 cells showed that many promoters are bound by ZNF217 and CtBP2 and that a subset of these promoters are activated upon removal of ZNF217. Thus, our in vivo studies corroborate the in vitro biochemical analyses of ZNF217-containing complexes and support the hypothesis that ZNF217 functions as a transcriptional repressor. Gene ontology analysis showed that ZNF217 targets in Ntera2 cells are involved in organ development, suggesting that one function of ZNF217 may be to repress differentiation. Accordingly we show that differentiation of Ntera2 cells with retinoic acid led to down-regulation of ZNF217. Our identification of thousands of ZNF217 target genes will enable further studies of the consequences of aberrant expression of ZNF217 during neoplastic transformation.	Univ Calif Davis, Dept Pharmacol, Davis, CA 95616 USA; Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA; NimbleGen Syst Inc, Madison, WI 53711 USA; Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	University of California System; University of California Davis; University of California System; University of California Davis; Roche Holding; Roche NimbleGen; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Farnham, PJ (corresponding author), Univ Calif Davis, Dept Pharmacol, 1 Shields Ave, Davis, CA 95616 USA.	pjfarnham@ucdavis.edu		Farnham, Peggy/0000-0003-4469-7914	NCI NIH HHS [CA45250, R01 CA045240-21, R01 CA045240] Funding Source: Medline; NHGRI NIH HHS [R01 HG003129, HG003129, R01 HG003129-03] Funding Source: Medline; NIDDK NIH HHS [R01 DK067889-03, DK067889, R01 DK067889, R56 DK067889] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045240] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003129] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK067889, R01DK067889] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Bailey TL, 1997, J COMPUT BIOL, V4, P45, DOI 10.1089/cmb.1997.4.45; Bar-Shira A, 2002, CANCER RES, V62, P6803; Bergman LM, 2006, APOPTOSIS, V11, P879, DOI 10.1007/s10495-006-6651-4; Bieda M, 2006, GENOME RES, V16, P595, DOI 10.1101/gr.4887606; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; COWGER JJ, 2007, IN PRESS ONCOGENE; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; Deb-Rinker P, 2005, J BIOL CHEM, V280, P6257, DOI 10.1074/jbc.C400479200; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Graves BJ, 1996, NATURE, V384, P322, DOI 10.1038/384322a0; Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200; Harrow J, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-s1-s4; Heisler LE, 2005, NUCLEIC ACIDS RES, V33, P2952, DOI 10.1093/nar/gki582; Huang GQ, 2005, HUM MOL GENET, V14, P3219, DOI 10.1093/hmg/ddi352; IWABUCHI H, 1995, CANCER RES, V55, P6172; JIN VX, 2007, IN PRESS GENOME RES; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; LASSMANN S, 2007, IN PRESS J MOL MED; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Nonet GH, 2001, CANCER RES, V61, P1250; O'Geen H, 2006, BIOTECHNIQUES, V41, P577, DOI 10.2144/000112268; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Pavesi G, 2004, NUCLEIC ACIDS RES, V32, pW199, DOI 10.1093/nar/gkh465; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Scacheri PC, 2006, PLOS GENET, V2, P406, DOI 10.1371/journal.pgen.0020051; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Yang SH, 2005, CLIN CANCER RES, V11, P612; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zhu H, 2007, CANCER LETT, V245, P303, DOI 10.1016/j.canlet.2006.01.020	45	66	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9703	9712		10.1074/jbc.M611752200	http://dx.doi.org/10.1074/jbc.M611752200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17259635	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000245421700044
J	Ma, YM; Boucrot, E; Villen, J; Affar, E; Gygi, SP; Gottlinger, HG; Kirchhausen, T				Ma, Yu May; Boucrot, Emmanuel; Villen, Judit; Affar, El Bachir; Gygi, Steven P.; Goettlinger, Heinrich G.; Kirchhausen, Tomas			Targeting of AMSH to endosomes is required for epidermal growth factor receptor degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC HOMOLOGY-3 DOMAIN; DEUBIQUITINATING ENZYMES; UBIQUITIN ISOPEPTIDASE; ESCRT-III; MAMMALIAN-CELLS; SACCHAROMYCES-CEREVISIAE; ENDOCYTIC PATHWAYS; DOWN-REGULATION; VPS PROTEIN; COMPLEX	To reach the lysosomes, down-regulated receptors such as the epidermal growth factor receptor must first be sorted into internal vesicles of late endosomes (multivesicular bodies), a ubiquitin-dependent event that requires the coordinated function of the endosome sorting complex required for transport (ESCRT) proteins. Here we report that CHMP3, an ESCRT-III complex component, and associated molecule of SH3 domain of STAM (AMSH), a deubiquitinating enzyme, interact with each other in cells. A dominant-negative version of CHMP3, which specifically prevents targeting of AMSH to endosomes, inhibits degradation but not internalization of EGFR, suggesting that endosomal AMSH is a functional component of the multivesicular body pathway.	Harvard Univ, Sch Med, CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Massachusetts, Sch Med, Program Gene Funct & Express, Worcester, MA 01605 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester	Kirchhausen, T (corresponding author), Harvard Univ, Sch Med, CBR Inst Biomed Res, 200 Longwood Ave, Boston, MA 02115 USA.	Kirchhausen@crystal.harvard.edu		Gottlinger, Heinrich/0000-0003-4124-5824; Villen, Judit/0000-0002-1005-1739	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029873, R01AI029873] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036548] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29873, R37 AI029873] Funding Source: Medline; NIGMS NIH HHS [GM036548] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agromayor M, 2006, J BIOL CHEM, V281, P23083, DOI 10.1074/jbc.M513803200; Amerik AY, 2000, MOL BIOL CELL, V11, P3365, DOI 10.1091/mbc.11.10.3365; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2005, TRAFFIC, V6, P2, DOI 10.1111/j.1600-0854.2004.00246.x; Bache KG, 2006, MOL BIOL CELL, V17, P2513, DOI 10.1091/mbc.E05-10-0915; Bowers K, 2006, J BIOL CHEM, V281, P5094, DOI 10.1074/jbc.M508632200; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Kaneko T, 2003, J BIOL CHEM, V278, P48162, DOI 10.1074/jbc.M306677200; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Luhtala N, 2004, J CELL BIOL, V166, P717, DOI 10.1083/jcb.200403139; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Massol RH, 2004, MOL BIOL CELL, V15, P3631, DOI 10.1091/mbc.E04-04-0283; McCullough J, 2006, CURR BIOL, V16, P160, DOI 10.1016/j.cub.2005.11.073; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Mizuno E, 2004, J BIOCHEM, V135, P385, DOI 10.1093/jb/mvh046; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Nakamura M, 2006, GENES CELLS, V11, P593, DOI 10.1111/j.1365-2443.2006.00963.x; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pankratz Nathan, 2004, NeuroRx, V1, P235, DOI 10.1007/BF03206607; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Row PE, 2006, J BIOL CHEM, V281, P12618, DOI 10.1074/jbc.M512615200; Scott A, 2005, P NATL ACAD SCI USA, V102, P13813, DOI 10.1073/pnas.0502165102; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Shiflett SL, 2004, J BIOL CHEM, V279, P10982, DOI 10.1074/jbc.M312669200; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Strack B, 2003, CELL, V114, P689, DOI 10.1016/S0092-8674(03)00653-6; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; Tsujita K, 2004, J BIOL CHEM, V279, P13817, DOI 10.1074/jbc.M312294200; von Schwedler UK, 2003, CELL, V114, P701, DOI 10.1016/S0092-8674(03)00714-1; Ward DMV, 2005, J BIOL CHEM, V280, P10548, DOI 10.1074/jbc.M413734200; Whitley P, 2003, J BIOL CHEM, V278, P38786, DOI 10.1074/jbc.M306864200; Yeo SCL, 2003, J CELL SCI, V116, P3957, DOI 10.1242/jcs.00751; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747; Zamborlini A, 2006, P NATL ACAD SCI USA, V103, P19140, DOI 10.1073/pnas.0603788103	43	63	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9805	9812		10.1074/jbc.M611635200	http://dx.doi.org/10.1074/jbc.M611635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17261583	Green Accepted, hybrid			2022-12-25	WOS:000245421700055
J	Mix, KS; Attur, MG; Al-Mussawir, H; Abramson, SB; Brinckerhoff, CE; Murphy, EP				Mix, Kimberlee S.; Attur, Mukundan G.; Al-Mussawir, Hayf; Abramson, Steven B.; Brinckerhoff, Constance E.; Murphy, Evelyn P.			Transcriptional repression of matrix metalloproteinase gene expression by the orphan nuclear receptor NURR1 in cartilage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE NUCLEOTIDE POLYMORPHISM; NF-KAPPA-B; RETINOID-X-RECEPTOR; ETS-BINDING-SITES; RHEUMATOID-ARTHRITIS; ARTICULAR CHONDROCYTES; DIFFERENTIAL REGULATION; COLLAGENASE 1; CELL-TYPE; PROMOTER	The NR4A orphan receptors (Nur77, NURR1, and NOR-1) are emerging as key regulators of cytokine and growth factor action in chronic inflammatory diseases. In this study, we address the role of these receptors in cartilage homeostasis during inflammatory joint disease. We document for the first time expression of the NR4A receptors in osteoarthritic cartilage. Relative to Nur77 and NOR- 1, NURR1. is expressed at the highest level and correlates with cyclooxygenase-2 levels in cartilage. Consistent with this observation, cyclooxygenase-2-derived prostaglandin E-2 (PGE(2)) rapidly and potently induces NURR1. expression in chondrocytes, suggesting that this receptor may regulate PGE2-mediated processes in cartilage. We demonstrate that PGE(2) represses interleukin-1 beta-induced matrix metalloproteinase (MMP)-1 and that transient overexpression of NURR1 is sufficient to antagonize expression of this gene. Furthermore, MMP-1 promoter activity is potently suppressed by NURR1, resulting in a significant reduction in endogenous NIMP-1 mRNA and secreted pro-MMP-1 protein. In addition, NURR1 selectively antagonizes cytokine-induced MMP-3 and -9 expression with minimal effects on MMP-2 and -13 and tissue inhibitor of matrix metalloproteinases-1 and -2. To explore the molecular mechanisms of NLJRR1 transrepression, we reveal that this receptor targets a critical region of the MMP-1 promoter (- 1772 to - 1546 bp) and that repression does not require consensus binding sites for NURR1. We confirm that NURR1. targets a 40-bp promoter sequence that is also positively regulated by ETS transcription factors. Finally, functional studies indicate that transcriptional antagonism exists between NURR1 and ETS1 on the NIMP-1 promoter. We propose a protective function for NURR1 in cartilage homeostasis by selectively repressing NIMP gene expression during inflammation.	Univ Coll Dublin, Vet Sci Ctr, Coll Life Sci, Dublin 4, Ireland; NYU, Hosp Joint Dis, Div Rheumatol, New York, NY 10003 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03756 USA	University College Dublin; New York University; NYU Langone Medical Center; Hospital for Joint Disease NYULMC; Dartmouth College; Norris Cotton Cancer Center	Mix, KS (corresponding author), Univ Coll Dublin, Vet Sci Ctr, Coll Life Sci, Dublin 4, Ireland.	kimberlee.mix@ucd.ie	Attur, Mukundan/O-1578-2019	Attur, Mukundan/0000-0001-7080-8118; Abramson, Steven/0000-0002-0668-6344; Murphy, Evelyn/0000-0002-6387-1992	NIAMS NIH HHS [AR-26599] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR026599, R37AR026599] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aarnisalo P, 2002, J BIOL CHEM, V277, P35118, DOI 10.1074/jbc.M201707200; Amin AR, 1997, J CLIN INVEST, V99, P1231, DOI 10.1172/JCI119280; Aoyama T, 2005, J BONE MINER RES, V20, P377, DOI 10.1359/JBMR.041122; Arkenbout EK, 2003, ARTERIOSCL THROM VAS, V23, P1535, DOI 10.1161/01.ATV.0000084639.16462.7A; Arkenbout EK, 2002, CIRCULATION, V106, P1530, DOI 10.1161/01.CIR.0000028811.03056.BF; Attur MG, 2001, ARTHRITIS RHEUM-US, V44, P578, DOI 10.1002/1529-0131(200103)44:3<578::AID-ANR106>3.3.CO;2-Z; Baillat D, 2006, ONCOGENE, V25, P5764, DOI 10.1038/sj.onc.1209583; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Barish GD, 2005, MOL ENDOCRINOL, V19, P2466, DOI 10.1210/me.2004-0529; Beehler BC, 2003, J RHEUMATOL, V30, P355; Bonta PI, 2006, ARTERIOSCL THROM VAS, V26, P2288, DOI 10.1161/01.ATV.0000238346.84458.5d; Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817; Castro DS, 1999, J BIOL CHEM, V274, P37483, DOI 10.1074/jbc.274.52.37483; Chaturvedi P, 2006, ARTHRITIS RHEUM-US, V54, P3513, DOI 10.1002/art.22170; Codina A, 2004, J BIOL CHEM, V279, P53338, DOI 10.1074/jbc.M409096200; Davies Mark R, 2005, J Inflamm (Lond), V2, P15, DOI 10.1186/1476-9255-2-15; de Waard V, 2006, AM J PATHOL, V168, P2027, DOI 10.2353/ajpath.2006.050932; Diatchenko L, 2005, J LEUKOCYTE BIOL, V78, P1366, DOI 10.1189/jlb.0405211; Eberhardt W, 2002, MOL ENDOCRINOL, V16, P1752, DOI 10.1210/me.2001-0278; Faour WH, 2005, J BIOL CHEM, V280, P9536, DOI 10.1074/jbc.M414067200; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Galleguillos D, 2004, J BIOL CHEM, V279, P2005, DOI 10.1074/jbc.M308113200; Gebauer M, 2005, OSTEOARTHR CARTILAGE, V13, P697, DOI 10.1016/j.joca.2005.04.004; Goldring Mary B., 1996, Am J Ther, V3, P9, DOI 10.1097/00045391-199601000-00003; Goldring MB, 2000, ARTHRITIS RHEUM-US, V43, P1916, DOI 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I; Goldring MB, 2004, CLIN ORTHOP RELAT R, pS37, DOI 10.1097/01.blo.0000144484.69656.e4; Gomez PF, 2005, J IMMUNOL, V175, P6924, DOI 10.4049/jimmunol.175.10.6924; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Gruber F, 2003, BLOOD, V101, P3042, DOI 10.1182/blood-2002-07-2331; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Harant H, 2004, NUCLEIC ACIDS RES, V32, P5280, DOI 10.1093/nar/gkh856; Holla VR, 2006, J BIOL CHEM, V281, P2676, DOI 10.1074/jbc.M507752200; Hong CY, 2004, MOL CELL BIOL, V24, P2593, DOI 10.1128/MCB.24.7.2593-2604.2004; Jacques C, 1999, REV RHUM, V66, P701; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kong G, 2005, CANCER RES, V65, P3462, DOI 10.1158/0008-5472.CAN-03-2912; Koshy PJT, 2002, ARTHRITIS RHEUM, V46, P961, DOI 10.1002/art.10212; Kraan TCTMV, 2003, ARTHRITIS RHEUM-US, V48, P2132, DOI 10.1002/art.11096; Lai HC, 2005, GYNECOL ONCOL, V96, P314, DOI 10.1016/j.ygyno.2004.09.065; Lammi J, 2004, MOL ENDOCRINOL, V18, P1546, DOI 10.1210/me.2003-0247; Le WD, 2003, NAT GENET, V33, P85, DOI 10.1038/ng1066; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Maxwell Megan A, 2006, Nucl Recept Signal, V4, pe002; McCready J, 2005, INT J CANCER, V117, P781, DOI 10.1002/ijc.21207; McEvoy AN, 2002, J IMMUNOL, V168, P2979, DOI 10.4049/jimmunol.168.6.2979; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mix KS, 2004, MOL PHARMACOL, V65, P309, DOI 10.1124/mol.65.2.309; Murphy EP, 1996, GENE EXPRESSION, V5, P169; Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8; Nelson KK, 2006, J BIOL CHEM, V281, P14100, DOI 10.1074/jbc.M601820200; Ordentlich P, 2003, J BIOL CHEM, V278, P24791, DOI 10.1074/jbc.M302167200; Park KC, 2005, MOL ENDOCRINOL, V19, P12, DOI 10.1210/me.2004-0107; Pei LM, 2006, MOL ENDOCRINOL, V20, P786, DOI 10.1210/me.2005-0331; Pei LM, 2005, J BIOL CHEM, V280, P29256, DOI 10.1074/jbc.M502606200; Petrow PK, 2000, ARTHRITIS RHEUM, V43, P1597, DOI 10.1002/1529-0131(200007)43:7<1597::AID-ANR25>3.0.CO;2-0; Pillinger MH, 2003, J IMMUNOL, V171, P6080, DOI 10.4049/jimmunol.171.11.6080; Pirih FQ, 2004, J BIOL CHEM, V279, P53167, DOI 10.1074/jbc.M405677200; Pirih FQ, 2005, BIOCHEM BIOPH RES CO, V332, P494, DOI 10.1016/j.bbrc.2005.04.132; Ralph JA, 2005, J IMMUNOL, V175, P555, DOI 10.4049/jimmunol.175.1.555; Raymond L, 2006, J CELL PHYSIOL, V207, P683, DOI 10.1002/jcp.20608; Richmond RS, 2000, ARTHRITIS RHEUM, V43, P2081, DOI 10.1002/1529-0131(200009)43:9<2081::AID-ANR20>3.0.CO;2-I; Riquet FB, 2000, MOL MED, V6, P705, DOI 10.1007/BF03402050; Rius J, 2006, ATHEROSCLEROSIS, V184, P276, DOI 10.1016/j.atherosclerosis.2005.04.008; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; Rutter JL, 1998, CANCER RES, V58, P5321; Sacchetti P, 2001, J NEUROCHEM, V76, P1565, DOI 10.1046/j.1471-4159.2001.00181.x; Sacchetti P, 2002, J BIOL CHEM, V277, P35088, DOI 10.1074/jbc.M205816200; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Schroen DJ, 1997, BIOCHEM BIOPH RES CO, V237, P52, DOI 10.1006/bbrc.1997.7073; Su L, 2005, CANCER EPIDEM BIOMAR, V14, P567, DOI 10.1158/1055-9965.EPI-04-0482; Tetlow LC, 2001, OSTEOARTHR CARTILAGE, V9, P423, DOI 10.1053/joca.2000.0408; Tetradis S, 2001, ENDOCRINOLOGY, V142, P663, DOI 10.1210/en.142.2.663; Tolon RM, 2000, MOL CELL BIOL, V20, P8793, DOI 10.1128/MCB.20.23.8793-8802.2000; Tower GB, 2003, EUR J BIOCHEM, V270, P4216, DOI 10.1046/j.1432-1033.2003.03821.x; Trojanowska M, 2000, ONCOGENE, V19, P6464, DOI 10.1038/sj.onc.1204043; Wang XM, 2006, CLIN PHARMACOL THER, V79, P303, DOI 10.1016/j.clpt.2005.12.306; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wu YM, 2005, ENDOCRINOLOGY, V146, P237, DOI 10.1210/en.2004-0889; Wyatt CA, 2002, CANCER RES, V62, P7200; Xu GW, 2005, J CLIN INVEST, V115, P1060; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	84	55	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9492	9504		10.1074/jbc.M608327200	http://dx.doi.org/10.1074/jbc.M608327200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17283078	hybrid			2022-12-25	WOS:000245421700022
J	Wang, ZX; Oh, EJ; Thurmond, DC				Wang, Zhanxiang; Oh, Eunjin; Thurmond, Debbie C.			Glucose-stimulated Cdc42 signaling is essential for the second phase of insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; LIGHT-CHAIN KINASE; DISSOCIATION INHIBITOR; CELL-MIGRATION; RHO-GTPASES; BETA-CELLS; PHOSPHORYLATION; ACTIVATION; MUNC18C; RAC	The small Rho family GTPases Cdc42 and Rac1 have each been shown to function in insulin exocytosis and are presumed to function in actin remodeling and insulin granule mobilization. However, whether either GTPase is required for the mobilization phase of insulin release (second phase) and are linked in a common signaling pathway has remained unknown. Here we demonstrate that small interfering RNA-mediated depletion of Cdc42 from isolated islets results in the selective loss of second-phase insulin release. Consistent with a role in this nutrient-dependent phase, Cdc42 activation was detected exclusively in response to D-glucose and was unresponsive to KCl or non-metabolizable glucose analogs in MIN6 beta-cells. Cdc42 activation occurred early in secretion (3 min), whereas Rac1 activation required similar to 15-20 min, suggesting Cdc42 as proximal and Rac1 as distal regulators of second-phase secretion. Importantly, Rac1 activation and function was linked in a common pathway downstream of Cdc42; Cdc42 depletion ablated glucose-induced Rac1 activation, and expression of constitutively active Rac1 in Cdc42-depleted cells functionally restored glucose-stimulated insulin secretion. Occurring at a time midway between Cdc42 and Racl activations was the phosphorylation of p21-activated-kinase 1 (Pak1), and this phosphorylation event required Cdc42. Moreover, small interfering RNA-mediated Pak1 depletion abolished Racl activation and glucose-stimulated insulin release, suggesting that Pak1 may mediate the link between Cdc42 and Racl in this pathway. Taken together, these data substantiate the existence of a novel signaling pathway in the islet beta-cell whereby Cdc42 functions as a key proximal transmitter of the glucose signal early in stimulus-secretion coupling to support the later stage of insulin release.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Ctr Diabet Res, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Thurmond, DC (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,M54053, Indianapolis, IN 46202 USA.	dthurmon@iupui.edu			NIDDK NIH HHS [R01 DK067912, R01 DK067912-04, DK-067912] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067912] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baird D, 2005, CURR BIOL, V15, P1, DOI 10.1016/j.cub.2004.12.040; Chen F, 2000, CURR BIOL, V10, P758, DOI 10.1016/S0960-9822(00)00571-6; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Diebold BA, 2004, J BIOL CHEM, V279, P28136, DOI 10.1074/jbc.M313891200; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Faure J, 1999, EUR J BIOCHEM, V262, P879, DOI 10.1046/j.1432-1327.1999.00458.x; Feng QY, 2004, EMBO J, V23, P3492, DOI 10.1038/sj.emboj.7600331; Finkielstein CV, 2006, J BIOL CHEM, V281, P27317, DOI 10.1074/jbc.M605560200; Gasman S, 2004, MOL BIOL CELL, V15, P520, DOI 10.1091/mbc.E03-06-0402; Gatti A, 1999, J BIOL CHEM, V274, P8022, DOI 10.1074/jbc.274.12.8022; Goeckeler ZM, 2000, J BIOL CHEM, V275, P18366, DOI 10.1074/jbc.M001339200; HUTTON JC, 1982, DIABETOLOGIA, V23, P365; IIDA Y, 1997, AM J PHYSIOL, V273, P782; Kowluru A, 2003, AM J PHYSIOL-ENDOC M, V285, pE669, DOI 10.1152/ajpendo.00196.2003; Kowluru A, 2005, DIABETES, V54, P3523, DOI 10.2337/diabetes.54.12.3523; Kowluru A, 1996, J CLIN INVEST, V98, P540, DOI 10.1172/JCI118822; Kowluru A, 1997, BIOCHEM PHARMACOL, V54, P1097, DOI 10.1016/S0006-2952(97)00314-6; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Lawrence JTR, 2003, P NATL ACAD SCI USA, V100, P13320, DOI 10.1073/pnas.2232129100; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li JS, 2004, AM J PHYSIOL-ENDOC M, V286, pE818, DOI 10.1152/ajpendo.00307.2003; MACDONALD MJ, 1982, DIABETES, V31, P566, DOI 10.2337/diabetes.31.6.566; Nevins AK, 2005, J BIOL CHEM, V280, P1944, DOI 10.1074/jbc.M409528200; Nevins AK, 2003, AM J PHYSIOL-CELL PH, V285, pC698, DOI 10.1152/ajpcell.00093.2003; Nevins AK, 2006, J BIOL CHEM, V281, P18961, DOI 10.1074/jbc.M603604200; NIKI I, 1993, BIOCHEM BIOPH RES CO, V191, P255, DOI 10.1006/bbrc.1993.1210; Niwa T, 1998, DIABETES, V47, P1699, DOI 10.2337/diabetes.47.11.1699; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Oh E, 2006, J BIOL CHEM, V281, P17624, DOI 10.1074/jbc.M601581200; Preitner F, 2004, J CLIN INVEST, V113, P635, DOI 10.1172/JCI200420518; Puls A, 1999, J CELL SCI, V112, P2983; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Spurlin BA, 2006, MOL ENDOCRINOL, V20, P183, DOI 10.1210/me.2005-0157; Spurlin BA, 2003, DIABETES, V52, P1910, DOI 10.2337/diabetes.52.8.1910; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; ten Klooster JP, 2006, J CELL BIOL, V172, P759, DOI 10.1083/jcb.200509096; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Trumper J, 2005, DIABETOLOGIA, V48, P1534, DOI 10.1007/s00125-005-1820-5; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Yu JS, 1998, BIOCHEM J, V334, P121, DOI 10.1042/bj3340121; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	44	113	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9536	9546		10.1074/jbc.M610553200	http://dx.doi.org/10.1074/jbc.M610553200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17289663	Green Accepted, hybrid			2022-12-25	WOS:000245421700026
J	Weng, N; Thomas, DDH; Groblewski, GE				Weng, Ning; Thomas, Diana D. H.; Groblewski, Guy E.			Pancreatic acinar cells express vesicle-associated membrane protein 2-and 8-specific populations of zymogen granules with distinct and overlapping roles in secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATED EXOCYTOSIS; EXOCRINE PANCREAS; PLASMA-MEMBRANE; FUSION; IDENTIFICATION; CALCIUM; SNARES; SYNTAXIN-2; CRHSP-28; SNAP-23	Previous studies have demonstrated roles for vesicle-associated membrane protein 2 (VAMP 2) and VAMP 8 in Ca2+-regulated pancreatic acinar cell secretion, however, their coordinated function in the secretory pathway has not been addressed. Here we provide evidence using immunofluorescence microscopy, cell fractionation, and SNARE protein interaction studies that acinar cells contain two distinct populations of zymogen granules (ZGs) expressing either VAMP 2 or VAMP 8. Further, VAMP 8-positive granules also contain the synaptosome-associated protein 29, whereas VAMP 2-expressing granules do not. Analysis of acinar secretion by Texas red-dextran labeling indicated that VAMP 2-positive ZGs mediate the majority of exocytotic events during constitutive secretion and also participate in Ca2+-regulated exocytosis, whereas VAMP 8-positive ZGs are more largely involved in Ca2+-stimulated secretion. Previously undefined functional roles for VAMP and syntaxin isoforms in acinar secretion were established by introducing truncated constructs of these proteins into permeabilized acini. VAMP 2 and VAMP 8 constructs each attenuated Ca2+-stimulated exocytosis by 50%, whereas the neuronal VAMP 1 had no effects. In comparison, the plasma membrane SNAREs syntaxin 2 and syntaxin 4 each inhibited basal exocytosis, but only syntaxin 4 significantly inhibited Ca2+-stimulated secretion. Syntaxin 3, which is expressed on ZGs, had no effects. Collectively, these data demonstrate that individual acinar cells express VAMP 2-and VAMP 8-specific populations of ZGs that orchestrate the constitutive and Ca2+-regulated secretory pathways.	Univ Wisconsin, Dept Nutr Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Groblewski, GE (corresponding author), Univ Wisconsin, Dept Nutr Sci, 1415 Linden Dr, Madison, WI 53706 USA.	groby@nutrisci.wisc.edu			NIDDK NIH HHS [DK062862, DK07088] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062862] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSON JW, 1989, AM J PHYSIOL, V256, pG817, DOI 10.1152/ajpgi.1989.256.5.G817; Antonin W, 2000, MOL BIOL CELL, V11, P3289, DOI 10.1091/mbc.11.10.3289; Castle AM, 2002, J CELL SCI, V115, P2963; Chen XQ, 2006, MOL CELL PROTEOMICS, V5, P306, DOI 10.1074/mcp.M500172-MCP200; Chen Y, 2005, AM J PHYSIOL-CELL PH, V289, pC1209, DOI 10.1152/ajpcell.00159.2005; CORNILLE F, 1995, J BIOL CHEM, V270, P16826, DOI 10.1074/jbc.270.28.16826; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Gaisano HY, 1997, FEBS LETT, V414, P298, DOI 10.1016/S0014-5793(97)01013-2; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; Giovannucci DR, 1998, AM J PHYSIOL-CELL PH, V275, pC732, DOI 10.1152/ajpcell.1998.275.3.C732; GROBLEWSKI GE, 1995, J BIOL CHEM, V270, P1437, DOI 10.1074/jbc.270.3.1437; Groblewski GE, 1996, J BIOL CHEM, V271, P31502, DOI 10.1074/jbc.271.49.31502; Hansen NJ, 1999, J BIOL CHEM, V274, P22871, DOI 10.1074/jbc.274.32.22871; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Low SH, 2003, DEV CELL, V4, P753, DOI 10.1016/S1534-5807(03)00122-9; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; Padfield PJ, 2000, FEBS LETT, V484, P129, DOI 10.1016/S0014-5793(00)02126-8; Pickett JA, 2005, J BIOL CHEM, V280, P1506, DOI 10.1074/jbc.M411967200; Polgar J, 2002, BLOOD, V100, P1081, DOI 10.1182/blood.V100.3.1081; Rotem-Yehudar R, 2001, J BIOL CHEM, V276, P33054, DOI 10.1074/jbc.M009913200; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Su QN, 2001, P NATL ACAD SCI USA, V98, P14038, DOI 10.1073/pnas.251532398; Sutton R, 2003, PANCREATOLOGY, V3, P497, DOI 10.1159/000075581; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Thomas DDH, 2004, AM J PHYSIOL-GASTR L, V287, pG253, DOI 10.1152/ajpgi.00033.2004; Thomas DDH, 2002, J BIOL CHEM, V277, P35496, DOI 10.1074/jbc.M110917200; Thomas DDH, 2001, J BIOL CHEM, V276, P28866, DOI 10.1074/jbc.M102214200; Turvey MR, 2004, PFLUG ARCH EUR J PHY, V448, P552, DOI 10.1007/s00424-004-1288-z; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Wang CC, 2004, DEV CELL, V7, P359, DOI 10.1016/j.devcel.2004.08.002; Washbourne P, 2001, BIOCHEM J, V357, P625, DOI 10.1042/0264-6021:3570625; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Weimbs T, 2003, METHODS, V30, P191, DOI 10.1016/S1046-2023(03)00025-2; Weng N, 2005, FASEB J, V19, pA742; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; WISHART MJ, 1994, AM J PHYSIOL-GASTR L, V267, pG676, DOI 10.1152/ajpgi.1994.267.4.G676; Yule DI, 1997, J BIOL CHEM, V272, P9093	41	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9635	9645		10.1074/jbc.M611108200	http://dx.doi.org/10.1074/jbc.M611108200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17272274	hybrid			2022-12-25	WOS:000245421700037
J	Yang, XXO; Panopoulos, AD; Nurieva, R; Chang, SH; Wang, DM; Watowich, SS; Dong, C				Yang, Xuexian O.; Panopoulos, Athanasia D.; Nurieva, Roza; Chang, Seon Hee; Wang, Demin; Watowich, Stephanie S.; Dong, Chen			STAT3 regulates cytokine-mediated generation of inflammatory helper T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MARROW; MICE; DIFFERENTIATION; LINEAGE; RECEPTOR; DISTINCT; INTERLEUKIN-17; PROLIFERATION; NEUTROPHILS; EXPRESSION	Interleukin-17 (IL-17)-producing helper T (TH) cells, named as THIL-17, TH17, or inflammatory TH (THi), have been recently identified as a novel effector lineage. However, how cytokine signals mediate THi differentiation is unclear. We found that IL-6 functioned to up-regulate IL-23R and that IL-23 synergized with IL-6 in promoting THi generation. STAT3, activated by both IL-6 and IL-23, plays a critical role in THi development. A hyperactive form of STAT3 promoted THi development, whereas this differentiation process was greatly impaired in STAT3-deficient T cells. Moreover, STAT3 regulated the expression of retinoic acid receptor-related orphan receptor,gamma-T (ROR gamma t), a THi-specific transcriptional regulator; STAT3 deficiency impaired ROR gamma t expression and led to elevated expression of T-box expressed in T cells (T-bet) and Forkhead box P3 (Foxp3). Our data thus demonstrate a pathway whereby cytokines regulate THi differentiation through a selective STAT transcription factor that functions to regulate lineage-specific gene expression.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; Blood Ctr Wisconsin, Blood Res Inst, Milwaukee, WI 53226 USA	University of Texas System; UTMD Anderson Cancer Center; Versiti Blood Center of Wisconsin	Dong, C (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	cdong@mdanderson.org	Chang, Seon Hee/AAQ-9521-2020; Wang, Demin/AAX-4449-2020; Yang, Xuexian/Y-2472-2019; dong, chen/B-3181-2009	Chang, Seon Hee/0000-0002-9389-508X; Wang, Demin/0000-0001-5549-3795; Yang, Xuexian/0000-0001-6816-7024; dong, chen/0000-0002-0084-9130; Watowich, Stephanie/0000-0003-1969-659X; Panopoulos, Athanasia/0000-0002-9610-2604				Akimzhanov AM, 2007, J BIOL CHEM, V282, P5969, DOI 10.1074/jbc.C600322200; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103; Cho ML, 2006, J IMMUNOL, V176, P5652, DOI 10.4049/jimmunol.176.9.5652; Chung YS, 2006, CELL RES, V16, P902, DOI 10.1038/sj.cr.7310106; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Dong C, 2000, ARTHRITIS RES, V2, P179, DOI 10.1186/ar85; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Glimcher LH, 2000, GENE DEV, V14, P1693; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kang HS, 2006, BIOCHEM J, V397, P89, DOI 10.1042/BJ20051781; Koni PA, 2001, J EXP MED, V193, P741, DOI 10.1084/jem.193.6.741; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Laouar Y, 2003, IMMUNITY, V19, P903, DOI 10.1016/S1074-7613(03)00332-7; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Panopoulos AD, 2006, BLOOD, V108, P3682, DOI 10.1182/blood-2006-02-003012; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Wen RR, 2003, J BIOL CHEM, V278, P43654, DOI 10.1074/jbc.M307318200	31	1084	1150	3	52	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9358	9363		10.1074/jbc.C600321200	http://dx.doi.org/10.1074/jbc.C600321200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17277312	hybrid			2022-12-25	WOS:000245421700007
J	Xia, XH; Huang, H; Carullo, M; Betran, E; Moriyama, EN				Xia, Xuhua; Huang, Huang; Carullo, Malisa; Betran, Esther; Moriyama, Etsuko N.			Conflict between Translation Initiation and Elongation in Vertebrate Mitochondrial Genomes	PLOS ONE			English	Article								The strand-biased mutation spectrum in vertebrate mitochondrial genomes results in an AC-rich L-strand and a GT-rich H-strand. Because the L-strand is the sense strand of 12 protein-coding genes out of the 13, the third codon position is overall strongly AC-biased. The wobble site of the anticodon of the 22 mitochondrial tRNAs is either U or G to pair with the most abundant synonymous codon, with only one exception. The wobble site of Met-tRNA is C instead of U, forming the Watson-Crick match with AUG instead of AUA, the latter being much more frequent than the former. This has been attributed to a compromise between translation initiation and elongation; i.e., AUG is not only a methionine codon, but also an initiation codon, and an anticodon matching AUG will increase the initiation rate. However, such an anticodon would impose selection against the use of AUA codons because AUA needs to be wobble-translated. According to this translation conflict hypothesis, AUA should be used relatively less frequently compared to UUA in the UUR codon family. A comprehensive analysis of mitochondrial genomes from a variety of vertebrate species revealed a general deficiency of AUA codons relative to UUA codons. In contrast, urochordate mitochondrial genomes with two tRNA Met genes with CAU and UAU anticodons exhibit increased AUA codon usage. Furthermore, six bivalve mitochondrial genomes with both of their tRNA-Met genes with a CAU anticodon have reduced AUA usage relative to three other bivalve mitochondrial genomes with one of their two tRNA-Met genes having a CAU anticodon and the other having a UAU anticodon. We conclude that the translation conflict hypothesis is empirically supported, and our results highlight the fine details of selection in shaping molecular evolution.	[Xia, Xuhua; Huang, Huang; Carullo, Malisa] Univ Ottawa, Dept Biol, Ottawa, ON, Canada; [Xia, Xuhua] Univ Ottawa, Ctr Adv Res Environm Genom, Ottawa, ON, Canada; [Xia, Xuhua] Univ Ottawa, Ottawa Inst Syst Biol, Ottawa, ON, Canada; [Betran, Esther] Univ Texas Arlington, Dept Biol, Arlington, TX 76019 USA; [Moriyama, Etsuko N.] Univ Nebraska, Sch Biol Sci, Lincoln, NE USA; [Moriyama, Etsuko N.] Univ Nebraska, Inst Plant Sci, Lincoln, NE USA	University of Ottawa; University of Ottawa; University of Ottawa; University of Texas System; University of Texas Arlington; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Xia, XH (corresponding author), Univ Ottawa, Dept Biol, Ottawa, ON, Canada.	xxia@uottawa.ca	Xia, Xuhua/E-5264-2010	Xia, Xuhua/0000-0002-3092-7566; Betran, Esther/0000-0002-4742-7963	Discovery Grant; Research Tools and Instrument Grant; NSERC-Canada	Discovery Grant; Research Tools and Instrument Grant; NSERC-Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	Discovery Grant, Research Tools and Instrument Grant, and Strategic Research Grant from NSERC-Canada. Funders are not involved in the study other than providing funds.	Agris PF, 2004, NUCLEIC ACIDS RES, V32, P223, DOI 10.1093/nar/gkh185; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P357, DOI 10.1016/S0968-0004(03)00132-4; BULMER M, 1987, NATURE, V325, P728, DOI 10.1038/325728a0; BULMER M, 1991, GENETICS, V129, P897; Clayton D A, 2000, Hum Reprod, V15 Suppl 2, P11; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Faith JJ, 2003, GENETICS, V165, P735; FOLLEY LS, 1991, GENETICS, V129, P659; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; Gissi C, 2004, J MOL EVOL, V58, P376, DOI 10.1007/s00239-003-2559-6; GOUY M, 1982, NUCLEIC ACIDS RES, V10, P7055, DOI 10.1093/nar/10.22.7055; HECKMAN JE, 1980, P NATL ACAD SCI-BIOL, V77, P3159, DOI 10.1073/pnas.77.6.3159; HOFFMANN RJ, 1992, GENETICS, V131, P397; IKEMURA T, 1981, J MOL BIOL, V151, P389, DOI 10.1016/0022-2836(81)90003-6; Ikemura T., 1992, TRANSFER RNA PROTEIN, P87; JERMIIN LS, 1995, MOL BIOL EVOL, V12, P558; Kondow A, 1998, NUCLEOS NUCLEOT NUCL, V17, P531, DOI 10.1080/07328319808005196; LILJENSTROM H, 1987, J THEOR BIOL, V124, P43, DOI 10.1016/S0022-5193(87)80251-5; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lobry JR, 2002, GENOME BIOL, V3; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; MARTIN RP, 1990, BIOCHEMISTRY-US, V29, P956, DOI 10.1021/bi00456a016; Matsuyama S, 1998, J BIOL CHEM, V273, P3363, DOI 10.1074/jbc.273.6.3363; McInerney JO, 1998, P NATL ACAD SCI USA, V95, P10698, DOI 10.1073/pnas.95.18.10698; MORIYA J, 1994, BIOCHEMISTRY-US, V33, P2234, DOI 10.1021/bi00174a033; MULERO JJ, 1994, MOL GEN GENET, V242, P383, DOI 10.1007/BF00281787; Nett JH, 2001, EUR J BIOCHEM, V268, P5209, DOI 10.1046/j.0014-2956.2001.02454.x; PERNA NT, 1995, J MOL EVOL, V41, P353, DOI 10.1007/BF01215182; Raina SZ, 2005, GENOME RES, V15, P665, DOI 10.1101/gr.3128605; Reyes A, 1998, MOL BIOL EVOL, V15, P957, DOI 10.1093/oxfordjournals.molbev.a026011; ROMERO A, 1991, FEMS MICROBIOL LETT, V84, P325, DOI 10.1016/0378-1097(91)90377-M; SANCAR A, 1988, ANNU REV BIOCHEM, V57, P29, DOI 10.1146/annurev.bi.57.070188.000333; Serb JM, 2003, MOL BIOL EVOL, V20, P1854, DOI 10.1093/molbev/msg218; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; TANAKA M, 1994, GENOMICS, V22, P327, DOI 10.1006/geno.1994.1391; Tong KL, 2004, GENE, V333, P169, DOI 10.1016/j.gene.2004.02.028; Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371; XIA X, 2001, DATA ANAL MOL BIOL E; Xia XH, 2005, GENE, V345, P13, DOI 10.1016/j.gene.2004.11.019; Xia XH, 1998, GENETICS, V149, P37; Yokobori S, 2005, MOL PHYLOGENET EVOL, V34, P273, DOI 10.1016/j.ympev.2004.10.002; Yokobori S, 2003, J MOL EVOL, V57, P574, DOI 10.1007/s00239-003-2511-9; Yokobori S, 1999, GENETICS, V153, P1851	44	24	25	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e227	10.1371/journal.pone.0000227	http://dx.doi.org/10.1371/journal.pone.0000227			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311091	Green Published, gold			2022-12-25	WOS:000207444500008
J	El-Shemy, HA; Aboul-Enein, AM; Aboul-Enein, KM; Fujita, K				El-Shemy, Hany A.; Aboul-Enein, Ahmed M.; Aboul-Enein, Khalid Mostafa; Fujita, Kounosuke			Willow Leaves' Extracts Contain Anti-Tumor Agents Effective against Three Cell Types	PLOS ONE			English	Article								Many higher plants contain novel metabolites with antimicrobial, antifungal and antiviral properties. However, in the developed world almost all clinically used chemotherapeutics have been produced by in vitro chemical synthesis. Exceptions, like taxol and vincristine, were structurally complex metabolites that were difficult to synthesize in vitro. Many non-natural, synthetic drugs cause severe side effects that were not acceptable except as treatments of last resort for terminal diseases such as cancer. The metabolites discovered in medicinal plants may avoid the side effect of synthetic drugs, because they must accumulate within living cells. The aim here was to test an aqueous extract from the young developing leaves of willow (Salix safsaf, Salicaceae) trees for activity against human carcinoma cells in vivo and in vitro. In vivo Ehrlich Ascites Carcinoma Cells (EACC) were injected into the intraperitoneal cavity of mice. The willow extract was fed via stomach tube. The (EACC) derived tumor growth was reduced by the willow extract and death was delayed (for 35 days). In vitro the willow extract could kill the majority (75%-80%) of abnormal cells among primary cells harvested from seven patients with acute lymphoblastic leukemia (ALL) and 13 with AML (acute myeloid leukemia). DNA fragmentation patterns within treated cells inferred targeted cell death by apoptosis had occurred. The metabolites within the willow extract may act as tumor inhibitors that promote apoptosis, cause DNA damage, and affect cell membranes and/or denature proteins.	[El-Shemy, Hany A.; Aboul-Enein, Ahmed M.] Cairo Univ, Fac Agr, Dept Biochem, Giza, Egypt; [Aboul-Enein, Khalid Mostafa] Cairo Univ, Natl Canc Inst, Dept Clin Pathol, Cairo, Egypt; [El-Shemy, Hany A.; Fujita, Kounosuke] Hiroshima Univ, Grad Sch Biosphere Sci, Hiroshima, Japan	Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Cairo University; National Cancer Institute - Egypt; Hiroshima University	El-Shemy, HA (corresponding author), Cairo Univ, Fac Agr, Dept Biochem, Giza, Egypt.	helshemy@hotmail.com	El-Shemy, Hany A./A-6367-2008	Aboul-Enein, Ahmed/0000-0002-3350-3451				ADAMKIEWICZ V, 1961, CAN J BIOCHEM PHYS, V39, P1097, DOI 10.1139/o61-111; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BHATT KKS, 1995, MEDICINAL PLANT INFO; Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x; Cheng JT, 2000, J CLIN PHARMACOL, V40, P445, DOI 10.1177/00912700022009198; CLAUDIA O, 2003, LANCET ONCOL, V4, P200; Clement MV, 1998, BLOOD, V92, P996; El-Shemy HA, 2003, J BIOCHEM MOL BIOL, V36, P387; Fiehn O, 2000, NAT BIOTECHNOL, V18, P1157, DOI 10.1038/81137; Freeman M, 2002, ANNU REV CELL DEV BI, V18, P515, DOI 10.1146/annurev.cellbio.18.012502.083458; Gao XH, 2002, J NUTR, V132, P2076, DOI 10.1093/jn/132.7.2076; GRONBECK M, 1995, BRIT MED J, V310, P1169; Han SS, 2002, J BIOCHEM MOL BIOL, V35, P337; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; KUPCHAN SM, 1976, SCIENCE, V191, P571, DOI 10.1126/science.1251193; Leven MD, 1979, PLANTA MED, V36, P311; MATSUMOTO Y, 1993, J PHARM SCI, V82, P399, DOI 10.1002/jps.2600820413; METZNER J, 1989, PHARMAZIE, V44, P555; Mungur R, 2005, J BIOMED BIOTECHNOL, V2, P198, DOI DOI 10.1016/J.CHEMOLAB.2010.04.010; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; STEINEGGER E, 1972, PHARM ACTA HELV, V47, P222; WILLETT WC, 1994, SCIENCE, V264, P532, DOI 10.1126/science.8160011; Wood M, 1997, BOOK HERBAL WISDOM U	25	47	52	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2007	2	1							e178	10.1371/journal.pone.0000178	http://dx.doi.org/10.1371/journal.pone.0000178			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DH	17264881	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444200003
J	Buchsbaum, S; Morris, C; Bochard, V; Jalinot, P				Buchsbaum, S.; Morris, C.; Bochard, V.; Jalinot, P.			Human INT6 interacts with MCM7 and regulates its stability during Sphase of the cell cycle	ONCOGENE			English	Article						INT6; MCM7; polyubiquitylation; protein degradation; DNA replication	MAMMARY-TUMOR VIRUS; DNA HELICASE ACTIVITY; EUKARYOTIC TRANSLATION INITIATION-FACTOR-3; FISSION YEAST HOMOLOG; COP9 SIGNALOSOME; NUCLEAR-BODIES; 26S PROTEASOME; HUMAN CLASPIN; SUBUNIT; PROTEIN	The mouse int6 gene is a frequent integration site of the mouse mammary tumor virus and INT6 silencing by RNA interference in HeLa cells causes an increased number of cells in the G2/M phases of the cell cycle, along with mitotic defects. In this report, we investigated the functional significance of the interaction between INT6 and MCM7, which was observed in a two-hybrid screen performed with INT6 as bait. It was found that proteasome inhibition strengthens interaction between both proteins and that INT6 stabilizes MCM7. Removal of MCM7 from chromatin as replication proceeds was accelerated in INT6-silenced cells and reduced amounts of protein were transiently observed, followed by a correction resulting from stimulation of mcm7 gene expression. Synchronized cells depleted for either INT6 or MCM7 display a reduction in thymidine incorporation and a reinforced association of RPA and claspin with chromatin. These data show that INT6 stabilizes chromatin-bound MCM7 and that alteration of this effect is associated with replication deficency.	Ecole Normale Super Lyon, CNRS, Lab Biol Mol Cellule, UMR 5161,IFR 128 Biosci Lyon Gerland, F-69364 Lyon 07, France	UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Universite Jean Monnet	Jalinot, P (corresponding author), Ecole Normale Super Lyon, CNRS, Lab Biol Mol Cellule, UMR 5161,IFR 128 Biosci Lyon Gerland, 46 Allee Italie, F-69364 Lyon 07, France.	pjalinot@ens-lyon.fr	Morris, Christelle/M-8168-2014	Morris, Christelle/0000-0003-1575-4609				Akiyoshi Y, 2001, J BIOL CHEM, V276, P10056, DOI 10.1074/jbc.M010188200; Alves KH, 2002, FEBS LETT, V527, P15, DOI 10.1016/S0014-5793(02)03147-2; Asano K, 1997, J BIOL CHEM, V272, P23477, DOI 10.1074/jbc.272.38.23477; Bandyopadhyay A, 2000, MOL BIOL CELL, V11, P4005, DOI 10.1091/mbc.11.11.4005; Blow JJ, 2005, NAT REV MOL CELL BIO, V6, P476, DOI 10.1038/nrm1663; Burks EA, 2001, J BIOL CHEM, V276, P2122, DOI 10.1074/jbc.M007236200; Buttitta F, 2005, CLIN CANCER RES, V11, P3198, DOI 10.1158/1078-0432.CCR-04-2308; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; Crane R, 2000, MOL BIOL CELL, V11, P3993, DOI 10.1091/mbc.11.11.3993; Desbois C, 1996, SCIENCE, V273, P951, DOI 10.1126/science.273.5277.951; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fitch MJ, 2003, J BIOL CHEM, V278, P25408, DOI 10.1074/jbc.M300699200; Fujita M, 1996, J BIOL CHEM, V271, P4349; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Harlow E., 1988, ANTIBODIES LAB MANUA, P447; Holthoff HP, 1998, J BIOL CHEM, V273, P7320, DOI 10.1074/jbc.273.13.7320; Hwang GW, 2005, MOL PHARMACOL, V68, P1074, DOI 10.1124/mol.105.013516; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kuo ML, 1997, INT J ONCOL, V10, P515; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Maiorano D, 2005, CELL, V120, P315, DOI 10.1016/j.cell.2004.12.010; MARCHETTI A, 1995, J VIROL, V69, P1932, DOI 10.1128/JVI.69.3.1932-1938.1995; Mayeur GL, 2002, FEBS LETT, V514, P49, DOI 10.1016/S0014-5793(02)02307-4; Morris C, 2005, ONCOGENE, V24, P1203, DOI 10.1038/sj.onc.1208268; Morris-Desbois C, 1999, J CELL SCI, V112, P3331; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rasmussen SB, 2001, ONCOGENE, V20, P5291, DOI 10.1038/sj.onc.1204624; Sar F, 2004, J BIOL CHEM, V279, P39289, DOI 10.1074/jbc.M405793200; Wang Y, 2000, FEBS LETT, V484, P17, DOI 10.1016/S0014-5793(00)02117-7; Yahalom A, 2001, J BIOL CHEM, V276, P334, DOI 10.1074/jbc.M006721200; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yen HCS, 2003, CELL, V112, P207, DOI 10.1016/S0092-8674(03)00043-6; Yen HCS, 2000, P NATL ACAD SCI USA, V97, P14370, DOI 10.1073/pnas.97.26.14370; You ZY, 2002, J BIOL CHEM, V277, P42471, DOI 10.1074/jbc.M205769200; Zhang X, 2004, J BIOL CHEM, V279, P25122, DOI 10.1074/jbc.M403287200; Zhou CS, 2005, BMC BIOL, V3, DOI 10.1186/1741-7007-3-14; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	41	15	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5132	5144		10.1038/sj.onc.1210314	http://dx.doi.org/10.1038/sj.onc.1210314			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310990				2022-12-25	WOS:000248487400012
J	Yonekura-Sakakibara, K; Tohge, T; Niida, R; Saito, K				Yonekura-Sakakibara, Keiko; Tohge, Takayuki; Niida, Rie; Saito, Kazuki			Identification of a flavonol 7-O-rhamnosyltransferase gene determining flavonoid pattern in Arabidopsis by transcriptome coexpression analysis and reverse genetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHOCYANIN PIGMENTATION; MEDIATED TRANSFORMATION; SECONDARY METABOLISM; FUNCTIONAL GENOMICS; COLORFUL MODEL; PLANT; BIOSYNTHESIS; GLYCOSYLTRANSFERASES; THALIANA; CDNA	Glycosylation plays a major role in the remarkable chemical diversity of flavonoids in plants including Arabidopsis thaliana. The wide diversity encoded by the large family-1 glycosyltransferase ( UGT) gene family makes it difficult to determine the biochemical function of each gene solely from its primary sequence. Here we used transcriptome coexpression analysis combined with a reverse genetics approach to identify a gene that is prominent in determining the flavonoid composition of Arabidopsis. Using transcriptome coexpression analysis accessible on the ATTED-II public data base, the expression pattern of a UGT gene, UGT89C1, was found to be highly correlated with known flavonoid biosynthetic genes. No C-7 rhamnosylated flavonols were detected in either of two T-DNA ugt89c1 mutants. This specific metabolite deficiency in the mutants was complemented by stable transformation with the genomic fragment containing intact UGT89C1. Glutathione S-transferasefused recombinant UGT89C1 protein converted kaempferol 3-O-glucoside to kaempferol 3-O-glucoside-7-O-rhamnoside and recognized 3-O-glycosylated flavonols and UDP-rhamnose as substrates, but not flavonol aglycones, 3-O-glycosylated anthocyanins or other UDP-sugars. These results show that UGT89C1 is a flavonol 7-O-rhamnosyltransferase. The abundance of UGT89C1 transcripts in floral buds was consistent with the flavonoid accumulation of C-7 rhamnosylated flavonols in Arabidopsis organs. Our present study demonstrates that the integration of transcriptome coexpression analysis with a reverse genetic approach is a versatile tool for understanding a multigene family of a metabolic pathway in Arabidopsis.	RIKEN, Plant Sci Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan	RIKEN; Chiba University	Saito, K (corresponding author), RIKEN, Plant Sci Ctr, Tsurumi Ku, Suehiro Cho 1-7-22, Yokohama, Kanagawa 2300045, Japan.	ksaito@faculty.chiba-u.jp	Saito, Kazuki/D-2670-2009; Yonekura-Sakakibara, Keiko/J-8749-2014; Tohge, Takayuki/G-7924-2017	Saito, Kazuki/0000-0001-6310-5342; Yonekura-Sakakibara, Keiko/0000-0002-0409-1523; Tohge, Takayuki/0000-0001-5555-5650				BARBER GA, 1991, ARCH BIOCHEM BIOPHYS, V288, P239, DOI 10.1016/0003-9861(91)90190-T; Birnbaum K, 2003, SCIENCE, V302, P1956, DOI 10.1126/science.1090022; Bowles D, 2002, BIOCHEM SOC T, V30, P301, DOI 10.1042/BST0300301; Bowles D, 2006, ANNU REV PLANT BIOL, V57, P567, DOI 10.1146/annurev.arplant.57.032905.105429; BRUGLIERA F, 1994, PLANT J, V5, P81, DOI 10.1046/j.1365-313X.1994.5010081.x; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Craigon DJ, 2004, NUCLEIC ACIDS RES, V32, pD575, DOI 10.1093/nar/gkh133; D'Auria JC, 2005, CURR OPIN PLANT BIOL, V8, P308, DOI 10.1016/j.pbi.2005.03.012; Davies K. M., 2006, Flavonoids: chemistry, biochemistry and applications, P143; DIXON RA, 1995, PLANT CELL, V7, P1085, DOI 10.1105/tpc.7.7.1085; Dixon RA, 2003, PHYTOCHEMISTRY, V62, P815, DOI 10.1016/S0031-9422(02)00712-4; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; Goossens A, 2003, P NATL ACAD SCI USA, V100, P8595, DOI 10.1073/pnas.1032967100; Graham TL, 1998, PLANT PHYSIOL BIOCH, V36, P135, DOI 10.1016/S0981-9428(98)80098-3; Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1; Hirai MY, 2004, P NATL ACAD SCI USA, V101, P10205, DOI 10.1073/pnas.0403218101; HOFGEN R, 1988, NUCLEIC ACIDS RES, V16, P9877, DOI 10.1093/nar/16.20.9877; Jones P, 2003, J BIOL CHEM, V278, P43910, DOI 10.1074/jbc.M303523200; Koes R, 2005, TRENDS PLANT SCI, V10, P236, DOI 10.1016/j.tplants.2005.03.002; KROON J, 1994, PLANT J, V5, P69, DOI 10.1046/j.1365-313X.1994.5010069.x; Kubo A, 2004, ARCH BIOCHEM BIOPHYS, V429, P198, DOI 10.1016/j.abb.2004.06.021; Mehrtens F, 2005, PLANT PHYSIOL, V138, P1083, DOI 10.1104/pp.104.058032; Morita Y, 2005, PLANT J, V42, P353, DOI 10.1111/j.1365-313X.2005.02383.x; Obayashi T, 2007, NUCLEIC ACIDS RES, V35, pD863, DOI 10.1093/nar/gkl783; Offen W, 2006, EMBO J, V25, P1396, DOI 10.1038/sj.emboj.7600970; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Paquette S, 2003, PHYTOCHEMISTRY, V62, P399, DOI 10.1016/S0031-9422(02)00558-7; Pelletier MK, 1996, PLANT PHYSIOL, V111, P339, DOI 10.1104/pp.111.1.339; Pelletier MK, 1997, PLANT PHYSIOL, V113, P1437, DOI 10.1104/pp.113.4.1437; QUATTROCCHIO F, 1993, PLANT CELL, V5, P1497, DOI 10.1105/tpc.5.11.1497; Rhee SY, 2003, NUCLEIC ACIDS RES, V31, P224, DOI 10.1093/nar/gkg076; Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957; Routaboul JM, 2006, PLANTA, V224, P96, DOI 10.1007/s00425-005-0197-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sawada S, 2005, J BIOL CHEM, V280, P899, DOI 10.1074/jbc.M410537200; Scalbert A, 2005, AM J CLIN NUTR, V81, p215S, DOI 10.1093/ajcn/81.1.215S; Seki M, 1998, PLANT J, V15, P707, DOI 10.1046/j.1365-313x.1998.00237.x; Seki M, 2002, SCIENCE, V296, P141, DOI 10.1126/science.1071006; Shinbo Y, 2006, BIOTECH AGR FOREST, V57, P165; STAFFORD HA, 1991, PLANT PHYSIOL, V96, P680, DOI 10.1104/pp.96.3.680; Tohge T, 2005, PLANT J, V42, P218, DOI 10.1111/j.1365-313X.2005.02371.x; Tohge T, 2007, PURE APPL CHEM, V79, P811, DOI 10.1351/pac200779040811; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; Veit M, 1999, J NAT PROD, V62, P1301, DOI 10.1021/np990080o; Williams C. A., 2006, Flavonoids: chemistry, biochemistry and applications, P749; Winkel-Shirley B, 2001, PLANT PHYSIOL, V126, P485, DOI 10.1104/pp.126.2.485; Yonekura-Sakakibara K, 2004, PLANT PHYSIOL, V134, P1654, DOI 10.1104/pp.103.037176	47	210	224	10	71	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2007	282	20					14932	14941		10.1074/jbc.M611498200	http://dx.doi.org/10.1074/jbc.M611498200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JR	17314094	hybrid			2022-12-25	WOS:000246589000031
J	Lea-Smith, DJ; Pyke, JS; Tull, D; McConville, MJ; Coppel, RL; Crellin, PK				Lea-Smith, David J.; Pyke, James S.; Tull, Dedreia; McConville, Malcolm J.; Coppel, Ross L.; Crellin, Paul K.			The reductase that catalyzes mycolic motif synthesis is required for efficient attachment of mycolic acids to arabinogalactan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYNEBACTERIUM-GLUTAMICUM; MYCOBACTERIUM-TUBERCULOSIS; CELL-WALL; CONDENSATION STEP; CLONING VECTORS; BIOSYNTHESIS; IDENTIFICATION; TREHALOSE; GENES; MACROPHAGES	Mycolic acids are essential components of the cell walls of bacteria belonging to the suborder Corynebacterineae, including the important human pathogens Mycobacterium tuberculosis and Mycobacterium leprae. Mycolic acid biosynthesis is complex and the target of several frontline antimycobacterial drugs. The condensation of two fatty acids to form a 2-alkyl-3-keto mycolate precursor and the subsequent reduction of this precursor represent two key and highly conserved steps in this pathway. Although the enzyme catalyzing the condensation step has recently been identified, little is known about the putative reductase. Using an extensive bioinformatic comparison of the genomes of M. tuberculosis and Corynebacterium glutamicum, we identified NCgl2385, the orthologue of Rv2509 in M. tuberculosis, as a potential reductase candidate. Deletion of the gene in C. glutamicum resulted in a slow growing strain that was deficient in arabinogalactan-linked mycolates and synthesized abnormal forms of the mycolate-containing glycolipids trehalose dicorynomycolate and trehalose mono-corynomycolate. Analysis of the native and acetylated trehalose glycolipids by MALDI-TOF mass spectrometry indicated that these novel glycolipids contained an unreduced beta-keto ester. This was confirmed by analysis of sodium borodeuteride-reduced mycolic acids by gas chromatography mass spectrometry. Reintroduction of the NCgl2385 gene into the mutant restored the transfer of mature mycolic acids to both the trehalose glycolipids and cell wall arabinogalactan. These data indicate that NCgl2385, which we have designated CmrA, is essential for the production of mature trehalose mycolates and subsequent covalent attachment of mycolic acids onto the cell wall, thus representing a focus for future structural and pathogenicity studies.	Monash Univ, Australian Res Council, Ctr Excellence Struct & Funct Microbial Genom, Dept Microbiol, Clayton, Vic 3800, Australia; Monash Univ, Dept Microbiol, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Inst Mol Sci & Biotechnol Bio21, Parkville, Vic 3010, Australia	Monash University; Monash University; University of Melbourne	Crellin, PK (corresponding author), Monash Univ, Australian Res Council, Ctr Excellence Struct & Funct Microbial Genom, Dept Microbiol, Clayton, Vic 3800, Australia.	paul.crellin@med.monash.edu.au	Coppel, Ross L/A-6626-2008; Lea-Smith, David/U-9151-2019	Coppel, Ross L/0000-0002-4476-9124; Lea-Smith, David/0000-0003-2463-406X; Crellin, Paul K/0000-0002-2017-4935; Tull, Dedreia/0000-0003-2546-6707				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BESRA GS, 1994, P NATL ACAD SCI USA, V91, P12735, DOI 10.1073/pnas.91.26.12735; Billman-Jacobe H, 1999, MOL MICROBIOL, V33, P1244, DOI 10.1046/j.1365-2958.1999.01572.x; Brennan PJ, 2003, TUBERCULOSIS, V83, P91, DOI 10.1016/S1472-9792(02)00089-6; Chami M, 2002, FEMS IMMUNOL MED MIC, V32, P141, DOI 10.1111/j.1574-695X.2002.tb00546.x; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DATTA AK, 1993, BIOCHIM BIOPHYS ACTA, V1169, P135, DOI 10.1016/0005-2760(93)90198-I; De Sousa-D'Auria C, 2003, FEMS MICROBIOL LETT, V224, P35, DOI 10.1016/S0378-1097(03)00396-3; GAILLY C, 1982, EUR J BIOCHEM, V125, P83, DOI 10.1111/j.1432-1033.1982.tb06654.x; Gande R, 2004, J BIOL CHEM, V279, P44847, DOI 10.1074/jbc.M408648200; GASTAMBIDEODIER M, 1959, NATURE, V184, P1563, DOI 10.1038/1841563b0; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Kovacevic S, 2006, J BIOL CHEM, V281, P9011, DOI 10.1074/jbc.M511709200; Lee RE, 1997, BBA-LIPID LIPID MET, V1346, P275, DOI 10.1016/S0005-2760(97)00051-9; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; McKean S, 2005, MICROBES INFECT, V7, P1352, DOI 10.1016/j.micinf.2005.05.002; Oswald IP, 1997, INFECT IMMUN, V65, P1364, DOI 10.1128/IAI.65.4.1364-1369.1997; Portevin D, 2005, J BIOL CHEM, V280, P8862, DOI 10.1074/jbc.M408578200; Portevin D, 2004, P NATL ACAD SCI USA, V101, P314, DOI 10.1073/pnas.0305439101; PUDLES J, 1953, BIOCHIM BIOPHYS ACTA, V11, P602, DOI 10.1016/0006-3002(53)90113-9; Puech V, 2002, MOL MICROBIOL, V44, P1109, DOI 10.1046/j.1365-2958.2002.02953.x; Raviglione MC, 2003, TUBERCULOSIS, V83, P4, DOI 10.1016/S1472-9792(02)00071-9; Sassetti CM, 2003, MOL MICROBIOL, V48, P77, DOI 10.1046/j.1365-2958.2003.03425.x; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; Schroeder E. K., 2002, Current Pharmaceutical Biotechnology, V3, P197, DOI 10.2174/1389201023378328; Takayama K, 2005, CLIN MICROBIOL REV, V18, P81, DOI 10.1128/CMR.18.1.81-101.2005; Tatituri RVV, 2007, J BIOL CHEM, V282, P4561, DOI 10.1074/jbc.M608695200; Tropis M, 2005, J BIOL CHEM, V280, P26573, DOI 10.1074/jbc.M502104200; van der Rest ME, 1999, APPL MICROBIOL BIOT, V52, P541, DOI 10.1007/s002530051557; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	32	71	73	0	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11000	11008		10.1074/jbc.M608686200	http://dx.doi.org/10.1074/jbc.M608686200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308303	hybrid			2022-12-25	WOS:000245941500020
J	Hattori, M; Miyake, H; Sugita, M				Hattori, Mitsuru; Miyake, Hiroshi; Sugita, Mamoru			A pentatricopeptide repeat protein is required for RNA processing of clpP pre-mRNA in moss chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEUS-ENCODED FACTOR; PHYSCOMITRELLA-PATENS; GENE-EXPRESSION; ARABIDOPSIS-THALIANA; RESTORES FERTILITY; HIGHER-PLANTS; LAND PLANT; PPR MOTIF; DNA; REVEALS	Pentatricopeptide repeat ( PPR) proteins are encoded by the nuclear genome as a large gene family in land plants. PPR proteins play essential roles in organelle-related functions, mostly in RNA-processing steps in plastids and mitochondria. In the moss Physcomitrella patens, there is also a large gene family, but the moss PPR proteins are likely to be divergent from those of higher plants. To investigate the function of plastid PPR proteins, we have generated and characterized a PPR protein gene disruptant of P. patens. The PPR531-11- disrupted mosses displayed abnormal phenotypic characteristics, such as a significantly smaller protonemal colony, different chloroplast morphology, and incomplete thylakoid membrane formation. In addition, the quantum yield of photosystem II was reduced in the disrupted mosses. To further investigate whether disruption of the PPR531-11 gene affects chloroplast gene expression, we performed Northern blot and reverse transcription polymerase chain reaction analyses. These analyses revealed that PPR531-11 has a role in intergenic RNA cleavage between clpP and 5'-rps12 and in the splicing of clpP pre-mRNA. Western blot analysis showed that disruption of PPR531-11 resulted in a reduced level of ClpP, photosystem II reaction center protein D1, and the stromal enzyme, ribulose-bisphosphate carboxylase/oxygenase. These reductions might result in the severely retarded growth of the protonemal colony. Taken together, we propose a model where PPR531-11 function affects the steady-state level of ClpP, which regulates the formation and maintenance of thylakoid membranes in chloroplasts. This is the first evidence of a PPR protein controlling the protein expression level of ClpP.	Nagoya Univ, Ctr Gene Res, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Sugita, M (corresponding author), Nagoya Univ, Ctr Gene Res, Chikusa Ku, Furo Cho 1, Nagoya, Aichi 4648602, Japan.	sugita@gene.nagoya-u.ac.jp						ARNON DI, 1949, SCIENCE, V110, P554, DOI 10.1126/science.110.2865.554; Bentolila S, 2002, P NATL ACAD SCI USA, V99, P10887, DOI 10.1073/pnas.102301599; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Cahoon AB, 2003, PLANT CELL PHYSIOL, V44, P93, DOI 10.1093/pcp/pcg003; Clarke AK, 2005, PHYSIOL PLANTARUM, V123, P406, DOI 10.1111/j.1399-3054.2005.00452.x; Cove D, 2005, ANNU REV GENET, V39, P339, DOI 10.1146/annurev.genet.39.073003.110214; Cushing DA, 2005, PLANTA, V221, P424, DOI 10.1007/s00425-004-1452-x; Ding YH, 2006, PLANT CELL, V18, P815, DOI 10.1105/tpc.105.039495; Duckett J.G., 1988, ADV BRYOL, V3, P33; Fisk DG, 1999, EMBO J, V18, P2621, DOI 10.1093/emboj/18.9.2621; GENTY E, 1989, BIOCHEM PHARMACOL, V38, P3885, DOI 10.1016/0006-2952(89)90600-X; Hasan R, 2005, PLANT PROD SCI, V8, P567, DOI 10.1626/pps.8.567; Hashimoto M, 2003, PLANT J, V36, P541, DOI 10.1046/j.1365-313X.2003.01900.x; Hattori M, 2004, GENE, V343, P305, DOI 10.1016/j.gene.2004.09.015; Herrmann R. G., 1992, Cell organelles., P275; Ichikawa K, 2004, PLANT PHYSIOL, V136, P4285, DOI 10.1104/pp.104.053033; Ikeda TM, 1999, MOL CELL BIOL, V19, P8113; Kabeya Y, 2005, PLANT PHYSIOL, V138, P369, DOI 10.1104/pp.105.059501; Kazama T, 2003, FEBS LETT, V544, P99, DOI 10.1016/S0014-5793(03)00480-0; Koizuka N, 2003, PLANT J, V34, P407, DOI 10.1046/j.1365-313X.2003.01735.x; Kotera E, 2005, NATURE, V433, P326, DOI 10.1038/nature03229; Kuroda H, 2003, NATURE, V425, P86, DOI 10.1038/nature01909; Kuroda H, 2002, PLANT PHYSIOL, V129, P1600, DOI 10.1104/pp.004986; Lurin C, 2004, PLANT CELL, V16, P2089, DOI 10.1105/tpc.104.022236; Majeran W, 2000, PLANT CELL, V12, P137; Meierhoff K, 2003, PLANT CELL, V15, P1480, DOI 10.1105/tpc.010397; Miyata Y, 2004, J PLANT PHYSIOL, V161, P113, DOI 10.1078/0176-1617-01220; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; Nakamura T, 2005, PLANT BIOLOGY, V7, P258, DOI 10.1055/s-2005-865620; Nakamura T, 2003, EUR J BIOCHEM, V270, P4070, DOI 10.1046/j.1432-1033.2003.03796.x; Nakamura T, 2001, J BIOL CHEM, V276, P147, DOI 10.1074/jbc.M008817200; Nishiyama T, 2000, DNA RES, V7, P9, DOI 10.1093/dnares/7.1.9; Nishiyama T, 2003, P NATL ACAD SCI USA, V100, P8007, DOI 10.1073/pnas.0932694100; Okuda K, 2006, J BIOL CHEM, V281, P37661, DOI 10.1074/jbc.M608184200; Olsson T, 2003, J BIOL CHEM, V278, P44439, DOI 10.1074/jbc.M306265200; Ostersetzer O, 2005, PLANT CELL, V17, P241, DOI 10.1105/tpc.104.027516; Pfalz J, 2006, PLANT CELL, V18, P176, DOI 10.1105/tpc.105.036392; Reski R, 1998, BOT ACTA, V111, P1; Schaefer DG, 1997, PLANT J, V11, P1195, DOI 10.1046/j.1365-313X.1997.11061195.x; Schmitz-Linneweber C, 2005, PLANT CELL, V17, P2791, DOI 10.1105/tpc.105.034454; Shikanai T, 2006, CELL MOL LIFE SCI, V63, P698, DOI 10.1007/s00018-005-5449-9; Shikanai T, 2001, PLANT CELL PHYSIOL, V42, P264, DOI 10.1093/pcp/pce031; Sjogren LLE, 2006, PLANT CELL, V18, P2635, DOI 10.1105/tpc.106.044594; Small ID, 2000, TRENDS BIOCHEM SCI, V25, P46, DOI 10.1016/S0968-0004(99)01520-0; Sugita M, 1996, PLANT MOL BIOL, V32, P315, DOI 10.1007/BF00039388; Sugiura C, 2003, NUCLEIC ACIDS RES, V31, P5324, DOI 10.1093/nar/gkg726; Sugiura C, 2004, PLANT J, V40, P314, DOI 10.1111/j.1365-313X.2004.02202.x; TERASAWA K, 2007, IN PRESS MOL BIOL EV; Williams PM, 2003, PLANT J, V36, P675, DOI 10.1046/j.1365-313X.2003.01915.x; YAMAGUCHI K, 2005, PHOTOSYSTEM2 LIGHT D, P650; Yamazaki H, 2004, PLANT J, V38, P152, DOI 10.1111/j.1365-313X.2004.02035.x; Zheng B, 2006, PLANTA, V224, P1103, DOI 10.1007/s00425-006-0292-2	52	70	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10773	10782		10.1074/jbc.M608034200	http://dx.doi.org/10.1074/jbc.M608034200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283080	hybrid			2022-12-25	WOS:000245941000071
J	Kono, M; Belyantseva, IA; Skoura, A; Frolenkov, GI; Starost, MF; Dreier, JL; Lidington, D; Bolz, SS; Friedman, TB; Hla, T; Proia, RL				Kono, Mari; Belyantseva, Inna A.; Skoura, Athanasia; Frolenkov, Gregory I.; Starost, Matthew F.; Dreier, Jennifer L.; Lidington, Darcy; Bolz, Steffen-Sebastian; Friedman, Thomas B.; Hla, Timothy; Proia, Richard L.			Deafness and stria Vascularis defects in S1P(2) receptor-null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE RECEPTOR; PROTEIN-COUPLED RECEPTOR; INNER-EAR; TIGHT JUNCTIONS; ENDOTHELIAL-CELLS; MOUSE; SPHINGOSINE-1-PHOSPHATE; DYSFUNCTION; MATURATION; HEARING	The S1P(2) receptor is a member of a family of G protein-coupled receptors that bind the extracellular sphingolipid metabolite sphingosine 1-phosphate with high affinity. The receptor is widely expressed and linked to multiple G protein signaling pathways, but its physiological function has remained elusive. Here we have demonstrated that S1P(2) receptor expression is essential for proper functioning of the auditory and vestibular systems. Auditory brainstem response analysis revealed that S1P(2) receptor-null mice were deaf by one month of age. These null mice exhibited multiple inner ear pathologies. However, some of the earliest cellular lesions in the cochlea were found within the stria vascularis, a barrier epithelium containing the primary vasculature of the inner ear. Between 2 and 4 weeks after birth, the basal and marginal epithelial cell barriers and the capillary bed within the stria vascularis of the S1P(2) receptor-null mice showed markedly disturbed structures. JTE013, an S1P(2) receptor-specific antagonist, blocked the S1P-induced vasoconstriction of the spiral modiolar artery, which supplies blood directly to the stria vascularis and protects its capillary bed from high perfusion pressure. Vascular disturbance within the stria vascularis is a potential mechanism that leads to deafness in the S1P(2) receptor-null mice.	NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA; NIDCD, Mol Genet Lab, NIH, Rockville, MD 20850 USA; Univ Connecticut, Ctr Hlth, Ctr Vasc Biol, Dept Cell Biol, Farmington, CT 06030 USA; NIH, Div Vet Resources, Bethesda, MD 20892 USA; Univ Toronto, Dept Physiol & Heart & Stroke, Richard Lewar Ctr Excellence, Toronto, ON M5S 1A8, Canada; NIDCD, Otolaryngol Branch, NIH, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Connecticut; National Institutes of Health (NIH) - USA; University of Toronto; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Proia, RL (corresponding author), NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA.	proia@nih.gov	Proia, Richard L/A-7908-2012; Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065; Frolenkov, Gregory/0000-0002-9810-5024; Proia, Richard/0000-0003-0456-1270; Lidington, Darcy/0000-0001-7582-7924; Kono, Mari/0000-0003-2447-4350	Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [R37-HL-67330, P01-HL-70694] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070694, R37HL067330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000060] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Allende ML, 2003, BLOOD, V102, P3665, DOI 10.1182/blood-2003-02-0460; ANNIKO M, 1980, ARCH OTO-RHINO-LARYN, V229, P281, DOI 10.1007/BF02565531; Arikawa K, 2003, J BIOL CHEM, V278, P32841, DOI 10.1074/jbc.M305024200; Everett LA, 2001, HUM MOL GENET, V10, P153, DOI 10.1093/hmg/10.2.153; Gon Y, 2005, P NATL ACAD SCI USA, V102, P9270, DOI 10.1073/pnas.0501997102; Gow A, 2004, J NEUROSCI, V24, P7051, DOI 10.1523/JNEUROSCI.1640-04.2004; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hibino H, 1997, J NEUROSCI, V17, P4711; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Ikeda H, 2003, GASTROENTEROLOGY, V124, P459, DOI 10.1053/gast.2003.50049; Khan Z, 2004, NEUROSCIENCE, V127, P785, DOI 10.1016/j.neuroscience.2004.05.052; Kitajiri SI, 2004, J CELL SCI, V117, P5087, DOI 10.1242/jcs.01393; Kono M, 2004, J BIOL CHEM, V279, P29367, DOI 10.1074/jbc.M403937200; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Lorenz JN, 2007, AM J PHYSIOL-REG I, V292, pR440, DOI 10.1152/ajpregu.00085.2006; MacLennan AJ, 2006, HEARING RES, V220, P38, DOI 10.1016/j.heares.2006.06.016; MacLennan AJ, 2001, EUR J NEUROSCI, V14, P203, DOI 10.1046/j.0953-816x.2001.01634.x; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Noguchi Y, 2006, GENETICS, V173, P2111, DOI 10.1534/genetics.106.057372; Osada M, 2002, BIOCHEM BIOPH RES CO, V299, P483, DOI 10.1016/S0006-291X(02)02671-2; Ruckenstein MJ, 1999, OTOLARYNG HEAD NECK, V121, P452, DOI 10.1016/S0194-5998(99)70236-6; SADANAGA M, 1995, HEARING RES, V89, P155, DOI 10.1016/0378-5955(95)00133-X; Scherer EQ, 2006, CARDIOVASC RES, V70, P79, DOI 10.1016/j.cardiores.2006.01.011; Scherer EQ, 2001, J MEMBRANE BIOL, V182, P183, DOI 10.1007/s00232-001-0041-1; SCHROTT A, 1990, HEARING RES, V46, P1, DOI 10.1016/0378-5955(90)90134-B; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; STEEL KP, 1987, HEARING RES, V27, P11, DOI 10.1016/0378-5955(87)90022-0; Wangemann P, 2006, J PHYSIOL-LONDON, V576, P11, DOI 10.1113/jphysiol.2006.112888; Wangemann P, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-30	30	143	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10690	10696		10.1074/jbc.M700370200	http://dx.doi.org/10.1074/jbc.M700370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284444	hybrid			2022-12-25	WOS:000245941000063
J	Silva, AM; Wang, D; Komar, AA; Castilho, BA; Williams, BRG				Silva, Aristobolo M.; Wang, Die; Komar, Anton A.; Castilho, Beatriz A.; Williams, Bryan R. G.			Salicylates trigger protein synthesis inhibition in a protein kinase R-like endoplasmic reticulum kinase-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 2-ALPHA KINASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; GLUCOSE-REGULATED PROTEINS; INDUCED GENE-EXPRESSION; TRANSLATION INITIATION; SODIUM-SALICYLATE; MAMMALIAN HOMOLOG; MESSENGER-RNA; KAPPA-B; CELLS	The non-steroidal anti-inflammatory drug aspirin and its metabolite, sodium salicylate, have profound effects on cellular protein synthesis and cell physiology. However, the underlying mechanism by which they cause these responses remains unclear. We show here that salicylates induce phosphorylation of the alpha-subunit of eukaryotic translation initiation factor 2 (eIF2 similar to), resulting in the inhibition of mRNA translation in cells. Exposure of cells to acetyl salicylic acid resulted in strong activation of eIF2 alpha stress-activated protein kinase R-like endoplasmic reticulum kinase ( PERK). Analysis of fibroblasts with a targeted deletion of the perk gene revealed that PERK is indispensable for triggering the phosphorylation of eIF2 alpha as well as the inhibition of protein synthesis induced by salicylates. Although salicylate treatment did not trigger activation of inositol-requiring enzyme 1, there was an increased expression of the pro-apoptotic transcription factor CHOP-( gadd153), a downstream event to eIF2 alpha phosphorylation known to mediate endoplasmic reticulum stress-mediated responses. Thus, salicylates selectively trigger an endoplasmic reticulum stress-responsive signaling pathway initiated through activation of PERK to induce their cellular effects.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Monash Univ, Monash Inst Med Res, Melbourne, Vic 3168, Australia; Cleveland State Univ, Dept Biol Geol & Environm Sci, Cleveland, OH 44115 USA; Escola Paulista Med, Dept Microbiol Imunol & Parasitol, BR-04023062 Sao Paulo, Brazil	Cleveland Clinic Foundation; Monash University; University System of Ohio; Cleveland State University; Universidade Federal de Sao Paulo (UNIFESP)	Williams, BRG (corresponding author), Monash Med Ctr, Mionash Inst Med Res, 246 Clayton Rd, Melbourne, Vic 3168, Australia.	bryan.williams@med.monash.edu.au	Williams, Bryan R. G./A-5021-2009; Silva, Aristobolo/CAF-4874-2022; Silva, Aristobolo AMS/F-7326-2016; Castilho, Beatriz A/C-2503-2012; Silva, Aristóbolo/AAA-2239-2021; Wang, Die/H-8860-2017	Williams, Bryan R. G./0000-0002-4969-1151; Castilho, Beatriz A/0000-0003-4509-5237; Silva, Aristóbolo/0000-0001-7473-7433; Wang, Die/0000-0001-7628-7309; Komar, Anton/0000-0003-4188-0633	NCI NIH HHS [U54CA116897] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann R, 2002, EUR J PHARMACOL, V447, P1, DOI 10.1016/S0014-2999(02)01828-9; Berlanga JJ, 1998, J BIOL CHEM, V273, P32340, DOI 10.1074/jbc.273.48.32340; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brune K, 1977, Agents Actions Suppl, V2, P163; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chefalo PJ, 1998, EUR J BIOCHEM, V258, P820, DOI 10.1046/j.1432-1327.1998.2580820.x; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CRONSTEIN BN, 1994, INFLAMMATION, V18, P323, DOI 10.1007/BF01534273; Deng WG, 2001, FASEB J, V15, P2463, DOI 10.1096/fj.01-0259com; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; EBLE JN, 1971, NATURE, V231, P181, DOI 10.1038/231181a0; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hardman J.G., 1996, GOODMAN GILSMANS PHA, P617; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; Jiang HY, 2004, MOL CELL BIOL, V24, P1365, DOI 10.1128/MCB.24.3.1365-1377.2004; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Kwon G, 1997, MOL PHARMACOL, V52, P398, DOI 10.1124/mol.52.3.398; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; Meric F, 2002, MOL CANCER THER, V1, P971; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Pierce JW, 1996, J IMMUNOL, V156, P3961; Schwenger P, 1997, P NATL ACAD SCI USA, V94, P2869, DOI 10.1073/pnas.94.7.2869; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sood R, 2000, GENETICS, V154, P787; SPOHN M, 1980, BIOCHIM BIOPHYS ACTA, V608, P409, DOI 10.1016/0005-2787(80)90186-0; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Williamson RT, 1901, BRIT MED J, V1901, P760, DOI 10.1136/bmj.1.2100.760; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	48	28	29	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10164	10171		10.1074/jbc.M609996200	http://dx.doi.org/10.1074/jbc.M609996200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284450	hybrid			2022-12-25	WOS:000245941000006
J	Fleischer, R; Heermann, R; Jung, K; Hunke, S				Fleischer, Rebecca; Heermann, Ralf; Jung, Kirsten; Hunke, Sabine			Purification, reconstitution, and characterization of the CpxRAP envelope stress system of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION SYSTEMS; BINDING CASSETTE TRANSPORTER; PERIPLASMIC PROTEASE; INHIBITORS; PATHWAY; GENE; EXPRESSION; CPXP; VANADATE; ENVZ	In Escherichia coli the Cpx sensor regulator system senses different kinds of envelope stress and responds by triggering the expression of periplasmic folding factors and proteases. It consists of the membrane-anchored sensor kinase CpxA, the response regulator CpxR, and the periplasmic protein CpxP. The Cpx pathway is induced in vivo by a variety of signals including pH variation, osmotic stress, and misfolded envelope proteins and is inhibited by overproduced CpxP. Because it is not clear how the Cpx pathway is able to recognize and correspond to so many different signals we overproduced, solubilized, purified, and incorporated the complete membrane-integral CpxA protein into proteoliposomes to analyze its biochemical properties in more detail. Autokinase and phosphotransfer activities of the reconstituted CpxA-His, protein were stimulated by KCI. NaCl also stimulated the activities but to a lesser extent. Other osmotic active solutes as glycine betaine, sucrose, and proline had no effect. The system was further characterized by testing for susceptibility to sensor kinase inhibitors. Among these, Closantel inhibited the activities of solubilized but not of the reconstituted CpxA-HiS(6) protein. We further analyzed the effect of CpxP on CpxA activities. Purified tagless CpxP protein reduced the phosphorylation status of CpxA to 50% but had no effect on CpxA phosphotransfer or phosphatase activities. As the in vitro system excludes the involvement of other factors our finding is the first biochemical evidence for direct protein-protein interaction between the sensor kinase CpxA and the periplasmic protein CpxP resulting in a down-regulation of the autokinase activity of CpxA.	Humboldt Univ, Inst Biol, Abt Physiol Mikroorganismen, D-10115 Berlin, Germany; Univ Munich, Dept Biol 1, Bereich Mikrobiol, D-80638 Munich, Germany	Humboldt University of Berlin; University of Munich	Hunke, S (corresponding author), Chausseestr 117, D-10115 Berlin, Germany.	sabine.hunke@rz.hu-berlin.de	Heermann, Ralf/E-1793-2013; Hunke, Sabine/B-7169-2011; Heermann, Ralf/CAF-8609-2022	Heermann, Ralf/0000-0003-0631-6156; 				Barrett JF, 1998, P NATL ACAD SCI USA, V95, P5317, DOI 10.1073/pnas.95.9.5317; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Buelow DR, 2005, J BACTERIOL, V187, P6622, DOI 10.1128/JB.187.19.6622-6630.2005; Danese PN, 1998, J BACTERIOL, V180, P831, DOI 10.1128/JB.180.4.831-839.1998; DANESE PN, 1995, GENE DEV, V9, P387, DOI 10.1101/gad.9.4.387; De Wulf P, 1999, J BACTERIOL, V181, P6772, DOI 10.1128/JB.181.21.6772-6778.1999; DONG JM, 1993, GENE, V136, P227; FORST S, 1987, J BIOL CHEM, V262, P16433; Foster JE, 2004, MICROBIOL-SGM, V150, P885, DOI 10.1099/mic.0.26824-0; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Hilliard JJ, 1995, ADV EXP MED BIOL, V390, P59; Hirakawa H, 2005, MOL MICROBIOL, V55, P1113, DOI 10.1111/j.1365-2958.2004.04449.x; Hlasta DJ, 1998, BIOORG MED CHEM LETT, V8, P1923, DOI 10.1016/S0960-894X(98)00326-6; Hunke S, 2003, MOL MICROBIOL, V50, P1579, DOI 10.1046/j.1365-2958.2003.03785.x; HUNKE S, 1995, BIOCHEM BIOPH RES CO, V216, P589, DOI 10.1006/bbrc.1995.2663; Isaac DD, 2005, P NATL ACAD SCI USA, V102, P17775, DOI 10.1073/pnas.0508936102; Jones CH, 1997, EMBO J, V16, P6394, DOI 10.1093/emboj/16.21.6394; Jubelin G, 2005, J BACTERIOL, V187, P2038, DOI 10.1128/JB.187.6.2038-2049.2005; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 2001, J BIOL CHEM, V276, P40896, DOI 10.1074/jbc.M107871200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACARA IG, 1980, TRENDS BIOCHEM SCI, V5, P92, DOI 10.1016/0968-0004(80)90256-X; MCEWEN J, 1980, P NATL ACAD SCI-BIOL, V77, P513, DOI 10.1073/pnas.77.1.513; Mileykovskaya E, 1997, J BACTERIOL, V179, P1029, DOI 10.1128/jb.179.4.1029-1034.1997; Nakayama SI, 1998, J BACTERIOL, V180, P3522, DOI 10.1128/JB.180.14.3522-3528.1998; Raivio TL, 1997, J BACTERIOL, V179, P7724, DOI 10.1128/jb.179.24.7724-7733.1997; Raivio TL, 1999, CURR OPIN MICROBIOL, V2, P159, DOI 10.1016/S1369-5274(99)80028-9; Raivio TL, 1999, J BACTERIOL, V181, P5263, DOI 10.1128/JB.181.17.5263-5272.1999; Raivio TL, 2001, ANNU REV MICROBIOL, V55, P591, DOI 10.1146/annurev.micro.55.1.591; Raivio TL, 2000, MOL MICROBIOL, V37, P1186, DOI 10.1046/j.1365-2958.2000.02074.x; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; ROYCHOUDHURY S, 1993, P NATL ACAD SCI USA, V90, P965, DOI 10.1073/pnas.90.3.965; SCHNEIDER E, 1994, J BIOL CHEM, V269, P20456; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; SNYDER WB, 1995, J BACTERIOL, V177, P4216, DOI 10.1128/jb.177.15.4216-4223.1995; Stephenson K, 2000, J BIOL CHEM, V275, P38900, DOI 10.1074/jbc.M006633200; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Ulijasz AT, 1999, J BACTERIOL, V181, P627, DOI 10.1128/JB.181.2.627-631.1999; WEBER RF, 1988, J MOL BIOL, V203, P467, DOI 10.1016/0022-2836(88)90013-7; Yamamoto K, 2005, J BIOL CHEM, V280, P1448, DOI 10.1074/jbc.M410104200	40	78	84	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8583	8593		10.1074/jbc.M605785200	http://dx.doi.org/10.1074/jbc.M605785200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17259177	hybrid			2022-12-25	WOS:000245780300004
J	Koizumi, A; Zeck, G; Ben, YX; Masland, RH; Jakobs, TC				Koizumi, Amane; Zeck, Guenther; Ben, Yixin; Masland, Richard H.; Jakobs, Tatjana C.			Organotypic Culture of Physiologically Functional Adult Mammalian Retinas	PLOS ONE			English	Article								Background. The adult mammalian retina is an important model in research on the central nervous system. Many experiments require the combined use of genetic manipulation, imaging, and electrophysiological recording, which make it desirable to use an in vitro preparation. Unfortunately, the tissue culture of the adult mammalian retina is difficult, mainly because of the high energy consumption of photoreceptors. Methods and Findings. We describe an interphase culture system for adult mammalian retina that allows for the expression of genes delivered to retinal neurons by particle-mediated transfer. The retinas retain their morphology and function for up to six days-long enough for the expression of many genes of interest-so that effects upon responses to light and receptive fields could be measured by patch recording or multielectrode array recording. We show that a variety of genes encoding pre- and post-synaptic marker proteins are localized correctly in ganglion and amacrine cells. Conclusions. In this system the effects on neuronal function of one or several introduced exogenous genes can be studied within intact neural circuitry of adult mammalian retina. This system is flexible enough to be compatible with genetic manipulation, imaging, cell transfection, pharmacological assay, and electrophysiological recordings.	[Koizumi, Amane; Masland, Richard H.; Jakobs, Tatjana C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA; [Zeck, Guenther] Max Planck Inst Neurobiol, Martinsried, Germany; [Ben, Yixin] Burke Inst, White Plains, NY USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Max Planck Society	Jakobs, TC (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.	Jakobs@helix.mgh.harvard.edu	Koizumi, Amane/E-7771-2011; Zeck, Günther/H-7419-2013	Zeck, Günther/0000-0003-3998-9883; Jakobs, Tatjana/0000-0002-8104-9206; Koizumi, Amane/0000-0003-1177-0185	NIH [RO1-017169]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by NIH grant RO1-017169. RHM is a Senior Investigator of Research to Prevent Blindness. The funding institution had no part in the design of the study, data collection, or the preparation of the manuscript.	Adler R, 2001, DEV BIOL, V236, P454, DOI 10.1006/dbio.2001.0331; AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992; AMES A, 1990, PREPARATIONS VERTEBR, P183; Berry MJ, 1997, P NATL ACAD SCI USA, V94, P5411, DOI 10.1073/pnas.94.10.5411; Cayouette M, 2003, DEVELOPMENT, V130, P2329, DOI 10.1242/dev.00446; Deans MR, 2002, NEURON, V36, P703, DOI 10.1016/S0896-6273(02)01046-2; DeVries SH, 1997, J NEUROPHYSIOL, V78, P2048, DOI 10.1152/jn.1997.78.4.2048; Euler T, 2002, NATURE, V418, P845, DOI 10.1038/nature00931; Famiglietti EV, 2002, VISUAL NEUROSCI, V19, P145, DOI 10.1017/S0952523802191139; FAMIGLIETTI EV, 1985, J NEUROSCI, V5, P562; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Fuhrmann S, 2000, DEVELOPMENT, V127, P4599; HUANG L, 2003, J COMP NEUROL, V455; Jakobs TC, 2005, J CELL BIOL, V171, P313, DOI 10.1083/jcb.200506099; Koch K, 2006, CURR BIOL, V16, P1428, DOI 10.1016/j.cub.2006.05.056; Kong JH, 2005, J COMP NEUROL, V489, P293, DOI 10.1002/cne.20631; Kuzmanovic M, 2003, INVEST OPHTH VIS SCI, V44, P3606, DOI 10.1167/iovs.02-1265; LO DC, 1994, NEURON, V13, P1263, DOI 10.1016/0896-6273(94)90412-X; Lohmann C, 2002, NATURE, V418, P177, DOI 10.1038/nature00850; MacNeil MA, 1998, NEURON, V20, P971, DOI 10.1016/S0896-6273(00)80478-X; Masland RH, 2004, CURR BIOL, V14, pR497, DOI 10.1016/j.cub.2004.06.035; Masland RH, 2001, CURR OPIN NEUROBIOL, V11, P431, DOI 10.1016/S0959-4388(00)00230-0; Meier J, 2004, J NEUROSCI, V24, P1398, DOI 10.1523/JNEUROSCI.4260-03.2004; Meier J, 2001, NAT NEUROSCI, V4, P253, DOI 10.1038/85099; Meister M, 1999, NEURON, V22, P435, DOI 10.1016/S0896-6273(00)80700-X; Nirenberg S, 2001, NATURE, V411, P698, DOI 10.1038/35079612; Pan ZM, 2006, J NEUROSCI, V26, P2599, DOI 10.1523/JNEUROSCI.4314-05.2006; Reid CA, 1997, J NEUROSCI, V17, P2738; Reidel B, 2006, VISION RES, V46, P4464, DOI 10.1016/j.visres.2006.07.019; Rockhill RL, 2000, P NATL ACAD SCI USA, V97, P2303, DOI 10.1073/pnas.030413497; Rockhill RL, 2002, J NEUROSCI, V22, P3831; RODIECK RW, 1991, VISUAL NEUROSCI, V6, P95, DOI 10.1017/S095252380001049X; Sinclair JR, 2004, J NEUROSCI, V24, P1459, DOI 10.1523/JNEUROSCI.3959-03.2004; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Streichert LC, 1999, J NEUROBIOL, V39, P475, DOI 10.1002/(SICI)1097-4695(19990615)39:4<475::AID-NEU2>3.0.CO;2-#; Xin H, 2007, J NEUROSCI METH, V159, P35, DOI 10.1016/j.jneumeth.2006.06.013; YAMAMOTO N, 1989, SCIENCE, V245, P192, DOI 10.1126/science.2749258; Yoshida K, 2001, NEURON, V30, P771, DOI 10.1016/S0896-6273(01)00316-6; Zeck GM, 2005, EUR J NEUROSCI, V22, P2016, DOI 10.1111/j.1460-9568.2005.04390.x; Zhang X, 1998, J CELL BIOL, V142, P1571, DOI 10.1083/jcb.142.6.1571	40	47	50	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e221	10.1371/journal.pone.0000221	http://dx.doi.org/10.1371/journal.pone.0000221			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311097	Green Published, gold			2022-12-25	WOS:000207444500002
J	Memezawa, A; Takada, I; Takeyama, K; Igarashi, M; Ito, S; Aiba, S; Kato, S; Kouzmenko, AP				Memezawa, A.; Takada, I.; Takeyama, K.; Igarashi, M.; Ito, S.; Aiba, S.; Kato, S.; Kouzmenko, A. P.			Id2 gene-targeted crosstalk between Wnt and retinoid signaling regulates proliferation in human keratinocytes	ONCOGENE			English	Article						keratinocytes; retinoids; Wnt; proliferation; Id2	BETA-CATENIN; SYNERGISTIC INDUCTION; NUCLEAR RECEPTORS; STEM-CELLS; ACID; PROTEINS; PATHWAY	We investigated the effect of all-trans-retinoic acid (atRA) on proliferation in several human skin cell lines and found that antiproliferative potency of atRA correlated with the endogenous activity of canonical Wnt signaling. In HaCaT keratinocytes, we found that atRA significantly suppressed the expression of Id2, a member of the inhibitor of differentiation family of transcription factors that regulate cell growth and differentiation. However, no apparent change in the expression of other Wnt targets, like c-Myc or cyclin D1, was observed. Retinoid-induced Id2 gene suppression was associated with decreased levels of histone H3 and H4 acetylation and histone H3 Lys-4 methylation, and with recruitment of the LSD1 demethylase at the Wnt-response element (WRE) (TCF/ LEF-binding site), in the Id2 gene promoter. None of such changes was detected at the WRE of c-Myc and cyclin D1 gene promoters. Inhibition of Id2 by short interfering RNA (siRNA) had a similar effect on the proliferation of HaCaT cells as exposure to atRA, whereas anti-beta-catenin siRNA significantly inhibited its antiproliferative effect. These data suggest that downregulation of Id2 gene expression through transcriptional convergence between Wnt and retinoid signaling pathways underlies the antiproliferative effect of retinoids in keratinocytes, and provide evidence of gene-targeted crosstalk between signaling pathways.	Univ Tokyo, Inst Mol & Cellular Biosci, Dept Nucl Signaling, Bunkyo Ku, Tokyo 1130032, Japan; Tohoku Univ, Grad Sch Med, Dept Dermatol, Aoba Ku, Sendai, Miyagi 980, Japan; Japan Sci & Technol Agcy, ERATO, Kawaguchi, Saitama, Japan	University of Tokyo; Tohoku University; Japan Science & Technology Agency (JST)	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Dept Nucl Signaling, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.	uskato@mail.ecc.u-tokyo.ac.jp; alexk@iam.u-tokyo.ac.jp						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Baghdoyan S, 2005, J BIOL CHEM, V280, P15836, DOI 10.1074/jbc.M414216200; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Buzzard JJ, 2003, ENDOCRINOLOGY, V144, P3722, DOI 10.1210/en.2003-0379; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Kitagawa H, 2003, CELL, V113, P905, DOI 10.1016/S0092-8674(03)00436-7; Kouzmenko AP, 2004, J BIOL CHEM, V279, P40255, DOI 10.1074/jbc.C400331200; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Liu T, 2002, J BIOL CHEM, V277, P30887, DOI 10.1074/jbc.M203852200; Ma Y, 2005, CANCER RES, V65, P6476, DOI 10.1158/0008-5472.CAN-05-0370; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; NEUMAN K, 1995, FEBS LETT, V374, P279, DOI 10.1016/0014-5793(95)01128-2; Nigten J, 2005, LEUKEMIA, V19, P799, DOI 10.1038/sj.leu.2403699; Niles RM, 2004, MUTAT RES-FUND MOL M, V555, P81, DOI 10.1016/j.mrfmmm.2004.05.020; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Okuno M, 2004, CURR CANCER DRUG TAR, V4, P285, DOI 10.2174/1568009043333023; Otero JJ, 2004, DEVELOPMENT, V131, P3545, DOI 10.1242/dev.01218; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sikder HA, 2003, CANCER CELL, V3, P525, DOI 10.1016/S1535-6108(03)00141-7; Simbulan-Rosenthal CM, 2005, ONCOGENE, V24, P5443, DOI 10.1038/sj.onc.1208709; Sundberg M, 2006, J NEUROSCI, V26, P5402, DOI 10.1523/JNEUROSCI.4906-05.2006; Szeto W, 2001, CANCER RES, V61, P4197; Tice DA, 2002, J BIOL CHEM, V277, P14329, DOI 10.1074/jbc.M200334200; Wagsater D, 2003, J EXP CLIN CANC RES, V22, P471; Weeraratna AT, 2005, CANCER METAST REV, V24, P237, DOI 10.1007/s10555-005-1574-z; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1	32	27	28	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5038	5045		10.1038/sj.onc.1210320	http://dx.doi.org/10.1038/sj.onc.1210320			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310985				2022-12-25	WOS:000248487400002
J	Blouw, B; Haase, VH; Song, H; Bergers, G; Johnson, RS				Blouw, B.; Haase, V. H.; Song, H.; Bergers, G.; Johnson, R. S.			Loss of vascular endothelial growth factor expression reduces vascularization, but not growth, of tumors lacking the Von Hippel-Lindau tumor suppressor gene	ONCOGENE			English	Article						hypoxia; angiogenesis; HIF-1; VEGF; tumor	RENAL-CELL-CARCINOMA; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RECEPTOR; VEGF; PVHL; TUMORIGENESIS; INACTIVATION; HIF-1-ALPHA; ACTIVATION; INDUCTION	Individuals bearing germ line mutations in the Von Hippel-Lindau (VHL) tumor suppressor gene are predisposed to the development of highly angiogenic tumors. This is correlated with an increased expression of the angiogenic factor vascular endothelial growth factor (VEGF) in these tumors, which is in part caused by elevated expression of the HIF-1 hypoxia inducible transcription factors. We created malignant astrocytes with genetic deletions of the VHL gene and implanted them in subcutaneous and intracranial sites; these sites are respectively vessel poor and vessel-rich tissues. When grown in a vessel poor site, VEGF expression in VHL null cells was important for both vascularization and tumor growth. However, when the same cells are grown in the vessel-rich intracranial environment, loss of VEGF expression reduces vascularization, but does not affect tumor growth. This indicates that antiangiogenic therapies for tumors that express high levels of angiogenic factors such as VEGF may vary in their efficacy, with potentially lowered effectiveness in sites, such as the brain, that are inherently vessel rich.	Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, Dept Neurosurg, San Francisco, CA USA	University of California System; University of California San Diego; University of Pennsylvania; University of California System; University of California San Francisco	Johnson, RS (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, 9500 Gilman Dr,Nat Sci Bldg Rm 5328, La Jolla, CA 92093 USA.	rjohnson@biomail.ucsd.edu	Haase, Volker Hans/A-6758-2013; Bergers, Gabriele/AAJ-5535-2020; Haase, Volker Hans/AAJ-5061-2021; Johnson, Randall/AAM-1189-2021	Haase, Volker Hans/0000-0002-7051-8994; Johnson, Randall/0000-0002-4084-6639; Bergers, Gabriele/0000-0003-3545-5171	NATIONAL CANCER INSTITUTE [R01CA082515, R01CA100787] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK062060, K08DK002668] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100787, CA082515, CA 100787] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; Gerber HP, 1999, DEVELOPMENT, V126, P1149; Grunstein J, 1999, CANCER RES, V59, P1592; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hansel DE, 2006, HISTOL HISTOPATHOL, V21, P437, DOI 10.14670/HH-21.437; Harris A L, 2000, Oncologist, V5 Suppl 1, P32; Hasselblatt M, 2005, NEUROPATH APPL NEURO, V31, P618, DOI 10.1111/j.1365-2990.2005.00669.x; Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Los M, 1999, CANCER RES, V59, P4440; Mack FA, 2005, MOL CELL BIOL, V25, P4565, DOI 10.1128/MCB.25.11.4565-4578.2005; Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Rankin EB, 2005, MOL CELL BIOL, V25, P3163, DOI 10.1128/MCB.25.8.3163-3172.2005; Rathmell WK, 2004, ANTICANCER RES, V24, P167; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Seagroves TN, 2003, DEVELOPMENT, V130, P1713, DOI 10.1242/dev.00403; Staehler M, 2005, CURR DRUG TARGETS, V6, P835, DOI 10.2174/138945005774574498; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Tang N, 2006, MOL CELL BIOL, V26, P2519, DOI 10.1128/MCB.26.7.2519-2530.2006; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Unruh A, 2003, ONCOGENE, V22, P3213, DOI 10.1038/sj.onc.1206385; Zagzag D, 2005, CANCER RES, V65, P6178, DOI 10.1158/0008-5472.CAN-04-4406; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W	30	6	6	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	31					4531	4540		10.1038/sj.onc.1210249	http://dx.doi.org/10.1038/sj.onc.1210249			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297464				2022-12-25	WOS:000247836100007
J	Brun, T; Duhamel, DL; He, KHH; Wollheim, CB; Gauthier, BR				Brun, T.; Duhamel, D. L.; He, K. H. Hu; Wollheim, C. B.; Gauthier, B. R.			The transcription factor PAX4 acts as a survival gene in INS-1E insulinoma cells	ONCOGENE			English	Article						RNAi; insulin; Pax4; proliferation; apoptosis; survival	GROWTH-FACTOR; BETA-CELLS; EXPRESSION; DIFFERENTIATION; PROLIFERATION; BETACELLULIN; DYSFUNCTION; SUSCEPTIBILITY; ASSOCIATION; METABOLISM	The paired/homeodomain transcription factor Pax4 is essential for islet beta-cell generation during pancreas development and their survival in adulthood. High Pax4 expression was reported in human insulinomas indicating that deregulation of the gene may be associated with tumorigenesis. We report that rat insulinoma INS-1E cells express 25-fold higher Pax4 mRNA levels than rat islets. In contrast to primary beta-cells, activin A but not betacellulin or glucose induced Pax4 mRNA levels indicating dissociation of Pax4 expression from insulinoma cell proliferation. Short hairpin RNA adenoviral constructs targeted to the paired domain or homeodomain (viPax4PD and viPax4HD) were generated. Pax4 mRNA levels were lowered by 73 and 50% in cells expressing either viPax4PD or viPax4HD. Transcript levels of the Pax4 target gene bcl-xl were reduced by 53 and 47%, whereas Pax6 and Pdx1 mRNA levels were unchanged. viPax4PD-infected cells displayed a twofold increase in spontaneous apoptosis and were more susceptible to cytokine-induced cell death. In contrast, proliferation was unaltered. RNA interference-mediated repression of insulin had no adverse effects on either Pax4 or Pdx1 expression as well as on cell replication or apoptosis. These results indicate that Pax4 is redundant for proliferation of insulinoma cells, whereas it is essential for survival through upregulation of the antiapoptotic gene bcl-xl.	Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland	University of Geneva	Brun, T (corresponding author), Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland.	thierry.brun@medecine.unige.ch; benoit.gauthier@medecine.unige.ch	Gauthier, Benoit R/C-3138-2017	Gauthier, Benoit R/0000-0001-8146-7486; BRUN, Thierry/0000-0002-1659-4283				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Barker CJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE1113, DOI 10.1152/ajpendo.00088.2002; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Biason-Lauber A, 2005, DIABETOLOGIA, V48, P900, DOI 10.1007/s00125-005-1723-5; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Brun T, 2005, DIABETOLOGIA, V48, pA27; Brun T, 2004, J CELL BIOL, V167, P1123, DOI 10.1083/jcb.200405148; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; Collier Dawn C, 2003, J Appl Clin Med Phys, V4, P17, DOI 10.1120/1.1521271; Collombat P, 2005, DEVELOPMENT, V132, P2969, DOI 10.1242/dev.01870; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Gauthier B, 1999, ATHEROSCLEROSIS, V142, P301, DOI 10.1016/S0021-9150(98)00245-7; Gauthier BR, 2004, J BIOL CHEM, V279, P31121, DOI 10.1074/jbc.M405030200; Gunton JE, 2005, CELL, V122, P337, DOI 10.1016/j.cell.2005.05.027; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He SJ, 2005, MOL CANCER THER, V4, P996, DOI 10.1158/1535-7163.MCT-04-0252; Henderson CC, 2005, ONCOGENE, V24, P7120, DOI 10.1038/sj.onc.1208887; Heremans Y, 2002, J CELL BIOL, V159, P303, DOI 10.1083/jcb.200203074; Holm P, 2004, DIABETES, V53, P1584, DOI 10.2337/diabetes.53.6.1584; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; Huotari MA, 1998, ENDOCRINOLOGY, V139, P1494, DOI 10.1210/en.139.4.1494; Ishihara H, 2003, NAT CELL BIOL, V5, P330, DOI 10.1038/ncb951; Kanatsuka A, 2002, METABOLISM, V51, P1161, DOI 10.1053/meta.2002.34707; Kojima H, 2003, NAT MED, V9, P596, DOI 10.1038/nm867; LI Y, 2006, LEUKEMIA RES, V9, P1547; Margue CM, 2000, ONCOGENE, V19, P2921, DOI 10.1038/sj.onc.1203607; Mauvais-Jarvis F, 2004, HUM MOL GENET, V13, P3151, DOI 10.1093/hmg/ddh341; Merglen A, 2004, ENDOCRINOLOGY, V145, P667, DOI 10.1210/en.2003-1099; Miyamoto T, 2001, BIOCHEM BIOPH RES CO, V282, P34, DOI 10.1006/bbrc.2001.4552; Muratovska A, 2003, ONCOGENE, V22, P7989, DOI 10.1038/sj.onc.1206766; Ostrom L, 2000, DEV BIOL, V219, P250, DOI 10.1006/dbio.2000.9618; Park D, 2006, DEVELOPMENT, V133, P4193, DOI 10.1242/dev.02614; Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778; Shima Akihiro, 2003, EMBO Reports, V4, P121, DOI 10.1038/sj.embor.embor743; Shimajiri Y, 2001, DIABETES, V50, P2864, DOI 10.2337/diabetes.50.12.2864; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Theander-Carrillo C, 2006, J CLIN INVEST, V116, P1983, DOI 10.1172/JCI25811; Theis M, 2004, EXP CELL RES, V294, P18, DOI 10.1016/j.yexcr.2003.09.031; Tokuyama Y, 2006, METABOLISM, V55, P213, DOI 10.1016/j.metabol.2005.08.014; Ueda Y, 2000, FEBS LETT, V480, P101, DOI 10.1016/S0014-5793(00)01914-1; Wang JF, 2004, DEV BIOL, V266, P178, DOI 10.1016/j.ydbio.2003.10.018; Yamaoka T, 2000, DIABETOLOGIA, V43, P332, DOI 10.1007/s001250050051; Zalzman M, 2003, P NATL ACAD SCI USA, V100, P7253, DOI 10.1073/pnas.1136854100; Zhang YQ, 2001, DIABETES, V50, pS10, DOI 10.2337/diabetes.50.2007.S10; Zhou J, 2005, IEEE T INTELL TRANSP, V6, P229, DOI 10.1109/TITS.2005.848359; Zhou YH, 2003, CLIN CANCER RES, V9, P3369	49	32	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2007	26	29					4261	4271		10.1038/sj.onc.1210205	http://dx.doi.org/10.1038/sj.onc.1210205			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CY	17260022				2022-12-25	WOS:000247619900009
J	Garner, CE; Smith, S; Costello, BD; White, P; Spencer, R; Probert, CSJ; Ratcliffe, NM				Garner, Catherine E.; Smith, Stephen; Costello, Ben de Lacy; White, Paul; Spencer, Robert; Probert, Chris S. J.; Ratcliffe, Norman M.			Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease	FASEB JOURNAL			English	Article						campylobacter; Clostridium difficile; ulcerative colitis	CHROMATOGRAPHY-MASS SPECTROMETRY; SULFATE-REDUCING BACTERIA; HUMAN LARGE-INTESTINE; CHAIN FATTY-ACIDS; DAUCUS-CAROTA L.; HEALTHY-VOLUNTEERS; RAT-LIVER; METABOLISM; IDENTIFICATION; ACETALDEHYDE	Little is known about the volatile organic compounds ( VOCs) in feces and their potential health consequences. Patients and healthcare professionals have observed that feces often smell abnormal during gastrointestinal disease. The aim of this work was to define the volatiles emitted from the feces of healthy donors and patients with gastrointestinal disease. Our hypotheses were that i) VOCs would be shared in health; ii) VOCs would be constant in individuals; and iii) specific changes in VOCs would occur in disease. Volatile emissions in health were defined in a cohort and a longitudinal study. Subsequently, the pattern of volatiles found in the cohort study were compared to that found from patients with ulcerative colitis, Campylobacter jejuni, and Clostridium difficile. Volatiles from feces were collected by solid-phase microextraction and analyzed by gas chromatography/ mass spectrometry. In the cohort study, 297 volatiles were identified. In all samples, ethanoic, butanoic, pentanoic acids, benzaldehyde, ethanal, carbon disulfide, dimethyldisulfide, acetone, 2- butanone, 2,3- butanedione, 6- methyl- 5- hepten-2- one, indole, and 4-methylphenol were found. Forty-four compounds were shared by 80% of subjects. In the longitudinal study, 292 volatiles were identified, with some inter and intra subject variations in VOC concentrations with time. When compared to healthy donors, volatile patterns from feces of patients with ulcerative colitis, C. difficile, and C. jejuni were each significantly different. These findings could lead the way to the development of a rapid diagnostic device based on VOC detection.-Garner, C. E., Smith, S., de Lacy Costello, B., White, P., Spencer, R., Probert, C. S. J., Ratcliffe, N. M. Volatile organic compounds from feces and their potential for diagnosis of gastrointestinal disease.	Bristol Royal Infirm & Gen Hosp, Hlth Protect Agcy, Bristol BS2 8HW, Avon, England; Univ W England, Fac Sci Appl, Ctr Res Analyt Mat & Sensor Sci, Bristol BS16 1QY, Avon, England	Bristol Royal Infirmary; Health Protection Agency; University of West England	Probert, CSJ (corresponding author), Bristol Royal Infirm & Gen Hosp, Hlth Protect Agcy, Marlborough St, Bristol BS2 8HW, Avon, England.	c.s.j.probert@bristol.ac.uk	de Lacy Costello, Ben/ABG-2043-2021; De Lacy Costello, Ben/I-8259-2019	de Lacy Costello, Ben/0000-0003-2999-6801; White, Paul/0000-0002-7503-9896; Probert, Christopher/0000-0003-4550-0239	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alasalvar C, 2001, J AGR FOOD CHEM, V49, P1410, DOI 10.1021/jf000595h; ALLOWAY BJ, 1993, CHEM PRINCIPLES ENV, P216; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Blaut M, 2002, BRIT J NUTR, V87, pS203, DOI 10.1079/BJN/2002539; Costello BPJD, 2001, PLANT PATHOL, V50, P489, DOI 10.1046/j.1365-3059.2001.00594.x; CUMMINGS JH, 1981, GUT, V22, P763, DOI 10.1136/gut.22.9.763; DECOMBAZ J, 1983, EUR J APPL PHYSIOL O, V52, P9, DOI 10.1007/BF00429018; DENERIS ES, 1985, J BIOL CHEM, V260, P1382; Diczfalusy MA, 2001, J LIPID RES, V42, P1025; Elgaali H, 2002, J BASIC MICROB, V42, P373, DOI 10.1002/1521-4028(200212)42:6<373::AID-JOBM373>3.0.CO;2-4; Ewen RJ, 2004, MYCOL RES, V108, P806, DOI 10.1017/S095375620400022X; GIBSON GR, 1993, GUT, V34, P437, DOI 10.1136/gut.34.4.437; GORBACH SL, 1971, GASTROENTEROLOGY, V60, P1110; Gostner A, 2006, BRIT J NUTR, V95, P40, DOI 10.1079/BJN20051589; HERRENFREUND SL, 1986, ENVIRON HEALTH PERSP, V69, P59, DOI 10.2307/3430371; Homann N, 2001, ADDICT BIOL, V6, P309, DOI 10.1080/13556210020077028; Johnson W, 2002, INT J TOXICOL, V21, P9, DOI 10.1080/10915810290096388; Kjeldsen F, 2003, J AGR FOOD CHEM, V51, P5400, DOI 10.1021/jf030212q; Kjeldsen F, 2001, J AGR FOOD CHEM, V49, P4342, DOI 10.1021/jf010213n; KLECKA WR, 1980, QUANTITATIVE APPL SO, V19; LACHENBRUCH PA, 1975, DISCRIMINANT ANAL; Lechner M, 2005, CURR MICROBIOL, V51, P267, DOI 10.1007/s00284-005-0018-x; Lington A.W., 1994, PATTYS IND HYGIENE T, P2585; Locas CP, 2004, J AGR FOOD CHEM, V52, P6830, DOI 10.1021/jf0490403; Logan BK, 2003, J PEDIATR GASTR NUTR, V36, P419, DOI 10.1097/00005176-200303000-00026; MAY T, 1994, SCAND J GASTROENTERO, V29, P916, DOI 10.3109/00365529409094863; MILLER TL, 1986, SYST APPL MICROBIOL, V7, P223; MOORE JG, 1987, GASTROENTEROLOGY, V93, P1321, DOI 10.1016/0016-5085(87)90262-9; Mortensen PB, 1996, SCAND J GASTROENTERO, V31, P132, DOI 10.3109/00365529609094568; Ott A, 2000, J AGR FOOD CHEM, V48, P724, DOI 10.1021/jf990487z; Pitcher MCL, 2000, GUT, V46, P64, DOI 10.1136/gut.46.1.64; Probert CSJ, 2004, GUT, V53, P58, DOI 10.1136/gut.53.1.58; Ruge E., 1861, SITZBER KAISER AKA, V44, P739; Salerno-Kennedy R, 2005, WIEN KLIN WOCHENSCHR, V117, P180, DOI 10.1007/s00508-005-0336-9; Smith EA, 1997, ANAEROBE, V3, P327, DOI 10.1006/anae.1997.0121; Suarez FL, 1998, GUT, V43, P100, DOI 10.1136/gut.43.1.100; SURAEZ F, 1997, AM J PHYSIOL, V272, pG1028; TOMLIN J, 1991, GUT, V32, P665, DOI 10.1136/gut.32.6.665; Vakevainen S, 2000, ALCOHOL CLIN EXP RES, V24, P873, DOI 10.1111/j.1530-0277.2000.tb02068.x; WEISIGER RA, 1980, BIOCHEM PHARMACOL, V29, P2885, DOI 10.1016/0006-2952(80)90029-5; Willis CL, 1997, CURR MICROBIOL, V35, P294, DOI 10.1007/s002849900257; YOKOYAMA MT, 1979, AM J CLIN NUTR, V32, P173	42	298	311	3	99	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1675	1688		10.1096/fj.06-6927com	http://dx.doi.org/10.1096/fj.06-6927com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314143				2022-12-25	WOS:000246866500009
J	Sredni, B; Geffen-Aricha, R; Duan, WZ; Albeck, M; Shalit, F; Lander, HM; Kinor, N; Sagi, O; Albeck, A; Yosef, S; Brodsky, M; Sredni-Kenigsbuch, D; Sonino, T; Longo, DL; Mattson, MP; Yadid, G				Sredni, Benjamin; Geffen-Aricha, Revital; Duan, Wenzhen; Albeck, Michael; Shalit, Frances; Lander, Harry M.; Kinor, Noa; Sagi, Ortal; Albeck, Amnon; Yosef, Sigal; Brodsky, Miri; Sredni-Kenigsbuch, Dvora; Sonino, Tali; Longo, Dan L.; Mattson, Mark P.; Yadid, Gal			Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models	FASEB JOURNAL			English	Article						6neuroprotection; apoptosis; inflammation; cytokines; neurotrophic	THIOL REDOX STATUS; IMMUNOMODULATOR AS101; NEUROTROPHIC FACTOR; APOPTOTIC DEATH; NIGROSTRIATAL SYSTEM; CELL-DEATH; TNF-ALPHA; NEURODEGENERATION; INTERLEUKIN-10; INHIBITION	In Parkinson's disease ( PD) dopaminergic neurons in the substantia nigra ( SN) become dysfunctional and many ultimately die. We report that the tellurium immunomodulating compound ammonium trichloro(dioxoethylene-O, O'-) tellurate(AS101) protects dopaminergic neurons and improves motor function in animal models of PD. It is effective when administered systemically or by direct infusion into the brain. Multifunctional activities of AS101 were identified in this study. These were mainly due to the peculiar Tellur(IV)- thiol chemistry of the compound, which enabled the compound to interact with cysteine residues on both inflammatory and apoptotic caspases, resulting in their inactivation. Conversely, its interaction with a key cysteine residue on p21(ras), led to its activation, an obligatory activity for AS101-induced neuronal differentiation. Furthermore, AS101 inhibited IL-10, resulting in up-regulation of GDNF in the SN. This was associated with activation of the neuroprotective kinases Akt and mitogen-activated protein kinases, and up- regulation of the antiapoptotic protein Bcl-2. Inhibition of caspase-1 and caspase-3 activities were associated with decreased neuronal death and inhibition of IL-1 beta. We suggest that, because multiple mechanisms are involved in the dysfunction and death of neurons in PD, use of a multifunctional compound, exerting antiapoptotic, anti-inflammatory, and neurotrophic-inducing capabilities may be potentially efficacious for the treatment of PD.-Sredni B., Geffen R., Duan W., Albeck M., Shalit F., Lander H., Kinor N., Sagi O., Albeck A., Yosef S., Brodsky M., Sredni-Kenigsbuch D., Sonino T., Longo D., Mattson M., Yadid G. Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models.	Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, CAIR Inst, Ramat Gan, Israel; Bar Ilan Univ, Interdisiplinary Dept, Ramat Gan, Israel; Bar Ilan Univ, Dept Chem, Ramat Gan, Israel; Bar Ilan Univ, Multidisciplinary Brain Res Ctr, Ramat Gan, Israel; Natl Inst Aging Intramural Res Program, Lab Neurosci, Baltimore, MD USA; Natl Inst Aging Intramural Res Program, Lab Immunol, Baltimore, MD USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY USA	Bar Ilan University; Bar Ilan University; Bar Ilan University; Bar Ilan University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Cornell University	Sredni, B (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, CAIR Inst, Keren Hayessod St, Ramat Gan, Israel.	srednib@mail.biu.ac.il	Longo, Dan L./F-6022-2011; Mattson, Mark P/F-6038-2012		Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		AKANEYA Y, 1995, EXP NEUROL, V136, P44, DOI 10.1006/exnr.1995.1082; Akhtar RS, 2004, BBA-MOL CELL RES, V1644, P189, DOI 10.1016/j.bbamcr.2003.10.013; Albeck A, 1998, INORG CHEM, V37, P1704, DOI 10.1021/ic971456t; ARIMOTO T, 2006, NEUROBIOL AGING 0610; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; COHEN BL, 1984, GEOCHIM COSMOCHIM AC, V48, P203, DOI 10.1016/0016-7037(84)90363-6; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Desire L, 2000, J NEUROCHEM, V75, P151, DOI 10.1046/j.1471-4159.2000.0750151.x; Di Monte DA, 2003, LANCET NEUROL, V2, P531, DOI 10.1016/S1474-4422(03)00501-5; Eriksen JL, 2005, ARCH NEUROL-CHICAGO, V62, P353, DOI 10.1001/archneur.62.3.353; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Heerssen HM, 2002, TRENDS NEUROSCI, V25, P160, DOI 10.1016/S0166-2236(02)02144-6; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Hirsch EC, 2003, ANN NY ACAD SCI, V991, P214; IRGOLIC KJ, 1990, ORGANOTELLURIUM E B, V12; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Kalechman Y, 1997, J IMMUNOL, V159, P2658; Kalechman Y, 2004, J BIOL CHEM, V279, P24724, DOI 10.1074/jbc.M312006200; Kalechman Y, 2003, J AM SOC NEPHROL, V14, P620, DOI 10.1097/01.ASN.0000053415.29636.4F; Kalechman Y, 2002, J IMMUNOL, V169, P384, DOI 10.4049/jimmunol.169.1.384; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Makarovsky D, 2003, ANN NY ACAD SCI, V1010, P659, DOI 10.1196/annals.1299.120; Mandel S, 2003, CNS DRUGS, V17, P729, DOI 10.2165/00023210-200317100-00004; Maswood N, 2004, P NATL ACAD SCI USA, V101, P18171, DOI 10.1073/pnas.0405831102; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Muller T, 2004, J NEUROL, V251, P44, DOI 10.1007/s00415-004-1610-x; Murata Y, 2002, MOL IMMUNOL, V38, P747, DOI 10.1016/S0161-5890(01)00111-0; Murata Y, 2002, INT IMMUNOL, V14, P201, DOI 10.1093/intimm/14.2.201; Nagatsu T, 2005, CURR PHARM DESIGN, V11, P999, DOI 10.2174/1381612053381620; Okun E, 2006, DEV COMP IMMUNOL, V30, P441, DOI 10.1016/j.dci.2005.07.002; Orike N, 2001, J CELL BIOL, V154, P995, DOI 10.1083/jcb.200101068; Patel NK, 2005, ANN NEUROL, V57, P298, DOI 10.1002/ana.20374; QIAN L, 2006, J PHARM EXP THE 0808; RAMSAY RR, 1986, J BIOL CHEM, V261, P7585; Rosenblatt-Bin H, 1998, CELL IMMUNOL, V184, P12, DOI 10.1006/cimm.1998.1251; SACCHETTA P, 1986, ANAL BIOCHEM, V154, P205, DOI 10.1016/0003-2697(86)90516-6; Schulz JB, 2004, CELL TISSUE RES, V318, P135, DOI 10.1007/s00441-004-0954-y; Sherer TB, 2002, NEUROSCIENTIST, V8, P192, DOI 10.1177/1073858402008003004; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; Slevin JT, 2005, J NEUROSURG, V102, P216, DOI 10.3171/jns.2005.102.2.0216; Smith AD, 2002, NEUROPSYCHOPHARMACOL, V26, P756, DOI 10.1016/S0893-133X(01)00420-1; Sredni B, 2003, FASEB J, V17, P400, DOI 10.1096/fj.03-0552fje; Sredni B, 2004, CANCER RES, V64, P1843, DOI 10.1158/0008-5472.CAN-03-3179; SREDNI B, 1987, NATURE, V330, P173, DOI 10.1038/330173a0; Sredni B, 1996, J NATL CANCER I, V88, P1276, DOI 10.1093/jnci/88.18.1276; SREDNI B, 1995, J CLIN ONCOL, V13, P2342, DOI 10.1200/JCO.1995.13.9.2342; Sredni B, 1996, INT J CANCER, V65, P97, DOI 10.1002/(SICI)1097-0215(19960103)65:1<97::AID-IJC17>3.0.CO;2-F; Strassmann G, 1997, CELL IMMUNOL, V176, P180, DOI 10.1006/cimm.1997.1087; Vila M, 2004, NAT MED, V10, pS58, DOI 10.1038/nm1068; Williams L, 2004, J IMMUNOL, V172, P567, DOI 10.4049/jimmunol.172.1.567; Zhang KZ, 1996, P NATL ACAD SCI USA, V93, P4504, DOI 10.1073/pnas.93.9.4504	59	56	57	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1870	1883		10.1096/fj.06-7500com	http://dx.doi.org/10.1096/fj.06-7500com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17314138				2022-12-25	WOS:000246866500028
J	Sansen, S; Yano, JK; Reynald, RL; Schoch, GA; Griffin, KJ; Stout, CD; Johnson, EF				Sansen, Stefaan; Yano, Jason K.; Reynald, Rosamund L.; Schoch, Guillaume A.; Griffin, Keith J.; Stout, C. David; Johnson, Eric F.			Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYTOCHROME-P450 1A2; CRYSTAL-STRUCTURE; AMINO-ACID; RESOLUTION; BINDING; ENZYMES; SITE; CRYSTALLOGRAPHY; PURIFICATION; ACTIVATION	Microsomal cytochrome P450 family 1 enzymes play prominent roles in xenobiotic detoxication and procarcinogen activation. P450 1A2 is the principal cytochrome P450 family 1 enzyme expressed in human liver and participates extensively in drug oxidations. This enzyme is also of great importance in the bioactivation of mutagens, including the N-hydroxylation of arylamines. P450-catalyzed reactions involve a wide range of substrates, and this versatility is reflected in a structural diversity evident in the active sites of available P450 structures. Here, we present the structure of human P450 1A2 in complex with the inhibitor alpha-naphthoflavone, determined to a resolution of 1.95 angstrom. alpha-Naphthoflavone is bound in the active site above the distal surface of the heme prosthetic group. The structure reveals a compact, closed active site cavity that is highly adapted for the positioning and oxidation of relatively large, planar substrates. This unique topology is clearly distinct from known active site architectures of P450 family 2 and 3 enzymes and demonstrates how P450 family 1 enzymes have evolved to catalyze efficiently polycyclic aromatic hydrocarbon oxidation. This report provides the first structure of a microsomal P450 from family 1 and offers a template to study further structure-function relationships of alternative substrates and other cytochrome P450 family 1 members.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Johnson, EF (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,MEM-255, La Jolla, CA 92037 USA.	johnson@scripps.edu		Yano, Jason/0000-0002-9774-2611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM031001] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agundez JAG, 2004, CURR DRUG METAB, V5, P211, DOI 10.2174/1389200043335621; BAUER E, 1995, CHEM RES TOXICOL, V8, P136, DOI 10.1021/tx00043a018; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cho US, 2003, BBA-PROTEINS PROTEOM, V1648, P195, DOI 10.1016/S1570-9639(03)00148-1; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; de Visser SP, 2003, J AM CHEM SOC, V125, P7413, DOI 10.1021/ja034142f; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GOTOH O, 1992, J BIOL CHEM, V267, P83; Hodek P, 2002, CHEM-BIOL INTERACT, V139, P1, DOI 10.1016/S0009-2797(01)00285-X; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kim D, 2005, ANNU REV PHARMACOL, V45, P27, DOI 10.1146/annurev.pharmtox.45.120403.100010; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Lewis DFV, 1996, XENOBIOTICA, V26, P723, DOI 10.3109/00498259609046745; Liu JG, 2004, ARCH BIOCHEM BIOPHYS, V424, P33, DOI 10.1016/j.abb.2003.12.040; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Nebert DW, 2004, J BIOL CHEM, V279, P23847, DOI 10.1074/jbc.R400004200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ozalp C, 2006, BIOCHEMISTRY-US, V45, P4629, DOI 10.1021/bi051372t; Parikh A, 1999, BIOCHEMISTRY-US, V38, P5283, DOI 10.1021/bi990142+; Poulos T. L., 2005, CYTOCHROME P450 STRU, P87; QUATTROCHI LC, 1986, P NATL ACAD SCI USA, V83, P6731, DOI 10.1073/pnas.83.18.6731; Rowland P, 2006, J BIOL CHEM, V281, P7614, DOI 10.1074/jbc.M511232200; SANDHU P, 1994, ARCH BIOCHEM BIOPHYS, V309, P168, DOI 10.1006/abbi.1994.1099; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Scott EE, 2003, P NATL ACAD SCI USA, V100, P13196, DOI 10.1073/pnas.2133986100; Scott EE, 2004, J BIOL CHEM, V279, P27294, DOI 10.1074/jbc.M403349200; Shimada T, 1998, CHEM RES TOXICOL, V11, P1048, DOI 10.1021/tx980090+; Wester MR, 2004, J BIOL CHEM, V279, P35630, DOI 10.1074/jbc.M405427200; Wester MR, 2003, BIOCHEMISTRY-US, V42, P9335, DOI 10.1021/bi034556l; Wester MR, 2002, METHOD ENZYMOL, V357, P73; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862; Williams PA, 2004, SCIENCE, V305, P683, DOI 10.1126/science.1099736; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6; Yano JK, 2005, NAT STRUCT MOL BIOL, V12, P822, DOI 10.1038/nsmb971; Yano JK, 2004, J BIOL CHEM, V279, P38091, DOI 10.1074/jbc.C400293200; Yun CH, 2000, BIOCHEMISTRY-US, V39, P11319, DOI 10.1021/bi000869u	36	379	387	3	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2007	282	19					14348	14355		10.1074/jbc.M611692200	http://dx.doi.org/10.1074/jbc.M611692200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	164PJ	17311915	hybrid			2022-12-25	WOS:000246245800046
J	Nizzari, M; Venezia, V; Repetto, E; Caorsi, V; Magrassi, R; Gagliani, MC; Carlo, P; Florio, T; Schettini, G; Tacchetti, C; Russo, T; Diaspro, A; Russo, C				Nizzari, Mario; Venezia, Valentina; Repetto, Emanuela; Caorsi, Valentina; Magrassi, Raffaella; Gagliani, Maria Cristina; Carlo, Pia; Florio, Tullio; Schettini, Gennaro; Tacchetti, Carlo; Russo, Tommaso; Diaspro, Alberto; Russo, Claudio			Amyloid precursor protein and presenilin1 interact with the adaptor GRB2 and modulate ERK1,2 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; GAMMA-SECRETASE CLEAVAGE; MAP KINASE PATHWAY; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; CELL-CYCLE; INTRAMEMBRANE PROTEOLYSIS; CHROMOSOME SEGREGATION; TERMINAL FRAGMENTS; BETA PRODUCTION	The amyloid precursor protein (APP) and the presenilins 1 and 2 are genetically linked to the development of familial Alzheimer disease. APP is a single-pass transmembrane protein and precursor of fibrillar and toxic amyloid-beta-peptides, which are considered responsible for Alzheimer disease neurodegeneration. Presenilins are multipass membrane proteins, involved in the enzymatic cleavage of APP and other signaling receptors and transducers. The role of APP and presenilins in Alzheimer disease development seems to be related to the formation of amyloid-beta-peptides; however, their physiological function, reciprocal interaction, and molecular mechanisms leading to neurodegeneration are unclear. APP and presenilins are also involved in multiple interactions with intracellular proteins, the significance of which is under investigation. Among the different APP-interacting proteins, we focused our interest on the GRB2 adaptor protein, which connects cell surface receptors to intracellular signaling pathways. In this study we provide evidence by co-immunoprecipitation experiments, confocal and electron microscopy, and by fluorescence resonance energy transfer experiments that both APP and presenilin1 interact with GRB2 in vesicular structures at the centrosome of the cell. The final target for these interactions is ERK1,2, which is activated in mitotic centrosomes in a PS1- and APP-dependent manner. These data suggest that both APP and presenilin1 can be part of a common signaling pathway that regulates ERK1,2 and the cell cycle.	Univ Genoa, Dipartimento Oncol Biol & Genet, I-16132 Genoa, Italy; Univ Genoa, LAMBS, Dipartmento Fis, I-16132 Genoa, Italy; Univ Genoa, MicroscoBio Res Ctr, I-16146 Genoa, Italy; Univ Genoa, Dipartimento Med Sperimentale, I-16132 Genoa, Italy; FIRC, Inst Mol Oncol, I-16132 Genoa, Italy; Univ Naples Federico II, CEINGE Biotecnol Avanzate, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Molise, Dipartimento Sci Salute, I-86100 Campobasso, Italy	University of Genoa; University of Genoa; University of Genoa; University of Genoa; IFOM - FIRC Institute of Molecular Oncology; CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Molise	Russo, C (corresponding author), Univ Genoa, Dipartimento Oncol Biol & Genet, Viale Benedetto 15 2, I-16132 Genoa, Italy.	Claudio.Russo@unimol.it	Russo, Claudio/AIA-1429-2022; FLORIO, TULLIO/ABG-3182-2020; Florio, Tullio/A-2211-2012; Russo, Tommaso/K-1331-2016; Diaspro, Alberto/E-7833-2010	Florio, Tullio/0000-0002-2394-996X; Russo, Tommaso/0000-0003-4426-0106; Diaspro, Alberto/0000-0002-4916-5928; russo, claudio/0000-0002-2520-2958; REPETTO, EMANUELA/0000-0002-6270-3540; gagliani, maria cristina/0000-0002-2902-2719; MAGRASSI, RAFFAELLA/0000-0003-3187-7764; TACCHETTI, CARLO/0000-0003-4602-000X				Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Badano JL, 2005, NAT REV GENET, V6, P194, DOI 10.1038/nrg1557; Benesch S, 2002, J BIOL CHEM, V277, P37771, DOI 10.1074/jbc.M204145200; Berezovska O, 2003, J NEUROSCI, V23, P4560; Boeras DI, 2008, NEUROBIOL AGING, V29, P319, DOI 10.1016/j.neurobiolaging.2006.10.027; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen YZ, 2000, J BIOL CHEM, V275, P8929, DOI 10.1074/jbc.275.12.8929; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Das I, 2004, J BIOL CHEM, V279, P30771, DOI 10.1074/jbc.M309252200; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Dranovsky A, 2001, NEUROBIOL AGING, V22, P517, DOI 10.1016/S0197-4580(00)00248-7; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Fratta P, 2005, AM J PATHOL, V167, P517, DOI 10.1016/S0002-9440(10)62994-X; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gao YH, 2001, P NATL ACAD SCI USA, V98, P14979, DOI 10.1073/pnas.261463298; Gianni D, 2003, J BIOL CHEM, V278, P9290, DOI 10.1074/jbc.M211899200; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; Golde TE, 2003, J CLIN INVEST, V111, P11, DOI 10.1172/JCI200317527; GOLDE TE, 2003, SCI STKE, pRE4; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Inomata H, 2003, J BIOL CHEM, V278, P22946, DOI 10.1074/jbc.M212160200; Jeong SJ, 2000, FASEB J, V14, P2171, DOI 10.1096/fj.99-1068com; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kang DE, 2005, J BIOL CHEM, V280, P31537, DOI 10.1074/jbc.M500833200; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; Kim MY, 2005, BIOCHEM BIOPH RES CO, V332, P609, DOI 10.1016/j.bbrc.2005.05.001; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Li JH, 1997, CELL, V90, P917, DOI 10.1016/S0092-8674(00)80356-6; Liu KN, 2002, BIOCHEMISTRY-US, V41, P3128, DOI 10.1021/bi015800g; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Matsuda S, 2005, J BIOL CHEM, V280, P28912, DOI 10.1074/jbc.C500217200; Matsumoto B, 2002, CELL BIOL APPL CONFO CELL BIOL APPL CONFO; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; McCarthy JV, 2005, BIOCHEM SOC T, V33, P568, DOI 10.1042/BST0330568; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; Millecamps S, 2005, BBA-MOL CELL RES, V1745, P84, DOI 10.1016/j.bbamcr.2004.12.008; Moritz M, 1998, J CELL BIOL, V142, P775, DOI 10.1083/jcb.142.3.775; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; Ni CY, 2003, J BIOL CHEM, V278, P4561, DOI 10.1074/jbc.M210504200; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nishimura M, 1999, NAT MED, V5, P164, DOI 10.1038/5526; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Parisiadou L, 2004, NEURODEGENER DIS, V1, P184, DOI 10.1159/000080984; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; Periasamy A., 2005, MOL IMAGING FRET MIC; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Raemaekers T, 2005, BIOCHEM SOC T, V33, P559, DOI 10.1042/BST0330559; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Russo C, 2005, BRAIN RES REV, V48, P257, DOI 10.1016/j.brainresrev.2004.12.016; Russo C, 1997, FEBS LETT, V409, P411, DOI 10.1016/S0014-5793(97)00564-4; Russo C, 1998, P NATL ACAD SCI USA, V95, P15598, DOI 10.1073/pnas.95.26.15598; Russo C, 2002, J BIOL CHEM, V277, P35282, DOI 10.1074/jbc.M110785200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Selkoe D, 2003, ANNU REV NEUROSCI, V26, P565, DOI 10.1146/annurev.neuro.26.041002.131334; Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054; Shaw RW, 2006, FASEB J, V20, pA898, DOI 10.1096/fj.05-4055fje; Shen TL, 2001, FEBS LETT, V499, P176, DOI 10.1016/S0014-5793(01)02545-5; Silva EFDE, 2003, NEUROCHEM RES, V28, P1553, DOI 10.1023/A:1025630627319; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Venezia V, 2004, J NEUROCHEM, V90, P1359, DOI 10.1111/j.1471-4159.2004.02618.x; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vingtdeux V, 2005, NEUROBIOL DIS, V20, P625, DOI 10.1016/j.nbd.2005.05.004; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Willard FS, 2001, CELL SIGNAL, V13, P653, DOI 10.1016/S0898-6568(01)00185-1; Yang Y, 2006, J NEUROSCI, V26, P775, DOI 10.1523/JNEUROSCI.3707-05.2006; Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001; Yoon SY, 2002, J CELL BIOCHEM, V84, P150, DOI 10.1002/jcb.1275; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200; Zhou DW, 2004, J BIOL CHEM, V279, P25374, DOI 10.1074/jbc.M400488200	81	78	81	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13833	13844		10.1074/jbc.M610146200	http://dx.doi.org/10.1074/jbc.M610146200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17314098	hybrid			2022-12-25	WOS:000246060300073
J	Lu, R; Wang, X; Chen, ZF; Sun, DF; Tian, XQ; Fang, JY				Lu, Rong; Wang, Xia; Chen, Zhao-Fei; Sun, Dan-Feng; Tian, Xiao-Qing; Fang, Jing-Yuan			Inhibition of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway decreases DNA methylation in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; CYCLE ARREST; EXPRESSION; METHYLTRANSFERASE; HYPOMETHYLATION; P21(CIP1); GENE; PCNA; HYPERMETHYLATION; PROLIFERATION	The extracellular signal-regulated kinase/mitogen-activated protein kinase ( ERK-MAPK) pathway is a critical intermediary for cell proliferation, differentiation, and survival. In the human colon cancer cell line SW1116, treatment with the DNA methyltransferase 1 ( DNMT1) inhibitor 5-aza-2'-deoxycytidine ( 5-aza-dC) or the ERK-MAPK inhibitors PD98059 or rottlerin, or transient transfection with the MAP/ERK kinase ( MEK)1/2 small interfering RNA down-regulates DNMT1 and proliferating cell nuclear antigen levels. In this report, we found that drug treatment or small interfering RNA transfection of SW1116 cells induced promoter demethylation of the p16(INK4A) and p21(WAF1) genes, which up-regulated their mRNA and protein expression levels. Flow cytometry revealed that rottlerin treatment induced cell cycle arrest at phase G(1) ( p < 0.05). Thus, the ERK-MAPK inhibitor treatment or siRNA-mediated knockdown of ERK-MAPK decreases DNA methylation via down-regulating DNMT1 expression and other unknown mediator( s) in SW1116 colon cancer cells.	Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Shanghai Inst Digest Dis, Shanghai 200001, Peoples R China	Shanghai Jiao Tong University	Fang, JY (corresponding author), 145 Shandong Rd Middle, Shanghai 200001, Peoples R China.	jingyuanfang@yahoo.com						Bender CM, 1999, MOL CELL BIOL, V19, P6690; Biro T, 2004, SCAND J IMMUNOL, V60, P421, DOI 10.1111/j.0300-9475.2004.01485.x; Chae HJ, 2004, ACTA PHARMACOL SIN, V25, P1372; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Deng C, 1998, BIOL CHEM, V379, P1113, DOI 10.1515/bchm.1998.379.8-9.1113; Deng C, 2001, ARTHRITIS RHEUM, V44, P397, DOI 10.1002/1529-0131(200102)44:2<397::AID-ANR59>3.3.CO;2-E; Enokida H, 2004, CANCER RES, V64, P5956, DOI 10.1158/0008-5472.CAN-04-0081; Esteller M, 2000, CANCER RES, V60, P4366; Fang JY, 2006, CANCER LETT, V233, P124, DOI 10.1016/j.canlet.2005.03.005; Fang JY, 2001, J VIROL, V75, P9753, DOI 10.1128/JVI.75.20.9753-9761.2001; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Gao ZQ, 1999, INT J CANCER, V82, P346, DOI 10.1002/(SICI)1097-0215(19990730)82:3<346::AID-IJC7>3.0.CO;2-#; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hofmann J, 2004, CURR CANCER DRUG TAR, V4, P125, DOI 10.2174/1568009043481579; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Iida T, 2002, GENES CELLS, V7, P997, DOI 10.1046/j.1365-2443.2002.00584.x; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jakubikova J, 2005, INT J ONCOL, V27, P1449; Jeon HK, 2005, CELL BIOL TOXICOL, V21, P115, DOI 10.1007/s10565-005-0148-8; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Knibiehler M, 1996, FEBS LETT, V391, P66, DOI 10.1016/0014-5793(96)00702-8; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lin SY, 2002, MOL CARCINOGEN, V35, P21, DOI 10.1002/mc.10070; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; Lunghi P, 2004, BLOOD, V104, P519, DOI 10.1182/blood-2003-08-2743; McMillan L, 2003, BRIT J CANCER, V88, P748, DOI 10.1038/sj.bjc.6600793; Qi XM, 2004, J BIOL CHEM, V279, P22138, DOI 10.1074/jbc.M313964200; Ramirez T, 2003, MUTAT RES-FUND MOL M, V528, P61, DOI 10.1016/S0027-5107(03)00099-X; Rylova SN, 2002, CANCER RES, V62, P801; Scanlan MJ, 2002, CANCER RES, V62, P4041; SCHEINBART LS, 1991, J RHEUMATOL, V18, P530; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Taupin D, 1999, GASTROENTEROLOGY, V116, P1072, DOI 10.1016/S0016-5085(99)70010-7; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; Williams TM, 2004, J BIOL CHEM, V279, P24745, DOI 10.1074/jbc.M402064200; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu SJ, 2005, LIFE SCI, V77, P938, DOI 10.1016/j.lfs.2005.02.005; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Zhang XM, 2005, CANCER CHEMOTH PHARM, V55, P251, DOI 10.1007/s00280-004-0863-5; Zhu HB, 2004, ONCOGENE, V23, P4984, DOI 10.1038/sj.onc.1207645	42	85	93	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12249	12259		10.1074/jbc.M608525200	http://dx.doi.org/10.1074/jbc.M608525200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17307743	hybrid			2022-12-25	WOS:000245941900068
J	Speck, C; Stillman, B				Speck, Christian; Stillman, Bruce			Cdc6 ATPase activity regulates ORC center dot Cdc6 stability and the selection of specific DNA sequences as origins of DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WALKER-A MOTIF; RECOGNITION COMPLEX; BUDDING YEAST; S-PHASE; SACCHAROMYCES-CEREVISIAE; FISSION YEAST; ESCHERICHIA-COLI; IN-VITRO; CHROMOSOMAL ORIGIN; BINDING-SITES	DNA replication, as with all macromolecular synthesis steps, is controlled in part at the level of initiation. Although the origin recognition complex ( ORC) binds to origins of DNA replication, it does not solely determine their location. To initiate DNA replication ORC requires Cdc6 to target initiation to specific DNA sequences in chromosomes and with Cdt1 loads the ring-shaped mini-chromosome maintenance ( MCM) 2-7 DNA helicase component onto DNA. ORC and Cdc6 combine to form a ring-shaped complex that contains six AAA(+) subunits. ORC and Cdc6 ATPase mutants are defective in MCM loading, and ORC ATPase mutants have reduced activity in ORC.Cdc6.DNA complex formation. Here we analyzed the role of the Cdc6 ATPase on ORC.Cdc6 complex stability in the presence or absence of specific DNA sequences. Cdc6 ATPase is activated by ORC, regulates ORC.Cdc6 complex stability, and is suppressed by origin DNA. Mutations in the conserved origin A element, and to a lesser extent mutations in the B1 and B2 elements, induce Cdc6 ATPase activity and prevent stable ORC.Cdc6 formation. By analyzing ORC.Cdc6 complex stability on various DNAs, we demonstrated that specific DNA sequences control the rate of Cdc6 ATPase, which in turn controls the rate of Cdc6 dissociation from the ORC.Cdc6.DNA complex. We propose a mechanism explaining how Cdc6 ATPase activity promotes origin DNA sequence specificity; on DNA that lacks origin activity, Cdc6 ATPase promotes dissociation of Cdc6, whereas origin DNA down-regulates Cdc6 ATPase resulting in a stable ORC.Cdc6.DNA complex, which can then promote MCM loading. This model has relevance for origin specificity in higher eukaryotes.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Stillman, B (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	Stillman@cshl.edu	Speck, Christian/G-2882-2011	Speck, Christian/0000-0001-6646-1692; Stillman, Bruce/0000-0002-9453-4091	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045436] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM045436, R01 GM045436-20, GM45436] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aladjem MI, 2004, EMBO REP, V5, P686, DOI 10.1038/sj.embor.7400185; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bowers JL, 2004, MOL CELL, V16, P967, DOI 10.1016/j.molcel.2004.11.038; Clarey MG, 2006, NAT STRUCT MOL BIOL, V13, P684, DOI 10.1038/nsmb1121; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Dai JL, 2005, P NATL ACAD SCI USA, V102, P337, DOI 10.1073/pnas.0408811102; DeBeer MAP, 2003, GENE DEV, V17, P1817, DOI 10.1101/gad.1096703; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Drury LS, 2000, CURR BIOL, V10, P231, DOI 10.1016/S0960-9822(00)00355-9; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; Erzberger JP, 2006, ANNU REV BIOPH BIOM, V35, P93, DOI 10.1146/annurev.biophys.35.040405.101933; FALCONI MM, 1996, P NATL ACAD SCI USA, V93, P1566; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; Giordano-Coltart J, 2005, P NATL ACAD SCI USA, V102, P69, DOI 10.1073/pnas.0408690102; Green BM, 2006, MOL BIOL CELL, V17, P2401, DOI 10.1091/mbc.E05-11-1043; Heichinger C, 2006, EMBO J, V25, P5171, DOI 10.1038/sj.emboj.7601390; JACOB F, 1963, CR HEBD ACAD SCI, V256, P298; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Lemaitre JM, 2002, NATURE, V419, P718, DOI 10.1038/nature01046; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MacAlpine D, 2005, CHROMOSOME RES, V13, P309, DOI 10.1007/s10577-005-1508-1; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; Mendez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Mimura S, 2004, NATURE, V431, P1118, DOI 10.1038/nature03024; Mizushima T, 2000, GENE DEV, V14, P1631; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Oehlmann M, 2004, J CELL BIOL, V165, P181, DOI 10.1083/jcb.200311044; Patel PK, 2006, MOL BIOL CELL, V17, P308, DOI 10.1091/mbc.E05-07-0657; Perkins G, 2001, EMBO J, V20, P4836, DOI 10.1093/emboj/20.17.4836; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Randell JCW, 2006, MOL CELL, V21, P29, DOI 10.1016/j.molcel.2005.11.023; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; Remus D, 2004, EMBO J, V23, P897, DOI 10.1038/sj.emboj.7600077; Roth A, 1998, MOL MICROBIOL, V28, P395, DOI 10.1046/j.1365-2958.1998.00813.x; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Schepers A, 2001, J MOL BIOL, V308, P597, DOI 10.1006/jmbi.2001.4637; Seki T, 2000, P NATL ACAD SCI USA, V97, P14115, DOI 10.1073/pnas.97.26.14115; Speck C, 2005, NAT STRUCT MOL BIOL, V12, P965, DOI 10.1038/nsmb1002; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Takahashi N, 2004, J BIOL CHEM, V279, P8469, DOI 10.1074/jbc.M305531200; Takahashi N, 2002, J BIOL CHEM, V277, P16033, DOI 10.1074/jbc.M108615200; Tanny RE, 2006, MOL BIOL CELL, V17, P2415, DOI 10.1091/mbc.E05-11-1037; Vashee S, 2003, GENE DEV, V17, P1894, DOI 10.1101/gad.1084203; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Wilmes GM, 2002, P NATL ACAD SCI USA, V99, P101, DOI 10.1073/pnas.012578499; Xu WH, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-276; Zou L, 2000, MOL CELL BIOL, V20, P3086, DOI 10.1128/MCB.20.9.3086-3096.2000	57	69	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11705	11714		10.1074/jbc.M700399200	http://dx.doi.org/10.1074/jbc.M700399200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314092	hybrid, Green Accepted			2022-12-25	WOS:000245941900012
J	Beguin, P; Ng, YJA; Krause, C; Mahalakshmi, RN; Ng, MY; Hunziker, W				Beguin, Pascal; Ng, Yu Jin Alvin; Krause, Carola; Mahalakshmi, Ramasubbu N.; Ng, Mei Yong; Hunziker, Walter			RGK small GTP-binding proteins interact with the nucleotide kinase domain of Ca2+-channel beta-subunits via an uncommon effector binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-CHANNEL ACTIVITY; GATED CA2+ CHANNELS; RAS FAMILY; CALMODULIN; COMPLEX; REM2; GEM; GTPASES; MEMBER; MODULATION	RGK proteins (Kir/Gem, Rad, Rem, and Rem2) form a small subfamily of the Ras superfamily. Despite a conserved GTP binding core domain, several differences suggest that structure, mechanism of action, and functional regulation differ from Ras. RGK proteins down-regulate voltage-gated calcium channel activity by binding in a GTP-dependent fashion to the Ca-v beta subunits. Mutational analysis combined with homology modeling reveal a novel effector binding mechanism distinct from that of other Ras GTPases. In this model the Switch 1 region acts as an allosteric activator that facilitates electrostatic interactions between Arg-196 in Kir/Gem and Asp-194, -270, and -272 in the nucleotide-kinase (NK) domain of Ca-v beta 3 and wedging Val-223 and His-225 of Kir/ Gem into a hydrophobic pocket in the NK domain. Kir/ Gem interacts with a surface on the NK domain that is distinct from the groove where the voltage-gated calcium channel Ca-v beta 1 subunit binds. A complex composed of the RGK protein and the Ca-v beta 3 and Cav1.2 subunits could be revealed in vivo using coimmunoprecipitation experiments. Intriguingly, docking of the RGK protein to the NK domain of the Ca-v beta subunit is reminiscent of the binding of GMP to guanylate kinase.	Inst Mol & Cell Biol, Epithelial Cell Biol Lab, Singapore 138673, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Hunziker, W (corresponding author), Inst Mol & Cell Biol, Epithelial Cell Biol Lab, 61 Biopolis Dr, Singapore 138673, Singapore.	Hunziker@imcb.a-star.edu.sg	Hunziker, Walter/B-3140-2010; Hunziker, Walter/GSM-8190-2022	Hunziker, Walter/0000-0002-5265-4933; Ng, Alvin/0000-0002-1744-6063				Beguin P, 2006, J MOL BIOL, V355, P34, DOI 10.1016/j.jmb.2005.10.013; Beguin P, 2005, BIOCHEM J, V390, P67, DOI 10.1042/BJ20050414; Beguin P, 2005, J CELL SCI, V118, P1923, DOI 10.1242/jcs.02321; Beguin P, 2001, NATURE, V411, P701, DOI 10.1038/35079621; Berrou L, 2002, BIOPHYS J, V83, P1429, DOI 10.1016/S0006-3495(02)73914-3; Berrou L, 2005, J BIOL CHEM, V280, P494, DOI 10.1074/jbc.M410859200; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Chen HM, 2005, J NEUROSCI, V25, P9762, DOI 10.1523/JNEUROSCI.3111-05.2005; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Finlin BS, 2006, J BIOL CHEM, V281, P23557, DOI 10.1074/jbc.M604867200; Finlin BS, 2005, J BIOL CHEM, V280, P41864, DOI 10.1074/jbc.M414261200; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; Finlin BS, 2003, P NATL ACAD SCI USA, V100, P14469, DOI 10.1073/pnas.2437756100; FLETCHER R, 1963, COMPUT J, V6, P163, DOI 10.1093/comjnl/6.2.163; Kelly K, 2005, TRENDS CELL BIOL, V15, P640, DOI 10.1016/j.tcb.2005.10.002; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; Menetrey J, 1999, PROTEINS, V37, P465, DOI 10.1002/(SICI)1097-0134(19991115)37:3<465::AID-PROT13>3.0.CO;2-O; Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111; Moyers JS, 1997, J BIOL CHEM, V272, P11832, DOI 10.1074/jbc.272.18.11832; Murata M, 2004, CIRC RES, V95, P398, DOI 10.1161/01.RES.0000138449.85324.c5; Opatowsky Y, 2003, J BIOL CHEM, V278, P52323, DOI 10.1074/jbc.M303564200; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; PIZON V, 1988, ONCOGENE, V3, P201; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Sasaki T, 2005, J BIOL CHEM, V280, P9308, DOI 10.1074/jbc.M413773200; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Ward Y, 2004, MOL CELL BIOL, V24, P651, DOI 10.1128/MCB.24.2.651-661.2004; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Yanuar A, 2006, GENES CELLS, V11, P961, DOI 10.1111/j.1365-2443.2006.00994.x	35	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11509	11520		10.1074/jbc.M606423200	http://dx.doi.org/10.1074/jbc.M606423200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303572	hybrid			2022-12-25	WOS:000245941500072
J	Ido, H; Nakamura, A; Kobayashi, R; Ito, S; Li, SL; Futaki, S; Sekiguchi, K				Ido, Hiroyuki; Nakamura, Aya; Kobayashi, Reiko; Ito, Shunsuke; Li, Shaoliang; Futaki, Sugiko; Sekiguchi, Kiyotoshi			The requirement of the glutamic acid residue at the third position from the carboxyl termini of the laminin gamma chains in integrin binding by laminins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-DYSTROGLYCAN-BINDING; CELL-ADHESION; GLOBULAR DOMAIN; EXTRACELLULAR-MATRIX; LG MODULES; LONG-ARM; IDENTIFICATION; RECOMBINANT; HEPARIN; LIGAND	Laminins are the major cell-adhesive proteins in the basement membrane, consisting of three subunits termed alpha, beta, and gamma. The putative binding site for integrins has been mapped to the G domain of the alpha chain, although trimerization with beta and gamma chains is necessary for the G domain to exert its integrin binding activity. The mechanism underlying the requirement of beta and gamma chains in integrin binding by laminins remains poorly understood. Here, we show that the C-terminal region of the gamma chain is involved in modulation of the integrin binding activity of laminins. We found that deletion of the C-terminal three but not two amino acids within the gamma 1 chain completely abrogated the integrin binding activity of laminin-511. Furthermore, substitution of Gln for Glu-1607, the amino acid residue at the third position from the C terminus of the gamma 1 chain, also abolished the integrin binding activity, underscoring the role of Glu-1607 in integrin binding by the laminin. We also found that the conserved Glu residue of the gamma 2 chain is necessary for integrin binding by laminin-332, suggesting that the same mechanism operates in the modulation of the integrin binding activity of laminins containing either gamma 1 or gamma 2 chains. However, the peptide segment modeled after the C-terminal region of gamma 1 chain was incapable of either binding to integrin or inhibiting integrin binding by laminin-511, making it unlikely that the Glu residue is directly recognized by integrin. These results, together, indicate a novel mechanism operating in ligand recognition by laminin binding integrins.	Osaka Univ, Inst Prot Res, Lab Extracellular Matrix Biochem, Suita, Osaka 5650871, Japan	Osaka University	Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, Lab Extracellular Matrix Biochem, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sekiguch@protein.osaka-u.ac.jp						Airenne T, 1996, GENOMICS, V32, P54, DOI 10.1006/geno.1996.0076; Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; ANTONSSON P, 1995, J MOL BIOL, V250, P74, DOI 10.1006/jmbi.1995.0359; Arnaout MA, 2002, CURR OPIN CELL BIOL, V14, P641, DOI 10.1016/S0955-0674(02)00371-X; Aumailley M, 2005, MATRIX BIOL, V24, P326, DOI 10.1016/j.matbio.2005.05.006; Belkin AM, 2000, MICROSC RES TECHNIQ, V51, P280, DOI 10.1002/1097-0029(20001101)51:3<280::AID-JEMT7>3.0.CO;2-O; BRUCH M, 1989, EUR J BIOCHEM, V185, P271, DOI 10.1111/j.1432-1033.1989.tb15112.x; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DELWEL GO, 1994, MOL BIOL CELL, V5, P203, DOI 10.1091/mbc.5.2.203; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; GRAF J, 1987, BIOCHEMISTRY-US, V26, P6896, DOI 10.1021/bi00396a004; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; Gu JG, 2002, J BIOL CHEM, V277, P19922, DOI 10.1074/jbc.M200383200; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Hayashi Y, 2002, BIOCHEM BIOPH RES CO, V299, P498, DOI 10.1016/S0006-291X(02)02642-6; Hirosaki T, 2002, J BIOL CHEM, V277, P49287, DOI 10.1074/jbc.M111096200; HUMPHRIES MJ, 1990, J CELL SCI, V97, P585; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ido H, 2006, MATRIX BIOL, V25, P112, DOI 10.1016/j.matbio.2005.10.003; Ido H, 2004, J BIOL CHEM, V279, P10946, DOI 10.1074/jbc.M313626200; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; Katayama M, 2003, CANCER RES, V63, P222; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Kunneken K, 2004, J BIOL CHEM, V279, P5184, DOI 10.1074/jbc.M310424200; Li SH, 2003, DEV CELL, V4, P613, DOI 10.1016/S1534-5807(03)00128-X; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Nishimune H, 2004, NATURE, V432, P580, DOI 10.1038/nature03112; Nishiuchi R, 2006, MATRIX BIOL, V25, P189, DOI 10.1016/j.matbio.2005.12.001; Nishiuchi R, 2003, J BIOCHEM, V134, P497, DOI 10.1093/jb/mvg185; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; Okazaki I, 2002, J BIOL CHEM, V277, P37070, DOI 10.1074/jbc.M201672200; Sasaki T, 2001, FEBS LETT, V509, P181, DOI 10.1016/S0014-5793(01)03167-2; Shang ML, 2001, J BIOL CHEM, V276, P33045, DOI 10.1074/jbc.M100798200; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2001, NAT STRUCT BIOL, V8, P412, DOI 10.1038/87569; Talts JF, 2000, J BIOL CHEM, V275, P35192, DOI 10.1074/jbc.M003261200; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; Yan HHN, 2006, J BIOL CHEM, V281, P17286, DOI 10.1074/jbc.M513218200; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Yu H, 2003, BIOCHEM J, V371, P289, DOI 10.1042/BJ20021500	51	78	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11144	11154		10.1074/jbc.M609402200	http://dx.doi.org/10.1074/jbc.M609402200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17307733	Green Published, hybrid			2022-12-25	WOS:000245941500035
J	Ott, CM; Akhavan, A; Lingappa, VR				Ott, Carolyn M.; Akhavan, Armin; Lingappa, Vishwanath R.			Specific features of the prion protein transmembrane domain regulate nascent chain orientation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; ENDOPLASMIC-RETICULUM; SIGNAL SEQUENCES; MEMBRANE-PROTEIN; TOPOGENIC SEQUENCE; CHARGED RESIDUES; TRANSLOCATION; CODON-129; BIOGENESIS; TOPOLOGY	The sequence of a transmembrane ( TM) domain and the adjacent regions are important for recognition, orientation, and integration at the translocon during membrane protein biosynthesis. However, the sequences of individual TM domains vary considerably. Although some general effects of electrostatic and hydrophobic interactions have been observed, it is still not clear what features of diverse sequences influence TM domain orientation. Here we utilized the ability of the prion protein ( PrP) to be synthesized in multiple topological forms to assay the effects of substitutions and mutations on TM domain orientation. Several of the TM domains we tested appear to contain no inherent information regulating orientation. In contrast, we found that the middle region of the PrP TM domain significantly reduces the ability of the chain to invert its orientation in the translocon. We also observed that the C-terminal region of the PrP TM domain influences orientation, and we characterized the orientation differences between two forms of a physiologically relevant polymorphism in this region. Specifically, we found that the identity of a single amino acid, that at position 129, can significantly alter PrP TM domain orientation. Because position 129 is the location of the disease-associated Met/Val polymorphism, we discuss both how this small change may affect TMD orientation and the larger biological implications of these results.	Univ Calif San Francisco, Dept Physiol & Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Calif Pacific Med Ctr, Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Pacific Medical Center; California Pacific Medical Center Research Institute	Lingappa, VR (corresponding author), Univ Calif San Francisco, Dept Physiol, 513 Parnassus Ave, San Francisco, CA 94143 USA.	vishwanath.lingappa@ucsf.edu		Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER; NIA NIH HHS [AG02132] Funding Source: Medline; NINDS NIH HHS [NS37365] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barclay GR, 1999, BRIT J HAEMATOL, V107, P804, DOI 10.1046/j.1365-2141.1999.01789.x; BELTZER JP, 1991, J BIOL CHEM, V266, P973; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; Collinge J, 1997, NATURE, V389, P526, DOI 10.1038/39116; COLLINGE J, 1991, LANCET, V337, P1441, DOI 10.1016/0140-6736(91)93128-V; Collinge J, 1996, LANCET, V348, P56, DOI 10.1016/S0140-6736(05)64378-4; Cooper JD, 2003, INT J EPIDEMIOL, V32, P784, DOI 10.1093/ije/dyg248; Fons RD, 2003, J CELL BIOL, V160, P529, DOI 10.1083/jcb.200210095; Gambetti P, 2003, BRIT MED BULL, V66, P213, DOI 10.1093/bmb/66.1.213; Garrison JL, 2005, NATURE, V436, P285, DOI 10.1038/nature03821; Goder V, 2003, EMBO J, V22, P3645, DOI 10.1093/emboj/cdg361; Goder V, 2001, FEBS LETT, V504, P87, DOI 10.1016/S0014-5793(01)02712-0; Gu YP, 2006, MOL CELL BIOL, V26, P2697, DOI 10.1128/MCB.26.7.2697-2715.2006; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Higy M, 2005, BIOCHEMISTRY-US, V44, P2039, DOI 10.1021/bi047976z; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Hosszu LLP, 2004, J BIOL CHEM, V279, P28515, DOI 10.1074/jbc.M313762200; Kim SJ, 2002, DEV CELL, V2, P207, DOI 10.1016/S1534-5807(01)00120-4; Lewis PA, 2006, J GEN VIROL, V87, P2443, DOI 10.1099/vir.0.81630-0; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; Ott CM, 2004, BIOCHEMISTRY-US, V43, P11973, DOI 10.1021/bi049156s; Ott CM, 2002, J CELL SCI, V115, P2003; Panegyres PK, 2001, ARCH NEUROL-CHICAGO, V58, P1899, DOI 10.1001/archneur.58.11.1899; Peden AH, 2004, LANCET, V364, P527, DOI 10.1016/S0140-6736(04)16811-6; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; Rutkowski DT, 2001, P NATL ACAD SCI USA, V98, P7823, DOI 10.1073/pnas.141125098; Sadlish H, 2005, NAT STRUCT MOL BIOL, V12, P870, DOI 10.1038/nsmb994; Santini S, 2003, PROTEINS, V51, P258, DOI 10.1002/prot.10348; Schatzl HM, 1997, LANCET, V349, P1603, DOI 10.1016/S0140-6736(05)61632-7; Shan SO, 2005, FEBS LETT, V579, P921, DOI 10.1016/j.febslet.2004.11.049; Stewart RS, 2001, J BIOL CHEM, V276, P2212, DOI 10.1074/jbc.M006763200; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; Zeidler M, 1997, LANCET, V350, P668, DOI 10.1016/S0140-6736(05)63366-1	42	9	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11163	11171		10.1074/jbc.M607660200	http://dx.doi.org/10.1074/jbc.M607660200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17276986	hybrid			2022-12-25	WOS:000245941500037
J	Schromm, AB; Howe, J; Ulmer, AJ; Wiesmuller, KH; Seyberth, T; Jung, G; Rossle, M; Koch, MHJ; Gutsmann, T; Brandenburg, K				Schromm, Andra B.; Howe, Joerg; Ulmer, Artur J.; Wiesmueller, Karl-Heinz; Seyberth, Tobias; Jung, Guenther; Roessle, Manfred; Koch, Michel H. J.; Gutsmann, Thomas; Brandenburg, Klaus			Physicochemical and biological analysis of synthetic bacterial lipopeptides - Validity of the concept of endotoxic conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; LPS-BINDING PROTEIN; INDUCED ACTIVATION; ESCHERICHIA-COLI; CELL ACTIVATION; LIPOPOLYSACCHARIDE; RECOGNITION; LIPOPROTEIN; INNATE; CD14	The importance of the biological function and activity of lipoproteins from the outer or cytoplasmic membranes of Gram-positive and Gram-negative bacteria is being increasingly recognized. It is well established that they are like the endotoxins ( lipopolysaccharide ( LPS)), which are the main amphiphilic components of the outer membrane of Gram-negative bacteria, potent stimulants of the human innate immune system, and elicit a variety of proinflammatory immune responses. Investigations of synthetic lipopeptides corresponding to N-terminal partial structures of bacterial lipoproteins defined the chemical prerequisites for their biological activity and in particular the number and length of acyl chains and sequence of the peptide part. Here we present experimental data on the biophysical mechanisms underlying lipopeptide bioactivity. Investigation of selected synthetic diacylated and triacylated lipopeptides revealed that the geometry of these molecules ( i.e. the molecular conformations and supramolecular aggregate structures) and the preference for membrane intercalation provide an explanation for the biological activities of the different lipopeptides. This refers in particular to the agonistic or antagonistic activity ( i.e. their ability to induce cytokines in mononuclear cells or to block this activity, respectively). Biological activity of lipopeptides was hardly affected by the LPS-neutralizing antibiotic polymyxin B, and the biophysical interaction characteristics were found to be in sharp contrast to that of LPS with polymyxin B. The analytical data show that our concept of "endotoxic conformation," originally developed for LPS, can be applied also to the investigated lipopeptide and suggest that the molecular mechanisms of cell activation by amphiphilic molecules are governed by a general principle.	Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany; Dept Immunochem & Biochem Microbiol, D-23845 Borstel, Germany; Emmy Noether Grp Immunobiophys, D-23845 Borstel, Germany; Div Biophys, D-23845 Borstel, Germany; Div Immunol, D-23845 Borstel, Germany; EMC Microcollect GmbH, D-72070 Tubingen, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; DESY, European Mol Biol Lab, D-22603 Hamburg, Germany	Forschungszentrum Borstel; EMC Microcollections GmbH; Eberhard Karls University of Tubingen; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Schromm, AB (corresponding author), Leibniz Ctr Med & Biosci, Res Ctr Borstel, D-23845 Borstel, Germany.	aschromm@fz-borstel.de	Gutsmann, Thomas/E-6100-2011; Schromm, Andra/O-3936-2018	Rossle, Manfred/0000-0003-4196-0430				BESSLER WG, 1985, J IMMUNOL, V135, P1900; Blondin C, 1997, EUR J IMMUNOL, V27, P3303, DOI 10.1002/eji.1830271229; Blunck R, 2001, J IMMUNOL, V166, P1009, DOI 10.4049/jimmunol.166.2.1009; Boncheva M, 1996, LANGMUIR, V12, P5636, DOI 10.1021/la9605753; Brandenburg K, 2005, BIOPHYS J, V88, P1845, DOI 10.1529/biophysj.104.047944; Brandenburg K, 2004, BIOCHEMISTRY-US, V43, P4039, DOI 10.1021/bi0361158; Brandenburg K, 2002, THERMOCHIM ACTA, V382, P189, DOI 10.1016/S0040-6031(01)00731-6; BRANDENBURG K, 1993, EUR J BIOCHEM, V218, P555, DOI 10.1111/j.1432-1033.1993.tb18409.x; Brandenburg K, 1998, CHEM PHYS LIPIDS, V91, P53, DOI 10.1016/S0009-3084(97)00093-5; Brandenburg K, 2004, CURR TOP MED CHEM, V4, P1127, DOI 10.2174/1568026043388213; BRAUN V, 1970, EUR J BIOCHEM, V14, P387, DOI 10.1111/j.1432-1033.1970.tb00301.x; Buwitt-Beckmann U, 2006, J BIOL CHEM, V281, P9049, DOI 10.1074/jbc.M512525200; Buwitt-Beckmann U, 2005, FEBS J, V272, P6354, DOI 10.1111/j.1742-4658.2005.05029.x; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; DELUDE RL, 1995, P NATL ACAD SCI USA, V92, P9288, DOI 10.1073/pnas.92.20.9288; El-Samalouti VT, 1999, FEMS IMMUNOL MED MIC, V23, P259, DOI 10.1111/j.1574-695X.1999.tb01247.x; GALANOS C, 1969, EUR J BIOCHEM, V9, P245, DOI 10.1111/j.1432-1033.1969.tb00601.x; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gioffre A, 2006, J VET MED B, V53, P34, DOI 10.1111/j.1439-0450.2006.00905.x; Gough M, 1996, INFECT IMMUN, V64, P4922, DOI 10.1128/IAI.64.12.4922-4927.1996; Gutsmann T, 2001, INFECT IMMUN, V69, P6942, DOI 10.1128/IAI.69.11.6942-6950.2001; Gutsmann T, 2000, PHYS CHEM CHEM PHYS, V2, P4521, DOI 10.1039/b004188m; Hashimoto M, 2006, J IMMUNOL, V177, P3162, DOI 10.4049/jimmunol.177.5.3162; Heine H, 2003, INT ARCH ALLERGY IMM, V130, P180, DOI 10.1159/000069517; Hoebe K, 2005, NATURE, V433, P523, DOI 10.1038/nature03253; Iontcheva I, 2004, INFECT IMMUN, V72, P2312, DOI 10.1128/IAI.72.4.2312-2320.2004; ISRAELACHVILI JN, 1991, INTERMOLECULAR SURFA, P366; Kataoka H, 2006, CELL MICROBIOL, V8, P1199, DOI 10.1111/j.1462-5822.2006.00702.x; KAUPPINEN JK, 1981, APPL SPECTROSC, V35, P271, DOI 10.1366/0003702814732634; KIELIAN TL, 1995, IMMUNOPHARMACOLOGY, V29, P187, DOI 10.1016/0162-3109(95)00003-C; KOCH MHJ, 1988, MAKROMOL CHEM-M SYMP, V15, P79, DOI 10.1002/masy.19880150106; Liu HY, 2006, P NATL ACAD SCI USA, V103, P7048, DOI 10.1073/pnas.0601554103; LUZZATI V, 1993, J MOL BIOL, V229, P540, DOI 10.1006/jmbi.1993.1053; MATHISON J, 1993, J CLIN INVEST, V92, P2053, DOI 10.1172/JCI116801; MELCHERS F, 1975, J EXP MED, V142, P473, DOI 10.1084/jem.142.2.473; METZGER J, 1991, INT J PEPT PROT RES, V37, P46; Metzger J W, 1995, J Pept Sci, V1, P184, DOI 10.1002/psc.310010305; METZGER JW, 1993, BIOCHIM BIOPHYS ACTA, V1149, P29, DOI 10.1016/0005-2736(93)90021-Q; Mueller M, 2005, J IMMUNOL, V174, P1091, DOI 10.4049/jimmunol.174.2.1091; Muller M, 2003, J ENDOTOXIN RES, V9, P181, DOI 10.1179/096805103125001595; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRASS W, 1987, BIOCHIM BIOPHYS ACTA, V900, P116, DOI 10.1016/0005-2736(87)90283-5; Reichel F, 2000, J ORG CHEM, V65, P3357, DOI 10.1021/jo991685s; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; Schroder NWJ, 2004, J IMMUNOL, V173, P2683, DOI 10.4049/jimmunol.173.4.2683; Schromm AB, 2000, EUR J BIOCHEM, V267, P2008, DOI 10.1046/j.1432-1327.2000.01204.x; Schromm AB, 1996, FEBS LETT, V399, P267, DOI 10.1016/S0014-5793(96)01338-5; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Sellati TJ, 2001, J IMMUNOL, V166, P4131, DOI 10.4049/jimmunol.166.6.4131; Seyberth T, 2006, J MED CHEM, V49, P1754, DOI 10.1021/jm050585d; Seydel U, 2003, EUR J IMMUNOL, V33, P1586, DOI 10.1002/eji.200323649; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Spohn R, 2004, VACCINE, V22, P2494, DOI 10.1016/j.vaccine.2003.11.074; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Triantafilou M, 2002, CRIT REV IMMUNOL, V22, P251; Triantafilou M, 2002, J CELL SCI, V115, P2603; UHL B, 1991, J LEUKOCYTE BIOL, V50, P10, DOI 10.1002/jlb.50.1.10; Underhill DM, 2002, CURR OPIN IMMUNOL, V14, P103, DOI 10.1016/S0952-7915(01)00304-1; Viriyakosol S, 2005, INFECT IMMUN, V73, P1553, DOI 10.1128/IAI.73.3.1553-1560.2005; Wardenburg JB, 2006, P NATL ACAD SCI USA, V103, P13831, DOI 10.1073/pnas.0603072103; WIESMULLER KH, 1992, INT J PEPT PROT RES, V40, P255; WOLF B, 1989, IMMUNOBIOLOGY, V180, P93, DOI 10.1016/S0171-2985(89)80033-6; WOLF B, 1989, IMMUNOL LETT, V20, P121, DOI 10.1016/0165-2478(89)90096-5; Yadav M, 2006, BLOOD, V108, P3168, DOI 10.1182/blood-2006-05-024406; Yang XFF, 2003, P NATL ACAD SCI USA, V100, P11001, DOI 10.1073/pnas.1834315100	66	42	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11030	11037		10.1074/jbc.M700287200	http://dx.doi.org/10.1074/jbc.M700287200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308304	Green Published, hybrid			2022-12-25	WOS:000245941500023
J	Grillo, C; D'Ambrosio, C; Consalvi, V; Chiaraluce, R; Scaloni, A; Maceroni, M; Eufemi, M; Altieri, F				Grillo, Caterina; D'Ambrosio, Chiara; Consalvi, Valerio; Chiaraluce, Roberta; Scaloni, Andrea; Maceroni, Manola; Eufemi, Margherita; Altieri, Fabio			DNA-binding activity of the ERp57 C-terminal domain is related to a redox-dependent conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; ENDOPLASMIC-RETICULUM; PHOSPHOLIPASE-C; THIOREDOXIN REDUCTASE; NMR-SPECTROSCOPY; B' DOMAIN; SITE; CALRETICULIN; CALNEXIN; CELLS	ERp57, a member of the protein-disulfide isomerase family, although mainly localized in the endoplasmic reticulum is here shown to have a nuclear distribution. We previously showed the DNA-binding properties of ERp57, its association with the internal nuclear matrix, and identified the C-terminal region, containing the a' domain, as being directly involved in the DNA-binding activity. In this work, we demonstrate that its DNA-binding properties are strongly dependent on the redox state of the a' domain active site. Site-directed mutagenesis experiments on the first cysteine residue of the -CGHC-thioredoxinlike active site lead to a mutant domain (C406S) lacking DNA-binding activity. Biochemical studies on the recombinant domain revealed a conformational change associated with the redox-dependent formation of a homodimer, having two disulfide bridges between the cysteine residues of two a' domain active sites. The formation of intermolecular disulfide bridges rather than intramolecular oxidation of active site cysteines is important to generate species with DNA-binding properties. Thus, in the absence of any dedicated motif within the protein sequence, this structural rearrangement might be responsible for the DNA-binding properties of the C-terminal domain. Moreover, NADH-dependent thioredoxin reductase is active on intermolecular disulfides of the a' domain, allowing the control of dimeric protein content as well as its DNA-binding activity. A similar behavior was also observed for whole ERp57.	Univ Roma La Sapienza, Dept Biochem Sci A Rossi Fanelli, CNR Inst Mol Biol & Pathol, I-00185 Rome, Italy; Univ Roma La Sapienza, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy; ISPAAM, Natl Res Council, Proteom & Mass Spectrometry, I-80147 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Fondazione Cenci Bolognetti; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Istituto Per Il Sistema Produzione Animale In Ambiente Mediterraneo (ISPAAM-CNR)	Altieri, F (corresponding author), Univ Roma La Sapienza, Dept Biochem Sci A Rossi Fanelli, CNR Inst Mol Biol & Pathol, P Moro 5, I-00185 Rome, Italy.	fabio.altieri@uniroma1.it	Grillo, Caterina Maria/ABD-3404-2021; consalvi, valerio/F-1918-2011; Chiaraluce, Roberta/F-1920-2011; Altieri, Fabio/D-2790-2009; D'Ambrosio, Chiara/C-2753-2012	Altieri, Fabio/0000-0002-6546-2738; D'Ambrosio, Chiara/0000-0003-2810-9270; Scaloni, Andrea/0000-0001-9362-8515				ALTIERI F, 1993, BIOCHEM BIOPH RES CO, V194, P992, DOI 10.1006/bbrc.1993.1919; Antoniou AN, 2002, EMBO J, V21, P2655, DOI 10.1093/emboj/21.11.2655; BOURDI M, 1995, ARCH BIOCHEM BIOPHYS, V323, P397, DOI 10.1006/abbi.1995.0060; Chichiarelli S, 2007, J CELL PHYSIOL, V210, P343, DOI 10.1002/jcp.20824; Coppari S, 2002, J CELL BIOCHEM, V85, P325, DOI 10.1002/jcb.10137; Dalle-Donne I, 2005, MASS SPECTROM REV, V24, P55, DOI 10.1002/mas.20006; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P11725, DOI 10.1021/bi00037a009; Ellgaard L, 2003, CELL BIOCHEM BIOPHYS, V39, P223, DOI 10.1385/CBB:39:3:223; Elliott JG, 1997, J BIOL CHEM, V272, P13849, DOI 10.1074/jbc.272.21.13849; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; Eufemi M, 2004, BIOCHEM BIOPH RES CO, V323, P1306, DOI 10.1016/j.bbrc.2004.09.009; Ferrari DM, 1999, BIOCHEM J, V339, P1, DOI 10.1042/0264-6021:3390001; Ferraro A, 1999, J CELL BIOCHEM, V72, P528, DOI 10.1002/(SICI)1097-4644(19990315)72:4<528::AID-JCB8>3.0.CO;2-V; Freedman RB, 2002, EMBO REP, V3, P136, DOI 10.1093/embo-reports/kvf035; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Frickel EM, 2004, J BIOL CHEM, V279, P18277, DOI 10.1074/jbc.M314089200; Gerner C, 1999, J CELL BIOCHEM, V74, P145, DOI 10.1002/(SICI)1097-4644(19990801)74:2<145::AID-JCB1>3.0.CO;2-#; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grillo C, 2002, BIOCHEM BIOPH RES CO, V295, P67, DOI 10.1016/S0006-291X(02)00634-4; Grillo C, 2006, FREE RADICAL BIO MED, V41, P1113, DOI 10.1016/j.freeradbiomed.2006.06.016; HANIU M, 1994, INT J PEPT PROT RES, V43, P81; Hennecke J, 1997, BIOCHEMISTRY-US, V36, P6391, DOI 10.1021/bi963017w; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON E, 1992, J BIOL CHEM, V267, P14412; Kang SJ, 2002, J BIOL CHEM, V277, P44838, DOI 10.1074/jbc.M207831200; Kemmink J, 1996, BIOCHEMISTRY-US, V35, P7684, DOI 10.1021/bi960335m; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; Klappa P, 1998, EMBO J, V17, P927, DOI 10.1093/emboj/17.4.927; Krynetski EY, 2003, CANCER RES, V63, P100; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; Markus M, 1999, J BIOL CHEM, V274, P1040, DOI 10.1074/jbc.274.2.1040; MAZZARELLA RA, 1994, ARCH BIOCHEM BIOPHYS, V308, P454, DOI 10.1006/abbi.1994.1064; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Mulkerrin Michael G., 1996, P5; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; OTHANI H, 1993, HISTOCHEMISTRY, V100, P423; Pirneskoski A, 2004, J BIOL CHEM, V279, P10374, DOI 10.1074/jbc.M312193200; Pollock S, 2004, EMBO J, V23, P1020, DOI 10.1038/sj.emboj.7600119; ROZELL B, 1988, EUR J CELL BIOL, V46, P470; Russell SJ, 2004, J BIOL CHEM, V279, P18861, DOI 10.1074/jbc.M400575200; Sambrook J, 2001, MOL CLONING LAB MANU; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Silvennoinen L, 2004, J BIOL CHEM, V279, P13607, DOI 10.1074/jbc.M313054200; SRIVASTAVA SP, 1993, BIOCHEM BIOPH RES CO, V193, P971, DOI 10.1006/bbrc.1993.1720; Thomas JO, 2001, BIOCHEM SOC T, V29, P395, DOI 10.1042/BST0290395; Tian G, 2006, CELL, V124, P61, DOI 10.1016/j.cell.2005.10.044; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Urade R, 1997, J BIOCHEM-TOKYO, V122, P834; Vilardo PG, 2001, BIOCHEMISTRY-US, V40, P11985, DOI 10.1021/bi0104975; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; Wyse B, 2002, AM J PHYSIOL-RENAL, V282, pF424, DOI 10.1152/ajprenal.0028.2001; Zapun A, 1998, J BIOL CHEM, V273, P6009, DOI 10.1074/jbc.273.11.6009	56	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10299	10310		10.1074/jbc.M700966200	http://dx.doi.org/10.1074/jbc.M700966200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17283067	hybrid			2022-12-25	WOS:000245941000020
J	Smrz, D; Draberova, L; Draber, P				Smrz, Daniel; Draberova, L'ubica; Draber, Petr			Non-apoptotic phosphatidylserine externalization induced by engagement of glycosylphosphatidylinositol-anchored proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; FC-EPSILON-RI; MEMBRANE PHOSPHOLIPID ASYMMETRY; RAT MAST-CELLS; PLASMA-MEMBRANE; SURFACE EXPOSURE; LIPID RAFTS; ANNEXIN-V; CARCINOEMBRYONIC ANTIGEN; BIOLOGICAL FUNCTIONS	The exposure of phosphatidylserine ( PS) on the cell surface is a general marker of apoptotic cells. Non-apoptotic PS externalization is induced by several activation stimuli, including engagement of immunoreceptors. Immune cells can also be activated by aggregation of glycosylphosphatidylinositol- anchored proteins ( GPI-APs). However, it is unknown whether cell triggering through these proteins, lacking transmembrane and cytoplasmic domains, also leads to PS externalization. Here we show that engagement of GPI-APs in rodent mast cells induces a rapid and reversible externalization of PS by a non-apoptotic mechanism. PS externalization triggered by GPI-AP-specific monoclonal antibodies was dependent on the activity of H+-ATP synthase and several other enzymes involved in mast cell signaling but was independent of cell degranulation, free cytoplasmic calcium up-regulation, and a decrease in lipid packing as determined by merocyanine 540 binding. Surprisingly, disruption of actin cytoskeleton by latrunculin B or plasma membrane integrity by methyl-beta-cyclodextrin had opposite effects on PS externalization triggered through GPI-AP or the high affinity IgE receptor. We further show that PS externalization mediated by GPI-APs was also observed in some other cells, and its extent varied with antibodies used. Interestingly, effects of different antibodies on PS externalization were additive, indicating that independent stimuli converge onto a signaling pathways leading to PS externalization. Our findings identify the cell surface PS exposure induced through GPI-AP as a distinct mechanism of cell signaling. Such a mechanism could contribute to "inside-out" signaling in response to pathogens and other external activators and/or to initiation of other functions associated with PS externalization.	Acad Sci Czech Republic, Inst Genet Mol, Dept Signal Transduct, CZ-14220 Prague 4, Czech Republic	Czech Academy of Sciences	Draber, P (corresponding author), Acad Sci Czech Republic, Inst Genet Mol, Dept Signal Transduct, Videnska 1083, CZ-14220 Prague 4, Czech Republic.	draberpe@biomed.cas.cz	Smrz, Daniel/D-4853-2014; Draberova, Lubica/G-3505-2014; Draber, Petr/E-1119-2018; Draber, Petr/G-3412-2014	Smrz, Daniel/0000-0003-0143-8744; Draberova, Lubica/0000-0002-2459-4435; Draber, Petr/0000-0002-3986-2025; Draber, Petr/0000-0002-3986-2025				BANIYASH M, 1987, J IMMUNOL, V138, P2999; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Brouckaert G, 2004, MOL BIOL CELL, V15, P1089, DOI 10.1091/mbc.E03-09-0668; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Daleke DL, 2003, J LIPID RES, V44, P233, DOI 10.1194/jlr.R200019-JLR200; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; Dias-Baruffi M, 2003, J BIOL CHEM, V278, P41282, DOI 10.1074/jbc.M306624200; Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322; DRABER P, 1980, J IMMUNOGENET, V7, P455; Draber P, 2002, MOL IMMUNOL, V38, P1247, DOI 10.1016/S0161-5890(02)00071-8; DRABEROVA L, 1991, EUR J IMMUNOL, V21, P1583, DOI 10.1002/eji.1830210703; Draberova L, 2004, EUR J IMMUNOL, V34, P2209, DOI 10.1002/eji.200322663; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; DRABEROVA L, 1989, EUR J IMMUNOL, V19, P1715, DOI 10.1002/eji.1830190928; Elliott JI, 2006, BLOOD, V108, P1611, DOI 10.1182/blood-2005-11-012328; Elliott JI, 2005, NAT CELL BIOL, V7, P808, DOI 10.1038/ncb1279; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; Finkielstein CV, 2006, J BIOL CHEM, V281, P27317, DOI 10.1074/jbc.M605560200; Fischer K, 2006, BLOOD, V108, P4094, DOI 10.1182/blood-2006-03-011742; Frigeri L, 1999, J IMMUNOL, V162, P2243; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Goth SR, 2001, INFECT IMMUN, V69, P1109, DOI 10.1128/IAI.69.2.1109-1119.2001; HAGGARTY A, 1986, CANCER RES, V46, P300; Halova I, 2002, INT IMMUNOL, V14, P213, DOI 10.1093/intimm/14.2.213; Heneberg P, 2006, EUR J IMMUNOL, V36, P2795, DOI 10.1002/eji.200636159; Hirt UA, 2003, CELL DEATH DIFFER, V10, P1156, DOI 10.1038/sj.cdd.4401286; Karmakar S, 2005, J BIOL CHEM, V280, P28623, DOI 10.1074/jbc.M414140200; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kunzelmann-Marche C, 2002, J BIOL CHEM, V277, P19876, DOI 10.1074/jbc.M200324200; Kunzelmann-Marche C, 2001, J BIOL CHEM, V276, P5134, DOI 10.1074/jbc.M007924200; Malaviya R, 2001, IMMUNOL REV, V179, P16, DOI 10.1034/j.1600-065X.2001.790102.x; Malaviya R, 1999, P NATL ACAD SCI USA, V96, P8110, DOI 10.1073/pnas.96.14.8110; Maniatis T, 1982, MOL CLONING LAB MANU, P61; Martin S, 2000, INT ARCH ALLERGY IMM, V123, P249, DOI 10.1159/000024451; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MASON DW, 1980, BIOCHEM J, V187, P1; MOWER DA, 1994, J IMMUNOL, V152, P4832; Munoz S, 2003, J IMMUNOL, V170, P5590, DOI 10.4049/jimmunol.170.11.5590; ORTEGA E, 1988, EMBO J, V7, P4101, DOI 10.1002/j.1460-2075.1988.tb03304.x; Pomorski T, 2006, CELL MOL LIFE SCI, V63, P2908, DOI 10.1007/s00018-006-6167-7; Pomorski T, 2004, J CELL SCI, V117, P805, DOI 10.1242/jcs.01055; Raff M C, 1971, Transplant Rev, V6, P52; Rege TA, 2006, FASEB J, V20, P1045, DOI 10.1096/fj.05-5460rev; RUDOLPH AK, 1981, EUR J IMMUNOL, V11, P527, DOI 10.1002/eji.1830110617; Saitoh S, 2000, IMMUNITY, V12, P525, DOI 10.1016/S1074-7613(00)80204-6; Scoltock AB, 2000, J BIOL CHEM, V275, P30586, DOI 10.1074/jbc.M004058200; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Surviladze Z, 2001, EUR J IMMUNOL, V31, P1, DOI 10.1002/1521-4141(200101)31:1<1::AID-IMMU1>3.0.CO;2-W; THON IL, 1967, ACTA PHYSIOL SCAND, V71, P303, DOI 10.1111/j.1748-1716.1967.tb03737.x; Tolarova H, 2004, EUR J IMMUNOL, V34, P1627, DOI 10.1002/eji.200424991; van den Eijnde SM, 1998, APOPTOSIS, V3, P9, DOI 10.1023/A:1009650917818; van den Eijnde SM, 2001, J CELL SCI, V114, P3631; Virji M, 2000, MOL MICROBIOL, V36, P784, DOI 10.1046/j.1365-2958.2000.01885.x; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; Volna P, 2004, J EXP MED, V200, P1001, DOI 10.1084/jem.20041213; WILLIAMSON P, 1983, BIOCHIM BIOPHYS ACTA, V732, P387, DOI 10.1016/0005-2736(83)90055-X; Williamson P, 2002, BBA-MOL CELL BIOL L, V1585, P53, DOI 10.1016/S1388-1981(02)00324-4; Wilson BS, 2004, MOL BIOL CELL, V15, P2580, DOI 10.1091/mbc.E03-08-0574; Windmiller DA, 2003, J BIOL CHEM, V278, P11874, DOI 10.1074/jbc.M211787200; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zwaal RFA, 2005, CELL MOL LIFE SCI, V62, P971, DOI 10.1007/s00018-005-4527-3	70	59	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10487	10497		10.1074/jbc.M611090200	http://dx.doi.org/10.1074/jbc.M611090200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17284440	hybrid			2022-12-25	WOS:000245941000041
J	Andersson, CX; Sopasakis, VR; Wallerstedt, E; Smith, U				Andersson, Christian X.; Sopasakis, Victoria Rotter; Wallerstedt, Emelie; Smith, Ulf			Insulin antagonizes interleukin-6 signaling and is anti-inflammatory in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; STAT3 SERINE PHOSPHORYLATION; ACTIVATED PROTEIN-KINASES; TYROSINE PHOSPHORYLATION; ADIPOSE-TISSUE; PPAR-GAMMA; FAT-CELLS; C-DELTA; RESISTANCE; INHIBITION	Adipose tissue secretes different adipokines, including interleukin-6 (IL-6), that have been implicated in the insulin resistance and inflammatory state characterizing obesity. We examined the putative cross-talk between insulin and IL-6 in adipose cells and found that insulin exerts an inhibitory effect on the IL-6 signaling pathway by altering the post-translational modifications of the signal transducer and activator of transcription 3 (STAT3). Insulin reduces the tyrosine phosphorylation and increases the serine phosphorylation of STAT3, thereby reducing its nuclear localization and transcriptional activity. Signaling through the MEK/MAPK pathway plays an important role as treatment with the MEK inhibitor PD98059 reduces the effects of insulin on IL-6 signaling. We also show that the protein tyrosine phosphatase SHP2 is activated upon insulin signaling and is required for the dephosphorylation of STAT3 and that insulin exerts a synergistic effect with IL-6 on suppressor of cytokine signaling 3 expression. As a consequence, the IL-6-induced expression of the inflammatory markers serum amyloid A 3 and haptoglobin are significantly decreased in celts incubated with both IL-6 and insulin. Thus, insulin exerts an important anti-inflammatory effect in adipose cells by impairing the IL-6 signal at several levels.	Univ Gothenburg, Lundberg Lab Diabet Res, Dept Mol & Clin Med, Sahlgrenska Acad, SE-41345 Gothenburg, Sweden	University of Gothenburg	Smith, U (corresponding author), Univ Gothenburg, Lundberg Lab Diabet Res, Dept Mol & Clin Med, Sahlgrenska Acad, SE-41345 Gothenburg, Sweden.	ulf.smith@medic.gu.se						Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; Ceresa BP, 1996, J BIOL CHEM, V271, P12121, DOI 10.1074/jbc.271.21.12121; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Dandona P, 2001, J CLIN ENDOCR METAB, V86, P3257, DOI 10.1210/jc.86.7.3257; do Nascimento CO, 2004, BIOCHEM BIOPH RES CO, V313, P702, DOI 10.1016/j.bbrc.2003.12.008; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; FLIER JS, 1987, SCIENCE, V237, P405, DOI 10.1126/science.3299706; Gunaje JJ, 2001, BIOCHEM BIOPH RES CO, V288, P252, DOI 10.1006/bbrc.2001.5759; Hammarstedt A, 2005, PROSTAG LEUKOTR ESS, V73, P65, DOI 10.1016/j.plefa.2005.04.008; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Krasilnikov M, 2003, ONCOGENE, V22, P4092, DOI 10.1038/sj.onc.1206598; Lehmann U, 2003, J BIOL CHEM, V278, P661, DOI 10.1074/jbc.M210552200; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Milocco LH, 1999, MOL CELL BIOL, V19, P2913; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Ng J, 1997, J BIOL CHEM, V272, P24542, DOI 10.1074/jbc.272.39.24542; Pajvani UB, 2005, NAT MED, V11, P797, DOI 10.1038/nm1262; RAMADORI G, 1988, EUR J IMMUNOL, V18, P1259, DOI 10.1002/eji.1830180817; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; Rotter V, 2003, J BIOL CHEM, V278, P45777, DOI 10.1074/jbc.M301977200; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; Shi H, 2004, J BIOL CHEM, V279, P34733, DOI 10.1074/jbc.M403886200; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Smith U, 1999, ANN NY ACAD SCI, V892, P119, DOI 10.1111/j.1749-6632.1999.tb07790.x; Sopasakis VR, 2004, OBES RES, V12, P454, DOI 10.1038/oby.2004.51; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Terstegen L, 2000, J BIOL CHEM, V275, P18810, DOI 10.1074/jbc.M904148199; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Ueki K, 2004, MOL CELL BIOL, V24, P5434, DOI 10.1128/MCB.24.12.5434-5446.2004; Wang CZ, 2006, MOL BIOL CELL, V17, P2839, DOI 10.1091/mbc.E05-11-1068; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Wu TR, 2002, J BIOL CHEM, V277, P47572, DOI 10.1074/jbc.M207536200; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7	38	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9430	9435		10.1074/jbc.M609980200	http://dx.doi.org/10.1074/jbc.M609980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17267401	hybrid			2022-12-25	WOS:000245421700015
J	Thuswaldner, S; Lagerstedt, JO; Rojas-Stutz, M; Bouhidel, K; Der, C; Leborgne-Castel, N; Mishra, A; Marty, F; Schoefs, B; Adamska, I; Persson, BL; Spetea, C				Thuswaldner, Sophie; Lagerstedt, Jens O.; Rojas-Stuetz, Marc; Bouhidel, Karim; Der, Christophe; Leborgne-Castel, Nathalie; Mishra, Arti; Marty, Francis; Schoefs, Benoit; Adamska, Iwona; Persson, Bengt L.; Spetea, Cornelia			Identification, expression, and functional analyses of a thylakoid ATP/ADP carrier from Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE TRANSPORT-SYSTEM; PHOTOSYSTEM-II; PROTEIN; MITOCHONDRIAL; MEMBRANES; ATP; LOCALIZATION; PROVIDES; PATHWAY; BINDING	In plants the chloroplast thylakoid membrane is the site of light-dependent photosynthetic reactions coupled to ATP synthesis. The ability of the plant cell to build and alter this membrane system is essential for efficient photosynthesis. A nucleotide translocator homologous to the bovine mitochondrial ADP/ATP carrier (AAC) was previously found in spinach thylakoids. Here we have identified and characterized a thylakoid ATP/ADP carrier (TAAC) from Arabidopsis. (i) Sequence homology with the bovine AAC and the prediction of chloroplast transit peptides indicated a putative carrier encoded by the At5g01500 gene, as a TAAC. (ii) Transiently expressed TAAC-green fluorescent protein fusion construct was targeted to the chloroplast. Western blotting using a peptide-specific antibody together with immunogold electron microscopy revealed a major location of TAAC in the thylakoid membrane. Previous proteomic analyses identified this protein in chloroplast envelope preparations. (iii) Recombinant TAAC protein specifically imports ATP in exchange for ADP across the cytoplasmic membrane of Escherichia coli. Studies on isolated thylakoids from Arabidopsis confirmed these observations. (iv) The lack of TAAC in an Arabidopsis T-DNA insertion mutant caused a 30-40% reduction in the thylakoid ATP transport and metabolism. (v) TAAC is readily expressed in dark-grown Arabidopsis seedlings, and its level remains stable throughout the greening process. Its expression is highest in developing green tissues and in leaves undergoing senescence or abiotic stress. We propose that the TAAC protein supplies ATP for energy-dependent reactions during thylakoid biogenesis and turnover in plants.	Linkoping Univ, Div Cell Biol, SE-58185 Linkoping, Sweden; Linkoping Univ, Dept Phys Chem & Biol, SE-58185 Linkoping, Sweden; Kalmar Univ, Dept Chem & Biomed Sci, SE-39182 Kalmar, Sweden; Univ Konstanz, Dept Physiol & Plant Biochem, D-78457 Constance, Germany; Univ Bourgogne, UMR Plante Microbe Environm 5184, CNRS, INRA 1088, F-21078 Dijon, France	Linkoping University; Linkoping University; Linnaeus University; University of Kalmar; University of Konstanz; Centre National de la Recherche Scientifique (CNRS); INRAE; Universite de Bourgogne	Spetea, C (corresponding author), Linkoping Univ, Div Cell Biol, SE-58185 Linkoping, Sweden.	cornelia.spetea@ibk.liu.se	Schoefs, Benoit/AAE-4010-2019; Wiklund, Cornelia Spetea/S-3635-2019; Marty, Francis/L-2638-2013; Lagerstedt, Jens/AAF-9567-2021	Schoefs, Benoit/0000-0002-7804-8130; Mishra, Arti/0000-0002-5214-0676; Lagerstedt, Jens/0000-0002-4313-2666; Leborgne-Castel, Nathalie/0000-0001-8756-4463				ABBOTT MS, 1984, J BIOL CHEM, V259, P2271; Abdel-Ghany SE, 2005, PLANT CELL, V17, P1233, DOI 10.1105/tpc.104.030452; ANDERSON JM, 1982, TRENDS BIOCHEM SCI, V7, P288, DOI 10.1016/0968-0004(82)90014-7; BERTRAND M, 1988, Z NATURFORSCH C, V43, P443; Borisjuk L, 2004, PLANT BIOLOGY, V6, P375, DOI 10.1055/s-2004-817908; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Che FS, 2000, PLANT PHYSIOL, V124, P59, DOI 10.1104/pp.124.1.59; Ephritikhine G, 2004, PLANT PHYSIOL BIOCH, V42, P943, DOI 10.1016/j.plaphy.2004.11.004; Eshaghi S, 1999, FEBS LETT, V446, P23, DOI 10.1016/S0014-5793(99)00149-0; Ettinger WF, 1999, PLANT PHYSIOL, V119, P1379, DOI 10.1104/pp.119.4.1379; Ferro M, 2003, MOL CELL PROTEOMICS, V2, P325, DOI 10.1074/mcp.M300030-MCP200; Gao H, 2006, P NATL ACAD SCI USA, V103, P6759, DOI 10.1073/pnas.0507287103; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Haferkamp I, 2002, EUR J BIOCHEM, V269, P3172, DOI 10.1046/j.1432-1033.2002.02991.x; Heazlewood JL, 2004, PLANT CELL, V16, P241, DOI 10.1105/tpc.016055; Hinnah SC, 1998, EUR J BIOCHEM, V253, P606, DOI 10.1046/j.1432-1327.1998.2530606.x; Inoue K, 2005, J CELL BIOL, V171, P425, DOI 10.1083/jcb.200506171; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kleffmann T, 2004, CURR BIOL, V14, P354, DOI 10.1016/j.cub.2004.02.039; Klingenberg M, 2006, BBA-BIOENERGETICS, V1757, P1229, DOI 10.1016/j.bbabio.2006.04.010; Kunji ERS, 2004, FEBS LETT, V564, P239, DOI 10.1016/S0014-5793(04)00242-X; Lagerstedt JO, 2004, FEBS LETT, V578, P262, DOI 10.1016/j.febslet.2004.11.012; Laloi M, 1999, CELL MOL LIFE SCI, V56, P918, DOI 10.1007/s000180050484; Lundin B, 2007, BBA-BIOENERGETICS, V1767, P500, DOI 10.1016/j.bbabio.2006.10.009; MAGNUSSON RP, 1976, J BIOL CHEM, V251, P7417; McCarty RE, 2005, J BIOENERG BIOMEMBR, V37, P289, DOI 10.1007/s10863-005-8640-7; Meurer J, 1998, EMBO J, V17, P5286, DOI 10.1093/emboj/17.18.5286; Millar AH, 2003, PLANT PHYSIOL, V131, P443, DOI 10.1104/pp.009985; Noren H, 2004, PHYSIOL PLANTARUM, V121, P343, DOI 10.1111/j.0031-9317.2004.00350.x; Nury H, 2006, ANNU REV BIOCHEM, V75, P713, DOI 10.1146/annurev.biochem.75.103004.142747; Palmieri L, 2006, PLANT PHYSIOL, V142, P855, DOI 10.1104/pp.106.086975; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Pottosin II, 1996, J MEMBRANE BIOL, V152, P223, DOI 10.1007/s002329900100; Rinalducci S, 2006, J PROTEOME RES, V5, P973, DOI 10.1021/pr050476n; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Shingles R, 2004, PLANT PHYSIOL, V135, P145, DOI 10.1104/pp.103.037895; SMITH DJ, 1976, P NATL ACAD SCI USA, V73, P4314, DOI 10.1073/pnas.73.12.4314; Spetea C, 1999, P NATL ACAD SCI USA, V96, P6547, DOI 10.1073/pnas.96.11.6547; Spetea C, 2004, P NATL ACAD SCI USA, V101, P1409, DOI 10.1073/pnas.0308164100; Sun Q, 2004, PLANT PHYSIOL, V135, P723, DOI 10.1104/pp.104.040717; Tjaden J, 1998, J BIOL CHEM, V273, P9630, DOI 10.1074/jbc.273.16.9630; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; VAMBUTAS V, 1994, ARCH BIOCHEM BIOPHYS, V312, P401, DOI 10.1006/abbi.1994.1325; van Wijk KJ, 2004, PLANT PHYSIOL BIOCH, V42, P963, DOI 10.1016/j.plaphy.2004.10.015; van Wijk KJ, 2001, ADV PHOTOSYNTH, V11, P153; Vothknecht UC, 2001, BBA-MOL CELL RES, V1541, P91, DOI 10.1016/S0167-4889(01)00153-7; Wagner V, 2006, EUKARYOT CELL, V5, P457, DOI 10.1128/EC.5.3.457-468.2006; Weber APM, 2005, ANNU REV PLANT BIOL, V56, P133, DOI 10.1146/annurev.arplant.56.032604.144228; Winkler HH, 1999, TRENDS BIOCHEM SCI, V24, P64, DOI 10.1016/S0968-0004(98)01334-6; WINKLER HH, 1968, J BIOL CHEM, V243, P20; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	53	63	71	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8848	8859		10.1074/jbc.M609130200	http://dx.doi.org/10.1074/jbc.M609130200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17261580	hybrid, Green Published			2022-12-25	WOS:000245780300032
J	Yang, YY; Liu, Y; Dong, ZZ; Xu, JK; Peng, H; Liu, ZQ; Zhang, JT				Yang, Youyun; Liu, Yang; Dong, Zizheng; Xu, Junkang; Peng, Hui; Liu, Zhaoqian; Zhang, Jian-Ting			Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; P-GLYCOPROTEIN; LEUKOTRIENE C-4; ELECTRON-MICROSCOPY; PLASMA-MEMBRANE; EXPORT PUMP; MRP1 ABCC1; TRANSPORT; GLUTATHIONE; TOPOLOGY	Overexpression of some ATP-binding cassette (ABC) membrane transporters such as ABCB1/P-glycoprotein/MDR1 and ABCC1/MRP1 causes multidrug resistance in cancer chemotherapy. It has been thought that half-ABC transporters with one nucleotide-binding domain and one membrane-spanning domain (MSD) likely work as dimers, whereas full-length transporters with two nucleotide-binding domains and two or three MSDs function as monomers. In this study, we examined the oligomeric status of the human full-length ABC transporter ABCC1/MRP1 using several biochemical approaches. We found 1) that it is a homodimer, 2) that the dimerization domain is located in the amino-terminal MSD0L0 (where L0 is loop 0) region, and 3) that MSD0L0 has a dominant-negative function when coexpressed with wild-type ABCC1/MRP1. These findings suggest that ABCC1/MRP1 may exist and function as a dimer and that MSD0L0 likely plays some structural and regulatory functions. It is also tempting to propose that the MSD0L0-mediated dimerization may be targeted for therapeutic development to sensitize ABCC1/MRP1-mediated drug resistance in cancer chemotherapy.	Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Ctr Canc, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Canc Inst, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Zhang, JT (corresponding author), Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Ctr Canc, 1044 W Walnut St,R4-166, Indianapolis, IN 46202 USA.	jianzhan@iupui.edu	Zhang, Jian-Ting/L-8334-2015	Liu, Zhaoqian/0000-0003-0428-3928	NATIONAL CANCER INSTITUTE [R01CA094961, R01CA120221] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER; NCI NIH HHS [CA94961, CA120221] Funding Source: Medline; NHLBI NIH HHS [T32 HL07910] Funding Source: Medline; NIDDK NIH HHS [T32 DK07519] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 2000, J CELL SCI, V113, P4451; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; Chen Q, 2002, BIOCHEMISTRY-US, V41, P9052, DOI 10.1021/bi025634s; Chen Q, 2006, J BIOL CHEM, V281, P31152, DOI 10.1074/jbc.M603529200; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Dong ZZ, 2003, MOL BIOL CELL, V14, P3942, DOI 10.1091/mbc.E02-12-0784; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; GEORGES E, 1993, J BIOL CHEM, V268, P1792; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Han B., 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P31, DOI 10.2174/1568011043482205; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hong M, 2005, J BIOL CHEM, V280, P32285, DOI 10.1074/jbc.M501447200; Ito K, 2003, BBA-BIOMEMBRANES, V1615, P103, DOI 10.1016/S0005-2736(03)00228-1; Jedlitschky G, 1996, CANCER RES, V56, P988; Jette L, 1997, BIOCHEMISTRY-US, V36, P13929, DOI 10.1021/bi970737+; Karwatsky J, 2003, BIOCHEMISTRY-US, V42, P3286, DOI 10.1021/bi0268807; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Kedei N, 2001, J BIOL CHEM, V276, P28613, DOI 10.1074/jbc.M103272200; Krishnamurthy P, 2006, ANNU REV PHARMACOL, V46, P381, DOI 10.1146/annurev.pharmtox.46.120604.141238; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012; Leslie EM, 2003, BIOCHEMISTRY-US, V42, P5214, DOI 10.1021/bi027076n; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Loo TW, 1996, J BIOL CHEM, V271, P27488, DOI 10.1074/jbc.271.44.27488; Mitic LL, 2003, PROTEIN SCI, V12, P218, DOI 10.1110/ps.0233903; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NAITO M, 1992, BIOCHEM BIOPH RES CO, V185, P284, DOI 10.1016/S0006-291X(05)80988-X; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Ramjeesingh M, 2003, BIOCHEM J, V374, P793, DOI 10.1042/BJ20030683; Ramjeesingh M, 2001, BIOCHEMISTRY-US, V40, P10700, DOI 10.1021/bi0108195; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; Schillers H, 2004, CELL PHYSIOL BIOCHEM, V14, P1, DOI 10.1159/000076921; Soszynski M, 1998, ARCH BIOCHEM BIOPHYS, V354, P311, DOI 10.1006/abbi.1998.0687; Taylor JC, 2001, J BIOL CHEM, V276, P36075, DOI 10.1074/jbc.C100345200; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Westlake CJ, 2005, MOL BIOL CELL, V16, P2483, DOI 10.1091/mbc.E04-12-1113; Xu JK, 2004, J BIOL CHEM, V279, P19781, DOI 10.1074/jbc.M310785200; Yang YY, 2002, J BIOL CHEM, V277, P44268, DOI 10.1074/jbc.M207003200; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886; Zerhusen B, 1999, J BIOL CHEM, V274, P7627, DOI 10.1074/jbc.274.12.7627; Zhang JT, 2000, BIOCHEM J, V348, P597, DOI 10.1042/0264-6021:3480597	47	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8821	8830		10.1074/jbc.M700152200	http://dx.doi.org/10.1074/jbc.M700152200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17264072	hybrid			2022-12-25	WOS:000245780300029
J	Binladen, J; Gilbert, MTP; Bollback, JP; Panitz, F; Bendixen, C; Nielsen, R; Willerslev, E				Binladen, Jonas; Gilbert, M. Thomas P.; Bollback, Jonathan P.; Panitz, Frank; Bendixen, Christian; Nielsen, Rasmus; Willerslev, Eske			The Use of Coded PCR Primers Enables High-Throughput Sequencing of Multiple Homolog Amplification Products by 454 Parallel Sequencing	PLOS ONE			English	Article								Background. The invention of the Genome Sequence 20 (TM) DNA Sequencing System (454 parallel sequencing platform) has enabled the rapid and high-volume production of sequence data. Until now, however, individual emulsion PCR (emPCR) reactions and subsequent sequencing runs have been unable to combine template DNA from multiple individuals, as homologous sequences cannot be subsequently assigned to their original sources. Methodology. We use conventional PCR with 5'-nucleotide tagged primers to generate homologous DNA amplification products from multiple specimens, followed by sequencing through the high-throughput Genome Sequence 20 (TM) DNA Sequencing System (GS20, Roche/454 Life Sciences). Each DNA sequence is subsequently traced back to its individual source through 5'tag-analysis. Conclusions. We demonstrate that this new approach enables the assignment of virtually all the generated DNA sequences to the correct source once sequencing anomalies are accounted for (miss-assignment rate <0.4%). Therefore, the method enables accurate sequencing and assignment of homologous DNA sequences from multiple sources in single high-throughput GS20 run. We observe a bias in the distribution of the differently tagged primers that is dependent on the 5' nucleotide of the tag. In particular, primers 5' labelled with a cytosine are heavily overrepresented among the final sequences, while those 5' labelled with a thymine are strongly underrepresented. A weaker bias also exists with regards to the distribution of the sequences as sorted by the second nucleotide of the dinucleotide tags. As the results are based on a single GS20 run, the general applicability of the approach requires confirmation. However, our experiments demonstrate that 5' primer tagging is a useful method in which the sequencing power of the GS20 can be applied to PCR-based assays of multiple homologous PCR products. The new approach will be of value to a broad range of research areas, such as those of comparative genomics, complete mitochondrial analyses, population genetics, and phylogenetics.	[Binladen, Jonas; Gilbert, M. Thomas P.; Willerslev, Eske] Univ Copenhagen, Inst Biol, Ctr Ancient Genet, Copenhagen, Denmark; [Bollback, Jonathan P.; Nielsen, Rasmus] Univ Copenhagen, Ctr Bioinformat, Copenhagen, Denmark; [Panitz, Frank; Bendixen, Christian] Res Ctr Foulum, Danish Inst Agr Sci, Dept Genet & Biotechnol, Tjele, Denmark	University of Copenhagen; University of Copenhagen; Aarhus University	Willerslev, E (corresponding author), Univ Copenhagen, Inst Biol, Ctr Ancient Genet, Copenhagen, Denmark.	ewillerslev@bi.ku.dk	Willerslev, Eske/A-9619-2011; Gilbert, Marcus TP/A-8936-2013; Panitz, Frank/A-3281-2017; Willerslev, Eske/AAA-5686-2019; Nielsen, Rasmus/D-4405-2009	Willerslev, Eske/0000-0002-7081-6748; Gilbert, Marcus TP/0000-0002-5805-7195; Panitz, Frank/0000-0002-6909-5162; Nielsen, Rasmus/0000-0003-0513-6591	Wellcome Trust, UK; Carlsberg Foundation, DK; National Science Foundation, DK; Marie Curie Actions [FP6-MEIF-CT-2005-025002]; Danish FSS	Wellcome Trust, UK(Wellcome Trust); Carlsberg Foundation, DK(Carlsberg Foundation); National Science Foundation, DK(National Science Foundation (NSF)); Marie Curie Actions(European Commission); Danish FSS	JB and EW were supported by the Wellcome Trust, UK, the Carlsberg Foundation, DK, and the National Science Foundation, DK. MTPG acknowledges the Marie Curie Actions FP6-MEIF-CT-2005-025002 'FORMAPLEX' grant for funding his research. JPB and RN were funded by the Danish FSS and the National Science Foundation, DK. None of the sponsors or funders have had any influence on the data or manuscript presented here.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; GILBERT MTP, NUCL ACIDS IN PRESS; Hofreuter D, 2006, INFECT IMMUN, V74, P4694, DOI 10.1128/IAI.00210-06; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Taylor PG, 1996, MOL BIOL EVOL, V13, P283, DOI 10.1093/oxfordjournals.molbev.a025566; Thomas RK, 2006, NAT MED, V12, P852, DOI 10.1038/nm1437; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	7	376	456	1	104	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e197	10.1371/journal.pone.0000197	http://dx.doi.org/10.1371/journal.pone.0000197			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299583	gold, Green Submitted, Green Published			2022-12-25	WOS:000207444400002
J	Meng, LH; Kohn, KW; Pommier, Y				Meng, L-H; Kohn, K. W.; Pommier, Y.			Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21(WAF1/CIP1) in response to the novel anticancer agent, aminoflone (NSC 686288)	ONCOGENE			English	Article						p53; proteasome; Akt; apoptosis; histone H2AX; DNA damage	ATM-DEPENDENT PHOSPHORYLATION; MOLECULAR INTERACTION MAP; DNA-DAMAGE; AMINOFLAVONE NSC-686288; ADENOCARCINOMA CELLS; IONIZING-RADIATION; TOPOISOMERASE-I; P53 ACTIVATION; CANCER CELLS; KINASE	Aminoflavone (AF, NSC 686288) is beginning clinical trials. It induces replication-mediated histone H2AX phosphorylation, DNA-protein crosslinks and activates p53. Here, we studied p21(CIP1/WAF1) and Mdm2 responses to AF. Although p53 stabilization and phosphorylation at serine 15 increased with dose and time of exposure, Mdm2 and p21(CIP1/WAF1) protein levels displayed a biphasic response, as they accumulated at submicromolar doses and then decreased with increasing AF. As both Mdm2 and p21(CIP1/WAF1) mRNA levels increased with AF concentration without reduction at higher concentrations, we measured the half- lives of Mdm2 and p21(CIP1/WAF1) proteins. Mdm2 and p21(CIP1/WAF1) half-lives were shortened with increasing AF concentrations. Proteasomal degradation appears responsible for the decrease of both Mdm2 and p21(CIP1/WAF1), as MG-132 prevented their degradation and revealed AF-induced Mdm2 polyubiquitylation. AF also induced protein kinase B (Akt) activation, which was reduced with increasing AF concentrations. Suppression of Akt by small interfering RNA was associated with downregulation of Mdm2 and p21(CIP1/WAF1) and with enhanced apoptosis. These results suggest that the cellular responses to AF are determined at least in part by Mdm2 and p21(CIP1/WAF1) protein levels, as well as by Akt activity, leading either to cell cycle arrest when Mdm2 and p21(CIP1/WAF1) are elevated, or to apoptosis when Mdm2 and p21(CIP1/WAF1) are degraded by the proteasome and Akt insufficiently activated to protect against apoptosis.	NCI, Canc Res Ctr, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pommier, Y (corresponding author), NCI, Canc Res Ctr, Mol Pharmacol Lab, NIH, 37 Convent Dr,Bldg 37,Room 5068, Bethesda, MD 20892 USA.	pommier@nih.gov	meng, linghua/Y-8110-2019		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC006150, ZIABC006150] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN C, 2006, J PHARM EXP THER; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Fujiwara Y, 2006, BIOCHEM BIOPH RES CO, V340, P560, DOI 10.1016/j.bbrc.2005.12.039; Furuta T, 2006, ONCOGENE, V25, P2839, DOI 10.1038/sj.onc.1209313; Hayward RL, 2003, CLIN CANCER RES, V9, P2856; Jin YT, 2003, EMBO J, V22, P6365, DOI 10.1093/emboj/cdg600; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim Y, 2002, IN VITRO CELL DEV-PL, V38, P1, DOI 10.1079/IVP2001243; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Kohn KW, 2005, BIOCHEM BIOPH RES CO, V331, P816, DOI 10.1016/j.bbrc.2005.03.186; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; Li YH, 2002, J INFRARED MILLIM W, V21, P1; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Meng LH, 2005, CANCER RES, V65, P5337, DOI 10.1158/0008-5472.CAN-05-0003; Meng LH, 2004, CANCER RES, V64, P9086, DOI 10.1158/0008-5472.CAN-04-0313; Meng LH, 2006, CANCER RES, V66, P9656, DOI 10.1158/0008-5472.CAN-06-0796; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Milne D, 2004, FEBS LETT, V577, P270, DOI 10.1016/j.febslet.2004.09.081; Monks A, 1997, ANTI-CANCER DRUG DES, V12, P533; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; Pommier Y, 2005, CURR PHARM DESIGN, V11, P2855, DOI 10.2174/1381612054546716; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shieh SY, 2000, GENE DEV, V14, P289; Sordet Olivier, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P271, DOI 10.2174/1568011033482378; Stommel JM, 2004, EMBO J, V23, P1547, DOI 10.1038/sj.emboj.7600145; Takimoto R, 2001, P NATL ACAD SCI USA, V98, P781, DOI 10.1073/pnas.98.3.781; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yoeli-Lerner M, 2006, CELL CYCLE, V5, P603, DOI 10.4161/cc.5.6.2561; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200; Zhao YQ, 2004, J CELL BIOCHEM, V91, P621, DOI 10.1002/jcb.10751	40	28	29	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4806	4816		10.1038/sj.onc.1210283	http://dx.doi.org/10.1038/sj.onc.1210283			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297446				2022-12-25	WOS:000248170400005
J	Luo, F; Brooks, DG; Ye, H; Hamoudi, R; Poulogiannis, G; Patek, CE; Winton, DJ; Arends, MJ				Luo, F.; Brooks, D. G.; Ye, H.; Hamoudi, R.; Poulogiannis, G.; Patek, C. E.; Winton, D. J.; Arends, M. J.			Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice	ONCOGENE			English	Article						K-ras; cre-LoxP; intestine; tumour; mouse	COLORECTAL-CANCER; MOUSE MODELS; MISMATCH REPAIR; GENE-EXPRESSION; BETA-CATENIN; ACTIVATION; MUTATIONS; APOPTOSIS; ONCOGENE; TUMORS	K- ras mutation occurs in 40 - 50% of human colorectal adenomas and carcinomas, but its contribution to intestinal tumorigenesis in vivo is K-ras mutation occurs in 40-50% of human colorectal adenomas and carcinomas, but its contribution to intestinal tumorigenesis in vivo is unclear. We developed K-ras(V12) transgenic mice that were crossed with Ah-Cre mice to generate K-ras(V12)/Cre mice, which showed beta-naphthofla. avone- (i)nduction of Cre- mediated LoxP recombination that activated intestinal expression of K-ras(V12) 4A and 4B transcripts and proteins. Only very occasional intestinal adenomas were observed in beta-naphtho. flavonetreated K-ras(V12)/Cre mice aged up to 2 years, suggesting that mutated K-ras expression alone does not signifi. cantly initiate intestinal tumourigenesis. To investigate the effects of mutated K-ras on DNA mismatch repair (MMR)-deficient intestinal tumour formation, these mice were crossed with Msh2(-/-) mice to generate K-ras(V12)/ Cre/ Msh2(-/-) offspring. After beta-naphtho. flavone treatment, K- ras(V12)/ Cre/ Msh2(-/-) mice showed reduced average life-span of 17.3 +/- 5.0 weeks from 26.9 +/- 6.8 (control Msh2(-/-) mice) ( P < 0.01). They demonstrated increased adenomas in the small intestine from 1.41 ( Msh2(-/-) controls) to 7.75 per mouse (increased. fivefold, P < 0.01). In the large intestine, very few adenomas were found in Msh2(-/-) 2 mice ( 0.13 per mouse) whereas K- ras(V12)/Cre/ Msh2(-/-) mice produced 2.70 ade nomas per mouse (increased 20-fold, P < 0.01). Over 80% adenomas from K- ras(V12)/Cre/Msh2(-/-) mice showed transgene recombination with expression of K-ras(V12) 4A and 4B transcripts and proteins. Sequencing of endogenous murine K-ras showed mutations in two out of 10 tumours examined from Msh2(-/-) mice, but no mutations in 17 tumours from K-ras(V12)/ Cre/ Msh2(-/-) mice. Expression of K-ras(V12) in tumours caused activation of the mitogen-activated protein kinase and Akt/protein kinase B signaling pathways, demonstrated by phosphorylation of p44MAPK, Akt and GSK3 beta, as well as transcriptional upregulation of Pem, Tcl-1 and Trap1a genes (known targets of K-ras(V12) expression in stem cells). Thus, mutated K-ras cooperates synergistically with MMR de. ficiency to accelerate intestinal tumorigenesis, particularly in the large intestine.	Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2Q, England; Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Lab, Mol Med Ctr, Edinburgh, Midlothian, Scotland; Univ Cambridge, Cambridge Inst Med Res, Dept Oncol, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Edinburgh; University of Cambridge	Arends, MJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Box 235,Hills Rd, Cambridge CB2 2Q, England.	mja40@cam.ac.uk	Luo, Feijun/AAF-5708-2019; Luo, Feijun/B-1424-2012; Poulogiannis, George/AAY-2210-2021; Poulogiannis, George/AAE-1966-2019	Luo, Feijun/0000-0001-7489-544X; Poulogiannis, George/0000-0002-0529-8614; Luo, Feijun/0000-0003-1951-4071; Hamoudi, Rifat/0000-0002-1402-0868	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Al-Aynati MM, 2004, CLIN CANCER RES, V10, P1235, DOI 10.1158/1078-0432.CCR-03-0087; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; ARENDS MJ, 1994, AM J PATHOL, V144, P1045; ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; ARENDS MJ, 2004, KEY ADV EFFECTIVE MA, P25; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Brooks DG, 2001, ONCOGENE, V20, P2144, DOI 10.1038/sj.onc.1204309; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Caulin C, 2004, CANCER RES, V64, P5054, DOI 10.1158/0008-5472.CAN-04-1488; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; Frayling IM, 2005, MOL DIAGNOSTICS CLIN, P375; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; James RM, 2003, MOL CANCER RES, V1, P820; Janssen KP, 2005, BBA-REV CANCER, V1756, P145, DOI 10.1016/j.bbcan.2005.07.004; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; LUO F, 2007, UNPUB BMC GENOMICS; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; Morris RG, 1996, J PATHOL, V180, P357; Otori K, 1997, GUT, V40, P660, DOI 10.1136/gut.40.5.660; Plowman SJ, 2006, J EXP CLIN CANC RES, V25, P259; Plowman SJ, 2006, EXP CELL RES, V312, P16, DOI 10.1016/j.yexcr.2005.10.004; Plowman SJ, 2003, MOL CELL BIOL, V23, P9245, DOI 10.1128/MCB.23.24.9245-9250.2003; Qian JY, 2005, CANCER RES, V65, P5045, DOI 10.1158/0008-5472.CAN-04-3208; Reitmair AH, 1996, CANCER RES, V56, P3842; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Sansom OJ, 2006, P NATL ACAD SCI USA, V103, P14122, DOI 10.1073/pnas.0604130103; Shivapurkar N, 1997, CANCER LETT, V115, P39, DOI 10.1016/S0304-3835(97)04709-5; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; Toft NJ, 1998, J PATHOL, V185, P123; Toft NJ, 2002, ONCOGENE, V21, P6299, DOI 10.1038/sj.onc.1205727; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Yamada S, 2005, INT J CANCER, V113, P1015, DOI 10.1002/ijc.20666; Zhu CQ, 2004, CLIN CANCER RES, V10, P1984, DOI 10.1158/1078-0432.CCR-03-0470	44	31	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4415	4427		10.1038/sj.onc.1210231	http://dx.doi.org/10.1038/sj.onc.1210231			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297472				2022-12-25	WOS:000247620000009
J	Takayama, K; Kaneshiro, K; Tsutsumi, S; Horie-Inoue, K; Ikeda, K; Urano, T; Ijichi, N; Ouchi, Y; Shirahige, K; Aburatani, H; Inoue, S				Takayama, K.; Kaneshiro, K.; Tsutsumi, S.; Horie-Inoue, K.; Ikeda, K.; Urano, T.; Ijichi, N.; Ouchi, Y.; Shirahige, K.; Aburatani, H.; Inoue, S.			Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis	ONCOGENE			English	Article						androgen receptor; androgen response element; chromatin immunoprecipitation; prostate cancer; UGT1A	FUNCTIONAL-ANALYSIS; C-MET; RECEPTOR; PROTEIN; EXPRESSION; CARCINOMA; ELEMENTS; LOCUS; TES; SPECIFICITY	The androgen receptor (AR) plays a key role as a transcriptional factor in prostate development and carcinogenesis. Identification of androgen-regulated genes is essential to elucidate the AR pathophysiology in prostate cancer. Here, we identifi. ed androgen target genes that are directly regulated by AR in LNCaP cells, by combining chromatin immunoprecipitation (ChIP) with tiling microarrays (ChIP-chip). ChIP-enriched or control DNAs from the cells treated with R1881 were hybridized with the ENCODE array, in which a set of regions representing approximately 1% of the whole genome. We chose 10 bona fide AR-binding sites (ARBSs) (P < 1e-5) and validated their signifi. cant AR recruitment ligand dependently. Eight upregulated genes by R1881 were identifi. ed in the vicinity of the ARBSs. Among the upregulated genes, we focused on UGT1A and CDH2 as AR target genes, because the ARBSs close to these genes (in UGT1A distal promoter and CDH2 intron 1) were most significantly associated with acetylated histone H3/H4, RNA polymerase II and p160 family co-activators. Luciferase reporter constructs including those two ARBSs exhibited ligand-dependent transcriptional regulator/enhancer activities. The present study would be powerful to extend our knowledge of the diversity of androgen genetic network and steroid action in prostate cancer cells.	Univ Tokyo, Grad Sch Sci, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Tokyo, Japan; Saitama Med Univ, Res Ctr Genom Med, Div Gene Regulat & Signal Transduct, Saitama, Japan; Tokyo Inst Technol, Ctr Biol Res & Informat, Div Gene Res, Tokyo 152, Japan; Japan Sci & Technol Agcy, CREST, Tokyo, Japan	University of Tokyo; University of Tokyo; Saitama Medical University; Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Horie-Inoue, K (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Geriatr Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	INOUE-GER@h.u-tokyo.ac.jp	Takayama, Kenichi/AAK-9238-2020; Urano, Tomohiko/AFS-9574-2022					Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen SJ, 2005, J BIOL CHEM, V280, P37547, DOI 10.1074/jbc.M506683200; Chene L, 2004, INT J CANCER, V111, P798, DOI 10.1002/ijc.20337; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Coutts AS, 2003, J CELL SCI, V116, P897, DOI 10.1242/jcs.00278; Diaz M, 2002, INT J BIOL MARKER, V17, P125, DOI 10.1177/172460080201700208; Duguay Y, 2004, CANCER RES, V64, P1202, DOI 10.1158/0008-5472.CAN-03-3295; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Giuliani L, 2005, ONCOL REP, V13, P185; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Harrington WR, 2006, ENDOCRINOLOGY, V147, P3843, DOI 10.1210/en.2006-0358; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Horie-Inoue K, 2006, BIOCHEM BIOPH RES CO, V339, P99, DOI 10.1016/j.bbrc.2005.10.188; Horie-Inoue K, 2004, BIOCHEM BIOPH RES CO, V325, P1312, DOI 10.1016/j.bbrc.2004.10.174; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; Jaggi M, 2006, PROSTATE, V66, P193, DOI 10.1002/pros.20334; Katou Y, 2006, METHOD ENZYMOL, V409, P389, DOI 10.1016/S0076-6879(05)09023-3; Kawana Y, 2002, PROSTATE, V53, P60, DOI 10.1002/pros.10131; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Laganiere J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102; Lepine J, 2004, J CLIN ENDOCR METAB, V89, P5222, DOI 10.1210/jc.2004-0331; Maeda A, 2006, BIOCHEM BIOPH RES CO, V347, P1158, DOI 10.1016/j.bbrc.2006.07.040; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Monks DA, 2001, BRAIN RES, V895, P73, DOI 10.1016/S0006-8993(01)02031-5; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022-5347(01)67297-5; Porkka KP, 2002, LAB INVEST, V82, P1573, DOI 10.1097/01.LAB.0000038554.26102.C6; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Strassburg CP, 1997, CANCER RES, V57, P2979; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; Tomita K, 2000, CANCER RES, V60, P3650; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100	40	86	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4453	4463		10.1038/sj.onc.1210229	http://dx.doi.org/10.1038/sj.onc.1210229			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297473				2022-12-25	WOS:000247620000013
J	Xue, ML; Campbell, D; Jackson, CJ				Xue, Meilang; Campbell, David; Jackson, Christopher J.			Protein C is an autocrine growth factor for human skin keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; EPIDERMAL DIFFERENTIATION; EXPRESSION; THROMBOMODULIN; ACTIVATION; INDUCTION; TRANSACTIVATION; PROLIFERATION; ANGIOGENESIS; INFLAMMATION	The protein C ( PC) pathway plays an important role in coagulation and inflammation. Many components of the PC pathway have been identified in epidermal keratinocytes, including endothelial protein C receptor ( EPCR), which is the specific receptor for PC/activatedPC (APC), but the core member of this pathway, PC, and its function in keratinocytes has not been defined. In this study, we reveal that PC is strongly expressed by human keratinocytes at both gene and protein levels. When endogenous PC was blocked by siRNA the proliferation of keratinocytes was significantly decreased. This inhibitory effect was restored by the addition of recombinant APC. PC siRNA treatment also increased cell apoptosis by 3-fold and inhibited cell migration by more than 20%. When keratinocytes were pretreated with RCR252, an EPCR-blocking antibody, or PD153035, an epidermal growth factor receptor (EGFR) inhibitor, cell proliferation was hindered by more than 30%. These inhibitors also completely abolished recombinant APC (10 mu g/ml)-stimulated proliferation. Blocking PC expression or inhibiting its binding to EPCR/EGFR decreased the phosphorylation of ERK1/2 but increased p38 activation. Furthermore, inhibition of ERK decreased cell proliferation by similar to 30% and completely abolished the stimulatory effect of APC on proliferation. Taken together, these results indicate that keratinocyte-derived PC promotes cell survival, growth, and migration in an autocrine manner via EPCR, EGFR, and activation of ERK1/2. Our results highlight a novel role for the PC pathway in normal skin physiology and wound healing.	Univ Sydney, Royal N Shore Hosp, Sutton Res Labs, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney	Xue, ML (corresponding author), Univ Sydney, Royal N Shore Hosp, Sutton Res Labs, Level 1,Block 4, St Leonards, NSW 2065, Australia.	mlxue@med.usyd.edu.au		Xue, Meilang/0000-0002-8563-7216; Jackson, Christopher/0000-0002-9234-9116				Artuc M, 2006, EXP DERMATOL, V15, P523, DOI 10.1111/j.1600-0625.2006.00444.x; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Dransfield DT, 2001, J INVEST DERMATOL, V117, P1588, DOI 10.1046/j.0022-202x.2001.01572.x; Eckert RL, 2002, J INVEST DERM SYMP P, V7, P36, DOI 10.1046/j.1523-1747.2002.19634.x; Feistritzer C, 2006, J IMMUNOL, V176, P1019, DOI 10.4049/jimmunol.176.2.1019; Fischer OM, 2003, BIOCHEM SOC T, V31, P1203; Fisher GJ, 2002, ARCH DERMATOL, V138, P1462, DOI 10.1001/archderm.138.11.1462; Fukudome K, 1998, J EXP MED, V187, P1029, DOI 10.1084/jem.187.7.1029; FUKUDOME K, 1994, J BIOL CHEM, V269, P26486; Griffin JH, 2002, SEMIN HEMATOL, V39, P197, DOI 10.1053/shem.2002.34093; Hague A, 2004, J PATHOL, V204, P175, DOI 10.1002/path.1630; Hudson LG, 1998, MICROSC RES TECHNIQ, V43, P444, DOI 10.1002/(SICI)1097-0029(19981201)43:5<444::AID-JEMT10>3.0.CO;2-C; Jackson CJ, 2005, WOUND REPAIR REGEN, V13, P284, DOI 10.1111/j.1067-1927.2005.00130311.x; JACKSON DE, 1995, J PATHOL, V175, P421, DOI 10.1002/path.1711750410; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Joyce DE, 2002, CRIT CARE MED, V30, pS288, DOI 10.1097/00003246-200205001-00019; Krajewska M, 1997, CANCER RES, V57, P1605; Krebs M, 1999, J INVEST DERMATOL, V113, P32, DOI 10.1046/j.1523-1747.1999.00644.x; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; MURAKAMI K, 1997, AM J PHYSIOL, V2, pL197; Nguyen M, 2000, J BIOL CHEM, V275, P9095, DOI 10.1074/jbc.275.13.9095; Piepkorn M, 2003, ARCH DERMATOL RES, V295, P93, DOI 10.1007/s00403-003-0391-x; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Pivarcsi A, 2003, INT IMMUNOL, V15, P721, DOI 10.1093/intimm/dxg068; Raife TJ, 1998, J INVEST MED, V46, P127; RAIFE TJ, 1994, J CLIN INVEST, V93, P1846, DOI 10.1172/JCI117171; Ravanti L, 2000, INT J MOL MED, V6, P391; Rezaie AR, 2003, TRENDS CARDIOVAS MED, V13, P8, DOI 10.1016/S1050-1738(02)00191-3; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sabri A, 2002, CIRC RES, V91, P532, DOI 10.1161/01.RES.0000035242.96310.45; StearnsKurosawa DJ, 1996, P NATL ACAD SCI USA, V93, P10212, DOI 10.1073/pnas.93.19.10212; Uchiba M, 2004, CIRC RES, V95, P34, DOI 10.1161/01.RES.0000133680.87668.FA; UCHIBA M, 1997, AM J HEMATOL, V2, P118; Villoutreix BO, 1999, PROTEIN ENG, V12, P833, DOI 10.1093/protein/12.10.833; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Xu J, 1999, J BIOL CHEM, V274, P6704, DOI 10.1074/jbc.274.10.6704; Xu YR, 2005, J BIOL CHEM, V280, P42694, DOI 10.1074/jbc.M507722200; Xue ML, 2005, J INVEST DERMATOL, V125, P1279, DOI 10.1111/j.0022-202X.2005.23952.x; Xue ML, 2004, EXP CELL RES, V299, P119, DOI 10.1016/j.yexcr.2004.05.015; Yuksel M, 2002, THROMB HAEMOSTASIS, V88, P267; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	45	42	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2007	282	18					13610	13616		10.1074/jbc.M610740200	http://dx.doi.org/10.1074/jbc.M610740200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	162BC	17293597	hybrid			2022-12-25	WOS:000246060300050
J	Lee, SH; Lee, H; Park, JS; Choi, H; Han, KY; Seo, HS; Ahn, KY; Han, SS; Cho, Y; Lee, KH; Lee, J				Lee, Sung-Hyun; Lee, Hyewon; Park, Jin-Seung; Choi, Hyoung; Han, Kyung-Yeon; Seo, Hyuk-Seong; Ahn, Keum-Young; Han, Sung-Sik; Cho, Yunjung; Lee, Kee-Hyoung; Lee, Jeewon			A novel approach to ultrasensitive diagnosis using supramolecular protein nanoparticles	FASEB JOURNAL			English	Article						human ferritin heavy chain; nanoprobe system; attomoloar sensitivity	GLUTAMIC-ACID DECARBOXYLASE; STIFF-MAN SYNDROME; DIABETES-MELLITUS; HUMAN FERRITIN; H-CHAIN; EPITOPE; AUTOANTIBODIES; EXPRESSION; IDENTIFICATION; ANTIBODIES	We report on the ultrasensitive protein nanoprobe system that specifically captures disease marker ( autoantibodies of Type I diabetes in this case) with attomolar sensitivity. The system relies on supramolecular protein nanoparticles that bind a specific antibody [ 65 kDa glutamate decarboxylase ( GAD(65))- specific autoantibody, i.e., the early marker of Type I diabetes]. The ultrasensitive detection of early marker of Type I diabetes during the early phase of pancreatic beta-cell destruction is important because individuals at high risk of developing Type I diabetes can be identified several years before the clinical onset of the ailment. The bacterial expression of chimera genes encoding N-[human ferritin heavy chain (hFTN- H)]::[ specific antigenic epitope]- C produces supramolecular nanoparticles with uniform diameters ( 10 - 15 nm), owing to self-assembly activity of hFTN- H. Each nanoparticle, formed by intermolecular self-assembly between the chimera protein molecules, is subjected to carrying a large number ( presumably, 24) of epitopes with a homogeneous and stable conformation per autoantibody binding, thereby allowing substantial enhancement of sensitivity. The sensitivity was finally boosted to 3 attomolar concentration of the autoantibodies, 4 - 9 orders of magnitude more sensitive than conventional immunoassays. Also, this ultrasensitive protein nanoprobe successfully detected natural autoantibodies in the sera from Type I diabetic patients. The attomolar sensitivity was successfully reproduced on the detection of other antibodies, i.e., monoclonal antibodies against hepatitis B surface antigen. With the two antibody markers above, the feasibility of simultaneous and multiplexing-mode detection was also demonstrated.	Korea Univ, Dept Chem & Biol Engn, Seoul 136713, South Korea; Korea Univ, Sch Life Sci & Biotechnol, Seoul 136713, South Korea; Korea Univ, Coll Med, Seoul 136713, South Korea	Korea University; Korea University; Korea University; Korea University Medicine (KU Medicine)	Lee, J (corresponding author), Korea Univ, Dept Chem & Biol Engn, Anam Dong 5-1, Seoul 136713, South Korea.	leejw@korea.ac.kr	Lee, Jeewon/J-1781-2015; Lee, Jeewon/F-7620-2013	Cho, Yunjung/0000-0002-6942-8385				Ahn JY, 2005, NUCLEIC ACIDS RES, V33, P3751, DOI 10.1093/nar/gki692; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; Bonifacio E, 2000, DIABETES, V49, P202, DOI 10.2337/diabetes.49.2.202; BU DF, 1992, P NATL ACAD SCI USA, V89, P2115, DOI 10.1073/pnas.89.6.2115; Daw K, 1996, J IMMUNOL, V156, P818; HAGOPIAN WA, 1993, DIABETES, V42, P631, DOI 10.2337/diabetes.42.4.631; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KIM J, 1993, DIABETES, V42, P1799, DOI 10.2337/diabetes.42.12.1799; LEVI S, 1989, BIOCHEM J, V264, P381, DOI 10.1042/bj2640381; LUZZAGO A, 1989, EMBO J, V8, P569, DOI 10.1002/j.1460-2075.1989.tb03411.x; Notkins AL, 2001, J CLIN INVEST, V108, P1247, DOI 10.1172/JCI200114257; PETERSEN JS, 1995, DIABETES, V43, P459; RICHTER W, 1992, P NATL ACAD SCI USA, V89, P8467, DOI 10.1073/pnas.89.18.8467; RICHTER W, 1993, P NATL ACAD SCI USA, V90, P2832, DOI 10.1073/pnas.90.7.2832; Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f; Santambrogio P, 1997, BIOCHEM J, V322, P461, DOI 10.1042/bj3220461; Sohnlein P, 2000, DIABETOLOGIA, V43, P210, DOI 10.1007/s001250050031; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; TUOMI T, 1994, CLIN IMMUNOL IMMUNOP, V71, P53, DOI 10.1006/clin.1994.1051; UJIHARA N, 1994, DIABETES, V43, P968, DOI 10.2337/diabetes.43.8.968; Wang J, 2004, ANGEW CHEM INT EDIT, V43, P2158, DOI 10.1002/anie.200453832; Yoon JW, 1999, SCIENCE, V284, P1183, DOI 10.1126/science.284.5417.1183	22	29	34	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1324	1334		10.1096/fj.06-7303com	http://dx.doi.org/10.1096/fj.06-7303com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17283220				2022-12-25	WOS:000246117000008
J	Neeley, WL; Delaney, S; Alekseyev, YO; Jarosz, DF; Delaney, JC; Walker, GC; Essigmann, JM				Neeley, William L.; Delaney, Sarah; Alekseyev, Yuriy O.; Jarosz, Daniel F.; Delaney, James C.; Walker, Graham C.; Essigmann, John M.			DNA polymerase V allows bypass of toxic guanine oxidation products in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXYNITRITE-INDUCED REACTIONS; ESCHERICHIA-COLI; NITRIC-OXIDE; POL-II; TRANSLESION REPLICATION; POTENT SOURCES; DAMAGE; LESIONS; SPIROIMINODIHYDANTOIN; IV	Reactive oxygen and nitrogen radicals produced during metabolic processes, such as respiration and inflammation, combine with DNA to form many lesions primarily at guanine sites. Understanding the roles of the polymerases responsible for the processing of these products to mutations could illuminate molecular mechanisms that correlate oxidative stress with cancer. Using M13 viral genomes engineered to contain single DNA lesions and Escherichia coli strains with specific polymerase ( pol) knockouts, we show that pol V is required for efficient bypass of structurally diverse, highly mutagenic guanine oxidation products in vivo. We also find that pol IV participates in the bypass of two spiroiminodihydantoin lesions. Furthermore, we report that one lesion, 5-guanidino-4-nitroimidazole, is a substrate for multiple SOS polymerases, whereby pol II is necessary for error-free replication and pol V for error-prone replication past this lesion. The results spotlight a major role for pol V and minor roles for pol II and pol IV in the mechanism of guanine oxidation mutagenesis.	MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Essigmann, JM (corresponding author), MIT, Dept Chem, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	jessig@mit.edu		/0000-0001-7243-8261; Alekseyev, Yuriy/0000-0001-6105-8861; Jarosz, Daniel/0000-0003-3497-5888	NATIONAL CANCER INSTITUTE [P01CA026731, R01CA080024, R01CA021615, R37CA080024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES002109] Funding Source: NIH RePORTER; NCI NIH HHS [CA080024, R01 CA080024-09, R01 CA080024-08, CA26731, R01 CA080024, CA21615] Funding Source: Medline; NIEHS NIH HHS [P30ES02109] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Al Mamun AAM, 2006, MUTAT RES-FUND MOL M, V593, P164, DOI 10.1016/j.mrfmmm.2005.07.016; Becherel OJ, 2001, P NATL ACAD SCI USA, V98, P8566, DOI 10.1073/pnas.141113398; Bjelland S, 2003, MUTAT RES-FUND MOL M, V531, P37, DOI 10.1016/j.mrfmmm.2003.07.002; BONNER CA, 1988, J BIOL CHEM, V263, P18946; Bridges B, 2001, MUTAT RES-DNA REPAIR, V485, P61, DOI 10.1016/S0921-8777(00)00074-4; Burney S, 1999, CHEM RES TOXICOL, V12, P513, DOI 10.1021/tx980254m; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; CADET J, 1994, J AM CHEM SOC, V116, P7403, DOI 10.1021/ja00095a052; CAI H, 1995, J BIOL CHEM, V270, P15327, DOI 10.1074/jbc.270.25.15327; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Delaney JC, 2005, NAT STRUCT MOL BIOL, V12, P855, DOI 10.1038/nsmb996; Delaney JC, 2004, P NATL ACAD SCI USA, V101, P14051, DOI 10.1073/pnas.0403489101; Duarte V, 1999, NUCLEIC ACIDS RES, V27, P496, DOI 10.1093/nar/27.2.496; Durandin A, 2006, CHEM RES TOXICOL, V19, P908, DOI 10.1021/tx060078e; ESCARCELLER M, 1994, J BACTERIOL, V176, P6221, DOI 10.1128/jb.176.20.6221-6228.1994; Finlay BB, 2006, CELL, V124, P767, DOI 10.1016/j.cell.2006.01.034; Gedik CM, 2005, FASEB J, V19, P82, DOI 10.1096/fj.04-1767fje; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Gu F, 2002, BIOCHEMISTRY-US, V41, P7508, DOI 10.1021/bi020148q; Hailer MK, 2005, CHEM RES TOXICOL, V18, P1378, DOI 10.1021/tx0501379; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Henderson PT, 2005, CHEM RES TOXICOL, V18, P12, DOI 10.1021/tx049757k; Henderson PT, 2003, BIOCHEMISTRY-US, V42, P9257, DOI 10.1021/bi0347252; Henderson PT, 2002, BIOCHEMISTRY-US, V41, P914, DOI 10.1021/bi0156355; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Jarosz DF, 2006, NATURE, V439, P225, DOI 10.1038/nature04318; Jia L, 2005, BIOCHEMISTRY-US, V44, P13342, DOI 10.1021/bi050790v; Joffe A, 2003, CHEM RES TOXICOL, V16, P966, DOI 10.1021/tx025578w; Juedes MJ, 1996, MUTAT RES-FUND MOL M, V349, P51, DOI 10.1016/0027-5107(95)00152-2; Karwowski B, 2006, CHEM RES TOXICOL, V19, P1357, DOI 10.1021/tx060088f; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Kornyushyna O, 2002, BIOCHEMISTRY-US, V41, P15304, DOI 10.1021/bi0264925; Kroeger KM, 2004, NUCLEIC ACIDS RES, V32, P5480, DOI 10.1093/nar/gkh873; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lee CH, 2006, J MOL GRAPH MODEL, V25, P87, DOI 10.1016/j.jmgm.2005.10.009; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; Luo WC, 2000, ORG LETT, V2, P613, DOI 10.1021/ol9913643; Maor-Shoshani A, 2000, P NATL ACAD SCI USA, V97, P565, DOI 10.1073/pnas.97.2.565; Maor-Shoshani A, 2003, P NATL ACAD SCI USA, V100, P14760, DOI 10.1073/pnas.2433503100; Maor-Shoshani A, 2003, DNA REPAIR, V2, P1227, DOI 10.1016/S1568-7864(03)00142-3; McKenzie GJ, 2001, MOL CELL, V7, P571, DOI 10.1016/S1097-2765(01)00204-0; McNulty JM, 1998, CHEM RES TOXICOL, V11, P666, DOI 10.1021/tx970225w; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; Neeley WL, 2006, CHEM RES TOXICOL, V19, P491, DOI 10.1021/tx0600043; Neeley WL, 2004, J BIOL CHEM, V279, P43568, DOI 10.1074/jbc.M407117200; Neeley WL, 2004, ORG LETT, V6, P245, DOI 10.1021/ol036188j; Niles JC, 2001, J AM CHEM SOC, V123, P12147, DOI 10.1021/ja004296k; Olinski R, 2002, FREE RADICAL BIO MED, V33, P192, DOI 10.1016/S0891-5849(02)00878-X; PazElizur T, 1996, J BIOL CHEM, V271, P24662, DOI 10.1074/jbc.271.40.24662; Prakash S, 2005, ANNU REV BIOCHEM, V74, P317, DOI 10.1146/annurev.biochem.74.082803.133250; Rangarajan S, 2002, MOL MICROBIOL, V43, P617, DOI 10.1046/j.1365-2958.2002.02747.x; Rangarajan S, 1999, P NATL ACAD SCI USA, V96, P9224, DOI 10.1073/pnas.96.16.9224; Raoul S, 1996, J AM CHEM SOC, V118, P1892, DOI 10.1021/ja952347l; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; Sawa T, 2006, NITRIC OXIDE-BIOL CH, V14, P91, DOI 10.1016/j.niox.2005.06.005; Seo KY, 2006, DNA REPAIR, V5, P515, DOI 10.1016/j.dnarep.2005.12.009; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; Steenken S, 2000, J AM CHEM SOC, V122, P2373, DOI 10.1021/ja993508e; Sugden KD, 2002, ENVIRON HEALTH PERSP, V110, P725, DOI 10.1289/ehp.02110s5725; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tretyakova NY, 1999, CHEM RES TOXICOL, V12, P459, DOI 10.1021/tx980235c; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wu XH, 2006, CANCER RES, V66, P748, DOI 10.1158/0008-5472.CAN-05-2884; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; Yang W, 2003, CURR OPIN STRUC BIOL, V13, P23, DOI 10.1016/S0959-440X(02)00003-9	69	56	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2007	282	17					12741	12748		10.1074/jbc.M700575200	http://dx.doi.org/10.1074/jbc.M700575200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LR	17322566	hybrid			2022-12-25	WOS:000245942800044
J	De Felice, FG; Velasco, PT; Lambert, MP; Viola, K; Fernandez, SJ; Ferreira, ST; Klein, WL				De Felice, Fernanda G.; Velasco, Pauline T.; Lambert, Mary P.; Viola, Kirsten; Fernandez, Sara J.; Ferreira, Sergio T.; Klein, William L.			A beta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICAL GENERATION; CENTRAL-NERVOUS-SYSTEM; HYDROGEN-PEROXIDE; MITOCHONDRIA; MEMORY; A-BETA(1-42); AGGREGATION; TRAFFICKING; PLASTICITY; IMBALANCE	Oxidative stress is a major aspect of Alzheimer disease ( AD) pathology. We have investigated the relationship between oxidative stress and neuronal binding of A beta oligomers ( also known as ADDLs). ADDLs are known to accumulate in brain tissue of AD patients and are considered centrally related to pathogenesis. Using hippocampal neuronal cultures, we found that ADDLs stimulated excessive formation of reactive oxygen species ( ROS) through a mechanism requiring N-methyl-D-aspartate receptor ( NMDA-R) activation. ADDL binding to neurons was reduced and ROS formation was completely blocked by an antibody to the extracellular domain of the NR1 subunit of NMDA-Rs. In harmony with a steric inhibition of ADDL binding by NR1 antibodies, ADDLs that were bound to detergent-extracted synaptosomal membranes co-immunoprecipitated with NMDA-R subunits. The NR1 antibody did not affect ROS formation induced by NMDA, showing that NMDA-Rs themselves remained functional. Memantine, an open channel NMDA-R antagonist prescribed as a memory-preserving drug for AD patients, completely protected against ADDL-induced ROS formation, as did other NMDA-R antagonists. Memantine and the anti-NR1 antibody also attenuated a rapid ADDL-induced increase in intraneuronal calcium, which was essential for stimulated ROS formation. These results show that ADDLs bind to or in close proximity to NMDA-Rs, triggering neuronal damage through NMDA-R-dependent calcium flux. This response provides a pathologically specific mechanism for the therapeutic action of memantine, indicates a role for ROS dysregulation in ADDL-induced cognitive impairment, and supports the unifying hypothesis that ADDLs play a central role in AD pathogenesis.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Univ Fed Rio de Janeiro, Inst Bioquim Med, Programa Bioquim & Biofis Celular, BR-21944590 Rio De Janeiro, Brazil	Northwestern University; Universidade Federal do Rio de Janeiro	Ferreira, ST (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	ferreira@bioqmed.ufrj.br; wklein@northwestern.edu	De Felice, Fernanda G/M-1074-2017; Ferreira, Sergio/AAZ-1576-2020	Ferreira, Sergio/0000-0001-7160-9866; Dunne, Sara/0000-0002-0273-680X	NIA NIH HHS [R01-AG18877, R01-AG11385, R01-AG22547] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011385, R01AG018877, R01AG022547] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Aracava Y, 2005, J PHARMACOL EXP THER, V312, P1195, DOI 10.1124/jpet.104.077172; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Butterfield DA, 2005, BBA-PROTEINS PROTEOM, V1703, P149, DOI 10.1016/j.bbapap.2004.10.014; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Chang DTW, 2006, J NEUROSCI, V26, P7035, DOI 10.1523/JNEUROSCI.1012-06.2006; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; da-Silva WS, 2004, J BIOL CHEM, V279, P39846, DOI 10.1074/jbc.M403835200; Demuro A, 2005, J BIOL CHEM, V280, P17294, DOI 10.1074/jbc.M500997200; DODD PR, 1981, BRAIN RES, V226, P107, DOI 10.1016/0006-8993(81)91086-6; Drake J, 2003, NEUROBIOL AGING, V24, P415, DOI 10.1016/S0197-4580(02)00225-7; Duchen MR, 2004, DIABETES, V53, pS96, DOI 10.2337/diabetes.53.2007.S96; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FISKUM G, 1985, ANN EMERG MED, V14, P810, DOI 10.1016/S0196-0644(85)80063-9; Georganopoulou DG, 2005, P NATL ACAD SCI USA, V102, P2273, DOI 10.1073/pnas.0409336102; Giasson BI, 2002, FREE RADICAL BIO MED, V32, P1264, DOI 10.1016/S0891-5849(02)00804-3; Glaser CB, 2005, BBA-PROTEINS PROTEOM, V1703, P157, DOI 10.1016/j.bbapap.2004.10.008; Gong YS, 2003, P NATL ACAD SCI USA, V100, P10417, DOI 10.1073/pnas.1834302100; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Kawai H, 2002, J NEUROSCI, V22, P7903; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelly BL, 2006, J BIOL CHEM, V281, P28079, DOI 10.1074/jbc.M605081200; Kim GW, 2002, STROKE, V33, P809, DOI 10.1161/hs0302.103745; Klein William L, 2006, Alzheimers Dement, V2, P43, DOI 10.1016/j.jalz.2005.11.003; Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert MP, 2007, J NEUROCHEM, V100, P23, DOI 10.1111/j.1471-4159.2006.04157.x; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; McShane R, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003154.pub5; Moreira Paula I, 2005, Curr Alzheimer Res, V2, P403; Moreira PI, 2006, BIOL RES, V39, P7, DOI 10.4067/S0716-97602006000100002; Morris RGM, 2001, PHILOS T R SOC B, V356, P1453, DOI 10.1098/rstb.2001.0945; Multhaup G, 1997, BIOCHEM PHARMACOL, V54, P533, DOI 10.1016/S0006-2952(97)00062-2; Nakazawa K, 2004, NAT REV NEUROSCI, V5, P361, DOI 10.1038/nrn1385; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Pratico D, 2000, AM J MED, V109, P577, DOI 10.1016/S0002-9343(00)00547-7; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Rizzuto R, 2003, J CELL BIOL, V163, P441, DOI 10.1083/jcb.200309111; Schmitt HP, 2005, MED HYPOTHESES, V65, P259, DOI 10.1016/j.mehy.2005.03.011; Schmitt HP, 2005, PSYCHOPHARMACOLOGY, V179, P151, DOI 10.1007/s00213-004-2110-5; Serrano F, 2004, AGEING RES REV, V3, P431, DOI 10.1016/j.arr.2004.05.002; Shulman RG, 2004, TRENDS NEUROSCI, V27, P489, DOI 10.1016/j.tins.2004.06.005; Skulachev VP, 2005, IUBMB LIFE, V57, P305, DOI 10.1080/15216540500092161; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Soucek T, 2003, NEURON, V39, P43, DOI 10.1016/S0896-6273(03)00367-2; Stork CJ, 2006, J NEUROSCI, V26, P10430, DOI 10.1523/JNEUROSCI.1588-06.2006; Tabner BJ, 2005, BIOCHEM SOC T, V33, P548, DOI 10.1042/BST0330548; Thiels E, 2002, PHYSIOL BEHAV, V77, P601, DOI 10.1016/S0031-9384(02)00900-9; Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010; Wilcock GK, 2003, LANCET NEUROL, V2, P503, DOI 10.1016/S1474-4422(03)00486-1; Zhu XW, 2006, J ALZHEIMERS DIS, V9, P147; Zhu XW, 2005, MOL NEUROBIOL, V31, P205, DOI 10.1385/MN:31:1-3:205	63	686	698	0	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11590	11601		10.1074/jbc.M607483200	http://dx.doi.org/10.1074/jbc.M607483200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308309	hybrid			2022-12-25	WOS:000245941500080
J	Gal, J; Strom, AL; Kilty, R; Zhang, FJ; Zhu, HN				Gal, Jozsef; Strom, Anna-Lena; Kilty, Renee; Zhang, Fujian; Zhu, Haining			p62 accumulates and enhances aggregate formation in model systems of familial amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN P62; MOTOR-NEURON DEGENERATION; NF-KAPPA-B; PHOSPHOTYROSINE-INDEPENDENT LIGAND; MURINE PERITONEAL-MACROPHAGES; CU,ZN SUPEROXIDE-DISMUTASE; NERVE-GROWTH-FACTOR; ALS-LINKED SOD1; TRANSGENIC MICE; PROTEASOMAL INHIBITION	Amyotrophic lateral sclerosis ( ALS) is a progressive neurodegenerative disease characterized by motor neuron death. A hallmark of the disease is the appearance of protein aggregates in the affected motor neurons. We have found that p62, a protein implicated in protein aggregate formation, accumulated progressively in the G93A mouse spinal cord. The accumulation of p62 was in parallel to the increase of polyubiquitinated proteins and mutant SOD1 aggregates. Immunostaining studies showed that p62, ubiquitin, and mutant SOD1 co-localized in the protein aggregates in affected cells in G93A mouse spinal cord. The p62 protein selectively interacted with familial ALS mutants, but not WT SOD1. When p62 was co-expressed with SOD1 in NSC34 cells, it greatly enhanced the formation of aggregates of the ALS-linked SOD1 mutants, but not wild-type SOD1. Cell viability was measured in the presence and absence of overexpressed p62, and the results suggest that the large aggregates facilitated by p62 were not directly toxic to cells under the conditions in this study. Deletion of the ubiquitin-association ( UBA) domain of p62 significantly decreased the p62-facilitated aggregate formation, but did not completely inhibit it. Further protein interaction experiments also showed that the truncated p62 with the UBA domain deletion remained capable of interacting with mutant SOD1. The findings of this study show that p62 plays a critical role in forming protein aggregates in familial ALS, likely by linking misfolded mutant SOD1 molecules and other cellular proteins together.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Nutr Sci, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Zhu, HN (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 741 S Limestone St, Lexington, KY 40536 USA.	haining@uky.edu	Zhu, Haining/A-6076-2008	Zhu, Haining/0000-0001-5498-6694; Gal, Jozsef/0000-0002-5865-6534	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049126] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS49126] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Babu JR, 2005, J NEUROCHEM, V94, P192, DOI 10.1111/j.1471-4159.2005.03181.x; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Bjorkoy G, 2006, AUTOPHAGY, V2, P138, DOI 10.4161/auto.2.2.2405; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; CASHMAN NR, 1992, DEV DYNAM, V194, P209, DOI 10.1002/aja.1001940306; Ciani B, 2003, J BIOL CHEM, V278, P37409, DOI 10.1074/jbc.M307416200; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Fukada K, 2004, MOL CELL PROTEOMICS, V3, P1211, DOI 10.1074/mcp.M400094-MCP200; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Geetha T, 2005, EMBO J, V24, P3859, DOI 10.1038/sj.emboj.7600845; Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; Hart PJ, 2006, CURR OPIN CHEM BIOL, V10, P131, DOI 10.1016/j.cbpa.2006.02.034; Ishii T, 1996, BIOCHEM BIOPH RES CO, V226, P456, DOI 10.1006/bbrc.1996.1377; Ishii T, 1997, BIOCHEM BIOPH RES CO, V232, P33, DOI 10.1006/bbrc.1997.6221; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Kabashi E, 2004, J NEUROCHEM, V89, P1325, DOI 10.1111/j.1471-4159.2004.02453.x; Kabuta T, 2006, J BIOL CHEM, V281, P30524, DOI 10.1074/jbc.M603337200; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009; Kuusisto E, 2001, BIOCHEM BIOPH RES CO, V280, P223, DOI 10.1006/bbrc.2000.4107; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Matsumoto G, 2005, J CELL BIOL, V171, P75, DOI 10.1083/jcb.200504050; Mizuno Y, 2006, J NEUROL SCI, V249, P13, DOI 10.1016/j.jns.2006.05.060; Nagaoka U, 2004, J NEUROCHEM, V91, P57, DOI 10.1111/j.1471-4159.2004.02692.x; Nakano T, 2004, ACTA NEUROPATHOL, V107, P359, DOI 10.1007/s00401-004-0821-7; Nakaso K, 2004, BRAIN RES, V1012, P42, DOI 10.1016/j.brainres.2004.03.029; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Paine MG, 2005, FEBS LETT, V579, P5029, DOI 10.1016/j.febslet.2005.08.010; Parkinson N, 2006, NEUROLOGY, V67, P1074, DOI 10.1212/01.wnl.0000231510.89311.8b; Piao YS, 2003, BRAIN PATHOL, V13, P10; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; Stieber A, 2000, J NEUROL SCI, V173, P53, DOI 10.1016/S0022-510X(99)00300-7; Stieber A, 2000, J NEUROL SCI, V177, P114, DOI 10.1016/S0022-510X(00)00351-8; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Wang J, 2002, NEUROBIOL DIS, V10, P128, DOI 10.1006/nbdi.2002.0498; Wang ZY, 2005, MOL CELL NEUROSCI, V29, P222, DOI 10.1016/j.mcn.2005.02.011; Watanabe M, 2001, NEUROBIOL DIS, V8, P933, DOI 10.1006/nbdi.2001.0443; Wilson MI, 2003, MOL CELL, V12, P39, DOI 10.1016/S1097-2765(03)00246-6; Wooten MW, 2005, J BIOL CHEM, V280, P35625, DOI 10.1074/jbc.C500237200; Wooten MW, 2001, J BIOL CHEM, V276, P7709, DOI 10.1074/jbc.C000869200; Zhang FJ, 2006, BBA-GEN SUBJECTS, V1760, P404, DOI 10.1016/j.bbagen.2005.11.024	50	139	140	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11068	11077		10.1074/jbc.M608787200	http://dx.doi.org/10.1074/jbc.M608787200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17296612	hybrid			2022-12-25	WOS:000245941500027
J	Lu, YJ; Zhang, F; Grimes, KD; Lee, RE; Rock, CO				Lu, Ying-Jie; Zhang, Fan; Grimes, Kimberly D.; Lee, Richard E.; Rock, Charles O.			Topology and active site of PlsY - The bacterial acylphosphate: Glycerol-3-phosphate acyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PHOSPHOLIPID-SYNTHESIS; TRANSMEMBRANE PROTEIN TOPOLOGY; SN-GLYCEROL 3-PHOSPHATE; ESCHERICHIA-COLI; SN-GLYCEROL-3-PHOSPHATE ACYLTRANSFERASE; FATTY-ACID; ATP-BINDING; TERMINAL DOMAIN; RECONSTITUTION; BIOSYNTHESIS	The most widely distributed biosynthetic pathway to initiate phosphatidic acid formation in bacterial membrane phospholipid biosynthesis involves the conversion of acyl-acyl carrier protein to acylphosphate by PlsX and the transfer of the acyl group from acylphosphate to glycerol 3-phosphate by an integral membrane protein, PlsY. The membrane topology of Streptococcus pneumoniae PlsY was determined using the substituted cysteine accessibility method. PlsY has five membrane-spanning segments with the amino terminus and two short loops located on the external face of the membrane. Each of the three larger cytoplasmic domains contains a highly conserved sequence motif. Site-directed mutagenesis revealed that each conserved domain was critical for PlsY catalysis. Motif 1 had an essential serine and arginine residue. Motif 2 had the characteristics of a phosphate-binding loop. Mutations of the conserved glycines in motif 2 to alanines resulted in a K-m defect for glycerol 3-phosphate binding leading to the conclusion that this motif corresponded to the glycerol 3-phosphate binding site. Motif 3 contained a conserved histidine and asparagine that were important for activity and a glutamate that was critical to the structural integrity of PlsY. PlsY was noncompetitively inhibited by palmitoyl-CoA. These data define the membrane architecture and the critical active site residues in the PlsY family of bacterial acyltransferases.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale, Memphis, TN 38105 USA.	charles.rock@stjude.org	Lee, Richard/J-4997-2013; Lee, Richard/AAX-3996-2021	Lee, Richard/0000-0002-2397-0443; Lee, Richard/0000-0002-2397-0443	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL RM, 1975, J BIOL CHEM, V250, P7147; BELL RM, 1974, J BACTERIOL, V117, P1065, DOI 10.1128/JB.117.3.1065-1076.1974; Bhat BG, 1999, BBA-MOL CELL BIOL L, V1439, P415, DOI 10.1016/S1388-1981(99)00103-1; Bogdanov M, 2005, METHODS, V36, P148, DOI 10.1016/j.ymeth.2004.11.002; Bogdanov M, 1998, EMBO J, V17, P5255, DOI 10.1093/emboj/17.18.5255; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cronan JE, 2003, ANNU REV MICROBIOL, V57, P203, DOI 10.1146/annurev.micro.57.030502.090851; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; GREEN PR, 1984, J BIOL CHEM, V259, P4688; GREEN PR, 1981, J BIOL CHEM, V256, P1151; Hammond LE, 2002, MOL CELL BIOL, V22, P8204, DOI 10.1128/MCB.22.23.8204-8214.2002; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; Heath RJ, 1999, J BACTERIOL, V181, P1944, DOI 10.1128/JB.181.6.1944-1946.1999; Heath RJ, 1998, J BACTERIOL, V180, P1425, DOI 10.1128/JB.180.6.1425-1430.1998; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lewin TM, 1999, BIOCHEMISTRY-US, V38, P5764, DOI 10.1021/bi982805d; LIGHTNER VA, 1983, J BIOL CHEM, V258, P856; LIGHTNER VA, 1980, J BIOL CHEM, V255, P9413; Lu YJ, 2006, MOL CELL, V23, P765, DOI 10.1016/j.molcel.2006.06.030; Lu YJ, 2006, MOL MICROBIOL, V59, P551, DOI 10.1111/j.1365-2958.2005.04951.x; Pellon-Maison M, 2006, ARCH BIOCHEM BIOPHYS, V450, P157, DOI 10.1016/j.abb.2006.03.009; RIORDAN JF, 1979, MOL CELL BIOCHEM, V26, P71; ROCK CO, 1981, J BIOL CHEM, V256, P736; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHEIDELER MA, 1991, J BIOL CHEM, V266, P14321; SCHEIDELER MA, 1989, J BIOL CHEM, V264, P12455; Scholz B, 2003, NUCLEIC ACIDS RES, V31, P1426, DOI 10.1093/nar/gkg229; Schujman GE, 2003, DEV CELL, V4, P663, DOI 10.1016/S1534-5807(03)00123-0; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; Zhang YM, 2006, J BIOL CHEM, V281, P107, DOI 10.1074/jbc.M508825200	34	29	33	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11339	11346		10.1074/jbc.M700374200	http://dx.doi.org/10.1074/jbc.M700374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17308305	hybrid			2022-12-25	WOS:000245941500056
J	Rivera, SP; Wang, F; Saarikoski, ST; Taylor, RT; Chapman, B; Zhang, RX; Hankinson, O				Rivera, Steven P.; Wang, Feng; Saarikoski, Sirkku T.; Taylor, Robert T.; Chapman, Brett; Zhang, Ruixue; Hankinson, Oliver			A novel promoter element containing multiple overlapping xenobiotic and hypoxia response elements mediates induction of cytochrome P4502S1 by both dioxin and hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARYL-HYDROCARBON RECEPTOR; PROTEIN-DNA INTERACTIONS; LIGANDED AH RECEPTOR; ADULT TISSUES; BINDING; MOUSE; EXPRESSION; GENE; ENHANCER; IDENTIFICATION	Cytochrome P4502S1 (CYP2S1) is expressed at high levels in epithelial tissues and is inducible by 2,3,7,8-tetrachlorodibenzop-dioxin (dioxin) via the aryl hydrocarbon receptor (AHR). Transcriptional initiation of mouse Cyp2s1 was found to occur at three regions, similar to 198, 102, and 22 nucleotides from the translational initiation codon. Approximately 400 nucleotides upstream of its translational initiation codon, mouse Cyp2s1 contains three overlapping xenobiotic-responsive element (XRE) sequences, which make a major contribution toward dioxin inducibility. Each XRE sequence in this trimeric XRE can bind the AHR/aryl hydrocarbon receptor nuclear translocator (ARNT) dimer in a dioxin-dependent fashion in vitro and can mediate dioxin-dependent transcription. Cyp2s1 is also markedly inducible by hypoxia. Induction is dependent on hypoxiai-nducible factor-1 (HIF-1) and is mediated in large part by three overlapping hypoxia response elements (HREs) embedded within the trimeric XRE segment. Although each HRE within this segment can bind HIF-1 alpha/ ARNT in vitro, the most 3' HRE contributes the most toward hypoxia inducibility. AHR/ARNT and HIF-1 alpha/ARNT dimers bind to the region containing the trimeric XRE segment of the endogenous Cyp2s1 gene in vivo in a dioxin-dependent fashion and hypoxia-dependent fashion, respectively. These observations identify a novel regulatory cassette that mediates changes in Cyp2s1 expression.	Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Mol Toxicol Interdept Doctoral Program, Los Angeles, CA 90095 USA; Finnish Inst Occupat Hlth, Dept Ind Hyg & Toxicol, FI-00250 Helsinki, Finland	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Finnish Institute of Occupational Health	Hankinson, O (corresponding author), Univ Calif Los Angeles, Dept Pathol & Lab Med, 10833 Le Conte Ave,POB 9517332, Los Angeles, CA 90095 USA.	ohank@mednet.ucla.edu			NCI NIH HHS [R01 CA028868] Funding Source: Medline; NIEHS NIH HHS [R01 ES015384] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015384] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arpiainen S, 2005, MOL PHARMACOL, V67, P1325, DOI 10.1124/mol.104.008078; BACSI SG, 1995, MOL PHARMACOL, V47, P432; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; Choudhary D, 2005, ARCH BIOCHEM BIOPHYS, V436, P50, DOI 10.1016/j.abb.2005.02.001; Choudhary D, 2003, ARCH BIOCHEM BIOPHYS, V414, P91, DOI 10.1016/S0003-9861(03)00174-7; Covello KL, 2004, CURR TOP DEV BIOL, V62, P37; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gassmann M, 1997, KIDNEY INT, V51, P567, DOI 10.1038/ki.1997.81; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Gradin K, 1996, MOL CELL BIOL, V16, P5221; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; Karlgren Maria, 2005, Toxicol Appl Pharmacol, V207, P57, DOI 10.1016/j.taap.2004.12.022; Kinoshita K, 2004, NUCLEIC ACIDS RES, V32, P3169, DOI 10.1093/nar/gkh637; Kress S, 1998, EUR J BIOCHEM, V258, P803, DOI 10.1046/j.1432-1327.1998.2580803.x; Kumarakulasingham M, 2005, CLIN CANCER RES, V11, P3758, DOI 10.1158/1078-0432.CCR-04-1848; LEGRAVEREND C, 1982, J BIOL CHEM, V257, P6402; Lewis DFV, 2003, CURR MED CHEM, V10, P1955, DOI 10.2174/0929867033456855; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Nelson DR, 2004, PHARMACOGENETICS, V14, P1, DOI 10.1097/00008571-200401000-00001; OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2; PROBST MR, 1993, MOL PHARMACOL, V44, P511; Rivera SP, 2002, MOL PHARMACOL, V61, P255, DOI 10.1124/mol.61.2.255; Rylander T, 2001, BIOCHEM BIOPH RES CO, V281, P529, DOI 10.1006/bbrc.2001.4390; Saarikoski Sirkku T, 2005, Toxicol Appl Pharmacol, V207, P62, DOI 10.1016/j.taap.2004.12.027; Saarikoski ST, 2005, J HISTOCHEM CYTOCHEM, V53, P549, DOI 10.1369/jhc.4C6576.2005; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHEN ES, 1992, J BIOL CHEM, V267, P6815; Smith G, 2003, LANCET, V361, P1336, DOI 10.1016/S0140-6736(03)13081-4; Stoilov I, 2001, TRENDS GENET, V17, P629, DOI 10.1016/S0168-9525(01)02444-1; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; WENGER RH, 2005, SCI STKE 2005; YAO EF, 1992, BIOCHEMISTRY-US, V31, P5060, DOI 10.1021/bi00136a019	35	50	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10881	10893		10.1074/jbc.M609617200	http://dx.doi.org/10.1074/jbc.M609617200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17277313	hybrid			2022-12-25	WOS:000245941500007
J	Baron, MJ; Filman, DJ; Prophete, GA; Hogle, JM; Madoff, LC				Baron, Miriam J.; Filman, David J.; Prophete, Gina A.; Hogle, James M.; Madoff, Lawrence C.			Identification of a glycosaminoglycan binding region of the alpha c protein that mediates entry of group B streptococci into host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; CRYSTAL-STRUCTURE; TERMINAL DOMAIN; ANTIGEN GENE; INVASION; ADHERENCE; RECEPTOR; AGALACTIAE; EXPRESSION; CLEARANCE	Group B Streptococcus ( GBS) frequently colonizes the human gastrointestinal and gynecological tracts and less frequently causes deep tissue infections. The transition between colonization and infection depends upon the ability of the organism to cross epithelial barriers. The alpha C protein ( ACP) on the surface of GBS contributes to this process. A virulence factor in mouse models of infection, and prototype for a family of Gram-positive bacterial surface proteins, ACP facilitates GBS entry into human cervical epithelial cells and movement across cell layers. ACP binds to host cell surface glycosaminoglycan ( GAG). From crystallography, we have identified a cluster of basic residues ( BR2) that is a putative GAG binding area in Domain 2, near the junction of the N-terminal domain of ACP and the first of a series of tandem amino acid repeats. D2-R, a protein construct including this region, binds to cells similarly to full-length ACP. We now demonstrate that the predicted charged BR2 residues confer GAG binding; site-directed mutagenesis of these residues ( Arg(172), Arg(185), or Lys(196)) eliminates cell-binding activity of construct D2-R. In addition, we have constructed a GBS strain expressing a variant ACP with a charge-neutralizing substitution at residue 185. This strain enters host cells less effectively than does the wild-type strain and similarly to an ACP null mutant strain. The point mutant strain transcytoses similarly to the wild-type strain. These data indicate that GAG-binding activity underlies ACP-mediated cellular entry of GBS. GBS entry into host cells and transcytosis of host cells may occur by distinct mechanisms.	Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Baron, MJ (corresponding author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	mbaron@partners.org	Hogle, James/HIG-9121-2022	Hogle, James/0000-0002-3655-1504; filman, david/0000-0002-8714-1644	NIAID NIH HHS [AI059495, AI38424] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI038424, K08AI059495, R56AI038424, R01AI038424] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adderson EE, 2003, INFECT IMMUN, V71, P6857, DOI 10.1128/IAI.71.12.6857-6863.2003; Alberti S, 1998, MOL MICROBIOL, V28, P343, DOI 10.1046/j.1365-2958.1998.00800.x; Auperin TC, 2005, J BIOL CHEM, V280, P18245, DOI 10.1074/jbc.M412391200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baron MJ, 2004, J BIOL CHEM, V279, P24714, DOI 10.1074/jbc.M402164200; Bolduc GR, 2002, CELL MICROBIOL, V4, P751, DOI 10.1046/j.1462-5822.2002.00227.x; Brown CK, 2005, P NATL ACAD SCI USA, V102, P18391, DOI 10.1073/pnas.0504954102; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; Carter WJ, 2005, J BIOL CHEM, V280, P2745, DOI 10.1074/jbc.M411606200; Cheng Q, 2002, INFECT IMMUN, V70, P6409, DOI 10.1128/IAI.70.11.6409-6415.2002; Cieslewicz MJ, 2001, J BIOL CHEM, V276, P139, DOI 10.1074/jbc.M005702200; Cywes C, 2001, NATURE, V414, P648, DOI 10.1038/414648a; Doran KS, 2002, J INFECT DIS, V185, P196, DOI 10.1086/338475; Dramsi S, 2006, MOL MICROBIOL, V60, P1401, DOI 10.1111/j.1365-2958.2006.05190.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fischer JR, 2006, INFECT IMMUN, V74, P435, DOI 10.1128/IAI.74.1.435-441.2006; Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543; Gao RP, 2004, J BIOL CHEM, V279, P8848, DOI 10.1074/jbc.M313204200; Gravekamp C, 1996, INFECT IMMUN, V64, P3576, DOI 10.1128/IAI.64.9.3576-3583.1996; Gutekunst H, 2004, INFECT IMMUN, V72, P3495, DOI 10.1128/IAI.72.6.3495-3504.2004; Henry-Stanley MJ, 2005, SHOCK, V24, P571, DOI 10.1097/01.shk.0000184286.95493.78; Kling DE, 1997, INFECT IMMUN, V65, P1462, DOI 10.1128/IAI.65.4.1462-1467.1997; LANCEFIELD RC, 1975, J EXP MED, V142, P165, DOI 10.1084/jem.142.1.165; Li J, 1997, P NATL ACAD SCI USA, V94, P13251, DOI 10.1073/pnas.94.24.13251; MADOFF LC, 1991, INFECT IMMUN, V59, P204, DOI 10.1128/IAI.59.1.204-210.1991; Madoff LC, 1996, P NATL ACAD SCI USA, V93, P4131, DOI 10.1073/pnas.93.9.4131; MICHEL JL, 1992, P NATL ACAD SCI USA, V89, P10060, DOI 10.1073/pnas.89.21.10060; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paoletti LC, 1996, INFECT IMMUN, V64, P1220, DOI 10.1128/IAI.64.4.1220-1226.1996; Patrie KM, 1999, BIOCHEMISTRY-US, V38, P9264, DOI 10.1021/bi9903345; PEREZCASAL J, 1993, MOL MICROBIOL, V8, P809, DOI 10.1111/j.1365-2958.1993.tb01628.x; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; Pinheiro J. C., 2000, MIXED EFFECTS MODELS, P3, DOI DOI 10.1007/0-387-22747-4_1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718; Schubert A, 2004, INFECT IMMUN, V72, P6197, DOI 10.1128/IAI.72.11.6197-6205.2004; Soriani M, 2006, J INFECT DIS, V193, P241, DOI 10.1086/498982; Summerford C, 1999, NAT MED, V5, P78, DOI 10.1038/4768; Tafazoli F, 2000, INFECT IMMUN, V68, P5335, DOI 10.1128/IAI.68.9.5335-5343.2000; TAMURA GS, 1994, INFECT IMMUN, V62, P2450, DOI 10.1128/IAI.62.6.2450-2458.1994; TETI G, 1987, INFECT IMMUN, V55, P3057, DOI 10.1128/IAI.55.12.3057-3064.1987; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; van Putten JPM, 1998, MOL MICROBIOL, V29, P369, DOI 10.1046/j.1365-2958.1998.00951.x	46	36	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10526	10536		10.1074/jbc.M608279200	http://dx.doi.org/10.1074/jbc.M608279200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17259175	Green Published, hybrid			2022-12-25	WOS:000245941000045
J	Dunys, J; Kawarai, T; Sevalle, J; Dolcini, V; George-Hyslop, PS; Da Costa, CA; Checler, F				Dunys, Julie; Kawarai, Toshitaka; Sevalle, Jean; Dolcini, Virginia; George-Hyslop, Peter St.; Da Costa, Cristine Alves; Checler, Frederic			p53-dependent Aph-1 and Pen-2 anti-apoptotic phenotype requires the integrity of the gamma-secretase complex but is independent of its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; BETA-SECRETASE; PRESENILIN-1 EXPRESSION; TRANSCRIPTION FACTORS; ASPARTYL PROTEASE; P53; NICASTRIN; ACTIVATION; CASPASE-3	The presenilin-dependent gamma-secretase activity, which is responsible for the generation of amyloid beta-peptide, is a high molecular weight complex composed of at least four components, namely, presenilin-1 ( or presenilin-2), nicastrin, Aph-1, and Pen-2. Previous data indicated that presenilins, which are thought to harbor the catalytic core of the complex, also control p53-dependent cell death. Whether the other components of the gamma-secretase complex could also modulate the cell death process in mammalian neurons remained to be established. Here, we examined the putative contribution of Aph-1 and Pen-2 in the control of apoptosis in TSM1 cells from a neuronal origin. We show by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling and DNA fragmentation analyses that the overexpression of Aph-1a, Aph-1b, or Pen-2 drastically lowered staurosporine-induced cellular toxicity. In support of an apoptosis rather than necrosis process, Aph-1 and Pen- 2 also lower staurosporine- and etoposide-induced caspase- 3 expression and diminished caspase- 3 activity and poly( ADP-ribose) polymerase inactivation. The Aph-1 and Pen-2 anti-apoptotic phenotype was associated with a drastic reduction of p53 expression and activity and lowered p53 mRNA transcription. Furthermore, the Aph-1- and Pen-2-associated reduction of staurosporine- induced caspase- 3 activation was fully abolished by p53 deficiency. Conversely, Aph-1a, Aph-1b, and Pen-2 gene inactivation increases both caspase- 3 activity and p53 mRNA levels. Finally, we show that Aph-1 and Pen-2 did not trigger an anti-apoptotic response in cells devoid of presenilins or nicastrin, whereas the protective response was still observed in fibroblasts devoid of beta-amyloid precursor protein and amyloid precursor protein like-protein 2. Furthermore, Aph-1- and Pen-2-associated protection against staurosporine-induced caspase-3 activation was not affected by the gamma-secretase inhibitors N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S- phenylglycine t-butyl ester and difluoromethylketone. Altogether, our study indicates that Aph-1 and Pen-2 trigger an anti-apoptotic response by lowering p53-dependent control of caspase-3. Our work also demonstrates that this phenotype is strictly dependent on the molecular integrity of the gamma-secretase complex but remains independent of the gamma-secretase catalytic activity.	Fdn Rech Med, Inst Pharmacol Mol & Cellulaire, UMR 6097,Equipe Labellisee, CNRS,UNSA, F-06560 Valbonne, France; Univ Toronto, Dept Med, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Toronto Western Hosp, Inst Res, Hlth Network, Toronto, ON M5S 3H2, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Da Costa, CA (corresponding author), Fdn Rech Med, Inst Pharmacol Mol & Cellulaire, UMR 6097,Equipe Labellisee, CNRS,UNSA, 660 Route Lucioles, F-06560 Valbonne, France.	acosta@ipmc.cnrs.fr; checler@ipmc.cnrs.fr	Kawarai, Toshitaka/C-2822-2013; Checler, Frederic/C-1241-2009; da Costa, Cristine Alves/G-8075-2011	Kawarai, Toshitaka/0000-0003-4547-8131; Checler, Frederic/0000-0003-2098-1750; da Costa, Cristine Alves/0000-0002-7777-005X				Araki W, 2001, J NEUROCHEM, V79, P1161, DOI 10.1046/j.1471-4159.2001.00638.x; Armogida M, 2001, NAT CELL BIOL, V3, P1030, DOI 10.1038/ncb1101-1030; Beglopoulos V, 2004, J BIOL CHEM, V279, P46907, DOI 10.1074/jbc.M409544200; Bursztajn S, 1998, J NEUROSCI, V18, P9790; Campbell WA, 2006, J NEUROCHEM, V96, P1423, DOI 10.1111/j.1471-4159.2006.03648.x; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chen FS, 2006, NATURE, V440, P1208, DOI 10.1038/nature04667; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; Cregan SP, 1999, J NEUROSCI, V19, P7860; da Costa CA, 2006, J NEUROSCI, V26, P6377, DOI 10.1523/JNEUROSCI.0651-06.2006; da Costa CA, 2003, J BIOL CHEM, V278, P12064, DOI 10.1074/jbc.M212379200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Decker Patrice, 2002, Current Pharmaceutical Biotechnology, V3, P275, DOI 10.2174/1389201023378265; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Dunys J, 2006, BIOCHEM J, V394, P501, DOI 10.1042/BJ20051197; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Engidawork E, 2001, NEUROSCI LETT, V303, P79, DOI 10.1016/S0304-3940(01)01618-4; Engidawork E, 2001, BIOCHEM BIOPH RES CO, V281, P84, DOI 10.1006/bbrc.2001.4306; Fisher DE, 2001, APOPTOSIS, V6, P7, DOI 10.1023/A:1009659708549; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Garcia-Ospina GP, 2003, REV NEUROLOGIA, V36, P1004, DOI 10.33588/rn.3611.2002533; GINSBERG D, 1990, ONCOGENE, V5, P1285; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Heber S, 2000, J NEUROSCI, V20, P7951; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hong CS, 1999, J NEUROSCI, V19, P637; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kitamura Y, 1997, BIOCHEM BIOPH RES CO, V232, P418, DOI 10.1006/bbrc.1997.6301; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Lai MT, 2006, J NEUROCHEM, V96, P118, DOI 10.1111/j.1471-4159.2005.03528.x; LaVoie MJ, 2003, J BIOL CHEM, V278, P37213, DOI 10.1074/jbc.M303941200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Li JH, 2003, J BIOL CHEM, V278, P33445, DOI 10.1074/jbc.M301288200; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Marx J, 2001, SCIENCE, V293, P2192, DOI 10.1126/science.293.5538.2192; Ohyagi Y, 2005, FASEB J, V19, P255, DOI 10.1096/fj.04-2637fje; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Rosen A, 1997, J CELL BIOCHEM, V64, P50, DOI 10.1002/(SICI)1097-4644(199701)64:1<50::AID-JCB8>3.0.CO;2-Z; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; Serneels L, 2005, P NATL ACAD SCI USA, V102, P1719, DOI 10.1073/pnas.0408901102; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wilson CA, 2002, NAT NEUROSCI, V5, P849, DOI 10.1038/nn898; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Xie ZC, 2004, J BIOL CHEM, V279, P34130, DOI 10.1074/jbc.M401094200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	66	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10516	10525		10.1074/jbc.M611572200	http://dx.doi.org/10.1074/jbc.M611572200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17276981	hybrid			2022-12-25	WOS:000245941000044
J	Hedou, J; Cieniewski-Bernard, C; Leroy, Y; Michalski, JC; Mounier, Y; Bastide, B				Hedou, Julie; Cieniewski-Bernard, Caroline; Leroy, Yves; Michalski, Jean-Claude; Mounier, Yvonne; Bastide, Bruno			O-linked N-acetylglucosaminylation is involved in the Ca2+ activation properties of rat skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY LIGHT-CHAINS; TIME-DEPENDENT CHANGES; RNA-POLYMERASE-II; SOLEUS MUSCLE; TROPONIN-C; HEAVY-CHAIN; CONTRACTILE PROPERTIES; CYTOPLASMIC PROTEINS; TERMINAL DOMAIN; NUCLEAR-PORE	O-Linked N-acetylglucosaminylation termed O-GlcNAc is a dynamic cytosolic and nuclear glycosylation that is dependent both on glucose flow through the hexosamine biosynthesis pathway and on phosphorylation because of the existence of a balance between phosphorylation and O-GlcNAc. This glycosylation is a ubiquitous post- translational modification, which probably plays an important role in many aspects of protein functions. We have previously reported that, in skeletal muscle, proteins of the glycolytic pathway, energetic metabolism, and contractile proteins were O-GlcNAc- modified and that O-GlcNAc variations could control the muscle protein homeostasis and be implicated in the regulation of muscular atrophy. In this paper, we report O-N-acetylglucosaminylation of a number of key contractile proteins ( i.e. myosin heavy and light chains and actin), which suggests that this glycosylation could be involved in skeletal muscle contraction. Moreover, our results showed that incubation of skeletal muscle skinned fibers in N-acetyl-D-glucosamine, in a concentration solution known to inhibit O-GlcNAc- dependent interactions, induced a decrease in calcium sensitivity and affinity of muscular fibers, whereas the cooperativity of the thin filament proteins was not modified. Thus, our results suggest that O-GlcNAc is involved in contractile protein interactions and could thereby modulate muscle contraction.	Univ Sci & Technol Lille, Lab Plast Neuromusculaire, Unite Neurosci & Physiol Adaptat, UPRES EA 4052, F-59655 Villeneuve Dascq, France; Univ Sci & Technol Lille, UMR Glycobiol Struct & Fonct 8576, CNRS, IFR 18, F-59655 Villeneuve Dascq, France	Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	Bastide, B (corresponding author), Univ Sci & Technol Lille, Lab Neurosci & Physiol Adaptat, EA 4052, UFR Biol, F-59655 Villeneuve Dascq, France.	bruno.bastide@univ-lille1.fr	Cieniewski-Bernard, Caroline/AAR-8967-2021; Cieniewski-Bernard, Caroline/AAK-7477-2021	Cieniewski-Bernard, Caroline/0000-0003-1449-0357; Bastide, bruno/0000-0002-7544-463X				Arnold CS, 1996, J BIOL CHEM, V271, P28741, DOI 10.1074/jbc.271.46.28741; Bastide B, 2002, PFLUG ARCH EUR J PHY, V444, P345, DOI 10.1007/s00424-002-0833-x; BLUMENTHAL DK, 1980, BIOCHEMISTRY-US, V19, P5608, DOI 10.1021/bi00565a023; Bozzo C, 2003, AM J PHYSIOL-CELL PH, V285, pC575, DOI 10.1152/ajpcell.00441.2002; BRANDT PW, 1982, J GEN PHYSIOL, V79, P997, DOI 10.1085/jgp.79.6.997; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; Cieniewski-Bernard C, 2006, J APPL PHYSIOL, V100, P1499, DOI 10.1152/japplphysiol.00865.2005; Cieniewski-Bernard C, 2004, MOL CELL PROTEOMICS, V3, P577, DOI 10.1074/mcp.M400024-MCP200; Cole RN, 1999, J NEUROCHEM, V73, P418, DOI 10.1046/j.1471-4159.1999.0730418.x; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; DATTA B, 1989, J BIOL CHEM, V264, P20620; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1993, J BIOL CHEM, V268, P16679; DONG DLY, 1994, J BIOL CHEM, V269, P19321; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Gao Y, 2003, ARCH BIOCHEM BIOPHYS, V415, P155, DOI 10.1016/S0003-9861(03)00234-0; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HANOVER JA, 1987, J BIOL CHEM, V262, P9887; Hanover JA, 2001, FASEB J, V15, P1865, DOI 10.1096/fj.01-0094rev; Hatsell S, 2003, J BIOL CHEM, V278, P37745, DOI 10.1074/jbc.M301346200; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; KELLY WG, 1993, J BIOL CHEM, V268, P10416; Kischel P, 2000, BRIT J PHARMACOL, V131, P1496, DOI 10.1038/sj.bjp.0703727; Kischel P, 2001, J APPL PHYSIOL, V90, P1095, DOI 10.1152/jappl.2001.90.3.1095; LUTHI T, 1991, J NEUROCHEM, V56, P1493; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MOISESCU DG, 1979, BIOCHIM BIOPHYS ACTA, V546, P64, DOI 10.1016/0005-2728(79)90170-1; MOSS RL, 1986, J BIOL CHEM, V261, P6096; MOUNIER Y, 1989, PFLUG ARCH EUR J PHY, V415, P136, DOI 10.1007/BF00370583; MURAKAMI N, 1988, J BIOCHEM, V103, P209, DOI 10.1093/oxfordjournals.jbchem.a122249; ORENTLICHER M, 1977, AM J PHYSIOL, V233, pC127, DOI 10.1152/ajpcell.1977.233.5.C127; PERSECHINI A, 1985, J BIOL CHEM, V260, P7951; Pol-Rodriguez MM, 2001, J MUSCLE RES CELL M, V22, P513, DOI 10.1023/A:1015083616319; REISER PJ, 1988, AM J PHYSIOL, V254, pC605, DOI 10.1152/ajpcell.1988.254.5.C605; ROQUEMORE EP, 1992, J BIOL CHEM, V267, P555; Roquemore EP, 1996, BIOCHEMISTRY-US, V35, P3578, DOI 10.1021/bi951918j; Stevens L, 1999, AM J PHYSIOL-CELL PH, V277, pC1044, DOI 10.1152/ajpcell.1999.277.6.C1044; Stevens L, 2002, AM J PHYSIOL-CELL PH, V282, pC1025, DOI 10.1152/ajpcell.00252.2001; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Szczesna D, 1996, J BIOL CHEM, V271, P8381, DOI 10.1074/jbc.271.14.8381; Szczesna D, 2002, J APPL PHYSIOL, V92, P1661, DOI 10.1152/japplphysiol.00858.2001; Szczesna D, 1996, J BIOL CHEM, V271, P5246; Terry M, 2006, CELL BIOCHEM BIOPHYS, V45, P265, DOI 10.1385/CBB:45:3:265; TORRES CR, 1984, J BIOL CHEM, V259, P3308; Toursel T, 2000, EXP NEUROL, V162, P311, DOI 10.1006/exnr.1999.7349; Verbert A., 1995, METHODS GLYCOCONJUGA; Wells L, 2003, BIOCHEM BIOPH RES CO, V302, P435, DOI 10.1016/S0006-291X(03)00175-X; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Whelan SA, 2003, CIRC RES, V93, P1047, DOI 10.1161/01.RES.0000103190.20260.37; WONG PC, 1990, J CELL BIOL, V111, P1987, DOI 10.1083/jcb.111.5.1987; XDING M, 1996, J BIOL CHEM, V271, P12555; Yki-Jarvinen H, 1998, METABOLISM, V47, P449, DOI 10.1016/S0026-0495(98)90058-0; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7	58	50	50	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10360	10369		10.1074/jbc.M606787200	http://dx.doi.org/10.1074/jbc.M606787200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17289664	Green Submitted, hybrid			2022-12-25	WOS:000245941000026
J	Kemp, M; Bae, B; Yu, JP; Ghosh, M; Leffak, M; Nair, SK				Kemp, Michael; Bae, Brian; Yu, John Paul; Ghosh, Maloy; Leffak, Michael; Nair, Satish K.			Structure and function of the c-myc DNA-unwinding element-binding protein DUE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; AUTOMATED STRUCTURE SOLUTION; REPLICATION ORIGIN ACTIVITY; HELA-CELLS; D-TYR-TRNA(TYR) DEACYLASE; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL LOCATION; DENSITY MODIFICATION; POLYMERASE-ALPHA	Local zones of easily unwound DNA are characteristic of prokaryotic and eukaryotic replication origins. The DNA-unwinding element of the human c-myc replication origin is essential for replicator activity and is a target of the DNA-unwinding element-binding protein DUE-B in vivo. We present here the 2.0 angstrom crystal structure of DUE-B and complementary biochemical characterization of its biological activity. The structure corresponds to a dimer of the N-terminal domain of the full-length protein and contains many of the structural elements of the nucleotide binding fold. A single magnesium ion resides in the putative active site cavity, which could serve to facilitate ATP hydrolytic activity of this protein. The structure also demonstrates a notable similarity to those of tRNA-editing enzymes. Consistent with this structural homology, the N-terminal core of DUE-B is shown to display both D-aminoacyl-tRNA deacylase activity and ATPase activity. We further demonstrate that the C-terminal portion of the enzyme is disordered and not essential for dimerization. However, this region is essential for DNA binding in vitro and becomes ordered in the presence of DNA.	Wright State Univ, Dept Biochem & Mol Biol, Boonshoft Sch Med, Dayton, OH 45435 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA	University System of Ohio; Wright State University Dayton; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Leffak, M (corresponding author), Wright State Univ, Dept Biochem & Mol Biol, Boonshoft Sch Med, Dayton, OH 45435 USA.	michael.leffak@wright.edu; snair@uiuc.edu	Nair, Satish/AAY-2510-2021; Kemp, Michael G./AAT-1545-2021	Kemp, Michael G./0000-0001-8203-0745; Yu, John-Paul/0000-0003-1878-052X	NIGMS NIH HHS [GM53819] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053819] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Benach J, 1998, J MOL BIOL, V282, P383, DOI 10.1006/jmbi.1998.2015; BERBERICH S, 1995, J MOL BIOL, V245, P92, DOI 10.1006/jmbi.1994.0010; Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237; Casper JM, 2005, J BIOL CHEM, V280, P13071, DOI 10.1074/jbc.M404754200; CASTROVIEJO M, 1982, BIOCHEM BIOPH RES CO, V107, P294, DOI 10.1016/0006-291X(82)91703-X; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DOBBS DL, 1994, NUCLEIC ACIDS RES, V22, P2479, DOI 10.1093/nar/22.13.2479; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Dwivedi S, 2005, NAT STRUCT MOL BIOL, V12, P556, DOI 10.1038/nsmb943; Fan L, 2006, J MOL BIOL, V358, P1229, DOI 10.1016/j.jmb.2006.02.073; Ferri-Fioni ML, 2001, J BIOL CHEM, V276, P47285, DOI 10.1074/jbc.M106550200; Ghosh M, 2004, MOL CELL BIOL, V24, P10193, DOI 10.1128/MCB.24.23.10193-10207.2004; Ghosh M, 2006, MOL CELL BIOL, V26, P5270, DOI 10.1128/MCB.02137-05; Gilbert DM, 2001, SCIENCE, V294, P96, DOI 10.1126/science.1061724; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Huang RY, 1996, NUCLEIC ACIDS RES, V24, P816, DOI 10.1093/nar/24.5.816; HUANG RY, 1993, EMBO J, V12, P4521, DOI 10.1002/j.1460-2075.1993.tb06141.x; Hussain T, 2006, EMBO J, V25, P4152, DOI 10.1038/sj.emboj.7601278; Iakoucheva LM, 2001, PROTEIN SCI, V10, P560, DOI 10.1110/ps.29401; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; Kemp MG, 2005, NUCLEIC ACIDS RES, V33, P325, DOI 10.1093/nar/gki177; Kim MJ, 2003, NAT GENET, V34, P330, DOI 10.1038/ng1182; LEFFAK M, 1989, MOL CELL BIOL, V9, P586, DOI 10.1128/MCB.9.2.586; Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30; Lim K, 2003, J BIOL CHEM, V278, P13496, DOI 10.1074/jbc.M213150200; Liu GQ, 2003, MOL CELL BIOL, V23, P1832, DOI 10.1128/MCB.23.5.1832-1842.2003; Malott M, 1999, MOL CELL BIOL, V19, P5685; MCWHINNEY C, 1995, DNA CELL BIOL, V14, P565, DOI 10.1089/dna.1995.14.565; MCWHINNEY C, 1990, NUCLEIC ACIDS RES, V18, P1233, DOI 10.1093/nar/18.5.1233; Mechali M, 2001, NAT REV GENET, V2, P640, DOI 10.1038/35084598; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NATALE DA, 1993, NUCLEIC ACIDS RES, V21, P555, DOI 10.1093/nar/21.3.555; Ng KKS, 2004, J BIOL CHEM, V279, P16638, DOI 10.1074/jbc.M400584200; Ng KKS, 2002, J BIOL CHEM, V277, P1381, DOI 10.1074/jbc.M109261200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park SG, 2005, TRENDS BIOCHEM SCI, V30, P569, DOI 10.1016/j.tibs.2005.08.004; RAPAPORT E, 1981, P NATL ACAD SCI-BIOL, V78, P838, DOI 10.1073/pnas.78.2.838; Rein T, 1999, J BIOL CHEM, V274, P25792, DOI 10.1074/jbc.274.36.25792; Romero Pedro, 2004, Appl Bioinformatics, V3, P105, DOI 10.2165/00822942-200403020-00005; Schwob E, 2004, CURR OPIN MICROBIOL, V7, P680, DOI 10.1016/j.mib.2004.10.017; Shi L, 1998, FEMS MICROBIOL REV, V22, P229, DOI 10.1016/S0168-6445(98)00015-1; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; Soutourina J, 2000, J BIOL CHEM, V275, P11626, DOI 10.1074/jbc.275.16.11626; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Tao L, 2000, J CELL BIOCHEM, V78, P442, DOI 10.1002/1097-4644(20000901)78:3<442::AID-JCB9>3.0.CO;2-1; Terwilliger TC, 2003, METHOD ENZYMOL, V374, P22, DOI 10.1016/S0076-6879(03)74002-6; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Trivedi A, 1998, DNA CELL BIOL, V17, P885, DOI 10.1089/dna.1998.17.885; UMEK RM, 1988, CELL, V52, P559, DOI 10.1016/0092-8674(88)90469-2; UMEK RM, 1990, P NATL ACAD SCI USA, V87, P2486, DOI 10.1073/pnas.87.7.2486; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; Waltz SE, 1996, NUCLEIC ACIDS RES, V24, P1887, DOI 10.1093/nar/24.10.1887; Wilmes GM, 2002, P NATL ACAD SCI USA, V99, P101, DOI 10.1073/pnas.012578499; Yang W, 2006, MOL CELL, V22, P5, DOI 10.1016/j.molcel.2006.03.013; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189	58	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10441	10448		10.1074/jbc.M609632200	http://dx.doi.org/10.1074/jbc.M609632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17264083	hybrid			2022-12-25	WOS:000245941000035
J	Esnault, S; Braun, RK; Shen, ZJ; Xiang, ZZ; Heninger, E; Love, RB; Sandor, M; Malter, JS				Esnault, Stephane; Braun, Ruedi K.; Shen, Zhong-Jian; Xiang, Zhuzai; Heninger, Erika; Love, Robert B.; Sandor, Matyas; Malter, James S.			Pin1 Modulates the Type 1 Immune Response	PLOS ONE			English	Article								Background/Abstract. Immune responses initiated by T cell receptor (TCR) and costimulatory molecule mediated signaling culminate in maximal cytokine mRNA production and stability. The transcriptional responses to co-stimulatory T cell signalling involve calcineurin and NF-AT, which can be antagonized by interference with the cis-trans peptidyl-prolyl isomerases (PPIase), cyclophilin A and FKBP. Signalling molecules downstream of CD28 which are essential for the stabilization of cytokine mRNAs are largely unknown. Methodology/Principal Findings. We now show that Pin1, a third member of the PPIase family mediates the post-transcriptional regulation of Th1 cytokines by activated T cells. Blockade of Pin1 by pharmacologic or genetic means greatly attenuated IFN-gamma, IL-2 and CXCL-10 mRNA stability, accumulation and protein expression after cell activation. In vivo, Pin1 blockade prevented both the acute and chronic rejection of MHC mismatched, orthotopic rat lung transplants by reducing the expression of IFN-gamma and CXCL-10. Combined transcriptional and post-transcriptional blockade with cyclosporine A and the Pin1 inhibitor, juglone, was synergistic. Conclusions/Significance. These data suggest Pin1 inhibitors should be explored for use as immunosuppressants and employed with available calcineurin inhibitors to reduce toxicity and enhance effectiveness.	[Esnault, Stephane; Shen, Zhong-Jian; Heninger, Erika; Sandor, Matyas; Malter, James S.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; [Esnault, Stephane; Shen, Zhong-Jian; Malter, James S.] Waisman Ctr Dev Disabil, Madison, WI USA; [Braun, Ruedi K.; Xiang, Zhuzai; Love, Robert B.] Univ Wisconsin, Dept Surg, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Malter, JS (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.	jsmalter@wisc.edu	Esnault, Stephane/AAJ-4511-2020; Heninger, Erika/AAJ-8408-2021; Esnault, Stephane/AAO-4712-2020	Esnault, Stephane/0000-0001-7238-8671; Braun, Rudolf/0000-0002-1778-9613; Heninger, Erika/0000-0003-0166-9972	NIH P50HL56396; Department of Surgery; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056396] Funding Source: NIH RePORTER	NIH P50HL56396; Department of Surgery; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	NIH (P50HL56396 to J.S.M.) and the Department of Surgery (to R. K. B.).	Agostini C, 2001, AM J PATHOL, V158, P1703, DOI 10.1016/S0002-9440(10)64126-0; Ayala G, 2003, CANCER RES, V63, P6244; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; Chao SH, 2001, NUCLEIC ACIDS RES, V29, P767, DOI 10.1093/nar/29.3.767; Duncan Michael D, 2005, Proc Am Thorac Soc, V2, P449, DOI 10.1513/pats.200507-073JS; Esnault S, 2006, J IMMUNOL, V177, P6999, DOI 10.4049/jimmunol.177.10.6999; Gothel SF, 1999, CELL MOL LIFE SCI, V55, P423, DOI 10.1007/s000180050299; Hancock WW, 2001, J EXP MED, V193, P975, DOI 10.1084/jem.193.8.975; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Haque MA, 2002, J IMMUNOL, V169, P1542, DOI 10.4049/jimmunol.169.3.1542; Haring JS, 2005, J IMMUNOL, V174, P6791, DOI 10.4049/jimmunol.174.11.6791; Hauser IA, 2005, J AM SOC NEPHROL, V16, P1849, DOI 10.1681/ASN.2004100836; Hennig L, 1998, BIOCHEMISTRY-US, V37, P5953, DOI 10.1021/bi973162p; Hodge G, 2005, CLIN EXP IMMUNOL, V139, P159, DOI 10.1111/j.1365-2249.2005.02671.x; Kitade H, 2004, TRANSPLANTATION, V78, P1747, DOI 10.1097/01.TP.0000147788.23922.5B; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lu KP, 2004, TRENDS BIOCHEM SCI, V29, P200, DOI 10.1016/j.tibs.2004.02.002; Lu KP, 1996, NATURE, V380, P544; Mavropoulos A, 2005, BLOOD, V105, P282, DOI 10.1182/blood-2004-07-2782; Mizobucbi T, 2003, J IMMUNOL, V171, P1140, DOI 10.4049/jimmunol.171.3.1140; Nickel P, 2004, TRANSPLANTATION, V78, P1640, DOI 10.1097/01.TP.0000144057.31799.6A; Pierog J, 2005, EUR J CARDIO-THORAC, V27, P1030, DOI 10.1016/j.ejcts.2005.03.008; Reinders MEJ, 2003, J CLIN INVEST, V112, P1655, DOI 10.1172/JCI200317712; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Sekine Y, 1997, J IMMUNOL, V159, P4084; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shen ZJ, 2005, NAT IMMUNOL, V6, P1280, DOI 10.1038/ni1266; van Besouw NM, 2005, CLIN EXP IMMUNOL, V141, P534, DOI 10.1111/j.1365-2249.2005.02871.x; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yi T, 2006, TRANSPLANTATION, V81, P559, DOI 10.1097/01.tp.0000198737.12507.19; Zhao DXM, 2002, J IMMUNOL, V169, P1556, DOI 10.4049/jimmunol.169.3.1556; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	34	30	37	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 21	2007	2	2							e226	10.1371/journal.pone.0000226	http://dx.doi.org/10.1371/journal.pone.0000226			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DK	17311089	Green Submitted, gold, Green Published			2022-12-25	WOS:000207444500007
J	Ramis, JM; Collart, C; Smith, JC				Ramis, Joana M.; Collart, Clara; Smith, James C.			Xnrs and Activin Regulate Distinct Genes during Xenopus Development: Activin Regulates Cell Division	PLOS ONE			English	Article								Background. The mesoderm of the amphibian embryo is formed through an inductive interaction in which vegetal cells of the blastula-staged embryo act on overlying equatorial cells. Candidate mesoderm-inducing factors include members of the transforming growth factor type beta family such as Vg1, activin B, the nodal-related proteins and derriere. Methodology and Principle Findings. Microarray analysis reveals different functions for activin B and the nodal-related proteins during early Xenopus development. Inhibition of nodal-related protein function causes the down-regulation of regionally expressed genes such as chordin, dickkopf and XSox17 alpha/beta, while genes that are mis-regulated in the absence of activin B tend to be more widely expressed and, interestingly, include several that are involved in cell cycle regulation. Consistent with the latter observation, cells of the involuting dorsal axial mesoderm, which normally undergo cell cycle arrest, continue to proliferate when the function of activin B is inhibited. Conclusions/Significance. These observations reveal distinct functions for these two classes of the TGF-beta family during early Xenopus development, and in doing so identify a new role for activin B during gastrulation.	[Smith, James C.] Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge, England; Univ Cambridge, Dept Zool, Cambridge, England	University of Cambridge; University of Cambridge	Smith, JC (corresponding author), Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge, England.	jim@gurdon.cam.ac.uk	Ramis, Joana Maria/AAF-4892-2020	Ramis, Joana Maria/0000-0001-9109-8362; Smith, Jim/0000-0003-2413-9392	Wellcome Trust; EC; Medical Research Council [G0300723B] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); EC(European CommissionEuropean Commission Joint Research Centre); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work is supported by the Wellcome Trust, an EC Marie Curie Individual Fellowship to JMR, and the EC Network of Excellence 'Cells into Organs'.	Agius E, 2000, DEVELOPMENT, V127, P1173; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; Bellefroid EJ, 1998, EMBO J, V17, P191, DOI 10.1093/emboj/17.1.191; Birsoy B, 2006, DEVELOPMENT, V133, P15, DOI 10.1242/dev.02144; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Burdette JE, 2005, CANCER RES, V65, P7968, DOI 10.1158/0008-5472.CAN-04-3553; Chalmers AD, 2005, MECH DEVELOP, V122, P355, DOI 10.1016/j.mod.2004.09.004; Deardorff' MA, 1998, DEVELOPMENT, V125, P2687; DOHRMANN CE, 1993, DEV BIOL, V157, P474, DOI 10.1006/dbio.1993.1150; Dorey K, 2006, DEV BIOL, V292, P303, DOI 10.1016/j.ydbio.2006.01.006; Dyson S, 1997, CURR BIOL, V7, P81, DOI 10.1016/S0960-9822(06)00030-3; Fletcher G, 2006, MECH DEVELOP, V123, P730, DOI 10.1016/j.mod.2006.07.007; Gilchrist MJ, 2004, DEV BIOL, V271, P498, DOI 10.1016/j.ydbio.2004.04.023; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Heasman J, 1997, DEVELOPMENT, V124, P4179; Ho J, 2004, CELL SIGNAL, V16, P693, DOI 10.1016/j.cellsig.2003.11.002; Hudson C, 1997, CELL, V91, P397, DOI 10.1016/S0092-8674(00)80423-7; Jones CM, 1996, CURR BIOL, V6, P1468, DOI 10.1016/S0960-9822(96)00751-8; Jones CM, 1999, CURR BIOL, V9, P946, DOI 10.1016/S0960-9822(99)80421-7; JONES CM, 1995, DEVELOPMENT, V121, P3651; JONES SD, 1993, DEV GENET, V14, P185, DOI 10.1002/dvg.1020140305; Joseph EM, 1997, DEV BIOL, V184, P367, DOI 10.1006/dbio.1997.8510; Khokha MK, 2002, DEV DYNAM, V225, P499, DOI 10.1002/dvdy.10184; Kumar A, 2001, J BIOL CHEM, V276, P656, DOI 10.1074/jbc.M004649200; Kurth T, 2005, MECH DEVELOP, V122, P1251, DOI 10.1016/j.mod.2005.09.002; Lee HX, 2006, CELL, V124, P147, DOI 10.1016/j.cell.2005.12.018; Lee MA, 2001, DEVELOPMENT, V128, P2939; Leise WF, 2004, DEVELOPMENT, V131, P1703, DOI 10.1242/dev.01054; Marchant L, 1998, DEV GENES EVOL, V208, P157, DOI 10.1007/s004270050167; Murakami MS, 2004, DEVELOPMENT, V131, P571, DOI 10.1242/dev.00971; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; Onuma Y, 2006, DEVELOPMENT, V133, P237, DOI 10.1242/dev.02188; Pera EM, 2003, GENE EXPR PATTERNS, V3, P147, DOI 10.1016/S1567-133X(03)00011-5; Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820; Piepenburg O, 2004, DEVELOPMENT, V131, P4977, DOI 10.1242/dev.01323; Pollet N, 2005, MECH DEVELOP, V122, P365, DOI 10.1016/j.mod.2004.11.009; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; Saka Y, 2001, DEV BIOL, V229, P307, DOI 10.1006/dbio.2000.0101; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Sinner D, 2006, DEVELOPMENT, V133, P1955, DOI 10.1242/dev.02358; SLACK JMW, 1984, J EMBRYOL EXP MORPH, V80, P289; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; Sun BI, 1999, DEVELOPMENT, V126, P1467; Takahashi S, 2000, DEVELOPMENT, V127, P5319; Toyoizumi R, 2005, INT J DEV BIOL, V49, P923, DOI 10.1387/ijdb.052008rt; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; Wessely O, 2004, DEV BIOL, V269, P552, DOI 10.1016/j.ydbio.2004.01.018; Williams PH, 2004, CURR BIOL, V14, P1916, DOI 10.1016/j.cub.2004.10.020	52	21	21	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2007	2	2							e213	10.1371/journal.pone.0000213	http://dx.doi.org/10.1371/journal.pone.0000213			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DJ	17299593	gold, Green Published, Green Submitted			2022-12-25	WOS:000207444400014
J	Lauth, M; Bergstrom, A; Toftgard, R				Lauth, M.; Bergstrom, A.; Toftgard, R.			Phorbol esters inhibit the Hedgehog signalling pathway downstream of Suppressor of Fused, but upstream of Gli	ONCOGENE			English	Article						hedgehog signalling; phorbol ester; protein kinase C	BASAL-CELL CARCINOMA; PROTEIN-KINASE-A; TRANSCRIPTIONAL ACTIVITY; BETA-TRCP; EXPRESSION; UBIQUITINATION; TRANSFORMATION; FIBROBLASTS; DEGRADATION; MODULATION	The developmentally important Hedgehog ( Hh) signal transduction pathway, which has recently been implicated in several forms of cancer, is subject to regulation by several protein kinases. Here, we address the role of protein kinase Cd in pathway inhibition and show that cellular depletion or pharmacological inhibition of this kinase isoform results in a blockade of signalling between Suppressor of Fused and the Gli transcription factors. We further provide evidence that the observed pathway inhibition is independent of primary cilia and the mitogen- activated protein kinase kinase ( Mek1) kinase. These. findings allowed for the rapid dissection of downstream Hh pathway activation mechanisms in human tumour cells and demonstrate a surprising variation in how cells can activate signalling in a ligand- and receptor-independent manner.	Karolinska Inst, Dept Biosci & Nutr, SE-14157 Huddinge, Sweden	Karolinska Institutet	Lauth, M (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Novum Res Pk,Halsovagen 7, SE-14157 Huddinge, Sweden.	matthias.lauth@biosci.ki.se		Lauth, Matthias/0000-0001-5922-5384				Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; Huangfu DW, 2003, NATURE, V426, P83, DOI 10.1038/nature02061; Kaesler S, 2000, BIOL CHEM, V381, P545, DOI 10.1515/BC.2000.070; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Liu QY, 2000, CANCER LETT, V153, P13, DOI 10.1016/S0304-3835(99)00417-6; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Mao JH, 2002, J BIOL CHEM, V277, P35156, DOI 10.1074/jbc.M206743200; Neill GW, 2003, CANCER RES, V63, P4692; Ohno S, 2002, J BIOCHEM, V132, P509, DOI 10.1093/oxfordjournals.jbchem.a003249; OKAZAKI K, 1995, ONCOGENE, V10, P1149; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Sheng T, 2006, J BIOL CHEM, V281, P9, DOI 10.1074/jbc.C500300200; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tempe D, 2006, MOL CELL BIOL, V26, P4316, DOI 10.1128/MCB.02183-05; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103	30	31	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5163	5168		10.1038/sj.onc.1210321	http://dx.doi.org/10.1038/sj.onc.1210321			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310984				2022-12-25	WOS:000248487400015
J	Murayama, K; Kimura, T; Tarutani, M; Tomooka, M; Hayashi, R; Okabe, M; Nishida, K; Itami, S; Katayama, I; Nakano, T				Murayama, K.; Kimura, T.; Tarutani, M.; Tomooka, M.; Hayashi, R.; Okabe, M.; Nishida, K.; Itami, S.; Katayama, I.; Nakano, T.			Akt activation induces epidermal hyperplasia and proliferation of epidermal progenitors	ONCOGENE			English	Article						Akt; epidermis; hair follicle; stem cells; proliferation	HAIR FOLLICLE MORPHOGENESIS; HEMATOPOIETIC STEM-CELLS; BETA-CATENIN; TRANSIENT ACTIVATION; PTEN; MOUSE; MICE; SKIN; POPULATIONS; SUFFICIENT	Various common signaling pathways maintain tissue stem cells, including Notch and Wnt/beta-catenin signals. Phosphoinositide3 kinase (PI3K)/Akt signaling regulates the 'stemness' of several stem cells in culture, specifically in maintaining embryonic stem and neural stem cells, and in deriving embryonic germ cells from primordial germ cells. We examined the effect of Akt signaling in epidermal cells in transgenic mice expressing an Akt-Mer fusion protein whose kinase activity was conditionally activated by treatment with 4-hydroxytamoxifen (4OHT). The topical application of 4OHT to adult skin of the transgenic mice induced new hair growth in resting phase follicles. In addition, the mice showed hyperplasia in interfollicular epidermis (IFE) and hair follicles, which was presumably caused by the extensive proliferation of keratinocytes in basal layer of IFE and outer root sheath of hair follicles, respectively. The progenitor cell population increased consistently in 4OHT-treated transgenic mice. Our results show that PI3K/Akt signaling induces epidermal hyperplasia and proliferation of epidermal progenitors.	Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 565, Japan; Osaka Univ, Grad Sch Med, Dept Dermatol, Suita, Osaka 565, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Pathol Div, Suita, Osaka 565, Japan; Tohoku Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Aoba Ku, Sendai, Miyagi 980, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Expt Genome Res, Genome Informat Res Ctr, Suita, Osaka 565, Japan; Grad Sch Med, Dept Regenerat Dermatol, Suita, Osaka, Japan	Osaka University; Osaka University; Osaka University; Tohoku University; Osaka University	Kimura, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Pathol, 2-2 Yamada Oka, Suita, Osaka 565, Japan.	tkimura@patho.med.osaka-u.ac.jp	Hayashi, Ryuhei/AAW-4737-2020; Okabe, Masaru/B-6917-2015	Kimura, Tohru/0000-0001-9227-0996; Nishida, Kohji/0000-0001-9069-3610; Hayashi, Ryuhei/0000-0002-4699-8617; Okabe, Masaru/0000-0002-0803-9044				Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Di-Poi N, 2005, MOL CELL BIOL, V25, P1696, DOI 10.1128/MCB.25.5.1696-1712.2005; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Ghazizadeh S, 2001, EMBO J, V20, P1215, DOI 10.1093/emboj/20.6.1215; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Kimura T, 2003, DEVELOPMENT, V130, P1691, DOI 10.1242/dev.00392; Kishimoto H, 2003, CELL STRUCT FUNCT, V28, P11; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Levy V, 2005, DEV CELL, V9, P855, DOI 10.1016/j.devcel.2005.11.003; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lo Celso C, 2004, DEVELOPMENT, V131, P1787, DOI 10.1242/dev.01052; MORRIS RJ, 1987, CANCER LETT, V34, P297, DOI 10.1016/0304-3835(87)90180-7; Muller-Rover S, 2001, J INVEST DERMATOL, V117, P3, DOI 10.1046/j.0022-202x.2001.01377.x; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Suzuki A, 2003, CANCER RES, V63, P674; Van Mater D, 2003, GENE DEV, V17, P1219, DOI 10.1101/gad.1076103; Watanabe S, 2006, ONCOGENE, V25, P2697, DOI 10.1038/sj.onc.1209307; Watt FM, 2001, CURR OPIN GENET DEV, V11, P410, DOI 10.1016/S0959-437X(00)00211-2; Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	31	59	61	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4882	4888		10.1038/sj.onc.1210274	http://dx.doi.org/10.1038/sj.onc.1210274			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297448				2022-12-25	WOS:000248170400014
J	Su, QN; Zhou, YF; Johns, RA				Su, Qingning; Zhou, Yifu; Johns, Roger A.			Bruton's tyrosine kinase (BTK) is a binding partner for hypoxia induced mitogenic factor (HIMF/FIZZ1) and mediates myeloid cell chemotaxis	FASEB JOURNAL			English	Article						resistin; LFM-A13; migration	X-LINKED AGAMMAGLOBULINEMIA; GENE FAMILY; INFLAMMATION; PLATELETS; DOMAIN	Hypoxia induced mitogenic factor (HIMF) is a member of the FIZZ/ resistin/RELM family of proteins that we have shown to have potent mitogenic, angiogenic, and vasoconstrictive effects in the lung vasculature. In the current report, we identified Bruton's tyrosine kinase (BTK) as a functional HIMF binding partner through glutathione S-transferase (GST)-HIMF pull-down studies and mass spectrometry. Using primary cultured HIMF-stimulated murine bone marrow cells, we demonstrated that HIMF causes redistribution of BTK to the leading edge of the cells. HIMF stimulation induced BTK autophosphorylation, which peaked at 2.5 min. A transwell migration assay showed that treatment with recombinant murine HIMF induced migration of primary cultured bone marrow cells that was completely blocked by the BTK inhibitor, LFM-A13. Our results demonstrate BTK as the first known functional binding partner of the HIMF/FIZZ family of proteins and that HIMF acts as a chemotatic molecule in stimulating the migration of myeloid cells through activation of the BTK pathway.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA	Johns Hopkins University	Johns, RA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Ross 361,720 Rutland Ave, Baltimore, MD 21205 USA.	rajohns@jhmi.edu						Abassi YA, 2003, J BIOL CHEM, V278, P35636, DOI 10.1074/jbc.M306438200; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chumakov AM, 2004, ONCOGENE, V23, P3414, DOI 10.1038/sj.onc.1207126; Hamazaki Y, 1998, ONCOGENE, V16, P2773, DOI 10.1038/sj.onc.1201799; Holcomb IN, 2000, EMBO J, V19, P4046, DOI 10.1093/emboj/19.15.4046; Jefferies CA, 2004, IMMUNOL LETT, V92, P15, DOI 10.1016/j.imlet.2003.11.017; Laffargue M, 1999, FEBS LETT, V443, P66, DOI 10.1016/S0014-5793(98)01680-9; Mangla A, 2004, BLOOD, V104, P1191, DOI 10.1182/blood-2004-01-0207; Scapini P, 2004, J IMMUNOL, V172, P5034, DOI 10.4049/jimmunol.172.8.5034; Teng XW, 2003, CIRC RES, V92, P1065, DOI 10.1161/01.RES.0000073999.07698.33; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wagner KF, 2004, AM J RESP CELL MOL, V31, P276, DOI 10.1165/rcmb.2003-0319OC; Xu K, 2000, J IMMUNOL, V164, P4916, DOI 10.4049/jimmunol.164.9.4916; YAMAJIKEGAN K, 2006, AM J PHYSL LUNG CELL	18	29	33	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1376	1382		10.1096/fj.06-6527com	http://dx.doi.org/10.1096/fj.06-6527com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264170				2022-12-25	WOS:000246117000013
J	Hines, JK; Fromm, HJ; Honzatko, RB				Hines, Justin K.; Fromm, Herbert J.; Honzatko, Richard B.			Structures of activated fructose-1,6-bisphosphatase from Escherichia coli - Coordinate regulation of bacterial metabolism and the conservation of the R-state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRUCTOSE-BISPHOSPHATASE; CRYSTAL-STRUCTURE; EXPRESSION; AMP; PURIFICATION; INHIBITION; MECHANISM; ENZYME; LIVER; GENE	The enteric bacterium Escherichia coli requires fructose-1,6-bisphosphatase ( FBPase) for growth on gluconeogenic carbon sources. Constitutive expression of FBPase and fructose-6-phosphate-1-kinase coupled with the absence of futile cycling implies an undetermined mechanism of coordinate regulation involving both enzymes. Tricarboxylic acids and phosphorylated three-carbon carboxylic acids, all intermediates of glycolysis and the tricarboxylic acid cycle, are shown here to activate E. coli FBPase. The two most potent activators, phosphoenolpyruvate and citrate, bind to the sulfate anion site, revealed previously in the first crystal structure of the E. coli enzyme. Tetramers ligated with either phosphoenolpyruvate or citrate, in contrast to the sulfate-bound structure, are in the canonical R-state of porcine FBPase but nevertheless retain sterically blocked AMP pockets. At physiologically relevant concentrations, phosphoenolpyruvate and citrate stabilize an active tetramer over a less active enzyme form of mass comparable with that of a dimer. The above implies the conservation of the R-state through evolution. FBPases of heterotrophic organisms of distantly related phylogenetic groups retain residues of the allosteric activator site and in those instances where data are available exhibit activation by phosphoenolpyruvate. Findings here unify disparate observations regarding bacterial FBPases, implicating a mechanism of feed-forward activation in bacterial central metabolism.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Honzatko, RB (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, 4206 Mol Biol Bldg, Ames, IA 50011 USA.	honzatko@iastate.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546, R01 NS010546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BABUL J, 1983, ARCH BIOCHEM BIOPHYS, V225, P944, DOI 10.1016/0003-9861(83)90109-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BLANGY D, 1968, J MOL BIOL, V31, P13, DOI 10.1016/0022-2836(68)90051-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAYLEY S, 1991, J MOL BIOL, V222, P281, DOI 10.1016/0022-2836(91)90212-O; CHAMBOST JP, 1980, J BIOL CHEM, V255, P2867; CHIN AM, 1989, J BACTERIOL, V171, P2424, DOI 10.1128/jb.171.5.2424-2434.1989; CHIN AM, 1987, J BACTERIOL, V169, P897, DOI 10.1128/jb.169.2.897-899.1987; Choe JY, 2003, J BIOL CHEM, V278, P51176, DOI 10.1074/jbc.M308396200; DALDAL F, 1983, J BACTERIOL, V153, P390, DOI 10.1128/JB.153.1.390-394.1983; Donahue JL, 2000, J BACTERIOL, V182, P5624, DOI 10.1128/JB.182.19.5624-5627.2000; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS P, 1992, MRC LAB MOL BIOL; FRAENKEL DG, 1966, ARCH BIOCHEM BIOPHYS, V114, P4, DOI 10.1016/0003-9861(66)90298-0; FRAENKEL DG, 1965, J BACTERIOL, V90, P837, DOI 10.1128/JB.90.4.837-842.1965; FRANZEN JS, 1961, J BIOL CHEM, V236, P515; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; Fujita Y, 1998, J BACTERIOL, V180, P4309, DOI 10.1128/JB.180.16.4309-4313.1998; FUJITA Y, 1979, J BIOL CHEM, V254, P5340; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Hines JK, 2006, J BIOL CHEM, V281, P18386, DOI 10.1074/jbc.M602553200; Iancu CV, 2006, BIOCHEMISTRY-US, V45, P11703, DOI 10.1021/bi0607498; Iancu CV, 2005, J BIOL CHEM, V280, P19737, DOI 10.1074/jbc.M501011200; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; Kelley-Loughnane N, 2002, BBA-PROTEIN STRUCT M, V1594, P6, DOI 10.1016/S0167-4838(01)00261-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWRY OH, 1971, J BIOL CHEM, V246, P6511; Lu GQ, 1997, J BIOL CHEM, V272, P5076, DOI 10.1074/jbc.272.8.5076; MARCUS F, 1984, BIOCHEM BIOPH RES CO, V119, P1103, DOI 10.1016/0006-291X(84)90888-X; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Movahedzadeh F, 2004, MICROBIOL-SGM, V150, P3499, DOI 10.1099/mic.0.27204-0; Naderer T, 2006, P NATL ACAD SCI USA, V103, P5502, DOI 10.1073/pnas.0509196103; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nelson SW, 2002, J BIOL CHEM, V277, P15539, DOI 10.1074/jbc.M112304200; Nelson SW, 2001, FEBS LETT, V492, P254, DOI 10.1016/S0014-5793(01)02262-1; Nishimasu H, 2004, STRUCTURE, V12, P949, DOI 10.1016/j.str.2004.03.026; Oh MK, 2002, J BIOL CHEM, V277, P13175, DOI 10.1074/jbc.M110809200; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; OPHEIM DJ, 1975, J BIOL CHEM, V250, P3024; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; RAMSEIER TM, 1995, MOL MICROBIOL, V16, P1157, DOI 10.1111/j.1365-2958.1995.tb02339.x; REEVES RE, 1973, BIOCHEM BIOPH RES CO, V50, P459, DOI 10.1016/0006-291X(73)90862-0; Rittmann D, 2003, ARCH MICROBIOL, V180, P285, DOI 10.1007/s00203-003-0588-6; Sato T, 2004, J BACTERIOL, V186, P5799, DOI 10.1128/JB.186.17.5799-5807.2004; SEDIVY JM, 1986, P NATL ACAD SCI USA, V83, P1656, DOI 10.1073/pnas.83.6.1656; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; Stec B, 2000, NAT STRUCT BIOL, V7, P1046, DOI 10.1038/80968; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Yanez AJ, 2003, J CELL PHYSIOL, V197, P189, DOI 10.1002/jcp.10337; YOSHIDA M, 1973, J BIOCHEM-TOKYO, V74, P1183, DOI 10.1093/oxfordjournals.jbchem.a130346; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	58	25	26	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11696	11704		10.1074/jbc.M611104200	http://dx.doi.org/10.1074/jbc.M611104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17314096	hybrid			2022-12-25	WOS:000245941900011
J	Mukrasch, MD; von Bergen, M; Biernat, J; Fischer, D; Griesinger, C; Mandelkow, E; Zweckstetter, M				Mukrasch, Marco D.; von Bergen, Martin; Biernat, Jacek; Fischer, Daniela; Griesinger, Christian; Mandelkow, Eckhard; Zweckstetter, Markus			The "jaws" of the Tau-microtubule interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; RESIDUAL DIPOLAR COUPLINGS; ALZHEIMERS-DISEASE BRAIN; BETA-STRUCTURE; PROTEIN-TAU; RANDOM COIL; CHEMICAL-SHIFTS; ALPHA-SYNUCLEIN; IN-VITRO; LIMITED PROTEOLYSIS	Tau is the major microtubule-associated protein in neuronal axons. It aggregates into "neurofibrillary tangles" during the course of Alzheimer disease. Binding to microtubules and microtubule assembly requires the "repeat domain" in the C-terminal half of Tau, as well as the two regions flanking the repeats. Here we report the NMR characterization of a 198-residue Tau fragment composed of the four tandem repeats and the flanking domains and containing the full microtubule binding and assembly activity of Tau. NMR secondary chemical shifts and dipolar couplings detect the highest propensity for beta-structure within the four-repeat region, whereas the flanking domains are largely random coil, with an increased rigidity in the proline-rich region. Chemical shift perturbation experiments identify two motifs in the upstream flanking domain, (225)KVAVVRT(231) and (243)LQTA(246), and one downstream of the repeats, (KIETHKTFREN380)-K-370, which strongly contribute to the binding to the acidic outside of microtubules, as well as to the binding of other polyanions such as heparin. This is consistent with the "jaws" model of Tau-microtubule interactions and highlights the importance of the regions flanking the repeats for both microtubule binding and pathological Tau aggregation.	Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, D-37077 Gottingen, Germany; DESY, Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany	Max Planck Society; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society	Zweckstetter, M (corresponding author), Max Planck Inst Biophys Chem, Dept NMR Based Struct Biol, Fassberg 11, D-37077 Gottingen, Germany.	mzwecks@gwdg.de	von Bergen, Martin/D-7960-2011	von Bergen, Martin/0000-0003-2732-2977; Zweckstetter, Markus/0000-0002-2536-6581				Ackmann M, 2000, J BIOL CHEM, V275, P30335, DOI 10.1074/jbc.M002590200; Barghorn S, 2004, BIOCHEMISTRY-US, V43, P1694, DOI 10.1021/bi0357006; Barre P, 2006, J MOL BIOL, V362, P312, DOI 10.1016/j.jmb.2006.07.018; Bernado P, 2005, J AM CHEM SOC, V127, P17968, DOI 10.1021/ja055538p; Berriman J, 2003, P NATL ACAD SCI USA, V100, P9034, DOI 10.1073/pnas.1530287100; Bertoncini CW, 2005, P NATL ACAD SCI USA, V102, P1430, DOI 10.1073/pnas.0407146102; Bielska AA, 2006, BIOCHEMISTRY-US, V45, P5527, DOI 10.1021/bi052662c; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; Bussell R, 2001, J BIOL CHEM, V276, P45996, DOI 10.1074/jbc.M106777200; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Cassimeris L, 2001, INT REV CYTOL, V210, P163; Craik D J, 1997, Methods Mol Biol, V60, P195; Delacourte Andre, 2000, Current Opinion in Neurology, V13, P371, DOI 10.1097/00019052-200008000-00002; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeTure MA, 2002, J BIOL CHEM, V277, P34755, DOI 10.1074/jbc.M201201200; Drewes G, 1997, CELL, V89, P297, DOI 10.1016/S0092-8674(00)80208-1; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; Eliezer D, 2005, BIOCHEMISTRY-US, V44, P1026, DOI 10.1021/bi048953n; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fischer D, 2007, BIOCHEMISTRY-US, V46, P2574, DOI 10.1021/bi061318s; Garcia ML, 2001, CURR OPIN CELL BIOL, V13, P41, DOI 10.1016/S0955-0674(00)00172-1; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; Hanger DP, 1998, J NEUROCHEM, V71, P2465; Inouye H, 2006, BIOPHYS J, V90, P1774, DOI 10.1529/biophysj.105.070136; JAKES R, 1991, EMBO J, V10, P2725, DOI 10.1002/j.1460-2075.1991.tb07820.x; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Jones JA, 1996, J MAGN RESON SER B, V113, P25, DOI 10.1006/jmrb.1996.0151; Kampers T, 1996, FEBS LETT, V399, P344, DOI 10.1016/S0014-5793(96)01386-5; Landrieu I, 2006, J AM CHEM SOC, V128, P3575, DOI 10.1021/ja054656+; LEE G, 1988, SCIENCE, V239, P285, DOI 10.1126/science.3122323; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Louhivuori M, 2003, J AM CHEM SOC, V125, P15647, DOI 10.1021/ja035427v; MANDELKOW EM, 1985, J MOL BIOL, V185, P311, DOI 10.1016/0022-2836(85)90406-1; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; Mukrasch MD, 2005, J BIOL CHEM, V280, P24978, DOI 10.1074/jbc.M501565200; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Palmer AG, 2001, METHOD ENZYMOL, V339, P204, DOI 10.1016/S0076-6879(01)39315-1; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; Pawar AP, 2005, J MOL BIOL, V350, P379, DOI 10.1016/j.jmb.2005.04.016; Perez M, 1996, J NEUROCHEM, V67, P1183; Preuss U, 1997, J CELL SCI, V110, P789; Quijano FAR, 2006, BIOCHEMISTRY-US, V45, P4638, DOI 10.1021/bi052226q; Schwarzinger S, 2000, J BIOMOL NMR, V18, P43, DOI 10.1023/A:1008386816521; Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i; Sibille N, 2006, BIOCHEMISTRY-US, V45, P12560, DOI 10.1021/bi060964o; Smet C, 2004, BIOCHEMISTRY-US, V43, P2032, DOI 10.1021/bi035479x; Smet C, 2004, CHEMBIOCHEM, V5, P1639, DOI 10.1002/cbic.200400145; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Tokimasa M, 2005, FEBS LETT, V579, P3481, DOI 10.1016/j.febslet.2005.05.020; TOLMAN JR, 1995, P NATL ACAD SCI USA, V92, P9279, DOI 10.1073/pnas.92.20.9279; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; von Bergen M, 2000, MOL BIOL CELL, V11, p363A; von Bergen M, 2005, BBA-MOL BASIS DIS, V1739, P158, DOI 10.1016/j.bbadis.2004.09.010; von Bergen M, 2006, BIOCHEMISTRY-US, V45, P6446, DOI 10.1021/bi052530j; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1994, METHOD ENZYMOL, V239, P363	62	136	138	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					12230	12239		10.1074/jbc.M607159200	http://dx.doi.org/10.1074/jbc.M607159200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17307736	hybrid, Green Published			2022-12-25	WOS:000245941900066
J	Im, HJ; Muddasani, P; Natarajan, V; Schmid, TM; Block, JA; Davis, F; van Wijnen, AJ; Loeser, RF				Im, Hee-Jeong; Muddasani, Prasuna; Natarajan, Viswanathan; Schmid, Thomas M.; Block, Joel A.; Davis, Francesca; van Wijnen, Andre J.; Loeser, Richard F.			Basic fibroblast growth factor stimulates matrix metalloproteinase-13 via the molecular cross-talk between the mitogen-activated protein kinases and protein kinase C delta pathways in human adult articular chondrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; RECEPTOR TYROSINE KINASES; FACTOR-KAPPA-B; GENE-EXPRESSION; RHEUMATOID-ARTHRITIS; FACTOR-I; OSTEOARTHRITIC CARTILAGE; INTERLEUKIN-8 SECRETION; OSTEOGENIC PROTEIN-1; PROMOTER ACTIVITY	Excessive release of basic fibroblast growth factor ( bFGF) during loading and/or injury of the cartilage matrix may contribute to the onset or progression of osteoarthritis. This pathological role may be related to the ability of bFGF to decrease proteoglycan synthesis and to antagonize the activity of anabolic growth factors in cartilage such as insulin-like growth factor-1 and bone morphogenetic protein 7 ( BMP7 or OP-1). Matrix metalloproteinase-13 ( MMP-13), a catabolic cartilage-degrading enzyme, is dramatically up-regulated by inflammatory cytokines or by fibronectin fragments in articular chondrocytes. In this study, we investigated MMP-13 production by bFGF using human articular chondrocytes. Endogenous concentration of bFGF in synovial fluids collected from arthritis patients and asymptomatic subjects showed a good linear correlation with the endogenous levels of MMP-13. bFGF stimulation of MMP-13 was mediated at the transcriptional level and, at least in part, by stimulation of interleukin-1 production. Also, our findings suggest that bFGF stimulation of MMP-13 required the activation of multiple MAPKs ( ERK, p38, and JNK) by bFGF, and more importantly, bFGF activation of protein kinase C ( PKC) delta played a key role in the MMP-13 stimulation. Indeed, PKC delta is the only isoform associated with MMP-13 stimulation among the PKC isoforms tested. PKC delta controls the bFGF response by regulating multiple MAPK pathways. Our results suggest that PKC delta activation is a principal rate-limiting event in the bFGF-dependent stimulation of MMP-13 in human adult articular chondrocytes. We propose that deregulation of cross-talk between MAPK and PKC delta signaling may contribute to the etiology of osteoarthritis in human patients.	Rush Univ, Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Rush Univ, Med Ctr, Dept Internal Med, Rheumatol Sect, Chicago, IL 60612 USA; Rush Univ, Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA; Univ Chicago, Dept Med, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Wake Forest Univ, Dept Internal Med, Sect Mol Med, Winston Salem, NC 27157 USA	Rush University; Rush University; Rush University; University of Chicago; University of Massachusetts System; University of Massachusetts Worcester; Wake Forest University	Im, HJ (corresponding author), Rush Univ, Med Ctr, Dept Biochem, Cohn Res Bldg 516,1735 W Harrison, Chicago, IL 60612 USA.	Hee-Jeong_Sampen@rush.edu	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946; Block, Joel/0000-0002-0330-7353	NIAMS NIH HHS [R01 AR053220-04, R01 AR049069, R37 AR049003, R01 AR049003, AR053220, AR49003, R01 AR053220] Funding Source: Medline; BLRD VA [I01 BX002647] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053220, R37AR049003, R01AR049069, R01AR049003] Funding Source: NIH RePORTER; Veterans Affairs [I01BX002647] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); BLRD VA; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Veterans Affairs(US Department of Veterans Affairs)		ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Bluteau G, 2002, BIORHEOLOGY, V39, P247; Boileau C, 2006, ANN RHEUM DIS, V65, P573, DOI 10.1136/ard.2005.041855; Bottomley MJ, 2000, CLIN EXP IMMUNOL, V119, P182, DOI 10.1046/j.1365-2249.2000.01097.x; Carreras I, 2001, AM J PHYSIOL-LUNG C, V281, pL766, DOI 10.1152/ajplung.2001.281.4.L766; COLLINS DH, 1949, OSTEOARTHRITIS PATHO, P74; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; Cummings R, 2004, J BIOL CHEM, V279, P41085, DOI 10.1074/jbc.M404045200; Daouti S, 2005, OSTEOARTHR CARTILAGE, V13, P508, DOI 10.1016/j.joca.2005.02.003; Davidson D, 2005, J BIOL CHEM, V280, P20509, DOI 10.1074/jbc.M410148200; Desai S, 2001, MATRIX BIOL, V20, P233, DOI 10.1016/S0945-053X(01)00140-8; Ellsworth JL, 2002, OSTEOARTHR CARTILAGE, V10, P308, DOI 10.1053/joca.2002.0514; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; Harris VK, 1998, J BIOL CHEM, V273, P19130, DOI 10.1074/jbc.273.30.19130; Iannone F, 2003, AGING CLIN EXP RES, V15, P364, DOI 10.1007/BF03327357; Im HJ, 2003, J BIOL CHEM, V278, P25386, DOI 10.1074/jbc.M302048200; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KEYSZER GM, 1995, J RHEUMATOL, V22, P275; Kilkenny DM, 1996, ENDOCRINOLOGY, V137, P5078, DOI 10.1210/en.137.11.5078; Li TF, 2004, EXP CELL RES, V300, P159, DOI 10.1016/j.yexcr.2004.06.019; Liacini A, 2002, MATRIX BIOL, V21, P251, DOI 10.1016/S0945-053X(02)00007-0; Loeser RF, 2005, ARTHRITIS RHEUM-US, V52, P3910, DOI 10.1002/art.21472; Loeser RF, 2005, ARTHRITIS RHEUM, V52, P2376, DOI 10.1002/art.21199; Loeser RF, 2003, J BIOL CHEM, V278, P24577, DOI 10.1074/jbc.M304530200; Lohmander L Stefan, 2004, Osteoarthritis Cartilage, V12 Suppl A, pS49; Manicourt DH, 2000, ARTHRITIS RHEUM, V43, P281, DOI 10.1002/1529-0131(200002)43:2<281::AID-ANR7>3.0.CO;2-7; Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529-0131(200004)43:4<801::AID-ANR10>3.0.CO;2-4; Mengshol JA, 2001, NUCLEIC ACIDS RES, V29, P4361, DOI 10.1093/nar/29.21.4361; MIDDLETON JFS, 1992, ANN RHEUM DIS, V51, P440, DOI 10.1136/ard.51.4.440; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827; Nedvetzki S, 2003, J CLIN INVEST, V111, P1211, DOI 10.1172/JCI200317100; Neuhold LA, 2001, J CLIN INVEST, V107, P35, DOI 10.1172/JCI10564; NICOLE BW, 1999, BIOCHEM J, V342, P677; Orito Keisuke, 2003, J Orthop Sci, V8, P294, DOI 10.1007/s10776-003-0647-6; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Pelletier JP, 2003, ARTHRITIS RHEUM-US, V48, P1582, DOI 10.1002/art.11014; Pendas AM, 2000, CLIN CHIM ACTA, V291, P137, DOI 10.1016/S0009-8981(99)00225-9; Pulai JI, 2005, J IMMUNOL, V174, P5781, DOI 10.4049/jimmunol.174.9.5781; QU ZH, 1995, LAB INVEST, V73, P339; Quintavalla J, 2005, J CELL PHYSIOL, V204, P560, DOI 10.1002/jcp.20345; Radons J, 2006, INT J MOL MED, V17, P661; Salminen HJ, 2002, ANN RHEUM DIS, V61, P591, DOI 10.1136/ard.61.7.591; Sawai H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-37; Sharaki Ola A, 2004, Egypt J Immunol, V11, P91; Shida J, 2001, J ORTHOPAED RES, V19, P259, DOI 10.1016/S0736-0266(00)90009-3; Smeets TJM, 2003, ANN RHEUM DIS, V62, P635, DOI 10.1136/ard.62.7.635; Starkman BG, 2005, BIOCHEM J, V389, P723, DOI 10.1042/BJ20041636; Tchetina EV, 2005, J RHEUMATOL, V32, P876; Valverde-Franco G, 2006, HUM MOL GENET, V15, P1783, DOI 10.1093/hmg/ddl100; van den Berg WB, 2001, CURR OPIN RHEUMATOL, V13, P452, DOI 10.1097/00002281-200109000-00019; Vincent T, 2002, P NATL ACAD SCI USA, V99, P8259, DOI 10.1073/pnas.122033199; Vincent TL, 2004, ARTHRITIS RHEUM, V50, P526, DOI 10.1002/art.20047; Wang XB, 2004, OSTEOARTHR CARTILAGE, V12, P963, DOI 10.1016/j.joca.2004.08.008; Yang GG, 2005, GENE, V363, P166, DOI 10.1016/j.gene.2005.08.006; Zhao YT, 2006, J BIOL CHEM, V281, P19501, DOI 10.1074/jbc.M511224200	58	135	145	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11110	11121		10.1074/jbc.M609040200	http://dx.doi.org/10.1074/jbc.M609040200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311929	Green Accepted, hybrid			2022-12-25	WOS:000245941500032
J	Kim, J; Temple, KA; Jones, SA; Meredith, KN; Basko, JL; Brady, MJ				Kim, Jaime; Temple, Karla A.; Jones, Sara A.; Meredith, Kimberly N.; Basko, Juliana L.; Brady, Matthew J.			Differential modulation of 3T3-L1 adipogenesis mediated by 11 beta-hydroxysteroid dehydrogenase-1 levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE STROMAL CELLS; CORTISOL METABOLISM; GLYCOGEN-SYNTHASE; VISCERAL OBESITY; TARGET-CELLS; TYPE-1; TISSUE; ADIPOCYTES; EXPRESSION; ISOFORM	The localized activation of circulating glucocorticoids in vivo by the enzyme 11 beta-hydroxysteroid dehydrogenase type 1 ( 11 beta-HSD1) plays a critical role in the development of the metabolic syndrome. However, the precise contribution of 11 beta-HSD1 in the initiation of adipogenesis by inactive glucocorticoids is not fully understood. 3T3-L1 fibroblasts can be terminally differentiated to mature adipocytes in a glucocorticoid-dependent manner. Both inactive rodent dehydrocorticosterone and human cortisone were able to substitute for the synthetic glucocorticoid dexamethasone in 3T3-L1 adipogenesis, suggesting a potential role for 11 beta-HSD1 in these effects. Differentiation of 3T3-L1 cells caused a strong increase in 11 beta-HSD1 protein levels, which occurred late in the differentiation protocol. Reduction of 11 beta-HSD1 activity in 3T3-L1 fibroblasts, achieved by pharmacological inhibition or adenovirally mediated delivery of short hairpin RNA constructs, specifically blocked the ability of inactive glucocorticoids to drive 3T3-L1 differentiation. However, even modest increases in exogenous 11 beta-HSD1 expression in 3T3-L1 fibroblasts, to levels comparable with endogenous 11 beta-HSD1 in differentiated 3T3-L1 adipocytes, were sufficient to block adipogenesis. Luciferase reporter assays indicated that overexpressed 11 beta-HSD1 was catalyzing the inactivating dehydrogenase reaction, because the ability of both active and inactive glucocorticoids to activate the glucocorticoid receptor were largely suppressed. These results suggest that the temporal regulation of 11 beta-HSD1 expression is tightly controlled in 3T3-L1 cells, so as to mediate the initiation of differentiation by inactive glucocorticoids and also to prevent the inhibitory activity of prematurely expressed 11 beta-HSD1 during adipogenesis.	Univ Chicago, Dept Med, Sect Endocrinol Diabet & Metab, Chicago, IL 60637 USA; Univ Chicago, Comm Mol Metab & Nutr, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Brady, MJ (corresponding author), MC1027,5841 S Maryland Ave, Chicago, IL 60637 USA.	mbrady@medicine.bsd.uchicago.edu			NHLBI NIH HHS [T32HL007909] Funding Source: Medline; NIDDK NIH HHS [P60DK020595] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020595] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL AK, 1994, J BIOL CHEM, V269, P25959; AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; Agarwal AK, 2003, ENDOCR RES, V29, P411, DOI 10.1081/ERC-120026947; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, P11; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; BROWN RW, 1993, ENDOCRINOLOGY, V132, P2614, DOI 10.1210/en.132.6.2614; Bujalska IJ, 1999, ENDOCRINOLOGY, V140, P3188, DOI 10.1210/en.140.7.3188; Bujalska IJ, 2002, J CLIN ENDOCR METAB, V87, P1205, DOI 10.1210/jc.87.3.1205; Chrousos GP, 1998, ANN NY ACAD SCI, V851, P311, DOI 10.1111/j.1749-6632.1998.tb09006.x; Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001; Gasa R, 2000, J BIOL CHEM, V275, P26396, DOI 10.1074/jbc.M002427200; Greenberg CC, 2006, MOL CELL BIOL, V26, P334, DOI 10.1128/MCB.26.1.334-342.2006; Greenberg CC, 2003, J BIOL CHEM, V278, P30835, DOI 10.1074/jbc.M303846200; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Hautanen A, 1997, J INTERN MED, V241, P451; Hirasawa G, 1997, J CLIN ENDOCR METAB, V82, P3859, DOI 10.1210/jc.82.11.3859; Jamieson PM, 1999, J STEROID BIOCHEM, V68, P245, DOI 10.1016/S0960-0760(99)00037-0; Kershaw EE, 2005, DIABETES, V54, P1023, DOI 10.2337/diabetes.54.4.1023; KOTELEVTSEV Y, 1997, P NATL ACAD SCI USA, V94, P14929; LAKSHMI V, 1985, ENDOCRINOLOGY, V116, P552, DOI 10.1210/endo-116-2-552; Lavery GG, 2006, J BIOL CHEM, V281, P6546, DOI 10.1074/jbc.M512635200; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; McEwen BS, 1997, BRAIN RES REV, V23, P79, DOI 10.1016/S0165-0173(96)00012-4; Morton NM, 2001, J BIOL CHEM, V276, P41293, DOI 10.1074/jbc.M103676200; Napolitano A, 1998, J STEROID BIOCHEM, V64, P251, DOI 10.1016/S0960-0760(97)00200-8; NARAYFEJESTOTH A, 1991, ENDOCRINOLOGY, V129, P17, DOI 10.1210/endo-129-1-17; Paterson JM, 2004, P NATL ACAD SCI USA, V101, P7088, DOI 10.1073/pnas.0305524101; Paulmyer-Lacroix O, 2002, J CLIN ENDOCR METAB, V87, P2701, DOI 10.1210/jc.87.6.2701; Peeke PM, 1995, ANN NY ACAD SCI, V771, P665, DOI 10.1111/j.1749-6632.1995.tb44719.x; Rask E, 2001, J CLIN ENDOCR METAB, V86, P1418, DOI 10.1210/jc.86.3.1418; Rask E, 2002, J CLIN ENDOCR METAB, V87, P3330, DOI 10.1210/jc.87.7.3330; REBUFFESCRIVE M, 1988, J CLIN ENDOCR METAB, V67, P1122, DOI 10.1210/jcem-67-6-1122; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; SCHADINGER SE, 2005, AM J PHYSIOL, V28, pR1195; SCHTEINGART DE, 2001, PRINCIPLES PRACTICE, P723; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/en.142.4.1371; Shimojo M, 1997, ENDOCRINOLOGY, V138, P1305, DOI 10.1210/en.138.3.1305; Tomlinson JW, 2004, ENDOCR REV, V25, P831, DOI 10.1210/er.2003-0031; Walker EA, 2001, J BIOL CHEM, V276, P21343, DOI 10.1074/jbc.M011142200; WHORWOOD CB, 1994, ENDOCRINOLOGY, V135, P2533, DOI 10.1210/en.135.6.2533; WHORWOOD CB, 1995, MOL CELL ENDOCRINOL, V110, pR7, DOI 10.1016/0303-7207(95)03546-J; Williams LJS, 2000, J BIOL CHEM, V275, P30232, DOI 10.1074/jbc.M001286200; Wu ZD, 1996, MOL CELL BIOL, V16, P4128	45	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11038	11046		10.1074/jbc.M606197200	http://dx.doi.org/10.1074/jbc.M606197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17311922	hybrid			2022-12-25	WOS:000245941500024
J	Seth, A; Sheth, P; Elias, BC; Rao, R				Seth, Ankur; Sheth, Parimal; Elias, Bertha C.; Rao, Radhakrishna			Protein phosphatases 2A and 1 interact with occludin and negatively regulate the assembly of tight junctions in the CACO-2 cell monolayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; OXIDATIVE STRESS; EPITHELIAL-CELLS; POSSIBLE INVOLVEMENT; HYDROGEN-PEROXIDE; LOCALIZATION; PERMEABILITY; INHIBITION; DISRUPTION	Occludin is hyperphosphorylated on Ser and Thr residues in intact epithelial tight junction ( TJ); however, the role of this phosphorylation in the assembly of TJ is unclear. The influence of protein phosphatases PP2A and PP1 on the assembly of TJ and phosphorylation of occludin was evaluated in Caco-2 cells. Protein phosphatase inhibitors and reduced expression of PP2A-C alpha and PP1 alpha accelerated the calcium-induced increase in transepithelial electrical resistance and barrier to inulin permeability and also enhanced the junctional organization of occludin and ZO-1 during TJ assembly. Phosphorylation of occludin on Thr residues, but not on Ser residues, was dramatically reduced during the disassembly of TJ and was gradually increased during the reassembly. PP2A and PP1 co-immunoprecipitate with occludin, and this association was reduced during the assembly of TJ. Glutathione S-transferase ( GST) pull-down assay using recombinant GST-occludin demonstrated that cellular PP2A and PP1 bind to the C-terminal tail of occludin, and these interactions were also reduced during the assembly of TJ. Apairwise binding assay using GST- occludin and purified PP2A and PP1 demonstrates that PP2A and PP1 directly interacts with the C-terminal tail of occludin. In vitro incubation of phospho- occludin with PP2A or PP1 indicated that PP2A dephosphorylates occludin on phospho- Thr residues, whereas PP1 dephosphorylates it on phospho- Ser. This study shows that PP2A and PP1 directly interact with occludin and negatively regulate the assembly of TJ by modulating the phosphorylation status of occludin.	Univ Tennessee, Dept Physiol, Hlth Sci Ctr, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Rao, R (corresponding author), Univ Tennessee, Dept Physiol, Hlth Sci Ctr, 894 Union Ave, Memphis, TN 38163 USA.	rkrao@physio1.utmem.edu	Seth, Ankur/AAE-1800-2020	Seth, Ankur/0000-0003-0140-4691	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012307] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA012307, R01-AA12307] Funding Source: Medline; NIDDK NIH HHS [R01 DK055532, R01-DK55532] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Andreeva AY, 2001, J BIOL CHEM, V276, P38480, DOI 10.1074/jbc.M104923200; Basuroy S, 2006, BIOCHEM J, V393, P69, DOI 10.1042/BJ20050959; Basuroy S, 2003, J BIOL CHEM, V278, P11916, DOI 10.1074/jbc.M211710200; Chen YH, 2002, MOL BIOL CELL, V13, P1227, DOI 10.1091/mbc.01-08-0423; Clarke H, 2000, J CELL SCI, V113, P3187; Denker BM, 1996, J BIOL CHEM, V271, P25750, DOI 10.1074/jbc.271.42.25750; Farshori P, 1999, J MEMBRANE BIOL, V170, P147, DOI 10.1007/s002329900544; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Goodenough DA, 1999, P NATL ACAD SCI USA, V96, P319, DOI 10.1073/pnas.96.2.319; Hirase T, 2001, J BIOL CHEM, V276, P10423, DOI 10.1074/jbc.M007136200; HOLLANDER D, 1994, GUT, V26, P1621; Kale G, 2003, BIOCHEM BIOPH RES CO, V302, P324, DOI 10.1016/S0006-291X(03)00167-0; Lee DBN, 2006, AM J PHYSIOL-RENAL, V290, pF20, DOI 10.1152/ajprenal.00052.2005; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Matthay MA, 2002, CHEST, V122, p340S, DOI 10.1378/chest.122.6_suppl.340S; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Rao R, 1999, BIOCHEM PHARMACOL, V57, P685, DOI 10.1016/S0006-2952(98)00333-5; Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804; Rao RK, 1997, AM J PHYSIOL-GASTR L, V273, pG812, DOI 10.1152/ajpgi.1997.273.4.G812; Rao RK, 2000, AM J PHYSIOL-GASTR L, V279, pG332, DOI 10.1152/ajpgi.2000.279.2.G332; Ries J, 1997, AM J PHYSIOL-CELL PH, V272, pC794, DOI 10.1152/ajpcell.1997.272.3.C794; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Sheth P, 2003, J BIOL CHEM, V278, P49239, DOI 10.1074/jbc.M305654200; Simonovic I, 2000, CELL MICROBIOL, V2, P305, DOI 10.1046/j.1462-5822.2000.00055.x; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Walsh SV, 2001, GASTROENTEROLOGY, V121, P566, DOI 10.1053/gast.2001.27060; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859, DOI 10.1152/ajpcell.1997.273.6.C1859	32	140	146	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11487	11498		10.1074/jbc.M610597200	http://dx.doi.org/10.1074/jbc.M610597200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17298946	hybrid			2022-12-25	WOS:000245941500070
J	Willmund, F; Muhlhaus, T; Wojciechowska, M; Schroda, M				Willmund, Felix; Muehlhaus, Timo; Wojciechowska, Maria; Schroda, Michael			The NH2-terminal domain of the chloroplast GrpE homolog CGE1 is required for dimerization and cochaperone function in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; DNAK CHAPERONE SYSTEM; ESCHERICHIA-COLI; CHLAMYDOMONAS-REINHARDTII; THERMUS-THERMOPHILUS; CRYSTAL-STRUCTURE; HSP70 CHAPERONES; ATPASE DOMAIN; PROTEIN; SUBSTRATE	GrpE proteins function as nucleotide exchange factors for DnaK-type Hsp70s. We have previously identified a chloroplast homolog of GrpE in Chlamydomonas reinhardtii, termed CGE1. CGE1 exists as two isoforms, CGE1a and CGE1b, which are generated by temperature-dependent alternative splicing. CGE1b contains additional valine and glutamine residues in its extreme NH2-terminal region. Here we show that CGE1a is predominant at lower temperatures but that CGE1b becomes as abundant as CGE1a at elevated temperatures. Coimmunoprecipitation experiments revealed that CGE1b had a similar to 25% higher affinity for its chloroplast chaperone partner HSP70B than CGE1a. Modeling of the structure of CGE1b revealed that the extended alpha-helix formed by GrpE NH2 termini is 34 amino acids longer in CGE1 than in Escherichia coli GrpE and appears to contain a coiled coil motif. Progressive deletions of this coiled coil increasingly impaired the ability of CGE1 to form dimers, to interact with DnaK at elevated temperatures, and to complement temperature-sensitive growth of a Delta grpE E. coli strain. In contrast, deletion of the four-helix bundle required for dimerization of E. coli GrpE did not affect CGE1 dimer formation. Circular dichroism measurements revealed that CGE1, like GrpE, undergoes two thermal transitions, the first of which is in the physiologically relevant temperature range ( midpoint similar to 45 degrees C). Truncating the NH2-terminal coiled coil shifted the second transition to lower temperatures, whereas removal of the four- helix bundle abolished the first transition. Our data suggest that bacterial GrpE and chloroplast CGE1 share similar structural and biochemical properties, but some of these, like dimerization, are realized by different domains.	Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	University of Freiburg	Schroda, M (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.	michael.schroda@biologie.uni-freiburg.de	Schroda, Michael/A-2651-2015	Schroda, Michael/0000-0001-6872-0483; Muhlhaus, Timo/0000-0003-3925-6778; Willmund, Felix/0000-0002-3988-4590				Borges JC, 2003, J BIOL CHEM, V278, P35337, DOI 10.1074/jbc.M305083200; Brehmer D, 2004, J BIOL CHEM, V279, P27957, DOI 10.1074/jbc.M403558200; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chesnokova LS, 2003, BIOCHEMISTRY-US, V42, P9028, DOI 10.1021/bi0346493; Deloche O, 1996, J BIOL CHEM, V271, P23960, DOI 10.1074/jbc.271.39.23960; Deloche O, 1997, J BACTERIOL, V179, P6066, DOI 10.1128/jb.179.19.6066-6075.1997; Diamant S, 1998, BIOCHEMISTRY-US, V37, P9688, DOI 10.1021/bi980338u; Drzymalla C, 1996, PLANT MOL BIOL, V31, P1185, DOI 10.1007/BF00040835; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Gelinas AD, 2002, J MOL BIOL, V323, P131, DOI 10.1016/S0022-2836(02)00915-4; Grimshaw JPA, 2003, J BIOL CHEM, V278, P19048, DOI 10.1074/jbc.M300924200; Grimshaw JPA, 2001, J BIOL CHEM, V276, P6098, DOI 10.1074/jbc.M009290200; Groemping Y, 2001, J MOL BIOL, V305, P1173, DOI 10.1006/jmbi.2000.4373; Groemping Y, 2001, J MOL BIOL, V314, P167, DOI 10.1006/jmbi.2001.5116; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P26; Harrison C, 2003, CELL STRESS CHAPERON, V8, P218, DOI 10.1379/1466-1268(2003)008<0218:GANEFF>2.0.CO;2; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LEMAIRE C, 1989, J BIOL CHEM, V264, P10235; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIU C, 2007, IN PRESS PLANT J; Liu CM, 2005, MOL BIOL CELL, V16, P1165, DOI 10.1091/mbc.E04-08-0736; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6; Mehl AF, 2003, PROTEIN SCI, V12, P1205, DOI 10.1110/ps.0300803; Mehl AF, 2001, BIOCHEM BIOPH RES CO, V282, P562, DOI 10.1006/bbrc.2001.4567; Moro F, 2006, J MOL BIOL, V358, P1367, DOI 10.1016/j.jmb.2006.03.027; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Schmidt M, 2006, PLANT CELL, V18, P1908, DOI 10.1105/tpc.106.041749; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schroda M, 2004, PHOTOSYNTH RES, V82, P221, DOI 10.1007/s11120-004-2216-y; Schroda M, 1999, PLANT CELL, V11, P1165, DOI 10.1105/tpc.11.6.1165; Schroda M, 2001, PLANT CELL, V13, P2823, DOI 10.1105/tpc.010202; Sichting M, 2005, EMBO J, V24, P1046, DOI 10.1038/sj.emboj.7600580; Siegenthaler RK, 2005, J BIOL CHEM, V280, P14395, DOI 10.1074/jbc.M413803200; Whitby FG, 2000, PROTEINS, V38, P49; Willmund F, 2005, PLANT PHYSIOL, V138, P2310, DOI 10.1104/pp.105.063578	42	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11317	11328		10.1074/jbc.M608854200	http://dx.doi.org/10.1074/jbc.M608854200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17289679	hybrid			2022-12-25	WOS:000245941500054
J	Haffner, C; Dettmer, U; Weiler, T; Haass, C				Haffner, Christof; Dettmer, Ulf; Weiler, Timotheus; Haass, Christian			The nicastrin-like protein nicalin regulates assembly and stability of the nicalin-nodal modulator (NOMO) membrane protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-ASSOCIATED PRESENILIN-1; GAMMA-SECRETASE CLEAVAGE; BETA-APP; VERTEBRATE DEVELOPMENT; APH-1; PEN-2; ACCUMULATION; TRAFFICKING; MATURATION; RECEPTOR	The assembly of the gamma-secretase complex, an Alzheimer disease-related protease required for beta-amyloid generation, is tightly regulated and predominantly limited by the stoichiometrical availability of its components. We have identified a novel endoplasmic reticulum-located protein complex that is regulated in a similar fashion. It contains the recently identified Nodal signaling antagonists Nicalin ( a distant homolog of the gamma-secretase component Nicastrin) and NOMO ( Nodal modulator). Using an RNA interference approach, we found that Nicalin and NOMO became unstable in the absence of the respective binding partner, suggesting that complex formation has a stabilizing effect. Overexpression of Nicalin resulted in an increase in NOMO, whereas endogenous Nicalin was reduced below the detection limit. Both effects were shown to occur at a post-transcriptional level. Thus, NOMO is most likely produced in excess amounts and either stabilized by Nicalin or rapidly degraded. In contrast, Nicalin levels are limited independently of NOMO. We, therefore, propose that Nicalin controls the assembly and stability of the Nicalin-NOMO complex.	Univ Munich, Dept Biochem, Lab Neurodegenerat Dis Res, D-80336 Munich, Germany; Univ Munich, Ctr Integrated Prot Sci, D-80336 Munich, Germany	University of Munich; University of Munich	Haffner, C (corresponding author), Univ Munich, Dept Biochem, Lab Neurodegenerat Dis Res, Schillerstr 44, D-80336 Munich, Germany.	chaffner@med.uni-muenchen.de	Haffner, Christof/AAG-6676-2020	Dettmer, Ulf/0000-0001-6676-0107				Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Haffner C, 2004, EMBO J, V23, P3041, DOI 10.1038/sj.emboj.7600307; Haffner C, 2004, NEURODEGENER DIS, V1, P192, DOI 10.1159/000080985; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Shah S, 2005, CELL, V122, P435, DOI 10.1016/j.cell.2005.05.022; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Wolfe MS, 2006, BIOCHEMISTRY-US, V45, P7931, DOI 10.1021/bi060799c; Xia XG, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng098; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang YW, 2005, J BIOL CHEM, V280, P17020, DOI 10.1074/jbc.M409467200	23	22	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10632	10638		10.1074/jbc.M611033200	http://dx.doi.org/10.1074/jbc.M611033200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17261586	hybrid			2022-12-25	WOS:000245941000057
J	Mascle, XH; Germain-Desprez, D; Huynh, P; Estephan, P; Aubry, M				Mascle, Xavier H.; Germain-Desprez, Delphine; Huynh, Phuong; Estephan, Patricia; Aubry, Muriel			Sumoylation of the transcriptional intermediary factor 1 beta (TIF1 beta), the co-repressor of the KRAB multifinger proteins, is required for its transcriptional activity and is modulated by the KRAB domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; UBIQUITIN-RELATED MODIFIER; SUMO E3 LIGASE; RESONANCE ENERGY-TRANSFER; NUCLEAR-MATRIX; HISTONE DEACETYLATION; DYNAMIC INTERPLAY; TRIPARTITE MOTIF; TIF1 FAMILY; COREPRESSOR	Small ubiquitin-related modifier (SUMO) has emerged as a key post-translational modulator of protein functions. Here we show that TIF1 ss, a developmental regulator proposed to act as a universal co-repressor for the large family of KRAB domain-containing zinc finger proteins, is a heavily SUMO-modified substrate. A combined analysis of deletion and punctual mutants identified TIF1 ss as a multilysine acceptor for SUMO which specifically targets six lysine residues (Lys(554), Lys(575), Lys(676), Lys(750), Lys(779), and Lys(804)) within the TIF1 ss C-terminal repressive region. Reporter gene assays indicate that TIF1 ss requires SUMO-modification for its repressive activity. Indeed, sumoylation-less mutants failed to recapitulate TIF1 ss-dependent repression. TIF1 ss homodimerization properties and interaction with the KRAB domain are preserved in the mutants with lysine to arginine substitutions as confirmed by in vivo bioluminescence resonance energy transfer (BRET). Using histone deacetylase ( HDAC) inhibitors, we also demonstrate that TIF1 ss sumoylation is a prerequisite for the recruitment of HDAC and that TIF1 ss SUMO-dependent repressive activity involves both HDAC-dependent and HDAC-independent components. Finally, we report that, in addition to relying on the integrity of its PHD finger and on its self-oligomerization, TIF1 ss sumoylation is positively regulated by its interaction with KRAB domain-containing proteins. Altogether, our results provide new mechanistic insights into TIF1 ss transcriptional repression and suggest that KRAB multifinger proteins not only recruit TIF1 ss co-repressor to target genes but also increase its repressive activity through enhancement of its sumoylation.	Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Aubry, M (corresponding author), Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada.	muriel.aubry@umontreal.ca						Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803; Azuma Y, 2002, DEV CELL, V2, P130, DOI 10.1016/S1534-5807(02)00124-7; Bailey D, 2004, J BIOL CHEM, V279, P692, DOI 10.1074/jbc.M306195200; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Beckstead R, 2001, MOL CELL, V7, P753, DOI 10.1016/S1097-2765(01)00220-9; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Binda O, 2006, MOL CELL BIOL, V26, P1917, DOI 10.1128/MCB.26.5.1917-1931.2006; Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Cammas F, 2000, DEVELOPMENT, V127, P2955; Cammas F, 2004, GENE DEV, V18, P2147, DOI 10.1101/gad.302904; Cammas F, 2002, J CELL SCI, V115, P3439; Cao TY, 1997, J CELL SCI, V110, P1563; Capili AD, 2001, EMBO J, V20, P165, DOI 10.1093/emboj/20.1.165; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Chupreta S, 2005, MOL CELL BIOL, V25, P4272, DOI 10.1128/MCB.25.10.4272-4282.2005; Cote F, 2001, DNA CELL BIOL, V20, P159, DOI 10.1089/104454901300069004; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fernandez-Lloris R, 2006, FEBS LETT, V580, P1215, DOI 10.1016/j.febslet.2006.01.031; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Germain-Desprez D, 2003, J BIOL CHEM, V278, P22367, DOI 10.1074/jbc.M302234200; Gill G, 2004, GENE DEV, V18, P2046, DOI 10.1101/gad.1214604; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Girdwood DWH, 2004, SEMIN CELL DEV BIOL, V15, P201, DOI 10.1016/j.semcdb.2003.12.001; Gong ZH, 2006, MOL CELL BIOL, V26, P4519, DOI 10.1128/MCB.00409-06; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; Hay RT, 2006, E SCHERING RES FDN W, V57, P173; Hsu SIH, 2001, EMBO J, V20, P2273, DOI 10.1093/emboj/20.9.2273; HSU YH, 2006, J BIOL CHEM; Huang WC, 2004, EUR J BIOCHEM, V271, P4114, DOI 10.1111/j.1432-1033.2004.04349.x; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Khetchoumian K, 2004, J BIOL CHEM, V279, P48329, DOI 10.1074/jbc.M404779200; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; Kim YE, 2005, BIOCHEM BIOPH RES CO, V330, P746, DOI 10.1016/j.bbrc.2005.03.052; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; LE DB, 1996, EMBO J, V15, P6701; Lechner MS, 2005, BIOCHEM BIOPH RES CO, V331, P929, DOI 10.1016/j.bbrc.2005.04.016; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; LEE YK, 2006, J BIOL CHEM; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Lin X, 2003, MOL CELL, V11, P1389, DOI 10.1016/S1097-2765(03)00175-8; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Long JY, 2004, BIOCHEM J, V379, P23, DOI 10.1042/BJ20031867; Looman C, 2002, MOL BIOL EVOL, V19, P2118, DOI 10.1093/oxfordjournals.molbev.a004037; Lorenz P, 2001, BIOL CHEM, V382, P637, DOI 10.1515/BC.2001.075; Matunis MJ, 2005, NAT STRUCT MOL BIOL, V12, P565, DOI 10.1038/nsmb0705-565; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Motohashi H, 2006, MOL CELL BIOL, V26, P4652, DOI 10.1128/MCB.02193-05; Nakagawa K, 2005, GENES CELLS, V10, P835, DOI 10.1111/j.1365-2443.2005.00880.x; Nathan D, 2006, GENE DEV, V20, P966, DOI 10.1101/gad.1404206; Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Peng HZ, 2000, J MOL BIOL, V295, P1139, DOI 10.1006/jmbi.1999.3402; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; Pichler A, 2004, NAT STRUCT MOL BIOL, V11, P984, DOI 10.1038/nsmb834; Quimby BB, 2006, ONCOGENE, V25, P2999, DOI 10.1038/sj.onc.1209335; Reverter D, 2005, NATURE, V435, P687, DOI 10.1038/nature03588; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rosendorff A, 2006, P NATL ACAD SCI USA, V103, P5308, DOI 10.1073/pnas.0601066103; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1997, TRENDS BIOCHEM SCI, V22, P374, DOI 10.1016/S0968-0004(97)01102-X; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Sentis S, 2005, MOL ENDOCRINOL, V19, P2671, DOI 10.1210/me.2005-0042; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100; Sripathy SP, 2006, MOL CELL BIOL, V26, P8623, DOI 10.1128/MCB.00487-06; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tiefenbach J, 2006, MOL BIOL CELL, V17, P1643, DOI 10.1091/mbc.E05-07-0610; Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; Verger A, 2003, EMBO REP, V4, P137, DOI 10.1038/sj.embor.embor738; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	90	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10190	10202		10.1074/jbc.M611429200	http://dx.doi.org/10.1074/jbc.M611429200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17298944	hybrid			2022-12-25	WOS:000245941000009
J	Tullai, JW; Chen, J; Schaffer, ME; Kamenetsky, E; Kasif, S; Cooper, GM				Tullai, John W.; Chen, Jie; Schaffer, Michael E.; Kamenetsky, Eliza; Kasif, Simon; Cooper, Geoffrey M.			Glycogen synthase kinase-3 represses cyclic AMP response element-binding protein (CREB)-targeted immediate early genes in quiescent cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOME-WIDE ANALYSIS; SMALL-MOLECULE INHIBITORS; SIGNALING PATHWAY; CREB; PHOSPHORYLATION; CAMP; TRANSCRIPTION; ACTIVATION; SITES; IDENTIFICATION	Despite its central role in cell survival and proliferation, the transcriptional program controlled by GSK-3 is poorly understood. We have employed a systems level approach to characterize gene regulation downstream of PI 3-kinase/Akt/GSK-3 signaling in response to growth factor stimulation of quiescent cells. Of 31 immediate-early genes whose induction was dependent on PI 3-kinase signaling, 12 were induced directly by inhibition of GSK-3. Most of the GSK-3-regulated genes encoded transcription factors, growth factors, and signaling molecules. Binding sites for QREB were highly over-represented in the upstream regions of these genes, with 9 genes containing CREB sites that were conserved in mouse orthologs. Binding sites predicted in 6 genes were confirmed by CREB chromatin immunoprecipitation and forskolin induction of CBP binding. Moreover, CREB siRNA substantially blocked induction of 5 genes by forskolin and of 3 genes following inhibition of GSK-3. These results indicate that GSK-3 actively represses gene expression in quiescent cells, with inhibition of CREB playing a key role in this transcriptional response.	Boston Univ, Dept Biol, Boston, MA 02215 USA; Boston Univ, Bioinformat Program, Boston, MA 02215 USA; Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA	Boston University; Boston University; Boston University	Cooper, GM (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gmcooper@bu.edu			NCI NIH HHS [1R01-CA18689, R01 CA018689] Funding Source: Medline; NHGRI NIH HHS [1R33-HG002850, R33 HG002850] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R33HG002850] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Conkright MD, 2003, MOL CELL, V11, P1101, DOI 10.1016/S1097-2765(03)00134-5; Conkright MD, 2003, MOL CELL, V12, P413, DOI 10.1016/j.molcel.2003.08.013; Cross DAE, 2001, J NEUROCHEM, V77, P94, DOI 10.1046/j.1471-4159.2001.00251.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x; Hardenbol P, 1997, NUCLEIC ACIDS RES, V25, P3339, DOI 10.1093/nar/25.16.3339; Hardt SE, 2004, CIRC RES, V94, P926, DOI 10.1161/01.RES.0000124977.59827.80; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI [10.2307/1390807, DOI 10.1080/10618600.1996.10474713]; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kel AE, 2003, NUCLEIC ACIDS RES, V31, P3576, DOI 10.1093/nar/gkg585; Kimball SR, 1998, J BIOL CHEM, V273, P30945, DOI 10.1074/jbc.273.47.30945; Liang MH, 2006, J BIOL CHEM, V281, P30479, DOI 10.1074/jbc.M607468200; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Pap M, 2002, MOL CELL BIOL, V22, P578, DOI 10.1128/MCB.22.2.578-586.2002; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Sauer T, 2006, BIOINFORMATICS, V22, P430, DOI 10.1093/bioinformatics/bti819; Tullai JW, 2004, J BIOL CHEM, V279, P20167, DOI 10.1074/jbc.M309260200; Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315; Wingender E, 2001, NUCLEIC ACIDS RES, V29, P281, DOI 10.1093/nar/29.1.281; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102	35	65	67	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2007	282	13					9482	9491		10.1074/jbc.M700067200	http://dx.doi.org/10.1074/jbc.M700067200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	153HA	17277356	hybrid, Green Accepted			2022-12-25	WOS:000245421700021
J	Liu, XP; Yan, QT; Baskerville, KL; Zweier, JL				Liu, Xiaoping; Yan, Qingtao; Baskerville, Kim L.; Zweier, Jay L.			Estimation of nitric oxide concentration in blood for different rates of generation - Evidence that intravascular nitric oxide levels are too low to exert physiological effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; HUMAN-ERYTHROCYTES; OXYGEN-UPTAKE; CARBON-MONOXIDE; DIFFUSION; CONSUMPTION; HEMOGLOBIN; KINETICS; O-2; NO	Endothelium-derived nitric oxide (NO) is a potent vasodilator in the cardiovascular system. Several lines of experimental evidence suggest that NO or NO equivalents may also be generated in the blood. However, blood contains a large amount of hemoglobin (Hb) in red blood cells (RBCs). The RBC-encapsulated Hb can react very quickly with NO, which is only limited by the rate of NO diffusion into the RBCs. It is unclear what the possible NO concentration levels in blood are and how the NO diffusion coefficient (D) and the permeability (P-m) of RBC membrane to NO affect the level of NO concentration. In this study, a steady-state concentration experimental method combined with a spherical diffusion model are presented for determining D and P-m and examining the effect of NO generation rate (V-o) and hematocrit (Hct) on NO concentration. It was determined that P-m is 4.5 +/- 1.5 cm/s and D is 3410 +/- 50 mu m(2)/s at 37 degrees C. Simulations based on experimental parameters show that, when the rate of NO formation is as high as 100 nM/s, the maximal NO concentration in blood is below 0.012 nM at P-m = 4.5 cm/s and Hct = 45%. Thus, it is unlikely that NO is directly exported or generated from the RBC as an intravascular signaling molecule, because its concentration would be too low to exert a physiological role. Furthermore, our results suggest that, if RBCs export NO bioactivity, this would be through NO-derived species that can release or form NO rather than NO itself.	Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Cardiovasc Med, Columbus, OH 43210 USA	Ohio State University; Ohio State University	Liu, XP (corresponding author), Ohio State Univ, Davis Heart & Lung Res Inst, 473 W 12th Ave, Columbus, OH 43210 USA.	Xiaoping.liu@osumc.edu	Liu, Xiaoping/A-4516-2008	Liu, Xiaoping/0000-0002-7516-382X	NHLBI NIH HHS [HL-38324, HL-63744, HL-65608] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL065608, R01HL063744, R01HL038324, R29HL038324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTMAN PL, 1974, BIOL DATA BOOK, P1598; Azarov I, 2005, J BIOL CHEM, V280, P39024, DOI 10.1074/jbc.M509045200; Butler AR, 1998, BBA-GEN SUBJECTS, V1425, P168, DOI 10.1016/S0304-4165(98)00065-8; CARLSEN E, 1958, J GEN PHYSIOL, V42, P83, DOI 10.1085/jgp.42.1.83; COIN JT, 1979, J BIOL CHEM, V254, P1178; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V328, P208, DOI 10.1006/abbi.1996.0162; Gladwin MT, 2005, NAT CHEM BIOL, V1, P245, DOI 10.1038/nchembio1005-245; Han TH, 2003, P NATL ACAD SCI USA, V100, P12504, DOI 10.1073/pnas.2133409100; Hartridge H, 1927, J PHYSIOL-LONDON, V52, P232, DOI 10.1113/jphysiol.1927.sp002354; HUXLEY VH, 1983, MICROVASC RES, V26, P89, DOI 10.1016/0026-2862(83)90058-4; HUXLEY VH, 1981, J PHYSIOL-LONDON, V316, P75, DOI 10.1113/jphysiol.1981.sp013773; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KREUZER F, 1960, J APPL PHYSIOL, V15, P1117, DOI 10.1152/jappl.1960.15.6.1117; KUTCHAI H, 1969, J GEN PHYSIOL, V53, P576, DOI 10.1085/jgp.53.5.576; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Liu XP, 2005, NITRIC OXIDE-BIOL CH, V13, P68, DOI 10.1016/j.niox.2005.04.011; Liu XP, 2002, J BIOL CHEM, V277, P26194, DOI 10.1074/jbc.M201939200; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; NICOLSON P, 1951, PROC R SOC SER B-BIO, V138, P241, DOI 10.1098/rspb.1951.0020; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Robinson JM, 2005, AM J RESP CELL MOL, V32, P257, DOI 10.1165/rcmb.F292; Roughton FJW, 1932, P R SOC LOND B-CONTA, V111, P1, DOI 10.1098/rspb.1932.0041; Russell JA, 2003, AM J PHYSIOL-HEART C, V285, pH251, DOI 10.1152/ajpheart.01086.2002; Subczynski WK, 1996, FREE RADICAL RES, V24, P343, DOI 10.3109/10715769609088032; Thomas DD, 2001, P NATL ACAD SCI USA, V98, P355, DOI 10.1073/pnas.98.1.355; Tsoukias NM, 2002, AM J PHYSIOL-HEART C, V282, pH2265, DOI 10.1152/ajpheart.01080.2001; VANDEGRIFF KD, 1984, BIOPHYS J, V45, P825, DOI 10.1016/S0006-3495(84)84226-5; VAUGHAN MW, 2003, AM J PHYSIOL, V274, pH1705; Vaughn MW, 2000, J BIOL CHEM, V275, P2342, DOI 10.1074/jbc.275.4.2342; Vaughn MW, 2001, NITRIC OXIDE-BIOL CH, V5, P18, DOI 10.1006/niox.2000.0328; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; Zacharia IG, 2005, ANN BIOMED ENG, V33, P214, DOI 10.1007/s10439-005-8980-9	35	34	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8831	8836		10.1074/jbc.M611684200	http://dx.doi.org/10.1074/jbc.M611684200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17267398	hybrid			2022-12-25	WOS:000245780300030
J	Rigby, RJ; Simmons, JG; Greenhalgh, CJ; Alexander, WS; Lund, PK				Rigby, R. J.; Simmons, J. G.; Greenhalgh, C. J.; Alexander, W. S.; Lund, P. K.			Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon	ONCOGENE			English	Article						SOCS3; colon; cancer; mouse model	GROWTH-HORMONE; STAT3 ACTIVATION; TRANSGENIC MICE; CELL-GROWTH; CANCER; HYPERMETHYLATION; CARCINOMA; INACTIVATION; SUPPRESSORS; INHIBITION	Intestinal injury or chronic inflammation induce cytokines that promote crypt regeneration and mucosal repair. If excessive or prolonged, such mechanisms may increase colon cancer risk. Factors that terminate or limit cytokine action in intestinal epithelial cells (IEC) may protect against crypt hyperplasia and neoplasia. We hypothesized that suppressor of cytokine signaling-3 (SOCS3) is such a factor. Mice with Vilin-promoter/Cre-recombinase (VC)mediated IEC-specific SOCS3 gene disruption (VC/HO), WT/HO littermates with floxed but intact SOCS3 genes and VC/WT mice were studied. Colon was examined after acute dextran sodium sulfate (DSS)-induced mucosal injury or after azoxymethane (AOM) and chronic DSS. Signaling pathways were examined in colon, cultured IEC or colon cancer cell lines. VC/HO mice showed no basal phenotype. After acute DSS, VC/HO exhibited enhanced crypt proliferation and crypt hyperplasia and reduced transforming growth factor ( TGF) beta expression in colon. Inflammation and mucosal damage were similar across genotypes. Following AOM/DSS, VC/HO mice had increased size, number and load of colonic tumors and increased STAT3 and nuclear factor-kappa B (NF-kappa B) activation in colon. In vitro, SOCS3 overexpression reduced proliferation, IL-6-mediated STAT3 activation and tumor necrosis factor (TNF) alpha-mediated NF-kappa B activation. We conclude that cytokine induction of SOCS3 normally provides an intrinsic mechanism to limit injury-induced crypt hyperproliferation and inflammation-associated colon cancer by regulating both STAT3 and NF-kappa B pathways.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Rigby, RJ (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, Rm 6336,MBRB,CB 7545,103 Mason Farm Rd, Chapel Hill, NC 27599 USA.	rachael_rigby@med.unc.edu	Rigby, Rachael/C-8206-2011; , Histology Research Core Facility/ABF-6317-2021	Rigby, Rachael/0000-0002-6605-9609	NIDDK NIH HHS [P30 DK34987] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonzi T, 2004, CYTOKINE, V26, P45, DOI 10.1016/j.cyto.2003.12.002; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Campbell JS, 2001, J CLIN INVEST, V107, P1285, DOI 10.1172/JCI11867; Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103; Chun KG, 2003, PHOTONIC NETW COMMUN, V6, P83, DOI 10.1023/A:1023642926131; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Greenhalgh CJ, 2002, GASTROENTEROLOGY, V123, P2064, DOI 10.1053/gast.2002.37068; Hanada T, 2006, J EXP MED, V203, P1391, DOI 10.1084/jem.20060436; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Itzkowitz S, 2003, J CLIN GASTROENTEROL, V36, P70; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Judd LM, 2006, GASTROENTEROLOGY, V131, P1073, DOI 10.1053/j.gastro.2006.07.018; Kimura A, 2004, INT IMMUNOL, V16, P991, DOI 10.1093/intimm/dxh102; Landi S, 2003, CANCER RES, V63, P3560; Miller ME, 2004, GASTROENTEROLOGY, V127, P570, DOI 10.1053/j.gastro.2004.05.016; Miller Megan E., 2000, Regulatory Peptides, V94, P67, DOI 10.1016/S0167-0115(00)80135-4; Miscia S, 2002, CELL GROWTH DIFFER, V13, P13; Mizoguchi E, 2003, GASTROENTEROLOGY, V125, P148, DOI 10.1016/S0016-5085(03)00665-6; Munkholm P, 2003, ALIMENT PHARM THER, V18, P1, DOI 10.1046/j.1365-2036.18.s2.2.x; Nakamura Y, 2005, CARCINOGENESIS, V26, P665, DOI 10.1093/carcin/bgi003; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Ogata H, 2006, ONCOGENE, V25, P2520, DOI 10.1038/sj.onc.1209281; Ogata H, 2006, GASTROENTEROLOGY, V131, P179, DOI 10.1053/j.gastro.2006.04.025; Oshimo Y, 2004, INT J CANCER, V112, P1003, DOI 10.1002/ijc.20521; Rivat C, 2004, ONCOGENE, V23, P3317, DOI 10.1038/sj.onc.1207437; Schneider M, 2000, HAEMOPHILIA, V6, P38; Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; ULSHEN MH, 1993, GASTROENTEROLOGY, V104, P973, DOI 10.1016/0016-5085(93)90263-C; Wang LX, 2003, J IMMUNOL, V171, P3194, DOI 10.4049/jimmunol.171.6.3194; Weber A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818; Williams KL, 2001, GASTROENTEROLOGY, V120, P925, DOI 10.1053/gast.2001.22470; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938	35	124	128	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4833	4841		10.1038/sj.onc.1210286	http://dx.doi.org/10.1038/sj.onc.1210286			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297444				2022-12-25	WOS:000248170400008
J	Tsang, WP; Kwok, TT				Tsang, W. P.; Kwok, T. T.			Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells	ONCOGENE			English	Article						H19; MDR1; drug resistance; P-glycoprotein; DNA methylation	PROMOTER REGION; MDR1 GENE; NONCODING RNA; CANCER-CELLS; OVEREXPRESSION; METHYLATION; EXPRESSION	Acquisition of drug resistance is one of the main obstacles encountered in cancer chemotherapy. Overexpression of multi-drug resistance 1 (MDR1) gene and its protein product P-glycoprotein, accompanied with a decrease in doxorubicin accumulation level, was observed in doxorubicinresistant R-HepG2 cells, a subline derived by selection of human hepatocellular carcinoma HepG2 cells with doxorubicin. In addition, Northern-blot analysis revealed an eight fold upregulation of the imprinted H19 mRNA in R-HepG2 cells. H19 knockdown bytrans fection with antisense H19 oligonucleotides suppressed the MDR1/P-glycoprotein expression, increased the cellular doxorubicin accumulation level and sensitized doxorubicin toxicityin both HepG2 parent cells and R-HepG2 cells. Results from methylation-specific polymerase chain reaction analysis indicated that the MDR1 gene promoter was hypomethylated in R-HepG2 cells. Antisense H19 oligonucleotides transfection induced a marked increase in the percentage of MDR1 promoter methylation and decrease in MDR1 expression in R- HepG2 cells. Thus, the H19 gene is believed to induce P- glycoprotein expression and MDR1-associated drug resistance at least in liver cancer cells through regulation of MDR1 promoter methylation.	Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong	Kwok, TT (corresponding author), Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China.	kwok2020@cuhk.edu.hk						Baylin SB, 1998, ADV CANCER RES, V72, P141; Doyle LA, 1996, CANCER RES, V56, P2904; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Enokida H, 2004, CANCER RES, V64, P5956, DOI 10.1158/0008-5472.CAN-04-0081; GLASER T, 1989, SOMAT CELL MOLEC GEN, V15, P477, DOI 10.1007/BF01534910; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x; Liu JQ, 1997, J CLIN ENDOCR METAB, V82, P1766, DOI 10.1210/jc.82.6.1766; Lottin S, 2002, ONCOGENE, V21, P1625, DOI 10.1038/sj.onc.1205233; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; Tada Y, 2000, CLIN CANCER RES, V6, P4618; Vernucci M, 2004, HUM MOL GENET, V13, P353, DOI 10.1093/hmg/ddh028	14	151	160	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4877	4881		10.1038/sj.onc.1210266	http://dx.doi.org/10.1038/sj.onc.1210266			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297456				2022-12-25	WOS:000248170400013
J	Gavins, FNE; Dalli, J; Flower, RJ; Granger, DN; Perretti, M				Gavins, Felicity N. E.; Dalli, Jesmond; Flower, Roderick J.; Granger, D. Neil; Perretti, Mauro			Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation	FASEB JOURNAL			English	Article						endogenous anti-inflammation; intravital microscopy	FORMYL-PEPTIDE RECEPTORS; N-FORMYLPEPTIDE RECEPTOR; LIPOXIN A(4) RECEPTOR; REPERFUSION INJURY; NITRIC-OXIDE; LIPOCORTIN 1; IN-VIVO; DISEASE; NEUTROPHIL; INFLAMMATION	The purpose of this study was to investigate the role of the homeostatic antiinflammatory axis centered on annexin 1 ( AnxA1) in cerebral microvascular dysfunction and tissue injury associated with middle cerebral artery ( MCA) occlusion and reperfusion. Intravital fluorescence microscopy was used to visualize the mouse cerebral microcirculation: AnxA1 null mice exhibited more white blood cell adhesion in cerebral venules than their wild-type counterparts, and this was accompanied by a larger cerebral infarct vol and worse neurological score. All parameters were rescued by delivery of human recombinant AnxA1. To further explore these findings using pharmacological tools, the effect of a short AnxA1 peptidomimetic was tested. When given during the reperfusion phase, peptide Ac2-26 produced similar cerebroprotection, which was associated with a marked attenuation of cell adhesion and markers of inflammation as measured in tissue homogenates. The pharmacological effects of peptide Ac2-26 occurred via receptors of the formyl-peptide receptor (FPR) family, most likely FPR-rs2, as deduced by displacement assays with transfected cells and in vivo experiments with transgenic mice and receptor antagonists. Our findings indicate that the endogenous antiinflammatory circuit centered on AnxA1 produces significant cerebral protection, and that these properties might have therapeutic potential for stroke treatment. -Gavins, F. N. E., Dalli, J., Flower, R. J., Granger, D. N., Perretti, M. Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation.	William Harvey Res Inst, London EC1M 6BQ, England; Louisiana State Univ, Sch Med, Shreveport, LA 71105 USA	University of London; Queen Mary University London; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Perretti, M (corresponding author), William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	m.perretti@qmul.ac.uk	Gavins, Felicity N. E./AAU-6010-2020	Gavins, Felicity N. E./0000-0001-7008-5423; Dalli, Jesmond/0000-0001-6328-3640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026441] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26441] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Babbin BA, 2006, J BIOL CHEM, V281, P19588, DOI 10.1074/jbc.M513025200; Chatterjee BE, 2005, J LEUKOCYTE BIOL, V78, P639, DOI 10.1189/jlb.0405206; Chiang N, 2003, BRIT J PHARMACOL, V139, P89, DOI 10.1038/sj.bjp.0705220; Chiang N, 2005, PROSTAG LEUKOTR ESS, V73, P163, DOI 10.1016/j.plefa.2005.05.003; Chiang N, 2006, PHARMACOL REV, V58, P463, DOI 10.1124/pr.58.3.4; COMERA C, 1995, BRIT J PHARMACOL, V115, P1043, DOI 10.1111/j.1476-5381.1995.tb15916.x; D'Amico M, 2000, FASEB J, V14, P1867; Damazo AS, 2005, AM J PATHOL, V166, P1607, DOI 10.1016/S0002-9440(10)62471-6; Ernst S, 2004, J IMMUNOL, V172, P7669, DOI 10.4049/jimmunol.172.12.7669; Frijns CJM, 2002, STROKE, V33, P2115, DOI 10.1161/01.STR.0000021902.33129.69; Frizzell JP, 2005, AACN ADV CRIT CARE, V16, P421, DOI 10.1097/00044067-200510000-00002; Frizzell JP., 2005, AACN CLIN ISSUES, V16, P597; Gao JL, 1999, J EXP MED, V189, P657, DOI 10.1084/jem.189.4.657; Gavins FNE, 2003, BLOOD, V101, P4140, DOI 10.1182/blood-2002-11-3411; Gavins FNE, 2004, FASEB J, V18, P100, DOI 10.1096/fj.04-2178fje; Getting SJ, 1997, BRIT J PHARMACOL, V120, P1075, DOI 10.1038/sj.bjp.0701029; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Gilroy DW, 2004, NAT REV DRUG DISCOV, V3, P401, DOI 10.1038/nrd1383; Granger DN, 1999, MICROCIRCULATION, V6, P167; Hachicha M, 1999, J EXP MED, V189, P1923, DOI 10.1084/jem.189.12.1923; Hannon R, 2002, FASEB J, V16, P253, DOI 10.1096/fj.02-0239fje; Hartt JK, 1999, J EXP MED, V190, P741, DOI 10.1084/jem.190.5.741; Hayhoe RPG, 2006, BLOOD, V107, P2123, DOI 10.1182/blood-2005-08-3099; Hughes PM, 2002, J CEREBR BLOOD F MET, V22, P308, DOI 10.1097/00004647-200203000-00008; Ishikawa M, 2005, CIRCULATION, V111, P1690, DOI 10.1161/01.CIR.0000160349.42665.0C; Ishikawa M, 2003, STROKE, V34, P1777, DOI 10.1161/01.STR.0000074921.17767.F2; Kenakin T, 2002, NAT REV DRUG DISCOV, V1, P103, DOI 10.1038/nrd722; Kieran NE, 2004, KIDNEY INT, V65, P1145, DOI 10.1111/j.1523-1755.2004.00487.x; Knott C, 2000, MOL CELL NEUROSCI, V16, P724, DOI 10.1006/mcne.2000.0914; Le YY, 2002, TRENDS IMMUNOL, V23, P541, DOI 10.1016/S1471-4906(02)02316-5; Liu N, 2004, J NEUROSCI RES, V77, P391, DOI 10.1002/jnr.20167; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maderna P, 2005, J IMMUNOL, V174, P3727, DOI 10.4049/jimmunol.174.6.3727; Matsumoto T, 1997, J LEUKOCYTE BIOL, V62, P581, DOI 10.1002/jlb.62.5.581; Minami M, 2003, LIFE SCI, V74, P321, DOI 10.1016/j.lfs.2003.09.019; Minghetti L, 1999, BRIT J PHARMACOL, V126, P1307, DOI 10.1038/sj.bjp.0702423; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Morgan L, 2005, CURR OPIN LIPIDOL, V16, P193, DOI 10.1097/01.mol.0000162324.85290.ac; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Perretti M, 2003, TRENDS PHARMACOL SCI, V24, P574, DOI 10.1016/j.tips.2003.09.010; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; RELTON JK, 1991, J EXP MED, V174, P305, DOI 10.1084/jem.174.2.305; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Wada K, 2006, FASEB J, V20, P1785, DOI 10.1096/fj.06-5809com; Wang ZG, 2002, GENE, V299, P57, DOI 10.1016/S0378-1119(02)01012-0; Yang YH, 1999, ARTHRITIS RHEUM, V42, P1538, DOI 10.1002/1529-0131(199907)42:7<1538::AID-ANR29>3.0.CO;2-3; Ying GG, 2004, J IMMUNOL, V172, P7078, DOI 10.4049/jimmunol.172.11.7078; Yona S, 2004, BRIT J PHARMACOL, V142, P890, DOI 10.1038/sj.bjp.0705858; YONA S, 2006, BR J PHARM; Young KA, 1999, GLIA, V26, P333, DOI 10.1002/(SICI)1098-1136(199906)26:4<333::AID-GLIA7>3.0.CO;2-S	51	99	103	1	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2007	21	8					1751	1758		10.1096/fj.06-7842com	http://dx.doi.org/10.1096/fj.06-7842com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	173IK	17317721				2022-12-25	WOS:000246866500017
J	Uhles, S; Moede, T; Leibiger, B; Berggren, PO; Leibiger, IB				Uhles, Sabine; Moede, Tilo; Leibiger, Barbara; Berggren, Per-Olof; Leibiger, Ingo B.			Selective gene activation by spatial segregation of insulin receptor B signaling	FASEB JOURNAL			English	Article						insulin signaling; gene expression regulation; pancreatic beta cell; endosomes; life cell imaging; c-fos gene; glucokinase gene	GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VITRO; ENDOCYTOSIS; SHC; CELLS; TRANSCRIPTION; DOMAINS; PHOSPHORYLATION; INTERNALIZATION	Insulin exerts pleiotropic effects at the cellular level. Signaling via the two isoforms of the insulin receptor (IR) may explain the activation of different signaling cascades, while it remains to be explored how selectivity is achieved when utilizing the same IR isoform. We now demonstrate that insulin-stimulated transcription of c-fos and glucokinase genes is activated simultaneously in the insulin-producing beta-cell via IR-B localized in different cellular compartments. Insulin activates the glucokinase gene from plasma membrane-standing IR-B, while c-fos gene activation is dependent on clathrin-mediated IR-B-endocytosis and signaling from early endosomes. Moreover, glucokinase gene up-regulation requires the integrity of the juxtamembrane IR-B NPEY-motif and signaling via PI3K-C2 alpha-like/ PDK1/PKB, while c-fos gene activation requires the intact C-terminal YTHM-motif and signaling via PI3K Ia/Shc/MEK1/ERK. By using IR-B as an example it is thus possible to demonstrate how spatial segregation allows simultaneous and selective signaling via the same receptor isoform in the same cell.	Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, S-17176 Stockholm, Sweden	Karolinska Institutet	Leibiger, IB (corresponding author), Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, S-17176 Stockholm, Sweden.	ingo.leibiger@ki.se		Moede, Tilo/0000-0002-2045-9244; Uhles, Sabine/0000-0002-2836-8726; Berggren, Per-Olof/0000-0001-8991-413X				BACKER JM, 1992, J CELL BIOL, V118, P831, DOI 10.1083/jcb.118.4.831; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; Boura-Halfon S, 2003, J BIOL CHEM, V278, P16397, DOI 10.1074/jbc.M212385200; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Denley A, 2003, HORM METAB RES, V35, P778; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Gruenberg J, 2001, NAT REV MOL CELL BIO, V2, P721, DOI 10.1038/35096054; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HAFT CR, 1994, J BIOL CHEM, V269, P26286; Hribal ML, 2003, FASEB J, V17, P1340, DOI 10.1096/fj.02-0685fje; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; Leibiger IB, 1998, MOL CELL, V1, P933, DOI 10.1016/S1097-2765(00)80093-3; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OBRAIN RM, 1996, PHYSIOL REV, V76, P1109; Olusanya O, 2001, CURR BIOL, V11, P896, DOI 10.1016/S0960-9822(01)00240-8; Paz K, 1996, J BIOL CHEM, V271, P6998, DOI 10.1074/jbc.271.12.6998; RAJAGOPALAN M, 1991, J BIOL CHEM, V266, P23068; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; Sasaoka T, 2000, ENDOCR J, V47, P373, DOI 10.1507/endocrj.47.373; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Ugi S, 2002, J BIOL CHEM, V277, P18592, DOI 10.1074/jbc.M201019200; Uhles S, 2003, J CELL BIOL, V163, P1327, DOI 10.1083/jcb.200306093; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; VANSCHRAVENDIJK CFH, 1987, ENDOCRINOLOGY, V121, P1784, DOI 10.1210/endo-121-5-1784; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; VOGT B, 1991, BIOCHEM BIOPH RES CO, V177, P1013, DOI 10.1016/0006-291X(91)90639-O; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	41	32	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1609	1621		10.1096/fj.06-7589com	http://dx.doi.org/10.1096/fj.06-7589com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264162				2022-12-25	WOS:000246117000035
J	Zhao, L; Kwon, MJ; Huang, SR; Lee, JY; Fukase, K; Inohara, N; Hwang, DH				Zhao, Ling; Kwon, Myung-Ja; Huang, Shurong; Lee, Joo Y.; Fukase, Koichi; Inohara, Naohiro; Hwang, Daniel H.			Differential modulation of nods signaling pathways by fatty acids in human colonic epithelial HCT116 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY-BOWEL-DISEASE; TOLL-LIKE RECEPTOR-4; KAPPA-B ACTIVATION; MURAMYL DIPEPTIDE RECOGNITION; HOST-MICROBIAL INTERACTIONS; INTERLEUKIN-8 EXPRESSION; BACTERIAL PEPTIDOGLYCAN; CROHNS-DISEASE; TNF-ALPHA; FAMILY	Nucleotide-binding oligomerization domain-containing proteins ( Nods) are intracellular pattern recognition receptors recognizing conserved moieties of bacterial peptidoglycan through their leucine-rich repeats domain. The agonists for Nods activate proinflammatory signaling pathways, including NF-kappa B pathways. The results from our previous studies showed that the activation of TLR4 and TLR2, leucine-rich repeat-containing pattern recognition receptors, were differentially modulated by saturated and n-3 polyunsaturated fatty acids in macrophages and dendritic cells. Here, we show the differential modulation of NF-kappa B activation and interleukin-8 ( IL-8) expression in colonic epithelial cells HCT116 by saturated and unsaturated fatty acids mediated through Nods proteins. Lauric acid ( C12:0) dose dependently activated NF-kappa B and induced IL-8 expression in HCT116 cells, which express both Nod1 and Nod2, but not detectable amounts of TLR2 and TLR4. These effects of lauric acid were inhibited by dominant negative forms of Nod1 or Nod2, but not by dominant negative forms of TLR2, TLR4, and TLR5. The effects of lauric acid were also attenuated by small RNA interference targeting Nod1 or Nod2. In contrast, polyunsaturated fatty acids, especially n-3 polyunsaturated fatty acids, inhibited the activation of NF-kappa B and IL-8 expression induced by lauric acid or known Nods ligands in HCT116. Furthermore, lauric acid induced, but docosahexaenoic acid inhibited lauric acid- or Nod2 ligand MDP-induced, Nod2 oligomerization in HEK293T cells transfected with Nod2. Together, these results provide new insights into the role of dietary fatty acids in modulating inflammation in colon epithelial cells. The results suggest that Nods may be involved in inducing sterile inflammation, one of the key etiological conditions in the development of many chronic inflammatory diseases.	USDA ARS, Western Human Nutr Res Ctr, Davis, CA 95616 USA; Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea; Osaka Univ, Grad Sch Sci, Dept Chem, Toyonaka, Osaka 5600043, Japan; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	United States Department of Agriculture (USDA); University of California System; University of California Davis; Gwangju Institute of Science & Technology (GIST); Osaka University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Hwang, DH (corresponding author), USDA ARS, Western Human Nutr Res Ctr, 430 W Hlth Sci Dr,1 Shields Ave, Davis, CA 95616 USA.	dhwang@whnrc.usda.gov			NATIONAL CANCER INSTITUTE [R01CA075613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064007, R01DK041868] Funding Source: NIH RePORTER; NCI NIH HHS [CA75613] Funding Source: Medline; NIDDK NIH HHS [DK064007, DK41868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Barnich N, 2005, J CELL BIOL, V170, P21, DOI 10.1083/jcb.200502153; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Belluzzi A, 2000, AM J CLIN NUTR, V71, p339S, DOI 10.1093/ajcn/71.1.339s; Carneiro LAM, 2004, MICROBES INFECT, V6, P609, DOI 10.1016/j.micinf.2004.01.012; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; CHANG HR, 1992, METABOLISM, V41, P1, DOI 10.1016/0026-0495(92)90181-9; Fritsche KL, 1997, CLIN SCI, V92, P95, DOI 10.1042/cs0920095; Furrie E, 2005, IMMUNOLOGY, V115, P565, DOI 10.1111/j.1365-2567.2005.02200.x; Gewirtz AT, 2003, CURR PHARM DESIGN, V9, P1, DOI 10.2174/1381612033392422; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Girardin SE, 2002, TRENDS MICROBIOL, V10, P193, DOI 10.1016/S0966-842X(02)02334-X; Hanauer SB, 2006, INFLAMM BOWEL DIS, V12, pS3, DOI 10.1097/01.MIB.0000195385.19268.68; Haraguchi M, 2002, ONCOL REP, V9, P159; Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153; Hisamatsu T, 2003, J BIOL CHEM, V278, P32962, DOI 10.1074/jbc.M304355200; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2002, CURR OPIN MICROBIOL, V5, P76, DOI 10.1016/S1369-5274(02)00289-8; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; INOHARA N, 2004, ANN REV BIOCH; Inoue K, 2000, CANCER RES, V60, P2290; IZZO RS, 1993, SCAND J GASTROENTERO, V28, P296, DOI 10.3109/00365529309090244; Johnson GB, 2004, J IMMUNOL, V172, P20, DOI 10.4049/jimmunol.172.1.20; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; Kitadai Y, 1998, AM J PATHOL, V152, P93; Kuniyasu H, 2000, AM J PATHOL, V157, P1523, DOI 10.1016/S0002-9440(10)64790-6; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; Lee JY, 2004, J BIOL CHEM, V279, P16971, DOI 10.1074/jbc.M312990200; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; MAZZUCCHELLI L, 1994, AM J PATHOL, V144, P997; McLaughlan JM, 1997, J PATHOL, V181, P87; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Melmed G, 2003, J IMMUNOL, V170, P1406, DOI 10.4049/jimmunol.170.3.1406; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Parilla NW, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-84; Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175; Taramelli D, 1998, T ROY SOC TROP MED H, V92, P57, DOI 10.1016/S0035-9203(98)90954-3; Uguccioni M, 1999, AM J PATHOL, V155, P331, DOI 10.1016/S0002-9440(10)65128-0; Villarete LH, 1996, AM J PATHOL, V149, P1685; Weatherill AR, 2005, J IMMUNOL, V174, P5390, DOI 10.4049/jimmunol.174.9.5390; Zhang HF, 2002, FEBS LETT, V532, P171, DOI 10.1016/S0014-5793(02)03669-4	55	90	96	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11618	11628		10.1074/jbc.M608644200	http://dx.doi.org/10.1074/jbc.M608644200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17303577	hybrid			2022-12-25	WOS:000245941900003
J	Liang, M; Tian, J; Liu, LJ; Pierre, S; Liu, J; Shapiro, J; Xie, ZJ				Liang, Man; Tian, Jiang; Liu, Lijun; Pierre, Sandrine; Liu, Jiang; Shapiro, Joseph; Xie, Zi-Jian			Identification of a pool of non-pumping Na/K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; CLATHRIN-DEPENDENT MECHANISM; SUBUNIT MESSENGER-RNAS; PROTEIN-KINASE-C; SODIUM-PUMP; CARDIAC-GLYCOSIDES; LLC-PK1 CELLS; ALPHA-SUBUNIT; OUABAIN; NA,K-ATPASE	Recent studies have ascribed many non-pumping functions to the Na/K-ATPase. Here, we present experimental evidence demonstrating that over half of the plasma membrane Na/K-ATPase in LLC-PK1 cells is performing cellular functions other than ion pumping. This "non-pumping" pool of Na/K-ATPase, like the pumping pump, binds ouabain. Depletion of either cholesterol or caveolin-1 moves some of the "non-pumping" Na/K-ATPase into the pumping pool. Graded knock-down of the alpha 1 subunit of the Na/K-ATPase eventually results in loss of this "non-pumping" pool while preserving the pumping pool. Our prior studies indicate that a loss of the non-pumping pool is associated with a loss of receptor function as evidenced by the failure of ouabain administration to induce the activation of Src and/or ERK. Therefore, our new findings suggest that a substantial amount of surface-expressed Na/K-ATPase, at least in some types of cells, may function as non-canonical ouabain-binding receptors.	Univ Toledo, Dept Physiol Pharmacol Metab & Cardiovasc Sci, Toledo, OH 43614 USA; Univ Toledo, Dept Med, Toledo, OH 43614 USA	University System of Ohio; University of Toledo; University System of Ohio; University of Toledo	Xie, ZJ (corresponding author), Univ Toledo, Dept Physiol Pharmacol Metab & Cardiovasc Sci, Hlth Sci Campus,Mail Stop 1008,3000 Arlington Ave, Toledo, OH 43614 USA.	zxie@meduohio.edu	Liu, Jiang/AAF-2742-2021		NHLBI NIH HHS [HL-67963, HL-36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573, R01HL067963] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aizman O, 2001, P NATL ACAD SCI USA, V98, P13420, DOI 10.1073/pnas.221315298; Aydemir-Koksoy A, 2001, J BIOL CHEM, V276, P46605, DOI 10.1074/jbc.M106178200; BAKER PF, 1972, J PHYSIOL-LONDON, V224, P441, DOI 10.1113/jphysiol.1972.sp009904; BERTORELLO AM, 1991, P NATL ACAD SCI USA, V88, P11359, DOI 10.1073/pnas.88.24.11359; BHUTADA A, 1990, AM J PHYSIOL, V258, pC1044, DOI 10.1152/ajpcell.1990.258.6.C1044; BHUTADA A, 1991, AM J PHYSIOL, V261, pC699, DOI 10.1152/ajpcell.1991.261.4.C699; BOARDMAN LJ, 1972, J PHYSIOL-LONDON, V225, P619, DOI 10.1113/jphysiol.1972.sp009960; Bossuyt J, 2005, CIRC RES, V97, P558, DOI 10.1161/01.RES.0000181172.27931.c3; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; ELMERNISSI G, 1984, AM J PHYSIOL, V247, pF158, DOI 10.1152/ajprenal.1984.247.1.F158; Ferrandi M, 1999, AM J PHYSIOL-HEART C, V277, pH1338, DOI 10.1152/ajpheart.1999.277.4.H1338; Gatto C, 2001, AM J PHYSIOL-CELL PH, V281, pC982, DOI 10.1152/ajpcell.2001.281.3.C982; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; Gimenez I, 2005, AM J PHYSIOL-RENAL, V289, pF1341, DOI 10.1152/ajprenal.00214.2005; GONZALEZMARISCA.L, 1990, AM J PHYSIOL, V259, P978; GOTTARDI CJ, 1995, AM J PHYSIOL, V268, P285; GRIFFITHS NM, 1991, BRIT J PHARMACOL, V104, P419, DOI 10.1111/j.1476-5381.1991.tb12445.x; HABER RS, 1987, AM J PHYSIOL, V253, pF26, DOI 10.1152/ajprenal.1987.253.1.F26; Hilgenberg LGW, 2006, CELL, V125, P359, DOI 10.1016/j.cell.2006.01.052; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; Iglesias-Bartolome R, 2006, FEBS J, V273, P1744, DOI 10.1111/j.1742-4658.2006.05194.x; ITO S, 1992, J PHARMACOL EXP THER, V262, P109; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; KIM D, 1984, J PHARMACOL EXP THER, V231, P326; KLAUSNER R, 1985, MATH MODELING RECEPT, P259; Kometiani P, 2005, MOL PHARMACOL, V67, P929, DOI 10.1124/mol.104.007302; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; LAMB JF, 1971, J PHYSL, V213; Lavoie L, 1997, BIOCHEMISTRY-US, V36, P7726, DOI 10.1021/bi970109s; Lee K, 2001, BIOCHEM J, V353, P377, DOI 10.1042/0264-6021:3530377; Liang M, 2006, J BIOL CHEM, V281, P19709, DOI 10.1074/jbc.M512240200; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Liu J, 2002, KIDNEY INT, V62, P2118, DOI 10.1046/j.1523-1755.2002.00672.x; Liu J, 2004, KIDNEY INT, V66, P227, DOI 10.1111/j.1523-1755.2004.00723.x; Liu J, 2000, J BIOL CHEM, V275, P27838; Liu JA, 2005, KIDNEY INT, V67, P1844, DOI 10.1111/j.1523-1755.2005.00283.x; LIU L, 2006, AM J PHYSIOL, pC659; Liu LJ, 2003, AM J PHYSIOL-CELL PH, V284, pC1550, DOI 10.1152/ajpcell.00555.2002; LUCIO FJ, 1991, EXP PHYSIOL, V76, P437, DOI 10.1113/expphysiol.1991.sp003510; Ma TY, 2000, MICROSC RES TECHNIQ, V51, P156, DOI 10.1002/1097-0029(20001015)51:2<156::AID-JEMT7>3.0.CO;2-J; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; POLLACK LR, 1981, AM J PHYSIOL, V241, pC173, DOI 10.1152/ajpcell.1981.241.5.C173; Rajasekaran SA, 2005, SEMIN NEPHROL, V25, P328, DOI 10.1016/j.semnephrol.2005.03.008; Schoner W, 2005, SEMIN NEPHROL, V25, P343, DOI 10.1016/j.semnephrol.2005.03.010; Sorkina T, 2005, TRAFFIC, V6, P157, DOI 10.1111/j.1600-0854.2005.00259.x; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Tian J, 2006, MOL BIOL CELL, V17, P317, DOI 10.1091/mbc.E05-08-0735; Wang HJ, 2004, J BIOL CHEM, V279, P17250, DOI 10.1074/jbc.M313239200; YEAGLE PL, 1988, BIOCHEMISTRY-US, V27, P6449, DOI 10.1021/bi00417a037; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297; Zhang XQ, 2006, J APPL PHYSIOL, V100, P212, DOI 10.1152/japplphysiol.00757.2005	51	192	205	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10585	10593		10.1074/jbc.M609181200	http://dx.doi.org/10.1074/jbc.M609181200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17296611	hybrid			2022-12-25	WOS:000245941000052
J	Lim, Y; Park, H; Jeon, J; Han, I; Kim, J; Jho, EH; Oh, ES				Lim, Yangmi; Park, Haein; Jeon, Jihyun; Han, Innoc; Kim, Jinsook; Jho, Eek-Hoon; Oh, Eok-Soo			Focal adhesion kinase is negatively regulated by phosphorylation at tyrosine 407	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; CELL-CYCLE; SRC SH2; FAK; DOMAIN; MIGRATION; PATHWAY; SITE	Focal adhesion kinase ( FAK) mediates signal transduction in response to multiple extracellular inputs via tyrosine phosphorylation at specific residues. Although several tyrosine phosphorylation events have been linked to FAK activation and downstream signal transduction, the function of FAK phosphorylation at Tyr(407) was previously unknown. Here, we show for the first time that phosphorylation of FAK Tyr(407) increases during serum starvation, contact inhibition, and cell cycle arrest, all conditions under which activating FAK Tyr(397) phosphorylation decreases. Transfection of NIH3T3 cells with a phosphorylationmimicking FAK 407E mutant decreased autophosphorylation at Tyr(397) and inhibited bothFAKkinase activity in vitro and FAK- mediated functions such as cell adhesion, spreading, proliferation, and migration. The opposite effects were observed in cells transfected with nonphosphorylatable mutant FAK F-407. Taken together, these data suggest the novel concept that FAK Tyr(407) phosphorylation negatively regulates the enzymatic and biological activities of FAK.	Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Dept Life Sci, Div Mol Life Sci, Seoul 120750, South Korea; Inha Univ, Coll Med, Dept Physiol & Biophys, Inchon 402751, South Korea; Univ Seoul, Dept Life Sci, Seoul 130743, South Korea	Ewha Womans University; Ewha Womans University; Inha University; University of Seoul	Oh, ES (corresponding author), Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea.	OhES@ewha.ac.kr		Jho, Eek-hoon/0000-0003-2414-6234				Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Busse D, 2001, SEMIN ONCOL, V28, P47, DOI 10.1053/sonc.2001.28550; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cooper LA, 2003, MOL CELL BIOL, V23, P8030, DOI 10.1128/MCB.23.22.8030-8041.2003; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Hamadi A, 2005, J CELL SCI, V118, P4415, DOI 10.1242/jcs.02565; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hauck CR, 2001, CANCER RES, V61, P7079; Jacamo RO, 2005, BIOCHEM BIOPH RES CO, V334, P1299, DOI 10.1016/j.bbrc.2005.07.034; Katz BZ, 2003, J BIOL CHEM, V278, P29115, DOI 10.1074/jbc.M212396200; Le Boeuf F, 2004, J BIOL CHEM, V279, P39175, DOI 10.1074/jbc.M405493200; Leu TH, 2002, ONCOGENE, V21, P6992, DOI 10.1038/sj.onc.1205904; Lim YM, 2004, J BIOL CHEM, V279, P29060, DOI 10.1074/jbc.M401183200; Lim YM, 2002, J BIOL CHEM, V277, P12735, DOI 10.1074/jbc.M111011200; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997	27	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10398	10404		10.1074/jbc.M609302200	http://dx.doi.org/10.1074/jbc.M609302200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17303567	hybrid			2022-12-25	WOS:000245941000030
J	Tomimatsu, N; Tahimic, CGT; Otsuki, A; Burma, S; Fukuhara, A; Sato, K; Shiota, G; Oshimura, M; Chen, DJ; Kurimasa, A				Tomimatsu, Nozomi; Tahimic, Candice G. T.; Otsuki, Akihiro; Burma, Sandeep; Fukuhara, Akiko; Sato, Kenzo; Shiota, Goshi; Oshimura, Mitsuo; Chen, David J.; Kurimasa, Akihiro			Ku70/80 modulates ATM and ATR signaling pathways in response to DNA double strand breaks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DAMAGE-INDUCED PHOSPHORYLATION; IONIZING-RADIATION; ATAXIA-TELANGIECTASIA; PHOSPHOINOSITIDE 3-KINASE; RADIOSENSITIZING AGENT; CATALYTIC SUBUNIT; REQUIRES ATM; KU PROTEIN; CHECKPOINT	Double strand break (DSB) recognition is the first step in the DSB damage response and involves activation of ataxia telangiectasiamutated( ATM) and phosphorylation of targets such as p53 to trigger cell cycle arrest, DNA repair, or apoptosis. It was reported that activation of ATM- and Rad3- related (ATR) kinase by DSBs also occurs in an ATM- dependent manner. On the other hand, Ku70/ 80 is known to participate at a later time point in the DSB response, recruiting DNA-PKcs to facilitate non-homologous end joining. Because Ku70/ 80 has a high affinity for broken DNA ends and is abundant in nuclei, we examined their possible involvement in other aspects of the DSB damage response, particularly in modulating the activity of ATM and other phosphatidylinositol ( PI) 3-related kinases during DSB recognition. We thus analyzed p53(Ser18) phosphorylation in irradiated Ku- deficient cells and observed persistent phosphorylation in these cells relative to wild type cells. ATM or ATR inhibition revealed that this phosphorylation is mainly mediated by ATM- dependent ATR activity at 2 h post-ionizing radiation in wild type cells, whereas in Ku-deficient cells, this occurs mainly through direct ATM activity, with a secondary contribution from ATR via a novel ATM- independent mechanism. Using ATM/Ku70 double-null cell lines, which we generated, we confirmed that ATM- independent ATR activity contributed to persistent phosphorylation of p53Ser18 in Ku- deficient cells at 12 h post- ionizing radiation. In summary, we discovered a novel role for Ku70/ 80 in modulating ATM-dependentATR activation during DSB damage response and demonstrated that these proteins confer a protective effect against ATM- independent ATR activation at later stages of the DSB damage response.	Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Tottori 6838503, Japan; Tottori Univ, Sch Life Sci, Tottori 6838503, Japan; Univ Texas, Southwestern Med Ctr, Dept Radiat Oncol, Dallas, TX 75390 USA; Tottori Univ, Century COE Program 21, Tottori 6838503, Japan; Tottori Univ, Res Core Chromosome Engn Technol, Tottori 6838503, Japan	Tottori University; Tottori University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tottori University; Tottori University	Kurimasa, A (corresponding author), Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, 86 Nishimachi, Tottori 6838503, Japan.		Otsuki, Akihiro/C-1179-2009; Otsuki, Akihiro/AAW-8479-2020; Otsuki, Akihiro/AAI-5904-2021	Otsuki, Akihiro/0000-0001-9173-1148; Tahimic, Candice/0000-0001-5862-2652				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; BLIER PR, 1993, J BIOL CHEM, V268, P7594; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Burma S, 2006, DNA REPAIR, V5, P1042, DOI 10.1016/j.dnarep.2006.05.026; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Cortez D, 2003, J BIOL CHEM, V278, P37139, DOI 10.1074/jbc.M307088200; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Downs JA, 2004, NAT REV MOL CELL BIO, V5, P367, DOI 10.1038/nrm1367; Drouet J, 2006, J BIOL CHEM, V281, P27784, DOI 10.1074/jbc.M603047200; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hu BC, 2001, J BIOL CHEM, V276, P17693, DOI 10.1074/jbc.M009340200; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Liu QH, 2000, GENE DEV, V14, P1448; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Muller C, 2005, CELL CYCLE, V4, P438, DOI 10.4161/cc.4.3.1565; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ohsawa T, 2000, J Dermatol, V27, P244; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; POWIS G, 1994, CANCER RES, V54, P2419; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sekiguchi J, 2001, P NATL ACAD SCI USA, V98, P3243, DOI 10.1073/pnas.051632098; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stavridi ES, 2005, NAT CELL BIOL, V7, P648, DOI 10.1038/ncb0705-648; Stiff T, 2005, EMBO J, V24, P199, DOI 10.1038/sj.emboj.7600504; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wang X, 2003, J BIOL CHEM, V278, P30869, DOI 10.1074/jbc.M301876200; Wang X, 2002, CANCER RES, V62, P6031; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou JQ, 2006, CANCER LETT, V243, P9, DOI 10.1016/j.canlet.2006.01.026; Zhou XY, 2002, ONCOGENE, V21, P6377, DOI 10.1038/sj.onc.1205782	49	28	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10138	10145		10.1074/jbc.M611880200	http://dx.doi.org/10.1074/jbc.M611880200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17272272	Green Submitted, hybrid			2022-12-25	WOS:000245941000003
J	Ciftci-Yilmaz, S; Morsy, MR; Song, LH; Coutu, A; Krizek, BA; Lewis, MW; Warren, D; Cushman, J; Connolly, EL; Mittler, R				Ciftci-Yilmaz, Sultan; Morsy, Mustafa R.; Song, Luhua; Coutu, Alicia; Krizek, Beth A.; Lewis, Michael W.; Warren, Daniel; Cushman, John; Connolly, Erin L.; Mittler, Ron			The EAR-motif of the Cys2/His2-type zinc finger protein Zat7 plays a key role in the defense response of Arabidopsis to salinity stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC ASCORBATE PEROXIDASE-1; ROLLING CIRCLE AMPLIFICATION; TRANSCRIPTION FACTORS; GENE-TRANSCRIPTION; OXIDATIVE STRESS; REACTIVE OXYGEN; ABIOTIC STRESS; SALT TOLERANCE; PLANT DEFENSE; REPRESSORS	Cyst/His2-type zinc finger proteins, which contain the EAR transcriptional repressor domain, are thought to play a key role in regulating the defense response of plants to biotic and abiotic stress conditions. Although constitutive expression of several of these proteins was shown to enhance the tolerance of transgenic plants to abiotic stress, it is not clear whether the EAR-motif of these proteins is involved in this function. In addition, it is not clear whether suppression of plant growth, induced in transgenic plants by different Cyst/His2 EAR-containing proteins, is mediated by the EAR-domain. Here we report that transgenic Arabidopsis plants constitutively expressing the Cyst/His2 zinc finger protein Zat7 have suppressed growth and are more tolerant to salinity stress. A deletion or a mutation of the EAR-motif of Zat7 abolishes salinity tolerance without affecting growth suppression. These results demonstrate that the EAR-motif of Zat7 is directly involved in enhancing the tolerance of transgenic plants to salinity stress. In contrast, the EAR-motif appears not to be involved in suppressing the growth of transgenic plants. Further analysis of Zat7 using RNAi lines suggests that Zat7 functions in Arabidopsis to suppress a repressor of defense responses. A yeast two-hybrid analysis identified putative interactors of Zat7 and the EAR-domain, including WRKY70 and HASTY, a protein involved in miRNA transport. Our findings demonstrate that the EAR-domain of Cyst/His2-type zinc finger proteins plays a key role in the defense response of Arabidopsis to abiotic stresses.	Univ Nevada, Dept Biochem & Mol Biol, Reno, NV 89557 USA; Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Mittler, R (corresponding author), Univ Nevada, Dept Biochem & Mol Biol, Mail Stop 200, Reno, NV 89557 USA.	ronm@unr.edu	Morsy, Mustafa R/E-6245-2013; Connolly, Erin L/B-7648-2013; Ciftci-Yilmaz, Sultan/D-7971-2017; Mittler, Ron/ABE-6496-2020	Morsy, Mustafa R/0000-0003-1803-4893; 	NCRR NIH HHS [RR-03-008] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; Blumwald E, 2003, BIOTECHNOL GENET ENG, V20, P261, DOI 10.1080/02648725.2003.10648046; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; Davletova S, 2005, PLANT CELL, V17, P268, DOI 10.1105/tpc.104.026971; Davletova S, 2005, PLANT PHYSIOL, V139, P847, DOI 10.1104/pp.105.068254; Ding XD, 2004, ANAL BIOCHEM, V331, P195, DOI 10.1016/j.ab.2004.03.052; Ding XD, 2003, BIOTECHNIQUES, V35, P774, DOI 10.2144/03354st08; Englbrecht CC, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-39; Eulgem T, 2005, TRENDS PLANT SCI, V10, P71, DOI 10.1016/j.tplants.2004.12.006; Horton P, 2006, SER ADV BIOINFORM, V3, P39, DOI 10.1142/9781860947292_0007; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Kazan K, 2006, TRENDS PLANT SCI, V11, P109, DOI 10.1016/j.tplants.2006.01.004; Kazuoka T, 2000, PLANT J, V24, P191, DOI 10.1046/j.1365-313x.2000.00864.x; LeClere S, 2001, PLANT MOL BIOL, V46, P695, DOI 10.1023/A:1011699722052; Lee H, 2002, EMBO J, V21, P2692, DOI 10.1093/emboj/21.11.2692; Li J, 2004, PLANT CELL, V16, P319, DOI 10.1105/tpc.016980; Li J, 2006, PLANT J, V46, P477, DOI 10.1111/j.1365-313X.2006.02712.x; Miller G, 2006, ANN BOT-LONDON, V98, P279, DOI 10.1093/aob/mcl107; Mittler R, 2001, PLANT J, V25, P407, DOI 10.1046/j.1365-313x.2001.00975.x; Mittler R, 2006, FEBS LETT, V580, P6537, DOI 10.1016/j.febslet.2006.11.002; Mulder NJ, 2003, NUCLEIC ACIDS RES, V31, P315, DOI 10.1093/nar/gkg046; Ohta M, 2001, PLANT CELL, V13, P1959, DOI 10.1105/tpc.13.8.1959; Park MY, 2005, P NATL ACAD SCI USA, V102, P3691, DOI 10.1073/pnas.0405570102; Pnueli L, 2003, PLANT J, V34, P187, DOI 10.1046/j.1365-313X.2003.01715.x; Rizhsky L, 2004, J BIOL CHEM, V279, P11736, DOI 10.1074/jbc.M313350200; Sakamoto H, 2000, GENE, V248, P23, DOI 10.1016/S0378-1119(00)00133-5; Sakamoto H, 2004, PLANT PHYSIOL, V136, P2734, DOI 10.1104/pp.104.046599; Sunkar R, 2006, PLANT CELL, V18, P2051, DOI 10.1105/tpc.106.041673; Suzuki N, 2005, PLANT PHYSIOL, V139, P1313, DOI 10.1104/pp.105.070110; Thiel G, 2004, EUR J BIOCHEM, V271, P2855, DOI 10.1111/j.1432-1033.2004.04174.x; Vinocur B, 2005, CURR OPIN BIOTECH, V16, P123, DOI 10.1016/j.copbio.2005.02.001; Vogel JT, 2005, PLANT J, V41, P195, DOI 10.1111/j.1365-313X.2004.02288.x; Wesley SV, 2001, PLANT J, V27, P581, DOI 10.1046/j.1365-313X.2001.01105.x; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	35	191	216	4	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					9260	9268		10.1074/jbc.M611093200	http://dx.doi.org/10.1074/jbc.M611093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17259181	hybrid, Green Published			2022-12-25	WOS:000245780300073
J	Janciauskiene, SM; Nita, IM; Stevens, T				Janciauskiene, Sabina M.; Nita, Izabela M.; Stevens, Tim			alpha(1)-Antitrypsin, old dog, new tricks - alpha 1-Antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevatin cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE-A; CYCLIC-AMP; CIGARETTE-SMOKE; TNF-ALPHA; INHIBITOR DEFICIENCY; ADENYLYL-CYCLASE; GENE-EXPRESSION; EMPHYSEMA; PHOSPHODIESTERASE-4	Regulation of serine protease activity is considered to be the sole mechanism for the function of alpha(1)-antitrypsin (AAT). However, recent reports of the anti-inflammatory effects of AAT are hard to reconcile with this classical mechanism. We discovered that two key activities of AAT in vitro, namely inhibition of endotoxin-stimulated tumor necrosis factor-a and enhancement of interleukin-10 in human monocytes, are mediated by an elevation of cAMP and activation of cAMP-dependent protein kinase A. As expected with this type of mechanism, the AAT mediated rise in cAMP and the impact on endotoxin-stimulated tumor necrosis factor-a and interleukin-10 was enhanced when the catabolism of cAMP was blocked by the phosphodiesterase inhibitor rolipram. These effects were still observed with modified forms of AAT lacking protease inhibitor activity.	Lund Univ, Wallenberg Lab, Dept Clin Sci, Malmo Univ Hosp, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Janciauskiene, SM (corresponding author), Lund Univ, Wallenberg Lab, Dept Clin Sci, Malmo Univ Hosp, SE-20502 Malmo, Sweden.	sabina.janciauskiene@med.lu.se						ARORA PK, 1978, NATURE, V274, P589, DOI 10.1038/274589a0; Banner KH, 2004, TRENDS PHARMACOL SCI, V25, P430, DOI 10.1016/j.tips.2004.06.008; Barnette M S, 2000, Curr Opin Pulm Med, V6, P164, DOI 10.1097/00063198-200003000-00014; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryce PJ, 1999, IMMUNOPHARMACOLOGY, V41, P139, DOI 10.1016/S0162-3109(98)00060-5; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CHUNG KF, 2005, SCI STKE, pPE47; Churg A, 2003, AM J RESP CRIT CARE, V168, P199, DOI 10.1164/rccm.200302-203OC; Churg A, 2003, AM J RESP CRIT CARE, V167, P1083, DOI 10.1164/rccm.200212-1396OC; Dhami R, 2000, AM J RESP CELL MOL, V22, P244, DOI 10.1165/ajrcmb.22.2.3809; Gao YS, 2001, EUR J PHARMACOL, V418, P111, DOI 10.1016/S0014-2999(01)00929-3; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; GRETEN TF, 1995, INT J IMMUNOPHARMACO, V17, P605, DOI 10.1016/0192-0561(95)00058-A; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Houslay MD, 1998, SEMIN CELL DEV BIOL, V9, P161, DOI 10.1006/scdb.1997.0221; HUTCHISON DCS, 1988, AM J MED, V84, P3; Janciauskiene S, 2004, BIOCHEM BIOPH RES CO, V321, P592, DOI 10.1016/j.bbrc.2004.06.123; Janciauskiene S, 2001, BBA-MOL BASIS DIS, V1535, P221, DOI 10.1016/S0925-4439(01)00025-4; JOSLIN G, 1992, J CLIN INVEST, V90, P1150, DOI 10.1172/JCI115934; KAMBAYASHI T, 1995, J IMMUNOL, V155, P4909; Knappstein S, 2004, INFECT IMMUN, V72, P4344, DOI 10.1128/IAI.72.8.4344-4350.2004; KUNKEL SL, 1988, J BIOL CHEM, V263, P5380; Lewis EC, 2005, P NATL ACAD SCI USA, V102, P12153, DOI 10.1073/pnas.0505579102; Lomas DA, 2002, NAT REV GENET, V3, P759, DOI 10.1038/nrg907; Mahadeva R, 1998, THORAX, V53, P501, DOI 10.1136/thx.53.6.501; MALEFYT RD, 1991, J EXP MED, V174, P1209; Martorana PA, 2005, AM J RESP CRIT CARE, V172, P848, DOI 10.1164/rccm.200411-1549OC; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NICOSIA S, 1989, FASEB J, V3, P1941, DOI 10.1096/fasebj.3.8.2542112; Nita I, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-12; Ollivier V, 1996, J BIOL CHEM, V271, P20828, DOI 10.1074/jbc.271.34.20828; Osawa Y, 2006, AM J PHYSIOL-CELL PH, V290, pC143, DOI 10.1152/ajpcell.00171.2005; Ouagued M, 2005, PULM PHARMACOL THER, V18, P49, DOI 10.1016/j.pupt.2004.09.031; Petrache L, 2006, AM J RESP CRIT CARE, V173, P1222, DOI 10.1164/rccm.200512-1842OC; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; Seldon Paul M., 1998, Cell Biochemistry and Biophysics, V29, P179, DOI 10.1007/BF02737835; SELDON PM, 1995, MOL PHARMACOL, V48, P747; Shames BD, 2001, J SURG RES, V99, P187, DOI 10.1006/jsre.2001.6178; Sheng T, 2006, J BIOL CHEM, V281, P9, DOI 10.1074/jbc.C500300200; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Stockley RA, 2000, CHEST, V117, p291S, DOI 10.1378/chest.117.5_suppl_1.291S; Stockley RA, 2000, THORAX, V55, P614, DOI 10.1136/thorax.55.7.614; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; TRAVIS J, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P313; TURINO GM, 1969, SCIENCE, V165, P709, DOI 10.1126/science.165.3894.709; Uchiba M, 2004, THROMB HAEMOSTASIS, V92, P1420, DOI 10.1160/TH04-03-0139; Yoshimura T, 1997, GEN PHARMACOL-VASC S, V29, P633, DOI 10.1016/S0306-3623(96)00580-0; Zhang YH, 1997, J CLIN INVEST, V99, P894, DOI 10.1172/JCI119254	56	106	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2007	282	12					8573	8582		10.1074/jbc.M607976200	http://dx.doi.org/10.1074/jbc.M607976200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	158GS	17261591	Green Submitted, hybrid			2022-12-25	WOS:000245780300003
J	Liu, CM; Lin, SH; Chen, YC; Lin, KCM; Wu, TSJ; King, CC				Liu, Chung-Ming; Lin, Shu-Hua; Chen, Ying-Chen; Lin, Katherine Chun-Min; Wu, Tsung-Shu Joseph; King, Chwan-Chuen			Temperature Drops and the Onset of Severe Avian Influenza A H5N1 Virus Outbreaks	PLOS ONE			English	Article								Global influenza surveillance is one of the most effective strategies for containing outbreaks and preparing for a possible pandemic influenza. Since the end of 2003, highly pathogenic avian influenza viruses (HPAI) H5N1 have caused many outbreaks in poultries and wild birds from East Asia and have spread to at least 48 countries. For such a fast and wide-spreading virulent pathogen, prediction based on changes of micro-and macro-environment has rarely been evaluated. In this study, we are developing a new climatic approach by investigating the conditions that occurred before the H5N1 avian influenza outbreaks for early predicting future HPAI outbreaks and preventing pandemic disasters. The results show a temperature drop shortly before these outbreaks in birds in each of the Eurasian regions stricken in 2005 and 2006. Dust storms, like those that struck near China's Lake Qinghai around May 4, 2005, exacerbated the spread of this HPAI H5N1 virus, causing the deaths of a record number of wild birds and triggering the subsequent spread of H5N1. Weather monitoring could play an important role in the early warning of outbreaks of this potentially dangerous virus.	[Liu, Chung-Ming; Lin, Shu-Hua; Chen, Ying-Chen] Natl Taiwan Univ, Global Change Res Ctr, Taipei 10764, Taiwan; [Liu, Chung-Ming] Natl Taiwan Univ, Dept Atmospher Sci, Coll Sci, Taipei 10764, Taiwan; [Lin, Katherine Chun-Min] Natl Taiwan Univ, Dept Publ Hlth, Coll Publ Hlth, Taipei 10764, Taiwan; [Wu, Tsung-Shu Joseph; King, Chwan-Chuen] Natl Taiwan Univ, Inst Epidemiol, Coll Publ Hlth, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University	Liu, CM (corresponding author), Natl Taiwan Univ, Global Change Res Ctr, Taipei 10764, Taiwan.	liucm@ntu.edu.tw; cc_king99@hotmail.com	Wu, Tsung Shu Joseph/K-6138-2018	Wu, Tsung Shu Joseph/0000-0001-6155-9340; King, Chwan-Chuen/0000-0002-6078-2601	National Science Council (NSC) of Republic of China [NSC-95-2621-Z002-004, NSC-95-EPA-Z-002-004, NSC-94-2621-Z002-013, NSC-95-2815-C-002-162-B]	National Science Council (NSC) of Republic of China(Ministry of Science and Technology, Taiwan)	The study was supported by funding grants NSC-95-2621-Z002-004, NSC-95-EPA-Z-002-004, NSC-94-2621-Z002-013 and NSC-95-2815-C-002-162-B from the National Science Council (NSC) of Republic of China.	BROWN IH, 2006, FAO OIE INT SCI C AV; Chen H, 2005, NATURE, V436, P191, DOI 10.1038/nature03974; Chen H, 2006, P NATL ACAD SCI USA, V103, P2845, DOI 10.1073/pnas.0511120103; Chretien JP, 2006, LANCET INFECT DIS, V6, P538, DOI 10.1016/S1473-3099(06)70556-4; DOMENECH J, 2006, FAO OIE INT SCI C AV; *FAO, 2006, AVIAN INFLUENZA DIS, V40, P1; FOUCHIER R, 2006, FAO OIE INT SCI C AV; Hangalapura BN, 2006, DEV COMP IMMUNOL, V30, P503, DOI 10.1016/j.dci.2005.07.001; Hangalapura BN, 2004, POULTRY SCI, V83, P1644, DOI 10.1093/ps/83.10.1644; KARESH W, 2006, FAO OIE INT SCI C AV; Liu CM, 2004, TERR ATMOS OCEAN SCI, V15, P999, DOI 10.3319/TAO.2004.15.5.999(ADSE); Olsen B, 2006, SCIENCE, V312, P384, DOI 10.1126/science.1122438; Steensels M, 2006, Verh K Acad Geneeskd Belg, V68, P103; *XFN VIA FORB COM, 2006, CHIN REP 2 NEW AV FL	14	34	34	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 7	2007	2	2							e191	10.1371/journal.pone.0000191	http://dx.doi.org/10.1371/journal.pone.0000191			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	V10DI	17297505	Green Published, Green Submitted, gold			2022-12-25	WOS:000207444300004
J	Wu, D; Zhau, HE; Huang, WC; Iqbal, S; Habib, FK; Sartor, O; Cvitanovic, L; Marshall, FF; Xu, Z; Chung, LWK				Wu, D.; Zhau, H. E.; Huang, W-C; Iqbal, S.; Habib, F. K.; Sartor, O.; Cvitanovic, L.; Marshall, F. F.; Xu, Z.; Chung, L. W. K.			cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis	ONCOGENE			English	Article						prostate cancer; bone metastasis; EMT; CREB; VEGF; HIF	EPITHELIAL-MESENCHYMAL TRANSITION; HYPOXIA-INDUCIBLE FACTOR-1; GENOME-WIDE ANALYSIS; TRANSCRIPTIONAL REGULATION; TUMOR PROGRESSION; CELLS; CREB; ACTIVATION; GENE; VEGF	Aberrant expression of vascular endothelial growth factor (VEGF) is associated with human prostate cancer (PCa) metastasis and poor clinical outcome. We found that both phosphorylation of cyclic AMP- responsive element- binding protein (CREB) and VEGF levels were significantly elevated in patient bone metastatic PCa specimens. A PCa ARCaP progression model demonstrating epithelial- to-mesenchymal transition exhibited increased CREB phosphorylation and VEGF expression as ARCaP cells became progressively more mesenchymal and bone- metastatic. Activation of CREB induced, whereas inhibition of CREB blocked, VEGF expression in ARCaP cells. CREB may regulate VEGF transcription via a hypoxia- inducible factor- dependent mechanism in normoxic conditions. Activation of CREB signaling is involved in the coordinated regulation of VEGF and may pre- dispose to PCa bone metastasis.	Emory Univ, Sch Med, Mol Urol & Therapeut Program, Dept Urol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Western Gen Hosp, Sch Mol & Clin Med, Div Oncol, Prostate Res Grp, Edinburgh EH4 2XU, Midlothian, Scotland; Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA; LSU, Ctr Hlth Sci, Stanley Scott Canc Ctr, New Orleans, LA USA	Emory University; Emory University; University of Edinburgh; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Wu, D (corresponding author), Emory Univ, Sch Med, Mol Urol & Therapeut Program, Dept Urol, 1365-B Clifton Rd,Suite 5100, Atlanta, GA 30322 USA.	dwu2@emory.edu; lwchung@emory.edu		, Shareen/0000-0002-9489-7781; Huang, William/0000-0001-5261-0650; Huang, Wen-Chin/0000-0003-2342-9099	NATIONAL CANCER INSTITUTE [R01CA108468, P01CA098912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM072069] Funding Source: NIH RePORTER; NCI NIH HHS [PC040260, 1 R01 CA108468, 1 P01 CA098912, PC060566] Funding Source: Medline; NIGMS NIH HHS [5 P20 GM072069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramovitch R, 2004, CANCER RES, V64, P1338, DOI 10.1158/0008-5472.CAN-03-2089; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arcinas M, 2001, CANCER RES, V61, P5202; Bates RC, 2003, CURR BIOL, V13, P1721, DOI 10.1016/j.cub.2003.09.002; Chen JH, 2004, CELL COMMUN ADHES, V11, P1, DOI 10.1080/15419060490471739; Chen TS, 1999, CANCER RES, V59, P213; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CHUNG LWK, 1991, CANCER SURV, V11, P91; Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; Duque JLF, 1999, UROLOGY, V54, P523, DOI 10.1016/S0090-4295(99)00167-3; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; George DJ, 2001, CLIN CANCER RES, V7, P1932; Huang WC, 2005, CANCER RES, V65, P2303, DOI 10.1158/0008-5472.CAN-04-3448; Huang WC, 2006, CANCER RES, V66, P9108, DOI 10.1158/0008-5472.CAN-06-1996; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Impey S, 2004, CELL, V119, P1041, DOI 10.1016/j.cell.2004.10.032; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Johannessen M, 2004, CELL SIGNAL, V16, P1211, DOI 10.1016/j.cellsig.2004.05.001; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kinjo K, 2005, CELL CYCLE, V4, P1134, DOI 10.4161/cc.4.9.1991; Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008-5472.CAN-05-1809; Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Melnikova VO, 2006, J BIOL CHEM, V281, P2911, DOI 10.1074/jbc.M508683200; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Sabbah M, 1999, P NATL ACAD SCI USA, V96, P11217, DOI 10.1073/pnas.96.20.11217; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Xu JC, 2006, PROSTATE, V66, P1664, DOI 10.1002/pros.20488; Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086; Yang YM, 1996, ONCOGENE, V12, P2223; Zhang XM, 2005, P NATL ACAD SCI USA, V102, P4459, DOI 10.1073/pnas.0501076102; Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152; Ziel KA, 2004, FASEB J, V18, P986, DOI 10.1096/fj.03-1160fje	38	110	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2007	26	35					5070	5077		10.1038/sj.onc.1210316	http://dx.doi.org/10.1038/sj.onc.1210316			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310988				2022-12-25	WOS:000248487400005
J	Igarashi, T; Izumi, H; Uchiumi, T; Nishio, K; Arao, T; Tanabe, M; Uramoto, H; Sugio, K; Yasumoto, K; Sasaguri, Y; Wang, KY; Otsuji, Y; Kohno, K				Igarashi, T.; Izumi, H.; Uchiumi, T.; Nishio, K.; Arao, T.; Tanabe, M.; Uramoto, H.; Sugio, K.; Yasumoto, K.; Sasaguri, Y.; Wang, K. Y.; Otsuji, Y.; Kohno, K.			Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines	ONCOGENE			English	Article						clock; ATF4; multidrug resistance; glutathione; chronotherapy	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; ADENOSINE-TRIPHOSPHATASE ATP7B; MRP/GS-X PUMP; MULTIDRUG-RESISTANCE; CISPLATIN RESISTANCE; TUMOR SUPPRESSION; STRESS-RESPONSE; DNA-REPAIR; EXPRESSION; BINDING	The mechanisms underlying cellular drug resistance have been extensively studied, but little is known about its regulation. We have previously reported that activating transcription factor 4 (ATF4) is upregulated in cisplatin-resistant cells and plays a role in cisplatin resistance. Here, we find out a novel relationship between the circadian transcription factor Clock and drug resistance. Clock drives the periodical expression of many genes that regulate hormone release, cell division, sleep-awake cycle and tumor growth. We demonstrate that ATF4 is a direct target of Clock, and that Clock is overexpressed in cisplatin-resistant cells. Furthermore, Clock expression significantly correlates with cisplatin sensitivity, and that the downregulation of either Clock or ATF4 confers sensitivity of A549 cells to cisplatin and etoposide. Notably, ATF4-overexpressing cells show multidrug resistance and marked elevation of intracellular glutathione. The microarray study reveals that genes for glutathione metabolism are generally downregulated by the knockdown of ATF4 expression. These results suggest that the Clock and ATF4 transcription system might play an important role in multidrug resistance through glutathione-dependent redox system, and also indicate that physiological potentials of Clock-controlled redox system might be important to better understand the oxidative stress-associated disorders including cancer and systemic chronotherapy.	Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 2, Kitakyushu, Fukuoka 8078555, Japan; Kinki Univ, Sch Med, Dept Genome Biol, Osaka 589, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Surg 2, Kitakyushu, Fukuoka 8078555, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Pathol 2, Kitakyushu, Fukuoka 8078555, Japan	University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan; Kindai University (Kinki University); University of Occupational & Environmental Health - Japan; University of Occupational & Environmental Health - Japan	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.	k-kohno@med.uoeh-u.ac.jp		wang, ke-yong/0000-0001-8295-1229				Annereau JP, 2004, MOL PHARMACOL, V66, P1397, DOI 10.1124/mol.104.005009; Arao T, 2006, INT J CANCER, V118, P483, DOI 10.1002/ijc.21340; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Canaple L, 2003, CANCER RES, V63, P7545; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Cui YH, 1999, MOL PHARMACOL, V55, P929; Deeley RG, 2006, PHYSIOL REV, V86, P849, DOI 10.1152/physrev.00035.2005; Dickinson DA, 2002, BIOCHEM PHARMACOL, V64, P1019, DOI 10.1016/S0006-2952(02)01172-3; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; FUJII R, 1994, JPN J CANCER RES, V85, P426, DOI 10.1111/j.1349-7006.1994.tb02376.x; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gorbacheva VY, 2005, P NATL ACAD SCI USA, V102, P3407, DOI 10.1073/pnas.0409897102; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Husain A, 1998, CANCER RES, V58, P1120; Ishikawa T, 1996, J BIOL CHEM, V271, P14981, DOI 10.1074/jbc.271.25.14981; Kohno K, 2005, EUR J CANCER, V41, P2577, DOI 10.1016/j.ejca.2005.08.007; Komatsu M, 2000, CANCER RES, V60, P1312; Krishnamurthy P, 2006, ANNU REV PHARMACOL, V46, P381, DOI 10.1146/annurev.pharmtox.46.120604.141238; Kuo MT, 1998, BIOCHEM PHARMACOL, V55, P605, DOI 10.1016/S0006-2952(97)00494-2; Kusaba H, 1999, EUR J BIOCHEM, V262, P924, DOI 10.1046/j.1432-1327.1999.00469.x; LAI GM, 1989, JNCI-J NATL CANCER I, V81, P535, DOI 10.1093/jnci/81.7.535; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Liebermann DA, 2002, LEUKEMIA, V16, P527, DOI 10.1038/sj.leu.2402477; Masuoka HC, 2002, BLOOD, V99, P736, DOI 10.1182/blood.V99.3.736; Moore RY, 1997, ANNU REV MED, V48, P253, DOI 10.1146/annurev.med.48.1.253; Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418; Nakayama K, 2002, INT J CANCER, V101, P488, DOI 10.1002/ijc.10608; Ohga T, 1996, CANCER RES, V56, P4224; Renes J, 2000, DRUG RESIST UPDATE, V3, P289, DOI 10.1054/drup.2000.0156; Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; SABURI Y, 1989, CANCER RES, V49, P7020; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; TAKANO H, 1992, ANTI-CANCER DRUG, V3, P323, DOI 10.1097/00001813-199208000-00002; Tanabe M, 2003, CANCER RES, V63, P8592; TEW KD, 1994, CANCER RES, V54, P4313; Tipnis SR, 1999, BIOCHEM J, V337, P559, DOI 10.1042/0264-6021:3370559; Torigoe Takayuki, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P15, DOI 10.2174/1568011053352587; Uramoto H, 2002, J BIOL CHEM, V277, P31694, DOI 10.1074/jbc.M200266200; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7; YAO KS, 1995, CANCER RES, V55, P4367; Yoshida A, 2006, CANCER RES, V66, P5772, DOI 10.1158/0008-5472.CAN-05-3916	46	108	113	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2007	26	33					4749	4760		10.1038/sj.onc.1210289	http://dx.doi.org/10.1038/sj.onc.1210289			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297441				2022-12-25	WOS:000248170400001
J	Chlenski, A; Guerrero, LJ; Yang, Q; Tian, Y; Peddinti, R; Salwen, HR; Cohn, SL				Chlenski, A.; Guerrero, L. J.; Yang, Q.; Tian, Y.; Peddinti, R.; Salwen, H. R.; Cohn, S. L.			SPARC enhances tumor stroma formation and prevents fibroblast activation	ONCOGENE			English	Article						tumor stroma; activated fibroblast; SPARC; tumor microenvironment	GRANULATION-TISSUE; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; GROWTH; EXPRESSION; CARCINOMA; ANGIOGENESIS; GLYCOPROTEIN; MYOFIBROBLASTS; TUMORIGENESIS	Tumor growth is influenced by interactions between malignant cells and the tumor stroma. Although the normal host microenvironment is nonpermissive for neoplastic progression, tumor-reactive stroma, characterized by the presence of activated fibroblasts, promotes neoplastic growth and metastasis. Secreted protein, acidic and rich in cysteine (SPARC) is a matricellular glycoprotein that is capable of inhibiting the growth of several different types of cancer. Recently, we reported that SPARC also impairs the growth of xenografts comprised of 293 cells. In this study, we show that in addition to enhancing stroma formation, SPARC prevents fibroblast activation in 293 xenografts, suggesting that the anticancer effects of SPARC may be due, at least in part, to the formation of tumor stroma that is not supportive of tumor growth. In vitro, 3T3 fibroblasts cocultured with SPARC-transfected 293 cells remain negative for alpha-smooth muscle actin, whereas wild-type 293 cells induce fibroblast activation. Moreover, activation of 3T3 cells and primary fibroblasts by transforming growth factor beta is blocked by SPARC treatment. We also demonstrate that SPARC significantly increases basic fibroblast growth factor-induced fibroblast migration in vitro, indicating that it may recruit host fibroblasts to the tumor stroma. Taken together, our results suggest that in addition to blocking angiogenesis, SPARC may inhibit tumor growth by promoting the assembly of stroma that is nonpermissive for tumor progression.	Univ Chicago, Inst Mol Pediat Sci, Div Clin Sci, Chicago, IL 60637 USA; Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL USA	University of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine	Cohn, SL (corresponding author), Univ Chicago, Inst Mol Pediat Sci, Div Clin Sci, 5841 Maryland Ave,MC 4060,Rm N114, Chicago, IL 60637 USA.	scohn@peds.bsd.uchicago.edu	Cohn, Susan/AAB-6010-2021	Cohn, Susan/0000-0001-5749-7650; , Qiwei Yang/0000-0001-7131-8946	NCI NIH HHS [5P30CA60553] Funding Source: Medline; NINDS NIH HHS [NS 049814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Chlenski A, 2006, INT J CANCER, V118, P310, DOI 10.1002/ijc.21357; Chlenski A, 2002, CANCER RES, V62, P7357; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Francki A, 2004, J CELL BIOCHEM, V91, P915, DOI 10.1002/jcb.20008; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamid T, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-3; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Liu SQ, 2005, AM J PATHOL, V166, P891, DOI 10.1016/S0002-9440(10)62309-7; Maeshima AM, 2002, CANCER, V95, P2546, DOI 10.1002/cncr.11006; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Paget S, 1889, LANCET, V133, P571, DOI [DOI 10.1016/S0140-6736(00)49915-0, 10.1016/S0140-6736(00)49915-0]; Perdue N, 2006, EXP EYE RES, V83, P1154, DOI 10.1016/j.exer.2006.06.007; Pichler RH, 1996, AM J PATHOL, V148, P1153; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; ROSEN ST, 1987, LAB INVEST, V56, P302; SAGE H, 1984, J BIOL CHEM, V259, P3993; Schiemann BJ, 2003, MOL BIOL CELL, V14, P3977, DOI 10.1091/mbc.E03-01-0001; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Wilkes MC, 2005, CANCER RES, V65, P10431, DOI 10.1158/0008-5472.CAN-05-1522; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; Yazhou C, 2004, TUMOR BIOL, V25, P290, DOI 10.1159/000081394	35	36	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4513	4522		10.1038/sj.onc.1210247	http://dx.doi.org/10.1038/sj.onc.1210247			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17260013				2022-12-25	WOS:000247836100005
J	Shimokawa, T; Svard, J; Heby-Henricson, K; Teglund, S; Toftgard, R; Zaphiropoulos, PG				Shimokawa, T.; Svard, J.; Heby-Henricson, K.; Teglund, S.; Toftgard, R.; Zaphiropoulos, P. G.			Distinct roles of first exon variants of the tumor-suppressor Patched1 in Hedgehog signaling	ONCOGENE			English	Article						alternative splicing; GLI; post-transcriptional regulation	BASAL-CELL CARCINOMA; SONIC HEDGEHOG; TRANSCRIPTIONAL ACTIVITY; HUMAN HOMOLOG; HUMAN GLI2; GENE; PATHWAY; PTCH2; EXPRESSION; PROTEIN	Patched1 (PTCH1) is one of the key molecules involved in the Hedgehog (HH) signaling pathway and acts as the receptor of HH ligands. Additionally, PTCH1 inhibits the positive signal transductor Smoothened (SMO). Several PTCH1 splice variants are known but the functional differences among them are not clear. Here, we demonstrate the unique biological properties of the PTCH1 isoforms generated by alternative. rst exon usage. All isoforms examined worked as functional receptors of both Sonic HH and Dese rt HH. However, the signaling upregulated isoform s PTCH1-1B and-1C inhibited SMO and the pathway transcription factors glioma 1 (GLI1) andGL I2 to a higher extent than PTCH1-1 and-1Ckid. Moreover, in situ hybridizations allowed the detection of the Ptch1 isoforms in speci. fic structures of the developing mouse embryo. Additionally, the differences in the N-terminal tail had a dramatic in. uence on the steady states of the proteins, with PTCH1-1B and-1C levels being signifi. cantly higher than PTCH1-1 and-1Ckid. This implies that the pronounced signaling inhibitory properties of PTCH1-1B and-1C may be mostly due to this high-protein expression rather than to intrinsic functional differences. Thus, our study supports a role of splicing variation and prom oter choice for HH signaling regulation.	Karolinska Inst, Dept biosci & Nutr, S-14157 Huddinge, Sweden	Karolinska Institutet	Shimokawa, T (corresponding author), Karolinska Inst, Dept biosci & Nutr, S-14157 Huddinge, Sweden.	Tash@biosci.ki.se; peza@cnt.ki.se	Shimokawa, Takashi/AAA-5870-2020	Shimokawa, Takashi/0000-0001-6549-9277; Zaphiropoulos, Peter/0000-0003-4298-3861				Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Bai CB, 2002, DEVELOPMENT, V129, P4753; Carninci P, 2006, NAT GENET, V38, P626, DOI 10.1038/ng1789; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hughes TA, 2006, TRENDS GENET, V22, P119, DOI 10.1016/j.tig.2006.01.001; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kalderon D, 2005, BIOCHEM SOC T, V33, P1509, DOI 10.1042/BST0331509; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kogerman P, 2002, ONCOGENE, V21, P6007, DOI 10.1038/sj.onc.1205865; Lee Y, 2006, CANCER RES, V66, P6964, DOI 10.1158/0008-5472.CAN-06-0505; Liu W, 2002, DEV BIOL, V248, P240, DOI 10.1006/dbio.2002.0733; Motoyama J, 1998, NAT GENET, V18, P104, DOI 10.1038/ng0298-104; Nagao K, 2005, GENOMICS, V85, P462, DOI 10.1016/j.ygeno.2004.11.014; Nybakken K, 2005, NAT GENET, V37, P1323, DOI 10.1038/ng1682; Rahnama F, 2006, BIOCHEM J, V394, P19, DOI 10.1042/BJ20050941; Rahnama F, 2004, BIOCHEM J, V378, P325, DOI 10.1042/BJ20031200; Roessler E, 2005, HUM MOL GENET, V14, P2181, DOI 10.1093/hmg/ddi222; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Shimokawa T, 2004, FEBS LETT, V578, P157, DOI 10.1016/j.febslet.2004.11.006; Smyth I, 1998, HUM GENET, V102, P598, DOI 10.1007/s004390050747; Smyth I, 1999, HUM MOL GENET, V8, P291, DOI 10.1093/hmg/8.2.291; Speek M, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-13; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Uchikawa H, 2006, BIOCHEM BIOPH RES CO, V349, P277, DOI 10.1016/j.bbrc.2006.08.046; Wang XQ, 2001, J BIOL CHEM, V276, P1311, DOI 10.1074/jbc.M005191200; Zaphiropoulos PG, 1999, CANCER RES, V59, P787	31	19	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	34					4889	4896		10.1038/sj.onc.1210301	http://dx.doi.org/10.1038/sj.onc.1210301			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17310997				2022-12-25	WOS:000248322500001
J	Zhang, SF; Zhou, YJ; Trusa, S; Meng, X; Lee, EYC; Lee, MYWT				Zhang, Sufang; Zhou, Yajing; Trusa, Sandra; Meng, Xiao; Lee, Ernest Y. C.; Lee, Marietta Y. W. T.			A novel DNA damage response - Rapid degradation of the p12 subunit of DNA polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE CHECKPOINT; REPLICATION DYNAMICS; CATALYTIC DOMAINS; PROTEIN; INITIATION; EPSILON; RECONSTITUTION; IDENTIFICATION; UBIQUITIN; ATR	Mammalian DNA polymerase (Pol) delta is essential for DNA replication. It consists of four subunits, p125, p50, p68, and p12. We report the discovery that the p12 subunit is rapidly degraded in cultured human cells by DNA damage or replication stress brought about by treatments with UV, methyl methanesulfonate, hydroxyurea, and aphidicolin. The degradation of p12 is due to an accelerated rate of proteolysis that is inhibited by the proteasome inhibitors, MG132 and lactacystin. UV treatment converts Pol delta in vivo to the three-subunit form lacking p12. This was demonstrated by its isolation using immunoaffinity chromatography. The three-subunit enzyme retains activity on poly(dA)/oligo(dT) templates but is impaired in its ability to extend singly primed M13 templates, clearly indicating that its in vivo functions are likely to be compromised. This transformation of Pol delta by modification of its quaternary structure is reversible in vitro by the addition of the p12 subunit and could represent a novel in vivo mechanism for the modulation of Pol delta function. UV and hydroxyurea-triggered p12 degradation is blocked in ATR(-/-) cells but not in ATM(-/-) cells, thereby demonstrating that p12 degradation is regulated by ATR, the apical kinase that regulates the damage response in S-phase. These findings reveal a novel addition to the cellular repertoire of DNA damage responses that also impacts our understanding of the role of Pol delta in both DNA replication and DNA repair.	New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA	New York Medical College	Lee, MYWT (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.	Marietta_Lee@NYMC.edu		Zhang, Sufang/0000-0003-3883-023X	NIGMS NIH HHS [GM31973] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Andreassen PR, 2006, CARCINOGENESIS, V27, P883, DOI 10.1093/carcin/bgi319; Brzovic PS, 2006, MOL CELL, V21, P873, DOI 10.1016/j.molcel.2006.02.008; Busby EC, 2000, CANCER RES, V60, P2108; BYRNES JJ, 1976, BIOCHEMISTRY-US, V15, P2817, DOI 10.1021/bi00658a018; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Chastain PD, 2006, CELL CYCLE, V5, P2160, DOI 10.4161/cc.5.18.3236; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Dell'Era P, 2005, ONCOGENE, V24, P1117, DOI 10.1038/sj.onc.1208359; Feng WY, 2001, MOL CELL BIOL, V21, P4495, DOI 10.1128/MCB.21.14.4495-4504.2001; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; Fuss J, 2002, J BIOL CHEM, V277, P8658, DOI 10.1074/jbc.M110615200; Garg P, 2005, CRIT REV BIOCHEM MOL, V40, P115, DOI 10.1080/10409230590935433; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Guterman A, 2004, CURR PROTEIN PEPT SC, V5, P201, DOI 10.2174/1389203043379756; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Helt CE, 2005, J BIOL CHEM, V280, P1186, DOI 10.1074/jbc.M410873200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; Jurvansuu J, 2005, J VIROL, V79, P569, DOI 10.1128/JVI.79.1.569-580.2005; Kaiser P, 2005, METHOD ENZYMOL, V399, P243, DOI 10.1016/S0076-6879(05)99016-2; Kaufmann WK, 2003, MUTAT RES-FUND MOL M, V532, P85, DOI 10.1016/j.mrfmmm.2003.08.012; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Kitagawa R, 2005, COLD SH Q B, V70, P99, DOI 10.1101/sqb.2005.70.002; Latonen L, 2005, BBA-REV CANCER, V1755, P71, DOI 10.1016/j.bbcan.2005.04.003; Lee M Y, 1981, Prog Nucleic Acid Res Mol Biol, V26, P83; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Lehmann AR, 2006, EXP CELL RES, V312, P2673, DOI 10.1016/j.yexcr.2006.06.010; Li H, 2006, J BIOL CHEM, V281, P14748, DOI 10.1074/jbc.M600322200; Liu G, 2006, BIOCHEM BIOPH RES CO, V349, P360, DOI 10.1016/j.bbrc.2006.08.049; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Liu L, 2003, J BIOL CHEM, V278, P10041, DOI 10.1074/jbc.M208694200; Liu PJ, 2006, J BIOL CHEM, V281, P30631, DOI 10.1074/jbc.M602982200; Luciani MG, 2004, J CELL SCI, V117, P6019, DOI 10.1242/jcs.01400; Machida YJ, 2005, CELL, V123, P13, DOI 10.1016/j.cell.2005.09.019; Merrick CJ, 2004, J BIOL CHEM, V279, P20067, DOI 10.1074/jbc.M400022200; Mo JY, 2000, BIOCHEMISTRY-US, V39, P7245, DOI 10.1021/bi0000871; Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532; PAINTER RB, 1985, MUTAT RES, V145, P63, DOI 10.1016/0167-8817(85)90041-0; Perucca P, 2006, J CELL SCI, V119, P1517, DOI 10.1242/jcs.02868; Petermann E, 2006, CELL CYCLE, V5, P2203, DOI 10.4161/cc.5.19.3256; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Podust VN, 2002, J BIOL CHEM, V277, P3894, DOI 10.1074/jbc.M109684200; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez-Bravo V, 2006, CANCER RES, V66, P8672, DOI 10.1158/0008-5472.CAN-05-4443; Rytkonen AK, 2006, FEBS J, V273, P2984, DOI 10.1111/j.1742-4658.2006.05310.x; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shikata K, 2001, J BIOCHEM-TOKYO, V129, P699, DOI 10.1093/oxfordjournals.jbchem.a002909; Shikata Koh, 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-21; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; Takeda DY, 2005, ONCOGENE, V24, P2827, DOI 10.1038/sj.onc.1208616; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tsurimoto T, 2005, GENES CELLS, V10, P13, DOI 10.1111/j.1365-2443.2004.00812.x; Volk S, 2005, METHOD ENZYMOL, V399, P3, DOI 10.1016/S0076-6879(05)99001-0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Xie B, 2002, BIOCHEMISTRY-US, V41, P13133, DOI 10.1021/bi0262707; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	62	70	74	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2007	282	21					15330	15340		10.1074/jbc.M610356200	http://dx.doi.org/10.1074/jbc.M610356200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	169JX	17317665	hybrid			2022-12-25	WOS:000246589600008
J	Lorenz, M; Hewing, B; Hui, JY; Zepp, A; Baumann, G; Bindereif, A; Stangl, V; Stangl, K				Lorenz, Mario; Hewing, Bernd; Hui, Jingyi; Zepp, Angela; Baumann, Gert; Bindereif, Albrecht; Stangl, Verena; Stangl, Karl			Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activity	FASEB JOURNAL			English	Article						NOS; endothelium NO; CA repeats	NITRIC-OXIDE SYNTHASE; PRE-MESSENGER-RNA; CA-REPEAT; EXPRESSION; PROTEINS; DISEASE; INHIBITION; ACTIVATION; ISOFORMS; SUBUNIT	NO, the product of endothelial NOS ( eNOS), is a major regulator of vascular homeostasis and a critical factor in preventing cardiovascular diseases. We previously established a positive correlation between the number of variable CA repeats in intron 13 of human eNOS and the risk of coronary artery disease, and demonstrated that these polymorphic CA repeats function as a length-dependent splicing enhancer. By 5'-RACE polymerase chain reaction (PCR), we detected three splice variants containing novel 3' splice sites within intron 13 - termed eNOS13A, eNOS13B, and eNOS13C - which share the first 13 exons of human eNOS and the same polyadenylation site at the end of the novel exon. When translated, all these splice variants would result in truncated proteins lacking eNOS activity. Coexpression of full- length eNOS with eNOS13A diminished eNOS enzyme activity in COS- 7 cells by formation of heterodimers. The splice variants were expressed in endothelial cells and various human tissues. Finally, we demonstrate, using minigene transfection, that the expression of the eNOS13A splice variant is increased with high CA repeat numbers in intron 13. These data suggest a new mechanism for the regulation of eNOS activity and NO production in the cardiovascular system by truncated, dominant- negative splice variants of human eNOS.	Charite Univ Med Berlin, CCM, Med Klin Schwerpunkt Kardiol & Angiol, D-10117 Berlin, Germany; Univ Giessen, Inst Biochem, Giessen, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Justus Liebig University Giessen	Stangl, K (corresponding author), Charite Univ Med Berlin, CCM, Med Klin Schwerpunkt Kardiol & Angiol, Charite Pl 1, D-10117 Berlin, Germany.	karl.stangl@charite.de		Lorenz, Mario/0000-0001-5267-4101				Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; BEHRENDS S, 1995, J BIOL CHEM, V270, P21109, DOI 10.1074/jbc.270.36.21109; Bodo I, 2001, BLOOD, V98, P2973, DOI 10.1182/blood.V98.10.2973; Caceres JF, 2002, TRENDS GENET, V18, P186, DOI 10.1016/S0168-9525(01)02626-9; Chavez-Gutierrez L, 2005, J NEUROCHEM, V92, P807, DOI 10.1111/j.1471-4159.2004.02916.x; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Eissa NT, 1996, J BIOL CHEM, V271, P27184, DOI 10.1074/jbc.271.43.27184; Eliasson MJL, 1997, P NATL ACAD SCI USA, V94, P3396, DOI 10.1073/pnas.94.7.3396; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; GOUX O, 1996, ANNU REV BIOCHEM, V65, P801; Hui JY, 2005, EMBO J, V24, P1988, DOI 10.1038/sj.emboj.7600677; Hui JY, 2003, NAT STRUCT BIOL, V10, P33, DOI 10.1038/nsb875; Jiang JH, 2003, J BIOL CHEM, V278, P49332, DOI 10.1074/jbc.M304738200; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Magee T, 1996, BIOCHEM BIOPH RES CO, V226, P145, DOI 10.1006/bbrc.1996.1324; NADAUD S, 1994, BIOCHEM BIOPH RES CO, V198, P1027, DOI 10.1006/bbrc.1994.1146; Park CS, 2000, NITRIC OXIDE-BIOL CH, V4, P459, DOI 10.1006/niox.2000.0300; RodriguezCrespo I, 1996, ARCH BIOCHEM BIOPHYS, V336, P151, DOI 10.1006/abbi.1996.0543; SESSA WC, 1993, HYPERTENSION, V21, P934, DOI 10.1161/01.HYP.21.6.934; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stangl K, 2000, PHARMACOGENETICS, V10, P133, DOI 10.1097/00008571-200003000-00005; Stangl V, 2005, J NUTR, V135, P172, DOI 10.1093/jn/135.2.172; Stangl V, 2004, FASEB J, V18, P272, DOI 10.1096/fj.03-0054com; Stasiv Y, 2004, GENE DEV, V18, P1812, DOI 10.1101/gad.298004; Stasiv Y, 2001, J BIOL CHEM, V276, P42241, DOI 10.1074/jbc.M105066200; Tiscornia AC, 2004, LEUKEMIA, V18, P48, DOI 10.1038/sj.leu.2403169; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; Wang Y, 1997, J BIOL CHEM, V272, P11392; XU WM, 1998, CELL RES, V4, P251	32	35	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2007	21	7					1556	1564		10.1096/fj.06-7434com	http://dx.doi.org/10.1096/fj.06-7434com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17264164				2022-12-25	WOS:000246117000030
J	Nussbaum, J; Minami, E; Laflamme, MA; Virag, JAI; Ware, CB; Masino, A; Muskheli, V; Pabon, L; Reinecke, H; Murry, CE				Nussbaum, Jeannette; Minami, Elina; Laflamme, Michael A.; Virag, Jitka A. I.; Ware, Carol B.; Masino, Amanda; Muskheli, Veronica; Pabon, Lil; Reinecke, Hans; Murry, Charles E.			Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response	FASEB JOURNAL			English	Article						cardiomyocyte differentiation; rejection; tolerance; fusion; autofluorescence	SKELETAL MYOBLAST TRANSPLANTATION; INFARCTED MYOCARDIUM; GENE-EXPRESSION; IN-VITRO; CELLULAR CARDIOMYOPLASTY; CARDIAC-FUNCTION; CARDIOMYOCYTES; DIFFERENTIATION; BODIES; REPAIR	Embryonic stem (ES) cells are promising for cardiac repair, but directing their differentiation toward cardiomyocytes remains challenging. We investigated whether the heart guides ES cells toward cardiomyocytes in vivo and whether allogeneic ES cells were immunologically tolerated. Undifferentiated mouse ES cells consistently formed cardiac teratomas in nude or immunocompetent syngeneic mice. Cardiac teratomas contained no more cardiomyocytes than hind-limb teratomas, suggesting lack of guided differentiation. ES cells also formed teratomas in infarcted hearts, indicating injury-related signals did not direct cardiac differentiation. Allogeneic ES cells also caused cardiac teratomas, but these were immunologically rejected after several weeks, in association with increased inflammation and up-regulation of class I and II histocompatibility antigens. Fusion between ES cells and cardiomyocytes occurred in vivo, but was rare. Infarct autofluorescence was identified as an artifact that might be mistaken for enhanced GFP expression and true regeneration. Hence, undifferentiated ES cells were not guided toward a cardiomyocyte fate in either normal or infarcted hearts, and there was no evidence for allogeneic immune tolerance of ES cell derivatives. Successful cardiac repair strategies involving ES cells will need to control cardiac differentiation, avoid introducing undifferentiated cells, and will likely require immune modulation to avoid rejection.	Univ Washington, Inst Stem Cell & Regenerat Med, Ctr Cardiovasc Biol, Seattle, WA 98109 USA; Univ Washington, Dept Pathol, Seattle, WA 98109 USA; Univ Washington, Dept Med Cardiol, Seattle, WA 98109 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98109 USA; Univ Washington, Ctr Cardiovasc Biol, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Murry, CE (corresponding author), Univ Washington, Inst Stem Cell & Regenerat Med, Ctr Cardiovasc Biol, 815 Mercer St, Seattle, WA 98109 USA.	murry@u.washington.edu	Virag, Jitka Amira Ismail/AAW-7427-2020; Laflamme, Michael/AAV-6791-2021; Virag, Jitka/AAW-6690-2020	Virag, Jitka Amira Ismail/0000-0003-3321-9861; Laflamme, Michael/0000-0001-5908-880X; 	NHLBI NIH HHS [R24 HL64387, R01 HL61553, P01 HL03174] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R24HL064387, R01HL061553, P01HL003174] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Atkins BZ, 1999, J HEART LUNG TRANSPL, V18, P1173, DOI 10.1016/S1053-2498(99)00096-0; Behfar A, 2002, FASEB J, V16, P1558, DOI 10.1096/fj.02-0072com; BOER PH, 1994, BIOCHEM BIOPH RES CO, V199, P954, DOI 10.1006/bbrc.1994.1322; CHEN U, 1993, DEV DYNAM, V197, P217, DOI 10.1002/aja.1001970306; CHIU RCJ, 1995, ANN THORAC SURG, V60, P12; Choi DH, 2002, CELL TRANSPLANT, V11, P359; Damjanov I, 1974, Curr Top Pathol, V59, P69; GANIM JR, 1992, CIRC RES, V71, P1021, DOI 10.1161/01.RES.71.5.1021; Hodgson DM, 2004, AM J PHYSIOL-HEART C, V287, pH471, DOI 10.1152/ajpheart.01247.2003; Ikawa M, 1999, CURR TOP DEV BIOL, V44, P1; ILES SA, 1977, J EMBRYOL EXP MORPH, V38, P63; Jackson KA, 2004, STEM CELLS, V22, P180, DOI 10.1634/stemcells.22-2-180; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Kolossov E, 2006, J EXP MED, V203, P2315, DOI 10.1084/jem.20061469; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Laflamme MA, 2005, AM J PATHOL, V167, P663, DOI 10.1016/S0002-9440(10)62041-X; Mallory GK, 1939, AM HEART J, V18, P647; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; Menasche P, 2003, J AM COLL CARDIOL, V41, P1078, DOI 10.1016/S0735-1097(03)00092-5; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; Min JY, 2002, J APPL PHYSIOL, V92, P288, DOI 10.1152/jappl.2002.92.1.288; Min JY, 2003, J THORAC CARDIOV SUR, V125, P361, DOI 10.1067/mtc.2003.101; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Murry CE, 1996, J CLIN INVEST, V98, P2512, DOI 10.1172/JCI119070; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Reinecke H, 1999, CIRCULATION, V100, P193, DOI 10.1161/01.CIR.100.2.193; Reinecke H, 2004, CIRC RES, V94, pE56, DOI 10.1161/01.RES.0000125294.04612.81; Reinecke Hans, 2003, Methods Mol Biol, V219, P97; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; Robinson SW, 1996, CELL TRANSPLANT, V5, P77, DOI 10.1016/0963-6897(95)02016-0; Rubart M, 2003, CIRC RES, V92, P1217, DOI 10.1161/01.RES.0000075089.39335.8C; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; Scorsin M, 1997, CIRCULATION, V96, P188; Singla DK, 2006, J MOL CELL CARDIOL, V40, P195, DOI 10.1016/j.yjmcc.2005.09.001; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Sun Y, 2000, CARDIOVASC RES, V46, P250, DOI 10.1016/S0008-6363(00)00032-8; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Teng CJ, 2006, J THORAC CARDIOV SUR, V132, P628, DOI 10.1016/j.jtcvs.2006.05.034; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; Virag JI, 2003, AM J PATHOL, V163, P2433, DOI 10.1016/S0002-9440(10)63598-5; Wakitani S, 2003, RHEUMATOLOGY, V42, P162, DOI 10.1093/rheumatology/keg024; Wang JF, 2002, CELL TRANSPLANT, V11, P753; Ware CB, 2003, TRANSGENIC RES, V12, P743, DOI 10.1023/B:TRAG.0000005246.35812.c8; Welikson RE, 2006, J MOL CELL CARDIOL, V40, P520, DOI 10.1016/j.yjmcc.2006.01.009; Yang YK, 2002, J APPL PHYSIOL, V93, P1140, DOI 10.1152/japplphysiol.00307.2002	50	462	485	0	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2007	21	7					1345	1357		10.1096/fj.06-6769com	http://dx.doi.org/10.1096/fj.06-6769com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	162VG	17284483				2022-12-25	WOS:000246117000010
J	Keppetipola, N; Jain, R; Shuman, S				Keppetipola, Niroshika; Jain, Ruchi; Shuman, Stewart			Novel triphosphate phosphohydrolase activity of Clostridium thermocellum TTM, a member of the triphosphate tunnel metalloenzyme superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA CAPPING APPARATUS; MUTATIONAL ANALYSIS; THIAMINE TRIPHOSPHATASE; PLASMODIUM-FALCIPARUM; 2-METAL MECHANISM; ENZYME LEF4; YEAST; SITE; POLYMERASE; COMPONENT	Triphosphate tunnel metalloenzymes ( TTMs) are a newly recognized superfamily of phosphotransferases defined by a unique active site residing within an eight-stranded beta barrel. The prototypical members are the eukaryal metal-dependent RNA triphosphatases, which catalyze the initial step in mRNA capping. Little is known about the activities and substrate specificities of the scores of TTM homologs present in bacterial and archaeal proteomes, nearly all of which are annotated as adenylate cyclases. Here we have conducted a biochemical and structure-function analysis of a TTM protein ( CthTTM) from the bacterium Clostridium thermocellum. CthTTM is a metal-dependent tripolyphosphatase and nucleoside triphosphatase; it is not an adenylate cyclase. We have identified 11 conserved amino acids in the tunnel that are critical for tripolyphosphatase and ATPase activity. The most salient findings are that ( i) CthTTM is 150-fold more active in cleaving tripolyphosphate than ATP and ( ii) the substrate specificity of CthTTM can be transformed by a single mutation ( K8A) that abolishes tripolyphosphatase activity while strongly stimulating ATP hydrolysis. Our results underscore the plasticity of CthTTM substrate choice and suggest how novel specificities within the TTM superfamily might evolve through changes in the residues that line the tunnel walls.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskc.org			NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bisaillon M, 2001, J BIOL CHEM, V276, P17261, DOI 10.1074/jbc.M100980200; Gallagher DT, 2006, J MOL BIOL, V362, P114, DOI 10.1016/j.jmb.2006.07.008; Gong CL, 2006, RNA, V12, P1468, DOI 10.1261/rna.119806; Gong CL, 2003, J BIOL CHEM, V278, P50843, DOI 10.1074/jbc.M309188200; Gong CL, 2003, VIROLOGY, V309, P125, DOI 10.1016/S0042-6822(03)00002-3; Gong CL, 2002, J BIOL CHEM, V277, P15317, DOI 10.1074/jbc.M200532200; Hausmann S, 2005, J BIOL CHEM, V280, P12077, DOI 10.1074/jbc.M412063200; Hausmann S, 2002, J BIOL CHEM, V277, P96, DOI 10.1074/jbc.M109649200; Ho CK, 2001, J BIOL CHEM, V276, P46182, DOI 10.1074/jbc.M108706200; Ho CK, 2001, P NATL ACAD SCI USA, V98, P3050, DOI 10.1073/pnas.061636198; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Iyer LM, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-33; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; Lakaye B, 2002, J BIOL CHEM, V277, P13771, DOI 10.1074/jbc.M111241200; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; Martins A, 2003, NUCLEIC ACIDS RES, V31, P1455, DOI 10.1093/nar/gkg244; Martins A, 2001, J BIOL CHEM, V276, P45522, DOI 10.1074/jbc.M107615200; Myette JR, 1996, J BIOL CHEM, V271, P11945, DOI 10.1074/jbc.271.20.11945; Pei Y, 2000, NUCLEIC ACIDS RES, V28, P1885, DOI 10.1093/nar/28.9.1885; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Sismeiro O, 1998, J BACTERIOL, V180, P3339, DOI 10.1128/JB.180.13.3339-3344.1998; Takagi T, 2001, MOL BIOCHEM PARASIT, V114, P239, DOI 10.1016/S0166-6851(01)00254-7	24	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11941	11949		10.1074/jbc.M611328200	http://dx.doi.org/10.1074/jbc.M611328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17303560	hybrid			2022-12-25	WOS:000245941900037
J	Ramamoorthy, S; Samuvel, DJ; Buck, ER; Rudnick, G; Jayanthi, LD				Ramamoorthy, Sammanda; Samuvel, Devadoss J.; Buck, Eric R.; Rudnick, Gary; Jayanthi, Lankupalle D.			Phosphorylation of threonine residue 276 is required for acute regulation of serotonin transporter by cyclic GMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE; NEUROTRANSMITTER TRANSPORTERS; RAT-BRAIN; SURFACE EXPRESSION; ADENOSINE RECEPTOR; RELEASE; PATHWAY; ALPHA; STIMULATION	Cellular protein kinases, phosphatases, and other serotonin transporter ( SERT) interacting proteins participate in several signaling mechanisms regulating SERT activity. The molecular mechanisms of protein kinase G ( PKG)-mediated SERT regulation and the site of transporter phosphorylation were investigated. Treatment of rat midbrain synaptosomes with 8-bromo-cGMP increased SERT activity, and the increase was selectively blocked by PKG inhibitors. The V-max value for serotonin ( 5-HT) transport increased following cGMP treatment. However, surface biotinylation studies showed no change in SERT surface abundance following PKG activation. P-32 metabolic labeling experiments showed increased SERT phosphorylation in the presence of cGMP that was abolished by selectively inhibiting PKG. Phosphoamino acid analysis revealed that cGMP-stimulated native SERT phosphorylation occurred only on threonine residues. When added to CHO-1 cells expressing SERT, 8-bromo-cGMP stimulated 5-HT transport and SERT phosphorylation. Mutation of SERT threonine 276 to alanine completely abolished cGMP- mediated stimulation of 5-HT transport and SERT phosphorylation. Although the T276A mutation had no significant effect on 5-HT transport or SERT protein expression, mutation to aspartate ( T276D) increased the level of 5-HT uptake to that of cGMP-stimulated 5-HT uptake in wild-type SERT-expressing cells and was no longer sensitive to cGMP. These findings provide the first identification of a phosphorylation site in SERT and demonstrate that phosphorylation of Thr-276 is required for cGMP-mediated SERT regulation. They also constitute the first evidence that in the central nervous system PKG activation stimulates endogenous SERT activity by a trafficking-independent mechanism.	Med Univ S Carolina, Dept Neurosci, Div Neurosci Res, Charleston, SC 29425 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06519 USA	Medical University of South Carolina; Yale University	Ramamoorthy, S (corresponding author), Med Univ S Carolina, Dept Neurosci, Div Neurosci Res, 173 Ashley Ave,BSB 403, Charleston, SC 29425 USA.	rama@musc.edu			NIDA NIH HHS [DA8213] Funding Source: Medline; NIGMS NIH HHS [GM081054] Funding Source: Medline; NIMH NIH HHS [MH62612] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH062612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008213] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Barker Eric L., 1995, P321; Bauman AL, 2000, J NEUROSCI, V20, P7571; Beuming T, 2006, MOL PHARMACOL, V70, P1630, DOI 10.1124/mol.106.026120; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; BOULTON CL, 1994, EUR J NEUROSCI, V6, P1528, DOI 10.1111/j.1460-9568.1994.tb00543.x; Drennan D, 2004, PROG BIOPHYS MOL BIO, V85, P1, DOI 10.1016/S0079-6107(03)00060-9; FINK K, 1990, N-S ARCH PHARMACOL, V342, P513; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Jayanthi LD, 2006, J BIOL CHEM, V281, P23326, DOI 10.1074/jbc.M601156200; JAYANTHI LD, 1994, J BIOL CHEM, V269, P14424; Kaehler ST, 1999, BRAIN RES, V835, P346, DOI 10.1016/S0006-8993(99)01599-1; Kilic F, 2003, MOL PHARMACOL, V64, P440, DOI 10.1124/mol.64.2.440; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LAUNAY JM, 1994, AM J PHYSIOL, V266, pR526, DOI 10.1152/ajpregu.1994.266.2.R526; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Okada M, 1999, EUR J NEUROSCI, V11, P1, DOI 10.1046/j.1460-9568.1999.00415.x; Ozaki N, 2003, MOL PSYCHIATR, V8, P933, DOI 10.1038/sj.mp.4001365; Prasad HC, 2005, P NATL ACAD SCI USA, V102, P11545, DOI 10.1073/pnas.0501432102; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; RAMAMOORTHY S, 1989, BIOCHEM J, V258, P777, DOI 10.1042/bj2580777; RAMAMOORTHY S, 2002, ENUROTRANSMITTER TRA, P1; Ramamoorthy S, 1998, METHOD ENZYMOL, V296, P347; Reith MEA., 1997, NEUROTRANSMITTER TRA, P29, DOI 10.1007/978-1-59259-470-2_2; Ruth P, 1999, PHARMACOL THERAPEUT, V82, P355, DOI 10.1016/S0163-7258(98)00067-9; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; Samuvel DJ, 2005, J NEUROSCI, V25, P29, DOI 10.1523/JNEUROSCI.3754-04.2005; Simpson KL, 2003, J COMP NEUROL, V466, P495, DOI 10.1002/cne.10912; Sinner C, 2001, N-S ARCH PHARMACOL, V364, P105, DOI 10.1007/s002100100428; SOUTHAM E, 1993, NEUROPHARMACOLOGY, V32, P1267, DOI 10.1016/0028-3908(93)90021-T; Threlfell S, 2004, J NEUROSCI, V24, P8704, DOI 10.1523/JNEUROSCI.2690-04.2004; Vaughan RA, 2004, J PHARMACOL EXP THER, V310, P1, DOI 10.1124/jpet.103.052423; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Zhang YW, 2006, J BIOL CHEM, V281, P36213, DOI 10.1074/jbc.M605468200; Zhang YW, 2005, J BIOL CHEM, V280, P30807, DOI 10.1074/jbc.M504087200; Zhu CB, 2004, MOL PHARMACOL, V65, P1462, DOI 10.1124/mol.65.6.1462; Zhu CB, 2004, EUR J PHARMACOL, V504, P1, DOI 10.1016/j.ejphar.2004.09.023	41	70	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2007	282	16					11639	11647		10.1074/jbc.M611353200	http://dx.doi.org/10.1074/jbc.M611353200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LK	17310063	hybrid			2022-12-25	WOS:000245941900005
J	Li, Y; Hu, YF; Zhang, XX; Xu, HM; Lescop, E; Xia, B; Jin, CW				Li, You; Hu, Yunfei; Zhang, Xinxin; Xu, Huimin; Lescop, Ewen; Xia, Bin; Jin, Changwen			Conformational fluctuations coupled to the thiol-disulfide transfer between thioredoxin and arsenate reductase in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AUREUS PLASMID PI258; STAPHYLOCOCCUS-AUREUS; CATALYSIS; MECHANISM; DYNAMICS; PROGRAMS; PEPTIDE; CASCADE; TARGET; NMR	Arsenic compounds commonly exist in nature and are toxic to nearly all kinds of life forms, which directed the evolution of enzymes in many organisms for arsenic detoxification. In bacteria, the thioredoxin-coupled arsenate reductase catalyzes the reduction of arsenate to arsenite by intramolecular thiol-disulfide cascade. The oxidized arsenate reductase ArsC is subsequently regenerated by thioredoxin through an intermolecular thiol-disulfide exchange process. The solution structure of the Bacillus subtilis thioredoxin-arsenate reductase complex represents the transiently formed intermediate during the intermolecular thiol-disulfide exchange reaction. A comparison of the complex structure with that of thioredoxin and arsenate reductase proteins in redox states showed substantial conformational changes coupled to the reaction process, with arsenate reductase, especially, adopting an "intermediate" conformation in the complex. Our current studies provide novel insights into understanding the reaction mechanisms of the thioredoxin-arsenate reductase pathway.	Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China; Peking Univ, Coll Chem & Mol Engn, Beijing 100871, Peoples R China; Peking Univ, Coll Life Sci, Beijing 100871, Peoples R China	Peking University; Peking University; Peking University	Jin, CW (corresponding author), Peking Univ, Beijing Nucl Magnet Resonance Ctr, Beijing 100871, Peoples R China.	changwen@pku.edu.cn	zhang, xinxin/E-8629-2012; Lescop, Ewen/AAA-8700-2019	Lescop, Ewen/0000-0002-2623-9365				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Bennett MS, 2001, P NATL ACAD SCI USA, V98, P13577, DOI 10.1073/pnas.241397198; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Guo XR, 2005, J BIOL CHEM, V280, P39601, DOI 10.1074/jbc.M508132200; Holmgren A, 2005, BIOCHEM SOC T, V33, P1375, DOI 10.1042/BST0331375; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; JI GY, 1994, BIOCHEMISTRY-US, V33, P7294, DOI 10.1021/bi00189a034; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; Messens J, 2004, J MOL BIOL, V339, P527, DOI 10.1016/j.jmb.2004.04.016; Messens J, 2004, ACTA CRYSTALLOGR D, V60, P1180, DOI 10.1107/S0907444904007334; Messens J, 2002, P NATL ACAD SCI USA, V99, P8506, DOI 10.1073/pnas.132142799; Messens J, 1999, BIOCHEMISTRY-US, V38, P16857, DOI 10.1021/bi9911841; Messens J, 2006, J MOL BIOL, V362, P1, DOI 10.1016/j.jmb.2006.07.002; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Peterson FC, 2005, PROTEIN SCI, V14, P2195, DOI 10.1110/ps.051477905; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Rosen BP, 2002, FEBS LETT, V529, P86, DOI 10.1016/S0014-5793(02)03186-1; Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954; Wahl MC, 2005, J MOL BIOL, V345, P1119, DOI 10.1016/j.jmb.2004.11.004; WAKSMAN G, 1994, J MOL BIOL, V236, P800, DOI 10.1006/jmbi.1994.1190; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Zegers I, 2001, NAT STRUCT BIOL, V8, P843, DOI 10.1038/nsb1001-843	26	35	38	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11078	11083		10.1074/jbc.M700970200	http://dx.doi.org/10.1074/jbc.M700970200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17303556	hybrid			2022-12-25	WOS:000245941500028
J	McIntosh, MT; Vaid, A; Hosgood, HD; Vijay, J; Bhattacharya, A; Sahani, MH; Baevova, P; Joiner, KA; Sharma, P				McIntosh, Michael T.; Vaid, Ankush; Hosgood, H. Dean; Vijay, Justin; Bhattacharya, Anindita; Sahani, Mayurbhai H.; Baevova, Pavlina; Joiner, Keith A.; Sharma, Pushkar			Traffic to the malaria parasite food vacuole - A novel pathway involving a phosphatidylinositol 3-phosphate-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; ALPHA-MANNOSIDASE; CRYSTAL-STRUCTURE; TARGETING SIGNAL; AMINOPEPTIDASE-I; FYVE; MEMBRANE; ENDOSOME; DOMAINS; YEAST	Phosphatidylinositol 3-phosphate (PI3P) is a key ligand for recruitment of endosomal regulatory proteins in higher eukaryotes. Subsets of these endosomal proteins possess a highly selective PI3P binding zinc finger motif belonging to the FYVE domain family. We have identified a single FYVE domain-containing protein in Plasmodium falciparum which we term FCP. Expression and mutagenesis studies demonstrate that key residues are involved in specific binding to PI3P. In contrast to FYVE proteins in other organisms, endogenous FCP localizes to a lysosomal compartment, the malaria parasite food vacuole ( FV), rather than to cytoplasmic endocytic organelles. Transfections of deletion mutants further indicate that FCP is essential for trophozoite and FV maturation and that it traffics to the FV via a novel constitutive cytoplasmic to vacuole targeting pathway. This newly discovered pathway excludes the secretory pathway and is directed by a C-terminal 44-amino acid peptide domain. We conclude that an FYVE protein that might be expected to participate in vesicle targeting in the parasite cytosol instead has a vital and functional role in the malaria parasite FV.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India	Yale University; Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Sharma, P (corresponding author), Yale Univ, Sch Epidemiol & Publ Hlth, 60 Coll St, New Haven, CT 06520 USA.	michael.mcintosh@yale.edu; pushkar@nii.res.in	Joiner, Keith/AAH-1059-2021	Joiner, Keith/0000-0003-3062-823X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akompong T, 2002, J BIOL CHEM, V277, P28923, DOI 10.1074/jbc.M201968200; ATKINSON CT, 1990, BLOOD CELLS, V16, P351; Bhaduri-McIntosh S, 1998, EXP PARASITOL, V88, P252, DOI 10.1006/expr.1998.4242; Birkeland HCG, 2004, CURR TOP MICROBIOL, V282, P89; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Danis M, 1998, Rev Prat, V48, P254; Deitsch KW, 2001, NUCLEIC ACIDS RES, V29, P850, DOI 10.1093/nar/29.3.850; Dumas JJ, 2001, MOL CELL, V8, P947, DOI 10.1016/S1097-2765(01)00385-9; ELABBADI N, 1994, MOL BIOCHEM PARASIT, V63, P179, DOI 10.1016/0166-6851(94)90054-X; Foth BJ, 2003, INT REV CYTOL, V224, P57, DOI 10.1016/S0074-7696(05)24003-2; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Gillooly DJ, 2003, HISTOCHEM CELL BIOL, V120, P445, DOI 10.1007/s00418-003-0591-7; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hayakawa A, 2004, J BIOL CHEM, V279, P5958, DOI 10.1074/jbc.M310503200; HENDRICKS LC, 1992, P NATL ACAD SCI USA, V89, P7242, DOI 10.1073/pnas.89.15.7242; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Hoppe HC, 2000, NAT CELL BIOL, V2, P449, DOI 10.1038/35017090; Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409; Jensen RB, 2001, BIOCHEM J, V359, P165, DOI 10.1042/0264-6021:3590165; Klemba M, 2004, J CELL BIOL, V164, P47, DOI 10.1083/jcb200307147; Klemba M, 2004, J BIOL CHEM, V279, P43000, DOI 10.1074/jbc.M408123200; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; KUTNER S, 1985, J CELL PHYSIOL, V125, P521, DOI 10.1002/jcp.1041250323; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Lopez-Estrano C, 2003, P NATL ACAD SCI USA, V100, P12402, DOI 10.1073/pnas.2133080100; Mao YX, 2000, CELL, V100, P447, DOI 10.1016/S0092-8674(00)80680-7; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; Misra S, 1999, CELL, V97, P657, DOI 10.1016/S0092-8674(00)80776-X; Nacer A, 2001, INT J PARASITOL, V31, P1371, DOI 10.1016/S0020-7519(01)00253-3; Oda MN, 1996, J CELL BIOL, V132, P999, DOI 10.1083/jcb.132.6.999; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; Pfeffer S, 2003, CELL, V112, P507, DOI 10.1016/S0092-8674(03)00118-1; Sato S, 2003, MOL BIOCHEM PARASIT, V130, P155, DOI 10.1016/S0166-6851(03)00166-X; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Skinner-Adams TS, 2003, TRENDS PARASITOL, V19, P17, DOI 10.1016/S1471-4922(02)00005-3; Stenmark H, 2002, FEBS LETT, V513, P77, DOI 10.1016/S0014-5793(01)03308-7; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Walshaw J, 2001, J MOL BIOL, V307, P1427, DOI 10.1006/jmbi.2001.4545; Woodman PG, 2000, TRAFFIC, V1, P695, DOI 10.1034/j.1600-0854.2000.010902.x; Wurmser AE, 2002, J CELL BIOL, V158, P761, DOI 10.1083/jcb.200112050; YOSHIHISA T, 1989, BIOCHEM BIOPH RES CO, V163, P908, DOI 10.1016/0006-291X(89)92308-5; YOSHIHISA T, 1990, J BIOL CHEM, V265, P22418; Ziegler J, 2001, CURR MED CHEM, V8, P171, DOI 10.2174/0929867013373840	46	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11499	11508		10.1074/jbc.M610974200	http://dx.doi.org/10.1074/jbc.M610974200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17289673	hybrid			2022-12-25	WOS:000245941500071
J	McKenna, SA; Lindhout, DA; Kim, I; Liu, CW; Gelev, VM; Wagner, G; Puglisi, JD				McKenna, Sean A.; Lindhout, Darrin A.; Kim, Insil; Liu, Corey W.; Gelev, Vladimir M.; Wagner, Gerhard; Puglisi, Joseph D.			Molecular framework for the activation of RNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; INTERFERON ACTION; BINDING DOMAIN; PKR ACTIVATION; SUBSTRATE RECOGNITION; MEDIATED ACTIVATION; TAR RNA; MECHANISM; AUTOPHOSPHORYLATION; DSRNA	The RNA-dependent protein kinase ( PKR) plays an integral role in the antiviral response to cellular infection. PKR contains three distinct domains consisting of two conserved N-terminal double-stranded RNA ( dsRNA)- binding domains, a C-terminal Ser-Thr kinase domain, and a central 80-residue linker. Despite rich structural and biochemical data, a detailed mechanistic explanation of PKR activation remains unclear. Here we provide a framework for understanding dsRNA-dependent activation of PKR using nuclear magnetic resonance spectroscopy, dynamic light scattering, gel filtration, and autophosphorylation kinetics. In the latent state, PKR exists as an extended monomer, with an increase in self-affinity upon dsRNA association. Subsequent phosphorylation leads to efficient release of dsRNA followed by a greater increase in self-affinity. Activated PKR displays extensive conformational perturbations within the kinase domain. We propose an updated model for PKR activation in which the communication between RNA binding, central linker, and kinase domains is critical in the propagation of the activation signal and for PKR dimerization.	Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Stanford Magnet Resonance Lab, Stanford, CA 94305 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Stanford University; Stanford University; Harvard University; Harvard Medical School	Puglisi, JD (corresponding author), Stanford Univ, Sch Med, Dept Biol Struct, Stanford, CA 94305 USA.	Puglisi@stanford.edu		McKenna, Sean/0000-0002-9407-7257	NIAID NIH HHS [AI47365] Funding Source: Medline; NIGMS NIH HHS [GM078346] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI047365, R01AI047365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078346] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bevilacqua PC, 1996, BIOCHEMISTRY-US, V35, P9983, DOI 10.1021/bi9607259; Dar AC, 2005, CELL, V122, P887, DOI 10.1016/j.cell.2005.06.044; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dey M, 2005, CELL, V122, P901, DOI 10.1016/j.cell.2005.06.041; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Gale MJ, 1998, CLIN DIAGN VIROL, V10, P157; Gelev V, 2006, J MOL BIOL, V364, P352, DOI 10.1016/j.jmb.2006.08.077; George CX, 1996, VIROLOGY, V221, P180, DOI 10.1006/viro.1996.0364; Jammi NV, 2001, NUCLEIC ACIDS RES, V29, P3020; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Kim I, 2006, J MOL BIOL, V358, P430, DOI 10.1016/j.jmb.2006.01.099; LASKY SR, 1982, J BIOL CHEM, V257, P1087; Lemaire PA, 2005, J MOL BIOL, V345, P81, DOI 10.1016/j.jmb.2004.10.031; Lemaire PA, 2006, BIOCHEMISTRY-US, V45, P9074, DOI 10.1021/bi060567d; Li SD, 2006, P NATL ACAD SCI USA, V103, P10005, DOI 10.1073/pnas.0602317103; Lukavsky PJ, 2004, RNA, V10, P889, DOI 10.1261/rna.5264804; MAITRA RK, 1994, VIROLOGY, V204, P823, DOI 10.1006/viro.1994.1601; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; McKenna SA, 2006, J MOL BIOL, V358, P1270, DOI 10.1016/j.jmb.2006.03.003; Nanduri S, 1998, J BIOMOL NMR, V12, P349, DOI 10.1023/A:1008259729432; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; Peel AL, 2004, J NEUROPATH EXP NEUR, V63, P97, DOI 10.1093/jnen/63.2.97; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Su QZ, 2006, P NATL ACAD SCI USA, V103, P63, DOI 10.1073/pnas.0508207103; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; THOMIS DC, 1995, J VIROL, V69, P5195, DOI 10.1128/JVI.69.8.5195-5198.1995; Vattem KM, 2001, EUR J BIOCHEM, V268, P3674, DOI 10.1046/j.1432-1327.2001.02273.x; Wang ZX, 2002, BIOCHEM J, V368, P947, DOI 10.1042/BJ20020557; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291	33	47	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					11474	11486		10.1074/jbc.M700301200	http://dx.doi.org/10.1074/jbc.M700301200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17284445	hybrid			2022-12-25	WOS:000245941500069
J	Pan, Y; Wang, BL				Pan, Yong; Wang, Baolin			A novel protein-processing domain in Gli2 and Gli3 differentially blocks complete protein degradation by the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLYCINE-RICH REGION; CUBITUS INTERRUPTUS; BETA-TRCP; TRANSCRIPTIONAL ACTIVATOR; REQUIRES PHOSPHORYLATION; PRECURSOR P105; HEDGEHOG; UBIQUITINATION; P50	The proteasome usually completely degrades its target proteins, but it can also degrade a handful of proteins in a limited and site-specific manner. The molecular mechanism for such limited degradation is unknown. The repressor forms of Gli2 and Gli3 transcription factors are generated from their full-length proteins through limited proteasome-mediated protein degradation. In this study, we have taken advantage of the fact that Gli3 is efficiently processed, whereas Gli2 is not, and identified a region of similar to 200 residues in their C termini that determine differential processing of the two proteins. This region, named processing determinant domain, functions as a signal for protein processing in the context of not only Gli2 and Gli3 protein sequences but also a heterologous hybrid protein, which would otherwise be completely degraded by the proteasome. Thus, the processing determinant domain constitutes a novel domain that functions independently. Our findings explain, at the molecular level, why Gli2 and Gli3 are differentially processed and, more importantly, may help understand a probably general mechanism by which the proteasome degrades some of its target proteins partially rather than completely.	Cornell Univ, Weill Med Coll, Dept Med Genet, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell & Dev Biol, New York, NY 10021 USA	Cornell University; Cornell University	Wang, BL (corresponding author), Cornell Univ, Weill Med Coll, Dept Med Genet, 1300 York Ave,W404, New York, NY 10021 USA.	baw2001@med.cornell.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070820] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM70820] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Cohen S, 2004, MOL CELL BIOL, V24, P475, DOI 10.1128/MCB.24.1.475-486.2004; Coux O, 1998, J BIOL CHEM, V273, P8820, DOI 10.1074/jbc.273.15.8820; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; JIA J, 2002, NATURE, V416, P823; Jia JH, 2005, DEV CELL, V9, P819, DOI 10.1016/j.devcel.2005.10.006; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Lin L, 1996, MOL CELL BIOL, V16, P2248; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Moorthy AK, 2006, EMBO J, V25, P1945, DOI 10.1038/sj.emboj.7601081; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Piwko W, 2006, NAT STRUCT MOL BIOL, V13, P691, DOI 10.1038/nsmb1122; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Smelkinson MG, 2006, CURR BIOL, V16, P110, DOI 10.1016/j.cub.2005.12.012; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Tempe D, 2006, MOL CELL BIOL, V26, P4316, DOI 10.1128/MCB.02183-05; Tian L, 2005, NAT STRUCT MOL BIOL, V12, P1045, DOI 10.1038/nsmb1018; Varjosalo M, 2006, DEV CELL, V10, P177, DOI 10.1016/j.devcel.2005.12.014; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Wang CB, 2007, DEV DYNAM, V236, P769, DOI 10.1002/dvdy.21082; Wang QT, 1999, DEVELOPMENT, V126, P5097; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270	34	106	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10846	10852		10.1074/jbc.M608599200	http://dx.doi.org/10.1074/jbc.M608599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17283082	hybrid			2022-12-25	WOS:000245941500003
J	Rak, M; Tetaud, E; Godard, F; Sagot, I; Salin, B; Duvezin-Caubet, S; Slonimski, PP; Rytka, J; di Rago, JP				Rak, Malgorzata; Tetaud, Emmanuel; Godard, Francois; Sagot, Isabelle; Salin, Benedicte; Duvezin-Caubet, Stephane; Slonimski, Piotr P.; Rytka, Joanna; di Rago, Jean-Paul			Yeast cells lacking the mitochondrial gene encoding the ATP synthase subunit 6 exhibit a selective loss of complex IV and unusual mitochondrial morphology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR GENE; OXIDATIVE-PHOSPHORYLATION; ADP/ATP CARRIER; ENZYME COMPLEX; H+-ATPASE; F-1-ATPASE; CRISTAE; MEMBRANE; MUTANTS	Atp6p is an essential subunit of the ATP synthase proton translocating domain, which is encoded by the mitochondrial DNA (mtDNA) in yeast. We have replaced the coding sequence of Atp6p gene with the non-respiratory genetic marker ARG8m. Due to the presence of ARG8m, accumulation of rho(-)/rho(0) petites issued from large deletions in mtDNA could be restricted to 20 - 30% by growing the atp6 mutant in media lacking arginine. This moderate mtDNA instability created favorable conditions to investigate the consequences of a specific lack in Atp6p. Interestingly, in addition to the expected loss of ATP synthase activity, the cytochrome c oxidase respiratory enzyme steady-state level was found to be extremely low (< 5%) in the atp6 mutant. We show that the cytochrome c oxidase-poor accumulation was caused by a failure in the synthesis of one of its mtDNA-encoded subunits, Cox1p, indicating that, in yeast mitochondria, Cox1p synthesis is a key target for cytochrome c oxidase abundance regulation in relation to the ATP synthase activity. We provide direct evidence showing that in the absence of Atp6p the remaining subunits of the ATP synthase can still assemble. Mitochondrial cristae were detected in the atp6 mutant, showing that neither Atp6p nor the ATP synthase activity is critical for their formation. However, the atp6 mutant exhibited unusual mitochondrial structure and distribution anomalies, presumably caused by a strong delay in inner membrane fusion.	Univ Victor Segalen, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland; Univ Paris 06, Lab Propre Associe, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	UDICE-French Research Universities; Universite de Bordeaux; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; UDICE-French Research Universities; Sorbonne Universite	di Rago, JP (corresponding author), Univ Victor Segalen, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	jp.dirago@ibgc.u-bordeaux2.fr		Duvezin-Caubet, Stephane/0000-0002-0243-2697				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Ackerman SH, 2005, PROG NUCLEIC ACID RE, V80, P95, DOI 10.1016/S0079-6603(05)80003-0; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ALLEN RD, 1995, PROTOPLASMA, V189, P1, DOI 10.1007/BF01280286; ALLEN RD, 1989, J CELL BIOL, V108, P2233, DOI 10.1083/jcb.108.6.2233; Amutha B, 2004, BIOCHEM J, V381, P19, DOI 10.1042/BJ20040566; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; Barrientos A, 2004, EMBO J, V23, P3472, DOI 10.1038/sj.emboj.7600358; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; Bonnefoy N, 2001, METHOD CELL BIOL, V65, P381, DOI 10.1016/S0091-679X(01)65022-2; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Brustovetsky N, 1996, P NATL ACAD SCI USA, V93, P664, DOI 10.1073/pnas.93.2.664; CHOO WM, 1985, BIOCHIM BIOPHYS ACTA, V806, P290, DOI 10.1016/0005-2728(85)90108-2; CLAISSE ML, 1980, MOL GEN GENET, V177, P375, DOI 10.1007/BF00271476; Contamine V, 2000, MICROBIOL MOL BIOL R, V64, P281, DOI 10.1128/MMBR.64.2.281-315.2000; DEZAMAROCZY M, 1986, GENE, V47, P155, DOI 10.1016/0378-1119(86)90060-0; DIRAGO JP, 1990, J BIOL CHEM, V265, P3332; Duvezin-Caubet S, 2003, P NATL ACAD SCI USA, V100, P13235, DOI 10.1073/pnas.2135169100; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Fillingame RH, 2000, NAT STRUCT BIOL, V7, P1002, DOI 10.1038/80902; Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7; Frey TG, 2002, BBA-BIOENERGETICS, V1555, P196, DOI 10.1016/S0005-2728(02)00278-5; Gavin PD, 2004, J CELL SCI, V117, P2333, DOI 10.1242/jcs.01074; Gilkerson RW, 2003, FEBS LETT, V546, P355, DOI 10.1016/S0014-5793(03)00633-1; GRENSON M, 1966, BIOCHIM BIOPHYS ACTA, V127, P325, DOI 10.1016/0304-4165(66)90387-4; GUELIN E, 1993, J BIOL CHEM, V268, P161; Guerin B, 1979, Methods Enzymol, V55, P149; HEIMBERG H, 1990, GENE, V90, P69, DOI 10.1016/0378-1119(90)90440-3; JAUNIAUX JC, 1978, J BACTERIOL, V133, P1096, DOI 10.1128/JB.133.3.1096-1107.1978; JEANFRANCOIS MJB, 1986, BIOCHIM BIOPHYS ACTA, V852, P133, DOI 10.1016/0005-2728(86)90066-6; Kadenbach B, 2003, BBA-BIOENERGETICS, V1604, P77, DOI 10.1016/S0005-2728(03)00027-6; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; KOTYLAK Z, 1977, MITOCHONDRIA 1977, P161; LABOUESSE M, 1983, EMBO J, V2, P269, DOI 10.1002/j.1460-2075.1983.tb01416.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lefebvre-Legendre L, 2005, J BIOL CHEM, V280, P18386, DOI 10.1074/jbc.M410789200; Lefebvre-Legendre L, 2001, J BIOL CHEM, V276, P6789, DOI 10.1074/jbc.M009557200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARZUKI S, 1989, BIOCHIM BIOPHYS ACTA, V975, P222, DOI 10.1016/S0005-2728(89)80252-X; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; NAKAGAWA K, 1991, J BIOL CHEM, V266, P1977; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Nury H, 2006, ANNU REV BIOCHEM, V75, P713, DOI 10.1146/annurev.biochem.75.103004.142747; Okamoto K, 1998, J CELL BIOL, V142, P613, DOI 10.1083/jcb.142.3.613; Ono S, 2004, J BIOL CHEM, V279, P33409, DOI 10.1074/jbc.M404993200; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; Perez-Martinez X, 2003, EMBO J, V22, P5951, DOI 10.1093/emboj/cdg566; RIGOULET M, 1979, FEBS LETT, V102, P18, DOI 10.1016/0014-5793(79)80919-9; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SIMON M, 1984, MOL GEN GENET, V196, P266, DOI 10.1007/BF00328059; SOMLO M, 1985, EUR J BIOCHEM, V150, P89, DOI 10.1111/j.1432-1033.1985.tb08992.x; SOMLO M, 1968, EUR J BIOCHEM, V5, P276, DOI 10.1111/j.1432-1033.1968.tb00368.x; Spannagel C, 1997, EUR J BIOCHEM, V247, P1111, DOI 10.1111/j.1432-1033.1997.01111.x; Steele DF, 1996, P NATL ACAD SCI USA, V93, P5253, DOI 10.1073/pnas.93.11.5253; Szczepanek T, 1996, EMBO J, V15, P3758, DOI 10.1002/j.1460-2075.1996.tb00746.x; Tzagoloff A, 2004, J BIOL CHEM, V279, P19775, DOI 10.1074/jbc.M401506200; TZAGOLOFF A, 1976, GENETIC FUNCTION MIT, P155; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547; Venard R, 2003, BIOCHEMISTRY-US, V42, P7626, DOI 10.1021/bi034394t; Wittig I, 2005, PROTEOMICS, V5, P4338, DOI 10.1002/pmic.200500081; Xiao Y, 2000, J BIOL CHEM, V275, P6963, DOI 10.1074/jbc.275.10.6963	69	92	92	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2007	282	15					10853	10864		10.1074/jbc.M608692200	http://dx.doi.org/10.1074/jbc.M608692200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LG	17261589	hybrid			2022-12-25	WOS:000245941500004
J	Noels, H; van Loo, G; Hagens, S; Broeckx, V; Beyaert, R; Marynen, P; Baens, M				Noels, Heidi; van Loo, Geert; Hagens, Sofie; Broeckx, Vicky; Beyaert, Rudi; Marynen, Peter; Baens, Mathijs			A novel TRAF6 binding site in MALT1 defines distinct mechanisms of NF-kappa B activation by API2 center dot MALT1 fusions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOID-TISSUE LYMPHOMAS; T-CELL; CHROMOSOMAL TRANSLOCATION; UBIQUITIN LIGASE; BCL10; CARMA1; KINASE; INHIBITOR; T(1/14)(P22,Q32); BIOTINYLATION	The recurrent translocation t(11;18)(q21; q21) associated with mucosa-associated lymphoid tissue (MALT) lymphoma results in the expression of an API2 center dot MALT1 fusion protein that constitutively activates NF-kappa B. The first baculovirus IAP repeat (BIR) domain of API2 and the C terminus of MALT1, which contains its caspase-like domain, are present in all reported fusion variants and interact with TRAF2 and TRAF6, respectively, suggesting their contribution to NF-kappa B signaling by API2 center dot MALT1. Also, the involvement of BCL10 has been suggested via binding to BIR1 of API2 and via its interaction with the immunoglobulin domains of MALT1, present in half of the fusion variants. However, conflicting reports exist concerning their roles in API2 center dot MALT1-induced NF-kappa B signaling. In this report, streptavidin pulldowns of biotinylated API2 center dot MALT1 fusion variants showed that none of the fusion variants interacted with endogenous BCL10; its role in NF-kappa B signaling by API2 center dot MALT1 was further questioned by RNA interference experiments. In contrast, TRAF6 was essential for NF-kappa B activation by all fusion variants, and we identified a novel TRAF6 binding site in the second immunoglobulin domain of MALT1, which enhanced NF-kappa B activation when present in the fusion protein. Furthermore, inclusion of both immunoglobulin domains in API2 center dot MALT1 further enhanced NF-kappa B signaling via intramolecular TRAF6 activation. Finally, binding of TRAF2 to BIR1 contributed to NF-kappa B activation by API2 center dot MALT1, although additional mechanisms involving BIR1-mediated raft association are also important. Taken together, these data reveal distinct mechanisms of NF-kappa B activation by the different API2 center dot MALT1 fusion variants with an essential role for TRAF6.	Flanders Inst Biotechnol, VIB, Human Genome Lab, Dept Mol & Dev Genet, B-3000 Louvain, Belgium; KU Leuvan, Ctr Human Genet Mol Genet, Human Genome Lab, B-3000 Louvain, Belgium; Flanders Inst Biotechnol, VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9052 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB)	Baens, M (corresponding author), KU Leuvan, Ctr Human Genet Mol Genet, Human Genome Lab, Herestr 49, B-3000 Louvain, Belgium.	Mathijs.Baens@Med.KULeuven.be	, van Loo Geert/AAD-1220-2019; Beyaert, Rudi/B-2589-2009; van Loo, Geert/C-1505-2009; Noels, Heidi/AAQ-2622-2020	, van Loo Geert/0000-0002-8427-4775; Beyaert, Rudi/0000-0002-5704-582X				Baens M, 2006, CANCER RES, V66, P5270, DOI 10.1158/0008-5472.CAN-05-4590; Beckett D, 1999, PROTEIN SCI, V8, P921, DOI 10.1110/ps.8.4.921; Bidere N, 2006, CURR BIOL, V16, P1666, DOI 10.1016/j.cub.2006.06.062; Che TJ, 2004, J BIOL CHEM, V279, P15870, DOI 10.1074/jbc.M310599200; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Hara H, 2004, J EXP MED, V200, P1167, DOI 10.1084/jem.20032246; Ho L, 2005, BLOOD, V105, P2891, DOI 10.1182/blood-2004-06-2297; Hosokawa Y, 2004, CANCER RES, V64, P3452, DOI 10.1158/0008-5472.CAN-03-3677; Hu SM, 2006, J CLIN INVEST, V116, P174, DOI 10.1172/JCI25641; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Rossman JS, 2006, MOL BIOL CELL, V17, P2166, DOI 10.1091/mbc.E05-10-0985; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Samuel T, 2006, J BIOL CHEM, V281, P1080, DOI 10.1074/jbc.M509381200; Sanchez-Izquierdo D, 2003, BLOOD, V101, P4539, DOI 10.1182/blood-2002-10-3236; Stilo R, 2004, J BIOL CHEM, V279, P34323, DOI 10.1074/jbc.M402244200; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Varfolomeev E, 2006, J BIOL CHEM, V281, P29022, DOI 10.1074/jbc.M605116200; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wooff J, 2004, FEBS LETT, V566, P229, DOI 10.1016/j.febslet.2004.04.038; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	30	68	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2007	282	14					10180	10189		10.1074/jbc.M611038200	http://dx.doi.org/10.1074/jbc.M611038200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	160LB	17287209	hybrid, Green Published			2022-12-25	WOS:000245941000008
J	Zuckerbraun, BS; Chin, BY; Bilban, M; d'Avila, JC; Rao, J; Billiar, TR; Otterbein, LE				Zuckerbraun, Brian S.; Chin, Beek Yoke; Bilban, Martin; d'Avila, Joana de Costa; Rao, Jayashree; Billiar, Timothy R.; Otterbein, Leo E.			Carbon monoxide signals via inhibition of cytochrome c oxidase and generation of mitochondrial reactive oxygen species	FASEB JOURNAL			English	Article						macrophage; p38 MAPK; tumor necrosis factor-alpha	ACTIVATED PROTEIN-KINASE; NITRIC-OXIDE; RESPIRATORY-CHAIN; RAT-BRAIN; IN-VIVO; HEME; SUPPRESSES; HYPOXIA; INJURY; CYTOPROTECTION	Carbon monoxide ( CO), which is produced endogenously in the breakdown of heme, has been recognized as an important physiological second messenger similar to NO. Additionally, pharmacological delivery of CO is protective in numerous models of injury, including ischemia/reperfusion, transplantation, hemorrhagic shock, and endotoxemia. However, the mechanism of action of CO is only partially elucidated focused primarily on how it modulates the cellular response to stress. The purpose of these investigations is to test the hypothesis that CO acts via inhibition of cytochrome c oxidase leading to the generation of low levels of reactive oxygen species (ROS) that in turn mediate subsequent adaptive signaling. We show here that CO increases ROS generation in RAW 264.7 cells, which is inhibited by antimycin A and is absent in respiration-deficient rho(0) cells. CO inhibits cytochrome c oxidase, while maintaining cellular ATP levels and increasing mitochondrial membrane potential. The addition of antioxidants or inhibition of complex III of the electron transport chain by antimycin A attenuates the inhibitory effects of CO on lipopolysaccharide ( LPS)-induced TNF-alpha and blocked CO-induced p38 MAPK phosphorylation, which we previously have shown to be important in the anti-inflammatory effects of CO.	Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Cambridge, MA 02138 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Beth Israel Deaconess Medical Center	Zuckerbraun, BS (corresponding author), Univ Pittsburgh, Sch Med, Dept Surg, NW653 MUH,3459 5th Ave, Pittsburgh, PA 15213 USA.	zuckerbraunbs@upmc.edu	d'Avila, Joana/L-8970-2013	d'Avila, Joana/0000-0002-2045-0813; Bilban, Martin/0000-0001-7043-7142				Almeida A, 2001, P NATL ACAD SCI USA, V98, P15294, DOI 10.1073/pnas.261560998; Amersi F, 2002, HEPATOLOGY, V35, P815, DOI 10.1053/jhep.2002.32467; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Beltran B, 2002, P NATL ACAD SCI USA, V99, P8892, DOI 10.1073/pnas.092259799; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; BROWN SD, 1990, J APPL PHYSIOL, V68, P604, DOI 10.1152/jappl.1990.68.2.604; BROWN SD, 1992, J CLIN INVEST, V89, P666, DOI 10.1172/JCI115633; Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHANDEL N, 1995, AM J PHYSIOL-LUNG C, V268, pL918, DOI 10.1152/ajplung.1995.268.6.L918; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; CHRZANOWSKALIGHTOWLERS ZMA, 1993, ANAL BIOCHEM, V214, P45, DOI 10.1006/abio.1993.1454; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Desmard M, 2005, CELL MOL BIOL, V51, P403, DOI 10.1170/T644; Emerling BM, 2005, MOL CELL BIOL, V25, P4853, DOI 10.1128/MCB.25.12.4853-4862.2005; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Katori M, 2002, TRANSPL IMMUNOL, V9, P227, DOI 10.1016/S0966-3274(02)00043-6; Kulisz A, 2002, AM J PHYSIOL-LUNG C, V282, pL1324, DOI 10.1152/ajplung.00326.2001; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Nakao A, 2003, SURGERY, V134, P285, DOI 10.1067/msy.2003.238; Nakao A, 2003, AM J PATHOL, V163, P1587, DOI 10.1016/S0002-9440(10)63515-8; Nakao A, 2003, GUT, V52, P1278, DOI 10.1136/gut.52.9.1278; Nystul TG, 2004, P NATL ACAD SCI USA, V101, P9133, DOI 10.1073/pnas.0403312101; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Otterbein LE, 2005, HEME OXYGENASE: THE ELEGANT ORCHESTRATION OF ITS PRODUCTS IN MEDICINE, pVII; Palacios-Callender M, 2004, P NATL ACAD SCI USA, V101, P7630, DOI 10.1073/pnas.0401723101; PIANTADOSI CA, 1989, AM J PHYSIOL, V256, pC840, DOI 10.1152/ajpcell.1989.256.4.C840; Piantadosi CA, 2002, ANTIOXID REDOX SIGN, V4, P259, DOI 10.1089/152308602753666316; Sarady JK, 2004, FASEB J, V18, P854, DOI 10.1096/fj.03-0643fje; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Sawle P, 2005, BRIT J PHARMACOL, V145, P800, DOI 10.1038/sj.bjp.0706241; Song RP, 2003, AM J PATHOL, V163, P231, DOI 10.1016/S0002-9440(10)63646-2; Srisook K, 2006, BIOCHEM PHARMACOL, V71, P307, DOI 10.1016/j.bcp.2005.10.042; Taille C, 2005, J BIOL CHEM, V280, P25350, DOI 10.1074/jbc.M503512200; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Zuckerbraun BS, 2003, J EXP MED, V198, P1707, DOI 10.1084/jem.20031003; Zuckerbraun BS, 2005, SHOCK, V23, P527, DOI 10.1097/01.shk.0000163206.22032.a1	41	240	245	4	47	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2007	21	4					1099	1106		10.1096/fj.06-6644com	http://dx.doi.org/10.1096/fj.06-6644com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	156LS	17264172				2022-12-25	WOS:000245650400014
